PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Tomkins, O; Shelef, I; Kaizerman, I; Eliushin, A; Afawi, Z; Misk, A; Gidon, M; Cohen, A; Zumsteg, D; Friedman, A				Tomkins, O.; Shelef, I.; Kaizerman, I.; Eliushin, A.; Afawi, Z.; Misk, A.; Gidon, M.; Cohen, A.; Zumsteg, D.; Friedman, A.			Blood-brain barrier disruption in post-traumatic epilepsy	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CORTEX; RAT; EPILEPTOGENESIS; SEIZURES; INJURY	Background: Traumatic brain injury (TBI) is an important cause of focal epilepsy. Animal experiments indicate that disruption of the blood-brain barrier (BBB) plays a critical role in the pathogenesis of post-traumatic epilepsy (PTE). Objective: To investigate the frequency, extent and functional correlates of increased BBB permeability in patient with PTE. Methods: 32 head trauma patients were included in the study, with 17 suffering from PTE. Patients underwent brain MRI (bMRI) and were evaluated for BBB disruption, using a novel semi-quantitative technique. Cortical dysfunction was measured using electroencephalography (EEG), and localised using standardised low-resolution brain electromagnetic tomography (sLORETA). Results: Spectral EEG analyses revealed significant slowing in patients with TBI, with no significant differences between patients with epilepsy and those without. Although bMRI revealed that patients with PTE were more likely to present with intracortical lesions (p = 0.02), no differences in the size of the lesion were found between the groups (p = 0.19). Increased BBB permeability was found in 76.9% of patients with PTE compared with 33.3% of patients without epilepsy (p = 0.047), and could be observed years following the trauma. Cerebral cortex volume with BBB disruption was larger in patients with PTE (p = 0.001). In 70% of patients, slow (delta band) activity was co-localised, by sLORETA, with regions showing BBB disruption. Conclusions: Lasting BBB pathology is common in patients with mild TBI, with increased frequency and extent being observed in patients with PTE. A correlation between disrupted BBB and abnormal neuronal activity is suggested.	[Tomkins, O.; Kaizerman, I.; Friedman, A.] Ben Gurion Univ Negev, Dept Physiol, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel; [Friedman, A.] Ben Gurion Univ Negev, Dept Neurosurg, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel; [Friedman, A.] Ben Gurion Univ Negev, Dept Physiol, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; [Friedman, A.] Ben Gurion Univ Negev, Dept Neurosurg, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; [Shelef, I.; Eliushin, A.; Gidon, M.; Cohen, A.] Soroka Med Ctr, Dept Neuroradiol, IL-84101 Beer Sheva, Israel; [Afawi, Z.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, IL-69978 Tel Aviv, Israel; [Misk, A.] Shaare Zedek Med Ctr, Dept Neurol, Jerusalem, Israel; [Zumsteg, D.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland		Friedman, A (corresponding author), Ben Gurion Univ Negev, Dept Physiol, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel.	alonf@bgu.ac.il		Tomkins-Netzer, Oren/0000-0002-1015-1641; shelef, ilan/0000-0002-8398-6455			Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Dreier JP, 2005, NEUROLOGY, V64, P2145, DOI 10.1212/01.WNL.0000176298.63840.99; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Tomkins O, 2001, CELL MOL NEUROBIOL, V21, P675, DOI 10.1023/A:1015147920283	13	147	153	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2008	79	7					774	777		10.1136/jnnp.2007.126425			4	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	314LI	WOS:000256810500009	17991703	Green Accepted			2022-02-06	
J	Swanik, CB; Covassin, T; Stearne, DJ; Schatz, P				Swanik, Charles Buz; Covassin, Tracey; Stearne, David J.; Schatz, Philip			The relationship between neurocognitive function and noncontact anterior cruciate ligament injuries	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						neuropsychological functioning; ImPACT; knee; neuromuscular	SPORTS-RELATED CONCUSSION; COMPUTER-BASED ASSESSMENT; TEAM HANDBALL; MECHANISMS; IMPACT; RECOVERY; GENDER; KNEE; PERFORMANCE; DEFICIENT	Background: Biomechanical analyses suggest that the loss of neuromuscular control is associated with noncontact anterior cruciate ligament sprains; however, previous research has not explored the link between neurocognitive function and unintentional knee injuries. Purpose: To determine if athletes who suffer a noncontact anterior cruciate ligament injury demonstrate decreased baseline neurocognitive performance when compared with matched controls. Study Design: Case control study; Level of evidence, 3. Methods: The baseline scores from a computerized neurocognitive test battery (ImPACT) were analyzed to compare verbal memory, visual memory, processing speed, and reaction time. Eighty intercollegiate athletes who, subsequent to testing, experienced noncontact anterior cruciate ligament injuries, were matched with 80 controls based on height, weight, age, gender, sport, position, and years of experience at the collegiate level. Results: Statistical differences were found between the noncontact anterior cruciate ligament injury group and the matched controls on all 4 neurocognitive subtests. Noncontact anterior cruciate ligament-injured athletes demonstrated significantly slower reaction time (F-1,F-158 = 9.66, P=.002) and processing speed (F-1,F-158 = 12.04, P =.001) and performed worse on visual (F-1,F-158 = 19.16, P =.000) and verbal memory (F-1,F-158 = 4.08, P =.045) composite scores when compared with controls. Conclusion: Neurocognitive differences may be associated with the loss of neuromuscular control and coordination errors, predisposing certain intercollegiate athletes to noncontact anterior cruciate ligament injuries.	Univ Delaware, Dept Hlth Nutr & Exercise Sci, Biomech & Movement Sci Program, Human Performance Lab 151, Newark, DE 19716 USA; Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; W Chester Univ, Dept Kinesiol, W Chester, PA 19380 USA; St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA		Swanik, CB (corresponding author), Univ Delaware, Dept Hlth Nutr & Exercise Sci, Biomech & Movement Sci Program, Human Performance Lab 151, 542 S Coll, Newark, DE 19716 USA.	cswanik@udel.edu	Swanik, Charles/C-4377-2014	Swanik, Charles/0000-0001-9701-2005; Schatz, Philip/0000-0002-6222-6545			ALLARD F, 1985, CAN J PSYCHOL, V39, P294, DOI 10.1037/h0080063; Baddeley A.D., 1986, WORKING MEMORY; BARTH J, 1989, MILD HEAD INJURY, P259; BECK JL, 1985, CLIN SPORT MED, V4, P345; BLYN N, 1991, SPINE, V16, P325; Boden BP, 2000, ORTHOPEDICS, V23, P573, DOI 10.3928/0147-7447-20000601-15; Carretta TR, 1996, INT J AVIAT PSYCHOL, V6, P21, DOI 10.1207/s15327108ijap0601_2; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Consiglio W, 2003, ACCIDENT ANAL PREV, V35, P495, DOI 10.1016/S0001-4575(02)00027-1; Dault MC, 2001, GAIT POSTURE, V14, P110, DOI 10.1016/S0966-6362(01)00113-8; Davis IM, 2001, CLIN BIOMECH, V16, P937; DeMont RG, 1999, J ATHL TRAINING, V34, P115; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DIFABIO RP, 1991, ARCH PHYS MED REHAB, V72, P292; EBERSBACH G, 1995, PERCEPT MOTOR SKILL, V81, P107, DOI 10.2466/pms.1995.81.1.107; FAHY FL, 1993, PROG BRAIN RES, V95, P401, DOI 10.1016/S0079-6123(08)60384-2; Fleming BC, 2003, AM J SPORT MED, V31, P701, DOI 10.1177/03635465030310051101; FORSSBERG H, 1982, J NEUROSCI, V2, P545; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GHEZ C, 1991, PRINCIPLES NEURAL SC, P756; GHEZ C, 1991, PRINCIPLES NEURAL SC, P653; Griffin L Y, 2000, J Am Acad Orthop Surg, V8, P141; Hamstra-Wright KL, 2006, CLIN J SPORT MED, V16, P56, DOI 10.1097/01.jsm.0000179232.10261.65; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; IVERSON GL, 2003, IMMEDIATE POST CONCU, P3; JOHANSSON H, 1991, CLIN ORTHOP RELAT R, V268, P161; Jones DG, 1996, AVIAT SPACE ENVIR MD, V67, P507; Kandell ER, 2000, PRINCIPLES NEURAL SC; Kirkendall DT, 2000, CLIN ORTHOP RELAT R, P64; Knapp CJ, 1996, AVIAT SPACE ENVIR MD, V67, P777; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; LANDERS DM, 1985, RES Q EXERCISE SPORT, V56, P122, DOI 10.1080/02701367.1985.10608446; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lum J, 2002, RES Q EXERCISE SPORT, V73, P156, DOI 10.1080/02701367.2002.10609004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McNair P J, 1999, J Sci Med Sport, V2, P86, DOI 10.1016/S1440-2440(99)80187-X; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Myklebust G, 1998, SCAND J MED SCI SPOR, V8, P149, DOI 10.1111/j.1600-0838.1998.tb00185.x; NIDEFFER RM, 1977, PERCEPT MOTOR SKILL, V45, P1291, DOI 10.2466/pms.1977.45.3f.1291; NOYES FR, 1983, J BONE JOINT SURG AM, V65, P154, DOI 10.2106/00004623-198365020-00003; O'Hare D, 1997, HUM FACTORS, V39, P540, DOI 10.1518/001872097778668004; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; Peters GA, 2001, J R SOC PROMO HEALTH, V121, P23, DOI 10.1177/146642400112100107; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; Swanik CB, 1997, J SPORT REHABIL, V6, P182, DOI 10.1123/jsr.6.2.182; Swanik CB, 1999, J ATHL TRAINING, V34, P121; TAIMELA S, 1990, PERCEPT MOTOR SKILL, V70, P155, DOI 10.2466/PMS.70.1.155-161; TAIMELA S, 1992, PERCEPT MOTOR SKILL, V75, P1075, DOI 10.2466/PMS.75.8.1075-1082; THOMPSON HW, 1995, NEUROREPORT, V6, P581, DOI 10.1097/00001756-199502000-00043; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; WEINBERG RS, 1979, J CLIN PSYCHOL, V35, P319, DOI 10.1002/1097-4679(197904)35:2<319::AID-JCLP2270350220>3.0.CO;2-3; Woo Eunice, 2003, Physiother Res Int, V8, P143, DOI 10.1002/pri.282	62	147	147	1	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2007	35	6					943	948		10.1177/0363546507299532			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	172KA	WOS:000246802000011	17369562				2022-02-06	
J	Marmarou, A; Lu, J; Butcher, I; McHugh, GS; Mushkudiani, NA; Murray, GD; Steyerberg, EW; Maas, AIR				Marmarou, Anthony; Lu, Juan; Butcher, Isabella; McHugh, Gillian S.; Mushkudiani, Nino A.; Murray, Gordon D.; Steyerberg, Ewout W.; Maas, Andrew I. R.			IMPACT database of traumatic brain injury: Design and description	JOURNAL OF NEUROTRAUMA			English	Article						coma; databank; head injury; IMPACT; traumatic brain injury	SEVERE HEAD-INJURY; CONJUGATED SUPEROXIDE-DISMUTASE; PLACEBO-CONTROLLED TRIAL; CLINICAL-TRIALS; MULTICENTER TRIAL; PRACTICAL SCALE; PEG-SOD; CONSORTIUM; EFFICACY; PEGORGOTEIN	The objective of this report is to describe the design and content of the International Mission for Prognosis And Clinical Trial (IMPACT) database of traumatic brain injury which contains the complete dataset from most clinical trials and organized epidemiologic studies conducted over the past 20 years. This effort, funded by the U.S. National Institutes of Health, has led to the accumulation thus far of data from 9205 patients with severe and moderate brain injuries from eight randomized placebo controlled trials and three observational studies. Data relevant to the design and analysis of pragmatic Phase III clinical trials, including pre-hospital, admission, and post-resuscitation assessments, information on the acute management, and short- and long-term outcome were merged into a top priority data set (TPDS). The major emphasis during the first phase of study is on information from time of injury to post-resuscitation and outcome at 6 months thereby providing a unique resource for prognostic analysis and for studies aimed at optimizing the design and analysis of Phase III trials in traumatic brain injury.	Virginia Commonwealth Univ, Sch Med, Dept Neurosurg, Richmond, VA USA; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands		Marmarou, A (corresponding author), Virginia Commonwealth Univ Hlth Syst, Dept Neurosurg, 1001 E Broad St,Suite 235, Richmond, VA 23219 USA.	Marmarou@hsc.vcu.edu	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122; Lu, Juan/0000-0002-5389-7603	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline		BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Beretta I, 2003, Minerva Anestesiol, V69, P223; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Braakman R, 1980, Ned Tijdschr Geneeskd, V124, P548; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Edwards P, 2005, LANCET, V365, P1957; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2004, ACT NEUR S, V89, P113; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 1996, ACT NEUR S, V66, P118; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marshall L F, 1988, Clin Neurosurg, V34, P549; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Muizelaar JP, 2001, HEAD TRAUMA, P417; MUIZELAAR JP, 1995, J NEUROSURG, V83, P942; MUIZELAAR JP, 1994, ADV EXP MED BIOL, V366, P389; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	33	147	150	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					239	250		10.1089/neu.2006.0036			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900003	17375988	Green Submitted			2022-02-06	
J	Clark, ME; Bair, MJ; Buckenmaier, CC; Gironda, RJ; Walker, RL				Clark, Michael E.; Bair, Matthew J.; Buckenmaier, Chester C., III; Gironda, Ronald J.; Walker, Robyn L.			Pain and combat injuries in soldiers returning from Operations Enduring Freedom and Iraqi Freedom: Implications for research and practice	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						acute pain; chronic pain; combat injuries; pain assessment; polytrauma; postacute pain; regional anesthesia; rehabilitation; trauma; traumatic brain injury	PERIPHERAL-NERVE BLOCK; NURSING-HOME RESIDENTS; LOW-BACK-PAIN; RISK-FACTORS; ANESTHESIA; EXPERIENCE; CARE; FEAR; MANAGEMENT; CASUALTIES	Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) have resulted in a growing number of seriously injured soldiers who are evacuated to the United States for comprehensive medical care. Trauma-related pain is an almost universal problem among these war-injured soldiers, and several military and Department of Veterans Affairs initiatives have been implemented to enhance pain care across the continuum of medical services. This article describes several innovative approaches for improving the pain care provided to OEF and OIF military personnel during acute stabilization, transport, medical-surgical treatment, and rehabilitation and presents summary data characterizing the soldiers, pain management services provided, and associated outcomes. We also identify some of the pain assessment, classification, and treatment challenges emerging from work with this population and provide recommendations for future research and practice priorities.	James A Haley Vet Hosp, Chron Pain Rehabil Program, Tampa, FL 33612 USA; Univ S Florida, Tampa, FL USA; Richard L Roudebush Dept Vet Affairs Med Ctr, Ctr Excellence Implementing Evidence Based Practi, Indianapolis, IN USA; Walter Reed Army Med Ctr, Dept Anesthesiol, Washington, DC 20307 USA		Clark, ME (corresponding author), James A Haley Vet Hosp, Chron Pain Rehabil Program, 2CW,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	michael.clark8@va.gov		Buckenmaier III, Chester/0000-0003-3623-5525			Almogy G, 2004, ANN SURG, V239, P295, DOI 10.1097/01.sla.0000114014.63423.55; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Barone F, 2005, REPROD BIOL ENDOCRIN, V3, P1, DOI 10.1186/1477-7827-3-13; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Bouillon B, 1998, LANGENBECK ARCH SURG, V383, P228, DOI 10.1007/s004230050123; BRAGANZA RJ, 2002, MANUAL PAIN MANAGEME, P231; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Buckenmaier CC, 2005, REGION ANESTH PAIN M, V30, P202, DOI 10.1016/j.rapm.2004.10.005; Buckenmaier CC, 2003, REGION ANESTH PAIN M, V28, P321, DOI 10.1016/S1098-7339(03)00198-6; Clark ME, 2004, PAIN MED, V5, P333, DOI 10.1111/j.1526-4637.2004.04059.x; Clark ME, 2006, WEINERS PAIN MANAGEM, P99; Closs SJ, 2004, J PAIN SYMPTOM MANAG, V27, P196, DOI 10.1016/j.jpainsymman.2003.12.010; Contreras-Diaz HG, 2006, CONSERV GENET, V7, P767, DOI 10.1007/s10592-005-9109-2; Crombez G, 1999, PAIN, V80, P329, DOI 10.1016/S0304-3959(98)00229-2; Davies Elizabeth, 2004, Nurs Stand, V19, P33; Dersh J, 2002, PSYCHOSOM MED, V64, P773, DOI 10.1097/01.PSY.0000024232.11538.54; Doan BK, 2005, AVIAT SPACE ENVIR MD, V76, pC34; EDWARDS W, 2001, BONICAS MANAGEMENT P, P788; Feldt K S, 1998, J Gerontol Nurs, V24, P14; Fritz JM, 2002, PHYS THER, V82, P973, DOI 10.1093/ptj/82.10.973; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Grant SA, 2001, REGION ANESTH PAIN M, V26, P209, DOI 10.1053/rapm.2001.22256; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; GREGORY J, 2004, J ORTHOPAEDIC NURSIN, V8, P91; Grissom Thomas E, 2005, Crit Care Med, V33, pS13, DOI 10.1097/01.CCM.0000151063.85112.5A; Hinsley DE, 2005, BRIT J SURG, V92, P637, DOI 10.1002/bjs.4911; International Association for the Study of Pain Subcommittee on Taxonomy, 1986, PAIN S, pS1, DOI DOI 10.1016/0304-3959(86)90106-5; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Klein SM, 2001, ANESTH ANALG, V93, P601, DOI 10.1097/00000539-200109000-00015; Kotwal RS, 2004, ANN EMERG MED, V44, P121, DOI 10.1016/j.annemergmed.2004.03.025; Machin P, 1998, CLIN J PAIN, V14, P290, DOI 10.1097/00002508-199812000-00004; Manz B D, 2000, Pain Manag Nurs, V1, P106, DOI 10.1053/jpmn.2000.19332; OSGOOD PF, 1990, ACUTE MANAGEMENT BUR, P201; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Peoples GE, 2005, MIL MED, V170, P451, DOI 10.7205/MILMED.170.6.451; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; *REH ACCR COMM, 2002, STAND MAN MED REH; Savoia G, 2005, CURR DRUG TARGETS, V6, P755, DOI 10.2174/138945005774574461; Shipton EA, 2005, EUR J ANAESTH, V22, P405, DOI 10.1017/S0265021505000694; Sondenaa K, 2001, EUR J SURG, V167, P125; Stojadinovic A, 2006, PAIN MED, V7, P330, DOI 10.1111/j.1526-4637.2006.00171.x; Stolee P, 2005, J AM GERIATR SOC, V53, P319, DOI 10.1111/j.1532-5415.2005.53121.x; Szycher M, 1986, J Biomater Appl, V1, P274, DOI 10.1177/088532828600100205; THOMPSON GE, 1967, J AMER MED ASSOC, V201, P215; TROUWBORST A, 1987, INJURY, V18, P96, DOI 10.1016/0020-1383(87)90181-1; Tsai Pao-Feng, 2006, J Nurs Manag, V14, P90, DOI 10.1111/j.1365-2934.2006.00560.x; Vadivelu N, 2005, CURR OPIN ANESTHESIO, V18, P540, DOI 10.1097/01.aco.0000183109.27297.75; *VET HLTH ADM, 2005, VHA HDB 3I, P3; Veterans Health Administration, 2005, VHA HDB 2A, P1; Vlaeyen JWS, 2002, CLIN J PAIN, V18, P251, DOI 10.1097/00002508-200207000-00006; Wu N, 2005, MED CARE, V43, P934, DOI 10.1097/01.mlr.0000173595.66356.12; Zieber CG, 2005, INT J PALLIAT NURS, V11, P71, DOI 10.12968/ijpn.2005.11.2.17673	55	147	150	0	13	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	2					179	193		10.1682/JRRD.2006.05.0057			15	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	176NJ	WOS:000247091700006	17551872	Bronze			2022-02-06	
J	Shaw, G; Yang, C; Ellis, R; Anderson, K; Mickle, JP; Scheff, S; Pike, B; Anderson, DK; Howland, DR				Shaw, G; Yang, C; Ellis, R; Anderson, K; Mickle, JP; Scheff, S; Pike, B; Anderson, DK; Howland, DR			Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						neurofilaments; NF-H; pNF-H; hyperphosphorylated NF-H; biomarker; traumatic brain injury; spinal cord injury; ELISA; axonal biomarker; asonal injury biomarker; neuronal cytoskeleton; neuronal injury biomarker	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; PHOSPHORYLATION STATE; CEREBROSPINAL-FLUID; CORTICAL CONTUSION; CYCLOSPORINE-A; HEAD-INJURY; PROTEINS; PROTEOLYSIS; CALPAIN	Several lines of reasoning suggest that the phosphorylated axonal form of the neurofilament subunit NF-H is likely to be released from damaged and diseased neurons in significant amounts. Detection of this protein in serum or CSF might therefore provide information about the presence and degree of neuronal loss. We therefore developed a sensitive NF-H ELISA capable of detecting picograrn quantities of phosphorylated NF-H (pNF-H). This assay showed that soluble pNF-H immunoreactivity is readily detectable in the sera of adult rats following various types of experimental spinal cord injury (SCI) and traumatic brain injury (TBI), but is undetectable in the sera of normal animals. Here we describe details of the time course and extent of serum pNF-H expression following experimental SO and TBI. Following SCI, serum pNF-H showed an initial peak of expression at 16 h and a second, usually larger, peak at 3 days. Following TBI, lower levels of serum pNF-H were detected with a peak at 2 days post-injury. We also show that the higher levels of pNF-H released from injured spinal cord as compared to brain are in line with the similar to 20-fold higher levels of pNF-H present in spinal cord. These findings suggest that serum levels of pNF-H immunoreactivity may be used to conveniently monitor neuronal damage and degeneration in experimental and presumably clinical situations. (c) 2005 Elsevier Inc. All rights reserved.	Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32611 USA; Univ Florida, Coll Med, McKnight Brain Inst, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Dept Physiol Sci, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Dept Neurosurg, Gainesville, FL 32611 USA; Malcolm Randall VAMC, Gainesville, FL USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; EnCor Biotechnol Inc, Alachua, FL 32615 USA		Shaw, G (corresponding author), Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32611 USA.	shaw@mbi.ufl.edu	, Gerry/X-2377-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER		Al-Chalabi A, 2003, BIOESSAYS, V25, P346, DOI 10.1002/bies.10251; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; DELACOURTE A, 1980, BIOCHEM J, V191, P543, DOI 10.1042/bj1910543; Evans J, 2002, J NEUROPHYSIOL, V87, P1076, DOI 10.1152/jn.00088.2001; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Harlow E, 1988, ANTIBODIES LAB MANUA; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; Hashimoto R, 1999, PSYCHIAT CLIN NEUROS, V53, P587, DOI 10.1046/j.1440-1819.1999.00610.x; Hu YY, 2002, NEUROSCI LETT, V320, P156, DOI 10.1016/S0304-3940(02)00047-2; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; JOHNSON GVW, 1991, NEUROCHEM RES, V16, P869, DOI 10.1007/BF00965535; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Loomans EEMG, 2003, ASSAY DRUG DEV TECHN, V1, P445, DOI 10.1089/154065803322163759; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Petzold A, 2004, J NEUROL NEUROSUR PS, V75, P1178, DOI 10.1136/jnnp.2003.017236; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; POLSON A, 1990, IMMUNOL INVEST, V19, P253; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; Shaw G, 2004, BIOCHEM BIOPH RES CO, V325, P619, DOI 10.1016/j.bbrc.2004.09.223; SHAW G, 1984, EUR J CELL BIOL, V34, P130; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Togo T, 2002, ACTA NEUROPATHOL, V104, P398, DOI 10.1007/s00401-002-0569-x; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	41	147	160	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X			BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	NOV 4	2005	336	4					1268	1277		10.1016/j.bbrc.2005.08.252			10	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	973IJ	WOS:000232515800039	16176808				2022-02-06	
J	Teasdale, GM; Murray, GD; Nicoll, JAR				Teasdale, GM; Murray, GD; Nicoll, JAR			The association between APOE epsilon 4, age and outcome after head injury: a prospective cohort study	BRAIN			English	Article						head injury; traumatic brain injury; genetics; outcome; apolipoprotein E	APOLIPOPROTEIN-E GENOTYPE; TRAUMATIC BRAIN-INJURY; E POLYMORPHISM; SUBARACHNOID HEMORRHAGE; RECOVERY; ALLELE; RISK; DAMAGE; MODEL; E3	Previous preliminary studies have suggested that possession of the APOE epsilon 4 allele is associated with a poor outcome after head injury. This study was designed to confirm and extend those observations in a larger study with examination of additional variables. We prospectively identified admissions to a Neurosurgical Unit for head injury, collected demographic and clinical data, determined APOE genotypes and obtained follow-up information at 6 months. A total of 1094 subjects were enrolled (age range: 0-93 years, mean 37 years). Outcome was assessed using the Glasgow Outcome Scale. There was no overall association between APOE genotype and outcome, with 36% of APOE epsilon 4 carriers having an unfavourable outcome compared with 33% of non-carriers of APOE epsilon 4. However, there was evidence of an interaction between age and APOE genotype on outcome (P = 0.007) such that possession of APOE epsilon 4 reduced the prospect of a favourable outcome in children and young adults. The influence of APOE genotype in younger patients after head injury can be expressed as, at age < 15 years, carriage of APOE epsilon 4 being equivalent to ageing by 25 years. This finding is consistent with experimental data suggesting that the effect of APOE genotype on outcome after head injury may be expressed through the processes of repair and recovery.	Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow, Lanark, Scotland; Univ Edinburgh, Sch Med, Div Community Hlth Sci, Edinburgh, Midlothian, Scotland		Nicoll, JAR (corresponding author), Univ Southampton, Southampton Gen Hosp, Level E,Mailpoint 813, Southampton SO16 6YD, Hants, England.	J.Nicoll@soton.ac.uk	; Nicoll, James/I-9253-2017	Murray, Gordon/0000-0001-9866-4734; Nicoll, James/0000-0002-9444-7246			Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CUMMING AM, 1984, CLIN GENET, V25, P310; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Dunn LT, 2001, NEUROSURGERY, V48, P1006, DOI 10.1097/00006123-200105000-00007; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GRADY MS, 1989, J NEUROSURG, V71, P534, DOI 10.3171/jns.1989.71.4.0534; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; JENNETT B, 1975, LANCET, V1, P480; Jorm AF, 2003, PSYCHOSOM MED, V65, P662, DOI 10.1097/01.PSY.0000077506.29218.60; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kay AD, 2003, J NEUROTRAUM, V20, P243, DOI 10.1089/089771503321532824; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Leung CHS, 2002, STROKE, V33, P548, DOI 10.1161/hs0202.102326; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Quinn TJ, 2004, NEUROPATH APPL NEURO, V30, P569, DOI 10.1111/j.1365-2990.2004.00581.x; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tang J, 2003, SURG NEUROL, V60, P391, DOI 10.1016/S0090-3019(03)00323-9; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Turic D, 2001, NEUROSCI LETT, V299, P97, DOI 10.1016/S0304-3940(00)01789-4; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	44	147	152	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2005	128		11				2556	2561		10.1093/brain/awh595			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980UV	WOS:000233044600008	16033781				2022-02-06	
J	Diskin, T; Tal-Or, P; Erlich, S; Mizrachy, L; Alexandrovich, A; Shohami, E; Pinkas-Kramarski, R				Diskin, T; Tal-Or, P; Erlich, S; Mizrachy, L; Alexandrovich, A; Shohami, E; Pinkas-Kramarski, R			Closed head injury induces upregulation of Beclin 1 at the cortical site of injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; autophagy; Beclin 1; brain; neurons; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CELL-DEATH; AUTOPHAGY; EXPRESSION; RECEPTOR; MICE; TUMORIGENESIS; INHIBITION; MICROGLIA; PROTEIN	Autophagy, a bulk degradation of subcellular constituents, is activated in several neurodegenerative conditions. Beclin 1, a Bcl2 interacting protein, was found to promote autophagy. The closed head injury model was used to investigate the possible role of autophagy and Beclin I after traumatic brain injury. It is demonstrated that levels of Beclin-1 are dramatically increased near the site of injury. Neurons constitute the major population of cells, with the highest Beclin 1 levels near the site of injury at early stages post injury. Elevated levels of Beclin 1 protein in neurons last for at least 3 weeks. In addition, Beclin-1 expression after injury is elevated also in astrocytes starting at 3 days after injury. Confocal microscopy analysis suggests that the high levels of Beclin 1 protein in astrocytes is confined to subcellular organelles, probably lysosomes or autophagosomes. Double staining of Beclin 1 and TUNEL indicate that most of the injured cells that exhibit double staining are neurons and not astrocytes. These findings show that Beclin 1 may play a role in brain responses to head trauma. Overexpression of Beclin 1 may be important for autophagy at the lesion site and may serve as a mechanism to discard injured cells and reduce damage to cells by disposing of injured components.	Tel Aviv Univ, Dept Neurobiochem, Ramat Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, IL-91010 Jerusalem, Israel		Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiochem, Ramat Aviv, Israel.	lironit@post.tau.ac.il		Pinkas-Kramarski, Ronit/0000-0002-1000-369X; Hoffmann, Tali/0000-0002-8893-3520			Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; AKIYAMA H, 1994, BRAIN RES, V635, P257, DOI 10.1016/0006-8993(94)91447-8; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Eilam R, 1998, P NATL ACAD SCI USA, V95, P1888, DOI 10.1073/pnas.95.4.1888; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Levi O, 2003, NEUROBIOL DIS, V13, P273, DOI 10.1016/S0969-9961(03)00045-7; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	27	147	157	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					750	762		10.1089/neu.2005.22.750			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800003	16004578				2022-02-06	
J	Lee, JB; Kuroda, S; Shichinohe, H; Ikeda, J; Seki, T; Hida, K; Tada, M; Sawada, K; Iwasaki, Y				Lee, JB; Kuroda, S; Shichinohe, H; Ikeda, J; Seki, T; Hida, K; Tada, M; Sawada, K; Iwasaki, Y			Migration and differentiation of nuclear fluorescence-labeled bone marrow stromal cells after transplantation into cerebral infarct and spinal cord injury in mice	NEUROPATHOLOGY			English	Article						bis-benzimide; bone marrow stromal cells; cerebral infarct; mice; spinal cord injury; transplantation	TRAUMATIC BRAIN INJURY; INTRACEREBRAL TRANSPLANTATION; THERAPEUTIC BENEFIT; ADULT-RAT; MODEL; ISCHEMIA; STROKE; ENGRAFTMENT; EXPRESSION; NEURONS	There is increasing evidence that bone marrow stromal cells (BMSC) have the potential to migrate into the injured neural tissue and to differentiate into the CNS cells, indicating the possibility of autograft transplantation therapy. The present study was aimed to clarify whether the mouse BMSC can migrate into the lesion and differentiate into the CNS cells when transplanted into the mice subjected to focal cerebral infarct or spinal cord injury. The BMSC were harvested from mice and characterized by flow cytometry. Then, the BMSC were labeled by bis-benzimide, a nuclear fluorescence dye, over 24 h, and were stereotactically transplanted into the brain or spinal cord of the mice. The cultured BMSC expressed low levels of CD45 and high levels of CD90 and Sca-1 on flow cytometry. A large number of grafted cells survived in the normal brain 4 weeks after transplantation, many of which were located close to the transplanted sites. They expressed the neuronal marker including NeuN, MAP2, and doublecortin on fluorescent immunohistochemistry. However, when the BMSC were transplanted into the ipsilateral striatum of the mice subjected to middle cerebral artery occlusion, many of the grafted cells migrated into the corpus callosum and injured cortex, and also expressed the neuronal markers 4 weeks after transplantation. In particular, NeuN was very useful to validate the differentiation of the grafted cells, because the marker was expressed in the nuclei and was overlapped with bis-benzimide. Similar results were obtained in the mice subjected to spinal cord injury. However, many of the transplanted BMSC expressed GFAP, an astrocytic protein, in injured spinal cord. The present results indicate that the mouse BMSC can migrate into the CNS lesion and differentiate into the neurons or astrocytes, and that bisbenzimide is a simple and useful marker to label the donor cells and to evaluate their migration and differentiation in the host neural tissues over a long period.	Hokkaido Univ, Dept Neurosurg, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Div Canc Genes, Inst Med Genet, Sapporo, Hokkaido, Japan; Akita Univ, Sch Med, Dept Internal Med 3, Akita 010, Japan		Kuroda, S (corresponding author), Hokkaido Univ, Dept Neurosurg, Grad Sch Med, Kita Ku, North 15 West 7, Sapporo, Hokkaido 0608638, Japan.	skuroda@med.hokudai.ac.jp	Shichinohe, Hideo/G-5367-2012				Akiyama Y, 2002, J NEUROSCI, V22, P6623; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; CRISSMAN HA, 1987, EXP CELL RES, V173, P256, DOI 10.1016/0014-4827(87)90350-8; Dunnett SB, 2001, NAT REV NEUROSCI, V2, P365, DOI 10.1038/35072572; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Ikeda J, 2001, INT J CANCER, V94, P35, DOI 10.1002/ijc.1431; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Majid A, 2000, STROKE, V31, P2707, DOI 10.1161/01.STR.31.11.2707; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Schwarz EJ, 1999, HUM GENE THER, V10, P2539, DOI 10.1089/10430349950016870; Seki T, 2002, NEUROSURGERY, V50, P1075, DOI 10.1097/00006123-200205000-00024; SHICHINOHE H, 2003, IN PRESS J CEREB BLO, V23; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C	30	147	179	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	SEP	2003	23	3					169	180		10.1046/j.1440-1789.2003.00496.x			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	719ER	WOS:000185191100003	14570283				2022-02-06	
J	Mahmood, A; Lu, DY; Wang, L; Chopp, M				Mahmood, A; Lu, DY; Wang, L; Chopp, M			Intracerebral transplantation of marrow stromal cells cultured with neurotrophic factors promotes functional recovery in adult rats subjected to traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						bone marrow stromal cells; neurotrophic factors; stem cells; transplantation; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; BONE-MARROW; STEM-CELLS; OSTEOGENESIS IMPERFECTA; PROGENITOR CELLS; NEURONS; GROWTH; BDNF; HIPPOCAMPUS; EXPRESSION	This study was designed to examine the effects of bone marrow stromal cells (MSCs) cultured in vitro with or without neurotrophic factors transplanted into adult male Wistar rats after traumatic brain injury (TBI). MSCs harvested from donor Wistar rats were cultured with either the culture medium containing brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) or the same culture media without these factors. Control and experimental animals were then traumatized by a controlled cortical impact. One day after the impact, either the placebo or the washed MSCs (1 X 10(6)) cultured with or without NGF and BDNF were transplanted adjacent to the site of injury. In addition, a nontreated group of rats was employed. Motor function of the animals was evaluated by the Rotarod test both before and after the injury. All animals were sacrificed 8 days after TBI, and the brain sections were stained by H&E as well as for immunohistochemistry. MSCs survived and migrated toward the injury site. The group treated with MSCs cultured with BDNF and NGF had a significantly higher number of engrafted cells than the group treated with MSCs cultured without BDNF and NGF (6.3 X 10(4) +/- 4,250 compared to 4.1 X 10(4) +/- 3,684; p < 0.05). In both groups, some transplanted MSCs showed positive staining for astrocytic (GFAP) and neuronal markers (Neu N and MAP-2). The groups treated with MSCs had better motor function than the groups receiving no treatment or receiving the placebo (PBS; p < 0.05); however, the improvement reached statistical significance only in the group treated with MSCs cultured with neurotrophic factors. These data suggest that more robust motor function described in rats subjected to TBI and treated with intracerebral transplantation of MSCs was achieved by the use of MSCs cultured with neurotrophic factors.	Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA		Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu					Andsberg G, 1998, EUR J NEUROSCI, V10, P2026, DOI 10.1046/j.1460-9568.1998.00214.x; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Borlongan CV, 1996, NEUROL RES, V18, P297; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DAVIES AM, 1991, INT REV CYTOL, V128, P109; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EAVES CJ, 1991, BLOOD, V78, P110; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Houweling DA, 1998, NEUROSCI LETT, V251, P193, DOI 10.1016/S0304-3940(98)00536-9; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; KORSCHING S, 1986, NEUROSCI LETT, V66, P175, DOI 10.1016/0304-3940(86)90186-2; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; Liu Y, 1999, J NEUROSCI, V19, P4370; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Ostergaard K, 1996, EXP NEUROL, V142, P340, DOI 10.1006/exnr.1996.0203; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PECHAN PA, 1995, NEUROREPORT, V6, P669, DOI 10.1097/00001756-199503000-00021; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; Postmantur R., 1997, NEUROSCIENCE, V77, P765; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RUSSELL RW, 1994, BEHAV NEURAL BIOL, V61, P81, DOI 10.1016/S0163-1047(05)80047-0; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SUTHERLAND DR, 1993, STEM CELLS, V11, P50, DOI 10.1002/stem.5530110914; WALKLEY SU, 1994, P NATL ACAD SCI USA, V91, P2970, DOI 10.1073/pnas.91.8.2970; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011	42	147	169	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1609	1617		10.1089/089771502762300265			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700008	12542861				2022-02-06	
J	Bellander, BM; Singhrao, SK; Ohlsson, M; Mattsson, P; Svensson, M				Bellander, BM; Singhrao, SK; Ohlsson, M; Mattsson, P; Svensson, M			Complement activation in the human brain after traumatic head injury	JOURNAL OF NEUROTRAUMA			English	Article						complement; human; traumatic brain injury	MEMBRANE ATTACK COMPLEX; PERIPHERAL-NERVE INJURY; SPINAL-CORD INJURY; SULFATED GLYCOPROTEIN-2; RAT-BRAIN; ADULT-RAT; CEREBROSPINAL-FLUID; CONTROLLED TRIAL; AMINO-ACIDS; FACTOR-B	The complement cascade has been suggested to be involved in the development of secondary brain injuries following brain contusions, based on animal experiments. The aim of the present study was to examine the possible involvement of the complement cascade following traumatic head injury in the human brain. Sixteen patients were included in this study, 12-77 years of age, treated at the neurointensive care unit for traumatic brain contusions. All of these patients were operated with frontal or temporal lobe resection due to intractable intracranial hypertension. The resected tissue was analyzed with regard to components related to complement activation. The time interval between accident and operation was 2-82 h. Brain tissue from three patients operated with hippocampectomy due to epilepsy, including temporal lobe resection, were used as controls. We found increased immunoreactivity for complement components C1q, C3b, and C3d and the membrane attack complex (MAC), C5b-9, in the immediate vicinity of neurons in the penumbra area of the contusion. These findings constitute histological evidence for activation of the complement cascade in the penumbra of cortical contusions in the human brain. Using in situ hybridization, we also found C3-mRNA in the penumbra, suggesting a local synthesis of complement. Furthermore, upregulation of the endogenous complement regulator clusterin was found in some neurons in the same area. We suggest that unknown compounds in the debris from injured neurons or myelin breakdown products trigger complement activation, including formation of C5b-9. Activated complement components may stimulate accumulation of inflammatory cells and formation of brain edema, as well as having membrane destructive effects by the end product MAC, thereby being mediators in the development of secondary brain damage.	Karolinska Hosp, Neurosurg Sect, Dept Clin Neurosci, S-10401 Stockholm, Sweden; Univ Wales Coll Cardiff, Coll Med, Dept Med Biochem, Cardiff CF1 3NS, S Glam, Wales		Bellander, BM (corresponding author), Karolinska Hosp, Neurosurg Sect, Dept Clin Neurosci, S-10401 Stockholm, Sweden.		Ohlsson, Marcus R/H-1395-2011; Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003			AGOSTONI A, 1992, INT J IMMUNOPATH PH, V5, P123, DOI 10.1177/039463209200500207; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BECKER P, 1987, ANAESTHESIST, V36, P301; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; Blumbergs PC, 1997, HEAD INJURY PATHOPHY, P39; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BRUCK W, 1991, J NEUROL SCI, V103, P182, DOI 10.1016/0022-510X(91)90162-Z; CAMPBELL AK, 1981, BIOCHEM J, V194, P551, DOI 10.1042/bj1940551; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DAY JR, 1990, MOL ENDOCRINOL, V4, P1995, DOI 10.1210/mend-4-12-1995; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FADEN AI, 1989, SCIENCE, V244, P790; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Gasque P, 1996, J NEUROIMMUNOL, V66, P29, DOI 10.1016/0165-5728(96)00015-X; GASQUE P, 1993, J BIOL CHEM, V268, P25068; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1993, HEAD INJURY, P91; HANSCH GM, 1992, IMMUNOPHARMACOLOGY, V24, P107, DOI 10.1016/0162-3109(92)90017-7; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KOSSMANN T, 1993, CIRC SHOCK S, V2, P62; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LACHMANN PJ, 1991, IMMUNOL TODAY, V12, P312, DOI 10.1016/0167-5699(91)90005-E; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361; LINDSTROM RL, 1991, CURR OPIN OPHTHALMOL, V2, P1, DOI 10.1097/00055735-199102000-00001; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Mattsson P, 1998, J NEUROIMMUNOL, V91, P180, DOI 10.1016/S0165-5728(98)00178-7; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCNEILL T H, 1990, Society for Neuroscience Abstracts, V16, P1291; MICHEL D, 1992, SYNAPSE, V11, P105, DOI 10.1002/syn.890110203; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; Morgan BP, 1990, COMPLEMENT CLIN ASPE; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKUSAWA S, 1987, J IMMUNOL, V139, P2635; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; REBHUN J, 1991, ANN ALLERGY, V66, P335; ROSEN H, 1990, J LEUKOCYTE BIOL, V48, P465, DOI 10.1002/jlb.48.5.465; ROSS GD, 1985, ADV IMMUNOL, V37, P217, DOI 10.1016/S0065-2776(08)60341-7; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Soares HD, 1995, J NEUROSCI, V15, P8223; STOLL G, 1991, ANN NEUROL, V30, P147, DOI 10.1002/ana.410300205; SVENSSON M, 1995, MOL CHEM NEUROPATHOL, V24, P53, DOI 10.1007/BF03160112; SVENSSON M, 1992, J NEUROIMMUNOL, V40, P99, DOI 10.1016/0165-5728(92)90217-9; Takayama A, 1996, PHYS PLASMAS, V3, P3, DOI 10.1063/1.871832; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; VANGURI P, 1988, J BIOL CHEM, V263, P7228; Volanakis JE., 1998, HUMAN COMPLEMENT SYS; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	90	147	151	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2001	18	12					1295	1311		10.1089/08977150152725605			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	504RE	WOS:000172869000001	11780861				2022-02-06	
J	Sullivan, PG; Thompson, M; Scheff, SW				Sullivan, PG; Thompson, M; Scheff, SW			Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						trauma; cortical contusion; immunosuppressant	CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL PERMEABILITY TRANSITION; TRANSIENT FOREBRAIN ISCHEMIA; RAT HIPPOCAMPAL-NEURONS; EXCITATORY AMINO-ACIDS; REACTIVE OXYGEN; RECEPTOR ACTIVATION; CA2+ HOMEOSTASIS; INNER MEMBRANE; NMDA RECEPTOR	Traumatic brain injury (TBI) results in the rapid necrosis of cortical tissue at the site of injury. In the ensuing hours and days, secondary injury exacerbates the original damage resulting in significant neurological dysfunction. Recent reports from our lab demonstrate that a bolus injection of the immunosuppressant cyclosporin A (CsA) is neuroprotective following TBI. CsA transiently inhibits the opening of the mitochondrial permeability transition pore and maintains calcium homeostasis in isolated mitochondria. The present study utilized a unilateral controlled cortical impact model of TBI to assess whether the neuroprotective effects of CsA could be extended by chronic infusion. Adult rats were subjected to a moderate (2 mm) cortical deformation and the extent of cortical damage was assessed using modern stereological techniques. Animals were administrated a 20 mg/kg intraperitoneal bolus of CsA or vehicle 15 min postinjury and osmotic minipumps were implanted subcutaneously to deliver CsA (4.5 or 10 mg/kg/day) or vehicle. All animals receiving CsA demonstrated a significant reduction in lesion volume, with the highest dose offering the most neuroprotection (74% reduction in lesion volume). These results extend our previous findings and demonstrate that chronic infusion of CsA is neuroprotective following TBI. These findings also suggest that the mechanisms responsible for tissue necrosis following TBI are amenable to manipulation. (C) 2000 Academic Press.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Sullivan, PG (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER		ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BERDEN JHM, 1985, LANCET, V1, P219; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Camins A, 1997, BRAIN RES, V777, P69, DOI 10.1016/S0006-8993(97)00947-5; Choi D W, 1990, Adv Exp Med Biol, V268, P501; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; Dessi F, 1995, NEUROSCI LETT, V201, P53, DOI 10.1016/0304-3940(95)12128-Q; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; DUGAN LL, 1995, J NEUROSCI, V15, P6377; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; ISAEV NK, 1995, B EXP BIOL MED+, V119, P365, DOI 10.1007/BF02445894; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KRAUS JF, 1996, NEUROTRAUMA, P12; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; NICHOLLS DG, 1985, PROG BRAIN RES, V63, P97; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PATCHELL RA, 1994, ANN NEUROL, V36, P688, DOI 10.1002/ana.410360503; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Prehn JHM, 1998, N-S ARCH PHARMACOL, V357, P316, DOI 10.1007/PL00005173; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Richter C, 1997, BIOSCIENCE REP, V17, P53, DOI 10.1023/A:1027387301845; Scanlon JM, 1998, J NEUROCHEM, V71, P2392; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Sriram K, 1998, J NEUROSCI, V18, P10287; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sureda FX, 1996, N-S ARCH PHARMACOL, V354, P420, DOI 10.1007/BF00168431; SZABO I, 1991, J BIOL CHEM, V266, P3376; TAPPEL AL, 1973, FED PROC, V32, P1870; THAYER SA, 1995, CLIN EXP PHARMACOL P, V22, P303, DOI 10.1111/j.1440-1681.1995.tb02004.x; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; White RJ, 1996, J NEUROSCI, V16, P5688; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812	75	147	150	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2000	161	2					631	637		10.1006/exnr.1999.7282			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	290FW	WOS:000085666500018	10686082				2022-02-06	
J	Ross, BD; Ernst, T; Kreis, R; Haseler, LJ; Bayer, S; Danielsen, E; Bluml, S; Shonk, T; Mandigo, JC; Caton, W; Clark, C; Jensen, SW; Lehman, NL; Arcinue, E; Pudenz, R; Shelden, CH				Ross, BD; Ernst, T; Kreis, R; Haseler, LJ; Bayer, S; Danielsen, E; Bluml, S; Shonk, T; Mandigo, JC; Caton, W; Clark, C; Jensen, SW; Lehman, NL; Arcinue, E; Pudenz, R; Shelden, CH			H-1 MRS in acute traumatic brain injury	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						MR spectroscopy; blunt head trauma; diffuse axonal injury; N-acetylaspartate; lactate; prognosis	MAGNETIC-RESONANCE SPECTROSCOPY; ABSOLUTE QUANTITATION; HEAD-INJURY; ENCEPHALOPATHY; METABOLITES; OSMOLYTES; WATER	The objective of this study was to demonstrate H-1 MR spectroscopy (MRS) changes in cerebral metabolites after acute head trauma, Twenty-five patients (12 children, 13 adults) were examined with quantitative H-1 MRS after closed head injury. Clinical grade (Glasgow Coma Scale [GCS]) and outcome (Rancho Los Amigos Medical Center Outcome Score [ROS]) were correlated with quantitative neurochemical findings. N-acetylaspartate (NAA), a neuronal and axonal marker, was reduced (P <.03-.001). In children, a reduced NAA/creatine plus phosphocreatine (Cr) level and the presence of detectable lipid/lactate predicted bad outcome (sensitivity, 89%; specificity, 89%). The first MRS examination of all patients correlated with ROS versus NAA (r =.65, P <.0001). Although most patients showed MRS abnormalities, striking heterogeneity of H-1 MRS characterized the individual patients. IH MRS identifies multiple patterns of diffuse brain injury after blunt head trauma. There was a strong correlation between MRS and outcome. Future prospective studies will be needed to determine the clinical usefulness of MRS in predicting outcome from closed head injury.	Huntington Med Res Inst, Pasadena, CA 91105 USA		Ross, BD (corresponding author), Huntington Med Res Inst, 660 S Fair Oaks Ave, Pasadena, CA 91105 USA.		Lehman, Norman L/A-7351-2015; Kreis, Roland/F-2550-2010	Kreis, Roland/0000-0002-8618-6875; Lehman, Norman/0000-0001-8394-2607; Bluml, Stefan/0000-0003-2124-797X; Haseler, Luke/0000-0003-1607-4402			Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Altman D.G., 1990, PRACTICAL STAT MED R; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; DANIELSEN ER, 1995, J MAGN RESON SER B, V106, P287, DOI 10.1006/jmrb.1995.1046; DUNCAN P, 1990, REHABILITATION ADULT, P265; ERNST T, 1993, J MAGN RESON SER B, V102, P1, DOI 10.1006/jmrb.1993.1055; Ernst T, 1993, P 12 ANN SCI M SOC M, V1, P323; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; HASELER LJ, 1995, P 3 SOC MAGNETIC RES, V1, P381; HAUSSINGER D, 1994, GASTROENTEROLOGY, V107, P1475; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; KREIS R, 1992, P SMRM, P237; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; ROSS B, 1994, MAGN RESON QUART, V10, P191; Ross Brian D., 1995, V134, P279; STRICH SJ, 1961, LANCET, V2, P443; TEASDALE G, 1974, LANCET, V2, P81; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058	23	147	156	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	JUL-AUG	1998	8	4					829	840		10.1002/jmri.1880080412			12	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	193NU	WOS:000080143600011	9702884				2022-02-06	
J	Gulliver, A; Griffiths, KM; Mackinnon, A; Batterham, PJ; Stanimirovic, R				Gulliver, Amelia; Griffiths, Kathleen M.; Mackinnon, Andrew; Batterham, Philip J.; Stanimirovic, Rosanna			The mental health of Australian elite athletes	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Athletes; Mental Disorders; Prevalence	EATING-DISORDERS; DEPRESSION; SYMPTOMS; PREVALENCE; SPORT; CONCUSSION; PREDICTORS; STUDENTS; RISK	Objectives: Currently, little is known about the prevalence of mental disorders in athletes. This study aims to investigate Australian elite athletes' symptoms of general psychological distress and common mental disorders. Design: A cross-sectional survey design was employed to assess self-reported symptom prevalence. Methods: A total of 224 elite athletes (118 female, 106 male) from national sporting organisations in Australia were administered a self-report internet-based survey comprising measures of demographic status and mental health symptoms. Results: Overall, 46.4% of athletes were experiencing symptoms of at least one of the mental health problems assessed. Percentages meeting criteria for mental disorders were similar to previous epidemiological studies of both international athlete and community samples: depression (27.2%), eating disorder (22.8%), general psychological distress (16.5%), social anxiety (14.7%), generalised anxiety disorder (7.1%), and panic disorder (4.5%). Injured athletes had higher levels of both symptoms of depression (t = 3.23, p = .001) and generalised anxiety disorder (t = 2.26, p = .025). Conclusions: The level of symptoms of mental health problems reported by elite athletes appears similar to that observed in the community. However, caution must be exercised in interpreting the findings, as possible demographic differences between athletes and comparison population datasets may exist. Furthermore, self-selection of respondents in the present study may have reduced the representativeness of the sample and the validity of the comparisons. Athletes, particularly those currently injured, should be well-supported to seek help for mental disorders through access to mental health professionals. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Gulliver, Amelia; Griffiths, Kathleen M.; Batterham, Philip J.] Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia; [Mackinnon, Andrew] Univ Melbourne, Orygen Youth Hlth Res Ctr, Melbourne, Vic 3010, Australia; [Stanimirovic, Rosanna] Mental Edge Consulting, Melbourne, Vic, Australia		Gulliver, A (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia.	Amelia.Gulliver@anu.edu.au	Zamora, Cristina Cuesta/E-2864-2016	Zamora, Cristina Cuesta/0000-0003-1121-9561; Mackinnon, Andrew/0000-0003-0831-9801; Batterham, Philip/0000-0002-4547-6876	Australian Institute of Sport (AIS); AIS; Brain and Mind Research Institute; Orygen; Australian National UniversityAustralian National University; National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [525413]; NHMRCNational Health and Medical Research Council of Australia [1035262]	We wish to thank Helen Christensen for her contributions to the design and management of this project and assistance with the composition of this paper, and Alison Parsons for trial management. The study was supported by funding from the Australian Institute of Sport (AIS). AG was supported by a joint scholarship from the AIS, the Brain and Mind Research Institute, Orygen, and The Australian National University without which this research could not be possible. KG is supported by National Health and Medical Research Council (NHMRC) Senior Research Fellowship No. 525413. PB is supported by NHMRC Early Career Fellowship 1035262. The AIS provided the funding for the present study and assisted with recruitment but was not involved in the analysis, interpretation or the right to approve or disapprove publication of the research.	A.B.o. Statistics, 2007, NAT SURV MENT HLTH W; Andrews G, 2007, LANCET, V370, P808, DOI 10.1016/S0140-6736(07)61393-2; Appaneal RN, 2009, J SPORT EXERCISE PSY, V31, P60, DOI 10.1123/jsep.31.1.60; Australian Bureau of Statistics, 2012, AUSTR HLTH SURV 1 RE; Bar KJ, 2013, EUR ARCH PSY CLIN N, V263, pS205, DOI 10.1007/s00406-013-0458-4; Baum AL, 2005, CLIN SPORT MED, V24, P853, DOI 10.1016/j.csm.2005.06.006; Bruner MW, 2008, J APPL SPORT PSYCHOL, V20, P236, DOI 10.1080/10413200701867745; Costin DL, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1294; Eisenberg D, 2011, J AM COLL HEALTH, V59, P700, DOI 10.1080/07448481.2010.546461; Gulliver A, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-157; Gulliver Amelia, 2012, J Med Internet Res, V14, pe69, DOI 10.2196/jmir.1864; Herman S, 2011, J AM COLL HEALTH, V59, P715, DOI 10.1080/07448481.2010.529625; Hill LS, 2010, INT J EAT DISORDER, V43, P344, DOI 10.1002/eat.20679; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Ivarsson A, 2013, J SPORT REHABIL, V22, P19, DOI 10.1123/jsr.22.1.19; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Memon Akhtar Amin, 2012, BMC Res Notes, V5, P84, DOI 10.1186/1756-0500-5-84; Mummery K, 2005, LANCET, V366, pS36, DOI 10.1016/S0140-6736(05)67840-3; Nattiv A, 1997, CLIN J SPORT MED, V7, P262, DOI 10.1097/00042752-199710000-00004; Noblet A, 2003, J APPL SPORT PSYCHOL, V15, P184, DOI 10.1080/10413200305394; RADLOFF LS, 1991, J YOUTH ADOLESCENCE, V20, P149, DOI 10.1007/BF01537606; Reardon CL, 2010, SPORTS MED, V40, P961, DOI 10.2165/11536580-000000000-00000; Schaal K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019007; Stanton R, 2014, J SCI MED SPORT, V17, P177, DOI 10.1016/j.jsams.2013.03.010; Sundgot-Borgen J, 2004, CLIN J SPORT MED, V14, P25, DOI 10.1097/00042752-200401000-00005; SUNDGOTBORGEN J, 1994, MED SCI SPORT EXER, V26, P414; Wilson CJ, 2007, CLIN PSYCHOL, V11, P98, DOI DOI 10.1080/13284200701870954; Wilson IG, 2005, AUST FAM PHYS, V34; Yang JZ, 2007, CLIN J SPORT MED, V17, P481, DOI 10.1097/JSM.0b013e31815aed6b; Yang JZ, 2014, RES SPORTS MED, V22, P147, DOI 10.1080/15438627.2014.881818	30	146	150	8	86	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAY	2015	18	3					255	261		10.1016/j.jsams.2014.04.006			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	CH4MS	WOS:000354008200005	24882147				2022-02-06	
J	Rogatzki, MJ; Ferguson, BS; Goodwin, ML; Gladden, LB				Rogatzki, Matthew J.; Ferguson, Brian S.; Goodwin, Matthew L.; Gladden, L. Bruce			Lactate is always the end product of glycolysis	FRONTIERS IN NEUROSCIENCE			English	Article						aerobic; anaerobic; lactate dehydrogenase; mitochondria; NADH; pyruvate; cytosolic lactate shuttle	TRAUMATIC BRAIN-INJURY; HUMAN SKELETAL-MUSCLE; LACTIC-ACID; PGC-1-ALPHA CONTROLS; INTRACELLULAR PO-2; METABOLISM; EXERCISE; TUMOR; DEHYDROGENASE; CELLS	Through much of the history of metabolism, lactate (La-) has been considered merely a dead-end waste product during periods of dysoxia. Congruently, the end product of glycolysis has been viewed dichotomously: pyruvate in the presence of adequate oxygenation, La- in the absence of adequate oxygenation. In contrast, given the near-equilibrium nature of the lactate dehydrogenase (LDH) reaction and that LDH has a much higher activity than the putative regulatory enzymes of the glycolytic and oxidative pathways, we contend that La- is always the end product of glycolysis. Cellular La- accumulation, as opposed to flux, is dependent on (1) the rate of glycolysis, (2) oxidative enzyme activity, (3) cellular O-2 level, and (4) the net rate of La- transport into (influx) or out of (efflux) the cell. For intracellular metabolism, we reintroduce the Cytosol-to-Mitochondria Lactate Shuttle. Our proposition, analogous to the phosphocreatine shuttle, purports that pyruvate, NAD(+), NADH, and La- are held uniformly near equilibrium throughout the cell cytosol due to the high activity of LDH. La- is always the end product of glycolysis and represents the primary diffusing species capable of spatially linking glycolysis to oxidative phosphorylation.	[Rogatzki, Matthew J.] Univ Wisconsin Platteville, Dept Hlth & Human Performance, Platteville, WI USA; [Ferguson, Brian S.] Univ Missouri, Dept Biomed Sci, Columbia, MO USA; [Goodwin, Matthew L.] Univ Utah, Dept Orthopaed, Salt Lake City, UT USA; [Goodwin, Matthew L.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Gladden, L. Bruce] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA		Gladden, LB (corresponding author), Auburn Univ, Sch Kinesiol, 301 Wire Rd, Auburn, AL 36849 USA.	gladdlb@auburn.edu					Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; BALINSKY D, 1984, J NATL CANCER I, V72, P217; Barnett JA, 2005, YEAST, V22, P835, DOI 10.1002/yea.1249; Brooks GA, 2000, MED SCI SPORT EXER, V32, P790, DOI 10.1097/00005768-200004000-00011; Brooks GA, 2003, EXERCISE PHYSL PEOPL, P322; Brooks GA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00408; CAHN RD, 1962, SCIENCE, V136, P962, DOI 10.1126/science.136.3520.962; CATALDO AM, 1986, J ELECTRON MICR TECH, V3, P413, DOI 10.1002/jemt.1060030406; CONNETT RJ, 1986, J APPL PHYSIOL, V61, P402, DOI 10.1152/jappl.1986.61.2.402; CONNETT RJ, 1990, J APPL PHYSIOL, V68, P833, DOI 10.1152/jappl.1990.68.3.833; Cori CF, 1925, J BIOL CHEM, V65, P397; Divakaruni AS, 2012, SCIENCE, V337, P41, DOI 10.1126/science.1225601; Donovan CM, 2000, MED SCI SPORT EXER, V32, P772, DOI 10.1097/00005768-200004000-00009; Downer J, 2006, J THEOR BIOL, V240, P464, DOI 10.1016/j.jtbi.2005.10.007; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fletcher WM, 1907, J PHYSIOL-LONDON, V35, P247; Gladden LB, 2008, EXERC SPORT SCI REV, V36, P109, DOI 10.1097/JES.0b013e31817c0038; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; Gladden LB, 2004, PRINCIPLES EXERCISE, P152; Goodwin ML, 2014, CANCER CELL, V26, P851, DOI 10.1016/j.ccell.2014.10.003; Hashimoto T, 2006, AM J PHYSIOL-ENDOC M, V290, pE1237, DOI 10.1152/ajpendo.00594.2005; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; IWANGOFF P, 1980, MECH AGEING DEV, V14, P203, DOI 10.1016/0047-6374(80)90120-7; JOBSIS FF, 1968, RESP PHYSIOL, V4, P292, DOI 10.1016/0034-5687(68)90035-2; Kompanje EJO, 2007, INTENS CARE MED, V33, P1967, DOI 10.1007/s00134-007-0788-7; Lambeth MJ, 2002, ANN BIOMED ENG, V30, P808, DOI 10.1114/1.1492813; LARNER EH, 1978, CANCER-AM CANCER SOC, V41, P1863, DOI 10.1002/1097-0142(197805)41:5<1863::AID-CNCR2820410530>3.0.CO;2-T; LATNER AL, 1966, SCIENCE, V154, P527; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006; LIAW KY, 1985, J TRAUMA, V25, P628, DOI 10.1097/00005373-198507000-00009; Maltais F, 1996, AM J RESP CRIT CARE, V153, P288, DOI 10.1164/ajrccm.153.1.8542131; Meyerhof O, 1942, S RESPIRATORY ENZYME, P3; Morland C, 2007, NEUROCHEM INT, V50, P703, DOI 10.1016/j.neuint.2007.01.003; Murin R, 2009, NEUROCHEM RES, V34, P480, DOI 10.1007/s11064-008-9806-6; Marie SKN, 2011, CLINICS, V66, P33, DOI 10.1590/S1807-59322011001300005; Newsholme E. A., 1983, BIOCH MED SCI, P167; Newsholme EA, 2004, MED SPORT SCI BASEL, P1; Nijsten MWN, 2009, MED HYPOTHESES, V73, P48, DOI 10.1016/j.mehy.2009.01.041; Pascoe DD, 1996, SPORTS MED, V21, P98, DOI 10.2165/00007256-199621020-00003; Pasteur L., 1858, ANN CHIM PHYS SER, V52, P404; Pasteur L, 1861, CR HEBD ACAD SCI, V53, P1260; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; PLAGEMANN PGW, 1960, J BIOL CHEM, V235, P2288; PONTEN U, 1973, J NEUROCHEM, V21, P1127, DOI 10.1111/j.1471-4159.1973.tb07567.x; Quistorff B., 2011, ISOENZYME PATTERN LD; Quistorff B, 2011, P NATL ACAD SCI USA, V108, pE21, DOI 10.1073/pnas.1017750108; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Richardson RS, 1998, J APPL PHYSIOL, V85, P627, DOI 10.1152/jappl.1998.85.2.627; SAHLIN K, 1976, PFLUG ARCH EUR J PHY, V367, P143, DOI 10.1007/BF00585150; Sahlin K, 1996, COMPR PHYSL S29, DOI [10.1002/cphy.cp120119, DOI 10.1002/CPHY.CP120119]; Sahuquillo J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102540; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; Schurr A, 2012, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00096; Semenza GL, 2008, J CLIN INVEST, V118, P3835, DOI 10.1172/JCI37373; SHONK CE, 1964, CANCER RES, V24, P709; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Spriet LL, 2000, MED SCI SPORT EXER, V32, P756, DOI 10.1097/00005768-200004000-00007; Stainsby W N, 1990, Exerc Sport Sci Rev, V18, P29; STAINSBY WN, 1966, AM J PHYSIOL, V211, P177, DOI 10.1152/ajplegacy.1966.211.1.177; STAMBAUGH R, 1966, J BIOL CHEM, V241, P1462; Summermatter S, 2013, P NATL ACAD SCI USA, V110, P8738, DOI 10.1073/pnas.1212976110; Tiidus P., 2012, BIOCH PRIMER EXERCIS, P250; Van Hall G, 2000, ACTA PHYSIOL SCAND, V168, P643, DOI 10.1046/j.1365-201x.2000.00716.x; Vega C, 1998, J NEUROCHEM, V71, P330; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	70	146	150	1	40	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	FEB 27	2015	9								22	10.3389/fnins.2015.00022			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG0MW	WOS:000352961700001	25774123	gold, Green Published			2022-02-06	
J	McAllister, TW; Flashman, LA; Maerlender, A; Greenwald, RM; Beckwith, JG; Tosteson, TD; Crisco, JJ; Brolinson, PG; Duma, SM; Duhaime, AC; Grove, MR; Turco, JH				McAllister, T. W.; Flashman, L. A.; Maerlender, A.; Greenwald, R. M.; Beckwith, J. G.; Tosteson, T. D.; Crisco, J. J.; Brolinson, P. G.; Duma, S. M.; Duhaime, A. -C.; Grove, M. R.; Turco, J. H.			Cognitive effects of one season of head impacts in a cohort of collegiate contact sport athletes	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; DESCRIPTIVE EPIDEMIOLOGY; SURVEILLANCE SYSTEM; FUNCTIONAL MRI; CONCUSSION; MILD; LOCATION; RECOVERY; ENCEPHALOPATHY	Objective: To determine whether exposure to repetitive head impacts over a single season negatively affects cognitive performance in collegiate contact sport athletes. Methods: This is a prospective cohort study at 3 Division I National Collegiate Athletic Association athletic programs. Participants were 214 Division I college varsity football and ice hockey players who wore instrumented helmets that recorded the acceleration-time history of the head following impact, and 45 noncontact sport athletes. All athletes were assessed prior to and shortly after the season with a cognitive screening battery (ImPACT) and a subgroup of athletes also were assessed with 7 measures from a neuropsychological test battery. Results: Few cognitive differences were found between the athlete groups at the preseason or postseason assessments. However, a higher percentage of the contact sport athletes performed more poorly than predicted postseason on a measure of new learning (California Verbal Learning Test) compared to the noncontact athletes (24% vs 3.6%; p < 0.006). On 2 postseason cognitive measures (ImPACT Reaction Time and Trails 4/B), poorer performance was significantly associated with higher scores on several head impact exposure metrics. Conclusion: Repetitive head impacts over the course of a single season may negatively impact learning in some collegiate athletes. Further work is needed to assess whether such effects are short term or persistent. Neurology (R) 2012;78:1777-1784	[McAllister, T. W.; Flashman, L. A.; Maerlender, A.; Grove, M. R.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA; [Tosteson, T. D.] Dartmouth Med Sch, Dept Community & Family Med, Lebanon, NH USA; [Turco, J. H.] Dartmouth Med Sch, Dept Med, Lebanon, NH USA; [Greenwald, R. M.; Beckwith, J. G.] Simbex, Lebanon, NH USA; [Greenwald, R. M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Crisco, J. J.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02912 USA; Rhode Isl Hosp, Providence, RI USA; [Brolinson, P. G.] Edward Via Virginia Coll Osteopath Med, Blacksburg, VA USA; [Duma, S. M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Duhaime, A. -C.] Dartmouth Hitchcock Med Ctr, Childrens Hosp Dartmouth, Hanover, NH USA; [Duhaime, A. -C.] Massachusetts Gen Hosp, Boston, MA 02114 USA		McAllister, TW (corresponding author), Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA.	thomas.w.mcallister@dartmouth.edu	Duma, Stefan/A-8368-2012	Crisco, Joseph/0000-0002-8786-0905	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, RO1NS055020]; National Operating Committee on Standards for Athletic Equipment (NOCSAE) [04-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	NIH R01HD048638 and RO1NS055020 and the National Operating Committee on Standards for Athletic Equipment (NOCSAE 04-07).	Agel J, 2007, J ATHL TRAINING, V42, P249; Beckwith JG, 2010, NEUROCOGNITIVE FUNCT; Benedict R., 1997, BRIEF VISUOSPATIAL M; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Chu J, 2006, 5 WORLD C BIOM, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOM IN PRESS; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dick R, 2007, J ATHL TRAINING, V42, P221; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gordon M., 1986, GORDON DIAGNOSTIC SY; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Johnson EK, 2006, REHABIL COUNS BULL, V50, P35, DOI 10.1177/00343552060500010501; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2010, PM&R, V2, pS241, DOI 10.1016/j.pmrj.2010.10.005; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Talavage T, J NEUROTRAUMA; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME; Wolfson, 1993, HALSTEAD REITAN NEUR	37	146	148	0	45	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAY	2012	78	22					1777	1784		10.1212/WNL.0b013e3182582fe7			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	948UZ	WOS:000304529600018	22592370	Green Published			2022-02-06	
J	Casa, DJ; Guskiewicz, KM; Anderson, SA; Courson, RW; Heck, JF; Jimenez, CC; McDermott, BP; Miller, MG; Stearns, RL; Swartz, EE; Walsh, KM				Casa, Douglas J.; Guskiewicz, Kevin M.; Anderson, Scott A.; Courson, Ronald W.; Heck, Jonathan F.; Jimenez, Carolyn C.; McDermott, Brendon P.; Miller, Michael G.; Stearns, Rebecca L.; Swartz, Erik E.; Walsh, Katie M.			National Athletic Trainers' Association Position Statement: Preventing Sudden Death in Sports	JOURNAL OF ATHLETIC TRAINING			English	Article						asthma; cardiac conditions; diabetes; exertional heat stroke; exertional hyponatremia; exertional sickling; head injuries; neck injuries; lightning safety	AUTOMATED EXTERNAL DEFIBRILLATORS; CERVICAL-SPINE INJURY; SICKLE-CELL TRAIT; COLLEGIATE FOOTBALL PLAYERS; EXERCISE-INDUCED ASTHMA; TRAUMATIC BRAIN-INJURY; EXERTIONAL HEAT-STROKE; COMBINED TOOL APPROACH; FACE MASK REMOVAL; HIGH-SCHOOL	Objective: To present recommendations for the prevention and screening, recognition, and treatment of the most common conditions resulting in sudden death in organized sports. Background: Cardiac conditions, head injuries, neck injuries, exertional heat stroke, exertional sickling, asthma, and other factors (eg, lightning, diabetes) are the most common causes of death in athletes. Recommendations: These guidelines are intended to provide relevant information on preventing sudden death in sports and to give specific recommendations for certified athletic trainers and others participating in athletic health care.	[Casa, Douglas J.; Stearns, Rebecca L.] Univ Connecticut, Korey Stringer Inst, Storrs, CT USA; [Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Courson, Ronald W.] Univ Georgia, Athens, GA 30602 USA; [Anderson, Scott A.] Univ Oklahoma, Norman, OK 73019 USA; [Heck, Jonathan F.] Richard Stockton Coll, Pomona, NJ USA; [McDermott, Brendon P.] Univ Tennessee, Chattanooga, TN USA; [Jimenez, Carolyn C.] W Chester Univ, Chester, PA USA; [Miller, Michael G.] Western Michigan Univ, Kalamazoo, MI 49008 USA; [Swartz, Erik E.] Univ New Hampshire, Durham, NH 03824 USA; [Walsh, Katie M.] E Carolina Univ, Greenville, NC USA		Casa, DJ (corresponding author), Natl Athlet Trainers Assoc, Dept Commun, 2952 Stemmons Freeway, Dallas, TX 75247 USA.			Guskiewicz, Kevin/0000-0002-8682-2130			Allen Thomas W, 2005, Curr Sports Med Rep, V4, P301; Almond CSD, 2005, NEW ENGL J MED, V352, P1550, DOI 10.1056/NEJMoa043901; Amer Diabet Assoc, 1999, DIABETES CARE, V22, P163; American Diabetes Association, LIV DIAB; American Diabetes Association, HYP LOW BLOOD GLUC; American Meteorological Society, LIGHTN SAF AW STAT; Andersen JC, 2002, J ATHL TRAINING, V37, P99; [Anonymous], 1997, DIABETES, V46, P271, DOI 10.2337/diab.46.2.271; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Anzalone ML, 2010, MED SCI SPORT EXER, V42, P3, DOI 10.1249/MSS.0b013e3181ae0700; APRAHAMIAN C, 1984, ANN EMERG MED, V13, P584, DOI 10.1016/S0196-0644(84)80278-4; Armed Forces Health Surveillance Center, 2011, MSMR, V18, P12; Armstrong L.E., 2003, EXERTIONAL HEAT ILLN, P103; Armstrong LE, 2007, MED SCI SPORT EXER, V39, P556, DOI 10.1249/MSS.0b013e31802fa199; Armstrong LE, 2007, J AM COLL NUTR, V26, p575S, DOI 10.1080/07315724.2007.10719661; ARMSTRONG LE, 1991, SPORTS MED, V12, P302, DOI 10.2165/00007256-199112050-00003; ARMSTRONG LE, 1993, MED SCI SPORT EXER, V25, P543; Armstrong LE, 2012, PREVENTING SUDDEN DE, P185; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; Banerjee R, 2004, AM J SPORT MED, V32, P1077, DOI 10.1177/0363546504265605; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Basso C, 2000, J AM COLL CARDIOL, V35, P1493, DOI 10.1016/S0735-1097(00)00566-0; Beck JD, 2005, CIRCULATION, V112, P19, DOI 10.1161/CIRCULATIONAHA.104.511998; Bennett B, 2010, NATL COLLEGIATE ATHL, P13; Berg RA, 2005, CIRCULATION, V112, pU1179; Berger M, 2002, HDB EXERCISE DIABETE, P365; Bergeron MF, 2005, MED SCI SPORT EXER, V37, P1421, DOI 10.1249/01.mss.0000174891.46893.82; Bernhardt D, 2010, PREPARTICIPATION PHY; Binkley HM, 2002, J ATHL TRAINING, V37, P329; Bishop PJ, 1996, AM J SPORT MED, V24, P235, DOI 10.1177/036354659602400222; BISHOP PJ, 1990, AM J SPORT MED, V18, P201, DOI 10.1177/036354659001800215; BIVINS HG, 1988, ANN EMERG MED, V17, P25, DOI 10.1016/S0196-0644(88)80498-0; Bolli CB, 1999, DIABETES CARE, V22, pB43; Bonham VL, 2010, NEW ENGL J MED, V363, P997, DOI 10.1056/NEJMp1007639; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; BOULET LP, 1994, DRUGS, V47, P207, DOI 10.2165/00003495-199447020-00001; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Burstein AH, 1982, ATHLETIC INJURIES HE, P139; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; CANTU RC, 1988, CLIN SPORT MED, V7, P459; Carek PJ, 1999, CLIN J SPORT MED, V9, P124, DOI 10.1097/00042752-199907000-00002; Casa DJ, 2000, J ATHL TRAINING, V35, P212; Casa DJ, 2003, NATA NEWS, P24; Casa DJ, 2003, EXERTIONAL HEAT ILLN, P169; Casa DJ, 2007, J ATHL TRAINING, V42, P333; Casa DJ, 2007, EXERC SPORT SCI REV, V35, P141; Casa DJ, 2006, J STRENGTH COND RES, V20, P462; Casa Douglas J, 2005, Curr Sports Med Rep, V4, P309; Casa Douglas J, 2005, Curr Sports Med Rep, V4, P115; Casa DJ, 2010, J ATHL TRAINING, V45, P147, DOI 10.4085/1062-6050-45.2.147; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; Castellani J, 2003, EXERTIONAL HEAT ILLN, P1; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P586; CHANDLER DR, 1992, ANN EMERG MED, V21, P1185, DOI 10.1016/S0196-0644(05)81743-3; Cherington M, 2003, NEUROLOGY, V60, P182, DOI 10.1212/01.WNL.0000033801.15204.B5; Cherington M, 2001, SPORTS MED, V31, P301, DOI 10.2165/00007256-200131040-00004; Clark Charles R., 1998; CLARKE KS, 1994, AM SOC TEST MATER, V1229, P3, DOI 10.1520/STP12798S; COOPER MA, 1995, SEMIN NEUROL, V15, P268, DOI 10.1055/s-2008-1041032; Cooper MA, 1995, SEMIN NEUROL, V15, P358, DOI 10.1055/s-2008-1041044; COOPER MA, 1980, ANN EMERG MED, V9, P134, DOI 10.1016/S0196-0644(80)80268-X; Cooper MA, LIGHTNING INJURIES; Copeland AJ, 2007, CLIN J SPORT MED, V17, P452, DOI 10.1097/JSM.0b013e31815b187d; COSTRINI A, 1990, MED SCI SPORT EXER, V22, P15; Crosby E, 2002, CAN J ANAESTH, V49, P733, DOI 10.1007/BF03017455; Crosby ET, 2006, ANESTHESIOLOGY, V104, P1293, DOI 10.1097/00000542-200606000-00026; Cryer PE, 2003, DIABETES CARE, V26, P1902, DOI 10.2337/diacare.26.6.1902; De Lorenzo Robert A., 1996, Journal of Emergency Medicine, V14, P603, DOI 10.1016/S0736-4679(96)00140-0; DeLorenzo RA, 1996, ANN EMERG MED, V28, P301, DOI 10.1016/S0196-0644(96)70029-X; Dennis RJ, 2008, BMJ CLIN EVIDENCE HD, P502; Diggs L W, 1976, J Natl Med Assoc, V68, P492; Domeier RM, 2005, ANN EMERG MED, V46, P123, DOI 10.1016/j.annemergmed.2005.02.004; Domeier RM, 2002, J TRAUMA, V53, P744, DOI 10.1097/00005373-200210000-00021; Donaldson WF, 1998, SPINE, V23, P1729, DOI 10.1097/00007632-199808150-00003; Drake GA, 1994, NATL FED NEWS    NOV, P18; Drezner JA, 2005, MED SCI SPORT EXER, V37, P1487, DOI 10.1249/01.mss.0000177591.30968.d4; Drezner JA, 2007, J ATHL TRAINING, V42, P143; Drezner JA, 2009, CIRCULATION, V120, P518, DOI 10.1161/CIRCULATIONAHA.109.855890; DUCLOS PJ, 1990, INT J EPIDEMIOL, V19, P673, DOI 10.1093/ije/19.3.673; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Eichner ER, 2007, J SPORT REHABIL, V16, P197, DOI 10.1123/jsr.16.3.197; Eichner ER, 2010, CURR SPORT MED REP, V9, P347, DOI 10.1249/JSR.0b013e3181fc73d7; Ellis Jessica L, 2007, Curr Sports Med Rep, V6, P56; Epstein Y, 1999, INT J SPORT NUTR, V9, P1; Epstein Y, SCAND J MED IN PRESS; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Gabbott DA, 1997, BRIT J ANAESTH, V79, P159, DOI 10.1093/bja/79.2.159; Gale SD, 2008, J ATHL TRAINING, V43, P14, DOI 10.4085/1062-6050-43.1.14; GARDNER JW, 1994, MIL MED, V159, P160, DOI 10.1093/milmed/159.2.160; Gerling MC, 2000, ANN EMERG MED, V36, P293, DOI 10.1067/mem.2000.109442; Guha A, 2004, POSTGRAD MED J, V80, P650, DOI 10.1136/pgmj.2004.019570; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Hale MH, 2008, AM MED SOC SPORTS ME; Halle RL, 2010, INT LIGHTN DET C APR; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Halstead PD, 2001, J ATHL TRAINING, V36, P322; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hargreaves M, 1996, J APPL PHYSIOL, V81, P1594, DOI 10.1152/jappl.1996.81.4.1594; Harmon KG, 2011, CIRCULATION, V123, P1594, DOI 10.1161/CIRCULATIONAHA.110.004622; Heck J, 2000, NCAA HELMET CONTACT; Heck J, HELMET CONTACT PENAL; Heck J F, 1994, J Athl Train, V29, P128; Heck J F, 1996, J Athl Train, V31, P31; HECK J F, 1992, Journal of Athletic Training, V27, P120; Heck JF, 1999, AM FOOTBALL COACH, V5, P52; HELZLSOUER KJ, 1983, JAMA-J AM MED ASSOC, V249, P777, DOI 10.1001/jama.249.6.777; Hew-Butler T, 2008, CLIN J SPORT MED, V18, P111, DOI 10.1097/JSM.0b013e318168ff31; Hodgson VR, 1985, NATL FED NEWS, V2, P24; Hoffman MD, INT J SPORT IN PRESS; Holle RL, 1995, SEMIN NEUROL, V15, P375, DOI 10.1055/s-2008-1041047; Holle RL, 2008, 3 C MET APPL LIGHTN; Holle RL, 2009, 4 C MET APPL LIGHTN; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hornsby WG., 2005, DIABETES SPECTR, V18, P102, DOI DOI 10.2337/DIASPECT.18.2.102; HUBBARD RW, 1988, HUMAN PERFORMANCE PH, P305; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; Johnson DR, 1996, AM J EMERG MED, V14, P369, DOI 10.1016/S0735-6757(96)90051-0; Kleiner DM, 2001, PREHOSPITAL CARE SPI; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Lengyel MM, 2005, AM MET SOC ANN M JAN; Lennarson PJ, 2001, J NEUROSURG, V94, P265, DOI 10.3171/spi.2001.94.2.0265; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; LOPEZ RE, 1993, B AM METEOROL SOC, V74, P2171, DOI 10.1175/1520-0477(1993)074<2171:TUOLIA>2.0.CO;2; LOPEZ RE, 1995, SEMIN NEUROL, V15, P286, DOI 10.1055/s-2008-1041034; Ludvigsson J, 1998, J PEDIATR ENDOCR MET, V11, P159; Luscombe MD, 2003, EMERG MED J, V20, P476, DOI 10.1136/emj.20.5.476; Marliss EB, 2002, DIABETES, V51, pS271, DOI 10.2337/diabetes.51.2007.S271; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; Maron BJ, 2005, J AM COLL CARDIOL, V45, P1322, DOI 10.1016/j.jacc.2005.02.007; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Maron BJ, 2006, AM HEART ASS SCI SES, V114; McAulay V, 2001, DIABETIC MED, V18, P690, DOI 10.1046/j.1464-5491.2001.00620.x; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McDermott BP, 2007, J SPORT REHABIL, V16, P163, DOI 10.1123/jsr.16.3.163; Metz CM, 1998, CLIN J SPORT MED, V8, P92, DOI 10.1097/00042752-199804000-00005; Mihalik JP, 2008, CLIN J SPORT MED, V18, P394, DOI 10.1097/JSM.0b013e31818115e3; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; MITCHELL TH, 1988, DIABETES CARE, V11, P311, DOI 10.2337/diacare.11.4.311; MONTAIN SJ, 1992, J APPL PHYSIOL, V73, P1340, DOI 10.1152/jappl.1992.73.4.1340; Mora-Rodriguez R, 2008, MED SCI SPORT EXER, V40, P1945, DOI 10.1249/MSS.0b013e31817f9843; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Mueller F, 2010, FOOTBALL FATALITIES; MUELLER FO, 1987, CLIN SPORT MED, V6, P185; MURPHY JR, 1973, JAMA-J AM MED ASSOC, V225, P981, DOI 10.1001/jama.225.8.981; Myerburg RJ, 2002, CIRCULATION, V106, P1058, DOI 10.1161/01.CIR.0000028147.92190.A7; National Asthma Education and Prevention Program, 1997, 20 ANN ALB 1977 1997, P12; National Athletic Trainers Association, 2006, HEADS RED RISK HEAD; National Athletic Trainers' Association, SICKL CELL TRAIT ATH; National Federation of State High School Associations, 2002, OFF FOOTB RUL; National Federation of State High School Associations, 1988, OFF FOOTB RUL; National Heart Lung and Blood Institute, WHAT IS ASTHM; National Institutes of Health National Heart Lung and Blood Institute, 2002, 023659 NAT I HLTH NA; National Lightning Safety Institute, MULT REC LIGHTN SAF; O'Connor FG, 2010, CURR SPORT MED REP, V9, P314, DOI 10.1249/JSR.0b013e3181f1d183; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Peterson TR, 1993, AM SOC TEST MAT INT; PRINSEN RKE, 1995, CLIN J SPORT MED, V5, P155, DOI 10.1097/00042752-199507000-00004; Rakov VA, 2000, INT LIGHTN DET C NOV; Register-Mihalik JK, 2010, THESIS U N CAROLINA; REIFF DB, 1989, AM REV RESPIR DIS, V139, P479, DOI 10.1164/ajrccm/139.2.479; Riddell MC, 2006, CAN J DIABETES, V30, P67, DOI [DOI 10.1016/S1499-2671(06)01010-0, 10.1016/ S1499-2671(06)01010-0]; Roeder WP, LIGHTNING SAFETY SCH; Rotmans JI, 2005, CIRCULATION, V112, P12, DOI 10.1161/CIRCULATIONAHA.104.504407; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Sanchez Anthony R 2nd, 2005, Curr Sports Med Rep, V4, P50; Sawka MN, 2007, MED SCI SPORT EXER, V39, P377, DOI 10.1249/mss.0b013e31802ca597; Sawka MN, 1998, INT J SPORTS MED, V19, pS108, DOI 10.1055/s-2007-971971; Schnebel B, 2008, MED SCI SPORTS EX S5, V40, pS537; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sherbondy PS, 2006, AM J SPORT MED, V34, P1675, DOI 10.1177/0363546506288849; Shirreffs SM, 1996, MED SCI SPORT EXER, V28, P1260, DOI 10.1097/00005768-199610000-00009; Sigal RJ, 2006, DIABETES CARE, V29, P1433, DOI 10.2337/dc06-9910; Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x; Speedy D B, 2001, Emerg Med (Fremantle), V13, P17, DOI 10.1046/j.1442-2026.2001.00173.x; STEINBAUM S, 1994, J TRAUMA, V36, P113, DOI 10.1097/00005373-199401000-00019; Swartz EE, 2007, J ATHL TRAINING, V42, P11; Swartz EE, 2009, J ATHL TRAINING, V44, P306, DOI 10.4085/1062-6050-44.3.306; The American Heart Association in collaboration with the International Liaison Committee on Resuscitation, 2000, CIRCULATION, V102, P160; Tierney RT, 2002, J ATHL TRAINING, V37, P185; Toler JD, 2010, CLIN J SPORT MED, V20, P92, DOI 10.1097/JSM.0b013e3181d2de5f; Torg J S, 1979, Am J Sports Med, V7, P127; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; TORG JS, 1990, AM J SPORT MED, V18, P50, DOI 10.1177/036354659001800109; TURNER L M, 1989, Journal of Emergency Medicine, V7, P385, DOI 10.1016/0736-4679(89)90311-9; Uman M, 1986, ALL LIGHTNING; Uman M. A., 2003, LIGHTNING PHYS EFFEC; USA Football, TACKL PROGR; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; Walsh KM, 2000, J ATHL TRAINING, V35, P471; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; Weiler JM, 1996, ALLERGY ASTHMA PROC, V17, P315, DOI 10.2500/108854196778606437; WEST S, 2004, J LEG ASPECTS SPORT, V14, P63; White RD, 2005, RESUSCITATION, V65, P279, DOI 10.1016/j.resuscitation.2004.10.018; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; WRIGHT DA, 1991, J APPL PHYSIOL, V71, P1082, DOI 10.1152/jappl.1991.71.3.1082	206	146	151	0	26	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2012	47	1					96	118					23	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	893DH	WOS:000300335300012	22488236	Green Published, Green Submitted, Bronze			2022-02-06	
J	Couture, SM; Granholm, EL; Fish, SC				Couture, Shannon M.; Granholm, Eric L.; Fish, Scott C.			A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia	SCHIZOPHRENIA RESEARCH			English	Article						Schizophrenia; Real-world functioning; Functional capacity; Social cognition; Neuropsychological functioning; Negative symptoms	TRAUMATIC BRAIN-INJURY; EMOTION RECOGNITION; COGNITIVE DEFICITS; PERCEPTION; SKILLS; PERFORMANCE; CAPACITY; INDEPENDENCE; RELIABILITY; SENSITIVITY	Problems in real-world functioning are pervasive in schizophrenia and much recent effort has been devoted to uncovering factors which contribute to poor functioning. The goal of this study was to examine the role of four such factors: social cognition (theory of mind), neurocognition, negative symptoms, and functional capacity (social competence). 178 individuals with schizophrenia or schizoaffective disorder completed measures of theory of mind, neurocognition, negative symptoms, social competence, and self-reported functioning. Path models sought to determine the relationships among these variables. Theory of mind as indexed by the Hinting Task partially mediated the relationship between neurocognition and social competence, and negative symptoms and social competence demonstrated significant direct paths with self-reported functioning. Study results suggest theory of mind serves as an important mediator in addition to previously investigated social cognitive domains of emotional and social perception. The current study also highlights the need to determine variables which mediate the relationship between functional capacity and real-world functioning. (C) 2010 Elsevier B.V. All rights reserved.	[Couture, Shannon M.] Univ Maryland, College Pk, MD 20742 USA; [Granholm, Eric L.; Fish, Scott C.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Granholm, Eric L.] Vet Affairs San Diego Hlth Care Syst, San Diego, CA 92161 USA		Couture, SM (corresponding author), Univ Maryland, 1123M Biol Psychol Bldg, College Pk, MD 20742 USA.	scouture@psyc.umd.edu; egranholm@ucsd.edu; scott.c.fish@gmail.com	Granholm, Eric/P-7680-2014		Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Office of Research and Development; Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RO1MH071410, P30MH080002]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH080002, R01MH071410] Funding Source: NIH RePORTER	This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service, and by the National Institute of Mental Health (RO1MH071410 and P30MH080002) to Dr. Granholm. The NIMH and the VA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Addington J, 2003, PSYCHOL MED, V33, P1119, DOI 10.1017/S0033291703007815; Addington J, 2006, BRIT J PSYCHIAT, V189, P373, DOI 10.1192/bjp.bp.105.021022; Beck A.T., 2009, SCHIZOPHRENIA COGNIT; Bell M, 2009, SCHIZOPHRENIA BULL, V35, P738, DOI 10.1093/schbul/sbm169; Bellack AS, 2006, BEHAV THER, V37, P339, DOI 10.1016/j.beth.2006.01.005; BELLACK AS, 1994, J ABNORM PSYCHOL, V103, P371, DOI 10.1037/0021-843X.103.2.371; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Bora E, 2006, PSYCHIAT RES, V145, P95, DOI 10.1016/j.psychres.2005.11.003; Bowie CR, 2008, BIOL PSYCHIAT, V63, P505, DOI 10.1016/j.biopsych.2007.05.022; Bowie CR, 2006, AM J PSYCHIAT, V163, P418, DOI 10.1176/appi.ajp.163.3.418; Brekke J, 2005, SCHIZOPHR RES, V80, P213, DOI 10.1016/j.schres.2005.07.008; Brekke JS, 2010, KEY ISSUES MENT HEAL, V177, P23; Brune M, 2005, PSYCHIAT RES, V133, P135, DOI 10.1016/j.psychres.2004.10.007; Cohen AS, 2006, SCHIZOPHR RES, V81, P227, DOI 10.1016/j.schres.2005.09.007; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Cornblatt B. A., 2009, OXFORD TXB PSYCHOPAT, P298; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sbl029; Cui M, 2005, J MARRIAGE FAM, V67, P1169, DOI 10.1111/j.1741-3737.2005.00208.x; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Dickerson FB, 2000, J CLIN PSYCHOL, V56, P1509, DOI 10.1002/1097-4679(200012)56:12<1509::AID-3>3.0.CO;2-J; Dickinson D, 2002, SCHIZOPHR RES, V56, P161, DOI 10.1016/S0920-9964(01)00229-8; Dickinson D, 2007, SCHIZOPHRENIA BULL, V33, P1213, DOI 10.1093/schbul/sbl067; Dickinson D, 2006, SCHIZOPHR RES, V85, P20, DOI 10.1016/J.SCHRES.2006.03.003; First MB, 1995, STRUCTURED CLIN INTE; Granholm E, 2005, AM J PSYCHIAT, V162, P520, DOI 10.1176/appi.ajp.162.3.520; Green MF, 2000, SCHIZOPHRENIA BULL, V26, P119, DOI 10.1093/oxfordjournals.schbul.a033430; Green MF, 2008, AM J PSYCHIAT, V165, P221, DOI 10.1176/appi.ajp.2007.07010089; Greig TC, 2004, J NERV MENT DIS, V192, P12, DOI 10.1097/01.nmd.0000105995.67947.fc; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; GUAIANA G, 2007, ARCH NEUROL PSYCHIAT, V158, P25; Harvey PD, 2006, SCHIZOPHRENIA BULL, V32, P250, DOI 10.1093/schbul/sbj011; Harvey PD, 2007, SCHIZOPHRENIA BULL, V33, P1138, DOI 10.1093/schbul/sbm040; Heaton RK, 1991, COMPREHENSIVE NORMS; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hoff AL, 2002, CURR OPIN PSYCHIATR, V15, P43, DOI 10.1097/00001504-200201000-00008; Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Keefe RSE, 2006, NEUROPSYCHOPHARMACOL, V31, P2033, DOI 10.1038/sj.npp.1301072; Keefe RSE, 2004, SCHIZOPHR RES, V68, P283, DOI 10.1016/j.schres.2003.09.011; Leifker FR, 2009, SCHIZOPHR RES, V115, P82, DOI 10.1016/j.schres.2009.09.004; MCCRAE RR, 1992, EDUC PSYCHOL MEAS, V52, P229, DOI 10.1177/001316449205200128; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McKibbin CL, 2004, SCHIZOPHR RES, V72, P53, DOI 10.1016/j.schres.2004.09.011; Meyer MB, 2009, SCHIZOPHR RES, V110, P173, DOI 10.1016/j.schres.2009.03.015; Mueser KT, 2010, J CONSULT CLIN PSYCH, V78, P561, DOI 10.1037/a0019629; Nienow TM, 2006, J ABNORM PSYCHOL, V115, P408, DOI 10.1037/0021-843X.115.3.408; Ostrom T. M., 1984, HDB SOCIAL COGNITION, P1; Patterson TL, 2010, ANNU REV CLIN PSYCHO, V6, P139, DOI 10.1146/annurev.clinpsy.121208.131339; PENN DL, 1994, SCHIZOPHR RES, V11, P277, DOI 10.1016/0920-9964(94)90022-1; Pinkham AE, 2006, PSYCHIAT RES, V143, P167, DOI 10.1016/j.psychres.2005.09.005; Reitan R., 1979, MANUAL ADM NEUROPSYC; Roberts DL, 2009, PSYCHIAT RES, V166, P141, DOI 10.1016/j.psychres.2008.02.007; SAYERS MD, 1995, BEHAV MODIF, V19, P267, DOI 10.1177/01454455950193001; Sergi MJ, 2007, SCHIZOPHR RES, V90, P316, DOI 10.1016/j.schres.2006.09.028; Sergi MJ, 2006, AM J PSYCHIAT, V163, P448, DOI 10.1176/appi.ajp.163.3.448; Twamley EW, 2002, AM J PSYCHIAT, V159, P2013, DOI 10.1176/appi.ajp.159.12.2013; Vauth R, 2004, PSYCHIAT RES, V128, P155, DOI 10.1016/j.psychres.2004.05.018; WALKER EF, 1994, SCHIZOPHRENIA BULL, V20, P453, DOI 10.1093/schbul/20.3.453; Wallace CJ, 2000, SCHIZOPHRENIA BULL, V26, P631, DOI 10.1093/oxfordjournals.schbul.a033483; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wiersma D, 2000, PSYCHOL MED, V30, P1155, DOI 10.1017/S0033291799002627	64	146	153	1	27	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	FEB	2011	125	2-3					152	160		10.1016/j.schres.2010.09.020			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	733ZW	WOS:000288304000007	20965699	Green Accepted			2022-02-06	
J	Perkes, I; Baguley, IJ; Nott, MT; Menon, DK				Perkes, Iain; Baguley, Ian J.; Nott, Melissa T.; Menon, David K.			A Review of Paroxysmal Sympathetic Hyperactivity after Acquired Brain Injury	ANNALS OF NEUROLOGY			English	Article							SEVERE HEAD-INJURY; INTRATHECAL BACLOFEN; AUTONOMIC DYSFUNCTION; DIENCEPHALIC EPILEPSY; HYPOTHALAMIC INSTABILITY; DYSAUTONOMIA; HYPERTHERMIA; HYPERTENSION; DYSREGULATION; HYPOTHERMIA	Severe excessive autonomic overactivity occurs in a subgroup of people surviving acquired brain injury, the majority of whom show paroxysmal sympathetic and motor overactivity. Delayed recognition of paroxysmal sympathetic hyperactivity (PSH) after brain injury may increase morbidity and long-term disability. Despite its significant clinical impact, the scientific literature on this syndrome is confusing; there is no consensus on nomenclature, etiological information for diagnoses preceding the condition is poorly understood, and the evidence base underpinning our knowledge of the pathophysiology and management strategies is largely anecdotal. This systematic literature review identified 2 separate categories of paroxysmal autonomic overactivity, 1 characterized by relatively pure sympathetic overactivity and another group of disorders with mixed parasympathetic/sympathetic features. The PSH group comprised 349 reported cases, with 79.4% resulting from traumatic brain injury (TBI), 9.7% from hypoxia, and 5.4% from cerebrovascular accident. Although TBI is the dominant causative etiology, there was some suggestion that the true incidence of the condition is highest following cerebral hypoxia. In total, 31 different terms were identified for the condition. Although the most common term in the literature was dysautonomia, the consistency of sympathetic clinical features suggests that a more specific term should be used. The findings of this review suggest that PSH be adopted as a more clinically relevant and appropriate term. The review highlights major problems regarding conceptual definitions, diagnostic criteria, and nomenclature. Consensus on these issues is recommended as an essential basis for further research in the area. ANN NEUROL 2010;68:126-135	[Perkes, Iain; Baguley, Ian J.; Nott, Melissa T.] Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; [Perkes, Iain; Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Perkes, Iain] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2308, Australia; [Baguley, Ian J.] Univ Sydney, Sydney Med Sch, Dept Rehabil Med, Sydney, NSW 2006, Australia		Baguley, IJ (corresponding author), Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Perkes, Iain/J-7001-2017; Nott, Melissa T/M-6778-2018; Baguley, Ian J/K-6878-2013	Perkes, Iain/0000-0001-8028-9032; Nott, Melissa T/0000-0001-7088-5826; Baguley, Ian J/0000-0001-5650-3705	Motor Accidents Authority of New South Wales, Australia [02/836]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This review was supported by the Motor Accidents Authority of New South Wales, Australia (grant 02/836 to I.J.B.).	ANDERSON VL, 2004, ARCH PHYS MED REHAB, V85, pE15; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Baguley I. J., 2006, NEUROREHAB NEURAL RE, V20, P98; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 2009, AM J PHYS MED REHAB, V88, P615, DOI 10.1097/PHM.0b013e3181aeab96; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; BAGULEY IJ, 2005, BRAIN INJURY S1, V19, P84; Baguley IJ, 2008, NEUROREHAB NEURAL RE, V22, P570; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; BENARROCH EE, 1993, MAYO CLIN PROC, V68, P988, DOI 10.1016/S0025-6196(12)62272-1; BENARROCH EE, 2004, PRIMER AUTONOMIC NER, P295; BHIGJEE AI, 1985, J NEUROL SCI, V71, P77, DOI 10.1016/0022-510X(85)90038-3; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CARRLOCKE D, 1977, J NEUROL NEUROSUR PS, V40, P808, DOI 10.1136/jnnp.40.8.808; Castelan DS, 2007, CRIT CARE NURSE, V27, P19, DOI 10.4037/ccn2007.27.3.19-a; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; De Tanti A, 2005, BRAIN INJURY, V19, P1277, DOI 10.1080/02699050500309270; Diamond AL, 2005, NEUROCRIT CARE, V2, P288, DOI 10.1385/NCC:2:3:288; Diesing TS, 2006, MOVEMENT DISORD, V21, P868, DOI 10.1002/mds.20831; Disability in Australia, 2007, DIS AUSTR ACQ BRAIN, V55; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; DOOLING EC, 1976, ARCH NEUROL-CHICAGO, V33, P196, DOI 10.1001/archneur.1976.00500030052011; DUNNE S, 2007, CLONIDINE TREATMENT; Dutau G, 1975, Pediatrie, V30, P117; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Follett KA, 2003, NEUROMODULATION, V6, P32, DOI 10.1046/j.1525-1403.2003.03005.x; FOX RH, 1973, BRIT MED J, V2, P693, DOI 10.1136/bmj.2.5868.693; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Francois B, 2001, J TRAUMA, V50, P158, DOI 10.1097/00005373-200101000-00035; GANDHAVADI B, 1988, ARCH PHYS MED REHAB, V69, P130; GIROUD M, 1988, CHILD NERV SYST, V4, P252, DOI 10.1007/BF00270925; Goddeau RP, 2007, NEUROCRIT CARE, V7, P217, DOI 10.1007/s12028-007-0066-0; Goh KYC, 1999, PEDIATR NEUROL, V21, P742, DOI 10.1016/S0887-8994(99)00069-7; Gottesman RF, 2003, INT REV PSYCHIATR, V15, P302, DOI 10.1080/09540260310001606683; Guyton A.C., 2006, TXB MED PHYSL, P748; Hamilton BB, 1990, REHABILITATION UNIFO; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; HIRAYAMA K, 1994, ARCH NEUROL-CHICAGO, V51, P494, DOI 10.1001/archneur.1994.00540170070018; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1977, LANCET, V1, P878; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Ketch T, 2002, CIRCULATION, V105, P2518, DOI 10.1161/01.CIR.0000017186.52382.F4; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; KISHNER S, 2008, POSTHEAD INJURY AUTO; KLUG N, 1984, ACTA NEUROCHIR, V72, P219, DOI 10.1007/BF01406872; Krach LE, 1997, J NEUROL REHABIL, V11, P41; Lemke DM, 2007, CRIT CARE NURSE, V27, P30; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; Leow MKS, 2007, J CLIN PATHOL, V60, P583, DOI 10.1136/jcp.2006.036640; LEWITT PA, 1983, NEUROLOGY, V33, P1122, DOI 10.1212/WNL.33.9.1122; LU CS, 1991, MOVEMENT DISORD, V6, P381, DOI 10.1002/mds.870060424; Manso R, 2008, EUR J NEUROL, V15, P241; McLean AJ, 1934, ARCH NEURO PSYCHIATR, V32, P189, DOI 10.1001/archneurpsyc.1934.02250070195012; Mehta NM, 2008, JPEN-PARENTER ENTER, V32, P281, DOI 10.1177/0148607108316196; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Oh Su Jin, 2007, Korean Journal of Internal Medicine, V22, P51; Pattoneri Paolo, 1800, J Clin Hypertens (Greenwich), V7, P734, DOI 10.1111/j.1524-6175.2005.04780.x; Penfield W, 1929, ARCH NEURO PSYCHIATR, V22, P358, DOI 10.1001/archneurpsyc.1929.02220020174010; Penfield W., 1954, EPILEPSY FUNCTIONAL, P378; Perkes IE, 2008, EUR J NEUROL, V15, P242; Perkes IE., 2008, ACNR, V8, P10; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rabinstein A.A., 2004, PRIMER AUTONOMIC NER, VSecond, P257, DOI [10.1016/B978-012589762-4/50069-4, DOI 10.1016/B978-012589762-4/50069-4]; Rabinstein AA, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-a; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rabinstein AA, 2007, J NEUROL NEUROSUR PS, V78, P1278, DOI 10.1136/jnnp.2006.112730; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rey M, 2005, J CARDIOTHOR VASC AN, V19, P654, DOI 10.1053/j.jvca.2005.07.008; ROPER JM, 2003, NURS SPECT, V16, P1; ROPPER AH, 1997, CLIN AUTONOMIC DISOR, P845; ROPPER AH, 1992, CLIN DISORDERS AUTON, P747; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; Ryan JB, 2003, J HEART LUNG TRANSPL, V22, P922, DOI 10.1016/S1053-2498(02)00558-2; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; Scott JS, 1997, AM J PHYS MED REHAB, V76, P200, DOI 10.1097/00002060-199705000-00007; Senno R, 2004, ARCH PHYS MED REHAB, V85, pe15; Seo W, 2009, WORLDV EVID-BASED NU, V6, P36, DOI 10.1111/j.1741-6787.2008.00139.x; SHIOZAKI T, 1993, J NEUROSURG, V78, P501, DOI 10.3171/jns.1993.78.3.0501; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; Singh SP, 2008, EPILEPSIA, V49, P65; SNEED RC, 1995, ARCH PHYS MED REHAB, V76, P101, DOI 10.1016/S0003-9993(95)80051-4; SOLOMON GE, 1973, J PEDIATR-US, V83, P277, DOI 10.1016/S0022-3476(73)80492-5; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; STEWART DG, 1997, PHYS MED REH CLIN N, V8, P7; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Taira T, 2007, ACTA NEUROCHIR SUPPL, V97, P227; Taira T, 2006, ACTA NEUROCHIR SUPPL, V99, P61, DOI 10.1007/978-3-211-35205-2_12; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Tong CY, 2000, ANESTH ANALG, V91, P1450, DOI 10.1097/00000539-200012000-00028; Turner MS, 2003, ACT NEUR S, V87, P81; WALKER M, 2006, J HOSP PALLIAT NURS, V8, P198; Whiteson JH, 2006, ARCH PHYS MED REHAB, V87, pS79, DOI 10.1016/j.apmr.2005.12.010; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808	114	146	162	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	AUG	2010	68	2					126	135		10.1002/ana.22066			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	636HD	WOS:000280721500006	20695005				2022-02-06	
J	Shekleton, JA; Parcell, DL; Redman, JR; Phipps-Nelson, J; Ponsford, JL; Rajaratnam, SMW				Shekleton, J. A.; Parcell, D. L.; Redman, J. R.; Phipps-Nelson, J.; Ponsford, J. L.; Rajaratnam, S. M. W.			Sleep disturbance and melatonin levels following traumatic brain injury	NEUROLOGY			English	Article							REM-SLEEP; INSOMNIA; PREVALENCE; PROPENSITY; COMPLAINTS; DISORDERS; RHYTHM; PHASE; EEG	Objectives: Sleep disturbances commonly follow traumatic brain injury (TBI) and contribute to ongoing disability. However, there are no conclusive findings regarding specific changes to sleep quality and sleep architecture measured using polysomnography. Possible causes of the sleep disturbances include disruption of circadian regulation of sleep-wakefulness, psychological distress, and a neuronal response to injury. We investigated sleep-wake disturbances and their underlying mechanisms in a TBI patient sample. Methods: This was an observational study comparing 23 patients with TBI (429.7 +/- 287.6 days post injury) and 23 age- and gender-matched healthy volunteers on polysomnographic sleep measures, salivary dim light melatonin onset (DLMO) time, and self-reported sleep quality, anxiety, and depression. Results: Patients with TBI reported higher anxiety and depressive symptoms and sleep disturbance than controls. Patients with TBI showed decreased sleep efficiency (SE) and increased wake after sleep onset (WASO). Although no significant group differences were found in sleep architecture, when anxiety and depression scores were controlled, patients with TBI showed higher amount of slow wave sleep. No differences in self-reported sleep timing or salivary DLMO time were found. However, patients with TBI showed significantly lower levels of evening melatonin production. Melatonin level was significantly correlated with REM sleep but not SE or WASO. Conclusions: Reduced evening melatonin production may indicate disruption to circadian regulation of melatonin synthesis. The results suggest that there are at least 2 factors contributing to sleep disturbances in patients with traumatic brain injury. We propose that elevated depression is associated with reduced sleep quality, and increased slow wave sleep is attributed to the effects of mechanical brain damage. Neurology (R) 2010; 74: 1732-1738	[Shekleton, J. A.; Parcell, D. L.; Redman, J. R.; Phipps-Nelson, J.; Ponsford, J. L.; Rajaratnam, S. M. W.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia		Rajaratnam, SMW (corresponding author), Monash Univ, Sch Psychol & Psychiat, Bldg 17,Clayton Campus, Clayton, Vic 3800, Australia.		Sanguansri, Luz/B-6630-2011; Rajaratnam, Shantha/D-8144-2012	Sanguansri, Luz/0000-0003-1908-7604; Rajaratnam, Shantha/0000-0001-7527-8558	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; NHMRCNational Health and Medical Research Council of Australia; Victorian Neurotrauma Initiative; Monash UniversityMonash University; Jack Brockhoff Foundation; Vanda Pharmaceuticals; Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Ltd; ResMed Foundation; Respironics Sleep and Respiratory Research Foundation; Cephalon, Inc.Teva Pharmaceutical Industries; Philips Lighting; Department of Homeland Security-Federal Emergency Management Agency (FEMA); Australia-India Council; NIH (NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL093279]; Royal Australasian College of General Practitioners/Centre of National Research on Disability and Rehabilitation Medicine; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; National Institute of Justice; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL093279] Funding Source: NIH RePORTER	J. A. Shekleton and Dr. Parcell report no disclosures. Dr. Redman has received research support from the National Health and Medical Research Council. J. Phipps-Nelson reports no disclosures. Dr. Ponsford has served on the Scientific Advisory Committee of the Victorian Neurotrauma Initiative; serves on the editorial boards of the Journal of the International Neuropsychological Society, Journal of Head Trauma Rehabilitation, Brain Injury, Neuropsychological Rehabilitation, NeuroRehabilitation, and Brain Impairment; receives royalties from the publication of Traumatic Brain Injury: Rehabilitation for Everyday Adaptive Living (Psychology Press, 1995) and Cognitive and Behavioral Rehabilitation: From Neurobiology to Clinical Practice (Guilford Press, 2004); receives research support from the NHMRC, the Victorian Neurotrauma Initiative, Monash University, and the Jack Brockhoff Foundation; and has provided medicolegal reports to numerous legal firms in relation to clients sustaining traumatic brain injury. Dr. Rajaratnam has received funding for travel from and served as a consultant (in capacity as an employee of Monash University) to Vanda Pharmaceuticals; has served as a paid expert witness or consultant to industry and government organizations on issues related to shift work, sleep, and/or circadian rhythms; and receives or has received research support as principal investigator or coinvestigator from Vanda Pharmaceuticals, Takeda Pharmaceutical Company Limited, ResMed Foundation, Respironics Sleep and Respiratory Research Foundation, Cephalon, Inc., Philips Lighting, the National Health and Medical Research Council, the Department of Homeland Security-Federal Emergency Management Agency (FEMA), Australia-India Council, NIH (NHLBI) R01 HL093279, the Royal Australasian College of General Practitioners/Centre of National Research on Disability and Rehabilitation Medicine, Centers for Disease Control and Prevention, and the National Institute of Justice; and has given expert testimony on behalf of New South Wales Nurses Association.	Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; BONNET MH, 1992, SLEEP, V15, P526; Cajochen C, 1997, AM J PHYSIOL-REG I, V272, pR1189, DOI 10.1152/ajpregu.1997.272.4.R1189; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Dijk DJ, 1997, J PHYSIOL-LONDON, V505, P851, DOI 10.1111/j.1469-7793.1997.851ba.x; DIJK DJ, 1995, J NEUROSCI, V15, P3526; Duffy JE, 2002, J BIOL RHYTHM, V17, P4, DOI 10.1177/074873002129002294; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; HAIMOV I, 1995, SLEEP, V18, P598, DOI 10.1093/sleep/18.7.598; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kunz D, 2004, J CLIN ENDOCR METAB, V89, P128, DOI 10.1210/jc.2002-021057; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Mayers AG, 2006, INT J PSYCHIAT CLIN, V10, P2, DOI 10.1080/13651500500328087; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Plante DT, 2009, SLEEP MED CLIN, V4, P407, DOI 10.1016/j.jsmc.2009.04.008; Rajaratnam SMW, 2009, SLEEP MED CLIN, V4, P179, DOI 10.1016/j.jsmc.2009.02.007; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Scheer FAJL, 2006, SPINAL CORD, V44, P78, DOI 10.1038/sj.sc.3101784; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Tobe EH, 1999, J NEUROPSYCH CLIN N, V11, P504, DOI 10.1176/jnp.11.4.504; VandenHeuvel CJ, 1997, PHYSIOL BEHAV, V61, P795, DOI 10.1016/S0031-9384(96)00534-3; Voultsios A, 1997, J BIOL RHYTHM, V12, P457, DOI 10.1177/074873049701200507; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189	40	146	152	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 25	2010	74	21					1732	1738		10.1212/WNL.0b013e3181e0438b			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	600WA	WOS:000278018400012	20498441	Green Published			2022-02-06	
J	Lei, P; Li, YH; Chen, X; Yang, SY; Zhang, JN				Lei, Ping; Li, Yaohua; Chen, Xin; Yang, Shuyuan; Zhang, Jianning			Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury	BRAIN RESEARCH			English	Article						Microarray; MicroRNA; Differential expression; Cerebral cortex; Traumatic brain injury	GENE-EXPRESSION; QUALITY-CONTROL; TARGETS; APOPTOSIS; INVASION; PLATFORM; CANCER; RNA; PCR	MicroRNAs (miRNAs) are very important regulators of biological processes such as development, cellular differentiation, and tumor generation. MiRNA microarray has been found to be a high throughput global analysis tool for detecting miRNA expression profiling, and miRNA expression profiling will facilitate the study of the biological function of miRNAs. In this report, we describe the miRNA expression level in rat cerebral cortex after traumatic brain injury using microarray method. We choose several time points post brain injury: 6 h, 24 h, 48 h and 72 h, respectively, to reveal differential expression of miRNAs in rat brain cortex compared with control groups. Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and S miRNAs were more than 2-fold down-regulated. Furthermore, we revealed global up-regulation of miR-21 expression within all the four time points post injury. Finally, we utilized qRT-PCR methods to verify the microarray results. The qRT-PCR results indicated good consistency with the results of the microarray method. Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course. (c) 2009 Elsevier B.V. All rights reserved.	[Lei, Ping; Li, Yaohua; Chen, Xin; Yang, Shuyuan; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Tianjin Neurol Inst, Gen Hosp,Lab TJIVR, Tianjin 300052, Peoples R China		Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Tianjin Neurol Inst, Gen Hosp,Lab TJIVR, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com			National 973 Projects of ChinaNational Basic Research Program of China [2005CB522604]; Tianjin Science and Technology Development Plan [05YFGDSF02500]; National Science FoundationNational Science Foundation (NSF) [30700865]	This work is supported by a National 973 Projects of China grant (2005CB522604), a Tianjin Science and Technology Development Plan grant (05YFGDSF02500), and a National Science Foundation grant (30700865).	Arikawa E, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Botling J, 2009, DIAGN MOL PATHOL, V18, P44, DOI 10.1097/PDM.0b013e3181857e92; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; CHENG Y, 2009, J MOL CELL CARDIOL; Chiu K, 2007, J VIS EXP, V269; Davis BN, 2009, J BIOL CHEM, V284, P3728, DOI 10.1074/jbc.M808788200; Ding W, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-32; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisenstein M, 2006, NATURE, V442, P1067, DOI [10.1038/4421067a, 10.1038/4421067b]; El Ouaamari A, 2008, DIABETES, V57, P2708, DOI 10.2337/db07-1614; Enright AJ, 2004, GENOME BIOL, V5; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grun D, 2005, PLOS COMPUT BIOL, V1, P51, DOI 10.1371/journal.pcbi.0010013; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; John Bino, 2006, V342, P101, DOI 10.1385/1-59745-123-1:101; Kajimoto K, 2006, RNA, V12, P1626, DOI 10.1261/rna.7228806; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Larsson O, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-129; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Mariani TJ, 2002, FASEB J, V16, P321, DOI 10.1096/fj.02-0351fje; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Pickering C, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-97; Pillay NS, 2007, BRAIN RES, V1153, P158, DOI 10.1016/j.brainres.2007.03.056; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Ribaudo R, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1011s04; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Shai RM, 2008, FUTURE ONCOL, V4, P525, DOI 10.2217/14796694.4.4.525; Shi LM, 2008, CURR OPIN BIOTECH, V19, P10, DOI 10.1016/j.copbio.2007.11.003; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Shilo S, 2007, DNA CELL BIOL, V26, P227, DOI 10.1089/dna.2006.0568; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Wang WX, 2008, BBA-GENE REGUL MECH, V1779, P749, DOI 10.1016/j.bbagrm.2008.01.005; Watanabe T, 2005, FEBS LETT, V579, P318, DOI 10.1016/j.febslet.2004.11.067; Watanabe Y, 2007, METHOD ENZYMOL, V427, P65, DOI 10.1016/S0076-6879(07)27004-1; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	59	146	159	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 11	2009	1284						191	201		10.1016/j.brainres.2009.05.074			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	488PA	WOS:000269360700017	19501075				2022-02-06	
J	Coles, JP; Fryer, TD; Coleman, MR; Smielewski, P; Gupta, AK; Minhas, PS; Aigbirhio, F; Chatfield, DA; Williams, GB; Boniface, S; Carpenter, TA; Clark, JC; Pickard, JD; Menon, DK				Coles, Jonathan P.; Fryer, Tim D.; Coleman, Martin R.; Smielewski, Peter; Gupta, Arun K.; Minhas, Pawan S.; Aigbirhio, Franklin; Chatfield, Doris A.; Williams, Guy B.; Boniface, Simon; Carpenter, T. Adrian; Clark, John C.; Pickard, John D.; Menon, David K.			Hyperventilation following head injury: Effect on ischemic burden and cerebral oxidative metabolism	CRITICAL CARE MEDICINE			English	Article						ischemia; hyperventilation; positron emission tomography; trauma; head injury	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; BLOOD-FLOW; GLUCOSE-UTILIZATION; OXYGEN UTILIZATION; CARBON-DIOXIDE; PET; TISSUE; DAMAGE; O-15	Objective: To determine whether hyperventilation exacerbates cerebral ischemia and compromises oxygen metabolism (CMRO2) following closed head injury. Design: A prospective interventional study. Setting: A specialist neurocritical care unit. Patients. Ten healthy volunteers and 30 patients within 10 days of closed head injury. Interventions. Subjects underwent oxygen-15 positron emission tomography imaging of cerebral blood flow, cerebral blood volume, CMRO2, and oxygen extraction fraction. In patients, positron emission tomography studies, somatosensory evoked potentials, and jugular venous saturation (SjO(2)) measurements were obtained at PaCO2 levels of 36 +/- 3 and 29 +/- 2 torr. Measurements and Main Results: We estimated the volume of ischemic brain and examined the efficiency of coupling between oxygen delivery and utilization using the So of the oxygen extraction fraction distribution. We correlated CMRO2 to cerebral electrophysiology and examined the effects of hyperventilation on the amplitude of the cortical somatosensory evoked potential response. Patients showed higher ischemic brain volume than controls (17 +/- 22 vs. 2 +/- 3 mL; p <=.05), with worse matching of oxygen delivery to demand (p <.001). Hyperventilation consistently reduced cerebral blood flow (p <.001) and resulted in increases in oxygen extraction fraction and ischemic brain volume (17 +/- 22 vs. 88 +/- 66 mL; p <.0001), which were undetected by SjO(2) monitoring. Mean CMRO2 was slightly increased following hyperventilation, but responses were extremely variable, with 28% of patients demonstrating a decrease in CMRO2 that exceeded 95% prediction intervals for zero change in one or more regions. CMRO2 correlated with cerebral electrophysiology, and cortical somatosensory evoked potential amplitudes were significantly increased by hyperventilation. Conclusions. The acute cerebral blood flow reduction and increase in CMRO2 secondary to hyperventilation represent physiologic challenges to the traumatized brain. These challenges exhaust physiologic reserves in a proportion of brain regions in many subjects and compromise oxidative metabolism. Such ischemia is underestimated by common bedside monitoring tools and may represent a significant mechanism of avoidable neuronal injury following head trauma.	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 1TN, England; Addenbrookes Hosp, Dept Clin Neurophysiol, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 1TN, England		Coles, JP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93, Cambridge CB2 2QQ, England.	jpc44@wbic.cam.ac.uk		Coles, Jonathan/0000-0003-4013-679X; Smielewski, Peter/0000-0001-5096-3938	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: Medline		ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BALESTRINO M, 1988, J PHYSIOL-LONDON, V396, P247, DOI 10.1113/jphysiol.1988.sp016961; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRANSTON NM, 1984, J CEREBR BLOOD F MET, V4, P68, DOI 10.1038/jcbfm.1984.9; Coles JP, 2006, J CEREBR BLOOD F MET, V26, P48, DOI 10.1038/sj.jcbfm.9600179; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; CORREIA JA, 1985, J CEREBR BLOOD F MET, V5, P591, DOI 10.1038/jcbfm.1985.88; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; Gibbs EL, 1942, J BIOL CHEM, V144, P325; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HERSCOVITCH P, 1983, J CEREBR BLOOD F MET, V3, P407, DOI 10.1038/jcbfm.1983.66; Huttunen J, 1999, EXP BRAIN RES, V125, P248, DOI 10.1007/s002210050680; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; LEBRUNGRANDIE P, 1983, ARCH NEUROL-CHICAGO, V40, P230, DOI 10.1001/archneur.1983.04050040060010; Ledsome JR, 1996, CAN J ANAESTH, V43, P1025, DOI 10.1007/BF03011904; Lee J, 1996, BRAIN RES, V706, P210, DOI 10.1016/0006-8993(95)01214-1; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; MADDEN JA, 1993, PHARMACOL THERAPEUT, V59, P229, DOI 10.1016/0163-7258(93)90045-F; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; Marion D W, 1995, New Horiz, V3, P439; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mauguiere F, 1999, EEG CL N SU, P255; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Robertson C S, 1995, New Horiz, V3, P410; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Smielewski Peter, 1800, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Talairach J, 1998, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; VANNIMMEN D, 1984, AM J PHYSIOL, V247, pR639, DOI 10.1152/ajpregu.1984.247.4.R639; VANNIMMEN D, 1986, J CEREBR BLOOD F MET, V6, P584, DOI 10.1038/jcbfm.1986.105; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	55	146	157	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2007	35	2					568	578		10.1097/01.CCM.0000254066.37187.88			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129OP	WOS:000243739100032	17205016				2022-02-06	
J	Zemlan, FP; Jauch, EC; Mulchahey, JJ; Gabbita, SP; Rosenberg, WS; Speciale, SG; Zuccarello, M				Zemlan, FP; Jauch, EC; Mulchahey, JJ; Gabbita, SP; Rosenberg, WS; Speciale, SG; Zuccarello, M			C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome	BRAIN RESEARCH			English	Article						brain trauma; biomarker; MAP-tau	SEVERE HEAD-INJURY; NEUROPROTECTIVE AGENTS; AXONAL INJURY; TRIAL; MULTICENTER; HYPOTHERMIA; NIMODIPINE; EFFICACY	Following traumatic brain injury, the neuronally-localized intracellular protein MAP-tau is proteolytically cleaved (C-tau) and gains access to cerebrospinal fluid (CSF) and serum. The present study compared initial CSF C-tau levels, initial Glasgow Coma Scale (GCS) scores and elevated intracranial pressure (ICP) as predictors of clinical outcome. In this preliminary, prospective study of consecutive severe traumatic brain injured patients (TBI) clinical outcome was quantified with the Glasgow Outcome Scale (GOS) at discharge (n=28). Sensitivity and specificity of initial C-tau levels,and initial GCS scores as predictors of clinical outcome is reported. To assess disease specificity C-tau levels were compared between TBI patients and neurologic (n=87) and non-neurologic control patients (n=67). Initial CSF C-tau levels were elevated 40,000 fold in TBI patients compared to either neurologic or non-neurologic control patients (P<0.001). Initial C-tau levels were correlated with clinical outcome (P=0.006) and were a significant predictor of dichotomized clinical outcome (P=0.011) demonstrating a sensitivity of prediction of 92% and a specificity of 94%. Initial C-tau levels were also a significant predictor of subsequent ICP with higher initial C-tau levels associated with elevated ICP (P=0.014). Initial GCS score were correlated with clinical outcome (P=0.026) and demonstrated a sensitivity of 50% and a specificity of 100% for predicting dichotomized clinical outcome. Statistical analysis indicated that initial C-tau levels and initial GCS scores were independent predictors of clinical outcome. The present preliminary study demonstrates that initial CSF C-tau levels are a significant predictor of ICP and clinical outcome with particular sensitivity for identifying severe TBI patients with good clinical outcome. Future studies employing a larger sample size and clinical outcome assessment at longer periods after hospitalization will be needed to determine the utility of initial C-tau levels as a clinical biomarker in TBI. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA		Zemlan, FP (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA.			Jauch, Edward/0000-0002-3533-4364			ALVES WM, 1996, NEUROTRAUMA, P947; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHATFIELD DA, IN PRESS BR J NEUROS; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1996, NEUROTRAUMA, P779; DOBBENBERG EM, 1997, ANN NY ACAD SCI, V825, P305; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; Griner P F, 1981, Ann Intern Med, V94, P557; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; IRAZUZTA JE, IN PRESS BRAIN RES; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; PETTUS EH, 1996, BRAIN RES, V772, P1; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; STRAW RN, 1995, P27000017 N AM STUD; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 1999, J NEUROCHEM, V73, P437; ZEMLAN FP, 1999, J NEUROTRAUM, V16, P960	37	146	152	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 23	2002	947	1					131	139	PII S0006-8993(02)02920-7	10.1016/S0006-8993(02)02920-7			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	589PR	WOS:000177769400016	12144861				2022-02-06	
J	Keyser-Marcus, LA; Bricout, JC; Wehman, P; Campbell, LR; Cifu, DX; Englander, J; High, W; Zafonte, RD				Keyser-Marcus, LA; Bricout, JC; Wehman, P; Campbell, LR; Cifu, DX; Englander, J; High, W; Zafonte, RD			Acute predictors of return to employment after traumatic brain injury: A longitudinal follow-up	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; rehabilitation	COMMUNITY INTEGRATION; HEAD-INJURY; VOCATIONAL-REHABILITATION; MULTICENTER ANALYSIS; WORK; PROGRAM; DISABILITIES; OUTCOMES; ADULTS	Objective: To investigate the relation between selected acute injury and patient characteristics and subsequent return to work 1 to 5 years postinjury. Design: Longitudinal design with prospectively collected data. Data were collected on patients at the time of injury and each year postinjury for up to 5 years. Setting: Four medical centers in the federally sponsored Traumatic Brain Injury Model Systems project that provide emergency medical services, intensive and acute medical care, inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Patients were selected from a national database of 538 rehabilitation inpatients admitted to acute care within 8 hours of traumatic brain injury (TBI) and seen at I to 5 years follow-up. Interventions: Not applicable. Main Outcome Measures: Employment status (employed vs not employed) at I to 5 years postinjury. Logistic regression analyses were performed to determine the extent to which selected variables predicted employment status at years I to 5 postinjury. Results: At year 1 postinjury, preinjury productivity, age, education, and rehabilitation length of stay were all significantly associated with postinjury employment. Preinjury employment and productivity and age significantly predicted employment at postinjury year 2. At year 3 postinjury, preinjury productivity, age, and FIM(TM) instrument discharge score significantly predicted employment status. Age was significantly associated with employment status at year 4 postinjury. Preinjury employment and productivity and Disability Rating Scale discharge score were found to be significant predictors of postinjury employment at year 5 follow-up. Conclusions: The relationship between certain acute injury and patient variables (eg, age, preinjury productivity, education, discharge FIM) and subsequent return to work may provide rehabilitation professionals with useful information regarding the intensity and types of services needed for individuals in the vocational rehabilitation planning process.	Virginia Commonwealth Univ, Rehabil Res & Training Ctr, Sch Educ, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Rehabil Inst Michigan, Dept Phys Med & Rehabil, Detroit, MI USA		Keyser-Marcus, LA (corresponding author), Virginia Commonwealth Univ, Rehabil Res & Training Ctr, Sch Educ, Box 842011, Richmond, VA 23284 USA.			Keyser-Marcus, Lori/0000-0001-6014-2500; Cifu, David/0000-0003-1600-9387	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H1333A980026, H133B980036] Funding Source: Medline		ADELMAN PB, 1993, LEARN DISABILITY Q, V16, P219, DOI 10.2307/1511328; ADLAF EM, 1992, AM J DRUG ALCOHOL AB, V18, P371, DOI 10.3109/00952999209051036; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS21, DOI 10.1016/S0003-9993(98)90116-2; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Burton K, 1997, J OCCUP REHABIL, V7, P139, DOI 10.1007/BF02767360; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CRISP R, 1992, J REHABIL, V58, P27; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; EAMES P, 1995, BRAIN INJURY, V10, P631; Gates LB, 2000, J OCCUP REHABIL, V10, P85, DOI 10.1023/A:1009445929841; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Hirsh A, 1996, J VOCAT REHABIL, V7, P217; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JOHNSON VA, 1988, REHABIL COUNS BULL, V32, P50; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; STOKES ME, 1995, CATEGORICAL DATA ANA; STONE D, 1996, J ORGAN BEHAV, V17, P99; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wall JR, 1998, NEUROREHABILITATION, V10, P39, DOI 10.3233/NRE-1998-10105; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; West MD, 1996, J VOCATIONAL REHABIL, V7, P143; [No title captured]	41	146	150	0	16	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2002	83	5					635	641		10.1053/apmr.2002.31605			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	550FY	WOS:000175494000008	11994802				2022-02-06	
J	Powell, J; Heslin, J; Greenwood, R				Powell, J; Heslin, J; Greenwood, R			Community based rehabilitation after severe traumatic brain injury: a randomised controlled trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HOSPITAL ANXIETY; DEPRESSION SCALE; INTERRATER RELIABILITY; HEAD-INJURY; OUTCOMES; INDIVIDUALS; SERVICES; FIM+FAM; STROKE; CARE	Objective: Evaluation of multidisciplinary community based outreach rehabilitation after severe traumatic brain injury (TBI). Methods: A randomised controlled trial compared outreach treatment (mean of two sessions a week for 27.3 (SD 19.1) weeks) in community settings such as participants' homes, day centres, or workplaces, with provision of written information detailing alternative resources. Follow up for an average of 24.8 months after initial allocation was by a blinded independent assessor. Participants were aged 16-65, had sustained severe TBI between 3 months and 20 years previously, and had no other neurological conditions. Of 110 initially allocated, 48 outreach and 46 information participants were successfully followed up. Primary outcome measures (Barthel index (BI) and the brain injury community rehabilitation outcome-39 (BICRO-39)) focused on levels of activity and participation. Secondary measures were the functional independence measure and the functional assessment measure (FIM+FAM) and, in a subgroup of 46 participants, the hospital anxiety and depression scale. Analyses were non-parametric. Results: outreach participants were significantly more likely to show gains on the BI and the BICRO-39 total score and self organisation and psychological wellbeing subscales. There were likewise strong trends (p<0.10) for BICRO personal care and mobility, and on the FIM+FAM for personal care and cognitive functions. Differential improvements were not seen for indices of socialising, productive employment, anxiety, or depression. Median changes on individual subscales were small, reflecting the diversity of the clinical population; however, 40% of outreach but only 20% of information participants made a clinically significant improvement of 2+ points on at least one BICRO-39 scale. Time since injury was unrelated to the magnitude of gains. Conclusions: This is the first RCT of multidisciplinary community rehabilitation after severe TBI, and suggests that even years after injury it can yield benefits which outlive the active treatment period.	Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; Homerton Hosp, Reg neurol Rehabil Unit, London E9 6SR, England		Powell, J (corresponding author), Univ London Goldsmiths Coll, Dept Psychol, Lewisham Way,New Cross, London SE14 6NW, England.						Alcott D, 1997, DISABIL REHABIL, V19, P355, DOI 10.3109/09638289709166551; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Collin C, 1988, Int Disabil Stud, V10, P61; EDWARDS M, 1995, OCCUP THER J RES, V15, P103, DOI 10.1177/153944929501500203; FLEMINGER S, 1999, EVALUATION OUTCOMES; FREDERICKSON M, 1995, ARCH PHYS MED REHAB, V76, pSC5; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; JOHNSON G, 1995, ACTA PSYCHIAT SCAND, V91, P252, DOI 10.1111/j.1600-0447.1995.tb09778.x; MAHONEY F I, 1965, Md State Med J, V14, P61; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Powell J, 1999, NEUROPSYCHOL REHABIL, V9, P457, DOI 10.1080/096020199389518; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Semlyen JK, 1996, J NEUROL REHABIL, V10, P251; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; STILWELL J, 1998, NATL TRAUMATIC BRAIN; Stilwell P, 1998, CLIN REHABIL, V12, P521, DOI 10.1191/026921598673761855; Stonnington HH, 1997, BRAIN INJURY, V11, P155, DOI 10.1080/026990597123755; Sutcliffe LM, 1998, CLIN REHABIL, V12, P506, DOI 10.1191/026921598672167702; Wade D, 1992, MEASUREMENT NEUROLOG; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	146	149	0	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2002	72	2					193	202		10.1136/jnnp.72.2.193			10	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	515AA	WOS:000173472200011	11796769	Green Published, Bronze, Green Accepted			2022-02-06	
J	Kutner, KC; Erlanger, DM; Tsai, J; Jordan, B; Relkin, NR				Kutner, KC; Erlanger, DM; Tsai, J; Jordan, B; Relkin, NR			Lower cognitive performance of older football players possessing apolipoprotein E epsilon 4	NEUROSURGERY			English	Article						apolipoprotein E; cognition; concussion; head injury; neuropsychology; sports	AMYLOID PROTEIN DEPOSITION; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; SOCCER PLAYERS; NEUROPSYCHOLOGICAL SEQUELAE; ALZHEIMERS-DISEASE; UNITED-STATES; CONCUSSION; SPORTS; BOXERS	OBJECTIVE: To determine whether the cognitive status of professional football players varies as a function of age and apolipoprotein E (APOE) genotype. METHODS: Fifty-three active players underwent APOE and neuropsychological assessments. Players were grouped according to age (proxy indicator of high/low exposure to contact) and the presence/absence of at least one copy of the epsilon 4 allele. Outcome measures were overall cognitive performance and scores in cognitive domains. RESULTS: As a group, older players possessing APOE epsilon 4 exhibited significantly lower cognitive test scores than did all other players studied, including non-epsilon 4-possessing players and younger epsilon 4-carriers. Measures of general cognitive functioning, information-processing speed and accuracy, and attention were related to poorer performance among the epsilon 4-carrying players. In an analysis of variance model, the interaction between APOE genotype and age was significant (P = 0.004). As determined using linear regression, age accounted for 34% of the variance in the memory index among APOE epsilon 4-possessing players but did not contribute significantly to variance among the non-epsilon 4-possessing players. Older APOE epsilon 4-carriers were significantly overrepresented among players whose scores indicated possible cognitive impairment, with the criterion of performing two or more standard deviations below the general normal Values in a summary index of general cognitive functioning. CONCLUSION: Older professional football players who possessed the APOE epsilon 4 allele scored lower on cognitive tests than did players without this allele or less experienced players of any genotype. The cognitive status of professional athletes with repeated exposure to head trauma may therefore be influenced by age, inherited factors such as APOE genotype, and cumulative exposure to contact.	Cornell Univ Med Coll, Presbyterian Hosp, Dept Neurol & Neurosci, New York, NY 10021 USA; Columbia Univ, Dept Neurosci, New York, NY USA; Burke Res Inst & Rehabil Hosp, White Plains, NY USA		Relkin, NR (corresponding author), Cornell Univ Med Coll, Presbyterian Hosp, Dept Neurol & Neurosci, 1300 York Ave, New York, NY 10021 USA.						Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT, 1989, MILD HEAD INJURY, P257; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CANTU RC, 1996, BR J SPORST MED, V30, P239; CANTU RC, 1991, ADOLESCENT MED STATE, V2, P17; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; COHEN SB, 1998, SPORTS NEUROLOGY, P393; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Friedman J, 1999, PHYS TODAY, V52, P24, DOI 10.1063/1.882550; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRONWALL D, 1975, LANCET, V2, P995; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Heaton RK, 1991, COMPREHENSIVE NORMS; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1993, MED ASPECTS BOXING, P177; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KANE RL, 1995, B NATL ACAD NEUROPSY, V11, P13; Katzman R, 1996, NEUROLOGY, V46, P889; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MATLAND HS, 1928, JAMA-J AM MED ASSOC, V19, P1103; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pitas RE, 1998, BIOCHEM SOC T, V26, P257, DOI 10.1042/bst0260257; POWELL DH, 1993, MICROCOG; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; REY A, 1964, EXAMIN CLIN PSYCHOL; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Sosin DM, 1996, BRAIN INJURY, V10, P47; *SPSS, 1998, STAT PACK SOC SCI; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tsuang D, 1996, J AM GERIATR SOC, V44, P704, DOI 10.1111/j.1532-5415.1996.tb01836.x; TYSVAER A, 1989, ACTA NEUROL SCAND, V80, P51; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	51	146	147	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	2000	47	3					651	657		10.1097/00006123-200009000-00026			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	349GJ	WOS:000089037100053	10981753				2022-02-06	
J	Guskiewicz, KM; Riemann, BL; Perrin, DH; Nashner, LM				Guskiewicz, KM; Riemann, BL; Perrin, DH; Nashner, LM			Alternative approaches to the assessment of mild head injury in athletes	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						concussion; postural stability; cognitive function	SENSORY INTERACTION; POSTURAL CONTROL; CONCUSSION; POSTUROGRAPHY; MANAGEMENT; ADAPTATION; DEFICITS; STANCE	Objectives: Athletic trainers and team physicians are often faced with decisions concerning the severity and timing of an athletes return to play following mild head injury (MHI). These decisions can be the most difficult ones facing clinicians because of the limited amount of quantitative information indicating injury severity. Several authors have published guidelines for return to play following MHI, however these guidelines are based on limited scientific data. The purpose of this paper was to examine the effects of MHI on two objective measures, postural stability and cognitive function, to determine their usefulness in MHI assessment. The data gathered from these two measures has the potential to establish recovery curves based on objective data. Methods: Eleven Division I collegiate athletes who sustained a MHI and eleven matched control subjects were assessed for postural stability and cognitive function at four intervals following injury. Postural stability was assessed using the Sensory Organization Test on the NeuroCom Smart Balance Master. Cognitive functioning was measured through the use of four neuropsychological tests: Stroop Test, Trail Making Test, Digits Span and Hopkins Verbal Learning Test. Separate mixed model repeated measures ANOVAs were calculated for the composite score and three ratio (vestibular, visual and somatosensory) scores from the Sensory Organization Test and the scores from the neuropsychological test to reveal significant differences between groups and across days postinjury. Results: A significant group by day interaction for overall postural stability (composite score) revealed that MHI athletes displayed increased postural instability for the first few days following MHI (p<.05). Analysis of the ratio scores revealed a significant interaction for the visual ratio. No significant group differences were revealed for any of the neuropsychological tests (p>.05), however significant day differences were revealed (p<.05). Conclusions: The results from this study indicate that athletes demonstrate decreased stability until 3 days postinjury. It appears this deficit is related to a sensory interaction problem, whereby the injured athlete fails to use their visual system effectively. These findings suggest that measures of postural stability may provide clinicians with a useful clinical tool for determining when an athlete may safely return to competition, although these findings need to be confirmed in larger groups of athletes.	UNIV VIRGINIA,CURRY SCH EDUC,DEPT HUMAN SERV,CHARLOTTESVILLE,VA; OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201		Guskiewicz, KM (corresponding author), UNIV N CAROLINA,DEPT PHYS EDUC EXERCISE & SPORT SCI,CHAPEL HILL,NC 27599, USA.			Guskiewicz, Kevin/0000-0002-8682-2130			ADAMS J, 1975, HDB CLIN NEUROLOGY I, P35; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALVES WM, 1987, CLIN SPORT MED, V6, P211; ARCAN M, 1977, SCAND J REHABIL MED, V9, P165; ASAI M, 1993, ACTA OTOLARYNGOL S S, V504, P120; Barth JT, 1989, MILD HEAD INJURY, P257; BRUCE D, 1982, PRIMARY CARE, V11, P175; CANTU R, 1992, ADOLESC MED, V2, P141; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CERVETT M, 1995, OTOLARYNGOL HEAD NEC, V122, P676; CHESTER JB, 1991, SPINE, V16, P716, DOI 10.1097/00007632-199107000-00004; *COL MED SOC SPORT, 1994, P MILD BRAIN INJ SPO, P106; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GOEBEL JA, IN PRESS OTOLARYNGOL; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guyton A., 1986, TXB MED PHYSL, P1610; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HOUGH D, 1994, P MILD BRAIN INJ SPO, P31; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JORDAN B, 1994, P MILD BRAIN INJ SPO, P43; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LIPP M, 1994, J OTOLARYNGOL, V23, P177; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MAURITZ KH, 1979, BRAIN, V102, P461, DOI 10.1093/brain/102.3.461; MCINTOSH T, 1989, MILD MODERATE HEAD I, P135; NASHNER L, 1978, BRAIN RES, V150, P403, DOI 10.1016/0006-8993(78)90291-3; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; NORRE ME, 1993, J LARYNGOL OTOL, V107, P496, DOI 10.1017/S0022215100123564; OLIARO S, 1996, THESIS ESTABLISHMENT; Ommaya A, 1994, P MILD BRAIN INJ SPO, P72; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Weir Mitchell S, 1886, AM J MED SCI, V92, P363	44	146	146	0	13	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUL	1997	29	7		S			S213	S221					9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	XM280	WOS:A1997XM28000002	9247918				2022-02-06	
J	Beetar, JT; Guilmette, TJ; Sparadeo, FR				Beetar, JT; Guilmette, TJ; Sparadeo, FR			Sleep and pain complaints in symptomatic traumatic brain injury and neurologic populations	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; POSTCONCUSSION SYNDROME; PREVALENCE	Objective: To compare the incidence of sleep and pain complaints in symptomatic traumatic brain injury (TBI) (mild vs moderate/severe) and neurologic populations. Design: Case-control study. Setting: Outpatient neuropsychology service at a university-affiliated tertiary care center. Patients: A consecutive sample of mild (n=127) and moderate to severe (n=75) patients with TBI and a general neurologic (non-TBI) group (n=123) referred for neuropsychological assessment. Main Outcome Measures: Patient report of sleep and/or pain problems. Results: TBI subjects had significantly more insomnia (56.4% vs 30.9%) and pain complaints (58.9% vs 22%) than non-TBI subjects (p <.0001). For both subject groups, the presence of pain increased insomnia approximately twofold. Poor sleep maintainance was the most common sleep problem. In those subjects without pain, TBI patients reported more sleep complaints that non-TBI patients (p=.05). Mild TBI patients reported significantly (p <.0001) more pain than patients with a moderate to severe injury (70% vs 40%). In TBI subjects without pain, there were significantly more insomnia complaints in mild than in moderate to severe injuries (p <.01). Conclusions: TBI patients with persistent cognitve complaints have more sleep and pain concerns than general neurologic patients. Pain is strongly associated with sleep problems. Aggressive evaluation and treatment of pain and sleep problems in the TBI, especially mild TBI, population appears warranted and may contribute to increased disability. The etiology of greater sleep and pain problems in the mild than in the more severe TBI patients requires further study. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA; RHODE ISLAND HOSP, PROVIDENCE, RI USA		Beetar, JT (corresponding author), EMMA PENDLETON BRADLEY HOSP, E PROVIDENCE, RI 02914 USA.		Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604			Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BIXLER EO, 1979, AM J PSYCHIAT, V136, P1257; BONNET MH, 1993, SLEEP, V16, pS65, DOI 10.1093/sleep/16.suppl_8.S65; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWN SJ, 1994, CLIN NEUROSCI, V6, P15; CARTLIDGE NEF, 1978, SCOT MED J, V23, P103, DOI 10.1177/003693307802300146; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Glovinsky PB, 1991, CASE STUDIES INSOMNI, P49; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; GREENBERG GD, 1987, SLEEP, V10, P254, DOI 10.1093/sleep/10.3.254; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Hauri P. J., 1991, CASE STUDIES INSOMNI, P65, DOI [10.1007/978-1-4757-9586-8_5, DOI 10.1007/978-1-4757-9586-8_5]; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; PARSONS LC, 1982, NURS RES, V31, P260; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; WILKINSON M, 1980, UPSALA J MED SCI, P48; Wooten V, 1994, PRINCIPLES PRACTICE, V2, P509; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004	25	146	147	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1996	77	12					1298	1302		10.1016/S0003-9993(96)90196-3			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	VX898	WOS:A1996VX89800014	8976315				2022-02-06	
J	YOGANANDAN, N; PINTAR, FA; SANCES, A; WALSH, PR; EWING, CL; THOMAS, DJ; SNYDER, RG				YOGANANDAN, N; PINTAR, FA; SANCES, A; WALSH, PR; EWING, CL; THOMAS, DJ; SNYDER, RG			BIOMECHANICS OF SKULL FRACTURE	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		BIOMECHANICS; DYNAMIC LOADING; HUMAN TOLERANCE; IMPACT RESPONSE; SKULL FRACTURE; STATIC LOADING	INJURIES	This study was conducted to determine the biomechanics of the human head under quasistatic and dynamic loads. Twelve unembalmed intact human cadaver heads were tested to failure using an electrohydraulic testing device. Quasistatic loading was done at a rate of 2.5 mm/s. Impact loading tests were conducted at a rate of 7.1 to 8.0 mis. Vertex, parietal, temporal, frontal, and occipital regions were selected as the loading sites. Pathological alterations were determined by pretest and posttest radiography, close-up computed tomography (CT) images, macroscopic evaluation, and defleshing techniques. Biomechanical force-deflection response, stiffness, and energy-absorbing characteristics were obtained. Results indicated the skull to have nonlinear structural response. The failure loads, deflections, stiffness, and energies ranged from 4.5 to 14.1 kN, 3.4 to 16.6 mm, 467 to 5867 N/mm, and 14.1 to 68.5 J, respectively. The overall mean values of these parameters for quasistatic and dynamic loads were 6.4 kN (+/-1.1), 12.0 mn (+/-1.6), 812 N/mm (+/-139), 33.5 J (+/-8.5), and 11.9 kN (+/-0.9), 5.8 mm (+/-1.0), 4023 N/mm (+/-541), 28.0 J (+/-5.1), respectively. It should be emphasized that these values do not account for the individual variations in the anatomical locations on the craniun of the specimens. While the X-rays and CT scans identified the fracture, the precise direction and location of the impact on the skull were not apparent in these images. Fracture widths were consistently wider at sites remote from the loading region. Consequently, based on retrospective images, it may not be appropriate to extrapolate the anatomical region that sustained the impact forces. The quantified biomechanical response parameters will assist in the development and validation of finite element models of head injury.	VET AFFAIRS MED CTR,MILWAUKEE,WI; EWING BIODYNAM CORP,NEW ORLEANS,LA; HOECHST CELANESE CORP,SOMERVILLE,NJ; BIODYNAM INT,TUCSON,AZ		YOGANANDAN, N (corresponding author), FMLH MED COLL WISCONSIN,MCW CLIN,DEPT NEUROSURG,9200 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR-507370, R49CCR-703640] Funding Source: Medline		ALLSOP DL, 1993, ACCIDENTAL INJURY BI, P247; BECKER DP, 1985, CENTRAL NERVOUS SYST; Cooper P, 1982, HEAD INJURY; DIMASI F, 1991, AUTO TRAFFIC SAFETY, P20; EWING CL, 1983, IMPACTS INJURY HEAD; GOLDSMITH W, 1972, BIOMECHANICS ITS F O, P585; GOT C, 1978, 22ND STAPP CAR CRASH, P55; Gurdjian ES, 1975, IMPACT HEAD INJURY M; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, P185; HARRIS H, 1981, HEAD NECK INJURY CRI, P6; HODGSON VR, 1967, AM J ANAT, V120, P113, DOI 10.1002/aja.1001200109; HODGSON VR, 1970, 14TH STAPP CAR CRASH, P341; HODGSON VR, 1972, 15TH STAPP CAR CRASH, P190; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; McElhaney J., 1972, HUMAN IMPACT TOLERAN, P85; Melvin J.W., 1993, ACCIDENTAL INJURY BI, P268; Nahum A., 1980, 24TH STAPP CAR CRASH, P43; NAHUM A, 1981, 25TH STAPP CAR CRASH, P241; NAKAMURA N, 1986, MECHANISMS HEAD SPIN, P219; NEWMAN JA, 1993, ACCIDENTAL INJURY BI, P292; ODOM GL, 1979, CENTRAL NERVOUS SYST; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; Ono K., 1980, SAE TECH PAP, V89, P101, DOI [10.4271/801303, DOI 10.4271/801303]; SANCES A, 1981, CRC CR REV BIOM ENG, V5, P79; SancesJr A., 1986, MECH HEAD SPINE TRAU, P189; Schneider DC, 1972, P 16 STAPP CAR CRASH, P186; SNYDER RG, 1970, INT AUTOMOBILE SAFET, P1375; YOGANANDAN N, 1995, NEUROSURGERY, V36, P956, DOI 10.1227/00006123-199505000-00011; YOGANANDAN N, 1991, J TRAUMA, V31, P699, DOI 10.1097/00005373-199105000-00015; Yoganandan N, 1990, SAE T, V98, P1790; YOGANANDAN N, 1989, SAE T, V97, P1104; YOGANANDAN N, 1994, SAE941727 PAP; [No title captured]	33	146	152	1	26	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					659	668		10.1089/neu.1995.12.659			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000017	8683617				2022-02-06	
J	Walker, AE; Kollros, JJ; Case, TJ				Walker, A. Earl; Kollros, Jerry J.; Case, Theodore J.			THE PHYSIOLOGICAL BASIS OF CONCUSSION	JOURNAL OF NEUROSURGERY			English	Article							EXTINCTION		[Walker, A. Earl] Univ Chicago, Div Neurol Surg, Chicago, IL 60637 USA; Univ Chicago, Otho SA Sprague Mem Inst, Chicago, IL 60637 USA		Walker, AE (corresponding author), Univ Chicago, Div Neurol Surg, Chicago, IL 60637 USA.				Committee on Medical Research	The work described in this paper was done under a contract recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and the University of Chicago.	Cannon WB, 1901, AM J PHYSIOL, V6, P91; Courville CB, 1942, ARCH SURG-CHICAGO, V45, P19, DOI 10.1001/archsurg.1942.01220010022002; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; de Barenne JGD, 1939, J NEUROPHYSIOL, V2, P319, DOI 10.1152/jn.1939.2.4.319; De No RL, 1938, J NEUROPHYSIOL, V1, P207; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON KC, 1940, J GERONTOL B-PSYCHOL, V2, P360; Duret H, 1920, REV NEUROL-FRANCE, V36, P888; FELIZET G.-M., 1873, THESIS, P167; GOODWIN CRAIG W., 1941, YALE JOUR BIOL AND MED, V14, P101; GURDJIAN E. S., 1943, RES PUBL AS IN PRESS, P24; HOLBOURN AHS, 1943, J GERONTOL B-PSYCHOL, V2, P438; KOCHER T., 1901, NOTHNAGELS SPECIELLE, V9; Krems KD, 1942, P SOC EXP BIOL MED, V49, P73; Meyers R, 1941, J NEUROPHYSIOL, V4, P250, DOI 10.1152/jn.1941.4.3.250; MILES A, 1892, BRAIN, V15, P153; PUDENZ R, 1943, M ASS RES NERV MENT; Ranson SB, 1930, AM J PHYSIOL, V94, P471; Rosenblueth A, 1942, AM J PHYSIOL, V135, P0690, DOI 10.1152/ajplegacy.1942.135.3.690; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; TROTTER W., 1924, J GERONTOL B-PSYCHOL, V1, P933; Webster JE, 1943, J NEUROPHYSIOL, V6, P255; White JC, 1943, ANN SURG, V119, P619, DOI 10.1097/00000658-194310000-00010; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	25	146	149	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1944	1	2					103	116		10.3171/jns.1944.1.2.0103			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	V25AG	WOS:000208450300003					2022-02-06	
J	Bazarian, JJ; Biberthaler, P; Welch, RD; Lewis, LM; Barzo, P; Bogner-Flatz, V; Brolinson, PG; Buki, A; Chen, JY; Christenson, RH; Hack, D; Huff, JS; Johar, S; Jordan, JD; Leidel, BA; Lindner, T; Ludington, E; Okonkwo, DO; Ornato, J; Peacock, WF; Schmidt, K; Tyndall, JA; Vossough, A; Jagoda, AS				Bazarian, Jeffrey J.; Biberthaler, Peter; Welch, Robert D.; Lewis, Lawrence M.; Barzo, Pal; Bogner-Flatz, Viktoria; Brolinson, P. Gunnar; Buki, Andras; Chen, James Y.; Christenson, Robert H.; Hack, Dallas; Huff, J. Stephen; Johar, Sandeep; Jordan, J. Dedrick; Leidel, Bernd A.; Lindner, Tobias; Ludington, Elizabeth; Okonkwo, David O.; Ornato, Joseph; Peacock, W. Frank; Schmidt, Kara; Tyndall, Joseph A.; Vossough, Arastoo; Jagoda, Andy S.			Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study	LANCET NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY FINDINGS; FIBRILLARY ACIDIC PROTEIN; TERMINAL HYDROLASE-L1; EMERGENCY-DEPARTMENTS; MILD; ADULTS; S100B; METAANALYSIS; LESIONS	Background More than 50 million people worldwide sustain a traumatic brain injury (TBI) annually. Detection of intracranial injuries relies on head CT, which is overused and resource intensive. Blood-based brain biomarkers hold the potential to predict absence of intracranial injury and thus reduce unnecessary head CT scanning. We sought to validate a test combining ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), at predetermined cutoff values, to predict traumatic intracranial injuries on head CT scan acutely after TBI. Methods This prospective, multicentre observational trial included adults (>= 18 years) presenting to participating emergency departments with suspected, non-penetrating TBI and a Glasgow Coma Scale score of 9-15. Patients were eligible if they had undergone head CT as part of standard emergency care and blood collection within 12 h of injury. UCH-L1 and GFAP were measured in serum and analysed using prespecified cutoff values of 327 pg/mL and 22 pg/mL, respectively. UCH-L1 and GFAP assay results were combined into a single test result that was compared with head CT results. The primary study outcomes were the sensitivity and the negative predictive value (NPV) of the test result for the detection of traumatic intracranial injury on head CT. Findings Between Dec 6, 2012, and March 20, 2014, 1977 patients were recruited, of whom 1959 had analysable data. 125 (6%) patients had CT-detected intracranial injuries and eight (<1%) had neurosurgically manageable injuries. 1288 (66%) patients had a positive UCH-L1 and GFAP test result and 671 (34%) had a negative test result. For detection of intracranial injury, the test had a sensitivity of 0.976 (95% CI 0.931-0.995) and an NPV of 0.996 (0.987-0.999). In three (<1%) of 1959 patients, the CT scan was positive when the test was negative. Interpretation These results show the high sensitivity and NPV of the UCH-L1 and GFAP test. This supports its potential clinical role for ruling out the need for a CT scan among patients with TBI presenting at emergency departments in whom a head CT is felt to be clinically indicated. Future studies to determine the value added by this biomarker test to head CT clinical decision rules could be warranted. Copyright (C) 2018 Elsevier Ltd. All rights reserved.	[Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY USA; [Biberthaler, Peter] Tech Univ Munich, Klinikum Rechts Isar, Munich, Germany; [Welch, Robert D.] Wayne State Univ, Detroit Receiving Hosp, Dept Emergency Med, Detroit, MI USA; [Lewis, Lawrence M.] Washington Univ, Div Emergency Med, St Louis, MO USA; [Barzo, Pal] Univ Szeged, Szeged, Hungary; [Bogner-Flatz, Viktoria] Ludwig Maximilians Univ Munchen, Dept Trauma Surg, Munich, Germany; [Brolinson, P. Gunnar] New River Valley Hosp, Edward Via Coll Osteopath Med, Blacksburg, VA USA; [Buki, Andras] Univ Pecs, MTA PTE Clin Neurosci MR Res Grp, Dept Neurosurg,Janos Szentagothai Res Ctr, Hungarian Brain Res Program,Med Sch, Pecs, Hungary; [Chen, James Y.] Univ Calif San Diego Hlth Syst, VA San Diego Healthcare Syst, Dept Radiol, La Jolla, CA USA; [Christenson, Robert H.] Univ Maryland, Med Ctr, Dept Pathol, Sch Med, Baltimore, MD 21201 USA; [Hack, Dallas; Schmidt, Kara] US Army Med Res & Mat Command, Ft Detrick, MD USA; [Huff, J. Stephen] Univ Virginia, Charlottesville, VA USA; [Jordan, J. Dedrick] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA; [Leidel, Bernd A.; Lindner, Tobias] Charite Univ Med Berlin, Berlin, Germany; [Ludington, Elizabeth] Agil Clin, Carlsbad, CA USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurosurg Sci, Pittsburgh, PA USA; [Ornato, Joseph] Virginia Commonwealth Univ Hlth Syst, Dept Emergency Med, Richmond, VA USA; [Peacock, W. Frank] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA; [Schmidt, Kara] US Army Med Res & Mat Command, Ft Detrick, MD USA; [Tyndall, Joseph A.] Univ Florida, Dept Emergency Med, Gainesville, FL USA; [Vossough, Arastoo] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Jagoda, Andy S.] Mt Sinai Hlth Syst, Dept Emergency Med, New York, NY USA		Welch, RD (corresponding author), Wayne State Univ, Sch Med, Dept Emergency Med, UHC 6G, Detroit, MI 48201 USA.	rwelch@med.wayne.edu		Jordan, Dedrick/0000-0002-0706-9583; LEIDEL, Bernd A./0000-0002-5149-8764	Banyan Biomarkers; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Banyan Biomarkers and US Army Medical Research and Materiel Command.	Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Easter JS, 2015, JAMA-J AM MED ASSOC, V314, P2672, DOI 10.1001/jama.2015.16316; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Heidari K, 2015, BRAIN INJURY, V29, P1146, DOI [10.3109/02699052.2014.948068, 10.3109/02699052.2015.1037349]; Huff JS, 2014, AM J EMERG MED, V32, P606, DOI 10.1016/j.ajem.2014.03.010; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sharp AL, 2017, ACAD EMERG MED, V24, P22, DOI 10.1111/acem.13061; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Tavender EJ, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-8; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149	27	145	149	4	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2018	17	9					782	789		10.1016/S1474-4422(18)30231-X			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GQ3AO	WOS:000441532100013	30054151	Green Accepted	Y	N	2022-02-06	
J	Shinozaki, Y; Shibata, K; Yoshida, K; Shigetomi, E; Gachet, C; Ikenaka, K; Tanaka, KF; Koizumi, S				Shinozaki, Youichi; Shibata, Keisuke; Yoshida, Keitaro; Shigetomi, Eiji; Gachet, Christian; Ikenaka, Kazuhiro; Tanaka, Kenji F.; Koizumi, Schuichi			Transformation of Astrocytes to a Neuroprotective Phenotype by Microglia via P2Y(1) Receptor Downregulation	CELL REPORTS			English	Article							TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; INTESTINAL EPITHELIAL-CELLS; BLOOD-BRAIN-BARRIER; IN-VIVO; NEURONAL DEGENERATION; REACTIVE ASTROCYTES; GENE-EXPRESSION; TRANSGENIC MICE; SCAR FORMATION	Microglia and astrocytes become reactive following traumatic brain injury (TBI). However, the coordination of this reactivity and its relation to pathophysiology are unclear. Here, we show that microglia transform astrocytes into a neuroprotective phenotype via downregulation of the P2Y(1) purinergic receptor. TBI initially caused microglial activation in the injury core, followed by reactive astrogliosis in the peri-injured region and formation of a neuroprotective astrocyte scar. Equivalent changes to astrocytes were observed in vitro after injury. This change in astrocyte phenotype resulted from P2Y(1) receptor downregulation, mediated by microglia-derived cytokines. In mice, astrocyte-specific P2Y(1) receptor overexpression (Astro-P2Y(1)OE) counteracted scar formation, while astrocyte-specific P2Y(1) receptor knockdown (Astro-P2Y(1)KD) facilitated scar formation, suggesting critical roles of P2Y(1) receptors in the transformation. Astro-P2Y(1)OE and Astro-P2Y(1)KD mice showed increased and reduced neuronal damage, respectively. Altogether, our findings indicate that microglia-astrocyte interaction, involving a purinergic signal, is essential for the formation of neuroprotective astrocytes.	[Shinozaki, Youichi; Shibata, Keisuke; Shigetomi, Eiji; Koizumi, Schuichi] Univ Yamanashi, Interdisciplinary Grad Sch Med, Dept Neuropharmacol, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan; [Yoshida, Keitaro; Tanaka, Kenji F.] Keio Univ, Sch Med, Dept Neuropsychiat, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan; [Gachet, Christian] INSERM, U 311, Etab Transfus Sanguine, 10 Rue Spielmann,BP 36, F-67065 Strasbourg, France; [Ikenaka, Kazuhiro] Natl Inst Physiol Sci, Div Neurobiol & Bioinformat, 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan		Koizumi, S (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med, Dept Neuropharmacol, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.	skoizumi@yamanashi.ac.jp	Shinozaki, Youichi/AAC-9431-2019; Gachet, Christian/H-9156-2016; Shinozaki, Youichi/E-8594-2010; Koizumi, Schuichi/E-8568-2010; SHIGETOMI, EIJI/I-2372-2012	Shinozaki, Youichi/0000-0002-6448-1304; Shinozaki, Youichi/0000-0002-6448-1304; Koizumi, Schuichi/0000-0001-6184-3106; Tanaka, Kenji/0000-0003-2511-0057; Shigetomi, Eiji/0000-0002-5267-6155; Yoshida, Keitaro/0000-0003-2196-7635	Japan Society for the Promotion of Science (JSPS) KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23700442, 16H04669, 25670622, 25117003]; Uehara FoundationUehara Memorial Foundation; Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED)	We thank Drs. Morizawa, Hirayama, and Imura and Mr. Hayashi and Mr. Komatsu (University of Yamanashi) for fruitful discussions. PLX5622 was provided under Materials Transfer Agreement (MTA) by Plexxikon Inc. This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI grants 23700442 to Y.S. and 16H04669, 25670622, and 25117003 to S.K., the Uehara Foundation to Y.S., grants-in-aid from the Japan Agency for Medical Research and Development (AMED) to S.K.	Alexianu ME, 2001, NEUROLOGY, V57, P1282, DOI 10.1212/WNL.57.7.1282; Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bilodeau MS, 2015, BIOCHEM CELL BIOL, V93, P38, DOI 10.1139/bcb-2014-0098; Braun N, 2000, EUR J NEUROSCI, V12, P4357, DOI 10.1046/j.1460-9568.2000.01342.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Campbell IL, 2014, J NEUROSCI, V34, P2503, DOI 10.1523/JNEUROSCI.2830-13.2014; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chucair-Elliott AJ, 2014, GLIA, V62, P1418, DOI 10.1002/glia.22689; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Degagne E, 2012, FEBS J, V279, P2957, DOI 10.1111/j.1742-4658.2012.08676.x; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Faideau M, 2010, HUM MOL GENET, V19, P3053, DOI 10.1093/hmg/ddq212; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Foka P, 2009, INT J BIOCHEM CELL B, V41, P1189, DOI 10.1016/j.biocel.2008.10.024; Friedle SA, 2011, GLIA, V59, P1, DOI 10.1002/glia.21071; Halassa MM, 2010, ANNU REV PHYSIOL, V72, P335, DOI 10.1146/annurev-physiol-021909-135843; Hamby ME, 2012, J NEUROSCI, V32, P14489, DOI 10.1523/JNEUROSCI.1256-12.2012; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; HED J, 1983, HISTOCHEMISTRY, V79, P105, DOI 10.1007/BF00494347; Heine P, 2001, EUR J BIOCHEM, V268, P364, DOI 10.1046/j.1432-1033.2001.01896.x; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Inoue K, 2008, CELL MOL LIFE SCI, V65, P3074, DOI 10.1007/s00018-008-8210-3; Kanemaru K, 2013, P NATL ACAD SCI USA, V110, P11612, DOI 10.1073/pnas.1300378110; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Leon C, 1999, THROMB HAEMOSTASIS, V81, P775, DOI 10.1055/s-0037-1614570; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Nedeljkovic N, 2006, CELL BIOL INT, V30, P541, DOI 10.1016/j.cellbi.2006.03.001; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Noguchi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057898; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rothaug M, 2016, BBA-MOL CELL RES, V1863, P1218, DOI 10.1016/j.bbamcr.2016.03.018; Safiulina VF, 2006, J BIOL CHEM, V281, P23464, DOI 10.1074/jbc.M601627200; Sapp E, 2001, J NEUROPATH EXP NEUR, V60, P161, DOI 10.1093/jnen/60.2.161; Schmid B, 2001, ENDOCRINOLOGY, V142, P1380, DOI 10.1210/en.142.4.1380; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shibata K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023510; Shinozaki Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep04329; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Tanaka KF, 2010, BIOL PSYCHIAT, V67, P770, DOI 10.1016/j.biopsych.2009.12.020; Tong XP, 2014, NAT NEUROSCI, V17, P694, DOI 10.1038/nn.3691; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Valdearcos M, 2014, CELL REP, V9, P2124, DOI 10.1016/j.celrep.2014.11.018; Vig S, 2012, INT J BIOCHEM CELL B, V44, P113, DOI 10.1016/j.biocel.2011.10.004; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Weiss T, 1998, J IMMUNOL, V161, P3136; Yang P, 2012, EXP NEUROL, V236, P19, DOI 10.1016/j.expneurol.2012.03.019; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097	70	145	148	2	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	MAY 9	2017	19	6					1151	1164		10.1016/j.celrep.2017.04.047			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	EV9SC	WOS:000402124700008	28494865	gold			2022-02-06	
J	Mysliwiec, V; McGraw, L; Pierce, R; Smith, P; Trapp, B; Roth, BJ				Mysliwiec, Vincent; McGraw, Leigh; Pierce, Roslyn; Smith, Patrick; Trapp, Brandon; Roth, Bernard J.			Sleep Disorders and Associated Medical Comorbidities in Active Duty Military Personnel	SLEEP			English	Article						Deployment; insomnia; mild traumatic brain injury (mTBI); military; obstructive sleep apnea (OSA); posttraumatic stress disorder (PTSD); short sleep duration (SSD)	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DISORDERS; CHRONIC INSOMNIA; COMBAT VETERANS; UNITED-STATES; US VETERANS; RISK-FACTOR; IRAQ; DURATION; AFGHANISTAN	Study Objectives: Describe the prevalence of sleep disorders in military personnel referred for polysomnography and identify relationships between demographic characteristics, comorbid diagnoses, and specific sleep disorders. Design: Retrospective cross-sectional study. Setting: Military medical treatment facility. Participants: Active duty military personnel with diagnostic polysomnogram in 2010. Measurements: Primary sleep disorder rendered by review of polysomnogram and medical record by a board certified sleep medicine physician. Demographic characteristics and conditions of posttraumatic stress disorder (PTSD), mild traumatic brain injury (mTBI), anxiety,depression, and pain syndromes determined by medical record review. Results: Primary sleep diagnoses (n = 725) included: mild obstructive sleep apnea (OSA), 207 (27.2%); insomnia, 188 (24.7%); moderate-to-severe OSA, 183 (24.0 %); and paradoxical insomnia, 39 (5.1%); behaviorally induced insufficient sleep syndrome, 68 (8.9%) and snoring, 40 (5.3%) comprised our control group. Short sleep duration (< 5 h) was reported by 41.8%. Overall 85.2% had deployed, with 58.1% having one or more comorbid diagnoses. Characteristics associated with moderate-to-severe OSA were age (adjusted odds ratio [OR], 1.03 [95% confidence interval {CI}, 1.0-1.05], sex (male) (adjusted OR, 19.97 [95% CI, 2.66-150.05], anxiety (adjusted OR, 0.58 [95% CI, 0.34-0.99]), and body mass index, BMI (adjusted OR 1.19 [95% CI, 1.13-1.25]; for insomnia, characteristics included PTSD (adjusted OR, 2.12 [95% CI, 1.31-3.44]), pain syndromes (adjusted OR, 1.48 [95% CI, 1.01-2.12]), sex (female) (adjusted OR, 0.22 [95% CI, 0.12-0.41]) and lower BMI (adjusted OR, 0.91 [95% CI, 0.87, 0.95]). Conclusions: Service-related illnesses are prevalent in military personnel who undergo polysomnography with significant associations between PTSD, pain syndromes, and insomnia. Despite having sleep disorders, almost half reported short sleep duration. Multidisciplinary assessment and treatment of military personnel with sleep disorders and service-related illnesses are required.	[Mysliwiec, Vincent; McGraw, Leigh; Pierce, Roslyn; Smith, Patrick; Trapp, Brandon; Roth, Bernard J.] Madigan Army Med Ctr, Joint Base Lewis McChord, Tacoma, WA 98431 USA		Mysliwiec, V (corresponding author), Madigan Army Med Ctr, Dept Pulm Crit Care & Sleep Med, 9040A Fitzsimmons Ave, Tacoma, WA 98431 USA.	vincent.mysliwiec@us.army.mil			Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855]	Vincent Mysliwiec, MD had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This study was supported, in part, by grant #60855 from the Center for Neuroscience and Regenerative Medicine. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The opinions and assertions in this manuscript are those of the authors and do not necessarily represent those of the Department of the Army, Department of Defense, US government, or the Center for Neuroscience and Regenerative Medicine.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Amin MM, 2010, MIL MED, V175, P155; [Anonymous], 2010, Medical Surveillance Monthly Report, V17, P12; [Anonymous], 2010, Medical Surveillance Monthly Report, V17, P8; Armed Forces Health Surveillance Center (AFHSC), 2011, MSMR, V18, P2; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Belmont Philip J, 2010, J Surg Orthop Adv, V19, P2; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Dinges DF, 1997, SLEEP, V20, P267; Drake C, 2010, SLEEP, V33, P745, DOI 10.1093/sleep/33.6.745; Fernandez-Mendoza J, 2011, PSYCHOSOM MED, V73, P88, DOI 10.1097/PSY.0b013e3181fe365a; Ferrie JE, 2007, SLEEP, V30, P1659, DOI 10.1093/sleep/30.12.1659; Gangwisch JE, 2007, SLEEP, V30, P1667, DOI 10.1093/sleep/30.12.1667; Gangwisch JE, 2005, SLEEP, V28, P1289, DOI 10.1093/sleep/28.10.1289; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Harvey AG, 2007, BEHAV RES THER, V45, P2491, DOI 10.1016/j.brat.2007.04.007; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iber C., 2007, AASM MANUAL SCORING, P7; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Knutson KL, 2010, SLEEP, V33, P37, DOI 10.1093/sleep/33.1.37; Kripke DF, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000850; Kripke DF, 2002, ARCH GEN PSYCHIAT, V59, P131, DOI 10.1001/archpsyc.59.2.131; Krueger PM, 2009, AM J EPIDEMIOL, V169, P1052, DOI 10.1093/aje/kwp023; Lettieri CJ, 2005, J CLIN SLEEP MED, V1, P381; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; Luyster FS, 2010, J CLIN SLEEP MED, V6, P196; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Miller NL, 2005, SLEEP, V28, P837, DOI 10.1093/sleep/28.7.837; Morphy H, 2007, SLEEP, V30, P274; Moul DE, 2002, SLEEP, V25, P553; Pace-Schott EF, 2009, SLEEP, V32, P19; Pack AI, 2006, AM J RESP CRIT CARE, V173, P7, DOI 10.1164/rccm.200509-1478OE; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Picchioni D, 2010, MIL PSYCHOL, V22, P340, DOI 10.1080/08995605.2010.491844; Pressman M, 2002, PRIMER POLYSOMNOGRAM; Punjabi NM, 2000, SLEEP, V23, P471, DOI 10.1093/sleep/23.4.471; Rajaratnam SMW, 2011, JAMA-J AM MED ASSOC, V306, P2567, DOI 10.1001/jama.2011.1851; ROSS RJ, 1989, AM J PSYCHIAT, V146, P697; Roth Thomas, 2003, Clin Cornerstone, V5, P5, DOI 10.1016/S1098-3597(03)90031-7; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; STAEDT J, 1993, J SLEEP RES, V2, P134, DOI 10.1111/j.1365-2869.1993.tb00076.x; Taylor DJ, 2005, SLEEP, V28, P1457, DOI 10.1093/sleep/28.11.1457; Ulmer CS, 2011, J CLIN SLEEP MED, V7, P57; United States Central Command, 2012, PPG TAB AMPL MIN STA; Vanable PA, 2000, SLEEP, V23, P71; Vgontzas AN, 2012, SLEEP, V35, P61, DOI 10.5665/sleep.1586; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Zayfert C, 2004, J TRAUMA STRESS, V17, P69, DOI 10.1023/B:JOTS.0000014679.31799.e7	56	145	152	0	26	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	FEB 1	2013	36	2					167	174		10.5665/sleep.2364			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	082LQ	WOS:000314393700005	23372263	Green Published, Bronze			2022-02-06	
J	Aoki, Y; Inokuchi, R; Gunshin, M; Yahagi, N; Suwa, H				Aoki, Yuta; Inokuchi, Ryota; Gunshin, Masataka; Yahagi, Naoki; Suwa, Hiroshi			Diffusion tensor imaging studies of mild traumatic brain injury: a meta-analysis	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CORPUS-CALLOSUM; AXONAL INJURY; MATTER CHANGES; MODERATE; ABNORMALITIES; TRACTOGRAPHY; DYSFUNCTION; INTEGRITY; SEVERITY; ADULTS	Objectives To assess the possibility that diffusion tensor imaging (DTI) can detect white matter damage in mild traumatic brain injury (mTBI) patients via systematic review and meta-analysis. Methods DTI studies that compared mTBI patients and controls were searched using MEDLINE, Web of Science, and EMBASE, (1980 through April 2012). Results A comprehensive literature search identified 28 DTI studies, of which 13 independent DTI studies of mTBI patients were eligible for the meta-analysis. Random effect model demonstrated significant fractional anisotropy (FA) reduction in the corpus callosum (CC) (p=0.023, 95% CIs -0.466 to -0.035, 280 mTBIs and 244 controls) with no publication bias and minimum heterogeneity, and a significant increase in mean diffusivity (MD) (p=0.015, 95% CIs 0.062 to 0.581, 154 mTBIs and 100 controls). Meta-analyses of the subregions of the CC demonstrated in the splenium FA was significantly reduced (p=0.025, 95% CIs -0.689 to -0.046) and MD was significantly increased (p=0.013, 95% CIs 0.113 to 0.950). FA was marginally reduced in the midbody (p=0.099, 95% CIs -0.404 to 0.034), and no significant change in FA (p=0.421, 95% CIs -0.537 to 0.224) and MD (p=0.264, 95% CIs -0.120 to 0.438) in the genu of the CC. Conclusions Our meta-analysis revealed the posterior part of the CC was more vulnerable to mTBI compared with the anterior part, and suggested the potential utility of DTI to detect white matter damage in the CC of mTBI patients.	[Aoki, Yuta; Suwa, Hiroshi] Ebara Hosp, Tokyo Metropolitan Hlth & Med Treatment Corp, Dept Psychiat, Ota, Tokyo 1450065, Japan; [Aoki, Yuta; Inokuchi, Ryota; Gunshin, Masataka; Yahagi, Naoki] Tokyo Univ Hosp, Dept Emergency & Crit Care Med, Tokyo 113, Japan; [Inokuchi, Ryota; Yahagi, Naoki] Univ Tokyo, Grad Sch Med, Dept Emergency & Crit Care Med, Tokyo, Japan		Aoki, Y (corresponding author), Ebara Hosp, Tokyo Metropolitan Hlth & Med Treatment Corp, Dept Psychiat, Ota, Tokyo 1450065, Japan.	youyouryuta@gmail.com		aoki, yuta/0000-0001-5617-4948			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Aoki Y, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2011.65; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; Chan YL, 2003, PEDIATR RADIOL, V33, P574, DOI 10.1007/s00247-003-0949-y; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Eickhoff SB, 2012, NEUROIMAGE, V59, P2349, DOI 10.1016/j.neuroimage.2011.09.017; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Higgins J.P., 2011, COCHRANE HDB SYSTEMA; Imperati D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023437; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Menzler K, 2011, NEUROIMAGE, V54, P2557, DOI 10.1016/j.neuroimage.2010.11.029; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nobuhara K, 2006, J NEUROL NEUROSUR PS, V77, P120, DOI 10.1136/jnnp.2004.055129; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pfefferbaum A, 2009, BIOL PSYCHIAT, V65, P680, DOI 10.1016/j.biopsych.2008.10.039; Radua J, 2009, BRIT J PSYCHIAT, V195, P393, DOI 10.1192/bjp.bp.108.055046; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Ridgway GR, 2008, NEUROIMAGE, V40, P1429, DOI 10.1016/j.neuroimage.2008.01.003; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	62	145	150	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2012	83	9					870	876		10.1136/jnnp-2012-302742			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	988QY	WOS:000307506800009	22797288	Green Published, hybrid			2022-02-06	
J	Tang, L; Ge, YL; Sodickson, DK; Miles, L; Zhou, YX; Reaume, J; Grossman, RI				Tang, Lin; Ge, Yulin; Sodickson, Daniel K.; Miles, Laura; Zhou, Yongxia; Reaume, Joseph; Grossman, Robert I.			Thalamic Resting-State Functional Networks: Disruption in Patients with Mild Traumatic Brain Injury	RADIOLOGY			English	Article							NERVE INJURY; CORTEX; CONNECTIVITY; ATTENTION; SEVERITY; NEUROPSYCHOLOGY; REORGANIZATION; PLASTICITY; RESPONSES; SCALE	Purpose: To explore the neural correlates of the thalamus by using resting-state functional magnetic resonance (MR) imaging and to investigate whether thalamic resting-state networks (RSNs) are disrupted in patients with mild traumatic brain injury (MTBI). Materials and Methods: This HIPAA-compliant study was approved by the institutional review board, and written informed consent was obtained from 24 patients with MTBI and 17 healthy control subjects. The patients had varying degrees of symptoms, with a mean disease duration of 22 days. The resting-state functional MR imaging data were analyzed by using a standard seed-based whole-brain correlation method to characterize thalamic RSNs. Student t tests were used to perform comparisons. The association between thalamic RSNs and performance on neuropsychologic and neurobehavioral measures was also investigated in patients with MTBI by using Spearman rank correlation. Results: A normal pattern of thalamic RSNs was demonstrated in healthy subjects. This pattern was characterized as representing relatively symmetric and restrictive functional thalamocortical connectivity, suggesting an inhibitory property of the thalamic neurons during the resting state. This pattern was disrupted, with significantly increased thalamic RSNs (P <= .005) and decreased symmetry (P = .03) in patients with MTBI compared with healthy control subjects. Increased functional thalamocortical redistributive connectivity was correlated with diminished neurocognitive functions and clinical symptoms in patients with MTBI. Conclusion: These findings of abnormal thalamic RSNs lend further support to the presumed subtle thalamic injury in patients with MTBI. Resting-state functional MR imaging can be used as an additional imaging modality for detection of thalamocortical connectivity abnormalities and for better understanding of the complex persistent postconcussive syndrome. (C) RSNA, 2011	[Tang, Lin; Ge, Yulin; Sodickson, Daniel K.; Miles, Laura; Zhou, Yongxia; Reaume, Joseph; Grossman, Robert I.] NYU, Sch Med, Dept Radiol, Ctr Biomed Imaging, New York, NY 10016 USA		Ge, YL (corresponding author), NYU, Sch Med, Dept Radiol, Ctr Biomed Imaging, 660 1st Ave,4th Floor, New York, NY 10016 USA.	yulin.ge@nyumc.org	Ge, Yulin/L-7052-2019; Ge, Yulin/D-9060-2019; Sodickson, Daniel/AAV-4715-2021	Ge, Yulin/0000-0002-2320-6031; Sodickson, Daniel/0000-0002-2436-4664; Zhou, Yongxia (Sharon)/0000-0002-4931-2318	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL069023] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039135, R01 NS029029] Funding Source: Medline		Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Aron AR, 2003, BRAIN, V126, P713, DOI 10.1093/brain/awg067; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Boly M, 2008, HUM BRAIN MAPP, V29, P868, DOI 10.1002/hbm.20602; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Churchill JD, 2001, BRAIN RES, V910, P142, DOI 10.1016/S0006-8993(01)02703-2; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Delis D.C., 2000, CALIFORNIA VERBAL LE; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; FRISTON KJ, 1995, J CEREBR BLOOD F MET, V15, P361, DOI 10.1038/jcbfm.1995.45; GARRAGHTY PE, 1991, NEUROREPORT, V2, P747, DOI 10.1097/00001756-199112000-00004; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Goldstein RZ, 2007, NEUROIMAGE, V35, P194, DOI 10.1016/j.neuroimage.2006.12.004; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; GRONWALL D, 1974, LANCET, V2, P1452; Hahn B, 2007, J NEUROSCI, V27, P3477, DOI 10.1523/JNEUROSCI.5129-06.2007; Kirov II, 2009, J NEUROL NEUROSUR PS, V80, P1330, DOI 10.1136/jnnp.2009.176263; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Levine Robert A, 2002, Curr Cardiol Rep, V4, P125, DOI 10.1007/s11886-002-0024-6; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Llinas RR, 1999, P NATL ACAD SCI USA, V96, P15222, DOI 10.1073/pnas.96.26.15222; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Meindl T, 2010, HUM BRAIN MAPP, V31, P237, DOI 10.1002/hbm.20860; Meyers JE., 1995, REY COMPLEX FIGURE T; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Reitan RM, 1992, TRAIL MAKING TEST MA; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Smith, 1973, SYMBOL DIGIT MODALIT; Sorg C, 2007, P NATL ACAD SCI USA, V104, P18760, DOI 10.1073/pnas.0708803104; Stein T, 2000, AM J NEURORADIOL, V21, P1397; Steriade M, 2005, TRENDS NEUROSCI, V28, P317, DOI 10.1016/j.tins.2005.03.007; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Welsh RC, 2010, SCHIZOPHRENIA BULL, V36, P713, DOI 10.1093/schbul/sbn145; Zhang DY, 2008, J NEUROPHYSIOL, V100, P1740, DOI 10.1152/jn.90463.2008; Zhou Y, 2007, NEUROSCI LETT, V417, P297, DOI 10.1016/j.neulet.2007.02.081; Zhu CZ, 2008, NEUROIMAGE, V40, P110, DOI 10.1016/j.neuroimage.2007.11.029	55	145	146	0	15	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	SEP	2011	260	3					831	840		10.1148/radiol.11110014			10	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	808AI	WOS:000293944700026	21775670	Green Published			2022-02-06	
J	Delanian, S; Chatel, C; Porcher, R; Depondt, J; Lefaix, JL				Delanian, Sylvie; Chatel, Cecile; Porcher, Raphael; Depondt, Joel; Lefaix, Jean-Louis			COMPLETE RESTORATION OF REFRACTORY MANDIBULAR OSTEORADIONECROSIS BY PROLONGED TREATMENT WITH A PENTOXIFYLLINE-TOCOPHEROL-CLODRONATE COMBINATION (PENTOCLO): A PHASE II TRIAL	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS			English	Article; Proceedings Paper	Workshop of the Royal-College-of-Surgeons-of-England	NOV, 2007	London, ENGLAND	Royal Coll Surg		Pentoxifylline; Alpha tocopherol; Clodronate; Osteoradionecrosis; Radiotherapy	TREATMENT COMBINING PENTOXIFYLLINE; VITAMIN-E SUPPLEMENTATION; TISSUE-INJURY; RADIATION; BISPHOSPHONATES; OSTEONECROSIS; PREVENTION; METAANALYSIS; MANAGEMENT; THERAPY	Purpose: Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Combined treatment with pentoxifylline and vitamin E reduces radiation-induced fibrosis and ORN with a good prognosis. We previously showed that the combination of pentoxifylline and vitamin E with clodronate (PENTOCLO) is useful in healing sternocostal and some mandibular ORN. Is PENTOCLO effective in ORN of poor prognosis? Methods: 54 eligible patients previously irradiated for head and neck cancer (among 72 treated) a mean 5 years previously received exteriorized refractory mandibular ORN for 1.4 +/- 1.8 years, mainly after local surgery and hyperbaric oxygen had been ineffective. The mean length of exposed bone (D) was 17 +/- 8 mm as primary endpoint, and the mean Subjective, Objective, Management, and Analytic evaluation of injury (SOMA) score was 16 +/- 4. Between August 2000 and August 2008, all patients were given daily oral PENTOCLO: 800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week. The duration of treatment was related to consolidated healing. Results: Prolonged treatment (16 +/- 9 months) was safe and well tolerated. All patients improved, with an exponential progressive-(f[t] = a.exp(-b.t)-and significant (p < 0.0001) reduction of exposed bone (D), respectively (months): D-2 -42%, D-4 -62%, D-6 -77%, D-12 -92%, and D-18 -96%, combined with iterative spontaneous sequestrectomies in 36 patients. All patients experienced complete recovery in a median of 9 months. Clinical improvement was measured in terms of discontinuation of analgesics, new fracture, closed skin fistulae, and delayed radiologic improvement: SOMA(6) -64%, SOMA(12) -89%, and SOMA(30) -96%. Conclusion: Long-term PENTOCLO treatment is effective, safe, and curative for refractory ORN and induces mucosal and bone healing with significant symptom improvement. These findings will need to be confirmed in a randomized trial. (c) 2011 Elsevier Inc.	Hop St Louis, APHP, Serv Oncol Radiotherapie, F-75010 Paris, France; [Porcher, Raphael] Hop St Louis, APHP, Dept Biostat & Informat Med, F-75010 Paris, France; [Chatel, Cecile] Inst Gustave Roussy, Villejuif, France; [Depondt, Joel] Hop Bichat Claude Bernard, APHP, Serv Chirurg Cervicofaciale, F-75877 Paris, France; [Lefaix, Jean-Louis] GANIL, CIRIL, LARIA, IRCM,CEA,DSV, F-14021 Caen, France		Delanian, S (corresponding author), Hop St Louis, APHP, Serv Oncol Radiotherapie, 1 Ave Claude Vellefaux, F-75010 Paris, France.	sylvie.delanian@sls.ap-hop-paris.fr		DELANIAN, Sylvie/0000-0003-1017-9502; Porcher, Raphael/0000-0002-5277-4679			Annane D, 2004, J CLIN ONCOL, V22, P4893, DOI 10.1200/JCO.2004.09.006; Annane D, 2009, JAMA-J AM MED ASSOC, V301, P2362, DOI 10.1001/jama.2009.815; Anscher MS, 2005, J CLIN ONCOL, V23, P8551, DOI 10.1200/JCO.2005.03.6194; Ayad T, 2008, ANN CHIR PLAST ESTH, V53, P487, DOI 10.1016/j.anplas.2008.04.001; BALOGH JM, 1989, J OTOLARYNGOL, V18, P245; BENDICH A, 1988, AM J CLIN NUTR, V48, P612, DOI 10.1093/ajcn/48.3.612; Berry D, 2009, CLIN TRIALS, V6, P28, DOI 10.1177/1740774508101279; Boerma M, 2008, INT J RADIAT ONCOL, V72, P170, DOI 10.1016/j.ijrobp.2008.04.042; BRAS J, 1990, AM J OTOLARYNG, V11, P244, DOI 10.1016/0196-0709(90)90084-9; CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459; Dambrain R., 1993, Revue de Stomatologie et de Chirurgie Maxillo-Faciale, V94, P140; Delanian S, 2005, J CLIN ONCOL, V23, P8570, DOI 10.1200/JCO.2005.02.4729; Delanian S, 2005, HEAD NECK-J SCI SPEC, V27, P114, DOI 10.1002/hed.20121; Delanian S, 2004, RADIOTHER ONCOL, V73, P119, DOI 10.1016/j.radonc.2004.08.021; Delanian S, 2002, Cancer Radiother, V6, P1, DOI 10.1016/S1278-3218(01)00142-1; Delanian S, 2002, BRIT J RADIOL, V75, P467, DOI 10.1259/bjr.75.893.750467; Delanian S, 2007, SEMIN RADIAT ONCOL, V17, P99, DOI 10.1016/j.semradonc.2006.11.006; Delanian S, 2008, J NEUROL SCI, V275, P164, DOI 10.1016/j.jns.2008.08.004; Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429; Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601; Diel IJ, 2007, CRIT REV ONCOL HEMAT, V64, P198, DOI 10.1016/j.critrevonc.2007.07.005; DION MW, 1990, INT J RADIAT ONCOL, V19, P401, DOI 10.1016/0360-3016(90)90549-Y; DUNN CJ, 1993, J PHARMACOL EXP THER, V266, P1691; Eidelman RS, 2004, ARCH INTERN MED, V164, P1552, DOI 10.1001/archinte.164.14.1552; Epstein J, 1997, ORAL SURG ORAL MED O, V83, P657, DOI 10.1016/S1079-2104(97)90314-0; EPSTEIN JB, 1987, J ORAL MAXIL SURG, V45, P104, DOI 10.1016/0278-2391(87)90399-5; Froom P, 2002, AM J MED SCI, V323, P115, DOI 10.1097/00000441-200202000-00012; Futran ND, 1997, LARYNGOSCOPE, V107, P391, DOI 10.1097/00005537-199703000-00022; Lin J, 2009, JNCI-J NATL CANCER I, V101, P14, DOI 10.1093/jnci/djn438; MARX RE, 1987, ORAL SURG ORAL MED O, V64, P379, DOI 10.1016/0030-4220(87)90136-8; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Okunieff P, 2004, J CLIN ONCOL, V22, P2207, DOI 10.1200/JCO.2004.09.101; PAVY JJ, 1995, INT J RADIAT ONCOL, V31, P1043, DOI 10.1016/0360-3016(95)00059-8; Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004; Saarto T, 2008, J CLIN ONCOL, V26, P4289, DOI 10.1200/JCO.2007.15.4997; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784-009-0266-4	38	145	156	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0360-3016	1879-355X		INT J RADIAT ONCOL	Int. J. Radiat. Oncol. Biol. Phys.	JUL 1	2011	80	3					832	839		10.1016/j.ijrobp.2010.03.029			8	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology; Radiology, Nuclear Medicine & Medical Imaging	778NP	WOS:000291711700027	20638190				2022-02-06	
J	Guskiewicz, KM				Guskiewicz, Kevin M.			Balance Assessment in the Management of Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Postural stability; Equilibrium; Clinical assessment; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; ERROR SCORING SYSTEM; MILD HEAD-INJURY; SCHOOL FOOTBALL PLAYERS; POSTURAL STABILITY; CEREBRAL CONCUSSION; SENSORY INTERACTION; MOTOR-PERFORMANCE; DEFICITS; COLLEGIATE	Although neuropsychological testing has proven to be a valuable tool in concussion management, it is most useful when administered as part of a comprehensive assessment battery that includes grading of symptoms and clinical balance tests. A thorough sideline and clinical examination by the certified athletic trainer and team physician is considered an important first step in the management of concussion. The evaluation should be conducted in a systematic manner, whether on the field or in the clinical setting. The evaluation should include obtaining a history for specific details about the injury (eg, mechanism, symptomatology, concussion history), followed by assessing neurocognitive function and balance, which is the focus of this article. The objective measures from balance testing can provide clinicians with an additional piece of the concussion puzzle, remove some of the guesswork in uncovering less obvious symptoms, and assist in determining readiness to return safely to participation.	Univ N Carolina, Dept Exercise & Sport Sci, Matthew Alan Gfeller Sport Related Traumat Brain, Chapel Hill, NC 27599 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Matthew Alan Gfeller Sport Related Traumat Brain, 209 Fetzer Hall,CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130			ARCAN M, 1977, SCAND J REHABIL MED, V9, P165; Bressel E, 2007, J ATHL TRAINING, V42, P42; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; DIENER HC, 1984, BRAIN RES, V296, P103, DOI 10.1016/0006-8993(84)90515-8; DIETZ V, 1989, PROG BRAIN RES, V80, P419; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; DORNAN J, 1978, ARCH PHYS MED REHAB, V59, P586; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Guyton A., 1986, TXB MED PHYSL, P1610; Hellebrandt FA, 1939, AM J PHYS ANTHROPOL, V24, P347, DOI 10.1002/ajpa.1330240318; HORSTMANN GA, 1988, NEUROSCI LETT, V95, P179, DOI 10.1016/0304-3940(88)90653-2; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JANSEN EC, 1982, ACTA NEUROL SCAND, V66, P93; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Mallinson AI, 1998, AM J OTOL, V19, P814; MAURITZ KH, 1979, BRAIN, V102, P461, DOI 10.1093/brain/102.3.461; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mihalik JP, 2008, J SPORT REHABIL, V17, P38, DOI 10.1123/jsr.17.1.38; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; NASHNER L, 1978, BRAIN RES, V150, P403, DOI 10.1016/0006-8993(78)90291-3; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; NORRE ME, 1993, J LARYNGOL OTOL, V107, P496, DOI 10.1017/S0022215100123564; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; ROSS LM, J SPORT REH IN PRESS; RUBIN AM, 1995, AM J OTOL, V16, P216; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; SUGANO H, 1970, JPN J PHYSIOL, V20, P296; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Vander A. J., 1990, HUMAN PHYSL MECH BOD, V5th ed; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	59	145	146	0	32	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					89	+		10.1016/j.csm.2010.09.004			15	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	691XR	WOS:000285114800009	21074084				2022-02-06	
J	Omalu, BI; Bailes, J; Hammers, JL; Fitzsimmons, RP				Omalu, Bennet I.; Bailes, Julian; Hammers, Jennifer Lynn; Fitzsimmons, Robert P.			Chronic Traumatic Encephalopathy, Suicides and Parasuicides in Professional American Athletes The Role of the Forensic Pathologist	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						suicide; chronic traumatic encephalopathy; autopsy; forensic pathologist	DEPRESSION; CONCUSSION; RISK	We present 5 cases of professional American contact sport athletes who committed parasuicides and suicides aged 50, 45, 44, 36, and 40 years old. Full forensic autopsies and immunohistochemical analyses of the brains revealed chronic traumatic encephalopathy (CTE). The brains appeared grossly normal at autopsy without gross evidence of remote traumatic injuries or neurodegenerative disease. Brain immunohistochemical analyses revealed widespread cerebral taupathy in the form of neurofibrillary tangles and neuritic threads without neuritic amyloid plaques. CTE refers to chronic cognitive and neuropsychiatric symptoms of chronic neurodegeneration following a single episode of severe traumatic brain injury or repeated episodes of mild traumatic brain injury. CTE can only be definitively diagnosed by direct tissue examination. Without full autopsies and immunohistochemical brain analyses these cases would never have been identified. Forensic pathologists will play a vital and central role in the emerging disease surveillance of CTE in professional American athletes, in the identification of CTE cases, and in the establishment of the epidemiology of CTE, with the goal of eventually developing preventive and interventional therapeutic protocols for CTE outcomes.			Hammers, JL (corresponding author), Off Chief Med Examiner, 520 1st Ave, New York, NY 10016 USA.	jhammers@ocme.nyc.gov					Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mauri Massimo Carlo, 2005, Clin Pract Epidemiol Ment Health, V1, P5, DOI 10.1186/1745-0179-1-5; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; ROSENBERG ML, 1988, J FORENSIC SCI, V33, P1445; Welch SS, 2001, PSYCHIAT SERV, V52, P368, DOI 10.1176/appi.ps.52.3.368	11	145	146	1	81	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	JUN	2010	31	2					130	132		10.1097/PAF.0b013e3181ca7f35			3	Medicine, Legal; Pathology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Legal Medicine; Pathology	603KI	WOS:000278207100007	20032774				2022-02-06	
J	Bayir, H; Fadeel, B; Palladino, MJ; Witasp, E; Kurnikov, IV; Tyurina, YY; Tyurin, VA; Amoscato, AA; Jiang, J; Kochanek, PM; DeKosky, ST; Greenberger, JS; Shvedova, AA; Kagan, VE				Bayir, H.; Fadeel, B.; Palladino, M. J.; Witasp, E.; Kurnikov, I. V.; Tyurina, Y. Y.; Tyurin, V. A.; Amoscato, A. A.; Jiang, J.; Kochanek, P. M.; DeKosky, S. T.; Greenberger, J. S.; Shvedova, A. A.; Kagan, V. E.			Apoptotic interactions of cyctochrome c: Redox flirting with anionic phospholipids within and outside of mitochondria	BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS			English	Article; Proceedings Paper	14th European Bioenergetic Conference	JUL 22-27, 2006	Moscow, RUSSIA			cytochrome c; phospholipid; mitochondrion	MANGANESE SUPEROXIDE-DISMUTASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; OXIDATION-SPECIFIC EPITOPES; PROGRAMMED NEURONAL DEATH; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C; REACTIVE OXYGEN; CELL-DEATH; MACROPHAGE CLEARANCE; NATURAL ANTIBODIES	Since the (re)discovery of cytochrome c (cyt c) in the early 1920s and subsequent detailed characterization of its structure and function in mitochondrial electron transport, it took over 70 years to realize that cyt c plays a different, not less universal role in programmed cell death, apoptosis, by interacting with several proteins and forming apoptosomes. Recently, two additional essential functions of cyt c in apoptosis have been discovered that are carried out via its interactions with anionic phospholipids: a mitochondria specific phospholipid, cardiolipin (CL), and plasma membrane phosphatidylserine (PS). Execution of apoptotic program in cells is accompanied by substantial and early mitochondrial production of reactive oxygen species (ROS). Because antioxidant enhancements protect cells against apoptosis, ROS production was viewed not as a meaningless side effect of mitochondrial disintegration but rather playing some - as yet unidentified - role in apoptosis. This conundrum has been resolved by establishing that mitochondria contain a pool of cyt e, which interacts with CL and acts as a CL oxygenase. The oxygenase is activated during apoptosis, utilizes generated ROS and causes selective oxidation of CL. The oxidized CL is required for the release of pro-apoptotic factors from mitochondria into the cytosol. This redox mechanism of cyt c is realized earlier than its other well-recognized functions in the formation of apoptosomes and caspase activation. In the cytosol, released cyt c interacts with another anionic phospholipid, PS, and catalyzes its oxidation in a similar oxygenase reaction. Peroxidized PS facilitates its externalization essential for the recognition and clearance of apoptotic cells by macrophages. Redox catalysis of plasma membrane PS oxidation constitutes an important redox-dependent function of cyt c in apoptosis and phagocytosis. Thus, cyt c acts as an anionic phospholipid specific oxygenase activated and required for the execution of essential stages of apoptosis. This review is focused on newly discovered redox mechanisms of complexes of cyt c with anionic phospholipids and their role in apoptotic pathways in health and disease.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Ctr Fee Radical & Antioxidant Hlth, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15260 USA; Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-10401 Stockholm, Sweden; Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA; NIOSH, Hlth Effects Lab Div, Physiol Pathol Res Branch, Morgantown, WV 26505 USA		Bayir, H (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	bayihx@ccm.upmc.edu; vkagan@eoh.pitt.edu		Tyurina, Yulia/0000-0003-0287-2091; Amoscato, Andrew/0000-0002-1340-9150; Tyurin, Vladimir/0000-0002-3474-1697; Kochanek, Patrick/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758; Kagan, Valerian E./0000-0002-7245-1885	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R01OH008282] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL70755] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U19 AIO68021] Funding Source: Medline; NIOSH CDC HHS [OH008282] Funding Source: Medline		Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Arroyo A, 2002, J BIOL CHEM, V277, P49965, DOI 10.1074/jbc.M204513200; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; BAI J, 1999, J BIOL CHEM, V274, P26124; Bai JX, 2001, BIOL SIGNAL RECEPT, V10, P189; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Belikova NA, 2006, BIOCHEMISTRY-US, V45, P4998, DOI 10.1021/bi0525573; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Binder CJ, 2005, J LIPID RES, V46, P1353, DOI 10.1194/jlr.R500005-JLR200; Binder CJ, 2005, SPRINGER SEMIN IMMUN, V26, P385, DOI 10.1007/s00281-004-0185-z; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Bratton DL, 2005, NAT MED, V11, P26, DOI 10.1038/nm0105-26; Brown JR, 2003, J LEUKOCYTE BIOL, V73, P591, DOI 10.1189/jlb.1202599; Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Chen YR, 2002, J BIOL CHEM, V277, P29781, DOI 10.1074/jbc.M200709200; Cossarizza A, 2002, J INFECT DIS, V185, P299, DOI 10.1086/338564; Cuzzocrea S, 2004, FREE RADICAL RES, V38, P813, DOI 10.1080/10715760410001710829; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dhanasekaran A, 2005, FREE RADICAL BIO MED, V39, P567, DOI 10.1016/j.freeradbiomed.2005.04.016; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067; Epperly MW, 2003, RADIAT RES, V160, P568, DOI 10.1667/RR3081; Fabisiak JP, 1997, AM J PHYSIOL-CELL PH, V272, pC675, DOI 10.1152/ajpcell.1997.272.2.C675; Fadeel B, 2006, CELL DEATH DIFFER, V13, P360, DOI 10.1038/sj.cdd.4401836; Fadeel B, 2003, CELL MOL LIFE SCI, V60, P2575, DOI 10.1007/s00018-003-3145-1; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Fadeel B, 2003, REDOX REP, V8, P143, DOI 10.1179/135100003225001511; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; Fleming C, 2005, NAT CHEM BIOL, V1, P270, DOI 10.1038/nchembio730; Flohe L, 1988, Basic Life Sci, V49, P663; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Frostegard J, 2005, ARTHRITIS RHEUM-US, V52, P192, DOI 10.1002/art.20780; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Gohil VM, 2005, ANAL BIOCHEM, V343, P350, DOI 10.1016/j.ab.2005.04.039; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; GONZALVEZ F, 2005, CELL DEATH DIFFER, V12, P266; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Greco A, 2004, CURR NEUROVASC RES, V1, P341, DOI 10.2174/1567202043362036; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Hampton MB, 1998, BIOCHEM J, V329, P95; Hampton MB, 2002, J LEUKOCYTE BIOL, V71, P775; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Horkko S, 2001, CIRCULATION, V103, P941; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Imai H, 2003, BIOCHEM J, V371, P799, DOI 10.1042/BJ20021342; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Iwase H, 1996, BIOCHEM BIOPH RES CO, V222, P83, DOI 10.1006/bbrc.1996.0701; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kagan VE, 2005, NANOMED-NANOTECHNOL, V1, P313, DOI 10.1016/j.nano.2005.10.003; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 2003, AM J PHYSIOL-LUNG C, V285, pL1, DOI 10.1152/ajplung.00365.2002; Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Kagan VE, 2000, FEBS LETT, V477, P1, DOI 10.1016/S0014-5793(00)01707-5; Kanai A, 2004, AM J PHYSIOL-HEART C, V286, pH13, DOI 10.1152/ajpheart.00737.2003; Kentner R, 2002, J TRAUMA, V53, P968, DOI 10.1097/00005373-200211000-00025; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kinchen JM, 2005, CURR TOP DEV BIOL, V65, P1; Kirkinezos IG, 2005, J NEUROSCI, V25, P164, DOI 10.1523/JNEUROSCI.3829-04.2005; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001; KONDURU NV, 2006, 1 INT C NAN BIOM ASP; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li HQ, 2002, FREE RADICAL BIO MED, V32, P712, DOI 10.1016/S0891-5849(02)00762-1; Liang QH, 2005, BIOCHEM PHARMACOL, V70, P1371, DOI 10.1016/j.bcp.2005.04.011; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Manfredi AA, 1998, ARTHRITIS RHEUM-US, V41, P205; Mantymaa P, 2000, BRIT J HAEMATOL, V108, P574, DOI 10.1046/j.1365-2141.2000.01852.x; Matsura T, 2005, BBA-MOL CELL BIOL L, V1736, P181, DOI 10.1016/j.bbalip.2005.08.011; Matsura T, 2004, CHEM RES TOXICOL, V17, P685, DOI 10.1021/tx030050s; Mileykovskaya E, 2001, FEBS LETT, V507, P187, DOI 10.1016/S0014-5793(01)02948-9; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Montine TJ, 2005, ANTIOXID REDOX SIGN, V7, P269, DOI 10.1089/ars.2005.7.269; Moreira PI, 2005, ANN NY ACAD SCI, V1043, P545, DOI 10.1196/annals.1333.062; Nakagawa Y, 2004, ANN NY ACAD SCI, V1011, P177, DOI 10.1196/annals.1293.018; Nantes IL, 2001, J BIOL CHEM, V276, P153, DOI 10.1074/jbc.M006338200; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Oellerich S, 2003, EUR BIOPHYS J BIOPHY, V32, P599, DOI 10.1007/s00249-003-0306-y; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; PANASENKO OM, 2003, FREE RADICAL BIO MED, V34, P362; Patel NSA, 2002, FREE RADICAL BIO MED, V33, P1575, DOI 10.1016/S0891-5849(02)01116-4; Pearce LL, 2005, NITRIC OXIDE-BIOL CH, V13, P254, DOI 10.1016/j.niox.2005.07.010; Pereverzev MO, 2003, BIOCHEM SOC T, V31, P1312; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; Prasad S, 2002, BBA-PROTEIN STRUCT M, V1596, P63, DOI 10.1016/S0167-4838(02)00205-4; Price BE, 1996, J IMMUNOL, V157, P2201; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Ran QT, 2004, J BIOL CHEM, V279, P55137, DOI 10.1074/jbc.M410387200; Ran QT, 2003, FREE RADICAL BIO MED, V35, P1101, DOI 10.1016/S0891-5849(03)00466-0; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; ROBINSON NC, 1990, BIOCHEMISTRY-US, V29, P8962, DOI 10.1021/bi00490a012; Roos D, 1996, BLOOD, V87, P1663; Sandra F, 2005, CANCER RES, V65, P8286, DOI 10.1158/0008-5472.CAN-04-1913; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Sepodes B, 2004, TRANSPL P, V36, P849, DOI 10.1016/j.transproceed.2004.03.050; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serinkan BF, 2005, CELL DEATH DIFFER, V12, P1141, DOI 10.1038/sj.cdd.4401619; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Shvedova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL698, DOI 10.1152/ajplung.00084.2005; Sorice M, 2004, CELL DEATH DIFFER, V11, P1133, DOI 10.1038/sj.cdd.4401457; STELLWAGEN E, 1968, BIOCHEMISTRY-US, V7, P2496, DOI 10.1021/bi00847a008; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tarkowski E, 1999, STROKE, V30, P321, DOI 10.1161/01.STR.30.2.321; Theorell H, 1941, J AM CHEM SOC, V63, P1812, DOI 10.1021/ja01852a006; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; TYURIN VA, 2005, SOC NEUR ANN M 12 16; Tyurina YY, 2004, ANTIOXID REDOX SIGN, V6, P209, DOI 10.1089/152308604322899288; Tyurina YY, 2004, J BIOL CHEM, V279, P6056, DOI 10.1074/jbc.M309929200; Vay D, 2006, J HEPATOL, V44, P183, DOI 10.1016/j.jhep.2005.06.010; VLASOVA II, 2006, EPUB J BIOL CHEM; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228; Waters KA, 1999, PEDIATR RES, V45, P166, DOI 10.1203/00006450-199902000-00002; Weinberg A, 2004, BRAIN RES, V1012, P13, DOI 10.1016/j.brainres.2004.03.048; Wipf P, 2005, J AM CHEM SOC, V127, P12460, DOI 10.1021/ja053679l; Yao Y, 2003, NEUROLOGY, V61, P475, DOI 10.1212/01.WNL.0000070185.02546.5D; Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200; Zucchi MR, 2003, BIOCHEM J, V370, P671, DOI 10.1042/BJ20021521	148	145	151	3	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0005-2728	1879-2650		BBA-BIOENERGETICS	Biochim. Biophys. Acta-Bioenerg.	MAY-JUN	2006	1757	5-6					648	659		10.1016/j.bbabio.2006.03.002			12	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Biophysics	069XF	WOS:000239481800046	16740248	Bronze			2022-02-06	
J	Sayeed, I; Guo, QM; Hoffman, SW; Stein, DG				Sayeed, I; Guo, QM; Hoffman, SW; Stein, DG			Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; INFLAMMATORY RESPONSE; THERAPEUTIC HYPOTHERMIA; NEUROACTIVE STEROIDS; COGNITIVE DEFICITS; INTEGRATED VIEW; BLOOD-FLOW; CELL-DEATH	Study objective: We compare the effects of postinjury administration of allopregnanolone, a metabolite of progesterone, to progesterone in an animal model of transient middle cerebral artery occlusion. Methods: Focal cerebral ischemia was induced in age-matched, adult, male, Sprague-Dawley rats by using an intraluminal filament and suture method to occlude the right middle cerebral artery. After 120 minutes of middle cerebral artery occlusion, the occluding filament was withdrawn to allow reperfusion. Laser-Doppler flowmetry was used to monitor cerebral blood flow for the entire 2-hour period of occlusion and for 5 minutes after reperfusion. Animals subjected to middle cerebral artery occlusion received injections of allopregnanolone (8 mg/kg, n=6), progesterone (8 mg/kg, n=6) and vehicle (2-hydroxypropyl-beta-cyclodextrin, n=7) at 2 hours (intraperitoneally 5 minutes before reperfusion) and 6 hours (subcutaneously) postocclusion. Brains were removed at 72 hours post-middle cerebral artery occlusion, sectioned into coronal slices, and stained with 2,3,5-triphenyltetrazolium chloride (TTC). In a blinded analysis, infarct volume was calculated by using computer-aided morphometry to measure brain areas not stained with TTC. Results: After progesterone or allopregnanolone treatment, stained sections revealed a significant reduction in cortical, caudate-putamen, and hemispheric infarct volumes (percentage of contralateral structure) compared with vehicle-injected controls. Cortical infarction (percentage of contralateral cortex) was 37.47%+/- 10.57% (vehicle), 25.49%+/- 7.38% (progesterone; P <.05 from vehicle), and 11.40%+/- 7.09% (allopregnanolone; P <.05 from vehicle; P <.05 from progesterone). Caudate-putamen infarction (percentage of contralateral caudate-putamen) was 78.02%+/- 22.81% (vehicle), 48.41%+/- 22.44% (progesterone; P <.05 from vehicle), and 50.44%+/- 10.90% (allopregnanolone; P <.05 from vehicle). Total hemispheric infarction (percentage of contralateral hemisphere) was 24.37%+/- 6.69% (vehicle), 15.95%+/- 3.59% (progesterone; P <.05 from vehicle), and 11.54%+/- 3.71% (allopregnanolone; P <.05 from vehicle). No significant differences in cerebral blood flow between groups and time points during ischemia and early reperfusion were observed, suggesting that the relative ischemic insult was equivalent among all groups. Conclusion: Although progesterone and allopregnanolone are effective in reducing infarct pathology, allopregnanolone is more potent than progesterone in attenuating cortical damage. Our results suggest that both neurosteroids should be examined for safety and efficacy in a clinical trial for ischemic stroke.	Emory Univ, Brain Res Lab, Dept Emergency Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, 1365 B Clifton Rd,Suite 5100, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040825, R01NS038664] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38664, 1 R01 NS40825] Funding Source: Medline		American Heart Association, 2005, STROK HEART STAT UPD; Andersson S, 1997, STEROIDS, V62, P143, DOI 10.1016/S0039-128X(96)00173-0; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; COMPAGNONE NA, 1995, ENDOCRINOLOGY, V136, P2689, DOI 10.1210/en.136.6.2689; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Fairchild KD, 2004, AM J PHYSIOL-CELL PH, V287, pC422, DOI 10.1152/ajpcell.00507.2003; Fisher M, 2000, ARCH INTERN MED, V160, P3196, DOI 10.1001/archinte.160.21.3196; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Ginsberg MD, 1996, ARCH NEUROL-CHICAGO, V53, P1065, DOI 10.1001/archneur.1996.00550100151024; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; HE J, 2001, J NEUROTRAUM, V18, P1140; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LAING RJ, 1993, STROKE, V24, P294, DOI 10.1161/01.STR.24.2.294; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; Mcilvoy LH, 2005, AACN ADV CRIT CARE, V16, P488, DOI 10.1097/00044067-200510000-00006; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; ORCHINIK M, 1994, BRAIN RES, V646, P258, DOI 10.1016/0006-8993(94)90087-6; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Perlman Jeffrey, 2005, Curr Treat Options Neurol, V7, P451, DOI 10.1007/s11940-005-0045-8; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; POLAN ML, 1989, J CLIN ENDOCR METAB, V69, P1200, DOI 10.1210/jcem-69-6-1200; Reglodi D, 2003, BRAIN RES BULL, V59, P459, DOI 10.1016/S0361-9230(02)00962-0; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rose JC, 2004, NEUROCRIT CARE, V1, P287, DOI 10.1385/NCC:1:3:287; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Salzman AL, 2000, INT J MOL MED, V6, P209; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; STEIN DG, 1999, COGNITIVE NEUROREHAB, P73; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	71	145	147	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	APR	2006	47	4					381	389		10.1016/j.annemergmed.2005.12.011			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	029IH	WOS:000236555300014	16546625				2022-02-06	
J	Keenan, HT; Bratton, SL				Keenan, Heather T.; Bratton, Susan L.			Epidemiology and outcomes of pediatric traumatic brain injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; epidemiology; neuropsychological outcomes	COLLEGIATE FOOTBALL PLAYERS; BOOSTER SEAT USE; YOUNG-CHILDREN; HEAD-INJURIES; BEHAVIOR PROBLEMS; TRAFFIC INJURIES; NCAA CONCUSSION; PREDICTORS; ADOLESCENTS; AGE	Traumatic brain injury is a leading cause of death and disability in the pediatric age group. Causes of injury vary with child developmental age, with more inflicted injuries in infants, fall-related injuries among toddlers, sports-related injuries among middle-school-aged children and motor vehicle crashes in older children. Prevention strategies exist for some pediatric traumatic brain injury; however, all suffer from lack of compliance and enforcement. Neuropsychological and behavioral outcomes for injured children vary with the severity of injury, child age at injury, premorbid child characteristics, family factors and the families' socioeconomic status. Each of these factors needs to be taken into account when designing rehabilitation strategies and assessing factors related to outcome. Copyright (c) 2006 S. Karger AG, Basel.	Univ Utah, Dept Pediat, Div Crit Care, Salt Lake City, UT 84158 USA		Keenan, HT (corresponding author), Univ Utah, Dept Pediat, Div Crit Care, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu	Bratton, Susan L./O-2353-2013	Bratton, Susan L./0000-0002-4605-8078; Bratton, Susan/0000-0002-9254-5491			Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; Agran PF, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.3.e39; Agran PF, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.3.e45; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brehaut JC, 2003, PEDIATRICS, V111, P262, DOI 10.1542/peds.111.2.262; Bull MJ, 2001, PEDIATRICS, V108, P1030; Buller DB, 2003, J TRAUMA, V55, P939, DOI 10.1097/01.TA.0000078694.53320.CA; Burke GS, 1996, PEDIATRICS, V97, P520; Durbin DR, 2004, EPIDEMIOLOGY, V15, P345, DOI 10.1097/01.ede.0000120046.09966.a8; Durkin MS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e74; Ebel BE, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e323; Eby DW, 2005, ACCIDENT ANAL PREV, V37, P1153, DOI 10.1016/j.aap.2005.06.013; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hameed SM, 2004, AM J PUBLIC HEALTH, V94, P554, DOI 10.2105/AJPH.94.4.554; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Langlois J. A., 2000, TRAUMATIC BRAIN INJU; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Muszynski CA, 2005, J NEUROSURG, V102, P374, DOI 10.3171/ped.2005.102.4.0374; Nadler EP, 2001, PEDIATRICS, V108, P326, DOI 10.1542/peds.108.2.326; *NAT CTR INJ, 2005, PREV CONTR WISCARS; *NAT HIGHW TRANSP, 2005, 2004 ANN ASS; Newacheck PW, 2004, PEDIATRICS, V114, P79, DOI 10.1542/peds.114.1.79; PICKNEY K, IN PRESS PEDIAT EMER; Ramsey A, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.2.e20; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Scuffham P, 2000, ACCIDENT ANAL PREV, V32, P565, DOI 10.1016/S0001-4575(99)00081-0; Silen ML, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e7; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tester JM, 2004, AM J PUBLIC HEALTH, V94, P646, DOI 10.2105/AJPH.94.4.646; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; Thompson DC, 2000, COCHRANE DB SYST REV, V2; THOMPSON J, 1997, DRUMCHAPEL PROJECT C; *US CONS PROD SAF, 1977, NAT EL SURV SYST NEI; *US CONS PROD SAF, 2005, NAT BIK HELM US SURV; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; 2003, CRIT CARE MED S6, V31, pS407	61	145	149	4	30	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					256	263		10.1159/000094152			8	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600003	16943649				2022-02-06	
J	Salmond, CH; Menon, DK; Chatfield, DA; Williams, GB; Pena, A; Sahakian, BJ; Pickard, JD				Salmond, CH; Menon, DK; Chatfield, DA; Williams, GB; Pena, A; Sahakian, BJ; Pickard, JD			Diffusion tensor imaging in chronic head injury survivors: Correlations with learning and memory indices	NEUROIMAGE			English	Article							TRAUMATIC BRAIN-INJURY; COMA SCALE SCORE; ALZHEIMERS-DISEASE; AXONAL INJURY; RISK-FACTOR; WEIGHTED MR; EPISODIC MEMORY; ATTENTION; COEFFICIENT; SEVERITY	Diffusion tensor imaging (DTI) provides a unique insight into the cellular integrity of the brain. While conventional magnetic resonance imaging underestimates the extent of pathology following closed head injury, diffusion-weighted imaging has been shown to more accurately delineate the extent of cerebral damage. There have only been a few case studies of DTI in chronic head injury, survivors. This study used DTI to investigate changes in anisotropy and diffusivity in survivors of head injury at least 6 months after their injury. The relationship between cognition and diffusion abnormality was also investigated. The voxel-based analysis revealed significant bilateral decreases in anisotropy, in major white matter tracts and association fibers in the temporal, frontal, parietal and occipital lobes. Statistically significant increases in diffusivity were also found in widespread areas of the cortex. A significant positive correlation was found between diffusivity, and impairment of learning and memory in the left posterior cingulate, left hippocampal formation and left temporal, frontal and occipital cortex. The common pattern of abnormality despite heterogeneous injury mechanism and lesion location in the group suggests that these cellular changes reflect secondary insults. The importance of diffusion abnormalities in head injury outcome is emphasized by the significant correlation between a learning and memory index and diffusivity in areas known to subserve this cognitive function. (c) 2005 Elsevier Inc. All rights reserved.	Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Anaesthet, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Psychiat, Cambridge CB2 2QQ, England		Salmond, CH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Box 65, Cambridge CB2 2QQ, England.	chs20@wbic.cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354, G9439390, G0001237] Funding Source: Medline		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Blackwell AD, 2004, DEMENT GERIATR COGN, V17, P42, DOI 10.1159/000074081; Blamire AM, 2002, BRIT J NEUROSURG, V16, P48, DOI 10.1080/02688690120114264; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Eriksson SH, 2001, BRAIN, V124, P617, DOI 10.1093/brain/124.3.617; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GENTRY LR, 1994, RADIOLOGY, V191, P1; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gould RL, 2003, NEUROIMAGE, V20, P1006, DOI 10.1016/S1053-8119(03)00365-3; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Habib R, 2003, TRENDS COGN SCI, V7, P241, DOI 10.1016/S1364-6613(03)00110-4; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lepage M, 2000, P NATL ACAD SCI USA, V97, P506, DOI 10.1073/pnas.97.1.506; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1080/028418501127346990; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nyberg L, 1996, P NATL ACAD SCI USA, V93, P11280, DOI 10.1073/pnas.93.20.11280; O'Sullivan M, 2004, J NEUROL NEUROSUR PS, V75, P441, DOI 10.1136/jnnp.2003.014910; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; PARK SB, 1994, NEUROPHARMACOLOGY, V33, P575, DOI 10.1016/0028-3908(94)90089-2; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Polo MD, 2002, NEUROPSYCHOLOGIA, V40, P2350, DOI 10.1016/S0028-3932(02)00127-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; RUGGGUNN FJ, 2001, J NEUROL, V124, P627; SAHAKIAN B, 1989, BRIT J PSYCHIAT, V154, P797, DOI 10.1192/bjp.154.6.797; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Swainson R, 2001, DEMENT GERIATR COGN, V12, P265, DOI 10.1159/000051269; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Weiss F, 2002, J NEUROSCI, V22, P3332; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; [No title captured]	75	145	149	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 1	2006	29	1					117	124		10.1016/j.neuroimage.2005.07.012			8	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	001ZO	WOS:000234581400012	16084738				2022-02-06	
J	Yeates, KO; Armstrong, K; Janusz, J; Taylor, HG; Wade, S; Stancin, T; Drotar, D				Yeates, KO; Armstrong, K; Janusz, J; Taylor, HG; Wade, S; Stancin, T; Drotar, D			Long-term attention problems in children with traumatic brain injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article; Proceedings Paper	Annual Meeting of the International-Neuropsychological-Society	FEB, 2001	Chicago, IL	Int Neuropsychol Soc		traumatic brain injury; attention; outcomes children	CLOSED-HEAD-INJURY; DEFICIT HYPERACTIVITY DISORDER; DEFICIT/HYPERACTIVITY DISORDER; PSYCHIATRIC-DISORDERS; RESPONSE-INHIBITION; BEHAVIOR; CHILDHOOD; ADHD; IMPAIRMENTS; PREVALENCE	Objective: To examine long-term attention problems and their cognitive correlates after childhood traumatic brain injury (TBI). Method: Data were drawn from a prospective, longitudinal study conducted between 1992 and 2002. Participants included 41 children with severe TBI, 41 with moderate TBI, and 50 with orthopedic injury (OI), who were all between 6 and 12 years of age at the time of injury. Parent ratings of attention problems were obtained at a long-term follow-up on average 4 years post-injury and compared with ratings of premorbid attention problems obtained shortly after injury. At the long-term follow-up, children also completed several cognitive tests of attention and executive functions. Results: Hierarchical linear and logistic regression analyses indicated that the severe TBI group displayed significantly more attention problems than the OI group at 4 years post-injury, both behaviorally and cognitively, after controlling for race, socioeconomic status, and premorbid attention problems. At long-term follow-up, 46% of the severe TBI group displayed significant attention problems on the Child Behavior Checklist, as opposed to 26% of the OI group (odds ratio = 3.38; 95% confidence interval, 1.15-9.94). On the Attention-Deficit/Hyperactivity Disorder Rating Scale, 20% of the severe TBI group displayed clinically significant attention problems compared with 4% in the OI group (odds ratio = 9.59; 95% confidence interval, 1.24-73.99). However, group differences in behavioral symptoms were significantly larger for children with more premorbid symptoms than for children with fewer premorbid problems. Measures of executive functions were significantly related to behavioral attention problems, after controlling for group membership, race, and socioeconomic status. Conclusions: Childhood TBI exacerbates premorbid attention problems. Long-term behavioral symptoms of attention problems are related to the cognitive deficits in attention and executive functions that often occur in association with childhood TBI.	Childrens Hosp, Dept Psychol, Columbus, OH 43220 USA; Ohio State Univ, Dept Pediat, Columbus, OH USA; Columbus Childrens Res Inst, Columbus, OH USA; Case Western Reserve Univ & Rainbow Babies, Dept Pediat, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH USA; MetroHlth Med Ctr, Cleveland, OH USA		Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43220 USA.	yeatesk@chi.osu.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892; Janusz, Jennifer/0000-0002-6877-0947	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01 NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline		Achenbach TM, 1991, MANUAL CHILD BEHAV C; *AM PSYCH ASS, 1994, DIATN STAT MAN MENT; Anderson PJ., 2000, CLIN NEUROPSYCHOL AS, V1, P247; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson VA, 2004, J CLIN EXP NEUROPSYC, V26, P684, DOI 10.1080/13803390490504344; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Barkley R.A., 1994, FRAMES REFERENCE ASS, P69; Barkley RA, 2004, J CHILD PSYCHOL PSYC, V45, P195, DOI 10.1111/j.1469-7610.2004.00214.x; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Berquin PC, 1998, NEUROLOGY, V50, P1087, DOI 10.1212/WNL.50.4.1087; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Boyle MH, 1997, ARCH GEN PSYCHIAT, V54, P793; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; Connor PD, 2000, DEV NEUROPSYCHOL, V18, P331, DOI 10.1207/S1532694204Connor; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Doyle AE, 2000, J CONSULT CLIN PSYCH, V68, P477, DOI [10.1037//0022-006X.68.3.477, 10.1037/0022-006X.68.3.477]; DuPaul G.J., 1998, ADHD RATING SCALE 4; DUPAUL GJ, 1991, J CLIN CHILD PSYCHOL, V20, P245, DOI 10.1207/s15374424jccp2003_3; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1910, FRAMES REFERENCE ASS; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Grodzinsky GM, 1999, CLIN NEUROPSYCHOL, V13, P12, DOI 10.1076/clin.13.1.12.1983; Heiligenstein, 2001, J ATTEN DISORD, VVol 5, P107, DOI DOI 10.1177/108705470100500204; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, BRAIN INJURY, V11, P699; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mostofsky SH, 1998, J CHILD NEUROL, V13, P434, DOI 10.1177/088307389801300904; Paniak C, 1997, CLIN NEUROPSYCHOL, V11, P198, DOI 10.1080/13854049708407051; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; Sattler J.M., 2001, ASSESSMENT CHILDREN; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wassenberg R, 2004, BRAIN INJURY, V18, P377, DOI 10.1080/02699050310001617325; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilens TE, 2002, ANNU REV MED, V53, P113, DOI 10.1146/annurev.med.53.082901.103945; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; [No title captured]	69	145	145	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JUN	2005	44	6					574	584		10.1097/01.chi.0000159947.50523.64			11	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Pediatrics; Psychiatry	928BH	WOS:000229245600012	15908840				2022-02-06	
J	Bibby, H; McDonald, S				Bibby, H; McDonald, S			Theory of mind after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						mental-state; inference; lesion; brain-damage; cognitive; module	FRONTAL-LOBE DAMAGE; THEORY-OF-MIND; EXECUTIVE FUNCTIONS; SOCIAL COGNITION; HEAD-INJURY; WORKING-MEMORY; IMPAIRMENTS; CHILDREN; PERFORMANCE; DEFICITS	This study investigated whether people with severe traumatic brain injury (TBI) demonstrate a specific impairment on tasks requiring them to make inferences about others' mental states (theory of mind tasks). Participants with severe TBI were compared to a healthy group on verbal first-order and second-order theory of mind (ToM) tasks, non-verbal ToM tasks and on verbal and non-verbal tasks requiring them to make general (non-mental) inferences (NMIs). The clinical group performed more poorly than controls on both ToM and NMI tasks. This performance was not completely accounted for by the working memory or implicit language demands of the tasks. Multiple regression analyses suggested that patients with TBI have a general weakness in inference-making that, combined with linguistic and working memory limitations, impairs their performance on both non-verbal and second-order ToM tasks. However, a specific ToM impairment may underlie their poor performance on verbal first-order tasks. Implications of this finding for the possibility of a separate cognitive module of ToM are discussed, as well as for the rehabilitation of social deficits after TBI. (C) 2004 Published by Elsevier Ltd.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; ARTUSO M, 2000, DISS ABSTR INT A, V60, P3601; Attwood T., 1998, ASPERGERS SYNDROME G; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BISHOP DVM, 1993, J CHILD PSYCHOL PSYC, V34, P279, DOI 10.1111/j.1469-7610.1993.tb00992.x; BOWLER DM, 1992, J CHILD PSYCHOL PSYC, V33, P877, DOI 10.1111/j.1469-7610.1992.tb01962.x; BUTLER ACL, 1997, DISS ABSTR INT A, V57, P3389; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; DAVIS HL, 1995, AUST J PSYCHOL, V47, P25, DOI 10.1080/00049539508258765; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dimitrov M, 1996, CORTEX, V32, P357, DOI 10.1016/S0010-9452(96)80057-8; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fine C, 2001, BRAIN, V124, P287, DOI 10.1093/brain/124.2.287; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; FODER JA, 1983, MODULARITY MIND; FODOR JA, 1985, BEHAV BRAIN SCI, V8, P1, DOI 10.1017/S0140525X0001921X; FODOR JA, 1992, COGNITION, V44, P283, DOI 10.1016/0010-0277(92)90004-2; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Garfield JL, 2001, MIND LANG, V16, P494, DOI 10.1111/1468-0017.00180; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Happe F, 1996, NEUROREPORT, V8, P197, DOI 10.1097/00001756-199612200-00040; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Hughes C, 1998, BRIT J DEV PSYCHOL, V16, P233, DOI 10.1111/j.2044-835X.1998.tb00921.x; Hughes C, 1999, PSYCHOL SCI, V10, P429, DOI 10.1111/1467-9280.00181; Hughes C, 2000, J CHILD PSYCHOL PSYC, V41, P483, DOI 10.1111/1469-7610.00633; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; Keenan T, 1998, NEW ZEAL J PSYCHOL, V27, P36; KEENAN T, 2000, MINDS MAKING ESSAYS, P234; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Langdon R, 1997, Cogn Neuropsychiatry, V2, P167, DOI 10.1080/135468097396324; LEEKAM SR, 1994, J CHILD PSYCHOL PSYC, V35, P901, DOI 10.1111/j.1469-7610.1994.tb02301.x; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LISHMAN WA, 2001, ORGANIC PSYCHIAT PSY; Lough S, 2001, NEUROCASE, V7, P123, DOI 10.1076/neur.7.2.123.16266; Mazza M, 2001, SCHIZOPHR RES, V47, P299, DOI 10.1016/S0920-9964(00)00157-2; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MOSCOVITCH M, 1991, PERSPECTIVES COGNITI, P229; OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1081, DOI 10.1111/j.1469-7610.1991.tb00351.x; Powell J., 2000, COGNITIVE NEUROPSYCH, V5, P175, DOI [DOI 10.1080/13546800050083520, 10.1080/13546800050083520]; REID F, 1977, J EDUC RES, V70, P335, DOI 10.1080/00220671.1977.10885018; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Sarfati Y, 2000, PSYCHOPATHOLOGY, V33, P246, DOI 10.1159/000029153; Siegal M, 1996, BRAIN LANG, V53, P40, DOI 10.1006/brln.1996.0035; Spatt J, 1997, ACTA NEUROL SCAND, V95, P173, DOI 10.1111/j.1600-0404.1997.tb00091.x; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Surian L, 2001, BRAIN LANG, V78, P224, DOI 10.1006/brln.2001.2465; TagerFlusberg H, 1997, DEV NEUROPSYCHOL, V13, P487, DOI 10.1080/87565649709540689; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Varley R, 2001, NEUROCASE, V7, P489, DOI 10.1093/neucas/7.6.489; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; Zelazo PD, 1996, J CHILD PSYCHOL PSYC, V37, P479, DOI 10.1111/j.1469-7610.1996.tb01429.x	66	145	149	1	39	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2005	43	1					99	114		10.1016/j.neuropsychologia.2004.04.027			16	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	874ZB	WOS:000225388100012	15488910				2022-02-06	
J	Peterson, CL; Ferrara, MS; Mrazik, M; Piland, T; Elliott, T				Peterson, CL; Ferrara, MS; Mrazik, M; Piland, T; Elliott, T			Evaluation of neuropsychological stability following cerebral domain scores and postural concussion in sports	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						neuropsychology; posturography; self reported symptoms; balance; mild brain injury	MILD HEAD-INJURY; HIGH-SCHOOL; STANDARDIZED ASSESSMENT; FOOTBALL PLAYERS; TEST-PERFORMANCE; SOCCER PLAYERS; COLLEGIATE; RECOVERY; DEFICITS; BALANCE	Context: With increasing knowledge and research about concussion, there have been few objective studies that have used neuropsychological domain scores and postural stability to assess concussion. Objective: To evaluate the recovery curve of athletes who incur sport-related concussion from repeated serial testing of neuropsychological and posturography testing. Design: A prospective epidemiological model was used for the course of the study. Setting: Division I intercollegiate athletics. Participants: Athletes participating in football, soccer, basketball, softball, and cheerleading. Main Outcome Measures: Neuropsychological scores and posturography measures were obtained preseason and serially at day 1, day 2, day 3, and day 10 postconcussion. Control participants were tested at the same intervals. Neuropsychological scores were converted to standards score and then into domains of attention, learning, speed of information processing, concentration, memory, and verbal fluency. Analysis of covariance with the baseline test as the covariate was used to analyze the data with univariate post hoc tests performed. Results: Significant group differences were found for self reported symptoms (P = 0.001), speed of information processing (P = 0.005), mean stability (P = 0.002), and vestibular function (P = 0.003) between injured and control participants. A group, by day, planned comparison found that speed of information processing and composite balance measures demonstrated significant differences through day 10 postinjury, while symptoms and the vestibular ratio remained significant only through day 3. Conclusions: The concussion recovery curve demonstrated short-term neuropsychological and posturography deficits following injury. A comprehensive approach to concussion management should be used to assess the injury and make return-to-play decisions.	James Madison Univ, Harrisonburg, VA 22807 USA; Univ Georgia, Athens, GA 30602 USA; Millard Hlth, Edmonton, AB, Canada		Peterson, CL (corresponding author), James Madison Univ, MSC 4301, Harrisonburg, VA 22807 USA.	peterscl@jmu.edu					Barth JT, 1989, MILD HEAD INJURY; Benton A., 1978, MULTILINGUAL APHASIA; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cooper ER, 2001, ATHLET THER TODAY, V6, P6, DOI 10.1123/att.6.1.6; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DIFABIO RP, 1991, ARCH PHYS MED REHAB, V72, P292; DIFABIO RP, 1995, PHYS THER, V75, P290, DOI 10.1093/ptj/75.4.290; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Ferrara Michael S., 2001, J Athl Train, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FURMAN JM, 1994, BAILLIERE CLIN NEUR, V3, P501; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, ATHLET THER TODAY, V6, P18, DOI 10.1123/att.6.1.18; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Keppel G., 1991, DESIGN ANAL RES HDB; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lepers R, 1997, EUR J APPL PHYSIOL, V76, P55, DOI 10.1007/s004210050212; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MAXWELL SE, 2000, DESIGNING EXPT ANAL; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McKeag DB, 2001, CLIN J SPORT MED, V11, P132, DOI 10.1097/00042752-200107000-00002; NASHNER LM, 1982, J NEUROSCI, V2, P536; PETERSON CL, 1999, J ATHL TRAINING, V34, pS44; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Randolph C, 2001, J ATHL TRAINING, V36, P288; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Smith A., 1982, SYMBOL DIGIT MODALIT; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wechsler, 1981, WECHSLER MEMORY SCAL	55	145	147	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2003	13	4					230	237		10.1097/00042752-200307000-00006			8	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	705AQ	WOS:000184374400006	12855925				2022-02-06	
J	McKinlay, A; Dalrymple-Alford, JC; Horwood, LJ; Fergusson, DM				McKinlay, A; Dalrymple-Alford, JC; Horwood, LJ; Fergusson, DM			Long term psychosocial outcomes after mild head injury in early childhood	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; MIDDLE CHILDHOOD; YOUNG ADULTHOOD; UNITED-STATES; FOLLOW-UP; CHILDREN; ADOLESCENTS; DISORDERS; SEQUELAE; PREVALENCE	Objectives: The question of whether any adverse cognitive or psychosocial outcomes occur after mild head injury in early childhood has evoked considerable controversy. This study examined mild head injury before age 10 and potential differences in late childhood/early adolescence as a function of severity of mild injury and age at injury. Methods: A fully prospective longitudinal design tracked a large birth cohort of children. Confirmed cases of mild head injury before age 10 were divided on the basis of outpatient medical attention (n=64-84) or inpatient observation (hospital overnight; n=26-28) and compared with the non-injured remainder of the cohort (reference group; n=613-807). A range of pre-injury and post-injury child and family characteristics were used to control for any potential confounds. Outcome after injury before and after age 5 was also assessed. Results: After accounting for several demographic, family, and pre-injury characteristics, the inpatient but not the outpatient group displayed increased hyperactivity/inattention and conduct disorder between ages 10 to 13, as rated by both mothers and teachers. Psychosocial deficits were more prevalent in the inpatient subgroup injured before age 5. No clear effects were evident for various cognitive/academic measures, irrespective of severity of mild injury or age at injury. Conclusions: Most cases of mild head injury in young children do not produce any adverse effects, but long term problems in psychosocial function are possible in more severe cases, perhaps especially when this event occurs during the preschool years. The view that all mild head injuries in children are benign events requires revision and more objective measures are required to identify cases at risk.	Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; Christchurch Movement Disorders & Brain Res Grp, Christchurch, New Zealand; Univ Otago, Dunedin, New Zealand; Christchurch Hlth & Dev Study, Christchurch Movement Disorders & Brain Res Grp, Dunedin, New Zealand		McKinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	aco24@student.canterbury.ac.nz		Horwood, L./0000-0003-4881-1956; McKinlay, Audrey/0000-0001-9846-8514; Fergusson, David/0000-0002-8117-017X			Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; BLACK P, 1971, HEAD INJURIES, P131; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cantwell DP, 1996, J AM ACAD CHILD PSY, V35, P978, DOI 10.1097/00004583-199608000-00008; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Cohen J., 2013, STAT POWER ANAL BEHA; COSTEFF H, 1988, BRAIN DEV-JPN, V10, P371, DOI 10.1016/S0387-7604(88)80095-0; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fergusson DM, 1996, J ABNORM CHILD PSYCH, V24, P533, DOI 10.1007/BF01670099; Fergusson DM, 1998, J EMOT BEHAV DISORD, V6, P2, DOI 10.1177/106342669800600101; FERGUSSON DM, 1993, INT J EPIDEMIOL, V22, P891, DOI 10.1093/ije/22.5.891; FERGUSSON DM, 1993, J AM ACAD CHILD PSY, V32, P1127, DOI 10.1097/00004583-199311000-00004; FERGUSSON DM, 1991, J CHILD PSYCHOL PSYC, V32, P257, DOI 10.1111/j.1469-7610.1991.tb00305.x; Fergusson DM, 1997, J CHILD PSYCHOL PSYC, V38, P633, DOI 10.1111/j.1469-7610.1997.tb01690.x; FERGUSSON DM, 1982, NEW ZEAL J EDUC STUD, V17, P171; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HART K, 1988, J CLIN PSYCHOL, V44, P780, DOI 10.1002/1097-4679(198809)44:5<780::AID-JCLP2270440519>3.0.CO;2-1; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Horowitz I, 1983, Int Rehabil Med, V5, P32; JOHNSON BT, 1993, DSTAT 1 10 UPGRADE S; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, BRAIN INJURY, V12, P41; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; PERRIN EC, 1991, J PEDIATR PSYCHOL, V16, P411, DOI 10.1093/jpepsy/16.4.411; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Prigatano G. P., 1993, NEUROPSYCHOL REHABIL, V3, P53; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; Reitman D, 1998, CLIN PSYCHOL REV, V18, P555, DOI 10.1016/S0272-7358(98)00003-8; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Voller B, 2001, BRAIN INJURY, V15, P107, DOI 10.1080/026990501458344; Webb C, 1996, BRAIN INJURY, V10, P303, DOI 10.1080/026990596124476; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	64	145	145	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2002	73	3					281	288		10.1136/jnnp.73.3.281			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	588LL	WOS:000177702900012	12185159	Green Published, Bronze			2022-02-06	
J	Bryant, RA; Harvey, AG				Bryant, RA; Harvey, AG			Postconcussive symptoms and posttraumatic stress disorder after mild traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article								Postconcussive symptoms after mild traumatic brain injury (MTBI) may be exacerbated by anxiety associated with posttraumatic stress. The aim of this study waste investigate the relationship between postconcussive symptoms and posttraumatic stress disorder (PTSD) in an MTBI population. Survivors of motor vehicle accidents who either sustained an MTBI (N = 46) or no TBI (N = 59) were assessed 6 months post-trauma for PTSD and postconcussive symptoms. Postconcussive symptoms were more evident in MTBI patients with PTSD than those without PTSD, and in MTBI patients than non-TBI patients. Further, postconcussive symptoms were significantly correlated with PTSD symptoms. These findings indicate that postconcussive symptoms may be mediated by an interaction of neurological and psychological factors after MTBI.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Oxford, Dept Psychiat, Oxford, England		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BRYANT RA, 1995, J ABNORM PSYCHOL, V104, P537, DOI 10.1037/0021-843X.104.3.537; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MIDDELBOE T, 1991, Acta Neurologica Scandinavica, V85, P5; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; RUTHERFORD WH, 1989, NEUROBEHAVIORAL RECO, P217; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302	19	145	147	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	MAY	1999	187	5					302	305		10.1097/00005053-199905000-00006			4	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	197BU	WOS:000080345400006	10348085				2022-02-06	
J	Barnes, BC; Cooper, L; Kirkendall, DT; McDermott, TP; Jordan, BD; Garrett, WE				Barnes, BC; Cooper, L; Kirkendall, DT; McDermott, TP; Jordan, BD; Garrett, WE			Concussion history in elite male and female soccer players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							FOOTBALL PLAYERS; BRAIN-DAMAGE; INJURIES; HEAD	A unique feature of soccer is the purposeful use of the head for controlling, passing, and shooting a soccer ball. Some concern has been expressed in the literature on the cumulative effects of heading on soccer players. Certain neurophysiologic and neuropsychologic changes have been reported in current or retired players, with heading being blamed. A major factor that could influence some of the findings is a player's history of concussive episodes, which are known to influence brain function. These episodes can occur during aspects of the game other than heading. We interviewed all male and female soccer players (N = 137, average age = 20.5 years) who competed at the U.S. Olympic Sports Festival in 1993. The mechanisms of injuries, frequency, and sequelae were determined. There were 74 concussions in 39 male players (grade 1 = 50) and 28 concussions in 23 female players (grade 1 = 19). For the men, 48 of the 74 episodes were from collisions with another player. For the women, 20 of 28 were from such collisions. Headaches, being "dazed," and dizziness were the most common symptoms reported. Based on concussion history, the odds are 50% that a man, and 22% that a woman, will sustain a concussion within a 10-year period. The data indicate that concussions from player-to-player contact are a frequent hazard in soccer. Head injuries incurred this way may be more of an influence for published findings of physiologic and psychologic deficiencies than routine heading of the soccer ball.	Duke Univ, Med Ctr, Div Orthopaed Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Phys & Occupat Therapy, Durham, NC 27710 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA		Kirkendall, DT (corresponding author), Duke Univ, Med Ctr, Div Orthopaed Surg, POB 3435, Durham, NC 27710 USA.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Bruce D A, 1982, Clin Sports Med, V1, P495; Carroll EJ, 1936, AM J MED SCI, V191, P706, DOI 10.1097/00000441-193619150-00014; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; IRRGANG, 1994, SPORTS INJURIES MECH, P349; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lohnes JH, 1994, SPORTS INJURIES MECH, P603; Nilsson S, 1978, Am J Sports Med, V6, P358, DOI 10.1177/036354657800600608; Reilly TT, 1976, J HUM MOV STUD, V2, P87; Roaas A, 1979, Br J Sports Med, V13, P3; SCHNEIDER PG, 1975, SPORTARZUT SPORTMEDI, V26, P10; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Watson AWS, 1996, AM J SPORT MED, V24, P323, DOI 10.1177/036354659602400313; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	20	145	146	2	29	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY-JUN	1998	26	3					433	438		10.1177/03635465980260031601			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	ZQ970	WOS:000073921700016	9617409				2022-02-06	
J	Boden, BP; Kirkendall, DT; Garrett, WE				Boden, BP; Kirkendall, DT; Garrett, WE			Concussion incidence in elite college soccer players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							FOOTBALL PLAYERS; BRAIN-DAMAGE; INJURIES	A unique aspect of soccer is the use of the head for directing the ball. The potential for resultant head injuries has been the focus of discussions worldwide. Prior work-has attributed neuropsychologic deficits to the cumulative effects of heading, without evaluating concussion rates in soccer players. We prospectively studied the seven men's and eight women's varsity soccer teams in the Atlantic Coast Conference during two seasons to document concussion incidence. The 29 concussions diagnosed over the 2 years in 26 athletes, 17 (59%) concussions in men and 12 (41%) in women, resulted from contact with an opponent's head (8, 28%), elbow (4, 14%), knee (1, 3%), or foot (1, 3%), the ball (7, 24%); the ground (3, 10%); concrete sidelines (1, 3%); goalpost (1, 3%); or a combination of objects (3, 10%). Twenty concussions (69%) occurred in games; none resulted from intentional heading of the ball. The basic incidence was 0.96 concussions per team per season. The overall incidence was 0.6 per 1000 athlete-exposures for men, and 0.4 per 1000 athlete-exposures for women. By concussion grade, there were 21 (72%) grade 1, 8 (28%) grade 2, and no grade 3 concussions. These findings suggest that concussions are more common in soccer than anticipated and that acute head injuries may have potential for long-term neuropsychologic changes.	Duke Univ, Med Ctr, Div Orthopaed Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Sports Med Sect, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Phys & Occupat Therapy, Durham, NC 27710 USA		Boden, BP (corresponding author), 2101 Med Pk Dr,Suite 305, Silver Spring, MD 20902 USA.						BARNES B, 1998, IN PRESS AM J SPORTS; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; GENNARELLI TA, 1982, ATHLETIC INJURIES HE, P65; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lohnes JH, 1994, SPORTS INJURIES MECH, P603; *NAT COLL ATHL ASS, 1996, 1990 1996 INJ SURV S; Sandelin J, 1985, Br J Sports Med, V19, P30; SANDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538; Schmidt-Olsen S, 1985, Br J Sports Med, V19, P161; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; *US CONS PROD SAF, 1993, NAT EL INJ SURV SYST	17	145	149	1	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR-APR	1998	26	2					238	241		10.1177/03635465980260021301			4	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	ZD693	WOS:000072713500013	9548117				2022-02-06	
J	RIS, L; DEWAELE, C; SERAFIN, M; VIDAL, PP; GODAUX, E				RIS, L; DEWAELE, C; SERAFIN, M; VIDAL, PP; GODAUX, E			NEURONAL-ACTIVITY IN THE IPSILATERAL VESTIBULAR NUCLEUS FOLLOWING UNILATERAL LABYRINTHECTOMY IN THE ALERT GUINEA-PIG	JOURNAL OF NEUROPHYSIOLOGY			English	Article							HEMILABYRINTHECTOMIZED CATS; CENTRAL COMPENSATION; OCULAR REFLEX; NERVE LESIONS; RECOVERY; DEFICITS; DEAFFERENTATION	1. Neuronal activity was investigated in the left superior vestibular nucleus (SVN), lateral vestibular nucleus (LVN), and rostral part of the medial vestibular nucleus (MVN) in the alert guinea pig after a unilateral (left) labyrinthectomy was performed. Vestibular neurons were recorded either immediately (just-postoperative group, n = 6) or 1 wk after labyrinthectomy (1-wk-postoperative group, n = 6) and compared with the activity recorded in intact animals (control group, n = 6). 2. Animals were prepared for extracellular recording of single-unit activity and for eye movement recording (scleral search coil technique). To enable stimulation of the left vestibular nerve, bipolar silver ball electrodes were chronically implanted either in contact with the bony labyrinth in the control group or close to the stump of the vestibular nerve after labyrinthectomy. Complete labyrinthectomy was performed under halothane anesthesia. 3. The criterion used to select vestibular neurons for analysis was their recruitment by an electric shock on the vestibular nerve. Of the 589 recorded neurons, 424, defined as second-order vestibular neurons, were recruited at monosynaptic latencies (0.85-1.15 ms) and 165 were recruited at polysynaptic latencies. One hundred three second-order vestibular neurons were recorded in the control group, 173 in the just-postoperative group, and 148 in the 1-wk-postoperative group. 4. The activity of the electrically recruited neurons was recorded during sinusoidal horizontal head rotation in the dark (0.3 Hz, 40 degrees/s peak velocity). The behavior of the neurons was analyzed by plotting their firing rate against head velocity. The Y-intercept of the regression line was used to express spontaneous firing rate (resting discharge), and its slope was used to express the sensitivity of the neuron-to-head velocity. 5. In the absence of statistically significant difference between the characteristics of the neuronal discharge of the second-order vestibular neurons recorded in the SVN, LVN, and rostral MVN, the data were pooled. The Resting discharge of these cells amounted to 41.0 +/- 24.7 (SD) spikes/s in the control state, fell to 7.2 +/- 13.9 spikes/s just after labyrinthectomy, and completely returned to normal values 1 wk after surgery (42.5 +/- 21.6 spikes/s). Among the monosynaptically recruited neurons, the percentage of silent units was 0% in the control group, 69% in the just-postoperative group, and 0% in the 1-wk-postoperative group. 6. By contrast, the sensitivity to head velocity of the second-order vestibular neurons, which was 0.69 +/- 0.48 (SD) spikes . s(-1)/deg . s(-1) in the control state and which fell to 0.03 +/- 0.11 spikes . s(-1)/deg . s(-1) just after labyrinthectomy, remained low 1 wk after injury (0.21 +/- 0.26 spikes . s(-1)/deg . s(-1)). Moreover, the slight recovery of sensitivity to head rotation was due only to units behaving as type II neurons. 7. The mean resting discharge of the polysynaptically recruited neurons (pooled from the 3 explored nuclei) was 31.6 +/- 19.3 spikes/s in the control group. It decreased to 11.6 +/- 12.1 spikes/s in the just-postoperative group and recovered to 39.8 +/- 20.2 spikes/s in the l-wk-postoperative group. No neuron was silent at rest either in the control group or in the 1-wk-postoperative group. Just after labyrinthectomy, 35% of the neurons had a null resting activity. The mean sensitivity to head velocity of these neurons was 0.55 +/- 0.42 spikes . s(-1)/deg . s(-1) in the control group. It decreased to 0.05 +/- 0.12 spikes . s(-1)/deg . s(-1) in the just-postoperative group and recovered to 0.22 +/- 0.17 spikes . s(-1)/deg . s(-1) in the 1-wk-postoperative group. 8. We conclude that, at least in the guinea pig, the restoration of the spontaneous activity of the deafferented neurons is complete 1 wk after a unilateral labyrinthectomy and thus probably plays an important role in vestibular compensation. Moreover, the difference seen between the complete recovery of the resting discharge and the absence of recovery of sensitivity to head velocity 1 wk after the lesion is further evidence that compensation of static vestibular symptoms and dynamic symptoms are mediated by two completely distinct mechanisms.	UNIV MONS,NEUROSCI LAB,B-7000 MONS,BELGIUM; CNRS,PHYSIOL PERCEPT & ACT LAB,PARIS,FRANCE								AZZENA GB, 1969, ARCH ITAL BIOL, V107, P43; BAARSMA EA, 1975, ARCH OTO-RHINO-LARYN, V211, P219, DOI 10.1007/BF00456342; COURJON JH, 1977, EXP BRAIN RES, V28, P235; CREMER PD, 1987, NEUROSCI LETT S, V27, P564; CURTHOYS IS, 1975, ACTA OTO-LARYNGOL, V80, P197, DOI 10.3109/00016487509121319; DENISE P, 1988, VESTIBULAR COMPENSAT, P59; DEWAELE C, 1989, EXP BRAIN RES, V77, P166, DOI 10.1007/BF00250579; DEWAELE C, 1990, EXP BRAIN RES, V81, P125, DOI 10.1007/BF00230108; DEWAELE C, 1988, SOC NEUR ABSTR, V14, P331; DIERINGER N, 1982, EXP BRAIN RES, V47, P394; DIERINGER N, 1981, LESION INDUCED NEURO, P184; DUENSING F, 1958, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V198, P225, DOI 10.1007/BF00941383; DUTIA MB, 1985, J PHYSIOL-LONDON, V366, P281, DOI 10.1113/jphysiol.1985.sp015797; ESCUDERO M, 1993, EXP BRAIN RES, V97, P254, DOI 10.1007/BF00228694; FETTER M, 1988, J NEUROPHYSIOL, V59, P370, DOI 10.1152/jn.1988.59.2.370; FETTER M, 1988, J NEUROPHYSIOL, V59, P399; Flohr H., 1981, LESION INDUCED NEURO, P153; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; GODAUX E, 1993, J PHYSIOL-LONDON, V469, P549, DOI 10.1113/jphysiol.1993.sp019829; GSTOETTNER W, 1987, J COMP NEUROL, V257, P176, DOI 10.1002/cne.902570205; GSTOETTNER W, 1992, ACTA OTO-LARYNGOL, V112, P486, DOI 10.3109/00016489209137430; HADDAD GM, 1977, BRAIN RES, V135, P192, DOI 10.1016/0006-8993(77)91066-6; JENSEN DW, 1979, NEUROSCIENCE, V4, P1059, DOI 10.1016/0306-4522(79)90187-8; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; LACOUR M, 1981, LESION INDUCED NEURO, P240; LLINAS R, 1975, SCIENCE, V190, P1230, DOI 10.1126/science.128123; Llinas R., 1979, INTEGRATION NERVOUS, P145; MAIOLI C, 1985, EXP BRAIN RES, V59, P267; MAIOLI C, 1983, EXP BRAIN RES, V50, P259; MCCABE BF, 1969, LARYNGOSCOPE, V79, P1728, DOI 10.1288/00005537-196910000-00004; MCCABE BF, 1972, LARYNGOSCOPE, V82, P381, DOI 10.1288/00005537-197203000-00005; NEWLANDS SD, 1990, EXP BRAIN RES, V82, P359, DOI 10.1007/BF00231255; POMPEIANO O, 1984, J NEUROPHYSIOL, V52, P18, DOI 10.1152/jn.1984.52.1.18; PRECHT W, 1965, J NEUROPHYSIOL, V28, P1014, DOI 10.1152/jn.1965.28.6.1014; PRECHT W, 1966, J NEUROPHYSIOL, V29, P996, DOI 10.1152/jn.1966.29.6.996; Rapisarda C, 1977, Arch Sci Biol (Bologna), V61, P1; RIED S, 1984, ACTA OTO-LARYNGOL, V98, P1, DOI 10.3109/00016488409107529; RYU JH, 1976, ARCH OTOLARYNGOL, V102, P71; SATO F, 1993, J COMP NEUROL, V333, P554, DOI 10.1002/cne.903330408; Schaefer K. P., 1974, HDB SENSORY PHYSL, P463; SERAFIN M, 1991, EXP BRAIN RES, V84, P417, DOI 10.1007/BF00231464; SHIMAZU H, 1966, J NEUROPHYSIOL, V29, P467, DOI 10.1152/jn.1966.29.3.467; SHIMAZU H, 1965, J NEUROPHYSIOL, V28, P991, DOI 10.1152/jn.1965.28.6.991; SMITH PF, 1986, BRAIN RES, V364, P195, DOI 10.1016/0006-8993(86)91004-8; SMITH PF, 1986, NEUROSCI LETT, V65, P209, DOI 10.1016/0304-3940(86)90306-X; SMITH PF, 1989, BRAIN RES REV, V14, P155, DOI 10.1016/0165-0173(89)90013-1; SMITH PF, 1988, BRAIN RES, V444, P308, DOI 10.1016/0006-8993(88)90939-0; STRAKA H, 1993, NEUROREPORT, V4, P1071; VIBERT N, 1993, EXP BRAIN RES, V97, P263, DOI 10.1007/BF00228695; WILSON VJ, 1972, J NEUROPHYSIOL, V35, P253, DOI 10.1152/jn.1972.35.2.253; XERRI C, 1985, J NEUROPHYSIOL, V54, P1006, DOI 10.1152/jn.1985.54.4.1006; Zennou-Azogui Y, 1993, Acta Otolaryngol Suppl, V509, P1	52	145	153	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	NOV	1995	74	5					2087	2099		10.1152/jn.1995.74.5.2087			13	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Physiology	TD640	WOS:A1995TD64000024	8592199				2022-02-06	
J	Kumar, Y; Dewal, ML; Anand, RS				Kumar, Yatindra; Dewal, M. L.; Anand, R. S.			Epileptic seizures detection in EEG using DWT-based ApEn and artificial neural network	SIGNAL IMAGE AND VIDEO PROCESSING			English	Article						Electroencephalogram (EEG); Discrete wavelet transforms(DWT); Approximate entropy (ApEn); Artificial neural network (ANN); Support vector machine (SVM)	EMPLOYING LYAPUNOV EXPONENTS; APPROXIMATE ENTROPY; CLASSIFICATION; SYSTEM; RECOGNITION; TRANSFORM	There are numerous neurological disorders such as dementia, headache, traumatic brain injuries, stroke, and epilepsy. Out of these epilepsy is the most prevalent neurological disorder in the human after stroke. Electroencephalogram (EEG) contains valuable information related to different physiological state of the brain. A scheme is presented for detecting epileptic seizures from EEG data recorded from normal subjects and epileptic patients. The scheme is based on discrete wavelet transform (DWT) analysis and approximate entropy (ApEn) of EEG signals. Seizure detection is performed in two stages. In the first stage, EEG signals are decomposed by DWT to calculate approximation and detail coefficients. In the second stage, ApEn values of the approximation and detail coefficients are calculated. Significant differences have been found between the ApEn values of the epileptic and the normal EEG allowing us to detect seizures with 100% classification accuracy using artificial neural network. The analysis results depicted that during seizure activity, EEG had lower ApEn values compared to normal EEG. This gives that epileptic EEG is more predictable or less complex than the normal EEG. In this study, feed-forward back-propagation neural network has been used for classification and training algorithm for this network that updates the weight and bias values according to Levenberg-Marquardt optimization technique.	[Kumar, Yatindra; Dewal, M. L.; Anand, R. S.] Indian Inst Technol, Dept Elect Engn, Roorkee 247667, Uttar Pradesh, India		Kumar, Y (corresponding author), Indian Inst Technol, Dept Elect Engn, Roorkee 247667, Uttar Pradesh, India.	kyatindra@gmail.com; mohanfee@iitr.ernet.in; anandfee@iitr.ernet.in		Kumar, Yatindra/0000-0002-0105-3011			Acharya UR, 2012, BIOMED SIGNAL PROCES, V7, P401, DOI 10.1016/j.bspc.2011.07.007; Adeli H, 2003, J NEUROSCI METH, V123, P69, DOI 10.1016/S0165-0270(02)00340-0; Andrzejak RG, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.061907; Andrzejak RG, 2001, EPILEPSY RES, V44, P129, DOI 10.1016/S0920-1211(01)00195-4; Diambra L, 1999, PHYSICA A, V273, P495, DOI 10.1016/S0378-4371(99)00368-4; Foo SY, 2002, ENG APPL ARTIF INTEL, V15, P253, DOI 10.1016/S0952-1976(02)00041-6; Gandhi T, 2011, NEUROCOMPUTING, V74, P3051, DOI 10.1016/j.neucom.2011.04.029; Gotman J, 1997, ELECTROEN CLIN NEURO, V103, P356, DOI 10.1016/S0013-4694(97)00003-9; Guler NF, 2005, EXPERT SYST APPL, V29, P506, DOI 10.1016/j.eswa.2005.04.011; GUO L, 2009, P 1 ACM SIGEVO SUMM, P177; Guo L, 2011, EXPERT SYST APPL, V38, P10425, DOI 10.1016/j.eswa.2011.02.118; Guo L, 2010, J NEUROSCI METH, V193, P156, DOI 10.1016/j.jneumeth.2010.08.030; Guo L, 2010, J NEUROSCI METH, V191, P101, DOI 10.1016/j.jneumeth.2010.05.020; Hsu KC, 2010, COMPUT BIOL MED, V40, P823, DOI 10.1016/j.compbiomed.2010.08.005; Iscan Z, 2011, EXPERT SYST APPL, V38, P10499, DOI 10.1016/j.eswa.2011.02.110; Jahankhani P, 2006, IEEE JV AT 2006 INT, P52, DOI DOI 10.1109/JVA.2006.17; KALAYCI T, 1995, IEEE ENG MED BIOL, V14, P160, DOI 10.1109/51.376754; Kannathal N, 2005, COMPUT METH PROG BIO, V80, P187, DOI 10.1016/j.cmpb.2005.06.012; Kayikcioglu T, 2010, PATTERN RECOGN LETT, V31, P1207, DOI 10.1016/j.patrec.2010.04.009; Khan YU, 2003, CLIN NEUROPHYSIOL, V114, P898, DOI 10.1016/S1388-2457(03)00035-X; Kiymik M Kemal, 2004, J Med Syst, V28, P511, DOI 10.1023/B:JOMS.0000044954.85566.a9; Kiymik MK, 2004, J NEUROSCI METH, V139, P231, DOI 10.1016/j.jneumeth.2004.04.027; LIU A, 1992, ELECTROEN CLIN NEURO, V82, P30, DOI 10.1016/0013-4694(92)90179-L; MALLAT SG, 1989, IEEE T PATTERN ANAL, V11, P674, DOI 10.1109/34.192463; Mohseni H, 2006, IET 3 INT C ADV MED, V14; Nicolaou N, 2012, EXPERT SYST APPL, V39, P202, DOI 10.1016/j.eswa.2011.07.008; Nigam VP, 2004, NEUROL RES, V26, P55, DOI 10.1179/016164104773026534; Ocak H, 2009, EXPERT SYST APPL, V36, P2027, DOI 10.1016/j.eswa.2007.12.065; Orhan U, 2011, EXPERT SYST APPL, V38, P13475, DOI 10.1016/j.eswa.2011.04.149; Petrosian A, 2000, NEUROCOMPUTING, V30, P201, DOI 10.1016/S0925-2312(99)00126-5; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Polat K, 2007, APPL MATH COMPUT, V187, P1017, DOI 10.1016/j.amc.2006.09.022; Radhakrishnan N, 1998, IEEE ENG MED BIOL, V17, P89, DOI 10.1109/51.677174; Schaltenbrand N, 1996, SLEEP, V19, P26, DOI 10.1093/sleep/19.1.26; Srinivasan V, 2005, J Med Syst, V29, P647, DOI 10.1007/s10916-005-6133-1; Subasi A, 2005, EXPERT SYST APPL, V29, P343, DOI 10.1016/j.eswa.2005.04.007; Subasi A, 2007, EXPERT SYST APPL, V32, P1084, DOI 10.1016/j.eswa.2006.02.005; Subasi A, 2007, COMPUT BIOL MED, V37, P227, DOI 10.1016/j.compbiomed.2005.12.003; Subasi A, 2006, EXPERT SYST APPL, V31, P320, DOI 10.1016/j.eswa.2005.09.027; Subasi A, 2010, EXPERT SYST APPL, V37, P8659, DOI 10.1016/j.eswa.2010.06.065; Tzallas A., 2007, COMPUT INTEL NEUROSC, V18, P80510; Ubeyli ED, 2006, NEURAL NETW WORLD, V16, P421; Ubeyli ED, 2010, EXPERT SYST APPL, V37, P233, DOI 10.1016/j.eswa.2009.05.012; Ubeyli ED, 2006, NEURAL NETW WORLD, V16, P257; Wang D, 2011, EXPERT SYST APPL, V38, P14314, DOI 10.1016/j.eswa.2011.05.096; Zarjam P, 2003, INT CONF ACOUST SPEE, P265	46	144	155	3	45	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1863-1703	1863-1711		SIGNAL IMAGE VIDEO P	Signal Image Video Process.	OCT	2014	8	7					1323	1334		10.1007/s11760-012-0362-9			12	Engineering, Electrical & Electronic; Imaging Science & Photographic Technology	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Imaging Science & Photographic Technology	AP6EJ	WOS:000342170100009					2022-02-06	
J	Ding, K; Wang, HD; Xu, JG; Li, T; Zhang, L; Ding, Y; Zhu, L; He, J; Zhou, ML				Ding, Ke; Wang, Handong; Xu, Jianguo; Li, Tao; Zhang, Li; Ding, Yu; Zhu, Lin; He, Jin; Zhou, Mengliang			Melatonin stimulates antioxidant enzymes and reduces oxidative stress in experimental traumatic brain injury: the Nrf2-ARE signaling pathway as a potential mechanism	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Melatonin; Traumatic brain injury; Nuclear factor erythroid 2-related factor 2; Signaling pathway; Antioxidant enzymes; Free radicals	ERYTHROID 2-RELATED FACTOR-2; NF-KAPPA-B; NUCLEAR FACTOR-KAPPAB; CLOSED-HEAD INJURY; GLUTATHIONE-PEROXIDASE; FUNCTIONAL RECOVERY; GENE-EXPRESSION; REACTIVE OXYGEN; ANIMAL-MODEL; LIVER-INJURY	The goal of this study was to evaluate the potential involvement of melatonin in the activation of the nuclear factor erythroid 2-related factor 2 and antioxidant-responsive element (Nrf2-ARE) signaling pathway and the modulation of antioxidant enzyme activity in an experimental model of traumatic brain injury (TBI). In experiment 1, ICR mice were divided into four groups: sham group, TBI group, TBI + vehicle group, and TBI + melatonin group (n = 38 per group). Melatonin (10 mg/kg) was administered via an intraperitoneal (ip) injection at 0, 1, 2, 3, and 4 h post-TBI. In experiment 2, Nrf2 wild-type (Nrf2(+/+) group) and Nrf2-knockout (Nrf2(-/-) group) mice received a TBI insult followed by melatonin administration (10 mg/kg, ip) at the corresponding time points (n = 35 per group). The administration of melatonin after TBI significantly ameliorated the effects of the brain injury, such as oxidative stress, brain edema, and cortical neuronal degeneration. Melatonin markedly promoted the translocation of Nrf2 protein from the cytoplasm to the nucleus; increased the expression of Nrf2-ARE pathway-related downstream factors, including heme oxygenase-1 and NAD(P)H:quinone oxidoreductase 1; and prevented the decline of antioxidant enzyme activities, including superoxide dismutase and glutathione peroxidase. Furthermore, knockout of Nrf2 partly reversed the neuroprotection of melatonin after TBI. In conclusion, melatonin administration may increase the activity of antioxidant enzymes and attenuate brain injury in a TBI model, potentially via mediation of the Nrf2-ARE pathway. (C) 2014 Elsevier Inc. All rights reserved.	[Ding, Ke; Wang, Handong; Xu, Jianguo; Li, Tao; Zhang, Li; Ding, Yu; Zhu, Lin; He, Jin; Zhou, Mengliang] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81271377, 81371357]	This work was supported by grants from the Natural Science Fund of China (Nos. 81271377 and 81371357).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Cho HY, 2005, FREE RADICAL BIO MED, V38, P325, DOI 10.1016/j.freeradbiomed.2004.10.013; Cong ZX, 2013, ONCOL REP, V30, P715, DOI 10.3892/or.2013.2485; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Crespo I, 2010, J PINEAL RES, V49, P193, DOI 10.1111/j.1600-079X.2010.00787.x; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Jung KH, 2010, J PINEAL RES, V48, P239, DOI 10.1111/j.1600-079X.2010.00748.x; Jung KH, 2009, J PINEAL RES, V47, P173, DOI 10.1111/j.1600-079X.2009.00698.x; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Koh PO, 2012, J PINEAL RES, V53, P358, DOI 10.1111/j.1600-079X.2012.01005.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laothong U, 2010, J PINEAL RES, V49, P271, DOI 10.1111/j.1600-079X.2010.00792.x; Lekic T, 2010, J NEUROTRAUM, V27, P627, DOI 10.1089/neu.2009.1163; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Negi G, 2011, J PINEAL RES, V50, P124, DOI 10.1111/j.1600-079X.2010.00821.x; Ordonez R, 2014, J PINEAL RES, V56, P20, DOI 10.1111/jpi.12092; Pablos MI, 1998, NEUROCHEM INT, V32, P69, DOI 10.1016/S0197-0186(97)00043-0; Park S, 2012, J PINEAL RES, V52, P107, DOI 10.1111/j.1600-079X.2011.00925.x; Peyrot F, 2008, J PINEAL RES, V45, P235, DOI 10.1111/j.1600-079X.2008.00580.x; POEGGELER B, 1994, ANN NY ACAD SCI, V738, P419, DOI 10.1111/j.1749-6632.1994.tb21831.x; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Tripathi DN, 2010, J PINEAL RES, V48, P324, DOI 10.1111/j.1600-079X.2010.00756.x; Tsai CY, 2013, INT J CARDIOL, V168, P1286, DOI 10.1016/j.ijcard.2012.12.004; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Wu KC, 2012, TOXICOL APPL PHARM, V263, P14, DOI 10.1016/j.taap.2012.05.017; Wu KC, 2012, TOXICOL APPL PHARM, V262, P321, DOI 10.1016/j.taap.2012.05.010; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	47	144	147	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	AUG	2014	73						1	11		10.1016/j.freeradbiomed.2014.04.031			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AM2QJ	WOS:000339695600001	24810171				2022-02-06	
J	Hoffer, ME; Balaban, C; Slade, MD; Tsao, JW; Hoffer, B				Hoffer, Michael E.; Balaban, Carey; Slade, Martin D.; Tsao, Jack W.; Hoffer, Barry			Amelioration of Acute Sequelae of Blast Induced Mild Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo Controlled Study	PLOS ONE			English	Article							TYMPANIC MEMBRANE; RAT MODEL; NOISE; ACETYLCYSTEINE; RELIABILITY; MECHANISMS; INDUCTION; PRESSURE; PROTECTS; EXPOSURE	Background: Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures. The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated with blast exposure mTBI in a combat setting. Methods: This study was a randomized double blind, placebo-controlled study that was conducted on active duty service members at a forward deployed field hospital in Iraq. All symptomatic U. S. service members who were exposed to significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome measure in this study. Logistic regression on the outcome of 'no day 7 symptoms' indicated that NAC treatment was significantly better than placebo (OR = 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received placebo. Conclusion: This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential use of NAC in civilian mTBI is warranted.	[Hoffer, Michael E.] USN, Med Ctr, Dept Otolaryngol, Spatial Orientat Ctr, San Diego, CA 92152 USA; [Balaban, Carey] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Balaban, Carey] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA; [Balaban, Carey] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA; [Balaban, Carey] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA; [Balaban, Carey; Slade, Martin D.] Yale Univ, Dept Internal Med, New Haven, CT USA; [Tsao, Jack W.] USN, Bur Med & Surg, Wounded Ill & Injured Directorate M9, Washington, DC USA; [Hoffer, Barry] Case Western Reserve Univ, Dept Neurosurg, Cleveland, OH 44106 USA		Hoffer, ME (corresponding author), USN, Med Ctr, Dept Otolaryngol, Spatial Orientat Ctr, San Diego, CA 92152 USA.	Michael.hoffer@med.navy.mil	Balaban, Carey/I-3467-2017; Balaban, Carey/O-6586-2019	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	Department of DefenseUnited States Department of Defense	Supported by the Department of Defense. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal Y, 2011, OTOL NEUROTOL, V32, P1309, DOI 10.1097/MAO.0b013e31822e5bee; Balaban CD, 2012, BRAIN INJUR IN PRESS; Bielefeld EC, 2007, ACTA OTO-LARYNGOL, V127, P914, DOI 10.1080/00016480601110188; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Cuzzocrea S, 2000, BRIT J PHARMACOL, V130, P1219, DOI 10.1038/sj.bjp.0703421; De Vries H, 1996, PHARMACOL REV, V49, P143; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; French L., 2009, CARE COMBAT AMPUTEE, P399; GARTH RJN, 1994, J LARYNGOL OTOL, V108, P925, DOI 10.1017/S0022215100128555; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hart AM, 2004, NEUROSCIENCE, V125, P91, DOI 10.1016/j.neuroscience.2003.12.040; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; James DJ, 1982, 0482 ARM WEAP RES ES; JENSEN JH, 1993, ACTA OTO-LARYNGOL, V113, P62, DOI 10.3109/00016489309135768; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Kopke RD, 2007, HEARING RES, V226, P114, DOI 10.1016/j.heares.2006.10.008; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Marchetti GF, 2008, PHYS THER, V88, P640, DOI 10.2522/ptj.20070130; Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pereira TV, 2012, JAMA-J AM MED ASSOC, V308, P1676, DOI 10.1001/jama.2012.13444; Pocock, 1983, CLIN TRIALS PRACTICA; Reitan RM, 1992, TRAIL MAKIGN TEST MA; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Santangelo F, 2003, CURR MED CHEM, V10, P2599, DOI 10.2174/0929867033456567; Schotter A., 2008, FDN POSITIVE NORMATI, P292, DOI [10.1093/acprof:oso/9780195328318.003.0012, DOI 10.1093/ACPROF:OSO/9780195328318.003.0012]; Schubert MC, 2004, PHYS THER, V84, P151, DOI 10.1093/ptj/84.2.151; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; Stranahan AM, 2009, CURR MED CHEM, V16, P4668, DOI 10.2174/092986709789878292; Strauss E., 1998, COMPENDIUM NEUROPSYC, P447; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Tombaugh TN, 1998, COMPENDIUM NEUROPSYC, P481; Tsai SY, 2009, P NATL ACAD SCI USA, V106, P22468, DOI 10.1073/pnas.0909089106; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Wagner S, 2011, ARCH CLIN NEUROPSYCH, V26, P314, DOI 10.1093/arclin/acr024	46	144	147	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2013	8	1							e54163	10.1371/journal.pone.0054163			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077IQ	WOS:000314021500034	23544123	Green Accepted, gold, Green Published, Green Submitted			2022-02-06	
J	Browne, KD; Chen, XH; Meaney, DF; Smith, DH				Browne, Kevin D.; Chen, Xiao-Han; Meaney, David F.; Smith, Douglas H.			Mild Traumatic Brain Injury and Diffuse Axonal Injury in Swine	JOURNAL OF NEUROTRAUMA			English	Article						concussion; diffuse axonal injury; head rotational acceleration; head rotational velocity; mild traumatic brain injury; post-concussion syndrome; traumatic axonal injury	AMYLOID-BETA; DAMAGE; ACCUMULATION; FOOTBALL; TIME; RECONSTRUCTION; TETRODOTOXIN; CONCUSSION; SEVERITY; COSTS	Until recently, mild traumatic brain injury (mTBI) or "concussion" was generally ignored as a major health issue. However, emerging evidence suggests that this injury is by no means mild, considering it induces persisting neurocognitive dysfunction in many individuals. Although little is known about the pathophysiological aspects of mTBI, there is growing opinion that diffuse axonal injury (DAI) may play a key role. To explore this possibility, we adapted a model of head rotational acceleration in swine to produce mTBI by scaling the mechanical loading conditions based on available biomechanical data on concussion thresholds in humans. Using these input parameters, head rotational acceleration was induced in either the axial plane (transverse to the brainstem; n=3), causing a 10- to 35-min loss of consciousness, or coronal plane (circumferential to the brainstem; n=2), which did not produce a sustained loss of consciousness. Seven days following injury, immunohistochemical analyses of the brains revealed that both planes of head rotation induced extensive axonal pathology throughout the white matter, characterized as swollen axonal bulbs or varicosities that were immunoreactive for accumulating neurofilament protein. However, the distribution of the axonal pathology was different between planes of head rotation. In particular, more swollen axonal profiles were observed in the brainstems of animals injured in the axial plane, suggesting an anatomic substrate for prolonged loss of consciousness in mTBI. Overall, these data support DAI as an important pathological feature of mTBI, and demonstrate that surprisingly overt axonal pathology may be present, even in cases without a sustained loss of consciousness.	[Browne, Kevin D.; Chen, Xiao-Han; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu		Meaney, David/0000-0002-0954-4122	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS08803, NS038104, NS056202]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS038104, P01NS056202] Funding Source: NIH RePORTER	We would like to thank Robert F. Groff, Jun Zhang, and Andrew Eng for their excellent technical assistance. This study was conducted with support from NIH grants NS08803, NS038104, and NS056202.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 1982, RECENT ADV NEUROPATH, P165; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Chen JR, 2010, NEUROSCIENCE, V167, P414, DOI 10.1016/j.neuroscience.2010.02.028; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Faul M, 2010, TRAUMATIC BRAIN INJU; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; GENNARELLI TA, 1982, ADV NEUROTRAUMOTOLOG, V612, P31; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miller R.T., 1998, STAPP CAR CRASH C SA, DOI [10.4271/983154, DOI 10.4271/983154]; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Newman J A, 2000, Stapp Car Crash J, V44, P215; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OMMAYA AK, 1967, P 11 STAPP CAR CRASH, P73; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; TEASDALE G, 1974, LANCET, V2, P81; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zhang J, 2008, EXP NEUROL, V210, P645, DOI 10.1016/j.expneurol.2007.12.019	60	144	148	1	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1747	1755		10.1089/neu.2011.1913			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000008	21740133	Green Published			2022-02-06	
J	Dash, PK; Orsi, SA; Zhang, M; Grill, RJ; Pati, S; Zhao, J; Moore, AN				Dash, Pramod K.; Orsi, Sara A.; Zhang, Min; Grill, Raymond J.; Pati, Shibani; Zhao, Jing; Moore, Anthony N.			Valproate Administered after Traumatic Brain Injury Provides Neuroprotection and Improves Cognitive Function in Rats	PLOS ONE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITION; CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY DEFICITS; CLOSED-HEAD INJURY; CELLS IN-VITRO; MOOD STABILIZER; MEDIATED NEUROPROTECTION; GENE-EXPRESSION; H3 ACETYLATION	Background: Traumatic brain injury (TBI) initiates a complex series of neurochemical and signaling changes that lead to pathological events including neuronal hyperactivity, excessive glutamate release, inflammation, increased blood-brain barrier (BBB) permeability and cerebral edema, altered gene expression, and neuronal dysfunction. It is believed that a drug combination, or a single drug acting on multiple targets, may be an effective strategy to treat TBI. Valproate, a widely used antiepileptic drug, has a number of targets including GABA transaminase, voltage-gated sodium channels, glycogen synthase kinase (GSK)-3, and histone deacetylases (HDACs), and therefore may attenuate a number of TBI-associated pathologies. Methodology/Principal Findings: Using a rodent model of TBI, we tested if post-injury administration of valproate can decrease BBB permeability, reduce neural damage and improve cognitive outcome. Dose-response studies revealed that systemic administration of 400 mg/kg (i.p.), but not 15, 30, 60 or 100 mg/kg, increases histone H3 and H4 acetylation, and reduces GSK-3 activity, in the hippocampus. Thirty min post-injury administration of 400 mg/kg valproate improved BBB integrity as indicated by a reduction in Evans Blue dye extravasation. Consistent with its dose response to inhibit GSK-3 and HDACs, valproate at 400 mg/kg, but not 100 mg/kg, reduced TBI-associated hippocampal dendritic damage, lessened cortical contusion volume, and improved motor function and spatial memory. These behavioral improvements were not observed when SAHA (suberoylanilide hydroxamic acid), a selective HDAC inhibitor, was administered. Conclusion/Significance: Our findings indicate that valproate given soon after TBI can be neuroprotective. As clinically proven interventions that can be used to minimize the damage following TBI are not currently available, the findings from this report support the further testing of valproate as an acute therapeutic strategy.	[Dash, Pramod K.; Orsi, Sara A.; Zhang, Min; Zhao, Jing; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX USA; [Dash, Pramod K.; Orsi, Sara A.; Zhang, Min; Zhao, Jing; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrated Biol & Pharmacol, Houston, TX USA; [Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX USA		Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX USA.	P.Dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0134]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD049350]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD049350] Funding Source: NIH RePORTER	This research was made possible by funding support from the Department of Defense (W81XWH-08-2-0134) and a training grant from National Institutes of Health (NIH) (5T32HD049350). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brandt C, 2006, NEUROPHARMACOLOGY, V51, P789, DOI 10.1016/j.neuropharm.2006.05.021; Butler LM, 2000, CANCER RES, V60, P5165; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash RR, 2009, J HAZARD MATER, V163, P1, DOI 10.1016/j.jhazmat.2008.06.051; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eleuteri S, 2009, NEUROTOX RES, V15, P127, DOI 10.1007/s12640-009-9013-5; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Gonzales E, 2006, SHOCK, V25, P395, DOI 10.1097/01.shk.0000209522.28120.c8; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hao YL, 2004, J NEUROSCI, V24, P6590, DOI 10.1523/JNEUROSCI.5747-03.2004; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Jallon P, 2001, DRUG SAFETY, V24, P969, DOI 10.2165/00002018-200124130-00004; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kanai H, 2004, PHARMACOGENOMICS J, V4, P336, DOI 10.1038/sj.tpj.6500269; Li YQ, 2008, SURGERY, V144, P217, DOI 10.1016/j.surg.2008.03.037; Li YQ, 2010, J SURG RES, V159, P474, DOI 10.1016/j.jss.2009.04.011; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; McDonald HY, 2005, NEUROSCI LETT, V385, P70, DOI 10.1016/j.neulet.2005.05.022; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miller JS, 2009, NEUROPHARMACOLOGY, V56, P1116, DOI 10.1016/j.neuropharm.2009.03.006; Miller Laura C, 2008, Expert Rev Neurother, V8, P1817, DOI 10.1586/14737175.8.12.1817; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Ooba S, 2008, NEUROSCI RES, V62, P195, DOI 10.1016/j.neures.2008.08.005; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Roberge MC, 2008, NEUROSCIENCE, V156, P11, DOI 10.1016/j.neuroscience.2008.05.062; Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Sharma S, 2005, BRAIN RES BULL, V67, P482, DOI 10.1016/j.brainresbull.2005.07.015; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Wada A, 2009, J PHARMACOL SCI, V110, P14, DOI 10.1254/jphs.09R02CR; Wada A, 2009, FRONT BIOSCI-LANDMRK, V14, P1558, DOI 10.2741/3324; Watterson JM, 2002, BRAIN RES, V934, P69, DOI 10.1016/S0006-8993(02)02362-4; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Yin D, 2007, CLIN CANCER RES, V13, P1045, DOI 10.1158/1078-0432.CCR-06-1261; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	72	144	152	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2010	5	6							e11383	10.1371/journal.pone.0011383			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	618QE	WOS:000279370000013	20614021	Green Submitted, Green Published, gold			2022-02-06	
J	Little, DM; Kraus, MF; Joseph, J; Geary, EK; Susmaras, T; Zhou, XJ; Pliskin, N; Gorelick, PB				Little, D. M.; Kraus, M. F.; Joseph, J.; Geary, E. K.; Susmaras, T.; Zhou, X. J.; Pliskin, N.; Gorelick, P. B.			Thalamic integrity underlies executive dysfunction in traumatic brain injury	NEUROLOGY			English	Article							MILD HEAD-INJURY; DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; EXPERIENCE; DAMAGE; COMA	Objective: To quantify the effects of traumatic brain injury on integrity of thalamocortical projection fibers and to evaluate whether damage to these fibers accounts for impairments in executive function in chronic traumatic brain injury. Methods: High-resolution (voxel size: 0.78 mm X 0.78 mm X 3 mm(3)) diffusion tensor MRI of the thalamus was conducted on 24 patients with a history of single, closed-head traumatic brain injury (TBI) (12 each of mild TBI and moderate to severe TBI) and 12 age- and education-matched controls. Detailed neuropsychological testing with an emphasis on executive function was also conducted. Fractional anisotropy was extracted from 12 regions of interest in cortical and corpus callosum structures and 7 subcortical regions of interest (anterior, ventral anterior, ventral lateral, dorsomedial, ventral posterior lateral, ventral posterior medial, and pulvinar thalamic nuclei). Results: Relative to controls, patients with a history of brain injury showed reductions in fractional anisotropy in both the anterior and posterior corona radiata, forceps major, the body of the corpus callosum, and fibers identified from seed voxels in the anterior and ventral anterior thalamic nuclei. Fractional anisotropy from cortico-cortico and corpus callosum regions of interest did not account for significant variance in neuropsychological function. However, fractional anisotropy from the thalamic seed voxels did account for variance in executive function, attention, and memory. Conclusions: The data provide preliminary evidence that traumatic brain injury and resulting diffuse axonal injury results in damage to the thalamic projection fibers and is of clinical relevance to cognition. Neurology (R) 2010; 74: 558-564	[Little, D. M.] Univ Illinois, Dept Ophthalmol, Med Ctr Chicago, Chicago, IL 60680 USA; [Kraus, M. F.; Geary, E. K.; Pliskin, N.] Univ Illinois, Dept Psychiat, Med Ctr Chicago, Chicago, IL 60680 USA; [Zhou, X. J.] Univ Illinois, Dept Neurosurg & Radiol, Med Ctr Chicago, Chicago, IL 60680 USA; [Zhou, X. J.] Univ Illinois, Dept Bioengn, Med Ctr Chicago, Chicago, IL 60680 USA; [Little, D. M.; Joseph, J.; Geary, E. K.; Susmaras, T.; Gorelick, P. B.] Univ Illinois, Ctr Stroke Res, Med Ctr Chicago, Chicago, IL 60680 USA; [Little, D. M.; Kraus, M. F.; Pliskin, N.] Univ Illinois, Ctr Cognit Med, Med Ctr Chicago, Chicago, IL 60680 USA; [Zhou, X. J.] Univ Illinois, MR Res, Med Ctr Chicago, Chicago, IL 60680 USA; [Little, D. M.; Kraus, M. F.; Joseph, J.; Geary, E. K.; Susmaras, T.; Gorelick, P. B.] Univ Illinois, Dept Neurol, Med Ctr Chicago, Chicago, IL 60680 USA; [Little, D. M.] Univ Illinois, Dept Anat, Med Ctr Chicago, Chicago, IL 60680 USA		Little, DM (corresponding author), 1645 W Jackson Suite 400, Chicago, IL 60612 USA.	little@uic.edu	Ritter, Stefanie L/D-9312-2012	Joseph, Joshua/0000-0001-9704-6635	Department of Defense/Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT 075675]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH068787]; Marshall Goldberg Traumatic Brain Injury Fund; Chicago Institute for Neurosurgery and Neuroresearch Foundation; Department of DefenseUnited States Department of Defense; National Institute on Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); CINN Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P50HD055751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH068787, R01MH081019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG028662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R03DA024975] Funding Source: NIH RePORTER	Study funding: Supported in part by a Department of Defense/Congressionally Directed Medical Research Program grant PT 075675 grant (D.M.L.), NIH grant K23 MH068787 from the National Institute of Mental Health (M.F.K.), the Marshall Goldberg Traumatic Brain Injury Fund (M.F.K.), and a grant from the Chicago Institute for Neurosurgery and Neuroresearch Foundation (D.M.L.). Sponsored by grants from the Department of Defense, National Institute on Mental Health, and the CINN Foundation.	AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carrera E, 2006, NEUROLOGY, V66, P1817, DOI 10.1212/01.wnl.0000219679.95223.4c; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; GRAHAM D, 1989, PATHOLOGY MILD HEAD, P63; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubat-Silman AK, 2002, BRAIN COGNITION, V50, P178, DOI 10.1016/S0278-2626(02)00502-X; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Poonawalla AH, 2004, J MAGN RESON IMAGING, V19, P489, DOI 10.1002/jmri.20020; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640	32	144	146	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 16	2010	74	7					558	564		10.1212/WNL.0b013e3181cff5d5			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	555MX	WOS:000274517100007	20089945	Green Published			2022-02-06	
J	Belanger, HG; Kretzmer, T; Vanderploeg, RD; French, LM				Belanger, Heather G.; Kretzmer, Tracy; Vanderploeg, Rodney D.; French, Louis M.			Symptom complaints following combat-related traumatic brain injury: Relationship to traumatic brain injury severity and posttraumatic stress disorder	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI; Mild TBI; Posttraumatic stress disorder; Postconcussion syndrome; Brain concussion; Brain injuries	MILD HEAD-INJURY; POSTCONCUSSION-SYNDROME; CHRONIC PAIN; DISABILITIES; IMPAIRMENTS; ADJUSTMENT; PREVALENCE	Patients with a history of mild (n = 134) or moderate-to-severe (n = 91) TBI were asked to complete the Neurobehavioral Symptom Inventory (NSI) and the Posttraumatic Stress Disorder Checklist. Consistent with prior research, significantly more postconcussion symptoms were endorsed by the mild group. After controlling for age, time since injury, and mechanism of injury, TBI severity continued to be significantly related to postconcussion complaints on the NSI. However, after controlling for these same variables, along with posttraumatic stress disorder symptom severity, there no longer were differences between the TBI severity groups. That is, patients with mild TBI did not endorse significantly more complaints (adjusted mean = 22.4) than the moderate-to-severe group (ad Listed mean = 21.8). These findings suggest that much of the symptom complaints in mildly injured patients may be due to emotional distress. (JINS, 2010, 16, 194-199.)	[Belanger, Heather G.; Kretzmer, Tracy; Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Belanger, Heather G.; Vanderploeg, Rodney D.; French, Louis M.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [French, Louis M.] Walter Reed Army Med Ctr, Dept Orthoped & Rehabil, Washington, DC 20307 USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Belanger, HG (corresponding author), James A Haley Vet Hosp, MHBS 116B,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	heather.belanger@va.gov	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Department of Veterans Affairs, Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; James A. Haley Veterans' HospitalUS Department of Veterans Affairs	The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), and the Defense and Veterans Brain Injury Center (DVBIC). Further support was provided by the James A. Haley Veterans' Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Army. Department of Defense, Department of Veterans Affairs. or U.S. Government.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaycox, 2008, INVISIBLE WOUNDS WAR; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; SCHWAB K, 2009, STRUCTURE POST UNPUB; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Weathers F.W., 1991, PTSD CHECKLIST MILIT; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	29	144	144	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2010	16	1					194	199		10.1017/S1355617709990841			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	543LR	WOS:000273579600021	19758488				2022-02-06	
J	Weichel, ED; Colyer, MH; Ludlow, SE; Bower, KS; Eiseman, AS				Weichel, Eric D.; Colyer, Marcus H.; Ludlow, Spencer E.; Bower, Kraig S.; Eiseman, Andrew S.			Combat Ocular Trauma Visual Outcomes during Operations Iraqi and Enduring Freedom	OPHTHALMOLOGY			English	Article							CLASSIFYING MECHANICAL INJURIES; UNITED-STATES; EYE INJURIES; PROGNOSTIC-FACTORS; GLOBE INJURIES; DESERT-SHIELD; BRAIN-INJURY; SURVIVAL; EPIDEMIOLOGY; MANAGEMENT	Objective: To report the visual and anatomic outcomes as well as to predict the visual prognosis of combat ocular trauma (COT) during Operations Iraqi and Enduring Freedom. Design: Retrospective, noncomparative, interventional, consecutive case series. Participants: Five hundred twenty-three consecutive globe or adnexal combat injuries, or both, sustained by 387 United States soldiers treated at Walter Reed Army Medical Center between March 2003 and October 2006. Methods: Two hundred one ocular trauma variables were collected on each injured soldier. Best-corrected visual acuity (BCVA) was categorized using the ocular trauma score (OTS) grading system and was analyzed by comparing initial and 6-month postinjury BCVA. Main Outcome Measures: Best-corrected visual acuity, OTS, and globe, oculoplastic, neuro-ophthalmic, and associated nonocular injuries. Results: The median age was 25 7 years (range, 18-57 years), with the median baseline OTS of 70 25 (range, 12-100). The types of COT included closed-globe (n = 234; zone 1+2, n = 103; zone 3, n = 131), open-globe (n = 198; intraocular foreign body, n = 86; perforating, n = 61; penetrating, n = 32; and rupture, n = 19), oculoplastic (n = 324), and neuro-ophthalmic (n = 135) injuries. Globe trauma was present in 432 eyes, with 253 eyes used for visual acuity analysis. Comparing initial versus 6-month BCVA, 42% of eyes achieved a BCVA of 20/40 or better, whereas 32% of eyes had a BCVA of no light perception. Closed-globe injuries accounted for 65% of BCVA of 20/40 or better, whereas 75% of open-globe injuries had a BCVA of 20/200 or worse. The ocular injuries with the worst visual outcomes included choroidal hemorrhage, globe perforation or rupture, retinal detachment, submacular hemorrhage, and traumatic optic neuropathy. Additionally, COT that combined globe injury with oculoplastic or neuro-ophthalmologic injury resulted in the highest risk of final BCVA worse than 20/200 (odds ratio, 11.8; 95% confidence interval, 4.0-34.7; P<0.0005). Nonocular injuries occurred in 85% of cases and included traumatic brain injury (66%) and facial injury (58%). Extremity injuries were 44% (170 of 387 soldiers). Amputation is a subset of extremity injury with 12% (46 of 387) having sustained a severe extremity injury causing amputation. Conclusions: Combat ocular trauma has high rates of nonocular injuries with better visual outcomes in closed-globe compared with open-globe trauma. The OTS is a valid classification scheme for COT and correlates the severity of injury with the final visual acuity and prognosis. Globe combined with oculoplastic or neuro-ophthalmologic injuries have the worst visual prognosis. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2008;115:2235-2245 (C) 2008 by the American Academy of Ophthalmology.	[Weichel, Eric D.] Walter Reed Army Med Ctr, Ophthalmol Serv, Washington, DC 20307 USA		Weichel, ED (corresponding author), Walter Reed Army Med Ctr, Ophthalmol Serv, 6900 Georgia Ave, Washington, DC 20307 USA.	eweichel@hotmail.com					Al-Omran AM, 2007, RETINA-J RET VIT DIS, V27, P236, DOI 10.1097/01.iae.0000225072.68265.ee; Ari Adrienne B, 2006, Optometry, V77, P329, DOI 10.1016/j.optm.2006.03.015; BELLOWS JG, 1947, AM J OPHTHALMOL, V30, P309, DOI 10.1016/0002-9394(47)91977-6; Biehl JW, 1999, MIL MED, V164, P780, DOI 10.1093/milmed/164.11.780; *BLIND VET ASS, 2007, BVA B; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Cardillo JA, 1997, OPHTHALMOLOGY, V104, P1166, DOI 10.1016/S0161-6420(97)30167-5; CHARTERS L, 2007, OPHTHALMOL TIME 0501; CHU A, 1989, OPHTHALMIC SURG LAS, V20, P729; Colyer MH, 2008, OPHTHALMOLOGY, V115, P2087, DOI 10.1016/j.ophtha.2008.05.013; Colyer MH, 2007, OPHTHALMOLOGY, V114, P1439, DOI 10.1016/j.ophtha.2006.10.052; COTTER F, 1991, MIL MED, V156, P126, DOI 10.1093/milmed/156.3.126; DEJUAN E, 1983, OPHTHALMOLOGY, V90, P1318; *DEP DEF PERS PROC, GLOB WAR TERR OP IR; *DEP DEF PERS PROC, OP IR FREED MIL WOUN; *DEP DEF PERS PROC, PRINC WARS US PART; *DEP DEF PERS PROC, GLOB WAR TERR OP END; Duke-Elder S, 1972, SYSTEM OPHTHALMOLOGY, V14, P49; Entezari M, 2006, INJURY, V37, P633, DOI 10.1016/j.injury.2006.02.043; ESMAELI B, 1995, OPHTHALMOLOGY, V102, P393; GUNDERSEN T, 1947, T AM ACAD OPHTHALMOL, V52, P604; Harlan J B Jr, 2002, Ophthalmol Clin North Am, V15, P153, DOI 10.1016/S0896-1549(02)00006-8; Harman DR, 2005, MIL MED, V170, P521, DOI 10.7205/MILMED.170.6.521; Hatton MP, 2002, OPHTHAL PLAST RECONS, V18, P458, DOI 10.1097/00002341-200211000-00013; HEIER JS, 1993, ARCH OPHTHALMOL-CHIC, V111, P795, DOI 10.1001/archopht.1993.01090060083028; HOEFLE FB, 1968, ARCH OPHTHALMOL-CHIC, V79, P33, DOI 10.1001/archopht.1968.03850040035011; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; HORNBLASS A, 1981, International Ophthalmology Clinics, V21, P121, DOI 10.1097/00004397-198102140-00008; Hornblass A, 1973, Surg Forum, V24, P500; JAFFE NS, 1953, AMA ARCH OPHTHALMOL, V49, P591; Jankovic S, 1998, MIL MED, V163, P423, DOI 10.1093/milmed/163.6.423; Johnson AJ, 2007, J TRAUMA, V62, pS20, DOI 10.1097/TA.0b013e3180653eb7; Kuhn F, 1996, GRAEF ARCH CLIN EXP, V234, P399, DOI 10.1007/BF00190717; Kuhn F, 1998, OPHTHALMOLOGE, V95, P332, DOI 10.1007/s003470050282; Kuhn F, 2006, OPHTHAL EPIDEMIOL, V13, P209, DOI 10.1080/09286580600665886; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P139, DOI 10.1016/S0896-1549(02)00004-4; Kuhn Ferenc, 2002, Ophthalmol Clin North Am, V15, P163, DOI 10.1016/S0896-1549(02)00007-X; La Piana FG, 1997, DOC OPHTHALMOL, V93, P29, DOI 10.1007/BF02569045; La Piana FG., 1999, OPHTHALMOL CLIN N AM, V12, P421; LADA J, 1975, MED STAT WORLD WAR 2, V21, P1227; LOWREY A, 1954, Trans Pac Coast Otoophthalmol Soc Annu Meet, V35, P39; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; MADER TH, 1993, OPHTHALMOLOGY, V100, P1462; Matthews GP, 1998, OPHTHALMIC SURG LAS, V29, P48; Montgomery SP, 2005, J AM COLL SURGEONS, V201, P7, DOI 10.1016/j.jamcollsurg.2005.03.038; Montgomery SP, 2005, J AM COLL SURGEONS, V201, P12, DOI 10.1016/j.jamcollsurg.2005.04.009; *NAT CTR HLTH STAT, 2005, BAR INJ DIAGN MATR C; Nguyen Quan Dong, 2002, International Ophthalmology Clinics, V42, P167, DOI 10.1097/00004397-200207000-00018; Parsons J., 1941, T OPHTHAL SOC UK, V61, P157; Pieramici DJ, 2003, J TRAUMA, V54, P750, DOI 10.1097/01.TA.0000047053.53821.C8; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Pieramici DJ, 2002, OPHTHALMOL CLIN N AM, V15, pvii; REISTER FA, 1973, BATTLE CASUALTIES ME, P48; Schmidt GW, 2008, OPHTHALMOLOGY, V115, P202, DOI 10.1016/j.ophtha.2007.04.008; SCOTT GI, 1946, BRIT J OPHTHALMOL, V30, P42, DOI 10.1136/bjo.30.1.42; SIMMONS ST, 1984, OPHTHALMOLOGY, V91, P977; Sobaci G, 2005, AM J OPHTHALMOL, V139, P937, DOI 10.1016/j.ajo.2004.11.009; SOMMERVILLELARG.LB, 1946, T OPHTHAL SOC UK, V66, P647; Steindorf K, 1914, BERL KLIN WOCHENSCHR, V51, P1789; STERNBERG P, 1984, AM J OPHTHALMOL, V98, P467, DOI 10.1016/0002-9394(84)90133-8; STONE W, 1950, JAMA-J AM MED ASSOC, V142, P151, DOI 10.1001/jama.1950.02910210007002; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; TREDICI TJ, 1968, MIL MED, V133, P355, DOI 10.1093/milmed/133.5.355; TREISTER G, 1969, AM J OPHTHALMOL, V68, P669, DOI 10.1016/0002-9394(69)91251-3; *US EYE INJ REG, SOURC EYE INJ; WILLIAMS DF, 1988, OPHTHALMOLOGY, V95, P911; Wong TY, 1997, SURV OPHTHALMOL, V41, P433, DOI 10.1016/S0039-6257(97)00022-2	68	144	151	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	DEC	2008	115	12					2235	2245		10.1016/j.ophtha.2008.08.033			11	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	381PK	WOS:000261548200017	19041478				2022-02-06	
J	Stulemeijer, M; van der Werf, S; Borm, GF; Vos, PE				Stulemeijer, M.; van der Werf, S.; Borm, G. F.; Vos, P. E.			Early prediction of favourable recovery 6 months after mild traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							POST-CONCUSSION SYMPTOMS; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; IMPACT; SCALE; WORK; BIAS	Background: Predicting outcome after mild traumatic brain injury (MTBI) is notoriously difficult. Although it is recognised that milder head injuries do not necessarily mean better outcomes, less is known about the factors that do enable early identification of patients who are likely to recover well. Objective: To develop and internally validate two prediction rules for identifying patients who have the highest chance for good 6 month recovery. Methods: A prospective cohort study was conducted among patients with MTBI admitted to the emergency department. Apart from MTBI severity indices, a range of pre-,peri-and early post- injury variables were considered as potential predictors, including emotional and physical functioning. Logistic regression modelling was used to predict the absence of postconcussional symptoms ( PCS) and full return to work ( RTW). Results: At follow- up, 64% of the 201 participating patients reported full recovery. Based on our prediction rules, patients without premorbid physical problems, low levels of PCS and post- traumatic stress early after injury had a 90% chance of remaining free of PCS. Patients with over 11 years of education, without nausea or vomiting on admission, with no additional extracranial injuries and only low levels of pain early after injury had a 90% chance of full RTW. The discriminative ability of the prediction models was satisfactory, with an area under the curve.0.70 after correction for optimism. Conclusions: Early identification of patients with MTBI who are likely to have good 6 month recovery was feasible on the basis of relatively simple prognostic models. A score chart was derived from the models to facilitate clinical application.	[Stulemeijer, M.; van der Werf, S.] Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, NL-6500 HB Nijmegen, Netherlands; [Borm, G. F.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol & Biostat, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands		Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol 935, POB 9101, NL-6500 HB Nijmegen, Netherlands.	P.Vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012				Alberts M, 1997, Ned Tijdschr Geneeskd, V141, P1526; ALBERTS M, 2007, ASSESSMENT BEHAV MED, P301; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schwarzer R., 1995, MEASURES HLTH PSYCHO, P35, DOI DOI 10.1037/T00393-000; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	40	144	145	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2008	79	8					936	942		10.1136/jnnp.2007.131250			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	328KF	WOS:000257796600018	17951281				2022-02-06	
J	Lovell, MR; Pardini, JE; Welling, J; Collins, MW; Bakal, J; Lazar, N; Roush, R; Eddy, WF; Becker, JT				Lovell, Mark R.; Pardini, Jamie E.; Welling, Joel; Collins, Michael W.; Bakal, Jennifer; Lazar, Nicole; Roush, Rebecca; Eddy, William F.; Becker, James T.			Functional brain abnormalities are related to clinical recovery and time to return-to-play in athletes	NEUROSURGERY			English	Article						concussion; functional magnetic resonance imaging; ImPACT; neuropsychological testing; sport injury; traumatic brain injury	SPORTS-RELATED CONCUSSION; COLLEGE FOOTBALL PLAYERS; HIGH-SCHOOL; AGREEMENT STATEMENT; IMPACT; INJURY; MEMORY; VISUALIZATION; PERFORMANCE; SOFTWARE	OBJECTIVE: The relationship between athlete reports of symptoms, neurophysiological activation, and neuropsychological functioning is investigated in a sample of high school athletes. METHODS: All athletes were evaluated using functional magnetic resonance imaging (fMRI), a computer-based battery of neurocognitive tests, and a subjective symptom scale. Athletes were evaluated within approximately 1 week of injury and again after clinical recovery using all assessment modalities. RESULTS: This study found that abnormal fMRI results during the first week of recovery predicted clinical recovery. As a group, athletes who demonstrated hyperactivation on fMRI scans at the time of their first fMRI scan demonstrated a more prolonged clinical recovery than athletes who did not demonstrate hyperactivation at the time of their first fMRI scan. CONCLUSION: These results demonstrate the relationship between neurophysiological, neuropsychological, and subjective symptom data in a relatively large sample composed primarily of concussed high school athletes. WRI represents an important evolving technology for the understanding of brain recovery after concussion and may help shape return-to-play guidelines in the future.	Univ Pittsburgh, Sch Med, Dept Orthoped Surg, Med Ctr Sports Med, Pittsburgh, PA 15203 USA; Carnegie Mellon Univ, Sch Comp Sci, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Univ Georgia, Dept Stat, Athens, GA 30602 USA; Psychol Software Tools, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15203 USA		Lovell, MR (corresponding author), Univ Pittsburgh, Sch Med, Dept Orthoped Surg, Med Ctr Sports Med, 3200 S Water St, Pittsburgh, PA 15203 USA.	lovellmr@upmc.edu		Becker, James/0000-0003-4425-4726; Bakal, Jeffrey/0000-0002-3658-2554			ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Eddy WF, 1996, MAGNET RESON MED, V36, P923, DOI 10.1002/mrm.1910360615; Ernst T, 2002, NEUROLOGY, V59, P1343, DOI 10.1212/01.WNL.0000031811.45569.B0; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FRISTON KJ, 1993, P ROY SOC B-BIOL SCI, V254, P47, DOI 10.1098/rspb.1993.0125; Herbster AN, 1996, NEUROIMAGE, V4, P67, DOI 10.1006/nimg.1996.0030; Hosmer D. W., 1999, APPL SURVIVAL ANAL; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Lazar NA, 2002, NEUROIMAGE, V16, P538, DOI 10.1006/nimg.2002.1107; Lazar NA, 2001, INT STAT REV, V69, P105, DOI 10.2307/1403532; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shulman RG, 2007, NEUROIMAGE, V36, P277, DOI 10.1016/j.neuroimage.2006.11.035; Talairach J., 1988, COPLANAR STEREOTACTI; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Xu JS, 2006, PSYCHIAT RES-NEUROIM, V148, P103, DOI 10.1016/j.pscychresns.2006.09.005	41	144	145	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2007	61	2					352	359		10.1227/01.NEU.0000279985.94168.7F			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400030	17762748				2022-02-06	
J	Blackwell, CD; Gorelick, M; Holmes, JF; Bandyopadhyay, S; Kuppermann, N				Blackwell, Charles D.; Gorelick, Marc; Holmes, James F.; Bandyopadhyay, Subhankar; Kuppermann, Nathan			Pediatric head trauma: Changes in use of computed tomography in emergency departments in the United States over time	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Pediatric-Research	MAY   11, 2004	San Francisco, CA	Soc Pediat Res			DECISION RULE; CHILDREN; INJURY	Study objective: Head trauma is common in children. In the absence of evidence-based recommendations, variations exist in the initial emergency department (ED) evaluation and treatment of children with head trauma. We sought to describe the use of computed tomography (CT) over time in the treatment of children with acute closed head trauma in US EDs. Methods: This was a cross-sectional analysis of data from the National Hospital Ambulatory Care Survey database from 1995 to 2003. We identified patients aged 0 to 18 years, with head trauma by chief complaint or discharge diagnosis. We collected the following data: chief complaint, patient demographics, patient disposition, discharge diagnosis, and use of CT. Frequency and characteristics of the use of CT scan for evaluation of children with head trauma. We used descriptive statistics with appropriate weighting to account for the survey methodology. We determined the frequency and the characteristics of the use of CT scans for evaluation of children with head trauma. We used descriptive statistics with appropriate weighting to account for the survey methodology. Results: We identified 2,747 patient encounters, representing 10,536,717 pediatric head trauma visits during the 9-year period. The use of CT increased from 12.8% to 22.4% from 1995 to 2003, with a peak of 28.6% in 2000. CT was used more frequently in the older age groups: 13% (<1 year), 11% (1 to 4 years), 20% (5 to 9 years), and 32% (10 to 18 years). CT was also used more frequently in general EDs (22%) than in pediatric-specific EDs (13%). There were no differences in CT use between teaching and nonteaching facilities (21% in each). Overall, 6.4% of children were either admitted to the hospital or transferred, and this rate remained stable over time. Conclusion: The use of CT has increased substantially in the evaluation of children with head trauma from 1995 to 2003. Further study is needed to identify objective criteria for cranial CT in head-injured children and to evaluate the impact of increased CT use on patient outcomes.	Childrens Hosp & Clin Minnesota, Dept Emergency Med, Minneapolis, MN 55404 USA; Med Coll Wisconsin, Childrens Hosp Wisconsin, Childrens Res Inst, Dept Pediat, Milwaukee, WI 53226 USA; Univ Calif Davis, Sch Med, Dept Emergency Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95616 USA; Emory Univ, Sch Med, Div Emergency Med, Dept Pediat, Atlanta, GA USA; Childrens Healthcare Atlanta Egleston, Atlanta, GA USA		Blackwell, CD (corresponding author), Childrens Hosp & Clin Minnesota, Dept Emergency Med, 2525 Chicago Ave S, Minneapolis, MN 55404 USA.	David.Blackwell@childrensmn.org					Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; HORNER CJ, 1909, PEDIATRICS, V104, pE78; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; *NAT CTR HLTH STAT, NHAMCS DESCR; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; SHUNK JE, 1996, PEDIATR EMERG CARE, V12, P160; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5	10	144	144	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAR	2007	49	3					320	324		10.1016/j.annemergmed.2006.09.025			5	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	142GI	WOS:000244637000013	17145113				2022-02-06	
J	Potter, S; Leigh, E; Wade, D; Fleminger, S				Potter, Seb; Leigh, Eleanor; Wade, Derick; Fleminger, Simon			The rivermead post concussion symptoms questionnaire - A confirmatory factor analysis	JOURNAL OF NEUROLOGY			English	Article						post-concussion syndrome; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; ROUTINE FOLLOW-UP; POSTCONCUSSION SYNDROME; SUBJECTIVE COMPLAINTS; MISERABLE MINORITY; RISK-FACTORS; BASE-RATE; MILD; EXPECTATION	Objective To investigate the factor structure of the Rivermead Post Concussion Symptoms Questionnaire (RPQ) among individuals seen as part of routine follow-up following traumatic brain injury. Methods RPQ data from 168 participants was examined (mean age 35.2, SD 14.3; 89% with post traumatic amnesia duration < 24 hours) six months after admission to an Accident & Emergency Department following TBI. Structural equation modelling was carried out to evaluate proposed models of the underlying structure of post-concussion symptoms (PCS). Results The results support the existence of separate cognitive, emotional and somatic factors, although there was a high degree of covariation between the three factors. A two-factor model that collapsed the emotional and somatic factors together showed a similar goodness-of-fit to the data, whilst a one-factor model proved a poor fit. Conclusions The results support the notion of post-concussion symptoms as a collection of associated but at least partially separable cognitive, emotional and somatic symptoms, although questions persist regarding symptom specificity. The use of the RPQ is discussed, and classification bands for use in clinical practice are suggested.	Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, London SE5 8AZ, England; Oxford Ctr Enablement, Oxford OX3 7LD, England		Potter, S (corresponding author), Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, Denmark Hill, London SE5 8AZ, England.	s.potter@iop.kcl.ac.uk		Wade, Derick/0000-0002-1188-8442; Leigh, Eleanor/0000-0003-2756-3770; Potter, Sebastian/0000-0002-2173-9870			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Axelrod BN, 1998, ARCH CLIN NEUROPSYCH, V13, P543, DOI 10.1016/S0887-6177(97)00044-9; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bouchard ME, 2003, BRAIN COGNITION, V53, P111; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eames PG, 2001, BRAIN DAM B, P29; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Hall S, 2004, HEALTH PSYCHOL, V23, P419, DOI 10.1037/0278-6133.23.4.419; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; MCKINLAY WW, 1992, BRAIN INJURY, V6, P401; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Middelboe T., 1992, European Psychiatry, V7, P183; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Piland SG, 2003, J ATHL TRAINING, V38, P104; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; TEASDALE G, 1974, LANCET, V2, P81; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 CLASSIFICATIO; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zasler ND, 2003, NEUROPSYCHOL REHABIL, V13, P31, DOI 10.1080/09602010	77	144	146	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	DEC	2006	253	12					1603	1614		10.1007/s00415-006-0275-z			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	125TN	WOS:000243465700012	17063314				2022-02-06	
J	Schneider, HJ; Schneider, M; Saller, B; Petersenn, S; Uhr, M; Husemann, B; von Rosen, F; Stalla, GK				Schneider, HJ; Schneider, M; Saller, B; Petersenn, S; Uhr, M; Husemann, B; von Rosen, F; Stalla, GK			Prevalence of anterior pituitary insufficiency 3 and 12 months after traumatic brain injury	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; HYPOPITUITARISM; DIAGNOSIS; DEFICIENCY; SYSTEM; TESTS	Objective: Cross-sectional Studies report it high prevalence of hypopituitarism after traumatic brain injury (TBI): however, no longitudinal studies oil time of manifestation and reversibility exist. This Study was conducted to assess hypopituitarism 3 and 12 months after TBI. Design: This was it prospective. longitudinal, diagnostic study. Methods: Seventy-eight patients (52 men, 26 women, mean age 36.0 years) with TBI grades I-III and 3 8 healthy subjects (2 5 men. 13 women, mean age 36.4 years) as a control group for the GHRH + arginine test were studied. The prevalence of hypopituitarism was assessed 3 and 12 months after TBI by GHRH + arginine test, short adrenocorticotropic hormone (ACTH) test, and basal hormone measurements in patients. Results: After 3 months. 56%, of all patients had impairment's of at least one pituitary axis with axes being affected its follows: gonadotropic 32%, corticotropic 19%, somatotropic 9% and thyrotropic 8%. After 12 months. fewer patients were affected. but ill some cases new impairments occurred: 36% still had impairments. The axes were affected its follows after 12 months: gonadotropic 21%, somatotropic 10%, corticotropic 9% and thyrotropic 3%. Conclusions: Hypopituitarism occurs often in the post-acute phase after TBI and may normalize later, but may also develop after the post-acute phase of TBI.	Max Planck Inst Psychiat, Clin Neuroendocrinol Grp, D-80804 Munich, Germany; Pfizer GmbH, D-76032 Karlsruhe, Germany; Univ Hosp Essen, Dept Endocrinol, D-45122 Essen, Germany; Neurol Clin Bad Aibling, D-83043 Bad Aibling, Germany		Stalla, GK (corresponding author), Max Planck Inst Psychiat, Clin Neuroendocrinol Grp, Kraepelinstr 10, D-80804 Munich, Germany.	stalla@mpipsykl.mpg.de					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LINDHOLM J, 1987, CLIN ENDOCRINOL, V26, P53, DOI 10.1111/j.1365-2265.1987.tb03638.x; Ruchholtz S, 2002, CHIRURG, V73, P194, DOI 10.1007/s00104-002-0424-6; SCHNEIDER HJ, 2004, DTSCH ARZTEBL, V101, pA712; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x	26	144	152	0	6	BIOSCIENTIFICA LTD	BRISTOL	STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	FEB	2006	154	2					259	265		10.1530/eje.1.02071			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	015II	WOS:000235544700011	16452539	Bronze			2022-02-06	
J	Kleindienst, A; McGinn, MJ; Harvey, HB; Colello, RJ; Hamm, RJ; Bullock, MR				Kleindienst, A; McGinn, MJ; Harvey, HB; Colello, RJ; Hamm, RJ; Bullock, MR			Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						differentiation; hippocampus; neurotrophic; proliferation; regeneration; S100B; trauma	TRANSIENT GLOBAL-ISCHEMIA; MARROW STROMAL CELLS; ADULT HIPPOCAMPUS; DENTATE GYRUS; ENVIRONMENTAL ENRICHMENT; PROGENITOR CELLS; S-100 PROTEIN; GRANULE CELLS; RAT; PROLIFERATION	Evidence of injury-induced neurogenesis in the adult hippocampus suggests that an endogenous repair mechanism exists for cognitive dysfunction following traumatic brain injury (TBI). One factor that may be associated with this restoration is S100B, a neurotrophic/mitogenic protein produced by astrocytes, which has been shown to improve memory function. Therefore, we examined whether an intraventricular S100B infusion enhances neurogenesis within the hippocampus following experimental TBI and whether the biological response can be associated with a measurable cognitive improvement. Following lateral fluid percussion or sham injury in male rats (n = 60), we infused S100B (50 ng/h) or vehicle into the lateral ventricle for 7 days using an osmotic micro-pump. Cell proliferation was assessed by injecting the mitotic marker bromodeoxyuridine (BrdU) on day 2 post-injury. Quantification of BrdU-immunoreactive cells in the dentate gyrus revealed an S100B-enhanced proliferation as assessed on day 5 post-injury (p < 0.05), persisting up to 5 weeks (p < 0.05). Using cell-specific markers, we determined the relative numbers of these progenitor cells that became neurons or glia and found that S100B profoundly increased hippocampal neurogenesis 5 weeks after TBI (p < 0.05). Furthermore, spatial learning ability, as assessed by the Morris water maze on day 30-34 post-injury, revealed an improved cognitive performance after S100B infusion (P < 0.05). Collectively, our findings indicate that an intraventricular S100B infusion induces neurogenesis within the hippocampus, which can be associated with an enhanced cognitive function following experimental TBI. These observations provide compelling evidence for the therapeutic potential of S100B in improving functional recovery following TBI.	Univ Gottingen, Dept Neurosurg, D-37075 Gottingen, Germany; Virginia Commonwealth Univ, Ctr Med, Dept Neurosurg, Richmond, VA USA; Virginia Commonwealth Univ, Ctr Med, Dept Anat & Neurobiol, Richmond, VA USA; Virginia Commonwealth Univ, Ctr Med, Dept Psychol, Richmond, VA USA		Kleindienst, A (corresponding author), Univ Gottingen, Dept Neurosurg, Robert Koch Str 40, D-37075 Gottingen, Germany.	andrea.kleindienst@med.uni-goettingen.de	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324			Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fazeli M S, 1990, Adv Exp Med Biol, V268, P369; Goncalves DS, 2000, NEUROREPORT, V11, P807, DOI 10.1097/00001756-200003200-00030; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Iwasaki Y, 1997, J NEUROL SCI, V151, P7, DOI 10.1016/S0022-510X(97)00073-7; Kawai T, 2004, J CEREBR BLOOD F MET, V24, P548, DOI 10.1097/00004647-200405000-00009; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; KLEIN JR, 1989, CANCER IMMUNOL IMMUN, V29, P133; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Komitova M, 2002, J CEREBR BLOOD F MET, V22, P852, DOI 10.1097/00004647-200207000-00010; Kornack DR, 2001, P NATL ACAD SCI USA, V98, P4752, DOI 10.1073/pnas.081074998; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Landar A, 1996, CELL CALCIUM, V20, P279, DOI 10.1016/S0143-4160(96)90033-0; Li YK, 1998, J NEUROCHEM, V71, P1421; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Nishi M, 1997, NEUROSCI LETT, V229, P212, DOI 10.1016/S0304-3940(97)00443-6; Nottebohm F, 2002, J NEUROSCI, V22, P624, DOI 10.1523/JNEUROSCI.22-03-00624.2002; ODowd BS, 1997, NEUROBIOL LEARN MEM, V67, P197, DOI 10.1006/nlme.1997.3766; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; RICKMANN M, 1995, BRAIN RES, V688, P8, DOI 10.1016/0006-8993(95)00495-C; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Souza TME, 2000, PHYSIOL BEHAV, V71, P29, DOI 10.1016/S0031-9384(00)00299-7; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	64	144	149	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					645	655		10.1089/neu.2005.22.645			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400004	15941374				2022-02-06	
J	Rieger, M; Gauggel, S; Burmeister, K				Rieger, M; Gauggel, S; Burmeister, K			Inhibition of ongoing responses following frontal, nonfrontal, and basal ganglia lesions	NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NO-GO REACTION; CARD SORTING TEST; ATTENTION DEFICIT/HYPERACTIVITY DISORDER; PREFRONTAL UNIT-ACTIVITY; PARKINSONS-DISEASE; HAND MOVEMENT; COLOR DISCRIMINATION; FUNCTIONAL MRI; CORTEX	The authors investigated the role of the frontal lobes and the basal ganglia in the inhibition of ongoing responses. Seventeen patients with frontal lesions (FG), 20 patients with lesions outside the frontal cortex (NFG), 8 patients with lesions to the basal ganglia (BG), and 20 orthopedic controls (OG) performed the stop-signal task that allows the estimation of the time it takes to inhibit an ongoing reaction (stop signal reaction time [SSRT]). The FG and the BG showed significantly longer SSRTs than the OG. Within the FG, patients with right and bilateral lesions showed significantly longer SSRTs than patients with left lesions. Results provide evidence for a role of the frontal lobes and the basal ganglia in the inhibition of ongoing responses.	Univ Marburg, Dept Psychol, D-3550 Marburg, Germany		Rieger, M (corresponding author), Max Planck Inst Psychol Res Cognit & Act, Amalienstr 33, D-80799 Munich, Germany.	rieger@mpipf-muenchen.mpg.de		Gauggel, Siegfried/0000-0002-2742-4917; Rieger, Martina/0000-0002-2421-296X			ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALIVISATOS B, 1989, NEUROPSYCHOLOGIA, V27, P495, DOI 10.1016/0028-3932(89)90054-7; APICELLA P, 1992, J NEUROPHYSIOL, V68, P945, DOI 10.1152/jn.1992.68.3.945; Baddeley, 1981, ATTENTION PERFORM, P205; Band GPH, 1999, ACTA PSYCHOL, V101, P179, DOI 10.1016/S0001-6918(99)00005-0; Band GPH, 1997, PREPARATION ADJUSTME; BRUNIA CHM, 1993, PSYCHOPHYSIOLOGY, V30, P327, DOI 10.1111/j.1469-8986.1993.tb02054.x; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Casey BJ, 2001, CARN S COGN, P327; Cohen J., 2013, STAT POWER ANAL BEHA; COOPER JA, 1994, BRAIN, V117, P517, DOI 10.1093/brain/117.3.517; Damasio H., 1989, LESION ANAL NEUROPSY; DAUM I, 1995, CORTEX, V31, P413, DOI 10.1016/S0010-9452(13)80057-3; DECARY A, 1995, NEUROPSYCHOLOGIA, V33, P1243, DOI 10.1016/0028-3932(95)00040-A; DELANGEN EG, 1995, REHABILITATION, V34, P9; deZubicaray G, 1996, CLIN NEUROPSYCHOL, V10, P245, DOI 10.1080/13854049608406687; Dimitrov M, 1999, NEUROPSYCHOLOGY, V13, P135, DOI 10.1037/0894-4105.13.1.135; DREWE E A, 1975, Cortex, V11, P8; DREWE EA, 1975, NEUROPSYCHOLOGIA, V13, P421, DOI 10.1016/0028-3932(75)90065-2; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; Falkenstein M, 1999, ACTA PSYCHOL, V101, P267, DOI 10.1016/S0001-6918(99)00008-6; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; Fuster JM, 1999, ACTA PSYCHIAT SCAND, V99, P51, DOI 10.1111/j.1600-0447.1999.tb05983.x; GEMBA DH, 1989, NEUROSCI LETT, V101, P263, DOI 10.1016/0304-3940(89)90543-0; GEMBA H, 1990, BRAIN RES, V537, P340, DOI 10.1016/0006-8993(90)90382-L; GOLDMANRAKIC PS, 1987, COGNITIVE NEUROCHEMI, P90; HEUBROCK D, 1995, EUR J PSYCHOL ASSESS, V11, P21, DOI 10.1027/1015-5759.11.1.21; Heubrock D, 1992, Z DIFFERENTIELLE DIA, V3, P161; Jahanshahi M, 1998, COGN NEUROPSYCHOL, V15, P483, DOI 10.1080/026432998381005; KAERNBACH C, 1991, PERCEPT PSYCHOPHYS, V49, P227, DOI 10.3758/BF03214307; KALASKA JF, 1995, CEREB CORTEX, V5, P410, DOI 10.1093/cercor/5.5.410; Kawashima R, 1996, BRAIN RES, V728, P79, DOI 10.1016/0006-8993(96)00389-7; Kiefer M, 1998, NEUROREPORT, V9, P765, DOI 10.1097/00001756-199803090-00037; KOK A, 1986, BIOL PSYCHOL, V23, P21, DOI 10.1016/0301-0511(86)90087-6; Konishi S, 1999, BRAIN, V122, P981, DOI 10.1093/brain/122.5.981; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kropotov JD, 1999, INT J PSYCHOPHYSIOL, V31, P197, DOI 10.1016/S0167-8760(98)00051-8; LAPPIN JS, 1966, J EXP PSYCHOL, V72, P805, DOI 10.1037/h0021266; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LHERMITTE F, 1983, BRAIN, V106, P237, DOI 10.1093/brain/106.2.237; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan Gordon D., 1994, P189; McGarry T, 1997, J EXP PSYCHOL HUMAN, V23, P1533, DOI 10.1037//0096-1523.23.5.1533; Milner B., 1964, FRONTAL GRANULAR COR, P313; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Partiot A, 1996, NEUROPSYCHOLOGIA, V34, P709, DOI 10.1016/0028-3932(95)00143-3; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PFEFFERBAUM A, 1985, ELECTROEN CLIN NEURO, V60, P423, DOI 10.1016/0013-4694(85)91017-X; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; SASAKI K, 1986, EXP BRAIN RES, V64, P603, DOI 10.1007/BF00340499; SASAKI K, 1989, BRAIN RES, V495, P100, DOI 10.1016/0006-8993(89)91222-5; SCHACHAR R, 1990, DEV PSYCHOL, V26, P710, DOI 10.1037/0012-1649.26.5.710; SCHACHAR RJ, 1993, CLIN PSYCHOL REV, V13, P721, DOI 10.1016/S0272-7358(05)80003-0; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Stefanova ED, 2001, J CLIN EXP NEUROPSYC, V23, P581, DOI 10.1076/jcen.23.5.581.1239; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Sturm W., 1993, LEISTUNGSPRUFSYSTEM; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; Truong MK, 1993, SHORT WISCONSIN CARD; Vallar G, 1999, HDB CLIN EXPT NEUROP, P95; VERFAELLIE M, 1987, ARCH NEUROL-CHICAGO, V44, P1265, DOI 10.1001/archneur.1987.00520240045010; WATANABE M, 1986, BRAIN RES, V382, P1, DOI 10.1016/0006-8993(86)90104-6; WATANABE M, 1986, BRAIN RES, V382, P15, DOI 10.1016/0006-8993(86)90105-8; Wechsler D, 1987, WMSR WECHSLER MEMORY; Wichmann T, 1996, CURR OPIN NEUROBIOL, V6, P751, DOI 10.1016/S0959-4388(96)80024-9; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205; Zakzanis KK, 1998, J CLIN EXP NEUROPSYC, V20, P419, DOI 10.1076/jcen.20.3.419.821; [No title captured]; [No title captured]	76	144	145	0	21	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	APR	2003	17	2					272	282		10.1037/0894-4105.17.2.272			11	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	682JX	WOS:000183089400011	12803433				2022-02-06	
J	Geddes, JF; Tasker, RC; Hackshaw, AK; Nickols, CD; Adams, GGW; Whitwell, HL; Scheimberg, I				Geddes, JF; Tasker, RC; Hackshaw, AK; Nickols, CD; Adams, GGW; Whitwell, HL; Scheimberg, I			Dural haemorrhage in non-traumatic infant deaths: does it explain the bleeding in 'shaken baby syndrome'?	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						infant head injury; non-accidental injury; subdural haemorrhage	INFLICTED HEAD-INJURY; SUBDURAL-HEMATOMA; INTRACRANIAL HEMORRHAGE; RETINAL HEMORRHAGES; BRAIN INJURY; CHILD-ABUSE; NEUROPATHOLOGY; NEWBORN	A histological review of dura mater taken from a post-mortem series of 50 paediatric cases aged up to 5 months revealed fresh bleeding in the dura in 36/50, the bleeding ranging from small perivascular haemorrhages to extensive haemorrhage which had ruptured onto the surface of the dura. Severe hypoxia had been documented clinically in 27 of the 36 cases (75%). In a similar review of three infants presenting with classical 'shaken baby syndrome', intradural haemorrhage was also found, in addition to subdural bleeding, and we believe that our findings may have relevance to the pathogenesis of some infantile subdural haemorrhage. Recent work has shown that, in a proportion of infants with fatal head injury, there is little traumatic brain damage and that the significant finding is craniocervical injury, which causes respiratory abnormalities, severe global hypoxia and brain swelling, with raised intracranial pressure. We propose that, in such infants, a combination of severe hypoxia, brain swelling and raised central venous pressure causes blood to leak from intracranial veins into the subdural space, and that the cause of the subdural bleeding in some cases of infant head injury is therefore not traumatic rupture of bridging veins, but a phenomenon of immaturity. Hypoxia with brain swelling would also account for retinal haemorrhages, and so provide a unified hypothesis for the clinical and neuropathological findings in cases of infant head injury, without impact or considerable force being necessary.	Univ London, Queen Mary, Barts & London Sch Med & Dent, Dept Histopathol, London, England; Univ London, Queen Mary, Barts & London Sch Med & Dent, Dept Environm & Prevent Med, London, England; Univ Cambridge, Dept Paediat, Cambridge, England; Univ Sheffield, Dept Forens Pathol, Sheffield, S Yorkshire, England; Moorfields Eye Hosp, London, England		Geddes, JF (corresponding author), Royal London Hosp, Dept Histopathol & Morbid Anat, London E1 1BB, England.	j.f.geddes@qmul.ac.uk	Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113			Anteby II, 2001, J AAPOS, V5, P90, DOI 10.1067/mpa.2001.113841; Betz P, 1996, INT J LEGAL MED, V108, P262, DOI 10.1007/BF01369823; BIAGGIONI I, 1994, HYPERTENSION, V23, P491, DOI 10.1161/01.HYP.23.4.491; Chase W. H., 1930, SURG GYNECOL OBSTET, V51, P31; Clark BJ, 2001, AM J FOREN MED PATH, V22, P415, DOI 10.1097/00000433-200112000-00017; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ehrenforth S, 1998, EUR J PEDIATR, V157, P1032, DOI 10.1007/s004310050993; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; FERRARIO CM, 1981, HYPERTENSION, V3, P2; Friede R. L, 1989, DEV NEUROPATHOLOGY; Geddes JF, 2001, CURR TOPICS PATHOL, V95, P101; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Govaert P, 1993, CRANIAL HAEMORRHAGE; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; Green PM, 1999, FETAL DIAGN THER, V14, P275, DOI 10.1159/000020938; KATSURA K, 1994, J CEREBR BLOOD F MET, V14, P243, DOI 10.1038/jcbfm.1994.31; KAUR B, 1992, SURV OPHTHALMOL, V37, P1, DOI 10.1016/0039-6257(92)90002-B; KIM KA, 2000, NEUROSURG FOCUS, V8; Lafont M, 1999, ARCH PEDIATRIE, V6, P962, DOI 10.1016/S0929-693X(99)80589-2; Medele RJ, 1998, J NEUROSURG, V88, P851, DOI 10.3171/jns.1998.88.5.0851; MONSON KL, 2000, ASME AMD, V246, P255; MORIMOTO Y, 1993, CRIT CARE MED, V21, P907, DOI 10.1097/00003246-199306000-00021; MORIMOTO Y, 1993, CRIT CARE MED, V21, P104, DOI 10.1097/00003246-199301000-00020; Ng PC, 1998, J PAEDIATR CHILD H, V34, P296, DOI 10.1046/j.1440-1754.1998.00220.x; Ohashi Koichiro, 1992, Neurologia Medico-Chirurgica, V32, P935, DOI 10.2176/nmc.32.935; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Pollack JS, 1996, AM J OPHTHALMOL, V121, P297, DOI 10.1016/S0002-9394(14)70278-8; Renzulli P, 1998, EUR J PEDIATR, V157, P663, DOI 10.1007/s004310050907; Rutty GN, 1999, AM J FOREN MED PATH, V20, P48, DOI 10.1097/00000433-199903000-00012; Sgro M, 1998, PRENATAL DIAG, V18, P496; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TONGUE AC, 1991, OPHTHALMOLOGY, V98, P1009; Volpe J., 2001, NEUROLOGY NEWBORN; WIGGLESWORTH JS, 1998, TXB FETAL PERINATAL, P255; Williams PL, 1989, GRAYS ANATOMY	36	144	148	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	FEB	2003	29	1					14	22		10.1046/j.1365-2990.2003.00434.x			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	644VU	WOS:000180941300002	12581336				2022-02-06	
J	Herrmann, M; Curio, N; Jost, S; Grubich, C; Ebert, AD; Fork, ML; Synowitz, H				Herrmann, M; Curio, N; Jost, S; Grubich, C; Ebert, AD; Fork, ML; Synowitz, H			Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; neuron-specific enolase; protein S-100B; neuropsychology; outcome	PROTEIN S-100; NEUROBIOCHEMICAL MARKERS; COMPUTED-TOMOGRAPHY; HEAD-INJURY; CELL-DEATH; SERUM; ENOLASE; SEVERITY; FAMILY	Objectives-The present study aimed at the analysis of release patterns of neurobiochemical markers of brain damage (neuron specific enolase (NSE) and protein S-100B) in patients with traumatic brain injury and their predictive value with respect to the short and long term neuropsychological outcome. Methods-Serial NSE and S-100B concentrations were analysed in blood samples taken at the first, second, and third day after traumatic brain injury. In 69 patients who fulfilled the inclusion criteria (no history of neurological or psychiatric disorder or alcohol or drug dependency, blood sampling according to the scheduled time scale, aged between 16 and 65 years) standardised neurological examinations and qualitative and quantitative evaluation of CT were performed. Comprehensive neuropsychological assessment was performed in 39 subjects 2 weeks after admission and in 29 subjects at a 6 month follow up examination. Results-Most patients presented with minor head injuries (GCS greater than or equal to 3) at the time of admission. Six months later most patients were fully independent in activities of daily living. Two thirds of the patients, however, still had neuropsychological dysfunction. Patients with short and long term neuropsychological disorders had significantly higher NSE and S-100B serum concentrations and a significantly longer lasting release of both markers. A comparative analysis of the predictive value of clinical, neuroradiological, and biochemical data showed initial S-100B values above 140 ng/l to have the highest predictive power. Conclusions-The analysis of posttraumatic release patterns of neurobiochemical markers of brain damage might help to identify patients with traumatic brain injury who run a risk of long term neuropsychological dysfunction.	Otto von Guericke Univ, Fac Med, Div Neuropsychol & Behav Neurol, D-39120 Magdeburg, Germany; Hanse Inst Adv Study, Dept Neurol 2, Bremen, Germany; Hanse Inst Adv Study, Dept Neurosurg, Bremen, Germany		Herrmann, M (corresponding author), Otto von Guericke Univ, Fac Med, Div Neuropsychol & Behav Neurol, Leipzigerstr 44, D-39120 Magdeburg, Germany.	manfred.herrman@medizin.uni-magdeburg.de	Herrmann, Manfred/H-3931-2011	Herrmann, Manfred/0000-0003-1872-8406			ETTLIN T, 1999, SCI PRACT NEUROPSYCH, P233; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huber W., 1983, AACHENER APHASIE TES; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; KESSLER J, 1988, DEMENZTEST MANUAL; KRAMER J, 1977, KRAMER TEST REVISION; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; McKeating EG, 1998, ACT NEUR S, V71, P117; Oswald W. D., 1986, NURNBERGER ALTERS IN; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); SULTZER DL, 1992, J AM GERIATR SOC, V40, P549, DOI 10.1111/j.1532-5415.1992.tb02101.x; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; ZIMMERMANN P, 1993, TEST ATTENTIONAL PER	39	144	156	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2001	70	1					95	100		10.1136/jnnp.70.1.95			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	388KC	WOS:000166178800020	11118255	Green Published, Bronze			2022-02-06	
J	Brooks, WM; Stidley, CA; Petropoulos, H; Jung, RE; Weers, DC; Friedman, SD; Barlow, MA; Sibbitt, WL; Yeo, RA				Brooks, WM; Stidley, CA; Petropoulos, H; Jung, RE; Weers, DC; Friedman, SD; Barlow, MA; Sibbitt, WL; Yeo, RA			Metabolic and cognitive response to human traumatic brain injury: A quantitative proton magnetic resonance study	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; N-acetylaspartate; neurochemistry; neuropsychological testing; proton magnetic resonance spectroscopy; traumatic brain injury	SEVERE HEAD-INJURY; MR SPECTROSCOPY; IN-VIVO; BIOCHEMICAL MARKERS; AXONAL INJURY; QUANTIFICATION; EXPERIENCE; SPECTRA; DISEASE; WATER	Proton magnetic resonance spectroscopy (H-1-MRS) offers a unique insight into brain cellular metabolism following traumatic brain injury (TBI). The aim of the present study was to assess change in neurometabolite markers of brain injury during the recovery period following TBI. We studied 19 TBI patients at 1.5, 3, and 6 months postinjury and 28 controls. We used H-1-MRS to quantify N-acetylaspartate (NAA), creatine (Cre), choline (Cho), and myoinositol (mIns) in occipitoparietal gray matter (GM) and white matter (WM) remote from the primary injury focus. Neuropsychological testing quantified cognitive impairment and recovery. At 1.5 months, we found cognitive impairment (mean z score = -1.36 vs. 0.18,p < 0.01), lower NAA (GM: 12.42 mM vs. 13.03, p = 0.01; WM: 11.75 vs. 12.81, p < 0.01), and elevated Cho (GM: 1.51 vs. 1.25, p < 0.01; WM: 1.98 vs. 1.79, p < 0.01) in TBI patients compared with controls. GM NAA at 1.5 months predicted cognitive function at outcome (6 months postinjury; r = 0.63, p = 0.04). GM NAA continued to fall by 0.46 mM between 1.5 and 3 months (p = 0.02) indicating continuing neuronal loss, metabolic dysfunction, off both. Between 3 and 6 months, WM NAA increased by 0.55 mM (p = 0.06) suggesting metabolic recovery. Patients with poorer outcomes had elevated mean GM Cho at 3 months postinjury, suggesting active inflammation, as compared to patients with better outcomes (p = 0.002). H-1-MRS offers a noninvasive approach to assessing neuronal injury and inflammation following TBI, and may provide unique data for patient management and assessment of therapeutic efficacy.	Univ New Mexico, Hlth Sci Ctr, Clin & Magnet Resonance Res Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Family & Community Med, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA; Univ Washington, Med Ctr, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Brooks, WM (corresponding author), Univ New Mexico, Hlth Sci Ctr, Clin & Magnet Resonance Res Ctr, 1201 Yale NE, Albuquerque, NM 87131 USA.		Sibbitt, Wilmer/AAI-7746-2020	Sibbitt, Wilmer/0000-0001-5872-160X; friedman, seth/0000-0001-8785-7215; brooks, william/0000-0001-6227-7636; Jung, Rex/0000-0003-3718-0597	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123, R01NS035708] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39123, NS35708] Funding Source: Medline		BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BRENNER RE, 1993, MAGNET RESON MED, V29, P737, DOI 10.1002/mrm.1910290605; Brooks WM, 1999, MAGNET RESON MED, V41, P193, DOI 10.1002/(SICI)1522-2594(199901)41:1<193::AID-MRM27>3.3.CO;2-G; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P107, DOI 10.1016/0730-725X(93)90418-D; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GARNETT MR, 1999, P INT SOC MAGN RESON, V7, P229; GENTLEMAN SM, 1999, J NEUROTRAUM, V16, P994; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; Jung RE, 1999, NEUROREPORT, V10, P3327, DOI 10.1097/00001756-199911080-00014; Jung RE, 1999, P ROY SOC B-BIOL SCI, V266, P1375, DOI 10.1098/rspb.1999.0790; Komoroski RA, 1999, MAGN RESON IMAGING, V17, P427, DOI 10.1016/S0730-725X(98)00186-6; KUGEL H, 1992, RADIOLOGY, V183, P701, DOI 10.1148/radiology.183.3.1584924; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEZAK M, 1995, NEUROPSYCHOLOGIC EVA; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; MACMILLAN CSA, 1999, P INT SOC MAGN RESON, V7, P224; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Petropoulos H, 1999, JMRI-J MAGN RESON IM, V9, P39, DOI 10.1002/(SICI)1522-2586(199901)9:1<39::AID-JMRI5>3.0.CO;2-8; PIJNAPPEL WWF, 1992, J MAGN RESON, V97, P122, DOI 10.1016/0022-2364(92)90241-X; ROSS B, 1994, MAGN RESON QUART, V10, P191; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Saunders DE, 1999, JMRI-J MAGN RESON IM, V9, P711, DOI 10.1002/(SICI)1522-2586(199905)9:5<711::AID-JMRI14>3.0.CO;2-3; Spreen O, 1991, COMPENDIUM NEUROPSYC; Tedeschi G, 1997, J NEUROSURG, V87, P516, DOI 10.3171/jns.1997.87.4.0516; TZIKA AA, 1993, AM J NEURORADIOL, V14, P1267; VANDENBOOGAART A, 1994, MAGNET RESON MED, V31, P347, DOI 10.1002/mrm.1910310402; Yamaki T, 1996, J NUCL MED, V37, P1166	35	144	151	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2000	17	8					629	640		10.1089/089771500415382			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	347WF	WOS:000088951600001	10972240				2022-02-06	
J	Garnett, MR; Blamire, AM; Rajagopalan, B; Styles, P; Cadoux-Hudson, TAD				Garnett, MR; Blamire, AM; Rajagopalan, B; Styles, P; Cadoux-Hudson, TAD			Evidence for cellular damage in normal-appearing white matter correlates with injury severity in patients following traumatic brain injury - A magnetic resonance spectroscopy study	BRAIN			English	Article						traumatic brain injury; magnetic resonance spectroscopy; injury severity; N-acetylaspartate; choline	PROTON NMR-SPECTROSCOPY; MODERATE HEAD-INJURY; AXONAL INJURY; H-1 MRS; IN-VIVO; MILD; DYSFUNCTION; INVIVO	Neuropsychological studies in patients who have suffered traumatic brain injury show that the eventual clinical outcome is frequently worse than might be predicted from using conventional (CT or T-1/T-2-weighted MRI) imaging. Furthermore, patients who have sustained an initial mild or moderate injury may show long-term disability. This implies that there may be abnormalities in areas of the brain that actually appear normal on conventional imaging. Proton magnetic resonance spectroscopy studies have shown that N-acetylaspartate and choline-containing compounds can provide measures of cellular injury. We report MRT and proton magnetic resonance spectroscopy studies of 19 head-injured patients performed once the patients were clinically stable (mean 11 days after injury, range 3-38 days), Proton magnetic resonance spectra were acquired from frontal white matter that on conventional MRI appeared normal. that brain matter The on N-acetylaspartate/creatine ratio was reduced [patients (mean +/- standard deviation), 1.28 +/- 0.25; controls, 1.47 +/- 0.24; P = 0.04] and the choline/creatine ratio was increased (patients, 0.85 +/- 0.18; controls, 0.63 +/- 0.10; P < 0.001) compared with controls, when the severity of the injury was assessed using either the Glasgow coma scale or the length of post-traumatic amnesia, the increase in the choline/creatine ratio was significant even in the mildly injured group (P = 0.008 and P = 0.04, respectively). Furthermore, there was a significant correlation (P 0.008) between the severity of head injury and the N-acetylaspartatelcholine ratio. We conclude that there is an early reduction in N-acetylaspartate and an increase in choline compounds in normal-appearing white matter which correlate with head injury severity, and that this may provide a pathological basis for the long-term neurological disability that is seen in these patients.	Univ Oxford, MRC, Biochem & Clin Magnet Resonance Unit, Oxford, England; Univ Oxford, Dept Biochem, Oxford, England; Radcliffe Infirm, Dept Neurosurg, Oxford OX2 6HE, England		Garnett, MR (corresponding author), Oxford Radcliffe Hosp, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England.		Blamire, Andrew/AAU-6100-2021	Blamire, Andrew/0000-0002-8749-1257			Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BROWN TR, 1982, P NATL ACAD SCI-BIOL, V79, P3523, DOI 10.1073/pnas.79.11.3523; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; De Stefano N, 1998, BRAIN, V121, P1469, DOI 10.1093/brain/121.8.1469; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; FRAHM J, 1989, MAGNET RESON MED, V11, P47, DOI 10.1002/mrm.1910110105; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; HAASE A, 1985, PHYS MED BIOL, V30, P341, DOI 10.1088/0031-9155/30/4/008; JENKINS A, 1986, LANCET, V2, P445; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Pendlebury ST, 1999, STROKE, V30, P956, DOI 10.1161/01.STR.30.5.956; Pouwels PJW, 1998, MAGN RESON MED, V39, P53, DOI 10.1002/mrm.1910390110; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	31	144	159	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2000	123		7				1403	1409		10.1093/brain/123.7.1403			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	334JP	WOS:000088183600009	10869052	Bronze			2022-02-06	
J	Guerrero, JL; Thurman, DJ; Sniezek, JE				Guerrero, JL; Thurman, DJ; Sniezek, JE			Emergency department visits associated with traumatic brain injury: United States, 1995-1996	BRAIN INJURY			English	Article							HEAD-INJURY; VIOLENCE	The purposes of this study were to provide a national estimate of the incidence of traumatic brain injuries (TBIs) seen in emergency departments (EDs), but not requiring hospitalization and to determine the causes of these injuries. Using the Centers for Disease Control and Prevention case definition of TBI, ED data was analysed from the National Hospital Ambulatory Medical Care Survey (1995-1996). The average overall incidence rate of TBI-related ED visits for persons who were not hospitalized was 392/100 000 population per year, or 1 027 000 visits to hospital EDs in the US each year. This estimate is nearly twice (392 vs. 216) the previously estimated incidence rate, which was based on data from the 1991 National Health Interview Survey Injury Supplement. It was found that the highest incidence rate occurred among children aged 0-14 years, the rate for males was higher than for females, and the primary reported causes of these injuries were 'falls', motor vehicle-related causes, and 'struck by an object'. Although often considered 'mild' TBIs, these injuries can lead to significant cognitive and emotional impairment. Thus, continued surveillance of TBI-related ED visits is an important part of a comprehensive TBI prevention strategy.	Natl Ctr Injury Prevent & Control, Off Stat & Programming, Atlanta, GA 30341 USA; Natl Ctr Injury Prevent & Control, Div Acute Care Rehabil Res & Disabil Prevent, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Hlth Care & Aging Studies Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA		Guerrero, JL (corresponding author), Natl Ctr Injury Prevent & Control, Off Stat & Programming, MS-K59,4770 Buford Hwy NE, Atlanta, GA 30341 USA.			Thurman, David/0000-0002-0533-7062			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; BERSTEIN DM, 1999, BRAIN INJURY, V13, P151; Gronwall D, 1989, MILD HEAD INJURY, P153; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; KRAUS JF, 1984, ANNU REV PUBL HEALTH, V5, P163; KRAUS JF, 1993, EPIDEMIOLOGY HEAD IN, V3, P1; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; *NAT CTR HLTH STAT, 1992, DAT FIL DOC NAT HOSP; *NAT CTR HLTH STAT, 1995, DAT FIL DOC NAT HOSP; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R. M., 1989, MILD HEAD INJURY, P176; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; THURMAN DJ, IN PRESS J HEAD TRAU; THURMAN DJ, 1995, SM GUIDELINES SURVEI; *US DHHS, 1996, INT CLASS DIS CLIM M; Zafonte RD, 1997, BRAIN INJURY, V11, P403	19	144	147	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2000	14	2					181	186		10.1080/026990500120827			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000007	10695573				2022-02-06	
J	Sander, AM; Fuchs, KL; High, WM; Hall, KM; Kreutzer, JS; Rosenthal, M				Sander, AM; Fuchs, KL; High, WM; Hall, KM; Kreutzer, JS; Rosenthal, M			The community integration questionnaire revisited: An assessment of factor structure and validity	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; DISABILITY RATING-SCALE; FUNCTIONAL INDEPENDENCE MEASURE; HEAD-INJURY; REHABILITATION OUTCOMES; AGREEMENT; RECOVERY	Objective: To investigate the factor structure and concurrent validity of the Community Integration Questionnaire (CIQ), using a large sample of persons with traumatic brain injury (TBI). Design: Principal components analysis with varimax rotation was performed on CIQ items completed through interview with patients at 1 year after injury. Correlational analyses compared CIQ scores to scores on other widely used outcome measures. Setting: Outpatient clinics affiliated with four TBI Model System rehabilitation centers funded by the National Institute on Disability and Rehabilitation Research. Participants: Three hundred twelve patients with medically documented TBI who were enrolled in the TBI Model Systems Project. The majority of patients were Caucasian males with severe TBI. Main Outcome Measures: CIQ; Functional Independence Measure (FIM); Functional Assessment Measure (FAM); Disability Rating Scale (DRS). Results: Three factors emerged: Home Competency, Social Integration, and Productive Activity. The financial management item was moved from Social Integration to Home Competency, and the travel item was moved from Productive Activity to Social Integration. Each CIQ scale score showed significant correlations in the expected direction with the FIM+FAM and DRS items. Conclusions: The results provide further evidence for the validity of the CIQ and improve the scoring system. The factor structure is clinically and theoretically meaningful. The subscale and total scores show significant relationships with other widely used measures of outcome. Future research should focus on increasing the range of questions, accounting for changes from preinjury functioning, and obtaining normative data on the new factors. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Baylor Coll Med, Dept Phys Med & Rehabil, Brain Injury Res Ctr, Houston, TX 77025 USA; Univ Houston, Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX USA; Univ Houston, Dept Psychol, Houston, TX USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Wayne State Univ, Rehabil Inst Michigan, Dept Phys Med & Rehabil, Detroit, MI USA		Sander, AM (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Brain Injury Res Ctr, 4007 Bellaire Blvd,Suite EE, Houston, TX 77025 USA.						CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; *STAT U NEW YORK B, 1996, UN DAT MED REH VERS; Tabachnick B. G., 1989, USING MULTIVARIATE S; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1993, INT CLASS IMP DIS HA	25	144	144	1	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1999	80	10					1303	1308		10.1016/S0003-9993(99)90034-5			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	244AW	WOS:000083030500017	10527092				2022-02-06	
J	Kiening, KL; Hartl, R; Unterberg, AW; Schneider, GH; Bardt, T; Lanksch, WR				Kiening, KL; Hartl, R; Unterberg, AW; Schneider, GH; Bardt, T; Lanksch, WR			Brain tissue pO(2)-monitoring in comatose patients: Implications for therapy	NEUROLOGICAL RESEARCH			English	Article						brain tissue pO(2); intracranial pressure; cerebral perfusion pressure; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; VENOUS OXYGEN-SATURATION; INTRACRANIAL-PRESSURE; MANNITOL; DAMAGE	Monitoring of brain tissue partial pressure of O-2 (ti-pO(2)) is a promising new technique that allows early detection of impending cerebral ischemia in brain-injured patients. The purpose of this study was to investigate the effects of standard therapeutic interventions used in the treatment of intracranial hypertension in comatose patients on cerebral oxygenation. In the neurosurgical intensive care unit ti-pO(2), arterial blood pressure, intracranial pressure (ICP), cerebral perfusion pressure (CPP) and jugular bulb oxygen saturation (SjvO(2)) were prospectively studied (0.1 Hz acquisition ratel in 23 comatose patients (21 with severe traumatic brain injury, 2 with intracerebral hematoma) during various treatment modalities: elevation of CPP with dopamine (n = 35), lowering of the head in = 22), induced arterial hypocapnia (n = 13), mannitol infusion (n = 16), and decompressive craniotomy (n = 1). Ischemic episodes ('IE'= ti-pO(2) < 10 mmHg for > 15 min) within the first week after the insult were always associated with unfavorable neurological outcome. Elevation oi CPP from 32 +/- 2 to 67 +/- 4 mmHg significantly improved ti-pO(2) by 62% (13 +/- 2 to 21 +/- 1 mmHg) and reduced ICP indicating intact cerebral autoregulation. Further raising CPP from 68 +/- 2 to 84 +/- 2 mmHg did not alter ti-pO(2). Mannitol-induced ICP reduction from 23 +/- 7 to 16 +/- 2 mmHg did not affect ti-pO(2), nor did lowering of the head from 30 degrees to 0 degrees. Hyperventilation from an endtidal pCO(2) of 29 +/- 3 to 21 +/- 3 mmHg normalized ICP and CPP, but significantly reduced ti-pO(2) from 31 +/- 2 to 14 +/- 13 mmHg. Decompressive craniotomy in a 15-year old patient with refractory intracranial hypertension instantly restored ti-pO(2). Based on the present data, our understanding of many interventions previously believed to improve brain oxygenation might have to be re-evaluated. A CPP > 60 mmHg emerges as the most important factor determining sufficient brain tissue pO(2). Any intervention used to further elevate CPP does not improve ti-pO(2), to the contrary, hyperventilation even bears the risk of inducing brain ischemia.			Kiening, KL (corresponding author), HUMBOLDT UNIV BERLIN, VIRCHOW KLINIKUM, DEPT NEUROSURG, AUGUSTENBURGER PL 1, D-13353 BERLIN, GERMANY.						BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CLARK LC, 1956, T AM SOC ART INT ORG, V2, P41; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GAAB MR, 1990, ACT NEUR S, V51, P326; GAAB MR, 1990, ACT NEUR S, V51, P320; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MAAS A, 1993, MONITORING CEREBRAL, P50; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SANTBRINK H, 1996, NEUROSURGERY, V38, P21; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHNEIDER GH, 1993, ACTA NEUROCHIR, P107; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TAKAGI H, 1983, INTRACRANIAL PRESSUR, V5, P729; THEODORSSONNORHEIM E, 1987, COMPUT BIOL MED, V17, P85, DOI 10.1016/0010-4825(87)90003-5; Unterberg A. W., 1995, Journal of Neurotrauma, V12, P405	30	144	159	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	1997	19	3					233	240		10.1080/01616412.1997.11740805			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XC468	WOS:A1997XC46800004	9192372				2022-02-06	
J	Clark, RSB; Kochanek, PM; Dixon, CE; Chen, MZ; Marion, DW; Heineman, S; DeKosky, ST; Graham, SH				Clark, RSB; Kochanek, PM; Dixon, CE; Chen, MZ; Marion, DW; Heineman, S; DeKosky, ST; Graham, SH			Early neuropathologic effects of mild or moderate hypoxemia after controlled cortical impact injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; brain injury; controlled cortical impact; hypoxemia; neuronal death; rat	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; HUMAN HEAD-INJURY; FLUID PERCUSSION; CELL-DEATH; HIPPOCAMPAL PATHOLOGY; HYPOXIA; MODEL; VULNERABILITY; MECHANISMS	Hypoxemia has detrimental effects after traumatic brain injury (TBI) in both experimental models and humans. The purpose of this study was to determine the effect of mild or moderate hypoxemia on early histologic and motor functional outcome after controlled cortical impact (CCI) in rats. Anesthetized rats under,vent CCI and were randomized to receive mild (FiO(2) = 13%, n = 6), moderate (FiO(2) = 11%, n = 9), or no (FiO(2) = 33%, n 6) hypoxemia for 30 min after trauma. Sham-operated rats without hypoxemia (n = 7) were used as controls. Motor function (beam balance latency) was assessed on days 0-5. Rats were killed 7 days after injury and their brains removed for assessment of survival of hippocampal neurons and contusion volume. Terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick end labeling (TUNEL) was performed on brain sections from rats killed at 6, 24, and 72 h after CCI and moderate hypoxemia to assess DNA fragmentation irt situ. Mild and moderate hypoxemia augmented motor function deficits after CCI in a dose-dependent manner. Moderate hypoxemia after CCI reduced 7-day survival of CA3 neurons but not CA1 neurons vs. sham (55 [46-86] vs. 99 [95-130], p < 0.05, and 79 [63-86] vs. 101 [81-123], NS, respectively; % uninjured hemisphere, median [range]). The addition of mild or moderate hypoxemia did not increase contusion volume. TUNEL-positive neurons were seen in ipsilateral cortex and dentate gyrus at 6, 24, and 72 h after trauma, and in ipsilateral CA3 hippocampal neurons and thalamus at 24 and 72 h. Moderate hypoxemia augments CA3 neuronal death and early motor functional deficits after CCI. The pattern of DNA fragmentation in selectively vulnerable neurons suggests that apoptosis may play a role in the delayed neuronal death seen after TBI.	UNIV PITTSBURGH, DEPT NEUROL, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL & CRIT CARE MED, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT PEDIAT, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT NEUROL SURG, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT PSYCHIAT, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15261 USA				Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, 2P50 NS 30318-04A1] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1KO8 01946-01] Funding Source: Medline		Amaral David G., 1995, P443; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NELSON LR, 1982, SEMINARS NEUROLOGICA, P117; NIDA TY, 1995, J NEUROTRAUM, V12, P77, DOI 10.1089/neu.1995.12.77; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pearigen P, 1996, BRAIN RES, V725, P184; RINK A, 1995, AM J PATHOL, V147, P1575; Schechter S., 1996, PREPARATION STAINING, P1; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUTTON RL, 1995, CENTRAL NERVOUS SYST, P497; WILBERGER JE, 1993, HEAD INJURY, P27; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	43	144	145	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1997	14	4					179	189		10.1089/neu.1997.14.179			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WY593	WOS:A1997WY59300001	9151767				2022-02-06	
J	JAFFE, KM; POLISSAR, NL; FAY, GC; LIAO, SQ				JAFFE, KM; POLISSAR, NL; FAY, GC; LIAO, SQ			RECOVERY TRENDS OVER 3 YEARS FOLLOWING PEDIATRIC TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURIES; CHILDREN; SEVERITY; SEQUELAE; COHORT	This cohort study investigated the magnitude of neurobehavioral, academic, and ''real world'' deficits over the course of 3 years in children with mild, moderate, and severe traumatic brain injury (TBI), and their individually matched controls. This series of analyses addresses the history of recovery, tracing changes in performance over time. Data on 72 case-control pairs (mild, n = 40; moderate, n = 17; severe, n = 15) were available for three testing times: 3 weeks, 1 year, and 3 years after the resolution of post-traumatic amnesia. The same standardized battery of tests was used at all testing times. The dependent variables in these analyses included individual test results, a variable summarizing results within each of 10 neurobehavioral domains, and an overall score across all domains. Three statistics were calculated for each variable: (1) the ''grand'' mean across the three testing times; (2) the slope (expressing the linear trend in performance); and (3) the change in slope over time (expressing the change in the rate of recovery). Use of the differences between case and control scores controlled for premorbid factors, maturation, and test-retest effects. Results indicate the chronicity of neurobehavioral deficits across all 3 years for moderately and severely injured children. They show a strong improvement rate during the first year, but a negligible rate of change during the following 2 years postinjury in most domains, All three of the time components-grand mean, slope, and change in slope-have significant Spearman correlations with severity ranging up to rho = -.5. Over time, the recovery rate slows down more for those with greater brain injury severity. The greatest slowing of recovery occurs in Performance IQ, adaptive problem solving, memory, and motor skills, as well as on a summary score of overall performance. Given this ''plateauing'' of recovery, achievement of parity with peers by the moderately and severely injured seems unlikely. Mildly injured children, however, exhibit negligible deficits or change in performance over time. (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; STAT & EPIDEMIOL RES CORP,SEATTLE,WA; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA		JAFFE, KM (corresponding author), UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,POB 5371,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Bruininks R. H., 1984, SCALES INDEPENDENT 4; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P69; Conover W.J., 1998, PRACTICAL NONPARAMET; DRAPER NR, 1981, APPLIED REGRESSION A; Edelbrock C., 1986, MANUAL TEACHERS REPO; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FRIDLUND AJ, 1987, CALIFORNIA VERBAL LE; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1979, ADV NEUROL, V22; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1974, WECHSLER ADULT INTEL; Wilkinson, 1984, WIDE RANGE ACHIEVEME	18	144	147	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1995	76	1					17	26		10.1016/S0003-9993(95)80037-9			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	QB197	WOS:A1995QB19700003	7811169				2022-02-06	
J	GODFREY, HPD; PARTRIDGE, FM; KNIGHT, RG; BISHARA, S				GODFREY, HPD; PARTRIDGE, FM; KNIGHT, RG; BISHARA, S			COURSE OF INSIGHT DISORDER AND EMOTIONAL DYSFUNCTION FOLLOWING CLOSED-HEAD INJURY - A CONTROLLED CROSS-SECTIONAL FOLLOW-UP-STUDY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article								Closed-head injury (CHI) patients at either 6 months (n = 24), 1 year (n = 19), or 2 to 3 years (n = 23) postinjury, were compared with a group of orthopedic control (OC) patients (n = 27). CHI patients assessed at 6 months postinjury experienced a Post-Traumatic Insight Disorder, in which they underreported the severity of their behavioural impairments. CHI patients in the 1 year and 2 to 3 year follow-up groups evidenced both greater insight about their level of behavioural impairment, and higher levels of emotional dysfunction. These findings suggested that the return of insight is associated with increased risk for emotional dysfunction. Implications of these findings for assessment and treatment of closed-head injury patients are discussed.	UNIV OTAGO,DEPT SURG,DUNEDIN,NEW ZEALAND		GODFREY, HPD (corresponding author), UNIV OTAGO,DEPT PSYCHOL,CTR COMMUNITY COUNSELLING,POB 56,DUNEDIN,NEW ZEALAND.						BOND M, 1984, CLOSED HEAD INJURY P; BROOKS N, 1984, CLOSED HEAD INJURY P; ELLEY WB, 1985, NEW ZEAL J EDUC STUD, V20, P115; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GODFREY HPD, 1992, UNPUB MANUAL HED INJ; Grove W. M., 1982, J NERV MENT DIS, V170, P2; HOLM S, 1979, SCAND J STAT, V6, P65; Jennett B, 1981, MANAGEMENT HEAD INJU; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LWEIN M, 1979, UNDERSTANDING PSYCHO; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Nelson H. E, 1982, NATIONAL ADULT READI; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; Nisbett R., 1980, HUMAN INFERENCE STRA; ODONNELL WE, 1984, J CLIN PSYCHOL, V40, P554; PLATT S, 1980, SOC PSYCHIATR, V15, P43, DOI 10.1007/BF00577960; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Rosenberg M., 1965, SOC ADOLESCENT SELF; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; [No title captured]	25	144	145	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	1993	15	4					503	515		10.1080/01688639308402574			13	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	LJ168	WOS:A1993LJ16800005	8354704				2022-02-06	
J	Broglio, SP; McCrea, M; McAllister, T; Harezlak, J; Katz, B; Hack, D; Hainline, B				Broglio, Steven P.; McCrea, Michael; McAllister, Thomas; Harezlak, Jaroslaw; Katz, Barry; Hack, Dallas; Hainline, Brian		CARE Consortium Investigators	A National Study on the Effects of Concussion in Collegiate Athletes and US Military Service Academy Members: The NCAA-DoD Concussion Assessment, Research and Education (CARE) Consortium Structure and Methods	SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; HEAD IMPACT EXPOSURES; RECURRENT CONCUSSION; HIGH-SCHOOL; POSTURAL STABILITY; RECOVERY; ENCEPHALOPATHY; RISK	Background The natural history of mild traumatic brain injury (TBI) or concussion remains poorly defined and no objective biomarker of physiological recovery exists for clinical use. The National Collegiate Athletic Association (NCAA) and the US Department of Defense (DoD) established the Concussion Assessment, Research and Education (CARE) Consortium to study the natural history of clinical and neurobiological recovery after concussion in the service of improved injury prevention, safety and medical care for student-athletes and military personnel. Objectives The objectives of this paper were to (i) describe the background and driving rationale for the CARE Consortium; (ii) outline the infrastructure of the Consortium policies, procedures, and governance; (iii) describe the longitudinal 6-month clinical and neurobiological study methodology; and (iv) characterize special considerations in the design and implementation of a multicenter trial. Methods Beginning Fall 2014, CARE Consortium institutions have recruited and enrolled 23,533 student-athletes and military service academy students (approximately 90% of eligible student-athletes and cadets; 64.6% male, 35.4% female). A total of 1174 concussions have been diagnosed in participating subjects, with both concussion and baseline cases deposited in the Federal Interagency Traumatic Brain Injury Research (FITBIR) database. Conclusions Challenges have included coordinating regulatory issues across civilian and military institutions, operationalizing study procedures, neuroimaging protocol harmonization across sites and platforms, construction and maintenance of a relational database, and data quality and integrity monitoring. The NCAA-DoD CARE Consortium represents a comprehensive investigation of concussion in student-athletes and military service academy students. The richly characterized study sample and multidimensional approach provide an opportunity to advance the field of concussion science, not only among student athletes but in all populations at risk for mild TBI.	[Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Injury Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Harezlak, Jaroslaw] Indiana Univ, Dept Epidemiol & Biostat, Bloomington, IN USA; [Katz, Barry] Indiana Univ, Dept Biostat, Indianapolis, IN 46204 USA; [Hack, Dallas; Hainline, Brian] Natl Collegiate Athlet Assoc, Indianapolis, IN USA		Broglio, SP (corresponding author), Univ Michigan, NeuroTrauma Res Lab, Injury Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	; Harezlak, Jaroslaw/P-8557-2014	Kontos, Anthony/0000-0002-3749-4310; Chrisman, Sara/0000-0001-5373-7223; Master, Christina/0000-0002-6717-4270; Harezlak, Jaroslaw/0000-0002-3070-7686; Ortega, Justus/0000-0002-9931-5605; Clugston, James/0000-0002-2103-1039	Grand Alliance CARE Consortium - NCAA; DoDUnited States Department of Defense; USAMRAA, Ford Detrick, MD, USA; Office of the Assistant Secretary of Defense for Health Affairs through Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; DoD (DHP funds)	Contributing investigators include Scott Anderson, ATC (University of Oklahoma); Allison Brooks, MD, MPH (University of Wisconsin); Stefan Duma, PhD (Virginia Tech); Christopher Giza, MD (University of California-Los Angeles); Steven J. Svoboda, MD (United States Military Academy); and Scott Pyne, MD (United States Naval Academy). The authors would also like to thank Jody Harland, Janetta Matesan, Larry Riggen (Indiana University); Ashley Rettmann (University of Michigan); Melissa Koschnitzke (Medical College of Wisconsin); Michael Jarrett, Vibeke Brinck and Bianca Byrne (Quesgen); Thomas Dompier, Melisssa Niceley Baker, and Sara Dalton (Datalys Center for Sports Injury Research and Prevention); and the research and medical staff at each of the participating sites. This publication was made possible, in part, with support from the Grand Alliance CARE Consortium, funded by the NCAA and the DoD. The USAMRAA, Ford Detrick, MD, USA, is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No. W81XWH-14-2-0151. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the DoD (DHP funds).	Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Association National Collegiate Athletic, 2007, J ATHL TRAINING, V42, P165; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cameron KL, 2012, J NEUROTRAUM, V29, P1313, DOI 10.1089/neu.2011.2168; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Matheson GO, 2011, CLIN J SPORT MED, V21, P25, DOI 10.1097/JSM.0b013e3182095f92; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2010, PM&R, V2, pS241, DOI 10.1016/j.pmrj.2010.10.005; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M., 1997, STANDARDIZED ASSESSM; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; National Collegiate Athletic Association, 2014, NCAA DOD LAUNCH MIND; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Ruppert D., 2003, SEMIPARAMETRIC REGRE; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weaver SM, 2014, BRAIN IMAGING BEHAV, V8, P420, DOI 10.1007/s11682-012-9197-9; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004	61	143	143	4	26	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	JUL	2017	47	7					1437	1451		10.1007/s40279-017-0707-1			15	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	EX2LU	WOS:000403058600014	28281095	hybrid, Green Published	Y	N	2022-02-06	
J	Fenn, AM; Gensel, JC; Huang, Y; Popovich, PG; Lifshitz, J; Godbout, JP				Fenn, Ashley M.; Gensel, John C.; Huang, Yan; Popovich, Phillip G.; Lifshitz, Jonathan; Godbout, Jonathan P.			Immune Activation Promotes Depression 1 Month After Diffuse Brain Injury: A Role for Primed Microglia	BIOLOGICAL PSYCHIATRY			English	Article						Cytokines; depression; fluid percussion injury; lipopolysaccharide; major histocompatibility complex II; microglia	INTRACEREBRAL INFLAMMATORY RESPONSE; CENTRAL-NERVOUS-SYSTEM; AGED MICE; EXPERIMENTAL-MODELS; SICKNESS BEHAVIOR; MESSENGER-RNA; MEMORY; NEUROINFLAMMATION; HIPPOCAMPUS; EXPRESSION	Background: Traumatic brain injury (TBI) is associated with a higher incidence of depression. The majority of individuals who suffer a TBI are juveniles and young adults, and thus, the risk of a lifetime of depressive complications is a significant concern. The etiology of increased TBI-associated depression is unclear but may be inflammatory-related with increased brain sensitivity to secondary inflammatory challenges (e.g., stressors, infection, and injury). Methods: Adult male BALB/c mice received a sham (n = 52) or midline fluid percussion injury (TBI; n = 57). Neuroinflammation, motor coordination (rotarod), and depressive behaviors (social withdrawal, immobility in the tail suspension test, and anhedonia) were assessed 4 hours, 24 hours, 72 hours, 7 days, or 30 days later. Moreover, 30 days after surgery, sham and TBI mice received a peripheral injection of saline or lipopolysaccharide (LPS) and microglia activation and behavior were determined. Results: Diffuse TBI caused inflammation, peripheral cell recruitment, and microglia activation immediately after injury coinciding with motor coordination deficits. These transient events resolved within 7 days. Nonetheless, 30 days post-TBI a population of deramified and major histocompatibility complex II+ (primed) microglia were detected. After a peripheral LPS challenge, the inflammatory cytokine response in primed microglia of TBI mice was exaggerated compared with microglia of controls. Furthermore, this LPS-induced microglia reactivity 30 days after TBI was associated with the onset of depressive-like behavior. Conclusions: These results implicate a primed and immune-reactive microglial population as a possible triggering mechanism for the development of depressive complications after TBI.	[Fenn, Ashley M.; Huang, Yan; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Gensel, John C.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, Columbus, OH 43210 USA; [Lifshitz, Jonathan] Univ Arizona, Phoenix Childrens Hosp, Coll Med, Dept Child Hlth,Barrow Neurol Inst, Phoenix, AZ USA		Godbout, JP (corresponding author), Ohio State Univ, 259 IBMR Bldg,460 Med Ctr Dr, Columbus, OH 43210 USA.	jonathan.godbout@osumc.edu		, John/0000-0001-8980-108X	National Institute on Aging GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG-033028]; Howard Hughes Medical InstituteHoward Hughes Medical Institute; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033028] Funding Source: NIH RePORTER	This research was supported by National Institute on Aging Grant No. R01-AG-033028 to JPG. AMF was supported by a Med to Grad scholarship from the Howard Hughes Medical Institute.	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; Barrientos RM, 2010, AGING DIS, V1, P212; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P46, DOI 10.1016/j.bbi.2008.07.002; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bilbo SD, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.014.2009; Bland ST, 2010, BRAIN BEHAV IMMUN, V24, P329, DOI 10.1016/j.bbi.2009.09.012; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Corona AW, 2013, BRAIN BEHAV IMMUN, V31, P134, DOI 10.1016/j.bbi.2012.08.008; Corona AW, 2012, J NEUROIMMUNE PHARM, V7, P7, DOI 10.1007/s11481-011-9313-4; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; Cunningham C, 2009, BIOL PSYCHIAT, V65, P304, DOI 10.1016/j.biopsych.2008.07.024; CUNNINGHAM ET, 1992, J NEUROSCI, V12, P1101; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dantzer R, 2011, PSYCHONEUROENDOCRINO, V36, P426, DOI 10.1016/j.psyneuen.2010.09.012; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; El Yacoubi M, 2003, P NATL ACAD SCI USA, V100, P6227, DOI 10.1073/pnas.1034823100; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Frenois F, 2007, PSYCHONEUROENDOCRINO, V32, P516, DOI 10.1016/j.psyneuen.2007.03.005; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Godbout JP, 2008, NEUROPSYCHOPHARMACOL, V33, P2341, DOI 10.1038/sj.npp.1301649; Godbout JP, 2009, IMMUNOL ALLERGY CLIN, V29, P321, DOI 10.1016/j.iac.2009.02.007; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; GUALTIERI T, 1991, Brain Injury, V5, P219, DOI 10.3109/02699059109008093; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Huang Y, 2008, NEUROBIOL AGING, V29, P1744, DOI 10.1016/j.neurobiolaging.2007.04.012; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Jurgens HA, 2012, EXP NEUROL, V233, P40, DOI 10.1016/j.expneurol.2010.11.014; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lanquillon S, 2000, NEUROPSYCHOPHARMACOL, V22, P370, DOI 10.1016/S0893-133X(99)00134-7; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Maher FO, 2005, NEUROBIOL AGING, V26, P717, DOI 10.1016/j.neurobiolaging.2004.07.002; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Miller AH., 2008, FOCUS, V6, P36; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Murray C, 2012, NEUROBIOL AGING, V33, P603, DOI 10.1016/j.neurobiolaging.2010.04.002; Palin K, 2008, NEUROBIOL DIS, V30, P19, DOI 10.1016/j.nbd.2007.11.012; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Steiner J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-94; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Williamson LL, 2013, BRAIN BEHAV IMMUN, V30, P186, DOI 10.1016/j.bbi.2013.01.077; Williamson LL, 2011, J NEUROSCI, V31, P15511, DOI 10.1523/JNEUROSCI.3688-11.2011; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Wohleb ES, 2011, J NEUROSCI, V31, P6277, DOI 10.1523/JNEUROSCI.0450-11.2011; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	75	143	152	2	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	OCT 1	2014	76	7					575	584		10.1016/j.biopsych.2013.10.014			10	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	AQ8QJ	WOS:000343094000012	24289885	Green Accepted			2022-02-06	
J	Papa, L; Lewis, LM; Silvestri, S; Falk, JL; Giordano, P; Brophy, GM; Demery, JA; Liu, MC; Mo, JX; Akinyi, L; Mondello, S; Schmid, K; Robertson, CS; Tortella, FC; Hayes, RL; Wang, KKW				Papa, Linda; Lewis, Lawrence M.; Silvestri, Salvatore; Falk, Jay L.; Giordano, Philip; Brophy, Gretchen M.; Demery, Jason A.; Liu, Ming Cheng; Mo, Jixiang; Akinyi, Linnet; Mondello, Stefania; Schmid, Kara; Robertson, Claudia S.; Tortella, Frank C.; Hayes, Ronald L.; Wang, Kevin K. W.			Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; biomarkers; serum; intracranial lesions; neurosurgical intervention	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; BIOMARKER; PROTEIN; S100B; RULE; RATS; COMA; US	BACKGROUND: This study compared early serum levels of ubiquitin C-terminal hydrolase (UCH-L1) from patients with mild and moderate traumatic brain injury (TBI) with uninjured and injured controls and examined their association with traumatic intracranial lesions on computed tomography (CT) scan (CT positive) and the need for neurosurgical intervention (NSI). METHODS: This prospective cohort study enrolled adult patients presenting to three tertiary care Level I trauma centers after blunt head trauma with loss of consciousness, amnesia, or disorientation and a Glasgow Coma Scale (GCS) score 9 to 15. Control groups included normal uninjured controls and nonhead injured trauma controls presenting to the emergency department with orthopedic injuries or motor vehicle crash without TBI. Blood samples were obtained in all trauma patients within 4 hours of injury and measured by enzyme-linked immunosorbent assay for UCH-L1 (ng/mL +/- standard error of the mean). RESULTS: There were 295 patients enrolled, 96 TBI patients (86 with GCS score 13-15 and 10 with GCS score 9-12), and 199 controls (176 uninjured, 16 motor vehicle crash controls, and 7 orthopedic controls). The AUC for distinguishing TBI from uninjured controls was 0.87 (95% confidence interval [CI], 0.82-0.92) and for distinguishing those TBIs with GCS score 15 from controls was AUC 0.87 (95% CI, 0.81-0.93). Mean UCH-L1 levels in patients with CT negative versus CT positive were 0.620 (+/- 0.254) and 1.618 (+/- 0.474), respectively (p < 0.001), and the AUC was 0.73 (95% CI, 0.62-0.84). For patients without and with NSI, levels were 0.627 (0.218) versus 2.568 (0.854; p < 0.001), and the AUC was 0.85 (95% CI, 0.76-0.94). CONCLUSION: UCH-L1 is detectable in serum within an hour of injury and is associated with measures of injury severity including the GCS score, CT lesions, and NSI. Further study is required to validate these findings before clinical application. (J Trauma. 2012;72: 1335-1344. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Papa, Linda; Silvestri, Salvatore; Falk, Jay L.; Giordano, Philip] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA; [Lewis, Lawrence M.] Washington Univ, Sch Med, Div Emergency Med, St Louis, MO USA; [Liu, Ming Cheng; Mo, Jixiang; Akinyi, Linnet; Mondello, Stefania; Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Richmond, VA USA; [Demery, Jason A.] Univ Florida, Forens Inst, UF Springhill Hlth Ctr, Gainesville, FL USA; [Schmid, Kara; Tortella, Frank C.] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, Silver Spring, MD USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Crit Care & Neurosurg, Houston, TX 77030 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA		Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood,S-200, Orlando, FL 32806 USA.	lpstat@aol.com	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473; Brophy, Gretchen/0000-0002-4749-2693	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS057676, R01NS057676] Funding Source: Medline		[Anonymous], 1999, JAMA, V282, P974; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Faul M, 2010, TRAUMATIC BRAIN INJU; Fayngersh V, 2009, LUNG, V187, P143, DOI 10.1007/s00408-009-9143-9; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; Heilbrun Marta E, 2005, J Am Coll Radiol, V2, P889, DOI 10.1016/j.jacr.2005.06.013; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Long A E, 1985, Emerg Med Clin North Am, V3, P437; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Mettler FA, 2008, HEALTH PHYS, V95, P502, DOI 10.1097/01.HP.0000326333.42287.a2; Mirvis S E, 1994, J Intensive Care Med, V9, P305; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Papa L, 2009, ACAD EMERG MED S1, V16, pS235; Papa L, 2011, ANN EMERG MED   1107; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P42, DOI 10.1017/S0317167100006296; Sapsford W, 2003, J R Army Med Corps, V149, P5; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; YEALY D M, 1991, Emergency Medicine Clinics of North America, V9, P707	41	143	147	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2012	72	5					1335	1344		10.1097/TA.0b013e3182491e3d			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	944JD	WOS:000304195100042	22673263	Green Accepted			2022-02-06	
J	McAllister, TW; Ford, JC; Ji, SB; Beckwith, JG; Flashman, LA; Paulsen, K; Greenwald, RM				McAllister, Thomas W.; Ford, James C.; Ji, Songbai; Beckwith, Jonathan G.; Flashman, Laura A.; Paulsen, Keith; Greenwald, Richard M.			Maximum Principal Strain and Strain Rate Associated with Concussion Diagnosis Correlates with Changes in Corpus Callosum White Matter Indices	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Mild traumatic brain injury; Strain; FEM brain model; Diffusion tensor imaging	TRAUMATIC BRAIN-INJURY; DESCRIPTIVE EPIDEMIOLOGY; SURVEILLANCE SYSTEM; HEAD ACCELERATION; FOOTBALL; MILD; SEGMENTATION; ENCEPHALOPATHY; DEFORMATION; GENERATION	On-field monitoring of head impacts, combined with finite element (FE) biomechanical simulation, allow for predictions of regional strain associated with a diagnosed concussion. However, attempts to correlate these predictions with in vivo measures of brain injury have not been published. This article reports an approach to and preliminary results from the correlation of subject-specific FE model-predicted regions of high strain associated with diagnosed concussion and diffusion tensor imaging to assess changes in white matter integrity in the corpus callosum (CC). Ten football and ice hockey players who wore instrumented helmets to record head impacts sustained during play completed high field magnetic resonance imaging preseason and within 10 days of a diagnosed concussion. The Dartmouth Subject-Specific FE Head model was used to generate regional predictions of strain and strain rate following each impact associated with concussion. Maps of change in fractional anisotropy (FA) and median diffusivity (MD) were generated for the CC of each athlete to correlate strain with change in FA and MD. Mean and maximum strain rate correlated with change in FA (Spearman rho = 0.77, p = 0.01; 0.70, p = 0.031), and there was a similar trend for mean and maximum strain (0.56, p = 0.10; 0.6, p = 0.07), as well as for maximum strain with change in MD (-0.63, p = 0.07). Change in MD correlated with injury-to-imaging interval (rho = -0.80, p = 0.006) but change in FA did not (rho = 0.18, p = 0.62). These results provide preliminary confirmation that model-predicted strain and strain rate in the CC correlate with changes in indices of white matter integrity.	[McAllister, Thomas W.; Ford, James C.; Flashman, Laura A.] Dartmouth Hitchcock Med Ctr, Dept Psychiat, Sect Neuropsychiat, Dartmouth Med Sch, Lebanon, NH 03756 USA; [Ji, Songbai; Paulsen, Keith; Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Beckwith, Jonathan G.; Greenwald, Richard M.] Simbex, Lebanon, NH USA		McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Psychiat, Sect Neuropsychiat, Dartmouth Med Sch, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	Ford, James/AAF-7039-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NS055020, R01HD048638]; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01/CE001254]; National Operating Committee on Standards for Athletic Equipment (NOCSAE) [04-07, SAC-1]; William H. Neukom Institute for Computational Science at Dartmouth College; HIT System, Sideline Response System (Riddell, Inc); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This study was supported through NIH RO1NS055020, R01HD048638, CDC R01/CE001254, the National Operating Committee on Standards for Athletic Equipment (NOCSAE 04-07 & SAC-1), and the William H. Neukom 1964 Institute for Computational Science at Dartmouth College.; Richard M. Greenwald, and Simbex have a financial interest in the instruments (HIT System, Sideline Response System (Riddell, Inc)) that were used to collect the biomechanical data reported in this study.	Agel J, 2007, J ATHL TRAINING, V42, P249; Alexander DC, 2002, MAGN RESON MED, V48, P331, DOI 10.1002/mrm.10209; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bonett DG, 2000, PSYCHOMETRIKA, V65, P23, DOI 10.1007/BF02294183; Chu, 2006, J BIOMECH, V39, DOI https://doi.org/10.1016/s0021-9290(06)83518-9; CHU JJ, 2006, 5 WORLD C BIOM MUN G; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dick R, 2007, J ATHL TRAINING, V42, P221; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Franceschini G, 2006, THESIS U TRENTO; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gwin J. T., 2009, J ASTM INT, V6, P1; Han X, 2007, IEEE T MED IMAGING, V26, P479, DOI 10.1109/TMI.2007.893282; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ji S., 2004, STAPP CAR CRASH J, V48, P527; Ji SB, 2007, J BIOMECH, V40, P92, DOI 10.1016/j.jbiomech.2005.11.009; Ji SB, 2011, FINITE ELEM ANAL DES, V47, P1178, DOI 10.1016/j.finel.2011.05.007; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Miller R.T., 1998, STAPP CAR CRASH J, P155; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Nahum AM, 1977, P 21 STAPP CAR CRASH, P337; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Penumetcha N, 2011, J NEUROIMAGING, V21, pe148, DOI 10.1111/j.1552-6569.2009.00405.x; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Schwarz A, 2010, NY TIMES; Smith C, 2011, TXB TRAUMATIC BRAIN; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thibault L., 1990, IRCOBI C BRON LYON F; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Trosseille X., 1992, P 36 STAPP CAR CRASH; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wiegell MR, 2000, RADIOLOGY, V217, P897, DOI 10.1148/radiology.217.3.r00nv43897; Wu ZH, 2005, NAT MED, V11, P959, DOI 10.1038/nm1287; Yang King H, 2006, Stapp Car Crash J, V50, P429; Zhang H., 2009, 17 SCI M EXH INT SOC; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	67	143	143	0	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		127	140		10.1007/s10439-011-0402-6			14	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700012	21994062	Green Accepted			2022-02-06	
J	Bragge, P; Clavisi, O; Turner, T; Tavender, E; Collie, A; Gruen, RL				Bragge, Peter; Clavisi, Ornella; Turner, Tari; Tavender, Emma; Collie, Alex; Gruen, Russell L.			The Global Evidence Mapping Initiative: Scoping research in broad topic areas	BMC MEDICAL RESEARCH METHODOLOGY			English	Article							SPINAL-CORD-INJURY; SYSTEMATIC REVIEWS; BRAIN-INJURY; PROGRAM; BOWEL	Background: Evidence mapping describes the quantity, design and characteristics of research in broad topic areas, in contrast to systematic reviews, which usually address narrowly-focused research questions. The breadth of evidence mapping helps to identify evidence gaps, and may guide future research efforts. The Global Evidence Mapping (GEM) Initiative was established in 2007 to create evidence maps providing an overview of existing research in Traumatic Brain Injury (TBI) and Spinal Cord Injury (SCI). Methods: The GEM evidence mapping method involved three core tasks: 1. Setting the boundaries and context of the map: Definitions for the fields of TBI and SCI were clarified, the prehospital, acute inhospital and rehabilitation phases of care were delineated and relevant stakeholders (patients, carers, clinicians, researchers and policymakers) who could contribute to the mapping were identified. Researchable clinical questions were developed through consultation with key stakeholders and a broad literature search. 2. Searching for and selection of relevant studies: Evidence search and selection involved development of specific search strategies, development of inclusion and exclusion criteria, searching of relevant databases and independent screening and selection by two researchers. 3. Reporting on yield and study characteristics: Data extraction was performed at two levels - 'interventions and study design' and 'detailed study characteristics'. The evidence map and commentary reflected the depth of data extraction. Results: One hundred and twenty-nine researchable clinical questions in TBI and SCI were identified. These questions were then prioritised into high (n = 60) and low (n = 69) importance by the stakeholders involved in question development. Since 2007, 58 263 abstracts have been screened, 3 731 full text articles have been reviewed and 1 644 relevant neurotrauma publications have been mapped, covering fifty-three high priority questions. Conclusions: GEM Initiative evidence maps have a broad range of potential end-users including funding agencies, researchers and clinicians. Evidence mapping is at least as resource-intensive as systematic reviewing. The GEM Initiative has made advancements in evidence mapping, most notably in the area of question development and prioritisation. Evidence mapping complements other review methods for describing existing research, informing future research efforts, and addressing evidence gaps.	[Bragge, Peter; Clavisi, Ornella; Tavender, Emma; Gruen, Russell L.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Bragge, Peter; Clavisi, Ornella; Tavender, Emma; Gruen, Russell L.] Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Turner, Tari] Monash Univ, Australasian Cochrane Ctr, Melbourne, Vic 3004, Australia; [Collie, Alex] Monash Univ, Inst Safety Compensat & Recovery Res, Melbourne, Vic 3004, Australia		Bragge, P (corresponding author), Monash Univ, Dept Surg, Level 6,99 Commercial Rd, Melbourne, Vic 3004, Australia.	peter.bragge@monash.edu		Tavender, Emma/0000-0002-7230-712X; Collie, Alex/0000-0003-2617-9339; Bragge, Peter/0000-0003-0745-5131; Turner, Tari/0000-0002-7990-1623	Victorian Neurotrauma Initiative	The GEM Initiative has been supported through a Targeted Grant from the Victorian Neurotrauma Initiative. For enabling the GEM Initiative to succeed we thank Anne Parkhill, Jason Wasiak, Loyal Pattuwage, Marisa Chau, Marion Cincotta, Haifa Sekkouah, and are grateful for the institutional support of the National Trauma Research Institute, Alfred Health, Monash University, the Australasian Cochrane Centre, the Cochrane Effective Practice & Organisation of Care (EPOC) Group, the Centre for Clinical Effectiveness, Melbourne Health, the National Health and Medical Research Council, National Information & Communication Technology Australia (NICTA), the National Institute of Clinical Studies, Southern Health and The University of Melbourne.	[Anonymous], ICF BROWSER; Arksey H, 2003, HEALTH SOC CARE COMM, V11, P335, DOI 10.1046/j.1365-2524.2003.00433.x; Arksey H., 2005, INT J SOC RES METHOD, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Ayas S, 2006, AM J PHYS MED REHAB, V85, P951, DOI 10.1097/01.phm.0000247649.00219.cO; Bates S., 2007, EVID POL J RES DEBAT, V3, P539, DOI [DOI 10.1332/174426407782516484, 10.1332/174426407782516484]; Bourke Dowling S., 1999, SCOPING REV LIT HLTH; Coleman K, 2008, NHMRC ADDITIONAL LEV; Collie A, 2010, MED J AUSTRALIA, V192, P712, DOI 10.5694/j.1326-5377.2010.tb03709.x; Flemming K., 1998, EVID BASED NURS, V1, P36; Furusawa K, 2007, ACTA MED OKAYAMA, V61, P221; Greenhalgh T, 1997, BRIT MED J, V315, P672, DOI 10.1136/bmj.315.7109.672; Jones T, 2000, Aust Crit Care, V13, P66, DOI 10.1016/S1036-7314(00)70624-2; Kastner M, 2009, J CLIN EPIDEMIOL, V62, P149, DOI 10.1016/j.jclinepi.2008.06.001; Katz DL, 2003, ALTERN THER HEALTH M, V9, P22; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Luther SL, 2005, J SPINAL CORD MED, V28, P387, DOI 10.1080/10790268.2005.11753838; Mortenson PA, 2003, PHYS THER, V83, P648, DOI 10.1093/ptj/83.7.648; PARKHILL A, 2009, 17 COCHR C 11 14 OCT; PARKHILL A, 2008, HLTH INFORM LIB J, V26, P47; Peersman G, 1996, DESCRIPTIVE MAPPING; PHILLIPS K, 2011, COCHRANE DATABASE SY, V1; Straus SE., 2005, EVIDENCE BASED MED P, V3rd; VANDEVEN A, 1971, ACAD MANAGE J, V14, P203, DOI 10.2307/255307; World Health Organization, 2002, COMM LANG FUNCT DIS; NHMRC VNI FELLOWSHIP; [No title captured]	26	143	146	0	15	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2288			BMC MED RES METHODOL	BMC Med. Res. Methodol.	JUN 17	2011	11								92	10.1186/1471-2288-11-92			12	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services	795WX	WOS:000293010300001	21682870	Green Published, gold			2022-02-06	
J	Mondello, S; Papa, L; Buki, A; Bullock, MR; Czeiter, E; Tortella, FC; Wang, KK; Hayes, RL				Mondello, Stefania; Papa, Linda; Buki, Andras; Bullock, M. Ross; Czeiter, Endre; Tortella, Frank C.; Wang, Kevin K.; Hayes, Ronald L.			Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study	CRITICAL CARE			English	Article						Traumatic Brain Injury; Biomarkers; Diagnostic; Outcome; Computed tomography	HEAD-INJURY; SERUM; PROTEIN; PREDICTION; MODERATE; DAMAGE	Introduction: Authors of several studies have studied biomarkers and computed tomography (CT) findings in the acute phase after severe traumatic brain injury (TBI). However, the correlation between structural damage as assessed by neuroimaging and biomarkers has not been elucidated. The aim of this study was to investigate the relationships among neuronal (Ubiquitin carboxy-terminal hydrolase L1 [UCH-L1]) and glial (glial fibrillary acidic protein [GFAP]) biomarker levels in serum, neuroradiological findings and outcomes after severe TBI. Methods: The study recruited patients from four neurotrauma centers. Serum samples for UCH-L1 and GFAP were obtained at the time of hospital admission and every 6 hours thereafter. CT scans of the brain were obtained within 24hrs of injury. Outcome was assessed by Glasgow Outcome Scale (GOS) at discharge and at 6 months. Results: 81 severe TBI patients and 167 controls were enrolled. The mean serum levels of UCH-L1 and GFAP were higher (p < 0.001) in TBI patients compared to controls. UCH-L1 and GFAP serum levels correlated significantly with Glasgow Coma Scale (GCS) and CT findings. GFAP levels were higher in patients with mass lesions than in those with diffuse injury (2.95 +/- 0.48 ng/ml versus 0.74 +/- 0.11 ng/ml) while UCH-L1 levels were higher in patients with diffuse injury (1.55 +/- 0.18 ng/ml versus 1.21 +/- 0.15 ng/ml, p = 0.0031 and 0.0103, respectively). A multivariate logistic regression showed that UCH-L1 was the only independent predictor of death at discharge [adjusted odds ratios 2.95; 95% confidence interval, 1.46-5.97], but both UCH-L1 and GFAP levels strongly predicted death 6 months post-injury. Conclusions: Relationships between structural changes detected by neuroimaging and biomarkers indicate each biomarker may reflect a different injury pathway. These results suggest that protein biomarkers could provide better characterization of subjects at risk for specific types of cellular damage than that obtained with neuroimaging alone, as well as provide valuable information about injury severity and outcome after severe TBI.	[Mondello, Stefania; Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL 32610 USA; [Mondello, Stefania] Banyan Biomarkers Inc, Ctr Innovat Res, Clin Dept, Alachua, FL 32615 USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA; [Buki, Andras; Czeiter, Endre] Univ Pecs, Dept Neurosurg, H-7624 Pecs, Hungary; [Bullock, M. Ross] Univ Miami, Dept Neurosurg, Miami, FL 33136 USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, Silver Spring, MD 20910 USA; [Wang, Kevin K.] Banyan Biomarkers Inc, Ctr Innovat Res, Diagnost Res & Dev Dept, Alachua, FL 32615 USA; [Wang, Kevin K.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Dept Clin Programs, Alachua, FL 32615 USA		Mondello, S (corresponding author), Univ Florida, Dept Anesthesiol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	stm_mondello@hotmail.com	Czeiter, Endre/B-1404-2009; Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473	Department of Defence [DAMD17-03-1-0772, DAMD17-03-1-0066]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01]; University of FloridaUniversity of Florida [N00014-06-1-1029]; Banyan Biomarkers, Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831, R01NS051431, R01NS049175] Funding Source: NIH RePORTER	We want to thank Professor Barzo, PI in Szeged, Dr. Paul Muizelaar, PI in UC Davis, and Dr. Richard Dutton, PI in Maryland Shock Trauma Center, for referring patients and for help collecting samples; We also acknowledge Dr. Komaromy as an independent CT reviewer; We are very grateful to medical and nursing staff of the neurointensive care unit for their valuable cooperation. This study was primarily sponsored by Department of Defence Award numbers DAMD17-03-1-0772 and DAMD17-03-1-0066; but we also acknowledge additional fund support from NIH (R01 NS049175-01, R01-NS052831-01, and R01 NS051431-01) and Navy grant number N00014-06-1-1029 (University of Florida).; Drs. Mondello, Papa, Buki, Bullock and Czeiter are consultants of and received consulting fees from Banyan Biomarkers, Inc.; Drs. Wang and Hayes own stock, receive royalties and salaries from, and are officers of Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication. Banyan Biomarkers, Inc. filled patent applications based upon the disclosure of this publication. Dr. Tortella reports no disclosures.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; [Anonymous], 2007, J NEUROTRAUMA S1, V24; BAKAY RAE, 1986, NEUROSURGERY, V18, P376, DOI 10.1227/00006123-198603000-00026; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Graham D.I., 1996, NEUROTRAUMA, P43; HEISS WD, 1983, ANN NEUROL, V14, P294, DOI 10.1002/ana.410140307; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Manolio T, 2003, NEW ENGL J MED, V349, P1587, DOI 10.1056/NEJMp038136; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McKeating EG, 1998, ACT NEUR S, V71, P117; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Vos PE, 2002, SHOCK, V18, P481, DOI 10.1097/00024382-200211000-00017; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x	32	143	146	1	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	3							R156	10.1186/cc10286			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832JB	WOS:000295799700038	21702960	gold, Green Published			2022-02-06	
J	Komogortsev, OV; Gobert, DV; Jayarathna, S; Koh, DH; Gowda, SM				Komogortsev, Oleg V.; Gobert, Denise V.; Jayarathna, Sampath; Koh, Do Hyong; Gowda, Sandeep M.			Standardization of Automated Analyses of Oculomotor Fixation and Saccadic Behaviors	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						Analysis; baseline; eye-movement classification; oculomotor behavior	TRAUMATIC BRAIN-INJURY; EYE-MOVEMENTS; NYSTAGMUS	In an effort toward standardization, this paper evaluates the performance of five eye-movement classification algorithms in terms of their assessment of oculomotor fixation and saccadic behavior. The results indicate that performance of these five commonly used algorithms vary dramatically, even in the case of a simple stimulus-evoked task using a single, common threshold value. The important contributions of this paper are: evaluation and comparison of performance of five algorithms to classify specific oculomotor behavior; introduction and comparison of new standardized scores to provide more reliable classification performance; logic for a reasonable threshold-value selection for any eye-movement classification algorithm based on the standardized scores; and logic for establishing a criterion-based baseline for performance comparison between any eye-movement classification algorithms. Proposed techniques enable efficient and objective clinical applications providing means to assure meaningful automated eye-movement classification.	[Komogortsev, Oleg V.; Jayarathna, Sampath; Koh, Do Hyong; Gowda, Sandeep M.] SW Texas State Univ, Dept Comp Sci, San Marcos, TX 78666 USA; [Gobert, Denise V.] SW Texas State Univ, Dept Phys Therapy, San Marcos, TX 78666 USA		Komogortsev, OV (corresponding author), SW Texas State Univ, Dept Comp Sci, San Marcos, TX 78666 USA.	ok11@txstate.edu; dg46@txstate.edu; sampath@txstate.edu; dk1132@txstate.edu; sm1499@txstate.edu	Jayarathna, Sampath/AAM-6816-2021		Texas State University-San Marcos [G200810150639]	Manuscript received January 12, 2010; revised May 8, 2010; accepted June 16, 2010. Date of publication July 26, 2010; date of current version October 15, 2010. This work was supported in part by grants from Texas State University-San Marcos and in part by the Sigma Xi Grant-in-Aid of Research Program under Grant G200810150639. Asterisk indicates corresponding author.	BAUM LE, 1970, ANN MATH STAT, V41, P164, DOI 10.1214/aoms/1177697196; Carpenter R. H. S, 1977, MOVEMENTS EYES; CEBALLOS N, 2009, J STUD ALCOHOL D SEP, P1; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; Duchowski A., 2007, EYE TRACKING METHODO; Duchowski AT, 2007, ACM T MULTIM COMPUT, V3, DOI 10.1145/1314303.1314309; Ehmke C., 2007, P 21 BR CHI GROUP AN, V1; Elina I, 2009, AURIS NASUS LARYNX, V36, P36, DOI 10.1016/j.anl.2008.03.010; EVINGER C, 1991, INVEST OPHTH VIS SCI, V32, P387; Field M, 2004, PSYCHOPHARMACOLOGY, V173, P116, DOI 10.1007/s00213-003-1689-2; FORNEY GD, 1973, P IEEE, V61, P268, DOI 10.1109/PROC.1973.9030; Garbutt S, 2003, INVEST OPHTH VIS SCI, V44, P3833, DOI 10.1167/iovs.03-0066; GRINDINGER T, 2006, COMPUTER SCI; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; JACOB RJK, 1990, SIGCHI C HUM FACT CO; Kollensperger M, 2008, MOVEMENT DISORD, V23, P1093, DOI 10.1002/mds.21992; KOH DH, 2001, P 1 ACM SIGCHI S ENG, P197; KOMOGORTSEV O, 2009, P INT C SOFTW ENG TH, P1; Komogortsev O. V., 2010, CLASSIFICATION ALGOR; Komogortsev O. V., 2009, QUALITATIVE QUANTITA; Komogortsev O.V, 2010, P 2010 S EYE TRACK R, P65, DOI [10.1145/1743666.1743682, DOI 10.1145/1743666.1743682]; Komogortsev O.V., 2007, P 12 INT C HUM COMP, P1; Leigh RJ, 2006, NEUROLOGY EYE MOVEME; Mosimann UP, 2005, BRAIN, V128, P1267, DOI 10.1093/brain/awh484; Munoz DP, 2003, J NEUROPHYSIOL, V90, P503, DOI 10.1152/jn.00192.2003; Newman-Toker DE, 2009, J NEUROL NEUROSUR PS, V80, P900, DOI 10.1136/jnnp.2009.174128; Parkhurst DJ, 2002, HUM FACTORS, V44, P611, DOI 10.1518/0018720024497015; Poole A, 2004, ENCY HUMAN COMPUTER; Radvay X, 2007, J VESTIBUL RES-EQUIL, V17, P183; Ramey NA, 2008, J AAPOS, V12, P498, DOI 10.1016/j.jaapos.2008.01.019; Rayner K, 1998, PSYCHOL BULL, V124, P372, DOI 10.1037/0033-2909.124.3.372; SALVUCCI DD, P 2000 S EYE TRACK R, P71; SAUTER D, 1991, MED BIOL ENG COMPUT, V29, P63, DOI 10.1007/BF02446297; SIBERT LE, 2000, SIGCHI C HUM FACT CO; Smyrnis N, 2008, BRAIN COGNITION, V68, P341, DOI 10.1016/j.bandc.2008.08.022; Zhai S., 1999, SIGCHI C HUM FACT CO; [No title captured]; [No title captured]	39	143	145	2	17	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	NOV	2010	57	11					2635	2645		10.1109/TBME.2010.2057429			11	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	670PN	WOS:000283439900001	20667803				2022-02-06	
J	McCrea, M; Guskiewicz, K; Randolph, C; Barr, WB; Hammeke, TA; Marshall, SW; Kelly, JP				McCrea, Michael; Guskiewicz, Kevin; Randolph, Christopher; Barr, William B.; Hammeke, Thomas A.; Marshall, Stephen W.; Kelly, James P.			EFFECTS OF A SYMPTOM-FREE WAITING PERIOD ON CLINICAL OUTCOME AND RISK OF REINJURY AFTER SPORT-RELATED CONCUSSION	NEUROSURGERY			English	Article						Brain injury; Concussion; Neuropsychological tests; Sports injuries	COLLEGIATE FOOTBALL PLAYERS; 2ND IMPACT; PROFESSIONAL FOOTBALL; RECOVERY; PERFORMANCE; MANAGEMENT	OBJECTIVE: This study is the first to investigate the influence of a symptom-free waiting period (SFWP) on clinical outcome and risk of repeat injury after sport-related concussion. METHODS: This was a prospective, nonrandomized study of 16 624 player seasons from 1999 to 2004, including a cohort. of 635 concussed high school and college athletes grouped on the basis of an SFWP or no SFWP observed after their concussion. Clinical outcome in symptoms, cognitive functioning, and postural stability 45 and 90 days postinjury was compared with preinjury baseline. Data on SFWP and same-season repeat concussion were recorded. RESULTS: An SFWP was observed in 60.3% of cases. There were no significant differences between the SFWP and no SFWP groups in acute injury characteristics or clinical outcome with respect to symptom recovery or postinjury performance on formal neuropsychological and balance testing. Most repeat concussions (79.2%) occurred within 10 days of the initial injury. The rate of repeat concussion was actually higher in the SFWP group (6.49%) than the no SFWP group (0.90%) (P < 0.005), but the repeat concussion subgroup's SFWP was 2.82 days shorter (95% confidence interval, 0.61-5.03; P < 0.01) and these athletes resumed participation 3.55 days sooner (95% confidence interval, 0.06-7.04; P < 0.05) than those in the SFWP group in which there was no repeat concussion. CONCLUSION: Our findings suggest that an SFWP did not intrinsically influence clinical recovery or reduce risk of a repeat concussion. The overall risk of same-season repeat concussion seems to be relatively low, but there may be a period of vulnerability that increases risk of repeat concussion during the first 7 to 10 days postinjury. Further study is required to investigate this preliminary finding and help determine whether this risk can be reduced further with specific injury-management strategies.	[McCrea, Michael] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI 53188 USA; [McCrea, Michael; Hammeke, Thomas A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin; Marshall, Stephen W.] Univ N Carolina, Dept Orthoped, Chapel Hill, NC USA; [Guskiewicz, Kevin; Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Randolph, Christopher] Loyola Univ, Sch Med, Dept Neurol, Maywood, IL 60153 USA; [Barr, William B.] NYU, Sch Med, Dept Neurol, New York, NY USA; [Barr, William B.] NYU, Sch Med, Dept Psychiat, New York, NY USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Rehabil Med, Denver, CO USA		McCrea, M (corresponding author), Waukesha Mem Hosp, Ctr Neurosci, 721 Amer Ave,Suite 406, Waukesha, WI 53188 USA.	michael.mccrea@phci.org		Barr, William/0000-0001-7711-7758; Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000058] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00058] Funding Source: Medline		Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ferrara Michael S., 2001, J Athl Train, V36, P145; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Randolph C., 1998, REPEATABLE BATTERY A; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	31	143	143	0	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2009	65	5					876	882		10.1227/01.NEU.0000350155.89800.00			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	507SX	WOS:000270876100007	19834399				2022-02-06	
J	Dischinger, PC; Ryb, GE; Kufera, JA; Auman, KM				Dischinger, Patricia C.; Ryb, Gabriel E.; Kufera, Joseph A.; Auman, Kimberly M.			Early Predictors of Postconcussive Syndrome in a Population of Trauma Patients With Mild Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Mild traumatic brain injury; Postconcussive syndrome; Noise sensitivity; Symptoms	POSTTRAUMATIC-STRESS-DISORDER; MOTOR-VEHICLE ACCIDENTS; MINOR HEAD-INJURY; ACOUSTIC HYPERESTHESIA; SYMPTOMS; CONCUSSION; MODERATE; DYSFUNCTION; ISSUES; LIGHT	Purpose: The purpose of this analysis was to determine which of the initial symptoms after mild traumatic brain injury (MTBI) can best predict the development of persistent postconcussive syndrome (PCS). Methods: One hundred eighty MTBI patients admitted to a level I trauma center were enrolled in a prospective study and 110 followed for 3 months. MTBI was defined as a Glasgow Coma Score of 13 to 15 with a transient loss of consciousness or report of being dazed or confused. PCs was defined as the persistence of four or more symptoms long term. Patients were screened at admission and at 3 days to 10 days and 3 months. Symptom checklists were administered to ascertain the presence of symptoms (cognitive, emotional, and physical) after concussion. For a subset of patients that were physically able, balance tests were also conducted. Step-wise logistic regression was used to identify which symptoms best predicted PCS. Results: The mean age of the subjects was 35 years, and 65% were men. Physical symptoms were the most prevalent in the 3 days to 10 days postinjury with most declining thereafter to baseline levels. Emotional and cognitive symptoms were less prevalent but more likely to remain elevated at 3 months; 41.8% of subjects reported PCS at 3 months. The strongest individual symptoms that predicted long-term PCS included anxiety, noise sensitivity (NS), and trouble thinking; reported by 49%, 27%, and 31% of the subjects at 3 days to 10 days, respectively. In multivariate regressions including age, gender, and early symptoms, only anxiety, NS and gender remained significant in the prediction of PCS. Interactions revealed that the effect of anxiety was seen primarily among women. NS had an odds ratio of 3.1 for PCS at 3 months. Conclusion: After MTBI, anxiety among women and NS are important predictors of PCS. Other physical symptoms, while more prevalent are poor predictors of PCS.	[Dischinger, Patricia C.; Ryb, Gabriel E.; Kufera, Joseph A.; Auman, Kimberly M.] Univ Maryland, Sch Med, Natl Study Ctr Trauma & EMS, Organized Res Ctr Trauma & Anesthesiol, Baltimore, MD 21201 USA; [Ryb, Gabriel E.] Univ Maryland, Program Trauma, Baltimore, MD 21201 USA; Prince Georges Hosp, Cheverly, MD USA		Dischinger, PC (corresponding author), 701 W Pratt St, Baltimore, MD 21201 USA.	pdischin@som.umaryland.edu					Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALEXANDER MP, 1982, TRAUMATIC BRAIN INJU, V2, P219; Attias J., 2005, Journal of Basic and Clinical Physiology and Pharmacology, V16, P117; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; BOHNEN N, 1991, BRIT J PSYCHIAT, V159, P860, DOI 10.1192/bjp.159.6.860; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; JONSSON CO, 1967, ACTA NEUROL SCAND, V43, P158, DOI 10.1111/j.1600-0404.1967.tb05725.x; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; Lidvall H., 1974, ACTA NEUROL SCAND, V50, P3; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; MULLIN J, 2002, PREMIER OUTLOOK, V3, P30; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruff RM, 1999, BRAIN INJURY, V13, P943; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Walsh K., 1987, NEUROPSYCHOLOGY CLIN	40	143	145	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2009	66	2					289	297		10.1097/TA.0b013e3181961da2			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	408NX	WOS:000263442800001	19204499				2022-02-06	
J	Wang, HC; Lynch, JR; Song, PP; Yang, HJ; Yales, RB; Mace, B; Warner, DS; Guyton, JR; Laskowitz, DT				Wang, Haichen; Lynch, John R.; Song, Pingping; Yang, Hyuk-Jun; Yales, Robert B.; Mace, Brian; Warner, David S.; Guyton, John R.; Laskowitz, Daniel T.			Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; atorvastatin; simvastatin; nitric oxide interleukin 6; TNF alpha; cerebral blood flow	NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; HYPERCHOLESTEROLEMIC PATIENTS; SUBARACHNOID HEMORRHAGE; CIRCULATING MONOCYTES; OPTICAL FRACTIONATOR; NEURONAL SURVIVAL; HEAD-INJURY; RATS; STATINS	The treatment of traumatic brain injury (TBI) remains limited, and aside from surgical hematoma evacuation, clinical management is largely Supportive and directed toward management of cerebral edema and intracranial hypertension. Secondary neuronal injury caused by ischemia and the development of cerebral edema may occur in the subacute phase, with intracranial pressures often peaking in the first several days following injury. Because inflammation contributes significantly to the pathophysiology of cerebral ischemia and endothelial dysfunction underlies the development of cerebral edema, therapeutic strategies that target the post-traumatic inflammatory cascade and reduce endothelial dysfunction hold enormous potential to improve clinical outcomes after TBI. Statins inhibit inflammation by suppressing inflammatory cytokine release, and by interfering with multiple steps of leukocyte recruitment and migration into the CNS. In this study, we demonstrate that treatment with atorvastatin and simvastatin markedly reduced functional neurological deficits after traumatic brain injury in mice. These effects were accompanied by histological reduction in degenerating hippocampal neurons and suppression of inflammatory cytokine mRNA expression in brain parenchyma. Furthermore, statin treatment improved cerebral hemodynamics following head injury. Thus, the administration of statins may represent a viable therapeutic strategy in the acute treatment of closed head injury. (C) 2007 Elsevier Inc. All rights reserved.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27710 USA; Gachon Med Sch, Gil Med Ctr, Dept Emergency Med, Inchon, South Korea		Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Mace, Brian/0000-0002-5478-6227; Guyton, John/0000-0003-0224-7923			Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; BOTTI RE, 1991, CLIN NEUROPHARMACOL, V14, P256, DOI 10.1097/00002826-199106000-00010; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Finkelstein E., 2006, INCIDENCE EC BURDEN; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lefer AM, 2001, CARDIOVASC RES, V49, P281, DOI 10.1016/S0008-6363(00)00247-9; Lennernas H, 2003, CLIN PHARMACOKINET, V42, P1141, DOI 10.2165/00003088-200342130-00005; Lennernas H, 1997, CLIN PHARMACOKINET, V32, P403, DOI 10.2165/00003088-199732050-00005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu DY, 2004, J NEUROSURG, V101, P822, DOI 10.3171/jns.2004.101.5.0822; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Rezaie-Majd A, 2003, ARTERIOSCL THROM VAS, V23, P397, DOI 10.1161/01.ATV.0000059384.34874.F0; Rezaie-Majd A, 2002, ARTERIOSCL THROM VAS, V22, P1194, DOI 10.1161/01.ATV.0000022694.16328.CC; Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Tsuchiya D, 2003, BRAIN RES, V970, P131, DOI 10.1016/S0006-8993(03)02300-X; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021	41	143	149	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2007	206	1					59	69		10.1016/j.expneurol.2007.03.031			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	187CN	WOS:000247825000009	17521631				2022-02-06	
J	Agel, J; Olson, DE; Dick, R; Arendt, EA; Marshall, SW; Sikka, RS				Agel, Julie; Olson, David E.; Dick, Randall; Arendt, Elizabeth A.; Marshall, Stephen W.; Sikka, Robby S.			Descriptive epidemiology of collegiate women's basketball injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; ankle sprains; knee injuries; anterior cruciate ligament injuries; stress fractures; concussions	CRUCIATE LIGAMENT INJURY; FEMALE RECRUITS; STRESS-FRACTURE; ANKLE INJURIES; RISK-FACTORS; KNEE INJURY; PREVENTION; SOCCER; PLAYERS; CONCUSSIONS	Objective: To review 16 years of National Collegiate Athletic Association (NCAA) injury surveillance data for women's basketball and to identify potential areas for injury prevention initiatives. Background: The number of colleges participating in women's college basketball has grown over the past 25 years. The Injury Surveillance System (ISS) has enabled the NCAA to collect and report injury trends over an extended period of time. This has allowed certified athletic trainers and coaches to be more informed regarding injuries and to adjust training regimens to reduce the risk of injury. It also has encouraged administrators to make rule changes that attempt to reduce the risk of injury. Main Results: From 1988-1989 through 2003-2004, 12.4% of schools across Divisions I, II, and III that sponsor varsity women's basketball programs participated in annual ISS data collection. Game and practice injury rates exhibited significant decreases over the study period. The rate of injury in a game situation was almost 2 times higher than in a practice (7.68 versus 3.99 injuries per 1000 athlete-exposures, rate ratio = 1.9, 95% confidence interval = 1.9, 2.0). Preseason-practice injury rates were more than twice as high as regular-season practice injury rates (6.75 versus 2.84 injuries per 1000 athlete-exposures, rate ratio = 2.4, 95% confidence interval = 2.2, 2.4). More than 60% of all game and practice injuries were to the lower extremity, with the most common game injuries being ankle ligament sprains, knee injuries (internal derangements and patellar conditions), and concussions. In practices, ankle ligament sprains, knee injuries (internal derangements and patellar conditions), upper leg muscle-tendon strains, and concussions were the most common injuries. Recommendations: Appropriate preseason conditioning and an emphasis on proper training may reduce the risk of injury and can optimize performance. As both player size and the speed of the women's game continue to increase, basketball's evolution from a finesse sport to a high-risk contact sport also will continue. The rates of concussions and other high-energy trauma injuries likely will increase. The NCAA ISS is an excellent tool for identifying new risk factors that may affect injury rates and for developing consistent injury definitions in order to improve the research and provide a source of clinically relevant data.	Univ Minnesota, CAQ Primary Care Sports Med, Minneapolis, MN 55417 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Univ So Calif, Sch Med, Los Angeles, CA 90089 USA		Olson, DE (corresponding author), Univ Minnesota, CAQ Primary Care Sports Med, 1020 W Broadway Ave, Minneapolis, MN 55417 USA.	minnesotadaveo@yahoo.com		Marshall, Stephen/0000-0002-2664-9233			Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; Anderson SJ, 2000, PEDIATRICS, V106, P154, DOI 10.1542/peds.106.1.154; Arendt E, 2003, AM J SPORT MED, V31, P959, DOI 10.1177/03635465030310063601; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden B P, 2000, J Am Acad Orthop Surg, V8, P344; Braam LAJLM, 2003, AM J SPORT MED, V31, P889, DOI 10.1177/03635465030310062601; Covassin T, 2003, J ATHL TRAINING, V38, P238; Deitch JR, 2006, AM J SPORT MED, V34, P1077, DOI 10.1177/0363546505285383; Devan MR, 2004, J ATHL TRAINING, V39, P263; Dick R, 2007, J ATHL TRAINING, V42, P194; Dick R, 2007, J ATHL TRAINING, V42, P173; GARRICK JG, 1973, MED SCI SPORT EXER, V5, P200; Hame SL, 2004, AM J SPORT MED, V32, P446, DOI 10.1177/0363546503261708; Hertel J, 2002, J ATHL TRAINING, V37, P364; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; Hewett TE, 2006, AM J SPORT MED, V34, P490, DOI 10.1177/0363546505282619; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Hosea TM, 2000, CLIN ORTHOP RELAT R, P45; Jones BH, 1999, SPORTS MED, V27, P111, DOI 10.2165/00007256-199927020-00004; Joy Elizabeth A, 2005, Curr Sports Med Rep, V4, P323; Koester MC, 2006, CLIN SPORT MED, V25, P63, DOI 10.1016/j.csm.2005.08.004; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; McKay GD, 2001, BRIT J SPORT MED, V35, P103, DOI 10.1136/bjsm.35.2.103; Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901; Mihata LCS, 2006, AM J SPORT MED, V34, P899, DOI 10.1177/0363546505285582; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA; Pfeiffer RP, 2006, J BONE JOINT SURG AM, V88A, P1769, DOI 10.2106/JBJS.E.00616; Rauh MJ, 2006, MED SCI SPORT EXER, V38, P1571, DOI 10.1249/01.mss.0000227543.51293.9d; ROME K, 2005, COCHRANE DB SYST REV, V18; Sanderlin BW, 2003, AM FAM PHYSICIAN, V68, P1527; Shaffer RA, 2006, AM J SPORT MED, V34, P108, DOI 10.1177/0363546505278703; Starkey C, 2000, J ATHL TRAINING, V35, P161; Thacker SB, 1999, AM J SPORT MED, V27, P753, DOI 10.1177/03635465990270061201	35	143	144	0	23	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					202	210					9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	180RC	WOS:000247382300006	17710168				2022-02-06	
J	Slomine, BS; McCarthy, ML; Ding, R; MacKenzie, EJ; Jaffe, KM; Aitken, ME; Durbin, DR; Christensen, JR; Dorsch, AM; Paidas, CN				Slomine, BS; McCarthy, ML; Ding, R; MacKenzie, EJ; Jaffe, KM; Aitken, ME; Durbin, DR; Christensen, JR; Dorsch, AM; Paidas, CN		CHAT Study Grp	Health care utilization and needs after pediatric traumatic brain injury	PEDIATRICS			English	Article						health service utilization; traumatic brain injury	QUALITY-OF-LIFE; GENERIC CORE SCALES; CLOSED-HEAD INJURY; SHORT-TERM; CHILDREN; SERVICES; RELIABILITY; VALIDITY; BEHAVIOR; PREDICTORS	OBJECTIVE. Children with moderate to severe traumatic brain injury (TBI) show early neurobehavioral deficits that can persist several years after injury. Despite the negative impact that TBI can have on a child's physical, cognitive, and psychosocial well-being, only 1 study to date has documented the receipt of health care services after acute care and the needs of children after TBI. The purpose of this study was to document the health care use and needs of children after a TBI and to identify factors that are associated with unmet or unrecognized health care needs during the first year after injury. METHODS. The health care use and needs of children who sustained a TBI were obtained via telephone interview with a primary caregiver at 2 and 12 months after injury. Of the 330 who enrolled in the study, 302 (92%) completed the 3-month and 288 (87%) completed the 12-month follow-up interviews. The health care needs of each child were categorized as no need, met need, unmet need, or unrecognized need on the basis of the child's use of post-acute services, the caregiver's report of unmet need, and the caregiver's report of the child's functioning as measured by the Pediatric Quality of Life Inventory (PedsQL). Regardless of the use of services or level of function, children of caregivers who reported an unmet need for a health care service were defined as having unmet need. Children who were categorized as having no needs were defined as those who did not receive services; whose caregiver did not report unmet need for a service; and the whose physical, socioemotional, and cognitive functioning was reported to be normal by the caregiver. Children with met needs were those who used services in a particular domain and whose caregivers did not report need for additional services. Finally, children with unrecognized needs were those whose caregiver reported cognitive, physical, or socioemotional dysfunction; who were not receiving services to address the dysfunction; and whose caregiver did not report unmet need for services. Polytomous logistic regression was used to model unmet and unrecognized need at 3 and 12 months after injury as a function of child, family, and injury characteristics. RESULTS. At 3 months after injury, 62% of the study sample reported receiving at least 1 outpatient health care service. Most frequently, children visited a doctor (56%) or a physical therapist (27%); however, 37% of caregivers reported that their child did not see a physician at all during the first year after injury. At 3 and 12 months after injury, 26% and 31% of children, respectively, had unmet/unrecognized health care needs. The most frequent type of unmet or unrecognized need was for cognitive services. The top 3 reasons for unmet need at 3 and 12 months were (1) not recommended by doctor (34% and 31%); (2) not recommended/provided by school (16% and 17%); and (3) cost too much (16% and 16%). Factors that were associated with unmet or unrecognized need changed over time. At 3 months after injury, the caregivers of children with a preexisting psychosocial condition were 3 times more likely to report unmet need compared with children who did not have one. Also, female caregivers were significantly more likely to report unmet need compared with male caregivers. Finally, the caregivers of children with Medicaid were almost 2 times more likely to report unmet need compared with children who were covered by commercial insurance. The only factor that was associated with unrecognized need at 3 months after injury was abnormal family functioning. At 12 months after injury, although TBI severity was not significant, children who sustained a major associated injury were 2 times more likely to report unmet need compared with children who did not. Consistent with the 3-month results, the caregivers of children with Medicaid were significantly more likely to report unmet needs at 1 year after injury. In addition to poor family functioning's being associated with unrecognized need, nonwhite children were significantly more likely to have unrecognized needs at 1 year compared with white children. CONCLUSIONS. A substantial proportion of children with TBI had unmet or unrecognized health care needs during the first year after injury. It is recommended that pediatricians be involved in the post-acute care follow-up of children with TBI to ensure that the injured child's needs are being addressed in a timely and appropriate manner. One of the recommendations that trauma center providers should make on hospital discharge is that the parent/primary caregiver schedule a visit with the child's pediatrician regardless of the post-acute services that the child may be receiving. Because unmet and unrecognized need was highest for cognitive services, it is important to screen for cognitive dysfunction in the primary care setting. Finally, because the health care needs of children with TBI change over time, it is important for pediatricians to monitor their recovery to ensure that children with TBI receive the services that they need to restore their health after injury.	Johns Hopkins Univ, Kennedy Keieger Inst, Dept Neuropsychol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA; Univ Washington, Sch Med, Dept Rehabil Med, Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA; Univ Arkansas Med Sci, Dept Pediat, Coll Med, Little Rock, AR 72205 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Kennedy Krieger Inst, Baltimore, MD USA; Univ Washington, Sch Med, Div Rehabil Psychol, Childrens Hosp & Reg Med Ctr, Seattle, WA USA; Univ S Florida, Coll Med, Dept Surg, Tampa, FL 33612 USA		Slomine, BS (corresponding author), Johns Hopkins Univ, Kennedy Keieger Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21205 USA.	slomine@kennedykrieger.org	Durbin, Dennis/AAD-7829-2022; ding, ru/B-1615-2009; Aitken, Mary/ABG-6119-2021	Aitken, Mary/0000-0002-8318-9755	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR319701] Funding Source: Medline		ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; Dusing SC, 2004, AMBUL PEDIATR, V4, P448, DOI 10.1367/A03-202R1.1; Fairbrother G, 2005, MED CARE RES REV, V62, P205, DOI 10.1177/1077558704273805; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FUNK P, 1996, PHYS DISABILITIES ED, V15, P49; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Glang A, 2004, NEUROREHABILITATION, V19, P219; GLANG A, 1996, CHILDREN ACQUIRED BR, P149; Greenspan AI, 2000, BRAIN INJURY, V14, P417; HIBBARD JH, 1986, WOMEN HEALTH, V11, P21, DOI 10.1300/J013v11n02_03; Hosmer D, 1989, APPL LOGISTIC REGRES; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Janicke DM, 2001, MED CARE, V39, P990, DOI 10.1097/00005650-200109000-00009; KINSELLA G, 2005, J PEDIATR PSYCHOL, V20, P753; KRAUS JF, 1995, TRAUMATIC HEAD INJUR; KUHLTHAU K, 2004, PEDIATRICS, V113; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P270; Mayer ML, 2004, PEDIATRICS, V114; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MCCARTHY ML, 2005, IN PRESS ARCH PEDIAT; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Newacheck PW, 2000, PEDIATRICS, V105, P989; RILEY AW, 1993, MED CARE, V31, P767, DOI 10.1097/00005650-199309000-00002; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; Silver EJ, 2001, AMBUL PEDIATR, V1, P314, DOI 10.1367/1539-4409(2001)001<0314:ATCUHN>2.0.CO;2; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Weller WE, 2003, PEDIATRICS, V112, P593, DOI 10.1542/peds.112.3.593; Witt WP, 2003, HEALTH SERV RES, V38, P1441, DOI 10.1111/j.1475-6773.2003.00187.x; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P159	41	143	145	0	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2006	117	4					E663	E674		10.1542/peds.2005-1892			12	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	029EA	WOS:000236540500008	16533894				2022-02-06	
J	Brown, AW; Malec, JF; McClelland, RL; Diehl, NN; Englander, J; Cifu, DX				Brown, AW; Malec, JF; McClelland, RL; Diehl, NN; Englander, J; Cifu, DX			Clinical elements that predict outcome after traumatic brain injury: A prospective multicenter recursive partitioning (decision-tree) analysis	JOURNAL OF NEUROTRAUMA			English	Article						amnesia; closed head injury; functional outcome; impairment; physical examination; rehabilitation	SEVERE HEAD-INJURY; FUNCTIONAL INDEPENDENCE MEASURE; DISABILITY RATING-SCALE; REHABILITATION; PROGNOSIS; RECOVERY; BALANCE; PERFORMANCE; VALIDATION; MANAGEMENT	Traumatic brain injury (TBI) often presents clinicians with a complex combination of clinical elements that can confound treatment and make outcome prediction challenging. Predictive models have commonly used acute physiological variables and gross clinical measures to predict mortality and basic outcome endpoints. The primary goal of this study was to consider all clinical elements available concerning a survivor of TBI admitted for inpatient rehabilitation, and identify those factors that predict disability, need for supervision, and productive activity one year after injury. The Traumatic Brain Injury Model Systems (TBIMS) database was used for decision tree analysis using recursive partitioning (n = 3463). Outcome measures included the Functional Independence Measure(TM), the Disability Rating Scale, the Supervision Rating Scale, and a measure of productive activity. Predictor variables included all physical examination elements, measures of injury severity (initial Glasgow Coma Scale score, duration of post-traumatic amnesia [PTA], length of coma, CT scan pathology), gender, age, and years of education. The duration of PTA, age, and most elements of the physical examination were predictive of early disability. The duration of PTA alone was selected to predict late disability and independent living. The duration of PTA, age, sitting balance, and limb strength were selected to predict productive activity at 1 year. The duration of PTA was the best predictor of outcome selected in this model for all endpoints and elements of the physical examination provided additional predictive value. Valid and reliable measures of PTA and physical impairment after TBI are important for accurate outcome prediction.	Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Coll Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Coll Med, Rochester, MN 55905 USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Dept Funct Restorat, San Jose, CA USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Brown, AW (corresponding author), Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Coll Med, 200 1st SW, Rochester, MN 55905 USA.	brown.allen@mayo.edu		Brown, Allen W./0000-0001-7228-3351; Cifu, David/0000-0003-1600-9387			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OVERGAARD J, 1973, LANCET, V2, P631; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; *TBIMS, 2002, TRAUM BRAIN INJ MOD; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P161; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362	38	143	144	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1040	1051		10.1089/neu.2005.22.1040			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600002	16238482				2022-02-06	
J	Yeates, KO; Taylor, HG; Wade, SL; Drotar, D; Stancin, T; Minich, N				Yeates, KO; Taylor, HG; Wade, SL; Drotar, D; Stancin, T; Minich, N			A prospective study of short- and long-term neuropsychological outcomes after traumatic brain injury in children	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; RECOVERY; FAMILY; SEVERITY; BEHAVIOR; CT; PREVALENCE; PREDICTORS; CHILDHOOD; ATTENTION	Longitudinal neuropsychological outcomes of traumatic brain injury (TBI) were investigated in 53 children with severe TBI, 56 children with moderate TBI, and 80 children with orthopedic injuries only. Neuropsychological functioning was assessed at baseline, at 6- and 12-month follow-ups, and at an extended follow-up (a mean of 4 years postinjury). Mixed model analyses revealed persistent neuropsychological sequelae of TBI that generally did not vary as a function of time postinjury. Some recovery occurred during the first year postinjury, but recovery reached a plateau after that time, and deficits were still apparent at the extended follow-up. Further recovery was uncommon after the first year postinjury. Family factors did not moderate neuropsychological outcomes, despite their demonstrated influence on behavior and academic achievement after childhood TBI.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; Metrohlth Med Ctr, Dept Pediat, Cleveland, OH 44109 USA		Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeates.1@osu.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Anderson PJ., 2000, CLIN NEUROPSYCHOL AS, V1, P247; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BURCHINAL MR, 1994, J EARLY INTERVENTION, V18, P403, DOI 10.1177/105381519401800409; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; Cohen J., 2013, STAT POWER ANAL BEHA; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MCDERMOTT PA, 1995, J SCHOOL PSYCHOL, V33, P75, DOI 10.1016/0022-4405(94)00025-4; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moos RH, 1994, LIFE STRESSORS SOCIA; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; *SAS I, 1990, STAT AN SYST VERS 6; SEMEL E, 1987, CELF R CLIN EV LANG; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O, 1991, COMPENDIUM NEUROPSYC; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Wechsler D., 1991, WISC 3 WECHSLER INTE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215; [No title captured]; [No title captured]; [No title captured]	56	143	145	0	25	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2002	16	4					514	523		10.1037//0894-4105.16.4.514			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	601HR	WOS:000178440800007	12382990				2022-02-06	
J	Mittenberg, W; Canyock, EM; Condit, D; Patton, C				Mittenberg, W; Canyock, EM; Condit, D; Patton, C			Treatment of post-concussion syndrome following mild head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							POSTCONCUSSION SYMPTOMS; EXPECTATION; DEPRESSION; MODERATE; TRIAL	Approximately 38% of patients who sustain head trauma characterized by a brief disturbance of consciousness and clinically unremarkable neuroradiologic findings meet International Classification of Diseases 10th edition (ICD-10) diagnostic criteria for postconcussion syndrome (PCS). Physicians treat a majority of cases with nonsteroidal analgesics or antidepressants, and refer about 40% for psychological consultation. Psychological treatment typically involves education, reassurance, and reattribution of symptoms to benign causes. A review of controlled treatment outcome studies conducted over the past 2 decades in Scandinavia, Great Britain, Canada, and the United States suggests that early single session treatment can prevent the syndrome as effectively as traditional outpatient therapy. Several standardized, empirically supported treatment manuals are available.	Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA		Mittenberg, W (corresponding author), Nova SE Univ, Ctr Psychol Studies, 3301 Coll Ave, Ft Lauderdale, FL 33314 USA.	wiley@nova.edu					Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BECK AT, 1985, ANXIETY DISORDER PHO; Beck AT., 1979, COGNITIVE THERAPY DE; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CYTOWIC RE, 1987, NEUROPSYCHOLOGICAL S, P226; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Ferguson R. J., 1995, SOURCEBOOK PSYCHOL T SOURCEBOOK PSYCHOL T, P615; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Gaultieri CT, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P411; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KAY T, 1986, UNSEEN INJURY MINOR; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; World Health Organization, 1992, ICD 10 CLASSIFICATIO	39	143	145	0	24	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					829	836		10.1076/jcen.23.6.829.1022			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200010	11910547				2022-02-06	
J	Fann, JR; Uomoto, JM; Katon, WJ				Fann, JR; Uomoto, JM; Katon, WJ			Sertraline in the treatment of major depression following mild traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	152nd Annual Meeting of the American-Psychiatric-Association	MAY 15-20, 1999	WASHINGTON, D.C.	Amer Psychiat Assoc			SICKNESS IMPACT PROFILE; HEALTH-STATUS MEASURE; HEAD-INJURY; MEDICAL OUTCOMES; NORTRIPTYLINE; DISABILITY; SYMPTOMS; DISORDER; DISEASE	An 8-week, nonrandomized, single-blind, placebo run-in trial Of sertraline was conducted on 15 patients diagnosed with major depression between 3 and 24 months after a mild traumatic brain injury. On the Hamilton Rating Scale for Depression, 13 (87%) han a decrease in score of greater than or equal to 50% ("response"), and 10 (67%) achieved ct score of less than or equal to 7 ("remission") by week 8 of sertraline. There was statistically significant improvement in psychological distress, anger and aggression, functioning, ann postconcussive symptoms with treatment.	Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Seattle Pacific Univ, Dept Grad Psychol, Seattle, WA 98119 USA		Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.		Uomoto, Jay/AAF-4809-2019				BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BORSON S, 1992, PSYCHOSOMATICS, V33, P190, DOI 10.1016/S0033-3182(92)71995-1; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Chen CPLH, 1996, J NEUROCHEM, V66, P1592, DOI 10.1046/j.1471-4159.1996.66041592.x; DEROGATIS LR, 1974, PSYCHOL MEASUREMENTS; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; GUY W, 1976, ADM76338 ECDEU DHEW; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hellings JA, 1996, J CLIN PSYCHIAT, V57, P333; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Knutson B, 1998, AM J PSYCHIAT, V155, P373, DOI 10.1176/ajp.155.3.373; MACKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; MAYEUX R, 1988, MOVEMENT DISORD, V3, P237, DOI 10.1002/mds.870030308; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MOBAYED M, 1990, J AFFECT DISORDERS, V19, P237, DOI 10.1016/0165-0327(90)90100-M; Ranen NG, 1996, J NEUROPSYCH CLIN N, V8, P338; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SHEAR MK, 1989, MEASURING MENTAL ILL; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; SULLIVAN M, 1993, ARCH INTERN MED, V153, P2251, DOI 10.1001/archinte.153.19.2251; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; TEASDALE G, 1974, LANCET, V2, P81; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; [No title captured], DOI DOI 10.1177/088626087002002003	36	143	144	0	4	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2000	12	2					226	232		10.1176/appi.neuropsych.12.2.226			7	Clinical Neurology; Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	314UH	WOS:000087075600007	11001601				2022-02-06	
J	HOLMIN, S; MATHIESEN, T; SHETYE, J; BIBERFELD, P				HOLMIN, S; MATHIESEN, T; SHETYE, J; BIBERFELD, P			INTRACEREBRAL INFLAMMATORY RESPONSE TO EXPERIMENTAL BRAIN CONTUSION	ACTA NEUROCHIRURGICA			English	Article						CNS TRAUMA; EXPERIMENTAL CONTUSION; INFLAMMATION	CENTRAL NERVOUS-SYSTEM; NATURAL-KILLER CELLS; RAT LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; CLASS-I; HISTOCOMPATIBILITY ANTIGENS; MONONUCLEAR PHAGOCYTES; IMMUNE REACTIVITY; AMINO-ACIDS; INJURY	The inflammatory reaction following experimental brain contusion was studied by immunohistochemistry in 22 rats during the first 16 days after trauma. An inflammatory mononuclear cell response was evident on day 2, with a maximum on days 5-6 and signs remained still 16 days after the trauma. The lime course of the cellular infiltration adjacent to the lesion correlated with blood brain barrier dysfunction in the contralateral side of the traumatized hemisphere. The cellular infiltrate comprised NK cells, T-helper cells and T-cytotoxic suppressor cells as well as monocytes/macrophages. Most of the macrophages appeared to be activated by T-cells. Surprisingly, polymorphonuclear cells appeared less engaged than mononuclear cells in the inflammation. The demonstration of immunocompetent cells and the induction of MHC-1 and MHC-II antigen provides a substrate for inflammatory reactions similar to those that cause neurological damage in inflammatory diseases such as viral infections, multiple sclerosis and experimental allergic encephalitis. Our observations indicate that the role of the inflammatory reactions may have a role, hitherto neglected, in the pathogenesis of secondary traumatic brain injury.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT NEUROSURG,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT PATHOL,S-10401 STOCKHOLM,SWEDEN				mathiesen, tiit/ABC-3627-2021	Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919			ANDERSSON PB, 1991, IMMUNOL LETT, V30, P177, DOI 10.1016/0165-2478(91)90022-3; BARBE E, 1990, IMMUNOBIOLOGY, V182, P88, DOI 10.1016/S0171-2985(11)80586-3; BARCLAY AN, 1981, IMMUNOLOGY, V42, P593; BILSSON B, 1977, J NEUROSURG, V47, P262; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; BRIDEAU RJ, 1980, EUR J IMMUNOL, V10, P609, DOI 10.1002/eji.1830100807; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; BULLOCK R, 1989, 7TH P INT S INTR PRE, P637; Cervos-Navarro J., 1991, J NEUROL SCI, V103, P3; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; CUZNER ML, 1988, J NEUROIMMUNOL, V20, P203, DOI 10.1016/0165-5728(88)90161-0; DALLMAN MJ, 1984, EUR J IMMUNOL, V14, P260, DOI 10.1002/eji.1830140311; DALLMAN MJ, 1982, EUR J IMMUNOL, V12, P511, DOI 10.1002/eji.1830120612; DAMOISEAUX JGMC, 1989, J LEUKOCYTE BIOL, V46, P246, DOI 10.1002/jlb.46.3.246; DIJKSTRA CD, 1987, SCAND J IMMUNOL, V26, P513, DOI 10.1111/j.1365-3083.1987.tb02285.x; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FUKUMOTO T, 1982, EUR J IMMUNOL, V12, P237, DOI 10.1002/eji.1830120313; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; HAYES GM, 1988, J NEUROIMMUNOL, V19, P177, DOI 10.1016/0165-5728(88)90001-X; HICKEY WF, 1992, J EXP MED, V176, P811, DOI 10.1084/jem.176.3.811; HICKEY WF, 1987, P NATL ACAD SCI USA, V84, P2082, DOI 10.1073/pnas.84.7.2082; JIE Z, 1986, ACTA PATHOL MIC SC, V94, P53; KATAYAMA Y, 1990, ACTA NEUROCHIR WIE S, V54, P308; KAUR C, 1987, J ANAT, V154, P215; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; LAMPSON LA, 1986, J IMMUNOL, V136, P4045; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; LJUNGGREN HG, 1988, J EXP MED, V167, P730, DOI 10.1084/jem.167.2.730; LUZ C, 1990, AM J PATHOL, V137, P1033; MAIN EK, 1988, J IMMUNOL, V141, P2943; MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLSSON T, 1987, J NEUROIMMUNOL, V16, P215, DOI 10.1016/0165-5728(87)90076-2; ORTALDO JR, 1981, J IMMUNOL, V127, P2401; PERRY VH, 1987, J EXP MED, V10, P1138; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; POLMAN CH, 1986, J NEUROIMMUNOL, V11, P215, DOI 10.1016/0165-5728(86)90005-6; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; ROGERS J, 1988, DRUG DEVELOP RES, V15, P227, DOI 10.1002/ddr.430150214; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; SMINIA T, 1987, IMMUNOBIOLOGY, V174, P43, DOI 10.1016/S0171-2985(87)80083-9; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; TODD NV, 1990, ACT NEUR S, V51, P296; TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147; TURNER WJD, 1990, J NEURO-ONCOL, V8, P121; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; VANDENBRINK MRM, 1990, J EXP MED, V171, P197, DOI 10.1084/jem.171.1.197; WEKERLE H, 1987, J EXP BIOL, V132, P43; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WHITE RAH, 1978, J EXP MED, V901, P664; WILLIAMS AF, 1977, CELL, V12, P633; WILMES F, 1979, ACTA NEUROPATHOL, V45, P47, DOI 10.1007/BF00691804; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WOOLLETT GR, 1985, EUR J IMMUNOL, V15, P168, DOI 10.1002/eji.1830150211	62	143	144	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	132	1-3					110	119		10.1007/BF01404857			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	QD726	WOS:A1995QD72600018	7754844				2022-02-06	
J	Huang, S; Ge, XT; Yu, JW; Han, ZL; Yin, ZY; Li, Y; Chen, FL; Wang, HC; Zhang, JN; Lei, P				Huang, Shan; Ge, Xintong; Yu, Jinwen; Han, Zhaoli; Yin, Zhenyu; Li, Ying; Chen, Fanglian; Wang, Haichen; Zhang, Jianning; Lei, Ping			Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons	FASEB JOURNAL			English	Article						extracellular vesicles; glia cells; polarization; PDE4B; mTOR signaling	MESENCHYMAL STROMAL CELLS; EXTRACELLULAR VESICLES; PHOSPHODIESTERASE 4B; IN-VITRO; PATHWAY; POLARIZATION; APOPTOSIS; DISEASE; AKT; NEUROINFLAMMATION	Neuronal inflammation is the characteristic pathologic change of acute neurologic impairment and chronic traumatic encephalopathy after traumatic brain injury (TBI). Inhibiting the excessive inflammatory response is essential for improving the neurologic outcome. To clarify the regulatory mechanism of microglial exosomes on neuronal inflammation in TBI, we focused on studying the impact of microglial exosomal miRNAs on injured neurons in this research. We used a repetitive (r) TBI mousemodel and harvested the injured brain extracts from the acute to the chronic phase of TBI to treat cultured BV2 microglia in vitro. The microglial exosomes were collected for miRNA microarray analysis, which showed that the expression level of miR-124-3p increased most apparently in the miRNAs. We found that miR-124-3p promoted the anti-inflamed M2 polarization in microglia, and microglial exosomal miR-124-3p inhibited neuronal inflammation in scratch-injured neurons. Further, the mammalian target of rapamycin (mTOR) signaling was implicated as being involved in the regulation of miR-124-3p by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. Using the mTOR activator MHY1485 we confirmed that the inhibitory effect of exosomalmiR-124-3p on neuronal inflammation was exerted by suppressing the activity of mTOR signaling. PDE4B was predicted to be the target gene of miR-124-3p by pathway analysis. We proved that it was directly targeted by miR-124-3p with a luciferase reporter assay. Using a PDE4B overexpressed lentivirus transfection system, we suggested that miR-124-3p suppressed the activity of m TOR signaling mainly through inhibiting the expression of PDE4B. In addition, exosomal miR-124-3p promoted neurite outgrowth after scratch injury, characterized by an increase on the number of neurite branches and total neurite length, and a decreased expression on RhoA and neurodegenerative proteins [A beta-peptide and p-Tau]. It also improved the neurologic outcome and inhibited neuro-inflammation in mice with rTBI. Taken together, increased miR-124-3p in microglial exosomes after TBI can inhibit neuronal inflammation and contribute to neurite outgrowth via their transfer into neurons. miR-124-3p exerted these effects by targeting PDE4B, thus inhibiting the activity of mTOR signaling. Therefore, miR-124-3p could be a promising therapeutic target for interventions of neuronal inflammation after TBI. miRNAs manipulated microglial exosomes may provide a novel therapy for TBI and other neurologic diseases.	[Huang, Shan; Ge, Xintong; Yu, Jinwen; Yin, Zhenyu; Lei, Ping] Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin, Peoples R China; [Huang, Shan; Ge, Xintong; Yu, Jinwen; Han, Zhaoli; Yin, Zhenyu; Li, Ying; Chen, Fanglian; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Huang, Shan; Yu, Jinwen; Yin, Zhenyu; Li, Ying; Chen, Fanglian; Zhang, Jianning] Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin, Peoples R China; [Ge, Xintong; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Han, Zhaoli; Lei, Ping] Tianjin Med Univ, Gen Hosp, Dept Geriatr, Anshan Rd, Tianjin 300054, Peoples R China; [Wang, Haichen] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA		Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Geriatr, Anshan Rd, Tianjin 300054, Peoples R China.	leiping1974@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501055, 81471252, 81772060]; Tianjin Municipal Science and Technology Commission Natural Fund Project [13JCYBJC23700]	This work was supported by Grants 81501055, 81471252, and 81772060 from the National Natural Science Foundation of China, and Grant 13JCYBJC23700 from the Tianjin Municipal Science and Technology Commission Natural Fund Project. The authors appreciate Chunsheng Kang, Lei Han, Anling Zhang, Li Liu, Weiyun Cui, and Lei Zhou (Tianjin Neurological Institute) for their technical support. The authors declare no conflicts of interest.	Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Bai R., 2017, NEUROCHEM RES; Bai RJ, 2017, MED SCI MONITOR, V23, P1707, DOI 10.12659/MSM.901124; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Byles V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3834; Chen ZQ, 2014, CANCER LETT, V350, P43, DOI 10.1016/j.canlet.2014.04.010; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Chopp M, 2015, EXPERT OPIN EMERG DR, V20, P523, DOI 10.1517/14728214.2015.1061993; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cunha C, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6986175; Dadsetan S, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00106; Edwards P, 2005, LANCET, V365, P1957; Ejlerskov P, 2015, CELL, V163, P324, DOI 10.1016/j.cell.2015.08.069; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gao C, 2017, MOL NEUROBIOL, V54, P8348, DOI 10.1007/s12035-016-0318-0; Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Glebov K, 2015, GLIA, V63, P626, DOI 10.1002/glia.22772; Gong X, 2016, AM J TRANSL RES, V8, P2127; Goto T, 2013, BIOORG MED CHEM LETT, V23, P3325, DOI 10.1016/j.bmcl.2013.03.104; Gurney ME, 2015, NEUROTHERAPEUTICS, V12, P49, DOI 10.1007/s13311-014-0309-7; Han RR, 2016, EXP NEUROL, V280, P106, DOI 10.1016/j.expneurol.2016.04.005; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Hartmann H, 2015, CELL TISSUE RES, V362, P9, DOI 10.1007/s00441-015-2183-y; Hooper C, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-144; Hu XK, 2016, MOL MED REP, V14, P3662, DOI 10.3892/mmr.2016.5729; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kim J, 2015, GENE, V558, P173, DOI 10.1016/j.gene.2015.01.001; Kim SW, 2011, CLIN CANCER RES, V17, P6723, DOI 10.1158/1078-0432.CCR-11-0770; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li DJ, 2016, FASEB J, V30, P3388, DOI 10.1096/fj.201600495R; Mantovani A, 2004, SEMIN CANCER BIOL, V14, P155, DOI 10.1016/j.semcancer.2003.10.001; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Naganuma K, 2009, BIOORG MED CHEM LETT, V19, P3174, DOI 10.1016/j.bmcl.2009.04.121; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Potolicchio A, 2005, J IMMUNOL, V175, P2237, DOI 10.4049/jimmunol.175.4.2237; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Takano T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00044-2; Thompson AG, 2016, NAT REV NEUROL, V12, P346, DOI 10.1038/nrneurol.2016.68; Wang YJ, 2016, ONCOTARGET, V7, P13328, DOI 10.18632/oncotarget.7798; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xin HQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009027; Xiong Y, 2015, EXPERT OPIN INV DRUG, V24, P743, DOI 10.1517/13543784.2015.1021919; Yu AY, 2017, IMMUNOL LETT, V182, P1, DOI 10.1016/j.imlet.2016.12.003; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zhang H, 2016, BIOCHEM RES INT, V2016, DOI 10.1155/2016/7498706; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang YQ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-253; Zhang Y, 2017, MOL NEUROBIOL, V54, P2659, DOI 10.1007/s12035-016-9851-0; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126; Zhu H, 2013, BRAIN RES, V1541, P69, DOI 10.1016/j.brainres.2013.10.002; Zhu LN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5696; Zhu XX, 2014, J CEREBR BLOOD F MET, V34, P1531, DOI 10.1038/jcbfm.2014.113	64	142	150	12	81	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2018	32	1					512	528		10.1096/fj.201700673R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FR6JU	WOS:000419172700045	28935818		Y	N	2022-02-06	
J	Ren, ZG; Iliff, JJ; Yang, LJ; Yang, JK; Chen, XL; Chen, MJ; Giese, RN; Wang, BZ; Shi, XF; Nedergaard, M				Ren, Zeguang; Iliff, Jeffrey J.; Yang, Lijun; Yang, Jiankai; Chen, Xiaolin; Chen, Michael J.; Giese, Rebecca N.; Wang, Baozhi; Shi, Xuefang; Nedergaard, Maiken			'Hit & Run' model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulation	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						astrocyte; aquaporin-4; AQP4; cerebral edema; traumatic brain injury	CONTROLLED CORTICAL IMPACT; HEAD-INJURY; AQUAPORIN-4 EXPRESSION; BARRIER DISRUPTION; CEREBRAL EDEMA; GENE DELETION; MALE RATS; BLOOD; MOUSE; MICE	Cerebral edema is a major contributor to morbidity associated with traumatic brain injury (TBI). The methods involved in most rodent models of TBI, including head fixation, opening of the skull, and prolonged anesthesia, likely alter TBI development and reduce secondary injury. We report the development of a closed-skull model of murine TBI, which minimizes time of anesthesia, allows the monitoring of intracranial pressure (ICP), and can be modulated to produce mild and moderate grade TBI. In this model, we characterized changes in aquaporin-4 (AQP4) expression and localization after mild and moderate TBI. We found that global AQP4 expression after TBI was generally increased; however, analysis of AQP4 localization revealed that the most prominent effect of TBI on AQP4 was the loss of polarized localization at endfoot processes of reactive astrocytes. This AQP4 dysregulation peaked at 7 days after injury and was largely indistinguishable between mild and moderate grade TBI for the first 2 weeks after injury. Within the same model, blood-brain barrieranalysis of variance permeability, cerebral edema, and ICP largely normalized within 7 days after moderate TBI. These findings suggest that changes in AQP4 expression and localization may not contribute to cerebral edema formation, but rather may represent a compensatory mechanism to facilitate its resolution.	[Ren, Zeguang; Iliff, Jeffrey J.; Yang, Lijun; Yang, Jiankai; Chen, Xiaolin; Chen, Michael J.; Giese, Rebecca N.; Nedergaard, Maiken] Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Ren, Zeguang; Nedergaard, Maiken] Univ Rochester, Med Ctr, Dept Neurol Surg, Rochester, NY 14642 USA; [Yang, Lijun; Wang, Baozhi] Hebei Med Univ, Dept Human Anat, Shijiazhuang, Hebei, Peoples R China; [Yang, Jiankai; Shi, Xuefang] Hebei Med Univ, Hosp 2, Shijiazhuang, Hebei, Peoples R China; [Chen, Xiaolin] Capital Univ Med Sci, Beijing Tiantan Hosp, Beijing, Peoples R China		Iliff, JJ (corresponding author), Ctr Translat Neuromed, Box 645,575 Elmwood Ave, Rochester, NY 14642 USA.	Jeffrey_Iliff@URMC.Rochester.edu; Nedergaard@URMC.Rochester.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; United States Department of DefenseUnited States Department of Defense; Harold and Leila Y. Mathers Charitable Foundation; American Heart AssociationAmerican Heart Association; Neurosurgical Research and Education Foundation from the American Association of Neurological Surgeons (AANS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078304, R01NS075177, R01NS078167] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (JJI, MN), the United States Department of Defense (MN), the Harold and Leila Y. Mathers Charitable Foundation (MN), the American Heart Association (JJI), and the Neurosurgical Research and Education Foundation from the American Association of Neurological Surgeons (AANS) (ZR).	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Finnie JW, 2001, AUST VET J, V79, P628, DOI 10.1111/j.1751-0813.2001.tb10785.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Ghajar J, 2009, MT SINAI J MED, V76, P190, DOI 10.1002/msj.20095; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Haj-Yasein NN, 2012, GLIA, V60, P867, DOI 10.1002/glia.22319; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Lopez NE, 2012, J TRAUMA ACUTE CARE, V72, P1562, DOI 10.1097/TA.0b013e3182569875; Lopez NE, 2012, J NEUROTRAUM, V29, P385, DOI 10.1089/neu.2011.2053; Lu DC, 2011, J NEUROTRAUM; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nielsen S, 1997, J NEUROSCI, V17, P171; Oliva AA, 2011, NEUROSCIENCE, V180, P272, DOI 10.1016/j.neuroscience.2011.02.020; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Tymianski M, 2010, STROKE, V41, pS87, DOI 10.1161/STROKEAHA.110.595496; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Wang MH, 2012, J NEUROSCI, V32, P17948, DOI 10.1523/JNEUROSCI.1860-12.2012; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	48	142	150	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2013	33	6					834	845		10.1038/jcbfm.2013.30			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	156KP	WOS:000319821100006	23443171	Green Published, Bronze			2022-02-06	
J	King, PR; Donnelly, KT; Donnelly, JP; Dunnam, M; Warner, G; Kittleson, CJ; Bradshaw, CB; Alt, M; Meier, ST				King, Paul R.; Donnelly, Kerry T.; Donnelly, James P.; Dunnam, Mina; Warner, Gary; Kittleson, C. J.; Bradshaw, Charles B.; Alt, Michelle; Meier, Scott T.			Psychometric study of the Neurobehavioral Symptom Inventory	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain concussion; brain injuries; comprehensive TBI evaluation; Neurobehavioral Symptom Inventory; neuropsychology; postconcussion symptoms; posttraumatic; stress disorders; traumatic brain injury; veterans	TRAUMATIC BRAIN-INJURY; POSTCONCUSSIVE SYMPTOMS; POSTTRAUMATIC-STRESS; IRAQ	The Department of Veterans Affairs (VA) uses the Neurobehavioral Symptom Inventory (NSI) to measure post-concussive symptoms in its comprehensive traumatic brain injury (TBI) evaluation. This study examined the NSI's item properties, internal consistency, and external validity. Data were obtained from a federally funded study of the experiences of combat veterans. Participants included 500 Operations Iraqi and Enduring Freedom veterans, 219 of whom sustained at least one TBI. Data were collected at five VA medical centers and one VA outpatient clinic across upstate New York. Measures included neuropsychological interview, NSI, Beck Anxiety Inventory, Beck Depression Inventory-II, and Posttraumatic Stress Disorder Checklist-Military Version. The NSI demonstrated high internal consistency (total alpha = 0.95; subscale alpha = 0.88 to 0.92). Subscale totals based on Caplan et al.'s factor analysis correlated highly with the NSI total score (r = 0.88 to 0.93). NSI scores differentiated veterans with TBI history from those without but were strongly influenced by variance associated with probable posttraumatic stress disorder, depression, and generalized anxiety. Results suggest that the NSI is a reliable and valid measure of postconcussive symptoms. Scale validity is evident in the differentiation of TBI and non-TBI classifications. The scale domain is not limited to TBI, however, and extends to detection of probable effects of additional affective disorders prevalent in the veteran population.	[King, Paul R.] Dept Vet Affairs VA Western New York Healthcare S, Ctr Integrated Healthcare, Buffalo, NY USA; [King, Paul R.; Donnelly, James P.; Meier, Scott T.] SUNY Buffalo, Dept Counseling Sch & Educ Psychol, Buffalo, NY 14260 USA; [Donnelly, Kerry T.; Alt, Michelle] VA Western New York Healthcare Syst Buffalo, Behav Hlth Careline, Buffalo, NY USA; [Dunnam, Mina] Stratton VA Med Ctr, Albany, NY USA; [Warner, Gary] Canandaigua VA Med Ctr, Canandaigua, NY USA; [Kittleson, C. J.] Bath VA Med Ctr, Bath, NY USA; [Bradshaw, Charles B.] Syracuse VA Med Ctr, Syracuse, NY USA		King, PR (corresponding author), VA Western New York Healthcare Syst, Ctr Integrated Healthcare, 3495 Bailey Ave, Buffalo, NY 14215 USA.	Paul.King2@va.gov	Donnelly, James/AAI-4840-2020		VA, Veterans Health Administration, Office of R&D, Health Sciences RD [06-162]; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, VA	This material was based on work supported in part by the VA, Veterans Health Administration, Office of R&D, Health Sciences R&D (Service Directed Research grant 06-162). Writing of this manuscript was supported in part by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, VA.	Beck AT, MANUAL BECK DEPRESSI; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Carlson K, 2009, ASSESSMENT TREATMENT; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Department of Veterans Affairs, 2007, SCREEN EV POSS TRAUM; Department of Veterans Affairs/Department of Defense, 2009, VA DOD CLIN PRACT GU; Donnelly K, 2008, VA QUERI NAT M DEC P; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Government Accountability Office, 2008, VA HLTH CAR MILD TRA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holmbeck GN, 2009, J PEDIATR PSYCHOL, V34, P691, DOI 10.1093/jpepsy/jsp046; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; National Center for PTSD and Walter Reed Army Medical Center, 2004, IR WAR CLIN GUID; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Steer, 1993, MANUAL BECK ANXIETY; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Weathers F., 1993, 9 ANN C ISTSS SAN AN; [No title captured]	26	142	142	1	12	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	6					879	888		10.1682/JRRD.2011.03.0051			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	149EX	WOS:000319302900006	23299259	Bronze			2022-02-06	
J	Rockswold, SB; Rockswold, GL; Zaun, DA; Zhang, XW; Cerra, CE; Bergman, TA; Liu, JN				Rockswold, Sarah B.; Rockswold, Gaylan L.; Zaun, David A.; Zhang, Xuewei; Cerra, Carla E.; Bergman, Thomas A.; Liu, Jiannong			A prospective, randomized clinical trial to compare the effect of hyperbaric to normobaric hyperoxia on cerebral metabolism, intracranial pressure, and oxygen toxicity in severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						hyperbaric oxygen; normobaric hyperoxia; oxygen toxicity; traumatic brain injury; cerebral metabolism; intracranial pressure	SEVERE HEAD-INJURY; BLOOD-FLOW; CEREBROSPINAL-FLUID; MITOCHONDRIAL-FUNCTION; TISSUE OXYGEN; INTRACEREBRAL MICRODIALYSIS; GLUCOSE-UTILIZATION; ISCHEMIC TOLERANCE; LIPID-PEROXIDATION; OXIDATIVE STRESS	Object. Oxygen delivered in supraphysiological amounts is currently under investigation as a therapy for severe traumatic brain injury (TBI). Hyperoxia can be delivered to the brain under normobaric as well as hyperbaric conditions. In this study the authors directly compare hyperbaric oxygen (HBO2) and normobaric hyperoxia (NBH) treatment effects. Methods. Sixty-nine patients who had sustained severe TBIs (mean Glasgow Coma Scale Score 5.8) were prospectively randomized to 1 of 3 groups within 24 hours of injury: 1) HBO2, 60 minutes of HBO2 at 1.5 ATA; 2) NBH, 3 hours of 100% fraction of inspired oxygen at 1 ATA; and 3) control, standard care. Treatments occurred once every 24 hours for 3 consecutive days. Brain tissue PO2, microdialysis, and intracranial pressure were continuously monitored. Cerebral blood flow (CBF), arteriovenous differences in oxygen, cerebral metabolic rate of oxygen (CMRO2), CSF lactate and F2-isoprostane concentrations, and bronchial alveolar lavage (BAL) fluid interleukin (IL)-8 and IL-6 assays were obtained pretreatment and 1 and 6 hours posttreatment. Mixed-effects linear modeling was used to statistically test differences among the treatment arms as well as changes from pretreatment to posttreatment. Results. In comparison with values in the control group, the brain tissue PO2 levels were significantly increased during treatment in both the HBO2 (mean +/- SEM, 223 +/- 29 mm Hg) and NBH (86 +/- 12 mm Hg) groups (p < 0.0001) and following HBO2 until the next treatment session (p = 0.003). Hyperbaric O-2 significantly increased CBF and CMRO2 for 6 hours (p <= 0.01). Cerebrospinal fluid lactate concentrations decreased posttreatment in both the HBO2 and NBH groups (p < 0.05). The dialysate lactate levels in patients who had received HBO2 decreased for 5 hours posttreatment (p = 0.017). Microdialysis lactate/pyruvate (L/P) ratios were significantly decreased posttreatment in both HBO2 and NBH groups (p < 0.05). Cerebral blood flow, CMRO2, microdialysate lactate, and the L/P ratio had significantly greater improvement when a brain tissue PO2 >= 200 mm Hg was achieved during treatment (p < 0.01). Intracranial pressure was significantly lower after HBO2 until the next treatment session (p < 0.001) in comparison with levels in the control group. The treatment effect persisted over all 3 days. No increase was seen in the CSF F2-isoprostane levels, microdialysate glycerol, and BAL inflammatory markers, which were used to monitor potential O-2 toxicity. Conclusions. Hyperbaric O-2 has a more robust posttreatment effect than NBH on oxidative cerebral metabolism related to its ability to produce a brain tissue PO2 >= 200 mm Hg. However, it appears that O-2 treatment for severe TBI is not an all or nothing phenomenon but represents a graduated effect. No signs of pulmonary or cerebral O-2 toxicity were present. (DOI: 10.3171/2009.7.JNS09363)	[Rockswold, Sarah B.; Rockswold, Gaylan L.; Zhang, Xuewei; Cerra, Carla E.; Bergman, Thomas A.] Univ Minnesota, Hennepin Cty Med Ctr, Dept Surg, Div Neurosurg, Minneapolis, MN 55415 USA; [Rockswold, Sarah B.] Univ Minnesota, Dept Phys Med & Rehabil, Minneapolis, MN 55415 USA; [Rockswold, Gaylan L.; Bergman, Thomas A.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55415 USA; [Zaun, David A.; Liu, Jiannong] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Analyt Serv, Minneapolis, MN USA		Rockswold, GL (corresponding author), Univ Minnesota, Hennepin Cty Med Ctr, Dept Surg, Div Neurosurg, 701 Pk Ave, Minneapolis, MN 55415 USA.	gaylan.rockswold@hcmed.org			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS042126, R01-NS042126-03S1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042126] Funding Source: NIH RePORTER		ARTRU F, 1976, EUR NEUROL, V14, P310, DOI 10.1159/000114753; BALLENTINE JD, 1982, PATHOLOGY OXYGEN TOX; Bardin H, 1970, QUANTITATIVE METHOD; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BROWN JA, 1988, PEDIATR NEUROSCI, V14, P286, DOI 10.1159/000120406; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; CONTRERAS FL, 1988, J NEUROSURG, V68, P137, DOI 10.3171/jns.1988.68.1.0137; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DEATON PR, 1994, AM J PHYSIOL, V267, pL187, DOI 10.1152/ajplung.1994.267.2.L187; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Desmarquest P, 1998, RESP MED, V92, P951, DOI 10.1016/S0954-6111(98)90195-0; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Fam SS, 2003, CURR MED CHEM, V10, P1723, DOI 10.2174/0929867033457115; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GOSSETT WA, 2009, UNDERSEA HY IN PRESS; HARABIN AL, 1990, J APPL PHYSIOL, V69, P328, DOI 10.1152/jappl.1990.69.1.328; HAYAKAWA T, 1971, J NEUROL NEUROSUR PS, V34, P580, DOI 10.1136/jnnp.34.5.580; HOLBACH KH, 1974, ACTA NEUROCHIR, V30, P247, DOI 10.1007/BF01405583; HOLBACH KH, 1973, ADV NEUROSURG, V1, P158; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JAIN KK, 1999, TXB HYPERBARIC MED; JAMIESON D, 1989, FREE RADICAL BIO MED, V7, P87, DOI 10.1016/0891-5849(89)90103-2; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KINDALL EP, 1999, HYPERBARIC MED PRACT; KLEIN J, 1990, ANESTH ANALG, V70, P195; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Mantell LL, 1999, ANN NY ACAD SCI, V887, P171, DOI 10.1111/j.1749-6632.1999.tb07931.x; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Matta BF, 1997, ANESTHESIOLOGY, V86, P806, DOI 10.1097/00000542-199704000-00010; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; METZEL E, 1971, ACTA NEUROCHIR, V25, P177, DOI 10.1007/BF01809099; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1971, ARCH NEUROL-CHICAGO, V24, P210, DOI 10.1001/archneur.1971.00480330038003; MILLER JD, 1970, J NEUROSURG, V33, P287, DOI 10.3171/jns.1970.33.3.0287; MINK RB, 1995, STROKE, V26, P2307, DOI 10.1161/01.STR.26.12.2307; MOGAMI H, 1969, J NEUROSURG, V31, P636, DOI 10.3171/jns.1969.31.6.0636; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340; Muehstedt SG, 2001, SURGERY, V130, P602, DOI 10.1067/msy.2001.117105; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NIDA TY, 1995, J NEUROTRAUM, V12, P77, DOI 10.1089/neu.1995.12.77; NODA Y, 1983, J NEUROCHEM, V40, P1329, DOI 10.1111/j.1471-4159.1983.tb13574.x; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; PUGLIA CD, 1984, TOXICOL APPL PHARM, V75, P258, DOI 10.1016/0041-008X(84)90208-4; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Siddiqui A, 1997, PLAST RECONSTR SURG, V99, P148, DOI 10.1097/00006534-199701000-00023; Siesj? BK., 1978, BRAIN ENERGY METABOL; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; SUKOFF MH, 1968, J NEUROSURG, V29, P236, DOI 10.3171/jns.1968.29.3.0236; SUKOFF MH, 1982, NEUROSURGERY, V10, P29, DOI 10.1227/00006123-198201000-00006; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Wada K, 2001, NEUROSURGERY, V49, P160; Wada K, 1996, BRAIN RES, V740, P15; WISPE JR, 1987, CLIN PERINATOL, V14, P651, DOI 10.1016/S0095-5108(18)30755-3; WRIGHT WB, 1972, 272 US NAV EXP DIV U; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	110	142	166	1	21	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2010	112	5					1080	1094		10.3171/2009.7.JNS09363			15	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	591BW	WOS:000277273600027	19852540				2022-02-06	
J	Brenner, LA; Vanderploeg, RD; Terrio, H				Brenner, Lisa A.; Vanderploeg, Rodney D.; Terrio, Heidi			Assessment and Diagnosis of Mild Traumatic Brain Injury, Posttraumatic Stress Disorder, and Other Polytrauma Conditions: Burden of Adversity Hypothesis	REHABILITATION PSYCHOLOGY			English	Article						Operation Enduring Freedom; Operation Iraqi Freedom; traumatic brain injury; posttraumatic stress disorder; war; polytrauma	MENTAL-HEALTH PROBLEMS; EMOTIONAL RISK-FACTORS; CUMULATIVE DISADVANTAGE; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; IRAQ; AFGHANISTAN; DEPLOYMENT; ADVANTAGE; PROFILES	Objective/Method. Military personnel returning from Iraq and Afghanistan have been exposed to physical and emotional trauma. Challenges related to assessment and intervention for those with posttraumatic stress disorder (PTSD) and/or history of mild traumatic brain injury (TBI) with sequelae are discussed, with an emphasis on complicating factors if conditions are co-occurring. Existing literature regarding cumulative disadvantage is offered as a means of increasing understanding regarding the complex symptom patterns reported by those with a history of mild TBI with enduring symptoms and PTSD. Implications: The importance of early screening for both conditions is highlighted. In addition, the authors suggest that current best practices include treating symptoms regardless of etiology to decrease military personnel and veteran burden of adversity.	[Brenner, Lisa A.] Univ Colorado, Sch Med, MIRECC, VA VISN 19, Denver, CO 80220 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80220 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO 80220 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO 80220 USA; [Vanderploeg, Rodney D.] Univ S Florida, James A Haley Vet Adm Med Ctr, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Tampa, FL USA; [Terrio, Heidi] Evans Army Community Hosp, Dept Deployment Hlth & Headquarters, Ft Carson, CO USA; [Terrio, Heidi] Def & Vet Brain Injury Ctr, Ft Carson, CO USA		Brenner, LA (corresponding author), Univ Colorado, Sch Med, MIRECC, VA VISN 19, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Brenner, Lisa A./AAG-2442-2019				Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BRADSHAW D, 2007, TRAUMATIC BRAIN INJU; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; *DEP VET AFF, 2009, VA DOD CLIN  PRACT G; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Ferraro KF, 2003, AM SOCIOL REV, V68, P707, DOI 10.2307/1519759; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Johnston SC, 2005, NEUROLOGY, V65, P360; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lesho EP, 2005, MIL MED, V170, P243, DOI 10.7205/MILMED.170.3.243; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; MERTON RK, 1968, SCIENCE, V159, P56, DOI 10.1126/science.159.3810.56; MERTON RK, 1988, ISIS, V79, P606, DOI 10.1086/354848; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Morgan C, 2008, PSYCHOL MED, V38, P1701, DOI 10.1017/S0033291708004534; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; ORand AM, 1996, GERONTOLOGIST, V36, P230, DOI 10.1093/geront/36.2.230; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Preston SH, 1998, SOC SCI MED, V47, P1231, DOI 10.1016/S0277-9536(98)00180-4; Price RK, 2004, DRUG ALCOHOL DEPEN, V76, pS31, DOI 10.1016/j.drugalcdep.2004.08.005; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seguin M, 2007, PSYCHOL MED, V37, P1575, DOI 10.1017/S0033291707000955; Soo C, 2007, COCHRANE DB SYST REV, V3; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TERRIO H, 2009, GRAND ROUNDS BROOK A; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VANDERPLOEG RD, 2009, ANN M AM AC CLIN NEU; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	48	142	144	1	21	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					239	246		10.1037/a0016908			8	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	488SW	WOS:000269371100001	19702422				2022-02-06	
J	Andelic, N; Hammergren, N; Bautz-Holter, E; Sveen, U; Brunborg, C; Roe, C				Andelic, N.; Hammergren, N.; Bautz-Holter, E.; Sveen, U.; Brunborg, C.; Roe, C.			Functional outcome and health-related quality of life 10 years after moderate-to-severe traumatic brain injury	ACTA NEUROLOGICA SCANDINAVICA			English	Article						traumatic brain injury; long-term outcome; epilepsy; depression; Glasgow Outcome Scale-Extended; health-related quality of life; SF-36	HEAD-INJURY; FOLLOW-UP; ADULTS; POPULATION; EPILEPSY; SCALE; SF-36; REHABILITATION; PREDICTORS; DEPRESSION	To describe the functional outcome and health-related quality of life (HRQL) 10 years after moderate-to-severe traumatic brain injury (TBI). A retrospective, population-based study of 62 survivors of working-age with moderate-to-severe TBI injured in 1995/1996, and hospitalized at the Trauma Referral Center in Eastern Norway. Functional status was measured by the Glasgow Outcome Scale-Extended (GOS-E). HRQL was assessed by the SF-36 questionnaire. The mean current-age was 40.8 years. The frequency of epilepsy was 19% and the depression rate 31%. A majority had good recovery (48%) or moderate disability (44%). Employment rate was 58%. Functional and employment status were associated with initial injury severity in contrast to HRQL. Study patients had significantly lower scores in all SF-36 dimensions when compared with the general Norwegian population. At 10-years follow-up, our study population is still in their most productive years and affected domains should be considered in long-term follow-up and intervention programs.	[Andelic, N.; Hammergren, N.; Bautz-Holter, E.; Sveen, U.; Roe, C.] Univ Oslo, Dept Phys Med & Rehabil, Ulleval Univ Hosp, N-0407 Oslo, Norway; [Hammergren, N.] Sunnaas Rehabil Hosp, Askim, Norway; [Brunborg, C.] Univ Oslo, Clin Res Ctr, Ulleval Univ Hosp, N-0407 Oslo, Norway; [Bautz-Holter, E.; Roe, C.] Univ Oslo, Fac Med, N-0407 Oslo, Norway		Andelic, N (corresponding author), Univ Oslo, Dept Phys Med & Rehabil, Ulleval Univ Hosp, N-0407 Oslo, Norway.	nada.andelic@ulleval.no		Andelic, Nada/0000-0002-3719-4406	The Norwegian Health South-East Authority	The Norwegian Health South-East Authority funded this study. We thank Clinical Documentary Center, Ulleval University Hospital for their practical support on collecting medical records and Susan Schanche for the proofreading English text.	Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Ayuso-Mateos JL, 2001, BRIT J PSYCHIAT, V179, P308, DOI 10.1192/bjp.179.4.308; Beck A T, 1974, Mod Probl Pharmacopsychiatry, V7, P151; Betty R., 2003, ESSENTIAL MED STAT, V2nd ed, P33; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Lasa L, 2000, J AFFECT DISORDERS, V57, P261, DOI 10.1016/S0165-0327(99)00088-9; Loge JH, 1998, SCAND J SOC MED, V26, P250; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pugh MJV, 2005, EPILEPSIA, V46, P1820, DOI 10.1111/j.1528-1167.2005.00291.x; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	34	142	143	1	14	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	JUL	2009	120	1					16	23		10.1111/j.1600-0404.2008.01116.x			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	454MO	WOS:000266686400002	18976326				2022-02-06	
J	Benson, BW; Hamilton, GM; Meeuwisse, WH; McCrory, P; Dvorak, J				Benson, B. W.; Hamilton, G. M.; Meeuwisse, W. H.; McCrory, P.; Dvorak, J.			Is protective equipment useful in preventing concussion? A systematic review of the literature	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				BICYCLE SAFETY HELMETS; HEAD-INJURIES; ICE HOCKEY; PROFESSIONAL FOOTBALL; FITTED MOUTHGUARDS; MOUTH PROTECTORS; FACIAL INJURIES; NECK INJURIES; GAME IMPACTS; EYE INJURIES	Objective: To determine if there is evidence that equipment use reduces sport concussion risk and/or severity. Data sources: 12 electronic databases were searched using a combination of Medical Subject Headings and text words to identify relevant articles. Review methods: Specific inclusion and exclusion criteria were used to select studies for review. Data extracted included design, study population, exposure/ outcome measures and results. The quality of evidence was assessed based on epidemiologic criteria regarding internal and external validity (ie, strength of design, sample size/power calculation, selection bias, misclassification bias, control of potential confounding and effect modification). Results: In total, 51 studies were selected for review. A comparison between studies was difficult due to the variability in research designs, definition of concussion, mouthguard/helmet/headgear/face shield types, measurements used to assess exposure and outcomes, and variety of sports assessed. The majority of studies were observational, with 23 analytical epidemiologic designs related to the subject area. Selection bias was a concern in the reviewed studies, as was the lack of measurement and control for potentially confounding variables. Conclusions: There is evidence that helmet use reduces head injury risk in skiing, snowboarding and bicycling, but the effect on concussion risk is inconclusive. No strong evidence exists for the use of mouthguards or face shields to reduce concussion risk. Evidence is provided to suggest that full facial protection in ice hockey may reduce concussion severity, as measured by time loss from competition.	[Benson, B. W.; Hamilton, G. M.; Meeuwisse, W. H.] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Benson, B. W.; Hamilton, G. M.; Meeuwisse, W. H.] Univ Calgary, Dept Community Hlth Sci, Fac Med, Calgary, AB T2N 1N4, Canada; [McCrory, P.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; [Dvorak, J.] F MARC, FIFA Med Assessment & Res Ctr, Schulthess Clin, Zurich, Switzerland		Benson, BW (corresponding author), Univ Calgary, Sport Med Ctr, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	bbenson@ucalgary.ca	McCrory, Paul/Q-8688-2019	Hamilton, Gavin/0000-0001-7607-2121; McCrory, Paul/0000-0003-4850-0568			ADA, 2006, J AM DENT ASSOC, V137, P1712; Alles W F, 1979, J Orthop Sports Phys Ther, V1, P103; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Barth JT, 2001, J ATHL TRAINING, V36, P253; Benson B., 2005, CLIN J SPORT MED, V15, P395; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Bishop P J, 1984, Can J Appl Sport Sci, V9, P94; Blignaut J B, 1987, Br J Sports Med, V21, P5; Brandenburg MA, 2002, CLIN J SPORT MED, V12, P360, DOI 10.1097/00042752-200211000-00007; Broglio SP, 2003, J ATHL TRAINING, V38, P220; Brukner P, 1996, Aust Fam Physician, V25, P1445; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; CASTALDI CR, 1993, ASTM STP, V1212, P164; Caswell SV, 2002, J ATHL TRAINING, V37, P164; Chalmers DJ, 1998, SPORTS MED, V25, P339, DOI 10.2165/00007256-199825050-00006; Chapman P., 1985, AUST J SCI MED SPORT, V17, P25; Chapman P., 1985, AUST J SCI MED SPORT, P23; Chapman P J, 1985, Br J Sports Med, V19, P34; CHAPMAN PJ, 1983, SPORT HLTH, V1, P13; Cohenca N, 2007, J AM DENT ASSOC, V138, P1121, DOI 10.14219/jada.archive.2007.0326; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Cummins NK, 2002, MED SCI SPORT EXER, V34, P942, DOI 10.1097/00005768-200206000-00006; de Wet F A, 1981, J Dent Assoc S Afr, V36, P249; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DORNEY B, 1994, AUST DENT J, V39, P372, DOI 10.1111/j.1834-7819.1994.tb03109.x; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finvers KA, 1996, CLIN J SPORT MED, V6, P102, DOI 10.1097/00042752-199604000-00007; FRICKER JP, 1983, AUST J SPORTS MED EX, V15, P22; Fukuda O, 2007, NEUROL MED-CHIR, V47, P491, DOI 10.2176/nmc.47.491; GARON MW, 1986, J AM DENT ASSOC, V112, P663, DOI 10.14219/jada.archive.1986.0063; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; HEINTZ WD, 1975, PHYSICIAN SPORTSMED, V3, P61; Heng K. W. J., 2006, SMJ Singapore Medical Journal, V47, P367; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Hrysomallis C, 2004, J SCI MED SPORT, V7, P156, DOI 10.1016/S1440-2440(04)80005-7; Ing E, 2002, CAN J OPHTHALMOL, V37, P161, DOI 10.1016/S0008-4182(02)80058-8; JOHNSON R, 2002, SPORTS MED ALERT, V8, P1; Kahanov Leamor, 2005, Res Sports Med, V13, P77, DOI 10.1080/15438620590956025; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; KERR IL, 1986, SPORTS MED, V3, P415, DOI 10.2165/00007256-198603060-00003; Kraus J F, 1970, Med Sci Sports, V2, P162; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Lemair M, 2007, SPORTS ENG, V10, P65, DOI 10.1007/BF02844204; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; MASTRANGELO F, 1989, ASTM STP, V1050, P52; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2003, BRIT J SPORT MED, V37, P325, DOI 10.1136/bjsm.37.4.325; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McNutt T., 1989, PEDIAT DENT, V11, P7; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Newsome P R, 2001, Int J Paediatr Dent, V11, P396, DOI 10.1046/j.0960-7439.2001.00304.x; PASHBY DP, 1993, SAFETY ICE HOCKEY, P159; PASHBY T, 1987, CAN J OPHTHALMOL, V22, P293; PASHBY T, 1985, CAN J OPHTHALMOL, V20, P2; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PICCININNI P, 2001, BRIT J SPORT MED, V35, P375; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; Ranalli DN, 2002, SPORTS MED, V32, P409, DOI 10.2165/00007256-200232070-00001; REYNEN PD, 1994, AM J SPORT MED, V22, P167, DOI 10.1177/036354659402200203; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Takeda T, 2005, DENT TRAUMATOL, V21, P134, DOI 10.1111/j.1600-9657.2005.00320.x; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC., 1999, COCHRANE DB SYST REV, V308, DOI 10.1002/14651858.CD001855; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Torg J S, 1999, Am J Orthop (Belle Mead NJ), V28, P128; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; Winters JE, 2001, J ATHL TRAINING, V36, P339; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; 1972, J AM DENT ASS, V84, P531	90	142	144	0	66	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I56	I67		10.1136/bjsm.2009.058271			12	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	450YO	WOS:000266438100010	19433427				2022-02-06	
J	Pineda, JA; Lewis, SB; Valadka, AB; Papa, L; Hannay, HJ; Heaton, SC; Demery, JA; Liu, MC; Aikman, JM; Akle, V; Brophy, GM; Tepas, JJ; Wang, KKW; Robertson, CS; Hayes, RL				Pineda, Jose A.; Lewis, Stephen B.; Valadka, Alex B.; Papa, Linda; Hannay, H. Julia; Heaton, Shelley C.; Demery, Jason A.; Liu, Ming Cheng; Aikman, Jada M.; Akle, Veronica; Brophy, Gretchen M.; Tepas, Joseph J., III; Wang, Kevin K. W.; Robertson, Claudia S.; Hayes, Ronald L.			Clinical significance of all-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; CSF; spectrin; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; ALPHA-II-SPECTRIN; CONTROLLED CORTICAL IMPACT; OUTCOME PREDICTION; SURROGATE MARKERS; SERUM MARKERS; CALPAIN-I; DAMAGE; PROTEIN	Following traumatic brain injury (TBI), the cytoskeletal protein alpha-II-spectrin is proteolyzed by calpain and caspase-3 to signature breakdown products. To determine whether alpha-II-spectrin proteolysis is a potentially reliable biomarker for TBI in humans, the present study (1) examined levels of spectrin breakdown products (SBDPs) in cerebrospinal fluid (CSF) from adults with severe TBI and (2) examined the relationship between these levels, severity of injury, and clinical outcome. This prospective case control study enrolled 41 patients with severe TBI, defined by a Glasgow Coma Scale (GCS) score of <= 8, who underwent intraventricular intracranial pressure monitoring. Patients without TBI requiring CSF drainage for other medical reasons served as controls. Ventricular CSF was sampled from each patient at 6, 12, 24, 48, 72, 96, and 120 h following TBI and analyzed for SBDPs. Outcome was assessed using the Glasgow Outcome Score (GOS) 6 months after injury. Calpain and caspase-3 mediated SBDP levels in CSF were significantly increased in TBI patients at several time points after injury, compared to control subjects. The time course of calpain mediated SBDP150 and SBDP145 differed from that of caspase-3 mediated SBDP120 during the post-injury period examined. Mean SBDP densitometry values measured early after injury correlated with severity of injury, computed tomography (CT) scan findings, and outcome at 6 months post-injury. Taken together, these results support that alpha-II-spectrin breakdown products are potentially useful biornarker of severe TBI in humans. Our data further suggests that both necrotic/oncotic and apoptotic cell death mechanisms are activated in humans following severe TBI, but with a different time course after injury.	Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosurg, Gainesville, FL 32610 USA; Univ Florida, Dept Emergency Med, Gainesville, FL 32610 USA; Univ Florida, Dept Surg, Gainesville, FL 32610 USA; Univ Florida, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; Washington Univ, Dept Pediat, St Louis, MO 63130 USA; Washington Univ, Dept Neurol, St Louis, MO 63130 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Houston, Dept Psychol, Houston, TX USA; Virginia Commonwealth Univ, Dept Pharm, Richmond, VA USA; Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA		Pineda, JA (corresponding author), Washington Univ, Sch Med, Div Crit Care Med, Campus Box 8116,1 Childrens Pl,Suite 5S20, St Louis, MO 63110 USA.	Pineda_J@kids.wustl.edu	akle, veronica/AAD-7577-2019; Pineda, Jose/W-2806-2019	Wang, Kevin/0000-0002-9343-6473; Akle, Veronica/0000-0002-2050-5511; Hannay, H. Julia/0000-0001-7023-912X; Brophy, Gretchen/0000-0002-4749-2693	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052831] Funding Source: Medline		Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; BTF Guidelines, 2000, J NEUROTRAUM, V17, P591; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Choi DW, 2002, NAT NEUROSCI, V5, P1023, DOI 10.1038/nn930; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Guan Wei, 2003, Chin J Traumatol, V6, P218; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hayes NVL, 1997, J NEUROCHEM, V68, P1686; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; JENNETT B, 1975, LANCET, V1, P480; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MEYER S, 1993, ANN EMERG MED, V22, P1052, DOI 10.1016/S0196-0644(05)82750-7; Michetti F, 2002, CLIN CHEM, V48, P2097; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; RIEDERER BM, 1987, J NEUROSCI, V7, P864; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; The Brain TraumaFoundation, 2000, J NEUROTRAUM, V17, P583, DOI [10.1089/neu.2000.17.583, DOI 10.1089/NEU.2000.17.583]; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	70	142	149	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					354	366		10.1089/neu.2006.003789			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900014	17375999				2022-02-06	
J	Stabenfeldt, SE; Garcia, AJ; LaPlaca, MC				Stabenfeldt, Sarah E.; Garcia, Andres J.; LaPlaca, Michelle C.			Thermoreversible laminin-functionalized hydrogel for neural tissue engineering	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A			English	Article						thermally responsive materials; hydrogel; laminin; neural tissue engineering; protein immobilization	TRAUMATIC BRAIN-INJURY; EXTRACELLULAR-MATRIX; PEPTIDES; METHYLCELLULOSE; ADHESION; COLLAGEN; GLYCOL); GELS; RAT; CONJUGATION	Traumatic injury to the central nervous system (CNS) triggers cell death and deafferentation, which may activate a cascade of cellular and network disturbances. These events often result in the formation of irregularly shaped lesions comprised of necrotic tissue and/or a fluid-filled cavity. Tissue engineering represents a promising treatment strategy for the injured neural tissue. To facilitate minimally invasive delivery of a tissue engineered system, a thermoreversible polymer is an attractive scaffold candidate. We have developed a bioactive scaffold for neural tissue engineering by tethering laminin-1 (LN) to methylcellulose (MC), a thermoresponsive hydrogel. The base MC chain was oxidized via sodium m-periodate to increase MC tethering capacity. Protein immobilization was facilitated by a Schiff base reaction between primary amine groups on LN and carbonyl groups of the oxidized MC chain. Immunoassays demonstrated tethering of LN at 1.6 +/- 0.5 ng of LN per milligram of MC. Rheological measurements for different MC-LN constructs indicated MC composition- and MC treatment-dependent effects on solution-gelation transition temperature. Cellular assays with primary rat cortical neurons demonstrated enhanced cell adhesion and viability on LN-functionalized MC when compared with base and oxidized MC. This bioadhesive thermoresponsive scaffold may provide a robust delivery vehicle to injured CNS tissue for neural cell transplantation strategies. (c) 2006 Wiley Periodicals, Inc.	Emory Univ, Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Lab Neuroengn, Atlanta, GA 30332 USA; Georgia Inst Technol, George W Woodruff Sch Mech Engn, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA		LaPlaca, MC (corresponding author), Emory Univ, Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Lab Neuroengn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB-001014] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Bussemer T, 2003, J CONTROL RELEASE, V93, P331, DOI 10.1016/j.jconrel.2003.08.012; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; DAI WG, 1994, BIO-TECHNOL, V12, P797, DOI 10.1038/nbt0894-797; Desbrieres J, 2000, POLYMER, V41, P2451, DOI 10.1016/S0032-3861(99)00413-9; El-Khatib RM, 2002, CARBOHYD POLYM, V47, P377, DOI 10.1016/S0144-8617(01)00192-8; Flynn L, 2003, BIOMATERIALS, V24, P4265, DOI 10.1016/S0142-9612(03)00334-X; Freire E, 2002, J CELL SCI, V115, P4867, DOI 10.1242/jcs.00173; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218; KEENER CR, 1994, BIOTECHNIQUES, V16, P894; Kobayashi K, 1999, MACROMOLECULES, V32, P7070, DOI 10.1021/ma990242n; KUMAR S, 1994, J OCUL PHARMACOL, V10, P47, DOI 10.1089/jop.1994.10.47; Labrador RO, 1998, EXP NEUROL, V149, P243, DOI 10.1006/exnr.1997.6650; Li J, 2003, BIOMACROMOLECULES, V4, P1055, DOI 10.1021/bm034069l; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; Margutti S, 2002, POLYMER, V43, P6183, DOI 10.1016/S0032-3861(02)00533-5; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Na K, 2000, BIOTECHNOL LETT, V22, P1553, DOI 10.1023/A:1005680800420; Nevell T. P, 1963, METHODS CARBOHYDRATE; O'Connor SM, 2001, NEUROSCI LETT, V304, P189, DOI 10.1016/S0304-3940(01)01769-4; Powell SK, 1997, INT J BIOCHEM CELL B, V29, P401, DOI 10.1016/S1357-2725(96)00110-0; Quirk RA, 2001, LANGMUIR, V17, P2817, DOI 10.1021/la001509a; Schense JC, 2000, NAT BIOTECHNOL, V18, P415, DOI 10.1038/74473; Shin H, 2002, J BIOMED MATER RES, V61, P169, DOI 10.1002/jbm.10193; SIESJO BK, 1988, BRAIN INJURY NEUROCH, P513; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Smith E, 2003, J POLYM SCI POL CHEM, V41, P3989, DOI 10.1002/pola.10965; Stile RA, 1999, MACROMOLECULES, V32, P7370, DOI 10.1021/ma990130w; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Taylor SJ, 2004, J CONTROL RELEASE, V98, P281, DOI 10.1016/j.jconrel.2004.05.003; Temenoff JS, 2003, BIOMACROMOLECULES, V4, P1605, DOI 10.1021/bm030056w; *U AL BIRM, 2004, 2004 ANN STAT REP NA; Varma AJ, 2002, POLYM DEGRAD STABIL, V77, P25, DOI 10.1016/S0141-3910(02)00073-3; VARMA AJ, 1995, POLYM DEGRAD STABIL, V49, P245, DOI 10.1016/0141-3910(95)87006-7; Wells MR, 1997, EXP NEUROL, V146, P395, DOI 10.1006/exnr.1997.6543; Woerly S, 1999, TISSUE ENG, V5, P467, DOI 10.1089/ten.1999.5.467; WOLFE CAC, 1995, ANAL BIOCHEM, V231, P123, DOI 10.1006/abio.1995.1511; Yang F, 2004, J BIOMAT SCI-POLYM E, V15, P1483, DOI 10.1163/1568562042459733; Yu XJ, 2003, TISSUE ENG, V9, P421, DOI 10.1089/107632703322066606; Zhbankov R. G., 1966, INFRARED SPECTRA CEL	46	142	148	1	50	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1549-3296	1552-4965		J BIOMED MATER RES A	J. Biomed. Mater. Res. Part A	JUN 15	2006	77A	4					718	725		10.1002/jbm.a.30638			8	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	046DT	WOS:000237792300008	16555267				2022-02-06	
J	Leyssen, M; Ayaz, D; Hebert, SS; Reeve, S; De Strooper, B; Hassan, BA				Leyssen, M; Ayaz, D; Hebert, SS; Reeve, S; De Strooper, B; Hassan, BA			Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain	EMBO JOURNAL			English	Article						Alzheimer's disease; amyloid precursor protein; axonal outgrowth; brain injury; Drosophila	ACTIN-DEPENDENT PROCESSES; ABL TYROSINE KINASE; ALZHEIMERS-DISEASE; AXONAL-TRANSPORT; CELL-SURFACE; C-JUN; GENE; JNK; BINDING; INJURY	The mechanisms regulating the outgrowth of neurites during development, as well as after injury, are key to the understanding of the wiring and functioning of the brain under normal and pathological conditions. The amyloid precursor protein ( APP) is involved in the pathogenesis of Alzheimer's disease ( AD). However, its physiological role in the central nervous system is not known. Many physical interactions between APP and intracellular signalling molecules have been described, but their functional relevance remains unclear. We show here that human APP and Drosophila APP-Like ( APPL) can induce postdevelopmental axonal arborization, which depends critically on a conserved motif in the C-terminus and requires interaction with the Abelson (Abl) tyrosine kinase. Brain injury induces APPL upregulation in Drosophila neurons, correlating with increased posttraumatic mortality in appl(d) mutant flies. Finally, we also found interactions between APP and the JNK stress kinase cascade. Our findings suggest a role for APP in axonal outgrowth after traumatic brain injury.	Univ Louvain VIB, Dept Human Genet VIB4, Neurogenet Lab, B-3000 Louvain, Belgium; Univ Louvain, Sch Med, Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB, Dept Human Genet, Neuronal Cell Biol & Gene Transfer Lab, Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB, Dept Human Genet, Neurogenet Lab, Louvain, Belgium		Hassan, BA (corresponding author), Univ Louvain VIB, Dept Human Genet VIB4, Neurogenet Lab, POB 602,O&N Bldg,Rm 06-547,Herestr 49, B-3000 Louvain, Belgium.	Bassem.Hassan@med.kuleuven.ac.be	Hebert, Sebastien S./Q-2729-2017; De Strooper, Bart/F-6507-2012; Hassan, Bassem A/D-5221-2012; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; Hassan, Bassem A/0000-0001-9533-4908; Hebert, Sebastien/0000-0002-0391-9325			Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BRAND AH, 1993, DEVELOPMENT, V118, P401; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; De Strooper B, 2000, J CELL SCI, V113, P1857; DEKOSKY ST, 1990, ANN NEUROL, V27, P457, DOI 10.1002/ana.410270502; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fogerty FJ, 1999, ONCOGENE, V18, P219, DOI 10.1038/sj.onc.1202239; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; Galko MJ, 2004, PLOS BIOL, V2, P1114, DOI 10.1371/journal.pbio.0020239; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gunawardena S, 2001, NEURON, V32, P389, DOI 10.1016/S0896-6273(01)00496-2; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hassan BA, 2000, NEURON, V25, P549, DOI 10.1016/S0896-6273(00)81059-4; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jasper H, 2001, DEV CELL, V1, P579, DOI 10.1016/S1534-5807(01)00045-4; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; JIN LW, 1994, J NEUROSCI, V14, P5461; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kaneko M, 2000, J COMP NEUROL, V422, P66, DOI 10.1002/(SICI)1096-9861(20000619)422:1<66::AID-CNE5>3.0.CO;2-2; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; LUO LQ, 1990, J NEUROSCI, V10, P3849, DOI 10.1523/JNEUROSCI.10-12-03849.1990; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MartinBlanco E, 1997, CURR OPIN GENET DEV, V7, P666, DOI 10.1016/S0959-437X(97)80015-9; MARTINMORRIS LE, 1990, DEVELOPMENT, V110, P185; Matsuda S, 2001, J NEUROSCI, V21, P6597; Merdes G, 2004, EMBO J, V23, P4082, DOI 10.1038/sj.emboj.7600413; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Reeve SR, 2005, CURR BIOL, V15, P1156, DOI 10.1016/j.cub.2005.05.050; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Torroja L, 1999, J NEUROSCI, V19, P7793; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van Gassen G, 2000, NEUROBIOL DIS, V7, P135, DOI 10.1006/nbdi.2000.0306; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200	49	142	145	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0261-4189	1460-2075		EMBO J	Embo J.	AUG 17	2005	24	16					2944	2955		10.1038/sj.emboj.7600757			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	963FN	WOS:000231789300010	16052209	Green Published			2022-02-06	
J	Panikashvili, D; Mechoulam, R; Beni, SM; Alexandrovich, A; Shohami, E				Panikashvili, D; Mechoulam, R; Beni, SM; Alexandrovich, A; Shohami, E			CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cannabinoid receptors; endocannabinoids; inflammation; neuroprotection; NF-kappa B; traumatic brain injury	CLOSED-HEAD INJURY; ACUTE NEURONAL INJURY; NECROSIS-FACTOR-ALPHA; NUCLEAR-FACTOR; DEXANABINOL HU-211; BRAIN; ENDOCANNABINOIDS; ACTIVATION; PROTEIN; EDEMA	We reported earlier that closed head injury (CHI) in mice causes a sharp elevation of brain 2-arachiclonoylglycerol (2-AG) levels, and that exogenous 2-AG reduces brain edema, infarct volume and hippocampal death and improved clinical recovery after CHI. The beneficial effect of 2-AG was attenuated by SR141716A, a CB1 cannabinoid receptor antagonist, albeit at relatively high doses. In the present study, we further explored the role of CB1 receptors in mediating 2-AG neuroprotection. CB1 receptor knockout mice (CB1(-/-)) showed minor spontaneous recovery at 24h after CHI, in contrast to the significant improvement in neurobehavioral function seen in wild-type (WT) mice. Moreover, administration of 2-AG did not improve neurological performance and edema formation in the CB,(-/-) mice. In addition, 2-AG abolished the three- to four-fold increase of nuclear factor kappa B (NF-kappa B) transactivation, at 24 h after CHI in the WT mice, while it had no effect on NF-kappa B in the CB1 (-/-) mice, which was as high as in the WT vehicle-treated mice. We thus propose that 2-AG exerts its neuroprotection after CHI, at least in part, via CB1 receptor-mediated mechanisms that involve inhibition of intracellular inflammatory signaling pathways.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Med Chem & Nat Prod, Jerusalem, Israel		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [9789] Funding Source: Medline		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Cernak I, 2004, J CEREBR BLOOD F MET, V24, P564, DOI 10.1097/00004647-200405000-00011; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clayton N, 2002, PAIN, V96, P253, DOI 10.1016/S0304-3959(01)00454-7; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Fride E, 2001, EUR J PHARMACOL, V419, P207, DOI 10.1016/S0014-2999(01)00953-0; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Grundy RI, 2001, MOL NEUROBIOL, V24, P29; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HS, 2002, PHARMACOL THERAPEUT, V95, P119, DOI 10.1016/S0163-7258(02)00251-6; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Herring AC, 1999, J PHARMACOL EXP THER, V291, P1156; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, PROSTAG LEUKOTR ESS, V66, P93, DOI 10.1054/plef.2001.0340; MECHOULAM R, 2002, SCI STKE; Nagayama T, 1999, J NEUROSCI, V19, P2987; Ouyang YL, 1998, MOL PHARMACOL, V53, P676, DOI 10.1124/mol.53.4.676; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paria BC, 2001, J BIOL CHEM, V276, P20523, DOI 10.1074/jbc.M100679200; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Shohami E, 2000, DRUG DEVELOP RES, V50, P211, DOI 10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; SOFIA RD, 1974, LIFE SCI, V15, P251; SOFIA RD, 1973, RES COMMUN CHEM PATH, V6, P909; SOFIA RD, 1973, J PHARMACOL EXP THER, V186, P646; Steiner H, 1999, P NATL ACAD SCI USA, V96, P5786, DOI 10.1073/pnas.96.10.5786; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sugiura T, 2000, BIOCHEM BIOPH RES CO, V271, P654, DOI 10.1006/bbrc.2000.2686; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; van der Stelt M, 2001, J NEUROSCI, V21, P6475, DOI 10.1523/JNEUROSCI.21-17-06475.2001; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015	46	142	147	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2005	25	4					477	484		10.1038/sj.jcbfm.9600047			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	915CH	WOS:000228274700008	15729296	Bronze			2022-02-06	
J	Colantonio, A; Ratcliff, G; Chase, S; Kelsey, S; Escobar, M; Vernich, L				Colantonio, A; Ratcliff, G; Chase, S; Kelsey, S; Escobar, M; Vernich, L			Long term outcomes after moderate to severe traumatic brain injury	DISABILITY AND REHABILITATION			English	Article							SELF-RATED HEALTH; HEAD-INJURY; FOLLOW-UP; COMMUNITY; ADULTS	Objective: This research examined the long-term outcomes of rehabilitation patients with moderate to severe traumatic brain injury (TBI). Design: Retrospective cohort study. Setting and subjects: We examined consecutive records of persons with moderate to severe traumatic brain injury who were discharged from a large rehabilitation hospital in Pennsylvania from 1973 to 1989. We interviewed consenting participants (n=306) up to 24 years post-injury. Main outcome measures: Self-rated health, activity limitations, employment, living arrangements, marital status, Community Integration Questionnaire, and use of rehabilitation services. Results: Participants were most limited in activities such as managing money and shopping. Twenty-nine per cent of our participants were working full time. There were significant relationships between activity limitations and residual cognitive impairment at follow-up. Self-rated health was correlated with most instrumental activities of daily living. Conclusion: Our findings document health and function in a large post acute TBI population and implications for rehabilitation are discussed.	Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Working Order, Pittsburgh, PA USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada		Colantonio, A (corresponding author), Univ Toronto, Fac Med, Grad Dept Rehabil Sci, 500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Escobar, Michael/0000-0001-9055-4709; Colantonio, Angela/0000-0003-2094-4765	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33 AGO5856-01A1] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34740-2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33AG005856] Funding Source: NIH RePORTER		Ashley M. J., 1997, J REHABILITATION OUT, V1, P40; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CORKIN S, 1989, J NEUROSCI, V9, P3876; *COUNC CLIN CLASS, 1980, INT CLASS DIS, P11; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; FILLENBAUM G, 1975, MULTIDIMENSIONAL FUN; HEATON RK, COMPREHENSIVE NORMS; Hoofien D, 2001, BRAIN INJURY, V15, P189; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Jylha M, 1998, J GERONTOL B-PSYCHOL, V53, pS144, DOI 10.1093/geronb/53B.3.S144; KIM JA, 1997, OCCUPATIONAL THERAPY, V4, P178; KINGMA J, 1992, ICD AIS COMPUTER PRO; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Reitan R, 1985, HALSTEAD REITAN NEUR; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; VOGENTHALER DR, 1989, BRAIN INJURY, V3, P1369; Ware J.E., 1993, SF 36 HLTH SURVEY MA; *WHO, 1997, ICIDH 2 INT CLASSIFI; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; WILSON B, 1991, RIVERMEAD BEHAV M S2; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; WILSON BA, 1997, J REHABILITATION OUT, V1, P60	31	142	143	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	MAR 4	2004	26	5					253	261		10.1080/09638280310001639722			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	801WV	WOS:000220126900001	15200240				2022-02-06	
J	Ewing-Cobbs, L; Barnes, M; Fletcher, JM; Levin, HS; Swank, PR; Song, J				Ewing-Cobbs, L; Barnes, M; Fletcher, JM; Levin, HS; Swank, PR; Song, J			Modeling of longitudinal academic achievement scores after pediatric traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; WORKING-MEMORY; ARITHMETIC DISABILITY; READING-DISABILITY; BEHAVIOR PROBLEMS; CHILDREN; PERFORMANCE; COHORT; ADOLESCENTS; CHILDHOOD	In a prospective longitudinal study, academic achievement scores were obtained from youth 5 to 15 years of age who sustained mild-moderate (n = 34) or severe (n = 43) traumatic brain injuries (TBI). Achievement scores were collected from baseline to 5 years following TBI and were subjected to individual growth curve analysis. The models fitted age at injury, years since injury, duration of impaired consciousness, and interaction effects to Reading Decoding, Reading Comprehension, Spelling, and Arithmetic standard scores. Although scores improved significantly over the follow-up relative to normative data from the standardization sample of the tests, children with severe TBI showed persistent deficits on all achievement scores in comparison to children with mild-moderate TBI. Interactions of the slope and age parameters for the Arithmetic and Reading Decoding scores indicated greater increases over time in achievement scores of the children injured at an older age, but deceleration in growth curves for the younger children with both mild-moderate and severe TBI. These results are compatible with the hypothesis that early brain injuries disrupt the acquisition of some academic skills. Hierarchical regression models revealed that indexes of academic achievement obtained 2 years following TBI had weak relations with the duration of impaired consciousness and socioeconomic status. In contrast, concurrent cognitive variables such as phonological processing and verbal memory accounted for more variability in academic scores. Given the significant and persistent decrement in basic academic skills in youth with severe TBI, it is clear that head-injured youth require intensive, long-term remediation and intervention not only of the academic skills themselves, but also of those cognitive abilities that support the development and maintenance of reading and math.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA; Bayer Pharmaceut, Dept Biometry, New Haven, CT USA		Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu	fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD027597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS029462, R01NS046308] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD-27597] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-21889, R01 NS-29462, R01 NS046308] Funding Source: Medline		Achenbach TM, 1991, MANUAL CHILD BEHAV C; ACKERMAN PT, 1995, DEV NEUROPSYCHOL, V11, P351, DOI 10.1080/87565649509540625; ADAMS MJ, 1990, BEGINNNG READ; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Beery K. E., 1982, DEV TEST VISUAL MOTO; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BUSCHKE H, 1972, J EXPT CHILD PSYCHOL, V18, P488; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Cohen J., 2013, STAT POWER ANAL BEHA; DENCKLA MB, 1976, NEUROPSYCHOLOGIA, V14, P471, DOI 10.1016/0028-3932(76)90075-0; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Dunn LM., 1981, PEABODY PICTURE VOCA; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, HANDBOOK OF PEDIATRIC PSYCHOLOGY IN SCHOOL SETTINGS, P313; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER JM, 1985, J EXP CHILD PSYCHOL, V40, P244, DOI 10.1016/0022-0965(85)90088-8; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; GEARY DC, 1993, PSYCHOL BULL, V114, P345, DOI 10.1037/0033-2909.114.2.345; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Ginsburg H. P., 1998, HDB CHILD PSYCHOL, V4, P401; Gottardo A, 1996, J EXP CHILD PSYCHOL, V63, P563, DOI 10.1006/jecp.1996.0062; Gough PB, 1996, READING COMPREHENSION DIFFICULTIES, P1; Hannon B, 2001, J EDUC PSYCHOL, V93, P103, DOI 10.1037/0022-0663.93.1.103; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; HINSHAW SP, 1992, PSYCHOL BULL, V111, P127, DOI 10.1037/0033-2909.111.1.127; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jastak S., 1978, WIDE RANGE ACHIEVEME; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Lennox C, 1996, J EXP CHILD PSYCHOL, V62, P60, DOI 10.1006/jecp.1996.0022; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LEVIN HS, 2001, PEDIAT NEUROSURGERY, P654; LEVIN HS, 1985, 2 EUR S DEV NEUR STU; Markwardt F., 1970, PEABODY INDIVIDUAL A; MCLEAN JF, 1992, J EXPT CHILD PSYCHOL, V74, P240; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; Morris RD, 1998, J EDUC PSYCHOL, V90, P347, DOI 10.1037/0022-0663.90.3.347; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVERABATIZ FL, 1992, J HUM RESOUR, V27, P313, DOI 10.2307/145737; ROURKE BP, 1993, J LEARN DISABIL, V26, P214, DOI 10.1177/002221949302600402; Sattler JM, 1992, ASSESSMENT CHILDREN, Vthird; SHARE DL, 1998, J LEARNING DISABILIT, V21, P313; SIEGEL LS, 1989, CHILD DEV, V60, P973, DOI 10.1111/j.1467-8624.1989.tb03528.x; Spreen O., 1988, LEARNING DISABLED CH; Spreen O., 1969, NEUROSENSORY CTR COM; STALLINGS GA, 1995, J INT NEUROPSYCH SOC, V1, P156; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; VANDERVLUGT H, 1985, NEUROPSYCHOLOGY LEAR, P212; WAGNER RK, 1994, DEV PSYCHOL, V30, P73, DOI 10.1037/0012-1649.30.1.73; Wechsler D., 1974, WECHSLER INTELLIGENC; Wolf M, 1999, J EDUC PSYCHOL, V91, P415, DOI 10.1037/0022-0663.91.3.415; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; [No title captured]	70	142	143	3	19	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					107	133		10.1207/s15326942dn2501&2_7			27	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	774CG	WOS:000188961700007	14984331				2022-02-06	
J	Cochran, A; Scaife, ER; Hansen, KW; Downey, EC				Cochran, A; Scaife, ER; Hansen, KW; Downey, EC			Hyperglycemia and outcomes from pediatric traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						children; head injury; hyperglycemia; outcomes	BLOOD-GLUCOSE; PROGNOSTIC SIGN; INSULIN; ADMISSION	Background. The clinical significance of hyperglycemia after pediatric traumatic brain injury is controversial. This study addresses the relationship between hyperglycemia and outcomes after traumatic brain injury in pediatric patients. Method. We identified trauma patients admitted during a single year to our regional pediatric referral center with head regional Abbreviated Injury Scale scores greater than or equal to 3. We studied identified patients for admission characteristics potentially influencing their outcomes. The primary outcome measure was Glasgow Outcome Scale score. Results. Patients who died had significantly higher admission serum glucose values than those patients who survived (267 mg/dL vs. 135 mg/dL; p = 0.000). Admission serum glucose greater than or equal to 300 mg/dL was uniformly associated with death. Admission Glasgow Coma Scale score (odds ratio, 0.560; 95% confidence interval, 0.358-0.877) and serum glucose (odds ratio, 1.013; 95% confidence interval, 1.003-1.023) are independent predictors of mortality in children with traumatic head injuries. Conclusion. Hyperglycemia and poor neurologic outcome in head-injured children are associated. The pathophysiology of hyperglycemia in neurologic injury after head trauma remains unclear.	Primary Childrens Med Ctr, Div Pediat Surg, Salt Lake City, UT 84113 USA; Univ Utah, Dept Surg, Intermt Injury Control Res Ctr, Sch Med, Salt Lake City, UT 84112 USA		Scaife, ER (corresponding author), Primary Childrens Med Ctr, Div Pediat Surg, Salt Lake City, UT 84113 USA.	eric.scaife@hsc.utah.edu					Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; Deloof T, 1979, Acta Neurochir Suppl (Wien), V28, P113; KING LR, 1971, ANN SURG, V173, P337, DOI 10.1097/00000658-197103000-00003; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; PARISH RA, 1988, J TRAUMA, V28, P517, DOI 10.1097/00005373-198804000-00017; Pentelenyi T, 1979, Acta Neurochir Suppl (Wien), V28, P103; PENTELENYI T, 1979, INJURY, V10, P201, DOI 10.1016/0020-1383(79)90009-3; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	14	142	148	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1035	1038		10.1097/01.TA.0000031175.96507.48			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	758TL	WOS:000187666200006	14676647				2022-02-06	
J	Shear, DA; Galani, R; Hoffman, SW; Stein, DG				Shear, DA; Galani, R; Hoffman, SW; Stein, DG			Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						progesterone; traumatic brain injury recovery; sensory neglect; learning; memory	CEREBRAL-ARTERY OCCLUSION; CORTICAL CONTUSION; LIPID-PEROXIDATION; PREFRONTAL CORTEX; FEMALE RATS; HEAD-INJURY; WITHDRAWAL; ATTENTION; PREGNANCY; STEROIDS	A single injection of progesterone can attenuate cerebral edema when administered during the first 24 h after traumatic brain injury (TBI) in rats but this regimen may not always produce functional benefits. In this experiment, we sought to find the duration of progesterone administration needed to facilitate both behavioral and morphological recovery. Male rats received bilateral contusions of the medial prefrontal cortex and were given progesterone (4 mg/kg) or vehicle for 3 or 5 days postoperatively. Both the 3- and the 5-day progesterone regimens reduced the size of injury-induced necrosis and cell loss, with the 5-day schedule being most effective. With regard to behavioral outcome, only 5 days of progesterone injections resulted in improved spatial learning performance and reduced sensory neglect. These results show that 5 days of post-injury progesterone treatment are needed to reduce significantly the neuropathological and behavioral abnormalities found in a rodent model of TBI. These benefits of progesterone, in the absence of any known side effects, provide further support for clinical testing of this neurosteroid. (C) 2002 Elsevier Science (USA).	Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; Emory Univ, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Evans Bldg,1648 Pierce Dr,Room 261B, Atlanta, GA 30322 USA.	dstei04@emory.edu	Shear, Deborah/B-3607-2011; Stein, Donald/AAJ-5139-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS 38664] Funding Source: Medline		Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Baulieu EE, 1997, MULT SCLER J, V3, P105, DOI 10.1177/135245859700300209; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; D'Esposito M, 1999, NEUROPSYCHOLOGIA, V37, P1303, DOI 10.1016/S0028-3932(99)00021-4; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Daffner KR, 2000, J NEUROL NEUROSUR PS, V68, P18, DOI 10.1136/jnnp.68.1.18; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Godefroy O, 1996, BRAIN COGNITION, V30, P155, DOI 10.1006/brcg.1996.0010; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kristiansson P, 2001, HUM REPROD, V16, P13, DOI 10.1093/humrep/16.1.13; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Mayberg MR, 1998, NEUROSURG CLIN N AM, V9, P615; Molinari C, 2001, EXP PHYSIOL, V86, P101, DOI 10.1113/eph8602076; Moran MH, 1998, BRAIN RES, V807, P84, DOI 10.1016/S0006-8993(98)00782-3; Moran MH, 1998, BRAIN RES, V807, P91, DOI 10.1016/S0006-8993(98)00781-1; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Pajovic SB, 1999, GEN PHYSIOL BIOPHYS, V18, P35; Perusquia M, 1996, GEN PHARMACOL, V27, P181, DOI 10.1016/0306-3623(95)00091-7; Reilly MT, 2000, PHARMACOL BIOCHEM BE, V67, P709, DOI 10.1016/S0091-3057(00)00416-0; Robert F, 2001, EUR J NEUROSCI, V13, P916, DOI 10.1046/j.0953-816x.2001.01463.x; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sakamoto H, 2001, J NEUROSCI, V21, P6221, DOI 10.1523/JNEUROSCI.21-16-06221.2001; Schumacher Michael, 1999, Journal de la Societe de Biologie, V193, P285; Seppala M, 2001, TRENDS ENDOCRIN MET, V12, P111, DOI 10.1016/S1043-2760(00)00365-9; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; STITES DP, 1983, IMMUNOL REV, V75, P117, DOI 10.1111/j.1600-065X.1983.tb01093.x; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SZEKERESBARTHO J, 1990, RES IMMUNOL, V141, P175, DOI 10.1016/0923-2494(90)90139-P; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x	48	142	149	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2002	178	1					59	67		10.1006/exnr.2002.8020			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	623BC	WOS:000179682400006	12460608				2022-02-06	
J	Mahmood, A; Lu, DY; Li, Y; Chen, JL; Chopp, M				Mahmood, A; Lu, DY; Li, Y; Chen, JL; Chopp, M			Intracranial bone marrow transplantation after traumatic brain injury improving functional outcome in adult rats	JOURNAL OF NEUROSURGERY			English	Article						bone marrow; traumatic brain injury; transplantation; rat	CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; AXOTOMIZED SEPTAL NEURONS; GROWTH-FACTOR PROMOTES; STROMAL CELLS; STEM-CELLS; HEMATOPOIETIC-CELLS; NEUROTROPHIC FACTOR; MICROGLIAL CELLS; PROGENITOR CELLS	Object. The authors tested the hypothesis that intracranial bone marrow (BM) transplantation after traumatic brain injury (TBI) in rats provides therapeutic benefit. Methods. Sixty-six adult Wistar rats, weighing 275 to 350 g each, were used for the experiment. Bone marrow prelabeled with bromodeoxyuridine (BrdU) was harvested from tibias and femurs of healthy adult rats. Other animals were subjected to controlled cortical impact, and BM was injected adjacent to the contusion 24 hours after the impact. The animals were killed at 4, 7, 14, or 28 days after transplantation. Motor function was evaluated both before and after the injury by using the rotarod test. After the animals had been killed, brain sections were examined using hemotoxylin and eosin and immunohistochemical staining methods. Histological examination revealed that, after transplantation, BM cells survived, proliferated, and migrated toward the injury site. Some of the BrdU-labeled BM cells were reactive, with astrocytic (glial fibrillary acid protein) and neuronal (NeuN and microtubule-associated protein) markers. Transplanted BM expressed proteins phenotypical of intrinsic brain cells, that is, neurons and astrocytes. A statistically significant improvement in motor function in rats that underwent BM transplantation, compared with control rats, was detected at 14 and 28 days posttransplantation. Conclusions. On the basis of their findings, the authors assert that BM transplantation improves neurological outcome and that BM cells survive and express nerve cell proteins after TBI.	Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA		Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu					Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BANKIEWICZ K, 1993, EXP NEUROL, V124, P140, DOI 10.1006/exnr.1993.1185; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; BJORKLUND A, 1991, TRENDS NEUROSCI, V14, P319, DOI 10.1016/0166-2236(91)90154-M; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bjorklund A., 1985, NEURAL GRAFTING MAMM; Borlongan CV, 1996, NEUROL RES, V18, P297; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; C J., 1867, PATH ANAT PHYSL KLIN, V40, P1, DOI DOI 10.1007/BF02968135; CANEVA L, 1995, BLOOD CELL MOL DIS, V21, P73, DOI 10.1006/bcmd.1995.0011; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clark WELG, 1942, J ANAT, V77, P20; DEGROOT CJA, 1992, GLIA, V6, P301, DOI 10.1002/glia.440060408; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUNNETT SB, 1990, NEURAL TRANSPLANTATI; EAVES CJ, 1991, BLOOD, V78, P110; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; Emerich DF, 1996, J NEUROSCI, V16, P5168; FANG JM, 1995, INT J DEV BIOL, V39, P519; FISHER LJ, 1993, PHYSIOL REV, V73, P583, DOI 10.1152/physrev.1993.73.3.583; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GASH DM, 1988, PROGR BRAIN RES, V78; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; Goto S, 1997, EXP NEUROL, V147, P503, DOI 10.1006/exnr.1997.6628; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEFTI F, 1986, J NEUROSCI, V6, P2155; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; KAWAJA MD, 1992, J NEUROSCI, V12, P2849; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Kaya SS, 1999, J NEUROTRAUM, V16, P1187, DOI 10.1089/neu.1999.16.1187; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; KRALL WJ, 1994, BLOOD, V83, P2737; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; KURTH MC, 1996, AM SOC NEUR TRANSPL, V3, P15; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Maysinger D, 1996, EXP NEUROL, V141, P47, DOI 10.1006/exnr.1996.0138; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; POSTMANTUR R, 1997, NEUROSCIENCE, V77, P875; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Ranson SW, 1914, J COMP NEUROL, V24, P547; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; Sharkis SJ, 1998, NAT MED, V4, P896, DOI 10.1038/nm0898-896; Sharkis SJ, 1997, STEM CELLS, V15, P41, DOI 10.1002/stem.5530150807; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; STOKES BT, 1991, EXP NEUROL, V111, P312, DOI 10.1016/0014-4886(91)90098-W; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; THOMPSON WG, 1890, NY MED J, V51, P701; Tidd CW, 1932, J COMP NEUROL, V55, P531, DOI 10.1002/cne.900550213; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; WALKLEY SU, 1994, P NATL ACAD SCI USA, V91, P2970, DOI 10.1073/pnas.91.8.2970	69	142	172	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2001	94	4					589	595		10.3171/jns.2001.94.4.0589			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	417YD	WOS:000167862300007	11302657				2022-02-06	
J	Sullivan, EV; Pfefferbaum, A; Swan, GE; Carmelli, D				Sullivan, EV; Pfefferbaum, A; Swan, GE; Carmelli, D			Heritability of hippocampal size in elderly twin men: Equivalent influence from genes and environment	HIPPOCAMPUS			English	Article						hippocampus; temporal horn; MRI; genetics; environment; aging	MEDIAL TEMPORAL-LOBE; TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; GRAY-MATTER; MEMORY IMPAIRMENT; DENDRITIC EXTENT; VOLUME DEFICITS; NEUROGENESIS; ATROPHY; NEURONS	Recent studies have established that environmental factors can modify hippocampal structure and enhance function in adult rodents, but the extent to which genes and the environment exert differential contributions to hippocampal structural integrity in humans is unknown. Here, we applied the twin model in a large sample of elderly twin men to examine in late life the balance of environmental and genetic effects on the size of the hippocampus in comparison with other brain structures. This study provides novel evidence that the volume of the hippocampus, as measured on MRI, is subject to substantially less genetic control than are comparison brain regions also measured: temporal horn volume, midsagittal area of the corpus callosum, and intracranial volume (ICV). In particular, about 60% of the temporal horn variance and 80% of the callosal and ICV variance was attributable to genetic influences, whereas only 40% of the hippocampal variance was attributable to genetic influences. These results suggest that environment, whether by itself or in interaction with genes, has the potential of exerting greater and possibly longer control in modifying hippocampal size than other brain regions that are under greater genetic control. Considering the potential of environmental modification of this structure suggested by lower heritability, the hippocampus appears well-suited to support the dynamic processes of encoding and consolidation of new, declarataive memories. Hippocampus 2001;11:754-762. (C) 2001 Wiley-Liss, Inc.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; SRI Int, Hlth Sci Ctr, Menlo Pk, CA 94025 USA		Sullivan, EV (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Quarry Rd, Stanford, CA 94305 USA.	edie@stanford.edu	Sullivan, Edith V/ABD-5684-2021	Sullivan, Edith V/0000-0001-6739-3716	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL051429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG017919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA010723, R01AA010723, R37AA005965, R01AA005965] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL51429] Funding Source: Medline; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA10723, AA05965] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG17919] Funding Source: Medline		ALBERT ML, 1984, CLIN NEUROLOGY AGING; Amaral D.G., 1990, HUMAN NERVOUS SYSTEM, P711, DOI [10.1016/B978-0-12-547625-6.50026-X, DOI 10.1016/B978-0-12-547625-6.50026-X]; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIRREN JE, 1985, HDB PSYCHOL AGING; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Cahn DA, 1998, J INT NEUROPSYCH SOC, V4, P106, DOI 10.1017/S1355617798001064; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Carmelli D, 1998, STROKE, V29, P1177, DOI 10.1161/01.STR.29.6.1177; Cohen NJ., 1993, MEMORY AMNESIA HIPPO; COLEMAN PD, 1987, NEUROBIOL AGING, V8, P521, DOI 10.1016/0197-4580(87)90127-8; CORKIN S, 1985, ANN NY ACAD SCI, V444, P10, DOI 10.1111/j.1749-6632.1985.tb37577.x; DECARLI C, 1994, ARCH NEUROL-CHICAGO, V51, P1088, DOI 10.1001/archneur.1994.00540230026006; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fama R, 1997, ARCH NEUROL-CHICAGO, V54, P719, DOI 10.1001/archneur.1997.00550180039010; Fama R, 2001, J INT NEUROPSYCH SOC, V7, P384, DOI 10.1017/S1355617701733127; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; Frisoni GB, 1996, DEMENTIA, V7, P15, DOI 10.1159/000106847; Frisoni GB, 1997, AM J NEURORADIOL, V18, P1192; Gallagher M, 1996, SCIENCE, V274, P484, DOI 10.1126/science.274.5287.484; Giedd JN, 1996, CEREB CORTEX, V6, P551, DOI 10.1093/cercor/6.4.551; GOLOMB J, 1993, ARCH NEUROL-CHICAGO, V50, P967, DOI 10.1001/archneur.1993.00540090066012; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Grove EA, 1999, CEREB CORTEX, V9, P551, DOI 10.1093/cercor/9.6.551; HANKS SD, 1991, BRAIN RES, V540, P63, DOI 10.1016/0006-8993(91)90493-F; Harding AJ, 1998, CEREB CORTEX, V8, P710, DOI 10.1093/cercor/8.8.710; Haydar TF, 1999, CEREB CORTEX, V9, P621, DOI 10.1093/cercor/9.6.621; Jack CR, 1998, NEUROLOGY, V51, P993, DOI 10.1212/WNL.51.4.993; Jack CR, 1997, AM J NEURORADIOL, V18, P25; JACK CR, 1990, RADIOLOGY, V175, P423, DOI 10.1148/radiology.175.2.2183282; JACKSON GD, 1990, NEUROLOGY, V40, P1869, DOI 10.1212/WNL.40.12.1869; Kempermann G, 1999, HIPPOCAMPUS, V9, P321, DOI 10.1002/(SICI)1098-1063(1999)9:3<321::AID-HIPO11>3.0.CO;2-C; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P690; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Laakso MP, 1998, NEUROBIOL AGING, V19, P23, DOI 10.1016/S0197-4580(98)00006-2; Marsh L, 1997, EPILEPSIA, V38, P576, DOI 10.1111/j.1528-1157.1997.tb01143.x; McClearn GE, 1997, SCIENCE, V276, P1560, DOI 10.1126/science.276.5318.1560; MILNER B, 1958, Res Publ Assoc Res Nerv Ment Dis, V36, P244; MOBBS CV, 2001, FUNCTIONAL NEUROBIOL, P13; Neale MC, 1997, MX STAT MODELING; Nunnaly J.C., 1978, PSYCHOMETRIC THEORY; PALMER CGS, 1994, GENET EPIDEMIOL, V11, P443, DOI 10.1002/gepi.1370110506; PFEF, 2001, IN PRESS NEUROREPORT, V12; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; Pfefferbaum A, 1998, ARCH GEN PSYCHIAT, V55, P905, DOI 10.1001/archpsyc.55.10.905; Pfefferbaum A, 2000, NEUROBIOL AGING, V21, P63, DOI 10.1016/S0197-4580(00)00086-5; Pruessner JC, 2001, J NEUROSCI, V21, P194, DOI 10.1523/JNEUROSCI.21-01-00194.2001; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rampon C, 2000, HIPPOCAMPUS, V10, P605, DOI 10.1002/1098-1063(2000)10:5<605::AID-HIPO11>3.0.CO;2-3; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; RAZ N, 1997, SOC NEUR ABSTR, V23, P576; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; SEAB JP, 1988, MAGN RESON MED, V8, P200, DOI 10.1002/mrm.1910080210; Simic G, 1997, J COMP NEUROL, V379, P482, DOI 10.1002/(SICI)1096-9861(19970324)379:4<482::AID-CNE2>3.0.CO;2-Z; Squire LR, 1996, COLD SPRING HARB SYM, V61, P185; SULLIVAN EV, 1995, NEUROBIOL AGING, V16, P591, DOI 10.1016/0197-4580(95)00074-O; SULLIVAN EV, 1995, ALCOHOL CLIN EXP RES, V19, P110, DOI 10.1111/j.1530-0277.1995.tb01478.x; SWAN GE, 1990, ARCH NEUROL-CHICAGO, V47, P259, DOI 10.1001/archneur.1990.00530030025010; Swan GE, 1999, ARCH NEUROL-CHICAGO, V56, P1127, DOI 10.1001/archneur.56.9.1127; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; ZOLAMORGAN S, 1992, NEUROPSYCHOLOGY MEMO, P325	65	142	142	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus		2001	11	6					754	762		10.1002/hipo.1091			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	506TX	WOS:000172988800016	11811670				2022-02-06	
J	Ingebrigtsen, T; Romner, B; Marup-Jensen, S; Dons, M; Lundqvist, C; Bellner, J; Alling, C; Borgesen, SE				Ingebrigtsen, T; Romner, B; Marup-Jensen, S; Dons, M; Lundqvist, C; Bellner, J; Alling, C; Borgesen, SE			The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study	BRAIN INJURY			English	Article							MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; BRAIN INJURY; MILD; MANAGEMENT; TRAUMA; CONCUSSION; SYMPTOMS; CLASSIFICATION; SEQUELAE	Purpose: This study of patients with minor head injury was designed to investigate the relation of S-100 protein measurements to computed tomograpy (CT) findings and patients outcomes. Increased serum levels of this protein were hypothetized to predict intracranial pathology and increased frequency of post-concussion symptoms. Methods: One hundred and eighty-two patients were studied with Glasgow Coma Scale scores of 13-15. The study recruited patients from three Scandinavian neurotrauma centres. Serum levels of S-100 protein were measured at admittance and CT scans of the brain were obtained within 24 hours postinjury in all patients. Outcome was evaluated with the Rivermead Postconcussion Symptoms Questionnaire (RPQ) 3 months after the injury. Results: Increased serum level of S-100 protein was detected in 69 (38%) patients, and CT scan demonstrated intracranial pathology in 10 (5%) (brain contusion in seven, epidural haematoma in two, traumatic subarachnoid haemorrhage in one). The proportion of patients with detectable serum level was significantly ( p < 0.01) higher among those with intracranial pathology (90%) compared to those without (35%). The negative predictive value of an undetectable S-100 level was 0.99. Sixty-two per cent reported one or more post-concussion symptoms at follow-up. A trend was observed towards an increased frequency of post-concussion symptoms among patients with detectable serum levels. Conclusions: Undetectable serum level of S-100 protein predicts normal intracranial findings on CT scan. Determination of S-100 protein in serum may be used to select patients for CT scanning. Increased S-100 serum levels may be more related to post-concussion symptoms caused by mild traumatic brain injury than to symptoms of psychological origin.	Univ Tromso Hosp, Dept Neurosurg, N-9038 Tromso, Norway; Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Neurol, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden; Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark		Ingebrigtsen, T (corresponding author), Univ Tromso Hosp, Dept Neurosurg, N-9038 Tromso, Norway.	nevktoi@rito.no		Ingebrigtsen, Tor/0000-0001-5966-9786; Lundqvist, Christofer/0000-0002-2596-9876			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM C REH MED MILD, 1993, J HEAD TRAUMA REHAB, V8, P83; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; *IT SOC NEUR STUD, 1996, J NEUROSURG SCI, V40, P11; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; JENKINS A, 1986, LANCET, V2, P445; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Nygaard O, 1997, CLIN CHEM, V43, P541; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; Stein SC, 1996, NEUROSURG QUART, V6, P108, DOI 10.1097/00013414-199606000-00004; TEASDALE G, 1974, LANCET, V2, P81; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WIESMANN M, 1997, ACTA NEUROCHIR, V139, P26; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1978, ICD 9 CLASS MENT BEH	39	142	148	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2000	14	12					1047	1055					9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	380YW	WOS:000165736100002	11147577				2022-02-06	
J	Zemlan, FP; Rosenberg, WS; Luebbe, PA; Campbell, TA; Dean, GE; Weiner, NE; Cohen, JA; Rudick, RA; Woo, D				Zemlan, FP; Rosenberg, WS; Luebbe, PA; Campbell, TA; Dean, GE; Weiner, NE; Cohen, JA; Rudick, RA; Woo, D			Quantification of axonal damage in traumatic brain injury: Affinity purification and characterization of cerebrospinal fluid tau proteins	JOURNAL OF NEUROCHEMISTRY			English	Article						tau protein; CSF; traumatic brain injury; neuroprotective agents; CNS tumors; Alzheimer's disease	NEURON-SPECIFIC ENOLASE; MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; HEAD-INJURY; IMMUNOLOGICAL CHARACTERIZATION; NEUROFILAMENT ANTIBODIES; NEUROFIBRILLARY TANGLES; AMINO-ACIDS; PHOSPHORYLATION	Diffuse axonal injury is a primary feature of head trauma and is one of the most frequent causes of mortality and morbidity, Diffuse axonal injury is microscopic in nature and difficult or impossible to detect with imaging techniques. The objective of the present study was to determine whether axonal injury in head trauma patients could be quantified by measuring levels of CSF tau proteins. Tau proteins are structural microtubule binding proteins primarily localized in the axonal compartment of neurons. Monoclonal antibodies recognizing the form of tau found in the CSF of head trauma patients were developed by differential CSF hybridoma screening using CSF from head trauma and control patients. Clones positive for head trauma CSF tau proteins were used to characterize this form of tau and for ELISA development. Using the developed ELISA, CSF tau levels were elevated >1,000-fold in head trauma patients (mean, 1,519 ng/ml of CSF) when compared with patients with multiple sclerosis (mean, 0.014 ng/ml of CSF; p < 0.001), normal pressure hydrocephalus (nondetectable CSF tau), neurologic controls (mean, 0.031 ng/ml of CSF; p < 0.001), or nonneurologic controls (nondetectable CSF tau; p < 0.001), in head trauma, a relationship between clinical improvement and decreased CSF tau levels was observed. These data suggest that CSF tau levels may prove a clinically useful assay for quantifying the axonal injury associated with head trauma and monitoring efficacy of neuroprotective agents. Affinity purification of CSF tau from head trauma patients indicated a uniform cleavage of similar to 18 kDa from all six tau isoforms, reducing their apparent molecular sizes to 30-50 kDa, These cleaved forms of CSF tau consisted of the interior portion of the tau sequence, including the microtubule binding domain, as judged by cyanogen bromide digestion. Consistent with these data, CSF cleaved tau bound taxolpolymerized microtubules, indicating a functionally intact microtubule binding domain. Furthermore, epitope mapping studies suggested that CSF cleaved tau proteins consist of the interior portion of the tau sequence with cleavage at both N and C terminals.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Isolab, Norton, MA USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA		Zemlan, FP (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 12572] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U10NS077311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R41AG012572] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ANDERTON BH, 1982, NATURE, V298, P84, DOI 10.1038/298084a0; ARAI H, 1995, ANN NEUROL, V38, P649, DOI 10.1002/ana.410380414; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; BOORSMA DM, 1975, J HISTOCHEM CYTOCHEM, V23, P200, DOI 10.1177/23.3.47869; CAPUTO CB, 1992, NEUROBIOL AGING, V13, P267, DOI 10.1016/0197-4580(92)90039-Z; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; COUCHIE D, 1985, FEBS LETT, V188, P331, DOI 10.1016/0014-5793(85)80397-5; DAUBERSCHMIDT R, 1983, CLIN CHIM ACTA, V131, P165, DOI 10.1016/0009-8981(83)90085-2; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1994, RADIOLOGY, V191, P1; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Johnson GVW, 1997, J NEUROCHEM, V68, P430; KALCHEVA N, 1994, J NEUROCHEM, V63, P2336; KANAI Y, 1995, NEURON, V14, P421, DOI 10.1016/0896-6273(95)90298-8; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1992, J CELL SCI, V102, P227; Li WP, 1997, J MOL NEUROSCI, V8, P75, DOI 10.1007/BF02736774; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; LIU WK, 1993, J NEUROSCI RES, V34, P371, DOI 10.1002/jnr.490340315; MABE H, 1991, SURG NEUROL, V36, P170, DOI 10.1016/0090-3019(91)90108-L; MARANGOS PJ, 1979, BIOL PSYCHIAT, V14, P563; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nishimoto I, 1997, Adv Pharmacol, V41, P337, DOI 10.1016/S1054-3589(08)61064-9; NUKINA N, 1987, P NATL ACAD SCI USA, V84, P3415, DOI 10.1073/pnas.84.10.3415; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SCARNA H, 1982, NEUROCHEM INT, V4, P405, DOI 10.1016/0197-0186(82)90083-3; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; SHINTAKU M, 1988, NEUROPATH APPL NEURO, V14, P505, DOI 10.1111/j.1365-2990.1988.tb01341.x; SOBEL RA, 1995, NEUROL CLIN, V13, P1; STRICH SJ, 1961, LANCET, V2, P443; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; WOLOZIN B, 1987, ANN NEUROL, V22, P521, DOI 10.1002/ana.410220412; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; Zelman FP, 1996, J NEUROSCI RES, V46, P90, DOI 10.1002/(SICI)1097-4547(19961001)46:1<90::AID-JNR11>3.0.CO;2-G	57	142	146	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	1999	72	2					741	750		10.1046/j.1471-4159.1999.0720741.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	159FR	WOS:000078161800033	9930748	Bronze			2022-02-06	
J	Fleming, JM; Strong, J; Ashton, R				Fleming, JM; Strong, J; Ashton, R			Cluster analysis of self-awareness levels in adults with traumatic brain injury and relationship to outcome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; head injury; motivation; rehabilitation	SICKNESS IMPACT PROFILE; HEAD-INJURY; DEFICITS	The purpose of this study was to investigate the relationship between self-awareness, emotional distress, motivation, and outcome in adults with severe traumatic brain injury. A sample of 55 patients were selected from 120 consecutive patients with severe traumatic brain injury admitted to the rehabilitation unit of a large metropolitan public hospital. Subjects received multidisciplinary inpatient rehabilitation and different types of outpatient rehabilitation and community-based services according to availability and need, Measures used in the cluster analysis were the Patient Competency Rating Scale, Self-Awareness of Deficits Interview, Head Injury Behavior Scale, Change Assessment Questionnaire, the Beck Depression Inventory, and Beck Anxiety Inventory; outcome measures were the Disability Rating Scale, Community Integration Questionnaire, and Sickness Impact Profile. A three-cluster solution was selected, with groups labeled as high self-awareness (n = 23), low self-awareness (n = 23), and good recovery (n = 8). The high self-awareness cluster had significantly higher levels of self-awareness, motivation, and emotional distress than the low self-awareness cluster but did not differ significantly in outcome. Self-awareness after brain injury is associated with greater motivation to change behavior and higher levels of depression and anxiety; however, it was not clear that this heightened motivation actually led to any improvement in outcome. Rehabilitation timing and approach may need to be tailored to match the individual's level of self-awareness, motivation, and emotional distress.	Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; Univ Queensland, Dept Occupat Therapy, Brisbane, Qld, Australia; Univ Queensland, Dept Psychol, Brisbane, Qld, Australia		Fleming, JM (corresponding author), 24 Kinkade Ave, Ashgrove, Qld 4060, Australia.		Fleming, Jennifer M/B-4436-2011; Strong, Jenny/F-1211-2010	Strong, Jenny/0000-0002-9367-8755			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BARRY P, 1989, ARCH PHYS MED REHAB, V70, P902; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; CICERONE KD, 1989, REHABIL PSYCHOL, V34, P105, DOI 10.1037//0090-5550.34.2.105; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; FLEMING J, 1997, BRIT J OCCUPATIONAL, V60, P295, DOI DOI 10.1177/030802269706000703; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; FLEMING JM, IN PRESS OCCUP THER; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HAIR JF, 1992, MULTIVARIATE DATA AN; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Langer KG., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [DOI 10.1080/09602019208401395, 10.1080/09602019208401395]; LEVINE J, 1975, J CONSULT CLIN PSYCH, V43, P751; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Marme M., 1993, J APPL REHABILITATIO, V24, P19; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1988, BRAIN INJURY RECOVER; PRIGATANO GP, 1992, NEUROPSYCHOLOGICAL R; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENSTIEL AK, 1981, J HUM STRESS, V7, P35, DOI 10.1080/0097840X.1981.9934542; Schacter D.L., 1990, NEUROPSYCHOLOGY EVER; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; Stuss D., 1991, AWARENESS DEFICIT BR, P63; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	35	142	144	0	18	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					39	51		10.1097/00001199-199810000-00006			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600006	9753534				2022-02-06	
J	Burns, SP; Golding, DG; Rolle, WA; Graziani, V; Ditunno, JF				Burns, SP; Golding, DG; Rolle, WA; Graziani, V; Ditunno, JF			Recovery of ambulation in motor-incomplete tetraplegia	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the American-Spinal-Injury-Association	APR   26, 1994	PHILADELPHIA, PA	Amer Spinal Injury Assoc			SPINAL-CORD INJURY; TRAUMATIC QUADRIPLEGIA; BRAIN INJURY; AGE; PROGNOSIS; OLDER; CORTEX; ADULT; RATS	Objective: To determine the effect of age and initial neurologic status on recovery of ambulation in patients with motor-incomplete tetraplegia. Study Design: Inception cohort study. Setting: Urban, tertiary care hospital with Regional Spinal Cord Injury Center. Patients: One hundred five patients with American Spinal Injury Association (ASIA) C or D tetraplegia at admission or within 72 hours of injury. Main Outcome Measure: Ambulatory status at time of discharge from inpatient rehabilitation. Results: Ninety-one percent (30/33) of ASIA C patients younger than 50 years of age became ambulatory by discharge, versus 42% (13/31) ASIA C patients age 50 or older (p < .0001), All (41/41) patients initially classified as ASIA D became ambulatory by discharge. Conclusion: For patients with ASIA D tetraplegia, prognosis for recovery of independent ambulation is excellent. For patients with ASIA C tetraplegia, recovery of ambulation is significantly less likely if age is 50 years or older. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	THOMAS JEFFERSON UNIV HOSP,DEPT REHABIL MED,PHILADELPHIA,PA 19107; UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195		Burns, SP (corresponding author), VET ADM PUGET SOUND HLTH CARE SYST,SPINAL CORD INJURY UNIT,SEATTLE DIV,SEATTLE,WA 98108, USA.						American Spinal Injury Association, 1992, STAND NEUR FUNCT CLA; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BOSCH A, 1971, J AMER MED ASSOC, V216, P473; CROZIER KS, 1991, ARCH PHYS MED REHAB, V72, P119; DAVERAT P, 1988, PARAPLEGIA, V26, P255, DOI 10.1038/sc.1988.39; DEVIVO MJ, 1990, ARCH NEUROL-CHICAGO, V47, P687, DOI 10.1001/archneur.1990.00530060101026; DITUNNO JF, 1994, NEW ENGL J MED, V330, P550, DOI 10.1056/NEJM199402243300808; Ditunno JF, 1995, SPINAL CORD INJURY C, P70; Elkington J S, 1944, Proc R Soc Med, V37, P547; FOO D, 1986, PARAPLEGIA, V24, P301, DOI 10.1038/sc.1986.42; Go Bette K., 1995, P21; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HUSSEY RW, 1973, ARCH PHYS MED REHAB, V54, P544; JELLINGE.K, 1967, J NEUROL NEUROSUR PS, V30, P195, DOI 10.1136/jnnp.30.3.195; KOEHLER PJ, 1986, ARCH NEUROL-CHICAGO, V43, P921, DOI 10.1001/archneur.1986.00520090051015; MAYNARD FM, 1979, J NEUROSURG, V50, P611, DOI 10.3171/jns.1979.50.5.0611; MERRIAM WF, 1986, J BONE JOINT SURG BR, V68, P708, DOI 10.1302/0301-620X.68B5.3782229; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENROD LE, 1990, ARCH PHYS MED REHAB, V71, P963; ROTH EJ, 1990, ARCH PHYS MED REHAB, V71, P18; ROTH EJ, 1992, PARAPLEGIA, V30, P520, DOI 10.1038/sc.1992.109; SCHEFF SW, 1980, BRAIN RES, V199, P21, DOI 10.1016/0006-8993(80)90227-9; SCHEIBEL ME, 1975, EXP NEUROL, V47, P392, DOI 10.1016/0014-4886(75)90072-2; SCHNEIDER RC, 1954, J NEUROSURG, V11, P546, DOI 10.3171/jns.1954.11.6.0546; SPIVAK JM, 1994, SPINE, V19, P2302, DOI 10.1097/00007632-199410150-00009; TAYLOR RG, 1957, J BONE JOINT SURG BR, V39, P438, DOI 10.1302/0301-620X.39B3.438; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	27	142	147	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1997	78	11					1169	1172		10.1016/S0003-9993(97)90326-9			4	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	YE945	WOS:A1997YE94500001	9365343				2022-02-06	
J	Kane, NM; Curry, SH; Rowlands, CA; Manara, AR; Lewis, T; Moss, T; Cummins, BH; Butler, SR				Kane, NM; Curry, SH; Rowlands, CA; Manara, AR; Lewis, T; Moss, T; Cummins, BH; Butler, SR			Event related potentials - Neurophysiological tools for predicting emergence and early outcome from traumatic coma	INTENSIVE CARE MEDICINE			English	Article						head injury; coma; prognosis; evoked and event-related potentials	SEVERE HEAD-INJURY; MULTIMODALITY EVOKED-POTENTIALS; CLINICAL EXAMINATION; BRAIN-FUNCTION; PROGNOSIS; P300; RECOVERY; CLASSIFICATION; CONDUCTION	Objective. To determine the prognostic value of multimodal evoked potentials (EPs) and event-relatcd (ERPs) potentials in coma (Glasgow Coma Score < 8), after severe traumatic brain injury (TBI). Design: Prospective, longitudinal stud:a of neurophysiological responses recorded during traumatic coma. Setting: Intensive Care Unit, Frenchay Hospital, Bristol, UK. Participants: Fifty-four comatose TBI patients (age range 1-80 years, mean 36.4). Methods. Neurophysiological responses were recorded from 11 scalp, electrodes with earlobe reference Conduction times were measured for brainstem auditory, Hash visual and somatosensory, short-latency EPs. Peak latencies and amplitudes were determined for long-latency components of visual and auditory ERPs, generated by passive ''oddball'' paradigms. These neurophysiological and various clinical parameters were correlated with patient outcome using Pearson's coefficient. Main outcome measure. Three month Glasgow Outcome Scale (GOS). Results and conclusion. Highly significant (P < 0.001) correlations exist between long-latency ERP components and 3-month outcome. Short-latency EPs, brainstem (wave I-V) and somatosensory conduction times, also correlate significantly with the GOS (P < 0.01). Of the clinical measurements, pupillary response patterns, APACHE II and Glasgow Coma Scores (GCS) correlate significantly with outcome, as do the retrospective measures of duration of coma and post-traumatic amnesia (PTA) in survivors. Unfortunately, due to variance of long-latency responses, even in controls, absolute values cannot be relied upon as prognosticators. The presence of ''mismatch negativity'' predicted the return of consciousness (89.7% sensitivity and 100% specificity) and preceded changes in GCS. Its latency was the single best indicator of 90-day outcome from coma (r = -0.641).	FRENCHAY HOSP,BRISTOL BS16 1LE,AVON,ENGLAND		Kane, NM (corresponding author), BURDEN NEUROL INST,STOKE LANE,BRISTOL BS16 1QT,AVON,ENGLAND.		Manara, Alex/ABD-9870-2020				ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; [Anonymous], 1988, Crit Care Med, V16, P807; BARNES MP, 1991, CURR OPIN NEUROL NEU, V4, P12; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1976, CLIN ELECTROENCEPHAL, V7, P184, DOI 10.1177/155005947600700402; CELESIA GG, 1992, CURR OPIN NEUROL NEU, V5, P733; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Curry S H, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P469; DIMITRIJEVIC M R, 1989, Journal of Neurotrauma, V6, P25, DOI 10.1089/neu.1989.6.25; GESCHWIND N, 1982, ANN NY ACAD SCI, V388, P683; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1982, ANN NY ACAD SCI, V388, P683, DOI 10.1111/j.1749-6632.1982.tb50835.x; HUME AL, 1979, ANN NEUROL, V5, P379, DOI 10.1002/ana.410050412; Jennett B, 1972, Clin Neurosurg, V19, P200; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEVIN HS, 1986, NEUROTRAUMA TREATMEN, P89; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Naatanen R, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P169; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OKEN BS, 1992, NEUROLOGY, V42, P519, DOI 10.1212/WNL.42.3.519; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; OMAHONY D, 1990, LANCET, V336, P1265, DOI 10.1016/0140-6736(90)92887-N; OVERGAARD J, 1973, LANCET, V2, P631; Petsche, 1978, ARCHITECTONICS CEREB, P443; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; POLICH J, 1989, ELECTROEN CLIN NEURO, V74, P312, DOI 10.1016/0168-5597(89)90061-0; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; Reuter B., 1989, TOPOGRAPHIC BRAIN MA, P192; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O	40	142	149	0	14	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0342-4642			INTENS CARE MED	Intensive Care Med.	JAN	1996	22	1					39	46		10.1007/BF01728329			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR900	WOS:A1996TR90000007	8857436				2022-02-06	
J	Meier, TB; Bellgowan, PSF; Singh, R; Kuplicki, R; Polanski, DW; Mayer, AR				Meier, Timothy B.; Bellgowan, Patrick S. F.; Singh, Rashmi; Kuplicki, Rayus; Polanski, David W.; Mayer, Andrew R.			Recovery of Cerebral Blood Flow Following Sports-Related Concussion	JAMA NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; TEMPORAL WINDOW; HEAD-INJURY; HIGH-SCHOOL; PERFUSION; VULNERABILITY; DEPRESSION; IMPAIRMENT; IMPACT	IMPORTANCE Animal models suggest that reduced cerebral blood flow (CBF) is one of the most enduring physiological deficits following concussion. Despite this, longitudinal studies documenting serial changes in regional CBF following human concussion have yet to be performed. OBJECTIVE To longitudinally assess the recovery of CBF in a carefully selected sample of collegiate athletes and compare time course of CBF recovery with that of cognitive and behavioral symptoms. DESIGN, SETTING, AND PARTICIPANTS A cohort of collegiate football athletes (N = 44) participated in this mixed longitudinal and cross-sectional study at a private research institute specializing in neuroimaging between March 2012 and December 2013. Serial imaging occurred approximately 1 day, 1 week, and 1 month postconcussion for a subset of participants (n = 17). All athletes reported no premorbid mood disorders, anxiety disorders, substance abuse, or alcohol abuse. MAIN OUTCOMES AND MEASURES Arterial spin labelingmagnetic resonance imaging was used to collect voxelwise relative CBF at each visit. Neuropsychiatric evaluations and a brief cognitive screen were also performed at all 3 points. Clinicians trained in sports medicine provided an independent measure of real-world concussion outcome (ie, number of days withheld from competition). RESULTS The results indicated both cognitive (simple reaction time) and neuropsychiatric symptoms at 1 day postinjury that resolved at either 1 week (cognitive; P < .005) or 1 month (neuropsychiatric; P < .005) postinjury. Imaging data suggested both cross-sectional (ie, healthy vs concussed athletes; P < .05) and longitudinal (1 day and 1 week vs 1 month postinjury; P < .001) evidence of CBF recovery in the right insular and superior temporal cortex. Importantly, CBF in the dorsal midinsular cortex was both decreased at 1 month postconcussion in slower-to-recover athletes (t(11) = 3.45; P = .005) and was inversely related to the magnitude of initial psychiatric symptoms (Hamilton Depression Scale: r = -0.64, P = .02; Hamilton Anxiety Scale: r = -0.56, P = .046), suggesting a potential prognostic indication for CBF as a biomarker. CONCLUSIONS AND RELEVANCE To our knowledge, these results provide the first prospective evidence of reduced CBF in human concussion and subsequent recovery. The resolution of CBF abnormalities closely mirrors previous reports from the animal literature and show real-world validity for predicting outcome following concussion.	[Meier, Timothy B.; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87106 USA; [Meier, Timothy B.; Bellgowan, Patrick S. F.; Singh, Rashmi; Kuplicki, Rayus] Laureate Inst Brain Res, Tulsa, OK USA; [Bellgowan, Patrick S. F.] Univ Tulsa, Fac Community Med, Tulsa, OK 74104 USA; [Polanski, David W.] Univ Tulsa, Dept Athlet, Tulsa, OK 74104 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Meier, TB (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	tmeier@mm.org		Bellgowan, Patrick/0000-0002-6753-8302	Laureate Institute for Brain Research; William K. Warren Foundation	This research was conducted using internal funds from the Laureate Institute for Brain Research, which is supported by The William K. Warren Foundation.	Agarwal SK, 2012, INT J GEN MED, V5, P541, DOI 10.2147/IJGM.S30113; Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Audenaert Kurt, 2003, Med Sci Monit, V9, pMT112; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Cauda F, 2011, NEUROIMAGE, V55, P8, DOI 10.1016/j.neuroimage.2010.11.049; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chen G, 2013, NEUROIMAGE, V73, P176, DOI 10.1016/j.neuroimage.2013.01.047; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kim SG, 2012, J CEREBR BLOOD F MET, V32, P1188, DOI 10.1038/jcbfm.2012.23; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kurth F, 2010, BRAIN STRUCT FUNCT, V214, P519, DOI 10.1007/s00429-010-0255-z; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McGoron Anthony J, 2008, BMC Med Imaging, V8, P4, DOI 10.1186/1471-2342-8-4; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; VAGNOZZI R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Zhu SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065884	53	141	141	1	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	MAY	2015	72	5					530	538		10.1001/jamaneurol.2014.4778			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CH9MY	WOS:000354361000010	25730545	Bronze			2022-02-06	
J	Aungst, SL; Kabadi, SV; Thompson, SM; Stoica, BA; Faden, AI				Aungst, Stephanie L.; Kabadi, Shruti V.; Thompson, Scott M.; Stoica, Bogdan A.; Faden, Alan I.			Repeated mild traumatic brain injury causes chronic neuroinflammation, changes in hippocampal synaptic plasticity, and associated cognitive deficits	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cognitive impairment; electrophysiology; glial cells; hippocampus; inflammation	CLOSED-HEAD-INJURY; LONG-TERM POTENTIATION; LIMITS MICROGLIAL ACTIVATION; MORRIS WATER MAZE; RECOGNITION MEMORY; REPEATED CONCUSSION; MOUSE MODEL; RATS; MECHANISMS; INHIBITION	Repeated mild traumatic brain injury (mTBI) can cause sustained cognitive and psychiatric changes, as well as neurodegeneration, but the underlying mechanisms remain unclear. We examined histologic, neurophysiological, and cognitive changes after single or repeated (three injuries) mTBI using the rat lateral fluid percussion (LFP) model. Repeated mTBI caused substantial neuronal cell loss and significantly increased numbers of activated microglia in both ipsilateral and contralateral hippocampus on post-injury day (PID) 28. Long-term potentiation (LTP) could not be induced on PID 28 after repeated mTBI in ex vivo hippocampal slices from either hemisphere. N-Methyl-D-aspartate (NMDA) receptor-mediated responses were significantly attenuated after repeated mTBI, with no significant changes in alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated responses. Long-term potentiation was elicited in slices after single mTBI, with potentiation significantly increased in ipsilateral versus contralateral hippocampus. After repeated mTBI, rats displayed cognitive impairments in the Morris water maze (MWM) and novel object recognition (NOR) tests. Thus, repeated mTBI causes deficits in the hippocampal function and changes in excitatory synaptic neurotransmission, which are associated with chronic neuroinflammation and neurodegeneration.	[Aungst, Stephanie L.; Kabadi, Shruti V.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Heath Sci Facil HSF2 2, Dept Anesthesiol,STAR Ctr, Baltimore, MD 21201 USA; [Thompson, Scott M.] Univ Maryland, Sch Med, Heath Sci Facil HSF2 2, Dept Physiol, Baltimore, MD 21201 USA		Faden, AI (corresponding author), Univ Maryland, Sch Med, Heath Sci Facil HSF2 2, Dept Anesthesiol,STAR Ctr, 20 Penn St,2nd Floor,Room S247, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013; Thompson, Scott M/K-8921-2015	STOICA, BOGDAN/0000-0002-2501-6434; Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052568]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH086828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health, R01 NS052568.	Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Clark RE, 2000, J NEUROSCI, V20, P8853; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kallarackal AJ, 2013, J NEUROSCI, V33, P15669, DOI 10.1523/JNEUROSCI.2588-13.2013; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; Langston RF, 2010, HIPPOCAMPUS, V20, P1139, DOI 10.1002/hipo.20714; Luo T, 2013, ANESTHESIOLOGY, V119, P1370, DOI 10.1097/ALN.0000000000000020; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sloviter R S, 1991, Hippocampus, V1, P31, DOI 10.1002/hipo.450010105; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	40	141	144	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2014	34	7					1223	1232		10.1038/jcbfm.2014.75			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AK7JT	WOS:000338605300019	24756076	Green Published, Bronze			2022-02-06	
J	Cantinieaux, D; Quertainmont, R; Blacher, S; Rossi, L; Wanet, T; Noel, A; Brook, G; Schoenen, J; Franzen, R				Cantinieaux, Dorothee; Quertainmont, Renaud; Blacher, Silvia; Rossi, Loic; Wanet, Thomas; Noel, Agnes; Brook, Gary; Schoenen, Jean; Franzen, Rachelle			Conditioned Medium from Bone Marrow-Derived Mesenchymal Stem Cells Improves Recovery after Spinal Cord Injury in Rats: An Original Strategy to Avoid Cell Transplantation	PLOS ONE			English	Article							OSTEOPONTIN INDUCES ANGIOGENESIS; TRAUMATIC BRAIN-INJURY; STROMAL CELLS; FUNCTIONAL RECOVERY; ADULT RATS; NEUROTROPHIC FACTOR; GROWTH-FACTOR; MICROGLIAL PHAGOCYTOSIS; LOCOMOTOR RECOVERY; CEREBRAL-ISCHEMIA	Spinal cord injury triggers irreversible loss of motor and sensory functions. Numerous strategies aiming at repairing the injured spinal cord have been studied. Among them, the use of bone marrow-derived mesenchymal stem cells (BMSCs) is promising. Indeed, these cells possess interesting properties to modulate CNS environment and allow axon regeneration and functional recovery. Unfortunately, BMSC survival and differentiation within the host spinal cord remain poor, and these cells have been found to have various adverse effects when grafted in other pathological contexts. Moreover, paracrine-mediated actions have been proposed to explain the beneficial effects of BMSC transplantation after spinal cord injury. We thus decided to deliver BMSC-released factors to spinal cord injured rats and to study, in parallel, their properties in vitro. We show that, in vitro, BMSC-conditioned medium (BMSC-CM) protects neurons from apoptosis, activates macrophages and is pro-angiogenic. In vivo, BMSC-CM administered after spinal cord contusion improves motor recovery. Histological analysis confirms the pro-angiogenic action of BMSC-CM, as well as a tissue protection effect. Finally, the characterization of BMSC-CM by cytokine array and ELISA identified trophic factors as well as cytokines likely involved in the beneficial observed effects. In conclusion, our results support the paracrine-mediated mode of action of BMSCs and raise the possibility to develop a cell-free therapeutic approach.	[Cantinieaux, Dorothee; Quertainmont, Renaud; Rossi, Loic; Wanet, Thomas; Schoenen, Jean; Franzen, Rachelle] Univ Liege, Axonal Regenerat & Cephal Pain Unit, GIGA Neurosci, Liege, Belgium; [Blacher, Silvia; Noel, Agnes] Univ Liege, Lab Biol Tumour & Dev, GIGA Canc, Liege, Belgium; [Brook, Gary] Univ Aachen, Dept Neuropathol, Aachen, Germany		Franzen, R (corresponding author), Univ Liege, Axonal Regenerat & Cephal Pain Unit, GIGA Neurosci, Liege, Belgium.	rfranzen@ulg.ac.be		Noel, Agnes/0000-0002-7670-6179	Fonds leon Fredericq; FWOR; IRME; University of Liege/Fonds speciauxUniversity of Liege	This work was supported by: 1) Fonds leon Fredericq (http://www.fondsleonfredericq.be/); 2) FWOR (http://home.scarlet.be/mtcbrowsers/fwor.htm); 3) IRME (http://www.irme.org/fre/); 4) University of Liege/Fonds speciaux (http://ulg.ac.be). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Assina R, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E3; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Boido M., 2012, WORLD NEUROSURG; Breitbach M, 2007, BLOOD, V110, P1362, DOI 10.1182/blood-2006-12-063412; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Choi JS, 2012, KOREAN J PHYSIOL PHA, V16, P405, DOI 10.4196/kjpp.2012.16.6.405; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cirillo G, 2011, NEUROBIOL DIS, V41, P630, DOI 10.1016/j.nbd.2010.11.012; Cizkova D, 2006, CELL MOL NEUROBIOL, V26, P1167, DOI 10.1007/s10571-006-9093-1; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189; Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064-007-9368-z; Dasari VR, 2007, J NEUROTRAUM, V24, P391, DOI 10.1089/neu.2006.0142; Dray C, 2009, P NATL ACAD SCI USA, V106, P9459, DOI 10.1073/pnas.0900222106; Fan CL, 2013, INT J BIOL SCI, V9, P78, DOI 10.7150/ijbs.5626; Figueiredo C, 2008, J NEUROCHEM, V107, P73, DOI 10.1111/j.1471-4159.2008.05577.x; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.3.CO;2-6; Fujiki M, 2004, J NEUROTRAUM, V21, P459, DOI 10.1089/089771504323004601; Fuller AD, 2008, J NEUROIMMUNE PHARM, V3, P246, DOI 10.1007/s11481-008-9118-2; Gabay C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1917; Geisbusch S, 2012, J THORAC CARDIOV SUR, V144, P1471, DOI 10.1016/j.jtcvs.2012.08.062; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4; Hans G, 2005, NEUROPHARMACOLOGY, V48, P105, DOI 10.1016/j.neuropharm.2004.09.001; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hobson MI, 2000, J ANAT, V197, P591, DOI 10.1046/j.1469-7580.2000.19740591.x; Hoch AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035579; Ide C, 2010, BRAIN RES, V1332, P32, DOI 10.1016/j.brainres.2010.03.043; Jain A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016135; Jeong JO, 2011, CIRC RES, V108, P1340, DOI 10.1161/CIRCRESAHA.110.239848; Kang ES, 2012, J KOREAN MED SCI, V27, P586, DOI 10.3346/jkms.2012.27.6.586; Karaoz E, 2012, TURK NEUROSURG, V22, P207, DOI 10.5137/1019-5149.JTN.5412-11.1; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Keimpema E, 2009, NEUROPATH APPL NEURO, V35, P89, DOI 10.1111/j.1365-2990.2008.00961.x; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kunter U, 2007, J AM SOC NEPHROL, V18, P1754, DOI 10.1681/ASN.2007010044; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lederle W, 2010, CARCINOGENESIS, V31, P1175, DOI 10.1093/carcin/bgp248; Li WM, 2004, CHINESE MED J-PEKING, V117, P621; Li X, 2012, FASEB J; Li XZ, 2009, NEUROSCI RES, V65, P252, DOI 10.1016/j.neures.2009.07.007; Liu J, 2013, J NEUROL SCI; Liu Z, 2011, NEUROTOX RES, V19, P484, DOI 10.1007/s12640-010-9215-x; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Nakano N, 2010, NEUROSCI LETT, V483, P57, DOI 10.1016/j.neulet.2010.07.062; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Nishio T, 2009, J NEUROL, V256, pS306, DOI 10.1007/s00415-009-5244-x; Oatway MA, 2005, J NEUROSCI, V25, P637, DOI 10.1523/JNEUROSCI.3960-04.2005; Osaka M, 2010, BRAIN RES, V1343, P226, DOI 10.1016/j.brainres.2010.05.011; Oudega M, 2006, J NEUROTRAUM, V23, P453, DOI 10.1089/neu.2006.23.453; Parish CL, 2002, J NEUROSCI, V22, P8034; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Park SI, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/362473; Paul C, 2009, SPINE, V34, P328, DOI 10.1097/BRS.0b013e31819403ce; Pedroza M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022667; Perrin FE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015914; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Quertainmont R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039500; Rooney GE, 2009, TISSUE ENG PT A, V15, P3049, DOI [10.1089/ten.tea.2009.0045, 10.1089/ten.TEA.2009.0045]; Samdani AF, 2009, SPINE, V34, P2605, DOI 10.1097/BRS.0b013e3181bdca87; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Simon CM, 2009, J NEUROTRAUM, V26, P563, DOI 10.1089/neu.2008.0523; Song Y, 2012, NEUROCHEM RES; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Sundberg LM, 2011, J NEUROTRAUM, V28, P565, DOI 10.1089/neu.2010.1533; Tejima E, 2009, J NEUROTRAUM, V26, P1935, DOI [10.1089/neu.2009-0959, 10.1089/neu.2009.0959]; Tewarie RDSN, 2009, J NEUROTRAUM, V26, P2313, DOI 10.1089/neu.2009.0987; Tharion G, 2011, NEUROL INDIA, V59, P77, DOI 10.4103/0028-3886.84339; Timmers L, 2011, STEM CELL RES, V6, P206, DOI 10.1016/j.scr.2011.01.001; Timmers L, 2008, STEM CELL RES, V1, P129, DOI 10.1016/j.scr.2008.02.002; Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006; Uccelli A, 2011, BEST PRACT RES CL HA, V24, P59, DOI 10.1016/j.beha.2011.01.004; Uchida K, 2012, SPINE, V37, P2125, DOI 10.1097/BRS.0b013e3182600ef7; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; WAGNER FC, 1977, PARAPLEGIA, V14, P245, DOI 10.1038/sc.1976.41; Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213; Wang YF, 2007, EUR J NEUROSCI, V26, P3159, DOI 10.1111/j.1460-9568.2007.05938.x; Wang YY, 2011, EUR J CELL BIOL, V90, P642, DOI 10.1016/j.ejcb.2011.03.005; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Weldon DT, 1998, J NEUROSCI, V18, P2161; Wislet-Gendebien S, 2003, J CELL SCI, V116, P3295, DOI 10.1242/jcs.00639; Wong RSY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/459510; WOZNIEWICZ B, 1983, PARAPLEGIA, V21, P312, DOI 10.1038/sc.1983.52; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Yang P, 2012, EXP NEUROL, V236, P19, DOI 10.1016/j.expneurol.2012.03.019; You SW, 2003, RESTOR NEUROL NEUROS, V21, P39; Zeng X, 2011, CELL TRANSPLANT, V20, P1881, DOI 10.3727/096368911X566181	102	141	144	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2013	8	8							e69515	10.1371/journal.pone.0069515			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210FR	WOS:000323815200002	24013448	Green Published, gold, Green Submitted			2022-02-06	
J	Adelson, PD; Wisniewski, SR; Beca, J; Brown, SD; Bell, M; Muizelaar, JP; Okada, P; Beers, SR; Balasubramani, GK; Hirtz, D				Adelson, P. David; Wisniewski, Stephen R.; Beca, John; Brown, S. Danielle; Bell, Michael; Muizelaar, J. Paul; Okada, Pamela; Beers, Sue R.; Balasubramani, Goundappa K.; Hirtz, Deborah		Paediat Traumatic Brain Injury Con	Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial	LANCET NEUROLOGY			English	Article							MODERATE HYPOTHERMIA; CEREBRAL HYPOTHERMIA; IMMATURE; VALIDITY; THERAPY; SCALE; RATS	Background On the basis of mixed results from previous trials, we assessed whether therapeutic hypothermia for 48-72 h with slow rewarming improved mortality in children after brain injury. Methods In this phase 3, multicenter, multinational, randomised controlled trial, we included patients with severe traumatic brain injury who were younger than 18 years and could be enrolled within 6 h of injury. We used a computer-generated randomisation sequence to randomly allocate patients (1:1; stratified by site and age [<6 years, 6-15 years, 16-17 years]) to either hypothermia (rapidly cooled to 32-33 degrees C for 48-72 h, then rewarmed by 0-5-1-0 degrees C every 12-24 h) or normothermia (maintained at 36-5-37-5 degrees C). The primary outcome was mortality at 3 months, assessed by intention-to-treat analysis; secondary outcomes were global function at 3 months after injury using the Glasgow outcome scale (GOS) and the GO S-extended pediatrics, and the occurrence of serious adverse events. Investigators assessing outcomes were masked to treatment. This trial is registered with ClinicalTrials.gov, number NCT00222742. Findings The study was terminated early for futility after an interim data analysis on data for 77 patients (enrolled between Nov 1,2007, and Feb 28,2011): 39 in the hypothermia group and 38 in the normothermia group. We detected no between-group difference in mortality 3 months after injury (6 [15%] of 39 patients in the hypothermia group vs two [5%] of 38 patients in the normothermia group; p=0-15). Poor outcomes did not differ between groups (in the hypothermia group, 16 [42%] patients had a poor outcome by GOS and 18 [47%] had a poor outcome by GOS-extended paediatrics; in the normothermia group, 16 [42%] patients had a poor outcome by GOS and 19 [51%] of 37 patients had a poor outcome by GOS-extended paediatrics). We recorded no between-group differences in the occurrence of adverse events or serious adverse events. Interpretation Hypothermia for 48 h with slow rewarming does not reduce mortality of improve global functional outcome after paediatric severe traumatic brain injury.	[Adelson, P. David; Brown, S. Danielle] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Wisniewski, Stephen R.; Bell, Michael; Beers, Sue R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Wisniewski, Stephen R.; Bell, Michael; Beers, Sue R.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Beca, John] Starship Childrens Hosp, Auckland, New Zealand; [Muizelaar, J. Paul] Univ Calif Davis, Davis, CA 95616 USA; [Okada, Pamela] Univ Texas, Dallas Childrens Hosp, Dallas, TX USA; [Balasubramani, Goundappa K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; [Hirtz, Deborah] NINDS, NIH, Bethesda, MD 20892 USA		Adelson, PD (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Bldg B,4th Floor,1915 East Thomas Rd, Phoenix, AZ 85016 USA.	dadelson@phoenixchildrens.com	Adelson, David/W-2083-2019	Wisniewski, Stephen/0000-0002-3877-9860; Goundappa K, Balasubramani/0000-0001-7221-1825	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS052478] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke and National Institutes of Health.	Adelson D, 2008, PEDIATR CRIT CARE ME, V9, P230, DOI [10.1097/PGC.0b013e318166d0e0, 10.1097/PCC.0b013e318166d0e0]; Adelson PD, 2009, J NEUROTRAUM, V26, P429, DOI 10.1089/neu.2008.0571; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1999, EXP TOXICOL PATHOL, V51, P130; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; BULLOCK MR, 2006, NEUROSURGERY S3, V58; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Frankowski RF, 1985, EPIDEMIOLOGICAL DE 1; Grinkeviciute D, 2009, REV NEUROSCIENCE, V20, P261, DOI 10.1515/REVNEURO.2009.20.3-4.261; Gruszkiewicz J, 1973, Surg Neurol, V1, P197; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; Li H, 2009, J NEUROTRAUM, V26, P1905, DOI [10.1089/neu.2008.0828, 10.1089/neu.2008-0828]; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MOYER DJ, 1992, STROKE, V23, P1812, DOI 10.1161/01.STR.23.12.1812; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101	30	141	146	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2013	12	6					546	553		10.1016/S1474-4422(13)70077-2			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161SL	WOS:000320213500009	23664370	hybrid			2022-02-06	
J	Kontos, AP; Covassin, T; Elbin, RJ; Parker, T				Kontos, Anthony P.; Covassin, Tracey; Elbin, R. J.; Parker, Tonya			Depression and Neurocognitive Performance After Concussion Among Male and Female High School and Collegiate Athletes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Concussion, mild; Depression; Rehabilitation; Symptoms	SPORT-RELATED CONCUSSION; TEST-RETEST RELIABILITY; IMPACT; INJURY; SYMPTOMS; PSYCHOLOGY; RECOVERY; RISK; SEX	Kontos AP, Covassin T, Elbin RJ, Parker T. Depression and neurocognitive performance after concussion among male and female high school and collegiate athletes. Arch Phys Med Rehabil 2012;93:1751-6. Objectives: To prospectively examine the relationship of sport-related concussion with depression and neurocognitive performance and symptoms among male and female high school and college athletes. A secondary objective was to explore age and sex differences. Design: Pretest, multiple posttest, repeated-measures design. Setting: Laboratory. Participants: High school and collegiate athletes (N = 75) with a diagnosed concussion. Interventions: Not applicable. Main Outcome Measures: Beck Depression Inventory-II and computerized neurocognitive test battery (Immediate Post-concussion Assessment and Cognitive Test), which includes concussion symptoms (Post-concussion Symptom Scale) at baseline and at 2, 7, and 14 days postinjury. Results: Concussed athletes exhibited significantly higher levels of depression from baseline at 2 days (P <=.001), 7 days (P = .006), and 14 days postconcussion (P = .04). Collegiate athletes demonstrated a significant increase in depression at 14 days postconcussion than did high school athletes (P = .03). There were no sex differences in depression levels. Neurocognitive decrements at 14 days were supported for reaction time (P = .001) and visual memory (P = .001). Somatic depression at 7 days postconcussion was related to slower reaction time at 7 days postconcussion. Somatic depression at 14 days postinjury was related to lower visual memory scores at 14 days postinjury. Conclusions: Although not clinically significant, athletes experienced increased depression scores up to 14 days after concussion that coincided with neurocognitive decrements in reaction time and visual memory. Somatic depression appears to be most salient with regard to lower neurocognitive performance. Mood assessments after concussion are warranted to help monitor and enhance recovery.	[Kontos, Anthony P.; Elbin, R. J.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Ctr Sports Med,UPMC Sports Med Concuss Progr, Pittsburgh, PA 15203 USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Parker, Tonya] Grand Valley State Univ, Dept Movement Sci, Allendale, MI 49401 USA		Kontos, AP (corresponding author), Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Ctr Sports Med,UPMC Sports Med Concuss Progr, 3200 S Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Operating Committee on Standards for Athletic Equipment	Supported by the National Operating Committee on Standards for Athletic Equipment.	Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Cullen KR, 2009, NEUROSCI LETT, V460, P227, DOI 10.1016/j.neulet.2009.05.022; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Hysenbegasi A, 2005, J MENT HEALTH POLICY, V8, P145; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Rees T, 2010, PSYCHOL SPORT EXERC, V11, P505, DOI 10.1016/j.psychsport.2010.07.002; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Yang JZ, 2007, CLIN J SPORT MED, V17, P481, DOI 10.1097/JSM.0b013e31815aed6b; Yang JZ, 2010, J ATHL TRAINING, V45, P372, DOI 10.4085/1062-6050-45.4.372	29	141	143	3	76	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2012	93	10					1751	1756		10.1016/j.apmr.2012.03.032			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	018FP	WOS:000309645800009	22503738				2022-02-06	
J	Capo-Aponte, JE; Urosevich, TG; Temme, LA; Tarbett, AK; Sanghera, NK				Capo-Aponte, Jose E.; Urosevich, Thomas G.; Temme, Leonard A.; Tarbett, Aaron K.; Sanghera, Navjit K.			Visual Dysfunctions and Symptoms During the Subacute Stage of Blast-Induced Mild Traumatic Brain Injury	MILITARY MEDICINE			English	Article								The purpose of the present study was to assess the occurrence of visual dysfunctions and associated symptoms in active duty warfighters during the subacute stage of blast-induced mild traumatic brain injury (mTBI). A comprehensive visual and oculomotor function evaluation was performed on 40 U.S. military personnel, 20 with blast-induced mTBI and 20 without. In addition, a comprehensive symptom questionnaire was used to assess the frequency of visual, vestibular, and neuropsychiatric-associated symptoms. The most common mTBI-induced visual dysfunctions were associated with near oculomotor deficits, particularly large exophoria, decreased fusion ranges, receded near point of convergence, defective pursuit and saccadic eye movements, decreased amplitude of accommodation, and monocular accommodative facility. These were associated with reduced reading speed and comprehension and an increased Convergence Insufficiency Symptom Survey score. Photosensitivity was a common visual dysfunction along with hearing, balance, and neuropsychiatric symptoms. The oculomotor testing for warfighters suspected of blast-induced mTBI should include, at a minimum, the assessment of near lateral and vertical phorias, positive fusional vergence, stereoacuity, near point of convergence, amplitude of accommodation, monocular accommodative facility, saccades, and pursuit eye movements. A reading test should be included in all routine exams as a functional assessment of the integration of oculomotor functions.	[Capo-Aponte, Jose E.; Urosevich, Thomas G.; Temme, Leonard A.] US Army Aero Med Res Lab, Sensory Res Div, Visual Sci Branch, Rucker, AL 36330 USA; [Tarbett, Aaron K.] Walter Reed Natl Mil Med Ctr, Optometry Serv, Bethesda, MD 20889 USA; [Sanghera, Navjit K.] Illinois Coll Optometry, Clin Serv, Chicago, IL 60616 USA		Capo-Aponte, JE (corresponding author), US Army Aero Med Res Lab, Sensory Res Div, Visual Sci Branch, 6901 Andrews Ave, Rucker, AL 36330 USA.				U.S. Army Medical Research and Materiel Command under the Military Operational Medicine Research Program	We thank Dr. Loraine St. Onge for her invaluable editorial review of this article. This study was supported by intramural funding from the U.S. Army Medical Research and Materiel Command under the Military Operational Medicine Research Program.	[Anonymous], 2011, TRAUM BRAIN INJ; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Carlson NB, 2004, CLIN PROCEDURES OCUL, P28; Ciuffreda K. J., 1994, EYE MOVEMENTS READIN, P163; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda KJ, 2007, JBO, V18, P72; Ciuffreda KJ, 2001, VISUAL VESTIBULAR CO, P77; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Doble JE, 2010, PM&R, V2, P244, DOI 10.1016/j.pmrj.2010.01.011; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Durch, 2006, NOISE MILITARY SERVI; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fischer H, US MIL CAS STAT OP N; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goss DA, 1991, CLIN PROCEDURES OPTO, P716; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hilber David J, 2011, MSMR, V18, P2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Maples W C, 1988, J Am Optom Assoc, V59, P549; Reilly JL, 2008, BRAIN COGNITION, V68, P415, DOI 10.1016/j.bandc.2008.08.026; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Scheiman M, 2002, OPTOMETRY VISION SCI, V79, P151, DOI 10.1097/00006324-200203000-00009; Scheiman M, ARVO 2011 MAY 1 5 FO; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Stuhmiller JH, 2008, BLAST INJURY TRANSLA; Trachtman JN, 2010, OPTOMETRY, V81, P240, DOI 10.1016/j.optm.2009.07.017	33	141	142	0	11	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	JUL	2012	177	7					804	813		10.7205/MILMED-D-12-00061			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V33NZ	WOS:000209026800008	22808887	Bronze			2022-02-06	
J	Rashid, B; Destrade, M; Gilchrist, MD				Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.			Mechanical characterization of brain tissue in compression at dynamic strain rates	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Traumatic brain injury (TBI); Impact; Intermediate strain rate; Friction coefficient; Ogden model	IN-VIVO; UNCONFINED COMPRESSION; CONSTITUTIVE MODEL; SOFT-TISSUES; BEHAVIOR; DEFORMATION; SHEAR; STRETCH; INJURY; VITRO	Traumatic brain injury (TBI) occurs when local mechanical load exceeds certain tolerance levels for brain tissue. Extensive research has been done previously for brain matter experiencing compression at quasistatic loading; however, limited data is available to model TBI under dynamic impact conditions. In this research, an experimental setup was developed to perform unconfined compression tests and stress relaxation tests at strain rates <= 90/s. The brain tissue showed a stiffer response with increasing strain rates, showing that hyperelastic models are not adequate. Specifically, the compressive nominal stress at 30% strain was 8.83 +/- 1.94, 12.8 +/- 3.10 and 16.0 +/- 1.41 kPa (mean +/- SD) at strain rates of 30, 60 and 90/s, respectively. Relaxation tests were also conducted at 10%- 50% strain with the average rise time of 10 ms, which can be used to derive time dependent parameters. Numerical simulations were performed using one-term Ogden model with initial shear modulus mu(0) = 6.06 +/- 1.44, 9.44 +/- 2.427 and 12.64 +/- 1.227 kPa (mean +/- SD) at strain rates of 30, 60 and 90/s, respectively. A separate set of bonded and lubricated tests were also performed under the same test conditions to estimate the friction coefficient mu, by adopting combined experimental-computational approach. The values of mu were 0.1 +/- 0.03 and 0.15 +/- 0.07 (mean +/- SD) at 30 and 90/s strain rates, respectively, indicating that pure slip conditions cannot be achieved in unconfined compression tests even under fully lubricated test conditions. The material parameters obtained in this study will help to develop biofidelic human brain finite element models, which can subsequently be used to predict brain injuries under impact conditions. (C) 2012 Elsevier Ltd. All rights reserved.	[Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland; [Destrade, Michel] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland		Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland.	Badar.Rashid@ucdconnect.ie; michel.destrade@nuigalway.ie; michael.gilchrist@ucd.ie	Destrade, Michel/O-5825-2019; Gilchrist, Michael D/B-6100-2017	Destrade, Michel/0000-0002-6266-1221; Gilchrist, Michael D/0000-0003-1765-429X	Irish Research Council for Science, Engineering and Technology (IRCSET), IrelandIrish Research Council for Science, Engineering and Technology	The authors thank Dr. Manuel Forero for his guidance with ABAQUS simulations, Aisling Ni Annaidh for her assistance with curve fitting by using MATLAB, and John Gahan, Tony Dennis and Pat McNally for their assistance in machining components and developing electronic circuits for the experimental setup. This work was supported for the first author by a Postgraduate Research Scholarship awarded by the Irish Research Council for Science, Engineering and Technology (IRCSET), Ireland.	Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; ESTES MS, 1970, 70BHF13 ASME; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fung Y. C., 1993, BIOMECHANICS MECH PR; FUNG YC, 1979, AM J PHYSIOL, V237, pH620, DOI 10.1152/ajpheart.1979.237.5.H620; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532, DOI 10.1152/ajplegacy.1967.213.6.1532; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gent AN, 1996, RUBBER CHEM TECHNOL, V69, P59, DOI 10.5254/1.3538357; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; Meaney D. F., 1990, INT C BIOM IMP IRCOB; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ogden R.W., 1997, NONLINEAR ELASTIC DE; Ogden RW, 2004, COMPUT MECH, V34, P484, DOI 10.1007/s00466-004-0593-y; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Pervin F, 2011, NEUROIMAGE, V54, pS98, DOI 10.1016/j.neuroimage.2010.03.077; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange M.T., 1999, SAE TECHNICAL PAPER; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tamura A, 2008, J BIOMECH SCI ENG, V3, P263, DOI DOI 10.1299/JBSE.3.263; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Wu JZ, 2004, J BIOMECH, V37, P147, DOI 10.1016/S0021-9290(03)00240-9; Zhang JY, 2011, J BIOMECH, V44, P391, DOI 10.1016/j.jbiomech.2010.10.024; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang M, 1999, PROSTHET ORTHOT INT, V23, P135	60	141	142	0	25	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	JUN	2012	10						23	38		10.1016/j.jmbbm.2012.01.022			16	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	944TU	WOS:000304227500003	22520416	Green Submitted			2022-02-06	
J	Frankola, KA; Greig, NH; Luo, WM; Tweedie, D				Frankola, Kathryn A.; Greig, Nigel H.; Luo, Weiming; Tweedie, David			Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Tumor necrosis factor-alpha; neuroinflammation; cytokine; chemokine; neurodegeneration; Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis; Japanese encephalitis; dementia; thalidomide; revlimid	TUMOR-NECROSIS-FACTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; INFLUENZA-ASSOCIATED ENCEPHALOPATHY; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; SYNUCLEIN ACTIVATES MICROGLIA; ENCEPHALITIS-VIRUS INFECTION; PRO-INFLAMMATORY CYTOKINES	Inflammatory signals generated within the brain and peripheral nervous system direct diverse biological processes. Key amongst the inflammatory molecules is tumor necrosis factor-alpha (TNF-alpha), a potent pro-inflammatory cytokine that, via binding to its associated receptors, is considered to be a master regulator of cellular cascades that control a number of diverse processes coupled to cell viability, gene expression, synaptic integrity and ion homeostasis. Whereas a self-limiting neuroinflammatory response generally results in the resolution of an intrinsically or extrinsically triggered insult by the elimination of toxic material or injured tissue to restore brain homeostasis and function, in the event of an unregulated reaction, where the immune response persists, inappropriate chronic neuroinflammation can ensue. Uncontrolled neuroinflammatory activity can induce cellular dysfunction and demise, and lead to a self-propagating cascade of harmful pathogenic events. Such chronic neuroinflammation is a typical feature across a range of debilitating common neurodegenerative diseases, epitomized by Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis, in which TNF-alpha expression appears to be upregulated and may represent a valuable target for intervention. Elaboration of the protective homeostasis signaling cascades from the harmful pathogenic ones that likely drive disease onset and progression could aid in the clinical translation of approaches to lower brain and peripheral nervous system TNF-alpha levels, and amelioration of inappropriate neuroinflammation.	[Greig, Nigel H.] NIA, Biomed Res Ctr, Drug Design & Dev Sect, Lab Neurosci,Intramural Res Program,NIH, Baltimore, MD 21224 USA		Greig, NH (corresponding author), NIA, Biomed Res Ctr, Drug Design & Dev Sect, Lab Neurosci,Intramural Res Program,NIH, Room 05C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	Greign@grc.nia.nih.gov			NIH, National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311] Funding Source: NIH RePORTER	This work was supported by the Intramural Research Program of the NIH, National Institute on Aging.	Aisen PS, 2000, ACTA NEUROL SCAND, V102, P85, DOI 10.1034/j.1600-0404.2000.00312.x; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alirezaei M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002906; Alkam T, 2008, BEHAV BRAIN RES, V189, P100, DOI 10.1016/j.bbr.2007.12.014; Aragon-Ching JB, 2007, RECENT PAT ANTI-CANC, V2, P167, DOI 10.2174/157489207780832478; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Babu GN, 2006, NEUROL RES, V28, P190, DOI 10.1179/016164106X98062; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Barak O, 2002, BRAIN RES, V933, P98, DOI 10.1016/S0006-8993(02)02280-1; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bellamy WT, 2001, BLOOD, V97, P1427, DOI 10.1182/blood.V97.5.1427; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Bilbo SD, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.014.2009; Boireau A, 1997, NEUROSCI LETT, V234, P123, DOI 10.1016/S0304-3940(97)00685-X; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Bostantjopoulou S, 2009, J CLIN NEUROSCI, V16, P458, DOI 10.1016/j.jocn.2008.03.016; Brabers NACH, 2006, EUR J CLIN INVEST, V36, P447, DOI 10.1111/j.1365-2362.2006.01657.x; CALNE DB, 1988, CAN J NEUROL SCI, V15, P135, DOI 10.1017/S0317167100027499; Chadwick W, 2008, TRENDS NEUROSCI, V31, P504, DOI 10.1016/j.tins.2008.07.005; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; Chen CJ, 2010, J GEN VIROL, V91, P1028, DOI 10.1099/vir.0.013565-0; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cicchetti F, 2009, TRENDS PHARMACOL SCI, V30, P475, DOI 10.1016/j.tips.2009.06.005; Ciesielska A, 2003, ACTA NEUROBIOL EXP, V63, P117; Clark IA, 2007, CYTOKINE GROWTH F R, V18, P335, DOI 10.1016/j.cytogfr.2007.04.002; Combs CK, 2001, J NEUROSCI, V21, P1179; D'Ambrosi N, 2009, J IMMUNOL, V183, P4648, DOI 10.4049/jimmunol.0901212; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; Ezcurra ALD, 2010, NEUROBIOL DIS, V37, P630, DOI 10.1016/j.nbd.2009.11.018; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207; DELANNOY I, 1993, VET RES, V24, P449; DENTON T, 1987, J NEUROCHEM, V49, P622, DOI 10.1111/j.1471-4159.1987.tb02909.x; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Dziegielewska KM, 2000, CELL TISSUE RES, V299, P335; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Elliott JL, 2001, MOL BRAIN RES, V95, P172, DOI 10.1016/S0169-328X(01)00242-X; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Ferri A, 2008, NEUROBIOL DIS, V32, P454, DOI 10.1016/j.nbd.2008.08.004; Fonseca MI, 2009, J IMMUNOL, V183, P1375, DOI 10.4049/jimmunol.0901005; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Funato H, 1998, AM J PATHOL, V152, P983; Gao HM, 2003, TRENDS PHARMACOL SCI, V24, P395, DOI 10.1016/S0165-6147(03)00176-7; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Ghoshal A, 2007, GLIA, V55, P483, DOI 10.1002/glia.20474; Gowing G, 2006, J NEUROSCI, V26, P11397, DOI 10.1523/JNEUROSCI.0602-06.2006; Greig NH, 2004, ACTA NEUROBIOL EXP, V64, P1; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Grell M, 1996, J INFLAMM, V47, P8; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hashimoto Y, 2008, ARCH PHARM, V341, P536, DOI 10.1002/ardp.200700217; He BP, 2002, J NEUROIMMUNOL, V128, P31, DOI 10.1016/S0165-5728(02)00141-8; Hebert G, 2003, NEUROSCI LETT, V349, P191, DOI 10.1016/S0304-3940(03)00832-2; Hensley K, 2002, J NEUROCHEM, V82, P365, DOI 10.1046/j.1471-4159.2002.00968.x; Hensley K, 2003, NEUROBIOL DIS, V14, P74, DOI 10.1016/S0969-9961(03)00087-1; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hosoya M, 2006, ARCH DIS CHILD, V91, P469, DOI 10.1136/adc.2005.078436; Hosoya M, 2005, PEDIATR INFECT DIS J, V24, P467, DOI 10.1097/01.inf.0000160995.07461.b8; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Imamura K, 2005, ACTA NEUROPATHOL, V109, P141, DOI 10.1007/s00401-004-0919-y; Iosif RE, 2008, J CEREBR BLOOD F MET, V28, P1574, DOI 10.1038/jcbfm.2008.47; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Janelsins MC, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-23; Janelsins MC, 2008, AM J PATHOL, V173, P1768, DOI 10.2353/ajpath.2008.080528; Jang H, 2009, BBA-MOL BASIS DIS, V1792, P714, DOI 10.1016/j.bbadis.2008.08.001; Kalita J, 2010, NEUROSCI LETT, V473, P48, DOI 10.1016/j.neulet.2010.02.017; Kamat A, 2009, J NEUROVIROL, V15, P25, DOI 10.1080/13550280802338652; Kang D, 1997, ARCH BIOCHEM BIOPHYS, V337, P75, DOI 10.1006/abbi.1996.9727; Katsuse O, 2003, NEUROPATHOLOGY, V23, P9, DOI 10.1046/j.1440-1789.2003.00483.x; Kawada J, 2003, J INFECT DIS, V188, P690, DOI 10.1086/377101; Keohane A, 2010, MOL CELL NEUROSCI, V43, P127, DOI 10.1016/j.mcn.2009.10.003; Kiaei M, 2006, J NEUROSCI, V26, P2467, DOI 10.1523/JNEUROSCI.5253-05.2006; Knight R, 2005, SEMIN ONCOL, V32, pS24, DOI 10.1053/j.seminoncol.2005.06.018; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOVACIC P, 1991, FREE RADICAL RES COM, V14, P25, DOI 10.3109/10715769109088938; Lahiri DK, 2009, MOL PSYCHIATR, V14, P992, DOI 10.1038/mp.2009.82; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lecca D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003579; Leng A, 2005, NEUROSCI LETT, V375, P107, DOI 10.1016/j.neulet.2004.10.077; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu JL, 2010, BRAIN RES, V1316, P101, DOI 10.1016/j.brainres.2009.12.055; Liu Y, 2009, J BIOL CHEM, V284, P3691, DOI 10.1074/jbc.M804446200; Lorz C, 2009, FRONT BIOSCI-LANDMRK, V14, P583, DOI [10.2741/3265, 10.2741/3264]; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Luo WM, 2008, SYNTHESIS-STUTTGART, P3415, DOI 10.1055/s-0028-1083179; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; Marini AM, 2000, J NEUROSCI RES, V62, P814, DOI 10.1002/1097-4547(20001215)62:6<814::AID-JNR8>3.0.CO;2-F; MAWDSLEY C, 1963, LANCET, V2, P795; McAlpine FE, 2009, NEUROBIOL DIS, V34, P163, DOI 10.1016/j.nbd.2009.01.006; McGeer PL, 2003, ANN NEUROL, V54, P599, DOI 10.1002/ana.10728; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Mebane-Sims I, 2009, ALZHEIMERS DEMENT, V5, P234, DOI 10.1016/j.jalz.2009.03.001; Melchert M, 2007, INT J BIOCHEM CELL B, V39, P1489, DOI 10.1016/j.biocel.2007.01.022; Mladenovic A, 2004, BRAIN RES, V996, P237, DOI 10.1016/j.brainres.2003.10.035; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 2000, J NEURAL TRANSM, V107, P335, DOI 10.1007/s007020050028; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Moreau C, 2005, NEUROLOGY, V65, P1958, DOI 10.1212/01.wnl.0000188907.97339.76; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; Neymotin A, 2009, EXP NEUROL, V220, P191, DOI 10.1016/j.expneurol.2009.08.028; NICKLAS WJ, 1987, LIFE SCI, V40, P721, DOI 10.1016/0024-3205(87)90299-2; Nolting T, 2009, J NEUROVIROL, V15, P390, DOI 10.3109/13550280903350192; Nunoi H, 2005, PEDIATR INT, V47, P175, DOI 10.1111/j.1442-200x.2005.02042.x; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Okamoto M, 2001, BIOCHEM PHARMACOL, V62, P747, DOI 10.1016/S0006-2952(01)00692-X; Park KM, 2010, CELL SIGNAL, V22, P977, DOI 10.1016/j.cellsig.2010.01.010; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Poloni M, 2000, NEUROSCI LETT, V287, P211, DOI 10.1016/S0304-3940(00)01177-0; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RANDALL T, 1990, JAMA-J AM MED ASSOC, V263, P1474; Reale M, 2009, MINI-REV MED CHEM, V9, P1229, DOI 10.2174/138955709789055199; Robertson J, 2001, J CELL BIOL, V155, P217, DOI 10.1083/jcb.200107058; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Rostasy K, 2005, J NEUROL NEUROSUR PS, V76, P960, DOI 10.1136/jnnp.2004.036889; Rousselet E, 2002, EXP NEUROL, V177, P183, DOI 10.1006/exnr.2002.7960; Rugbjerg Kathrine, 2008, BMJ, V337, pa2494, DOI 10.1136/bmj.a2494; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/S1074-7613(04)00234-1; Schroeter ML, 2008, J AFFECT DISORDERS, V111, P271, DOI 10.1016/j.jad.2008.03.005; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shiraki M, 2010, NUTRITION, V26, P269, DOI 10.1016/j.nut.2009.04.016; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Stommel EW, 2007, NEUROSCIENCE, V146, P1013, DOI 10.1016/j.neuroscience.2007.02.036; Stommel EW, 2009, AMYOTROPH LATERAL SC, V10, P393, DOI 10.3109/17482960802709416; Streit WJ, 2001, NEUROTOXICOLOGY, V22, P619, DOI 10.1016/S0161-813X(01)00033-X; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Su XM, 2008, NEUROBIOL AGING, V29, P1690, DOI 10.1016/j.neurobiolaging.2007.04.006; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Swarup V, 2008, NEUROCHEM INT, V52, P1310, DOI 10.1016/j.neuint.2008.01.014; Swarup V, 2007, J NEUROCHEM, V103, P771, DOI 10.1111/j.1471-4159.2007.04790.x; Tansey MG, 2010, NEUROBIOL DIS, V37, P510, DOI 10.1016/j.nbd.2009.11.004; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Terenghi F, 2006, J PERIPHER NERV SYST, V11, P67, DOI 10.1111/j.1085-9489.2006.00065.x; Tobinick Edward, 2006, MedGenMed, V8, P25; Tobinick EL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-27; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Togo T, 2001, J NEUROL SCI, V184, P71, DOI 10.1016/S0022-510X(00)00498-6; Tsao CH, 2008, J GEN VIROL, V89, P1930, DOI 10.1099/vir.0.2008/000182-0; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2009, J NEUROSCI METH, V183, P182, DOI 10.1016/j.jneumeth.2009.06.034; Varani K, 2010, FASEB J, V24, P587, DOI 10.1096/fj.09-141044; von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x; Wang JY, 2003, VIROLOGY, V305, P66, DOI 10.1006/viro.2002.1690; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Westerlund M, 2010, PROG NEUROBIOL, V90, P146, DOI 10.1016/j.pneurobio.2009.11.001; Williams R, 2009, GLIA, V57, P734, DOI 10.1002/glia.20801; Wines Nina Y, 2002, Australas J Dermatol, V43, P229, DOI 10.1046/j.1440-0960.2002.00608.x; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xing HQ, 2009, NEUROPATHOLOGY, V29, P433, DOI 10.1111/j.1440-1789.2008.00996.x; Xing HQ, 2009, NEUROPATHOLOGY, V29, P13, DOI 10.1111/j.1440-1789.2008.00929.x; Xing HQ, 2009, J NEUROPATH EXP NEUR, V68, P199, DOI 10.1097/NEN.0b013e31819715df; Yan YP, 2009, BRAIN RES, V1288, P116, DOI 10.1016/j.brainres.2009.06.073; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Ye ZC, 1996, NEUROREPORT, V7, P2181, DOI 10.1097/00001756-199609020-00025; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Zhang C, 2010, CURR ALZHEIMER RES, V7, P21, DOI 10.2174/156720510790274428; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com; Zhu XX, 2003, J MED CHEM, V46, P5222, DOI 10.1021/jm030152f	184	141	145	0	16	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	MAY	2011	10	3					391	403					13	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	764EZ	WOS:000290613100014	21288189				2022-02-06	
J	Levack, WMM; Kayes, NM; Fadyl, JK				Levack, William M. M.; Kayes, Nicola M.; Fadyl, Joanna K.			Experience of recovery and outcome following traumatic brain injury: a metasynthesis of qualitative research	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; lived experience; recovery; rehabilitation outcomes; qualitative research; metasynthesis	HEAD-INJURY; PEOPLE; SELF; REHABILITATION; PERSPECTIVES; INDIVIDUALS; REFLECTIONS; RELIABILITY; NARRATIVES; IDENTITY	Purpose. To explore the use of qualitative metasynthesis to inform debate on the selection of outcome measures for evaluation of services provided to adults with traumatic brain injury (TBI). Method. Fifteen databases were searched for qualitative research published between 1965 and June 2009, investigating the lived experience of recovery following TBI acquired during adulthood. Two reviewers independently screened all abstracts. Included studies were evaluated using methodological criteria to provide a context for interpretation of substantive findings. Data were extracted and synthesised by three reviewers, using QSR NVivo to assist with data management. Results. From 23 studies, eight inter-related themes were identified to describe the enduring experience of TBI: 1) mind/body disconnect; 2) disconnect with pre-injury identity; 3) social disconnect; 4) emotional sequelae; 5) internal and external resources; 6) reconstruction of self-identity; 7) reconstruction of a place in the world; 8) reconstruction of personhood. Conclusion. Currently, there are outcome measures for some but not all of the issues identified in qualitative research on surviving TBI. In particular, new outcome measures may be required to evaluate experiences of loss of personal identity, satisfaction with reconstructed identity and sense of connection with one's body and one's life following TBI.	[Levack, William M. M.] Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand		Levack, WMM (corresponding author), Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand.	wlevack@wnmeds.ac.nz	Levack, William Mark Magnus/F-9607-2018	Levack, William Mark Magnus/0000-0001-6631-908X			Arango MF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005400.pub3; BANJA J, 1994, ARCH PHYS MED REHAB, V75, pSC19; BREWIN J, 2001, INJURY, V8, P218; Chamberlain DJ, 2006, J ADV NURS, V54, P407, DOI 10.1111/j.1365-2648.2006.03840.x; Charmaz K., 2014, BROKERAGE CLOSURE IN; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; Crisp R., 1993, DISABIL HANDICAP SOC, V8, P393, DOI DOI 10.1080/02674649366780371; Crotty M., 1998, FDN SOCIAL RES MEANI; Daly J, 2007, J CLIN EPIDEMIOL, V60, P43, DOI 10.1016/j.jclinepi.2006.03.014; Ellis-Hill C, 2008, DISABIL REHABIL, V30, P150, DOI 10.1080/09638280701195462; ENABLE UN, 2004, NOTHING US US INT DA; Finfgeld DL, 2003, QUAL HEALTH RES, V13, P893, DOI 10.1177/1049732303253462; Flemming K, 2007, J ADV NURS, V57, P95, DOI 10.1111/j.1365-2648.2006.04083.x; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Gutman SA, 1996, AM J OCCUP THER, V50, P535, DOI 10.5014/ajot.50.7.535; Hallberg LRM, 2005, SCAND J CARING SCI, V19, P410, DOI 10.1111/j.1471-6712.2005.00361.x; Hammell K.W., 2006, PERSPECTIVES DISABIL; *HLTHC, 2001, TRAUM BRAIN INJ TBI; Howes H, 2005, PSYCHOL HEALTH, V20, P129, DOI 10.1080/0887044042000272903; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JUMISKO E, 2005, J NEUROSCI NURS, V50, P37; Karlovits T, 1999, BRAIN INJURY, V13, P845; Kayes NM, 2010, DISABIL REHABIL, V32, P1011, DOI 10.3109/09638281003775501; Ker K, 2008, COCHRANE DB SYST REV, V1, DOI 10.1002/14651858.CD006686.pub2; Kersten P, 2010, DISABIL REHABIL, V32, P1028, DOI 10.3109/09638281003775568; LANDIS JR, 1977, BIOMETRICS, V33, P174; Lawson S, 2008, THER RECREAT J, V42, P236; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; Morris Paul Graham, 2005, BMC Fam Pract, V6, P30, DOI 10.1186/1471-2296-6-30; Morris S, 2008, ANAESTHESIA, V63, P499, DOI 10.1111/j.1365-2044.2007.05432.x; Morris SL, 2008, BRAIN INJURY, V22, P1030, DOI 10.1080/02699050802533775; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; O'Callaghan C, 2006, NEUROPSYCHOL REHABIL, V16, P579, DOI 10.1080/09602010500368834; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; Padilla R, 2003, AM J OCCUP THER, V57, P413, DOI 10.5014/ajot.57.4.413; Parsons L, 2008, AUST OCCUP THER J, V55, P231, DOI 10.1111/j.1440-1630.2008.00753.x; Paterson J., 2002, REHABIL NURS, V27, P13, DOI DOI 10.1002/J.2048-7940.2002.TB01973.X; Patterson FL, 2009, J MENT HLTH COUNS, V31, P149; Petrella L, 2005, BRAIN INJURY, V19, P643, DOI 10.1080/02699050410001671874; Piolino P, 2007, CORTEX, V43, P176, DOI 10.1016/S0010-9452(08)70474-X; Popay J, 2005, J CLIN EPIDEMIOL, V58, P1079, DOI 10.1016/j.jclinepi.2005.08.004; Reichard AA, 2007, J HEAD TRAUMA REHAB, V22, P390, DOI 10.1097/01.HTR.0000300234.36361.b1; Roscigno CI, 2008, J NEUROSCI NURS, V40, P212, DOI 10.1097/01376517-200808000-00005; Salter K, 2008, BRAIN INJURY, V22, P820, DOI 10.1080/02699050802425428; Salter K, 2008, J REHABIL MED, V40, P595, DOI 10.2340/16501977-0238; Sandelowski M, 2006, NURS OUTLOOK, V54, P10, DOI 10.1016/j.outlook.2005.05.004; Sandelowski M., 2007, HDB SYNTHESIZING QUA; Saxena M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006811.pub2; Shaw Rachel L, 2004, BMC Med Res Methodol, V4, P5, DOI 10.1186/1471-2288-4-5; Shotton L, 2007, BRAIN INJURY, V21, P857, DOI 10.1080/02699050701481621; STRANDBERG T, 2009, HLTH CARE, V48, P276; The Joanna Briggs Institute, 2008, J BRIGGS I REV MAN 2; Thorne S, 2004, QUAL HEALTH RES, V14, P1342, DOI 10.1177/1049732304269888; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Yeates GN, 2008, NEUROPSYCHOL REHABIL, V18, P566, DOI 10.1080/09602010802151532	60	141	141	0	31	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2010	32	12					986	999		10.3109/09638281003775394			14	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	608OC	WOS:000278592600005	20450406				2022-02-06	
J	Huang, MX; Theilmann, RJ; Robb, A; Angeles, A; Nichols, S; Drake, A; D'Andrea, J; Levy, M; Holland, M; Song, T; Ge, S; Hwang, E; Yoo, K; Cui, L; Baker, DG; Trauner, D; Coimbra, R; Lee, RR				Huang, Ming-Xiong; Theilmann, Rebecca J.; Robb, Ashley; Angeles, Annemarie; Nichols, Sharon; Drake, Angela; D'Andrea, John; Levy, Michael; Holland, Martin; Song, Tao; Ge, Sheng; Hwang, Eric; Yoo, Kevin; Cui, Li; Baker, Dewleen G.; Trauner, Doris; Coimbra, Raul; Lee, Roland R.			Integrated Imaging Approach with MEG and DTI to Detect Mild Traumatic Brain Injury in Military and Civilian Patients	JOURNAL OF NEUROTRAUMA			English	Article						concussion; diffusion tensor imaging; head injury; magnetoencephalography; slow wave; traumatic brain injury	DIFFUSE AXONAL INJURY; DELTA WAVES; VOXELWISE ANALYSIS; HEAD-INJURY; REGISTRATION; EEG; INTERFERENCE; LOCALIZATION; OPTIMIZATION; FEATURES	Traumatic brain injury (TBI) is a leading cause of sustained impairment in military and civilian populations. However, mild (and some moderate) TBI can be difficult to diagnose due to lack of obvious external injuries and because the injuries are often not visible on conventional acute MRI or CT. Injured brain tissues in TBI patients generate pathological low-frequency neuronal magnetic signal (delta waves 1-4 Hz) that can be measured and localized by magnetoencephalography (MEG). We hypothesize that abnormal MEG delta waves originate from gray matter neurons that experience de-afferentation due to axonal injury to the underlying white matter fiber tracts, which is manifested on diffusion tensor imaging (DTI) as reduced fractional anisotropy. The present study used a neuroimaging approach integrating findings of magnetoencephalography (MEG) and diffusion tensor imaging (DTI), evaluating their utility in diagnosing mild TBI in 10 subjects in whom conventional CT and MRI showed no visible lesions in 9. The results show: (1) the integrated approach with MEG and DTI is more sensitive than conventional CT and MRI in detecting subtle neuronal injury in mild TBI; (2) MEG slow waves in mild TBI patients originate from cortical gray matter areas that experience de-afferentation due to axonal injuries in the white matter fibers with reduced fractional anisotropy; (3) findings from the integrated imaging approach are consistent with post-concussive symptoms; (4) in some cases, abnormal MEG delta waves were observed in subjects without obvious DTI abnormality, indicating that MEG may be more sensitive than DTI in diagnosing mild TBI.	[Huang, Ming-Xiong] Univ Calif San Diego, Radiol Imaging Lab, Dept Radiol, San Diego, CA 92121 USA; [Nichols, Sharon; Trauner, Doris] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92121 USA; [Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92121 USA; [Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92121 USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Baker, Dewleen G.; Coimbra, Raul; Lee, Roland R.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Baker, Dewleen G.; Coimbra, Raul; Lee, Roland R.] VA San Diego Healthcare Syst, Serv Radiol, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Baker, Dewleen G.; Coimbra, Raul; Lee, Roland R.] VA San Diego Healthcare Syst, Rehabil Serv, San Diego, CA USA; [Huang, Ming-Xiong; Robb, Ashley; Angeles, Annemarie; D'Andrea, John; Baker, Dewleen G.; Coimbra, Raul; Lee, Roland R.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Nichols, Sharon; Drake, Angela; Holland, Martin] San Diego Naval Hosp, Def & Vet Brain Injury Ctr, San Diego, CA USA; [Levy, Michael] Univ Calif San Diego, Childrens Hosp San Diego, San Diego, CA 92121 USA; [Yoo, Kevin] Palomar Neurosurg Ctr, Poway, CA USA		Huang, MX (corresponding author), Univ Calif San Diego, Radiol Imaging Lab, Dept Radiol, 3510 Dunhill St, San Diego, CA 92121 USA.	mxhuang@ucsd.edu	Baker, Dewleen/O-4957-2019; Levy, Michael/AAL-4647-2020; Coimbra, Raul/AAP-3019-2020	Baker, Dewleen/0000-0002-1736-9838; Coimbra, Raul/0000-0002-3759-6851	Department of Veterans AffairsUS Department of Veterans Affairs [051455]; M.-X. H [060812]; R.R.L [E4477-R]	This work was supported in part by three merit review grants from the Department of Veterans Affairs (051455 and 060812 to M.-X. H.; E4477-R to R.R.L.). We thank Michael Kilmer, Diane Delrey, Catherine Cheung, Angelica Dilay, Susan Yoder, Richard Daugherty, and Terry Curry for their efforts with patient recruitment. We would also like to thank two anonymous reviewers' constructive suggestions that substantially strengthened the present study.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; Cheour M, 2004, EXP NEUROL, V190, pS44, DOI 10.1016/j.expneurol.2004.06.030; Cohen D, 2002, P 13 INT C BIOM, P919; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030; DECKER DA, 1972, ELECTROEN CLIN NEURO, V33, P303, DOI 10.1016/0013-4694(72)90157-5; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Huang MX, 2006, NEUROIMAGE, V31, P1025, DOI 10.1016/j.neuroimage.2006.01.029; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Maris E, 2007, J NEUROSCI METH, V164, P177, DOI 10.1016/j.jneumeth.2007.03.024; Maris E, 2007, J NEUROSCI METH, V163, P161, DOI 10.1016/j.jneumeth.2007.02.011; Mosher JC, 1999, IEEE T BIO-MED ENG, V46, P245, DOI 10.1109/10.748978; NAGATA K, 1985, NEUROSURGERY, V17, P613, DOI 10.1227/00006123-198510000-00014; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; SONG T, 2008, MED BIOL ENG COMPUT; Talairach J., 1988, COPLANAR STEREOTACTI; Taulu S, 2006, PHYS MED BIOL, V51, P1759, DOI 10.1088/0031-9155/51/7/008; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; TAULU S, 2004, NEUROL CLIN NEUROPHY, P35; Thottakara P, 2006, NEUROIMAGE, V29, P868, DOI 10.1016/j.neuroimage.2005.08.051; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trauner DA, 2001, PEDIATR NEUROL, V24, P365, DOI 10.1016/S0887-8994(01)00268-5; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	55	141	142	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1213	1226		10.1089/neu.2008.0672			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900005	19385722				2022-02-06	
J	Mayes, SD; Calhoun, SL; Bixler, EO; Vgontzas, AN; Mahr, F; Hillwig-Garcia, J; Elamir, B; Edhere-Ekezie, L; Parvin, M				Mayes, Susan Dickerson; Calhoun, Susan L.; Bixler, Edward O.; Vgontzas, Alexandros N.; Mahr, Fauzia; Hillwig-Garcia, Jolene; Elamir, Belal; Edhere-Ekezie, Linda; Parvin, Matthew			ADHD Subtypes and Comorbid Anxiety, Depression, and Oppositional-Defiant Disorder: Differences in Sleep Problems	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						ADHD; anxiety; depression; sleep; medication; oppositional-defiant disorder	ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; DEFICIT-HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; WECHSLER INTELLIGENCE SCALE; GORDON DIAGNOSTIC SYSTEM; DSM-IV SUBTYPES; PSYCHIATRIC-DISORDERS; DAYTIME SLEEPINESS; PROCESSING SPEED; CHILDREN	Objective Sleep problems were analyzed in children with ADHD (Attention-deficit hyperactivity disorder). Methods Scales were completed by parents of 135 control children and 681 children with ADHD combined type (ADHD-C) or inattentive type (ADHD-I) with or without comorbid oppositional defiant disorder (ODD), anxiety, or depression. Results Children with ADHD-I alone had the fewest sleep problems and did not differ from controls. Children with ADHD-C had more sleep problems than controls and children with ADHD-I. Comorbid anxiety/depression increased sleep problems, whereas ODD did not. Daytime sleepiness was greatest in ADHD-I and was associated with sleeping more (not less) than normal. Medicated children had greater difficulty falling asleep than unmedicated children. Conclusions Differences in sleep problems were found as a function of ADHD subtype, comorbidity, and medication.	[Mayes, Susan Dickerson; Calhoun, Susan L.; Bixler, Edward O.; Vgontzas, Alexandros N.; Mahr, Fauzia; Hillwig-Garcia, Jolene; Elamir, Belal; Edhere-Ekezie, Linda; Parvin, Matthew] Penn State Coll Med, Milton S Hershey Med Ctr, Dept Psychiat, Hershey, PA 17033 USA		Mayes, SD (corresponding author), Penn State Coll Med, Milton S Hershey Med Ctr, Dept Psychiat, POB 850, Hershey, PA 17033 USA.	smayes@psu.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CO6-RR016499] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR010732, MO1-RR10732, C06 RR016499] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01-HL63722, R01 HL063722] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR010732] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL063722] Funding Source: NIH RePORTER		Alfano CA, 2006, SLEEP MED, V7, P467, DOI 10.1016/j.sleep.2006.05.002; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armitage R, 2000, BIOL PSYCHIAT, V47, P338, DOI 10.1016/S0006-3223(99)00129-8; Baeyens D, 2006, CHILD PSYCHIAT HUM D, V36, P403, DOI 10.1007/s10578-006-0011-z; Ball JD, 1997, J PEDIATR PSYCHOL, V22, P389, DOI 10.1093/jpepsy/22.3.389; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; BARKLEY RA, 1990, J CONSULT CLIN PSYCH, V58, P775, DOI 10.1037/0022-006X.58.6.775; Calhoun SL, 2005, PSYCHOL SCHOOLS, V42, P333, DOI 10.1002/pits.20067; CANTWELL DP, 1992, J AM ACAD CHILD PSY, V31, P432, DOI 10.1097/00004583-199205000-00008; Chervin RD, 1997, SLEEP, V20, P1185, DOI 10.1093/sleep/20.12.1185; Chervin RD, 2001, SLEEP, V24, P313, DOI 10.1093/sleep/24.3.313; Chervin RD, 2000, SLEEP MED, V1, P21, DOI 10.1016/S1389-9457(99)00009-X; Cooper J, 2004, CLIN PEDIATR, V43, P609, DOI 10.1177/000992280404300704; Corkum P, 1999, J AM ACAD CHILD PSY, V38, P1285, DOI 10.1097/00004583-199910000-00018; Corkum P, 1998, J AM ACAD CHILD PSY, V37, P637, DOI 10.1097/00004583-199806000-00014; Corkum P, 2001, SLEEP, V24, P303, DOI 10.1093/sleep/24.3.303; Cortese S, 2006, SLEEP, V29, P504; Crowell E., 1998, J ATTEN DISORD, V2, P217, DOI [10.1177/108705479800200402, DOI 10.1177/108705479800200402]; Dahl RE, 2001, CLIN DEV MED, P161; de Nijs PFA, 2007, EUR CHILD ADOLES PSY, V16, P25, DOI 10.1007/s00787-006-0572-1; Faraone SV, 1998, J AM ACAD CHILD PSY, V37, P185, DOI 10.1097/00004583-199802000-00011; Garland EJ, 2001, CLIN DEV MED, P155; Golan N, 2004, SLEEP, V27, P261, DOI 10.1093/sleep/27.2.261; GOODYEAR P, 1992, J CLIN CHILD PSYCHOL, V21, P273, DOI 10.1207/s15374424jccp2103_9; Gordon M, 1983, GORDON DIAGNOSTIC SY; Greene RW, 2002, J EMOT BEHAV DISORD, V10, P79, DOI 10.1177/10634266020100020201; Gross-Tsur V, 2006, DEV MED CHILD NEUROL, V48, P901, DOI 10.1017/S0012162206001976; Gruber R, 2004, SLEEP, V27, P267, DOI 10.1093/sleep/27.2.267; Gruber R, 2000, J AM ACAD CHILD PSY, V39, P495, DOI 10.1097/00004583-200004000-00019; Hartman CA, 2004, J ABNORM CHILD PSYCH, V32, P491, DOI 10.1023/B:JACP.0000037779.85211.29; Huang YS, 2004, J SLEEP RES, V13, P269, DOI 10.1111/j.1365-2869.2004.00408.x; HYND GW, 1991, J CHILD NEUROL, V6, pS37, DOI 10.1177/0883073891006001S05; Ivanenko A, 2004, PEDIATR CLIN N AM, V51, P51, DOI 10.1016/S0031-3955(03)00181-0; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; JENSEN PS, 1993, AM J PSYCHIAT, V150, P1203; KENT JD, 1995, PEDIATRICS, V96, P320; Kirov R, 2004, J SLEEP RES, V13, P87, DOI 10.1111/j.1365-2869.2004.00387.x; Konofal E, 2001, PSYCHIAT CLIN NEUROS, V55, P97, DOI 10.1046/j.1440-1819.2001.00808.x; Lalonde J, 1998, CAN J PSYCHIAT, V43, P623, DOI 10.1177/070674379804300612; LeBourgeois MK, 2004, SLEEP, V27, P520; Lecendreux M, 2000, J CHILD PSYCHOL PSYC, V41, P803, DOI 10.1017/S0021963099005971; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Mayes SD, 2004, CLIN NEUROPSYCHOL, V18, P559, DOI 10.1080/13854040490888530; Mayes SD, 2002, PSYCHOL REP, V91, P575, DOI 10.2466/PR0.91.6.575-587; Mayes SD, 2001, CHILD NEUROPSYCHOL, V7, P32, DOI 10.1076/chin.7.1.32.3151; Mayes SD, 2000, J LEARN DISABIL-US, V33, P417, DOI 10.1177/002221940003300502; MAYES SD, J DEV BEHAV IN PRESS; Mayes SD, 2007, SCHOOL PSYCHOL QUART, V22, P234, DOI 10.1037/1045-3830.22.2.234; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; Mayes Susan Dickerson, 2006, J Atten Disord, V9, P486, DOI 10.1177/1087054705283616; Mayes SD, 2006, LEARN INDIVID DIFFER, V16, P145, DOI 10.1016/j.lindif.2005.07.004; Melendres MCS, 2004, PEDIATRICS, V114, P768, DOI 10.1542/peds.2004-0730; Milich R, 2001, CLIN PSYCHOL-SCI PR, V8, P463, DOI 10.1093/clipsy/8.4.463; Morgan AE, 1996, J AM ACAD CHILD PSY, V35, P325, DOI 10.1097/00004583-199603000-00014; Nichols S, 2000, J PEDIATR PSYCHOL, V25, P545, DOI 10.1093/jpepsy/25.8.545; PLATON MJR, 1990, INT J NEUROSCI, V53, P87, DOI 10.3109/00207459008986591; Power TJ, 2004, J ABNORM CHILD PSYCH, V32, P27, DOI 10.1023/B:JACP.0000007578.30863.93; Prinz R., 1987, ADV BEHAV ASSESSMENT, P57; Ring A, 1998, J LEARN DISABIL, V31, P572, DOI 10.1177/002221949803100607; Sadeh A, 2002, CHILD DEV, V73, P405, DOI 10.1111/1467-8624.00414; STANFORD LD, 1994, J LEARN DISABIL, V27, P243, DOI 10.1177/002221949402700406; Stein D, 2002, J LEARN DISABIL-US, V35, P268, DOI 10.1177/002221940203500308; Stein MA, 1999, J CHILD ADOL PSYCHOP, V9, P157, DOI 10.1089/cap.1999.9.157; Stores G, 2001, CLIN DEV MED, P15; TIROSH E, 1993, AM J DIS CHILD, V147, P1313, DOI 10.1001/archpedi.1993.02160360055018; van der Heijden KB, 2005, CLIN PEDIATR, V44, P201, DOI 10.1177/000992280504400303; Van Der Heijden KB, 2007, J AM ACAD CHILD PSY, V46, P233, DOI 10.1097/01.chi.0000246055.76167.0d; Vgontzas AN, 1998, ARCH INTERN MED, V158, P1333, DOI 10.1001/archinte.158.12.1333; Weiss MD, 2006, J AM ACAD CHILD PSY, V45, P512, DOI [10.1097/01.chi.0000205706.78818.ef, 10.1097/01 chi.0000205706.78818.ef]; Wilens TE, 2002, J AM ACAD CHILD PSY, V41, P262, DOI 10.1097/00004583-200203000-00005; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501; Woo BSC, 2005, AUST NZ J PSYCHIAT, V39, P344, DOI 10.1080/j.1440-1614.2005.01580.x; [No title captured]	75	141	142	1	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	APR	2009	34	3					328	337		10.1093/jpepsy/jsn083			10	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	421YL	WOS:000264394100011	18676503	Green Published, Bronze			2022-02-06	
J	Johansson, B; Berglund, P; Ronnback, L				Johansson, Birgitta; Berglund, Peter; Ronnback, Lars			Mental fatigue and impaired information processing after mild and moderate traumatic brain injury	BRAIN INJURY			English	Article						Mental fatigue; TBI; MTBI; self-assessment questionnaire; information processing speed; working memory; digit symbol-coding; reading speed; TMT	III DIGIT; DIVIDED ATTENTION; COGNITIVE FATIGUE; SPEED; DEPRESSION; COMPLAINTS; SYMPTOMS; MEMORY; SCALE; SPAN	Primary objective: Mental fatigue is a common symptom after brain injury. Its mechanisms are not fully understood and it has been difficult to find an objective way of measuring it. The aim was to compare cognitive tests with a new self-assessment questionnaire about mental fatigue. Methods and procedures: Individuals reporting mental fatigue for 6 months or more after mild traumatic brain injury (MTBI) or traumatic brain injury (TBI) and controls were assessed for subjective fatigue, information processing speed, working memory and attention. Depression and anxiety were also assessed in the individuals with brain injury. Results: Individuals with MTBI or TBI reported significantly more problems with mental fatigue and related symptoms than controls. A significantly decreased information processing speed (digit symbol-coding, reading speed, trail making test) was found in those on sick leave due to MTBI or TBI, compared to controls. Divided attention was affected to a lesser extent and no effect was detected on working memory. Conclusion: Mental fatigue after MTBI can last for several years. It can be profoundly disabling and affect working capacity as well as social activities. Subjective mental fatigue following brain injury is suggested to mainly correlate with objectively measured information processing speed.	[Johansson, Birgitta; Berglund, Peter; Ronnback, Lars] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden		Johansson, B (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Dubbsgatan 14,1Tr, SE-41345 Gothenburg, Sweden.	birgitta.johansson2@vgregion.se		Berglund, Peter/0000-0003-2367-1686; , Birgitta/0000-0003-0240-1142	Region Vastra Gotaland, Swedish Research CouncilSwedish Research Council [21X-13015]; Fyrbodalinstitutet	This work was supported by grants from The Health & Medical Care Committee of the Region Vastra Gotaland, Swedish Research Council, 21X-13015 and from Fyrbodalinstitutet.	ANDERSSON EH, 2004, THESIS U GOTHENBURG; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Cratty MS, 1999, PEPTIDES, V20, P93, DOI 10.1016/S0196-9781(98)00147-8; DeLuca J., 2007, INFORM PROCESSING SP; DELUCA J, 2007, INFORM PROCESSING SP, P265; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; ELLIS DC, 2001, DELISKAPLAN EXECUTIV; Elovic EP, 2005, ISS CLIN COGN NEUROP, P89; Hansson E, 2004, NEUROCHEM RES, V29, P989, DOI 10.1023/B:NERE.0000021243.86287.43; JARPSTEN B, 2002, DLS HANDLEDNING SKOL; JOHANSSON B, BRAIN INJURY UNPUB; Joy S, 2004, ARCH CLIN NEUROPSYCH, V19, P759, DOI 10.1016/j.acn.2003.09.009; Kessels RPC, 2008, ASSESSMENT, V15, P426, DOI 10.1177/1073191108315611; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Mathew S J, 2001, CNS Spectr, V6, P555; MATHEW SJ, 2001, CNS SPECTRUMS, V6, P561, DOI DOI 10.1017/S1092852900002091; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Reitan RM, 1985, HALSTEADREITAN NEURO; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Ronnback L, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-22; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; STULEMEIJER M, 2006, J NEUROL, V253, P1432; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Tombaugh TN, 2007, ARCH CLIN NEUROPSYCH, V22, P25, DOI 10.1016/j.acn.2006.06.013; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; VANNAALT J, 1999, J NEUROL NEUROSUR PS, V66, P207; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D., 2004, WECHSLER ADULT INTEL; Wilde N, 2002, CLIN NEUROPSYCHOL, V16, P322, DOI 10.1076/clin.16.3.322.13858; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	52	141	145	0	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	13-14					1027	1040		10.3109/02699050903421099			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	529YR	WOS:000272556000005	19909051				2022-02-06	
J	Cicerone, KD; Mott, T; Azulay, J; Sharlow-Galella, MA; Ellmo, WJ; Paradise, S; Friel, JC				Cicerone, Keith D.; Mott, Tasha; Azulay, Joanne; Sharlow-Galella, Mary A.; Ellmo, Wendy J.; Paradise, Susan; Friel, John C.			A Randomized Controlled Trial of Holistic Neuropsychologic Rehabilitation After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Quality of life; Rehabilitation	PRACTICAL CLINICAL-TRIALS; QUALITY-OF-LIFE; POSTACUTE REHABILITATION; ERROR-AWARENESS; SELF-AWARENESS; EFFICACY; NEUROREHABILITATION; PARTICIPATION; INDIVIDUALS; OUTCOMES	Objective: To evaluate the effectiveness of comprehensive, holistic neuropsychologic (NP) rehabilitation compared with standard, multidisciplinary rehabilitation for people with traumatic brain injury (TBI). Design: Randomized practical controlled trial. Setting: Postacute brain injury rehabilitation center within a suburban rehabilitation hospital. Participants: Participants with TBI were recruited from clinical referrals and referrals from the community. Sixty-eight participants who met inclusion criteria were randomly allocated to treatment conditions. Most participants (88%) had sustained moderate or severe TBI, and greater than half (57%) were more than 1 year postinjury at the beginning of treatment. Interventions: Treatment was conducted 15 hours per week for 16 weeks. Standard neurorehabilitation consisted primarily of individual, discipline specific therapies (n=34). Intensive cognitive rehabilitation emphasized the integration of cognitive, interpersonal, and functional interventions within a therapeutic environment (n=34). Main Outcome Measures: Primary outcomes were the Community Integration Questionnaire (CIQ) and Perceived Quality of Life scale (PQOL). Secondary outcomes included NP functioning, perceived self-efficacy, and community-based employment. Results: NP functioning improved in both conditions. Intensive cognitive rehabilitation participants showed greater improvements on the CIQ (effect size [ES]=0.59) and PQOL (ES=0.30) as well as improved self-efficacy for the management of symptoms (ES=0.26) compared with standard neurorehabilitation treatment. These gains were maintained at the 6-month follow-up. Standard neurorehabilitation participants showed improved productivity at the 6-month follow-up associated with the need for continued rehabilitation. Conclusions: Improvements seen after intensive cognitive rehabilitation may be related to interventions directed at the self-regulation of cognitive and emotional processes and the integrated treatment of cognitive, interpersonal, and functional skills. The results show the effectiveness of comprehensive holistic NP rehabilitation for improving community functioning and quality of life after TBI compared with standard rehabilitation.	[Cicerone, Keith D.; Mott, Tasha; Azulay, Joanne; Sharlow-Galella, Mary A.; Ellmo, Wendy J.; Paradise, Susan; Friel, John C.] JFK Johnson Rehabil Inst, Dept Cognit Rehabil, Edison, NJ USA; [Cicerone, Keith D.] JFK Johnson Rehabil Inst, Dept Phys Med & Rehabil, Edison, NJ USA		Cicerone, KD (corresponding author), 2048 Oak Tree Rd, Edison, NJ 08820 USA.	kcicerone@solarishs.org					BANDURA A, 1989, DEV PSYCHOL, V25, P729, DOI 10.1037/0012-1649.25.5.729; BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x; Ben-Yishay Y, 2000, REHABIL PSYCHOL, V45, P112, DOI 10.1037/0090-5550.45.2.112; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BENYISHAY Y, 1990, NEUROBEHAVIORAL SEQU; Bergquist TF, 1994, J HEAD TRAUMA REHAB, V9, P50, DOI 10.1097/00001199-199412000-00007; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; CICERONE KD, 1990, NEUROPSYCHOLOGY EVER; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Delis D.C., 2000, CALIFORNIA VERBAL LE; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dixon G, 2007, CLIN REHABIL, V21, P230, DOI 10.1177/0269215506071784; GIST ME, 1992, ACAD MANAGE REV, V17, P183, DOI 10.2307/258770; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Glasgow RE, 2005, MED CARE, V43, P551, DOI 10.1097/01.mlr.0000163645.41407.09; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Heaton RK, 1991, COMPREHENSIVE NORMS; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; Keith N, 2005, J APPL PSYCHOL, V90, P677, DOI 10.1037/0021-9010.90.4.677; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malouff JM, 2007, CLIN PSYCHOL REV, V27, P46, DOI 10.1016/j.cpr.2005.12.005; Meyers JE., 1995, REY COMPLEX FIGURE T; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Shewchuk RM, 2000, BEHAV RES THER, V38, P727, DOI 10.1016/S0005-7967(99)00122-9; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624	52	141	143	1	25	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12					2239	2249		10.1016/j.apmr.2008.06.017			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	385GY	WOS:000261803900002	19061735				2022-02-06	
J	Brody, DL; Mac Donald, C; Kessens, CC; Yuede, C; Parsadanian, M; Spinner, M; Kim, E; Schwetye, KE; Holtzman, DM; Bayly, PV				Brody, David L.; Mac Donald, Christine; Kessens, Chad C.; Yuede, Carla; Parsadanian, Maia; Spinner, Mike; Kim, Eddie; Schwetye, Katherine E.; Holtzman, David M.; Bayly, Philip V.			Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; controlled cortical impact; experimental traumatic brain injury; histology; mice	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; TRANSGENIC MICE; APOLIPOPROTEIN-E; COGNITIVE FUNCTION; MOUSE MODEL; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; AXONAL INJURY; CELL LOSS	Genetically modified mice represent useful tools for traumatic brain injury (TBI) research and attractive preclinical models for the development of novel therapeutics. Experimental methods that minimize the number of mice needed may increase the pace of discovery. With this in mind, we developed and characterized a prototype electromagnetic (EM) controlled cortical impact device along with refined surgical and behavioral testing techniques. By varying the depth of impact between 1.0 and 3.0 mm, we found that the EM device was capable of producing a broad range of injury severities. Histologically, 2.0-mm impact depth injuries produced by the EM device were similar to 1.0-mm impact depth injuries produced by a commercially available pneumatic device. Behaviorally, 2.0-, 2.5-, and 3.0-mm impacts impaired hidden platform and probe trial water maze performance, whereas 1.5-mm impacts did not. Rotorod and visible platform water maze deficits were also found following 2.5- and 3.0-mm impacts. No impairment of conditioned fear performance was detected. No differences were found between sexes of mice. Inter-operator reliability was very good. Behaviorally, we found that we could statistically distinguish between injury depths differing by 0.5 mm using 12 mice per group and between injury depths differing by 1.0 rum with 7-8 mice per group. Thus, the EM impactor and refined surgical and behavioral testing techniques may offer a reliable and convenient framework for preclinical TBI research involving mice.	Washington Univ, Hope Ctr Neurol Disorders, Dept Neurol, St Louis, MO USA; Washington Univ, Hope Ctr Neurol Disorders, Dept Biomed Engn, St Louis, MO USA; Washington Univ, Hope Ctr Neurol Disorders, Dept Engn Mech, St Louis, MO USA; Washington Univ, Hope Ctr Neurol Disorders, Dept Psychiat, St Louis, MO USA; Washington Univ, Hope Ctr Neurol Disorders, Dept Mol Biol & Pharmacol, St Louis, MO USA; Washington Univ, Hope Ctr Neurol Disorders, Dept Anat & Neurobiol, St Louis, MO USA		Brody, DL (corresponding author), Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237, R44NS046825, R43NS046825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37AG013956, R01AG013956] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37 AG013956, AG13956, R01 AG013956] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS049237-04, R44 NS46825, R44 NS046825, K08 NS049237, NS049237, R43 NS046825] Funding Source: Medline		Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chang EF, 2003, J NEUROSCI, V23, P3689; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; Crawley JN, 2000, WHATS WRONG MY MOUSE; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Faden AI, 2005, NEUROPHARMACOLOGY, V49, P410, DOI 10.1016/j.neuropharm.2005.04.001; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; HOWARD V, 2005, UNIBASED STEREOLOGY; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Khuchua Z, 2003, NEUROSCIENCE, V119, P101, DOI 10.1016/S0306-4522(03)00094-0; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sun YL, 1998, J NEUROSCI, V18, P3261; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023	55	141	148	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					657	673		10.1089/neu.2006.0011			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000008	17439349	Green Submitted, Green Accepted			2022-02-06	
J	Himanen, L; Portin, R; Isoniemi, H; Helenius, H; Kurki, T; Tenovuo, O				Himanen, L; Portin, R; Isoniemi, H; Helenius, H; Kurki, T; Tenovuo, O			Longitudinal cognitive changes in traumatic brain injury - A 30-year follow-up study	NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; GENDER-DIFFERENCES; PERFORMANCE; PREDICTION; SEQUELAE; RISK; TBI	Objective: To evaluate longitudinal cognitive changes in patients over three decades following traumatic brain injury (TBI). Method: Two hundred ten patients with substantial TBI of variable severity were initially assessed between 1966 and 1972 at Turku University Hospital (Finland). Of these, 61 patients could be studied using the same assessments in the follow-up examination, on average 30 years after the TBI. The results of the follow-up assessment were also compared with an age-and education-matched control group. During each examination, patients were assessed with five subtests of the Wechsler Adult Intelligence Scale, three tests for episodic memory, and the general cognitive decline was determined. Results: The general pattern of slight cognitive decline during a 30-year follow-up contrasted with improvement in semantic memory. Women maintained their cognitive level, but men showed a decline during the follow-up, especially in visuospatial ability and visual memory. Younger patients were likely to maintain or even improve their cognitive functioning. Conclusions: Most of the patients had mild cognitive decline during the follow-up, but this decline was influenced by gender and age at injury. Unlike the long-term course in the other domains of cognition, semantic memory showed good recovery potential after traumatic brain injury (TBI). The profile of long-term cognitive decline after TBI seems to be qualitatively different from the early signs of dementia of the Alzheimer type.	Turky Univ Hosp, Dept Neurol, FIN-20521 Turku, Finland; Turky Univ Hosp, Dept Biostat, FIN-20521 Turku, Finland; Turky Univ Hosp, Dept Radiol, FIN-20521 Turku, Finland		Himanen, L (corresponding author), Turky Univ Hosp, Dept Neurol, POB 52, FIN-20521 Turku, Finland.	ls.himanen@kolumbus.fi	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Kurki, Timo/0000-0001-5532-3534; Himanen, Leena/0000-0001-7261-8027			Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; Benton AL, 1963, REVISED VISUAL RETEN; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BERNSTEIN DM, 1996, J INT NEUROPSYCH SOC, V2, P18; Birren JamesE., 1977, HDB PSYCHOL AGING, V2nd, P580; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KUJALA P, 1994, BRAIN, V117, P1115, DOI 10.1093/brain/117.5.1115; Laatu S, 1997, CORTEX, V33, P27, DOI 10.1016/S0010-9452(97)80003-2; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nybo T, 1999, BRAIN INJURY, V13, P759; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; PORTIN R, 1995, PSYCHOL MED, V25, P1295, DOI 10.1017/S0033291700033262; PORTIN R, 1980, PARKINSONS DISEASE C, P271; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Spaan PEJ, 2003, J CLIN EXP NEUROPSYC, V25, P216, DOI 10.1076/jcen.25.2.216.13638; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089	42	141	146	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 24	2006	66	2					187	192		10.1212/01.wnl.0000194264.60150.d3			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	005SA	WOS:000234842900010	16434651				2022-02-06	
J	Braga, LW; Da Paz, AC; Ylvisaker, M				Braga, LW; Da Paz, AC; Ylvisaker, M			Direct clinician-delivered versus indirect family-supported rehabilitation of children with traumatic brain injury: A randomized controlled trial	BRAIN INJURY			English	Article						brain injuries/rehabilitation; randomized controlled trial; family; children	ACADEMIC-ACHIEVEMENT; YOUNG-CHILDREN; ADOLESCENTS; OUTCOMES; INTERVENTIONS; DISABILITIES; PREDICTORS; SEQUELAE; STUDENTS	Primary objectives: To explore the relative effectiveness of clinician-delivered vs family-supported interventions for children with chronic impairment after TBI. Research design: Randomized controlled clinical trial. Methods and procedures: Children aged 5-12 years in the chronic phase of their recovery were randomly assigned to the clinician-delivered or to the family-supported intervention group; both samples received intensive services for 1 year; physical outcome was measured by the SARAH scales, cognitive outcome by the WISC-III. Main outcomes and results: Parents in the family-supported intervention sample efficiently acquired the skills needed to deliver physical and cognitive interventions within the context of everyday routines of the child's life at home; family education level was not a factor. Although both groups demonstrated improvements, only the children in the family-supported intervention group demonstrated statistically significant - and clinically important - improvements on both outcome measures. Conclusions: This RCT provides compelling evidence for organizing cognitive and physical interventions and supports for children with TBI around the everyday routines of their lives, with intensive supports for their families.	SARAH Univ Rehabil Sci, SARAH Network Rehabil Hosp, Brasilia, DF, Brazil; Coll St Rose, Sch Educ, Albany, NY USA		Braga, LW (corresponding author), Rede SARAH Hosp, SMHS Q 501,Conj A,Andar Terreo, BR-70335901 Brasilia, DF, Brazil.	luciabraga@sarah.br	Braga, Lucia/AAQ-1030-2020; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X			Anderson, 1989, TRANSFER COGNITIVE S; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ARMSTRONG K, 2003, PEDIAT REHABIL, V5, P149; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BUTTERFIELD EC, 1993, TRANSFER TRIAL INTEL, P192; CLANCEY WJ, 1997, SITUATED COGNITION H; Conoley JC, 1996, J LEARN DISABIL-US, V29, P662, DOI 10.1177/002221949602900610; D'Zurilla TJ, 1986, PROBLEM SOLVING THER; Drotar D, 1997, J PEDIATR PSYCHOL, V22, P149; Emanuelson I, 1996, CHILD NERV SYST, V12, P460, DOI 10.1007/BF00261625; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gersten R, 2001, REV EDUC RES, V71, P279, DOI 10.3102/00346543071002279; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Girolametto L, 1996, J SPEECH HEAR RES, V39, P1274, DOI 10.1044/jshr.3906.1274; Girolametto L, 1996, J CHILDHOOD COMMUNIC, V17, P39, DOI DOI 10.1177/152574019501700205; GIROLAMETTO L, 2003, EFFECTS LANGUAGE INT; Greeno JG, 1998, AM PSYCHOL, V53, P5, DOI 10.1037/0003-066X.53.1.5; Gresham FM, 2001, EXCEPT CHILDREN, V67, P331, DOI 10.1177/001440290106700303; Howle JM, 2003, NEURODEVELOPMENTAL T; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Lave J., 1996, UNDERSTANDING PRACTI, P3; Mann L, 1979, TRAIL PROCESS HIST P; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McConachie H, 2000, J PEDIATR-US, V137, P769, DOI 10.1067/mpd.2000.110135; Miller S.A., 2002, COGNITIVE DEV, V4th; Nelson J E, 2002, Pediatr Rehabil, V5, P37, DOI 10.1080/1363849021000007088; Patterson GeraldR., 1988, STRESS COPING DEV CH, P235; Pressley M., 2006, READING INSTRUCTION, V3rd ed; PRESSLEY M, 1995, COGNITIVE STRATEGY I; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Robin AL, 1989, NEGOTIATING PARENT A; Rogoff B., 1990, APPRENTICESHIP THINK; SANDERS MR, 1989, J CLIN CHILD PSYCHOL, V18, P72, DOI 10.1207/s15374424jccp1801_9; *SAR NETW REH HOSP, 1989, SAR SCAL MOT DEV; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; SPORNS O, 1994, INT REV NEUROBIOL, V37, P3; SPORNS O, 1993, CHILD DEV, V64, P960, DOI 10.1111/j.1467-8624.1993.tb04182.x; Sternberg R., 1993, TRANSFER TRIAL INTEL, P25; SWANSON HL, 1999, LEARN DISABIL RES PR, V14, P129, DOI DOI 10.1207/SLDRP1403_; SWANSON HL, 2001, LEARN DISABIL RES PR, V16, P109, DOI DOI 10.1111/0938-8982.00012; Sweet AP, 2002, IMPROVING COMPREHENS, P17; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; Vygotsky L.V., 1986, THOUGHT LANGUAGE; Vygotsky LS., 1978, MIND SOC DEV HIGHER; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WADE SL, 2003, ANN M INT NEUR SOC O; WADE SL, UNPUB PUTTING PIECES; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; Ylvisaker M., 2003, BRAIN IMPAIR, V4, P1, DOI [DOI 10.1375/brim.4.1.1.27031, https://doi.org/10.1375/brim.4.1.1.27031, DOI 10.1375/BRIM.4.1.1.27031]; Ylvisaker M., 1998, COLLABORATIVE BRAIN	67	141	142	1	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2005	19	10					819	831		10.1080/02699050500110165			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800008	16175842				2022-02-06	
J	Bryant, RA; Moulds, M; Guthrie, R; Nixon, RDV				Bryant, RA; Moulds, M; Guthrie, R; Nixon, RDV			Treating acute stress disorder following mild traumatic brain injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							THERAPY; SCALE	Objective: Acute stress disorder permits early identification of trauma survivors who are at risk of developing chronic posttraumatic stress disorder (PTSD). This study aimed to prevent PTSD in people who developed acute stress disorder after a mild brain injury by early provision of cognitive behavior therapy. Method: Twenty-four civilian trauma survivors with acute stress disorder were given five individually administered sessions of either cognitive behavior therapy or supportive counseling within 2 weeks of their trauma. Results: Fewer patients receiving cognitive behavior therapy than supportive counseling met criteria for PTSD at a posttreatment evaluation (8% versus 58%, respectively). There were also fewer cases of PTSD at a 6-month follow-up evaluation among those receiving cognitive behavior therapy (17%) than among those receiving supportive counseling (58%). Patients in the cognitive behavior therapy condition displayed less reexperiencing and avoidance symptoms at the follow-up evaluation than patients receiving supportive counseling. Conclusions: These findings suggest that PTSD following mild brain injury can be effectively prevented with early provision of cognitive behavior therapy.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Moulds, Michelle/B-2928-2010; Bryant, Richard/AAA-6479-2019; Nixon, Reginald/A-6095-2015	Bryant, Richard/0000-0002-9607-819X; Nixon, Reginald/0000-0003-1507-8428; Moulds, Michelle/0000-0001-7064-4248			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BEC AT, 1993, BECK ANXIETY INVENTO; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Cohen J., 2013, STAT POWER ANAL BEHA; Fleiss J.L., 1981, STAT METHODS RATES P; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004	15	141	142	0	8	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	MAR	2003	160	3					585	587		10.1176/appi.ajp.160.3.585			3	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	655MX	WOS:000181557600028	12611847	Green Published			2022-02-06	
J	Tate, DF; Bigler, ED				Tate, DF; Bigler, ED			Fornix and hippocampal atrophy in traumatic brain injury	LEARNING & MEMORY			English	Article							TEMPORAL-LOBE EPILEPSY; AMINO-ACIDS; MEMORY; DEMENTIA; DEGENERATION; AMNESIA; VOLUME	This study compared a fornix cross-sectional-area measurement and hippocampal volume in 86 traumatic brain injury (TBI) subjects with 46 normal controls. The TBI group showed a significant reduction in fornix area and hippocampal volume. It was also shown that initial injury severity was related to the degree of atrophy in both structures. Although fornix size and hippocampal volume correlated, such a modest correlation between these two structures suggests differential and potentially independent mechanisms of injury. The General Memory Index score from the Wechsler Memory Scale-Revised was shown to be significantly correlated with hippocampal volume following TBI.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.	erin_bigler@byu.edu	Tate, David F/I-3963-2013; Tate, David/G-5166-2011	Tate, David F/0000-0003-0213-1920; Tate, David/0000-0003-0213-1920			ADAMS JH, 1985, CENTRAL NERVOUS SYST; Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brodal A., 1981, NEUROLOGICAL ANATOMY; CARPENTER MB, 1983, HUMAN NEUROANATOMY; Chance SA, 1999, AM J PSYCHIAT, V156, P1720; DESPOSITO M, 1995, NEUROLOGY, V45, P1546, DOI 10.1212/WNL.45.8.1546; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fujita T, 1996, J EPILEPSY, V9, P87, DOI 10.1016/0896-6974(95)00075-5; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GEAN AD, 1994, IMAGING HED TRAUMA; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Heun R, 1997, DEMENT GERIATR COGN, V8, P329, DOI 10.1159/000106651; LENCZ T, 1992, ANN NEUROL, V31, P629, DOI 10.1002/ana.410310610; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; Martin RC, 1999, J INT NEUROPSYCH SOC, V5, P540, DOI 10.1017/S1355617799566083; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RASBAND W, 1993, IMAGE VERSION 1 52; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; SQUIRE LR, 1991, MEMORY ORG LOCUS CHA; Stout JC, 1999, NEUROPSYCHOLOGY, V13, P188, DOI 10.1037/0894-4105.13.2.188; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; Wechsler D, 1987, MEMORY SCALE REVISED; White RJ, 1996, J NEUROSCI, V16, P5688; WILHELM KL, 1997, APPL NEUROPSYCHOL, V2, P42	33	141	142	1	6	COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT	COLD SPRING HARBOR	1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	1072-0502	1549-5485		LEARN MEMORY	Learn. Mem.	NOV-DEC	2000	7	6					442	446		10.1101/lm.33000			5	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	387RD	WOS:000166134800009	11112803	Bronze			2022-02-06	
J	Li, M; Ona, VO; Chen, M; Kaul, M; Tenneti, L; Zhang, X; Stieg, PE; Lipton, SA; Friedlander, RM				Li, M; Ona, VO; Chen, M; Kaul, M; Tenneti, L; Zhang, X; Stieg, PE; Lipton, SA; Friedlander, RM			Functional role and therapeutic implications of neuronal caspase-1 and-3 in a mouse model of traumatic spinal cord injury	NEUROSCIENCE			English	Article						apoptosis; ICE; zVAD-fmk; interleukin-1 beta; neuroprotection	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TROPHIC FACTOR WITHDRAWAL; DOMINANT-NEGATIVE MUTANT; CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; BRAIN INJURY; CYSTEINE PROTEASE; FAMILY PROTEASES; CONTUSION INJURY; MICE DEFICIENT	Evidence indicates that both necrotic and apoptotic cell death contribute to tissue injury and neurological dysfunction following spinal cord injury. Caspases have been implicated as important mediators of apoptosis following acute central nervous system insults. We investigated whether caspase-1 and caspase-3 are involved in spinal cord injury-mediated cell death, and whether caspase inhibition may reduce tissue damage and improve outcome following spinal cord injury. We demonstrate a 17-fold increase in caspase-1 activity in traumatized spinal cord samples when compared with samples from sham-operated mice. Caspase-1 and caspase-3 activation were also detected by western blot following spinal cord injury, which was significantly inhibited by the broad caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. By immunofluorescence or in situ fluorogenic substrate assay, caspase-1 and caspase-3 expression were detected in neuronal and non-neuronal cells following spinal cord injury. N-Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone treated mice, and transgenic mice expressing a caspase-1 dominant negative mutant, demonstrated a significant improvement of motor function and a reduction of lesion size compared with vehicle-treated mice. Our results demonstrate for the first time that both caspase-1 and caspase-3 are activated in neurons following spinal cord injury, and that caspase inhibition reduces post-traumatic lesion size and improves motor performance. Caspase inhibitors may be one of the agents to be used for the treatment of spinal cord injury. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Neuroapoptosis Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Neurosurg Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Cerebrovasc & Neurosci Res Inst, Boston, MA 02115 USA		Friedlander, RM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Neuroapoptosis Lab, Boston, MA 02115 USA.	rfriedlander@rics.bwh.harvard.edu	Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD29587] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD029587] Funding Source: NIH RePORTER		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAUGHLER JM, 1985, J NEUROSURG, V62, P806, DOI 10.3171/jns.1985.62.6.0806; Burne JF, 1996, J NEUROSCI, V16, P2064; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GERHART KA, 1991, J TRAUMA, V31, P1529, DOI 10.1097/00005373-199111000-00012; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lee TT, 1999, J NEUROTRAUM, V16, P347, DOI 10.1089/neu.1999.16.347; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Mao PL, 1998, J BIOL CHEM, V273, P23621, DOI 10.1074/jbc.273.37.23621; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Namura S, 1998, J NEUROSCI, V18, P3659; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; SAMBROOK J, 1989, MOL CLONING LABORATO, V9, P16; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; Wamil AW, 1998, P NATL ACAD SCI USA, V95, P13188, DOI 10.1073/pnas.95.22.13188; Xu DG, 1999, J NEUROSCI, V19, P5026; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	51	141	159	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2000	99	2					333	342		10.1016/S0306-4522(00)00173-1			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	346VF	WOS:000088891200015	10938439				2022-02-06	
J	Holmin, S; Almqvist, P; Lendahl, U; Mathiesen, T				Holmin, S; Almqvist, P; Lendahl, U; Mathiesen, T			Adult nestin-expressing subependymal cells differentiate to astrocytes in response to brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						nestin; GFAP; neurofilament; stem cell; rat	CENTRAL-NERVOUS-SYSTEM; INTERMEDIATE FILAMENT NESTIN; FIBRILLARY ACIDIC PROTEIN; FOREBRAIN SUBVENTRICULAR ZONE; AP-1 TRANSCRIPTION FACTORS; FIBROBLAST GROWTH-FACTOR; FACTOR MESSENGER-RNA; NEURAL STEM-CELLS; RAT-BRAIN; MAMMALIAN BRAIN	The adult brain contains a small population of central nervous system (CNS) cells in the subependyma which, like embryonic CNS progenitor cells, express the intermediate filament nestin. In this report, the differentiation capacity in vivo of these cells was analysed following a standardized trauma. Before the trauma, the subependymal cells expressed nestin but not the astrocytic and neuronal differentiation markers glial fibrillary acidic protein (GFAP) and neurofilament respectively. In response to injury, the majority of the subependymal cells coexpressed nestin and GFAP, but never nestin and neurofilament. Furthermore, cells coexpressing nestin and GFAP were found progressively further away from the subependyma and closer to the lesion at later time points after the injury, indicating that these cells migrate towards the lesion. Nestin was in addition re-expressed in reactive astrocytes near the lesion and in non-reactive astrocytes very far from the lesion throughout the ipsilateral cortex. In conclusion, our data indicate that the nestin-positive subependymal cells are an in vivo source for the generation of new astrocytes but not neurons after injury, and that nestin re-expression in astrocytes following traumatic stimuli can be used as a sensitive marker for astroglial activation.	KAROLINSKA INST, DEPT CLIN NEUROSCI, NEUROSURG SECT, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT CELL & MOL BIOL, MED NOBEL INST, S-17176 STOCKHOLM, SWEDEN				mathiesen, tiit/ABC-3627-2021	Mathiesen, Tiit/0000-0001-9463-1919; Almqvist, Per/0000-0002-0383-8189; Holmin, Staffan/0000-0002-1628-1615; Lendahl, Urban/0000-0001-9543-8141			AGUAYO AJ, 1991, PHILOS T R SOC B, V331, P337, DOI 10.1098/rstb.1991.0025; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CAVANAGH JB, 1970, J ANAT, V106, P471; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; ENG LF, 1992, PROG BRAIN RES, V94, P353; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; ISHIKAWA R, 1991, NEUROSCI LETT, V127, P70, DOI 10.1016/0304-3940(91)90897-3; JENSEN I, 1976, ACTA NEUROL SCAND, V54, P391, DOI 10.1111/j.1600-0404.1976.tb04372.x; JIE Z, 1986, ACTA PATH MICRO IM A, V94, P353; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KILPATRICK TJ, 1995, MOL CELL NEUROSCI, V6, P2, DOI 10.1006/mcne.1995.1002; KOSHINAGA M, 1993, EXP NEUROL, V120, P32, DOI 10.1006/exnr.1993.1038; KRAIG RP, 1991, J NEUROSCI, V11, P2187; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; LEVISON SW, 1993, DEVELOPMENT, V119, P611; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1994, GLIA, V11, P211, DOI 10.1002/glia.440110302; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NORDQVIST ACS, 1996, BRAIN RES MOL BRAIN, V38, P285; OSBORN M, 1982, VIRCHOWS ARCH B, V40, P141, DOI 10.1007/BF02932859; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; POLLEN D A, 1970, Science (Washington D C), V167, P1252, DOI 10.1126/science.167.3922.1252; Price Jack, 1994, Current Opinion in Neurobiology, V4, P680, DOI 10.1016/0959-4388(94)90009-4; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SEJERSEN T, 1993, J CELL SCI, V106, P1291; SMART I, 1961, J COMP NEUROL, V116, P349, DOI 10.1002/cne.901160307; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG K, 1993, P SOC NEUROSCI, V13, P1880; ZHENG M, 1988, MOL BRAIN RES, V3, P133, DOI 10.1016/0169-328X(88)90058-7; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	53	141	164	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JAN	1997	9	1					65	75		10.1111/j.1460-9568.1997.tb01354.x			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WJ179	WOS:A1997WJ17900009	9042570				2022-02-06	
J	Harmon, KG; Clugston, JR; Dec, K; Hainline, B; Herring, S; Kane, SF; Kontos, AP; Leddy, JJ; McCrea, M; Poddar, SK; Putukian, M; Wilson, JC; Roberts, WO				Harmon, Kimberly G.; Clugston, James R.; Dec, Katherine; Hainline, Brian; Herring, Stanley; Kane, Shawn F.; Kontos, Anthony P.; Leddy, John J.; McCrea, Michael; Poddar, Sourav K.; Putukian, Margot; Wilson, Julie C.; Roberts, William O.			American Medical Society for Sports Medicine position statement on concussion in sport	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							KING-DEVICK TEST; HIGH-SCHOOL FOOTBALL; CEREBRAL-BLOOD-FLOW; EXTREMITY MUSCULOSKELETAL INJURY; CHRONIC TRAUMATIC ENCEPHALOPATHY; METABOLIC BRAIN VULNERABILITY; VOLUNTARY EXERCISE; TEMPORAL WINDOW; SCREENING TOOL; NUTRITIONAL SUPPLEMENTS	Sport-related concussion (SRC) is a common injury in recreational and organised sport. Over the past 30 years, there has been significant progress in our scientific understanding of SRC, which in turn has driven the development of clinical guidelines for diagnosis, assessment and management of SRC. In addition to a growing need for knowledgeable healthcare professionals to provide evidence-based care for athletes with SRC, media attention and legislation have created awareness and, in some cases, fear about many issues and unknowns surrounding SRC. The American Medical Society for Sports Medicine (AMSSM) formed a writing group to review the existing literature on SRC, update its previous position statement, and to address current evidence and knowledge gaps regarding SRC. The absence of definitive outcomes-based data is challenging and requires relying on the best available evidence integrated with clinical experience and patient values. This statement reviews the definition, pathophysiology and epidemiology of SRC, the diagnosis and management of both acute and persistent concussion symptoms, the short-term and long-term risks of SRC and repetitive head impact exposure, SRC prevention strategies, and potential future directions for SRC research. The AMSSM is committed to best clinical practices, evidence-based research and educational initiatives that positively impact the health and safety of athletes.	[Harmon, Kimberly G.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA; [Harmon, Kimberly G.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL USA; [Clugston, James R.] Univ Florida, Dept Neurol, Gainesville, FL USA; [Dec, Katherine] Virginia Commonwealth Univ, Dept Phys Med & Rehabil & Orthopaed Surg, Richmond, VA USA; [Hainline, Brian] NCAA, Indianapolis, IN USA; [Herring, Stanley] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Kane, Shawn F.] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27515 USA; [Kontos, Anthony P.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA; [Leddy, John J.] SUNY Buffalo, UBMD Dept Orthopaed & Sports Med, Buffalo, NY USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Poddar, Sourav K.] Univ Colorado, Dept Family Med & Orthoped, Denver, CO 80202 USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Rutgers Robert Wood Johnson Med Sch, Internal Med Sports Med, New Brunswick, NJ USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Wilson, Julie C.] Univ Colorado, Dept Orthoped, Aurora, CO USA; [Roberts, William O.] Univ Minnesota, Dept Family Med & Community Hlth, Minneapolis, MN USA		Harmon, KG (corresponding author), Univ Washington, Dept Family Med, Seattle, WA 98195 USA.; Harmon, KG (corresponding author), Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA.	kharmon@uw.edu		Roberts, William O/0000-0003-4517-4330; Clugston, James/0000-0002-2103-1039; kane, Shawn/0000-0002-9110-5224; Harmon, Kimberly/0000-0002-3670-6609			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Ashbaugh A, 2016, CURR SPORT MED REP, V15, P16, DOI 10.1249/JSR.0000000000000219; Asken BM, 2018, AM J SPORT MED, V46, P1465, DOI 10.1177/0363546518757984; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bernhardt D, 2010, PREPARTICIPATION PHY; Besnier F, 2017, ANN PHYS REHABIL MED, V60, P27, DOI 10.1016/j.rehab.2016.07.002; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Bretzin AC, 2018, AM J SPORT MED, V46, P2263, DOI 10.1177/0363546518778251; Broglio SP, 2018, SPORTS MED, V48, P1255, DOI 10.1007/s40279-017-0813-0; Broglio SP, 2017, J NEUROTRAUM, V34, P2675, DOI 10.1089/neu.2016.4767; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Davis-Hayes C, 2018, NEUROL-CLIN PRACT, V8, P40, DOI 10.1212/CPJ.0000000000000424; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; Dhawan PS, 2017, NEUROL-CLIN PRACT, V7, P464, DOI 10.1212/CPJ.0000000000000381; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Echemendia RJ, 2018, BRIT J SPORT MED, V52, P1149, DOI 10.1136/bjsports-2016-097090; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Eckner JT, 2011, PM&R, V3, P1092, DOI 10.1016/j.pmrj.2011.04.022; Eddy R, 2020, CLIN J SPORT MED, V30, P239, DOI 10.1097/JSM.0000000000000586; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Emery CA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097452; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Fuller GW, 2019, BRIT J SPORT MED, V53, P1526, DOI 10.1136/bjsports-2017-098560; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Garcia GGP, 2018, SPORTS MED, V48, P1739, DOI 10.1007/s40279-018-0880-x; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hecimoyich M, 2018, J SCI MED SPORT, V21, P1004, DOI 10.1016/j.jsams.2018.03.011; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Hoffman NL, 2020, CLIN J SPORT MED, V30, pS29, DOI 10.1097/JSM.0000000000000538; Houck Z, 2016, AM J SPORT MED, V44, P2269, DOI 10.1177/0363546516645070; Howell DR, 2020, CLIN J SPORT MED, V30, pS42, DOI 10.1097/JSM.0000000000000570; Hugentobler JA, 2015, INT J SPORTS PHYS TH, V10, P676; Iverson GL, 2018, J ALZHEIMERS DIS, V61, P17, DOI 10.3233/JAD-170654; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Janssen PHH, 2017, MAYO CLIN PROC, V92, P66, DOI 10.1016/j.mayocp.2016.09.004; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Kerr ZY, 2017, J ATHL TRAINING, V52, P167, DOI 10.4085/1062-6050-51.6.05; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; Krolikowski MP, 2017, AM J SPORT MED, V45, P468, DOI 10.1177/0363546516669701; Lawrence DW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196062; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2019, CLIN J SPORT MED, V29, P353, DOI 10.1097/JSM.0000000000000663; Leddy JJ, 2018, CURR SPORT MED REP, V17, P262, DOI 10.1249/JSR.0000000000000505; Leddy JJ, 2018, CLIN J SPORT MED, V28, P13, DOI 10.1097/JSM.0000000000000431; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lehman EJ, 2016, AM J SPORT MED, V44, P2486, DOI 10.1177/0363546516645093; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lucas JA, 2019, BRIT J SPORT MED, V53, P495, DOI 10.1136/bjsports-2018-099118; Mainwaring L, 2018, INT J PSYCHOPHYSIOL, V132, P39, DOI 10.1016/j.ijpsycho.2018.01.007; Makdissi M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097470; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAvoy K, 2018, NEUROREHABILITATION, V42, P325, DOI 10.3233/NRE-172381; McCarty CA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0459; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McLeod TCV, 2015, BRAIN INJURY, V29, P175, DOI 10.3109/02699052.2014.965206; Mead GE, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004366.pub6, 10.1002/14651858.CD004366.pub4]; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; National Collegiate Athletic Association (NCAA), 2016, INT CONS DIAGN MAN S; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Norheim N, 2018, BMJ OPEN SPORT EXERC, V4, DOI 10.1136/bmjsem-2018-000412; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; O'Neill JA, 2017, REHABIL PSYCHOL, V62, P300, DOI 10.1037/rep0000155; Oliver JM, 2018, SPORTS MED, V48, pS39, DOI 10.1007/s40279-017-0847-3; Oliver JM, 2016, MED SCI SPORT EXER, V48, P974, DOI 10.1249/MSS.0000000000000875; Patricios J, 2017, BRIT J SPORT MED, V51, P888, DOI 10.1136/bjsports-2016-097441; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Randolph C, 2005, J ATHL TRAINING, V40, P139; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, pe000012, DOI DOI 10.1136/BMJSEM-2015-000012; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schmidt JD, 2017, J NEUROTRAUM, V34, P1571, DOI 10.1089/neu.2016.4668; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Seidman DH, 2015, J NEUROL SCI, V356, P97, DOI 10.1016/j.jns.2015.06.021; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stovitz SD, 2017, CURR SPORT MED REP, V16, P50, DOI 10.1249/JSR.0000000000000326; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Trojian TH, 2017, CURR SPORT MED REP, V16, P247, DOI 10.1249/JSR.0000000000000387; Tsushima WT, 2019, ARCH CLIN NEUROPSYCH, V34, P60, DOI 10.1093/arclin/acy019; Tucker R, 2017, BRIT J SPORT MED, V51, P1147, DOI 10.1136/bjsports-2017-097883; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	128	140	139	7	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2019	53	4					213	225		10.1136/bjsports-2018-100338			13	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	HL0BB	WOS:000458357900007	30705232		Y	N	2022-02-06	
J	Ham, PB; Raju, R				Ham, P. Benson, III; Raju, Raghavan			Mitochondrial function in hypoxic ischemic injury and influence of aging	PROGRESS IN NEUROBIOLOGY			English	Article; Proceedings Paper	International Conference on Aging and Disease (ICAD)	NOV 01-02, 2014	Beijing, PEOPLES R CHINA	Int Soc Aging & Dis, Xuanwu Hosp, Beijing Capital Univ, Wenzhou Med Univ, First Affiliated Hosp		Ischemia/reperfusion; Hypoxia; Mitokine; Oxidative phosphorylation; Resveratrol, SIRT1, sirtuins; Mitoquinone; Tempol; Blood brain barrier; Tunneling nanotube; Nuclear-mitochondria cross-talk; Intermitochondrial signal propagation; Pseudohypoxia; Stroke, myocardial infarction; Alzheimer's disease; Parkinson's disease; Autophagy; Apoptosis	EXTENDS LIFE-SPAN; NF-KAPPA-B; TARGETED ANTIOXIDANT MITOQ; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; PERMEABLE RADICAL SCAVENGER; INFORMATION REGULATOR 1; AGE-RELATED DIFFERENCES; REDUCES INFARCT SIZE; PYRUVATE-DEHYDROGENASE KINASE	Mitochondria are a major target in hypoxic/ischemic injury. Mitochondrial impairment increases with age leading to dysregulation of molecular pathways linked to mitochondria. The perturbation of mitochondrial homeostasis and cellular energetics worsens outcome following hypoxic-ischemic insults in elderly individuals. In response to acute injury conditions, cellular machinery relies on rapid adaptations by modulating posttranslational modifications. Therefore, post-translational regulation of molecular mediators such as hypoxia-inducible factor lot (HIF-1 alpha), peroxisome proliferator-activated receptor gamma coactivator alpha (PGC-1 alpha), c-MYC, SIRT1 and AMPK play a critical role in the control of the glycolytic-mitochondrial energy axis in response to hypoxic-ischemic conditions. The deficiency of oxygen and nutrients leads to decreased energetic reliance on mitochondria, promoting glycolysis. The combination of pseudohypoxia, declining autophagy, and dysregulation of stress responses with aging adds to impaired host response to hypoxic-ischemic injury. Furthermore, intermitochondrial signal propagation and tissue wide oscillations in mitochondrial metabolism in response to oxidative stress are emerging as vital to cellular energetics. Recently reported intercellular transport of mitochondria through tunneling nanotubes also play a role in the response to and treatments for ischemic injury. In this review we attempt to provide an overview of some of the molecular mechanisms and potential therapies involved in the alteration of cellular energetics with aging and injury with a neurobiological perspective. (C) 2016 Elsevier Ltd. All rights reserved.	[Ham, P. Benson, III; Raju, Raghavan] Georgia Regents Univ, Dept Surg, Augusta, GA USA; [Raju, Raghavan] Georgia Regents Univ, Dept Lab Sci, Augusta, GA USA; [Raju, Raghavan] Georgia Regents Univ, Dept Biochem & Mol Biol, Augusta, GA USA		Raju, R (corresponding author), Georgia Regents Univ, CB 2601,Sanders Bldg,1479 Laney Walker Blvd, Augusta, GA 30912 USA.	RRaju@augusta.edu		Raju, Raghavan/0000-0002-4516-8654	National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM 101927]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM101927] Funding Source: NIH RePORTER	The corresponding author (RR) acknowledges financial support from the National Institute of General Medical Sciences (R01 GM 101927), National Institutes of Health, Bethesda, MD.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Adam T, 2013, J CARDIOVASC PHARM T, V18, P46, DOI 10.1177/1074248412458723; Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Adler A, 2003, AM J PHYSIOL-HEART C, V285, pH1015, DOI 10.1152/ajpheart.01047.2002; Ahmad T, 2014, EMBO J, V33, P994, DOI 10.1002/embj.201386030; Ahmadiasl N, 2014, ADV PHARM BULL, V4, P49, DOI 10.5681/apb.2014.008; Alberts B., 2008, MOL BIOL CELL, V5th; Alcain FJ, 2009, EXPERT OPIN THER PAT, V19, P403, DOI 10.1517/13543770902762893; Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Aliev G, 2002, BRAIN PATHOL, V12, P21; Anderson R, 2009, BBA-GEN SUBJECTS, V1790, P1059, DOI 10.1016/j.bbagen.2009.04.005; Andres-Lacueva C, 2012, J AGR FOOD CHEM, V60, P4833, DOI 10.1021/jf3001108; Antonenko YN, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1273, DOI 10.1134/S0006297908120018; Aon MA, 2004, P NATL ACAD SCI USA, V101, P4447, DOI 10.1073/pnas.0307156101; Arrington DD, 2006, AM J PHYSIOL-CELL PH, V291, pC1159, DOI 10.1152/ajpcell.00207.2006; Atamna H, 2008, FASEB J, V22, P703, DOI 10.1096/fj.07-9610com; Atsma F, 2006, MENOPAUSE, V13, P265, DOI 10.1097/01.gme.0000218683.97338.ea; Avraham Y, 2010, CURR NEUROVASC RES, V7, P136, DOI 10.2174/156720210791184943; Ayub A, 2015, MOL MED, V21, P305, DOI 10.2119/molmed.2015.00013; Baarine M, 2011, GENES NUTR, V6, P161, DOI 10.1007/s12263-011-0232-z; Bai Bing, 2014, Biomed Res Int, V2014, P671362, DOI 10.1155/2014/671362; Ballinger SW, 2005, FREE RADICAL BIO MED, V38, P1278, DOI 10.1016/j.freeradbiomed.2005.02.014; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bavaresco L, 2003, DRUG EXP CLIN RES, V29, P181; BEAUCHAMP RO, 1984, CRC CR REV TOXICOL, V13, P25, DOI 10.3109/10408448409029321; Berdichevsky A, 2006, CELL, V125, P1165, DOI 10.1016/j.cell.2006.04.036; Bhat AH, 2015, BIOMED PHARMACOTHER, V74, P101, DOI 10.1016/j.biopha.2015.07.025; Biala AK, 2015, J MOL CELL CARDIOL, V83, P37, DOI 10.1016/j.yjmcc.2015.04.015; Biermann J, 2011, MOL VIS, V17, P1275; Bonanni L, 2006, J NEUROSCI, V26, P6851, DOI 10.1523/JNEUROSCI.5444-05.2006; Boocock DJ, 2007, J CHROMATOGR B, V848, P182, DOI 10.1016/j.jchromb.2006.10.017; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brenmoehl J, 2013, MITOCHONDRION, V13, P755, DOI 10.1016/j.mito.2013.04.002; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Bruning CA, 2012, NEUROCHEM RES, V37, P2249, DOI 10.1007/s11064-012-0853-7; Bruintjes JJ, 2014, NEUROSCI LETT, V563, P135, DOI 10.1016/j.neulet.2014.01.049; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Buga AM, 2008, ROM J MORPHOL EMBRYO, V49, P279; Bukoreshtliev NV, 2009, FEBS LETT, V583, P1481, DOI 10.1016/j.febslet.2009.03.065; Burkon A, 2008, MOL NUTR FOOD RES, V52, P549, DOI 10.1002/mnfr.200700290; Cairns CB, 1997, J TRAUMA, V42, P532, DOI 10.1097/00005373-199703000-00023; Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720; Camins A, 2010, BBA-GENE REGUL MECH, V1799, P740, DOI 10.1016/j.bbagrm.2010.06.005; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Cao L, 2013, BRAZ J MED BIOL RES, V46, P659, DOI 10.1590/1414-431X20132903; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cechella JL, 2014, AGE, V36, DOI 10.1007/s11357-014-9666-8; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chang CC, 2012, CHINESE J PHYSIOL, V55, P192, DOI [10.4077/CJP.2012.BAA012, 10.4077/CJP.2011.BAA012]; Chang DTW, 2006, PROG NEUROBIOL, V80, P241, DOI 10.1016/j.pneurobio.2006.09.003; Chatterjee PK, 2000, KIDNEY INT, V58, P658, DOI 10.1046/j.1523-1755.2000.00212.x; Chen G, 2005, CHEM PHARM BULL, V53, P1587, DOI 10.1248/cpb.53.1587; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen N, 2008, BIOL PHARM BULL, V31, P1387, DOI 10.1248/bpb.31.1387; Chen Q, 2011, BIOCHEM BIOPH RES CO, V415, P533, DOI 10.1016/j.bbrc.2011.10.037; Chen Q, 2007, AM J PHYSIOL-CELL PH, V292, pC137, DOI 10.1152/ajpcell.00270.2006; Chen TS, 2015, AM J PHYSIOL-HEART C, V308, pH424, DOI 10.1152/ajpheart.00454.2014; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng G, 2009, NEUROSCI LETT, V451, P105, DOI 10.1016/j.neulet.2008.12.045; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chiu PY, 2006, BIOGERONTOLOGY, V7, P199, DOI 10.1007/s10522-006-9017-y; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Chung HY, 2000, J AM AGING ASSOC, V23, P123, DOI 10.1007/s11357-000-0013-x; Chung JH, 2012, TRENDS CELL BIOL, V22, P546, DOI 10.1016/j.tcb.2012.07.004; Clark D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047792; Clouser CL, 2012, BIOORG MED CHEM LETT, V22, P6642, DOI 10.1016/j.bmcl.2012.08.108; Cohen A., 2015, MOL MED; CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G; Correia-Melo C, 2015, BBA-BIOENERGETICS, V1847, P1373, DOI 10.1016/j.bbabio.2015.05.017; Corsini Fabrizio, 2006, Monaldi Arch Chest Dis, V66, P13; Cui J, 2013, TRENDS MOL MED, V19, P197, DOI 10.1016/j.molmed.2012.12.007; Curry N, 2011, CRIT CARE, V15, DOI 10.1186/cc10096; Cuzzocrea S, 2000, J PINEAL RES, V29, P217, DOI 10.1034/j.1600-0633.2002.290404.x; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; Dai H, 2010, J BIOL CHEM, V285, P32695, DOI 10.1074/jbc.M110.133892; Dai SH, 2014, INT J MOL MED, V34, P1159, DOI 10.3892/ijmm.2014.1876; Davalos A, 2012, LANCET, V380, P349, DOI 10.1016/S0140-6736(12)60813-7; Davis M, 1997, ACT NEUR S, V70, P56; DAY JJ, 1987, AGE AGEING, V16, P239; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Dessolin J, 2002, EUR J PHARMACOL, V447, P155, DOI 10.1016/S0014-2999(02)01839-3; Di Y, 2015, MOL MED, V21, P420, DOI 10.2119/molmed.2015.00038; Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119; Dobrachinski F, 2014, NEUROTOX RES, V26, P317, DOI 10.1007/s12640-014-9463-2; Dong WP, 2008, J VASC SURG, V48, P709, DOI 10.1016/j.jvs.2008.04.007; Dong XB, 2012, MOL CELL BIOCHEM, V362, P149, DOI 10.1007/s11010-011-1137-2; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; Durand G, 2008, J PHYS CHEM A, V112, P12498, DOI 10.1021/jp804929d; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Durrant JR, 2009, J PHYSIOL-LONDON, V587, P3271, DOI 10.1113/jphysiol.2009.169771; Ehninger D, 2014, CELL MOL LIFE SCI, V71, P4325, DOI 10.1007/s00018-014-1677-1; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Erfani S, 2015, J MOL NEUROSCI, V56, P237, DOI 10.1007/s12031-014-0486-1; Esplugues JV, 2006, CIRC RES, V99, P1067, DOI 10.1161/01.RES.0000250430.62775.99; Fardoun RZ, 2006, AM J PHYSIOL-RENAL, V291, pF945, DOI 10.1152/ajprenal.00111.2006; Ferrara N, 2008, REJUV RES, V11, P139, DOI 10.1089/rej.2007.0576; Fillingame RH, 2014, BBA-BIOENERGETICS, V1837, P1063, DOI 10.1016/j.bbabio.2014.03.005; Finck BN, 2007, CIRCULATION, V115, P2540, DOI 10.1161/CIRCULATIONAHA.107.670588; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fischer H., 2014, GUIDE US MILITARY CA; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Forester BP, 2010, NMR BIOMED, V23, P242, DOI 10.1002/nbm.1444; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Fresta M, 1997, LIFE SCI, V61, P1227, DOI 10.1016/S0024-3205(97)00667-X; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; FUNAHASHI T, 1994, NEUROBIOL AGING, V15, P161, DOI 10.1016/0197-4580(94)90107-4; Gao DK, 2006, LIFE SCI, V78, P2564, DOI 10.1016/j.lfs.2005.10.030; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Gao L, 2008, VET CLIN N AM-SMALL, V38, P137, DOI 10.1016/j.cvsm.2007.10.004; GELLERICH FN, 1992, FEBS LETT, V297, P55, DOI 10.1016/0014-5793(92)80326-C; Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071; Ghosh S, 2010, NEUROSCIENCE, V171, P1287, DOI 10.1016/j.neuroscience.2010.09.049; Gioscia-Ryan RA, 2014, J PHYSIOL-LONDON, V592, P2549, DOI 10.1113/jphysiol.2013.268680; Godfrey R., 2013, BMJ CASE REP, V2013; Gomes AP, 2013, CELL, V155, P1624, DOI 10.1016/j.cell.2013.11.037; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Gong Y, 2005, ACT NEUR S, V95, P425; Gong Y, 2004, STROKE, V35, P2571, DOI 10.1161/01.STR.0000145485.67827.d0; Gong ZW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00210; Goyal MS, 2014, CELL METAB, V19, P49, DOI 10.1016/j.cmet.2013.11.020; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074050; Gupta A, 2004, MOL CELL BIOCHEM, V259, P9, DOI 10.1023/B:MCBI.0000021339.34784.81; Gurke S, 2008, EXP CELL RES, V314, P3669, DOI 10.1016/j.yexcr.2008.08.022; Haberman F, 2007, NEUROMOL MED, V9, P315, DOI 10.1007/s12017-007-8010-1; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Hallberg BM, 2014, CELL METAB, V20, P226, DOI 10.1016/j.cmet.2014.07.001; HANSFORD RG, 1982, MECH AGEING DEV, V19, P5, DOI 10.1016/0047-6374(82)90044-6; Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hattori Y, 2015, NEUROREPORT, V26, P113, DOI 10.1097/WNR.0000000000000308; Hattori Y, 2014, STROKE, V45, P3403, DOI 10.1161/STROKEAHA.114.006265; Hernandez-Jimenez M, 2013, STROKE, V44, P2333, DOI 10.1161/STROKEAHA.113.001715; Hernando V, 2010, J MOL CELL CARDIOL, V49, P271, DOI 10.1016/j.yjmcc.2010.02.024; Herrmann JM, 2010, ANTIOXID REDOX SIGN, V13, P1341, DOI 10.1089/ars.2009.3063; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hirst J, 2010, BIOCHEM J, V425, P327, DOI 10.1042/BJ20091382; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hsu CP, 2010, CIRCULATION, V122, P2170, DOI 10.1161/CIRCULATIONAHA.110.958033; Hsu CP, 2009, CIRC RES, V105, P481, DOI 10.1161/CIRCRESAHA.109.203703; Hu YY, 2015, J STROKE CEREBROVASC, V24, P601, DOI 10.1016/j.jstrokecerebrovasdis.2014.10.006; Huang SS, 2001, LIFE SCI, V69, P1057, DOI 10.1016/S0024-3205(01)01195-X; Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imai S, 2011, FEBS LETT, V585, P1657, DOI 10.1016/j.febslet.2011.04.060; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Itoh T, 2013, BRAIN STRUCT FUNCT, V218, P209, DOI 10.1007/s00429-012-0394-5; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Izmaylov DM, 1996, MECH AGEING DEV, V91, P155, DOI 10.1016/S0047-6374(96)01776-9; Jannin B, 2004, BIOCHEM PHARMACOL, V68, P1113, DOI 10.1016/j.bcp.2004.04.028; Jastroch M, 2010, ESSAYS BIOCHEM, V47, P53, DOI [10.1042/bse0470053, 10.1042/BSE0470053]; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jian BX, 2014, MOL MED, V20, P10, DOI 10.2119/molmed.2013.00077; Jian BX, 2012, MOL MED, V18, P209, DOI 10.2119/molmed.2011.00365; Jian BX, 2011, BBA-MOL BASIS DIS, V1812, P1446, DOI 10.1016/j.bbadis.2011.04.010; Jian BX, 2011, MOL MED, V17, P542, DOI 10.2119/molmed.2010.00195; Jiang HK, 2014, CLIN EXP PHARMACOL P, V41, P192, DOI 10.1111/1440-1681.12211; Jiang JF, 2007, J PHARMACOL EXP THER, V320, P1050, DOI 10.1124/jpet.106.114769; Jiang ML, 2012, NAT MED, V18, P153, DOI 10.1038/nm.2558; Jordan JE, 2003, J PHARMACOL EXP THER, V307, P1007, DOI 10.1124/jpet.103.055970; Judge S, 2005, FASEB J, V19, P419, DOI 10.1096/fj.04-2622fje; Judge S, 2007, AM J PHYSIOL-CELL PH, V292, pC1983, DOI 10.1152/ajpcell.00285.2006; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kaeberlein M, 2006, SCIENCE, V312, DOI 10.1126/science.1124608; Kane LA, 2010, J MOL MED, V88, P971, DOI 10.1007/s00109-010-0674-6; Kanfi Y, 2012, NATURE, V483, P218, DOI 10.1038/nature10815; Kang D, 2005, ANN NY ACAD SCI, V1042, P101, DOI 10.1196/annals.1338.010; Kato N, 2003, BRAIN RES, V979, P188, DOI 10.1016/S0006-8993(03)02918-4; Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007; Kawai Y, 2011, J BIOL CHEM, V286, P7629, DOI 10.1074/jbc.M110.208173; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Khalil PN, 2005, EUR J PHARMACOL, V528, P124, DOI 10.1016/j.ejphar.2005.10.032; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; KIM JH, 1988, MECH AGEING DEV, V46, P279, DOI 10.1016/0047-6374(88)90130-3; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim TH, 2015, CNS NEUROSCI THER, V21, P327, DOI 10.1111/cns.12346; Kimura S, 2005, HYPERTENSION, V45, P438, DOI 10.1161/01.HYP.0000157169.27818.ae; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; King RW, 1996, ACAD EMERG MED, V3, P1041, DOI 10.1111/j.1553-2712.1996.tb03351.x; Kireev RA, 2012, J SURG RES, V178, P922, DOI 10.1016/j.jss.2012.04.060; KLAR AJS, 1979, GENETICS, V93, P37; Korzick DH, 2013, PFLUG ARCH EUR J PHY, V465, P669, DOI 10.1007/s00424-013-1255-7; Kowald A, 2014, P NATL ACAD SCI USA, V111, P2972, DOI 10.1073/pnas.1314970111; Kowald A, 2013, AGING CELL, V12, P728, DOI 10.1111/acel.12098; Koyanagi M, 2005, CIRC RES, V96, P1039, DOI 10.1161/01.RES.0000168650.23479.0c; Laemmle A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033433; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lapointe J, 2010, CELL MOL LIFE SCI, V67, P1, DOI 10.1007/s00018-009-0138-8; Las G, 2014, EMBO J, V33, P939, DOI 10.1002/embj.201488441; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lee CH, 2013, TRENDS ENDOCRIN MET, V24, P222, DOI 10.1016/j.tem.2013.01.005; Lee Hahn-Ey, 2013, J Biomark, V2013, P413853, DOI 10.1155/2013/413853; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lee TH, 2012, FOOD CHEM TOXICOL, V50, P4239, DOI 10.1016/j.fct.2012.08.047; Leiser SF, 2010, BIOL CHEM, V391, P1131, DOI 10.1515/BC.2010.123; Leite MR, 2015, CYTOKINE, V71, P119, DOI 10.1016/j.cyto.2014.09.006; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Lesnefsky EJ, 2009, J MOL CELL CARDIOL, V46, P1008, DOI 10.1016/j.yjmcc.2009.03.007; LESNEFSKY EJ, 1994, J LAB CLIN MED, V124, P843; Lesniewski LA, 2009, J GERONTOL A-BIOL, V64, P9, DOI 10.1093/gerona/gln049; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li H, 2011, NEUROPHARMACOLOGY, V60, P252, DOI 10.1016/j.neuropharm.2010.09.005; Li NL, 2011, REJUV RES, V14, P261, DOI 10.1089/rej.2010.1115; Li X, 2014, AM J RESP CELL MOL, V51, P455, DOI 10.1165/rcmb.2013-0529OC; Li XJ, 1997, ACTA PHARMACOL SIN, V18, P394; Li Z, 2012, BRAIN RES, V1450, P116, DOI 10.1016/j.brainres.2012.02.019; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Lin AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046585; Lin MY, 2015, EXP CELL RES, V334, P35, DOI 10.1016/j.yexcr.2015.01.004; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Ling X, 1999, ACTA PHARMACOL SIN, V20, P409; Liou CM, 2010, CELL BIOCHEM FUNCT, V28, P521, DOI 10.1002/cbf.1687; Liu AJ, 2013, J CEREBR BLOOD F MET, V33, P906, DOI 10.1038/jcbfm.2013.28; Liu B, 2013, CELL PHYSIOL BIOCHEM, V32, P1050, DOI 10.1159/000354505; Liu B, 2013, CELL PHYSIOL BIOCHEM, V32, P655, DOI 10.1159/000354469; Liu Tie Fu, 2013, Genes Cancer, V4, P135, DOI 10.1177/1947601913476948; Lowicka E, 2007, PHARMACOL REP, V59, P4; Lu KT, 2006, J AGR FOOD CHEM, V54, P3126, DOI [10.1021/jf053011q, 10.1021/JF053011Q]; Lu TM, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-57; Lund DD, 2009, AM J PHYSIOL-HEART C, V296, pH1920, DOI 10.1152/ajpheart.01342.2008; Luo YG, 2013, NEUROCHEM INT, V63, P826, DOI 10.1016/j.neuint.2013.06.004; Lynn EG, 2008, FEBS LETT, V582, P2857, DOI 10.1016/j.febslet.2008.07.016; Ma H, 2009, J NEUROSCI, V29, P13019, DOI 10.1523/JNEUROSCI.2517-09.2009; Ma J, 2012, J BIOL CHEM, V287, P27480, DOI 10.1074/jbc.M112.358929; Maksin-Matveev A, 2015, EXP CELL RES, V330, P81, DOI 10.1016/j.yexcr.2014.07.013; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Mariappan N, 2009, FREE RADICAL BIO MED, V46, P462, DOI 10.1016/j.freeradbiomed.2008.10.049; Marzetti E, 2013, AM J PHYSIOL-HEART C, V305, pH459, DOI 10.1152/ajpheart.00936.2012; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Mayhan WG, 2008, MICROCIRCULATION, V15, P225, DOI 10.1080/10739680701641421; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; McDonald MC, 1999, FREE RADICAL BIO MED, V27, P493, DOI 10.1016/S0891-5849(99)00100-8; McManus MJ, 2014, MOL CELL NEUROSCI, V63, P13, DOI 10.1016/j.mcn.2014.09.002; Mees ST, 2008, SHOCK, V29, P670, DOI 10.1097/SHK.0b013e31815c3ea0; Meli E, 2003, TOXICOL LETT, V139, P153, DOI 10.1016/S0378-4274(02)00429-0; Menghini R, 2009, CIRCULATION, V120, P1524, DOI 10.1161/CIRCULATIONAHA.109.864629; MERCADIER JJ, 1981, CIRC RES, V49, P525, DOI 10.1161/01.RES.49.2.525; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178; Mitchell JB, 2003, FREE RADICAL BIO MED, V34, P93, DOI 10.1016/S0891-5849(02)01193-0; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Mitchell SJ, 2014, CELL REP, V6, P836, DOI 10.1016/j.celrep.2014.01.031; MOORADIAN AD, 1988, NEUROBIOL AGING, V9, P31, DOI 10.1016/S0197-4580(88)80013-7; Morselli E, 2010, AUTOPHAGY, V6, P186, DOI 10.4161/auto.6.1.10817; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Mukhopadhyay P, 2012, FREE RADICAL BIO MED, V53, P1123, DOI 10.1016/j.freeradbiomed.2012.05.036; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Murphy E, 2008, PHYSIOL REV, V88, P581, DOI 10.1152/physrev.00024.2007; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Nadtochiy SM, 2011, AM J PHYSIOL-HEART C, V301, pH1506, DOI 10.1152/ajpheart.00587.2011; Nadtochiy SM, 2011, CARDIOVASC RES, V89, P643, DOI 10.1093/cvr/cvq287; Nasrin N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008414; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Neuhof C, 2004, BIOL CHEM, V385, P1077, DOI 10.1515/BC.2004.139; Neuhof C, 2003, BIOL CHEM, V384, P1597, DOI 10.1515/BC.2003.177; Neuhof C, 2014, WORLD J CARDIOL, V6, P638, DOI 10.4330/wjc.v6.i7.638; Neuhof C, 2008, BIOL CHEM, V389, P1505, DOI 10.1515/BC.2008.172; Ng LF, 2014, FREE RADICAL BIO MED, V71, P390, DOI 10.1016/j.freeradbiomed.2014.03.003; Nicolini G, 2001, NEUROSCI LETT, V302, P41, DOI 10.1016/S0304-3940(01)01654-8; NOHL H, 1980, MECH AGEING DEV, V14, P137, DOI 10.1016/0047-6374(80)90112-8; Nohl H, 1997, EXP GERONTOL, V32, P485, DOI 10.1016/S0531-5565(96)00169-6; Ohsawa S, 2006, FEBS LETT, V580, P5875, DOI 10.1016/j.febslet.2006.09.051; Ohtsuji M, 2008, J BIOL CHEM, V283, P33554, DOI 10.1074/jbc.M804597200; ONODERA H, 1986, J NEUROCHEM, V46, P1704; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Palacios HH, 2011, CNS NEUROL DISORD-DR, V10, P149; PALADE GE, 1953, J HISTOCHEM CYTOCHEM, V1, P188, DOI 10.1177/1.4.188; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; PARADIES G, 1990, BIOCHIM BIOPHYS ACTA, V1016, P207, DOI 10.1016/0005-2728(90)90060-H; PARADIES G, 1991, ARCH BIOCHEM BIOPHYS, V284, P332, DOI 10.1016/0003-9861(91)90304-2; Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017; Patel NSA, 2002, FREE RADICAL BIO MED, V33, P1575, DOI 10.1016/S0891-5849(02)01116-4; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Payne JA, 2003, AM J PHYSIOL-REG I, V285, pR542, DOI 10.1152/ajpregu.00056.2003; PEARCE FJ, 1985, J SURG RES, V39, P390, DOI 10.1016/0022-4804(85)90092-7; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Pervaiz S, 2009, ANTIOXID REDOX SIGN, V11, P2851, DOI [10.1089/ars.2008.2412, 10.1089/ARS.2008.2412]; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pillai JB, 2008, AM J PHYSIOL-HEART C, V294, pH1388, DOI 10.1152/ajpheart.01339.2007; Plotnikov EY, 2008, J CELL MOL MED, V12, P1622, DOI 10.1111/j.1582-4934.2007.00205.x; POEGGELER B, 1994, ANN NY ACAD SCI, V738, P419, DOI 10.1111/j.1749-6632.1994.tb21831.x; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Porat-Shliom N, 2014, CELL REP, V9, P514, DOI 10.1016/j.celrep.2014.09.022; Porter GA, 2014, AM J PHYSIOL-HEART C, V306, pH1602, DOI 10.1152/ajpheart.00027.2014; Poulose N, 2015, BBA-MOL BASIS DIS, V1852, P2442, DOI 10.1016/j.bbadis.2015.08.017; Poulose N, 2014, AGING DIS, V5, P101, DOI 10.14336/AD.2014.0500101; Powell RD, 2015, J TRAUMA ACUTE CARE, V78, P573, DOI 10.1097/TA.0000000000000533; Powell RD, 2014, J TRAUMA ACUTE CARE, V76, P409, DOI 10.1097/TA.0000000000000096; Prentice RL, 2014, SEMIN REPROD MED, V32, P419, DOI 10.1055/s-0034-1384624; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Pung YF, 2012, ARTERIOSCL THROM VAS, V32, P325, DOI 10.1161/ATVBAHA.111.241802; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Qabazard B, 2014, ANTIOXID REDOX SIGN, V20, P2621, DOI 10.1089/ars.2013.5448; Qabazard B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080135; Raju R, 2011, AGING DIS, V2, P174; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102; Raval AP, 2008, CURR MED CHEM, V15, P1545, DOI 10.2174/092986708784638861; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Regnier-Vigouroux A, 2003, INT REV CYTOL, V226, P321, DOI 10.1016/S0074-7696(03)01006-4; Reiter RJ, 1998, ANN NY ACAD SCI, V854, P410, DOI 10.1111/j.1749-6632.1998.tb09920.x; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Riera CE, 2015, NAT CELL BIOL, V17, P196, DOI 10.1038/ncb3107; RINE J, 1987, GENETICS, V116, P9; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rogers RS, 2013, PHYSIOLOGY, V28, P414, DOI 10.1152/physiol.00032.2013; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Ryou MG, 2015, NEUROSCIENCE, V301, P193, DOI 10.1016/j.neuroscience.2015.05.064; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Sasaki T, 2008, AGING CELL, V7, P459, DOI 10.1111/j.1474-9726.2008.00394.x; Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020; Satoh A, 2013, CELL METAB, V18, P416, DOI 10.1016/j.cmet.2013.07.013; Saver Jeffrey L, 2008, Rev Neurol Dis, V5, P167; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006; Schmeisser S, 2013, MOL METAB, V2, P92, DOI 10.1016/j.molmet.2013.02.002; Schonfeld P, 2010, BBA-BIOENERGETICS, V1797, P929, DOI 10.1016/j.bbabio.2010.01.010; Sebastian D, 2012, P NATL ACAD SCI USA, V109, P5523, DOI 10.1073/pnas.1108220109; Semenza, 2007, SCI STKE, V2007, pCM8, DOI [10.1126/stke.4072007cm8, DOI 10.1126/STKE.4072007CM8]; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; Semenza Gregg L, 2011, Biochim Biophys Acta, V1813, P1263, DOI 10.1016/j.bbamcr.2010.08.006; Sepodes B, 2004, TRANSPL P, V36, P849, DOI 10.1016/j.transproceed.2004.03.050; Shalwala M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086977; Shao AW, 2014, CNS NEUROSCI THER, V20, P182, DOI 10.1111/cns.12194; Shen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079833; Shin JA, 2012, NEUROCHEM RES, V37, P2686, DOI 10.1007/s11064-012-0858-2; Shinmura K, 2008, AM J PHYSIOL-HEART C, V295, pH2348, DOI 10.1152/ajpheart.00602.2008; Shinozaki S, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005375; Simao F, 2011, J NUTR BIOCHEM, V22, P921, DOI 10.1016/j.jnutbio.2010.07.013; Simpkins JW, 2008, MOL CELL ENDOCRINOL, V290, P51, DOI 10.1016/j.mce.2008.04.013; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Snow BJ, 2010, MOVEMENT DISORD, V25, P1670, DOI 10.1002/mds.23148; Solaini G, 2010, BBA-BIOENERGETICS, V1797, P1171, DOI 10.1016/j.bbabio.2010.02.011; Spanier G, 2009, J PHYSIOL PHARMACOL, V60, P111; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI 10.1089/ARS.2008.2331; Strong R, 2013, J GERONTOL A-BIOL, V68, P6, DOI 10.1093/gerona/gls070; Sun AY, 2010, MOL NEUROBIOL, V41, P375, DOI 10.1007/s12035-010-8111-y; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00095; Sun T, 2013, CELL REP, V4, P413, DOI 10.1016/j.celrep.2013.06.040; Suzman R, 2011, GLOBAL HLTH AGING; Tani M, 1997, J MOL CELL CARDIOL, V29, P3081, DOI 10.1006/jmcc.1997.0533; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Tatarkova Z, 2011, PHYSIOL RES, V60, P281, DOI 10.33549/physiolres.932019; Tay AS, 2010, NEUROSCIENCE, V167, P277, DOI 10.1016/j.neuroscience.2010.02.006; Tegla CA, 2014, EXP MOL PATHOL, V96, P139, DOI 10.1016/j.yexmp.2013.12.010; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TOKUMITSU Y, 1973, BIOCHIM BIOPHYS ACTA, V292, P310, DOI 10.1016/0005-2728(73)90038-8; Tomasello F, 2009, CELL RES, V19, P1363, DOI 10.1038/cr.2009.98; Tong C, 2013, FASEB J, V27, P4332, DOI 10.1096/fj.12-216473; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Tsai SK, 2007, J VASC SURG, V46, P346, DOI 10.1016/j.jvs.2007.04.044; Tsai YF, 2012, J SURG RES, V176, P171, DOI 10.1016/j.jss.2011.05.039; Tsuchiya M, 2006, AGING CELL, V5, P505, DOI 10.1111/j.1474-9726.2006.00240.x; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TUMMINO PJ, 1991, MECH AGEING DEV, V59, P177, DOI 10.1016/0047-6374(91)90083-C; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Udenigwe CC, 2008, NUTR REV, V66, P445, DOI 10.1111/j.1753-4887.2008.00076.x; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vaishnavi SN, 2010, P NATL ACAD SCI USA, V107, P17757, DOI 10.1073/pnas.1010459107; Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H., 2001, HSIR2 SIRT1 FUNCTION, P53; Vemuganti R, 2010, TRANSL STROKE RES, V1, P158, DOI 10.1007/s12975-010-0030-8; Vinciguerra M, 2010, AGING-US, V2, P43; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wakatsuki A, 1999, J PINEAL RES, V26, P147, DOI 10.1111/j.1600-079X.1999.tb00576.x; Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885; Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749-6632.2010.05842.x; Walters JW, 2016, CURR OPIN PHARMACOL, V27, P50, DOI 10.1016/j.coph.2016.01.006; Wan WH, 2007, AM J MED SCI, V334, P265, DOI 10.1097/MAJ.0b013e318068b5ed; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang H, 2015, SHOCK, V44, P173, DOI 10.1097/SHK.0000000000000390; Wang JH, 2011, GASTROENTEROLOGY, V141, P2188, DOI 10.1053/j.gastro.2011.08.005; Wang P, 2012, AUTOPHAGY, V8, P77, DOI 10.4161/auto.8.1.18274; Wang P, 2011, ANN NEUROL, V69, P360, DOI 10.1002/ana.22236; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Wang SP, 2008, STROKE, V39, P2587, DOI 10.1161/STROKEAHA.107.509158; Wang T, 2009, FREE RADICAL BIO MED, V47, P229, DOI 10.1016/j.freeradbiomed.2009.02.027; Wang X, 2015, CELL DEATH DIFFER, V22, P1181, DOI 10.1038/cdd.2014.211; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Wang Y, 2011, CELL DEATH DIFFER, V18, P732, DOI 10.1038/cdd.2010.147; Wang Y., 2015, J NANOMATER, V2015, P1, DOI [DOI 10.1038/SREP18296, 10.1155/2015/191793, DOI 10.1155/2015/191793]; Wang Y, 2015, SCIENCE, V350, P1204, DOI 10.1126/science.aac4357; Wani WY, 2011, NEUROPHARMACOLOGY, V61, P1193, DOI 10.1016/j.neuropharm.2011.07.008; Warach S, 2000, ANN NEUROL, V48, P713, DOI 10.1002/1531-8249(200011)48:5<713::AID-ANA4>3.0.CO;2-#; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wei YZ, 2009, AM J PATHOL, V174, P1329, DOI 10.2353/ajpath.2009.080697; Wen Y, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.208447; Wenz Tina, 2011, J Aging Res, V2011, P810619, DOI 10.4061/2011/810619; Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010; Whitaker R, 2013, AGING-US, V5, P682, DOI 10.18632/aging.100599; Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003; Winterbourn CC, 2013, METHOD ENZYMOL, V528, P3, DOI 10.1016/B978-0-12-405881-1.00001-X; Wipf P, 2005, J AM CHEM SOC, V127, P12460, DOI 10.1021/ja053679l; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu CC, 2013, ANTIOXID REDOX SIGN, V19, P546, DOI 10.1089/ars.2012.4905; Wu CT, 2008, CHINESE J PHYSIOL, V51, P363; Wu YC, 2011, NEUROSIGNALS, V19, P163, DOI 10.1159/000328516; Xing GQ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00196; Xu K, 2008, ADV EXP MED BIOL, V614, P379, DOI 10.1007/978-0-387-74911-2_42; Xu K, 2010, BRAIN RES, V1328, P181, DOI 10.1016/j.brainres.2010.02.080; XUE JY, 1992, FREE RADICAL BIO MED, V12, P127, DOI 10.1016/0891-5849(92)90006-3; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamamoto T, 2011, TRENDS CARDIOVAS MED, V21, P27, DOI 10.1016/j.tcm.2012.01.005; Yang C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016229; Yang XL, 2010, CARDIOVASC DRUG THER, V24, P225, DOI 10.1007/s10557-010-6236-x; Yang Y, 2013, NEUROBIOL AGING, V34, P2879, DOI 10.1016/j.neurobiolaging.2013.06.008; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yoon H, 2014, BIOCHEM BIOPH RES CO, V444, P36, DOI 10.1016/j.bbrc.2014.01.001; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068; Yu HP, 2011, SHOCK, V35, P517, DOI 10.1097/SHK.0b013e318209e931; Yu HP, 2010, SURGERY, V148, P103, DOI 10.1016/j.surg.2009.12.008; Yu HP, 2010, CRIT CARE MED, V38, P1147, DOI 10.1097/CCM.0b013e3181cd124e; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1; Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167; Zang QS, 2014, AGING DIS, V5, P137, DOI 10.14336/AD.2014.0500137; Zang QS, 2012, AM J PHYSIOL-HEART C, V302, pH1847, DOI 10.1152/ajpheart.00203.2011; Zarzaur BL, 2008, J SURG RES, V147, P229, DOI 10.1016/j.jss.2008.03.025; Zhang F, 2011, PROG NEUROBIOL, V95, P373, DOI 10.1016/j.pneurobio.2011.09.001; Zhao G, 2012, NEUROBIOL AGING, V33, P176, DOI 10.1016/j.neurobiolaging.2010.02.013; Zhao G, 2011, J NUTR BIOCHEM, V22, P929, DOI 10.1016/j.jnutbio.2010.07.014; Zhao G, 2010, NEUROCHEM INT, V56, P168, DOI 10.1016/j.neuint.2009.09.015; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zheng YQ, 2014, J PHARMACOL SCI, V124, P354, DOI 10.1254/jphs.13220FP; Zhou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.530; Zhu HR, 2010, NEUROPHARMACOLOGY, V59, P70, DOI 10.1016/j.neuropharm.2010.03.017; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	470	140	143	3	88	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0301-0082	1873-5118		PROG NEUROBIOL	Prog. Neurobiol.	OCT	2017	157				SI		92	116		10.1016/j.pneurobio.2016.06.006			25	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	FJ7TG	WOS:000412961200006	27321753	Green Accepted	Y	N	2022-02-06	
J	Kumar, A; Alvarez-Croda, DM; Stoica, BA; Faden, AI; Loane, DJ				Kumar, Alok; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.			Microglial/Macrophage Polarization Dynamics following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						M1-like; M2-like; microglia/macrophage; NOX2; polarization; traumatic brain injury	NADPH OXIDASE; MICROGLIAL ACTIVATION; PROGRESSIVE NEURODEGENERATION; NEUROINFLAMMATORY PHENOTYPE; LIMITS NEUROINFLAMMATION; MACROPHAGE POLARIZATION; INFLAMMATORY RESPONSE; GENE-EXPRESSION; NEURONAL DEATH; WHITE-MATTER	Activated microglia and macrophages exert dual beneficial and detrimental roles after central nervous system injury, which are thought to be due to their polarization along a continuum from a classical pro-inflammatory M1-like state to an alternative anti-inflammatory M2-like state. The goal of the present study was to analyze the temporal dynamics of microglia/macrophage polarization within the lesion micro-environment following traumatic brain injury (TBI) using a moderate-level controlled cortical impact (CCI) model in mice. We performed a detailed phenotypic analysis of M1-and M2-like polarized microglia/macrophages, as well as nicotinamide adenine dinucleotide phosphate oxidase (NOX2) expression, through 7 days post-injury using real-time polymerase chain reaction (qPCR), flow cytometry and image analyses. We demonstrated that microglia/macrophages express both M1-and M2-like phenotypic markers early after TBI, but the transient up-regulation of the M2-like phenotype was replaced by a predominant M1-or mixed transitional (Mtran) phenotype that expressed high levels of NOX2 at 7 days post-injury. The shift towards the M1-like and Mtran phenotype was associated with increased cortical and hippocampal neurodegeneration. In a follow up study, we administered a selective NOX2 inhibitor, gp91ds-tat, to CCI mice starting at 24 h post-injury to investigate the relationship between NOX2 and M1-like/Mtran phenotypes. Delayed gp91ds-tat treatment altered M1-/M2-like balance in favor of the anti-inflammatory M2-like phenotype, and significantly reduced oxidative damage in neurons at 7 days post-injury. Therefore, our data suggest that despite M1-like and M2-like polarized microglia/macrophages being activated after TBI, the early M2-like response becomes dysfunctional over time, resulting in development of pathological M1-like and Mtran phenotypes driven by increased NOX2 activity.	[Kumar, Alok; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Kumar, Alok; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Alvarez-Croda, Dulce-Mariely] Univ Veracruzana, Posgrado Neuroetol, Xalapa, Veracruz, Mexico		Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@anes.umm.edu	Zhang, Xiaolei/E-2761-2012; STOICA, BOGDAN/H-9782-2013; Loane, David/ABD-5177-2021	Zhang, Xiaolei/0000-0003-0117-7599; STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG028747] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037313, R01 NS082308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS082308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER		Abais JM, 2013, ANTIOXID REDOX SIGN, V18, P1537, DOI 10.1089/ars.2012.4666; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Collins-Praino Lyndsey E., 2016, BRAIN BEHAV IMMUNITY; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Deonarine K, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-11; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Donat CK, 2016, NEUROMOL MED, V18, P158, DOI 10.1007/s12017-016-8385-y; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar Alok, 2016, BRAIN BEHAV IMMUNITY; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Mander P, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-20; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rangarajan P, 2016, NEUROMOL MED, V18, P453, DOI 10.1007/s12017-016-8430-x; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; Silva ART, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099897; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Sudduth TL, 2013, NEUROBIOL AGING, V34, P1051, DOI 10.1016/j.neurobiolaging.2012.09.012; Tian DS, 2016, J NEUROCHEM, V139, P96, DOI 10.1111/jnc.13751; Tian RF, 2016, BRAIN RES, V1637, P1, DOI 10.1016/j.brainres.2016.01.029; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Wan Shu, 2016, TRANSLATIONAL STROKE; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Weekman EM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-127; Yang JJ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00061; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	62	140	147	1	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2016	33	19					1732	+		10.1089/neu.2015.4268			20	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DY8KP	WOS:000385379100002	26486881	Green Published			2022-02-06	
J	Iverson, GL; Silverberg, ND; Mannix, R; Maxwell, BA; Atkins, JE; Zafonte, R; Berkner, PD				Iverson, Grant L.; Silverberg, Noah D.; Mannix, Rebekah; Maxwell, Bruce A.; Atkins, Joseph E.; Zafonte, Ross; Berkner, Paul D.			Factors Associated With Concussion-like Symptom Reporting in High School Athletes	JAMA PEDIATRICS			English	Article							SPORTS-RELATED CONCUSSION; BASE-LINE VALUES; NEUROCOGNITIVE PERFORMANCE; SEX-DIFFERENCES; MANAGEMENT; RECOVERY; CONSEQUENCES; HISTORY; STRESS; INJURY	IMPORTANCE Every state in the United States has passed legislation for sport-related concussion, making this health issue important for physicians and other health care professionals. Safely returning athletes to sport after concussion relies on accurately determining when their symptoms resolve. OBJECTIVE To evaluate baseline concussion-like symptom reporting in uninjured adolescent student athletes. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional, observational study, we studied 31 958 high school athletes from Maine with no concussion in the past 6 months who completed a preseason baseline testing program between 2009 and 2013. RESULTS Symptom reporting was more common in girls than boys. Most students with preexisting conditions reported one or more symptoms (60%-82% of boys and 73%-97% of girls). Nineteen percent of boys and 28% of girls reported having a symptom burden resembling an International Classification of Diseases, 10th Revision (ICD-10) diagnosis of postconcussional syndrome (PCS). Students with preexisting conditions were even more likely to endorse a symptom burden that resembled PCS (21%-47% for boys and 33%-72% for girls). Prior treatment of a psychiatric condition was the strongest independent predictor for symptom reporting in boys, followed by a history of migraines. For girls, the strongest independent predictors were prior treatment of a psychiatric condition or substance abuse and attention-deficit/hyperactivity disorder. The weakest independent predictor of symptoms for both sexes was history of prior concussions. CONCLUSIONS AND RELEVANCE In the absence of a recent concussion, symptom reporting is related to sex and preexisting conditions. Consideration of sex and preexisting health conditions can help prevent misinterpretation of symptoms in student athletes who sustain a concussion.	[Iverson, Grant L.; Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Children Sports Concuss Program, Boston, MA 02114 USA; [Iverson, Grant L.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Maxwell, Bruce A.] Colby Coll, Dept Comp Sci, Waterville, ME 04901 USA; [Atkins, Joseph E.] Colby Coll, Dept Psychol, Waterville, ME USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA		Iverson, GL (corresponding author), Harvard Univ, Sch Med, Ctr Hlth & Rehabil, Dept Phys Med & Rehabil, 79-96 13th St Charlestown Navy Yard, Charlestown, MA 02129 USA.	giverson@mgh.harvard.edu	Mannix, Rebekah/AAD-8702-2020	Iverson, Grant/0000-0001-7348-9570	Goldfarb Center for Public Policy and Civic Engagement/Colby College; Bill and Joan Alfond Foundation; Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members; Mooney-Reed Charitable Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This study was supported by the Goldfarb Center for Public Policy and Civic Engagement/Colby College, the Bill and Joan Alfond Foundation, the Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members (Dr Zafonte), and the Mooney-Reed Charitable Foundation (Drs Iverson and Zafonte).	Albinson CB, 2003, J SPORT REHABIL, V12, P306, DOI 10.1123/jsr.12.4.306; Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, pix; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gershon J, 2002, J Atten Disord, V5, P143, DOI 10.1177/108705470200500302; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; ImPACT Applications Inc, 2007, IMPACT IMM POSTC ASS; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Shuer ML, 1997, WESTERN J MED, V166, P104; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	40	140	140	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	DEC	2015	169	12					1132	1140		10.1001/jamapediatrics.2015.2374			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	CY3UE	WOS:000366334600017	26457403	Green Accepted, Bronze			2022-02-06	
J	Demertzi, A; Antonopoulos, G; Heine, L; Voss, HU; Crone, JS; de Los Angeles, C; Bahri, MA; Di Perri, C; Vanhaudenhuyse, A; Charland-Verville, V; Kronbichler, M; Trinka, E; Phillips, C; Gomez, F; Tshibanda, L; Soddu, A; Schiff, ND; Whitfield-Gabrieli, S; Laureys, S				Demertzi, Athena; Antonopoulos, Georgios; Heine, Lizette; Voss, Henning U.; Crone, Julia Sophia; de Los Angeles, Carlo; Bahri, Mohamed Ali; Di Perri, Carol; Vanhaudenhuyse, Audrey; Charland-Verville, Vanessa; Kronbichler, Martin; Trinka, Eugen; Phillips, Christophe; Gomez, Francisco; Tshibanda, Luaba; Soddu, Andrea; Schiff, Nicholas D.; Whitfield-Gabrieli, Susan; Laureys, Steven			Intrinsic functional connectivity differentiates minimally conscious from unresponsive patients	BRAIN			English	Article						consciousness; traumatic brain injury; resting state connectivity; sensory systems; anoxia	DEFAULT-MODE NETWORK; ANTI-CORRELATED NETWORKS; GLOBAL SIGNAL REGRESSION; TRAUMATIC BRAIN-INJURY; RESTING-STATE NETWORKS; VEGETATIVE STATE; DIFFUSION-TENSOR; DISORDERS; ACTIVATION; AWARENESS	Demertzi et al. use resting-state fMRI to distinguish single patients with disorders of consciousness. They show that long-range and sensory networks discriminate unresponsive from minimally conscious patients. The auditory-visual interaction, supported by the auditory network, has the highest classification accuracy, producing diagnoses congruent with independent assessments in 20/22 cases.Demertzi et al. use resting-state fMRI to distinguish single patients with disorders of consciousness. They show that long-range and sensory networks discriminate unresponsive from minimally conscious patients. The auditory-visual interaction, supported by the auditory network, has the highest classification accuracy, producing diagnoses congruent with independent assessments in 20/22 cases.Despite advances in resting state functional magnetic resonance imaging investigations, clinicians remain with the challenge of how to implement this paradigm on an individualized basis. Here, we assessed the clinical relevance of resting state functional magnetic resonance imaging acquisitions in patients with disorders of consciousness by means of a systems-level approach. Three clinical centres collected data from 73 patients in minimally conscious state, vegetative state/unresponsive wakefulness syndrome and coma. The main analysis was performed on the data set coming from one centre (LiSge) including 51 patients (26 minimally conscious state, 19 vegetative state/unresponsive wakefulness syndrome, six coma; 15 females; mean age 49 +/- 18 years, range 11-87; 16 traumatic, 32 non-traumatic of which 13 anoxic, three mixed; 35 patients assessed > 1 month post-insult) for whom the clinical diagnosis with the Coma Recovery Scale-Revised was congruent with positron emission tomography scanning. Group-level functional connectivity was investigated for the default mode, frontoparietal, salience, auditory, sensorimotor and visual networks using a multiple-seed correlation approach. Between-group inferential statistics and machine learning were used to identify each network's capacity to discriminate between patients in minimally conscious state and vegetative state/unresponsive wakefulness syndrome. Data collected from 22 patients scanned in two other centres (Salzburg: 10 minimally conscious state, five vegetative state/unresponsive wakefulness syndrome; New York: five minimally conscious state, one vegetative state/unresponsive wakefulness syndrome, one emerged from minimally conscious state) were used to validate the classification with the selected features. Coma Recovery Scale-Revised total scores correlated with key regions of each network reflecting their involvement in consciousness-related processes. All networks had a high discriminative capacity (> 80%) for separating patients in a minimally conscious state and vegetative state/unresponsive wakefulness syndrome. Among them, the auditory network was ranked the most highly. The regions of the auditory network which were more functionally connected in patients in minimally conscious state compared to vegetative state/unresponsive wakefulness syndrome encompassed bilateral auditory and visual cortices. Connectivity values in these three regions discriminated congruently 20 of 22 independently assessed patients. Our findings point to the significance of preserved abilities for multisensory integration and top-down processing in minimal consciousness seemingly supported by auditory-visual crossmodal connectivity, and promote the clinical utility of the resting paradigm for single-patient diagnostics.	[Demertzi, Athena; Antonopoulos, Georgios; Heine, Lizette; Di Perri, Carol; Charland-Verville, Vanessa; Laureys, Steven] Univ Liege, GIGA Res & Cyclotron Res Ctr, Coma Sci Grp, B-4000 Liege, Belgium; [Demertzi, Athena; Antonopoulos, Georgios; Heine, Lizette; Di Perri, Carol; Charland-Verville, Vanessa; Laureys, Steven] CHU Univ Hosp Liege, Liege, Belgium; [Voss, Henning U.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA; [Voss, Henning U.] Weill Cornell Med Coll, Citigrp Biomed Imaging Ctr, New York, NY USA; [Crone, Julia Sophia; Kronbichler, Martin] Dept Psychol, Salzburg, Austria; [Crone, Julia Sophia; Kronbichler, Martin] Ctr Neurocognit Res, Salzburg, Austria; [Crone, Julia Sophia; Kronbichler, Martin] Paracelsus Private Med Univ, Inst Neurosci, Salzburg, Austria; [Crone, Julia Sophia; Kronbichler, Martin] Paracelsus Private Med Univ, Christian Doppler Klin, Ctr Neurocognit Res, Salzburg, Austria; [Crone, Julia Sophia; Trinka, Eugen] Paracelsus Private Med Univ, Christian Doppler Klin, Dept Neurol, Salzburg, Austria; [de Los Angeles, Carlo; Whitfield-Gabrieli, Susan] MIT, McGovern Inst Brain Res, Martinos Imaging Ctr, Cambridge, MA 02139 USA; [Bahri, Mohamed Ali; Phillips, Christophe] Univ Liege, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Vanhaudenhuyse, Audrey] CHU Univ Hosp Liege, Dept Algol & Palliat Care, Liege, Belgium; [Gomez, Francisco] Univ Cent Colombia, Dept Comp Sci, Bogota, Colombia; [Tshibanda, Luaba] CHU Univ Hosp Liege, Dept Radiol, Liege, Belgium; [Soddu, Andrea] Univ Western Ontario, Dept Phys & Astron, Brain & Mind Inst, London, ON, Canada; [Schiff, Nicholas D.] Weill Cornell Grad Sch Med Sci, Dept Neurosci, New York, NY USA; [Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA		Demertzi, A (corresponding author), Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, Allee 6 Aout 8,Sart Tilman B30, B-4000 Liege, Belgium.	a.demertzi@ulg.ac.be	Kronbichler, Martin/AAY-1519-2021; Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Demertzi, Athena/I-1251-2019; Kronbichler, Martin/A-5599-2008; Voss, Henning/C-2194-2009; Phillips, Christophe/M-3025-2017; Soddu, Andrea/K-7087-2014	Kronbichler, Martin/0000-0003-2240-2812; Laureys, Steven/0000-0002-3096-3807; Demertzi, Athena/0000-0001-8021-3759; Kronbichler, Martin/0000-0003-2240-2812; Voss, Henning/0000-0003-2811-2074; Di Perri, Carol/0000-0003-0284-770X; Trinka, Eugen/0000-0002-5950-2692; Antonopoulos, Georgios/0000-0002-1274-5160; Heine, Lizette/0000-0003-1369-8199; Phillips, Christophe/0000-0002-4990-425X; Soddu, Andrea/0000-0001-6833-745X; Crone, Julia Sophia/0000-0002-0787-7003	European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation; European Space AgencyEuropean Space AgencyEuropean Commission; Mind Science Foundation; French Speaking Community Concerted Research Action [ARC - 06/11 - 340]; Public Utility Foundation 'Universite Europeenne du Travail'; Fondazione Europea di Ricerca Biomedica; University and University Hospital of Liege	A.D. is postdoctoral Researcher at the Belgian National Funds for Scientific Research (FNRS), L.H. and V.C.V. are Research Fellows at the FNRS, S.L. is Research Director at the FNRS. This work was further supported by the European Commission, the James McDonnell Foundation, the European Space Agency, Mind Science Foundation, the French Speaking Community Concerted Research Action (ARC - 06/11 - 340), the Public Utility Foundation 'Universite Europeenne du Travail', 'Fondazione Europea di Ricerca Biomedica' and the University and University Hospital of Liege.	Achard S, 2011, NEURORADIOL J, V24, P311, DOI 10.1177/197140091102400222; Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; Amico E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100012; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Barttfeld P, 2015, P NATL ACAD SCI USA, V112, P887, DOI 10.1073/pnas.1418031112; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Bekinschtein TA, 2009, P NATL ACAD SCI USA, V106, P1672, DOI 10.1073/pnas.0809667106; Bishop CM., 2006, PATTERN RECOGN; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Boly M, 2012, P NATL ACAD SCI USA, V109, P5856, DOI 10.1073/pnas.1111133109; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Bruno MA, 2010, COGN NEUROSCI-UK, V1, P193, DOI 10.1080/17588928.2010.485677; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555; Casali AG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006294; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Clavagnier S, 2004, COGN AFFECT BEHAV NE, V4, P117, DOI 10.3758/CABN.4.2.117; Cole DM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00008; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Martino F, 2007, NEUROIMAGE, V34, P177, DOI 10.1016/j.neuroimage.2006.08.041; Dehaene S, 2005, PLOS BIOL, V3, P910, DOI 10.1371/journal.pbio.0030141; Dehaene S, 2003, P NATL ACAD SCI USA, V100, P8520, DOI 10.1073/pnas.1332574100; Demertzi A, 2014, CORTEX, V52, P35, DOI 10.1016/j.cortex.2013.11.005; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Eckert MA, 2008, HUM BRAIN MAPP, V29, P848, DOI 10.1002/hbm.20560; Edlow BL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0375-y; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Fernandez-Espejo D, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-77; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; Guldenmund P, 2013, BRAIN CONNECT, V3, P273, DOI 10.1089/brain.2012.0117; Heine L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00295; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Huang ZR, 2014, HUM BRAIN MAPP, V35, P1997, DOI 10.1002/hbm.22308; JENNETT B, 1972, LANCET, V1, P734; Kelly RE, 2010, J NEUROSCI METH, V189, P233, DOI 10.1016/j.jneumeth.2010.03.028; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Larson-Prior LJ, 2009, P NATL ACAD SCI USA, V106, P4489, DOI 10.1073/pnas.0900924106; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Maki-Marttunen V, 2013, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00024; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Maudoux A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036222; Monti MM, 2015, NEUROLOGY, V84, P167, DOI 10.1212/WNL.0000000000001123; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Norton L, 2012, NEUROLOGY, V78, P175, DOI 10.1212/WNL.0b013e31823fcd61; Ovadia-Caro S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037238; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Phillips CL, 2011, NEUROIMAGE, V56, P797, DOI 10.1016/j.neuroimage.2010.05.083; Ploner M, 2010, P NATL ACAD SCI USA, V107, P355, DOI 10.1073/pnas.0906186106; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Samann PG, 2011, CEREB CORTEX, V21, P2082, DOI 10.1093/cercor/bhq295; Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344; Sanders RD, 2012, ANESTHESIOLOGY, V116, P946, DOI 10.1097/ALN.0b013e318249d0a7; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schifilliti D, 2010, CNS DRUGS, V24, P893, DOI 10.2165/11584760-000000000-00000; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Soddu A, 2011, FUNCT NEUROL, V26, P37; Stamatakis EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014224; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Stevens RD, 2014, CURR OPIN CRIT CARE, V20, P168, DOI 10.1097/MCC.0000000000000069; Tononi G, 2008, BIOL BULL-US, V215, P216, DOI 10.2307/25470707; Tsai YH, 2014, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00956; van der Eerden AW, 2014, RADIOLOGY, V270, P506, DOI 10.1148/radiol.13122720; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Wiech K, 2010, J NEUROSCI, V30, P16324, DOI 10.1523/JNEUROSCI.2087-10.2010; Wong CW, 2012, NEUROIMAGE, V63, P356, DOI 10.1016/j.neuroimage.2012.06.035; Yu F, 2015, BRAIN, V138, DOI 10.1093/brain/awu239	89	140	147	3	24	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP 1	2015	138		9				2619	2631		10.1093/brain/awv169			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR5PS	WOS:000361396200023	26117367				2022-02-06	
J	Laird, MD; Shields, JS; Sukumari-Ramesh, S; Kimbler, DE; Fessler, RD; Shakir, B; Youssef, P; Yanasak, N; Vender, JR; Dhandapani, KM				Laird, Melissa D.; Shields, Jessica S.; Sukumari-Ramesh, Sangeetha; Kimbler, Donald E.; Fessler, R. David; Shakir, Basheer; Youssef, Patrick; Yanasak, Nathan; Vender, John R.; Dhandapani, Krishnan M.			High Mobility Group Box Protein-1 Promotes Cerebral Edema After Traumatic Brain Injury via Activation of Toll-Like Receptor 4	GLIA			English	Article						neuroinflammation; DAMP; intracranial pressure; innate immunity; controlled cortical impact	INTRACRANIAL HYPERTENSION; INTRACEREBRAL HEMORRHAGE; DIFFERENTIAL REGULATION; CLINICAL-TRIALS; NMDA RECEPTORS; HEAD-INJURY; MICE; CONTUSION; APOPTOSIS; NEUROINFLAMMATION	Traumatic brain injury (TBI) is a major cause of mortality and morbidity worldwide. Cerebral edema, a life-threatening medical complication, contributes to elevated intracranial pressure (ICP) and a poor clinical prognosis after TBI. Unfortunately, treatment options to reduce post-traumatic edema remain suboptimal, due in part, to a dearth of viable therapeutic targets. Herein, we tested the hypothesis that cerebral innate immune responses contribute to edema development after TBI. Our results demonstrate that high-mobility group box protein 1 (HMGB1) was released from necrotic neurons via a NR2B-mediated mechanism. HMGB1 was clinically associated with elevated ICP in patients and functionally promoted cerebral edema after TBI in mice. The detrimental effects of HMGB1 were mediated, at least in part, via activation of microglial toll-like receptor 4 (TLR4) and the subsequent expression of the astrocytic water channel, aquaporin-4 (AQP4). Genetic or pharmacological (VGX-1027) TLR4 inhibition attenuated the neuroinflammatory response and limited post-traumatic edema with a delayed, clinically implementable therapeutic window. Human and rodent tissue culture studies further defined the cellular mechanisms demonstrating neuronal HMGB1 initiates the microglial release of interleukin-6 (IL-6) in a TLR4 dependent mechanism. In turn, microglial IL-6 increased the astrocytic expression of AQP4. Taken together, these data implicate microglia as key mediators of post-traumatic brain edema and suggest HMGB1-TLR4 signaling promotes neurovascular dysfunction after TBI. GLIA 2013;62:26-38	[Laird, Melissa D.; Shields, Jessica S.; Sukumari-Ramesh, Sangeetha; Kimbler, Donald E.; Fessler, R. David; Shakir, Basheer; Youssef, Patrick; Vender, John R.; Dhandapani, Krishnan M.] Georgia Regents Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA USA; [Yanasak, Nathan] Georgia Regents Univ, Med Coll Georgia, Dept Radiol, Augusta, GA USA		Dhandapani, KM (corresponding author), Med Coll Georgia, Dept Neurosurg, 1120 15th St, Augusta, GA 30912 USA.	kdhandapani@gru.edu	Youssef, Patrick/O-9451-2014	Dhandapani, Krishnan/0000-0001-7044-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172, NS075774, NS084228]; American Heart AssociationAmerican Heart Association [BGIA2300135, PRE2250690]; TriServices Nursing Research Program [HU0001-10-1-TS11]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS084228, R01NS065172, R21NS075774] Funding Source: NIH RePORTER	Grant sponsor: National Institutes of Health; Grant numbers: NS065172, NS075774, NS084228; Grants sponsor: American Heart Association; Grant numbers: BGIA2300135, PRE2250690; Grant sponsor: TriServices Nursing Research Program; Grant number: HU0001-10-1-TS11.	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Anastasio NC, 2009, NEUROSCIENCE, V163, P1181, DOI 10.1016/j.neuroscience.2009.07.058; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Chaperon F, 2003, BEHAV PHARMACOL, V14, P477, DOI 10.1097/01.fbp.0000091471.79060.ed; Cull-Candy Stuart G, 2004, Sci STKE, V2004, pre16, DOI 10.1126/stke.2552004re16; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox CJ, 2006, HIPPOCAMPUS, V16, P907, DOI 10.1002/hipo.20230; Gao HM, 2011, J NEUROSCI, V31, P1081, DOI 10.1523/JNEUROSCI.3732-10.2011; Gunnarson E, 2008, GLIA, V56, P587, DOI 10.1002/glia.20627; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawamata T, 2006, ACTA NEUROCHIR SUPPL, V96, P3; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Malherbe P, 2003, J PHARMACOL EXP THER, V307, P897, DOI 10.1124/jpet.103.056291; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Milnerwood AJ, 2012, NEUROBIOL DIS, V48, P40, DOI 10.1016/j.nbd.2012.05.013; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nase G, 2008, GLIA, V56, P895, DOI 10.1002/glia.20664; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Orlent H, 2006, J HEPATOL, V45, P539, DOI 10.1016/j.jhep.2006.05.015; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Parker LC, 2007, CLIN EXP IMMUNOL, V147, P199, DOI 10.1111/j.1365-2249.2006.03203.x; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Stojanovic I, 2007, CLIN IMMUNOL, V123, P311, DOI 10.1016/j.clim.2007.03.004; Stosic-Grujicic S, 2007, J PHARMACOL EXP THER, V320, P1038, DOI 10.1124/jpet.106.109272; Sukumari-Ramesh S, 2012, J NEUROTRAUM, V29, P2798, DOI 10.1089/neu.2011.2243; Sukumari-Ramesh S, 2010, GLIA, V58, P1858, DOI 10.1002/glia.21055; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Won JJ, 2006, NAT CHEM BIOL, V2, P369, DOI 10.1038/nchembio800; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yang K, 2012, EMBO J, V31, P805, DOI 10.1038/emboj.2011.453; Youn HS, 2006, BIOCHEM PHARMACOL, V72, P62, DOI 10.1016/j.bcp.2006.03.022; Zhou F, 2009, BRAIN INJURY, V23, P353, DOI 10.1080/02699050902788527	59	140	148	2	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN	2014	62	1					26	38		10.1002/glia.22581			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	255JM	WOS:000327235200003	24166800	Green Accepted			2022-02-06	
J	Wang, WX; Wilfred, BR; Madathil, SK; Tang, GL; Hu, YL; Dimayuga, J; Stromberg, AJ; Huang, QW; Saatman, KE; Nelson, PT				Wang, Wang-Xia; Wilfred, Bernard R.; Madathil, Sindhu K.; Tang, Guiliang; Hu, Yanling; Dimayuga, James; Stromberg, Arnold J.; Huang, Qingwei; Saatman, Kathryn E.; Nelson, Peter T.			miR-107 Regulates Granulin/Progranulin with Implications for Traumatic Brain Injury and Neurodegenerative Disease	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; GROWTH-FACTOR; MESSENGER-RNAS; RIBONUCLEOPROTEIN COMPLEXES; ARGONAUTE PROTEINS; ALZHEIMERS-DISEASE; MICRORNA TARGETS; RIP-CHIP; PROGRANULIN; EXPRESSION	Granulin (GRN, or progranulin) is a protein involved in wound repair, inflammation, and neoplasia. GRN has also been directly implicated in frontotemporal dementia and may contribute to Alzheimer's disease pathogenesis. However, GRN regulation expression is poorly understood. A high-throughput experimental microRNA assay showed that GRN is the strongest target for miR-107 in human H4 neuroglioma cells. miR-107 has been implicated in Alzheimer's disease pathogenesis, and sequence elements in the open reading frame-rather than the 3 ' untranslated region-of GRN mRNA are recognized by miR-107 and are highly conserved among vertebrate species. To better understand the mechanism of this interaction, FLAG-tagged Argonaute constructs were used following miR-107 transfection. GRN mRNA interacts preferentially with Argonaute 2. In vitro and in vivo studies indicate that regulation of GRN by miR-107 may be functionally important. Glucose supplementation in cultured cells that leads to increased miR-107 levels also results in decreased GRN expression, including changes in cell compartmentation and decreased secretion of GRN protein. This effect was eliminated following miR-107 transfection. We also tested a mouse model where miR-107 has been shown to be down-regulated. In brain tissue subjacent to 1 0 mm depth controlled cortical impact, surviving hippocampal neurons show decreased miR-107 with augmentation of neuronal GRN expression. These findings indicate that miR-107 contributes to GRN expression regulation with implications for brain disorders. (Am J Pathol 2010, 177:334-345; DOI: 10.2353/ajpath.2010.091202)	[Nelson, Peter T.] Univ Kentucky, Dept Pathol, Div Neuropathol, Med Ctr, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Nelson, PT (corresponding author), Univ Kentucky, Dept Pathol, Div Neuropathol, Med Ctr, Rm 311,Sanders Brown Ctr,800 S Limestone, Lexington, KY 40536 USA.	pnels2@email.uky.edu	Wilfred, Bernard Srambical/AAC-8221-2020; Tang, Guiliang/F-1450-2010; Wang, Wang-Xia/AAD-6900-2019; Tang, Guiliang/C-7989-2012; Madathil, Sindhu K/E-9407-2012	Wilfred, Bernard Srambical/0000-0002-0674-0187; Wang, Wang-Xia/0000-0002-8104-3779	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS061933, K08 NS050110, P30 AG028383]; Kentucky Spinal Cord and Head Injury Research Trust [7-20]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061933, K08NS050110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028383] Funding Source: NIH RePORTER	Supported by grants R01 NS061933, K08 NS050110, and P30 AG028383 from NIH, and Kentucky Spinal Cord and Head Injury Research Trust grant 7-20.	Ahmed FE, 2007, EXPERT REV MOL DIAGN, V7, P569, DOI 10.1586/14737159.7.5.569; Ahmed Z, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-7; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Andachi Y, 2008, RNA, V14, P2440, DOI 10.1261/rna.1139508; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; ARNSTEIN P, 1974, J NATL CANCER I, V52, P71, DOI 10.1093/jnci/52.1.71; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bateman A, 2009, BIOESSAYS, V31, P1245, DOI 10.1002/bies.200900086; Beitzinger M, 2007, RNA BIOL, V4, P76, DOI 10.4161/rna.4.2.4640; Bilen J, 2006, MOL CELL, V24, P157, DOI 10.1016/j.molcel.2006.07.030; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Cairns NJ, 2007, ACTA NEUROPATHOL, V114, P5, DOI 10.1007/s00401-007-0237-2; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Chang S, 2009, HUM MOL GENET, V18, pR18, DOI 10.1093/hmg/ddp072; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Cruts Marc, 2006, Current Alzheimer Research, V3, P485, DOI 10.2174/156720506779025251; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Cuellar TL, 2008, P NATL ACAD SCI USA, V105, P5614, DOI 10.1073/pnas.0801689105; Cummins JM, 2006, ONCOGENE, V25, P6220, DOI 10.1038/sj.onc.1209914; Donald CD, 2001, ANTICANCER RES, V21, P3739; Easow G, 2007, RNA, V13, P1198, DOI 10.1261/rna.563707; Eriksen JL, 2008, J NEUROCHEM, V104, P287, DOI 10.1111/j.1471-4159.2007.04968.x; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Gass J, 2006, HUM MOL GENET, V15, P2988, DOI 10.1093/hmg/ddl241; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; Hebert SS, 2009, TRENDS NEUROSCI, V32, P199, DOI 10.1016/j.tins.2008.12.003; Heimberg AM, 2008, P NATL ACAD SCI USA, V105, P2946, DOI 10.1073/pnas.0712259105; Hendrickson DG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002126; Hsu SD, 2008, NUCLEIC ACIDS RES, V36, pD165, DOI 10.1093/nar/gkm1012; Hugon Jacques, 2008, Expert Rev Neurother, V8, P1615, DOI 10.1586/14737175.8.11.1615; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321; Karginov FV, 2007, P NATL ACAD SCI USA, V104, P19291, DOI 10.1073/pnas.0709971104; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481; Kosik KS, 2005, NEURON, V47, P779, DOI 10.1016/j.neuron.2005.08.019; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kubo T, 2002, J NEUROCHEM, V82, P1129, DOI 10.1046/j.1471-4159.2002.01060.x; Kunin V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-401; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li N, 2011, NEUROBIOL AGING, V32, P944, DOI 10.1016/j.neurobiolaging.2009.04.020; Liau LM, 2000, CANCER RES, V60, P1353; Liscic RM, 2008, EUR J NEUROL, V15, P772, DOI 10.1111/j.1468-1331.2008.02195.x; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu X, 2008, BRAIN PATHOL, V18, P113, DOI 10.1111/j.1750-3639.2007.00121.x; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Lukiw WJ, 2007, NEUROREPORT, V18, P297, DOI 10.1097/WNR.0b013e3280148e8b; Makeyev EV, 2008, SCIENCE, V319, P1789, DOI 10.1126/science.1152326; Marsit CJ, 2006, CANCER RES, V66, P10843, DOI 10.1158/0008-5472.CAN-06-1894; Masellis M, 2006, BRAIN, V129, P3115, DOI 10.1093/brain/awl276; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nelson PT, 2008, BRAIN PATHOL, V18, P130, DOI 10.1111/j.1750-3639.2007.00120.x; Nelson PT, 2007, J NEUROPATH EXP NEUR, V66, P461, DOI 10.1097/01.jnen.0000240474.27791.f3; Nelson PT, 2007, RNA, V13, P1787, DOI 10.1261/rna.646007; Nelson PT, 2009, NEUROSCI LETT, V466, P69, DOI 10.1016/j.neulet.2009.04.044; Nelson PT, 2008, BBA-GENE REGUL MECH, V1779, P758, DOI 10.1016/j.bbagrm.2008.03.012; Nelson PT, 2006, RNA, V12, P187, DOI 10.1261/rna.2258506; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nishino J, 2004, EMBO J, V23, P1998, DOI 10.1038/sj.emboj.7600202; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Pereson S, 2009, J PATHOL, V219, P173, DOI 10.1002/path.2580; Rademakers R, 2008, HUM MOL GENET, V17, P3631, DOI 10.1093/hmg/ddn257; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; RESOLE G, 1997, GENE, V205, P95; Rigoutsos I, 2009, CANCER RES, V69, P3245, DOI 10.1158/0008-5472.CAN-09-0352; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schaefer A, 2007, J EXP MED, V204, P1553, DOI 10.1084/jem.20070823; Serrero G, 2003, BIOCHEM BIOPH RES CO, V308, P409, DOI 10.1016/S0006-291X(03)01452-9; Snowden JS, 2006, BRAIN, V129, P3091, DOI 10.1093/brain/awl267; Su H, 2009, GENE DEV, V23, P304, DOI 10.1101/gad.1749809; Suzuki M, 2002, MOL GENET METAB, V75, P31, DOI 10.1006/mgme.2001.3274; Tan LP, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp715; Tang XQ, 2007, RNA, V13, P1803, DOI 10.1261/rna.498607; Tang XQ, 2009, RNA, V15, P287, DOI 10.1261/rna.1211209; Tolkatchev D, 2008, PROTEIN SCI, V17, P711, DOI 10.1110/ps.073295308; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; Van Deerlin VM, 2007, ARCH NEUROL-CHICAGO, V64, P1148, DOI 10.1001/archneur.64.8.1148; WANG W, 2008, RNA INTERFERENCE MEC, P1; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Wang WX, 2010, RNA, V16, P394, DOI 10.1261/rna.1905910; Wang WX, 2008, BBA-GENE REGUL MECH, V1779, P749, DOI 10.1016/j.bbagrm.2008.01.005; Wei JJ, 2008, SEMIN REPROD MED, V26, P515, DOI 10.1055/s-0028-1096131; Weinmann L, 2009, CELL, V136, P496, DOI 10.1016/j.cell.2008.12.023; Wilfred BR, 2007, MOL GENET METAB, V91, P209, DOI 10.1016/j.ymgme.2007.03.011; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Zanocco-Marani T, 1999, CANCER RES, V59, P5331	95	140	144	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2010	177	1					334	345		10.2353/ajpath.2010.091202			12	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	624GM	WOS:000279805100035	20489155	Green Published, Bronze			2022-02-06	
J	Zhang, K; Johnson, B; Pennell, D; Ray, W; Sebastianelli, W; Slobounov, S				Zhang, K.; Johnson, B.; Pennell, D.; Ray, W.; Sebastianelli, W.; Slobounov, S.			Are functional deficits in concussed individuals consistent with white matter structural alterations: combined FMRI & DTI study	EXPERIMENTAL BRAIN RESEARCH			English	Article						Mild traumatic brain injury (MTBI); Functional magnetic resonance imaging (FMRI); Diffusion tensor imaging (DTI); Fractional Anisotropy (FA); White matter (WM)	TRAUMATIC BRAIN-INJURY; DIFFUSION-TENSOR; AXONAL INJURY; MILD; ABNORMALITIES	There is still controversy in the literature whether a single episode of mild traumatic brain injury (MTBI) results in short-term functional and/or structural deficits as well as any induced long-term residual effects. With the inability of traditional structural brain imaging techniques to accurately diagnosis MTBI, there is hope that more advanced applications like functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) will be more specific in diagnosing MTBI. In this study, 15 subjects who have recently suffered from sport-related MTBI and 15 age-matched normal controls underwent both fMRI and DTI to investigate the possibility of traumatic axonal injury associated with functional deficits in recently concussed but asymptomatic individuals. There are several findings of interest. First, MTBI subjects had a more disperse brain activation pattern with additional increases in activity outside of the shared regions of interest (ROIs) as revealed by FMRI blood oxygen level-dependent (BOLD) signals. The MTBI group had additional activation in the left dorsal-lateral prefrontal cortex during encoding phase of spatial navigation working memory task that was not observed in normal controls. Second, neither whole-brain analysis nor ROI analysis showed significant alteration of white matter (WM) integrity in MTBI subjects as evidenced by fractional anisotropy FA (DTI) data. It should be noted, however, there was a larger variability of fractional anisotropy (FA) in the genu, and body of the corpus callosum in MTB subjects. Moreover, we observed decreased diffusivity as evidenced by apparent diffusion coefficient (ADC) at both left and right dorsolateral prefrontal cortex (DL-PFC) in MTBI subjects (P < 0.001). There was also a positive correlation (P < 0.05) between ADC and % change of fMRI BOLD signals at DL-PFC in MTBI subjects, but not in normal controls. Despite these differences we conclude that overall, no consistent findings across advanced brain imaging techniques (fMRI and DTI) were observed. Whether the lack of consistency across research techniques (fMRI & DTI) is due to time frame of scanning, unique nature of MTBI and/or technological issues involved in FA and Apparent Diffusion Coefficient (ADC) quantification is yet to be determined.	[Slobounov, S.] NINDS, NIH, Bethesda, MD 20892 USA; [Zhang, K.; Johnson, B.; Slobounov, S.] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Ray, W.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Pennell, D.] Penn State Univ, Chandlee Lab, Social Life & Engn Sci Imaging Ctr, University Pk, PA 16802 USA; [Sebastianelli, W.; Slobounov, S.] Penn State Univ, Ctr Sport Med, University Pk, PA 16802 USA; [Sebastianelli, W.; Slobounov, S.] Penn State Univ, Hershey Med Sch, University Pk, PA 16802 USA		Slobounov, S (corresponding author), NINDS, NIH, MSC10 Ctr Dr, Bethesda, MD 20892 USA.	sms18@psu.edu	Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	This study was supported by NIH Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury'' awarded to Dr. Slobounov, PI.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Andersson JL, 2007, TR07JA1 FMRIB FMRIB TECH REP TRO7J; Andersson JL, 2007, FMRIB TECH REP TRO7J FMRIB TECHNICAL REPO; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BIGLER E, 2010, NEUROLOGY; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GREENBERG G, 2008, ARCH PHYS MED REH S2, V89; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Imfeld A, 2009, NEUROIMAGE, V46, P600, DOI 10.1016/j.neuroimage.2009.02.025; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Oechslin MS, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.076.2009; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	45	140	143	0	26	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JUL	2010	204	1					57	70		10.1007/s00221-010-2294-3			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	610MO	WOS:000278737200006	20496060	Green Accepted			2022-02-06	
J	Moore, DF; Jerusalem, A; Nyein, M; Noels, L; Jaffee, MS; Radovitzky, RA				Moore, David F.; Jerusalem, Antoine; Nyein, Michelle; Noels, Ludovic; Jaffee, Michael S.; Radovitzky, Raul A.			Computational biology - Modeling of primary blast effects on the central nervous system	NEUROIMAGE			English	Article							VIRTUAL TEST FACILITY; BRAIN-TISSUE; MECHANICAL-PROPERTIES; CONSTITUTIVE MODEL; DYNAMIC-RESPONSE; HUMAN HEAD; INJURY; IMPACT; SIMULATION; DESIGN	Objectives: Recent military conflicts in Iraq and Afghanistan have highlighted the wartime effect of traumatic brain injury (TBI). The reason for the prominence of TBI in these particular conflicts as opposed to others is unclear but may result from the increased survivability of blast due to improvements in body armor. In the military context blunt, ballistic and blast effects may all contribute to CNS injury, however blast in Particular, has been suggested as a primary cause of military TBI. While blast effects on some biological tissues, such as the lung, are documented in terms of injury thresholds, this is not the case for the CNS. We hypothesized that using bio-fidelic models, allowing for fluid-solid interaction and basic material properties available in the literature, a blast wave would interact with CNS tissue and cause a possible concussive effect. Methods: The modeling approach employed for this investigation consisted of a computational framework suitable for simulating coupled fluid-solid dynamic interactions. The model included a complex finite element mesh of the head and intra-cranial contents. The effects of threshold and 50% lethal blast lung injury were compared with concussive impact injury using the full head model allowing upper and lower bounds of tissue injury to be applied using pulmonary injury as the reference tissue. Results: The effects of a 50% lethal dose blast lung injury (LD50) were Comparable with concussive impact injury using the DVBIC-MIT full head model. Interpretation: CNS blast concussive effects were found to be similar between impact mild TBI and the blast field associated with LD50 lung blast injury sustained without personal protective equipment. With the ubiquitous use of personal protective equipment this suggests that blast concussive effects may more readily ascertained in personnel due to enhanced survivability in the current conflicts. (C) 2009 Published by Elsevier Inc.	[Moore, David F.; Jaffee, Michael S.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20309 USA; [Jerusalem, Antoine; Nyein, Michelle; Radovitzky, Raul A.] MIT, Dept Aeronaut & Astronaut, Cambridge, MA 02139 USA; [Noels, Ludovic] Univ Liege, Dept Aerosp & Mech Engn, Liege, Belgium		Moore, DF (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Bldg 1,Room B207,6900 Georgia Ave NW, Washington, DC 20309 USA.	david.f.moore@amedd.army.mil	Noels, Ludovic/H-3313-2019; Radovitzky, Raul A/A-5353-2009	Noels, Ludovic/0000-0002-7224-5539; Radovitzky, Raul A/0000-0001-6339-2708; Jerusalem, Antoine/0000-0001-5026-8038			BASS C, 2006, P PERS ARM SYST S PA; Belingardi G, 2005, 19 INT TECHN C ENH S; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; BRAZARIAN J, 2005, BRAIN INJURY, V18, P85; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Collins DL, 1998, IEEE T MED IMAGING, V17, P463, DOI 10.1109/42.712135; COURTNEY A, 2007, BRAIN INJ, V21; Cuitino A., 1992, ENG COMPUT-GERMANY, V9, P437, DOI DOI 10.1108/EB023876>; CULLIS I, 2001, J ROY ARMY MED CORPS, V147, P18; Cummings J, 2002, J SUPERCOMPUT, V23, P39, DOI 10.1023/A:1015733102520; Deiterding R, 2006, ENG COMPUT-GERMANY, V22, P325, DOI 10.1007/s00366-006-0043-9; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Drapaca CS, 2006, J ELASTICITY, V85, P65, DOI 10.1007/s10659-006-9071-3; Drumheller D. S., 1998, INTRO WAVE PROPAGATI; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Holzapfel GA., 2001, NONLINEAR SOLID MECH; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; IVERSON G, 2006, BRAIN INJURY MED; Kambouchev N, 2006, J APPL PHYS, V100, DOI 10.1063/1.2349483; KAMBOUCHEV N, 2007, COMPUT STRUCT, V23, P325; Kambouchev N, 2007, J APPL MECH-T ASME, V74, P1042, DOI 10.1115/1.2712230; Kelly JP, 1997, NEUROLOGY, V48, P581; Kolsky H., 1963, STRESS WAVES SOLIDS; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Meyers MA., 1994, DYNAMIC BEHAV MAT, V2nd ed.; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 2005, J BIOMECH, V38, P153, DOI 10.1016/j.jbiomech.2004.03.004; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Ortiz M, 1999, COMPUT METHOD APPL M, V171, P419, DOI 10.1016/S0045-7825(98)00219-9; Ortiz M, 2001, INT J NUMER METH ENG, V52, P1431, DOI 10.1002/nme.263; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; STREHLOW RA, 1976, PROG ENERG COMBUST, V2, P27, DOI 10.1016/0360-1285(76)90007-1; STUHMILLER J, 1987, TOXICOLOGY, V121, P91; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TAYLOR P, 2006, SIM HEAD IMP LEAD TR; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; WHITE C, 1971, DEFENSE NUCL AGENCY; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; ZELDOVICH T, 1967, PHYS SHOCK WAVES HIG; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	55	140	150	0	32	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	AUG	2009	47			2			T10	T20		10.1016/j.neuroimage.2009.02.019			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	487FX	WOS:000269257400004	19248833				2022-02-06	
J	Faul, M; Wald, MM; Rutland-Brown, W; Sullivent, EE; Sattin, RW				Faul, Mark; Wald, Marlena M.; Rutland-Brown, Wesley; Sullivent, Ernest E.; Sattin, Richard W.			Using a cost-benefit analysis to estimate outcomes of a clinical treatment guideline: Testing the brain trauma foundation guidelines for the treatment of severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						cost benefit; traumatic brain injury; TBI; treatment guidelines; acute care; societal impact; rehabilitation; Glasgow Outcome Score	SEVERE HEAD-INJURY; UNITED-STATES; MANAGEMENT; CARE; CHARGES; PATHWAY	Background: A decade after promulgation of treatment guidelines by the Brain Trauma Foundation (BTF), few studies exist that examine the application of these guidelines for severe traumatic brain injury TBI) patients. These studies have reported both cost savings and reduced mortality. Materials: We projected the results of previous studies of BTF guideline adoption to estimate the impact of widespread adoption across the United States. We used surveillance systems and national surveys to estimate the number of severely injured TBI patients and compared the lifetime costs of BTF adoption to the current state of treatment. Results: After examining the health outcomes and costs, we estimated that a substantial savings in annual medical costs ($262 million), annual rehabilitation costs ($43 million) and lifetime societal costs ($3.84 billion) would be achieved if treatment guidelines were used more routinely. Implementation costs were estimated to be $61 million. The net savings were primarily because of better health outcomes and a decreased burden on lifetime social support systems. We also estimate that mortality would be reduced by 3,607 lives if the guidelines were followed. Conclusions: Widespread adoption of the BTF guidelines for the treatment of severe TBI would result in substantial savings in costs and lives. The majority of cost savings are societal costs. Further validation work to identify the most effective aspects of the BTF guidelines is warranted.	[Faul, Mark; Wald, Marlena M.; Rutland-Brown, Wesley; Sullivent, Ernest E.; Sattin, Richard W.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, Atlanta, GA 30341 USA		Faul, M (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, Atlanta, GA 30341 USA.	mfaul@cdc.gov		Faul, Mark/0000-0002-7683-0348			Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; *BRAIN TRAUM FDN A, MAN PROGN SEV TRAUM; *BRAIN TRAUM FDN A, GUID PREH MAN TRAUM; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; *CRAIG HOSP, 2001, COL TRAUM BRAIN INJ; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Finkelstein E., 2006, INCIDENCE EC BURDEN; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Huizenga JE, 2002, ACAD EMERG MED, V9, P806, DOI 10.1197/aemj.9.8.806; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Marr A., 2004, CENTRAL NERVOUS SYST; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; *NAT CTR INJ PREV, 2005, CDC AC INJ CAR RES A; *OV TECHN INC, 2006, MEDLINE; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Rizzo Matthew, 1996, P1; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; Thurman DJ, 2001, HEAD TRAUMA, P327; United States Department of Labor, INFL CALC; *US DEP HHS, 2002, NCHS PUBL US DAT FIL; *US DEP HHS, 1998, REH PERS TRAUM BRAIN, V16, P1; Vitaz TW, 2001, J TRAUMA, V51, P369, DOI 10.1097/00005373-200108000-00025	28	140	143	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2007	63	6					1271	1278		10.1097/TA.0b013e3181493080			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	243AU	WOS:000251768100015	18212649				2022-02-06	
J	Sterr, A; Herron, KA; Hayward, C; Montaldi, D				Sterr, A; Herron, KA; Hayward, C; Montaldi, D			Are mild head injuries as mild as we think? Neurobehavioral concomitants of chronic post-concussion syndrome	BMC NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; EVENT-RELATED POTENTIALS; DIFFUSE AXONAL INJURY; NEUROPSYCHOLOGICAL DEFICITS; POSTCONCUSSION SYNDROME; SYMPTOMS; PSYCHOGENESIS; PHYSIOGENESIS; COHORT; DAMAGE	Background: Mild traumatic brain injury (MTBI) can sometimes lead to persistent postconcussion symptoms. One well accepted hypothesis claims that chronic PCS has a neural origin, and is related to neurobehavioral deficits. But the evidence is not conclusive. In the attempt to characterise chronic MTBI consequences, the present experiment used a group comparison design, which contrasted persons (a) with MTBI and PCS, (b) MTBI without PCS, and (c) matched controls. We predicted that participants who have experienced MTBI but show no signs of PCS would perform similar to controls. At the same time, a subgroup of MTBI participants would show PCS symptoms and only these volunteers would have poorer cognitive performance. Thereby, the performance deficits should be most noticeable in participants with highest PCS severity. Method: 38 patients with a single MTBI that had occurred at least 12 month prior to testing, and 38 matched controls, participated in the experiment. A combination of questionnaires and neuropsychological test batteries were used to assess the extent of PCS and related deficits in neurobehavioral performance. Results: 11 out of 38 MTBI participants (29%) were found to suffer from PCS. This subgroup of MTBI patients performed poorly on neuropsychological test batteries. Thereby, a correlation was found between PCS symptom severity and test performance suggesting that participants with more pronounced PCS symptoms performed worse in cognitive tasks. In contrast, MTBI patients with no PCS showed performed similar to matched control. We further found that loss of consciousness, a key criterion for PCS diagnosis, was not predictive of sustained PCS. Conclusion: The results support the idea that MTBI can have sustained consequences, and that the subjectively experienced symptoms and difficulties in everyday situations are related to objectively measurable parameters in neurocognitive function.	Univ Surrey, Sch Human Sci, Guildford GU2 5XH, Surrey, England; Univ Manchester, Sch Psychol Sci, Manchester, Lancs, England		Sterr, A (corresponding author), Univ Surrey, Sch Human Sci, Guildford GU2 5XH, Surrey, England.	a.sterr@surrey.ac.uk; k.herron@surrey.ac.uk; chantal_hayward@yahoo.co.uk; Daniela.montaldi@manchester.ac.uk		Sterr, Annette/0000-0003-4490-985X	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0200128] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0200128] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Association AP, 2000, DIAGN STAT MAN MENT; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Callaghan M, 2001, DEV MED CHILD NEUROL, V43, P819, DOI 10.1017/S0012162201001487; CAMBRIDGE C, 2002, CAMBRIDGE NEUROPSYCH; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P84; Cassidy J. David, 2004, Journal of Rehabilitation Medicine Supplement, P28; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 1999, ARCH CLIN NEUROPSYCH, V14, P735, DOI 10.1016/S0887-6177(99)80228-5; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; DAVIS, 2002, DISS ABSTR INT B, V62, P3395; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Edna T H, 1987, J Oslo City Hosp, V37, P41; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gronwall D, 1974, PSYCHOL EFFECTS CONC; Hilsabeck RC, 1999, ARCH CLIN NEUROPSYCH, V14, P741, DOI 10.1016/S0887-6177(99)80238-8; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nelson H.E., 1982, NATL ADULT READING T; Peloso Paul M., 2004, Journal of Rehabilitation Medicine Supplement, P22; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Roth JS, 1999, ARCH CLIN NEUROPSYCH, V14, P41; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; VANZOMEREN AH, 1984, CLOSED INJURY PSYCHO; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zimmermann, 1997, TEST ATTENTIONAL PER	56	140	140	1	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	FEB 6	2006	6								7	10.1186/1471-2377-6-7			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	024TW	WOS:000236220100001	16460567	Green Published, gold			2022-02-06	
J	Boake, C; McCauley, SR; Levin, HS; Pedroza, C; Contant, CE; Song, JX; Brown, SA; Goodman, H; Brundage, SI; Diaz-Marchan, PJ				Boake, C; McCauley, SR; Levin, HS; Pedroza, C; Contant, CE; Song, JX; Brown, SA; Goodman, H; Brundage, SI; Diaz-Marchan, PJ			Diagnostic criteria for postconcussional syndrome after mild to moderate traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	30th Annual Meeting of the International-Neuropsychological-Society	FEB 13-16, 2002	TORONTO, CANADA	Int Neuropsychol Soc			OUTCOME MEASURES	This study evaluated the prevalence and specificity of diagnostic criteria for postconcussional syndrome (PCS) in 178 adults with mild to moderate traumatic brain injury (TBI) and 104 with extracranial trauma. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and International Classification of Diseases (ICD-10) criteria for PCS were evaluated 3 months after injury. The results showed that prevalence of PCS was higher using ICD-10 (64%) than DSM-IV criteria U M. Specificity to TBI was limited because PCS criteria were often fulfilled by patients with extracranial trauma. The authors conclude that further refinement of the DSM-IV and ICD-10 criteria for PCS is needed before these criteria are routinely employed.	Univ Texas, Sch Med, Baylor Coll Med, Dept Med Phys, Houston, TX USA; Univ Texas, Sch Med, Baylor Coll Med, Dept Rehabil, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Bayer Corp, Global Biometry, Pittsburgh, PA USA; Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA		Boake, C (corresponding author), TIRR, 1333 Moursund, Houston, TX 77030 USA.	corwin.boake@uth.tmc.edu		Pedroza, Claudia/0000-0003-4235-1282	ODCDC CDC HHS [R49/CCR612707-01] Funding Source: Medline		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; Hannay HJ, 1996, J HEAD TRAUMA REHAB, V11, P41, DOI 10.1097/00001199-199612000-00007; HEATON R, 1991, COMPEHENSIVE NORMS E; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; *NAT CTR INJ PREV, 2003, STEPS PREV SER PUBL; Smith, 1973, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 CLASSIFICATIO	16	140	146	1	9	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2005	17	3					350	356		10.1176/appi.neuropsych.17.3.350			7	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Psychiatry	962BB	WOS:000231704900008	16179657				2022-02-06	
J	Anderson, VA; Catroppa, C; Haritou, F; Morse, S; Rosenfeld, JV				Anderson, VA; Catroppa, C; Haritou, F; Morse, S; Rosenfeld, JV			Identifying factors contributing to child and family outcome 30 months after traumatic brain injury in children	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							PEDIATRIC HEAD-INJURY; BEHAVIOR PROBLEMS; PRACTICAL SCALE; SHORT-TERM; FOLLOW-UP; PREDICTORS; ACHIEVEMENT; ADOLESCENTS; RECOVERY; SEQUELAE	Objective: To examine the contributions of injury severity, physical and cognitive disability, child and family function to outcome 30 months after traumatic brain injury (TBI) in children. Design: A prospective, longitudinal, between group design, comparing function before and after injury across three levels of injury severity. Subjects: One hundred and fifty children, 3.0-12.11 years old, admitted to hospital with a diagnosis of TBI. The sample was divided according to injury severity: mild (n =42), moderate (n = 70), severe (n = 38). Children with a history of neurological, developmental, and psychiatric disorders were excluded from participation. Main outcome measures: Post injury physical function, cognitive ability (incorporating intellect, memory, and attention), behavioural and family functioning, and level of family burden. Results: A dose-response relation was identified for injury severity and physical and cognitive outcome, with significant recovery documented from acute to six months after TBI. Behavioural functioning was not related to injury severity, and where problems were identified, little recovery was noted over time. Family functioning remained unchanged from preinjury to post injury assessments. The level of family burden was high at both six and 30 months after injury, and was predicted by injury severity, functional impairment, and post injury child behavioural disturbance. Conclusions: These results suggest ongoing problems for the child and significant family burden 30 months after TBI. The nature and severity of the physical and cognitive problems are closely related to injury severity, with child and family function predicted by psychosocial and premorbid factors.	Univ Melbourne, Melbourne, Vic 3010, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Alfred Med Ctr, Melbourne, Vic, Australia		Anderson, VA (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	v.anderson@vaa.animels.edu.au	Catroppa, Cathy/AAX-9458-2021; Rosenfeld, Jeffrey V/B-7249-2011	Catroppa, Cathy/0000-0002-9750-0436; 			ADAMS W, 1989, MANUAL WIDE RANGE AS; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V., 1995, NEUROPSYCHOLOGICAL A; ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson-Parente JK., 1990, COGN REHABIL, V8, P22; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; BRESLAU N, 1990, ARCH GEN PSYCHIAT, V47, P15; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROOKS N, CLOSED HEAD INJURY P; Brown SW, 1998, SOLID STATE NUCL MAG, V11, P49, DOI 10.1016/S0926-2040(97)00095-7; Christensen AL, 1979, LURIAS NEUROPSYCHOLO; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; Kaufman, 1979, INTELLIGENT TESTING; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P165; Lachar D., 1992, PERSONALITY INVENTOR; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LHERMITTE J, 1972, REV NEUROL, V74, P20; MAX J, 1997, J AM ACAD CHILD ADOL, V36, P83; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NOLLER P, 1988, UNPUB ICPS FAMILY FU; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROWE KJ, 1992, J AM ACAD CHILD PSY, V31, P357, DOI 10.1097/00004583-199203000-00026; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wechsler D., 1987, MANUAL PRESCHOOL PRI; [No title captured]	53	140	143	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2005	76	3					401	408		10.1136/jnnp.2003.019174			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	901TM	WOS:000227304800023	15716536	Green Published, Bronze			2022-02-06	
J	Howells, T; Elf, K; Jones, PA; Ronne-Engstrom, E; Piper, I; Nilsson, P; Andrews, P; Enblad, P				Howells, T; Elf, K; Jones, PA; Ronne-Engstrom, E; Piper, I; Nilsson, P; Andrews, P; Enblad, P			Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; intracranial pressure; cerebral perfusion pressure; pressure reactivity; outcome	SEVERE HEAD-INJURIES; INTRACRANIAL-PRESSURE; THERAPY; AUTOREGULATION; MANAGEMENT; METABOLISM; EDEMA	Object. The aim of this study was to compare the effects of two different treatment protocols on physiological characteristics and outcome in patients with brain trauma. One protocol was primarily oriented toward reducing intracranial pressure (ICP), and the other primarily on maintaining cerebral perfusion pressure (CPP). Methods. A series of 67 patients in Uppsala were treated according to a protocol aimed at keeping ICP less than 20 mm Hg and, as a secondary target, CPP at approximately 60 mm Hg. Another series of 64 patients in Edinburgh were treated according to a protocol aimed primarily at maintaining CPP greater than 70 mm Hg and, secondarily, ICP less than 25 mm Hg for the first 24 hours and 30 mm Hg subsequently. The ICP and CPP insults were assessed as the percentage of monitoring time that ICP was greater than or equal to 20 mm Hg and CPP less than 60 mm Hg, respectively. Pressure reactivity in each patient was assessed based on the slope of the regression line relating mean arterial blood pressure (MABP) to ICP. Outcome was analyzed at 6 months according to the Glasgow Outcome Scale (GOS). The prognostic value of secondary insults and pressure reactivity was determined using linear methods and a neural network. In patients treated according to the CPP-oriented protocol, even short durations of CPP insults were strong predictors of death. In patients treated according to the ICP-oriented protocol, even long durations of CPP insult-mostly in the range of 50 to 60 mm Hg-were significant predictors of favorable outcome (GOS Score 4 or 5). Among those who had undergone ICP-oriented treatment, pressure-passive patients (MABP/ICP slope >= 0.13) had a better outcome. Among those who had undergone CPP-oriented treatment, the more pressure-active (MABP/ICP slope < 0.13) patients had a better outcome. Conclusions. Based on data from this study, the authors concluded that ICP-oriented therapy should be used in patients whose slope of the MABP/ICP regression line is at least 0.13, that is, in pressure-passive patients. If the slope is less than 0.13, then hypertensive CPP therapy is likely to produce a better outcome.	Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; So Gen Hosp, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland; Univ Edinburgh, Edinburgh, Midlothian, Scotland; Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland; Western Gen Hosp, Dept Anesthesiol, Edinburgh EH4 2XU, Midlothian, Scotland		Howells, T (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden.	timothy.howells@lul.se					ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Beaumont A, 1999, CRIT REV NEUROSURG, V9, P207, DOI 10.1007/s003290050135; BULLOCK MR, 2000, MANAGEMENT PROGNOSIS, P91; Clifton GL, 2001, J NEUROSURG, V95, P733; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Howells T. P., 1995, Journal of Neurotrauma, V12, P471; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; MILLER JD, 1994, INTENS CARE MED, V20, P249, DOI 10.1007/BF01708957; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Neal R., 1996, BAYESIAN LEARNING NE; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; UNTERBERG AW, 1997, J TRAUMA S, V42, P32	21	140	144	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2005	102	2					311	317		10.3171/jns.2005.102.2.0311			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	897YQ	WOS:000227043200018	15739560				2022-02-06	
J	Wong, G; Goldshmit, Y; Turnley, AM				Wong, G; Goldshmit, Y; Turnley, AM			Interferon-gamma but not TNF alpha promotes neuronal differentiation and neurite outgrowth of murine adult neural stem cells	EXPERIMENTAL NEUROLOGY			English	Article						stem cell; neuronal differentiation; inflammation; interferon; TNF; cytotoxicity; proliferation; neurosphere	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; HIPPOCAMPAL-NEURONS; SUBVENTRICULAR ZONE; PROGENITOR CELLS; DENTATE GYRUS; GROWTH-FACTOR; IFN-GAMMA; BRAIN; NEUROGENESIS	Neural trauma, such as traumatic brain injury or stroke, results in a vigorous inflammatory response at and near the site of injury, with cytokine production by endogenous glial cells and invading immune cells. Little is known of the effect that these cytokines have on neural stem cell function. Here we examine the effects of two inflammatory cytokines, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNFalpha), on adult neural stein cells. Neural stem cells grown in the presence of either cytokine failed to generate neurospheres. Cytotoxicity assays showed that TNFalpha but not IFNgamma was toxic to the neural stem cells under proliferative conditions. Under differentiating conditions, neither cytokine was toxic; however, IFNgamma enhanced neuronal differentiation, rapidly increasing betaIII-tubulin positive cell numbers 3-4 fold and inhibiting astrocyte generation. Furthermore, neurite outgrowth and the number of neurites per neuron was enhanced in cells differentiated in the presence of IFNgamma. Therefore, both inflammatory cytokines examined have substantial, but different effects on neural stem cell function and suggests that regulation of the inflammatory environment following brain injury may influence the ability of neural stem cells to repair the damage. (C) 2004 Elsevier Inc. All rights reserved.	Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia; Univ Melbourne, Sch Physiotherapy, Melbourne, Vic 3010, Australia		Turnley, AM (corresponding author), Univ Melbourne, Ctr Neurosci, Grattan St, Melbourne, Vic 3010, Australia.	turnley@unimelb.edu.au	Turnley, Ann/A-8125-2010	Turnley, Ann/0000-0002-8442-127X			Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; BARISH ME, 1991, DEV BIOL, V144, P412, DOI 10.1016/0012-1606(91)90433-4; Billiau A, 1998, ANN NY ACAD SCI, V856, P22, DOI 10.1111/j.1749-6632.1998.tb08309.x; CHANG JY, 1990, J NEUROCHEM, V55, P436, DOI 10.1111/j.1471-4159.1990.tb04155.x; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Clarke DJ, 2002, EXP NEUROL, V176, P154, DOI 10.1006/exnr.2002.7911; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; GOLDSHMIT Y, 2004, IN PRESS J BIOL CHEM; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; IMPROTA T, 1988, EXP CELL RES, V179, P1, DOI 10.1016/0014-4827(88)90342-4; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; JONAKAIT GM, 1994, NEURON, V12, P1149; Kim IJ, 2002, J NEUROSCI, V22, P4530, DOI 10.1523/JNEUROSCI.22-11-04530.2002; Liu JL, 1998, J NEUROSCI, V18, P7768; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MALE D, 1988, IMMUNOL LETT, V17, P267, DOI 10.1016/0165-2478(88)90040-5; MEINERS S, 1993, DEV BIOL, V160, P480, DOI 10.1006/dbio.1993.1322; Mousa A, 1999, CYTOKINE, V11, P55, DOI 10.1006/cyto.1998.0381; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Neumann H, 1997, J EXP MED, V186, P2023, DOI 10.1084/jem.186.12.2023; Parent JM, 1997, J NEUROSCI, V17, P3727; Parish CL, 2002, J NEUROSCI, V22, P8034; PETITO CK, 1993, INT J DEV NEUROSCI, V11, P239, DOI 10.1016/0736-5748(93)90082-O; PLIOPLYS AV, 1988, J NEUROL SCI, V85, P209, DOI 10.1016/0022-510X(88)90157-8; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Turnley AM, 2002, NAT NEUROSCI, V5, P1155, DOI 10.1038/nn954; Turnley AM, 2001, NEUROREPORT, V12, P3443, DOI 10.1097/00001756-200111160-00013; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Zhang L, 2000, NEUROREPORT, V11, P409, DOI 10.1097/00001756-200002070-00037; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	39	140	150	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2004	187	1					171	177		10.1016/j.expneurol.2004.01.009			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	813FE	WOS:000220892200017	15081598				2022-02-06	
J	Beni, SM; Kohen, R; Reiter, RJ; Tan, DX; Shohami, E				Beni, SM; Kohen, R; Reiter, RJ; Tan, DX; Shohami, E			Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-kappa B and AP-1	FASEB JOURNAL			English	Article						ascorbic acid; cyclic voltammetry; reactive oxygen species; traumatic brain injury	TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITIES; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTORS; OXIDATIVE STRESS; REDOX REGULATION; GENE-EXPRESSION; FACTOR-ALPHA; DAMAGE	Traumatic brain injury (TBI) is followed by massive production of reactive oxygen species (ROS), which mediate secondary cellular damage. Low molecular weight antioxidants (LMWA)constitute one of the defense mechanisms of the brain, and their levels correlate with post-TBI outcome. Melatonin, the main pineal hormone, possesses antioxidant properties. We investigated the effects of melatonin on neurobehavioral recovery, brain LMWA, and activation of the redoxsensitive transcription factors nuclear factor-kappaB (NF-kappa B) and AP-1 in mice subjected to closed head injury (CHI). Given 1 h after CHI, melatonin facilitated recovery during at least 1 wk (P<0.05) and decreased lesion size by similar to twofold (P<0.01). The dose response displayed a bell-shape, i.e., neuroprotection was achieved with 5 but not 1 or 10 mg/kg. At the neuroprotective dose, melatonin treatment was associated with sustained (4 days) elevation of brain LMWA, including ascorbic acid (P<0.05). In contrast, LMWA were unaffected by the administration of the neuroprotective endocannabinoid 2-arachidonoyl glycerol. Furthermore, melatonin did not alter early phase (24 h) CHI-induced activation of NF-kappa B and AP-1; however, it blocked the robust late-phase (8 days) activation of NF-kappa B and decreased that of AP-1 to below basal levels. Our results demonstrate that melatonin induces neuroprotection, presumably via potentiation of brain antioxidants and attenuation of NF-kappa B and AP-1 activation.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel; Univ Texas, Dept Cellular & Struct Biol, San Antonio, TX USA		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Kohen, Ron/ABC-2281-2021; tan, dun-xian/E-3610-2010	Kohen, Ron/0000-0001-7268-9845; 	US-Israeli Bi-National Science FoundationUS-Israel Binational Science Foundation [97-00259-2]; Israel Science FoundationIsrael Science Foundation [117/00]	This study was supported by the US-Israeli Bi-National Science Foundation (#97-00259-2) and the Israel Science Foundation (117/00). E. Shohami and R. Kohen are affiliated with the David R. Bloom Center for Pharmacy, The Hebrew University School of Pharmacy, Jerusalem.	ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Antunes F, 1999, FREE RADICAL BIO MED, V26, P117, DOI 10.1016/S0891-5849(98)00168-3; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chen ST, 1999, EXP BRAIN RES, V124, P241, DOI 10.1007/s002210050619; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Clapp-Lilly KL, 2001, NEUROREPORT, V12, P1277, DOI 10.1097/00001756-200105080-00044; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Dabbeni-Sala F, 2001, FASEB J, V15, P164, DOI 10.1096/fj.00-0129com; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fowler G, 2003, FREE RADICAL BIO MED, V34, P77, DOI 10.1016/S0891-5849(02)01186-3; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Ginis I, 2000, MOL MED, V6, P1028, DOI 10.1007/BF03402054; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Kamata H, 2002, ANN NY ACAD SCI, V973, P419, DOI 10.1111/j.1749-6632.2002.tb04675.x; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kohen R, 1999, METHOD ENZYMOL, V300, P428; Kotler M, 1998, J PINEAL RES, V24, P83, DOI 10.1111/j.1600-079X.1998.tb00371.x; Letechipia-Vallejo G, 2001, ARCH MED RES, V32, P186, DOI 10.1016/S0188-4409(01)00268-5; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Livrea MA, 1997, FREE RADICAL BIO MED, V23, P706, DOI 10.1016/S0891-5849(97)00018-X; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Martin M, 2000, FASEB J, V14, P1677; Martin V, 2002, J PINEAL RES, V33, P204, DOI 10.1034/j.1600-079X.2002.02113.x; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mathews KS, 2000, J NEUROSCI METH, V102, P43, DOI 10.1016/S0165-0270(00)00277-6; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; OGITA K, 1994, J NEUROCHEM, V63, P525; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Osseni RA, 2000, LIFE SCI, V68, P387, DOI 10.1016/S0024-3205(00)00955-3; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Polidori MC, 2001, STROKE, V32, P898, DOI 10.1161/01.STR.32.4.898; POVLISHOCK JT, 1992, HUM CELL, V4, P345; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Sasaki M, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-3; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Siushansian R, 1997, J NEUROCHEM, V68, P2378; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; YONEDA Y, 1994, BRAIN RES, V667, P54, DOI 10.1016/0006-8993(94)91713-2	73	140	147	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					149	151		10.1096/fj.03-0323fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	WOS:000188829300057	14597558				2022-02-06	
J	Geddes, DM; Cargill, RS; LaPlaca, MC				Geddes, DM; Cargill, RS; LaPlaca, MC			Mechanical stretch to neurons results in a strain rate and magnitude-dependent increase in plasma membrane permeability	JOURNAL OF NEUROTRAUMA			English	Article						cortical neurons; plasma membrane permeability; stretch; TBI	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; ULTRASOUND-MEDIATED DISRUPTION; SPINAL-CORD AXONS; SQUID GIANT-AXON; QUANTITATIVE-DETERMINATION; ELECTRON-MICROSCOPY; MOLECULAR UPTAKE; CELL-MEMBRANES; NEURAL TRAUMA	The mechanism by which mechanical impact to brain tissue is transduced to neuronal impairment remains poorly understood. Using an in vitro model of neuronal stretch, we found that mechanical stretch of neurons resulted in a transient plasma membrane permeability increase. Primary cortical neurons, seeded on silicone substrates, were subjected to a defined rate and magnitude strain pulse by stretching the substrates over a fixed cylindrical form. To identify plasma membrane defects, various sized fluorescent molecules were added to the bathing media either immediately before injury or 1, 2, 5, or 10 min after injury and removed one minute later. The percent of cells that took up dye depended on the applied strain rate, strain magnitude and molecular size. Severe stretch (10 sec(-1), 0.30) resulted in significant uptake of all tested molecules (ranging between 0.5 and 8.9 nm radii) with up to 60% of cells positively stained. Furthermore, the neurons remained permeable to the smallest molecule (carboxyfluorescein, 380 Da) up to 5 min after severe stretch but were only permeable to larger molecules (greater than or equal to10 kDa) immediately after stretch. These transiently formed membrane defects may be the initiating mechanism that translates mechanical stretch to cellular dysfunction.	Georgia Inst Technol, Sch Biomed Engn, Atlanta, GA 30332 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Exponent Failure Anal Associates Inc, Philadelphia, PA USA		LaPlaca, MC (corresponding author), Georgia Inst Technol, Sch Biomed Engn, 315 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu					BARTOLETTI DC, 1989, FEBS LETT, V256, P4, DOI 10.1016/0014-5793(89)81707-7; Bier M, 1999, BIOELECTROMAGNETICS, V20, P194, DOI 10.1002/(SICI)1521-186X(1999)20:3<194::AID-BEM6>3.0.CO;2-0; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHANG DC, 1990, BIOPHYS J, V58, P1, DOI 10.1016/S0006-3495(90)82348-1; Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989; Cheng DKL, 1999, AM J PHYSIOL-HEART C, V277, pH351, DOI 10.1152/ajpheart.1999.277.1.H351; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; Cochran SA, 2001, ULTRASOUND MED BIOL, V27, P841, DOI 10.1016/S0301-5629(01)00382-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDWARDS DA, 1995, J CONTROL RELEASE, V34, P211, DOI 10.1016/0168-3659(94)00132-E; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gallant PE, 1997, J NEUROTRAUM, V14, P811, DOI 10.1089/neu.1997.14.811; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Gift EA, 2000, CYTOMETRY, V39, P243; Guzman HR, 2001, J ACOUST SOC AM, V110, P588, DOI 10.1121/1.1376131; Guzman HR, 2001, J ACOUST SOC AM, V110, P597, DOI 10.1121/1.1376130; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HIBINO M, 1993, BIOPHYS J, V64, P1789, DOI 10.1016/S0006-3495(93)81550-9; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Hoyer J, 1997, HYPERTENSION, V30, P112, DOI 10.1161/01.HYP.30.1.112; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; McNeil PL, 2001, CELL TISSUE RES, V304, P141, DOI 10.1007/s004410000286; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; OLIVER JD, 1992, J AM SOC NEPHROL, V3, P214; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 1996, ACT NEUR S, V66, P81; PRAUSNITZ MR, 1993, BIOPHYS J, V65, P414, DOI 10.1016/S0006-3495(93)81081-6; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; Shimizu N, 1996, BIOL PHARM BULL, V19, P1023; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Teruel MN, 1997, BIOPHYS J, V73, P1785, DOI 10.1016/S0006-3495(97)78209-2; Togo T, 2000, MOL BIOL CELL, V11, P4339, DOI 10.1091/mbc.11.12.4339; Tymianski M, 1996, NEUROSURGERY, V38, P1176; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wright M, 1996, CLIN SCI, V90, P61, DOI 10.1042/cs0900061; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1985, J NEUROSCI, V5, P1626	45	140	142	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					1039	1049		10.1089/089771503770195885			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300012	14588120				2022-02-06	
J	O'Donnell, ML; Creamer, M; Bryant, RA; Schnyder, U; Shalev, A				O'Donnell, ML; Creamer, M; Bryant, RA; Schnyder, U; Shalev, A			Posttraumatic disorders following injury: an empirical and methodological review	CLINICAL PSYCHOLOGY REVIEW			English	Article						injury; methodology; assessment; posttraumatic stress disorder; depression	TRAUMATIC BRAIN INJURY; ACUTE STRESS DISORDER; MOTOR-VEHICLE ACCIDENTS; PSYCHIATRIC-DISORDERS; GENDER DIFFERENCES; GENERAL HEALTH; BURN PATIENTS; MAJOR TRAUMA; HEAD-INJURY; SURVIVORS	Although there has been a marked increase in research on psychological disorders following physical injury in recent years, there are many discrepancies between the reported findings. This paper reviews the prevalence outcomes of recent studies of the mental health sequelae of physical injury with a focus on posttraumatic stress disorder (PTSD), acute stress disorder (ASD), and depression. The review critically outlines some of the methodological factors that may have contributed to these discrepancies. The phenomenological overlap between organic and psychogenic symptoms, the use of narcotic analgesia, the role of brain injury, the timing and content of assessments, and litigation are discussed in terms of their potential to confound findings with this population. Recommendations are proposed to clarify methodological approaches in this area. It is suggested that a clearer understanding of the psychological effects of physical injury will require the widespread adoption of more rigorous, standardized and transparent methodological procedures. (C) 2003 Elsevier Science Ltd. All rights reserved.	Australian Ctr Posttraumat Ment Hlth, Heidelberg, Vic 3081, Australia; Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia; Univ New S Wales, Kensington, NSW 2033, Australia; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel		O'Donnell, ML (corresponding author), Australian Ctr Posttraumat Ment Hlth, ARMC Repat Campus,Waterdale Rd, Heidelberg, Vic 3081, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; Shalev, Arieh/0000-0001-9425-050X; O'Donnell, Meaghan/0000-0003-4349-0022; Schnyder, Ulrich/0000-0003-3556-7990			Aaron JN, 1996, SLEEP, V19, P707, DOI 10.1093/sleep/19.9.707; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM ASS AUT MED, 1980, ABBR INJ SCSAL REV; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1980, DIAGN STAT MAN MENT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blanchard EB, 1998, J TRAUMA STRESS, V11, P337, DOI 10.1023/A:1024407321677; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Blaszczynski A, 1998, COMPR PSYCHIAT, V39, P111, DOI 10.1016/S0010-440X(98)90069-4; Bohnen N., 1992, J NERV MENT DIS, V180, P183; Brady KT, 2000, J CLIN PSYCHIAT, V61, P22; Breslau N, 1999, PSYCHOL MED, V29, P813, DOI 10.1017/S0033291799008612; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brown ES, 2000, COMPR PSYCHIAT, V41, P19, DOI 10.1016/S0010-440X(00)90126-3; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; BRYANT RA, 1995, AUST J PUBLIC HEALTH, V19, P185; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2002, AUST NZ J PSYCHIAT, V36, P205, DOI 10.1046/j.1440-1614.2002.01009.x; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Foa E.B., 1993, AM PSYCHIAT PRESS RE, V12, P273; Freedman SA, 2002, J TRAUMA STRESS, V15, P407, DOI 10.1023/A:1020189425935; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; FRUEH BC, IN PRESS J TRAUMATIC; Fuglsang AK, 2002, PSYCHOTHER PSYCHOSOM, V71, P214; Fuglsang AK, 2000, NORD PSYKOL, V52, P95, DOI 10.1080/00291463.2000.11863966; Fukunishi I, 1999, PSYCHOTHER PSYCHOSOM, V68, P82, DOI 10.1159/000012317; Fullerton CS, 2001, AM J PSYCHIAT, V158, P1486, DOI 10.1176/appi.ajp.158.9.1486; GORONWALL D, 1980, J CLIN NEUROPSYCHOLO, V2, P51; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Harvey AG, 1999, J NERV MENT DIS, V187, P443, DOI 10.1097/00005053-199907000-00009; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; Harvey AG, 1999, J TRAUMA STRESS, V12, P519, DOI 10.1023/A:1024723205259; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; KELLY R, 1981, J ROY SOC MED, V74, P275, DOI 10.1177/014107688107400407; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; Koren D, 1999, AM J PSYCHIAT, V156, P367; Madianos MG, 2001, PSYCHOTHER PSYCHOSOM, V70, P30, DOI 10.1159/000056222; Marmar Charles R., 1997, P412; Marshall RD, 1999, AM J PSYCHIAT, V156, P1677; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; Mayou R, 2001, AM J PSYCHIAT, V158, P1231, DOI 10.1176/appi.ajp.158.8.1231; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050118030; Mellman TA, 2001, DEPRESS ANXIETY, V14, P226, DOI 10.1002/da.1071; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; Michaels AJ, 1999, J TRAUMA, V47, P867, DOI 10.1097/00005373-199911000-00009; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; *NAT CTR INJ PREV, 2000, NONF INJ REP; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Raymond I, 2001, PAIN, V92, P381, DOI 10.1016/S0304-3959(01)00282-2; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Schnyder U, 2001, AM J RESP CRIT CARE, V164, P653, DOI 10.1164/ajrccm.164.4.2008087; SCHREIBER S, 1993, PAIN, V54, P107, DOI 10.1016/0304-3959(93)90105-X; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; SIVEC HJ, 1995, CLIN PSYCHOL REV, V15, P297, DOI 10.1016/0272-7358(95)00012-E; Solomon Z., 1989, MIL PSYCHOL, V1, P35, DOI [10.1207/s15327876mp0101_3, DOI 10.1207/S15327876MP0101_3]; TEASDALE G, 1974, LANCET, V2, P81; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Yu BH, 1999, J BURN CARE REHABIL, V20, P426, DOI 10.1097/00004630-199909000-00017; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI 10.1001/archsurg.137.2.200; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941; Zatzick DF, 2001, GEN HOSP PSYCHIAT, V23, P114, DOI 10.1016/S0163-8343(01)00140-2	84	140	140	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358			CLIN PSYCHOL REV	Clin. Psychol. Rev.	JUL	2003	23	4					587	603		10.1016/S0272-7358(03)00036-9			17	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	691FM	WOS:000183595300004	12788111				2022-02-06	
J	Servadei, F; Murray, GD; Penny, K; Teasdale, GM; Dearden, M; Iannotti, F; Lapierre, F; Maas, AJR; Karimi, A; Ohman, J; Persson, L; Stocchetti, N; Trojanowski, T; Unterberg, A				Servadei, F; Murray, GD; Penny, K; Teasdale, GM; Dearden, M; Iannotti, F; Lapierre, F; Maas, AJR; Karimi, A; Ohman, J; Persson, L; Stocchetti, N; Trojanowski, T; Unterberg, A		European Brain Injury Consortium	The value of the "worst" computed tomographic scan in clinical studies of moderate and severe head injury	NEUROSURGERY			English	Article						computed tomographic changes; computed tomographic classification; diffuse brain injury; mass lesion; moderate and severe head injury	MANAGEMENT; HEMATOMA	OBJECTIVE: Computed tomographic (CT) scanning can reveal the pattern and severity of structural brain damage after head injury. With the proliferation of CT scanners in general hospitals, and with improvements in patient transport, the interval from injury to the first CT scan is decreasing. The potential result is an "admission" scan missing an evolving and potentially operable lesion. Furthermore, the literature is confusing regarding the timing and coding of CT findings. We sought to establish the frequency of deterioration in CT appearance from an admission scan to subsequent scans and the prognostic significance of such deterioration. METHODS: In a survey organized by the European Brain Injury Consortium, data on initial severity, management, and subsequent outcome were gathered prospectively for 1005 patients with moderate or severe head injury admitted to one of 67 European neurosurgical units during a 3-month period in 1995. The findings of the initial and the final ("worst") CT scan were classified according to the Traumatic Coma Data Bank system and were related to outcome as assessed using the Glasgow Outcome Scale 6 months after injury. RESULTS: Data on an initial and a final CT scan were available for 897 patients; of these, 724 patients were assessed using the Glasgow Outcome Scare at 6 months. The initial CT findings were classified as a diffuse injury for 53% of the cohort, with 16% of these diffuse injuries demonstrating deterioration on a subsequent scan. In 56 (74%) of 76 deteriorations, the change was from a diffuse injury to a mass lesion. When the initial CT scan demonstrated a diffuse injury without swelling or shift, evolution to a mass lesion was associated with a statistically significant increase in the risk of an unfavorable outcome (62% versus 38%). When the initial scan demonstrated evidence of swelling or shift, there was a nonsignificant trend in the opposite direction, although the numbers were limited. CONCLUSION: When an admission CT scan demonstrates evidence of a diffuse injury, follow-up scans should be performed, because approximately one in six such patients will demonstrate significant CT evolution. In studies comparing series of head-injured patients, correspondence of timing of CT scans is necessary for valid comparison.	Osped Gen Provinciale M Bufalini, Div Neurochirurg Traumatol, I-47023 Cesena, Italy; Univ Edinburgh, Sch Med, Med Stat Unit, Edinburgh, Midlothian, Scotland; So Gen Hosp, Univ Dept Neurosurg, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland; Leeds Gen Infirm, Dept Anaesthet, Leeds, W Yorkshire, England; Southampton Gen Hosp, Dept Clin Neurosci, Southampton SO9 4XY, Hants, England; Ctr Hosp Univ Poitiers, Poitiers, France; Serv Neurochirurg, Poitiers, France; Univ Rotterdam Hosp, Dept Neurosurg, Rotterdam, Netherlands; Univ Cologne, Neurochirurg Klin, Cologne, Germany; Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland; Akad Hosp, Dept Neurosurg, Uppsala, Sweden; Osped Maggiore Policlin, Ist Ricovero & Cura Carettere Sci Milano, Terapia Intens Neurochirurgia Serv Anestesia & Ri, Milan, Italy; Univ Med Sch Lublin, Dept Neurosurg, Lublin, Poland; Humboldt Univ, Fak Med, Virchow Klinikum, Dept Neurosurg, D-1040 Berlin, Germany		Servadei, F (corresponding author), Osped Gen Provinciale M Bufalini, Div Neurochirurg Traumatol, I-47023 Cesena, Italy.		Maas, Andrew IR/C-5584-2013; Stocchetti, Nino/O-7444-2017	Maas, Andrew IR/0000-0003-1612-1264; Stocchetti, Nino/0000-0003-3250-6834; Servadei, Franco/0000-0002-3595-3464; Trojanowski, Tomasz/0000-0002-4914-1838; Murray, Gordon/0000-0001-9866-4734; Ohman, Juha/0000-0002-6592-1367			Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; JENNETT B, 1975, LANCET, V1, P480; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; *SOC NEUR STUD GRO, 1996, J NEUROSURG SCI, V40, P11; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	22	140	148	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2000	46	1					70	75		10.1093/neurosurgery/46.1.70			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	270MT	WOS:000084540200033	10626937				2022-02-06	
J	Baguley, IJ; Nicholls, JL; Felmingham, KL; Crook, J; Gurka, JA; Wade, LD				Baguley, IJ; Nicholls, JL; Felmingham, KL; Crook, J; Gurka, JA; Wade, LD			Dysautonomia after traumatic brain injury: a forgotten syndrome?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; dysautonomia; autonomic dysfunction; dystonia	SEVERE HEAD-INJURY; DIENCEPHALIC SEIZURES; HYPERTENSION; PROPRANOLOL; SCALE; FEVER	Objectives-To better establish the clinical features, natural history, clinical management, and rehabilitation implications of dysautonomia after traumatic brain injury, and to highlight difficulties with previous nomenclature. Methods-Retrospective file review on 35 patients with dysautonomia and 35 sex and Glasgow coma scale score matched controls. Groups were compared on injury details, CT findings, physiological indices, and evidence of infections over the first 28 days after injury, clinical progress, and rehabilitation outcome. Results-the dysautonomia group were significantly worse than the control group on all variables studied except duration of stay in intensive care, the rate of clinically significant infections found, and changes in functional independence measure (FIM) scores. Conclusions-Dysautonomia is a distinct clinical syndrome, associated with severe diffuse axonal injury and preadmission hypoxia. It is associated with a poorer functional outcome; however, both the controls and patients with dysautonomia show a similar magnitude of improvement as measured by changes in FIM scores. It is argued that delayed recognition and treatment of dysautonomia results in a preventable increase in morbidity.	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ Sydney, Dept Rehabil Med, Sydney, NSW 2006, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.		Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; HAMILL RW, 1987, ANN NEUROL, V21, P483; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Keith R., 1987, ADV CLIN REHABILITAT, V1, P10; KLUG N, 1984, ACTA NEUROCHIR, V72, P219, DOI 10.1007/BF01406872; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; PLUM F, 1996, DIAGNOSIS STUPOR COM; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; ROPPER AH, 1993, CLIN AUTONOMIC DISOR, P747; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; SCOTT JS, 1997, ARCH PHYS MED REHAB, V78, P200; SHIOZAKI T, 1993, J NEUROSURG, V78, P501, DOI 10.3171/jns.1993.78.3.0501; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; SNEED RC, 1995, ARCH PHYS MED REHAB, V76, P101, DOI 10.1016/S0003-9993(95)80051-4; SOLOMON GE, 1973, J PEDIATR-US, V83, P277, DOI 10.1016/S0022-3476(73)80492-5; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013	26	140	146	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	1999	67	1					39	43		10.1136/jnnp.67.1.39			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	207FL	WOS:000080925400010	10369820	Bronze, Green Published			2022-02-06	
J	Sherer, M; Bergloff, P; Boake, C; High, W; Levin, E				Sherer, M; Bergloff, P; Boake, C; High, W; Levin, E			The Awareness Questionnaire: factor structure and internal consistency	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; HEAD-INJURY; BEHAVIORAL LIMITATIONS; REHABILITATION; DEFICITS; ADULTS	Patients with traumatic brain injuries often show impaired awareness of their impairments. This impaired awareness can decrease motivation for treatment and limit eventual functional outcome. The importance of this phenomenon has led to the development of multiple techniques and scales for measuring impaired awareness. The present paper briefly reviews the various methods of operationalizing impaired awareness and describes a new scale (the Awareness Questionnaire) designed to incorporate all these methods. Findings of previous studies supporting the validity of the Awareness Questionnaire are presented. The present investigation examined the factor structure and internal consistency of the Awareness Questionnaire with samples of 126 traumatic brain injury survivors and 75 family members/significant others. Principal components factor analysis with varimax rotation indicated three factors: cognitive, behavioural/affective, and motor/sensory. Investigation of internal consistency (Cronbach Coefficient Alpha) in both the patient and family sample yielded satisfactory results. These findings are supportive of continued use and investigation of the Awareness Questionnaire.	Inst Rehabil & Res, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, Ctr Hlth, Houston, TX USA		Sherer, M (corresponding author), Mississippi Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.						ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; SHERER M, UNPUB IMPAIRED SELF; SHERER M, 1997, J INT NEUROPSYCH SOC, V3, P75; SHERER M, 1996, J INT NEUROPSYCH SOC, V2, P17; [No title captured], DOI DOI 10.1097/00001199-199412000-00004	21	140	142	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1998	12	1					63	68		10.1080/026990598122863			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	YT347	WOS:000071592500006	9483338				2022-02-06	
J	Clark, RSB; Kochanek, PM; Schwarz, MA; Schiding, JK; Turner, DS; Chen, MZ; Carlos, TM; Watkins, SC				Clark, RSB; Kochanek, PM; Schwarz, MA; Schiding, JK; Turner, DS; Chen, MZ; Carlos, TM; Watkins, SC			Inducible nitric oxide synthase expression in cerebrovascular smooth muscle and neutrophils after traumatic brain injury in immature rats	PEDIATRIC RESEARCH			English	Article							CEREBRAL BLOOD-FLOW; HEAD-INJURY; L-ARGININE; METABOLISM; CYTOKINES; INDUCTION; CELLS; ICP	The inflammatory response after traumatic brain injury (TBI) includes cytokine production, leukocyte infiltration, and microglial activation. Production of nitric oxide by inducible nitric oxide synthase (iNOS) occurs during acute inflammation outside of the CNS and in models of cerebral ischemia, and therefore may contribute to the inflammatory response after TBI. The purpose of this study was to localize and define the time course of iNOS expression after TBI in the immature rat. Immature Wistar rats (age 3.5-4.5 wk) were anesthetized and subjected to percussive trauma to the right parietal cortex. Nontraumatized rats were used as controls (n = 7). At 2, 24, 48, or 168 h (n = 3/group) posttrauma rats were killed by perfusion fixation. Brains were removed, frozen, sectioned, immunostained with antibodies against iNOS and glial fibrillary acidic protein (GFAP, a marker specific for astrocytes), and imaged using fluorescent detection systems. There was no detectable expression of iNOS in control brains. At 2 h, minimal cerebrovascular iNOS expression was seen in the peritrauma area. At 24 and 48 h, there was marked peritrauma cerebrovascular INOS expression that appeared to be restricted to vascular smooth muscle cells and infiltrated leukocytes. Further dual-immunolabeling showed that the leukocytes expressing iNOS were predominantly neutrophils. At 168 h, iNOS expression was no longer detectable. iNOS was not detectable in GFAP-positive cells. The prominent expression of iNOS protein after TBI in cerebrovascular smooth muscle cells and infiltrated neutrophils suggests that iNOS may play a role in cerebrovascular disturbances and secondary brain injury after trauma.	SAFAR CTR RESUSCITAT RES, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA; SAFAR CTR RESUSCITAT RES, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; CHILDRENS HOSP PITTSBURGH, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PHYSIOL & CELL BIOL, PITTSBURGH, PA 15260 USA; COLUMBIA UNIV, DEPT PEDIAT, NEW YORK, NY 10032 USA				Kochanek, Patrick M/D-2371-2015; Watkins, Simon/ABG-2590-2021	Kochanek, Patrick M/0000-0002-2627-913X; Watkins, Simon/0000-0003-4092-1552	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2 P50 NS 30318-04A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BIAGAS KV, 1992, IN PRESS J NEUROTRAU; CHAO CC, 1992, J IMMUNOL, V149, P2736; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; DING AH, 1988, J IMMUNOL, V141, P2407; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Horner H. C., 1992, Society for Neuroscience Abstracts, V18, P173; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; KANNO K, 1993, HYPERTENSION, V22, P34, DOI 10.1161/01.HYP.22.1.34; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; MCCALL TB, 1991, EUR J IMMUNOL, V21, P2523, DOI 10.1002/eji.1830211032; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NAKAYAMA DK, 1992, AM J RESP CELL MOL, V7, P471, DOI 10.1165/ajrcmb/7.5.471; NUSSLER AK, 1994, AM J PHYSIOL, V267, pC394, DOI 10.1152/ajpcell.1994.267.2.C394; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHRODER ML, 1992, J NEUROTRAUM, V9, P400; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96, DOI 10.1002/jlb.46.2.96; STOCLET JC, 1993, CIRCULATION, V87, P77; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; WONG HR, 1995, CRIT CARE MED S, V23, pA229; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576; Yakovlev A., 1994, Society for Neuroscience Abstracts, V20, P423; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAN L, 1994, J IMMUNOL, V153, P1825	39	140	142	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	MAY	1996	39	5					784	790		10.1203/00006450-199605000-00007			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	UG001	WOS:A1996UG00100007	8726229	Bronze			2022-02-06	
J	SIESJO, BK				SIESJO, BK			BASIC MECHANISMS OF TRAUMATIC BRAIN-DAMAGE	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	SYMP ON NEUROTRAUMA : CONCEPTS, CURRENT PRACTICE AND EMERGING THERAPIES	JUN 11-12, 1992	DEARBORN, MI	WAYNE STATE UNIV SCH MED, DEPT EMERGENCY MED		NEUROTRAUMA; BRAIN INJURY		Brain damage induced by blunt head trauma is multifactorial in that the initial injury both induces extensive depolarization and damages tissue through transient sheer forces that mechanically deform tissue components, especially axons and microvessels. Furthermore, although there is little evidence for initial energy depletion, subsequent tissue edema and microvascular perfusion shunting may result in areas of focal ischemia. This review suggests that these events lead to a final common pathway of neuronal death that involves loss of cellular calcium homeostasis, production of injurious free radicals, and tissue acidosis.			SIESJO, BK (corresponding author), UNIV LUND HOSP,EXPTL RES CTR,EXPTL BRAIN RES LAB,S-22185 LUND,SWEDEN.							0	140	141	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	1993	22	6					959	969		10.1016/S0196-0644(05)82736-2			11	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	LE338	WOS:A1993LE33800002	8503534				2022-02-06	
J	Echemendia, RJ; Meeuwisse, W; McCrory, P; Davis, GA; Putukian, M; Leddy, J; Makdissi, M; Sullivan, SJ; Broglio, SP; Raftery, M; Schneider, K; Kissick, J; McCrea, M; Dvorak, J; Sills, AK; Aubry, M; Engebretsen, L; Loosemore, M; Fuller, G; Kutcher, J; Ellenbogen, R; Guskiewicz, K; Patricios, J; Herring, S				Echemendia, Ruben J.; Meeuwisse, Willem; McCrory, Paul; Davis, Gavin A.; Putukian, Margot; Leddy, John; Makdissi, Michael; Sullivan, S. John; Broglio, Steven P.; Raftery, Martin; Schneider, Kathryn; Kissick, James; McCrea, Michael; Dvorak, Jiri; Sills, Allen K.; Aubry, Mark; Engebretsen, Lars; Loosemore, Mike; Fuller, Gordon; Kutcher, Jeffrey; Ellenbogen, Richard; Guskiewicz, Kevin; Patricios, Jon; Herring, Stanley			The Sport Concussion Assessment Tool 5th Edition (SCAT5): Background and rationale	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INTERNATIONAL-CONFERENCE; STATEMENT; SCALE	This paper presents the Sport Concussion Assessment Tool 5th Edition (SCAT5), which is the most recent revision of a sport concussion evaluation tool for use by healthcare professionals in the acute evaluation of suspected concussion. The revision of the SCAT3 (first published in 2013) culminated in the SCAT5. The revision was based on a systematic review and synthesis of current research, public input and expert panel review as part of the 5th International Consensus Conference on Concussion in Sport held in Berlin in 2016. The SCAT5 is intended for use in those who are 13 years of age or older. The Child SCAT5 is a tool for those aged 5-12 years, which is discussed elsewhere.	[Echemendia, Ruben J.] Univ Orthoped Ctr, Concuss Care Clin, 101 Regent Ct, State Coll, PA 16801 USA; [Echemendia, Ruben J.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Meeuwisse, Willem] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB, Canada; [McCrory, Paul] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Davis, Gavin A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Davis, Gavin A.; Makdissi, Michael] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Putukian, Margot] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA; [Leddy, John] Univ Buffalo, UBMD Orthopaed & Sports Med, Concuss Management Clin, Buffalo, NY USA; [Leddy, John] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA; [Makdissi, Michael] La Trobe Univ, La Trobe Sport & Exercise Med Res Ctr, Bundoora, Vic, Australia; [Sullivan, S. John] Univ Otago, Sch Physiotherapy, Ctr Hlth & Rehabil Res Act, Dunedin, New Zealand; [Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [Raftery, Martin] World Rugby, Dublin, Ireland; [Schneider, Kathryn] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Schneider, Kathryn] Alberta Childrens Prov Gen Hosp, Res Inst Child & Maternal Hlth, Cumming Sch Med, Calgary, AB, Canada; [Schneider, Kathryn] Univ Calgary, Cuming Sch Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Kissick, James] Univ Ottawa, Dept Family Med, Carleton Univ, Sport Med Clin,Int Paralymp Comm Med Comm, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Dvorak, Jiri] Schulthess Clin, Dept Neurol, Zurich, Switzerland; [Sills, Allen K.] Vanderbilt Univ, Dept Neurosurg, 221 Kirkland Hall, Nashville, TN 37235 USA; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Engebretsen, Lars] Int Olymp Comm, Dept Med Sci, Lausanne, Switzerland; [Engebretsen, Lars] Oslo Univ Hosp, Dept Orthopaed Surg, Oslo, Norway; [Loosemore, Mike] Univ Coll Hosp, Inst Sport Exercise & Hlth, London, England; [Fuller, Gordon] Univ Sheffield, Ctr Urgent & Emergency Care Res, Sheffield, S Yorkshire, England; [Kutcher, Jeffrey] Sports Neurol Clin, Brighton, MI USA; [Ellenbogen, Richard; Herring, Stanley] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Guskiewicz, Kevin] Univ N Carolina, Matthew Gfeller Sport Related TBI Res Ctr, Chapel Hill, NC USA; [Patricios, Jon] Univ Pretoria, Fac Hlth Sci, Sect Sports Med, Pretoria, South Africa; [Patricios, Jon] Univ Witwatersrand, Fac Hlth Sci, Dept Emergency Med, Johannesburg, South Africa; [Herring, Stanley] Univ Washington, Orthopaed & Sports Med, Dept Rehabil Med, Seattle, WA 98195 USA		Echemendia, RJ (corresponding author), Univ Orthoped Ctr, Concuss Care Clin, 101 Regent Ct, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019; McCrory, Paul/Q-8688-2019	Davis, Gavin/0000-0001-8293-4496; Patricios, Jon/0000-0002-6829-4098; Fuller, Gordon Ward/0000-0001-8532-3500; McCrory, Paul/0000-0003-4850-0568; Schneider, Kathryn/0000-0002-5951-5899; makdissi, michael/0000-0003-0334-7133	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish		Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Davis GA, 2017, BJ SPORTS MED; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Echemendia RJ, 2017, BJ SPORTS MED; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meeuwisse W, 2017, BR J SPORTS MED; Schneiders AG, 2010, J SCI MED SPORT, V13, P382, DOI 10.1016/j.jsams.2010.01.003; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004	15	139	141	1	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2017	51	11					848	850		10.1136/bjsports-2017-097506			3	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EW3QP	WOS:000402416500004	28446453	Bronze			2022-02-06	
J	Ryan, NS; Keihaninejad, S; Shakespeare, TJ; Lehmann, M; Crutch, SJ; Malone, IB; Thornton, JS; Mancini, L; Hyare, H; Yousry, T; Ridgway, GR; Zhang, H; Modat, M; Alexander, DC; Rossor, MN; Ourselin, S; Fox, NC				Ryan, Natalie S.; Keihaninejad, Shiva; Shakespeare, Timothy J.; Lehmann, Manja; Crutch, Sebastian J.; Malone, Ian B.; Thornton, John S.; Mancini, Laura; Hyare, Harpreet; Yousry, Tarek; Ridgway, Gerard R.; Zhang, Hui; Modat, Marc; Alexander, Daniel C.; Rossor, Martin N.; Ourselin, Sebastien; Fox, Nick C.			Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease	BRAIN			English	Article						familial Alzheimer's disease; presenilin 1 (PSEN1, PS1); presymptomatic; diffusion tensor imaging; subcortical atrophy	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; PRESENILIN-1 MUTATION CARRIERS; WHITE-MATTER; MICROGLIAL ACTIVATION; AMYLOID DEPOSITION; ISCHEMIC-STROKE; TEMPORAL-LOBE; COMPOUND-B; IN-VIVO	Amyloid imaging studies of presymptomatic familial Alzheimer's disease have revealed the striatum and thalamus to be the earliest sites of amyloid deposition. This study aimed to investigate whether there are associated volume and diffusivity changes in these subcortical structures during the presymptomatic and symptomatic stages of familial Alzheimer's disease. As the thalamus and striatum are involved in neural networks subserving complex cognitive and behavioural functions, we also examined the diffusion characteristics in connecting white matter tracts. A cohort of 20 presenilin 1 mutation carriers underwent volumetric and diffusion tensor magnetic resonance imaging, neuropsychological and clinical assessments; 10 were symptomatic, 10 were presymptomatic and on average 5.6 years younger than their expected age at onset; 20 healthy control subjects were also studied. We conducted region of interest analyses of volume and diffusivity changes in the thalamus, caudate, putamen and hippocampus and examined diffusion behaviour in the white matter tracts of interest (fornix, cingulum and corpus callosum). Voxel-based morphometry and tract-based spatial statistics were also used to provide unbiased whole-brain analyses of group differences in volume and diffusion indices, respectively. We found that reduced volumes of the left thalamus and bilateral caudate were evident at a presymptomatic stage, together with increased fractional anisotropy of bilateral thalamus and left caudate. Although no significant hippocampal volume loss was evident presymptomatically, reduced mean diffusivity was observed in the right hippocampus and reduced mean and axial diffusivity in the right cingulum. In contrast, symptomatic mutation carriers showed increased mean, axial and in particular radial diffusivity, with reduced fractional anisotropy, in all of the white matter tracts of interest. The symptomatic group also showed atrophy and increased mean diffusivity in all of the subcortical grey matter regions of interest, with increased fractional anisotropy in bilateral putamen. We propose that axonal injury may be an early event in presymptomatic Alzheimer's disease, causing an initial fall in axial and mean diffusivity, which then increases with loss of axonal density. The selective degeneration of long-coursing white matter tracts, with relative preservation of short interneurons, may account for the increase in fractional anisotropy that is seen in the thalamus and caudate presymptomatically. It may be owing to their dense connectivity that imaging changes are seen first in the thalamus and striatum, which then progress to involve other regions in a vulnerable neuronal network.	[Ryan, Natalie S.; Keihaninejad, Shiva; Shakespeare, Timothy J.; Lehmann, Manja; Crutch, Sebastian J.; Malone, Ian B.; Ridgway, Gerard R.; Modat, Marc; Rossor, Martin N.; Ourselin, Sebastien; Fox, Nick C.] UCL, Inst Neurol, Dept Neurodegenerat Dis, Dementia Res Ctr, London WC1N 3BG, England; [Keihaninejad, Shiva; Zhang, Hui; Modat, Marc; Alexander, Daniel C.; Ourselin, Sebastien] UCL, Ctr Med Image Comp, London WC1E 6BT, England; [Thornton, John S.; Mancini, Laura; Yousry, Tarek] UCLH NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, Lysholm Dept Neuroradiol, London WC1N 3BG, England; [Thornton, John S.; Mancini, Laura; Yousry, Tarek] UCL Inst Neurol, Neuroradiol Acad Unit, London WC1N 3BG, England; [Hyare, Harpreet] UCL Inst Neurol, Dept Neurodegenerat Dis, MRC Prion Unit, London WC1N 3BG, England; [Ridgway, Gerard R.] UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London WC1N 3BG, England		Ryan, NS (corresponding author), Natl Hosp Neurol & Neurosurg, Dementia Res Ctr, Box 16,Queen Sq, London WC1N 3BG, England.	natalie.ryan@ucl.ac.uk	Rossor, Martin/C-1598-2008; Lehmann, Manja/B-9717-2014; Fox, Nick C/AAE-1849-2021; Ridgway, Gerard/F-5145-2010; Fox, Nick C/B-1319-2009	Fox, Nick C/0000-0002-6660-657X; Ridgway, Gerard/0000-0002-7676-7860; Fox, Nick C/0000-0002-6660-657X; Malone, Ian/0000-0001-7512-7856; Thornton, John/0000-0003-3248-8437; Zhang, Hui/0000-0002-5426-2140; Shakespeare, Timothy/0000-0002-2155-4948; Alexander, Daniel/0000-0003-2439-350X; Crutch, Sebastian/0000-0002-4160-0139; Rossor, Martin/0000-0001-8215-3120	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0900421, MR/J014267/1, G116/143]; Alzheimer's Research UKAlzheimer's Research UK (ARUK); Department of Health's National Institute for Health Research (NIHR) Biomedical Research Centres funding schemeNational Institute for Health Research (NIHR); NIHR Queen Square Dementia Biomedical Research Unit; Brain Research Trust; Wellcome TrustWellcome TrustEuropean Commission [091593/Z/10/Z]; Comprehensive Biomedical Research Centre Strategic Investment Award [168]; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/E007748]; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/J020990/1, EP/G007748/1] Funding Source: UKRI; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/J014257/1, MR/K000608/1, G0900421, G116/143, G0601846] Funding Source: UKRI; Alzheimers Research UKAlzheimer&apos;s Research UK (ARUK) [ARUK-RF2013-5, ARUK-Network2011-6-ICE, ART-EG2010B-1] Funding Source: researchfish; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/J020990/1, EP/G007748/1] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K000608/1, MR/J014257/1, G0601846] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10123, NF-SI-0512-10033] Funding Source: researchfish	This work was supported by the Medical Research Council (Clinical Research Training Fellowship G0900421 to N.S.R., Special Training Fellowship in Biomedical Informatics MR/J014267/1 to G. R. R., Senior Clinical Fellowship G116/143 to NCF) and Alzheimer's Research UK (Senior Research Fellowship to SJC, Travelling Research Fellowship to M. L.). The study was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's National Institute for Health Research (NIHR) Biomedical Research Centres funding scheme and was supported by the NIHR Queen Square Dementia Biomedical Research Unit. N.C.F. and M.N.R. are NIHR senior investigators. The Dementia Research Centre is an Alzheimer's Research UK Co-ordinating Centre and has also received equipment funded by Alzheimer's Research UK and Brain Research Trust. The Wellcome Trust Centre for Neuroimaging is supported by core funding from the Wellcome Trust, 091593/Z/10/Z. M. M. is supported by a Comprehensive Biomedical Research Centre Strategic Investment Award (Ref. 168). The Engineering and Physical Sciences Research Council support D. C. A. with grant EP/E007748.	Acosta-Cabronero J, 2010, BRAIN, V133, P529, DOI 10.1093/brain/awp257; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Ashburner J, 2009, NEUROIMAGE, V45, P333, DOI 10.1016/j.neuroimage.2008.12.008; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Batchelor PG, 2005, MAGN RESON MED, V53, P221, DOI 10.1002/mrm.20334; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; Benedetti B, 2006, NEUROLOGY, V66, P535, DOI 10.1212/01.wnl.0000198510.73363.c6; Bohanna I, 2011, NEUROBIOL DIS, V42, P475, DOI 10.1016/j.nbd.2011.02.010; Bozzali M, 2002, AM J NEURORADIOL, V23, P985; BRAAK H, 1991, ACTA NEUROPATHOL, V81, P261, DOI 10.1007/BF00305867; BRAAK H, 1990, J NEUROPATH EXP NEUR, V49, P215, DOI 10.1097/00005072-199005000-00003; Budde MD, 2010, P NATL ACAD SCI USA, V107, P14472, DOI 10.1073/pnas.1004841107; Chua TC, 2008, CURR OPIN NEUROL, V21, P83, DOI 10.1097/WCO.0b013e3282f4594b; Ciccarelli O, 2001, NEUROLOGY, V56, P926, DOI 10.1212/WNL.56.7.926; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Cook PA, 2006, P INT SOC MAG RESON, V14; de Jong LW, 2008, BRAIN, V131, P3277, DOI 10.1093/brain/awn278; Douaud G, 2011, NEUROIMAGE, V55, P880, DOI 10.1016/j.neuroimage.2010.12.008; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Fortea J, 2010, J ALZHEIMERS DIS, V22, P909, DOI 10.3233/JAD-2010-100678; Gerschlager W, 2009, CURR OPIN NEUROL, V22, P414, DOI 10.1097/WCO.0b013e32832d9d4f; Gholipour A, 2011, IEEE ENG MED BIO, P6997, DOI 10.1109/IEMBS.2011.6091769; Godbolt AK, 2004, ARCH NEUROL-CHICAGO, V61, P1743, DOI 10.1001/archneur.61.11.1743; Grahn JA, 2008, PROG NEUROBIOL, V86, P141, DOI 10.1016/j.pneurobio.2008.09.004; Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123; Hampel F.R., 1986, ROBUST STAT APPROACH; Haroon HA, 2011, P INT SOC MAG RESON, V682; Herve D, 2005, J NEUROL NEUROSUR PS, V76, P200, DOI 10.1136/jnnp.2004.041012; Huang J, 2007, AM J NEURORADIOL, V28, P1943, DOI 10.3174/ajnr.A0700; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Kanaan NM, 2012, EXP NEUROL; Keihaninejad S, 2012, ALZHEIMERS DEMENT, V8, P4; Keihaninejad S, 2011, ALZHEIMERS DEMEN, V7, P4; Keihaninejad S, 2011, ALZHEIMERS DEMEN, V7, pS50; Keihaninejad S, 2012, ALZHEIMERS DEMENT, V8, pP31; Keihaninejad S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045996; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klunk WE, 2007, J NEUROSCI, V27, P6174, DOI 10.1523/JNEUROSCI.0730-07.2007; Knight WD, 2011, NEUROBIOL AGING, V32, P1765, DOI 10.1016/j.neurobiolaging.2009.11.013; Knight WD, 2011, BRAIN, V134, P293, DOI 10.1093/brain/awq310; Lee GJ, 2013, J NEUROL NEUROSUR PS, V84, P154, DOI 10.1136/jnnp-2011-302087; Leung KK, 2011, NEUROIMAGE, V55, P1091, DOI 10.1016/j.neuroimage.2010.12.067; Leung KK, 2010, NEUROIMAGE, V51, P1345, DOI 10.1016/j.neuroimage.2010.03.018; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; McKinstry RC, 2002, CEREB CORTEX, V12, P1237, DOI 10.1093/cercor/12.12.1237; Middleton FA, 2000, BRAIN COGNITION, V42, P183, DOI 10.1006/brcg.1999.1099; Modat M, 2010, COMPUT METH PROG BIO, V98, P278, DOI 10.1016/j.cmpb.2009.09.002; Mori S, 2005, MRI ATLAS HUMAN WHIT; Neave N, 1997, EUR J NEUROSCI, V9, P941, DOI 10.1111/j.1460-9568.1997.tb01445.x; Nelson O, 2010, J ALZHEIMERS DIS, V21, P781, DOI 10.3233/JAD-2010-100159; Nestor PJ, 2003, ANN NEUROL, V54, P343, DOI 10.1002/ana.10669; O'Dwyer L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048895; O'Riordan S, 2002, NEUROLOGY, V59, P1108, DOI 10.1212/WNL.59.7.1108; Olabarria M, 2010, GLIA, V58, P831, DOI 10.1002/glia.20967; Ourselin S, 2001, IMAGE VISION COMPUT, V19, P25, DOI 10.1016/S0262-8856(00)00052-4; OYANAGI K, 1987, BRAIN RES, V411, P205, DOI 10.1016/0006-8993(87)91071-7; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; Pedro T, 2012, DEMENT GERIATR COGN, V34, P149, DOI 10.1159/000342118; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reiman EM, 2012, LANCET NEUROL, V11, P1048, DOI 10.1016/S1474-4422(12)70228-4; Reiman EM, 2010, BIOMARK MED, V4, P3, DOI [10.2217/bmm.09.91, 10.2217/BMM.09.91]; Ridgway G., 2011, ALZHEIMERS DEMENT, V7, pS62, DOI [10.1016/j.jalz.2011.05.099, DOI 10.1016/J.JALZ.2011.05.099]; Ridha BH, 2006, LANCET NEUROL, V5, P828, DOI 10.1016/S1474-4422(06)70550-6; Ringman JM, 2007, BRAIN, V130, P1767, DOI 10.1093/brain/awm102; Rodriguez JJ, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.2; Ryan NS, 2010, BIOMARK MED, V4, P99, DOI 10.2217/BMM.09.92; Schmahmann JD, 2003, STROKE, V34, P2264, DOI 10.1161/01.STR.0000087786.38997.9E; Smith CD, 2010, NEUROBIOL AGING, V31, P1122, DOI 10.1016/j.neurobiolaging.2008.08.006; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stebbins GT, 2009, BEHAV NEUROL, V21, P39, DOI [10.3233/BEN-2009-0234, 10.1155/2009/915041]; Sun SW, 2005, EXP NEUROL, V191, P77, DOI 10.1016/j.expneurol.2004.09.006; Tovar-Moll F, 2009, AM J NEURORADIOL, V30, P1380, DOI 10.3174/ajnr.A1564; Van Der Werf YD, 2003, CORTEX, V39, P1047, DOI 10.1016/S0010-9452(08)70877-3; Wang Y, 2011, NEUROIMAGE, V55, P1577, DOI 10.1016/j.neuroimage.2011.01.038; Warfield SK, 2004, IEEE T MED IMAGING, V23, P903, DOI 10.1109/TMI.2004.828354; Warren JD, 2012, NEURON, V73, P1060, DOI 10.1016/j.neuron.2012.03.006; Warrington EK, 2001, J NEUROL, V248, P45, DOI 10.1007/s004150170268; Weiskopf N, 2011, NEUROIMAGE, V54, P2116, DOI 10.1016/j.neuroimage.2010.10.023; Wiegell MR, 2000, P INT SOC MAGN RES I, V8, P481; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; XUEREB JH, 1991, BRAIN, V114, P1363; Zhang H, 2006, MED IMAGE ANAL, V10, P764, DOI 10.1016/j.media.2006.06.004; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072	89	139	140	0	24	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	MAY	2013	136		5				1399	1414		10.1093/brain/awt065			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	140DN	WOS:000318634600007	23539189	Green Published, Green Submitted, hybrid			2022-02-06	
J	Small, GW; Kepe, V; Siddarth, P; Ercoli, LM; Merrill, DA; Donoghue, N; Bookheimer, SY; Martinez, J; Omalu, B; Bailes, J; Barrio, JR				Small, Gary W.; Kepe, Vladimir; Siddarth, Prabha; Ercoli, Linda M.; Merrill, David A.; Donoghue, Natacha; Bookheimer, Susan Y.; Martinez, Jacqueline; Omalu, Bennet; Bailes, Julian; Barrio, Jorge R.			PET Scanning of Brain Tau in Retired National Football League Players: Preliminary Findings	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article						Positron emission tomography; FDDNP; tau; amyloid; mood disorder; depression; mild cognitive impairment; dementia	CHRONIC TRAUMATIC ENCEPHALOPATHY; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; DEPRESSION; DISEASE; BINDING	Objective: Mild traumatic brain injury due to contact sports may cause chronic behavioral, mood, and cognitive disturbances associated with pathological deposition of tau protein found at brain autopsy. To explore whether brain tau deposits can be detected in living retired players, we used positron emission tomography (PET) scans after intravenous injections of 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP). Methods: Five retired National Football League players (age range: 45 to 73 years) with histories of mood and cognitive symptoms received neuropsychiatric evaluations and FDDNP-PET PET signals in subcortical (caudate, putamen, thalamus, subthalamus, midbrain, cerebellar white matter) and cortical (amygdala, frontal, parietal, posterior cingulate, medial and lateral temporal) regions were compared with those of five male controls of comparable age, education, and body mass index. Results: FDDNP signals were higher in players compared with controls in all subcortical regions and the amygdala, areas that produce tau deposits following trauma. Conclusions: The small sample size and lack of autopsy confirmation warrant larger, more definitive studies, but if future research confirms these initial findings, FDDNP-PET may offer a means for premorbid identification of neurodegeneration in contact-sports athletes. (Am J Geriatr Psychiatry 2013; 21:138-144)	[Small, Gary W.; Siddarth, Prabha; Ercoli, Linda M.; Merrill, David A.; Donoghue, Natacha; Bookheimer, Susan Y.; Martinez, Jacqueline] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA; [Small, Gary W.; Siddarth, Prabha; Ercoli, Linda M.; Merrill, David A.; Donoghue, Natacha; Bookheimer, Susan Y.; Martinez, Jacqueline] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, David Geffen Sch Med, Los Angeles, CA USA; [Kepe, Vladimir; Barrio, Jorge R.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA USA; [Bookheimer, Susan Y.] Univ Calif Los Angeles, Ctr Cognit Neurosci, David Geffen Sch Med, Los Angeles, CA USA; [Small, Gary W.; Siddarth, Prabha; Ercoli, Linda M.; Merrill, David A.] Univ Calif Los Angeles, UCLA Longev Ctr, David Geffen Sch Med, Los Angeles, CA USA; [Bookheimer, Susan Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychol, Los Angeles, CA 90095 USA; [Omalu, Bennet] Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA; [Bailes, Julian] NorthShore Univ Hlth Syst, Dept Neurosurg, Chicago, IL USA		Small, GW (corresponding author), Semel Inst, 760 Westwood Plaza, Los Angeles, CA 90024 USA.	gsmall@ucla.edu		Merrill, David/0000-0003-2181-3839; Bookheimer, Susan/0000-0002-3417-5891	Brain Injury Research Institute; Fran and Ray Stark Foundation Fund for Alzheimer's Disease Research; Ahmanson Foundation; Parlow-Solomon Professorship; JanssenJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc; LillyEli Lilly; NovartisNovartis; PfizerPfizer; Nihon Medi-Physics Co; Bristol-Meyer Squibb; PETNet Pharmaceuticals; SiemensSiemens AG	Supported by the Brain Injury Research Institute; the Fran and Ray Stark Foundation Fund for Alzheimer's Disease Research; the Ahmanson Foundation; and the Parlow-Solomon Professorship. No company provided support of any kind for this study.; The University of California, Los Angeles, owns a U.S. patent (6, 274, 119) entitled "Methods for Labeling beta-Amyloid Plaques and Neurofibrillary Tangles," that uses the approach outlined in this article. Drs. Small and Barrio are among the inventors, have received royalties, and may receive royalties on future sales. Dr. Small reports having served as a consultant and/or having received lecture fees from Janssen, Lilly, Novartis, and Pfizer. Dr. Barrio reports having served as a consultant and having received lecture fees from Nihon Medi-Physics Co, Bristol-Meyer Squibb, PETNet Pharmaceuticals, and Siemens. Drs. Ercoli, Kepe, Siddarth, Merrill, Bookheimer, Omalu, and Bailes and Ms. Donoghue and Ms. Martinez have no financial conflicts of interest.	*CDCP, 2007, MORTALITY MORBIDITY, V0056; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fodero-Tavoletti MT, 2011, BRAIN, V134, P1089, DOI 10.1093/brain/awr038; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Kumar A, 2011, ARCH GEN PSYCHIAT, V68, P1143, DOI 10.1001/archgenpsychiatry.2011.122; Lavretsky H, 2009, AM J GERIAT PSYCHIAT, V17, P493, DOI 10.1097/JGP.0b013e3181953b82; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Shoghi-Jadid K, 2002, AM J GERIAT PSYCHIAT, V10, P24, DOI 10.1176/appi.ajgp.10.1.24; Silverman DHS, 2002, J NUCL MED, V43, P253; Small GW, 2012, ARCH NEUROL-CHICAGO, V69, P215, DOI 10.1001/archneurol.2011.559; Small GW, 2006, NEW ENGL J MED, V355, P2652, DOI 10.1056/NEJMoa054625; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Zhang W, 2012, J ALZHEIMERS DIS, V31, P601, DOI 10.3233/JAD-2012-120712	17	139	139	1	90	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1064-7481			AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	FEB	2013	21	2					138	144		10.1016/j.jagp.2012.11.019			7	Geriatrics & Gerontology; Gerontology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Psychiatry	077FB	WOS:000314012200006	23343487				2022-02-06	
J	Harvey, LA; Close, JCT				Harvey, Lara A.; Close, Jacqueline C. T.			Traumatic brain injury in older adults: characteristics, causes and consequences	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Trauma; Traumatic brain injury; Falls, Older people; Accidents; Injuries; Epidemiology; Hospitalisation	TERM VITAMIN-D; CALCIUM SUPPLEMENTATION; ATRIAL-FIBRILLATION; HEAD-INJURIES; FALL; POPULATION; WARFARIN; HOSPITALIZATIONS; PREVENTION; MANAGEMENT	Introduction: Traumatic brain injury is of particular concern in the older population. We aimed to examine the trends in hospitalisations, causes and consequences of TBI in older adults in New South Wales, Australia. Methods: TBI cases from 1 July 1998 to 30 June 2011 were identified from hospitalisation data for all public and private hospitals in NSW. Direct aged standardised admission rates were calculated. Negative binomial regression modelling was used to examine the statistical significance of changes in trend over time. Results: There were 12,564 hospitalisations for TBI over the 13 year study period. Hospitalisation rates for TBI among the older population increased by 7.2% (95% CI 6.4-8.0, p < .0001) per year from 19.3/100,000 to 72.2/100,000. Males had a consistently higher hospitalisation rate. Just under one third of all hospitalisations were for adults aged 85 years and over. Traumatic subdural haemorrhage (42.9%), concussive injury (24.1%) and traumatic subarachnoid haemorrhage (12.7%) were the most common type of injury. Falls were the most common cause of TBI (82.9%). Rates of fall-related TBI increased by 8.4% (95% CI 7.5-9.3, p < .001) per year, whilst non-fall related head injury increased by 2.1% (95% CI 0.9-3.3, p < .0001) per year. The majority of falls were as a result of a fall on the same level and occurred at home. 13% of hospitalisations resulted in death, and the majority occurred in those who sustained a traumatic subdural haemorrhage. Conclusions: The rapid increase in hospitalised TBI is being predominantly driven by falls in the oldest old and the greatest increase predominantly in intracranial haemorrhages, highlighting the need for future research to quantify the risk versus benefit of anticoagulant therapies. (C) 2012 Elsevier Ltd. All rights reserved.	[Harvey, Lara A.; Close, Jacqueline C. T.] Univ New S Wales, Falls & Injury Prevent Grp, Sydney, NSW 2052, Australia; [Close, Jacqueline C. T.] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW 2052, Australia		Harvey, LA (corresponding author), Neurosci Res Australia, Falls & Injury Prevent Grp, Barker St, Randwick, NSW 2031, Australia.	l.harvey@neura.edu.au	Harvey, Lara/J-6146-2012; Close, Jacqueline CT/C-9803-2011	Close, Jacqueline CT/0000-0003-2908-9507	NSW Ministry of Health	Lara Harvey was supported by the NSW Ministry of Health. We thank the Centre for Epidemiology and Research at the NSW Ministry of Health for providing the APCD data from the Health Outcomes and Information Statistical Toolkit (HOIST) analysed in this study. The HOIST system refers to a data access, analysis and reporting facility established and operated by the Centre for Epidemiology and Research, Population Health Division, NSW Ministry of Health.	Annoni J M, 1992, Disabil Rehabil, V14, P23; Australian Bureau of Statistics, 2012, POP EST OBT HLTH OUT; Australian Bureau of Statistics, 2008, POP PROJ AUSTR 2006; Australian Commission on Safety and Quality in Healthcare, 2009, PREV FALLS HARM FALL; Berry J., 2006, GUIDE STAT METHODS I; Bischoff HA, 2003, J BONE MINER RES, V18, P343, DOI 10.1359/jbmr.2003.18.2.343; Bischoff-Ferrari HA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3692; Centre for Epidemiology and Research, 2012, HLTH OUTC INF STAT T; Centre for Epidemiology and Research. Health statistics New South Wales, 2012, SEL REP FALL REL INJ; Centre for Health Advancement, 2011, FALLS PREV FALLS HAR; Centre for Health Advancement and Centre for Epidemiology and Research, 2010, NEW S WAL FALLS PREV; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Faul M, 2010, TRAUMATIC BRAIN INJU; Flaherty ML, 2008, NEUROLOGY, V71, P1084, DOI 10.1212/01.wnl.0000326895.58992.27; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Gillespie LD, 2010, COCHRANE DATABASE SY; Hartholt KA, 2011, J NEUROTRAUM, V28, P739, DOI 10.1089/neu.2010.1488; Helps Y., 2008, HOSP SEPARATIONS DUE; Hill AM, 2011, ARCH PHYS MED REHAB, V92, P1395, DOI 10.1016/j.apmr.2011.04.009; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Institute SAS, 2003, SAS STAT SOFTW VERS; Jamieson LM, 2007, INJURY PREV, V13, P243, DOI 10.1136/ip.2007.015354; Jeffree RL, 2009, J CLIN NEUROSCI, V16, P882, DOI 10.1016/j.jocn.2008.10.004; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Karni A, 2001, AM SURGEON, V67, P1098; Lip GYH, 2011, EUROPACE, V13, P723, DOI 10.1093/europace/eur126; McInnes Elizabeth, 2004, Worldviews Evid Based Nurs, V1, P20, DOI 10.1111/j.1741-6787.2004.04013.x; Mountain D, 2010, MED J AUSTRALIA, V193, P202, DOI 10.5694/j.1326-5377.2010.tb03868.x; National Centre for Classification in Health, 2010, INT STAT CLASS DIS R; Pfeifer M, 2009, OSTEOPOROSIS INT, V20, P315, DOI 10.1007/s00198-008-0662-7; Pfeifer M, 2000, J BONE MINER RES, V15, P1113, DOI 10.1359/jbmr.2000.15.6.1113; Pieracci FM, 2008, J TRAUMA, V63, P525; Prevention of Falls in Older Person, 2010, AGS BGS CLIN PRACT G; Ramananathan DM, 2011, J NEUROTRAUMA; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Tadros R, 2010, AUST FAM PHYSICIAN, V39, P476; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Watson W, 2010, INCIDENCE COST FALLS; Watson WL, 2011, OSTEOPOROSIS INT, V22, P2623, DOI 10.1007/s00198-010-1511-z; Yardley L, 2006, GERONTOLOGIST, V46, P650, DOI 10.1093/geront/46.5.650	45	139	143	1	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	NOV	2012	43	11					1821	1826		10.1016/j.injury.2012.07.188			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014VR	WOS:000309404300008	22884759				2022-02-06	
J	Washington, PM; Forcelli, PA; Wilkins, T; Zapple, DN; Parsadanian, M; Burns, MP				Washington, Patricia M.; Forcelli, Patrick A.; Wilkins, Tiffany; Zapple, David N.; Parsadanian, Maia; Burns, Mark P.			The Effect of Injury Severity on Behavior: A Phenotypic Study of Cognitive and Emotional Deficits after Mild, Moderate, and Severe Controlled Cortical Impact Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						elevated-plus maze; forced swim test; Morris water maze; prepulse inhibition; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ELEVATED PLUS-MAZE; MEMORY DYSFUNCTION; MODEL; EXPOSURE; ANXIETY; SCALE; RATS	Traumatic brain injury (TBI) can cause a broad array of behavioral problems including cognitive and emotional deficits. Human studies comparing neurobehavioral outcomes after TBI suggest that cognitive impairments increase with injury severity, but emotional problems such as anxiety and depression do not. To determine whether cognitive and emotional impairments increase as a function of injury severity we exposed mice to sham, mild, moderate, or severe controlled cortical impact (CCI) and evaluated performance on a variety of neurobehavioral tests in the same animals before assessing lesion volume as a histological measure of injury severity. Increasing cortical impact depth successfully produced lesions of increasing severity in our model. We found that cognitive impairments in the Morris water maze increased with injury severity, as did the degree of contralateral torso flexion, a measure of unilateral striatal damage. TBI also caused deficits in emotional behavior as quantified in the forced swim test, elevated-plus maze, and prepulse inhibition of acoustic startle, but these deficits were not dependent on injury severity. Stepwise regression analyses revealed that Morris water maze performance and torso flexion predicted the majority of the variability in lesion volume. In summary, we find that cognitive deficits increase in relation to injury severity, but emotional deficits do not. Our data suggest that the threshold for emotional changes after experimental TBI is low, with no variation in behavioral deficits seen between mild and severe brain injury.	[Washington, Patricia M.; Wilkins, Tiffany; Parsadanian, Maia] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20057 USA; [Forcelli, Patrick A.] Georgetown Univ, Med Ctr, Dept Physiol & Pharmacol, Washington, DC 20057 USA		Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, New Res Bldg WP22a,3970 Reservoir Rd NW, Washington, DC 20057 USA.	mpb37@georgetown.edu		Forcelli, Patrick/0000-0003-1763-060X; Burns, Mark P/0000-0003-4750-2000	Georgetown University's Neural Injury and Plasticity Training Program [T32NS041218]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute for Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS067417]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218, R03NS067417, R01NS081068] Funding Source: NIH RePORTER	This work was supported by grant number T32NS041218 from Georgetown University's Neural Injury and Plasticity Training Program, supported by the National Institutes of Health (P. M. W., PIs: Dr. Jean Wrathall and Dr. Kathleen Maguire-Zeiss), and grant no. NS067417 from the National Institute for Neurological Disorders and Stroke (M.P.B.).	Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Bhardwaj SK, 2012, NEUROPHARMACOLOGY, V62, P2337, DOI 10.1016/j.neuropharm.2012.02.001; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Forcelli PA, 2008, ADDICT BIOL, V13, P52, DOI 10.1111/j.1369-1600.2007.00078.x; Forcelli PA, 2012, BEHAV NEUROSCI, V126, P290, DOI 10.1037/a0026898; Forcelli PA, 2012, J PHARMACOL EXP THER, V340, P558, DOI 10.1124/jpet.111.188862; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harkin A, 2004, EUR NEUROPSYCHOPHARM, V14, P274; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Olmos-Serrano JL, 2011, DEV NEUROSCI-BASEL, V33, P395, DOI 10.1159/000332884; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Petullo D, 1999, LIFE SCI, V64, P1099, DOI 10.1016/S0024-3205(99)00038-7; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Wobbrock J.O., 2011, P ACM C HUM FACT COM, P4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	39	139	142	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2283	2296		10.1089/neu.2012.2456			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900004	22642287	Green Published			2022-02-06	
J	Hayakawa, K; Pham, LDD; Katusic, ZS; Arai, K; Lo, EH				Hayakawa, Kazuhide; Pham, Loc-Duyen D.; Katusic, Zvonimir S.; Arai, Ken; Lo, Eng H.			Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						reactive glia; vascular repair; brain remodeling	END-PRODUCTS RAGE; TRAUMATIC BRAIN-INJURY; NEURITE OUTGROWTH; ISCHEMIC-STROKE; NEUROGENESIS; ANGIOGENESIS; RECEPTOR; HMGB1; MECHANISMS; INFLAMMATION	Crosstalk between the brain and systemic responses in blood is increasingly suspected of playing critical roles in stroke. However, how this communication takes place remains to be fully understood. Here, we show that reactive astrocytes can release a damage-associated molecular-pattern molecule called high-mobilitygroup-box-1 (HMGB1) that promotes endothelial progenitor cell (EPC)-mediated neurovascular remodeling during stroke recovery. Conditioned media from reactive astrocytes increase EPC proliferation in vitro. siRNA suppression of HMGB1 in astrocytes or blockade of the HMGB1 receptor for advanced glycation end-products in EPCs prevents this effect. In a mouse model of focal cerebral ischemia, reactive astrocytes in the peri-infarct cortex upregulate HMGB1 at 14 d poststroke, along with an accumulation of endogenous EPCs. In vivo siRNA suppression of HMGB1 blocks this EPC response, reduces peri-infact angiogenesis, and worsens neurological deficits. Taken together, these molecular and in vivo findings support a previously undescribed mechanism of crosstalk between reactive astrocytes and EPCs wherein HMGB1 promotes neurovascular remodeling and functional recovery after stroke and brain injury.	[Hayakawa, Kazuhide; Pham, Loc-Duyen D.; Arai, Ken; Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA 02129 USA; [Hayakawa, Kazuhide; Pham, Loc-Duyen D.; Arai, Ken; Lo, Eng H.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; [Hayakawa, Kazuhide; Pham, Loc-Duyen D.; Arai, Ken; Lo, Eng H.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Katusic, Zvonimir S.] Mayo Clin, Coll Med, Dept Anesthesiol, Rochester, MN 55905 USA		Lo, EH (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA 02129 USA.	Lo@helix.mgh.harvard.edu			Deane Foundation; American Heart AssociationAmerican Heart Association; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This work was supported in part by the Deane Foundation, the American Heart Association, and the National Institutes of Health.	Arai K, 2009, FEBS J, V276, P4644, DOI 10.1111/j.1742-4658.2009.07176.x; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Borlongan CV, 2011, PROG NEUROBIOL, V95, P213, DOI 10.1016/j.pneurobio.2011.08.005; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; de Souza DF, 2009, J NEUROIMMUNOL, V206, P52, DOI 10.1016/j.jneuroim.2008.10.012; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Faraco G, 2007, J NEUROCHEM, V103, P590, DOI 10.1111/j.1471-4159.2007.04788.x; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Hayakawa K, 2010, GLIA, V58, P1007, DOI 10.1002/glia.20982; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 2002, J BIOL CHEM, V277, P38635, DOI 10.1074/jbc.M202515200; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lin L, 2009, FRONT BIOSCI-LANDMRK, V14, P1403, DOI 10.2741/3315; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Navarro-Sobrino M, 2011, ATHEROSCLEROSIS, V216, P205, DOI 10.1016/j.atherosclerosis.2011.01.030; Navarro-Sobrino M, 2010, MICROVASC RES, V80, P317, DOI 10.1016/j.mvr.2010.05.008; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Rouhl RPW, 2008, STROKE, V39, P2158, DOI 10.1161/STROKEAHA.107.507251; Schlueter C, 2005, AM J PATHOL, V166, P1259, DOI 10.1016/S0002-9440(10)62344-9; Srikrishna G, 2009, NEOPLASIA, V11, P615, DOI 10.1593/neo.09284; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Treutiger CJ, 2003, J INTERN MED, V254, P375, DOI 10.1046/j.1365-2796.2003.01204.x; Xin HQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009027; Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648; Yip HK, 2008, STROKE, V39, P69, DOI 10.1161/STROKEAHA.107.489401; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	36	139	150	1	19	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAY 8	2012	109	19					7505	7510		10.1073/pnas.1121146109			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	942ZQ	WOS:000304090600076	22529378	Green Published, Bronze			2022-02-06	
J	Beers, SR; Wisniewski, SR; Garcia-Filion, P; Tian, Y; Hahner, T; Berger, RP; Bell, MJ; Adelson, PD				Beers, Sue R.; Wisniewski, Stephen R.; Garcia-Filion, Pamela; Tian, Ye; Hahner, Thomas; Berger, Rachel P.; Bell, Michael J.; Adelson, P. David			Validity of a Pediatric Version of the Glasgow Outcome Scale-Extended	JOURNAL OF NEUROTRAUMA			English	Article						children; GOS-E; infants; pediatrics; TBI; toddlers; Vineland Adaptive Behavior Scales	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; PRACTICAL SCALE; INTENSIVE-CARE	The Glasgow Outcome Scale (GOS) and its most recent revision, the GOS-Extended (GOS-E), provide the gold standard for measuring traumatic brain injury (TBI) outcome. The GOS-E exhibits validity when used with adults and some adolescents, but validity with younger children is not established. Because the GOS-E lacks the developmental specificity necessary to evaluate children, toddlers, and infants, we modified the original version to create the GOS-E Pediatric Revision (GOS-E Peds), a developmentally appropriate structured interview, to classify younger patients. The criterion, predictive, and discriminant validity of the GOS-E Peds was measured in 159 subjects following TBI (mild: 36%; moderate: 12%; severe: 50%) at 3 and 6 months after injury. Participants were included from two studies completed at the Pediatric Neurotrauma Center at Children's Hospital of Pittsburgh. We assessed the relationship among GOS-E Peds, the GOS, and the Vineland Adaptive Behavior Scales as well as other standardized measures of functional, behavioral, intellectual, and neuropsychological outcome. Premorbid function was assessed 24-36 h after injury. The GOS-E Peds showed a strong correlation with the GOS at 3 and 6 month time points. Criterion-related validity was also indicated by GOS-E Peds' association with most measures at both time points and at injury severity levels. The 3 month GOS-E Peds was associated with the 6 month GOS-E Peds, everyday function, behavior, and most cognitive abilities. Discriminant validity is suggested by weak correlations between both 3 and 6 month GOS-E Peds and premorbid measures. The GOS-E Peds is sensitive to severity of injury and is associated with changes in TBI sequelae over time. This pediatric revision provides a valid outcome measure in infants, toddlers, children, and adolescents through age 16. Findings support using the GOS-E Peds as the primary outcome variable in pediatric clinical trials.	[Beers, Sue R.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Berger, Rachel P.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Wisniewski, Stephen R.; Tian, Ye] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Clin Sci, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Hahner, Thomas] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA		Beers, SR (corresponding author), UPMC, Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.	beerssr@upmc.edu	Adelson, David/W-2083-2019	Wisniewski, Stephen/0000-0002-3877-9860	National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS 38448-01]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038448] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorders and Stroke (NINDS) grant RO1 NS 38448-01.; Salary support for Sue R. Beers, Stephen R. Wisniewski, Rachel Berger, and P. David Adelson, and partial salary support for Michael Bell was provided by the National Institutes of Health. The other authors have no competing financial interests.	Bayley N., 1993, MANUAL BAYLEY SCALES; Beers S.R., 2008, PRINCIPLES PRACTICE, P848; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Conners C., 2001, CONNERS RATING SCALE; Delis DC., 1994, CALIFORNIA VERBAL LE; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Murphy KR, 1991, PSYCHOL TESTING PRIN; Sparrow S, 2006, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thorndike R. L., 1986, STANFORD BINET INTEL; Wechsler, 1991, WESCHLER INTELLIGENC; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763	19	139	141	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1126	1139		10.1089/neu.2011.2272			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100013	22220819	Green Published			2022-02-06	
J	Benedictus, MR; Spikman, JM; van der Naalt, J				Benedictus, Marieke R.; Spikman, Jacoba M.; van der Naalt, Joukje			Cognitive and Behavioral Impairment in Traumatic Brain Injury Related to Outcome and Return to Work	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Behavior; Cognition; Outcome measures; Rehabilitation; Traumatic brain injury; Work	SEVERE HEAD-INJURY; MODERATE; PREDICTORS; EMPLOYMENT; DISABILITY; RECOVERY; SCALE; REHABILITATION; EPIDEMIOLOGY; ADJUSTMENT	Benedictus MR, Spikman JM, van der Naalt J. Cognitive and behavioral impairment in traumatic brain injury related to outcome and return to work. Arch Phys Med Rehabil 2010;91:1436-41. Objective: To evaluate the cognitive and behavioral disturbances related to return to work (RTW) in patients with traumatic brain injury (TBI) with the application of a differentiated outcome scale. Design: Longitudinal cohort study. Setting: Level trauma center. Participants: Adults (N=434) with TBI of various severity. Interventions: Not applicable. Main Outcome Measures: Extended Glasgow Outcome Scale (GOS-E), Differentiated Outcome Scale (DOS), and RTW. Results: Patients encountered problems in the physical (40%), cognitive (62%), behavioral (55%), and social domains (49%) of the DOS, with higher frequency related to severity of injury. Even those with mild TBI experienced cognitive (43%) and behavioral problems (33%). Patients with good recovery (58%) according to the GOS-E experienced problems in 1 or more domains of the DOS. Half the patients were able to resume previous vocational activities completely, although 1 in 3 experienced cognitive or behavioral problems. Using multivariate logistic regression analysis, the cognitive (odds ratio [OR], 10.548; confidence interval [CI], 5.99-18.67), behavioral (OR, 2.648; CI, 1.63-4.29), and physical domains (OR, 2.763; Cl, 1.60-4.78) were significant (P<.01) predictors of RTW. For subcategories of TBI, the cognitive domain was predictive for RTW in those with moderate and severe TBI, whereas both the cognitive and behavioral domains were predictive for RTW in those with mild TBI. Conclusions: With application of a more detailed outcome scale, cognitive and behavioral impairments interfering with RTW were present in a substantial part of patients with TBI in the chronic phase after injury. More research is needed exploring the cognitive and behavioral outcome in different categories of injury severity separately.	[van der Naalt, Joukje] Univ Groningen, Univ & Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Benedictus, Marieke R.; Spikman, Jacoba M.] Univ Groningen, Univ & Med Ctr Groningen, Dept Neuropsychol, NL-9700 RB Groningen, Netherlands		van der Naalt, J (corresponding author), Univ Groningen, Univ & Med Ctr Groningen, Dept Neurol, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@neuro.umcg.nl	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; van der Naalt, Joukje/0000-0001-9873-2418; Spikman, Jacoba/0000-0002-6477-0763			Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 2000, BRAIN INJURY, V14, P781; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553	44	139	141	0	39	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2010	91	9					1436	1441		10.1016/j.apmr.2010.06.019			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	651IM	WOS:000281921400019	20801264				2022-02-06	
J	West, AK; Hidalgo, J; Eddins, D; Levin, ED; Aschner, M				West, Adrian K.; Hidalgo, Juan; Eddins, Donnie; Levin, Edward D.; Aschner, Michael			Metallothionein in the central nervous system: Roles in protection, regeneration and cognition	NEUROTOXICOLOGY			English	Article; Proceedings Paper	11th Meeting of the International-Neurotoxicology-Association	JUN, 2007	Pacific Grove, CA	Int Neurotoxicol Assoc		metallothionein; central nervous system; neuroprotection; regeneration; transgenic animal; methylmercury; cognition; astrocyte	GROWTH-INHIBITORY FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; AMYOTROPHIC-LATERAL-SCLEROSIS; II-DEFICIENT MICE; ASTROCYTE-TARGETED EXPRESSION; TRAUMATIC BRAIN-INJURY; LOW-MOLECULAR-WEIGHT; CULTURED PRIMARY ASTROCYTES; FOCAL CEREBRAL-ISCHEMIA; ACID-INDUCED SEIZURES	Metallothionein (MT) is an enigmatic protein, and its physiological role remains a matter of intense study and debate 50 years after its discovery. This is particularly true of its function in the central nervous system (CNS), where the challenge remains to link its known biochemical properties of metal binding and free radical scavenging to the intricate workings of brain. In this compilation of four reports, first delivered at the 11th International Neurotoxicology Association (INA-11) Meeting, June 2007, the authors present the work of their laboratories, each of which gives an important insight into the actions of MT in the brain. What emerges is that MT has the potential to contribute to a variety of processes, including neuroprotection, regeneration, and even cognitive functions. In this article, the properties and CNS expression of NIT are briefly reviewed before Dr Hidalgo describes his pioneering work using transgenic models of NIT expression to demonstrate how this protein plays a major role in the defence of the CNS against neurodegenerative disorders and other CNS injuries. His group's work leads to two further questions, what are the mechanisms at the cellular level by which NIT acts, and does this protein influence higher order issues of architecture and cognition? These topics are addressed in the second and third sections of this review by Dr West, and Dr Levin and Dr Eddins, respectively. Finally, Dr Aschner examines the ability of MT to protect against a specific toxicant, methylmercury, in the CNS. (C) 2008 Elsevier Inc. All rights reserved.	[West, Adrian K.] Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas 7001, Australia; [Hidalgo, Juan] Autonomous Univ Barcelona, Inst Neurosci, E-08193 Barcelona, Spain; [Hidalgo, Juan] Autonomous Univ Barcelona, Dept Cellular Biol Phys & Immunol, Anim Phys Unit, Fac Sci, E-08193 Barcelona, Spain; [Eddins, Donnie; Levin, Edward D.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; [Aschner, Michael] Vanderbilt Univ, Med Ctr, Kennedy Ctr Res Human Dev, Nashville, TN USA		West, AK (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Private Bag 58, Hobart, Tas 7001, Australia.	awest@utas.edu.au	Hidalgo, Juan/C-9082-2011; West, Adrian/AAR-8857-2021	Hidalgo, Juan/0000-0003-0921-1122; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES007331, R01ES010563, P42ES010356] Funding Source: NIH RePORTER; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01 ES007331-05, R01 ES007331, R01 ES007331-06, R01 ES007331-11, R01 ES007331-05S1, R01 ES010563-04, R01 ES007331-04, R01 ES010563-05, ES 07331, R01 ES010563, P42 ES010356, R01 ES010563-01A1, R01 ES007331-12, R01 ES007331-09, R01 ES007331-07, ES 010356, R01 ES010563-02, R01 ES007331-10, R01 ES007331-08, R01 ES007331-13, R01 ES010563-08, R01 ES010563-06, R01 ES010563-03, R01 ES007331-14, R01 ES010563-07] Funding Source: Medline		AbdelMageed AB, 1997, CANCER GENE THER, V4, P199; Acarin L, 1999, NEUROSCIENCE, V92, P827, DOI 10.1016/S0306-4522(99)00022-6; Acarin L, 1999, J NEUROPATH EXP NEUR, V58, P389, DOI 10.1097/00005072-199904000-00009; Adlard PA, 1998, NEUROBIOL DIS, V5, P349, DOI 10.1006/nbdi.1998.0203; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Allen JW, 2001, BRAIN RES, V902, P92, DOI 10.1016/S0006-8993(01)02375-7; Allen JW, 2001, BRAIN RES, V894, P131, DOI 10.1016/S0006-8993(01)01988-6; Ambjorn M, 2008, J NEUROCHEM, V104, P21, DOI 10.1111/j.1471-4159.2007.05036.x; Amoureux MC, 1997, MOL CHEM NEUROPATHOL, V32, P101, DOI 10.1007/BF02815170; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; ANEZAKI T, 1995, NEUROCHEM INT, V27, P89, DOI 10.1016/0197-0186(94)00170-Y; Arai Y, 1997, PEDIATR NEUROL, V17, P134, DOI 10.1016/S0887-8994(97)00085-4; Asanuma M, 2002, NEUROSCI LETT, V327, P61, DOI 10.1016/S0304-3940(02)00346-4; Aschner M, 2007, BRAZ J MED BIOL RES, V40, P285, DOI 10.1590/S0100-879X2007000300001; Aschner M, 1996, NEUROTOXICOLOGY, V17, P93; ASCHNER M, 1993, BRAIN RES, V602, P181, DOI 10.1016/0006-8993(93)90680-L; Aschner M, 2002, BRAIN PATHOL, V12, P475; Aschner M, 1999, ANNU REV PHARMACOL, V39, P151, DOI 10.1146/annurev.pharmtox.39.1.151; Aschner M, 1996, FASEB J, V10, P1129, DOI 10.1096/fasebj.10.10.8751715; Aschner M, 1998, BRAIN RES, V813, P254, DOI 10.1016/S0006-8993(98)00947-0; Aschner M, 2006, EXP BIOL MED, V231, P1468, DOI 10.1177/153537020623100904; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Blaauwgeers HGT, 1996, J NEUROL SCI, V142, P39, DOI 10.1016/0022-510X(96)00013-5; Bogumil R, 1998, EUR J BIOCHEM, V255, P172, DOI 10.1046/j.1432-1327.1998.2550172.x; Bramanti E, 1999, ANAL BIOCHEM, V274, P163, DOI 10.1006/abio.1999.4257; BREMNER I, 1987, PROG FOOD NUTR SCI, V11, P1; Bremner I, 1987, Experientia Suppl, V52, P81; BROOKES N, 1992, TOXICOLOGY, V76, P245, DOI 10.1016/0300-483X(92)90193-I; BROOKES N, 1989, J NEUROCHEM, V53, P1228, DOI 10.1111/j.1471-4159.1989.tb07419.x; Businaro R, 2006, J NEUROSCI RES, V83, P897, DOI 10.1002/jnr.20785; Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Carrasco J, 1999, J NEUROTRAUM, V16, P1115, DOI 10.1089/neu.1999.16.1115; Carrasco J, 2000, EXP NEUROL, V163, P46, DOI 10.1006/exnr.1999.7335; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Carrasco J, 2006, NEUROSCIENCE, V143, P911, DOI 10.1016/j.neuroscience.2006.08.054; Carrier D, 2003, SOURCE-NOTE HIST ART, V22, P36, DOI 10.1086/sou.22.2.23206841; CARTY AJ, 1979, BIOGEOCHEMISTRY MERC, P433; Ceballos D, 2003, CELL MOL LIFE SCI, V60, P1209, DOI 10.1007/s00018-003-3047-2; Charleston JS, 1996, NEUROTOXICOLOGY, V17, P127; CHARLESTON JS, 1994, TOXICOL APPL PHARM, V129, P196, DOI 10.1006/taap.1994.1244; Chen Y, 2002, BIOCHEMISTRY-US, V41, P8360, DOI 10.1021/bi020030+; Chen YM, 2003, J NEUROCHEM, V84, P1332, DOI 10.1046/j.1471-4159.2003.01630.x; Chuah MI, 1999, NEUROREPORT, V10, P1919, DOI 10.1097/00001756-199906230-00023; Chung RS, 2008, J NEUROCHEM, V104, P14, DOI 10.1111/j.1171-4159.2007.05026.x; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Chung RS, 2002, EXP NEUROL, V178, P1, DOI 10.1006/exnr.2002.8017; Chung RS, 2002, BIOCHEM J, V365, P323, DOI 10.1042/BJ20011751; Chung RS, 2004, NEUROSCIENCE, V123, P595, DOI 10.1016/j.neuroscience.2003.10.019; COX DR, 1983, HUM GENET, V64, P61, DOI 10.1007/BF00289481; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1995, NEUROCHEM INT, V27, P59, DOI 10.1016/0197-0186(94)00168-T; Daumas S, 2004, EUR J NEUROSCI, V20, P597, DOI 10.1111/j.1460-9568.2004.03484.x; Dittmann J, 2005, NEUROTOX RES, V7, P87, DOI 10.1007/BF03033779; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; EDDINS D, 2007, NEUROTOXICOL TE 1215; *ENV PROT AG OFF S, 2001, EPA823R01001; ERICKSON JC, 1995, NEUROCHEM INT, V27, P35, DOI 10.1016/0197-0186(94)00166-R; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Erickson JC, 1997, J NEUROSCI, V17, P1271; Faller P, 1999, BIOCHEMISTRY-US, V38, P10158, DOI 10.1021/bi990489c; Fitzgerald M, 2007, EXP BRAIN RES, V183, P171, DOI 10.1007/s00221-007-1032-y; Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357; Giralt M, 2002, NEUROBIOL DIS, V9, P319, DOI 10.1006/nbdi.2002.0480; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gonzalez P, 2005, ENVIRON SCI TECHNOL, V39, P3972, DOI 10.1021/es0483490; Goulet S, 2003, NEUROTOXICOL TERATOL, V25, P335, DOI 10.1016/S0892-0362(03)00007-2; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.bi.55.070186.004405; Hernandez J, 1997, MOL BRAIN RES, V48, P125, DOI 10.1016/S0169-328X(97)00087-9; HIDALGO J, 1990, J NEUROCHEM, V55, P651, DOI 10.1111/j.1471-4159.1990.tb04182.x; HIDALGO J, 1994, CHEM-BIOL INTERACT, V93, P197, DOI 10.1016/0009-2797(94)90020-5; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Holloway AF, 1997, INT J DEV NEUROSCI, V15, P195, DOI 10.1016/S0736-5748(96)00091-3; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; Hozumi I, 1996, BRAIN RES, V741, P197, DOI 10.1016/S0006-8993(96)00912-2; HUGHES WL, 1957, ANN NY ACAD SCI, V65, P454, DOI 10.1111/j.1749-6632.1956.tb36650.x; Inuzuka T, 1996, BRAIN RES, V709, P151, DOI 10.1016/0006-8993(95)01444-6; Isumi H, 2000, CLIN NEUROPATHOL, V19, P77; Juarez BI, 2002, NEUROTOXICOL TERATOL, V24, P767, DOI 10.1016/S0892-0362(02)00270-2; KAEGI JH, 1961, J BIOL CHEM, V236, P2435; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P5494, DOI 10.1073/pnas.81.17.5494; Kawashima T, 2000, DEMENT GERIATR COGN, V11, P251, DOI 10.1159/000017247; Kelly EJ, 1997, P NATL ACAD SCI USA, V94, P10045, DOI 10.1073/pnas.94.19.10045; Kelly EJ, 1996, J NUTR, V126, P1782; Klassen RB, 2004, AM J PHYSIOL-RENAL, V287, pF393, DOI 10.1152/ajprenal.00233.2003; KOBAYASHI H, 1993, MOL BRAIN RES, V19, P188, DOI 10.1016/0169-328X(93)90025-K; Kohler LB, 2003, BRAIN RES, V992, P128, DOI 10.1016/j.brainres.2003.08.049; KONDO Y, 1995, CANCER RES, V55, P2021; Kramer KK, 1996, TOXICOL APPL PHARM, V141, P1; Kramer KK, 1996, TOXICOL APPL PHARM, V136, P94, DOI 10.1006/taap.1996.0011; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Levin ED, 2006, PHYSIOL BEHAV, V87, P513, DOI 10.1016/j.physbeh.2005.11.014; LEYSHONSORLAND K, 1994, HISTOCHEM J, V26, P161, DOI 10.1007/BF00157965; LIMA FR, 2007, J NEUROCHEM; LIU J, 1992, IN VITRO CELL DEV-AN, V28A, P320; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; MARGOSHES M, 1957, J AM CHEM SOC, V79, P4813, DOI 10.1021/ja01574a064; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MATYJA E, 1993, NEUROSCI LETT, V158, P155, DOI 10.1016/0304-3940(93)90252-G; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; Miyamoto K, 2001, BRAIN RES, V901, P252, DOI 10.1016/S0006-8993(01)02281-8; MIYAMOTO K, 1999, P 5 INT C, P376; Molinero A, 2003, J NEUROPATH EXP NEUR, V62, P315, DOI 10.1093/jnen/62.3.315; Montoliu C, 2000, J NEUROCHEM, V75, P266, DOI 10.1046/j.1471-4159.2000.0750266.x; MORTON KA, 1992, J BIOL CHEM, V267, P2880; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nagano S, 2001, EUR J NEUROSCI, V13, P1363, DOI 10.1046/j.0953-816x.2001.01512.x; NAGANUMA A, 1979, TOXICOL APPL PHARM, V47, P613, DOI 10.1016/0041-008X(79)90532-5; Neal JW, 1996, NEUROPATH APPL NEURO, V22, P243; OMATA S, 1978, BIOCHEM PHARMACOL, V27, P1700; OYAKE Y, 1966, ADV NEUROL SCI, V10, P744; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Peixoto NC, 2007, INT J DEV NEUROSCI, V25, P39, DOI 10.1016/j.ijdevneu.2006.11.002; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, EXP NEUROL, V170, P1, DOI 10.1006/exnr.2001.7675; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2003, CELL MOL LIFE SCI, V60, P1258, DOI 10.1007/s00018-003-3021-z; Penkowa M, 2003, GLIA, V42, P287, DOI 10.1002/glia.10208; Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5; Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T; PENKOWA M, 2003, CELL MOL LIFE SCI, V60; Penkowa M, 2006, J NEUROSCI RES, V84, P1452, DOI 10.1002/jnr.21043; PHILBERT MA, 1991, TOXICOL APPL PHARM, V107, P215, DOI 10.1016/0041-008X(91)90204-R; Portala K, 2001, EUR ARCH PSY CLIN N, V251, P262, DOI 10.1007/PL00007543; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Puttaparthi K, 2002, J NEUROSCI, V22, P8790; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Quintana A, 2007, J NEUROSCI RES, V85, P2668, DOI 10.1002/jnr.21126; RABENSTEIN DL, 1975, J AM CHEM SOC, V97, P2086, DOI 10.1021/ja00841a015; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; REFSVIK T, 1975, ACTA PHARMACOL TOX, V36, P67; RISING L, 1995, BRAIN RES, V678, P91, DOI 10.1016/0006-8993(95)00170-U; Robinson MB, 2005, J NEUROSCI, V25, P9735, DOI 10.1523/JNEUROSCI.1912-05.2005; Sakamoto T, 2003, NEUROREPORT, V14, P2147, DOI 10.1097/00001756-200312020-00003; Samson SLA, 1998, PROG NUCLEIC ACID RE, V59, P257, DOI 10.1016/S0079-6603(08)61034-X; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SEWELL AK, 1995, BIOCHEMISTRY-US, V34, P4740, DOI 10.1021/bi00014a031; Shanker G, 2002, MOL BRAIN RES, V106, P1, DOI 10.1016/S0169-328X(02)00403-5; Shanker G, 2001, BRAIN RES, V914, P159, DOI 10.1016/S0006-8993(01)02791-3; Shanker G, 2001, BRAIN RES, V902, P156, DOI 10.1016/S0006-8993(01)02342-3; Shi YB, 2003, BIOMETALS, V16, P383, DOI 10.1023/A:1022582209196; Sillevis Smitt Peter A. E., 1994, Biological Signals, V3, P193; SMITT PAES, 1992, NEUROSCI LETT, V144, P107, DOI 10.1016/0304-3940(92)90727-O; SUZUKI K, 1994, PATHOL INT, V44, P20, DOI 10.1111/j.1440-1827.1994.tb02581.x; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; THOMAS DJ, 1982, TOXICOL APPL PHARM, V62, P104, DOI 10.1016/0041-008X(82)90106-5; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; TSUJI S, 1992, EMBO J, V11, P4843, DOI 10.1002/j.1460-2075.1992.tb05590.x; Turner BJ, 2005, J NEUROSCI, V25, P108, DOI 10.1523/JNEUROSCI.4253-04.2005; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Y, 2002, J BIOL CHEM, V277, P32353, DOI 10.1074/jbc.M111263200; Uchida Yoko, 1994, Biological Signals, V3, P211; VAHTER M, 1994, TOXICOL APPL PHARM, V124, P221, DOI 10.1006/taap.1994.1026; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VASAK M, 1994, ENCY INORGANIC CHEM, P229; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; West AK, 2004, REV NEUROSCIENCE, V15, P157; WEST AK, 1990, GENOMICS, V8, P513, DOI 10.1016/0888-7543(90)90038-V; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Wolff NA, 2006, J PHARMACOL EXP THER, V318, P782, DOI 10.1124/jpet.106.102574; Xie T, 2004, J NEUROSCI, V24, P7043, DOI 10.1523/JNEUROSCI.1626-04.2004; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; Yao CP, 1999, BRAIN RES, V818, P414, DOI 10.1016/S0006-8993(98)01229-3; Yasutake A, 1998, ARCH TOXICOL, V72, P187, DOI 10.1007/s002040050486; Yin ZB, 2007, BRAIN RES, V1131, P1, DOI 10.1016/j.brainres.2006.10.070; Yoshida M, 2005, TOXICOL LETT, V155, P361, DOI 10.1016/j.toxlet.2004.11.001; Youn J, 2002, CLIN EXP IMMUNOL, V129, P232, DOI 10.1046/j.1365-2249.2002.01922.x; Yu WH, 2001, BRAIN RES, V894, P37, DOI 10.1016/S0006-8993(00)03196-6; YUGUCHI T, 1995, MOL BRAIN RES, V28, P181, DOI 10.1016/0169-328X(94)00205-S; YUGUCHI T, 1995, J NEUROTRAUM, V12, P299, DOI 10.1089/neu.1995.12.299; Zambenedetti P, 1998, J CHEM NEUROANAT, V15, P21, DOI 10.1016/S0891-0618(98)00024-6	188	139	142	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	MAY	2008	29	3			SI		489	503		10.1016/j.neuro.2007.12.006			15	Neurosciences; Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	317MV	WOS:000257025200018	18313142	Green Accepted			2022-02-06	
J	Berger, RP; Beers, SR; Richichi, R; Wiesman, D; Adelson, PD				Berger, Rachel Pardes; Beers, Sue R.; Richichi, Rudolph; Wiesman, Daniel; Adelson, P. David			Serum biomarker concentrations and outcome after pediatric traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Outcome Scale-Extended Pediatric version; Glasgow Outcome Scale score; myelin-basic; protein; neuron-specific enolase; S100B	NEURON-SPECIFIC ENOLASE; GLASGOW COMA SCALE; ABUSIVE HEAD TRAUMA; YOUNG-CHILDREN; S100B; TOMOGRAPHY; PREDICTION; INFANTS; DAMAGE; AGE	Predicting outcome after pediatric traumatic brain injury (TBI) is important for providing information to families and prescribing rehabilitation services. The study objective was to assess whether biomarkers concentrations obtained at the time of injury are associated with outcome. Serial serum concentrations of neuron-specific enolase (NSE), S100B and myelin basic protein (MBP) were measured in 152 children with acute TBI. Outcome was assessed with the Glasgow Outcome Scale (GOS) score and/or GOS-Extended Pediatric (GOS-E Peds). Spearman's rank correlation and binary logistic regression assessed the relationship between biomarker concentrations and outcome. For all biomarkers and time points, higher biomarker concentrations were associated with worse outcome. Initial and peak NSE concentrations and initial MBP concentrations were more strongly correlated with outcome in children <= 4 years compared with those > 4 years of age. Using binary logistic regression to evaluate the simultaneous affect of all biomarkers on outcome, there was significant overall model fit predicting a dichotomous GOS from biomarker concentrations with a 77% correct classification rate and a negative and positive predictive value of 97% and 75%, respectively. We conclude that NSE, S100B, and MBP concentrations obtained at the time of TBI may be useful in predicting outcome. Future studies should focus on assessing the differential benefit of biomarkers compared with clinical variables and in assessing a continuous rather than categorical outcome variable.	[Berger, Rachel Pardes] Univ Pittsburgh, Childrens Hosp, Sch Med,Safar Ctr Resuscitat Res, Div Child Advocacy,Dept Pediat, Pittsburgh, PA 15260 USA; [Beers, Sue R.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Richichi, Rudolph] Stat Anal & Measurement Consultants Inc, Lanexa, VA USA; [Wiesman, Daniel] Childrens Hosp, Div Child Advocacy, Pittsburgh, PA USA; [Adelson, P. David] Univ Pittsburgh, Childrens Hosp, Sch Med,Safar Ctr Resuscitat Res, Dept Neurosurg, Pittsburgh, PA USA		Berger, RP (corresponding author), Univ Pittsburgh, Childrens Hosp, Sch Med,Safar Ctr Resuscitat Res, Div Child Advocacy,Dept Pediat, Pittsburgh, PA 15260 USA.		Adelson, David/W-2083-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000005] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [01-K23HD43843] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beers SR, 2005, J NEUROTRAUM, V22, P1224; BEERS SR, 2007, PRINCIPLES PRACTICE, P848; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Carter BG, 2005, INTENS CARE MED, V31, P840, DOI 10.1007/s00134-005-2634-0; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; GREWAL M, 1991, J PEDIATR SURG, V26, P1161, DOI 10.1016/0022-3468(91)90323-L; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; Lima JE, 2004, BRAZ J MED BIOL RES, V37, P19, DOI 10.1590/S0100-879X2004000100003; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; THOMAS D G T, 1978, Lancet, V1, P113; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	35	139	145	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1793	1801		10.1089/neu.2007.0316			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000001	18159990				2022-02-06	
J	Dahlberg, CA; Cusick, CP; Hawley, LA; Newman, JK; Morey, CE; Harrison-Felix, CL; Whiteneck, GG				Dahlberg, Cynthia A.; Cusick, Christopher P.; Hawley, Lenore A.; Newman, Jody K.; Morey, Clare E.; Harrison-Felix, Cynthia L.; Whiteneck, Gale G.			Treatment efficacy of social communication skills training after traumatic brain injury: A randomized treatment and deferred treatment controlled trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	TBI Interagency Conference 2006	MAR   10, 2006	Bethesda, MD			brain injuries; rehabilitation; social interaction	CLOSED-HEAD-INJURY; COMMUNITY INTEGRATION QUESTIONNAIRE; QUALITY-OF-LIFE; REHABILITATION PROGRAM; FOLLOW-UP; SATISFACTION; COMPETENCE; CONVERSATION; DYSFUNCTION; IMPAIRMENT	Objective: To evaluate the efficacy of a replicable group treatment program to improve social communication skills after traumatic brain injury (TBI). Design: Randomized treatment and defer-red treatment controlled trial, with follow-up at 3, 6, and 9 months post-treatment. Setting: Community. Participants: Volunteer sample of 52 people with TBI who were at least 1 year postinjury, who received rehabilitation, and who had identified social communication deficits. Intervention: Twelve weekly group sessions (1.5h each) to improve social communication. Main Outcome Measures: The Profile of Functional Impairment in Communication (PFIC), Social Communication Skills Questionnaire-Adapted (SCSQ-A), Goal Attainment Scale (GAS), Craig Handicap Assessment and Reporting Technique-Short Form social integration and occupation subscales, Community Integration Questionnaire social integration and productivity subscales, and Satisfaction With Life Scale (SWLS). Results: Independent samples t test analysis showed significant treatment effect compared with no treatment on 7 of 10 of the PFIC subscales (P range,.024 to <.001) and the SCSQ-A (P=.005) after the first 12 weeks of the study. After 12 weeks of treatment for all participants, repeated-measures analysis showed significant improvements from baseline on 9 of 10 PFlC subscales (P range,.01-.001), SCSQ-A (P <=.001), GAS (P <=.001), and SWLS (P=.011). At 6-month follow-up, scores were significantly better than baseline on 6 of 10 PFIC scales (P range,.01-.001), the SCSQ-A (P <=.001), GAS (P <=.001), and SWLS (P <=.001). Conclusions: TBI subjects who received social communication skills training had improved communication skills that were maintained on follow-up. Overall life satisfaction for participants was improved.	[Dahlberg, Cynthia A.; Cusick, Christopher P.; Hawley, Lenore A.; Newman, Jody K.; Morey, Clare E.; Harrison-Felix, Cynthia L.; Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO USA		Dahlberg, CA (corresponding author), Craig Hosp, 3425 S Clarkson, Englewood, CO 80113 USA.	cdahlberg@craighospital.org					Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; BRABENDER V, 2004, ESSENTIALS GROUP THE; Braverman SE, 1999, BRAIN INJURY, V13, P405; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikengil A. T., 1992, BUILDING FUNCTIONAL; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Ehrlich J. S, 1985, COGNITIVE REHABILITA, P32; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Giles G M, 1988, Brain Inj, V2, P75, DOI 10.3109/02699058809150933; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Goldblum G, 2001, S Afr J Commun Disord, V48, P3; Hagen C, 1974, RANCHO LOS AMIGOS SC; HARRIS R, 2001, EC B, V5, P1; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hawley L, 2006, SOCIAL SKILLS TRAUMA; HELFFENSTEIN DA, 1982, CLIN NEUROPSYCHOLOGY, V4, P139; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEWIS FD, 1988, BEHAV THER, V19, P203, DOI 10.1016/S0005-7894(88)80043-1; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; LoBello SC, 2003, J REHABIL RES DEV, V40, P293, DOI 10.1682/JRRD.2003.07.0293; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MESSENGER B, 2004, BEHAV FUNCTIONAL REH; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SMIGIELSKI JS, 1992, MAYO CLIN PROC, V67, P767, DOI 10.1016/S0025-6196(12)60802-7; Snow P, 1997, BRAIN INJURY, V11, P409; Sohlberg M. M., 1992, IMPROVING PRAGMATIC; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; *STAT U NEW YORK, 1996, GUID UN DAT SET MED; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trower P., 1978, SOCIAL SKILLS MENTAL, P7; UPTON TD, 2001, BRAIN INJ SOURCE, V5, P30; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005; YLVISAKER M, 2001, BRAIN INJ SOURCE, P12; Ylvisaker M., 1987, COMMUNITY REENTRY HE, P137; [No title captured]	58	139	139	1	44	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2007	88	12					1561	1573		10.1016/j.apmr.2007.07.033			13	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	242OE	WOS:000251734200002	18047870				2022-02-06	
J	Xiong, YQ; Rabchevsky, AG; Hall, ED				Xiong, Yiqin; Rabchevsky, Alexander G.; Hall, Edward D.			Role of peroxynitrite in secondary oxidative damage after spinal cord injury	JOURNAL OF NEUROCHEMISTRY			English	Article						alpha-spectrin; calpain; oxidative damage; peroxynitrite; reactive oxygen species; spinal cord injury	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION PRODUCT; ACTIVATED NEUTRAL PROTEASE; NITRIC-OXIDE; CALPAIN ACTIVITY; IMPAIRED MITOCHONDRIAL; RADICAL FORMATION; CA2+ RELEASE; CALCIUM	Peroxynitrite (PON, ONOO-), formed by nitric oxide synthase-generated nitric oxide radical ((NO)-N-.) and superoxide radical (O-2(.-)), is a crucial player in post-traumatic oxidative damage. In the present study, we determined the spatial and temporal characteristics of PON-derived oxidative damage after a moderate contusion injury in rats. Our results showed that 3-nitrotyrosine (3-NT), a specific marker for PON, rapidly accumulated at early time points (1 and 3 h) and a significant increase compared with sham rats was sustained to 1 week after injury. Additionally, there was a coincident and maintained increase in the levels of protein oxidation-related protein carbonyl and lipid peroxidation-derived 4-hydroxynonenal (4-HNE). The peak increases of 3-NT and 4-HNE were observed at 24 h post-injury. In our immunohistochemical results, the co-localization of 3-NT and 4-HNE results indicates that PON is involved in lipid peroxidative as well as protein nitrative damage. One of the consequences of oxidative damage is an exacerbation of intracellular calcium overload, which activates the cysteine protease calpain leading to the degradation of several cellular targets including cytoskeletal protein (alpha-spectrin). Western blot analysis of alpha-spectrin breakdown products showed that the 145-kDa fragments of alpha-spectrin, which are specifically generated by calpain, were significantly increased as soon as 1 h following injury although the peak increase did not occur until 72 h post-injury. The later activation of calpain is most likely linked to PON-mediated secondary oxidative impairment of calcium homeostasis. Scavengers of PON, or its derived free radical species, may provide an improved antioxidant neuroprotective approach for the treatment of post-traumatic oxidative damage in the injured spinal cord.	Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,Room B383,BBSRB, Lexington, KY 40536 USA.	edhall@uky.edu	Xiong, Yiqin/H-1710-2012; Hall, Edward D/F-8930-2013; Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915			Aksenova M, 2002, J NEUROTRAUM, V19, P491, DOI 10.1089/08977150252932433; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Bartosz G, 1996, ACTA BIOCHIM POL, V43, P645; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BENUCK M, 1992, BRAIN RES, V596, P296, DOI 10.1016/0006-8993(92)91560-2; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; Cohen TI, 1996, J NEUROTRAUM, V13, P361, DOI 10.1089/neu.1996.13.361; Diaz-Ruiz A, 2004, NEUROSCI LETT, V357, P49, DOI 10.1016/j.neulet.2003.12.042; GUTTERIDGE JMC, 1989, CLIN HAEMATOL, V2, P195; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 1991, J NEUROTRAUM, V8, P86; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; JAMIE R, 2001, NEUROSCI LETT, V311, P129; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kruman I, 1997, J NEUROSCI, V17, P5089; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Kurnellas MP, 2004, FASEB J, V18, P298, DOI 10.1096/fj.04-2549fje; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Okabe E, 2000, ANTIOXID REDOX SIGN, V2, P47, DOI 10.1089/ars.2000.2.1-47; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; Schmidt MF, 1996, ADV MOD MANAG STORMW, V4, P15; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1989, J NEUROSCI, V9, P1579; Springer JE, 1997, J NEUROCHEM, V68, P2469; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; ZIMMERMAN UJP, 1984, PROG NEUROBIOL, V23, P63, DOI 10.1016/0301-0082(84)90012-1	68	139	144	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2007	100	3					639	649		10.1111/j.1471-4159.2006.04312.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	125AC	WOS:000243412900007	17181549	Bronze			2022-02-06	
J	Brody, DL; Holtzman, DM				Brody, DL; Holtzman, DM			Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; Alzheimer's disease; behavior; Morris water maze; search strategy; amyloid precursor protein; PDAPP mice	AMYLOID PRECURSOR PROTEIN; A-BETA DEPOSITION; CONTROLLED CORTICAL IMPACT; TRANSGENIC MICE; ALZHEIMERS-DISEASE; KNOCKOUT MICE; MOUSE MODEL; HEAD-INJURY; DEFICITS; NAVIGATION	Traumatic brain injury (TBI) is a common cause of cognitive dysfunction and a major risk factor for Alzheimer's disease (AD). PDAPP mice, a transgenic line overexpressing a mutant human amyloid precursor protein (APP) implicated in familial AD, have markedly impaired behavioral performance in the Morris water maze relative to wild-type (WT) littermates. Performance further deteriorates following experimental TBI in both PDAPP and WT mice. However, the aspects of cognitive function involved are not well understood. Here, we have analyzed search strategies used in the water maze by 3-4 month old PDAPP and WT C57B16 littermates both before and after moderate controlled cortical impact TBI. Prior to TBI, PDAPP mice used less spatial strategies and more nonspatial systematic strategies and strategies involving repetitive looping than WT mice. With training, PDAPP mice used more spatial strategies and less repetitive looping. After TBI, PDAPP mice lost use of spatial strategies and relied more on repetitive looping. TBI in WT mice also reduced their use of spatial strategies but instead caused a switch to nonspatial systematic strategies. We also analyzed changes in the efficiency with which mice used each individual strategy, but found that differences in which strategies were used quantitatively accounted for most of the differences in performance between groups. These results demonstrate that suboptimal search strategy use in addition to effects on spatial learning and memory underlies the impaired performance of PDAPP mice and further deterioration following TBI. Human TBI patients may have analogous poor use of problem solving strategies. (c) 2005 Elsevier Inc. All rights reserved.	Washington Univ, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, St Louis, MO 63110 USA; Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; Washington Univ, Alzheimers Dis Res Ctr, St Louis, MO 63110 USA		Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020222, R37AG013956, R01AG013956] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37 AG013956, AG13956, R01 AG013956, AG 20222, R01 AG020222] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS049237-01, NS049237, K08 NS049237] Funding Source: Medline		Arendash GW, 2001, DNA CELL BIOL, V20, P737, DOI 10.1089/10445490152717604; Burke R, 2004, BRAIN INJURY, V18, P497, DOI 10.1080/02699050310001645784; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Chen KS, 1998, PROG BRAIN RES, V117, P327; Colombo PJ, 2003, J NEUROSCI, V23, P3547; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, pCH6; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dodart JC, 1999, BEHAV NEUROSCI, V113, P982, DOI 10.1037/0735-7044.113.5.982; Dodart JC, 2000, NEUROREPORT, V11, P603, DOI 10.1097/00001756-200002280-00034; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Graziano A, 2003, J NEUROSCI METH, V130, P33, DOI 10.1016/S0165-0270(03)00187-0; Grootendorst J, 2001, NEUROSCIENCE, V108, P237, DOI 10.1016/S0306-4522(01)00412-2; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Huitron-Resendiz S, 2002, BRAIN RES, V928, P126, DOI 10.1016/S0006-8993(01)03373-X; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; Kennedy MRT, 2003, BRAIN INJURY, V17, P1043, DOI 10.1080/0269905031000110436; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Lang UE, 2003, BEHAV BRAIN RES, V145, P179, DOI 10.1016/S0166-4328(03)00108-6; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Saber AJ, 2003, NEUROPSYCHOPHARMACOL, V28, P1247, DOI 10.1038/sj.npp.1300163; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SUTHERLAND RJ, 1982, J COMP PHYSIOL PSYCH, V96, P563, DOI 10.1037/h0077914; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WHISHAW IQ, 1988, BEHAV NEUROSCI, V102, P662, DOI 10.1037/0735-7044.102.5.662; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6; WHISHAW IQ, 1989, BRAIN RES BULL, V23, P347, DOI 10.1016/0361-9230(89)90221-9; Wolfer DP, 2000, EXP PHYSIOL, V85, P627, DOI 10.1017/S0958067000020959; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745	40	139	142	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2006	197	2					330	340		10.1016/j.expneurol.2005.10.020			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	009RV	WOS:000235131000008	16309676	Green Accepted			2022-02-06	
J	Wirrell, EC				Wirrell, Elaine C.			Epilepsy-related injuries	EPILEPSIA			English	Article						epilepsy; seizures; accidental injury; submersion	SEIZURE-RELATED INJURIES; YOUNG-PEOPLE; BONE MASS; RISK; CHILDREN; ACCIDENTS; FRACTURES; THERAPY; BURNS; MORBIDITY	Only one prospective, controlled study has compared the risk of accidental injury in persons with epilepsy to controls without seizures. A mildly increased risk in the epilepsy group was found, predominantly due to injuries that result directly from a seizure. With regard to injury type, this study found significantly higher rates of only head and soft tissue injury; however, most injuries were minor. Several retrospective, population-based studies have suggested increased rates of more serious injury types. Submersion injury has a high mortality; the risk of submersion in children with epilepsy is 7.5-13.9 fold higher than in the general population. The risk of fracture is elevated approximately twofold, either resulting directly from seizure-induced injury or predisposed by drug-induced reduction in bone mineral density. Burns due to seizures account for between 1.6% and 3.7% of burn unit admissions. The risk of motor vehicle accidents in drivers with epilepsy also appears increased, albeit marginally. Several factors predispose to a higher risk of injury among those with epilepsy. Seizures resulting in falls increase the risk of concussion and other injuries. Higher seizure frequency, lack of a prolonged seizure-free interval, comorbid attention deficit disorder, or cognitive handicap may also increase the risk of injury. While some restrictions are necessary to protect the safety of the person with epilepsy, undue limitations may further limit achievement of independence. Given the high morbidity and mortality of submersion injury, those with active epilepsy should bathe or swim only with supervision; however, showering is a reasonable option. Appropriate vitamin D and calcium supplementation and periodic measurement of bone mineral density in those at risk for osteopenia are recommended.	Alberta Childrens Prov Gen Hosp, Dept Pediat, Div Neurol, Calgary, AB T3B 6A8, Canada		Wirrell, EC (corresponding author), Alberta Childrens Prov Gen Hosp, Dept Pediat, Div Neurol, 2888 Shanganappi Tr NW, Calgary, AB T3B 6A8, Canada.	elaine.wirrell@calgaryhealthregion.ca					Aldenkamp T, 2004, EPILEPSIA, V45, P54, DOI 10.1111/j.0013-9580.2004.33403.x; ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; Appleton RE, 2002, EPILEPSIA, V43, P764, DOI 10.1046/j.1528-1157.2002.41101.x; Beghi E, 2002, EPILEPSIA, V43, P1076, DOI 10.1046/j.1528-1157.2002.18701.x; Buck D, 1997, EPILEPSIA, V38, P439, DOI 10.1111/j.1528-1157.1997.tb01733.x; Carpay HA, 1997, DEV MED CHILD NEUROL, V39, P521; Deekollu D, 2005, SEIZURE-EUR J EPILEP, V14, P347, DOI 10.1016/j.seizure.2005.04.008; Desai KB, 1996, INJURY, V27, P97, DOI 10.1016/0020-1383(95)00189-1; DIEKEMA DS, 1993, PEDIATRICS, V91, P612; Drezner MK, 2004, EPILEPSY BEHAV, V5, pS41, DOI 10.1016/j.yebeh.2003.11.028; Dunn DW, 2003, DEV MED CHILD NEUROL, V45, P50, DOI 10.1017/S0012162203000094; Elterman RD, 1999, NEUROLOGY, V52, P1338, DOI 10.1212/WNL.52.7.1338; FISHER RS, 1994, EPILEPSIA, V35, P675, DOI 10.1111/j.1528-1157.1994.tb02491.x; HAMPTON KK, 1988, BRIT MED J, V296, P1659, DOI 10.1136/bmj.296.6637.1659; HANSOTIA P, 1993, EPILEPSIA, V34, P852, DOI 10.1111/j.1528-1157.1993.tb02102.x; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; Josty IC, 2000, EPILEPSIA, V41, P453, DOI 10.1111/j.1528-1157.2000.tb00188.x; KEMP AM, 1993, ARCH DIS CHILD, V68, P684, DOI 10.1136/adc.68.5.684; KIRBY S, 1995, EPILEPSIA, V36, P25, DOI 10.1111/j.1528-1157.1995.tb01660.x; Kirsch R, 2001, J CHILD NEUROL, V16, P100, DOI 10.2310/7010.2001.6916; Krauss GL, 1999, NEUROLOGY, V52, P1324, DOI 10.1212/WNL.52.7.1324; Lawn ND, 2004, NEUROLOGY, V63, P1565, DOI 10.1212/01.WNL.0000142991.14507.B5; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Lings S, 2001, NEUROLOGY, V57, P435, DOI 10.1212/WNL.57.3.435; NAKKEN KO, 1993, EPILEPSIA, V34, P836, DOI 10.1111/j.1528-1157.1993.tb02099.x; Neufeld MY, 1999, EPILEPSY RES, V34, P123, DOI 10.1016/S0920-1211(98)00105-3; Pack AM, 2004, EPILEPSY BEHAV, V5, pS24, DOI 10.1016/j.yebeh.2003.11.029; Pack AM, 2003, EPILEPSY BEHAV, V4, P169, DOI 10.1016/S1525-5050(03)00036-2; Pack AM, 2005, ANN NEUROL, V57, P252, DOI 10.1002/ana.20378; Persson HBI, 2002, EPILEPSIA, V43, P768, DOI 10.1046/j.1528-1157.2002.15801.x; QUAN L, 1989, PEDIATRICS, V83, P1035; Redelmeier DA, 1997, NEW ENGL J MED, V336, P453, DOI 10.1056/NEJM199702133360701; Remillard GM, 2002, CAN J NEUROL SCI, V29, P315, DOI 10.1017/S0317167100002171; RUSSELLJONES DL, 1989, J NEUROL NEUROSUR PS, V52, P659, DOI 10.1136/jnnp.52.5.659; RYAN CA, 1993, CAN MED ASSOC J, V148, P781; Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445; Sherrard J, 2002, J INTELL DISABIL RES, V46, P6, DOI 10.1046/j.1365-2788.2002.00346.x; Sheth SG, 2004, NEUROLOGY, V63, P1002, DOI 10.1212/01.WNL.0000138590.00074.9A; Souverein PC, 2005, EPILEPSIA, V46, P304, DOI 10.1111/j.0013-9580.2005.23804.x; SPITZ MC, 1992, EPILEPSIA, V33, P103, DOI 10.1111/j.1528-1157.1992.tb02290.x; Swensen A., 2004, Journal of Adolescent Health, V35, P346, DOI 10.1016/S1054-139X(04)00055-2; Taylor J, 1996, J NEUROL NEUROSUR PS, V60, P621, DOI 10.1136/jnnp.60.6.621; van den Broek M, 2004, EPILEPSIA, V45, P71, DOI 10.1111/j.0013-9580.2004.33803.x; VANDERLUGT PJM, 1975, EPILEPSIA, V16, P747, DOI 10.1111/j.1528-1157.1975.tb04760.x; Vestergaard P, 1999, ACTA NEUROL SCAND, V99, P269, DOI 10.1111/j.1600-0404.1999.tb00675.x; Wirrell EC, 1996, ARCH NEUROL-CHICAGO, V53, P929, DOI 10.1001/archneur.1996.00550090141020; ZIEGLER AL, 1994, ARCH PEDIATRIE, V1, P801; Zwimpfer TJ, 1997, J NEUROSURG, V86, P433, DOI 10.3171/jns.1997.86.3.0433	48	139	142	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2006	47			1			79	86		10.1111/j.1528-1167.2006.00666.x			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	092QP	WOS:000241112700017	17044832				2022-02-06	
J	Sherwood, PR; Given, CW; Given, BA; Von Eye, A				Sherwood, PR; Given, CW; Given, BA; Von Eye, A			Caregiver burden and depressive symptoms: Analysis of common outcomes in caregivers of elderly patients	JOURNAL OF AGING AND HEALTH			English	Article						caregiver; burden; depressive symptoms; structural equation model; inception cohort	TRAUMATIC BRAIN-INJURY; REACTION ASSESSMENT CRA; CANCER-PATIENTS; FAMILY CAREGIVERS; DISTRESS; DEMENTIA; PARTNERS; GENDER; HEALTH; CARE	Objective: Despite widespread use of caregiver burden and depressive symptoms in caregiving research, the relationship between these two concepts and the way in which burden and depressive symptoms are affected are not clear. Methods: The authors used structural equation modeling with an inception cohort of 488 family caregivers to examine the relationship between care recipients' mental and functional status and recency of care demands and caregivers' burden and depressive symptoms. Results: Care recipients' mental and functional status and recency of care demands predicted caregiver burden; burden, in turn, was nearly significant in predicting depressive symptoms. Care recipients'mental status and recency of care demands had a near significant indirect effect on caregiver depressive symptoms. There were no significant direct paths between care recipients' mental status, functional status, recency of care demands, and caregivers' depressive symptoms. Discussion: Health care practitioners should assist caregivers with new care demands stemming from care recipients' mental and functional status to decrease burdens and should monitor caregivers with higher levels of burden for the development of depressive symptoms.	Michigan State Univ, E Lansing, MI 48824 USA		Sherwood, PR (corresponding author), Michigan State Univ, E Lansing, MI 48824 USA.				NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR008069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG006584] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG06584] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31 NR08069] Funding Source: Medline		Aarsland D, 1999, INT J GERIATR PSYCH, V14, P866, DOI 10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.3.CO;2-Q; Annerstedt L, 2000, SCAND J PUBLIC HEALT, V28, P23, DOI 10.1177/140349480002800106; Clyburn LD, 2000, J GERONTOL B-PSYCHOL, V55, pS2, DOI 10.1093/geronb/55.1.s2; Farran CJ, 1997, J AGING HEALTH, V9, P316, DOI 10.1177/089826439700900303; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P571, DOI 10.1037/0022-3514.50.3.571; Fortinsky RH, 2002, AGING MENT HEALTH, V6, P153, DOI 10.1080/13607860220126763; Gallicchio L, 2002, INT J GERIATR PSYCH, V17, P154, DOI 10.1002/gps.538; Geisser ME, 1997, CLIN J PAIN, V13, P163, DOI 10.1097/00002508-199706000-00011; GERSTEL N, 1993, J MARRIAGE FAM, V55, P598, DOI 10.2307/353341; Given B., 2001, NURSING CARE OLDER A, P679; Given B A, 1994, J Aging Health, V6, P353, DOI 10.1177/089826439400600305; Given CW, 1999, GERONTOLOGIST, V39, P76, DOI 10.1093/geront/39.1.76; GIVEN CW, 1993, HEALTH PSYCHOL, V12, P277, DOI 10.1037/0278-6133.12.4.277; GIVEN CW, 1992, RES NURS HEALTH, V15, P271, DOI 10.1002/nur.4770150406; Gonzalez-Salvador MT, 1999, INT J GERIATR PSYCH, V14, P701, DOI 10.1002/(SICI)1099-1166(199909)14:9<701::AID-GPS5>3.0.CO;2-#; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Jacobi CE, 2003, RHEUMATOLOGY, V42, P1226, DOI 10.1093/rheumatology/keg366; Jepson C, 1999, Image J Nurs Sch, V31, P115, DOI 10.1111/j.1547-5069.1999.tb00444.x; Joreskog K, 1996, LISREL 8 USERS REFER; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; Knight RG, 1997, BEHAV RES THER, V35, P373, DOI 10.1016/S0005-7967(96)00107-6; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kristjanson LJ, 1997, J PALLIATIVE CARE, V13, P5; Labbe EE, 2002, PSYCHOL REP, V90, P1129, DOI 10.2466/PR0.90.3.1129-1135; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; MATSUDA O, 1995, PSYCHIAT CLIN NEUROS, V49, P209, DOI 10.1111/j.1440-1819.1995.tb01886.x; Moskowitz JT, 2003, PSYCHOSOM MED, V65, P620, DOI 10.1097/01.PSY.0000073873.74829.23; Nagatomo I, 1999, INT J GERIATR PSYCH, V14, P618, DOI 10.1002/(SICI)1099-1166(199908)14:8<618::AID-GPS989>3.0.CO;2-B; Nijboer C, 1999, SOC SCI MED, V48, P1259, DOI 10.1016/S0277-9536(98)00426-2; Nijboer C, 1999, CANCER, V86, P577, DOI 10.1002/(SICI)1097-0142(19990815)86:4<577::AID-CNCR6>3.0.CO;2-S; Nijboer C, 2000, GERONTOLOGIST, V40, P738, DOI 10.1093/geront/40.6.738; Northouse LL, 2000, SOC SCI MED, V50, P271, DOI 10.1016/S0277-9536(99)00281-6; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112; Pomerleau CS, 2003, ADDICT BEHAV, V28, P575, DOI 10.1016/S0306-4603(01)00257-X; Prescop K L, 1999, Int Psychogeriatr, V11, P235, DOI 10.1017/S1041610299005803; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Raveis VH, 1998, CANCER, V83, P1652, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1652::AID-CNCR22>3.3.CO;2-H; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; Song LY, 1997, COMMUNITY MENT HLT J, V33, P269, DOI 10.1023/A:1025090906696; STOMMEL M, 1992, RES NURS HEALTH, V15, P399, DOI 10.1002/nur.4770150508; TOSELAND RW, 1995, SOC SCI MED, V40, P517, DOI 10.1016/0277-9536(94)E0093-8; Whitlatch CJ, 1997, J AGING HEALTH, V9, P222; YOUNG R, 1995, GERONTOLOGIST, V35, P665	45	139	144	1	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0898-2643	1552-6887		J AGING HEALTH	J. Aging Health	APR	2005	17	2					125	147		10.1177/0898264304274179			23	Gerontology; Health Policy & Services	Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Health Care Sciences & Services	904DM	WOS:000227476300002	15750048				2022-02-06	
J	Lee, H; Kim, SW; Kim, JM; Shin, IS; Yang, SJ; Yoon, JS				Lee, H; Kim, SW; Kim, JM; Shin, IS; Yang, SJ; Yoon, JS			Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury	HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL			English	Article						methylphenidate; sertraline; depression; cognitive function; traumatic brain injury	CLOSED-HEAD-INJURY; DOUBLE-BLIND; DEPRESSION; SYMPTOMS; REHABILITATION; AMITRIPTYLINE; QUESTIONNAIRE; CONCUSSION; RECOVERY; MODERATE	Background This study aimed to investigate the effects of methylphenidatc and sertraline compared with placebo on various neuropsychiatric sequelae associated with traumatic brain injury (TBI). Methods This was a 4 week, double-blind, parallel-group trial. Thirty patients with mild to moderate degrees of TBI were randomly allocated to one of three treatment groups (n = 10 in each group) with matching age, gender and education, i.e. methylphenidate (starting at 5 mg/day and increasing to 20 mg/day in a week), sertraline (starting at 25 mg/day and increasing to 100 mg/day in a week) or placebo. At the baseline and at the 4 week endpoint, the following assessments were administered: subjective (Beck Depression Inventory) and objective (Hamilton Depression Rating Scale) measures of depression; Rivermead Postconcussion Symptoms Questionnaire for postconcussional symptoms; SmithKline Beecham Quality of Life Scale for quality of life; seven performance tests (Critical Flicker Fusion, Choice Reaction Time, Continuous Tracking, Mental Arithmetic, Short-Term memory, Digit Symbol Substitution and Mini-Mental State Examination); subjective measures of sleep (Leeds Sleep Evaluation Questionnaire) and daytime sleepiness (Epworth Sleepiness Scale). All adverse events during the study period were recorded and their relationships to the drugs were assessed. Results Neuropsychiatric sequelae seemed to take a natural recovery course in patients with traumatic brain injury. Methylphenidate had significant effects on depressive symptoms compared with the placebo, without hindering the natural recovery process of cognitive function. Although sertraline also had significant effects on depressive symptoms compared with the placebo, it did not improve many tests on cognitive performances. Daytime sleepiness was reduced by methylphenidate, while it was not by sertraline. Conclusions Methylphenidate and sertraline had similar effects on depressive symptoms. However, methylphenidate seemed to be more beneficial in improving cognitive function and maintaining daytime alertness. Methylphenidate also offered a better tolerability than sertraline. Copyright (C) 2005 John Wiley Sons, Ltd.	Chonnam Natl Univ, Sch Med, Dept Psychiat, Kwangju 501746, South Korea; Chonnam Natl Univ, Sch Med, Inst Med Sci, Kwangju 501746, South Korea		Yoon, JS (corresponding author), Chonnam Natl Univ, Sch Med, Dept Psychiat, 5 Hak Dong, Kwangju 501746, South Korea.	jsyoon@chonnam.ac.kr	KIM, Jae-Min/S-7637-2019				American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; GAULTIERI CT, 1988, BRAIN INJURY, V2, P273; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HINDMARCH I, 1982, PHARMACOPSYCHIATRIA, V15, P44, DOI 10.1055/s-2007-1019549; HINDMARCH I, 1980, BRIT J CLIN PHARMACO, V10, P189, DOI 10.1111/j.1365-2125.1980.tb01745.x; HINDMARCH I, 1977, BRIT J CLIN PHARMACO, V4, pS167, DOI 10.1111/j.1365-2125.1977.tb05747.x; HINDMARCH I, 1983, ACTA PSYCHIAT SCAND, V68, P141, DOI 10.1111/j.1600-0447.1983.tb11115.x; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; LAZARUS LW, 1994, ARCH PHYS MED REHAB, V75, P403, DOI 10.1016/0003-9993(94)90163-5; Lee, 1992, MANUAL KOREAN WECHSL; Lee, 1998, J KOREAN NEUROPSYCHI, V37, P280; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; McAllister Thomas W., 1994, P357; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; PARROTT AC, 1980, PSYCHOPHARMACOLOGY, V71, P173, DOI 10.1007/BF00434408; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SMITH CS, 1989, J APPL PSYCHOL, V74, P728, DOI 10.1037/0021-9010.74.5.728; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stoker M J, 1992, Qual Life Res, V1, P385, DOI 10.1007/BF00704433; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; Wechsler, 1997, WECHSLER ADULT INTEL; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; WOODWORTH RS, 1958, EXPT PSYCHOL; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; Yoon JS, 1997, J KOREAN NEUROPSYCHI, V36, P122	48	139	141	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-6222	1099-1077		HUM PSYCHOPHARM CLIN	Hum. Psychopharmacol.-Clin. Exp.	MAR	2005	20	2					97	104		10.1002/hup.668			8	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology	904MC	WOS:000227501300002	15641125				2022-02-06	
J	Siman, R; McIntosh, TK; Soltesz, KM; Chen, ZM; Neumar, RW; Roberts, VL				Siman, R; McIntosh, TK; Soltesz, KM; Chen, ZM; Neumar, RW; Roberts, VL			Proteins released from degenerating neurons are surrogate markers for acute brain damage	NEUROBIOLOGY OF DISEASE			English	Article						neurodegeneration; calpain; caspase; necrosis; apoptosis; cytoskeleton; cerebral ischemia; traumatic brain injury; 14-3-3 proteins; surrogate marker	ALPHA-II-SPECTRIN; ADULT-RAT BRAIN; CEREBROSPINAL-FLUID; BREAKDOWN PRODUCTS; ALZHEIMERS-DISEASE; FOREBRAIN ISCHEMIA; S-100 PROTEIN; INJURY; SERUM; CALPAIN	The experimental and clinical study of degenerative brain disorders would benefit from new surrogate markers for brain damage. To identify novel candidate markers for acute brain injury, we report that rat cortical neurons release over 60 cytoskeletal and other proteins, as well as their proteolytic fragments into the medium during neuronal death. The profiles of released proteins differ for necrosis and apoptosis, although a subset of proteins is released generally during neurodegeneration. The value of this approach was established by immunodetection of the released proteins 14-3-3zeta and 14-3-3beta, as well as calpain and caspase derivatives of tau and alpha-spectrin in cerebrospinal fluid (CSF) following traumatic brain injury (TBI) or transient forebrain ischemia in the rat. These results indicate that proteins and their proteolytic fragments released from degenerating neurons are cerebrospinal fluid markers for acute brain damage and suggest that efflux of proteins from the injured brain may reflect underlying mechanisms for neurodegeneration. (C) 2004 Elsevier Inc. All rights reserved.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA		Siman, R (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	siman@pharm.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS-08803] Funding Source: Medline		AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Andersson J, 2000, IMECHE CONF TRANS, V2001, P49; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Beems T, 2003, ACTA NEUROCHIR, V145, P37, DOI 10.1007/s00701-002-1019-1; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cb.09.110193.000331; Berg D, 2003, NAT REV NEUROSCI, V4, P752, DOI 10.1038/nrn1197; Blennow K, 1998, J NEURAL TRANSM-SUPP, P223; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Canu N, 1998, J NEUROSCI, V18, P7061; Chen J, 1998, J NEUROSCI, V18, P4914; Collins RJ, 2000, CNS DRUGS, V14, P203, DOI 10.2165/00023210-200014030-00003; Dahmen N, 2002, PROG NEURO-PSYCHOPH, V26, P693, DOI 10.1016/S0278-5846(01)00319-0; DEGRAAN PNE, 1986, PROG BRAIN RES, V69, P37; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GIONET TX, 1992, BRAIN RES, V586, P188, DOI 10.1016/0006-8993(92)91626-P; Green AJE, 1997, NEUROSCI LETT, V235, P5, DOI 10.1016/S0304-3940(97)00701-5; Green AJE, 2002, NEUROPATH APPL NEURO, V28, P427, DOI 10.1046/j.1365-2990.2002.t01-2-00427.x; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hsia Amie W, 2003, Curr Atheroscler Rep, V5, P252, DOI 10.1007/s11883-003-0047-5; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKeating EG, 1998, ACT NEUR S, V71, P117; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nacher J, 2000, J COMP NEUROL, V424, P628, DOI 10.1002/1096-9861(20000904)424:4<628::AID-CNE5>3.0.CO;2-4; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Otto M, 1998, BRIT MED J, V316, P577, DOI 10.1136/bmj.316.7131.577; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Qureshi AI, 2002, CRIT CARE MED, V30, P2778, DOI 10.1097/00003246-200212000-00029; ROBERTS AR, 1994, CRISIS INTERV TIME-L, V1, P1; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; SIMAN R, 1998, CEREBROVASC DIS, P721; SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	50	139	144	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUL	2004	16	2					311	320		10.1016/j.nbd.2004.03.016			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	830AG	WOS:000222093400003	15193288				2022-02-06	
J	Rahnama, N; Reilly, T; Lees, A				Rahnama, N; Reilly, T; Lees, A			Injury risk associated with playing actions during competitive soccer	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL FOOTBALL; INCIDENTS; SEVERITY; PLAYERS	Objective: To assess the exposure of players to injury risk during English Premier League soccer matches in relation to selected factors. Methods: Injury risk was assessed by rating the injury potential of playing actions during competition with respect to (a) type of playing action, (b) period of the game, (c) zone of the pitch, and (d) playing either at home or away. In all, 10 games from the English Premier League 1999-2000 were chosen for analysis. A notation system was used whereby 16 soccer specific playing actions were classified into three categories: those inducing actual injury, those with a potential for injury (graded as mild, moderate, or high), and those deemed to have no potential for injury. The pitch was divided into 18 zones, and the position of each event was recorded along with time elapsed in the game, enabling six 15 minute periods to be defined. Results: Close to 18 000 actions were notated. On average (mean (SD)), 1788 (73) events (one every three seconds), 767 (99) events with injury potential (one every six seconds), and 2 (1) injuries (one every 45 minutes) per game were recorded. An overall injury incidence of 53 per 1000 playing hours was calculated. Receiving a tackle, receiving a "charge", and making a tackle were categorised as having a substantial injury risk, and goal catch, goal punch, kicking the ball, shot on goal, set kick, and heading the ball were all categorised as having a significant injury risk. All other actions were deemed low in risk. The first 15 minutes of each half contained the highest number of actions with mild injury potential, the last 15 minutes having the highest number of actions with moderate injury potential (p<0.01). The first and last 15 minutes of the game had the highest number of actions with high injury potential, although not significant. More actions with mild injury potential occurred in the goal area, and more actions with moderate and high injury potential occurred in the zone adjacent to the goal area (p<0.001). There was no significant difference between home and away with regard to injury potential. Conclusions: Playing actions with high injury risk were linked to contesting possession. Injury risk was highest in the first and last 15 minutes of the game, reflecting the intense engagements in the opening period and the possible effect of fatigue in the closing period. Injury risk was concentrated in the areas of the pitch where possession of the ball is most vigorously contested, which were specific attacking and defending zones close to the goal. Injury potential was no greater in away matches than at. home.	Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool L3 2ET, Merseyside, England		Reilly, T (corresponding author), Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Henry Cotton Campus,Webster St, Liverpool L3 2ET, Merseyside, England.		Rahnama, Nader/A-3945-2009; Winwood, Peter/A-6363-2008				Anglietti P, 1994, CLIN PRACTICE SPORTS, P277; Arnason A, 1996, SCAND J MED SCI SPOR, V6, P40, DOI 10.1111/j.1600-0838.1996.tb00069.x; Ball DJ., 2000, ABC SPORTS MED, P88; EKSTRAND J, 1983, MED SCI SPORT EXER, V15, P267, DOI 10.1249/00005768-198315030-00014; EKSTRAND J, 1982, THESIS LINKOPING U; ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408; FRIED T, 1992, SPORTS MED, V14, P269, DOI 10.2165/00007256-199214040-00005; Hawkins RD, 1998, BRIT J SPORT MED, V32, P326, DOI 10.1136/bjsm.32.4.326; Hawkins RD, 1996, BRIT J SPORT MED, V30, P165, DOI 10.1136/bjsm.30.2.165; Hawkins RD, 1999, BRIT J SPORT MED, V33, P196, DOI 10.1136/bjsm.33.3.196; Hawkins RD, 2001, BRIT J SPORT MED, V35, P43, DOI 10.1136/bjsm.35.1.43; HOFF GL, 1986, AM J SPORT MED, V14, P231, DOI 10.1177/036354658601400309; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Junge A, 2000, AM J SPORT MED, V28, pS40; Lewin G., 1989, PHYSIOTHERAPY, V75, P601, DOI [10.1016/S0031-9406(10)62366-8, DOI 10.1016/S0031-9406(10)62366-8]; MCGREGOR JC, 1995, SCOT MED J, V40, P16, DOI 10.1177/003693309504000107; McMaster W C, 1978, Am J Sports Med, V6, P354, DOI 10.1177/036354657800600607; NIELSEN AB, 1989, AM J SPORT MED, V17, P803, DOI 10.1177/036354658901700614; Pollard R, 1986, J SPORT SCI, V4, P237, DOI 10.1080/02640418608732122; Reilly T, 1997, J SPORT SCI, V15, P257, DOI 10.1080/026404197367263; REILLY T, 1996, SCI SOCCER, P161; REILLY T, 1993, SCI FOOTBALL, V2, P3; SALTIN B, 1973, MED SCI SPORT EXER, V5, P137; Sandelin J, 1985, Br J Sports Med, V19, P30; SILVA JM, 1987, INT J SPORT PSYCHOL, V18, P188; Tucker AM, 1997, SPORTS MED, V23, P21, DOI 10.2165/00007256-199723010-00003	26	139	143	2	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT	2002	36	5					354	359		10.1136/bjsm.36.5.354			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	602RN	WOS:000178518400011	12351333	Bronze, Green Published			2022-02-06	
J	Mori, T; Wang, XY; Jung, TC; Sumii, T; Singhal, AB; Fini, ME; Dixon, CE; Alessandrini, A; Lo, EH				Mori, T; Wang, XY; Jung, TC; Sumii, T; Singhal, AB; Fini, ME; Dixon, CE; Alessandrini, A; Lo, EH			Mitogen-activated protein kinase inhibition in traumatic brain injury: In vitro and in vivo effects	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cell death; cell signaling; neuroprotection	SPINAL-CORD INJURY; CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; TRANSIENT FOREBRAIN ISCHEMIA; SEVERE HEAD-INJURY; CELL-DEATH; SIGNAL-TRANSDUCTION; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; MAP KINASES	The authors provide the first in vitro and in vivo evidence that perturbations in mitogen-activated protein kinase (MAPK) signal-transduction pathways are involved in the pathophysiology of traumatic brain injury. In primary rat cortical cultures, mechanical trauma induced a rapid and selective phosphorylation of the extracellular signal-regulated kinase (ERK) and p38 kinase, whereas there was no detectable change in the c-jun N-terminal kinase (JNK) pathway. Treatment with PD98059, which inhibits MAPK/ERK 1/2, the upstream activator of ERK, significantly increased cell survival in vitro. The p38 kinase and JNK inhibitor SB203580 had no protective effect. Similar results were obtained in vivo using a controlled cortical impact model of traumatic injury in mouse brain. Rapid and selective upregulation occurred in ERK and p38 pathways with no detectable changes in JNK. Confocal immunohistochemistry showed that phospho-ERK colocalized with the neuronal nuclei marker but not the astrocytic marker glial fibrillary acidic protein. Inhibition of the ERK pathway with PD98059 resulted in a significant reduction of cortical lesion volumes 7 days after trauma. The p39 kinase and JNK inhibitor SB203580 had no detectable beneficial effect. These data indicate that critical perturbations in MAPK pathways mediate cerebral damage after acute injury, and further suggest that ERK is a novel therapeutic target in traumatic brain injury.	Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA USA; Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, Charlestown, MA USA; Harvard Univ, Med Sch, Program Neurosci, Boston, MA USA; Tufts Univ, Sch Med, New England Eye Ctr, Vis Res Labs, Boston, MA USA; Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA USA; Massachusetts Gen Hosp, Dept Med, Boston, MA USA		Lo, EH (corresponding author), Harvard Univ, Sch Med, Neuroprotect Res Lab, MGH East 149-2401, Charlestown, MA 02129 USA.				NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01-EY09828] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS37074, R01-NS40529, R01-NS38731, R01-NS33150] Funding Source: Medline; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY009828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, R01NS040529, R01NS038731, R01NS037074] Funding Source: NIH RePORTER		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Clark RSB, 1997, J NEUROSCI, V17, P9172; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; CUZNER ML, 2002, NEUROPROTECTION, P265; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7; Katano H, 1999, NEUROREPORT, V10, P2439, DOI 10.1097/00001756-199908200-00002; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kraus J, 1996, NEUROTRAUMA, P13; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu XZ, 1997, J NEUROSCI, V17, P5395; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1996, NEUROTRAUMA, P1445; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Wang X, 2001, J CEREB BLOOD FLOW M, V21, pS264; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wang XY, 1999, NEUROSCI LETT, V274, P79, DOI 10.1016/S0304-3940(99)00682-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	59	139	153	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2002	22	4					444	452		10.1097/00004647-200204000-00008			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	538EY	WOS:000174802900008	11919515	Bronze			2022-02-06	
J	Marmarou, A; Fatouros, PP; Barzo, P; Portella, G; Yoshihara, M; Tsuji, O; Yamamoto, T; Laine, F; Signoretti, S; Ward, JD; Bullock, MR; Young, HF				Marmarou, A; Fatouros, PP; Barzo, P; Portella, G; Yoshihara, M; Tsuji, O; Yamamoto, T; Laine, F; Signoretti, S; Ward, JD; Bullock, MR; Young, HF			Contribution of edema and cerebral blood volume to traumatic brain swelling in head-injured patients	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain edema; vascular engorgement; brain swelling; water map	COMPUTED-TOMOGRAPHY; FLOW MEASUREMENTS; WATER-CONTENT; PRESSURE; XENON; MANAGEMENT; RESOLUTION; COMA; RATS	Object. The pathogenesis of traumatic brain swelling remains unclear. The generally held view is that brain swelling is caused primarily by vascular engorgement and that edema plays a relatively minor role in the swelling process. The goal of this: study was to examine the roles of cerebral blood volume (CBV) and edema in traumatic brain swelling. Methods. Both brain-tissue water and CBV were measured in 76 head-injured patients, and the relative contribution of edema and blood to total brain swelling was determined. Comparable measures of brain-tissue water were obtained in 30 healthy volunteers and CBV in seven volunteers. Brain edema was measured using magnetic resonance imaging, implementing a new technique fur accurate measurement of total tissue water. Measurements of CBV in a subgroup of 31 head-injured patients were based on consecutive measures of cerebral blood flow (CBF) obtained using stable xenon and calculation of mean transit time by dynamic computerized tomography scanning after a rapid bolus injection of iodinated contrast material. The mean (+/- standard deviation) percentage of swelling due to water was 9.37 +/- 8.7%, whereas that due to blood was -0.8 +/- 1.32%. Conclusions. The results of this study showed that brain edema is the major fluid component contributing to traumatic brain swelling. Moreover, CBV is reduced in proportion to CBF reduction following severe brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiol, Richmond, VA 23298 USA		Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980508, Richmond, VA 23298 USA.	Marmarou@abic.vcu.edu	Signoretti, stefano/AAL-5631-2020	Signoretti, stefano/0000-0002-8086-1622	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, R56NS019235, P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587, NS-19235] Funding Source: Medline		Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Barzo P, 1997, ACT NEUR S, V70, P243; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bouma G J, 1995, New Horiz, V3, P384; Bouma GJ, 1998, ACT NEUR S, V71, P272; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; DEWITT DS, 1989, STROKE, V20, P1716, DOI 10.1161/01.STR.20.12.1716; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; FATOUROS PP, 1991, MAGNET RESON MED, V17, P402, DOI 10.1002/mrm.1910170212; FATOUROS PP, 1987, INVEST RADIOL, V22, P705, DOI 10.1097/00004424-198709000-00003; ISHII S, 1959, J NEUROSURG, V16, P152, DOI 10.3171/jns.1959.16.2.0152; Ishii S, 1968, Trans Am Neurol Assoc, V93, P43; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; ITO U, 1988, ACTA NEUROCHIR, V90, P35, DOI 10.1007/BF01541264; KITA H, 1994, ACTA NEUROCHIR, P452; Klatzo I, 1980, Adv Neurol, V28, P359; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1983, ACTA NEUROPATHOL, P81; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; Langfitt T W, 1966, W V Med J, V62, P49; LANGFITT THOMAS W., 1964, TRANS AMER NEUROL ASS, V89, P214; LANGFITT TW, 1968, JOHNS HOPKINS MED J, V122, P261; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1968, SAND J CLIN LAB IN S, V102, pR14; Marmarou A, 1990, Adv Neurol, V52, P233; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Marshall W J, 1968, Surg Forum, V19, P431; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Muizelaar JP, 1997, STROKE, V28, P1998, DOI 10.1161/01.STR.28.10.1998; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Reulen H J, 1980, Adv Neurol, V28, P375; REULEN HJ, 1978, J NEUROSURG, V48, P754, DOI 10.3171/jns.1978.48.5.0754; ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; TEASDALE G, 1974, LANCET, V2, P81; YOSHIHARA M, 1995, J NEUROSURG, V82, P386, DOI 10.3171/jns.1995.82.3.0386; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	48	139	144	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2000	93	2					183	193		10.3171/jns.2000.93.2.0183			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	338HY	WOS:000088414500003	10930002				2022-02-06	
J	van Reekum, R; Cohen, T; Wong, J				van Reekum, R; Cohen, T; Wong, J			Can traumatic brain injury cause psychiatric disorders?	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							POSTTRAUMATIC-STRESS-DISORDER; CLOSED-HEAD-INJURY; BEHAVIORAL SEQUELAE; SOCIAL-ADJUSTMENT; FOLLOW-UP; DEPRESSION; MILD; ACETYLCHOLINE; SCHIZOPHRENIA; PREVALENCE	Traumatic brain injury (TBI) may cause psychiatric illness. This article reviews the evidence on the basis of an established set of causation criteria. The evidence is convincing for a strong association between TBI and moon and anxiety disorders. Substance abuse and schizophrenia are not strongly associated with TBI and there is little search into the rates of personality disorders after TBI. Evidence for a biologic gradient is lacking, but such a gradient may not be relevant to TBI. Evidence for the correct temporal sequence is present. Preliminary evidence suggests a biologic rationale for TBI causing psychiatric illness. Further and methodologically improved research is supported and required.	Baycrest Ctr Geriatr Care, Dept Psychiat, N York, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, N York, ON M6A 2E1, Canada; Univ Toronto, Div Geriatr Psychiat, Toronto, ON, Canada		van Reekum, R (corresponding author), Baycrest Ctr Geriatr Care, Dept Psychiat, 3560 Bathurst St, N York, ON M6A 2E1, Canada.						ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ALAVI A, 1989, J NEUROPSYCHIAT, V1, P545; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1975, PSYCHIAT ASPECTS NEU, P219; American Psychiatric Association, 1980, DIAGN STAT MAN MENT; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BLACKBURN BK, 1989, STEREOCHEMISTRY ORGA, V3, P143; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BUCKLEY P, 1993, AM J PSYCHIAT, V150, P146; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Epstein Richard S., 1994, P285; Fann JR, 1997, J PSYCHOSOM RES, V43, P335, DOI 10.1016/S0022-3999(97)00130-X; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HILL AB, 1965, P ROY SOC MED, V58, P293; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kant R, 1996, BRAIN INJURY, V10, P55; Karakucuk EI, 1997, NEUROPEPTIDES, V31, P259, DOI 10.1016/S0143-4179(97)90057-3; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Lannoo E, 1997, J PSYCHOSOM RES, V43, P505, DOI 10.1016/S0022-3999(97)00152-9; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Persinger MA, 1997, PERCEPT MOTOR SKILL, V84, P1284, DOI 10.2466/pms.1997.84.3c.1284; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Robinson Robert G., 1994, P219; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SHERMAN AG, 1994, NEUROPSYCHOL REV, V4, P45, DOI 10.1007/BF01875021; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; SILVER JM, 1992, AM PSYCHIAT PRESS TX, P363; Silver Jonathan M., 1994, P631; Smeltzer Donald J., 1994, P251; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; STUSS DT, IN PRESS NEUROPSYCHO; Tanaka K, 1997, REGUL PEPTIDES, V70, P173, DOI 10.1016/S0167-0115(97)01013-6; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; VANREEKUM R, 1993, CAN J PSYCHIAT, V38, pS4; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	75	139	144	0	15	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2000	12	3					316	327		10.1176/appi.neuropsych.12.3.316			12	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	343BX	WOS:000088682800004	10956565				2022-02-06	
J	Sullivan, PG; Keller, JN; Mattson, MP; Scheff, SW				Sullivan, PG; Keller, JN; Mattson, MP; Scheff, SW			Traumatic brain injury alters synaptic homeostasis: Implications for impaired mitochondrial and transport function	JOURNAL OF NEUROTRAUMA			English	Article						ATP; glutamate and glucose transport; lipid peroxidation; synaptosomes; traumatic brain injury	EXCITATORY AMINO-ACIDS; NERVOUS-SYSTEM TRAUMA; AMYLOID BETA-PEPTIDE; LIPID-PEROXIDATION PRODUCT; GLUTAMATE TRANSPORT; CORTICAL CONTUSION; ION HOMEOSTASIS; AEROBIC GLYCOLYSIS; ALDEHYDIC PRODUCT; MEMBRANE-PROTEINS	This study utilized a unilateral controlled cortical impact model of traumatic brain injury to assess disruptions of synaptic homeostasis following trauma. Adult rats were subjected to a moderate (2 mm) cortical deformation and synaptosomes were prepared from the entire ipsilateral (injured) hemisphere or dissected into different regions (hippocampus, injured cortical area including penumbra, residual hemisphere) at various times postinjury (10 and 30 min, and 1, 6, and 24 h), Synaptosomes from the corresponding regions of the contralateral hemisphere were used as controls to assess alterations in synaptic ATP levels, lipid peroxidation, and glutamate and glucose transport. The results demonstrate significant time-dependent alterations in synaptic homeostasis, which included an immediate reduction in ATP levels, coupled with a significant increase in lipid peroxidation within 30 min postinjury, Lipid peroxidation demonstrated a biphasic response with elevations observed 24 h postinjury, a time at which decreases in glutamate and glucose transport occurred. These results suggest that disruption of synaptic homeostasis is an extremely early event following trauma that should be considered when designing pharmacological interventions.	Univ Kentucky, Ctr Aging, Lexington, KY 40536 USA		Scheff, SW (corresponding author), Univ Kentucky, Ctr Aging, 311 Sanders Brown, Lexington, KY 40536 USA.		Mattson, Mark P/F-6038-2012; Keller, Jeffrey N/N-1975-2017	keller, jeffrey/0000-0002-9892-7423	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER		ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRAUGHLER JM, 1985, J NEUROCHEM, V45, P1288, DOI 10.1111/j.1471-4159.1985.tb05555.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; Choi D W, 1990, Adv Exp Med Biol, V268, P501; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; DZHAFAROV A I, 1985, Byulleten' Eksperimental'noi Biologii i Meditsiny, V100, P433; Erecinska M, 1996, BBA-BIOENERGETICS, V1277, P13, DOI 10.1016/S0005-2728(96)00103-X; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1992, J NEUROTRAUM, V9, pS165; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Keller JN, 1997, J NEUROCHEM, V69, P273; Keller JN, 1996, J NEUROCHEM, V67, P2300; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; KONAT GW, 1985, J NEUROCHEM, V45, P1113, DOI 10.1111/j.1471-4159.1985.tb05530.x; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; Magistretti PJ, 1997, ADV EXP MED BIOL, V413, P161; Mark RJ, 1997, J NEUROCHEM, V68, P255; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MATTSON MP, 1995, NEUROBIOL AGING, V16, P679, DOI 10.1016/0197-4580(95)00063-K; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Mattson MP, 1997, CHEM RES TOXICOL, V10, P507, DOI 10.1021/tx9601317; OPPONG KNW, 1995, HEPATOLOGY, V22, P553, DOI 10.1016/0270-9139(95)90579-0; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; POGUN S, 1994, SYNAPSE, V18, P21, DOI 10.1002/syn.890180104; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Santos MS, 1996, STROKE, V27, P941, DOI 10.1161/01.STR.27.5.941; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Subramaniam R, 1997, J NEUROCHEM, V69, P1161; TAPPEL AL, 1973, FED PROC, V32, P1870; TATOR CH, 1994, NEUROBIOLOGY CENTRAL, P209; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; WHITTAKER VP, 1964, BIOCHEM J, V90, P293, DOI 10.1042/bj0900293; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	62	139	143	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1998	15	10					789	798		10.1089/neu.1998.15.789			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	132LW	WOS:000076632400004	9814635				2022-02-06	
J	Mathiesen, T; Edner, G; Ulfarsson, E; Andersson, B				Mathiesen, T; Edner, G; Ulfarsson, E; Andersson, B			Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; ischemia; inflammation; interleukin-1; tumor necrosis factor-alpha	EXPERIMENTAL CEREBRAL VASOSPASM; MESSENGER-RNA; RAT-BRAIN; NERVOUS-SYSTEM; NITRIC-OXIDE; INJURY; EXPRESSION; CYTOKINES; CELLS; LIPOPOLYSACCHARIDE	Subarachnoid hemorrhage (SAH) causes an inflammatory reaction and may lead to ischemic brain damage. Experimental ischemia has been shown to be connected with the alarm-reaction cytokines interleukin-1 receptor antagonist (IL-1Ra) and tumor necrosis factor-alpha (TNF alpha). Increased levels of these cytokines, however, have not been detected thus far in patients following an SAH event. For this reason daily cerebrospinal fluid (CSF) samples were collected from 22 consecutively enrolled patients with SAH and from 10 non-SAH patients (controls). The CSF samples were studied using immunoassays for IL-1Ra and TNF alpha to investigate whether an SAH caused increased cytokine levels. The mean IL-1R alpha levels were significantly higher in patients with SAH who were in poor clinical condition on admission than in those who were in good condition (318 pg/ml vs. 82 pg/ml, p < 0.02). The IL-1Ra levels increased during delayed ischemic episodes and after surgery in patients who were in poor clinical condition. Significant increases in IL-1Ra and TNF alpha were detected during Days 4 through 10 in patients suffering from SAH who eventually had a poor outcome (p < 0.05). Patients with good outcomes and control patients had low levels of these cytokines. The levels of IL-1Ra increased after surgery in patients with Hunt and Hess Grades III through V, but not in those with Grade I or II. This finding indicates that patients in poor clinical condition have a labile biochemical state in the brain that is reflected in increased cytokine levels following the surgical trauma. Both IL-1Ra and TNF alpha are known to induce fever, malaise, leukocytosis, and nitric oxide synthesis and to mediate ischemic and traumatic brain injuries. The present study shows that levels of these cytokines increase after SAH occurs and that high cytokine levels correlate with brain damage. It is therefore likely that fever, leukocytosis, and nitric oxide synthesis are also mediated by IL-l in patients suffering from SAH and it is probable that the inflammatory mediators contribute to brain damage.	CALAB MED LABS, STOCKHOLM, SWEDEN		Mathiesen, T (corresponding author), KAROLINSKA HOSP, DEPT NEUROSURG, S-17176 STOCKHOLM, SWEDEN.		mathiesen, tiit/ABC-3627-2021	Mathiesen, Tiit/0000-0001-9463-1919			BEAMER NB, 1995, ANN NEUROL, V37, P800, DOI 10.1002/ana.410370614; BORGERDING RA, 1995, J NEUROCHEM, V65, P1342, DOI 10.1046/j.1471-4159.1995.65031342.x; BOURDIOL F, 1991, BRAIN RES, V543, P194, DOI 10.1016/0006-8993(91)90028-T; BUTTINI M, 1995, NEUROSCIENCE, V65, P523, DOI 10.1016/0306-4522(94)00525-A; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; DINARELLO CA, 1985, J CLIN IMMUNOL, V5, P287, DOI 10.1007/BF00918247; DINARELLO CA, 1993, IMMUNOL TODAY, V14, P260, DOI 10.1016/0167-5699(93)90042-J; ECKER A, 1951, J NEUROSURG, V8, P660, DOI 10.3171/jns.1951.8.6.0660; ENGERVALL P, 1995, BRIT J HAEMATOL, V91, P838, DOI 10.1111/j.1365-2141.1995.tb05398.x; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FINDLAY JM, 1991, CEREBROVAS BRAIN MET, V3, P336; FISHER M, 1993, J NEUROL SCI, V119, P189, DOI 10.1016/0022-510X(93)90133-J; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hopkins Stephen J., 1995, Trends in Neurosciences, V18, P83, DOI 10.1016/0166-2236(95)93881-W; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JACOBSSON M, 1987, J CEREB BLOOD FLO S1, V7, pS660; Jennett B, 1981, MANAGEMENT HEAD INJU; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Maiuri F, 1987, J Neurosurg Sci, V31, P45; MARZATICO F, 1990, SURG NEUROL, V34, P294, DOI 10.1016/0090-3019(90)90004-9; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MATHIESEN T, 1990, J NEUROSURG, V73, P69, DOI 10.3171/jns.1990.73.1.0069; Mathiesen T, 1996, BRIT J NEUROSURG, V10, P89, DOI 10.1080/02688699650040584; MORIMOTO A, 1988, BRAIN RES, V475, P345, DOI 10.1016/0006-8993(88)90623-3; NEILDWYER G, 1974, BRAIN, V97, P79, DOI 10.1093/brain/97.1.79; PELLETTIERI L, 1986, NEUROSURGERY, V19, P767, DOI 10.1227/00006123-198611000-00008; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PETERSON JW, 1990, J NEUROSURG, V72, P767, DOI 10.3171/jns.1990.72.5.0767; PETERSON JW, 1989, J NEUROSURG, V71, P718, DOI 10.3171/jns.1989.71.5.0718; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SUZUKI S, 1994, J NEUROSURG, V81, P895, DOI 10.3171/jns.1994.81.6.0895; SVENDGAARD NA, 1987, J CEREBR BLOOD F MET, V7, P21, DOI 10.1038/jcbfm.1987.4; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; Walton J., 1956, SUBARACHNOID HEMORRH; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002; WILKINS RH, 1990, CRIT REV NEUROBIOL, V6, P51; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YABUUCHI K, 1994, MOL BRAIN RES, V26, P135, DOI 10.1016/0169-328X(94)90084-1	48	139	143	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	1997	87	2					215	220		10.3171/jns.1997.87.2.0215			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XN706	WOS:A1997XN70600009	9254084				2022-02-06	
J	VanReekum, R; Bolago, I; Finlayson, MAJ; Garner, S; Links, PS				VanReekum, R; Bolago, I; Finlayson, MAJ; Garner, S; Links, PS			Psychiatric disorders after traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; SOCIAL-ADJUSTMENT; RELATIVES; SEQUELAE	Substantial psychological and neurobehavioural evidence is available to support the hypothesis that traumatic brain injury (TBI) is a risk factor for subsequent psychiatric disorders. However, studies utilizing established psychiatric diagnostic schemes to study these outcomes after TBI are scarce, and no studies have included an assessment of personality disorders in addition to the major psychiatric disorders. This study utilizes structured psychiatric interviews to measure the prevalence of DSM-III(R) disorders in a sample of 18 subjects derived from a TBI rehabilitation programme. Results revealed high rates for major depression, bipolar affective disorder, generalized anxety disorder, borderline and avoidant personality disorders. Co-morbidity was also high. A preliminary study of postulated predictive factors revealed possible roles for sex and for initial severity of injury. The study supports the association between TBI and psychiatric disorder, and suggests the need for monitoring, for prevention, and for treatment of psychiatric disorders after TBI.	UNIV TORONTO,DEPT PSYCHIAT,DIV GERIATR PSYCHIAT,TORONTO,ON,CANADA; HAMILTON PSYCHIAT HOSP,HAMILTON,ON,CANADA; CHEDOKE MCMASTER HOSP,HAMILTON,ON,CANADA; MCMASTER UNIV,HAMILTON,ON L8S 4L8,CANADA								ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 1980, DIAGN STAT MAN MENT; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gualtari CT, 1991, BRAIN INJURY, V5, P219; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MERSKY H, 1961, BRAIN, V95, P521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; PRIGATANO GP, 1988, J HEAD TRAUMA REHAB, V3, P23; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; SILVER JM, 1992, AM PSYCHIAT PRESS TX, P363; STANGL D, 1985, ARCH GEN PSYCHIAT, V42, P491; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	29	139	140	2	11	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1996	10	5					319	327		10.1080/026990596124340			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UL742	WOS:A1996UL74200001	8735663				2022-02-06	
J	ICHISE, M; CHUNG, DG; WANG, P; WORTZMAN, G; GRAY, BG; FRANKS, W				ICHISE, M; CHUNG, DG; WANG, P; WORTZMAN, G; GRAY, BG; FRANKS, W			TECHNETIUM-99M-HMPAO SPECT, CT AND MRI IN THE EVALUATION OF PATIENTS WITH CHRONIC TRAUMATIC BRAIN INJURY - A CORRELATION WITH NEUROPSYCHOLOGICAL PERFORMANCE	JOURNAL OF NUCLEAR MEDICINE			English	Article						CHRONIC TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL DYSFUNCTION; TECHNETIUM-99M-HMPAO; COMPUTED TOMOGRAPHY; MAGNETIC RESONANCE IMAGING; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY	CLOSED-HEAD-INJURY; CEREBRAL BLOOD-FLOW; COMPUTERIZED-TOMOGRAPHY; PERFUSION; LESIONS; EXPERIENCE; RECOVERY; DISEASE; MILD	The purposes of this study were: (1) to compare Tc-99m-hexamethylpropyleneamineoxime (HMPAO) SPECT with CT and MRI in chronic traumatic brain injury (TBI) patients and (2) to correlate both functional and structural neuroimaging measurements of brain damage with neuropsychological (NP) performance. Methods: Twenty-nine patients (minor TBI, n = 15 and major TB[, n = 14) and 17 normal controls (NC) underwent HMPAO SPECT, CT, MRI and NP testing. Imaging data were analyzed both visually and quantitatively. Results: Nineteen (66%) patients showed 42 abnormalities on SPECT images, whereas 13 (45%) and 10 (34%) patients showed 29 abnormalities on MRI and 24 abnormalities on CT, SPECT detected relatively more abnormalities than CT or MRI in the minor TBI subgroup. The TBI group showed impairment on 11 tests for memory, attention and executive function. Of these, the anterior-posterior ratio (APR) correlated with six tests, whereas the ventricle-to-brain ratio (VBR), a known structural index of a poor NP outcome, correlated with only two tests. Conclusion: In evaluating chronic TBI patients, HMPAO SPECT, as a complement to CT or MRI, may play a useful role by demonstrating brain dysfunction in morphologically intact brain regions and providing objective evidence for some of the impaired NP performance.	UNIV TORONTO,TORONTO M5S 1A1,ON,CANADA; W PK HOSP,DEPT REHABIL MED,TORONTO,ON,CANADA; MT SINAI HOSP,DEPT PSYCHOL,TORONTO,ON,CANADA		ICHISE, M (corresponding author), MT SINAI HOSP,DEPT RADIOL,ROOM 635,600 UNIV AVE,TORONTO M5G 1X5,ON,CANADA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ARMITAGE P, 1987, STATISTICAL METHODS, P200; BARRON SA, 1976, NEUROLOGY, V26, P1011, DOI 10.1212/WNL.26.11.1011; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; FORD I, 1991, J CEREBR BLOOD F MET, V11, pA89, DOI 10.1038/jcbfm.1991.43; GENERALLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GROSWASSER R, 1993, AJR, V160, P147; HEATON RK, 1981, MANUAL WISCONSIN CAR, P1; HERHOLZ K, 1990, ARCH NEUROL-CHICAGO, V47, P392, DOI 10.1001/archneur.1990.00530040034016; HOLMAN BL, 1992, J NUCL MED, V33, P1888; ICHISE M, 1992, NUCL MED COMMUN, V13, P861, DOI 10.1097/00006231-199212000-00002; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JENNETT B, 1979, CENTRAL NERVOUS SYST, P204; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KURTZKE JF, 1987, CLIN NEUROLOGY, V4, P1; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MAEDER P, 1991, ACTA RADIOL, V32, P271; MCCRORY SJ, 1991, STAT MED, V10, P1711, DOI 10.1002/sim.4780101109; MOSELEY IF, 1977, SURG NEUROL, V7, P171; MOUNTZ JM, 1991, NUCLEAR MED ANN 1991, P67; MYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; REITAN RM, 1985, HALSTEAD REITAN NEUR, P15; ROPER SN, 1991, J NUCL MED, V32, P1684; RUFF RM, 1990, NEUROPSYCHOLOGICAL F, P161; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; VANHEERTUM RL, 1991, SEMIN NUCL MED, V21, P24, DOI 10.1016/S0001-2998(05)80077-7; WECHSLER D, 1981, WECHSLER ADULT INTEL, P1; WECHSLER DA, 1955, WECHSLER ADULT INTEL, P1; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILSON J T L, 1990, Brain Injury, V4, P349; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; [No title captured]	48	139	142	0	5	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316	0161-5505			J NUCL MED	J. Nucl. Med.	FEB	1994	35	2					217	226					10	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	MX196	WOS:A1994MX19600010	8294988				2022-02-06	
J	Coughlin, JM; Wang, YC; Munro, CA; Ma, S; Yue, C; Chen, SJ; Airan, R; Kim, PK; Adams, AV; Garcia, C; Higgs, C; Sair, HI; Sawa, A; Smith, G; Lyketsos, CG; Caffo, B; Kassiou, M; Guilarte, TR; Pomper, MG				Coughlin, Jennifer M.; Wang, Yuchuan; Munro, Cynthia A.; Ma, Shuangchao; Yue, Chen; Chen, Shaojie; Airan, Raag; Kim, Pearl K.; Adams, Ashley V.; Garcia, Cinthya; Higgs, Cecilia; Sair, Haris I.; Sawa, Akira; Smith, Gwenn; Lyketsos, Constantine G.; Caffo, Brian; Kassiou, Michael; Guilarte, Tomas R.; Pomper, Martin G.			Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study	NEUROBIOLOGY OF DISEASE			English	Article						Mild traumatic brain injury; Translocator protein; Neuroinflammation; Microglia; Molecular neuroimaging	PROFESSIONAL FOOTBALL PLAYERS; PROTEIN 18 KDA; PERIPHERAL BENZODIAZEPINE-RECEPTOR; CHRONIC TRAUMATIC ENCEPHALOPATHY; RADIOLIGAND BINDING; LEAGUE PLAYERS; RECURRENT CONCUSSION; PET RADIOLIGAND; HEAD IMPACTS; INJURY	There are growing concerns about potential delayed, neuropsychiatric consequences (e.g, cognitive decline, mood or anxiety disorders) of sports-related traumatic brain injury (TBI). Autopsy studies of brains from a limited number of former athletes have described characteristic, pathologic changes of chronic traumatic encephalopathy (CTE) leading to questions about the relationship between these pathologic and the neuropsychiatric disturbances seen in former athletes. Research in this area will depend on in vivo methods that characterize molecular changes in the brain, linking CTE and other sports-related pathologies with delayed emergence of neuropsychiatric symptoms. In this pilot project we studied former National Football League (NFL) players using new neuroimaging techniques and clinical measures of cognitive functioning. We hypothesized that former NFL players would show molecular and structural changes in medial temporal and parietal lobe structures as well as specific cognitive deficits, namely those of verbal learning and memory. We observed a significant increase in binding of [C-11]DPA-713 to the translocator protein (TSPO), a marker of brain injury and repair, in several brain regions, such as the supramarginal gyrus and right amygdala, in 9 former NFL players compared to 9 age-matched, healthy controls. We also observed significant atrophy of the right hippocampus. Finally, we report that these same former players had varied performance on a test of verbal learning and memory, suggesting that these molecular and pathologic changes may play a role in cognitive decline. These results suggest that localized brain injury and repair, indicated by increased [C-11]DPA-713 binding to TSPO, may be linked to history of NFL play. [11C]DPA-713 PET is a promising new tool that can be used in future study design to examine further the relationship between TSPO expression in brain injury and repair, selective regional brain atrophy, and the potential link to deficits in verbal learning and memory after NFL play. (C) 2014 Elsevier Inc. All rights reserved.	[Coughlin, Jennifer M.; Munro, Cynthia A.; Kim, Pearl K.; Adams, Ashley V.; Garcia, Cinthya; Higgs, Cecilia; Sawa, Akira; Smith, Gwenn; Lyketsos, Constantine G.; Pomper, Martin G.] Johns Hopkins Med Inst, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Wang, Yuchuan; Airan, Raag; Sair, Haris I.; Pomper, Martin G.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Ma, Shuangchao] Johns Hopkins Med Inst, Dept Hlth Sci Informat, Baltimore, MD 21205 USA; [Yue, Chen; Chen, Shaojie; Caffo, Brian] Johns Hopkins Med Inst, Dept Biostat, Baltimore, MD 21205 USA; [Munro, Cynthia A.] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21205 USA; [Kassiou, Michael] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; [Kassiou, Michael] Univ Sydney, Discipline Med Radiat Sci, Sydney, NSW 2006, Australia; [Guilarte, Tomas R.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY USA		Pomper, MG (corresponding author), CRB 2,Room 492,1550 Orleans St, Baltimore, MD 21231 USA.	mpomper@jhmi.edu	Coughlin, Jennifer M/O-8179-2018	Coughlin, Jennifer M/0000-0002-2514-9640; Kassiou, Michael/0000-0002-6655-0529; Wang, Yuchuan/0000-0001-5111-6562	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R21MH082277, 5R01MH092443, R01EB012547, 5T32EB006351, P50AG005146]; NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES007062]; Lupus Foundation for America; NFL Charities; GE NFL Head Health challengeGeneral Electric; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB006351, R01EB012547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES009089, T32ES007062, R01ES007062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH082277, R01MH092443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005146] Funding Source: NIH RePORTER	We are grateful to Alimamy Kargbo for performing PET metabolite analyses, and to the Johns Hopkins PET Center for provision of the radiotracer. This project was funded in part by financial support from the following NIH grants and foundations: NIH 5R21MH082277, NIH 5R01MH092443, NIH R01EB012547, NIEHS ES007062, NIH 5T32EB006351, NIH P50AG005146, the Lupus Foundation for America, NFL Charities and the GE NFL Head Health challenge.	Boutin H, 2007, J NUCL MED, V48, P573, DOI 10.2967/jnumed.106.036764; Cai DS, 2013, TRENDS ENDOCRIN MET, V24, P40, DOI 10.1016/j.tem.2012.11.003; Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Coughlin JM, 2014, J NEUROVIROL, V20, P219, DOI 10.1007/s13365-014-0239-5; Delis DC, 2005, J INT NEUROPSYCH SOC, V11, P708, DOI 10.1017/S1355617705050812; Drugan RC, 1996, CLIN NEUROPHARMACOL, V19, P475, DOI 10.1097/00002826-199619060-00002; Dukart J, 2010, NEUROIMAGE, V49, P1490, DOI 10.1016/j.neuroimage.2009.09.017; Endres CJ, 2009, J NUCL MED, V50, P1276, DOI 10.2967/jnumed.109.062265; Erlandsson K, 2012, PHYS MED BIOL, V57, pR119, DOI 10.1088/0031-9155/57/21/R119; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Folkersma H, 2011, J NUCL MED, V52, P1235, DOI 10.2967/jnumed.110.084061; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; Gavish M, 1999, PHARMACOL REV, V51, P629; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hellstrom-Lindahl E, 2000, J NEUROCHEM, V74, P777, DOI 10.1046/j.1471-4159.2000.740777.x; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kreisl WC, 2013, BRAIN, V136, P2228, DOI 10.1093/brain/awt145; Kreisl WC, 2013, J CEREBR BLOOD F MET, V33, P53, DOI 10.1038/jcbfm.2012.131; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miller AA, 2014, BRAIN BEHAV IMMUN, V42, P10, DOI 10.1016/j.bbi.2014.04.001; Mizrahi R, 2012, J CEREBR BLOOD F MET, V32, P968, DOI 10.1038/jcbfm.2012.46; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Papadopoulos V, 2009, EXP NEUROL, V219, P53, DOI 10.1016/j.expneurol.2009.04.016; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Rahmim A, 2004, PHYS MED BIOL, V49, P4239, DOI 10.1088/0031-9155/49/18/004; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rubio A, 2006, CURR MOL MED, V6, P423, DOI 10.2174/156652406777435444; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Thominiaux C, 2006, APPL RADIAT ISOTOPES, V64, P570, DOI 10.1016/j.apradiso.2005.12.003; Weir DR., 2009, NATL FOOTBALL LEAGUE	52	138	138	2	68	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2015	74						58	65		10.1016/j.nbd.2014.10.019			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB5GQ	WOS:000349655900006	25447235	Green Accepted			2022-02-06	
J	Petraglia, AL; Plog, BA; Dayawansa, S; Chen, M; Dashnaw, ML; Czerniecka, K; Walker, CT; Viterise, T; Hyrien, O; Iliff, JJ; Deane, R; Nedergaard, M; Huang, JH				Petraglia, Anthony L.; Plog, Benjamin A.; Dayawansa, Samantha; Chen, Michael; Dashnaw, Matthew L.; Czerniecka, Katarzyna; Walker, Corey T.; Viterise, Tyler; Hyrien, Ollivier; Iliff, Jeffrey J.; Deane, Rashid; Nedergaard, Maiken; Huang, Jason H.			The Spectrum of Neurobehavioral Sequelae after Repetitive Mild Traumatic Brain Injury: A Novel Mouse Model of Chronic Traumatic Encephalopathy	JOURNAL OF NEUROTRAUMA			English	Article						animal model; chronic traumatic encephalopathy; concussion; mild traumatic brain injury; repetitive	CLOSED-HEAD INJURY; PROFESSIONAL FOOTBALL PLAYERS; RISK-TAKING BEHAVIOR; ELEVATED PLUS-MAZE; COGNITIVE-IMPAIRMENT; RECURRENT CONCUSSION; AXONAL INJURY; CEREBRAL CONCUSSION; LIPID-PEROXIDATION; NCAA CONCUSSION	There has been an increased focus on the neurological sequelae of repetitive mild traumatic brain injury (TBI), particularly neurodegenerative syndromes, such as chronic traumatic encephalopathy (CTE); however, no animal model exists that captures the behavioral spectrum of this phenomenon. We sought to develop an animal model of CTE. Our novel model is a modification and fusion of two of the most popular models of TBI and allows for controlled closed-head impacts to unanesthetized mice. Two-hundred and eighty 12-week-old mice were divided into control, single mild TBI (mTBI), and repetitive mTBI groups. Repetitive mTBI mice received six concussive impacts daily for 7 days. Behavior was assessed at various time points. Neurological Severity Score (NSS) was computed and vestibulomotor function tested with the wire grip test (WGT). Cognitive function was assessed with the Morris water maze (MWM), anxiety/risk-taking behavior with the elevated plus maze, and depression-like behavior with the forced swim/tail suspension tests. Sleep electroencephalogram/electromyography studies were performed at 1 month. NSS was elevated, compared to controls, in both TBI groups and improved over time. Repetitive mTBI mice demonstrated transient vestibulomotor deficits on WGT. Repetitive mTBI mice also demonstrated deficits in MWM testing. Both mTBI groups demonstrated increased anxiety at 2 weeks, but repetitive mTBI mice developed increased risk-taking behaviors at 1 month that persist at 6 months. Repetitive mTBI mice exhibit depression-like behavior at 1 month. Both groups demonstrate sleep disturbances. We describe the neurological sequelae of repetitive mTBI in a novel mouse model, which resemble several of the neuropsychiatric behaviors observed clinically in patients sustaining repetitive mild head injury.	[Petraglia, Anthony L.; Dayawansa, Samantha; Dashnaw, Matthew L.; Czerniecka, Katarzyna; Walker, Corey T.; Viterise, Tyler; Huang, Jason H.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Plog, Benjamin A.; Chen, Michael; Deane, Rashid; Nedergaard, Maiken] Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed,Dept Neurosurg, Rochester, NY 14642 USA; [Hyrien, Ollivier] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Peri Operat Med, Portland, OR 97201 USA		Petraglia, AL (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, 601 Elmwood Ave Box 670, Rochester, NY 14642 USA.	anthony_petraglia@urmc.rochester.edu	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH-R25-NS-065748, NIH-R01-NS-067435]; University of Rochester; University of Rochester (CTSA) from the National Center for Advancing Translational Sciences of the NIH [UL1 TR000042]; Novo Nordisk FondenNovo Nordisk Foundation [NNF13OC0004258] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078167, R01NS075177] Funding Source: NIH RePORTER	The authors are thankful to Ken Kellerson of Millenium Machinery for his assistance in developing the helmet and modified rubber impactor. This work was supported, in part, by the NIH (grant nos. NIH-R25-NS-065748 [to A. L. P.] and NIH-R01-NS-067435 [to J.H.H.]), as well as a University of Rochester Institutional grant (to J.H.H.). Additionally, the project described in this publication was supported by the University of Rochester (CTSA award no. UL1 TR000042) from the National Center for Advancing Translational Sciences of the NIH (to A. L. P.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; ALMEIDA SS, 1993, PHYSIOL BEHAV, V54, P749, DOI 10.1016/0031-9384(93)90086-U; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; BECKMAN DL, 1969, P SOC EXP BIOL MED, V130, P5; Bedirli N, 2012, J NEUROSURG ANESTH, V24, P336, DOI 10.1097/ANA.0b013e318266791e; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bilkei-Gorzo A, 2002, J NEUROSCI, V22, P10046; Bowles Eric D, 2012, AANA J, V80, P445; Brooks PL, 2011, J NEUROSCI, V31, P7111, DOI 10.1523/JNEUROSCI.0347-11.2011; Bryan CJ, 2013, SUICIDE LIFE-THREAT, V43, P223, DOI 10.1111/sltb.12011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Dong YY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0034435, 10.1371/journal.pone.0051643, 10.1371/journal.pone.0039386]; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LASKA EM, 1989, BIOMETRICS, V45, P1139, DOI 10.2307/2531766; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Laviola G, 2003, NEUROSCI BIOBEHAV R, V27, P19, DOI 10.1016/S0149-7634(03)00006-X; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Macri S, 2002, ANIM BEHAV, V64, P541, DOI 10.1006/anbe.2002.4004; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MASUZAWA H, 1976, Neurologia Medico-Chirurgica, V16, P77, DOI 10.2176/nmc.16pt1.77; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Petit-Demouliere B, 2005, PSYCHOPHARMACOLOGY, V177, P245, DOI 10.1007/s00213-004-2048-7; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Povlishock JT., 1996, NEUROTRAUMA, P1325; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; SEKINO H, 1980, Neurologia Medico-Chirurgica, V20, P127; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Tang XD, 2002, SLEEP, V25, P691; Tang XD, 2007, BEHAV BRAIN RES, V180, P62, DOI 10.1016/j.bbr.2007.02.022; Tasan RO, 2009, NEUROSCIENCE, V158, P1717, DOI 10.1016/j.neuroscience.2008.11.048; Toledo-Rodriguez M, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00017; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; YARNELL P, 1969, B NEW YORK ACAD MED, V45, P39; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Yurdakoc A, 2008, ACTA ANAESTH SCAND, V52, P658, DOI 10.1111/j.1399-6576.2008.01635.x; Zhang SW, 2007, J PHYSIOL-LONDON, V581, P649, DOI 10.1113/jphysiol.2007.129510	92	138	140	1	47	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1211	1224		10.1089/neu.2013.3255			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500010	24766454	Green Published			2022-02-06	
J	Zhou, YX; Kierans, A; Kenul, D; Ge, YL; Rath, J; Reaume, J; Grossman, RI; Lui, YW				Zhou, Yongxia; Kierans, Andrea; Kenul, Damon; Ge, Yulin; Rath, Joseph; Reaume, Joseph; Grossman, Robert I.; Lui, Yvonne W.			Mild Traumatic Brain Injury: Longitudinal Regional Brain Volume Changes	RADIOLOGY			English	Article							ANTERIOR CINGULATE CORTEX; COGNITIVE CONTROL; UNITED-STATES; CONCUSSION; SEVERITY; SYMPTOMS; STROOP; INTERFERENCE; VALIDATION; DISRUPTION	Purpose: To investigate longitudinal changes in global and regional brain volume in patients 1 year after mild traumatic brain injury (MTBI) and to correlate such changes with clinical and neurocognitive metrics. Materials and Methods: This institutional review board-approved study was HIPAA compliant. Twenty-eight patients with MTBI (with 19 followed up at 1 year) with posttraumatic symptoms after injury and 22 matched control subjects (with 12 followed up at 1 year) were enrolled. Automated segmentation of brain regions to compute regional gray matter (GM) and white matter (WM) volumes was performed by using three-dimensional T1-weighted 3.0-T magnetic resonance imaging, and results were correlated with clinical metrics. Pearson and Spearman rank correlation coefficients were computed between longitudinal brain volume and neurocognitive scores, as well as clinical metrics, over the course of the follow-up period. Results: One year after MTBI, there was measurable global brain atrophy, larger than that in control subjects. The anterior cingulate WM bilaterally and the left cingulate gyrus isthmus WM, as well as the right precuneal GM, showed significant decreases in regional volume in patients with MTBI over the 1st year after injury (corrected P < .05); this was confirmed by means of cross-sectional comparison with data in control subjects (corrected P < .05). Left and right rostral anterior cingulum WM volume loss correlated with changes in neurocognitive measures of memory (r = 0.65, P = .005) and attention (r = 0.60, P = .01). At 1-year follow-up, WM volume in the left cingulate gyrus isthmus correlated with clinical scores of anxiety (Spearman rank correlation r = 20.68, P = .007) and postconcussive symptoms (Spearman rank correlation r = 20.65, P = .01). Conclusion: These observations demonstrate structural changes to the brain 1 year after injury after a single concussive episode. Regional brain atrophy is not exclusive to moderate and severe traumatic brain injury but may be seen after mild injury. In particular, the anterior part of the cingulum and the cingulate gyrus isthmus, as well as the precuneal GM, may be distinctively vulnerable 1 year after MTBI.	[Zhou, Yongxia; Kierans, Andrea; Kenul, Damon; Ge, Yulin; Rath, Joseph; Reaume, Joseph; Grossman, Robert I.; Lui, Yvonne W.] NYU, Sch Med, Dept Radiol, New York, NY 10016 USA		Lui, YW (corresponding author), NYU, Sch Med, Dept Radiol, 660 1st Ave,2nd Floor, New York, NY 10016 USA.	Yvonne.Lui@nyumc.org	Ge, Yulin/L-7052-2019; Rath, Joseph F./C-4823-2008; Ge, Yulin/D-9060-2019	Rath, Joseph F./0000-0003-2933-6299; Ge, Yulin/0000-0002-2320-6031; Zhou, Yongxia (Sharon)/0000-0002-4931-2318	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [TR000038, R01 NS039135-10]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000038] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (grants UL1 TR000038 and R01 NS039135-10). Conflicts of interest are listed at the end of this article.	Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.3.CO;2-H; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Delis D.C., 2000, CALIFORNIA VERBAL LE; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; di Pellegrino G, 2007, J COGNITIVE NEUROSCI, V19, P275, DOI 10.1162/jocn.2007.19.2.275; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Freeborough PA, 1997, IEEE T MED IMAGING, V16, P623, DOI 10.1109/42.640753; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GRONWALL D, 1974, LANCET, V2, P605; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Haupt S, 2009, HUM BRAIN MAPP, V30, P3043, DOI 10.1002/hbm.20731; Haznedar MM, 2004, SCHIZOPHR RES, V71, P249, DOI 10.1016/j.schres.2004.02.025; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kiehl KA, 2000, PSYCHOPHYSIOLOGY, V37, P216, DOI 10.1017/S0048577200990231; Kolassa IT, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-56; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; Leung KK, 2010, NEUROIMAGE, V50, P516, DOI 10.1016/j.neuroimage.2009.12.059; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyers JE., 1995, REY COMPLEX FIGURE T; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Polli FE, 2005, P NATL ACAD SCI USA, V102, P15700, DOI 10.1073/pnas.0503657102; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Reitan RM, 1992, TRAIL MAKING TEST MA; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2011, NEUROIMAGE, V57, P19, DOI 10.1016/j.neuroimage.2011.02.076; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salat DH, 2009, NEUROIMAGE, V44, P1247, DOI 10.1016/j.neuroimage.2008.10.030; Silver JM, 2011, TXB TRAUMATIC BRAIN, VSecond; Smith, 1973, SYMBOL DIGIT MODALIT; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Vogt BA, 2005, PROG BRAIN RES, V150, P205, DOI 10.1016/S0079-6123(05)50015-3; Wechsler D, 1985, WECHSLER ADULT INTEL; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	64	138	139	2	22	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	JUN	2013	267	3					880	890		10.1148/radiol.13122542			11	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	151FF	WOS:000319445400025	23481161	Green Published			2022-02-06	
J	Jeter, CB; Hergenroeder, GW; Hylin, MJ; Redell, JB; Moore, AN; Dash, PK				Jeter, Cameron B.; Hergenroeder, Georgene W.; Hylin, Michael J.; Redell, John B.; Moore, Anthony N.; Dash, Pramod K.			Biomarkers for the Diagnosis and Prognosis of Mild Traumatic Brain Injury/Concussion	JOURNAL OF NEUROTRAUMA			English	Article						chronic traumatic encephalopathy; polytrauma; post-concussive syndrome; repeated mTBI; return to play	POSTTRAUMATIC-STRESS-DISORDER; NEURON-SPECIFIC ENOLASE; FIBRILLARY ACIDIC PROTEIN; SPORTS-RELATED CONCUSSION; MINOR HEAD-INJURY; DIFFUSE AXONAL INJURY; C-TERMINAL HYDROLASE; CEREBRAL-BLOOD-FLOW; HIGH-SCHOOL; COMPUTED-TOMOGRAPHY	Mild traumatic brain injury (mTBI) results from a transfer of mechanical energy into the brain from traumatic events such as rapid acceleration/deceleration, a direct impact to the head, or an explosive blast. Transfer of energy into the brain can cause structural, physiological, and/or functional changes in the brain that may yield neurological, cognitive, and behavioral symptoms that can be long-lasting. Because mTBI can cause these symptoms in the absence of positive neuroimaging findings, its diagnosis can be subjective and often is based on self-reported neurological symptoms. Further, proper diagnosis can be influenced by the motivation to conceal or embellish signs and/or an inability of the patient to notice subtle dysfunctions or alterations of consciousness. Therefore, appropriate diagnosis of mTBI would benefit from objective indicators of injury. Concussion and mTBI are often used interchangeably, with concussion being primarily used in sport medicine, whereas mTBI is used in reference to traumatic injury. This review provides a critical assessment of the status of current biomarkers for the diagnosis of human mTBI. We review the status of biomarkers that have been tested in TBI patients with injuries classified as mild, and introduce a new concept for the discovery of biomarkers (termed symptophenotypes) to predict common and unique symptoms of concussion. Finally, we discuss the need for biomarker/biomarker signatures that can detect mTBI in the context of polytrauma, and to assess the consequences of repeated injury on the development of secondary injury syndrome, prolongation of post-concussion symptoms, and chronic traumatic encephalopathy.	[Jeter, Cameron B.] Univ Texas Houston, Sch Dent, Dept Diagnost & Biomed Sci, Houston, TX 77225 USA; [Hergenroeder, Georgene W.] Univ Texas Houston, Sch Med, Vivian L Smith Dept Neurosurg, Houston, TX 77225 USA; [Hylin, Michael J.; Redell, John B.; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019; Jeter, Cameron B./AAO-1797-2021	Jeter, Cameron B./0000-0001-5303-5897; Dash, Pramod/0000-0001-6746-1002; Hergenroeder, Georgene/0000-0002-6170-2191	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0134, W81XWH-11-2-0056]; Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [R38OT10585]; Institute for Rehabilitation and Research Foundation/Mission Connect; Vivian L. Smith Foundation; Smith Foundation; Gilson-Longenbaugh Foundation	This work was supported by the Department of Defense (W81XWH-08-2-0134, W81XWH-11-2-0056); the Health Resources and Services Administration (R38OT10585); The Institute for Rehabilitation and Research Foundation/Mission Connect; The Vivian L. Smith Foundation, The Smith Foundation; and the Gilson-Longenbaugh Foundation.	[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Avnit-Sagi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005033; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bartels CL, 2009, CLIN CHEM, V55, P623, DOI 10.1373/clinchem.2008.112805; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Belin AC, 2008, FEBS J, V275, P1377, DOI 10.1111/j.1742-4658.2008.06301.x; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cordes KR, 2009, CIRC RES, V104, P724, DOI 10.1161/CIRCRESAHA.108.192872; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Crick FC, 2005, PHILOS T R SOC B, V360, P1271, DOI 10.1098/rstb.2005.1661; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; D'Aversa TG, 2013, NEUROPATH APPL NEURO, V39, P270, DOI 10.1111/j.1365-2990.2012.01279.x; d'Hemecourt P, 2011, CLIN SPORT MED, V30, P63, DOI 10.1016/j.csm.2010.08.008; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; De Stefano N, 2001, ARCH NEUROL-CHICAGO, V58, P65, DOI 10.1001/archneur.58.1.65; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Dhaka A, 2006, ANNU REV NEUROSCI, V29, P135, DOI 10.1146/annurev.neuro.29.051605.112958; Dharap A, 2011, STROKE, V42, P1105, DOI 10.1161/STROKEAHA.110.598391; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Edelman GM, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00004; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Freund Y, 1997, J COMPUT SYST SCI, V55, P119, DOI 10.1006/jcss.1997.1504; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hovda DA, 2007, CRIT CARE MED, V35, P663, DOI 10.1097/01.CCM.0000254442.66789.52; Hulsebosch CE, 2008, EXP NEUROL, V214, P6, DOI 10.1016/j.expneurol.2008.07.016; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jeter CB, 2012, J NEUROTRAUM, V29, P119, DOI 10.1089/neu.2011.2029; Johnson VE, 2012, EXP NEUROL; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kalra S, 1999, J NEUROL SCI, V165, pS27, DOI 10.1016/S0022-510X(99)00023-4; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kelly JP, 1997, NEUROLOGY, V48, P581; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Little DM, 2010, NEUROREHABILITATION, V26, P15, DOI 10.3233/NRE-2010-0532; Lo TYM, 2010, J NEUROTRAUM, V27, P2139, DOI 10.1089/neu.2010.1387; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McGowan PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014739; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Nelson EC, 2009, MOL PSYCHIATR, V14, P234, DOI 10.1038/mp.2008.81; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Rakofsky JJ, 2012, MOL PSYCHIATR, V17, P22, DOI 10.1038/mp.2011.121; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Rogelj B, 2004, REV NEUROSCIENCE, V15, P185; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Ruff RM, 1999, BRAIN INJURY, V13, P943; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; SCHAPIRE RE, 1990, MACH LEARN, V5, P197, DOI 10.1023/A:1022648800760; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schuff N, 2006, ADV EXP MED BIOL, V576, P241; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Setsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stirling DP, 2010, TRENDS MOL MED, V16, P160, DOI 10.1016/j.molmed.2010.02.002; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; TRUE WR, 1993, ARCH GEN PSYCHIAT, V50, P257, DOI 10.1001/archpsyc.1993.01820160019002; Uchino Y, 2001, ACTA NEUROCHIR, V143, P1031, DOI 10.1007/s007010170008; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Vemuganti R, 2010, TRANSL STROKE RES, V1, P158, DOI 10.1007/s12975-010-0030-8; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wichers M, 2008, AM J MED GENET B, V147B, P120, DOI 10.1002/ajmg.b.30576; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wu LJ, 2010, PHARMACOL REV, V62, P381, DOI 10.1124/pr.110.002725; Xian H, 2000, DRUG ALCOHOL DEPEN, V61, P95, DOI 10.1016/S0376-8716(00)00127-7; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Ye YM, 2011, PHYSIOL GENOMICS, V43, P534, DOI 10.1152/physiolgenomics.00130.2010; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	167	138	144	2	58	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		657	670		10.1089/neu.2012.2439			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500008	23062081				2022-02-06	
J	Gallagher, CN; Carpenter, KL; Grice, P; Howe, DJ; Mason, A; Timofeev, I; Menon, DK; Kirkpatrick, PJ; Pickard, JD; Sutherland, GR; Hutchinson, PJ				Gallagher, Clare N.; Carpenter, Keri L. H.; Grice, Peter; Howe, Duncan J.; Mason, Andrew; Timofeev, Ivan; Menon, David K.; Kirkpatrick, Peter J.; Pickard, John D.; Sutherland, Garnette R.; Hutchinson, Peter J.			The human brain utilizes lactate via the tricarboxylic acid cycle: a C-13-labelled microdialysis and high-resolution nuclear magnetic resonance study	BRAIN			English	Article						brain metabolism; C-13-labelling; microdialysis; NMR; traumatic brain injury (human)	HUMAN CEREBRAL-CORTEX; GLUCOSE-METABOLISM; ENERGY-METABOLISM; AMINO-ACIDS; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; GLUTAMATE RELEASE; NEURONAL-ACTIVITY; PH-DEPENDENCE; RAT-BRAIN	Energy metabolism in the human brain is not fully understood. Classically, glucose is regarded as the major energy substrate. However, lactate (conventionally a product of anaerobic metabolism) has been proposed to act as an energy source, yet whether this occurs in man is not known. Here we show that the human brain can indeed utilize lactate as an energy source via the tricarboxylic acid cycle. We used a novel combination of C-13-labelled cerebral microdialysis both to deliver C-13 substrates into the brain and recover C-13 metabolites from the brain, and high-resolution C-13 nuclear magnetic resonance. Microdialysis catheters were placed in the vicinity of focal lesions and in relatively less injured regions of brain, in patients with traumatic brain injury. Infusion with 2-C-13-acetate or 3-C-13-lactate produced C-13 signals for glutamine C4, C3 and C2, indicating tricarboxylic acid cycle operation followed by conversion of glutamate to glutamine. This is the first direct demonstration of brain utilization of lactate as an energy source in humans.	[Gallagher, Clare N.; Carpenter, Keri L. H.; Timofeev, Ivan; Kirkpatrick, Peter J.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Gallagher, Clare N.; Sutherland, Garnette R.] Univ Calgary, Dept Clin Neurosci, Div Neurosurg, Calgary, AB T2N 2T9, Canada; [Carpenter, Keri L. H.; Menon, David K.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 0QQ, England; [Grice, Peter; Howe, Duncan J.; Mason, Andrew] Univ Cambridge, Univ Chem Lab, Dept Chem, Cambridge CB2 1EW, England; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England		Carpenter, KL (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	klc1000@wbic.cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	Grice, Peter/0000-0003-4658-4534; Timofeev, Ivan/0000-0002-1168-0393; Carpenter, Keri/0000-0001-8236-7727	The Canadian Institute of Health Research, the Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)Canadian Institutes of Health Research (CIHR) [G9439390, ID 65883, G0600986, ID79068]; Academy of Medical Sciences/Health Foundation; MRC ( Acute Brain Injury Programme Grant)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); The Evelyn Trust; Academy of Medical Sciences/ Health Foundation Senior Surgical Scientist Fellowship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	The Canadian Institute of Health Research, the Medical Research Council ( Grant Nos. G9439390 ID 65883 and G0600986 ID79068); Academy of Medical Sciences/Health Foundation; MRC ( Acute Brain Injury Programme Grant) and the National Institute for Health Research Biomedical Research Centre, Cambridge ( to K. L. H. C.); The Evelyn Trust ( to I. T.); Academy of Medical Sciences/ Health Foundation Senior Surgical Scientist Fellowship ( to P. J. H.).	Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; AOKI C, 1991, J NEUROSCI RES, V28, P531, DOI 10.1002/jnr.490280410; ARCHER DP, 1990, J CEREBR BLOOD F MET, V10, P624, DOI 10.1038/jcbfm.1990.114; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Bluml S, 2002, NMR BIOMED, V15, P1, DOI 10.1002/nbm.725; Bouzier-Sore AK, 2006, EUR J NEUROSCI, V24, P1687, DOI 10.1111/j.1460-9568.2006.05056.x; Cholet N, 2002, CEREB CORTEX, V12, P515, DOI 10.1093/cercor/12.5.515; CISTOLA DP, 1982, J LIPID RES, V23, P795; DAGER SR, 1992, LIFE SCI, V51, P973, DOI 10.1016/0024-3205(92)90404-D; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GLENN TC, 2005, J CEREB BLOOD FLOW M, V25, pS567; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gustafsson J, 2007, SCAND J CLIN LAB INV, V67, P155, DOI 10.1080/00365510600995259; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Ide K, 2000, J PHYSIOL-LONDON, V522, P159, DOI 10.1111/j.1469-7793.2000.t01-2-00159.xm; JUNG G, 1972, EUR J BIOCHEM, V24, P438, DOI 10.1111/j.1432-1033.1972.tb19704.x; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Larsen TS, 2008, J PHYSIOL-LONDON, V586, P2807, DOI 10.1113/jphysiol.2008.151449; Lebon V, 2002, J NEUROSCI, V22, P1523, DOI 10.1523/JNEUROSCI.22-05-01523.2002; LONDON RE, 1978, J AM CHEM SOC, V100, P3723, DOI 10.1021/ja00480a012; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; NI Y, 2007, J NEUROCHEM, V103, P1723; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; QUIRT AR, 1974, J AM CHEM SOC, V96, P570, DOI 10.1021/ja00809a038; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Schousboe A, 2005, NEUROTOX RES, V8, P221, DOI 10.1007/BF03033975; SCHOUSBOE A, 1993, DEV NEUROSCI-BASEL, V15, P359, DOI 10.1159/000111356; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; NMR METABOLOMICS DAT	53	138	140	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2009	132		10				2839	2849		10.1093/brain/awp202			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	505IG	WOS:000270685600030	19700417	Bronze			2022-02-06	
J	Bryant, RA; Creamer, M; O'Donnell, M; Silove, D; McFarlane, AC				Bryant, Richard A.; Creamer, Mark; O'Donnell, Meaghan; Silove, Derrick; McFarlane, Alexander C.			A Study of the Protective Function of Acute Morphine Administration on Subsequent Posttraumatic Stress Disorder	BIOLOGICAL PSYCHIATRY			English	Article						Fear conditioning; morphine; posttraumatic stress disorder	INTERVIEW; EXPOSURES; AMNESIA; PTSD; FEAR	Background: To index the extent to which acute administration of morphine is protective against development of posttraumatic stress disorder (PTSD). Methods: Consecutive patients admitted to hospital after traumatic injury (n = 155) were assessed for current psychiatric disorder, pain, and morphine dose in the initial week after injury and were reassessed for PTSD and other psychiatric disorders 3 months later (n = 120). Results: Seventeen patients (14%) met criteria for PTSD at 3 months. Patients who met criteria for PTSD received significantly less morphine than those who did not develop PTSD; there was no difference in morphine levels in those who did and did not develop major depressive episode or another anxiety disorder. Hierarchical regression analysis indicated that PTSD severity at 3 months was significantly predicted by acute pain, mild traumatic brain injury, and elevated morphine dose in the initial 48 hours after trauma, after controlling for injury severity, gender, age, and type of injury. Conclusions: Acute administration of morphine may limit fear conditioning in the aftermath of traumatic injury and may serve as a secondary prevention strategy to reduce PTSD development.	[Bryant, Richard A.; Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW 2052, Australia; [Creamer, Mark; O'Donnell, Meaghan] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia; [McFarlane, Alexander C.] Univ Adelaide, Dept Psychiat, Adelaide, SA, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	Naitonal Health and Medical Research Council (NHMRC) ProgramNational Health and Medical Research Council of Australia [300403]; Victorian Medical Research Council Australian Clinical Research Fellowship [359284]	This study was supported by an Naitonal Health and Medical Research Council (NHMRC) Program Grant (300403), Victorian Medical Research Council Australian Clinical Research Fellowship (359284); The authors reported no biomedical financial interests or potential conflicts of interest.	*AM ASS AUT MED, 1990, ABBR INJ SCAL 1990 R; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bryant RA, 2006, ANN NY ACAD SCI, V1071, P19, DOI 10.1196/annals.1364.002; Fendt M, 1999, NEUROSCI BIOBEHAV R, V23, P743, DOI 10.1016/S0149-7634(99)00016-0; FREEDMAN JE, 1985, J NEUROSCI, V5, P3016; *GLOBALRPH COM, 2007, CLIN ULT REF; GOOD AJ, 1995, BEHAV NEUROSCI, V109, P631, DOI 10.1037/0735-7044.109.4.631; McNally GP, 2003, J EXP PSYCHOL-ANIM B, V29, P222, DOI 10.1037/0097-7403.29.3.222; McNally GP, 2003, J EXP PSYCHOL ANIM B, V29, P130, DOI 10.1037/0097-7403.29.2.130; PAULSEN AS, 1988, ARCH GEN PSYCHIAT, V45, P62; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; PITMAN RK, 1989, BIOL PSYCHIAT, V26, P221, DOI 10.1016/0006-3223(89)90033-4; Reisine T., 1996, GOODMAN GILMANS PHAR, pp 521; Ritschel W.A., 1999, HDB BASIC PHARMACOKI, V5th ed.; Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; TANAKA M, 1983, BRAIN RES, V275, P105, DOI 10.1016/0006-8993(83)90422-5	18	138	140	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	MAR 1	2009	65	5					438	440		10.1016/j.biopsych.2008.10.032			3	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	408SM	WOS:000263455300012	19058787				2022-02-06	
J	Hensel, A; Angermeyer, MC; Riedel-Heller, SG				Hensel, A.; Angermeyer, M. C.; Riedel-Heller, S. G.			Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							DSM-III-R; MULTIINFARCT DEMENTIA; STRUCTURED INTERVIEW; ALZHEIMER-TYPE; ICD-10; POPULATION; CONCUSSION; DIAGNOSIS; ETIOLOGY; SCORES	Background: In clinical and research settings, the Mini-Mental State Examination ( MMSE) is commonly used to measure cognitive change over time. The interpretation of changes in MMSE is often difficult. They do not necessarily result from true clinical change. Their interpretation requires comparison with normative data for change. However, MMSE change norms are lacking for long intervals. Objective: To examine what is a reliable change in MMSE for long follow-up periods commonly used in clinic. To provide normative data for change. Methods: A sample of 119 cognitively normal individuals, aged 75 years and over, who participated in the Leipzig Longitudinal Study of the Aged ( LEILA 75+). All participants were tested six times at 1.5 year intervals with the MMSE over a mean period of 7.1 years. Reliable change indices were computed for a common confidence interval (90%). Results: In repeated assessments with 1.5 year intervals, a change in MMSE of at least 2-4 points indicated a reliable change at the 90% confidence level. Conclusion: Small changes in MMSE can be interpreted only with great uncertainty. They have a reasonable probability of being caused by measurement error, regression to the mean or practice.	[Hensel, A.; Angermeyer, M. C.; Riedel-Heller, S. G.] Univ Leipzig, Dept Psychiat, Res Dept Evaluat & Epidemiol, Leipzig, Germany		Riedel-Heller, SG (corresponding author), Univ Leipzig, Dept Psychiat, Johannisallee 20, D-04317 Leipzig, Germany.	Steffi.Riedel-Heller@medizin.uni-leipzig.de	Riedel-Heller, Steffi/ABG-1537-2021				Busse A, 2002, Z GERONTOL GERIATR, V35, P565, DOI 10.1007/s00391-002-0068-7; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frerichs RJ, 2005, ARCH CLIN NEUROPSYCH, V20, P321, DOI 10.1016/j.acn.2004.08.002; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hsu LM, 1999, J CONSULT CLIN PSYCH, V67, P594, DOI 10.1037/0022-006X.67.4.594; Iverson GL, 1998, INT J GERIATR PSYCH, V13, P661, DOI 10.1002/(SICI)1099-1166(1998100)13:10<661::AID-GPS838>3.0.CO;2-0; Ivnik RJ, 2000, NEUROPSYCHOLOGY, V14, P163, DOI 10.1037/0894-4105.14.2.163; Ivnik RJ, 1999, NEUROPSYCHOLOGY, V13, P121, DOI 10.1037/0894-4105.13.1.121; JacqminGadda H, 1997, AM J EPIDEMIOL, V145, P498; Maassen GH, 2005, BRIT J SPORT MED, V39, P483, DOI 10.1136/bjsm.2004.015594; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P537, DOI 10.1002/1097-4679(199107)47:4<537::AID-JCLP2270470411>3.0.CO;2-9; Olin JT, 1991, PSYCHOL ASSESSMENT J, V3, P427; Palmer K, 2003, ACTA NEUROL SCAND, V107, P14, DOI 10.1034/j.1600-0404.107.s179.2.x; Park HL, 2003, INT J GERIATR PSYCH, V18, P1121, DOI 10.1002/gps.1023; Riedel-Heller SG, 2001, BRIT J PSYCHIAT, V179, P250, DOI 10.1192/bjp.179.3.250; Sawrie SM, 1999, J GERONTOL B-PSYCHOL, V54, pP116, DOI 10.1093/geronb/54B.2.P116; SCHMAND B, 1995, INT J GERIATR PSYCH, V10, P411, DOI 10.1002/gps.930100510; SCHNEEKLOTH U, 1993, SCHRIFTENREIHE BMFUS; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Tombaugh TN, 2005, ARCH CLIN NEUROPSYCH, V20, P485, DOI 10.1016/j.acn.2004.11.004; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; ZAUDIG M, 1991, PSYCHOL MED, V21, P225, DOI 10.1017/S0033291700014811	25	138	140	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2007	78	12					1298	1303		10.1136/jnnp.2006.109074			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	240CD	WOS:000251563700004	17442763	Green Published			2022-02-06	
J	Bayir, H; Tyurin, VA; Tyurina, YY; Viner, R; Ritov, V; Amoscato, AA; Zhao, Q; Zhang, XJJ; Janesko-Feldman, KL; Alexander, H; Basova, LV; Clark, RSB; Kochanek, PM; Kagan, VE				Bayir, Huelya; Tyurin, Vladimir A.; Tyurina, Yulia Y.; Viner, Rosa; Ritov, Vladimir; Amoscato, Andrew A.; Zhao, Qing; Zhang, Xiaojing J.; Janesko-Feldman, Keri L.; Alexander, Henry; Basova, Liana V.; Clark, Robert S. B.; Kochanek, Patrick M.; Kagan, Valerian E.			Selective early cardiolipin peroxidation after traumatic brain injury: An oxidative lipidomics analysis	ANNALS OF NEUROLOGY			English	Article							10-N-NONYL ACRIDINE-ORANGE; CONTROLLED CORTICAL IMPACT; PROGRAMMED NEURONAL DEATH; DEVELOPING RAT-BRAIN; CYTOCHROME-C; MITOCHONDRIAL DYSFUNCTION; GLUTATHIONE-PEROXIDASE; OXIDIZED PHOSPHOLIPIDS; DOCOSAHEXAENOIC ACID; CEREBROSPINAL-FLUID	Objective: Enhanced lipid peroxidation is well established in traumatic brain injury. However, its molecular targets, identity of peroxidized phospholipid species, and their signaling role have not been deciphered. Methods: Using controlled cortical impact as a model of traumatic brain injury, we employed a newly developed oxidative lipidomics approach to qualitatively and quantitatively characterize the lipid peroxidation response. Results: Electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry analysis of rat cortical mitochondrial/synaptosomal fractions demonstrated the presence of highly oxidizable molecular species containing C-22:6 fatty acid residues in all major classes of phospholipids. However, the pattern of phospholipid oxidation at 3 hours after injury displayed a nonrandom character independent of abundance of oxidizable species and included only one mitochondria-specific phospholipid, cardiolipin (CL). This selective CL peroxidation was followed at 24 hours by peroxidation of other phospholipids, most prominently phosphatidylserine, but also phosphatidylcholine and phosphatidylethanolamine. CL oxidation preceded appearance of biomarkers of apoptosis (caspase-3 activation, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positivity) and oxidative stress (loss of glutathione and ascorbate). Interpretation: The temporal sequence combined with the recently demonstrated role of CL hydroperoxides (CL-OOH) in in vitro models of apoptosis suggest that CL-OOH may be both a key in vivo trigger of apoptotic cell death and a therapeutic target in experimental traumatic brain injury.	Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; Thermofisher Sci, San Jose, CA USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA		Bayir, H (corresponding author), 3434 5th Ave, Pittsburgh, PA 15213 USA.	bayihx@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Tyurin, Vladimir/0000-0002-3474-1697; Amoscato, Andrew/0000-0002-1340-9150; Tyurina, Yulia/0000-0003-0287-2091; Kagan, Valerian E./0000-0002-7245-1885	NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19 AI068021] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NIOSH CDC HHS [OH008282] Funding Source: Medline; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R01OH008282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER		ABDELRAHMAN A, 1995, P SOC EXP BIOL MED, V209, P170; Adayev T, 1998, J NEUROCHEM, V71, P1854; Adelson PD, 2003, CRIT CARE MED, V4, pS2; Basova LV, 2007, BIOCHEMISTRY-US, V46, P3423, DOI 10.1021/bi061854k; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BAYIR H, 2006, TOXICOL SCI, V90, P410; Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; De Simone R, 2004, MOL NEUROBIOL, V29, P197, DOI 10.1385/MN:29:2:197; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Fernandez MIG, 2004, ANAL BIOCHEM, V328, P174, DOI 10.1016/j.ab.2004.01.020; Fernandez-Gomez FJ, 2005, NEUROBIOL DIS, V20, P384, DOI 10.1016/j.nbd.2005.03.019; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garrett TJ, 2006, ANAL CHEM, V78, P2465, DOI 10.1021/ac0522761; Gohil VM, 2005, ANAL BIOCHEM, V343, P350, DOI 10.1016/j.ab.2005.04.039; Gostimskaya IS, 2003, ANAL BIOCHEM, V313, P46, DOI 10.1016/S0003-2697(02)00534-1; Greenberg ME, 2006, J EXP MED, V203, P2613, DOI 10.1084/jem.20060370; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; GURD JW, 1974, J NEUROCHEM, V22, P281, DOI 10.1111/j.1471-4159.1974.tb11591.x; Gylys KH, 2000, J NEUROSCI RES, V61, P186, DOI 10.1002/1097-4547(20000715)61:2<186::AID-JNR9>3.0.CO;2-X; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Hong S, 2007, J AM SOC MASS SPECTR, V18, P128, DOI 10.1016/j.jasms.2006.09.002; Horkko S, 2001, CIRCULATION, V103, P941; Hsu FF, 2006, J AM SOC MASS SPECTR, V17, P420, DOI 10.1016/j.jasms.2005.11.019; Jackson SN, 2007, J AM SOC MASS SPECTR, V18, P17, DOI 10.1016/j.jasms.2006.08.015; Jacobson J, 2002, J NEUROCHEM, V82, P224, DOI 10.1046/j.1471-4159.2002.00945.x; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jiang JF, 2003, FREE RADICAL BIO MED, V35, P814, DOI 10.1016/S0891-5849(03)00429-5; Kagan V E, 1998, Methods Mol Biol, V108, P71; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Kanter JL, 2006, NAT MED, V12, P138, DOI 10.1038/nm1344; Kirkinezos IG, 2005, J NEUROSCI, V25, P164, DOI 10.1523/JNEUROSCI.3829-04.2005; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001; Langmuir ME, 1996, FLUORESCENCE MICROSCOPY AND FLUORESCENT PROBES, P229; Leitinger N, 2005, MOL NUTR FOOD RES, V49, P1063, DOI 10.1002/mnfr.200500086; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Marathe GK, 2000, FREE RADICAL BIO MED, V28, P1762, DOI 10.1016/S0891-5849(00)00234-3; MAVELLI I, 1982, BIOCHEM J, V204, P535, DOI 10.1042/bj2040535; Meagher EA, 2000, FREE RADICAL BIO MED, V28, P1745, DOI 10.1016/S0891-5849(00)00232-X; Mileykovskaya E, 2001, FEBS LETT, V507, P187, DOI 10.1016/S0014-5793(01)02948-9; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; RashbaStep J, 1997, ARCH BIOCHEM BIOPHYS, V343, P44, DOI 10.1006/abbi.1997.0134; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Ritov VB, 2006, J CHROMATOGR B, V831, P63, DOI 10.1016/j.jchromb.2005.11.031; Ritov VB, 2004, ANAL BIOCHEM, V333, P27, DOI 10.1016/j.ab.2004.05.014; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Taguchi R, 2000, J MASS SPECTROM, V35, P953, DOI 10.1002/1096-9888(200008)35:8<953::AID-JMS23>3.3.CO;2-W; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1; Urano S, 1997, EUR J BIOCHEM, V245, P64, DOI 10.1111/j.1432-1033.1997.00064.x; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WEILER MH, 1981, J NEUROCHEM, V36, P1802, DOI 10.1111/j.1471-4159.1981.tb00434.x; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	70	138	144	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	AUG	2007	62	2					154	169		10.1002/ana.21168			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	215TI	WOS:000249831500009	17685468				2022-02-06	
J	Olivecrona, M; Rodling-Wahlstrom, M; Naredi, S; Koskinen, LOD				Olivecrona, Magnus; Rodling-Wahlstrom, Marie; Naredi, Silvana; Koskinen, Lars-Owe D.			Effective ICP reduction by decompressive craniectomy in patients with severe traumatic brain injury treated by an ICP-targeted therapy	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; head injury; ICP; Lund concept; outcome	CEREBRAL-ARTERY INFARCTION; SEVERE HEAD-INJURIES; INTRACRANIAL HYPERTENSION; VOLUME REGULATION; LUND CONCEPT; BLOOD-FLOW; MANAGEMENT; HEMICRANIECTOMY; CRANIOPLASTY; EDEMA	Severe traumatic brain injury (TBI) is one of the major causes of death in younger age groups. In Umea, Sweden, an intracranial pressure (ICP) targeted therapy protocol, the Lund concept, has been used in treatment of severe TBI since 1994. Decompressive craniectomy is used as a protocol-guided treatment step. The primary aim of the investigation was to study the effect of craniectomy on ICP changes over time in patients with severe TBI treated by an ICP-targeted protocol. In this retrospective study, all patients treated for severe TBI during 1998-2001 who fulfilled the following inclusion criteria were studied: GCS <= 8 at intubation and sedation, first recorded cerebral perfusion pressure (CPP) of > 10 mm Hg, arrival within 24 h of trauma, and need of intensive care for > 72 h. Craniectomy was performed when the ICP could not be controlled by evacuation of hematomas, sedation, ventriculostomy, or low-dose pentothal infusion. Ninety-three patients met the inclusion criteria. Mean age was 37.6 years. Twenty-one patients underwent craniectomy as a treatment step. We found a significant reduction of the ICP directly after craniectomy, from 36.4 mm Hg (range, 18-80 mm Hg) to 12.6 mm Hg (range, 2-51 mm Hg). During the following 72 h, we observed an increase in ICP during the first 8-12 h after craniectomy, reaching approximately 20 mm Hg, and later levelling out at approximately 25 mm Hg. The reduction of ICP was statistically significant during the 72 h. The outcome as measured by Glasgow Outcome Scale (GOS) did not significantly differ between the craniectomized group (DC) and the non-craniectomized group (NDC). The outcome was favorable (GOS 5-4) in 71 % in the craniectomized group, and in 61 % in the non-craniectomized group. Craniectomy is a useful tool in achieving a significant reduction of ICP over time in TBI patients with progressive intracranial hypertension refractory to medical therapy. The procedure seems to have a satisfactory effect on the outcome, as demonstrated by a high rate of favorable outcome and low mortality in the craniectomized group, which did not significantly differ compared with the non-craniectomized group.	Univ Umea Hosp, Dept Neurosurg, S-90185 Umea, Sweden; Univ Umea Hosp, Dept Anesthesiol, S-90185 Umea, Sweden		Olivecrona, M (corresponding author), Univ Umea Hosp, Dept Neurosurg, S-90185 Umea, Sweden.	magnus.olivecrona@vll.se	Koskinen, Lars-Owe/AAQ-8957-2020	Koskinen, Lars-Owe/0000-0003-3528-8502; Naredi, Silvana/0000-0002-4409-6089; Olivecrona, Magnus/0000-0001-8457-4711			Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Fodstad H, 1979, Acta Neurochir Suppl (Wien), V28, P514; GAAB MR, 1990, ACT NEUR S, V51, P326; Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; GRANDE PO, 1997, J TRAUMA, V42, P23; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; KOCHER ET, 1901, SPECIELLE PATHOLOGIE, P255; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; Malm J, 2006, ACTA NEUROL SCAND, V113, P25, DOI 10.1111/j.1600-0404.2005.00537.x; Meier U, 2003, ACTA NEUROCHIR SUPPL, V86, P367; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RINALDI A, 1990, ACT NEUR S, V51, P394; Schneider GH, 2002, ACT NEUR S, V81, P77; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166	30	138	144	1	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					927	935		10.1089/neu.2005.356E			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700002	17600510	Green Submitted			2022-02-06	
J	Sun, D; McGinn, MJ; Zhou, ZW; Ben Harvey, H; Bullock, MR; Colello, RJ				Sun, Dong; McGinn, Melissa J.; Zhou, Zhengwen; Ben Harvey, H.; Bullock, M. Ross; Colello, Raymond J.			Anatomical integration of newly generated dentate granule neurons following traumatic brain injury in adult rats and its association to cognitive recovery	EXPERIMENTAL NEUROLOGY			English	Article						neurogenesis; traumatic brain injury; hippocampus; cognition; Morris water maze; axon connection	CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; HIPPOCAMPAL NEUROGENESIS; ENRICHED ENVIRONMENT; SUBVENTRICULAR ZONE; CA3 REGION; GYRUS; PROLIFERATION; DIFFERENTIATION; PERFORMANCE	The hippocampus is particularly vulnerable to traumatic brain injury (TB1), the consequences of which are manifested as learning and memory deficits. Following injury, substantive spontaneous cognitive recovery occurs, suggesting that innate repair mechanisms exist in the brain. However, the underlying mechanism contributing to this is largely unknown. The existence of neural stem cells in the adult hippocampal dentate gyrus (DG) and their proliferative response following injury led us to speculate that neurogenesis may contribute to cognitive recovery following TBI. To test this, we first examined the time course of cognitive recovery following lateral fluid percussion injury in rats. Cognitive deficits were tested at 11-15, 26-30 or 56-60 days post-injury using Morris Water Maze. At 11-15 and 26-30 days post-injury, animals displayed significant cognitive deficits, which were no longer apparent at 56-60 days post-TBI, suggesting an innate cognitive recovery at 56-60 days. We next examined the proliferative response, maturational fate and integration of newly generated cells in the DG following injury. Specifically, rats received BrdU at 2-5 days post-injury followed by Fluorogold (FG) injection into the CA3 region at 56 days post-TBI. We found the majority of BrdU+ cells which survived for 10 weeks became dentate granule neurons, as assessed by NeuN and calbindin labeling, approximately 30% being labeled with FG, demonstrating their integration into the hippocampus. Additionally, some BrdU+ cells were synaptophysin-positive, suggesting they received synaptic input. Collectively, our data demonstrate the extensive anatomical integration of new born dentate granule neurons at the time when innate cognitive recovery is observed. (c) 2006 Elsevier Inc. All rights reserved.	Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia Campus,POB 980631, Richmond, VA 23298 USA.	dsun@vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER		Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; Hagood SK, 2006, J NEUROTRAUM, V23, P205, DOI 10.1089/neu.2006.23.205; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2002, EUR J NEUROSCI, V16, P129, DOI 10.1046/j.1460-9568.2002.02042.x; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Markakis EA, 1999, J COMP NEUROL, V406, P449; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011	40	138	144	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2007	204	1					264	272		10.1016/j.expneurol.2006.11.005			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	148PC	WOS:000245086100027	17198703				2022-02-06	
J	De Beaumont, L; Brisson, B; Lassonde, M; Jolicoeur, P				De Beaumont, Louis; Brisson, Benoit; Lassonde, Maryse; Jolicoeur, Pierre			Long-term electrophysiological changes in athletes with a history of multiple concussions	BRAIN INJURY			English	Article						sports concussion; Event-Related Potentials (ERPs); P3; visual-spatial attention; N2pc	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; VISUAL-SPATIAL ATTENTION; CLOSED-HEAD INJURY; P300 LATENCY; PROCESSING DEFICITS; MENTAL CHRONOMETRY; COMPONENT; FOOTBALL; TASK	Primary objective: This event-related potentials study investigated the long- term effects associated with a history of one or multiple concussions on the N2pc and P3 components using a visual search oddball paradigm. Methods and procedure: A total of 47 university football players were assigned to three experimental groups based on prior concussion history: Athletes with a history of one concussion (single-concussion group); Athletes with two or more concussions (multi-concussion group); non-concussed athletic controls. The average post-concussion period was 31 months for athletes in the multi-concussion group and 59 months for the single-concussion group. Results: This study found significantly suppressed P3 amplitude in the multi-concussed athletes group compared to the single-concussion and non-concussed athletes even when using the time since the latest concussion as a covariate. Conclusion: This finding suggests that the multi- concussed athletes group showed long-lasting P3 amplitude suppression when compared with single- concussion or non-concussed athletes despite equivalent neuropsychological test scores and post-concussion symptoms self-reports. This pattern of results is important because it shows that 'old' concussions do not cause general or ubiquitous electrophysiological suppression. The specificity of the long-term effects of previous concussions to the P3, along with an intact N2pc response, suggests that further work may allow one to pinpoint the cognitive system that is specifically affected by multiple concussions.	Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada		De Beaumont, L (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, CP 6128 Succ Ctr Ville Montreal,Pavillon Marie Vi, Montreal, PQ H3C 3J7, Canada.	louis.de.beaumont@umontreal.ca		Brisson, Benoit/0000-0002-3717-3365			Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BRISSON B, IN PRESS PSYCHONOMIC; Brisson B, 2007, PSYCHOPHYSIOLOGY, V44, P323, DOI 10.1111/j.1469-8986.2007.00503.x; Coles M. G. H., 1994, OX PSYCH S, P86; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; COOPER R, 1980, EEG TECHNOLOGY; Dell'Acqua R, 2006, PSYCHOPHYSIOLOGY, V43, P394, DOI 10.1111/j.1469-8986.2006.00411.x; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DONCHIN E, 1966, IEEE T BIO-MED ENG, VBM13, P131, DOI 10.1109/TBME.1966.4502423; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Duncan-Johnson C C, 1980, Prog Brain Res, V54, P717, DOI 10.1016/S0079-6123(08)61693-3; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Eimer M, 1996, ELECTROEN CLIN NEURO, V99, P225, DOI 10.1016/0013-4694(96)95711-9; EMMERSON RY, 1989, EXP AGING RES, V15, P151, DOI 10.1080/03610738908259769; FABIANI M, 1990, ELECTROEN CLIN NEURO, V75, P22, DOI 10.1016/0013-4694(90)90149-E; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GAETZ M, 2001, BRAIN INJURY, V14, P386; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Holbourn AHS, 1943, LANCET, V2, P438; Holguin SR, 1999, ALCOHOL CLIN EXP RES, V23, P582, DOI 10.1097/00000374-199904000-00003; Ilan AB, 1999, CLIN NEUROPHYSIOL, V110, P367; IVERSON GL, 2004, AM J PHYS MED REHABI, V82, P653; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; JOHNSON R, 1978, ELECTROEN CLIN NEURO, V44, P424, DOI 10.1016/0013-4694(78)90027-5; Johnson R, 1995, EEG CL N SU, P110; Jolicoeur P, 2006, EUR J COGN PSYCHOL, V18, P560, DOI 10.1080/09541440500423210; Jolicoeur P, 2006, PSYCHOL RES-PSYCH FO, V70, P414, DOI 10.1007/s00426-005-0008-4; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; KRAMER AF, 1988, BIOL PSYCHOL, V26, P231, DOI 10.1016/0301-0511(88)90022-1; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Luck SJ, 1997, COGNITIVE PSYCHOL, V33, P64, DOI 10.1006/cogp.1997.0660; LUCK SJ, 1994, J EXP PSYCHOL HUMAN, V20, P1000, DOI 10.1037/0096-1523.20.5.1000; LUCK SJ, 1994, PSYCHOPHYSIOLOGY, V31, P291, DOI 10.1111/j.1469-8986.1994.tb02218.x; Lum J, 2002, RES Q EXERCISE SPORT, V73, P156, DOI 10.1080/02701367.2002.10609004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAuliffe J, 2004, J GEN PSYCHOL, V131, P426, DOI 10.3200/GENP.131.4.426-437; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Miller J, 1998, PSYCHOPHYSIOLOGY, V35, P99, DOI 10.1111/1469-8986.3510099; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; PFEFFERBAUM A, 1986, ELECTROEN CLIN NEURO, V64, P424, DOI 10.1016/0013-4694(86)90076-3; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POLICH J, 1989, ELECTROEN CLIN NEURO, V74, P312, DOI 10.1016/0168-5597(89)90061-0; Polich J, 1998, J CLIN NEUROPHYSIOL, V15, P14, DOI 10.1097/00004691-199801000-00004; POLICH J, 1983, PSYCHOPHYSIOLOGY, V20, P665, DOI 10.1111/j.1469-8986.1983.tb00936.x; POLICH J, 1988, J CLIN NEUROPHYSIOL, V5, P287, DOI 10.1097/00004691-198807000-00004; POLICH J, 1992, BIOL PSYCHIAT, V31, P647; Polich John, 2004, Phys Med Rehabil Clin N Am, V15, P133, DOI 10.1016/S1047-9651(03)00109-8; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Reinvang I, 1999, NEUROPSYCHOL REV, V9, P231, DOI 10.1023/A:1021638723486; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Sawaki R, 2006, NEUROSCI LETT, V407, P86, DOI 10.1016/j.neulet.2006.08.006; Shutter L, 2006, J HEAD TRAUMA REHAB, V21, P334, DOI 10.1097/00001199-200607000-00005; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207; Woodman GF, 2003, J EXP PSYCHOL HUMAN, V29, P121, DOI 10.1037/0096-1523.29.1.121; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	73	138	138	0	35	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	6					631	644		10.1080/02699050701426931			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	192LU	WOS:000248204100010	17577714				2022-02-06	
J	Sye, G; Sullivan, SJ; McCrory, P				Sye, Garry; Sullivan, S. John; McCrory, Paul			High school rugby players' understanding of concussion and return to play guidelines	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							FOOTBALL PLAYERS; INJURIES; EPIDEMIOLOGY	Objective: To document high school players' understanding and attitudes towards concussion return to play guidelines. Methods: A questionnaire based survey was performed of national high school rugby players as to their knowledge of existing concussion return to play guidelines. Results: A total of 600 male players were surveyed, and 477 responded (response rate 80%). Half (237/477) were aware of concussion guidelines, and 60% (288/477) identified the mandated stand down period that is part of the regulations governing rugby football. Players obtained their information primarily from: teachers/coaches (239 responses), medical personnel (200), and other players (116). Of those players who suspected that they had been concussed (296/477, 62%), only 66 returned to play after medical clearance. Conclusions and implications: This sample of high school players showed a limited knowledge of the concussion guidelines covering their sport, and even when concussed did not follow recommended protocols. This indicates the need for an increased focus on player education.	Univ Otago, Dunedin, New Zealand; Univ Melbourne, Melbourne, Vic, Australia; Kennedy Rd Physiotherapy, Napier, New Zealand		Sullivan, SJ (corresponding author), Univ Otago, Dunedin, New Zealand.	sjohn.sullivan@otago.ac.nz	McCrory, Paul/Q-8688-2019				Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Carson JD, 1999, CLIN J SPORT MED, V9, P75, DOI 10.1097/00042752-199904000-00006; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DELANEY JS, 1997, CLIN J SPORT MED, V10, P9; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GIANOTTI S, 2004, BRIT J SPORT MED, V38, P660; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; LEES AJ, 1996, BRIT J SPORT MED, V30, P213; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; MILNE C, 1999, NZ J SPORTS MED, V27, P15; ROUX CE, 1987, S AFR MED J, V71, P307	14	138	140	0	25	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	DEC	2006	40	12					1003	1004		10.1136/bjsm.2005.020511			2	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	108IY	WOS:000242234700019	17124109	Green Published			2022-02-06	
J	LaPlaca, MC; Cullen, DK; McLoughlin, JJ; Cargill, RS				LaPlaca, MC; Cullen, DK; McLoughlin, JJ; Cargill, RS			High rate shear strain of three-dimensional neural cell cultures: a new in vitro traumatic brain injury model	JOURNAL OF BIOMECHANICS			English	Article						strain rate; 3-D; astrocyte; neuron; traumatic injury; cell mechanics	DIFFUSE AXONAL INJURY; NEURONAL INJURY; HEAD-INJURY; SPINAL-CORD; TISSUE; DEGENERATION; ANTAGONISTS; DIMENSIONS; RECEPTOR; PRIMATE	The fidelity of cell culture simulations of traumatic brain injury (TBI) that yield tolerance and mechanistic information relies on both the cellular models and mechanical insult parameters. We have designed and characterized an electro-mechanical cell shearing device in order to produce a controlled high strain rate injury (up to 0.50 strain, 30 s(-1) strain rate) that deforms three-dimensional (3-D) neural cultures (neurons or astrocytes in an extracellular matrix scaffold). Theoretical analysis revealed that these parameters generate a heterogeneous 3-D strain field throughout the cultures that is dependent on initial cell orientation within the matrix, resulting in various combinations of normal and shear strain. The ability to create a linear shear strain field over a range of input parameters was verified by tracking fluorescent microbeads in an acellular matrix during maximal displacement for a range of strains and strain rates. In addition, cell death was demonstrated in rat cortical astrocytes and neurons in response to high rate, high magnitude shear strain. Furthermore, cell response within the 3-D neuronal cultures depended on orientation, with higher predicted shear strain correlating with an increased loss of neurites, indicating that culture configuration may be an important factor in the mechanical, and hence cellular, response to traumatic insults. Collectively, these results suggest that differential responses exist within a 3-D culture subjected to mechanical insult, perhaps mimicking the in vivo environment, and that this new model can be used to investigate the complex cellular mechanisms associated with TBI. (c) 2004 Elsevier Ltd. All rights reserved.	Georgia Inst Technol, Lab Neuroengn, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Woodruff Sch Mech Engn, Atlanta, GA 30332 USA		LaPlaca, MC (corresponding author), Georgia Inst Technol, Lab Neuroengn, Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001014-2] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER		BALENTINE JD, 1988, LAB INVEST, V58, P93; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHU CS, 1994, J BIOMECH, V27, P187, DOI 10.1016/0021-9290(94)90208-9; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FAWCETT JW, 1995, EXP BRAIN RES, V106, P275; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1993, J EMERG MED, V1, P5; Granet C, 1998, MED BIOL ENG COMPUT, V36, P513, DOI 10.1007/BF02523224; GROSS GW, 1983, J NEUROSCI, V3, P1979; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P615, DOI 10.1016/0955-0674(95)80101-4; Holbourn AHS, 1943, LANCET, V2, P438; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Mukhin A, 1996, J NEUROSCI, V16, P6012; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Ogden, 1984, NONLINEAR ELASTIC DE; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Sieg F, 1999, J NEUROTRAUM, V16, P1197, DOI 10.1089/neu.1999.16.1197; Sievers C, 2003, NEUROSCI RES, V46, P161, DOI 10.1016/S0168-0102(03)00039-7; Takeshita K, 1998, IN VITRO CELL DEV-AN, V34, P482; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Wallis RA, 1995, EUR J PHARMACOL, V294, P475, DOI 10.1016/0014-2999(95)00568-4; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001	40	138	142	1	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	MAY	2005	38	5					1093	1105		10.1016/j.jbiomech.2004.05.032			13	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	916RX	WOS:000228404700013	15797591				2022-02-06	
J	Arima, H; Yamamoto, N; Sobue, K; Umenishi, F; Tada, T; Katsuya, H; Asai, K				Arima, H; Yamamoto, N; Sobue, K; Umenishi, F; Tada, T; Katsuya, H; Asai, K			Hyperosmolar mannitol stimulates expression of aquaporins 4 and 9 through a p38 mitogen-activated protein kinase-dependent pathway in rat astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTONICITY-RESPONSIVE ELEMENT; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; WATER CHANNEL; MAP KINASE; GENE-EXPRESSION; DIFFERENTIAL REGULATION; MAMMALIAN-CELLS; MESSENGER-RNA; IN-VITRO	The membrane pore proteins, aquaporins (AQPs), facilitate the osmotically driven passage of water and, in some instances, small solutes. Under hyperosmotic conditions, the expression of some AQPs changes, and some studies have shown that the expression of AQP1 and AQP5 is regulated by MAPKs. However, the mechanisms regulating the expression of AQP4 and AQP9 induced by hyperosmotic stress are poorly understood. In this study, we observed that hyperosmotic stress induced by mannitol increased the expression of AQP4 and AQP9 in cultured rat astrocytes, and intraperitoneal infusion of mannitol increased AQP4 and AQP9 in the rat brain cortex. In addition, a p38 MAPK inhibitor, but not ERK and JNK inhibitors, suppressed their expression in cultured astrocytes. AQPs play important roles in maintaining brain homeostasis. The expression of AQP4 and AQP9 in astrocytes changes after brain ischemia or traumatic injury, and some studies have shown that p38 MAPK in astrocytes is activated under similar conditions. Since mannitol is commonly used to reduce brain edema, understanding the regulation of AQPs and p38 MAPK in astrocytes under hyperosmotic conditions induced with mannitol may lead to a control of water movements and a new treatment for brain edema.	Okazaki City Hosp, Dept Anesthesia & Crit Care, Okazaki, Aichi 4448553, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Anesthesiol & Med Crisis Management, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Neurobiol, Nagoya, Aichi 4678601, Japan; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA; Nagoya City Univ, Sch Nursing, Dept Pathol, Mizuho Ku, Nagoya, Aichi 4678601, Japan		Arima, H (corresponding author), Okazaki City Hosp, Dept Anesthesia & Crit Care, 3-1 goshoai,Koryuji Cho, Okazaki, Aichi 4448553, Japan.	arima@sb.starcat.ne.jp	Asai, Kiyofumi/H-2356-2014	Asai, Kiyofumi/0000-0001-7015-2251			Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; BEDFORD JJ, 1993, AM J PHYSIOL, V264, pR1164, DOI 10.1152/ajpregu.1993.264.6.R1164; Borok Z, 1998, AM J RESP CELL MOL, V18, P554, DOI 10.1165/ajrcmb.18.4.2838; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Connolly DL, 1998, INT J BIOCHEM CELL B, V30, P169, DOI 10.1016/S1357-2725(97)00124-6; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Endo M, 1999, MICROVASC RES, V58, P89, DOI 10.1006/mvre.1999.2158; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Furuno M, 1996, AM J PHYSIOL-RENAL, V271, pF854, DOI 10.1152/ajprenal.1996.271.4.F854; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hasler U, 2002, J BIOL CHEM, V277, P10379, DOI 10.1074/jbc.M111880200; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; Hozawa S, 1996, AM J PHYSIOL-CELL PH, V270, pC1695, DOI 10.1152/ajpcell.1996.270.6.C1695; Ishibashi K, 2000, REV PHYSIOL BIOCH P, V141, P1, DOI 10.1007/BFb0119576; Jenq W, 1998, BIOCHEM BIOPH RES CO, V245, P804, DOI 10.1006/bbrc.1998.8518; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KATO T, 1979, BIOCHIM BIOPHYS ACTA, V579, P216, DOI 10.1016/0005-2795(79)90100-4; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Ko SBH, 1999, BIOCHEM MOL BIOL INT, V47, P309; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; Kultz D, 1998, J EXP BIOL, V201, P3015; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Matsuzaki T, 2001, AM J PHYSIOL-CELL PH, V281, pC55, DOI 10.1152/ajpcell.2001.281.1.C55; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nakahama K, 1999, GLIA, V25, P240, DOI 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.0.CO;2-C; Nico B, 2001, J CELL SCI, V114, P1297; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; SATO Y, 1986, AM J PATHOL, V125, P431; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Sugiyama Y, 2001, BBA-GENE STRUCT EXPR, V1522, P82, DOI 10.1016/S0167-4781(01)00320-7; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Uehara T, 1999, BRAIN RES, V823, P226, DOI 10.1016/S0006-8993(99)01178-6; Umenishi F, 2003, J BIOL CHEM, V278, P15765, DOI 10.1074/jbc.M209980200; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V292, P771, DOI 10.1006/bbrc.2002.6709; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Yamamoto N, 2002, MOL BRAIN RES, V104, P96, DOI 10.1016/S0169-328X(02)00322-4; Yamamoto N, 2001, MOL BRAIN RES, V95, P110, DOI 10.1016/S0169-328X(01)00254-6; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Yoneda K, 2001, MOL BRAIN RES, V89, P94, DOI 10.1016/S0169-328X(01)00067-5; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	55	138	162	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44525	44534		10.1074/jbc.M304368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	WOS:000186306700081	12944406	hybrid			2022-02-06	
J	Meixensberger, J; Jaeger, M; Vath, A; Dings, J; Kunze, E; Roosen, K				Meixensberger, J; Jaeger, M; Vath, A; Dings, J; Kunze, E; Roosen, K			Brain tissue oxygen guided treatment supplementing ICP/CPP therapy after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; PARTIAL-PRESSURE; MANAGEMENT; METABOLISM; INSULTS	Objective: To evaluate the effects of a brain tissue oxygen (PtiO2) guided treatment in patients with traumatic brain injury. Methods: PtiO2 was monitored in 93 patients with severe traumatic brain injury. Forty patients admitted from 1993 to 1996 were treated with intracranial pressure/cerebral perfusion pressure (ICP/CPP) management alone (ICP < 20 mm Hg, CPP > 70 mm Hg). Fifty three patients admitted from 1997 to 2000 were treated using ICP/CPP management, but in this second group CPP was also increased as individually required to raise the PtiO2 above 1.33 kPa (10 mm Hg) (PtiO2 guided group). Results: Cerebral hypoxic phases with PtiO2 values below 1.33 kPa occurred significantly less often in the PtiO2 guided group. PtiO2 values were higher over the whole monitoring period. No statistical differences could be observed in outcome at six months, despite a positive trend in the PtiO2 guided group. Conclusions: Cerebral hypoxic events can be reduced significantly by increasing cerebral perfusion pressure as required. To show a clear beneficial effect of PtiO2 guided cerebral perfusion pressure management on outcome, a multicentre randomised trial needs to be undertaken.	Univ Klinikum Leipzig, Neurochirurg Klin, D-04103 Leipzig, Germany; Univ Wurzburg, Neurochirurg Klin, Wurzburg, Germany; Acad Ziekenhuis Maastricht, Dept Neurosurg, Maastricht, Netherlands		Meixensberger, J (corresponding author), Univ Klinikum Leipzig, Neurochirurg Klin, Johannisallee 34, D-04103 Leipzig, Germany.	meix@medizin.uni-leipzig.de	Kunze, Ekkehard/AAE-6926-2019				Bardt TF, 1998, ACT NEUR S, V71, P153; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Dings J, 1998, NEUROL RES, V20, pS71; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; JENNETT B, 1975, LANCET, V1, P480; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P28; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; TEASDALE G, 1974, LANCET, V2, P81; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	30	138	141	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2003	74	6					760	764		10.1136/jnnp.74.6.760			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	679QC	WOS:000182932600016	12754347	Green Published, Bronze			2022-02-06	
J	Whitfield, PC; Patel, H; Hutchinson, PJA; Czosnyka, M; Parry, D; Menon, D; Pickard, JD; Kirkpatrick, PJ				Whitfield, PC; Patel, H; Hutchinson, PJA; Czosnyka, M; Parry, D; Menon, D; Pickard, JD; Kirkpatrick, PJ			Bifrontal decompressive craniectomy in the management of posttraumatic intracranial hypertension	BRITISH JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; head injury; intracranial pressure; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; INFARCTION; EDEMA; CARE	Bifrontal decompressive craniectomy has been used on an ad hoc basis for the treatment of post-traumatic intracranial hypertension for more than thirty years. In this observational study we report the clinical outcome and physiological effects of the procedure in a series of 26 patients with refractory intracranial hypertension treated on a protocol driven basis. Bifrontal decompressive craniectomy was associated with significant reductions in mean ICP from 37.5 to 18.1 mmHg (p = 0.003). In addition, craniectomy reduced the amplitude of ICP waves (p < 0.02) and increased compensatory reserve (p < 0.05). A favourable outcome was achieved in 69% of patients; 8% were severely disabled and 23% died. We conclude that this study provides pathophysiological evidence that bifrontal decompressive craniectomy significantly reduces posttraumatic intracranial hypertension and improves pressure dynamics. Our results support the continued use of bifrontal decompressive craniectomy in selected patients after head injury.	Addenbrookes NHS Trust, Dept Acad Neurosurg, Cambridge CB2 2QQ, England; Addenbrookes NHS Trust, Dept Neuroanaesthesia, Cambridge CB2 2QQ, England		Whitfield, PC (corresponding author), Aberdeen Royal Infirm, Dept Neurosurg, Ward 40, Aberdeen AB25 2ZN, Scotland.				MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; GAAB MR, 1990, ACT NEUR S, V51, P326; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; JENKINSON C, 1993, SF36 HLTH SERV RES U; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kirkpatrick PJ, 1996, J NEUROL NEUROSUR PS, V60, P131, DOI 10.1136/jnnp.60.2.131; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Kunze E, 1998, ACT NEUR S, V71, P16; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PRICE DJ, 1994, INTRACRANIAL PRESSUR, V9, P464; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RINALDI A, 1990, ACT NEUR S, V51, P394; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; Spiller WG, 1906, J AMER MED ASSOC, V47, P679; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; WHITFIELD P, 1995, STROKE, V26, P1125; WHITFIELD PC, 2000, BRIT J NEUROSURG, V14, P170; WHITFIELD PC, 2000, BRIT J NEUROSURG, V14, P292; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; YAMAURA A, 1979, Neurologia Medico-Chirurgica, V19, P717, DOI 10.2176/nmc.19.717; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	30	138	153	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	DEC	2001	15	6					500	507		10.1080/02688690120105110			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	513NZ	WOS:000173385800008	11814002				2022-02-06	
J	King, NS				King, NS			Emotional, neuropsychological, and organic factors: Their use in the prediction of persisting postconcussion symptoms after moderate and mild head injuries	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						postconcussion symptoms; predictors of mild head injury; head injury	CONCUSSION; SEQUELAE; TIME; RECOVERY; SCALE	Background-After mild and moderate bead injuries a range of postconcussion symptoms (PCS) are often reported by patients. Both organic and psychogenic factors can contribute to these. Full recovery from PCS usually occurs within three months of the injury. A significant minority, however, continue to experience symptoms beyond this time. To date, no means of identifying these patients early after injury has been reported. This study investigates whether a combination of neuropsychological, emotional, and traditional measures of severity of head injury taken early after the injury can help predict severity of FCS three months after injury. Methods-50 patients with mild or moderate head injury had a range of measures administered at 7-10 days after injury. These included three tests of divided attention, a PCS rating scale-the Rivermead postconcussion symptoms questionnaire (RPQ), the hospital anxiety and depression scale (BADS), the impact of event scale (IES), and post-traumatic amnesia. An RPQ was then completed by all patients three months after injury. Results-Stepwise multiple regression analysis was performed with the RPQ score at three months as the dependent measure. A combination of eight of the scores from the early measures gave a multiple correlation coefficient of R = 0.86 accounting for 74% of the variance in RPQ scores. The most predictive individual measures were the HADS and IES. Regression analysis with RPQ score at 7-10 days as dependent measure showed that 10 of the scores gave a coefficient of R = 0.84 accounting for 71% of the variance. Conclusions-A combination of measures may significantly aid the prediction of persistent PCS. Five measures: HADS, post-traumatic amnesia, SOMC, PASAT, and RPQ are recommended for their predictive value and clinical utility. Independent cross validation studies are required before these results can be generally applied. They do, however, provide valuable indications regarding those measures that are most likely to demonstrate utility.	UNIV BIRMINGHAM,DEPT CLIN PSYCHOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND		King, NS (corresponding author), RIVERMEAD REHABIL CTR,ABINGDON RD,OXFORD OX1 4XD,ENGLAND.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1989, MILD HEAD INJURY, P229; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HOWELL DC, 1992, STAT METHODS PSYCHOL, P484; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; KATZMAN R, 1983, AM J PSYCHIAT, V140, P737; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V5, P5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Moss NE., 1994, CLIN REHABIL, V8, P149; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R. M., 1989, MILD HEAD INJURY, P176; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	36	138	139	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	1996	61	1					75	81		10.1136/jnnp.61.1.75			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	UW072	WOS:A1996UW07200018	8676166	Bronze, Green Published			2022-02-06	
J	Annegers, JF; Rocca, WA; Hauser, WA				Annegers, JF; Rocca, WA; Hauser, WA			Causes of epilepsy: Contributions of the Rochester epidemiology project	MAYO CLINIC PROCEEDINGS			English	Article							SEIZURE DISORDERS; FEBRILE CONVULSIONS; RISK-FACTORS; UNPROVOKED SEIZURES; ALZHEIMERS-DISEASE; OLMSTED-COUNTY; HEAD TRAUMA; MINNESOTA; POPULATION; CHILDHOOD	The contributions of the Rochester (Minnesota) Epidemiology Project and Mayo Clinic studies in the evaluation of the causes of epilepsy are summarized, The development of the unique population-based medical records-linkage resource is chronicled, and the measures of occurrence and association used in epidemiologic study designs to assess the causes of epilepsy are presented, The historical cohort design is optimal for the study of the relationship between common central nervous system insults and seizures, and case-control studies are best used for analysis of relatively rare seizure disorders, The major findings about the etiologic roles of traumatic brain injuries, central nervous system infections, cerebrovascular disease, brain tumors, neurodegenerative diseases, developmental disabilities, perinatal insults, and familial factors are discussed, The role of genetic factors in epilepsy has been controversial, perhaps because of the numerous causes of seizures and their episodic nature, Both potential environmental and genetic causes will continue to be assessed.	MAYO CLIN & MAYO FDN,CLIN EPIDEMIOL SECT,ROCHESTER,MN 55905; COLUMBIA UNIV COLL PHYS & SURG,GH SERGIEVSKY CTR,NEW YORK,NY 10032		Annegers, JF (corresponding author), UNIV TEXAS,HLTH SCI CTR,SCH PUBL HLTH,DIV EPIDEMIOL,HOUSTON,TX, USA.		Rocca, Walter/Z-5335-2019; Hauser, W Allen/AAB-5277-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS016308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 16308] Funding Source: Medline		ALSTROM C H, 1950, Acta Psychiatr Neurol Suppl, V63, P1; ANDERSON VE, 1993, TXB EPILEPSY, P47; ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ANNEGERS JF, 1982, NEUROLOGY, V32, P174, DOI 10.1212/WNL.32.2.174; ANNEGERS JF, 1976, EPILEPSIA, V17, P1, DOI 10.1111/j.1528-1157.1976.tb03375.x; ASCROFT PB, 1941, BRIT MED J, V1, P739; BLAKLEY SA, 1988, THESIS U TEXAS SCH P; EISNER V, 1960, J PEDIATR-US, V56, P347, DOI 10.1016/S0022-3476(60)80186-2; GREENBERG DA, 1988, AM J MED GENET, V31, P185, DOI 10.1002/ajmg.1320310125; HARVALD E, 1954, HEREDITY EPILEPSY EL; HAUSER WA, 1985, NEUROLOGY, V35, P1268, DOI 10.1212/WNL.35.9.1268; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HAUSER WA, 1986, NEUROLOGY, V36, P1226, DOI 10.1212/WNL.36.9.1226; HESDORFFER DC, IN PRESS NEUROLOGY; JENNETT WB, 1975, EPILEPSY NONMISSILE; KOKMEN E, 1993, NEUROLOGY, V43, P1887, DOI 10.1212/WNL.43.10.1887; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; MCVICKER RW, 1994, BRIT J PSYCHIAT, V164, P528, DOI 10.1192/bjp.164.4.528; METRAKOS K, 1961, NEUROLOGY, V11, P474, DOI 10.1212/WNL.11.6.474; NELSON KB, 1986, AM J DIS CHILD, V140, P1053, DOI 10.1001/archpedi.1986.02140240099034; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; OTTMAN R, 1988, AM J HUM GENET, V43, P257; PENFIELD W, 1945, RES PUBL ASSOC RES N, V24, P620; RICH SS, 1987, AM J HUM GENET, V41, P249; ROCCA WA, 1987, ANN NEUROL, V21, P22, DOI 10.1002/ana.410210106; ROCCA WA, 1987, NEUROLOGY, V37, P1315, DOI 10.1212/WNL.37.8.1315; ROCCA WA, 1987, NEUROLOGY, V37, P1309, DOI 10.1212/WNL.37.8.1309; ROMANELLI MF, 1990, ARCH NEUROL-CHICAGO, V47, P847, DOI 10.1001/archneur.1990.00530080029006; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; WALKER AE, 1970, EPILEPSIA, V11, P17, DOI 10.1111/j.1528-1157.1970.tb03861.x	37	138	143	0	14	MAYO CLINIC PROCEEDINGS	ROCHESTER	660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905	0025-6196			MAYO CLIN PROC	Mayo Clin. Proc.	JUN	1996	71	6					570	575		10.4065/71.6.570			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP773	WOS:A1996UP77300006	8642886				2022-02-06	
J	Cicerone, KD				Cicerone, KD			Attention deficits and dual task demands after mild traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD INJURY; NEUROPSYCHOLOGICAL DEFICITS; CONCUSSION; SEARCH	Attention deficits are a prominent aspect of cognitive dysfunction after mild traumatic brain injury (MTBI). Patients frequently complain of distractibility and difficulty attending to more than one thing at a time, and several neuropsychological studies have found evidence for a specific attention deficit without general neuropsychological impairment. The present study examined the nature of attentional disturbance after MTBI using an extended version of the 2 and 7 Test, which introduced two conditions reflecting patients' subjective complaints: the ability to perform with background 'noise', and while simultaneously attending to a secondary task. The dual task demands produced a significant slowing in processing speed for both the MTBI patients and control subjects. However, the relative decline in processing speed appeared much greater for the patients with MTBI, and they differed from control subjects only in this condition. The results are consistent with findings that patients with MTBI exhibit relatively subtle cognitive deficits which are apparent primarily under conditions which require effortful or controlled cognitive processing and exceed their available cognitive resources. Thus, the attentional deficits apparent during dual task demands may represent decreased cognitive, and perhaps neural, efficiency which reflects MTBI patients' subjective complaints and functional impairments.			Cicerone, KD (corresponding author), JFK JOHNSON REHABIL INST,2048 OAK TREE RD,EDISON,NJ 08820, USA.						BENTON A, 1986, CORTEX, V22, P129, DOI 10.1016/S0010-9452(86)80037-5; BERNAD PG, 1988, CLIN ELECTROENCEPHAL, V19, P174; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Committee on Mild Traumatic Brain Injury American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1228; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gentilini M., 1989, MILD HEAD INJURY, P162; GRONWALL D, 1975, LANCET, V2, P995; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; RUFF RM, 1992, PERCEPT MOTOR SKILL, V75, P1311, DOI 10.2466/PMS.75.8.1311-1319; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; VANZOMERAN AH, 1994, CLIN NEUROPSYCHOLOGY; WICKENS C. D., 1984, VARIETIES ATTENTION, P63	23	138	142	1	14	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1996	10	2					79	89		10.1080/026990596124566			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	UB726	WOS:A1996UB72600001	8696318				2022-02-06	
J	SBORDONE, RJ; LITER, JC				SBORDONE, RJ; LITER, JC			MILD TRAUMATIC BRAIN INJURY DOES NOT PRODUCE POSTTRAUMATIC-STRESS-DISORDER	BRAIN INJURY			English	Article							HEAD-INJURY; EFFICACY	It has been widely assumed that patients who sustain mild traumatic brain injury (MTBI) or post-concussive syndrome develop post-traumatic stress disorder (PTSD) in response to their cognitive difficulties, diminished coping skills, or other losses. This study examined 70 patients who had previously been diagnosed as having either PTSD or MTBI. Each patient was asked to provide a highly detailed chronological history of the events which preceded, followed, and occurred during the traumatic event, to indicate whether they were rendered unconscious or had amnesia for the event, and to describe the various symptoms they developed. All (100.0%) of the PTSD patients were able to provide a highly detailed and emotionally charged recollection of the events which occurred within 15 minutes of the traumatic event in comparison to none (0.0%) of the MTBI patients. None of the MTBI patients reported symptoms such as intrusive recollections of the traumatic event, nightmares, hypervigilance, phobic or startle reactions, or became upset when they were asked to describe the traumatic event or were exposed to stimuli associated with it. These data suggest that PTSD and MTBI are two mutually exclusive disorders, and that it is highly unlikely that MTBI patients develop PTSD symptoms. Furthermore, these findings suggest that clinicians should exercise considerable caution in ruling out PTSD prior to making the diagnosis of MTBI.	UNIV CALIF IRVINE,COLL MED,DEPT NEUROSURG,IRVINE,CA 92717; UNIV CALIF IRVINE,COLL MED,DEPT PHYS MED & REHABIL,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT COGNIT SCI,IRVINE,CA 92717								BALLENGER JC, 1988, ARCH GEN PSYCHIAT, V45, P413; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; EITINGER L, 1985, INTEGRATIVE PSYCHIAT, V3, P115; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, P807, DOI 10.2466/pms.1989.68.3.807; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; Horton A.M., 1991, ARCH CLIN NEUROPSYCH, V6, P195; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LAYTON BS, IN PRESS CLIN NEUROP; LEVY PC, 1991, AM J RESP CELL MOL, V5, P307, DOI 10.1165/ajrcmb/5.4.307; LONG C, 1983, PSYCHIAT MED, V1, P33; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Middelboe T., 1992, European Psychiatry, V7, P183; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Peterson L G, 1986, Adv Psychosom Med, V16, P84; Price K. P., 1994, DEF LAW J, V43, P113; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SBORDONE RJ, 1991, NEUROPSYCHOLOGY ATTO; SBORDONE RJ, 1992, NEUROLAW LETT   0503; SOLOMON SD, 1992, JAMA-J AM MED ASSOC, V268, P633, DOI 10.1001/jama.268.5.633; [No title captured]	21	138	138	0	5	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1995	9	4					405	412		10.3109/02699059509005780			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QY080	WOS:A1995QY08000008	7640686				2022-02-06	
J	MILLIGAN, CE; LEVITT, P; CUNNINGHAM, TJ				MILLIGAN, CE; LEVITT, P; CUNNINGHAM, TJ			BRAIN MACROPHAGES AND MICROGLIA RESPOND DIFFERENTLY TO LESIONS OF THE DEVELOPING AND ADULT VISUAL-SYSTEM	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						CELL DEATH; DORSAL LATERAL GENICULATE NUCLEUS; PHAGOCYTES	CENTRAL NERVOUS-SYSTEM; LATERAL GENICULATE-NUCLEUS; GLIA-PROMOTING FACTORS; NECROSIS FACTOR-ALPHA; ACID-INDUCED LESIONS; OPTIC-NERVE; IMMUNOHISTOCHEMICAL LOCALIZATION; WALLERIAN DEGENERATION; TRANSITORY MACROPHAGES; STIMULATED MACROPHAGES	Traumatic injury in the brain usually results in rapid degeneration of neuronal elements and a response by peripherally derived macrophages (brain macrophages, BMOs) and resident microglia. One intriguing result of lesions performed in the developing brain as compared to lesions of the mature brain is the faster resolution of the cellular debris and the absence of significant scarring. The purpose of this study was to examine the response of BMOs to induced cell death distant to the lesion site and to investigate possible differences in the responding phagocytic populations (BMOs versus microglia) following lesions in neonates and adults. Ablation of the visual cortex at birth results in very rapid retrograde degeneration and removal of neurons of the dorsal lateral geniculate nucleus (dLGN) within a few days. Lesions to the visual cortex of adult rats also induce neurons within the dLGN to die, but these cells do so over a much more protracted time course. Utilizing differences in morphology and immunocytochemical staining with the monoclonal antibodies ED1 and OX-42 to distinguish between BMOs and microglia, we found that in the developing CNS, BMOs are signalled rapidly and specifically to the location of induced cell death. Microglia are not involved in this response. As might be expected, the temporal response in the adult is much more protracted. In contrast to the developing brain, microglia and not macrophages are the predominant responding cell class after the adult lesion. The data suggest that these are distinct populations of phagocytic cells that respond to brain damage during development and in the adult, which may be critical in modulating the resolution and growth response after injury.	MED COLL PENN,EASTERN PENN PSYCHIAT INST DIV,DEPT ANAT & NEUROBIOL,PHILADELPHIA,PA 19129						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS016487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010560] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10560] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 16487] Funding Source: Medline		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; BARRON KD, 1990, BRAIN RES, V523, P219, DOI 10.1016/0006-8993(90)91490-8; BARRON KD, 1986, J NEUROCYTOL, V15, P345, DOI 10.1007/BF01611437; BOYA J, 1986, ACTA ANAT, V127, P142; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; COFFEY PJ, 1988, NEUROSCI LETT, V84, P178, DOI 10.1016/0304-3940(88)90404-1; CUNNINGHAM TJ, 1979, J COMP NEUROL, V184, P423, DOI 10.1002/cne.901840213; CUNNINGHAM TJ, 1982, INT REV CYTOL, V74, P163, DOI 10.1016/S0074-7696(08)61172-9; CUNNINGHAM TJ, 1987, ANN NY ACAD SCI, V495, P153, DOI 10.1111/j.1749-6632.1987.tb23673.x; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; del Rio-Hortega P., 1932, CYTOLOGY CELLULAR PA, V2, P482; DOUGHERTY PM, 1990, J NEUROIMMUNOL, V28, P201, DOI 10.1016/0165-5728(90)90013-D; EZEKOWITZ RAB, 1984, MACROPHAGE ACTIVATIO, P33; FALK W, 1980, INFECT IMMUN, V29, P953; FINLAY BL, 1982, J COMP NEUROL, V204, P318, DOI 10.1002/cne.902040403; Fujita S., 1976, PROGR NEUROPATHOLOGY, P1; FULCRAND J, 1977, J COMP NEUROL, V176, P189, DOI 10.1002/cne.901760204; GIULIAN D, 1986, J CELL BIOL, V102, P812, DOI 10.1083/jcb.102.3.812; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GIULIAN D, 1986, J CELL BIOL, V102, P803, DOI 10.1083/jcb.102.3.803; GORDON S, 1974, J EXP MED, V140, P995, DOI 10.1084/jem.140.4.995; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HAUN F, 1987, J COMP NEUROL, V256, P561, DOI 10.1002/cne.902560408; HETIER E, 1988, J NEUROSCI RES, V21, P391, DOI 10.1002/jnr.490210230; HEUMANN D, 1980, EXP BRAIN RES, V38, P75; HONDA M, 1983, J IMMUNOL, V131, P2989; HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253; HUTCHINS KD, 1990, DEV BRAIN RES, V55, P95, DOI 10.1016/0165-3806(90)90109-C; IMAMOTO K, 1977, J COMP NEUROL, V174, P255, DOI 10.1002/cne.901740205; INNOCENTI GM, 1983, DEV BRAIN RES, V11, P39, DOI 10.1016/0165-3806(83)90200-6; INNOCENTI GM, 1983, DEV BRAIN RES, V11, P55, DOI 10.1016/0165-3806(83)90201-8; JOO F, 1987, INT J DEV NEUROSCI, V5, P369, DOI 10.1016/0736-5748(87)90013-X; KAMBARA T, 1985, MACROPHAGE BIOL, P271; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; LINDHOLM P, 1988, NATURE, V330, P658; LING EA, 1979, J ANAT, V128, P847; MALONE JD, 1986, P NATL ACAD SCI USA, V83, P3307, DOI 10.1073/pnas.83.10.3307; MCCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077; MCGLADEMCCULLOH E, 1989, PNAS, V83, P1093; MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112; MOONEN G, 1981, HISTOCHEMISTRY, V71, P45; MURABE Y, 1981, CELL TISSUE RES, V216, P569, DOI 10.1007/BF00238652; MURABE Y, 1981, CELL TISSUE RES, V218, P75; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SATORRE J, 1986, ANAT EMBRYOL, V174, P321, DOI 10.1007/BF00698782; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; STAGAARD M, 1987, J NEUROCYTOL, V16, P131, DOI 10.1007/BF02456704; STOLL G, 1989, J NEUROSCI, V9, P2327; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; WERB Z, 1975, J EXP MED, V142, P346, DOI 10.1084/jem.142.2.346; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	60	138	139	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0021-9967			J COMP NEUROL	J. Comp. Neurol.	DEC 1	1991	314	1					136	146		10.1002/cne.903140113			11	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	GY244	WOS:A1991GY24400012	1797869				2022-02-06	
J	WOOLF, PD; HAMILL, RW; LEE, LA; COX, C; MCDONALD, JV				WOOLF, PD; HAMILL, RW; LEE, LA; COX, C; MCDONALD, JV			THE PREDICTIVE VALUE OF CATECHOLAMINES IN ASSESSING OUTCOME IN TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article									UNIV ROCHESTER,MED CTR,DEPT NEUROL,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT NEUROSURG,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DIV BIOSTAT,ROCHESTER,NY 14642		WOOLF, PD (corresponding author), UNIV ROCHESTER,MED CTR,DEPT MED,ENDOCRINE METAB UNIT,POB 693,ROCHESTER,NY 14642, USA.						ASKANAZI J, 1981, SURGERY, V89, P478; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRACKETT CE, 1979, CENTRAL NERVOUS SYST, P232; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; COLTON T, 1974, STATISTICS MED; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; CRYER PE, 1980, NEW ENGL J MED, V303, P436; FREDHOLM BB, 1979, ACTA PHYSIOL SCAND, V105, P481, DOI 10.1111/j.1748-1716.1979.tb00113.x; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HAMILL RW, 1987, ANN NEUROL, V21, P439; JACHUCK SJ, 1975, BRIT MED J, V1, P242, DOI 10.1136/bmj.1.5952.242; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LANGFITT TW, 1982, CLIN NEUR, V29, P353; McCullagh P, 1983, GENERALIZED LINEAR M, P127; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; PASSON PG, 1973, ANAL BIOCHEM, V51, P618, DOI 10.1016/0003-2697(73)90517-4; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; POSTEL J, 1977, ANN SURG, V185, P475, DOI 10.1097/00000658-197704000-00018; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SCHENK EA, 1966, CIRC RES, V18, P605, DOI 10.1161/01.RES.18.5.605; TEASDALE G, 1974, LANCET, V2, P81; WILMORE DW, 1974, ANN SURG, V180, P653, DOI 10.1097/00000658-197410000-00031; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444	33	138	141	1	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUN	1987	66	6					875	882		10.3171/jns.1987.66.6.0875			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	H4541	WOS:A1987H454100013	3572517				2022-02-06	
J	Hammel, J; Magasi, S; Heinemann, A; Gray, DB; Stark, S; Kisala, P; Carlozzi, NE; Tulsky, D; Garcia, SF; Hahn, EA				Hammel, Joy; Magasi, Susan; Heinemann, Allen; Gray, David B.; Stark, Susan; Kisala, Pamela; Carlozzi, Noelle E.; Tulsky, David; Garcia, Sofia F.; Hahn, Elizabeth A.			Environmental Barriers and Supports to Everyday Participation: A Qualitative Insider Perspective From People With Disabilities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Environment; Focus groups; Qualitative research; Rehabilitation; Social determinants of health; Social participation	FOCUS GROUPS; HEALTH; ENFRANCHISEMENT; INSTRUMENTS; LIMITATIONS; RELEVANT; INJURY; ISSUES	Objective: To describe environmental factors that influence participation of people with disabilities. Design: Constant comparative, qualitative analyses of transcripts from 36 focus groups across 5 research projects. Setting: Home, community, work, and social participation settings. Participants: Community-dwelling people (N=201) with diverse disabilities (primarily spinal cord injury, traumatic brain injury, and stroke) from 8 states. Interventions: None. Main Outcome Measures: Environmental barriers and supports to participation. Results: We developed a conceptual framework to describe how environmental factors influence the participation of people with disabilities, highlighting 8 domains of environmental facilitators and barriers (built, natural, assistive technology, transportation, information and technology access, social support and attitudes, systems and policies, economics) and a transactional model showing the influence of environmental factors on participation at the micro (individual), mesa (community), and macro (societal) levels. Focus group data validated some International Classification of Functioning, Disability and Health environmental categories while also bringing unique factors (eg, information and technology access, economic quality of life) to the fore. Data were used to construct items to enable people with disabilities to assess the impact of environmental factors on everyday participation from their firsthand experience. Conclusions: Participants with disabilities voiced the need to evaluate the impact of the environment on their participation at the immediate, community, and societal levels. The results have implications for assessing environmental facilitators and barriers to participation within rehabilitation and community settings, evaluating outcomes of environmental interventions, and effecting system and policy changes to target environmental barriers that may result in societal participation disparities versus opportunities. (C) 2015 by the American Congress of Rehabilitation Medicine	[Hammel, Joy; Magasi, Susan] Univ Illinois, Dept Occupat Therapy, Chicago, IL 60612 USA; [Hammel, Joy] Univ Illinois, Dept Disabil & Human, Chicago, IL 60612 USA; [Heinemann, Allen] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA; [Heinemann, Allen] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Gray, David B.] Washington Univ, Program Occupat Therapy, St Louis, MO USA; [Stark, Susan] Washington Univ, Occupat Therapy Neurol & Social Work, St Louis, MO USA; [Kisala, Pamela; Tulsky, David] Univ Delaware, Coll Hlth Sci, Dept Phys Therapy, Newark, DE USA; [Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ctr Clin Outcomes & Assessment Res, Ann Arbor, MI USA; [Tulsky, David] Kessler Fdn Res Ctr, W Orange, NJ USA; [Garcia, Sofia F.; Hahn, Elizabeth A.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Garcia, Sofia F.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; [Hahn, Elizabeth A.] Northwestern Univ, Feinberg Sch Med, Ctr Patient Ctr Outcomes, Chicago, IL 60611 USA		Hammel, J (corresponding author), Univ Illinois, Dept Occupat Therapy & Disabil & Human Dev, 1919 W Taylor St,Room 311, Chicago, IL 60612 USA.	hammel@uic.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Tulsky, David/0000-0002-4335-4509	National Institute on Disability through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant [H133B090024]; Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness [H133B040032]; National Institute on Disability and Rehabilitation Research (NIDRR) (Spinal Cord Injury-Quality of Life National Institute of Health R-01 [5R01HD054659]; Spinal Cord Injury-Quality of Life National Institute of Health R-01 (National Institute of Child Health and Human Development and National Institute of Neurological Disorders and Stroke); Traumatic Brain Injury, Quality of Life NIDRR Field-initiated grant [H133G070138]; Mobility Impaired Individuals with Secondary Conditions: Health, Participation and Environments [R04/CCR714134]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; National Center for Complementary and Alternative MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U54AR057951]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U54AR057951] Funding Source: NIH RePORTER	Supported by the National Institute on Disability through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant (grant no. H133B090024); Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness (award no. H133B040032); National Institute on Disability and Rehabilitation Research (NIDRR) (Spinal Cord Injury-Quality of Life National Institute of Health R-01 [award no. 5R01HD054659; cofunded by the National Institute of Child Health and Human Development and National Institute of Neurological Disorders and Stroke], Traumatic Brain Injury, Quality of Life NIDRR Field-initiated grant [grant no. H133G070138]; Mobility Impaired Individuals with Secondary Conditions: Health, Participation and Environments [award no. R04/CCR714134]); Centers for Disease Control and Prevention; and the National Center for Complementary and Alternative Medicine and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (award no U54AR057951).	[Anonymous], 2014, MERR WEBST ONL COLL; Barr O, 2003, DISABIL SOC, V18, P577, DOI 10.1080/0968759032000097834; Brod M, 2009, QUAL LIFE RES, V18, P1263, DOI 10.1007/s11136-009-9540-9; Bronfenbrenner U., 1999, MEASURING ENV LIFE S, P3, DOI [DOI 10.1037/10317-001, 10.1037/10317-001]; Byerts, 1982, AGING ENV THEORETICA; Calderon J L, 2000, Educ Health (Abingdon), V13, P91; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Centers for Disease Control (CDC), 2014, SOC DET HLTH DEF; Charlton J., 2000, NOTHING US US DISABI; Charmaz K, 2012, SAGE HDB INTERVIEW R, P311; Charmaz K., 2014, BROKERAGE CLOSURE IN; DeWalt DA, 2007, MED CARE, V45, pS12, DOI 10.1097/01.mlr.0000254567.79743.e2; Gray DB, 2008, DISABIL REHABIL, V30, P434, DOI 10.1080/09638280701625377; Gray DB, 2006, ARCH PHYS MED REHAB, V87, P189, DOI 10.1016/j.apmr.2005.09.014; Gray DB, 2003, J ARCHIT PLAN RES, V20, P29; Gray DB, 2012, AM PUBL HLTH ASS C 2; HAHN H, 1985, AM BEHAV SCI, V28, P293, DOI 10.1177/000276485028003002; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Heinemann AW, 2015, ARCH PHYS MED REHAB, V96, P589, DOI 10.1016/j.apmr.2013.11.024; Heinemann AW, 2013, ARCH PHYS MED REHAB, V94, P2157, DOI 10.1016/j.apmr.2013.05.017; Heinemann AW, 2011, ARCH PHYS MED REHAB, V92, P564, DOI 10.1016/j.apmr.2010.07.220; Huberman AM., 1994, HDB QUALITATIVE RES, P428; Institute of Medicine, FUTURE DISABILITY AM; Krueger R.A., 2008, FOCUS GROUPS PRACTIC; Magasi S, 2015, ARCH PHYS MED REHAB, V96, P569, DOI 10.1016/j.apmr.2014.12.002; Magasi S, 2012, QUAL LIFE RES, V21, P739, DOI 10.1007/s11136-011-9990-8; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; MISHLER EG, 1990, HARVARD EDUC REV, V60, P415, DOI 10.17763/haer.60.4.n4405243p6635752; Morse JM., 2009, DEV GROUNDED THEORY; Noonan VK, 2009, DISABIL REHABIL, V31, P1883, DOI 10.1080/09638280902846947; Oliver M., 1991, INT J REHABILITATION, V14, P185, DOI [10.1097/00004356-199106000-00012, DOI 10.1097/00004356-199106000-00012]; PROMIS&REG; Validity Standards Committee on behalf of the PROMIS Network of Investigators, 2012, PROMIS INSTR DEV VAL; Saldana J, 2012, CODING MANUAL QUALIT; Schulz A, 2004, HEALTH EDUC BEHAV, V31, P455, DOI 10.1177/1090198104265598; Tarlov A., 1996, HLTH SOCIAL ORG, P71; Tulsky DS, 2015, ARCH PHYS MED REHAB, V96, P604, DOI 10.1016/j.apmr.2014.02.030; Tulsky DS, 2011, ARCH PHYS MED REHAB, V92, pS44, DOI 10.1016/j.apmr.2011.04.024; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; Willgerodt MA, 2003, WESTERN J NURS RES, V25, P798, DOI 10.1177/0193945903256708; World Health Organization, 2008, CLOSING GAP GENERATI; World Health Organization, 2007, INT CLASS FUNCT DIS	41	137	138	4	74	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2015	96	4					578	588		10.1016/j.apmr.2014.12.008			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	CE9RC	WOS:000352180100002	25813890				2022-02-06	
J	Gerber, LM; Chiu, YL; Carney, N; Hartl, R; Ghajar, J				Gerber, Linda M.; Chiu, Ya-Lin; Carney, Nancy; Haertl, Roger; Ghajar, Jamshid			Marked reduction in mortality in patients with severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure monitoring; guidelines; mortality; traumatic brain injury	SEVERE HEAD-INJURY; COMA DATA-BANK; INTRACRANIAL-PRESSURE; UNITED-STATES; MANAGEMENT; TRIAL; DEATH; CARE	Object. In spite of evidence that use of the Brain Trauma Foundation Guidelines for the Management of Severe Traumatic Brain Injury (Guidelines) would dramatically reduce morbidity and mortality, adherence to these Guidelines remains variable across trauma centers. The authors analyzed 2-week mortality due to severe traumatic brain injury (TBI) from 2001 through 2009 in New York State and examined the trends in adherence to the Guidelines. Methods. The authors calculated trends in adherence to the Guidelines and age-adjusted 2-week mortality rates between January 1, 2001, and December 31, 2009. Univariate and multivariate logistic regression analyses were performed to evaluate the effect of time period on case-fatality. Intracranial pressure (ICP) monitor insertion was modeled in a 2-level hierarchical model using generalized linear mixed effects to allow for clustering by different centers. Results. From 2001 to 2009, the case-fatality rate decreased from 22% to 13% (p < 0.0001), a change that remained significant after adjusting for factors that independently predict mortality (adjusted OR 0.52, 95% CI 0.39-0.70; p < 0.0001). Guidelines adherence increased, with the percentage of patients with ICP monitoring increasing from 56% to 75% (p < 0.0001). Adherence to cerebral perfusion pressure treatment thresholds increased from 15% to 48% (p < 0.0001). The proportion of patients having an ICP elevation greater than 25 mm Hg dropped from 42% to 29% (p = 0.0001). Conclusions. There was a significant reduction in TBI mortality between 2001 and 2009 in New York State. Increase in Guidelines adherence occurred at the same time as the pronounced decrease in 2-week mortality and decreased rate of intracranial hypertension, suggesting a causal relationship between Guidelines adherence and improved outcomes. Our findings warrant future investigation to identify methods for increasing and sustaining adherence to evidence-based Guidelines recommendations.	[Gerber, Linda M.; Chiu, Ya-Lin] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Haertl, Roger] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Ghajar, Jamshid] Jamaica Hosp Med Ctr, Dept Surg, Queens, NY USA; [Carney, Nancy] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA		Ghajar, J (corresponding author), Brain Trauma Fdn, World Trade Ctr 7, 34th Floor,250 Greenwich St, New York, NY 10007 USA.	ghajar@braintrauma.org			Brain Trauma Foundation; New York State Department of Health, Division of Healthcare Financing and Acute	The Brain Trauma Foundation funded the development of the database TBI-Trac. The trauma centers and the Brain Trauma Foundation were funded by New York State Department of Health, Division of Healthcare Financing and Acute and Primary Care reimbursement to implement the TBI-Trac database quality assurance program. The NewYork-Presbyterian Hospital TBI fund supported the data analysis.	Brain Trauma F, 2008, J NEUROTRAUM, V25, P276; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003	28	137	141	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2013	119	6					1583	1590		10.3171/2013.8.JNS13276			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	257EU	WOS:000327367200032	24098983	Bronze			2022-02-06	
J	Daniel, RW; Rowson, S; Duma, SM				Daniel, Ray W.; Rowson, Steven; Duma, Stefan M.			Head Impact Exposure in Youth Football	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Brain injury; Biomechanics; Helmet; Linear; Rotational; Acceleration; Pediatric; Children	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; BRAIN-INJURY; COLLEGIATE; CONCUSSION; EPIDEMIOLOGY; LOCATION; GAME; PLAYERS	The head impact exposure for athletes involved in football at the college and high school levels has been well documented; however, the head impact exposure of the youth population involved with football has yet to be investigated, despite its dramatically larger population. The objective of this study was to investigate the head impact exposure in youth football. Impacts were monitored using a custom 12 accelerometer array equipped inside the helmets of seven players aged 7-8 years old during each game and practice for an entire season. A total of 748 impacts were collected from the 7 participating players during the season, with an average of 107 impacts per player. Linear accelerations ranged from 10 to 100 g, and the rotational accelerations ranged from 52 to 7694 rad/s(2). The majority of the high level impacts occurred during practices, with 29 of the 38 impacts above 40 g occurring in practices. Although less frequent, youth football can produce high head accelerations in the range of concussion causing impacts measured in adults. In order to minimize these most severe head impacts, youth football practices should be modified to eliminate high impact drills that do not replicate the game situations.	[Daniel, Ray W.; Rowson, Steven; Duma, Stefan M.] Wake Forest Univ, Virginia Tech, Ctr Injury Biomech, Blacksburg, VA 24061 USA		Rowson, S (corresponding author), Wake Forest Univ, Virginia Tech, Ctr Injury Biomech, 440 ICTAS Bldg,Stanger St, Blacksburg, VA 24061 USA.	srowson@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596; Daniel, Ray/0000-0002-8666-0979	National Highway Traffic Safety Administration	The authors gratefully acknowledge the National Highway Traffic Safety Administration for supporting this work.	Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; CDC, 2011, SPORTS REL CONC, V60; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003	33	137	137	0	35	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	APR	2012	40	4					976	981		10.1007/s10439-012-0530-7			6	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	916JH	WOS:000302097600022	22350665	Green Published, hybrid			2022-02-06	
J	Lau, BC; Collins, MW; Lovell, MR				Lau, Brian C.; Collins, Michael W.; Lovell, Mark R.			Sensitivity and Specificity of Subacute Computerized Neurocognitive Testing and Symptom Evaluation in Predicting Outcomes After Sports-Related Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; prognosis; symptoms; neurocognitive testing	NEUROPSYCHOLOGICAL TEST PROTOCOL; HIGH-SCHOOL; FOOTBALL PLAYERS; PROFESSIONAL FOOTBALL; RECOVERY; IMPACT; PERFORMANCE; MANAGEMENT; HISTORY; RETURN	Background: Concussions affect an estimated 136 000 high school athletes yearly. Computerized neurocognitive testing has been shown to be appropriately sensitive and specific in diagnosing concussions, but no studies have assessed its utility to predict length of recovery. Determining prognosis during subacute recovery after sports concussion will help clinicians more confidently address return-to-play and academic decisions. Purpose: To quantify the prognostic ability of computerized neurocognitive testing in combination with symptoms during the subacute recovery phase from sports-related concussion. Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: In sum, 108 male high school football athletes completed a computer-based neurocognitive test battery within 2.23 days of injury and were followed until returned to play as set by international guidelines. Athletes were grouped into protracted recovery (>14 days; n = 50) or short-recovery (<= 14 days; n = 58). Separate discriminant function analyses were performed using total symptom score on Post-Concussion Symptom Scale, symptom clusters (migraine, cognitive, sleep, neuropsychiatric), and Immediate Postconcussion Assessment and Cognitive Testing neurocognitive scores (verbal memory, visual memory, reaction time, processing speed). Results: Multiple discriminant function analyses revealed that the combination of 4 symptom clusters and 4 neurocognitive composite scores had the highest sensitivity (65.22%), specificity (80.36%), positive predictive value (73.17%), and negative predictive value (73.80%) in predicting protracted recovery. Discriminant function analyses of total symptoms on the Post-Concussion Symptom Scale alone had a sensitivity of 40.81%; specificity, 79.31%; positive predictive value, 62.50%; and negative predictive value, 61.33%. The 4 symptom clusters alone discriminant function analyses had a sensitivity of 46.94%; specificity, 77.20%; positive predictive value, 63.90%; and negative predictive value, 62.86%. Discriminant function analyses of the 4 computerized neurocognitive scores alone had a sensitivity of 53.20%; specificity, 75.44%; positive predictive value, 64.10%; and negative predictive value, 66.15%. Conclusion: The use of computerized neurocognitive testing in conjunction with symptom clusters results improves sensitivity, specificity, positive predictive value, and negative predictive value of predicting protracted recovery compared with each used alone. There is also a net increase in sensitivity of 24.41% when using neurocognitive testing and symptom clusters together compared with using total symptoms on Post-Concussion Symptom Scale alone.	[Collins, Michael W.] UPMC, Ctr Sports Med, Pittsburgh, PA 15203 USA		Collins, MW (corresponding author), UPMC, Ctr Sports Med, 3200 S Water St, Pittsburgh, PA 15203 USA.	CollinsMW@upmc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Pardini J., 2004, BRIT J SPORT MED, V38, P661; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	28	137	138	0	32	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2011	39	6					1209	1216		10.1177/0363546510392016			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	772BJ	WOS:000291204200018	21285444				2022-02-06	
J	Svetlov, SI; Prima, V; Kirk, DR; Gutierrez, H; Curley, KC; Hayes, RL; Wang, KKW				Svetlov, Stanislav I.; Prima, Victor; Kirk, Daniel R.; Gutierrez, Hector; Curley, Kenneth C.; Hayes, Ronald L.; Wang, Kevin K. W.			Morphologic and Biochemical Characterization of Brain Injury in a Model of Controlled Blast Overpressure Exposure	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Blast; Brain injury; Experimental models; Biomarkers; UCH-L1; GFAP; CNPase	NEURON-SPECIFIC ENOLASE; ALPHA-II-SPECTRIN; INDUCED NEUROTRAUMA; TERMINAL HYDROLASE; SILVER TECHNIQUE; UP-REGULATION; RAT-BRAIN; SERUM; DEGENERATION; BIOMARKERS	Objectives: Existing experimental approaches for studies of blast impact in small animals are insufficient and lacking consistency. Here, we present a comprehensive model, with repeatable blast signatures of controlled duration, peak pressure, and transmitted impulse, accurately reproducing blast impact in laboratory animals. Materials: Rat survival, brain pathomorphology, and levels of putative biomarkers of brain injury glial fibrillary acid protein (GFAP), neuron-specific enolase, and ubiquitin C-terminal hydrolase (UCH)-L1 were examined in brain, cerebrospinal fluid (CSF), and blood after 10 msec of 358 kPa peak overpressure blast exposure. Results: The high-speed imaging demonstrated a strong head acceleration/jolting accompanied by typical intracranial hematomas and brain swelling. Microscopic injury was revealed by prominent silver staining in deep brain areas, including the nucleus subthalamicus zone, suggesting both diffused and focal neurodegeneration. GFAP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), markers of astroglia and oligodendroglia, accumulated substantially in the hippocampus 24 hours after blast and persisted for 30 days postblast. However, GFAP content in the blood significantly increased 24 hours after injury, followed by a decline and subsequent accumulation in CSF in a time-dependent fashion. A similar profile is shown for UCH-L1 increase in blood, whereas increased CSF levels of UCH-L1 persisted throughout 14 days after blast and varied significantly in individual rats. Neuron-specific enolase levels in blood were significantly elevated within 24 hours and 48 hours postblast. Conclusions: The proposed model of controlled nonpenetrating blast in rats demonstrates the critical pathologic and biochemical signatures of blast brain injury that may be triggered by cerebrovascular responses, including blood-brain barrier disruption, glia responses, and neuroglial alterations.	[Svetlov, Stanislav I.; Prima, Victor; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Kirk, Daniel R.; Gutierrez, Hector] Florida Inst Technol, Dept Mech & Aerosp Engn, Melbourne, FL 32901 USA; [Svetlov, Stanislav I.] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Curley, Kenneth C.] USA, Med Res & Mat Command MRMC, Frederick, MD USA		Svetlov, SI (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	ssvetlov@banyanbio.com		Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [N14-06-1-1029, W81XWH-8-1-0376, W81XWH-07-01-0701]	Supported by Department of Defense grants N14-06-1-1029, W81XWH-8-1-0376, and W81XWH-07-01-0701.	Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Cernak I, 1991, Vojnosanit Pregl, V48, P515; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1991, Vojnosanit Pregl, V48, P507; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cernak Ibolja, 1995, Magnesium Research, V8, P249; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2009, SHOCK, V32, P325, DOI 10.1097/SHK.0b013e31819c38f1; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Cooper PW., 1996, EXPLOSIVES ENG; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Elsayed NM, 2003, TOXICOLOGY, V189, P63, DOI 10.1016/S0300-483X(03)00153-7; Elsayed NM, 1997, TOXICOLOGY, V121, P81, DOI 10.1016/S0300-483X(97)03657-3; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Gorbunov NV, 1997, AM J PHYSIOL-LUNG C, V272, pL320, DOI 10.1152/ajplung.1997.272.2.L320; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Harada T, 2004, AM J PATHOL, V164, P59, DOI 10.1016/S0002-9440(10)63096-9; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; JAFFIN JH, 1987, J TRAUMA, V27, P349, DOI 10.1097/00005373-198704000-00002; Januszkiewicz AJ, 1997, TOXICOLOGY, V121, P51, DOI 10.1016/S0300-483X(97)03655-X; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; KIRK DR, J APPL MECH IN PRESS; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Liu ZH, 2009, P NATL ACAD SCI USA, V106, P4635, DOI 10.1073/pnas.0806474106; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Savic J, 1991, Vojnosanit Pregl, V48, P499; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Stuhmiller JH, 1997, TOXICOLOGY, V121, P91, DOI 10.1016/S0300-483X(97)03658-5; Stuhmiller JH, 1996, J BIOMECH, V29, P227, DOI 10.1016/0021-9290(95)00039-9; STUHMILLER JH, 1990, BLAST INJURY THRESHO; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tenkova Tatyana I., 2007, V399, P31, DOI 10.1007/978-1-59745-504-6_3; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; VINORES SA, 1984, J HISTOCHEM CYTOCHEM, V32, P1295, DOI 10.1177/32.12.6389693; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603	57	137	140	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2010	69	4					795	804		10.1097/TA.0b013e3181bbd885			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	664KP	WOS:000282959100026	20215974				2022-02-06	
J	Kim, HJ; Lee, JH; Kim, SH				Kim, Hwa-Jung; Lee, Jae-Ho; Kim, Se-Hyuk			Therapeutic Effects of Human Mesenchymal Stem Cells on Traumatic Brain Injury in Rats: Secretion of Neurotrophic Factors and Inhibition of Apoptosis	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; functional recovery; human mesenchymal stem cells; neurotrophic factors; traumatic brain injury	NERVE GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; REGENERATION; TRANSPLANTS; RECOVERY; SURVIVAL; STROKE	To investigate the therapeutic effects and mechanisms of action of human mesenchymal stem cells (hMSCs), rats were intravenously treated with hMSCs 24 h after traumatic brain injury (TBI). Neurological function was significantly recovered in the hMSC-treated group by 15 days after TBI compared to the placebo group treated with saline. Quantitative ELISA of extracts from the entire traumatized cerebral hemispheres showed significantly increased expression of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) in the hMSC group at 2 days after TBI, with expression decreasing over time. Western blot analysis demonstrated that pAkt expression was upregulated at 2 days after TBI, and caspase-3 cleavage was significantly decreased at 8 days after TBI in the hMSC group. Our results show that treatment of TBI with hMSCs during the acute phase of injury can enhance neurological functional outcome, and suggest that increased levels of neurotrophic factors in the injured hemisphere leading to decreased neuronal apoptosis is one mechanism by which functional recovery may occur.	[Kim, Hwa-Jung; Kim, Se-Hyuk] Ajou Univ, Sch Med, Dept Neurosurg, Suwon 443721, South Korea; [Lee, Jae-Ho] Ajou Univ, Sch Med, Dept Biochem, Suwon 441749, South Korea; [Lee, Jae-Ho] Ajou Univ, Sch Med, Dept Mol Sci & Technol, Suwon 441749, South Korea		Kim, SH (corresponding author), Ajou Univ, Sch Med, Dept Neurosurg, 5 San, Suwon 443721, South Korea.	nsksh@ajou.ac			Brain Korea 21Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea; Ministry of Health and Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [0412-DB00-010-0007]	This study was supported by a grant from Brain Korea 21 and the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (grant no. 0412-DB00-010-0007).	Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Bregman BS, 2002, PROG BRAIN RES, V137, P257; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Choong PF, 2007, CYTOTHERAPY, V9, P170, DOI 10.1080/14653240701196829; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032; Kim C, 2007, SMALL, V3, P91, DOI 10.1002/smll.200600243; Lee PH, 2008, CLIN PHARMACOL THER, V83, P723, DOI 10.1038/sj.clpt.6100386; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Pierchala BA, 2004, J BIOL CHEM, V279, P27986, DOI 10.1074/jbc.M312237200; Saito A, 2004, J NEUROSCI, V24, P1584, DOI 10.1523/JNEUROSCI.5209-03.2004; Sykova E, 2007, CELL DEATH DIFFER, V14, P1336, DOI 10.1038/sj.cdd.4402140; Vicario-Abejon C, 2002, NAT REV NEUROSCI, V3, P965, DOI 10.1038/nrn988	20	137	148	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					131	138		10.1089/neu.2008.0818			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200011	19508155				2022-02-06	
J	Vik, A; Nag, T; Fredriksli, OA; Skandsen, T; Moen, KG; Schirmer-Mikalsen, K; Manley, GT				Vik, Anne; Nag, Torbjorn; Fredriksli, Oddrun Anita; Skandsen, Toril; Moen, Kent Goran; Schirmer-Mikalsen, Kari; Manley, Geoffrey T.			Relationship of "dose" of intracranial hypertension to outcome in severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						dose-response relationship; intracranial hypertension; intracranial pressure; secondary brain insult; severe head injury	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; COMPUTERIZED-TOMOGRAPHY; PREDICTIVE-VALUE; CLASSIFICATION; INSULTS; IMPACT; MANAGEMENT; SCAN; CARE	Object. It has recently been suggested that the degree of intracranial pressure (ICP) above the treatment goal call be estimated by the area tinder the curve (AUC) of ICP versus time in patients with severe traumatic brain injury TBI). The objective of this Study was to determine whether the calculated "ICP dose"-the ICPAUC-is related to mortality rate, Outcome. and Marshall CT classification. Methods. Of 135 patients (age range 1-82 years) with severe TBI treated during a 5-year period at the authors' institution, 113 patients Underwent ICP monitoring (84%). Ninety-three patients with a monitoring time > 24 hours were included for analysis of ICP AUC calculated Using the trapezoidal method. Computed tomography scans were assessed according to the Marshall TBI classification. Patients with Glasgow Outcome Scale scores at 6 months and > 3),cars were separated into 2 groups based oil outcome. Results. Sixty patients (65%) had ICP values > 20 mm Hg, and 12 (13%) developed severe intracranial hypertension and died secondary to herniation. A Multiple regression analysis adjusting for Glasgow Coma Scale score. age. pupillary abnormalities and Injury Severity Scale score demonstrated that the ICPAUC was a significant predictor of poor Outcome at 6 months (1) = 0.034) and of death (p = 0.035). However. it did not predict long-term outcome (p = 0.157). The ICP AUC was significantly higher in patients with Marshall head injury Categories 3 and 4 (24 patients) than in those with Category 2 (23 patients. p = 0.025) and Category 5 (46 patients. p = 0.021) TBIs using the worst CT scan obtained. Conclusions. The authors found a significant relationship between the close of ICP the worst Marshall CT score. and patient Outcome, Suggesting that the AUC method may be useful in refining and improving the treatment of ICP in patients with TBI.	[Vik, Anne; Fredriksli, Oddrun Anita] Norwegian Univ Sci & Technol, St Olav Univ Hosp, Dept Neurosurg, N-7489 Trondheim, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol, St Olav Univ Hosp, Dept Phys Med & Rehabil, N-7489 Trondheim, Norway; [Schirmer-Mikalsen, Kari] Norwegian Univ Sci & Technol, St Olav Univ Hosp, Dept Anaesthesia & Acute Med, N-7489 Trondheim, Norway; [Vik, Anne; Nag, Torbjorn; Skandsen, Toril; Moen, Kent Goran] Norwegian Univ Sci & Technol, Dept Neurosci, N-7489 Trondheim, Norway; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; [Manley, Geoffrey T.] Univ Calif San Francisco Brain, San Francisco, CA USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Spinal Injury Ctr, San Francisco, CA 94143 USA		Vik, A (corresponding author), Norwegian Univ Sci & Technol, St Olav Univ Hosp, Dept Neurosurg, N-7489 Trondheim, Norway.	anne.vik@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Liaison Committee between the Central Norway Regional Health Authority; Norwegian University of Science and Technology; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS050173]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050173] Funding Source: NIH RePORTER	This work was supported by a fellowship from the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology (T.S.) and by NIH grant NS050173 (G.T.M.).	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS55, DOI DOI 10.1089/NEU.2007.9988; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Poca MA, 1998, ACT NEUR S, V71, P27; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003	21	137	141	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					678	684		10.3171/JNS/2008/109/10/0678			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100013	18826355				2022-02-06	
J	Anderson, K; Aito, S; Atkins, M; Biering-Sorensen, F; Charlifue, S; Curt, A; Ditunno, J; Glass, C; Marino, R; Marshall, R; Mulcahey, MJ; Post, M; Savic, G; Scivoletto, G; Catz, A				Anderson, Kim; Aito, Sergio; Atkins, Michal; Biering-Sorensen, Fin; Charlifue, Susan; Curt, Armin; Ditunno, John; Glass, Clive; Marino, Ralph; Marshall, Ruth; Mulcahey, Mary Jane; Post, Marcel; Savic, Gordana; Scivoletto, Giorgio; Catz, Amiram			Functional recovery measures for spinal cord injury: An evidence-based review for clinical practice and research - Functional recovery outcome measures work group	JOURNAL OF SPINAL CORD MEDICINE			English	Article; Proceedings Paper	American-Spinal-Injury-Association/45th Annual Meeting of the International-Spinal-Cord-Society	JUN 27, 2006	Boston, MA	Amer Spinal Injury Assoc, Int Spinal Cord Soc		recovery of function; spinal cord injuries; outcome measures; Functional Independence Measure; Spinal Cord Independence Measure; Quadriplegia Index of Function; Modified Barthel Index; ASIA impairment scale; paraplegia; tetraplegia; validity; reliability	MODIFIED BARTHEL INDEX; INDEPENDENCE MEASURE FIM; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; QUADRIPLEGIA INDEX; NEUROLOGICAL LEVEL; ASSESSMENT SCALES; CONTROLLED-TRIAL; LESION PATIENTS; RASCH ANALYSIS	Background/Objective: The end goal of clinical care and clinical research involving spinal cord injury (SCI) is to improve the overall ability of persons living with SCI to function on a daily basis. Neurologic recovery does not always translate into functional recovery. Thus, sensitive outcome measures designed to assess functional status relevant to SCI are important to develop. Method: Evaluation of currently available SCI functional outcome measures by a multinational work group. Results: The 4 measures that fit the prespecified inclusion criteria were the Modified Barthel Index (MBI), the Functional Independence Measure (FIM), the Quadriplegia Index of Function (QIF), and the Spinal Cord Independence Measure (SCIM). The MBI and the QIF were found to have minimal evidence for validity, whereas the FIM and the SCIM were found to be reliable and valid. The MBI has little clinical utility for use in the SCI population. Likewise, the FIM applies mainly when measuring burden of care, which is not necessarily a reflection of functional recovery. The QIF is useful for measuring functional recovery but only in a subpopulation of people with SCI, and substantial validity data are still required. The SCIM is the only functional recovery outcome measure designed specifically for SCI. Conclusions: The multinational work group recommends that the latest version of the SCIM (SCIM III) continue to be refined and validated and subsequently implemented worldwide as the primary functional recovery outcome measure for SCI. The QIF may continue to be developed and validated for use as a supplemental tool for the nonambulatory tetraplegic population.	[Anderson, Kim] Univ Calif Irvine, Reeve Irvine Res Ctr, Dept Neurol Surg, Irvine, CA 92697 USA; [Aito, Sergio] Careggi Hosp, Florence, Italy; [Atkins, Michal] Rancho Los Amigos Natl Rehabil Ctr, Downey, CA USA; [Biering-Sorensen, Fin] Rigshosp, DK-2100 Copenhagen, Denmark; [Charlifue, Susan] Craig Hosp, Englewood, CO USA; [Curt, Armin] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Ditunno, John; Marino, Ralph] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Glass, Clive] NW Reg Spinal Injuries Ctr, Southport, Qld, England; [Marshall, Ruth] Hampstead Rehabil Ctr, Northfield, MN, Australia; [Mulcahey, Mary Jane] Shriners Hosp Children, Philadelphia, PA USA; [Post, Marcel] Inst Rehabil Res, Groningen, Netherlands; [Savic, Gordana] Stoke Mandeville Hosp, Aylesbury HP21 8AL, Bucks, England; [Scivoletto, Giorgio] IRCCS Fdn, Florence, Italy; [Catz, Amiram] Lowenstein Hosp, Tel Aviv, Israel		Anderson, K (corresponding author), Univ Calif Irvine, Reeve Irvine Res Ctr, Dept Neurol Surg, 843 Med Sci Court,Hewitt Hall Rm 1113, Irvine, CA 92697 USA.	kanderso@uci.edu	Anderson, Kimberly/AAB-6460-2022; Post, Marcel/AAS-2502-2021; Anderson, Kim/ABA-2258-2020; Scivoletto, Giorgio/J-3030-2018	Anderson, Kim/0000-0001-9252-161X; Scivoletto, Giorgio/0000-0001-5766-6952; Biering-Sorensen, Fin/0000-0002-2186-0144; mulcahey, MJ/0000-0002-0837-714X; Marino, Ralph/0000-0003-2670-4113; Catz, Amiram/0000-0002-7879-2015			ANDERSON PA, 1992, J BONE JOINT SURG AM, V74A, P683, DOI 10.2106/00004623-199274050-00007; Bennett M, 2000, BRIT MED J, V321, P1381, DOI 10.1136/bmj.321.7273.1381; Berry C, 2003, SPINAL CORD, V41, P490, DOI 10.1038/sj.sc.3101460; Blight AR, 2006, J NEUROTRAUM, V23, P586, DOI 10.1089/neu.2006.23.586; Catz A, 2007, SPINAL CORD, V45, P275, DOI 10.1038/sj.sc.3101960; Catz A, 1997, SPINAL CORD, V35, P850, DOI 10.1038/sj.sc.3100504; Catz A, 2004, SPINE, V29, P2278, DOI 10.1097/01.brs.0000142008.49907.c7; Catz A, 2004, ARCH PHYS MED REHAB, V85, P399, DOI 10.1016/S0003-9993(03)00475-1; Catz A, 2001, DISABIL REHABIL, V23, P263; Catz A, 2001, SPINAL CORD, V39, P97, DOI 10.1038/sj.sc.3101118; Chau N, 1994, Disabil Rehabil, V16, P63; Chua KSG, 1996, ARCH PHYS MED REHAB, V77, P194, DOI 10.1016/S0003-9993(96)90167-7; Crotty M, 2003, ARCH PHYS MED REHAB, V84, P1237, DOI 10.1016/S0003-9993(03)00141-2; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P1477, DOI 10.1016/S0003-9993(99)90261-7; Ditunno JF, 2000, SPINAL CORD, V38, P234, DOI 10.1038/sj.sc.3100993; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Donnelly C, 2004, SPINAL CORD, V42, P302, DOI 10.1038/sj.sc.3101589; Garcia RA, 2002, AM J PHYS MED REHAB, V81, P458, DOI 10.1097/00002060-200206000-00011; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRESHAM GE, 1986, PARAPLEGIA, V24, P38, DOI 10.1038/sc.1986.7; GREY N, 1993, PARAPLEGIA, V31, P457, DOI 10.1038/sc.1993.74; Grijalva I, 2003, PHARMACOTHERAPY, V23, P823, DOI 10.1592/phco.23.7.823.32731; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; Hocking C, 1999, CLIN REHABIL, V13, P141, DOI 10.1191/026921599668105029; Hoenig H, 1998, ARCH PHYS MED REHAB, V79, P378, DOI 10.1016/S0003-9993(98)90137-X; Itzkovich M, 2007, DISABIL REHABIL, V29, P1926, DOI 10.1080/09638280601046302; Itzkovich M, 2003, AM J PHYS MED REHAB, V82, P267, DOI 10.1097/01.PHM.0000057226.22271.44; Itzkovich M, 2002, SPINAL CORD, V40, P396, DOI 10.1038/sj.sc.3101315; Johnston MV, 2008, J SPINAL CORD MED, V31, P13, DOI 10.1080/10790268.2008.11753976; Karamehmetoglu SS, 1997, SPINAL CORD, V35, P22, DOI 10.1038/sj.sc.3100341; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Kucukdeveci AA, 2001, CLIN REHABIL, V15, P311, DOI 10.1191/026921501676877265; Kucukdeveci AA, 2000, SCAND J REHABIL MED, V32, P87; Lawton G, 2006, SPINAL CORD, V44, P746, DOI 10.1038/sj.sc.3101895; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LINACRE JM, 2000, J OUTCOME MEAS, V42, P616; MAHONEY F I, 1965, Md State Med J, V14, P61; MARCIELLO MA, 1995, J NEUROTRAUM, V12, P99, DOI 10.1089/neu.1995.12.99; Marino RJ, 1999, SPINAL CORD, V37, P289, DOI 10.1038/sj.sc.3100772; MARINO RJ, 1993, PARAPLEGIA, V31, P225, DOI 10.1038/sc.1993.41; MARINO RJ, 1995, PARAPLEGIA, V33, P510, DOI 10.1038/sc.1995.111; Marino RJ, 1998, ARCH PHYS MED REHAB, V79, P1512, DOI 10.1016/S0003-9993(98)90412-9; Masedo AI, 2005, AM J PHYS MED REHAB, V84, P167, DOI 10.1097/01.PHM.0000154898.25609.4A; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; McKinley WO, 2001, AM J PHYS MED REHAB, V80, P693, DOI 10.1097/00002060-200109000-00010; MENTER RR, 1991, PARAPLEGIA, V29, P613, DOI 10.1038/sc.1991.90; Middleton JW, 2006, SPINAL CORD, V44, P495, DOI 10.1038/sj.sc.3101872; Middleton JW, 1998, ARCH PHYS MED REHAB, V79, P1428, DOI 10.1016/S0003-9993(98)90239-8; Morganti B, 2005, SPINAL CORD, V43, P27, DOI 10.1038/sj.sc.3101658; Mulcahey MJ, 2004, SPINAL CORD, V42, P146, DOI 10.1038/sj.sc.3101573; Nas K, 2004, JOINT BONE SPINE, V71, P312, DOI 10.1016/S1297-319X(03)00135-0; Ng YS, 2005, NEUROREHABILITATION, V20, P97; Nilsson AL, 2005, ACTA NEUROL SCAND, V111, P264, DOI 10.1111/j.1600-0404.2005.00404.x; Noreau L, 1993, Int J Rehabil Res, V16, P265; Ota T, 1996, SPINAL CORD, V34, P531, DOI 10.1038/sc.1996.96; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Popovic D, 1999, ARCH PHYS MED REHAB, V80, P299, DOI 10.1016/S0003-9993(99)90141-7; Popovic MR, 2006, SPINAL CORD, V44, P143, DOI 10.1038/sj.sc.3101822; Ronen J, 2004, SPINAL CORD, V42, P353, DOI 10.1038/sj.sc.3101590; Rothwell AG, 2003, J HAND SURG-AM, V28A, P489, DOI 10.1053/jhsu.2003.50083; Scivoletto G, 2003, SPINAL CORD, V41, P457, DOI 10.1038/sj.sc.3101489; SEGAL ME, 1993, PARAPLEGIA, V31, P622, DOI 10.1038/sc.1993.101; Shah S, 2000, CLIN REHABIL, V14, P551, DOI 10.1191/0269215500cr360oa; SHAH S, 1990, STROKE, V21, P241, DOI 10.1161/01.STR.21.2.241; SHAH S, 1989, STROKE, V20, P766, DOI 10.1161/01.STR.20.6.766; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Shah S, 2003, OTJR-OCCUP PARTICI H, V23, P2, DOI 10.1177/153944920302300101; SHAH S, 1991, J CLIN EPIDEMIOL, V44, P21, DOI 10.1016/0895-4356(91)90197-H; Stineman MG, 1999, SPINAL CORD, V37, P717, DOI 10.1038/sj.sc.3100914; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; Tow AMPE, 1998, SPINAL CORD, V36, P156, DOI 10.1038/sj.sc.3100618; Wang A, 1998, AUST NZ J SURG, V68, P580, DOI 10.1111/j.1445-2197.1998.tb02104.x; YAMAMOTO M, 1992, JAPAN J NURSING TECH, V38, P922; Yap EC, 2003, INT J REHABIL RES, V26, P137, DOI 10.1097/00004356-200306000-00009; Yap EC, 2002, BRAIN INJURY, V16, P491, DOI 10.1080/02699050110113651; Yavuz N, 1998, SPINAL CORD, V36, P832, DOI 10.1038/sj.sc.3100726	85	137	141	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.		2008	31	2					133	144		10.1080/10790268.2008.11760704			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	315KA	WOS:000256876200002	18581660	Green Published			2022-02-06	
J	Cohan, MJ; Brohi, K; Ganter, MT; Manley, GT; Mackersie, RC; Pittet, JF				Cohan, Mitchell Jay; Brohi, Karim; Ganter, Michael T.; Manley, Geoffrey T.; Mackersie, Robert C.; Pittet, Jean-Francois			Early coagulopathy after traumatic brain injury: The role of hypoperfusion and the protein C pathway	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		bleeding; coagulopathy; protein C; brain injury	SEVERE HEAD-INJURY; BASE DEFICIT; INTRAVASCULAR COAGULATION; MULTIPLE TRAUMA; INDICATOR; HYPERCOAGULABILITY; RESUSCITATION; ABNORMALITIES; COMPLICATIONS; FIBRINOLYSIS	Introduction: Early coagulopathy after traumatic brain injury (TBI) is thought to be the result of injury-mediated local release of tissue factor, although the precise mechanisms that cause hypoperfusion and early systemic coagulopathy in TBI patients are unknown. We have previously reported that early systemic coagulopathy after trauma is present only when tissue injury is associated with severe hypoperfusion leading to the activation of the protein C pathway. However, the role of hypoperfusion as an important mechanism for the development of coagulopathy early after TBI is unclear. The objective of the present study was to determine the importance of hypoperfusion and protein C activation in causing early coagulopathy in TBI patients. Materials: We performed a prospective cohort study including patients with isolated brain injury admitted to a single trauma center. Blood was drawn on aver-age 32 minutes after injury. Plasma samples were assayed for protein C and thrombomodulin by standard laboratory techniques. Routine coagulation measures (prothrombin time, partial tbromboplastin time) and arterial blood gas analysis were performed concurrently. Severe hypoperfusion was evidenced by the presence of an arterial base deficit greater than 6. Results: Thirty-nine TBI patients were included in the study during a 15month period. TBI patients without concurrent hypoperfusion (n = 28) did not develop an early coagulopathy after trauma, no matter the severity of injury. In contrast, patients with TBI who also had severe hypoperfusion (BD >6) (n = 11) were coagulopathic early after injury. Indeed, these patients had higher prothrombin time and partial thromboplastin time, compared with those with TBI and a BD <6 (17.6 +/- 3.6 vs. 14.3 +/- 2.3, p < 0.005; and 43.13 +/- 18.3 vs. 27.4 +/- 3.8, p < 0.0001). Unactivated protein C levels were lower in the TBI group with BD >6 (56 +/- 32 vs. 85 +/- 35, p = 0.03) and thrombomodulin levels were significantly higher (48 +/- 26 vs. 35 +/- 10, p = 0.04). Without hypoperfusion, there was no effect of increasing brain injury on protein C pathway or fibrinolysis pathway mediators. Conclusions: TBI alone does not cause early coagulopathy, but must be coupled with hypoperfusion to lead to coagulation derangements, associated with the activation of the protein C pathway. This novel finding has significant implications for the treatment of coagulopathy after severe brain injury.	[Cohan, Mitchell Jay; Brohi, Karim; Mackersie, Robert C.; Pittet, Jean-Francois] San Francisco Gen Hosp, Dept Surg, San Francisco, CA 94143 USA; [Ganter, Michael T.; Pittet, Jean-Francois] San Francisco Gen Hosp, Dept Anesthesia, San Francisco, CA 94110 USA; [Manley, Geoffrey T.] San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94110 USA; [Pittet, Jean-Francois] Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA		Cohan, MJ (corresponding author), San Francisco Gen Hosp, Dept Surg Ward 3A, 1001 Potrevo Ave, San Francisco, CA 94110 USA.	mcohen@sfghsurg.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM062188] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM62188] Funding Source: Medline		Armand R, 2003, TRANSFUS MED REV, V17, P223, DOI 10.1016/S0887-7963(03)00022-1; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; ATTAR S, 1969, J TRAUM, V9, P939, DOI 10.1097/00005373-196911000-00004; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boldt J, 2000, CRIT CARE MED, V28, P445, DOI 10.1097/00003246-200002000-00026; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; CLARK JA, 1980, J NEUROSURG, V52, P266, DOI 10.3171/jns.1980.52.2.0266; DAVIS JW, 1994, J TRAUMA, V36, P168, DOI 10.1097/00005373-199402000-00002; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; DAVIS JW, 1991, SURG GYNECOL OBSTET, V173, P473; Engelman DT, 1996, WORLD J SURG, V20, P5, DOI 10.1007/s002689900001; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; HOOTS WK, 1996, NEUROTRAUMA, P673; Kaups KL, 1998, J BURN CARE REHABIL, V19, P346, DOI 10.1097/00004630-199807000-00013; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Liaw PCY, 2003, J THROMB HAEMOST, V1, P662, DOI 10.1046/j.1538-7836.2003.00153.x; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PENICK G D, 1960, Int Rec Med, V173, P491; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Rezaie AR, 2001, J BIOL CHEM, V276, P15567, DOI 10.1074/jbc.C100123200; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; Schreiber MA, 2005, J TRAUMA, V58, P475, DOI 10.1097/01.TA.0000153938.77777.26; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	34	137	146	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2007	63	6					1254	1261		10.1097/TA.0b013e318156ee4c			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	243AU	WOS:000251768100011	18212647				2022-02-06	
J	Cicerone, KD; Azulay, J				Cicerone, Keith D.; Azulay, Joanne			Perceived self-efficacy and life satisfaction after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; participation; predictors; quality of life; outcomes	QUALITY-OF-LIFE; COMMUNITY INTEGRATION QUESTIONNAIRE; WELL-BEING MEASURES; REHABILITATION OUTCOMES; PARTICIPATION; INDIVIDUALS; VALIDATION; PREDICTORS; DISABILITY; INDICATORS	Objective: To the contribution of activity-related satisfaction and perceived self-efficacy to global life satisfaction after traulmatic brain injury (TBI). Participants: Convenience sample of 97 adults who were living in their community at least 6 months after sustaining a TBI. Measures: Community Integration Questionnaire, Quality of Community Integration Questionnaire, Self-Efficacy Questionnaire for TBI, Perceived Quality of Life Scale, Satisfaction with Life Scale. Results: Among demographic and injury-related variables, gender and time since injury made significant contributions to the prediction of global life satisfaction. Productivity made a modest, significant contribution to life satisfaction. Satisfaction with productivity and with leisure/social activities both contributed to global life satisfaction. The greatest contribution to the prediction of global life satisfaction was made by the person's perceived self-efficacy, particularly perceived self-efficacy for the management of cognitive symptoms. Perceived cognitive self-efficacy also appeared to mediate the relation between community integration and global life satisfaction. Conclusion: Community integration, activity-related satisfaction, and global life satisfaction represent distinct constructs, and dissociable aspects of psychosocial outcome after TBI. Perceived self-efficacy for the management of cognitive symptoms may mediate the relation between the individual's expectations and achievements and thereby contribute to overall subjective well-being.	JFK Johnson Rehabil Inst, Dept Cognit Rehabil, Edison, NJ 08820 USA; JFK Johnson Rehabil Inst, Dept Phys Med & Rehabil, Edison, NJ USA		Cicerone, KD (corresponding author), JFK Johnson Rehabil Inst, Dept Cognit Rehabil, 2048 Oak Tree Rd, Edison, NJ 08820 USA.	kcicerone@solarishs.org			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H1331020518] Funding Source: Medline		AZOUVI P, 2001, 4 WORLD C BRAIN INJ; BANDURA A, 1989, DEV PSYCHOL, V25, P729, DOI 10.1037/0012-1649.25.5.729; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Belsley DA., 1980, REGRESSION DIAGNOSTI, DOI 10.1002/0471725153; Ben-Yishay Y, 2000, REHABIL PSYCHOL, V45, P112, DOI 10.1037/0090-5550.45.2.112; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Carifio James, 2002, Work, V19, P125; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIJKERS M, 1997, ASSESSING MED REHABI, P153; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Diller L, 2005, ARCH PHYS MED REHAB, V86, P1075, DOI 10.1016/j.apmr.2004.11.009; Dumont C, 2004, J HEAD TRAUMA REHAB, V19, P431, DOI 10.1097/00001199-200411000-00002; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GIST ME, 1992, ACAD MANAGE REV, V17, P183, DOI 10.2307/258770; Goldstein K, 1942, EFFECTS BRAIN INJURI; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; HOLDEN G, 1991, SOC WORK HEALTH CARE, V16, P53; Jerusalem M., 1992, SELF EFFICACY THOUGH, P195, DOI DOI 10.4324/9781315800820; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; Jones F, 2006, DISABIL REHABIL, V28, P841, DOI 10.1080/09638280500534952; Judge TA, 1998, J APPL PSYCHOL, V83, P17, DOI 10.1037/0021-9010.83.1.17; Judge TA, 2002, J PERS SOC PSYCHOL, V83, P693, DOI 10.1037//0022-3514.83.3.693; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Keyes CLM, 2002, J PERS SOC PSYCHOL, V82, P1007, DOI 10.1037//0022-3514.82.6.1007; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Lorig K., 1996, OUTCOME MEASURES HLT; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lucas RE, 1996, J PERS SOC PSYCHOL, V71, P616, DOI 10.1037/0022-3514.71.3.616; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Man DWK, 2006, BRAIN INJURY, V20, P959, DOI 10.1080/02699050600909789; Marks P, 2005, ATHEROSCLEROSIS SUPP, V6, P148, DOI 10.1016/S1567-5688(05)80579-3; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Reistetter TA, 2005, NEUROREHABILITATION, V20, P139; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SHERER M, 1983, PSYCHOL REP, V53, P899, DOI 10.2466/pr0.1983.53.3.899; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Snyder CR, 2006, REHABIL PSYCHOL, V51, P89, DOI 10.1037/0090-5550.51.2.89; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Waldrop D, 2001, J COUNS PSYCHOL, V48, P233, DOI 10.1037/0022-0167.48.2.233; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	60	137	139	1	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2007	22	5					257	266		10.1097/01.HTR.0000290970.56130.81			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	216RA	WOS:000249895500001	17878767				2022-02-06	
J	Lundborg, G; Rosen, B				Lundborg, G.; Rosen, B.			Hand function after nerve repair	ACTA PHYSIOLOGICA			English	Article; Proceedings Paper	13th Acta Physiologica International Symposium	AUG 24-26, 2005	Copenhagen, DENMARK			brain plasticity; cortical reorganization; hand function; nerve regeneration; nerve repair	DORSAL-ROOT GANGLIA; PERIPHERAL-NERVE; ULNAR NERVE; SCIATIC-NERVE; GROWTH-FACTOR; MOTOR AXONS; 2-POINT DISCRIMINATION; SOMATOSENSORY CORTEX; NEUROTROPHIC FACTORS; TACTILE SENSIBILITY	Treatment of injuries to major nerve trunks in the hand and upper extremity remains a major and challenging reconstructive problem. Such injuries may cause long-lasting disabilities in terms of lost fine sensory and motor functions. Nowadays there is no surgical repair technique that can ensure recovery of tactile discrimination in the hand of an adult patient following nerve repair while very young individuals usually regain a complete recovery of functional sensibility. Post-traumatic nerve regeneration is a complex biological process where the outcome depends on multiple biological and environmental factors such as survival of nerve cells, axonal regeneration rate, extent of axonal misdirection, type of injury, type of nerve, level of the lesion, age of the patient and compliance to training. A major problem is the cortical functional reorganization of hand representation which occurs as a result of axonal misdirection. Although protective sensibility usually occurs following nerve repair, tactile discriminative functions seldom recover - a direct result of cortical remapping. Sensory re-education programmes are routinely applied to facilitate understanding of the new sensory patterns provided by the hand. New trends in hand rehabilitation focus on modulation of central nervous processes rather than peripheral factors. Principles are being evolved to maintain the cortical hand representation by using the brain capacity for visuo-tactile and audio-tactile interaction for the initial phase following nerve injury and repair (phase 1). After the start of the re-innervation of the hand (phase 2), selective de-afferentation, such as cutaneous anaesthesia of the forearm of the injured hand, allows expansion of the nerve-injured cortical hand representation, thereby enhancing the effects of sensory relearning. Recent data support the view that training protocols specifically addressing the relearning process substantially increase the possibilities for improved functional outcome after nerve repair.	Lund Univ, Malmo Univ Hosp, Dept Hand Surg, SE-20502 Malmo, Sweden		Lundborg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Hand Surg, SE-20502 Malmo, Sweden.	goran.lundborg@med.lu.se					ALDSKOGIUS H, 1978, J NEUROCYTOL, V7, P229, DOI 10.1007/BF01217921; Allan CH, 2000, HAND CLIN, V16, P67; ARCHIBALD SJ, 1991, J COMP NEUROL, V306, P685, DOI 10.1002/cne.903060410; ARCHIBALD SJ, 1995, J NEUROSCI, V15, P4109; Avikainen S, 2002, NEUROIMAGE, V15, P640, DOI 10.1006/nimg.2001.1029; Bavelier D, 2002, NAT REV NEUROSCI, V3, P443, DOI 10.1038/nrn848; Bell-Krotoski J, 2002, REHABILITATION HAND, P194; BIRCH R, 1991, J BONE JOINT SURG BR, V73, P154, DOI 10.1302/0301-620X.73B1.1991753; Brushart T M, 1990, Restor Neurol Neurosci, V1, P281, DOI 10.3233/RNN-1990-13416; BRUSHART TME, 1988, J NEUROSCI, V8, P1026; BRUSHART TME, 1987, EXP NEUROL, V97, P289, DOI 10.1016/0014-4886(87)90090-2; BRUSHART TME, 1993, J NEUROSCI, V13, P2730, DOI 10.1523/JNEUROSCI.13-06-02730.1993; Bruyns CNP, 2003, J HAND SURG-AM, V28A, P28, DOI 10.1053/jhsu.2003.50026; BUCHTHAL F, 1979, J NEUROL NEUROSUR PS, V42, P436, DOI 10.1136/jnnp.42.5.436; CALLAHAN AD, 1995, REHABILITATION HAND, P701; Carlsson I, 2003, SCAND J PLAST RECONS, V37, P371, DOI 10.1080/02844310310013055; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; Dahlin L.B., 2004, OPER TECH ORTHOP, V14, P138; Dahlin L. B., 2004, J AM SOC SURG HAND, V4, P143, DOI DOI 10.1016/J.JASSH.2004.06.006; DAHLIN LB, 1987, EXP NEUROL, V95, P611, DOI 10.1016/0014-4886(87)90303-7; DeFelipe J., 1991, CAJALS DEGENERATION; Dellon A, 1981, SENSIBILITY REEDUCAT; DELLON AL, 1974, PLAST RECONSTR SURG, V53, P297, DOI 10.1097/00006534-197403000-00008; DELLON AL, 1997, SOMATOSENSORY TESTIN; Diao E, 2000, HAND CLIN, V16, P53; FESS E, 1990, REHABILITATION HAND; Florence SL, 2001, EUR J NEUROSCI, V13, P1755, DOI 10.1046/j.0953-816x.2001.01555.x; FLORENCE SL, 1994, CEREB CORTEX, V4, P391, DOI 10.1093/cercor/4.4.391; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; GIBSON JJ, 1962, PSYCHOL REV, V69, P477, DOI 10.1037/h0046962; GRAFSTEIN B, 1975, EXP NEUROL, V48, P32, DOI 10.1016/0014-4886(75)90170-3; Grezes J, 2003, NEUROIMAGE, V18, P928, DOI 10.1016/S1053-8119(03)00042-9; Hansson T, 2003, J NEUROSURG, V99, P100, DOI 10.3171/jns.2003.99.1.0100; HANSSON T, 2005, 5 FESSH C GOT SWED 1; Hauk O, 2004, NEURON, V41, P301, DOI 10.1016/S0896-6273(03)00838-9; HEUMANN R, 1991, ANN NY ACAD SCI, V633, P581; HEUMANN R, 1987, J EXP BIOL, V132, P133; Jain N, 1998, NEWS PHYSIOL SCI, V13, P143; JAQUET J, 2004, THESIS ERASMUS U ROT; Jaquet JB, 2001, J TRAUMA, V51, P687, DOI 10.1097/00005373-200110000-00011; Jerosch-Herold C, 2005, J HAND SURG-BRIT EUR, V30B, P252, DOI 10.1016/jshb.2004.12.006; Jerosch-Herold C, 2000, SCAND J PLAST RECONS, V34, P339, DOI 10.1080/028443100750059129; JEROSCHHEROLD C, 1993, J HAND SURG-BRIT EUR, V18B, P624, DOI 10.1016/0266-7681(93)90019-C; JOHANSSON RS, 1983, TRENDS NEUROSCI, V6, P27, DOI 10.1016/0166-2236(83)90011-5; JOHANSSON RS, 1979, J PHYSIOL-LONDON, V286, P283, DOI 10.1113/jphysiol.1979.sp012619; Johansson RS, 2002, ADV EXP MED BIOL, V508, P397; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; Kaas JH, 1997, ADV NEUROL, V73, P147; KALLIO PK, 1993, J HAND SURG-BRIT EUR, V18B, P97, DOI 10.1016/0266-7681(93)90205-T; Keysers C, 2004, NEURON, V42, P335, DOI 10.1016/S0896-6273(04)00156-4; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; LIEBERMAN AR, 1971, INT REV NEUROBIOL, V14, P99; Liss AG, 1996, SCAND J PLAST RECONS, V30, P1; Lundborg G, 2004, J HAND SURG-BRIT EUR, V29B, P418, DOI 10.1016/j.jhsb.2004.02.008; Lundborg G, 2003, J PERIPHER NERV SYST, V8, P209, DOI 10.1111/j.1085-9489.2003.03027.x; Lundborg G, 2001, LANCET, V358, P809, DOI 10.1016/S0140-6736(01)06001-9; Lundborg G, 2000, J HAND SURG-AM, V25A, P391, DOI 10.1053/jhsu.2000.4165; Lundborg G, 2000, J HAND SURG-BRIT EUR, V25B, P242, DOI 10.1054/jhsb.1999.0339; Lundborg G, 2004, J HAND SURG-BRIT EUR, V29B, P100, DOI 10.1016/j.jhsb.2003.09.018; LUNDBORG G, 2003, J HAND SURG AM S1, V28, P38; Lundborg G, 2004, NERVE INJURY REPAIR; LUNDBORG G, 2005, 5 FESSH C GOT SWED 1; Ma JJ, 2003, SCAND J PLAST RECONS, V37, P1; MacDermid Joy C, 2005, J Hand Ther, V18, P297, DOI 10.1197/j.jht.2005.02.009; Maki Y, 1996, J RECONSTR MICROSURG, V12, P547, DOI 10.1055/s-2007-1006628; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; McAllister RMR, 1996, J HAND SURG-BRIT EUR, V21B, P4, DOI 10.1016/S0266-7681(96)80004-0; Merzenich M M, 1993, J Hand Ther, V6, P89; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MOBERG E, 1958, J BONE JOINT SURG BR, V40, P454, DOI 10.1302/0301-620X.40B3.454; MOBERG E, 1962, NEUROLOGY, V12, P8, DOI 10.1212/WNL.12.1.8; Moberg E., 1991, J HAND THER, V4, P105; Muellbacher W, 2002, ARCH NEUROL-CHICAGO, V59, P1278, DOI 10.1001/archneur.59.8.1278; Noble J, 1998, J TRAUMA, V45, P116, DOI 10.1097/00005373-199807000-00025; NOVIKOV L, 1995, NEUROSCI LETT, V200, P45, DOI 10.1016/0304-3940(95)12078-I; Parry C B, 1976, Hand, V8, P250; PARRY CBW, 1986, J BONE JOINT SURG BR, V68, P15, DOI 10.1302/0301-620X.68B1.3941133; RAMACHANDRAN VS, 1995, NATURE, V377, P489, DOI 10.1038/377489a0; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; Ramon y Cajal, 1928, DEGENERATION REGENER; Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rosberg HE, 2005, J HAND SURG-BRIT EUR, V30B, P35, DOI 10.1016/j.jhsb.2004.09.003; Rose'n B., 2003, BR J HAND THER, V8, P48; Rosen B, 2006, J HAND SURG-BRIT EUR, V31B, P126, DOI 10.1016/j.jhsb.2005.10.017; Rosen B, 2004, Handchir Mikrochir Plast Chir, V36, P8; Rosen B, 2003, HAND CLIN, V19, P463, DOI 10.1016/S0749-0712(03)00003-9; Rosen B, 2001, J HAND SURG-BRIT EUR, V26, P196, DOI 10.1054/jhsb.2001.0567; Rosen B, 2000, SCAND J PLAST RECONS, V34, P71; Rosen B, 1998, J Hand Ther, V11, P251; Rosen B, 1996, J Hand Ther, V9, P315; ROSEN B, 1994, J HAND SURG-BRIT EUR, V19B, P452, DOI 10.1016/0266-7681(94)90209-7; Rosen B, 2000, J HAND SURG-AM, V25A, P535, DOI 10.1053/jhsu.2000.6458; ROSEN B, 2000, THESIS LUND U; Rowshan K, 2004, OPER TECH ORTHOP, V14, P163, DOI DOI 10.1053/J0T0.2004.06.006; Ruijs ACJ, 2005, PLAST RECONSTR SURG, V116, P484, DOI 10.1097/01.prs.0000172896.86594.07; Schlosshauer B, 2006, NEUROSURGERY, V59, P740, DOI 10.1227/01.NEU.0000235197.36789.42; Seddon HJ, 1954, PER NERV INJ, P1; Silva AC, 1996, J COMP NEUROL, V366, P700, DOI 10.1002/(SICI)1096-9861(19960318)366:4<700::AID-CNE9>3.0.CO;2-8; Stark B, 1998, J HAND SURG-BRIT EUR, V23B, P370, DOI 10.1016/S0266-7681(98)80060-0; Szabo RM, 2001, J HAND SURG-AM, V26A, P993, DOI 10.1053/jhsu.2001.29487; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; Terenghi G, 1999, J ANAT, V194, P1, DOI 10.1046/j.1469-7580.1999.19410001.x; Terzis JK, 1997, J RECONSTR MICROSURG, V13, P215, DOI 10.1055/s-2007-1006407; THOENEN H, 1988, CELL MOL NEUROBIOL, V8, P35, DOI 10.1007/BF00712909; Trumble TE, 2000, HAND CLIN, V16, P37; VALLBO AB, 1968, EXP NEUROL, V21, P270, DOI 10.1016/0014-4886(68)90041-1; VALLBO AB, 1984, HUM NEUROBIOL, V3, P3; von Frey M, 1922, Z GESAMTE NEUROL PSY, V79, P324, DOI 10.1007/BF02878457; WALL JT, 1986, J NEUROSCI, V6, P218; Wall JT, 2002, BRAIN RES REV, V39, P181, DOI 10.1016/S0165-0173(02)00192-3; Witzel C, 2005, J COMP NEUROL, V485, P183, DOI 10.1002/cne.20436; YGGE J, 1989, BRAIN RES, V478, P193, DOI 10.1016/0006-8993(89)91497-2; Yin Q, 1998, J HAND SURG-BRIT EUR, V23B, P433, DOI 10.1016/S0266-7681(98)80117-4	117	137	141	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-1708	1748-1716		ACTA PHYSIOL	Acta Physiol.	FEB	2007	189	2					207	217		10.1111/j.1748-1716.2006.01653.x			11	Physiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Physiology	128RK	WOS:000243675800010	17250571	Green Submitted			2022-02-06	
J	Ely, EW; Girard, TD; Shintani, AK; Jackson, JC; Gordon, SM; Thomason, JWW; Pun, BT; Canonico, AE; Light, RW; Pandharipande, P; Laskowitz, DT				Ely, E. Wesley; Girard, Timothy D.; Shintani, Ayumi K.; Jackson, James C.; Gordon, Sharon M.; Thomason, Jason W. W.; Pun, Brenda T.; Canonico, Angelo E.; Light, Richard W.; Pandharipande, Pratik; Laskowitz, Daniel T.			Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients	CRITICAL CARE MEDICINE			English	Article						delirium; critical care; sepsis; respiratory failure; aging; apolipoprotein E4	INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; E-DEFICIENT MICE; AGITATION-SEDATION SCALE; CLOSED-HEAD INJURY; NERVOUS-SYSTEM; INFLAMMATORY RESPONSE; COGNITIVE DECLINE; MEDICAL PATIENTS	Objective., To test for an association between apolipoprotein E (APOE) genotypes and duration of intensive care unit delirium. Design: Prospective, observational cohort study. Setting: A 541-bed, community-based teaching hospital. Patients: Fifty-three mechanically ventilated intensive care unit patients. Interventions. None. Measurements and Main Results., All patents were managed with standardized sedation and ventilator weaning protocols as part of an ongoing clinical trial and were evaluated prospectively for delirium with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). DNA was extracted from whole blood samples obtained on enrollment and APOE genotype was determined using polymerase chain reaction followed by restriction enzyme digestion by investigators blinded to the clinical information. Delirium occurred in 47 (89%) patients at some point during the intensive care unit stay. Of the 53 patients, 12 (23%) had an APOE4 allele (APOE4+) and 41 (77%) had only APOE2 or APOE3 alleles (APOE4-). APOE4+ patients were younger (53.2 +/- 21.9 vs. 65.4 +/- 13.4, p =.08) and less often admitted for pneumonia (0% vs. 29.3%, p =.05) compared with APOE4- patients, yet they had a duration of delirium that was twice as long: median (interquartile range), 4 (3, 4.5) vs. 2 (1, 4) days (p =.05). No other clinical outcomes were significantly different between the APOE4+ and APOE4- patients. Using multivariable regression analysis to adjust for age, admission diagnosis of sepsis or acute respiratory distress syndrome or pneumonia, severity of illness, and duration of coma, the presence of APOE4 allele was the strongest predictor of delirium duration (odds ratio, 7.32; 95% confidence interval, 1.82-29.51, p =.005). Conclusions. APOE4 allele represents the first demonstrated genetic predisposition to longer duration of delirium in humans.	St Thomas Hosp, Dept Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Internal Med, Div Gen Internal Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN USA; Vanderbilt Univ, Sch Med, VA Tennessee Valley Geriatr Res Educ & Clin Ctr, Nashville, TN USA; Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN USA; Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Lab, Durham, NC USA; Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC USA; Duke Univ, Med Ctr, Dept Crit Care, Durham, NC USA		Ely, EW (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, ICU Cognit Impairment Study Grp, 6th Floor Med Ctr E,6109, Nashville, TN 37232 USA.	wes.ely@vanderbilt.edu	Ely, E. Wesley/Z-2018-2019; Girard, Timothy/I-3008-2019	Ely, E. Wesley/0000-0003-3957-2172; Girard, Timothy/0000-0002-9833-4871; Pandharipande, Pratik/0000-0002-1389-8580	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG001023] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00095] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 24080 3, K23 AG 01023-01A1] Funding Source: Medline		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Basler T, 2002, INTENS CARE MED, V28, P293, DOI 10.1007/s00134-002-1217-6; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Corder EH, 2000, ANN NY ACAD SCI, V908, P295; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; de Bont N, 1999, J LIPID RES, V40, P680; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2004, CRIT CARE MED, V32, P106, DOI 10.1097/01.CCM.0000098033.94737.84; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; ELY EW, 2006, CONFUSION ASSESSMENT; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; Gay EA, 2006, J PHARMACOL EXP THER, V316, P835, DOI 10.1124/jpet.105.095505; Grocott HP, 2001, J THORAC CARDIOV SUR, V122, P622, DOI 10.1067/mtc.2001.115152; HIXSON JE, 1990, J LIPID RES, V31, P545; Inouye SK, 1999, AM J MED, V106, P565, DOI 10.1016/S0002-9343(99)00070-4; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McNicoll L, 2003, J AM GERIATR SOC, V51, P591, DOI 10.1034/j.1600-0579.2003.00201.x; Micek ST, 2005, CRIT CARE MED, V33, P1260, DOI 10.1097/01.CCM.0000164540.58515.BF; Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92; Moretti EW, 2005, CRIT CARE MED, V33, P2521, DOI 10.1097/01.CCM.0000186368.96146.FB; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; PANDHARIPANDE P, 2006, CRIT CARE MED, V33, pA45; Rao R., 1964, SANKHYA SER A, V26, P329; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shawcross DL, 2004, J HEPATOL, V40, P247, DOI 10.1016/j.jhep.2003.10.016; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007	57	137	146	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2007	35	1					112	117		10.1097/01.CCM.0000251925.18961.CA			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119XC	WOS:000243046700017	17133176				2022-02-06	
J	Parker, TM; Osternig, LR; Van Donkelaar, P; Chou, LS				Parker, Tonya M.; Osternig, Louis R.; Van Donkelaar, Paul; Chou, Li-Shan			Gait stability following concussion	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						mild traumatic brain injury; gait stability; attention; recovery	COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; IMPAIRMENT; STATEMENT; RECOVERY; SPORT	Introduction: The need to identify functional impairment following a brain injury is critical to prevent reinjury during the period of recovery. However, little is known about the effect of concussion on dynamic motor function. Purpose: The purpose of this study was to examine the effect of concussion on a dynamic motor task under conditions of divided and undivided attention over the course of 28 d. Methods: Fifteen subjects with concussions (CONC) and 15 uninjured controls (NORM) were observed while walling with undivided attention and while concurrently completing simple mental tasks. The CONC were assessed within 48 h of injury and again at 5, 14, and 28 d postinjury. The NORM were evaluated at the same time intervals. Whole-body motion data were collected to examine displacement and velocity of the center of mass (COM) and the maximum separation between the COM and center of pressure (COP). Three-way repeated-measures mixed-design ANOVA and Tukey post hoc tests were completed to determine differences between group, task, and testing day (P < 0.05). Results: Several aspects of gait stability were compromised in the CONC group for up to 4 wk after injury. CONC were found to walk significantly slower during dual tasks on all testing days when compared with the uninjured controls. The injured subjects were also found to have greater sway and sway velocity than controls when attention was divided for up to 28 d postinjury. Conclusion: The findings of this study suggest that concussion may have long-term observable and measurable effects on the control of gait stability.	1240 Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu					Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; EBERSBACH G, 1995, PERCEPT MOTOR SKILL, V81, P107, DOI 10.2466/pms.1995.81.1.107; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Kahneman D, 1973, ATTENTION EFFORT, P178; Kelly JP, 1997, NEUROLOGY, V48, P581; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Pai YC, 1997, J BIOMECH, V30, P347, DOI 10.1016/S0021-9290(96)00165-0; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; WINTER DA, 1990, BIOMECHANICS MOTOR C, P56; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	137	138	3	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2006	38	6					1032	1040		10.1249/01.mss.0000222828.56982.a4			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	052BI	WOS:000238205200002	16775541				2022-02-06	
J	Contestabile, A; Ciani, E				Contestabile, A; Ciani, E			Role of nitric oxide in the regulation of neuronal proliferation, survival and differentiation	NEUROCHEMISTRY INTERNATIONAL			English	Article; Proceedings Paper	International Symposium on Nitric Oxide-Cyclic GMP Signal Transduction in Brain	NOV 23-25, 2003	Valencia, SPAIN	Catedra Santiago Grisolia, Fdn Museo Ciencias Principe Felipe		nitric oxide; neurogenesis; survival; apoptosis; neurodegeneration; neuroprotection	LONG-TERM POTENTIATION; ELEMENT-BINDING PROTEIN; ROOT GANGLION NEURONS; SOLUBLE GUANYLATE-CYCLASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; REDOX MODULATORY SITE; CELL-DEATH; NMDA RECEPTOR; PC12 CELLS	Nitric oxide (NO), an important cellular messenger, has been linked to both neurodegenerative and neuroprotective actions. In the present review, we focus on recent data establishing a survival and differentiation role for NO in several neural in vitro and in vivo models. Nitric oxide has been found to be essential for survival of neuronal cell lines and primary neurons in culture under various death challenges. Furthermore, its lack may aggravate some neuropathological conditions in experimental animals. Several cellular pathways and signaling systems subserving this neuroprotective role of NO are considered in the review. Survey of recent data related to the developmental role of NO mainly focus on its action as a negative regulator of neuronal precursor cells proliferation and on its role of promotion of neuronal differentiation. Discussion on discrepancies arising from the literature is focused on the Janus-faced properties of the molecule and it is proposed that most controversial results are related to the intrinsic property of NO to compensate among functionally opposed effects. As an example, the increased proliferation of neural cell precursors under conditions of NO shortage may be, later on in the development, compensated by increased elimination through programmed cell death as a consequence of the lack of the survival-promoting action of the molecule. To elucidate these complex, and possibly contrasting, effects of NO is indicated as an important task for future researches. (C) 2004 Published by Elsevier Ltd.	Univ Bologna, Dept Biol, I-40126 Bologna, Italy; Univ Bologna, Dept Human & Gen Physiol, Bologna, Italy		Contestabile, A (corresponding author), Univ Bologna, Dept Biol, Via Selmi 3, I-40126 Bologna, Italy.	acontest@alma.unibo.it	Ciani, Elisabetta/AAL-6462-2020	ciani, elisabetta/0000-0003-3130-5168			Aizenman E, 1999, BRIT J PHARMACOL, V126, P296, DOI 10.1038/sj.bjp.0702295; Aizenman E, 1998, PROG BRAIN RES, V118, P53; Arnhold S, 2002, INT J DEV NEUROSCI, V20, P83, DOI 10.1016/S0736-5748(02)00020-5; Audesirk T, 2003, INT J DEV NEUROSCI, V21, P225, DOI 10.1016/S0736-5748(03)00032-7; Ayata C, 1997, J NEUROSCI, V17, P6908; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; Boxall AR, 1996, EUR J NEUROSCI, V8, P2209, DOI 10.1111/j.1460-9568.1996.tb00743.x; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Brenman JE, 1997, CURR OPIN NEUROBIOL, V7, P374, DOI 10.1016/S0959-4388(97)80065-7; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Cheng AW, 2003, DEV BIOL, V258, P319, DOI 10.1016/S0012-1606(03)00120-9; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Chiueh CC, 1999, ANN NY ACAD SCI, V890, P301, DOI 10.1111/j.1749-6632.1999.tb08007.x; Choi YB, 2000, CELL MOL LIFE SCI, V57, P1535, DOI 10.1007/PL00000638; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Ciani E, 2001, BRAIN RES BULL, V56, P29, DOI 10.1016/S0361-9230(01)00589-5; Ciani E, 2002, J BIOL CHEM, V277, P49896, DOI 10.1074/jbc.M206177200; Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Contestabile A, 2000, BRAIN RES REV, V32, P476, DOI 10.1016/S0165-0173(00)00018-7; Contestabile A, 2003, CURR MED CHEM, V10, P2147, DOI 10.2174/0929867033456792; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; Cramer KS, 1997, DEV BRAIN RES, V98, P287, DOI 10.1016/S0165-3806(96)00188-5; Dawson T M, 1993, NIDA Res Monogr, V136, P258; Dawson TM, 1998, PROG BRAIN RES, V118, P3; Dawson VL, 1998, PROG BRAIN RES, V118, P215; DiGregorio PJ, 2001, J BIOL CHEM, V276, P1930, DOI 10.1074/jbc.M003911200; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CELL GROWTH DIFFER, V9, P415; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDELMAN GM, 1992, P NATL ACAD SCI USA, V89, P11651, DOI 10.1073/pnas.89.24.11651; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Espey MG, 2002, ANN NY ACAD SCI, V962, P195, DOI 10.1111/j.1749-6632.2002.tb04068.x; Estevez AG, 1998, J NEUROSCI, V18, P923; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Estevez AG, 1998, J NEUROSCI, V18, P3708; FAGNI L, 1995, MOL PHARMACOL, V47, P1239; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Friedlander MJ, 1996, J PHYSIOLOGY-PARIS, V90, P179, DOI 10.1016/S0928-4257(97)81420-9; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Gibbs SM, 2003, MOL NEUROBIOL, V27, P107, DOI 10.1385/MN:27:2:107; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Gibbs SM, 2001, J NEUROSCI, V21, P7705, DOI 10.1523/JNEUROSCI.21-19-07705.2001; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; Halliwell B, 2002, ANN NY ACAD SCI, V962, P182, DOI 10.1111/j.1749-6632.2002.tb04067.x; Hawkins RD, 1998, PROG BRAIN RES, V118, P155; HAWKINS RD, 1994, J NEUROBIOL, V25, P652, DOI 10.1002/neu.480250607; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Hemish J, 2003, J BIOL CHEM, V278, P42321, DOI 10.1074/jbc.M308192200; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; Hindley S, 1997, J NEUROSCI RES, V47, P427; Holscher C, 1997, TRENDS NEUROSCI, V20, P298, DOI 10.1016/S0166-2236(97)01065-5; HOYT KR, 1992, BRAIN RES, V592, P310, DOI 10.1016/0006-8993(92)91690-G; Huang DY, 2000, FASEB J, V14, P407, DOI 10.1096/fasebj.14.2.407; Huang EP, 1998, CURR BIOL, V8, pR350, DOI 10.1016/S0960-9822(98)70219-2; Huang EP, 1999, CURR BIOL, V9, pR168, DOI 10.1016/S0960-9822(99)80104-3; HUANG EP, 1997, CURR BIOL, V7, P141; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Huang PL, 1996, J MOL MED-JMM, V74, P415, DOI 10.1007/BF00217517; Huang PL, 1999, BRAZ J MED BIOL RES, V32, P1353, DOI 10.1590/S0100-879X1999001100005; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IMAI N, 1997, J JPN OPHTHALMOL SOC, V101, P639; Inglis FM, 1998, J NEUROSCI, V18, P10493; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; KALB RG, 1993, NEUROSCIENCE, V57, P1, DOI 10.1016/0306-4522(93)90107-Q; Kalisch BE, 2002, J NEUROCHEM, V81, P624, DOI 10.1046/j.1471-4159.2002.00854.x; Kara P, 1998, PROG BRAIN RES, V118, P183; KATO K, 1993, J NEUROPHYSIOL, V70, P1260, DOI 10.1152/jn.1993.70.3.1260; Keilhoff G, 2002, J CHEM NEUROANAT, V24, P181, DOI 10.1016/S0891-0618(02)00055-8; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; Kim KY, 2002, DEV NEUROSCI-BASEL, V24, P313, DOI 10.1159/000066745; Kim NY, 1999, PLANTA MED, V65, P656, DOI 10.1055/s-2006-960840; Kim PKM, 2002, ANN NY ACAD SCI, V962, P42, DOI 10.1111/j.1749-6632.2002.tb04054.x; Kim TW, 2003, NEUROSCI LETT, V344, P209, DOI 10.1016/S0304-3940(03)00451-8; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Kuzin B, 2000, CURR BIOL, V10, P459, DOI 10.1016/S0960-9822(00)00443-7; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LE WD, 1995, BRAIN RES, V686, P49, DOI 10.1016/0006-8993(95)00450-5; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Liberatore GT, 1999, NAT MED, V5, P1403; Lievremont JP, 1999, J BIOL CHEM, V274, P15466, DOI 10.1074/jbc.274.22.15466; Lipton SA, 1998, BIOFACTORS, V8, P33, DOI 10.1002/biof.5520080107; Lipton SA, 1998, PROG BRAIN RES, V118, P73; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; McCann SM, 1998, ANN NY ACAD SCI, V840, P174, DOI 10.1111/j.1749-6632.1998.tb09561.x; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Mize RR, 1998, PROG BRAIN RES, V118, P133; Mohanakumar KP, 2002, ANN NY ACAD SCI, V962, P389, DOI 10.1111/j.1749-6632.2002.tb04083.x; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; Moore PK, 1997, TRENDS PHARMACOL SCI, V18, P204, DOI 10.1016/S0165-6147(97)01064-X; Moreno-Lopez B, 2000, BRAIN RES, V869, P244, DOI 10.1016/S0006-8993(00)02474-4; Murillo-Carretero M, 2002, J NEUROCHEM, V83, P119, DOI 10.1046/j.1471-4159.2002.01116.x; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; Oh SJ, 2002, DEV BRAIN RES, V136, P179, DOI 10.1016/S0165-3806(02)00366-8; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Packer MA, 2003, P NATL ACAD SCI USA, V100, P9566, DOI 10.1073/pnas.1633579100; Panahian N, 1996, NEUROSCIENCE, V72, P343, DOI 10.1016/0306-4522(95)00563-3; Park C, 2001, NEUROSCI LETT, V309, P9, DOI 10.1016/S0304-3940(01)02003-1; Perez-Severiano F, 1998, NEUROCHEM RES, V23, P1297, DOI 10.1023/A:1020700401678; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Peunova N, 2001, J NEUROSCI, V21, P8809, DOI 10.1523/JNEUROSCI.21-22-08809.2001; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Phung YT, 1999, MOL BRAIN RES, V64, P165, DOI 10.1016/S0169-328X(98)00315-5; Plachta N, 2003, EXP CELL RES, V288, P354, DOI 10.1016/S0014-4827(03)00215-5; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Prickaerts J, 1998, NEUROSCIENCE, V87, P181, DOI 10.1016/S0306-4522(98)00083-9; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Ramos-Zuniga R, 1998, MINIM INVAS NEUROSUR, V41, P152, DOI 10.1055/s-2008-1052033; Rauhala P, 1998, FREE RADICAL BIO MED, V24, P1065, DOI 10.1016/S0891-5849(97)00386-9; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Renteria RC, 1996, J NEUROBIOL, V29, P415; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Salom JB, 2000, BRAIN RES, V865, P149, DOI 10.1016/S0006-8993(00)02095-3; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.ne.17.030194.001101; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Snider BJ, 2000, NEUROSCIENCE, V100, P651, DOI 10.1016/S0306-4522(00)00311-0; SNYDER SH, 1993, NATURE, V364, P577, DOI 10.1038/364577a0; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; TANAKA M, 1994, NEUROREPORT, V5, P2049, DOI 10.1097/00001756-199410270-00015; Tenneti L, 1997, NEUROSCI LETT, V236, P139, DOI 10.1016/S0304-3940(97)00780-5; Thippeswamy T, 1997, BRAIN RES, V774, P116, DOI 10.1016/S0006-8993(97)81694-0; Thippeswamy T, 1997, NEUROSCI LETT, V230, P9, DOI 10.1016/S0304-3940(97)00459-X; Thippeswamy T, 2001, NITRIC OXIDE-BIOL CH, V5, P105, DOI 10.1006/niox.2001.0316; Thippeswamy T, 2001, NEUROSCI RES, V40, P37, DOI 10.1016/S0168-0102(01)00205-X; Thippeswamy T, 2001, EUR J NEUROSCI, V14, P1229, DOI 10.1046/j.0953-816x.2001.01752.x; Tsai MJ, 1998, FREE RADICAL BIO MED, V24, P705, DOI 10.1016/S0891-5849(97)00329-8; VERRECCHIA C, 1994, ANN NY ACAD SCI, V738, P341; Virgili M, 1999, BRAIN RES, V839, P164, DOI 10.1016/S0006-8993(99)01750-3; Walton M, 1999, J NEUROCHEM, V73, P1836; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wang W, 1998, DEV BRAIN RES, V111, P65, DOI 10.1016/S0165-3806(98)00123-0; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Wortwein G, 1997, INT J DEV NEUROSCI, V15, P147, DOI 10.1016/S0736-5748(97)00002-6; Yamada M, 2001, J NEUROCHEM, V78, P940, DOI 10.1046/j.1471-4159.2001.00497.x; Yun HY, 1997, MOL PSYCHIATR, V2, P300, DOI 10.1038/sj.mp.4000272; Zhang RL, 2001, ANN NEUROL, V50, P602, DOI 10.1002/ana.1249; Zhao Y, 2003, J NEUROCHEM, V85, P759, DOI 10.1046/j.1471-4159.2003.01719.x; Zhu DY, 2003, J NEUROSCI, V23, P223; ZORUMSKI CF, 1993, BIOCHEM PHARMACOL, V46, P777, DOI 10.1016/0006-2952(93)90484-E	162	137	139	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	NOV	2004	45	6					903	914		10.1016/j.neuint.2004.03.021			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Neurosciences & Neurology	845IB	WOS:000223234600014	15312985				2022-02-06	
J	Yoshimura, S; Teramoto, T; Whalen, MJ; Irizarry, MC; Takagi, Y; Qiu, JH; Harada, J; Waeber, C; Breakefield, XO; Moskowitz, MA				Yoshimura, S; Teramoto, T; Whalen, MJ; Irizarry, MC; Takagi, Y; Qiu, JH; Harada, J; Waeber, C; Breakefield, XO; Moskowitz, MA			FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice	JOURNAL OF CLINICAL INVESTIGATION			English	Article							FIBROBLAST-GROWTH-FACTOR; CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; HIPPOCAMPAL-NEURONS; ADULT-RAT; NEURAL PROGENITORS; ENDOTHELIAL-CELLS; TRANSGENIC MICE; PROLIFERATION; ISCHEMIA	We studied the role of FGF-2 on regulation of neurogenesis and cell loss in the granule cell layer (GCL) of the hippocampal dentate gyrus after experimental traumatic brain injury (TBI). in both FGF-2(-/-) and FGF-2(+/+) mice subjected to controlled cortical impact, the number of dividing cells labeled with BrdU, injected on posttrauma days 6 through 8, increased at 9 days after TBI, and the number of BrdU-positive cells colabeled with neuron-specific nuclear antigen significantly increased at 35 days. However, in injured FGF-2(-/-) mice, BrdU-positive cells and BrdU-positive neurons (days 9, 35) were fewer compared with FGF-2(+/+) mice. The re was also a decrease in the volume of the GCL and the number of GCL neurons after TBI in both FGF-2(-/-) and FGF-2(+/+) mice, but the decrease in both was greater in FGF-2(-/-) mice at 35 days. Overexpression of FGF-2 by intracerebral injection of herpes simplex virus-1 amplicon vectors encoding this factor increased numbers of dividing cells (day 9) and BrdU-positive neurons (day 35) significantly in C57BL/6 mice. Furthermore, the decrease in GCL volume was also attenuated. These results suggest that FGF-2 upregulates neurogenesis and protects neurons against degeneration in the adult hippocampus after TBI, and that FGF-2 supplementation via gene transfer can reduce GCL degeneration after TBI.	Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA USA; Harvard Univ, Sch Med, Neurosci Ctr, Radiol Dept, Boston, MA USA; Harvard Univ, Sch Med, Alzheimer Dis Res Unit, Ctr Aging, Boston, MA USA; Harvard Univ, Sch Med, Alzheimer Dis Res Unit, Ctr Genet, Boston, MA USA; Harvard Univ, Sch Med, Alzheimer Dis Res Unit, Ctr Neurodegenerat, Boston, MA USA		Moskowitz, MA (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Bldg 149,13th St Rm 6403, Charlestown, MA 02129 USA.		Waeber, Christian/A-8333-2009; Waeber, Christian/B-3171-2016	Waeber, Christian/0000-0001-6078-0027; Waeber, Christian/0000-0001-6078-0027	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS010828, K08 NS041969, 5 P50 NS10828, P01 NS024279, NS24279, KO8 NS41969-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS010828, K08NS041969, P01NS024279] Funding Source: NIH RePORTER		ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.3.CO;2-E; CAVALIERI B, 1966, GEOMETRIA INDIVISIBL; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Covolan L, 2000, HIPPOCAMPUS, V10, P169, DOI 10.1002/(SICI)1098-1063(2000)10:2<169::AID-HIPO6>3.0.CO;2-W; Cuevas P, 1997, NEUROL RES, V19, P355, DOI 10.1080/01616412.1997.11740824; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fraefel C, 1996, J VIROL, V70, P7190, DOI 10.1128/JVI.70.10.7190-7197.1996; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; KU PT, 1995, J CELL BIOCHEM, V58, P328, DOI 10.1002/jcb.240580307; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Liu JL, 1998, J NEUROSCI, V18, P7768; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; PETTMANN B, 1986, NEUROSCI LETT, V68, P175, DOI 10.1016/0304-3940(86)90137-0; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; Reilly JF, 1996, EXP NEUROL, V140, P139, DOI 10.1006/exnr.1996.0124; RINK A, 1995, AM J PATHOL, V147, P1575; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; Takeuchi A, 2000, AM J PATHOL, V157, P331, DOI 10.1016/S0002-9440(10)64544-0; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; Tretter YP, 2000, NAT MED, V6, P812, DOI 10.1038/77548; Vaccarino FM, 1999, NAT NEUROSCI, V2, P246, DOI 10.1038/6350; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; WALICKE PA, 1989, J BIOL CHEM, V264, P4120; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	52	137	145	0	4	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	OCT	2003	112	8					1202	1210		10.1172/JCI200316618			9	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	733KW	WOS:000186000300012	14561705	Green Published, Bronze			2022-02-06	
J	Harvey, AG; Bryant, RA; Tarrier, N				Harvey, AG; Bryant, RA; Tarrier, N			Cognitive behaviour therapy for posttraumatic stress disorder	CLINICAL PSYCHOLOGY REVIEW			English	Article						cognitive behaviour therapy; posttraumatic stress disorder; trauma	EYE-MOVEMENT DESENSITIZATION; 2-YEAR PROSPECTIVE EVALUATION; RANDOMIZED CONTROLLED TRIALS; TRAUMATIC BRAIN INJURY; EXPOSURE THERAPY; CONSORT STATEMENT; IMAGINAL EXPOSURE; ASSAULT VICTIMS; RAPE VICTIMS; FOLLOW-UP	Following considerable empirical scrutiny, cognitive behaviour therapy (CBT) has proven to be a safe and effective treatment for posttraumatic stress disorder (PTSD). This article overviews the general principles of treatment and describes the components that comprise CBT for PTSD. We then move on to review the efficacy of CBT for the treatment of PTSD caused by various traumas, including assault, road traffic accident (RTA), combat, and terrorism. Recent advances in early intervention and in the treatment of disorders that are comorbid with PTSD are reviewed. Finally, future directions are discussed. In particular, it is proposed that randomised controlled trials (RCT) of CBT for PTSD must be conducted with enhanced methodological rigour and public health relevance. (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; Univ Manchester, Sch Psychiat & Behav Sci, Acad Div Clin Psychol, Manchester M13 9PL, Lancs, England		Harvey, AG (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	allison.harvey@psy.ox.ac.uk	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			Altman DG, 1996, BRIT MED J, V313, P570; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; BECKER JV, 1981, HDB CLIN BEHAV THERA, P347; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bisson JI, 2003, CLIN PSYCHOL REV, V23, P481, DOI 10.1016/S0272-7358(03)00034-5; Blanchard E. B., 1997, CRASH ASSESSMENT TRE; Blanchard EB, 2003, BEHAV RES THER, V41, P79, DOI 10.1016/S0005-7967(01)00131-0; BLEICH A, 1992, J TRAUMA STRESS, V5, P265, DOI 10.1007/BF00976715; BOUDEWYNS PA, 1990, BEHAV THER, V21, P63, DOI 10.1016/S0005-7894(05)80189-3; Boudewyns PA, 1990, J TRAUMA STRESS, V3, P359, DOI DOI 10.1002/JTS.2490030305; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; BROM D, 1993, J CLIN PSYCHOL, V49, P131, DOI 10.1002/1097-4679(199303)49:2<131::AID-JCLP2270490202>3.0.CO;2-2; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, IN PRESS J CONSULTIN; BRYANT RA, IN PRESS AM J PSYCHI; Cahill SP, 1999, J ANXIETY DISORD, V13, P5, DOI 10.1016/S0887-6185(98)00039-5; Chemtob CM, 1997, J CONSULT CLIN PSYCH, V65, P184, DOI 10.1037/0022-006X.65.1.184; Cloitre M, 2002, J CONSULT CLIN PSYCH, V70, P1067, DOI 10.1037//0022-006X.70.5.1067; COOPER NA, 1989, BEHAV THER, V20, P381, DOI 10.1016/S0005-7894(89)80057-7; Creamer M, 2002, J NERV MENT DIS, V190, P183, DOI 10.1097/00005053-200203000-00007; Devilly GJ, 1999, J ANXIETY DISORD, V13, P131, DOI 10.1016/S0887-6185(98)00044-9; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; EHLERS A, IN PRESS ARCH GEN PS; EVERITT BS, 1999, STAT ASPECTS DESIGN; EVERITT BS, 1998, BRIT J PSYCHIAT, V169, P602; Fecteau G., 1999, BEHAV COGN PSYCHOTHE, V27, P201; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; FOA EB, 1991, J CONSULT CLIN PSYCH, V59, P715, DOI 10.1037/0022-006X.59.5.715; Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194; FOA EB, 1995, J CONSULT CLIN PSYCH, V63, P948, DOI 10.1037/0022-006X.63.6.948; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; FRANK E, 1988, BEHAV THER, V19, P403, DOI 10.1016/S0005-7894(88)80012-1; FRANK E, 1979, J AFFECT DISORDERS, V1, P269, DOI 10.1016/0165-0327(79)90013-2; FRANK E, 1983, BEHAV MODIFICATION W, P245; Gillespie K, 2002, BEHAV RES THER, V40, P345, DOI 10.1016/S0005-7967(02)00004-9; Glynn SM, 1999, J CONSULT CLIN PSYCH, V67, P243, DOI 10.1037/0022-006X.67.2.243; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 1998, BEHAV RES THER, V36, P583, DOI 10.1016/S0005-7967(98)00052-7; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; Herbert JD, 2000, CLIN PSYCHOL REV, V20, P945, DOI 10.1016/S0272-7358(99)00017-3; Holeva V, 2001, BEHAV THER, V32, P65, DOI 10.1016/S0005-7894(01)80044-7; Jaycox LH, 1996, CLIN PSYCHOL PSYCHOT, V3, P176; Johnson T, 1998, Stat Methods Med Res, V7, P209; KAZDIN AE, 1989, J CONSULT CLIN PSYCH, V57, P138, DOI 10.1037/0022-006X.57.1.138; KEANE TM, 1989, BEHAV THER, V20, P245, DOI 10.1016/S0005-7894(89)80072-3; KILPATRICK DG, 1988, BEHAV THER, V19, P421, DOI 10.1016/S0005-7894(88)80013-3; KILPATRICK DG, 1983, CRISIS INTERVENTION, P165; LICHSTEIN KL, 1994, ADV BEHAV RES THER, V16, P1, DOI 10.1016/0146-6402(94)90001-9; Lohr JM, 1999, J ANXIETY DISORD, V13, P185, DOI 10.1016/S0887-6185(98)00047-4; Macklin ML, 2000, COMPR PSYCHIAT, V41, P24, DOI 10.1016/S0010-440X(00)90127-5; Marks I, 1998, ARCH GEN PSYCHIAT, V55, P317, DOI 10.1001/archpsyc.55.4.317; McNally R. J., 1999, PTSD RES Q, V10, P1; Meichenbaum D., 1975, HELPING PEOPLE CHANG, P357; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; PAUNOVIC N, 1991, BEHAV RES THER, V39, P1183; PENISTON E G, 1986, Clinical Biofeedback and Health, V9, P35; Rassin E, 2000, CLIN PSYCHOL REV, V20, P973, DOI 10.1016/S0272-7358(99)00019-7; Resick P. A., 1993, COGNITIVE PROCESSING; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI 10.1037/0022-006X.60.5.748; RICHARDS DA, 1994, J TRAUMA STRESS, V7, P669, DOI 10.1002/jts.2490070412; RIGGS DS, 1995, J INTERPERS VIOLENCE, V10, P201, DOI 10.1177/0886260595010002005; Rothbaum BO, 2002, AM J PSYCHOTHER, V56, P59, DOI 10.1176/appi.psychotherapy.2002.56.1.59; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; Rothbaum BO, 2001, J TRAUMA STRESS, V14, P481, DOI 10.1023/A:1011104521887; Rothbaum BO, 2001, J CLIN PSYCHIAT, V62, P617, DOI 10.4088/JCP.v62n0808; Salmon K, 2002, CLIN PSYCHOL REV, V22, P163, DOI 10.1016/S0272-7358(01)00086-1; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shapiro F., 1995, EYE MOVEMENT DESENSI; SOLOMON Z, 1992, J TRAUMA STRESS, V5, P225, DOI 10.1007/BF00976713; Tarrier N, 1999, BEHAV THER, V30, P597, DOI 10.1016/S0005-7894(99)80027-6; Tarrier N, 2000, BRIT J CLIN PSYCHOL, V39, P27, DOI 10.1348/014466500163086; Tarrier N, 2001, J CONSULT CLIN PSYCH, V69, P117, DOI 10.1037/0022-006X.69.1.117; Tarrier N, 2000, BEHAV RES THER, V38, P191, DOI 10.1016/S0005-7967(99)00030-3; Tarrier N, 1999, J CONSULT CLIN PSYCH, V67, P13, DOI 10.1037/0022-006X.67.1.13; Tarrier N, 1999, BRIT J PSYCHIAT, V175, P571, DOI 10.1192/bjp.175.6.571; TARRIER N, 2002, 32 C EABCT 18 21 SEP; TARRIER N, IN PRESS J COGNITIVE; TARRIER N, 2003, TREATMENT CHRONIC PT; Tarrier N, 2002, BEHAV COGN PSYCHOTH, V30, P129, DOI 10.1017/S1352465802002011; Taylor S, 2001, J CONSULT CLIN PSYCH, V69, P541, DOI 10.1037//0022-006X.69.3.541; TAYLOR S, IN PRESS J CONSULTIN; VAUGHAN K, 1992, BRIT J PSYCHIAT, V161, P658, DOI 10.1192/bjp.161.5.658; VINEY LL, 1985, J COUNS PSYCHOL, V32, P29, DOI 10.1037/0022-0167.32.1.29; Wolpe J., 1958, PSYCHOTHERAPY RECIPR; Yule W, 2001, J CLIN PSYCHIAT, V62, P23	93	137	141	2	39	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358	1873-7811		CLIN PSYCHOL REV	Clin. Psychol. Rev.	MAY	2003	23	3					501	522		10.1016/S0272-7358(03)00035-7			22	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	678ZL	WOS:000182896500006	12729682				2022-02-06	
J	Keane, RW; Kraydieh, S; Lotocki, G; Alonso, OF; Aldana, P; Dietrich, WD				Keane, RW; Kraydieh, S; Lotocki, G; Alonso, OF; Aldana, P; Dietrich, WD			Apoptotic and antiapoptotic brain mechanisms after traumatic injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; caspases; IAPs; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CORTICAL IMPACT INJURY; TEMPORAL PROFILE; HEAD-INJURY; NEURONAL APOPTOSIS; SIGNALING COMPLEX; RAT HIPPOCAMPUS; PROTEINS; EXPRESSION; INHIBITOR	Caspase and inhibitor of apoptosis (IAP) expression was examined in rats subjected to moderate traumatic brain injury (TBI) using a parasagittal fluid-percussion brain insult (1.7 to 2.2 atm). Within 1 hour after injury, caspase-8 and -9, two initiators of apoptosis, were predominantly expressed in superficial cortical areas adjacent to the impact site and in the thalamus. Caspase-3, an effector caspase, was evident at 6 hours throughout the traumatized cerebral cortex and hippocampus. Moreover, the authors observed that XIAP, cIAP-1, and cIAP-2, members of the IAP family, were constitutively expressed in the brain. Colocalization of XIAP-immunolabled cells with cell-specific markers indicated that XIAP is expressed within neurons and a subpopulation of oligodendrocytes. Immunoblots of brain extracts revealed that the processed forms of caspase-8, -9, and -3 are present as early as 1 hour after trauma. The appearance of activated caspases corresponded with the detection of cleavage of XIAP into fragments after injury and a concomitant increase in the levels of cIAP-1 and cIAP-2 in the traumatized hemispheres. The current data are consistent with the hypotheses that caspases in both the extrinsic and intrinsic apoptotic pathways are activated after moderate TBI and that IAPs may have a protective role within the brain with alterations in levels and cleavage of IAPs that contribute to cell death in this setting.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Miami Project Cure Paralysis, Miami, FL USA		Keane, RW (corresponding author), Univ Miami, Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave,R-430, Miami, FL 33136 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(02)02075-5; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Johnson DE, 2000, CANCER RES, V60, P1818; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Korhonen L, 2001, MOL CELL NEUROSCI, V17, P364, DOI 10.1006/mcne.2000.0935; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; RINK A, 1995, AM J PATHOL, V147, P1575; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	50	137	147	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2001	21	10					1189	1198		10.1097/00004647-200110000-00007			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	479YR	WOS:000171432300007	11598496	Bronze			2022-02-06	
J	Herrmann, M; Jost, S; Kutz, S; Ebert, AD; Kratz, T; Wunderlich, MT; Synowitz, H				Herrmann, M; Jost, S; Kutz, S; Ebert, AD; Kratz, T; Wunderlich, MT; Synowitz, H			Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography	JOURNAL OF NEUROTRAUMA			English	Article						CCT; NSE; protein S-100B; traumatic brain injury	NEURON-SPECIFIC ENOLASE; MINOR HEAD-INJURY; CALCIUM-BINDING PROTEINS; DIFFUSE AXONAL INJURY; S-100 PROTEIN; CARDIOPULMONARY BYPASS; SERUM MARKER; CELL-DEATH; ASTROCYTES; S100-BETA	This study aimed at the investigation of release patterns of neuron specific enolase (NSE) and protein S-100B after traumatic brain injury (TBI) and their association with intracranial pathologic changes as demonstrated in computerized tomography (CT). We analyzed NSE and S-100B concentrations in serial venous blood samples taken one to three days after TBI in 66 patients by the use of immunoluminometric assays. These markers are considered to be specific neurobiochemical indicators of damage to glial (S-100B) or neuronal (NSE) brain tissue. Standardized neurological examination and plani- and volumetric evaluation of computerized tomography scans were performed in all patients. Patients with medium severe to severe TBI [Glasgow Coma Scale (GCS) score at the site of accident less than or equal to 12] exhibited significantly higher NSE and S-100B concentrations and a significantly longer release compared to patients with minor head injury (GCS: 13-15). Both, patients with and without visible intracerebral pathology in CT scans exhibited elevated concentrations of NSE and S-100B after TBI and a significant decrease in the follow-up blood samples. Release patterns of S-100B and NSE differed in patients with primary cortical contusions, diffuse axonal injury (DAI), and signs of cerebral edema (ICP) without focal mass lesions. All serum concentrations of NSE and S-100B were significantly correlated with the volume of contusions. The data of the present study indicate that the early release patterns of NSE and S-100 may mirror different pathophysiological consequences of traumatic brain injury.	Otto Von Guericke Univ, Fac Med, Div Neuropsychol & Behav Neurol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurosurg, D-39120 Magdeburg, Germany		Herrmann, M (corresponding author), Otto Von Guericke Univ, Fac Med, Div Neuropsychol & Behav Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	herrmann@medizin.uni-magdeburg.de	Herrmann, Manfred/H-3931-2011	Herrmann, Manfred/0000-0003-1872-8406			ABERG T, 1995, ANN THORAC SURG, V59, P1312, DOI 10.1016/0003-4975(95)00194-P; Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; BARONE FC, 1993, BRAIN RES, V623, P77, DOI 10.1016/0006-8993(93)90012-C; BETZ AL, 1992, NEUROSURGERY SCI BAS, P353; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Butterworth RJ, 1996, STROKE, V27, P2064, DOI 10.1161/01.STR.27.11.2064; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HATFIELD RH, 1992, BRAIN RES, V577, P249, DOI 10.1016/0006-8993(92)90280-M; Herrmann M, 1999, EUR J CARDIO-THORAC, V16, P513, DOI 10.1016/S1010-7940(99)00245-6; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X; Hu JR, 1997, J NEUROCHEM, V69, P2294; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.3.CO;2-0; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; KAHN HJ, 1991, MODERN PATHOL, V4, P698; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; McKeating EG, 1998, ACT NEUR S, V71, P117; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; TEASDALE G, 1974, LANCET, V2, P81; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	47	137	152	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2000	17	2					113	122		10.1089/neu.2000.17.113			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	286MB	WOS:000085448800001	10709869				2022-02-06	
J	Blesch, A; Uy, HS; Grill, RJ; Cheng, JG; Patterson, PH; Tuszynski, MH				Blesch, A; Uy, HS; Grill, RJ; Cheng, JG; Patterson, PH; Tuszynski, MH			Leukemia inhibitory factor augments neurotrophin expression and corticospinal axon growth after adult CNS injury	JOURNAL OF NEUROSCIENCE			English	Article						leukemia inhibitory factor; LIF; gene therapy; corticospinal; spinal cord injury; regeneration; neurotrophic factors	FACTOR MESSENGER-RNA; CULTURED SYMPATHETIC NEURONS; SPINAL-CORD INJURY; DIFFERENTIATION FACTOR; NERVOUS-SYSTEM; FACTOR CNTF; SENSORY NEURONS; SCIATIC-NERVE; CELL-LINE; EMBRYONIC MOTONEURONS	The cytokine leukemia inhibitory factor (LIF) modulates glial and neuronal function in development and after peripheral nerve injury, but little is known regarding its role in the injured adult CNS. To further understand the biological role of LIF and its potential mechanisms of action after CNS injury, effects of cellularly delivered LIF on axonal growth, glial activation, and expression of trophic factors were examined after adult mammalian spinal cord injury. Fibroblasts genetically modified to produce high amounts of LIF were grafted to the injured spinal cords of adult Fischer 344 rats. Two weeks after injury, animals with LIF-secreting cells showed a specific and significant increase in corticospinal axon growth compared with control animals. Furthermore, expression of neurotrophin-3, but not nerve growth factor, brain-derived neurotrophic factor, glia cell line-derived neurotrophic factor, or ciliary neurotrophic factor, was increased at the lesion site in LIF-grafted but not in control subjects. No differences in astroglial and microglial/macrophage activation were observed. Thus, LIF can directly or indirectly modulate molecular and cellular responses of the adult CNS to injury. These findings also demonstrate that neurotrophic molecules can augment expression of other trophic factors in vivo after traumatic injury in the adult CNS.	Univ Calif San Diego, Dept Neurosci 0626, La Jolla, CA 92093 USA; Vet Adm Med Ctr, San Diego, CA 92165 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA		Tuszynski, MH (corresponding author), Univ Calif San Diego, Dept Neurosci 0626, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Blesch, Armin/0000-0003-1133-1174	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG010435, AG01435] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20916, NS37083] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037083, R01NS020916] Funding Source: NIH RePORTER		ALOISI F, 1994, J IMMUNOL, V152, P5022; Apfel SC, 1996, MOL CELL NEUROSCI, V7, P134, DOI 10.1006/mcne.1996.0010; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; BANNER LR, 1998, LEUKEMIA INHIBOTORY, V18, P5456; BARRES BA, 1993, DEVELOPMENT, V118, P283; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; CANNOSA M, 1997, P NATL ACAD SCI USA, V94, P13279; CHEEMA SS, 1994, J NEUROSCI RES, V37, P213, DOI 10.1002/jnr.490370207; CHEEMA SS, 1994, NEUROREPORT, V5, P989, DOI 10.1097/00001756-199404000-00034; CURTIS R, 1994, NEURON, V12, P191, DOI 10.1016/0896-6273(94)90163-5; DALE SM, 1995, EXP NEUROL, V135, P67, DOI 10.1006/exnr.1995.1066; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; FANN MJ, 1993, J NEUROCHEM, V61, P1349, DOI 10.1111/j.1471-4159.1993.tb13628.x; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; FIGUEIREDO BC, 1995, MOL BRAIN RES, V33, P1, DOI 10.1016/0169-328X(95)00099-E; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; GARD AL, 1995, DEVELOPMENT, V121, P2187; Grill R, 1997, J NEUROSCI, V17, P5560; HAGG T, 1993, J NEUROIMMUNOL, V48, P177, DOI 10.1016/0165-5728(93)90190-A; HENDRY IA, 1992, J NEUROSCI, V12, P3427; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KAHN MA, 1995, BRAIN RES, V685, P55, DOI 10.1016/0006-8993(95)00411-I; KAHN MA, 1994, GLIA, V12, P87, DOI 10.1002/glia.440120202; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; KORSCHING S, 1993, J NEUROSCI, V13, P2739; Kurek JB, 1996, NEUROMUSCULAR DISORD, V6, P105, DOI 10.1016/0960-8966(95)00029-1; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDHOLM D, 1994, INT J DEV NEUROSCI, V12, P745, DOI 10.1016/0736-5748(94)90054-X; Lisovoski F, 1997, J NEUROSCI, V17, P7228; MAGAL E, 1993, NEUROREPORT, V4, P779, DOI 10.1097/00001756-199306000-00046; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MAYER M, 1994, DEVELOPMENT, V120, P143; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; MURPHY GM, 1995, NEUROSCI LETT, V184, P48, DOI 10.1016/0304-3940(94)11165-F; Murphy M, 1997, PROG NEUROBIOL, V52, P355, DOI 10.1016/S0301-0082(97)00020-8; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; MURPHY M, 1994, DEVELOPMENT, V120, P3519; Patterson P. H., 1997, Society for Neuroscience Abstracts, V23, P997; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; RAO MS, 1993, NEURON, V11, P1175, DOI 10.1016/0896-6273(93)90229-K; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; Richards LJ, 1996, EUR J NEUROSCI, V8, P291, DOI 10.1111/j.1460-9568.1996.tb01213.x; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; SUN Y, 1994, J NEUROBIOL, V25, P415, DOI 10.1002/neu.480250407; Sun Y, 1996, J NEUROCHEM, V67, P1751; THALER CD, 1994, DEV BIOL, V161, P338, DOI 10.1006/dbio.1994.1035; Tham S, 1997, J NEUROSCI RES, V47, P208, DOI 10.1002/(SICI)1097-4547(19970115)47:2<208::AID-JNR9>3.0.CO;2-J; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Tuszynski MH, 1996, EXP NEUROL, V137, P157, DOI 10.1006/exnr.1996.0016; ULICH TR, 1994, AM J PHYSIOL-LUNG C, V267, pL442, DOI 10.1152/ajplung.1994.267.4.L442; WARE CB, 1995, DEVELOPMENT, V121, P1283; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; Yee K. T., 1996, Society for Neuroscience Abstracts, V22, P1468	61	137	145	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 1	1999	19	9					3556	3566					11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	189BF	WOS:000079883700029	10212315				2022-02-06	
J	Huang, W; Chen, Y; Shohami, E; Weinstock, M				Huang, W; Chen, Y; Shohami, E; Weinstock, M			Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						brain oedema; cholinergic mediation; monoamine oxidase-B inhibition; motor function; neuroprotection; spatial memory	TRAUMATIC BRAIN INJURY; ACETYLCHOLINE-RELEASE; FACIAL MOTONEURONS; PYRAMIDAL CELLS; RAT; HIPPOCAMPUS; SELEGILINE; ISCHEMIA; DAMAGE; PERFORMANCE	The potential neuroprotective effects of rasagiline, N-propareyl-1 R-aminoindan, a selective monoamine oxidase-B inhibitor and its inactive enantiomer TVP1022, N-propargyl-1 S-aminoindan were assessed against the sequelae of closed head injury in the mouse, injury was induced in the left hemisphere under ether anaesthesia. Rasagiline (0.2 and 1 mg/kg) or TVP1022 (1 and 2 mg/kg) injected 5 min after injury accelerated the recovery of motor function and spatial memory and reduced the cerebral oedema by about 40-50%, (P < 0.01). The neuroprotective effects on motor function and spatial memory, but not on cerebral oedema, were prevented by scopolamine (0.3 mg/kg). Daily injection of rasagiline (1 mg/kg) from day 3 after injury accelerated the recovery of spatial memory but not motor function. Conclusions: Early administration of rasagiline or TVP1022 can reduce the immediate sequelae of brain injury. The mechanism of action does not appear to involve monoamine oxidase-B inhibition but could be mediated by the maintenance of cholinergic transmission in brain neurons. (C) 1999 Elsevier Science B.V. All rights reserved.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91120 Jerusalem, Israel		Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91120 Jerusalem, Israel.	martar@cc.huji.ac.il					ANSARI KS, 1993, J NEUROSCI, V13, P4042; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Finberg JPM, 1998, NEUROREPORT, V9, P703; FINBERG JPM, 1998, IN PRESS PARKINSONS; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HEINONEN EH, 1994, CLIN PHARMACOL THER, V56, P742, DOI 10.1038/clpt.1994.204; Imperato A, 1996, NEUROSCIENCE, V70, P653, DOI 10.1016/S0306-4522(96)83004-1; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KNOLLEMA S, 1995, STROKE, V26, P1883, DOI 10.1161/01.STR.26.10.1883; Lahtinen H, 1997, BRAIN RES, V757, P260, DOI 10.1016/S0006-8993(97)00227-8; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; MARTINEZMURILLO R, 1988, BRAIN RES, V451, P227, DOI 10.1016/0006-8993(88)90767-6; NILSSON OG, 1992, BRAIN RES, V584, P132, DOI 10.1016/0006-8993(92)90886-E; OCARROLL AM, 1983, N-S ARCH PHARMACOL, V322, P198, DOI 10.1007/BF00500765; OH C, 1994, J NEUROSCI RES, V38, P64, DOI 10.1002/jnr.490380109; OTSUKA S, 1964, BIOCHEM PHARMACOL, V13, P995, DOI 10.1016/0006-2952(64)90096-6; Paterson IA, 1997, NEUROSCI BIOBEHAV R, V21, P181, DOI 10.1016/S0149-7634(96)00008-5; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; Semkova I, 1996, EUR J PHARMACOL, V315, P19, DOI 10.1016/S0014-2999(96)00593-6; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMILEY JF, 1996, ALZHEIMER DIS MOL BI, P159; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SPEIZER Z, 1998, PHARM BIOCH BEHAV, V60, P1; Sterling J, 1998, J NEURAL TRANSM-SUPP, P301; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Yamaguchi T, 1996, NEUROPHARMACOLOGY, V35, P329, DOI 10.1016/0028-3908(95)00171-9; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	34	137	140	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	FEB 5	1999	366	2-3					127	135		10.1016/S0014-2999(98)00929-7			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	166EV	WOS:000078564000001	10082192				2022-02-06	
J	Goldstein, B; Toweill, D; Lai, S; Sonnenthal, K; Kimberly, B				Goldstein, B; Toweill, D; Lai, S; Sonnenthal, K; Kimberly, B			Uncoupling of the autonomic and cardiovascular systems in acute brain injury	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						variability; power spectral analysis; transfer function magnitude; brain death	HEART-RATE-VARIABILITY; TRAUMATIC QUADRIPLEGIC HUMANS; ARTERIAL BLOOD-PRESSURE; POWER SPECTRUM ANALYSIS; DEATH; FLUCTUATIONS; VASOPRESSIN; MAINTENANCE; MODULATION; CHILDREN	We hypothesized that acute brain injury results in decreased heart rate (HR) variability and baroreflex sensitivity indicative of uncoupling of the autonomic and cardiovascular systems and that the degree of uncoupling should be proportional to the degree of neurological injury. We used HR and blood pressure (BP) power spectral analysis to measure neuroautonomic regulation of HR and BP and the transfer function magnitude (TF) between BP and HR as a measure of baroreflex modulation of HR. In 24 brain-injured patients [anoxic/ischemic injury (n = 7), multiple trauma (n = 6), head trauma (n = 5), central nervous system infection (n = 4), and intracranial hemorrhage (n = 2)], neurological injury and survival was associated with low-frequency (0.01-0.15 Hz) HR and BP power and TF. Brain-dead patients showed decreased low-frequency HR power [0.51 +/- 0.36 (SE) vs. 2.54 +/- 0.14 beats/min(2), P = 0.03] and TF [0.61 +/- 0.16 (SE) vs. 1.29 +/- 0.07 beats.min(-1).mmHg(-1), P = 0.05] compared with non-brain-dead patients. We conclude that 1) severity of neurological injury and outcome are inversely associated with HR and BP variability and 2) there is direct evidence for cardiovascular and autonomic uncoupling in acute brain injury with complete uncoupling during brain death.	Oregon Hlth Sci Univ, Div Pediat Crit Care, Dept Pediat, Portland, OR 97201 USA		Goldstein, B (corresponding author), Oregon Hlth Sci Univ, Div Pediat Crit Care, Dept Pediat, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.						AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; BERGER RD, 1989, AM J PHYSIOL, V256, pH142, DOI 10.1152/ajpheart.1989.256.1.H142; BERNARDI L, 1995, CIRCULATION, V92, P2895, DOI 10.1161/01.CIR.92.10.2895; Godin PJ, 1996, CRIT CARE MED, V24, P1117, DOI 10.1097/00003246-199607000-00009; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P228, DOI 10.1097/00003246-199302000-00014; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; GOLDSTEIN B, IN PRESS J INTENSIVE; GOLDSTEIN B, 1994, PEDIATR RES, V36, P353; GOLDSTEIN B, 1997, CLIN INTENSIVE CARE, V7, P297; INOUE K, 1991, AM J PHYSIOL, V260, pH842, DOI 10.1152/ajpheart.1991.260.3.H842; INOUE K, 1990, AM J PHYSIOL, V258, pH1722, DOI 10.1152/ajpheart.1990.258.6.H1722; IWAI A, 1989, TRANSPLANTATION, V48, P613; JENNETT B, 1975, LANCET, P480; KITNEY RL, 1980, STUDY HEART RATE VAR, V1; NOVITZKY D, 1988, TRANSPLANTATION, V45, P32; NOVITZKY D, 1987, TRANSPLANTATION, V43, P852, DOI 10.1097/00007890-198743060-00016; PARATI G, 1988, HYPERTENSION, V12, P214, DOI 10.1161/01.HYP.12.2.214; Persson P.B., 1991, BARORECEPTOR REFLEXE; RAEDER EA, 1987, J APPL CARDIOL, V2, P283; RANDALL DC, 1991, AM J PHYSIOL, V260, pH980; SANDS KEF, 1989, CIRCULATION, V79, P76, DOI 10.1161/01.CIR.79.1.76; SAUL JP, 1990, NEWS PHYSIOL SCI, V5, P32, DOI 10.1152/physiologyonline.1990.5.1.32; SAUL JP, 1991, AM J PHYSIOL, V261, pH1231, DOI 10.1152/ajpheart.1991.261.4.H1231; SHADE RE, 1991, BARORECEPTOR REFLEXE, P209; *SPEC TASK FORC, 1987, PEDIATRICS, V80, P298; TEASDALE G, 1974, LANCET, V2, P81; VANDENMEIRACKER AH, 1993, J HYPERTENS, V11, pS152; Weise F, 1993, Clin Auton Res, V3, P303, DOI 10.1007/BF01827331; WINCOMB WN, 1986, TRANSPLANTATION, V41, P29; YOSHIOKA T, 1986, NEUROSURGERY, V18, P565, DOI 10.1227/00006123-198605000-00009	31	137	141	0	8	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	OCT	1998	275	4					R1287	R1292		10.1152/ajpregu.1998.275.4.R1287			6	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	125KB	WOS:000076235800043					2022-02-06	
J	Nochi, M				Nochi, M			"Loss of self" in the narratives of people with traumatic brain injuries: A qualitative analysis	SOCIAL SCIENCE & MEDICINE			English	Article; Proceedings Paper	20th Annual Postgraduate Course on Rehabilitation of the Brain Injured Adult and Child	JUN 06-09, 1996	WILLIAMSBURG, VA			brain injury; rehabilitation; self; narrative		To discover how people with traumatic brain injuries (TBI) experience themselves, narrative data from ten individuals with TBI were analyzed. The findings suggest that people with TBI experience loss of self in various forms although they may successfully use strategies to avoid or minimize the sense of loss. First, people with TBI find it difficult to develop clear self-knowledge about how they have become as they are and what they can and cannot do. Second, loss of self is conspicuous when they compare their present status with their past in many aspects of their lives. Third, their senses of self are threatened by labels that they feel the society imposes upon them. This categorization of loss of self can serve for rehabilitation counseling of this population. It may assist counselors to enhance their understanding of emotional distress after TBI and to make use of their clients' narratives for the intervention. (C) 1998 Elsevier Science Ltd. All rights reserved.	Univ Tokyo, Dept Life Sci Psychol, Meguro Ku, Tokyo 153, Japan		Nochi, M (corresponding author), Univ Tokyo, Dept Life Sci Psychol, Meguro Ku, Komaba 3-8-1, Tokyo 153, Japan.						Bogdan R., 1992, QUALITATIVE RES ED I; BRUNER J, 1986, ACTUAL MIND POSSIBLE; CORBIN J, 1990, Z SOZIOL, V19, P418, DOI 10.1007/BF00988593; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; DANN MD, 1984, COGNITIVE REHABILITA, V2, P11; Epston, 1990, NARRATIVE MEANS THER; Glaser B., 1967, DISCOVERY GROUNDED T; HAGNER DC, 1994, REHABIL COUNS BULL, V37, P290; HERMANS HJM, 1992, AM PSYCHOL, V47, P23, DOI 10.1037/0003-066X.47.1.23; Hewitt J., 1997, SELF SOC SYMBOLIC IN, V7th; HOWARD GS, 1991, AM PSYCHOL, V46, P187; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; Lewington PJ, 1993, CANADIAN J COUNSELIN, V1993, P274; LINGE FR, 1990, CAN J PSYCHOL, V44, P116, DOI 10.1037/h0084383; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MELTZER ML, 1983, J CLIN PSYCHOL, V39, P3, DOI 10.1002/1097-4679(198301)39:1<3::AID-JCLP2270390102>3.0.CO;2-F; MILLER L, 1993, PSYCHOTHERAPY BRAIN; Neisser, 1988, PHILOS PSYCHOL, V1, P35, DOI [10.1080/09515088808572924, https://doi.org/10.1080/09515088808572924, DOI 10.1080/09515088808572924]; NOCHI M, IN PRESS DISABILITYS; Polkinghorne, 1988, NARRATIVE KNOWING HU; Pollack Irwin W., 1994, P671; Sarbin T. E., 1986, NARRATIVE PSYCHOL ST; Stake R. E., 1994, HDB QUALITATIVE RES, P443; THOMAS KR, 1986, APPL REHABILITATION, P34; VANDERHAEGHEN CE, 1986, J GEN PSYCHOL, V113, P139, DOI 10.1080/00221309.1986.9710551; Yin R.K., 2009, CASE STUDY RES DESIG; YLVISAKER M, 1987, COMMUNITY REENTRY HE	27	137	139	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	APR	1998	46	7					869	878		10.1016/S0277-9536(97)00211-6			10	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Public, Environmental & Occupational Health; Biomedical Social Sciences	YZ647	WOS:000072276000009	9541072				2022-02-06	
J	Parizel, PM; Ozsarlak, O; Van Goethem, JW; van den Hauwe, L; Dillen, C; Verlooy, J; Cosyns, P; De Schepper, AM				Parizel, PM; Ozsarlak, O; Van Goethem, JW; van den Hauwe, L; Dillen, C; Verlooy, J; Cosyns, P; De Schepper, AM			Imaging findings in diffuse axonal injury after closed head trauma	EUROPEAN RADIOLOGY			English	Article						brain, hemorrhage; brain, injuries; brain, MR; brain, CT; MR, gradient echo imaging; MR, FLAIR imaging	FEATURES	Even in patients with closed head trauma. brain parenchyma can be severely injured due to disruption of axonal fibers by shearing forces during acceleration, deceleration, and rotation of the head. In this article we review the spectrum of imaging findings in patients with diffuse axonal injuries (DAI) after closed head trauma. Knowledge of the location and imaging characteristics of DAI is important to radiologists for detection and diagnosis. Common locations of DAI include: cerebral hemispheric gray-white matter interface and subcortical white matter, body and splenium of corpus callosum, basal ganglia, dorsolateral aspect of brainstem, and cerebellum. In the acute phase, CT may show punctate hemorrhages. The true er;tent of brain involvement is better appreciated with MR imaging, because both hemorrhagic and non-hemorrhagic lesions (gliotic scars) can be detected. The MR appearance of DAI lesions depends on several factors, including age of injury, presence of hemorrhage or blood-breakdown products (e.g., hemosiderin), and type of sequence used. Technical aspects in MR imaging of these patients are discussed. Non-hemorrhagic lesions can be detected with fluid attenuated inversion recovery (I;LAIR), Droton-density-, or T2-weighted images, whereas gradient echo sequences with long TE increase the visibility of old hemorrhagic lesions.	Univ Ziekenhuis Antwerpen, Dept Radiol, B-2650 Edegem, Belgium; Univ Ziekenhuis Antwerpen, Dept Psychiat, B-2650 Edegem, Belgium; Univ Ziekenhuis Antwerpen, Dept Neurosurg, B-2650 Edegem, Belgium		Parizel, PM (corresponding author), Univ Ziekenhuis Antwerpen, Dept Radiol, Wilrijkstr 10, B-2650 Edegem, Belgium.			Parizel, Paul M./0000-0002-0221-2854; Van Goethem, Johan/0000-0003-3993-4583			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Holbourn AHS, 1943, LANCET, V2, P438; PELLICANO G, 1997, NEURORADIOLOGY, V39, pS82; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163	12	137	146	0	16	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0938-7994			EUR RADIOL	Eur. Radiol.		1998	8	6					960	965		10.1007/s003300050496			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	108XL	WOS:000075291100015	9683701				2022-02-06	
J	Albanese, J; Arnaud, S; Rey, M; Thomachot, L; Alliez, B; Martin, C				Albanese, J; Arnaud, S; Rey, M; Thomachot, L; Alliez, B; Martin, C			Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation	ANESTHESIOLOGY			English	Article						anesthetics, ketamine; brain, intracranial pressure; trauma, head	CEREBRAL BLOOD-FLOW; EXPERIMENTAL HEAD TRAUMA; METABOLISM; ANESTHESIA; CRANIOTOMY; MIDAZOLAM; INDUCTION; VELOCITY; RATS	Background: The potential adverse effects of ketamine in neurosurgical anesthesia have been well established and involve increased intracranial pressure (ICP) and cerebral blood flow. However, reexamination of ketamine is warranted because data regarding the effects of ketamine on cerebral hemodynamics are conflicting. Methods: Eight patients with traumatic brain injury were studied, In all patients, PCP monitoring tvas instituted before the study. Control of ICP (less than 25 mmHG), hemodynamic values, and blood gas tension (partial pressure of carbon dioxide In arterial blood between 35-38 mmHg) was obtained with propofol infusion (3 mg.kg(-1).h(-1)) and mechanical ventilation, The effects of three doses of ketamine, 1.5, 3, and 4 mg/kg , respectively, on ICP, cerebral perfusion pressure, jugular vein bulb oxygen saturation, middle cerebral artery blood flow velocity, and electric activity of the brain (EEG) were measured. The three doses were administered intravenously at Gh intervals over 30 s through a central venous line. Systemic and cerebral hemodynamics and end-tidal carbon dioxide were continuously monitored and recorded at 1-min intervals throughout the 30-min study periods. Results: Ketamine, in all three doses studied (1.5, 3, and 5 mg/kg) was associated with a significant decrease in ICP (mean +/- SD: 2 +/- 0.5 mmHg [P < 0.05], 4 +/- 1 mmHg [P < 0.05], and 5 +/- 2 mmHg [P < 0.05]) among the study patients regardless of the ketamine dose used, There were no significant differences in cerebral perfusion pressure, jugular vein bulb oxygen saturation, and middle cerebral artery blood flow-velocity. Ketamine induced a low-amplitude fast-activity electroencephalogram, with marked depression, such as burst suppression. Conclusions: These results suggest that ketamine may not adversely alter cerebral hemodynamics of mechanically ventilated head-trauma patients sedated with propofol. These encouraging results should be confirmed in larger groups of similar patients.	HOP NORD MARSEILLE,SERV NEUROCHIRURG,F-13195 MARSEILLE 20,FRANCE		Albanese, J (corresponding author), HOP NORD MARSEILLE,SERV EXPLORAT FONCTIONNELLE SYST NERVEUX,DEPT ANESTHESIE REANIMAT,F-13195 MARSEILLE 20,FRANCE.		Albanese, Jacques/AAS-7466-2021				AKESON J, 1993, ACTA ANAESTH SCAND, V37, P211, DOI 10.1111/j.1399-6576.1993.tb03703.x; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, P458; BJORKMAN S, 1992, J PHARMACOKINET BIOP, V20, P637, DOI 10.1007/BF01064423; DAWSON B, 1971, ANESTH ANAL CURR RES, V50, P443; FUJIKAWA DG, 1995, EPILEPSIA, V36, P186, DOI 10.1111/j.1528-1157.1995.tb00979.x; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; HOFFMAN WE, 1989, CLIN ANESTH, P819; HUI TW, 1995, ANESTHESIOLOGY, V82, P641, DOI 10.1097/00000542-199503000-00005; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; MICHENFELDER JD, 1973, ANESTHESIOLOGY, V39, P510, DOI 10.1097/00000542-197311000-00010; MUNRO HM, 1993, ACTA ANAESTH SCAND, V37, P75, DOI 10.1111/j.1399-6576.1993.tb03602.x; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; PFENNINGER E, 1985, ACTA NEUROCHIR, V78, P113, DOI 10.1007/BF01808689; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; THORSEN T, 1980, ACTA ANAESTH SCAND, V24, P1, DOI 10.1111/j.1399-6576.1980.tb01494.x; WHITE PF, 1982, ANESTHESIOLOGY, V57, P279, DOI 10.1097/00000542-198210000-00005	20	137	138	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0003-3022			ANESTHESIOLOGY	Anesthesiology	DEC	1997	87	6					1328	1334		10.1097/00000542-199712000-00011			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	YK509	WOS:A1997YK50900011	9416717				2022-02-06	
J	MACKAY, LE; BERNSTEIN, BA; CHAPMAN, PE; MORGAN, AS; MILAZZO, LS				MACKAY, LE; BERNSTEIN, BA; CHAPMAN, PE; MORGAN, AS; MILAZZO, LS			EARLY INTERVENTION IN SEVERE HEAD-INJURY - LONG-TERM BENEFITS OF A FORMALIZED PROGRAM	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						HEAD INJURIES; OUTCOME AND PROCESS ASSESSMENT (HEALTH-CARE); TRAUMA		With traumatic brain injuries numbering more than two million per year, health professionals are faced with the challenges of restoring and maximizing quality of life. This study quantifies the benefits of a formalized head injury program, including the concept of trauma rehabilitation, defined as early, aggressive rehabilitation during acute hospitalization. Thirty-eight severely head injured patients received treatment at the same rehabilitation facility. Twenty-one of these patients received acute care services at ten different hospitals without formalized traumatic brain injury programs, and 17 received services at a hospital with a formalized early intervention program. Comparison of outcome data for the two programs revealed that patients in the formalized program had comas and rehabilitation stays approximately one third the length of patients in nonformalized programs (18.9 vs 53.8 days and 106.5 vs 239.5 days, respectively). Mean cognitive levels at discharge from the acute hospitals (5.6 vs 4.0) and the rehabilitation facility (7.4 vs 6.7) were significantly higher for the formalized program, and they facilitated a significantly higher percentage of discharges to home vs extended care facility (94% vs 57%).	NEW BRITAIN MEM HOSP,NEW BRITAIN,CT; ST FRANCIS HOSP & MED CTR,DEPT PEDIAT,HARTFORD,CT 06105; ST FRANCIS HOSP & MED CTR,DEPT SURG,HARTFORD,CT 06105; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032		MACKAY, LE (corresponding author), ST FRANCIS HOSP & MED CTR,DEPT REHABIL MED,HARTFORD,CT 06105, USA.						ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CERVELLI L, 1982, DESCRIPTION MODEL CA; CHOW KL, 1972, EXP NEUROL, V34, P409, DOI 10.1016/0014-4886(72)90038-6; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COPE N, 1982, BENEFIT EALRY REHABI; Frazee J G, 1986, Emerg Med Clin North Am, V4, P859; Hagen C, 1981, TOP LANG DIS, V1, P73; HAGEN C, 1979, AM SPEECH LANGUAGE H; JENNETT B, 1975, BRIT MED J, V3, P267, DOI 10.1136/bmj.3.5978.267; LEWIN W, 1976, BRIT MED J, V2, P1234, DOI 10.1136/bmj.2.6046.1234; MACKAYFAHAN L, 1987, COGN REHABIL, V5, P6; MORGAN AS, 1988, 1ST E ASS SURG TRAUM; PARKER R, 1982, DISCIPLINE REPORT PH; RAPPAPORT M, 1982, FUTURE DIRECTIONS RE; ROSENZWEIG MR, 1980, S RECOVERY FUNCTION, P127; SCHWARTZCOWLEY R, 1986, TRAUMA Q, V3, P63; TEASDALE G, 1974, LANCET, V2, P81; WOOD CO, 1983, HOSP PHYSICIAN, V19, P89; YU J, 1976, ARCH PHYS MED REHAB, V57, P38	20	137	137	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1992	73	7					635	641					7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	JD139	WOS:A1992JD13900006	1622318				2022-02-06	
J	Yuan, XQ; Prough, DS; Smith, TL; DeWitt, DS				Yuan, Xiao-Quan; Prough, Donald S.; Smith, Thomas L.; DeWitt, Douglas S.			The Effects of Traumatic Brain Injury on Regional Cerebral Blood Flow in Rats	JOURNAL OF NEUROTRAUMA			English	Article							FLUID-PERCUSSION INJURY; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CARDIAC OUTPUT; RADIOLABELED MICROSPHERES; SPREADING DEPRESSION; ARACHIDONIC-ACID; SMOOTH-MUSCLE; PROSTAGLANDINS; MODEL	Alterations in cerebral blood flow (CBF) are among the most important secondary pathophysiologic consequences of traumatic brain injury. The present study compared CBF in control rats (n = 20) and in rats that received a calibrated experimental traumatic brain injury (n = 17). The traumatized rats were anesthetized with ketamine (25 mg/kg) and xylazine (10 mg/kg), and prepared for fluid percussion injury (FPI). Twenty-four hours later, the rats were anesthetized with 1% halothane in nitrous oxide-oxygen (70: 30) and the left atrium was catheterized via a thoroacotomy. The atrial cannula was used to inject 15 mu m radiolabeled microspheres to measure CBF. Following surgery, the concentration of halothane was reduced to 0.5% and the rats were paralyzed with pancuronium bromide (0.1 mg/kg). Thirty minutes later, baseline microsphere determinations were made, and the rats were injured (2.47 +/- 0.08 atm). Each rat received additional injections of microspheres at two of the following four times (T): 5, 15, 30, and 60 min after the brain injury. The procedures for the control group rats were the same as described above except that the rats were not subjected to the craniotomy and the FPI. The traumatized group exhibited heterogeneous decreases in CBF following trauma. Global CBF in this group was 78% (p < 0.01), 64% (p < 0.05), 52% (p < 0.001) of those in the control group at T5, 15, 30, and 60, respectively. In rats, the most prominent cerebral circulatory changes following fluid percussion injury were early reductions of CBF and an increasingly heterogeneous CBF pattern. Hemorrhage, edema, and elevated prostagandin levels are mechanisms that may contribute to these changes.	[Yuan, Xiao-Quan; Prough, Donald S.; DeWitt, Douglas S.] Wake Forest Univ, Med Ctr, Bowman Gray Sch Med, Dept Anesthesia, Winston Salem, NC 27103 USA; [Prough, Donald S.] Wake Forest Univ, Med Ctr, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; [Smith, Thomas L.] Wake Forest Univ, Med Ctr, Bowman Gray Sch Med, Dept Physiol, Winston Salem, NC 27103 USA		DeWitt, DS (corresponding author), Wake Forest Univ, Med Ctr, Bowman Gray Sch Med, Dept Anesthesia, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NIH/NINCDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 19355]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019355] Funding Source: NIH RePORTER	We thank Ms. Esther Wooten and Ms. Amy Ward for their expert technical assistance. We also thank Ms. Vicky Cranfill for her secretarial assistance. This work was supported by NIH/NINCDS grant NS 19355.	ALM A, 1975, ACTA PHYSIOL SCAND, V95, P60, DOI 10.1111/j.1748-1716.1975.tb10025.x; ALTURA BM, 1976, FED PROC, V35, P2360; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; Buckberg G.D., 1971, J APPL PHYSIOL, V31, P589; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; de Valois J C, 1972, Prog Brain Res, V35, P349; DELGADO TJ, 1986, J CEREBR BLOOD F MET, V6, P590, DOI 10.1038/jcbfm.1986.106; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DEWITT D S, 1987, Society for Neuroscience Abstracts, V13, P1677; DeWitt D.S., 1988, SOC NEUR ABSTR, V14, P691; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOLE WP, 1982, AM J PHYSIOL, V243, pH371, DOI 10.1152/ajpheart.1982.243.3.H371; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1977, STROKE, V8, P480, DOI 10.1161/01.STR.8.4.480; Frazee J G, 1986, Emerg Med Clin North Am, V4, P859; Friedman A.H., 1986, TXB SURG, P1382; Geisler F.H., 1987, TRAUMA EMERGENCY SUR, P919; GREGORY PC, 1979, STROKE, V10, P719, DOI 10.1161/01.STR.10.6.719; GRICE SC, 1987, STROKE, V18, P787, DOI 10.1161/01.STR.18.4.787; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HEYMANN MA, 1977, PROG CARDIOVASC DIS, V20, P55, DOI 10.1016/S0033-0620(77)80005-4; HOFFBRAND BI, 1969, CARDIOVASC RES, V3, P426, DOI 10.1093/cvr/3.4.426; HORTON RW, 1980, STROKE, V11, P39, DOI 10.1161/01.STR.11.1.39; KOCHANEK PM, 1987, STROKE, V18, P634, DOI 10.1161/01.STR.18.3.634; Kontos H.A., 1980, CEREBRAL MICROVASCUL; KONTOS HA, 1981, FED PROC, V40, P2326; LAURITZEN M, 1982, ANN NEUROL, V12, P469, DOI 10.1002/ana.410120510; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; Malik B.A., 1976, J APPL PHYSIOL, V40, P472; MARCUS ML, 1976, J APPL PHYSIOL, V40, P501, DOI 10.1152/jappl.1976.40.4.501; Marovitch S., 1983, J CEREB BLOOD FLOW M, V3, pS196; MENT LR, 1986, J NEUROSURG, V65, P851, DOI 10.3171/jns.1986.65.6.0851; MOUFARRIJ NA, 1984, J NEUROSURG, V61, P1107, DOI 10.3171/jns.1984.61.6.1107; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; Povlishock J.T., 1980, CEREBRAL VASCULATURE; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; PROUGH DS, 1986, STROKE, V17, P1272, DOI 10.1161/01.STR.17.6.1272; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; SASAKI Y, 1971, J APPL PHYSIOL, V30, P879, DOI 10.1152/jappl.1971.30.6.879; SEELIG JM, 1985, BIOMECHANICS TRAUMA, P225; SHAPIRO HM, 1986, ANESTHESIA, P1264; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; STANEK KA, 1983, AM J PHYSIOL, V245, pH920, DOI 10.1152/ajpheart.1983.245.6.H920; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sumami K., 1987, J CEREB BLOOD FLO S1, V7, pS117; SVENDGAARD NA, 1985, STROKE, V16, P602, DOI 10.1161/01.STR.16.4.602; THOMPSON RK, 1988, NEUROSURGERY, V22, P623, DOI 10.1227/00006123-198804000-00001; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WOLFE LS, 1979, ANNU REV PHYSIOL, V41, P669, DOI 10.1146/annurev.ph.41.030179.003321; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMAKAMI I, 1987, Society for Neuroscience Abstracts, V13, P1501; YUAN X Q, 1988, Anesthesiology (Hagerstown), V69, pA538, DOI 10.1097/00000542-198809010-00538	63	137	139	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	4					289	U58		10.1089/neu.1988.5.289			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V21VO	WOS:000208235300003	3249308				2022-02-06	
J	[Anonymous]				[Anonymous]			2021 Alzheimer's disease facts and figures	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's dementia; Alzheimer's disease; Biomarkers; Caregivers; COVID-19; Dementia; Diagnostic criteria; Discrimination; Diversity; Equity; Ethnicity; Family caregiver; Health care costs; Health care disparities; Health care expenditures; Health care professional; Health disparities; Implicit bias; Incidence; Long-term care costs; Medicaid spending; Medicare spending; Morbidity; Mortality; Prevalence; Race; Risk factors; Spouse caregiver	MILD COGNITIVE IMPAIRMENT; NURSING-HOME RESIDENTS; TRAUMATIC BRAIN-INJURY; VASCULAR RISK-FACTORS; APOLIPOPROTEIN-E GENOTYPE; HEALTH-CARE USE; LONG-TERM-CARE; OF-LIFE CARE; AMBIENT AIR-POLLUTION; ALL-CAUSE MORTALITY	This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report discusses the challenges of providing equitable health care for people with dementia in the United States. An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Official death certificates recorded 121,499 deaths from AD in 2019, the latest year for which data are available, making Alzheimer's the sixth-leading cause of death in the United States and the fifth-leading cause of death among Americans age 65 and older. Between 2000 and 2019, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 145%. This trajectory of deaths from AD was likely exacerbated in 2020 by the COVID-19 pandemic. More than 11 million family members and other unpaid caregivers provided an estimated 15.3 billion hours of care to people with Alzheimer's or other dementias in 2020. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at $256.7 billion in 2020. Its costs, however, extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes - costs that have been aggravated by COVID-19. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are more than three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 23 times as great. Total payments in 2021 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $355 billion. Despite years of efforts to make health care more equitable in the United States, racial and ethnic disparities remain - both in terms of health disparities, which involve differences in the burden of illness, and health care disparities, which involve differences in the ability to use health care services. Blacks, Hispanics, Asian Americans and Native Americans continue to have a higher burden of illness and lower access to health care compared with Whites. Such disparities, which have become more apparent during COVID-19, extend to dementia care. Surveys commissioned by the Alzheimer's Association recently shed new light on the role of discrimination in dementia care, the varying levels of trust between racial and ethnic groups in medical research, and the differences between groups in their levels of concern about and awareness of Alzheimer's disease. These findings emphasize the need to increase racial and ethnic diversity in both the dementia care workforce and in Alzheimer's clinical trials.									AARP, AGING BABY BOOM GROW; AARP, FAM CAR OUT OF POCK; Abell JG, 2018, EUR HEART J, V39, P3119, DOI 10.1093/eurheartj/ehy288; Administration on Aging Administration for Community Living U.S. Department of Health and Human Services, PROF OLD AM 2016; Aguirre E, 2013, AGEING RES REV, V12, P253, DOI 10.1016/j.arr.2012.07.001; Ahmadi-Abhari S, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2856; Akarsu NE, 2019, INT J GERIATR PSYCH, V34, P790, DOI 10.1002/gps.5070; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Allen AP, 2017, NEUROSCI BIOBEHAV R, V73, P123, DOI 10.1016/j.neubiorev.2016.12.006; Alsaeed D, 2016, INT J PHARMACEUT, V512, P396, DOI 10.1016/j.ijpharm.2015.12.050; Altmann A, 2014, ANN NEUROL, V75, P563, DOI 10.1002/ana.24135; Alzheimer's Association, 2019 ALZH DIS FACTS; Alzheimer's Association, ALZHEIMERS DEMENT; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Amjad H, 2021, J AM GERIATR SOC, V69, P129, DOI 10.1111/jgs.16817; Amjad H, 2016, J AM GERIATR SOC, V64, P1223, DOI 10.1111/jgs.14164; [Anonymous], ROSALYNN CARTER I CA; [Anonymous], 2016, PREP CONTR AV UNPUB; [Anonymous], WALMART 2020 ANN REP; [Anonymous], HLTH PEOPLE 2030; [Anonymous], CAREGIVING US 2020 R; [Anonymous], **NON-TRADITIONAL**; [Anonymous], MCDONALDS CORPORATIO; [Anonymous], 2015 2016 2017 BEHAV; Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Arrighi HM, 2010, ALZ DIS ASSOC DIS, V24, P90, DOI 10.1097/WAD.0b013e31819fe7d1; Arthur PB, 2018, INT PSYCHOGERIATR, V30, P1099, DOI 10.1017/S104161021700237X; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Aston L, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0638-6; Atteih S, 2015, INT J STROKE, V10, P918, DOI 10.1111/ijs.12535; Badana ANS, 2019, J AGING HEALTH, V31, P925, DOI 10.1177/0898264317743611; Bahar-Fuchs A, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013069.pub2; Bailey ZD, 2017, LANCET, V389, P1453, DOI 10.1016/S0140-6736(17)30569-X; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52; Barker WW, 2002, ALZ DIS ASSOC DIS, V16, P203, DOI 10.1097/00002093-200210000-00001; Barnes DE, 2018, JAMA NEUROL, V75, P1055, DOI 10.1001/jamaneurol.2018.0815; Barnes LL, 2015, NEUROLOGY, V85, P528, DOI 10.1212/WNL.0000000000001834; Barnes LL, 2005, ARCH GEN PSYCHIAT, V62, P685, DOI 10.1001/archpsyc.62.6.685; Barrett AM, 2006, J AM GERIATR SOC, V54, P1968, DOI 10.1111/j.1532-5415.2006.00992.x; Barthelemy NR, 2020, NAT MED, V26, P398, DOI 10.1038/s41591-020-0781-z; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Baumgart M, 2015, ALZHEIMERS DEMENT, V11, P718, DOI 10.1016/j.jalz.2015.05.016; BAUMGARTEN M, 1992, J CLIN EPIDEMIOL, V45, P61, DOI 10.1016/0895-4356(92)90189-T; Beck C, 1999, INT J GERIATR PSYCH, V14, P197, DOI 10.1002/(SICI)1099-1166(199903)14:3<197::AID-GPS972>3.0.CO;2-Q; Bejot Y, 2018, INT J STROKE, V13, P687, DOI 10.1177/1747493018772800; Bekris LM, 2010, J GERIATR PSYCH NEUR, V23, P213, DOI 10.1177/0891988710383571; Bennett DA, 2006, NEUROLOGY, V66, P1837, DOI 10.1212/01.wnl.0000219668.47116.e6; Bercovitz AR, 2009, VITAL HLTH STAT, V13, P1; Bernard SM, 2003, PEDIATRICS, V112, P1308, DOI 10.1542/peds.112.6.1308; Beydoun MA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-643; Bin Sallim A, 2015, J AM MED DIR ASSOC, V16, P1034, DOI 10.1016/j.jamda.2015.09.007; Blondell SJ, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-510; Bloudek LM, 2011, J ALZHEIMERS DIS, V26, P627, DOI 10.3233/JAD-2011-110458; Boots LMM, 2014, INT J GERIATR PSYCH, V29, P331, DOI 10.1002/gps.4016; Boustani M, 2003, ANN INTERN MED, V138, P927, DOI 10.7326/0003-4819-138-11-200306030-00015; Boustani M, 2018, J AM GERIATR SOC, V66, P1372, DOI 10.1111/jgs.15283; Boyle PA, 2019, ANN NEUROL, V85, P114, DOI 10.1002/ana.25380; Boyle PA, 2018, ANN NEUROL, V83, P74, DOI 10.1002/ana.25123; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Bradford A, 2009, ALZ DIS ASSOC DIS, V23, P306, DOI 10.1097/WAD.0b013e3181a6bebc; Bremer P, 2015, HEALTH POLICY, V119, P1459, DOI 10.1016/j.healthpol.2015.09.014; Brenowitz WD, 2017, ALZHEIMERS DEMENT, V13, P654, DOI 10.1016/j.jalz.2016.09.015; Briesacher BA, 2020, J AM GERIATR SOC, V68, P2931, DOI 10.1111/jgs.16830; Brodaty H, 2012, INT PSYCHOGERIATR, V24, P1034, DOI 10.1017/S1041610211002924; Brookmeyer R, 2002, ARCH NEUROL-CHICAGO, V59, P1764, DOI 10.1001/archneur.59.11.1764; Brookmeyer R, 2018, ALZHEIMERS DEMENT, V14, P121, DOI 10.1016/j.jalz.2017.10.009; Brown CH, 2015, NEUROLOGY, V84, P1443, DOI 10.1212/WNL.0000000000001439; Brunnstrom HR, 2009, EUR J NEUROL, V16, P488, DOI 10.1111/j.1468-1331.2008.02503.x; Buchman AS, 2019, NEUROLOGY, V92, pE811, DOI 10.1212/WNL.0000000000006954; Buckley RF, 2018, ALZHEIMERS DEMENT, V14, P1193, DOI 10.1016/j.jalz.2018.04.010; Buckley RF, 2016, ALZHEIMERS DEMENT, V12, P796, DOI 10.1016/j.jalz.2015.12.013; BURNS A, 1990, AGE AGEING, V19, P341, DOI 10.1093/ageing/19.5.341; Butler M, 2018, ANN INTERN MED, V168, P52, DOI 10.7326/M17-1530; Carter CL, 2012, J WOMENS HEALTH, V21, P1018, DOI 10.1089/jwh.2012.3789; Cavallazzi R, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-49; Centers for Disease Control and Prevention, POT EFF; Centers for Disease Control and Prevention, 2020, EXC DEATHS ASS COVID; Centers for Disease Control and Prevention, CURR CIG SMOK AD US; Centers for Disease Control and Prevention, 2014, SURV REP TRAUM BRAIN; Centers for Disease Control and Prevention. National Center for Health Statistics, WEEKL UPD SEL DEM GE; Cerasuolo JO, 2017, ALZHEIMERS DEMENT, V13, P1081, DOI 10.1016/j.jalz.2017.02.010; Chen H, 2017, ENVIRON INT, V108, P271, DOI 10.1016/j.envint.2017.08.020; Chene G, 2015, ALZHEIMERS DEMENT, V11, P310, DOI 10.1016/j.jalz.2013.10.005; Cheng ST, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01547-2; Cheng ST, 2020, PSYCHOL AGING, V35, P55, DOI 10.1037/pag0000401; Cheng ST, 2016, GERONTOLOGIST, V56, P451, DOI 10.1093/geront/gnu118; Cherbuin N, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008853; Chin AL, 2011, ALZ DIS ASSOC DIS, V25, P187, DOI 10.1097/WAD.0b013e318211c6c9; Choi D, 2018, ANN CLIN TRANSL NEUR, V5, P1192, DOI 10.1002/acn3.633; Choi H, 2018, J GERONTOL B-PSYCHOL, V73, pS29, DOI 10.1093/geronb/gbx155; Christakis NA, 2006, NEW ENGL J MED, V354, P719, DOI 10.1056/NEJMsa050196; Clark PC, 2005, J AM GERIATR SOC, V53, P2012, DOI 10.1111/j.1532-5415.2005.53569.x; Collins RN, 2020, AGEING SOC, V40, P2355, DOI 10.1017/S0144686X19000527; Corrada MM, 2017, ALZHEIMERS DEMENT, V13, P103, DOI 10.1016/j.jalz.2016.09.007; Crane PK, 2013, NEW ENGL J MED, V369, P540, DOI [10.1056/NEJMoa1215740, 10.1056/NEJMc1311765]; Crimmins EM, 2018, J GERONTOL B-PSYCHOL, V73, pS20, DOI 10.1093/geronb/gbx135; Dassel KB, 2016, GERONTOLOGIST, V56, P444, DOI 10.1093/geront/gnu078; Dassel KB, 2017, GERONTOLOGIST, V57, P319, DOI 10.1093/geront/gnv148; Davis DHJ, 2012, BRAIN, V135, P2809, DOI 10.1093/brain/aws190; De Reuck J, 2018, FOLIA NEUROPATHOL, V56, P81, DOI 10.5114/fn.2018.76610; Deb A, 2017, EXPERT REV PHARM OUT, V17, P189, DOI 10.1080/14737167.2017.1313118; Debette S, 2011, NEUROLOGY, V77, P461, DOI 10.1212/WNL.0b013e318227b227; Dekhtyar S, 2019, ANN NEUROL, V86, P68, DOI 10.1002/ana.25501; Demirovic J, 2003, ANN EPIDEMIOL, V13, P472, DOI 10.1016/S1047-2797(02)00437-4; Derby CA, 2017, JAMA NEUROL, V74, P1345, DOI 10.1001/jamaneurol.2017.1964; Di Marco LY, 2014, J ALZHEIMERS DIS, V42, P119, DOI 10.3233/JAD-132225; Dilworth-Anderson P, 2008, ALZHEIMERS DEMENT, V4, P305, DOI 10.1016/j.jalz.2008.03.001; Dilworth-Anderson P, 2020, GERONTOLOGIST, V60, P797, DOI 10.1093/geront/gnaa050; Ehlenbach WJ, 2010, JAMA-J AM MED ASSOC, V303, P763, DOI 10.1001/jama.2010.167; Elvish R, 2018, DEMENTIA-LONDON, V17, P96, DOI 10.1177/1471301216634926; Evans DA, 2003, ARCH NEUROL-CHICAGO, V60, P185, DOI 10.1001/archneur.60.2.185; Fabius CD, 2020, GERONTOLOGIST, V60, P1244, DOI 10.1093/geront/gnaa042; Fann JR, 2018, LANCET PSYCHIAT, V5, P424, DOI 10.1016/S2215-0366(18)30065-8; Farina N, 2014, INT PSYCHOGERIATR, V26, P9, DOI 10.1017/S1041610213001385; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fauth EB, 2019, J APPL GERONTOL, V38, P1253, DOI 10.1177/0733464817714564; Feast A, 2016, INT PSYCHOGERIATR, V28, P1761, DOI 10.1017/S1041610216000922; Fernandez-Blazquez MA, 2016, J ALZHEIMERS DIS, V52, P271, DOI 10.3233/JAD-150956; Fisher GG, 2014, J OCCUP HEALTH PSYCH, V19, P231, DOI 10.1037/a0035724; Fisher GG, 2011, J AM GERIATR SOC, V59, P488, DOI 10.1111/j.1532-5415.2010.03304.x; Fitten LJ, 2001, J AM GERIATR SOC, V49, P1301, DOI 10.1046/j.1532-5415.2001.49257.x; Fitzpatrick AL, 2004, J AM GERIATR SOC, V52, P195, DOI 10.1111/j.1532-5415.2004.52058.x; Fitzpatrick AL, 2009, ARCH NEUROL-CHICAGO, V66, P336, DOI 10.1001/archneurol.2008.582; Folbre N., 2012, UNIVERSAL COVERAGE L, P155; Fonareva I, 2014, INT PSYCHOGERIATR, V26, P725, DOI 10.1017/S1041610214000039; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; Fredman L, 2006, PREV MED, V43, P226, DOI 10.1016/j.ypmed.2006.04.009; Fredriksen-Goldsen KI, 2018, J APPL GERONTOL, V37, P545, DOI 10.1177/0733464816672047; Freedman VA, 2018, J GERONTOL B-PSYCHOL, V73, pS48, DOI 10.1093/geronb/gbx144; Friedman EM, 2015, HEALTH AFFAIR, V34, P1637, DOI 10.1377/hlthaff.2015.0510; Froehlich TE, 2001, J AM GERIATR SOC, V49, P477, DOI 10.1046/j.1532-5415.2001.49096.x; Fukushima Raiana Lídice Mór, 2016, Dement. neuropsychol., V10, P178, DOI 10.1590/S1980-5764-2016DN1003003; Gallagher-Thompson D, 2009, AGING FAMILIES CAREG, P85; Ganguli M, 2005, ARCH NEUROL-CHICAGO, V62, P779, DOI 10.1001/archneur.62.5.779; Ganguli M, 1999, J AM GERIATR SOC, V47, P842, DOI 10.1111/j.1532-5415.1999.tb03842.x; Gao CL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.9891; Gao SJ, 2019, J AM GERIATR SOC, V67, P1361, DOI 10.1111/jgs.16027; Gaugler JE, 2002, INT J AGING HUM DEV, V54, P205, DOI 10.2190/FACK-QE61-Y2J8-5L68; Gaugler Joseph E, 2018, Alzheimers Dement (N Y), V4, P688, DOI 10.1016/j.trci.2018.08.010; Gaugler JE, 2019, GERONTOLOGIST, V59, P78, DOI 10.1093/geront/gny078; Gaugler JE, 2017, INT PSYCHOGERIATR, V29, P19, DOI 10.1017/S1041610216001514; Gaugler JE, 2016, GERONTOLOGIST, V56, P1161, DOI 10.1093/geront/gnv150; Gaugler JE, 2014, CLIN GERIATR MED, V30, P493, DOI 10.1016/j.cger.2014.04.003; Gaugler JE, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-85; Gianattasio KZ, 2019, ALZH DEMENT-TRCI, V5, P891, DOI 10.1016/j.trci.2019.11.008; Gifford KA, 2014, ALZHEIMERS DEMENT, V10, P319, DOI 10.1016/j.jalz.2013.02.007; Gillespie CD, 2013, MMWR-MORBID MORTAL W, V62, P144; Gillespie R, 2014, J CLIN NURS, V23, P3296, DOI 10.1111/jocn.12519; Gilmore-Bykovskyi A, 2018, AM J ALZHEIMERS DIS, V33, P145, DOI 10.1177/1533317517749465; Gitlin L. N., 2015, FAMILY CAREGIVING NE, P305, DOI DOI 10.1016/B978-0-12-417046-9.00017-9; Gitlin LN, 2015, GERONTOLOGIST, V55, P210, DOI 10.1093/geront/gnu123; Glymour MM, 2008, NEUROPSYCHOL REV, V18, P194, DOI 10.1007/s11065-008-9066-x; Goldman JS, 2011, GENET MED, V13, P597, DOI 10.1097/GIM.0b013e31821d69b8; Gonzalez HM, 2019, ALZHEIMERS DEMENT, V15, P1507, DOI 10.1016/j.jalz.2019.08.202; Gordon BA, 2018, LANCET NEUROL, V17, P241, DOI 10.1016/S1474-4422(18)30028-0; Goren A, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0298-y; Gottesman RF, 2017, JAMA NEUROL, V74, P1246, DOI 10.1001/jamaneurol.2017.1658; Gottesman RF, 2017, JAMA-J AM MED ASSOC, V317, P1443, DOI 10.1001/jama.2017.3090; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; Greenwood N, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1185-0; Griffith M, 2007, INT J HEALTH SERV, V37, P259, DOI 10.2190/R410-7263-4811-4415; Griffiths PC, 2016, GERONTOLOGIST, V56, P145, DOI 10.1093/geront/gnv123; Groot C, 2016, AGEING RES REV, V25, P13, DOI 10.1016/j.arr.2015.11.005; Grossberg George T, 2010, Prim Care Companion J Clin Psychiatry, V12, DOI 10.4088/PCC.09cs00833oli; Grzywacz JG, 2016, J OCCUP ENVIRON MED, V58, P535, DOI 10.1097/JOM.0000000000000727; Gudala K, 2013, J DIABETES INVEST, V4, P640, DOI 10.1111/jdi.12087; Guerreiro R, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0232-5; Gurland BJ, 1999, INT J GERIATR PSYCH, V14, P481, DOI 10.1002/(SICI)1099-1166(199906)14:6<481::AID-GPS959>3.3.CO;2-X; Guure CB, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9016924; Haan MN, 2003, J AM GERIATR SOC, V51, P169, DOI 10.1046/j.1532-5415.2003.51054.x; Hall CB, 2009, NEUROLOGY, V73, P356, DOI 10.1212/WNL.0b013e3181b04ae3; Hall KS, 2009, ALZHEIMERS DEMENT, V5, P227, DOI 10.1016/j.jalz.2009.01.026; Hanseeuw BJ, 2019, JAMA NEUROL, V76, P915, DOI 10.1001/jamaneurol.2019.1424; Hardman RJ, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00022; Harrington M., ALZRISK DATABASE; Harris CD, 2013, MMWR-MORBID MORTAL W, V62, P326; Harwood D G, 2000, Curr Psychiatry Rep, V2, P40, DOI 10.1007/s11920-000-0040-4; He W, 2016, AGING WORLD 2015 INT; Hebert LE, 2010, NEUROLOGY, V75, P786, DOI 10.1212/WNL.0b013e3181f0754f; Hebert LE, 2001, AM J EPIDEMIOL, V153, P132, DOI 10.1093/aje/153.2.132; Hebert LE, 2001, ALZ DIS ASSOC DIS, V15, P169, DOI 10.1097/00002093-200110000-00002; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Helzner EP, 2008, NEUROLOGY, V71, P1489, DOI 10.1212/01.wnl.0000334278.11022.42; Hendrie HC, 2018, J GERONTOL B-PSYCHOL, V73, pS82, DOI 10.1093/geronb/gbx143; Hendrie HC, 2014, INT PSYCHOGERIATR, V26, P977, DOI 10.1017/S1041610214000167; Nguyen H, 2019, J CLIN NURS, V28, P1050, DOI 10.1111/jocn.14697; Hodgson N., BRIDGING FAMILY CARE; Hogan DB, 2016, CAN J NEUROL SCI, V43, pS96, DOI 10.1017/cjn.2016.25; Hohman TJ, 2018, JAMA NEUROL, V75, P989, DOI 10.1001/jamaneurol.2018.0821; Holtzman DM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006312; Hopwood J, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9548; Hudomiet P, 2018, J GERONTOL B-PSYCHOL, V73, pS10, DOI 10.1093/geronb/gbx169; Institute of Medicine, 2015, COGNITIVE AGING PROG; Institute of Medicine, 2008, RET AG AM BUILD HLTH; Ives DG, 2009, J AM GERIATR SOC, V57, P133, DOI 10.1111/j.1532-5415.2008.02056.x; Jack CR, 2019, JAMA NEUROL, V76, P1174, DOI 10.1001/jamaneurol.2019.1971; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062; James BD, 2019, NEUROLOGY, V92, pe690, DOI 10.1212/WNL.0000000000006918; James BD, 2016, BRAIN, V139, P2983, DOI 10.1093/brain/aww224; James BD, 2014, NEUROLOGY, V82, P1045, DOI 10.1212/WNL.0000000000000240; James BD, 2012, JAMA-J AM MED ASSOC, V307, P1798, DOI 10.1001/jama.2012.3556; James BD, 2011, J INT NEUROPSYCH SOC, V17, P998, DOI 10.1017/S1355617711000531; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Jellinger KA, 2007, J NEUROL SCI, V257, P80, DOI 10.1016/j.jns.2007.01.045; Jellinger KA, 2007, ALZHEIMERS DEMENT, V3, P40, DOI 10.1016/j.jalz.2006.09.002; Jellinger KA, 2010, ACTA NEUROPATHOL, V119, P421, DOI 10.1007/s00401-010-0654-5; Jennings LA, 2018, J AM GERIATR SOC, V66, P2120, DOI 10.1111/jgs.15541; Jessen F, 2014, ALZHEIMERS DEMENT, V10, P844, DOI 10.1016/j.jalz.2014.01.001; Jessen F, 2014, ALZHEIMERS DEMENT, V10, P76, DOI 10.1016/j.jalz.2012.09.017; Johnson KA, 2013, ALZHEIMERS DEMENT, V9, pE1, DOI [10.1016/j.jalz.2013.06.001, 10.1016/j.jalz.2013.01.002, 10.1016/j.jalz.2012.10.007]; Jones RW, 2017, DEMENT GER COGN D EX, V7, P87, DOI 10.1159/000461577; Jutkowitz E, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01613-9; Jutkowitz E, 2020, MED CARE, V58, P601, DOI 10.1097/MLR.0000000000001323; Jutkowitz E, 2017, J AM GERIATR SOC, V65, P2169, DOI 10.1111/jgs.15043; Jutten LH, 2018, J ALZHEIMERS DIS, V66, P149, DOI 10.3233/JAD-180508; Kaddour L, 2019, INT PSYCHOGERIATR, V31, P961, DOI 10.1017/S1041610218001436; Kang JH, 2012, NEUROBIOL AGING, V33, P1129, DOI 10.1016/j.neurobiolaging.2010.10.007; Kapasi A, 2017, ACTA NEUROPATHOL, V134, P171, DOI 10.1007/s00401-017-1717-7; Karnatovskaia LV, 2015, J CRIT CARE, V30, P130, DOI 10.1016/j.jcrc.2014.09.024; Karp A, 2006, DEMENT GERIATR COGN, V21, P65, DOI 10.1159/000089919; Kasper J., 2014, DISABILITY CARE NEED; Kasper JD, 2015, HEALTH AFFAIR, V34, P1642, DOI 10.1377/hlthaff.2015.0536; Kaup AR, 2015, NEUROLOGY, V85, P1852, DOI 10.1212/WNL.0000000000002153; Kawas C, 2000, NEUROLOGY, V54, P2072, DOI 10.1212/WNL.54.11.2072; Kawas CH, 2015, NEUROLOGY, V85, P535, DOI 10.1212/WNL.0000000000001831; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Khatutsky G., 2011, UNDERSTANDING DIRECT; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; Kishita N, 2020, J GERIATR PSYCH NEUR, V33, P28, DOI 10.1177/0891988719856690; Kishita N, 2018, INT PSYCHOGERIATR, V30, P1679, DOI 10.1017/S1041610218000947; Kivimaki M, 2018, ALZHEIMERS DEMENT, V14, P601, DOI 10.1016/j.jalz.2017.09.016; Knopman DS, 2003, J NEUROPATH EXP NEUR, V62, P1087, DOI 10.1093/jnen/62.11.1087; Koran MEI, 2017, BRAIN IMAGING BEHAV, V11, P205, DOI 10.1007/s11682-016-9523-8; Kotagal V, 2015, NEUROLOGY, V84, P64, DOI 10.1212/WNL.0000000000001096; Kramarow Ellen A, 2019, Natl Vital Stat Rep, V68, P1; Kramer NA, 2000, PROFESSIONAL PSYCHOL, P227; Krieger N, 2020, AM J PUBLIC HEALTH, V110, P1046, DOI 10.2105/AJPH.2020.305656; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Kulick ER, 2020, NEUROLOGY, V94, pE1782, DOI 10.1212/WNL.0000000000009314; Kulmala J, 2018, J ALZHEIMERS DIS, V64, pS191, DOI 10.3233/JAD-179919; Langa KM, 2017, JAMA INTERN MED, V177, P51, DOI 10.1001/jamainternmed.2016.6807; Langa KM, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0118-1; Langa KM, 2005, NEUROEPIDEMIOLOGY, V25, P181, DOI 10.1159/000087448; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; Larson EB, 2013, NEW ENGL J MED, V369, P2275, DOI 10.1056/NEJMp1311405; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; Lee TC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027670; Leggett AN, 2020, J AGING HEALTH, V32, P871, DOI 10.1177/0898264319860975; Letenneur L, 1999, J NEUROL NEUROSUR PS, V66, P177, DOI 10.1136/jnnp.66.2.177; Liu C, 2021, GERONTOLOGIST, V61, pE228, DOI 10.1093/geront/gnaa028; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Llanque SM, 2012, AM J ALZHEIMERS DIS, V27, P23, DOI 10.1177/1533317512439794; Lloyd J, 2016, DEMENTIA-LONDON, V15, P1534, DOI 10.1177/1471301214564792; LoBue C, 2017, CLIN NEUROPSYCHOL, V31, P85, DOI 10.1080/13854046.2016.1257069; Loef M, 2013, OBESITY, V21, pE51, DOI 10.1002/oby.20037; Lott IT, 2010, LANCET NEUROL, V9, P623, DOI 10.1016/S1474-4422(10)70112-5; Lourida I, 2013, EPIDEMIOLOGY, V24, P479, DOI 10.1097/EDE.0b013e3182944410; Loy CT, 2014, LANCET, V383, P828, DOI 10.1016/S0140-6736(13)60630-3; Luchsinger JA, 2018, J AM GERIATR SOC, V66, P1708, DOI 10.1111/jgs.15450; Manly J. J., 2004, CRIT PERSPECT, P95; Maslow K., 2012, TRANSLATING INNOVATI; Matthews FE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11398; Matthews FE, 2013, LANCET, V382, P1405, DOI 10.1016/S0140-6736(13)61570-6; Matthews KA, 2019, ALZHEIMERS DEMENT, V15, P17, DOI 10.1016/j.jalz.2018.06.3063; Mausbach BT, 2017, PSYCHOSOM MED, V79, P735, DOI 10.1097/PSY.0000000000000497; Mausbach BT, 2014, PSYCHOL AGING, V29, P776, DOI 10.1037/a0037626; Mausbach BT, 2013, AM J GERIAT PSYCHIAT, V21, P5, DOI 10.1016/j.jagp.2012.10.001; Mausbach BT, 2010, J AM COLL CARDIOL, V55, P2599, DOI 10.1016/j.jacc.2009.11.093; Maust DT, 2015, JAMA PSYCHIAT, V72, P438, DOI 10.1001/jamapsychiatry.2014.3018; Mayeda ER, 2017, ALZ DIS ASSOC DIS, V31, P181, DOI 10.1097/WAD.0000000000000189; Mayeda ER, 2020, NEUROLOGY, V95, pE3072, DOI 10.1212/WNL.0000000000010989; Mayeda ER, 2016, ALZHEIMERS DEMENT, V12, P216, DOI 10.1016/j.jalz.2015.12.007; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; MAYEUX R, 1991, ARCH NEUROL-CHICAGO, V48, P269, DOI 10.1001/archneur.1991.00530150037014; McCabe MP, 2007, AGING MENT HEALTH, V11, P505, DOI 10.1080/13607860601086405; McDowell I, 2007, J CLIN EXP NEUROPSYC, V29, P127, DOI 10.1080/13803390600582420; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKhann GM, 2012, ADV BIOL PSYCH-KARG, V28, P115; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Mehta KM, 2017, ALZHEIMERS DEMENT, V13, P72, DOI 10.1016/j.jalz.2016.06.2360; Meng XF, 2014, J ALZHEIMERS DIS, V42, P1295, DOI 10.3233/JAD-140954; Menke A, 2015, JAMA-J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029; Mergenthaler P, 2013, TRENDS NEUROSCI, V36, P587, DOI 10.1016/j.tins.2013.07.001; Mez J, 2020, ANN NEUROL, V87, P116, DOI 10.1002/ana.25611; Michaelson DM, 2014, ALZHEIMERS DEMENT, V10, P861, DOI 10.1016/j.jalz.2014.06.015; Mielke MM, 2020, NEUROLOGY, V95, P1027, DOI 10.1212/WNL.0000000000010987; Mielke MM, 2018, ALZHEIMERS DEMENT, V14, P1101, DOI 10.1016/j.jalz.2018.08.003; Mielke MM, 2014, CLIN EPIDEMIOL, V6, P37, DOI 10.2147/CLEP.S37929; Mikati I, 2018, AM J PUBLIC HEALTH, V108, P480, DOI [10.2105/AJPH.2017.304297, 10.2105/ajph.2017.304297]; Mitchell SL, 2005, J AM GERIATR SOC, V53, P299, DOI 10.1111/j.1532-5415.2005.53118.x; Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158; Monin JK, 2015, GERONTOLOGIST, V55, P981, DOI 10.1093/geront/gnu001; Morris MC, 2015, ALZHEIMERS DEMENT, V11, P1015, DOI 10.1016/j.jalz.2015.04.011; Morris MC, 2015, ALZHEIMERS DEMENT, V11, P1007, DOI 10.1016/j.jalz.2014.11.009; Najar J, 2019, NEUROLOGY, V92, pE1322, DOI 10.1212/WNL.0000000000007021; Napoles AM, 2010, AM J ALZHEIMERS DIS, V25, P389, DOI 10.1177/1533317510370957; National Alliance for Caregiving and AARP, 2009, CAR US; National Alliance for Caregiving and AARP, CAR US 2015 REP; National Alliance for Caregiving in Partnership with the Alzheimer's Association, DEM CAR US; National Down Syndrome Society, ALZH DIS SYNDR; National Institute on Aging, WHAT AR FRONT DIS; National Institute on Aging, WHAT CAUSES ALZHEIME; National Poll on Healthy Aging, DEM CAR JUGGL DEL LO; Nelson PT, 2011, ACTA NEUROPATHOL, V121, P571, DOI 10.1007/s00401-011-0826-y; Neu SC, 2017, JAMA NEUROL, V74, P1178, DOI 10.1001/jamaneurol.2017.2188; Ninomiya T, 2011, HYPERTENSION, V58, P22, DOI 10.1161/HYPERTENSIONAHA.110.163055; Official Data Foundation, CPI INFL CALC; Ogino E, 2019, ALZHEIMERS DEMENT, V15, P1603, DOI 10.1016/j.jalz.2019.07.013; Ohara T, 2015, J AM GERIATR SOC, V63, P2332, DOI 10.1111/jgs.13794; Ornstein K, 2012, INT PSYCHOGERIATR, V24, P1536, DOI 10.1017/S1041610212000737; Ornstein KA, 2019, HEALTH AFFAIR, V38, P964, DOI 10.1377/hlthaff.2019.00087; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Paraprofessional Healthcare Institute (PHI), DIR CAR WORK US KEY; Patnode CD, 2020, JAMA-J AM MED ASSOC, V323, P764, DOI 10.1001/jama.2019.22258; Peacock SC, 2013, PALLIAT SUPPORT CARE, V11, P155, DOI 10.1017/S1478951512000831; Peng HL, 2013, PERSPECT PSYCHIATR C, V49, P135, DOI 10.1111/ppc.12005; Perkins M, 2013, J GERONTOL B-PSYCHOL, V68, P504, DOI 10.1093/geronb/gbs084; Perkins P, 1997, NEUROLOGY, V49, P44, DOI 10.1212/WNL.49.1.44; Peters R, 2019, J ALZHEIMERS DIS, V70, pS145, DOI 10.3233/JAD-180631; Petersen RC, 2018, NEUROLOGY, V90, P126, DOI 10.1212/WNL.0000000000004826; Petersen RC, 2013, ANN NEUROL, V74, P199, DOI 10.1002/ana.23931; Pinquart M, 2006, J GERONTOL B-PSYCHOL, V61, pP33, DOI 10.1093/geronb/61.1.P33; Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polenick CA, 2020, J AM GERIATR SOC, V68, P609, DOI 10.1111/jgs.16244; Polenick CA, 2020, GERONTOLOGIST, V60, P165, DOI 10.1093/geront/gny130; Pool LR, 2016, NEUROLOGY, V86, P1386, DOI 10.1212/WNL.0000000000002569; Port CL, 2005, GERONTOLOGIST, V45, P87, DOI 10.1093/geront/45.suppl_1.87; Potter GG, 2009, ALZHEIMERS DEMENT, V5, P445, DOI 10.1016/j.jalz.2009.04.1234; Power MC, 2021, JAMA NEUROL, V78, P275, DOI 10.1001/jamaneurol.2020.4471; Power MC, 2016, NEUROTOXICOLOGY, V56, P235, DOI 10.1016/j.neuro.2016.06.004; Prentice, 2017, AGING MENT HEALTH, V5, P1; Prince MJ, 2015, WORLD ALZHEIMER REPO; Qiu CX, 2013, NEUROLOGY, V80, P1888, DOI 10.1212/WNL.0b013e318292a2f9; Quiroz YT, 2020, LANCET NEUROL, V19, P513, DOI 10.1016/S1474-4422(20)30137-X; Rabarison KM, 2018, AM J PUBLIC HEALTH, V108, P1370, DOI 10.2105/AJPH.2018.304573; Rabinovici GD, 2019, JAMA-J AM MED ASSOC, V321, P1286, DOI 10.1001/jama.2019.2000; Rajan KB, 2019, ALZHEIMERS DEMENT, V15, P1, DOI 10.1016/j.jalz.2018.07.216; Rajan KB, 2017, J AM GERIATR SOC, V65, P2425, DOI 10.1111/jgs.15059; Ralph SJ, 2018, J ALZHEIMERS DIS REP, V2, P1, DOI 10.3233/ADR-170042; Rattinger GB, 2015, ALZHEIMERS DEMENT, V11, P946, DOI 10.1016/j.jalz.2014.11.004; Rehm J, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-018-0453-0; Reiman EM, 2012, LANCET NEUROL, V11, P1048, DOI 10.1016/S1474-4422(12)70228-4; Reisberg B, 2008, INT PSYCHOGERIATR, V20, P1, DOI 10.1017/S1041610207006412; Reisberg B, 2010, ALZHEIMERS DEMENT, V6, P11, DOI 10.1016/j.jalz.2009.10.002; Reitz C, 2013, JAMA-J AM MED ASSOC, V309, P1483, DOI 10.1001/jama.2013.2973; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI [10.1038/nrneurol.2011.2, 10.1101/cshperspect.a006239]; Riffin C, 2017, J AM GERIATR SOC, V65, P1821, DOI 10.1111/jgs.14910; Rocca WA, 2017, ALZ DIS ASSOC DIS, V31, P76, DOI 10.1097/WAD.0000000000000187; Rocca WA, 2014, MATURITAS, V79, P196, DOI 10.1016/j.maturitas.2014.05.008; Rocca WA, 2011, ALZHEIMERS DEMENT, V7, P80, DOI 10.1016/j.jalz.2010.11.002; Romero JP, 2014, J ALZHEIMERS DIS, V41, P213, DOI 10.3233/JAD-132765; Ronnemaa E, 2011, DEMENT GERIATR COGN, V31, P460, DOI 10.1159/000330020; Rosenberg A, 2018, ALZHEIMERS DEMENT, V14, P263, DOI 10.1016/j.jalz.2017.09.006; Rote SM, 2021, GERONTOLOGIST, V61, P374, DOI 10.1093/geront/gnaa100; Roth DL, 2015, J GERONTOL B-PSYCHOL, V70, P813, DOI 10.1093/geronb/gbv034; Roth DL, 2015, GERONTOLOGIST, V55, P309, DOI 10.1093/geront/gnu177; Rusanen M, 2011, ARCH INTERN MED, V171, P333, DOI 10.1001/archinternmed.2010.393; Russ TC, 2013, BRIT J PSYCHIAT, V203, P10, DOI 10.1192/bjp.bp.112.119479; Saczynski JS, 2006, AM J EPIDEMIOL, V163, P433, DOI 10.1093/aje/kwj061; Sajeev G., DIABETES ALZRISK DAT; Sajeev G, 2016, EPIDEMIOLOGY, V27, P732, DOI 10.1097/EDE.0000000000000513; Samieri C, 2018, JAMA-J AM MED ASSOC, V320, P657, DOI 10.1001/jama.2018.11499; Samper-Ternent R, 2012, J AM MED DIR ASSOC, V13, P254, DOI 10.1016/j.jamda.2010.07.010; Sando SB, 2008, INT J GERIATR PSYCH, V23, P1156, DOI 10.1002/gps.2043; Satizabal CL, 2016, NEW ENGL J MED, V374, P523, DOI 10.1056/NEJMoa1504327; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schaffert J, 2018, NEUROPSYCHOLOGY, V32, P410, DOI 10.1037/neu0000423; Schneider JA, 2007, NEUROLOGY, V69, P2197, DOI 10.1212/01.wnl.0000271090.28148.24; Schneider JA, 2009, ANN NEUROL, V66, P200, DOI 10.1002/ana.21706; Schrijvers EMC, 2012, NEUROLOGY, V78, P1456, DOI 10.1212/WNL.0b013e3182553be6; Schubert CC, 2008, J GEN INTERN MED, V23, P1736, DOI 10.1007/s11606-008-0711-0; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 2004, JAMA-J AM MED ASSOC, V292, P961, DOI 10.1001/jama.292.8.961; Schulz R, 2003, NEW ENGL J MED, V349, P1936, DOI 10.1056/NEJMsa035373; Schulz R, 1998, HEALTH PSYCHOL, V17, P107, DOI 10.1037/h0092707; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Sekita A, 2010, ACTA PSYCHIAT SCAND, V122, P319, DOI 10.1111/j.1600-0447.2010.01587.x; Serrano-Pozo A, 2014, ANN NEUROL, V75, P597, DOI 10.1002/ana.24125; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; Shaw LM, 2018, ALZHEIMERS DEMENT, V14, P1505, DOI 10.1016/j.jalz.2018.07.220; Shaw WS, 1999, J PSYCHOSOM RES, V46, P215, DOI 10.1016/S0022-3999(98)00084-1; Sheehan OC, 2021, GERONTOLOGIST, V61, P670, DOI 10.1093/geront/gnaa108; Sheffield KM, 2011, AM J EPIDEMIOL, V174, P274, DOI 10.1093/aje/kwr074; Shi L, 2018, SLEEP MED REV, V40, P4, DOI 10.1016/j.smrv.2017.06.010; Sims M, 2011, ANN EPIDEMIOL, V21, P892, DOI 10.1016/j.annepidem.2011.05.006; Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980; Soni M, 2019, AGING MENT HEALTH, V23, P15, DOI 10.1080/13607863.2017.1390731; Sorensen S, 2006, LANCET NEUROL, V5, P961, DOI 10.1016/S1474-4422(06)70599-3; Sperling RA, 2020, JAMA NEUROL, V77, P735, DOI 10.1001/jamaneurol.2020.0387; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Spillman B., INFORMAL CAREGIVING; Spillman BC, 2020, J GERONTOL B-PSYCHOL, V75, P1563, DOI 10.1093/geronb/gbz065; Spinney L, 2014, NATURE, V510, P26, DOI 10.1038/510026a; Sprung J, 2021, J AM GERIATR SOC, V69, P660, DOI 10.1111/jgs.16909; Staff RT, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4925; Stall NM, 2019, J AM GERIATR SOC, V67, P609, DOI 10.1111/jgs.15690; Steenland K, 2016, J ALZHEIMERS DIS, V50, P71, DOI 10.3233/JAD-150778; Stephen R, 2017, J GERONTOL A-BIOL, V72, P733, DOI 10.1093/gerona/glw251; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 2020, ALZHEIMERS DEMENT, V16, P1305, DOI 10.1016/j.jalz.2018.07.219; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Stojkovska I, 2018, CELL TISSUE RES, V373, P51, DOI 10.1007/s00441-017-2704-y; Stokes AC, 2020, JAMA NEUROL, V77, P1543, DOI 10.1001/jamaneurol.2020.2831; Stone R. I., 2015, FAMILY CAREGIVING NE, P57, DOI 10.1016/B978-0-12-417046-9.00006-4; Sullivan KJ, 2019, J GERONTOL A-BIOL, V74, P1439, DOI 10.1093/gerona/gly236; Tallon LA, 2017, ENVIRON INT, V104, P102, DOI 10.1016/j.envint.2017.03.019; Tan ZS, 2017, J GERONTOL A-BIOL, V72, P789, DOI 10.1093/gerona/glw130; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Taylor CA, 2017, MMWR-MORBID MORTAL W, V66, pS21, DOI 10.15585/mmwr.mm6620a1; Taylor DH, 2009, J ALZHEIMERS DIS, V17, P807, DOI 10.3233/JAD-2009-1099; TEASDALE G, 1974, LANCET, V2, P81; Tejada-Vera B., 2013, NATL CTR HLTH STAT D, V116; Then FS, 2014, J OCCUP MED TOXICOL, V9, DOI 10.1186/1745-6673-9-23; Thomson RS, 2017, LARYNGOSCOPE INVEST, V2, P69, DOI 10.1002/lio2.65; Thunyadee C, 2015, NURS HEALTH SCI, V17, P412, DOI 10.1111/nhs.12205; Tivadar BK, 2017, BIOGERONTOLOGY, V18, P477, DOI 10.1007/s10522-017-9708-6; Todd S, 2013, INT J GERIATR PSYCH, V28, P1109, DOI 10.1002/gps.3946; Tom SE, 2015, AM J PUBLIC HEALTH, V105, P408, DOI 10.2105/AJPH.2014.301935; Trinkoff AM, 2013, J NURS ADMIN, V43, P630, DOI 10.1097/NNA.0000000000000004; U.S. Census Bureau, 2017 NATL POPULATION; U.S. Census Bureau, 2014 NAT POP PROJ DO; U.S. Department of Health and Human Services, NAT RES SUMM CAR SER; U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics, CDC WONDER ONL DAT U; U.S. Environmental Protection Agency, EPA600R19188 US EPA; Ungar L, 2014, BRAIN IMAGING BEHAV, V8, P262, DOI 10.1007/s11682-013-9272-x; Vagelatos NT, 2013, EPIDEMIOL REV, V35, P152, DOI 10.1093/epirev/mxs012; Vaingankar JA, 2016, COMPR PSYCHIAT, V68, P178, DOI 10.1016/j.comppsych.2016.04.017; Valimaki TH, 2016, QUAL LIFE RES, V25, P687, DOI 10.1007/s11136-015-1100-x; van den Kommer TN, 2018, J GERONTOL B-PSYCHOL, V73, pS57, DOI 10.1093/geronb/gbx151; Van Mierlo LD, 2016, INT PSYCHOGERIATR, V28, P801, DOI 10.1017/S1041610215001817; Vermunt L, 2019, ALZHEIMERS DEMENT, V15, P888, DOI 10.1016/j.jalz.2019.04.001; Vickrey BG, 2006, ANN INTERN MED, V145, P713, DOI 10.7326/0003-4819-145-10-200611210-00004; Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9; Viswanathan A, 2009, NEUROLOGY, V72, P368, DOI 10.1212/01.wnl.0000341271.90478.8e; Vitaliano PP, 2017, GERONTOLOGIST, V57, P637, DOI 10.1093/geront/gnv690; Vitaliano PP, 2002, PSYCHOSOM MED, V64, P418, DOI 10.1097/00006842-200205000-00006; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Voisin T, 2009, DRUG AGING, V26, P135, DOI 10.2165/0002512-200926020-00005; von Kanel R, 2006, J GERONTOL A-BIOL, V61, P963, DOI 10.1093/gerona/61.9.963; Wacker P, 2006, DEMENT GERIATR COGN, V21, P221, DOI 10.1159/000091022; Waller A, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0654-6; Wang HX, 2012, BBA-MOL BASIS DIS, V1822, P482, DOI 10.1016/j.bbadis.2011.09.002; Wang HX, 2002, AM J EPIDEMIOL, V155, P1081, DOI 10.1093/aje/155.12.1081; Wang ZD, 2020, ALZHEIMERS DEMENT, V16, P316, DOI 10.1016/j.jalz.2019.09.003; Ward A, 2013, DEMENT GER COGN D EX, V3, P320, DOI 10.1159/000354370; Ward A, 2012, NEUROEPIDEMIOLOGY, V38, P1, DOI 10.1159/000334607; Waring SC, 2005, ALZ DIS ASSOC DIS, V19, P178, DOI 10.1097/01.wad.0000189033.35579.2d; Warshaw GA, 2014, HEALTH AFFAIR, V33, P633, DOI 10.1377/hlthaff.2013.1232; Watt JA, 2019, ANN INTERN MED, V171, P633, DOI 10.7326/M19-0993; Wethington E, 2015, FAMILY CAREGIVING NE, P193; Weuve J, 2018, J GERONTOL B-PSYCHOL, V73, pS73, DOI 10.1093/geronb/gbx167; Weuve J, 2018, EPIDEMIOLOGY, V29, P151, DOI [10.1097/EDE.0000000000000747, 10.1097/ede.0000000000000747]; Weuve J, 2015, EPIDEMIOLOGY, V26, pE4, DOI 10.1097/EDE.0000000000000199; Weuve Jennifer, 2014, Alzheimers Dement, V10, pe40, DOI 10.1016/j.jalz.2014.01.004; Whitlatch CJ, 2018, GERONTOLOGIST, V58, pS58, DOI 10.1093/geront/gnx162; WHO, 2004, INT STAT CLASS DIS R; Wiberg P, 2013, PSYCHOL MED, V43, P2627, DOI 10.1017/S0033291713000299; Wiener JM., 2014, RACIAL ETHNIC DISPAR; Willey JZ, 2016, NEUROLOGY, V86, P1897, DOI 10.1212/WNL.0000000000002582; Williams F, 2019, AGING MENT HEALTH, V23, P1629, DOI 10.1080/13607863.2018.1515886; Williamson JD, 2019, JAMA-J AM MED ASSOC, V321, P553, DOI 10.1001/jama.2018.21442; Wilson RS, 2012, PSYCHOL AGING, V27, P1008, DOI 10.1037/a0029857; Wilson RS, 2011, ALZHEIMERS DEMENT, V7, P74, DOI 10.1016/j.jalz.2010.11.006; Wilson RS, 2002, NEUROLOGY, V59, P1910, DOI 10.1212/01.WNL.0000036905.59156.A1; Wimo A, 2016, J ALZHEIMERS DIS, V50, P387, DOI 10.3233/JAD-150708; Wolff JL, 2018, GERONTOLOGIST, V58, P1021, DOI 10.1093/geront/gnx093; Wolfsgruber S, 2016, J ALZHEIMERS DIS, V54, P1135, DOI 10.3233/JAD-160407; Wolters AE, 2013, INTENS CARE MED, V39, P376, DOI 10.1007/s00134-012-2784-9; Wolters FJ, 2017, NEUROLOGY, V88, P1642, DOI 10.1212/WNL.0000000000003871; World Health Organization, RISK RED COGN DECL D; Wu W, 2008, ANN NEUROL, V64, P698, DOI 10.1002/ana.21557; Wu YT, 2017, NAT REV NEUROL, V13, P327, DOI 10.1038/nrneurol.2017.63; Xie J, 2008, BMJ-BRIT MED J, V336, P258, DOI 10.1136/bmj.39433.616678.25; Xiong C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231848; Xu Jiaquan, 2020, NCHS Data Brief, P1; Yaffe K, 2000, NEUROLOGY, V54, P1949, DOI 10.1212/WNL.54.10.1949; Yaffe K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7051; Yates LA, 2016, INT PSYCHOGERIATR, V28, P1791, DOI 10.1017/S1041610216001137; Younan D, 2020, BRAIN, V143, P289, DOI 10.1093/brain/awz348; Young HM, 2020, GERONTOLOGIST, V60, pS14, DOI 10.1093/geront/gnz148; Yu DSF, 2018, INT J NURS STUD, V79, P1, DOI 10.1016/j.ijnurstu.2017.10.008; Zahodne LB, 2014, NEUROPSYCHOLOGY, V28, P238, DOI 10.1037/neu0000014; Zaleta AK, 2012, ALZ DIS ASSOC DIS, V26, P232, DOI 10.1097/WAD.0b013e3182351c04; Zarit SH, 2017, AGING MENT HEALTH, V16, P1; Zarit SH, 2013, AGING MENT HEALTH, V17, P197, DOI 10.1080/13607863.2012.717252; Zarit SH, 2012, AGING MENT HEALTH, V16, P673, DOI 10.1080/13607863.2012.692768; Zhang ZM, 2016, J HEALTH SOC BEHAV, V57, P184, DOI 10.1177/0022146516645925; Zheng H, 2021, J GERONTOL B-PSYCHOL, V76, P1652, DOI 10.1093/geronb/gbaa107; Zhu CW, 2015, ALZHEIMERS DEMENT, V11, P444, DOI 10.1016/j.jalz.2013.12.018; Adelman RD, 2014, JAMA-J AM MED ASSOC, V311, P1052, DOI 10.1001/jama.2014.304; Agency for Healthcare Research and Quality, NAT HEATHC QUAL DIS; Agrawal S., 2020, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20200108.34515/full/, DOI 10.1377/HBLOG20200108.34515/FULL]; Aigbogun MS, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1260-3; Alcala HE, 2018, J GEN INTERN MED, V33, P1760, DOI 10.1007/s11606-018-4614-4; Alzheimer's Association, 2016, Alzheimers Dement, V12, P459; Alzheimer's Association, 2020, NEW RES STUD DEM VAL; Alzheimer's Association, COR COVID 19 TIPS DE; Alzheimer's Association, NEW IDEAS BIOR; Alzheimer's Association, ALZH ASS DEM CAR PRA; Alzheimer's Association, ALZH IMP MOV US MED; Alzheimers Association, CHANG TRAJ ALZH DIS; American Association of Nurse Practitioners, NP FACT SHEET; American Geriatrics Society, AGS21 ETHN; Anderson C., 2020, IMPLICIT BIAS TRAINI; [Anonymous], 2020, ALZHEIMERS DEMENT, V16, P391, DOI 10.1002/alz.12068; [Anonymous], 2020, ALZHEIMERS DEMENT; [Anonymous], MED GLOSS; [Anonymous], HLTH PEOPL 2020; Arean PA, 1996, J CONSULT CLIN PSYCH, V64, P875, DOI 10.1037/0022-006X.64.5.875; Artiga S., 2019, KEY FACTS HLTH HLTH; Artiga S, 2020, DISPARITIES HLTH HLT; Artiga S., 2020, KFF; Association of American Medical Colleges, DIV MED FACTS FIG 20; Association of American Medical Colleges, 2018, DIV MED FACTS FIG 20; Austrom MG, 2016, AGING MENT HEALTH, V20, P781, DOI 10.1080/13607863.2015.1119802; Beydoun MA, 2015, J ALZHEIMERS DIS, V48, P361, DOI 10.3233/JAD-150228; Borson S, 2016, ALZHEIMERS DEMENT, V12, P334, DOI 10.1016/j.jalz.2016.01.005; Borson S, 2014, CLIN GERIATR MED, V30, P395, DOI 10.1016/j.cger.2014.05.001; Bott NT, 2019, AM J GERIAT PSYCHIAT, V27, P149, DOI 10.1016/j.jagp.2018.09.015; Boustani M, 2019, HEALTH AFFAIR, V38, P54, DOI 10.1377/hlthaff.2018.05154; Bray Jennifer, 2015, Nurs Older People, V27, P29, DOI 10.7748/nop.27.10.29.s21; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Budiman, 2020, FINANCIAL HLTH IMPAC; Burton A, 2019, CURR OPIN PSYCHIATR, V32, P557, DOI 10.1097/YCO.0000000000000548; Bynum, 2016, OUR PARENTS OURSELVE; Bynum J., 2009, CHARACTERISTICS COST; Callahan CM, 2017, J AM GERIATR SOC, V65, P892, DOI 10.1111/jgs.14808; Callahan CM, 2014, HEALTH AFFAIR, V33, P626, DOI 10.1377/hlthaff.2013.1260; Callahan CM, 2012, J AM GERIATR SOC, V60, P813, DOI 10.1111/j.1532-5415.2012.03905.x; Camp CJ, 2019, CLIN GERONTOLOGIST, V42, P221, DOI 10.1080/07317115.2019.1591056; Centers for Disease Control, HLTH PEOPL 2020; Centers for Disease Control, COVID 19 CAS HOSP DE; Centers for Disease Control and Prevention, ALZH DIS HLTH AG ROA; Centers for Disease Control and Prevention National Center for Health Statistics (2021), UND CAUS DEATH 1999; Centers for Medicare and Medicaid Services, 2020, MED HOSP BEN GETT ST; Centers for Medicare and Medicaid Services, SKILL NURS FAC SNF C; Centers for Medicare and Medicaid Services, WHATS MED WHATS MED; Centers for Medicare and Medicaid Services, CHRONIC CONDITIONS C; Centers for Medicare and Medicaid Services, 2019, WHAT AR LONG TERM CA; Centers for Medicare and Medicaid Services, DO MED ADV PLANS WOR; Centers for Medicare and Medicaid Services, 2020, OR MED A; Chapman EN, 2013, J GEN INTERN MED, V28, P1504, DOI 10.1007/s11606-013-2441-1; Clark JL, 2018, CLIN GERONTOLOGIST, V41, P255, DOI 10.1080/07317115.2017.1420725; Clarkson P, 2017, VALUE HEALTH, V20, P1198, DOI 10.1016/j.jval.2017.04.004; Clevenger CK, 2018, J AM GERIATR SOC, V66, P2401, DOI 10.1111/jgs.15528; ClinicalTrials.gov, NEW IDEAS IM DEM EV; Damico A, 2020, DOZEN FACTS MED ADVA; Davis BH, 2009, KAOHSIUNG J MED SCI, V25, P503, DOI 10.1016/S1607-551X(09)70557-1; Davydow DS, 2014, J GEN INTERN MED, V29, P1362, DOI 10.1007/s11606-014-2916-8; De Vleminck A, 2018, J AM MED DIR ASSOC, V19, P633, DOI 10.1016/j.jamda.2017.10.003; Denny A., 2020, PERSPECTIVE AFRICAN, DOI [10.1002/alz.12160, DOI 10.1002/ALZ.12160]; Department of Health and Human Services Centers for Medicare and Medicaid Services, 2020, FED REGISTER, V85, P47070; Dreier-Wolfgramm A, 2017, Z GERONTOL GERIATR, V50, pS68, DOI 10.1007/s00391-017-1220-8; Dwibedi N, 2018, MED CARE, V56, P240, DOI 10.1097/MLR.0000000000000869; Eiken S., 2018, MEDICAID EXPENDITURE; Ejiogu N, 2011, GERONTOLOGIST, V51, pS33, DOI 10.1093/geront/gnr027; Eligon J., 2020, NY TIMES; Feng ZL, 2014, HEALTH AFFAIR, V33, P683, DOI 10.1377/hlthaff.2013.1179; French DD, 2014, HEALTH AFFAIR, V33, P613, DOI 10.1377/hlthaff.2013.1221; Gaugler JE, 2019, ALZH DEMENT-TRCI, V5, P388, DOI 10.1016/j.trci.2019.02.008; Gaugler JE, 2016, INT PSYCHOGERIATR, V28, P1029, DOI 10.1017/S1041610215002318; Geldmacher DS, 2013, APPL HEALTH ECON HEA, V11, P407, DOI 10.1007/s40258-013-0038-9; Genworth, 2020, GENW COST CAR SURV 2; Gibson DM, 2020, J AM GERIATR SOC, V68, P2721, DOI 10.1111/jgs.16883; Gilligan AM, 2013, AM J ALZHEIMERS DIS, V28, P84, DOI 10.1177/1533317512467679; Godard-Sebillotte C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218426; Gozalo P, 2015, NEW ENGL J MED, V372, P1823, DOI 10.1056/NEJMsa1408705; Gozalo P, 2011, NEW ENGL J MED, V365, P1212, DOI 10.1056/NEJMsa1100347; Greenberg NE, 2020, PSYCHOL TRAUMA-US, V12, pS220, DOI 10.1037/tra0000793; Griffin JM, 2020, J APPL GERONTOL, V39, P1184, DOI 10.1177/0733464819880449; Guterman EL, 2019, JAMA NEUROL, V76, P1166, DOI 10.1001/jamaneurol.2019.1820; Hagiwara N, 2020, LANCET, V395, P1457, DOI 10.1016/S0140-6736(20)30846-1; Harris-Kojetin L., 2019, VITAL HLTH STAT, V3; Hennelly N, 2021, GERONTOLOGIST, V61, pE85, DOI 10.1093/geront/gnz159; Hoffman D, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.160233; Hurd MD, 2013, NEW ENGL J MED, V368, P1326, DOI 10.1056/NEJMsa1204629; Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD, IMPACT AD; Jackson CS, 2014, PUBLIC HEALTH REP, V129, P57, DOI 10.1177/00333549141291S211; Jennings LA, 2019, JAMA INTERN MED, V179, P161, DOI 10.1001/jamainternmed.2018.5579; Jones J, 2020, J MED INTERNET RES, V22, DOI 10.2196/20001; Kane, 2015, FAMILY CAREGIVING NE; Kelley AS, 2015, ANN INTERN MED, V163, P729, DOI 10.7326/M15-0381; Kiely DK, 2010, J AM GERIATR SOC, V58, P2284, DOI 10.1111/j.1532-5415.2010.03185.x; Kirson NY, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0303-5; Koma W., MED BENEFICIARIRES F; LaMantia MA, 2015, J AM GERIATR SOC, V63, P1209, DOI 10.1111/jgs.13447; Landon BE, 2018, JAMA INTERN MED, V178, P66, DOI 10.1001/jamainternmed.2017.5034; Haggerty KL, 2020, J AM GERIATR SOC, V68, P2478, DOI 10.1111/jgs.16807; Leggett A, 2019, J AM MED DIR ASSOC, V20, P1307, DOI 10.1016/j.jamda.2019.04.006; Leibson CL, 2015, ALZHEIMERS DEMENT, V11, P917, DOI 10.1016/j.jalz.2015.01.007; Lin PJ, 2017, ALZHEIMERS DEMENT, V13, P1174, DOI 10.1016/j.jalz.2017.08.010; Lin PJ, 2016, J AM GERIATR SOC, V64, P1549, DOI 10.1111/jgs.14227; Lin PJ, 2013, ALZHEIMERS DEMENT, V9, P30, DOI 10.1016/j.jalz.2012.11.002; Liu J. L. H., 2017, ASSESSING PREPAREDNE; MacNeil-Vroomen JL, 2020, AM J EMERG MED, V38, P127, DOI 10.1016/j.ajem.2019.07.023; Melillo G., 2020, AM J MANAGES CARE; Miller SC, 2001, AM J MED, V111, P38, DOI 10.1016/S0002-9343(01)00747-1; Miller SC, 2017, J PAIN SYMPTOM MANAG, V54, P9, DOI 10.1016/j.jpainsymman.2017.03.005; Miller SC, 2012, J PALLIAT MED, V15, P43, DOI 10.1089/jpm.2011.0210; Mitchell SL, 2016, JAMA-J AM MED ASSOC, V316, P769, DOI 10.1001/jama.2016.9374; Monin JK, 2020, AM J GERIAT PSYCHIAT, V28, P1299, DOI 10.1016/j.jagp.2020.09.008; Mukora A., 2019, DIMENSIONS-NBS, P24; Murman DL, 2002, NEUROLOGY, V59, P1721, DOI 10.1212/01.WNL.0000036904.73393.E4; National Academies of Sciences Engineering and Medicine, 2016, FAM CAR AG AM; National Association of Insurance Commissioners and the Center for Insurance Policy and Research, 2016, CIPR STUD SER 2016 1; National Institute on Aging, NAT STRAT RECR PART; National Institute on Aging, IMPL BIAS RES; National Institute on Aging, 2018, TOG WE MAK DIFF NAT; National Institute on Aging, HLTH DISP FRAM; Nickel F, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0751-1; Noel MA, 2017, J APPL GERONTOL, V36, P195, DOI 10.1177/0733464815589986; O'Donnell J., 2020, USA TODAY; Odenheimer G, 2013, AM J OCCUP THER, V67, P704, DOI 10.5014/ajot.2013.676004; Ortman JM, 2014, AGING NATION OLDER P, V1140, P1; Ouslander JG, 2020, J AM GERIATR SOC, V68, P2153, DOI 10.1111/jgs.16784; Palmer JL, 2014, J CONTIN EDUC NURS, V45, P416, DOI 10.3928/00220124-20140825-20; Patel A, 2015, CIRC-HEART FAIL, V8, P8, DOI 10.1161/CIRCHEARTFAILURE.114.001438; Portacolone E, 2020, ETHNIC DIS, V30, P719, DOI 10.18865/ed.30.S2.719; Possin KL, 2019, JAMA INTERN MED, V179, P1658, DOI 10.1001/jamainternmed.2019.4101; Quinones AR, 2020, AM J ALZHEIMERS DIS, V35, DOI 10.1177/1533317520960874; Reaves EL., 2015, PUBLICATIONS, V8617; Reschovsky JD, 2014, HEALTH SERV RES, V49, P32, DOI 10.1111/1475-6773.12087; Reuben DB, 2019, J AM GERIATR SOC, V67, P2267, DOI 10.1111/jgs.16085; Reuben DB, 2013, J AM GERIATR SOC, V61, P2214, DOI 10.1111/jgs.12562; Rome V., 2020, SERIES-J SPAN ECON, V45, P1; Rudolph JL, 2010, J AM GERIATR SOC, V58, P1542, DOI 10.1111/j.1532-5415.2010.02924.x; Rui PKK, NATL HOSP AMBULATORY; Russell D, 2017, J AM GERIATR SOC, V65, P1726, DOI 10.1111/jgs.14859; Savla J, 2021, J GERONTOL B-PSYCHOL, V76, pE241, DOI 10.1093/geronb/gbaa129; Sengupta M., 2015, VARIATION OPERATING; Sengupta M., 2018, VARIATION RESIDENTIA; Sengupta M., 2020, NATL HLTH STAT REPOR, V148, P1; Seshadri S, 2021, INFECT CONT HOSP EP, V42, P1020, DOI 10.1017/ice.2020.393; Shega JW, 2008, J PAIN SYMPTOM MANAG, V35, P499, DOI 10.1016/j.jpainsymman.2007.06.011; Spector A, 2013, AGEING RES REV, V12, P354, DOI 10.1016/j.arr.2012.06.005; Suehs BT, 2013, AM J ALZHEIMERS DIS, V28, P384, DOI 10.1177/1533317513488911; Surr CA, 2016, INT J NURS STUD, V53, P144, DOI 10.1016/j.ijnurstu.2015.09.009; Tan ZS, 2014, HEALTH AFFAIR, V33, P619, DOI 10.1377/hlthaff.2013.1294; Taylor DH, 2018, J PALLIAT MED, V21, P645, DOI 10.1089/jpm.2017.0485; Teno J, 2014, HEALTH AFFAIR, V33, P675, DOI 10.1377/hlthaff.2013.1248; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Teno JM, 2009, J PALLIAT MED, V12, P359, DOI 10.1089/jpm.2008.0168; The American Academy of Family Physicians Foundation, EVERYONE PROJ TOOLK; The COVID Tracking Project, LONG TERM CAR COVID; The COVID Tracking Project at the Atlantic, COVID 19 IS AFF BLAC; The Lewin Group, PROC EV OLD AM ACT T; Thyrian JR, 2017, JAMA PSYCHIAT, V74, P996, DOI 10.1001/jamapsychiatry.2017.2124; U.S. Bureau of Labor Statistics, 2019, LAB FORC CHAR RAC ET; U.S. Centers for Medicare & Medicaid Services, STAT LEV CHRON COND; U.S. Centers for Medicare & Medicaid Services, NURS HOM DAT COMP 20; U.S. Centers for Medicare & Medicaid Services, LONG TERM CARE; U.S. Centers for Medicare & Medicaid Services, POST CAR HOSP DAT 20; U.S. Department of Agriculture Economic Research Service, FOOD SEC US KEY STAT; U.S. Department of Health and Human Services, NAT CLAS STAND; U.S. Department of Health and Human Services, 2014, RACIAL ETHNIC DISPAR; U.S. Department of Health and Human Services, WHAT IS LONG TERM CA; U.S. Department of Health and Human Services, NAT REG PROJ SUPPL D; U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion, HLTH PEOPL 2030 FRAM; U.S. Food and Drug Administration, 2020, ENH DIV CLIN TRIAL P; US Department of Labor, CHANG BAS MIN WAG NO; Watson JL, 2014, HEALTH AFFAIR, V33, P574, DOI 10.1377/hlthaff.2013.1314; Werner P, 2019, INT PSYCHOGERIATR, V31, P307, DOI 10.1017/S1041610219000346; White L, 2019, HEALTH SERV RES, V54, P773, DOI 10.1111/1475-6773.13134; Wood D., 2020, NATL PUBLIC RADIO, DOI [14427907/as-pandemic-deaths-add-up-racial-disparities-persist-and-in-some-cases-worsen, DOI 14427907/AS-PANDEMIC-DEATHS-ADD-UP-RACIAL-DISPARITIES-PERSIST-AND-IN-SOME-CASES-WORSEN]; Yang Z, 2015, WOMEN HEALTH ISS, V25, P436, DOI 10.1016/j.whi.2015.06.001; Yang Z, 2012, HEALTH SERV RES, V47, P1660, DOI 10.1111/j.1475-6773.2011.01365.x; Zhu CW, 2015, J GERONTOL A-BIOL, V70, P1448, DOI 10.1093/gerona/glv124; Zissimopoulos Julie, 2014, Forum Health Econ Policy, V18, P25	679	136	136	146	208	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	MAR	2021	17	3					327	406		10.1002/alz.12328		MAR 2021	80	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	RH5KD	WOS:000632432400001	33756057	Bronze	Y	Y	2022-02-06	
J	Zheng, H; Dong, YL; Xu, ZP; Crosby, G; Culley, DJ; Zhang, YY; Xie, ZC				Zheng, Hui; Dong, Yuanlin; Xu, Zhipeng; Crosby, Gregory; Culley, Deborah J.; Zhang, Yiying; Xie, Zhongcong			Sevoflurane Anesthesia in Pregnant Mice Induces Neurotoxicity in Fetal and Offspring Mice	ANESTHESIOLOGY			English	Article							NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; AMYLOID PROTEIN-LEVELS; ENVIRONMENTAL ENRICHMENT; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; SYSTEMIC INFECTION; SYNAPSE LOSS; ISOFLURANE; ACTIVATION	Background: Each year, over 75,000 pregnant women in the United States undergo anesthesia care. The authors set out to assess the effects of the anesthetic sevoflurane on neurotoxicity in pregnant mice and on learning and memory in fetal and offspring mice. Methods: Pregnant mice (gestational day 14) and mouse primary neurons were treated with 2.5% sevoflurane for 2 h and 4.1% sevoflurane for 6 h, respectively. Brain tissues of both fetal and offspring mice (P31) and the primary neurons were harvested and subjected to Western blot and immunohistochemistry to assess interleukin-6, the synaptic markers postsynaptic density-95 and synaptophysin, and caspase-3 levels. Separately, learning and memory function in the offspring mice was determined in the Morris water maze. Results: Sevoflurane anesthesia in pregnant mice induced caspase-3 activation, increased interleukin-6 levels (256 +/- 50.98% [ mean +/- SD] vs. 100 +/- 54.12%, P = 0.026), and reduced postsynaptic density-95 (61 +/- 13.53% vs. 100 +/- 10.08%, P = 0.036) and synaptophysin levels in fetal and offspring mice. The sevoflurane anesthesia impaired learning and memory in offspring mice at P31. Moreover, interleukin-6 antibody mitigated the sevoflurane-induced reduction in postsynaptic density-95 levels in the neurons. Finally, environmental enrichment attenuated the sevoflurane- induced increases in interleukin-6 levels, reductions of synapse markers, and learning and memory impairment. Conclusions: These results suggest that sevoflurane may induce detrimental effects in fetal and offspring mice, which can be mitigated by environmental enrichment. These findings should promote more studies to determine the neurotoxicity of anesthesia in the developing brain.	Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA		Xie, ZC (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, 149 13th St,Room 4310, Charlestown, MA 02129 USA.	zxie@partners.org	Crosby, Gregory/N-6578-2019		National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AG029856, R21AG038994, R01 GM088801]; Cure Alzheimer's Fund, Wellesley, Massachusetts; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM088801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS044155, R21NS070153, R01NS027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG038994, R01AG041274, R21AG029856] Funding Source: NIH RePORTER	Received from the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Submitted for publication March 14, 2012. Accepted for publication August 14, 2012. Supported by grants R21AG029856, R21AG038994, and R01 GM088801 from the National Institutes of Health, Bethesda, Maryland; and from Cure Alzheimer's Fund, Wellesley, Massachusetts (to Dr. Xie). The cost of anesthetic sevoflurane was generously provided by the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Drs. Zheng and Dong contributed equally to this work.	[Anonymous], 2011, NY TIMES; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bianchi SL, 2008, NEUROBIOL AGING, V29, P1002, DOI 10.1016/j.neurobiolaging.2007.02.009; Bouet V, 2011, MECH AGEING DEV, V132, P240, DOI 10.1016/j.mad.2011.04.006; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Creeley CE, 2010, ANESTH ANALG, V110, P442, DOI 10.1213/ANE.0b013e3181c6b9ca; De Velde MV, 2007, MINERVA ANESTESIOL, V73, P235; Dong YL, 2009, ARCH NEUROL-CHICAGO, V66, P620, DOI 10.1001/archneurol.2009.48; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Hongpaisan J, 2011, J NEUROSCI, V31, P630, DOI 10.1523/JNEUROSCI.5209-10.2011; Hudetz JA, 2011, J ANESTH, V25, P1, DOI 10.1007/s00540-010-1042-y; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kim D, 2010, PEPTIDES, V31, P101, DOI 10.1016/j.peptides.2009.10.011; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kuczkowski KM, 2004, OBSTET GYNECOL SURV, V59, P52, DOI 10.1097/01.OGX.0000103191.73078.5F; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Liang G, 2010, ANESTHESIOLOGY, V112, P1325, DOI 10.1097/ALN.0b013e3181d94da5; Liu QA, 2010, J NEUROSCI, V30, P17068, DOI 10.1523/JNEUROSCI.4067-10.2010; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Palanisamy A, 2011, ANESTHESIOLOGY, V114, P521, DOI 10.1097/ALN.0b013e318209aa71; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Rappaport B, 2011, NEW ENGL J MED, V364, P1387, DOI 10.1056/NEJMp1102155; Reichenberg A, 2001, ARCH GEN PSYCHIAT, V58, P445, DOI 10.1001/archpsyc.58.5.445; Reitman E, 2011, BRIT J ANAESTH, V107, P72, DOI 10.1093/bja/aer343; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schuitemaker A, 2009, NEUROBIOL AGING, V30, P1885, DOI 10.1016/j.neurobiolaging.2008.01.014; Shu Y, 2012, NEUROBIOL DIS, V45, P743, DOI 10.1016/j.nbd.2011.10.021; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Sparkman NL, 2006, J NEUROSCI, V26, P10709, DOI 10.1523/JNEUROSCI.3376-06.2006; Sun L, 2010, BRIT J ANAESTH, V105, pI61, DOI 10.1093/bja/aeq302; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Teeling JL, 2009, NEUROSCIENCE, V158, P1062, DOI 10.1016/j.neuroscience.2008.07.031; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2; Veena J, 2009, J NEUROSCI RES, V87, P831, DOI 10.1002/jnr.21907; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Wan YJ, 2007, ANESTHESIOLOGY, V106, P436, DOI 10.1097/00000542-200703000-00007; Wan YJ, 2010, CRIT CARE MED, V38, P2190, DOI 10.1097/CCM.0b013e3181f17bcb; Weaver JD, 2002, NEUROLOGY, V59, P371, DOI 10.1212/WNL.59.3.371; Wei HF, 2008, ANESTHESIOLOGY, V108, P251, DOI 10.1097/01.anes.0000299435.59242.0e; Willard LB, 1999, NEUROSCIENCE, V88, P193; Wu X, 2012, NEUROBIOL AGING, V33, P1364, DOI 10.1016/j.neurobiolaging.2010.11.002; Xie ZC, 2008, ANN NEUROL, V64, P618, DOI 10.1002/ana.21548; Yang H, 2008, ANESTHESIOLOGY, V109, P243, DOI 10.1097/ALN.0b013e31817f5c47; Zhang GH, 2008, J NEUROSCI, V28, P4551, DOI 10.1523/JNEUROSCI.5694-07.2008; Zhang J, 2011, ANESTH ANALG, V113, P1468, DOI 10.1213/ANE.0b013e31822e913c; Zhang YY, 2012, ANN NEUROL, V71, P687, DOI 10.1002/ana.23536; Zhang YY, 2010, J BIOL CHEM, V285, P4025, DOI 10.1074/jbc.M109.065664; Zhen Y, 2009, ANESTHESIOLOGY, V111, P741, DOI 10.1097/ALN.0b013e3181b27fd4	55	136	152	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAR	2013	118	3					516	526		10.1097/ALN.0b013e3182834d5d			11	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	093LH	WOS:000315192900010	23314109	Bronze, Green Accepted			2022-02-06	
J	Siegel, SR; Mackenzie, J; Chaplin, G; Jablonski, NG; Griffiths, L				Siegel, Sue Rutherford; Mackenzie, Jason; Chaplin, George; Jablonski, Nina G.; Griffiths, Lyn			Circulating microRNAs involved in multiple sclerosis	MOLECULAR BIOLOGY REPORTS			English	Article						miRNA; MS; Expression analysis; Microarray; Plasma; Case-control population	CELL TRANSLOCATION GENE-1; EXPRESSION; PROTEIN; RNA; BIOMARKER; DIFFERENTIATION; EPIDEMIOLOGY; CHOLESTEROL; AUTOANTIGEN; LYMPHOCYTES	Multiple sclerosis (MS) is an immune-mediated, demyelinating and neurodegenerative disease of the central nervous system. After traumatic brain injury, it is the leading cause of neurology disability in young adults. Considerable advances have been made in identifying genes involved in MS but the genetic and phenotypic complexity associated with this disease significantly hinders any progress. A novel class of small RNA molecules, microRNAs (miRNAs) has acquired much attention because they regulate the expression of up to 30% of protein-coding genes and may play a pivotal role in the development of many, if not all, complex diseases. Seven published studies investigated miRNAs from peripheral blood mononuclear cells, CD4+, CD8+ T cell, B lymphocytes, peripheral blood leukocytes, whole blood and brain astrocytes with MS risk. The absence of MS studies investigating plasma miRNA prompted the current investigation of identifying a circulating miRNA signature in MS. We conducted a microarray analysis of over 900 known miRNA transcripts from plasma samples collected from four MS individuals and four sex-aged and ethnicity matched healthy controls. We identified six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. Both miR-422a and miR-22 have previously been implicated in MS. The present study is the first to show a circulating miRNA signature involved in MS that could serve as a potential prognostic and diagnostic biomarker for MS.	[Siegel, Sue Rutherford] Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; [Mackenzie, Jason; Griffiths, Lyn] Griffith Univ, Griffith Hlth Inst, Genom Res Ctr, Gold Coast, Qld 9726, Australia; [Chaplin, George; Jablonski, Nina G.] Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA		Siegel, SR (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr,MC H171, Hershey, PA 17033 USA.	srs40@psu.edu; Jason.mackenzie@griffith.edu.au; gvc5@psu.edu; ngj2@psu.edu; l.griffiths@griffith.edu.au		Griffiths, Lyn/0000-0002-6774-5475	Toray IndustriesToray Industries, Inc.; MSRA	We are very grateful to the participants in this project. We thank Satoko Takizawa for her technical assistance. This research was supported by funding from a 3D-Gene (R) Competition Award for Microarray analysis 2009 from Toray Industries. Also, we gratefully acknowledge an MSRA Postgraduate scholarship supporting Jason Mackenzie.	Ai J, 2010, BIOCHEM BIOPH RES CO, V391, P73, DOI 10.1016/j.bbrc.2009.11.005; Al-Omaishi J, 1999, J LEUKOCYTE BIOL, V65, P444, DOI 10.1002/jlb.65.4.444; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Banerjee Diponkar, 2011, Adv Hematol, V2011, P439456, DOI 10.1155/2011/439456; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bostjancic E, 2010, CARDIOLOGY, V115, P163, DOI 10.1159/000268088; Byun E, 2008, ARCH NEUROL-CHICAGO, V65, P337, DOI 10.1001/archneurol.2008.47; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Caporali A, 2011, CIRCULATION, V123, P282, DOI 10.1161/CIRCULATIONAHA.110.952325; Chen XG, 2000, GENE DEV, V14, P777; Chen XG, 2004, J MOL MED, V82, P232, DOI 10.1007/s00109-004-0529-0; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Corsten MF, 2010, CIRC-CARDIOVASC GENE, V3, P499, DOI 10.1161/CIRCGENETICS.110.957415; Cox MB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012132; D'Alessandra Y, 2010, EUR HEART J, V31, P2765, DOI 10.1093/eurheartj/ehq167; De Santis G, 2010, J NEUROIMMUNOL, V226, P165, DOI 10.1016/j.jneuroim.2010.06.009; De Smaele E, 2010, BRAIN RES, V1338, P100, DOI 10.1016/j.brainres.2010.03.103; Dinger ME, 2008, J MOL ENDOCRINOL, V40, P151, DOI 10.1677/JME-07-0160; Doi Y, 2008, P NATL ACAD SCI USA, V105, P8381, DOI 10.1073/pnas.0803454105; Du CS, 2009, NAT IMMUNOL, V10, P1252, DOI 10.1038/ni.1798; Fichtlscherer S, 2010, CIRC RES, V107, P677, DOI 10.1161/CIRCRESAHA.109.215566; Hill A.F., 2009, CURR MED LIT NEUROL, V25, P27; Ji X, 2009, CLIN CHEM, V55, P1944, DOI 10.1373/clinchem.2009.125310; Jung R, 1997, BIOTECHNIQUES, V23, P24, DOI 10.2144/97231bm03; Junker A, 2009, BRAIN, V132, P3342, DOI 10.1093/brain/awp300; Kaushansky N, 2010, AUTOIMMUN REV, V9, P233, DOI 10.1016/j.autrev.2009.08.002; Keller A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007440; Kim JW, 2010, CANCER RES, V70, P4820, DOI 10.1158/0008-5472.CAN-10-0659; Lee H, 2003, J IMMUNOL, V171, P5802, DOI 10.4049/jimmunol.171.11.5802; Lelu K, 2011, J IMMUNOL, V187, P2386, DOI 10.4049/jimmunol.1101578; Lin L, 2006, J IMMUNOL, V176, P4793, DOI 10.4049/jimmunol.176.8.4793; Lindberg RLP, 2010, EUR J IMMUNOL, V40, P888, DOI 10.1002/eji.200940032; Mandel M, 2004, CLIN EXP IMMUNOL, V138, P164, DOI 10.1111/j.1365-2249.2004.02587.x; Massaro AR, 2009, EUR REV MED PHARMACO, V13, P397; Nagino K, 2006, J BIOCHEM, V139, P697, DOI 10.1093/jb/mvj086; Nahta R, 2006, MOL CANCER THER, V5, P1593, DOI 10.1158/1535-7163.MCT-06-0133; Otaegui D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006309; PAGE WF, 1993, ANN NEUROL, V33, P632, DOI 10.1002/ana.410330612; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; POSER CM, 1994, ANN NEUROL, V36, pS180, DOI 10.1002/ana.410360805; Ramagopalan SV, 2011, NEUROLOGY, V76, P1410, DOI 10.1212/WNL.0b013e318216715e; Ramagopalan SV, 2008, LANCET, V371, P283, DOI 10.1016/S0140-6736(08)60145-2; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Rothwell PM, 1998, J NEUROL NEUROSUR PS, V64, P730, DOI 10.1136/jnnp.64.6.730; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Saini HK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-564; Simons M, 2002, J CELL BIOL, V157, P327, DOI 10.1083/jcb.200110138; Song KH, 2010, J LIPID RES, V51, P2223, DOI 10.1194/jlr.M004531; Tijsen AJ, 2010, CIRC RES, V106, P1035, DOI 10.1161/CIRCRESAHA.110.218297; Tufekci KU, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/807426; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Van Vlierberghe P, 2009, BRIT J HAEMATOL, V147, P686, DOI 10.1111/j.1365-2141.2009.07909.x; Verhagen APM, 2011, BIOESSAYS, V33, P674, DOI 10.1002/bies.201100048; Wang GK, 2010, EUR HEART J, V31, P659, DOI 10.1093/eurheartj/ehq013; Wang JX, 2011, NAT MED, V17, P71, DOI 10.1038/nm.2282; WEINSHENKER BG, 1994, ANN NEUROL, V36, pS6, DOI 10.1002/ana.410360704; Xue DH, 2003, P NATL ACAD SCI USA, V100, P7503, DOI 10.1073/pnas.0832411100; Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357; Zhang KX, 2010, CIRC-CARDIOVASC GENE, V3, P187, DOI 10.1161/CIRCGENETICS.109.904813	60	136	144	1	21	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-4851	1573-4978		MOL BIOL REP	Mol. Biol. Rep.	MAY	2012	39	5					6219	6225		10.1007/s11033-011-1441-7			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917BU	WOS:000302147800138	22231906				2022-02-06	
J	Stuss, DT				Stuss, Donald T.			Traumatic brain injury: relation to executive dysfunction and the frontal lobes	CURRENT OPINION IN NEUROLOGY			English	Article						frontal lobes; functional fractionation; neuronal systems; rehabilitation; traumatic brain injury	SELF-AWARENESS; REACTION-TIME; REHABILITATION; DEFICITS	Purpose of review This review examines the applicability of a framework of frontal lobe functioning to understand the sequelae of traumatic brain injury (TBI). Recent findings TBI research illustrates the need for improved phenotyping of TBI outcome. The functions of the frontal lobes are divisible into four distinct anatomically discrete categories: executive functions, speed of processing, personality changes, and problems with empathy and social cognition. Research on the outcome after TBI demonstrates several different types of impairment that map onto this framework. Summary TBI predominantly causes damage to the frontal/temporal regions, regardless of the pathophysiology. Limiting the spotlight to the frontal lobes, a model is presented describing four separate general categories of functions within the frontal lobes, with specific types of processes within each category. A selective review of TBI literature supports the importance of evaluating TBI patients with this framework in mind. In addition, there is growing evidence that rehabilitation of TBI patients must consider this broader approach to direct rehabilitation efforts and improve outcome.	Univ Toronto, Ontario Brain Inst, Rotman Res Inst, Baycrest Ctr, Toronto, ON M5S 1A1, Canada		Stuss, DT (corresponding author), Univ Toronto, Ontario Brain Inst, Rotman Res Inst, Baycrest Ctr, Toronto, ON M5S 1A1, Canada.	dstuss@braininstitute.ca			Canadian Institutes of Mental Health; JSF McDonnell Foundation; Ontario Mental Health Foundation	There are no conflicts of interest. Funding for my original research comes from the Canadian Institutes of Mental Health, the JSF McDonnell Foundation, and the Ontario Mental Health Foundation.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Beck KD, 2010, PM&R, V2, P195, DOI 10.1016/j.pmrj.2009.12.007; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; BLUMER D, 1975, PSYCHIATRIC ASPECTS, V1, P151; Carey CL, 2008, STROKE, V39, P397, DOI 10.1161/STROKEAHA.107.491795; CATANI M, ATLAS HUMAN IN PRESS; Channon S, 2010, NEUROPSYCHOL REHABIL, V20, P739, DOI 10.1080/09602011003794583; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Krpan KM, 2011, J INT NEUROPSYCH SOC, V17, P248, DOI 10.1017/S1355617710001499; KRPAN KM, BRAIN INJ IN PRESS; Levine B., 2008, COGNITIVE NEUROREHAB, V2nd, P464, DOI [10.1017/CBO9781316529898.033, DOI 10.1017/CBO9781316529898.033]; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Matheson L, 2010, WORK, V36, P413, DOI 10.3233/WOR-2010-1043; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ramirez J., 2008, COGNITIVE NEUROREHAB, P124; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Simblett SK, 2011, NEUROPSYCHOL REHABIL, V21, P1, DOI [10.1080/09602011.2010.531216, 10.1080/09602011.2011.592099]; Simmons JM, 2010, J NEUROSCI, V30, P15878, DOI 10.1523/JNEUROSCI.1802-10.2010; Spikman JM, 2010, J NEUROTRAUM, V27, P1195, DOI 10.1089/neu.2010.1277; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Stuss DT, 2006, J INT NEUROPSYCH SOC, V12, P261, DOI 10.1017/S1355617706060358; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 2007, HUMAN FRONTAL LOBES, P292; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; ZAPPALA G, CORTEX IN PRESS	36	136	136	0	84	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2011	24	6					584	589		10.1097/WCO.0b013e32834c7eb9			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	845VC	WOS:000296850900011	21968550				2022-02-06	
J	Tate, CC; Shear, DA; Tate, MC; Archer, DR; Stein, DG; LaPlaca, MC				Tate, Ciara C.; Shear, Deborah A.; Tate, Matthew C.; Archer, David R.; Stein, Donald G.; LaPlaca, Michelle C.			Laminin and fibronectin scaffolds enhance neural stem cell transplantation into the injured brain	JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE			English	Article						cell transplantation; tissue engineering; fibronectin; laminin; neural stem cells; traumatic brain injury; scaffold; extracellular matrix	CONTROLLED CORTICAL IMPACT; MESENCEPHALIC TISSUE; ARBITRARY PARTICLES; COGNITIVE DEFICITS; MOUSE-BRAIN; TIME-COURSE; RAT; MIGRATION; SURVIVAL; APOPTOSIS	Cell transplantation offers the potential to treat central nervous system injuries, largely because multiple mechanisms can be targeted in a sustained fashion. It is crucial that cells are transplanted into an environment that is favourable for extended survival and integration within the host tissue. Given the success of using fetal tissue grafts for traumatic brain injury, it may be beneficial to mimic key aspects of these grafts (e.g. three-dimensionality, cell-cell and cell-matrix support) to deliver cells. Extracellular matrix proteins such as fibronectin and laminin are involved in neural development and may provide adhesive support for donor cells and mediate subsequent cell signalling events. In this study, neural stem cells were transplanted into the traumatically injured mouse brain within a tissue-engineered construct containing either a laminin- or fibronectin-based scaffold. Cells delivered within the scaffolds were more widely distributed in the injured brain compared to cells delivered in media alone. There were no differences in donor cell survival at 1 week post-transplant; however, by 8 weeks post-transplant, cells delivered within the scaffolds showed improved survival compared to those transplanted in media alone. Survival was more enhanced with the laminin-based scaffold compared to the fibronectin-based scaffold. Furthermore, behavioural analyses indicated that mice receiving neural stem cells within the laminin-based scaffold performed significantly better than untreated mice on a spatial learning task, supporting the notion that functional recovery correlates positively with donor cell survival. Together these results suggest that the use of appropriate extracellular matrix-based scaffolds can be exploited to improve cell transplantation therapy. Copyright (c) 2009 John Wiley & Sons, Ltd.	[Tate, Ciara C.; LaPlaca, Michelle C.] Emory Univ, Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; [Shear, Deborah A.] Field Neurosci Inst, Saginaw, MI USA; [Tate, Matthew C.] Emory Univ, Sch Med, Atlanta, GA 30332 USA; [Archer, David R.] Emory Univ, Dept Pediat, Atlanta, GA 30332 USA; [Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30332 USA; [Stein, Donald G.] Emory Univ, Dept Neurol, Atlanta, GA 30332 USA		LaPlaca, MC (corresponding author), Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu	Shear, Deborah/B-3607-2011; Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EB001014]; NSFNational Science Foundation (NSF) [BES-0093830]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER	Technical assistance with rheometry was provided by Sarah Stabenfeldt. The authors acknowledge Dr Masaru Okabe (Osaka University, Osaka, Japan) for a generous donation of EGFP transgenic mice. Funding was provided from the NIH (Grant No. EB001014) and NSF (Grant No. BES-0093830).	Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141; Clarkson ED, 1998, BRAIN RES, V806, P60, DOI 10.1016/S0006-8993(98)00717-3; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; CONNOLLY MS, 1981, PHYSIOL BEHAV, V27, P1045, DOI 10.1016/0031-9384(81)90368-1; Cullen DK, 2007, J NEUROSCI RES, V85, P3642, DOI 10.1002/jnr.21434; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Emgard M, 2003, J NEUROCHEM, V86, P1223, DOI 10.1046/j.1471-4159.2003.01931.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gibson RM, 2005, MOL CELL NEUROSCI, V28, P588, DOI 10.1016/j.mcn.2004.11.004; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Hall PE, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-71; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; HOOVLER DW, 1991, ACTA NEUROPATHOL, V81, P303, DOI 10.1007/BF00305872; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Kato H, 2000, BRAIN PATHOL, V10, P137; Kobayashi K, 1999, MACROMOLECULES, V32, P7070, DOI 10.1021/ma990242n; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Lindvall O, 2003, PHARMACOL RES, V47, P279, DOI 10.1016/S1043-6618(03)00037-9; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Ma W, 2004, EXP NEUROL, V190, P276, DOI 10.1016/j.expneurol.2003.10.016; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Perris R, 2000, MECH DEVELOP, V95, P3, DOI 10.1016/S0925-4773(00)00365-8; Raub CB, 2007, BIOPHYS J, V92, P2212, DOI 10.1529/biophysj.106.097998; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stabenfeldt SE, 2006, J BIOMED MATER RES A, V77A, P718, DOI 10.1002/jbm.a.30638; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Takeuchi M, 2003, COLLOID POLYM SCI, V281, P1178, DOI 10.1007/s00396-003-0893-2; Tate CC, 2007, J NEUROTRAUM, V24, P226, DOI 10.1089/neu.2006.0043; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Testaz S, 2001, DEV DYNAM, V222, P127, DOI 10.1002/dvdy.1181; Yu XJ, 1999, TISSUE ENG, V5, P291, DOI 10.1089/ten.1999.5.291	40	136	141	1	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-6254	1932-7005		J TISSUE ENG REGEN M	J. Tissue Eng. Regen. Med.	MAR	2009	3	3					208	217		10.1002/term.154			10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Engineering	434IM	WOS:000265268400005	19229887				2022-02-06	
J	Hunt, RF; Scheff, SW; Smith, BN				Hunt, Robert F.; Scheff, Stephen W.; Smith, Bret N.			Posttraumatic epilepsy after controlled cortical impact injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Seizures; Temporal lobe epilepsy; Hyperexcitability; Dentate gyrus; Mossy fiber sprouting	TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; FLUID PERCUSSION INJURY; TEMPORAL-LOBE EPILEPSY; KAINIC ACID; SYNAPTIC REORGANIZATION; HIPPOCAMPAL SLICES; STATUS EPILEPTICUS; HILAR NEURONS; HEAD-INJURY	Many patients develop temporal lobe epilepsy after trauma, but basic mechanisms underlying the development of chronic seizures after head injury remain poorly understood. Using the controlled cortical impact injury model we examined whether mice developed spontaneous seizures after mild (0.5 mm injury depth) or severe (1.0 mull injury depth) brain injury and how subsequent posttraumatic mossy fiber sprouting was associated with excitability in the dentate gyrus 42-71 d after injury. After several weeks, spontaneous behavioral seizures were observed in 20% of mice with mild and 36% of mice with severe injury. Mossy fiber sprouting was typically present in septal slices of the dentate gyrus ipsilateral to the injury, but not in control mice. In slices with mossy fiber sprouting, perforant path stimulation revealed a significant reduction (P<0.01) in paired-pulse ratios in dentate granule cells at 20 ms and 40 ms interpulse intervals, but not at 80 ms or 160 ins intervals. These slices were also characterized by spontaneous and hilar-evoked epileptiform activity in the dentate gyrus in the presence of Mg2+-free ACSF containing 100 mu M picrotoxin. In contrast, paired-pulse and hilar-evoked responses in slices from injured animals that did not display mossy fiber sprouting were not different from controls. These data suggest the development of spontaneous posttraumatic seizures as well as structural and functional network changes associated with temporal lobe epilepsy in the mouse dentate gyrus by 71 d after CCI injury. Identifying experimental injury models that exhibit similar pathology to injury-induced epilepsy in humans should help to elucidate the mechanisms by which the injured brain becomes epileptic. (c) 2008 Elsevier Inc. All rights reserved.	[Hunt, Robert F.; Smith, Bret N.] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Smith, BN (corresponding author), Univ Kentucky, Dept Physiol, MS-508 Chandler Med Ctr,800 Rose St, Lexington, KY 40536 USA.	bret.smith@uky.edu	Ritter, Stefanie L/D-9312-2012	Hunt, Robert/0000-0003-4490-8718	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS052302, AG21981]; Epilepsy Foundation Training Fellowship; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER	This research was supported by NIH NS052302 to B.N.S., NIH AG21981 to S.W.S., and an Epilepsy Foundation Training Fellowship to R.F.H. We wish to thank Kelly Roberts for technical assistance with the injury models.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Buckmaster PS, 1997, J NEUROPHYSIOL, V77, P2685, DOI 10.1152/jn.1997.77.5.2685; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dudek FE, 1997, J CLIN NEUROPHYSIOL, V14, P90, DOI 10.1097/00004691-199703000-00002; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hirota K, 1997, ANESTH ANALG, V85, P426, DOI 10.1097/00000539-199708000-00032; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Jiao YQ, 2007, EXP NEUROL, V205, P569, DOI 10.1016/j.expneurol.2007.03.025; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; KIRBY MT, 1995, BRAIN RES, V688, P114, DOI 10.1016/0006-8993(95)00521-Q; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lynch M, 2000, J NEUROPHYSIOL, V83, P693, DOI 10.1152/jn.2000.83.2.693; Molnar P, 1999, J NEUROPHYSIOL, V82, P1883, DOI 10.1152/jn.1999.82.4.1883; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Patrylo PR, 2006, EPILEPSIA, V47, P257, DOI 10.1111/j.1528-1167.2006.00417.x; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418, DOI 10.1152/jn.1998.79.1.418; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scharfman HE, 2003, J NEUROPHYSIOL, V90, P2536, DOI 10.1152/jn.00251.2003; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; Smith BN, 2002, J NEUROPHYSIOL, V87, P1655, DOI 10.1152/jn.00581.2001; Smith BN, 2001, J NEUROPHYSIOL, V85, P1, DOI 10.1152/jn.2001.85.1.1; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Sullivan PG, 1999, J NEUROSCI, V19, P6248; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Swanson TH, 1998, J NEURAL TRANSM, V105, P613, DOI 10.1007/s007020050083; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin N R, 1998, Adv Neurol, V76, P179; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; TUFF LP, 1983, BRAIN RES, V277, P79, DOI 10.1016/0006-8993(83)90909-5; WALDBAUM S, 2005, SOC NEUR ABSTR, V31; Waldbaum S, 2007, EPILEPSIA, V48, P387; Winokur RS, 2004, EPILEPSY RES, V58, P93, DOI 10.1016/j.eplepsyres.2004.01.002; Wuarin JP, 1996, J NEUROSCI, V16, P4438; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067, DOI 10.1152/jn.2001.85.3.1067	65	136	138	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2009	215	2					243	252		10.1016/j.expneurol.2008.10.005			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	400TG	WOS:000262890900006	19013458	Green Accepted			2022-02-06	
J	Ayr, LK; Yeates, KO; Taylor, HG; Browne, M				Ayr, Lauren K.; Yeates, Keith Owen; Taylor, H. Gerry; Browne, Michael			Dimensions of postconcussive symptoms in children with mild traumatic brain injuries	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Nervous system trauma; Pediatric; Postconcussion syndrome; Factor analysis; Parent-child agreement; Prospective studies; Head injuries	HEAD-INJURY; NEUROBEHAVIORAL SYMPTOMS; SAMPLE-SIZE; AGREEMENT; VALIDITY; CRITERIA	The dimensions of postconcussive Symptoms (PCS) were examined in a prospective, longitudinal study of 196 8 to 15 year old children with mild traumatic brain injuries (TBI). Parents and children completed a 50-item questionnaire within 2 weeks of injury and again at 3 months after injury, rating the frequency of PCS on a 4-point scale. Common factor analysis with target rotation was used to rotate the ratings to four hypothesized dimensions, representing cognitive, somatic, emotional, and behavioral symptoms. The rotated factor matrix for baseline parent ratings was consistent with the target matrix. The rotated matrix for baseline child ratings was consistent with the target matrix for cognitive and somatic symptoms but not for emotional and behavioral symptoms. The rotated matrices for ratings obtained 3 months after injury were largely consistent with the target matrix derived from analyses of baseline ratings, except that parent ratings of behavioral symptoms did not cluster as before. Parent and child ratings of PCS following mild TBI yield consistent factors reflecting cognitive and somatic symptom dimensions, but dimensions of emotional and behavioral symptoms are less robust across time and raters. (JINS, 2009. 15, 19-30.)	[Ayr, Lauren K.; Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, Columbus, OH 43205 USA; [Ayr, Lauren K.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Browne, Michael] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39834, K02 HD44099]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	The research reported here served as the basis for a dissertation Submitted by the first author to The Ohio State University in partial fulfillment of the requirements for a doctoral degree. Portions of the research were presented at the annual meeting of the International Neuropsychological Society, Boston, February 2006. The larger project from which the research was derived was supported by grants R01 HD39834 and K02 HD44099 from the National Institute of Child Health and Human Development to the second author.	Achenbach TM, 2006, CURR DIR PSYCHOL SCI, V15, P94, DOI 10.1111/j.0963-7214.2006.00414.x; Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Browne MW, 2001, MULTIVAR BEHAV RES, V36, P111, DOI 10.1207/S15327906MBR3601_05; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; EDELBROCK C, 1986, J CHILD PSYCHOL PSYC, V27, P181, DOI 10.1111/j.1469-7610.1986.tb02329.x; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gorsuch R.L., 1983, FACTOR ANAL; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GUADAGNOLI E, 1988, PSYCHOL BULL, V103, P265, DOI 10.1037/0033-2909.103.2.265; HODGES K, 1990, J CHILD PSYCHOL PSYC, V31, P427, DOI 10.1111/j.1469-7610.1990.tb01579.x; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MacCallum RC, 1999, PSYCHOL METHODS, V4, P84, DOI 10.1037/1082-989x.4.1.84; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Millsap RE, 2007, FACTOR ANAL 100 HIST, P131; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; TEASDALE G, 1974, LANCET, V2, P81; Velicer WF, 1998, PSYCHOL METHODS, V3, P231, DOI 10.1037/1082-989X.3.2.231; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; YEATES KO, PEDIATRICS IN PRESS; [No title captured]	47	136	136	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					19	30		10.1017/S1355617708090188			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300003	19128525	Green Accepted			2022-02-06	
J	Ewing-Cobbs, L; Prasad, MR; Swank, P; Kramer, L; Cox, CS; Fletcher, JM; Barnes, M; Zhang, XL; Hasan, KM				Ewing-Cobbs, Linda; Prasad, Mary R.; Swank, Paul; Kramer, Larry; Cox, Charles S., Jr.; Fletcher, Jack M.; Barnes, Marcia; Zhang, Xiaoling; Hasan, Khader M.			Arrested development and disrupted callosal microstructure following pediatric traumatic brain injury: relation to neurobehavioral outcomes	NEUROIMAGE			English	Article						traumatic brain injury; diffusion tensor imaging; fractional anisotropy; corpus callosum; outcome	HUMAN CORPUS-CALLOSUM; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DIFFUSION TENSOR EIGENVALUES; WHITE-MATTER; WALLERIAN DEGENERATION; HEAD-INJURY; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; AXONAL INJURY; INTERHEMISPHERIC-TRANSFER	Chronic pediatric traumatic brain injury (TBI) is associated with significant and persistent neurobehavioral deficits. Using diffusion tensor imaging (DTI), we examined area, fractional anisotropy (FA), radial diffusion, and axial diffusion from six regions of the corpus callosum (CC) in 41 children and adolescents with TBI and 31 comparison children. Midsagittal cross-sectional area of the posterior body and isthmus was similar in younger children irrespective of injury status; however, increased area was evident in the older comparison children but was obviated in older children with TBI, suggesting arrested development. Similarly, age was correlated significantly with indices of tissue microstructure only for the comparison group. TBI was associated with significant reduction in FA and increased radial diffusivity in the posterior third of the CC and in the genu. The axial diffusivity did not differ by either age or group. Logistic regression analyses revealed that FA and radial diffusivity were equally sensitive to post-traumatic changes in 4 of 6 callosal regions; radial diffusivity was more sensitive for the rostral midbody and splenium. IQ working memory, motor, and academic skills were correlated significantly with radial diffusion and/or FA from the isthmus and splenium only in the TBI group. Reduced size and microstructural changes in posterior callosal regions after TBI suggest arrested development, decreased organization, and disrupted myelination. Increased radial diffusivity was the most sensitive DTI-based surrogate marker of the extent of neuronal damage following TBI; FA was most strongly Correlated with neuropsychological outcomes. Published by Elsevier Inc.	[Ewing-Cobbs, Linda] Univ Texas Houston Hlth Sci Ctr, Dept Pediat, Childrens Learning Inst, Houston, TX 77030 USA; [Kramer, Larry; Hasan, Khader M.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Radiol, Houston, TX 77030 USA; [Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Fletcher, Jack M.] Univ Houston, Dept Psychol, Houston, TX 77004 USA; [Barnes, Marcia] Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada		Ewing-Cobbs, L (corresponding author), Univ Texas Houston Hlth Sci Ctr, Dept Pediat, Childrens Learning Inst, 7000 Fannin,UCT 2401, Houston, TX 77030 USA.	Linda.Ewing-Cobbs@uth.tmc.edu	fletcher, jack/Q-5975-2019; Hasan, Khader M./ABB-5767-2020; Fletcher, Jack/AAX-2931-2020		National Institutes of Health-National Institute for Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS046308, R01-NS052505-03]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052505, R01NS046308] Funding Source: NIH RePORTER	This work was funded by the National Institutes of Health-National Institute for Neurological Diseases and Stroke grants R01-NS046308 awarded to LEC and R01-NS052505-03 awarded to KMH. The authors wish to thank Ambika Sankar for assisting in data processing and Vipul Kumar Patel for helping in data acquisition.	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Alexander AL, 2007, NEUROIMAGE, V34, P61, DOI 10.1016/j.neuroimage.2006.08.032; Anderson NG, 2005, AM J NEURORADIOL, V26, P2685; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashtari M, 2005, BIOL PSYCHIAT, V57, P448, DOI 10.1016/j.biopsych.2004.11.047; Back SA, 2002, J NEUROSCI, V22, P455, DOI 10.1523/JNEUROSCI.22-02-00455.2002; Bammer R, 2002, MAGNET RESON MED, V48, P128, DOI 10.1002/mrm.10184; Barkovich AJ, 2005, J INHERIT METAB DIS, V28, P311, DOI 10.1007/s10545-005-5952-z; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Basser PJ, 1997, ANN NY ACAD SCI, V820, P123, DOI 10.1111/j.1749-6632.1997.tb46192.x; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BOSKA MD, 2007, NEUROBIOL DIS; CARLSON M, 1988, PSYCHIAT DEV, V6, P1; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Dougherty RF, 2007, P NATL ACAD SCI USA, V104, P8556, DOI 10.1073/pnas.0608961104; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Giedd JN, 1999, PROG NEURO-PSYCHOPH, V23, P571; Hasan KM, 2007, NEUROIMAGE, V34, P1497, DOI 10.1016/j.neuroimage.2006.10.029; Hasan KM, 2006, MAGN RESON MED, V56, P130, DOI 10.1002/mrm.20935; Hasan KM, 2008, NMR BIOMED, V21, P1094, DOI 10.1002/nbm.1286; Hasan KM, 2006, RADIOLOGY, V239, P611, DOI 10.1148/radiol.2392051172; Hasan KM, 2005, J MAGN RESON IMAGING, V21, P735, DOI 10.1002/jmri.20296; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Huang H, 2005, NEUROIMAGE, V26, P195, DOI 10.1016/j.neuroimage.2005.01.019; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jaermann T, 2004, MAGN RESON MED, V51, P230, DOI 10.1002/mrm.10707; JENNETT B, 1975, LANCET, V1, P480; Johansen-Berg H, 2007, NEUROIMAGE, V36, pT16, DOI 10.1016/j.neuroimage.2007.03.041; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; Keshavan MS, 2002, LIFE SCI, V70, P1909, DOI 10.1016/S0024-3205(02)01492-3; Klaas PA, 1999, J CLIN EXP NEUROPSYC, V21, P837, DOI 10.1076/jcen.21.6.837.851; KlOve H, 1963, MED CLIN N AM; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LAMANTIA AS, 1990, J NEUROSCI, V10, P2156; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Moseley M, 2002, BRAIN COGNITION, V50, P396, DOI 10.1016/S0278-2626(02)00524-9; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Nosarti C, 2004, BRAIN, V127, P2080, DOI 10.1093/brain/awh230; Olesen PJ, 2003, COGNITIVE BRAIN RES, V18, P48, DOI 10.1016/j.cogbrainres.2003.09.003; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Rajapakse JC, 1996, BRAIN DEV-JPN, V18, P379, DOI 10.1016/0387-7604(96)00034-4; RAKIC P, 1968, J COMP NEUROL, V132, P45, DOI 10.1002/cne.901320103; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Shaywitz BA, 2002, BIOL PSYCHIAT, V52, P101, DOI 10.1016/S0006-3223(02)01365-3; Simos PG, 2002, J CHILD NEUROL, V17, P159, DOI 10.1177/088307380201700301; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Verger K, 2001, BRAIN INJURY, V15, P211; Wagner RK., 1999, COMPREHENSIVE TEST P; Wahl M, 2007, J NEUROSCI, V27, P12132, DOI 10.1523/JNEUROSCI.2320-07.2007; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wiederholt J.L., 2001, GRAY ORAL READING TE; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; WOODCOCK RW, 2001, WOODCOCKJOHNSON ILL; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	95	136	138	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT 1	2008	42	4					1305	1315		10.1016/j.neuroimage.2008.06.031			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	351CB	WOS:000259401000005	18655838	Green Accepted			2022-02-06	
J	Timofeev, I; Czosnyka, M; Nortje, J; Smielewski, P; Kirkpatrick, P; Gupta, A; Hutchinson, P				Timofeev, Ivan; Czosnyka, Marek; Nortje, Jurgens; Smielewski, Peter; Kirkpatrick, Peter; Gupta, Arun; Hutchinson, Peter			Effect of decompressive craniectomy on intracranial pressure and cerebrospinal compensation following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral compliance; cerebrovascular reactivity; decompressive craniectomy; head injury; intracranial pressure	SEVERE HEAD-INJURY; SURGICAL DECOMPRESSION; CEREBRAL EDEMA; HYPERTENSION; MANAGEMENT; ICP; CONSORTIUM	Object. Decompressive craniectomy is an advanced treatment option for intracranial pressure (ICP) control in patients with traumatic brain injury. The purpose of this study was to evaluate the effect of decompressive craniectomy on ICP and cerebrospinal compensation both within and beyond the first 24 hours of craniectomy. Methods. This study was a retrospective analysis of the physiological parameters from 27 moderately to severely head-injured patients who underwent decompressive craniectomy for progressive brain edema. Of these, 17 patients had. undergone prospective digital recording of ICP with estimation of ICP waveform-derived indices. The pressure-volume compensatory reserve (RAP) index and the cerebrovascular pressure reactivity index (PRx) were used to assess those parameters. The values of parameters prior to and during the 72 hours after decompressive craniectomy were included in the analysis. Results. Decompressive craniectomy led to a sustained reduction in median (interquartile range) ICP values (21.2 mm Hg [18.7; 24.2 mm Hg] preoperatively compared with 15.7 mm Hg [12.3; 19.2 mm Hg] postoperatively; p = 0.01). A similar improvement was observed in RAP. A significantly lower mean arterial pressure (MAP) was needed after decompressive craniectomy to maintain optimum cerebral perfusion pressure (CPP) levels, compared with the preoperative period (99.5 mm Hg [96.2; 102.9 mm Hg] compared with 94.2 mm Hg [87.9; 98.9 mm Hg], respectively; p = 0.017). Following decompressive craniectomy, the PRx had positive values in all patients, suggesting acquired derangement in pressure reactivity. Conclusions. In this study, decompressive craniectomy led to a sustained reduction in ICP and improvement in cerebral compliance. Lower MAP levels after decompressive craniectomy are likely to indicate a reduced intensity of treatment. Derangement in cerebrovascular pressure reactivity requires further studies to evaluate its significance and influence on outcome.	[Timofeev, Ivan; Czosnyka, Marek; Smielewski, Peter; Kirkpatrick, Peter; Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; [Nortje, Jurgens; Gupta, Arun] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England		Timofeev, I (corresponding author), Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Box 166,Hills Rd, Cambridge CB2 2QQ, England.	it227@cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	Smielewski, Peter/0000-0001-5096-3938; Timofeev, Ivan/0000-0002-1168-0393	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390, G0601025] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0001237, G0601025, G0600986] Funding Source: UKRI		Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Abdullah J, 2005, ACT NEUR S, V95, P311; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; *BRAIN TRAUM FDN, 2003, MAN PROG SEV TRAUM B; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; CZOSNYKA M, 1994, ACTA NEUROCHIR, V126, P113, DOI 10.1007/BF01476419; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; Guendling K, 2006, ACTA NEUROCHIR SUPPL, V96, P108; Harrington ML, 1996, AM J VET RES, V57, P1659; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Jaeger M, 2005, ACT NEUR S, V95, P117; JENNETT B, 1975, LANCET, V1, P480; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Reithmeier T, 2005, ACTA NEUROCHIR, V147, P947, DOI 10.1007/s00701-005-0543-1; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schneider GH, 2002, ACT NEUR S, V81, P77; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; WHITFIELD P, 1995, STROKE, V26, P1125; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	34	136	138	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2008	108	1					66	73		10.3171/JNS/2008/108/01/0066			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	248AI	WOS:000252123300009	18173312				2022-02-06	
J	Hutchinson, PJ; O'Connell, MT; Rothwell, NJ; Hopkins, SJ; Nortje, J; Carpenter, KLH; Timofeev, I; Al-Rawi, PG; Menon, DK; Pickard, JD				Hutchinson, Peter J.; O'Connell, Mark T.; Rothwell, Nancy J.; Hopkins, Stephen J.; Nortje, Juergens; Carpenter, Keri L. H.; Timofeev, Ivan; Al-Rawi, Pippa G.; Menon, David K.; Pickard, John D.			Inflammation in human brain injury: Intracerebral concentrations of IL-1 alpha, IL-1 beta, and their endogenous inhibitor IL-1r	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; microdialysis; inflammation	INTERLEUKIN-1 RECEPTOR ANTAGONIST; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; CEREBRAL MICRODIALYSIS; SEVERE SEPSIS; POLYMORPHISM; DISEASE; ASSOCIATION; CATHETERS; CYTOKINES	Following traumatic brain injury TBI), cascades of inflammatory processes occur. Laboratory studies implicate the cytokines interleukin-la (IL-1 alpha) and IL-1 beta in the pathophysiology of TBI and cerebral ischemia, whilst exogenous and endogenous interleukin-1 receptor antagonist (IL-1ra) is neuroprotective. We analyzed IL-1 alpha, IL-1 beta, and IL-1ra in brain microdialysates (100-kDa membrane) in 15 TBI patients. We also analyzed energy-related molecules (glucose, lactate, pyruvate, glutamate, and the lactate/pyruvate ratio) in these brain microdialysates. Mean of mean (+/- SD) in vitro microdialysis percentage recoveries (extraction efficiencies) were IL-1 alpha 19.7 +/- 7.6%, IL-1 beta 23.9 +/- 10.5%, and IL-1ra 20.9 +/- 6.3%. In the patients' brain microdialysates, mean of mean cytokine concentrations (not corrected for percentage recovery) were IL-1 alpha 5.6 +/- 14.8 pg/mL, IL-1 beta 10.4 +/- 14.7 pg/mL, and IL-1ra 2796 +/- 2918 pg/mL. IL-1ra was consistently much higher than IL-1 alpha and IL-1 beta. There were no significant relationships between IL-1 family cytokines and energy-related molecules. There was a significant correlation between increasing IL-1 beta and increasing IL-1ra (Spearman r = 0.59, p = 0.028). There was also a significant relationship between increasing IL-1ra and decreasing intracranial pressure (Spearman r = -0.57, p = 0.041). High concentrations of IL-1ra, and also high IL-1ra/IL-1 beta ratio, were associated with better outcome (Mann Whitney, p = 0.018 and p = 0.0201, respectively), within these 15 patients. It is unclear whether these IL-1ra concentrations are sufficient to antagonize the effects of IL-1 beta in vivo. This study demonstrates feasibility of our microdialysis methodology in recovering IL-1 family cytokines for assessing their inter-relationships in the injured human brain, and suggests a neuroprotective role for IL-1ra. It remains to be seen whether exogenous IL-1ra or other agents can be used to manipulate cytokine levels in the brain, for potential therapeutic effect.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Acad Unit Neurosic, Cambridge CB2 0QQ, England; Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; Univ Manchester, Sch Med, Manchester, Lancs, England		Hutchinson, PJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Acad Unit Neurosic, Box 167, Cambridge CB2 0QQ, England.	pjah2@cam.ac.uk	Hopkins, Stephen/I-7363-2015; Timofeev, Ivan/AAE-7019-2019	Hopkins, Stephen/0000-0001-7644-2823; O'Connell, Mark/0000-0001-6272-8767; Carpenter, Keri/0000-0001-8236-7727; Timofeev, Ivan/0000-0002-1168-0393	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390, G19/24] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G19/24, G0600986, G9439390] Funding Source: UKRI		Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BORASCHI D, 1996, FRONT BIOSCI, V1, P270; Boutin H, 2003, MOL NEUROBIOL, V27, P239, DOI 10.1385/MN:27:3:239; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Camp NJ, 2005, GENES IMMUN, V6, P467, DOI 10.1038/sj.gene.6364228; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Fang XM, 1999, CRIT CARE MED, V27, P1330, DOI 10.1097/00003246-199907000-00024; Furse RK, 2002, J CLIN IMMUNOL, V22, P83, DOI 10.1023/A:1014479702575; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Griffin BD, 2006, J BIOL CHEM, V281, P10316, DOI 10.1074/jbc.M509973200; GUTIERREZ EG, 1994, J NEUROIMMUNOL, V55, P153, DOI 10.1016/0165-5728(94)90005-1; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hillman J, 2006, ACTA NEUROCHIR, V148, P319, DOI 10.1007/s00701-005-0670-8; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Kett-White R, 2002, ADV TECH STAND NEUR, V27, P87; Loddick SA, 1997, BIOCHEM BIOPH RES CO, V234, P211, DOI 10.1006/bbrc.1997.6436; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Mikuniya Takeshi, 2004, Journal of Infection and Chemotherapy, V10, P293, DOI 10.1007/s10156-004-0335-1; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mulcahy NJ, 2003, BRIT J PHARMACOL, V140, P471, DOI 10.1038/sj.bjp.0705462; OPP MR, 1991, AM J PHYSIOL, V260, pR453, DOI 10.1152/ajpregu.1991.260.2.R453; PARRY TJ, 1990, J NEUROSCI METH, V32, P175, DOI 10.1016/0165-0270(90)90138-6; Rambeck B, 2006, EPILEPSIA, V47, P681, DOI 10.1111/j.1528-1167.2006.00504.x; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shore PM, 2004, J NEUROTRAUM, V21, P1113; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; Tanriverdi T, 2006, SURG NEUROL, V65, P7, DOI 10.1016/j.surneu.2005.05.024; Tarkowski E, 2001, DEMENT GERIATR COGN, V12, P314, DOI 10.1159/000051276; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Uzan M, 2005, ACTA NEUROCHIR, V147, P715, DOI 10.1007/s00701-005-0529-z; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; Yokoyama T, 1998, PEDIATR ALLERGY IMMU, V9, P91	55	136	140	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2007	24	10					1545	1557		10.1089/neu.2007.0295			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	227HZ	WOS:000250649100001	17970618				2022-02-06	
J	Xu, J; Rasmussen, IA; Lagopoulos, J; Haberg, A				Xu, Jian; Rasmussen, Inge-Andre, Jr.; Lagopoulos, Jim; Haberg, Asta			Diffuse axonal injury in severe traumatic brain injury visualized using high-resolution diffusion tensor imaging	JOURNAL OF NEUROTRAUMA			English	Article						apparent diffusion coefficient; brain damage; DTI; fractional anisotropy; Glasgow Coma Scale (GCS); motor vehicle accident; region of interest analysis; ROI; voxel-based analysis; white matter	AMYLOID PRECURSOR PROTEIN; VOXEL-BASED MORPHOMETRY; CLOSED-HEAD INJURY; ANISOTROPY MEASUREMENTS; WHITE-MATTER; MRI; MILD; TRACKING; EPILEPSY; FEATURES	Traumatic brain injury TBI) is the most common cause of death and disability in young people. The functional outcome in patients with TBI cannot be explained by focal pathology alone, and diffuse axonal injury (DAI) is considered a major contributor to the neurocognitive deficits experienced by this group. The aim of the present study was to investigate whether diffusion tensor imaging (DTI) offers additional information as to the extent of damage not visualized with standard magnetic resonance imaging (MRI) in patients with severe TBI. Nine chronic male TBI patients and 11 matched healthy controls were recruited. Results of the voxel-based analysis of fractional anisotropy (FA) maps and apparent diffusion coefficient (ADC) maps revealed significant differences in anisotropy in major white matter tracts, including the corpus callosum (CC), internal and external capsule, superior and inferior longitudinal fascicles, and the fornix in the TBI group. The FA and ADC measurements offered superior sensitivity compared to conventional MRI diagnosis of DAL Region-of-interest (ROI) analyses confirmed these results in the investigated regions. The findings of this study support the hypothesis that severe TBI is accompanied by DAL The DTI changes were more prominent on the right side that contained the focal pathology in most of the patients and accurately reflected differences in both hemispheres. In conclusion, DTI holds great promise as a diagnostic tool to identify and quantify the degree of white matter injury in TBI patients.	Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Fac Med, N-7014 Trondheim, Norway; Univ Sydney, Discipline Psychol Med, No Clin Sch, Sydney, NSW 2006, Australia; Royal N Shore Hosp, CADE Clin, St Leonards, NSW 2065, Australia		Rasmussen, IA (corresponding author), Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Fac Med, N-7014 Trondheim, Norway.	inge.rasmussen@ntnu.no					ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Arfanakis K, 2002, MAGN RESON IMAGING, V20, P511, DOI 10.1016/S0730-725X(02)00509-X; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; Diaz-Marchan PG, 1996, NEUROTRAUMA, V1st, P137; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kanaan RA, 2006, PSYCHIAT RES-NEUROIM, V146, P73, DOI 10.1016/j.pscychresns.2005.11.002; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCLELLAN DR, 1990, COMA EMERGING PATIEN, P389; Melhem ER, 2000, AM J NEURORADIOL, V21, P1813; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Povlishock JT, 2001, HEAD TRAUMA, P281; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Salat DH, 2005, ANN NY ACAD SCI, V1064, P37, DOI 10.1196/annals.1340.009; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Skare S, 2001, MAGN RESON IMAGING, V19, P1125, DOI 10.1016/S0730-725X(01)00415-5; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; Westerhausen R, 2004, COGNITIVE BRAIN RES, V21, P418, DOI 10.1016/j.cogbrainres.2004.07.002; Whyte J, 1993, REHABILITATION MED P, P825	42	136	144	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					753	765		10.1089/neu.2006.0208			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300001	17518531				2022-02-06	
J	Pitkanen, A; Kharatishvili, I; Karhunen, H; Lukasiuk, K; Immonen, R; Nairismagi, J; Grohn, O; Nissinen, J				Pitkanen, Asla; Kharatishvili, Irina; Karhunen, Heli; Lukasiuk, Katarzyna; Immonen, Riikka; Nairismagi, Jaak; Grohn, Olli; Nissinen, Jari			Epileptogenesis in experimental models	EPILEPSIA			English	Article						endothelin-1; gene array; lateral fluid-percussion injury; magnetic resonance imaging; photothrombotic stroke; traumatic brain injury; video-EEG monitoring.	SPONTANEOUS RECURRENT SEIZURES; STATUS EPILEPTICUS; GENE-EXPRESSION; FEBRILE SEIZURES; DENTATE GYRUS; BRAIN-INJURY; RAT MODEL; EPILEPSY; NEUROGENESIS; HIPPOCAMPUS	Epileptogenesis refers to a phenomenon in which the brain undergoes molecular and cellular alterations after a brain-damaging insult, which increase its excitability and eventually lead to the occurrence of recurrent spontaneous seizures. Common epileptogenic factors include traumatic brain injury (TBI), stroke, and cerebral infections. Only a subpopulation of patients with any of these brain insults, however, will develop epilepsy. Thus, there are two great challenges: (1) identifying patients at risk, and (2) preventing and/or modifying the epileptogenic process. Target identification for antiepileptogenic treatments is difficult in humans because patients undergoing epileptogenesis cannot currently be identified. Animal models of epileptogenesis are therefore necessary for scientific progress. Recent advances in the development of experimental models of epileptogenesis have provided tools to investigate the molecular and cellular alterations and their temporal appearance, as well as the epilepsy phenotype after various clinically relevant epileptogenic etiologies, including TBI and stroke. Studying these models will lead to answers to critical questions such as: Do the molecular mechanisms of epileptogenesis depend on the etiology? Is the spectrum of network alterations during epileptogenesis the same after various clinically relevant etiologies? Is the temporal progression of epileptogenesis similar? Work is ongoing, and answers to these questions will facilitate the identification of molecular targets for antiepileptogenic treatments, the design of treatment paradigms, and the determination of whether data from one etiology can be extrapolated to another.	Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland; Polish Acad Sci, M Nencki Inst Expt Biol, PL-00901 Warsaw, Poland		Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	Asla.Pitkanen@uku.fi	Lukasiuk, Katarzyna/F-4636-2010	Lukasiuk, Katarzyna/0000-0002-1582-0920			Banerjee PN, 1997, EPILEPSY COMPREHENSI, P47, DOI 10.1007/978-88-470-2903-3_81; Battaglia G, 2006, MODELS OF SEIZURES AND EPILEPSY, P305, DOI 10.1016/B978-012088554-1/50025-6; Bernard C, 2004, SCIENCE, V305, P532, DOI 10.1126/science.1097065; Bidmon HJ, 1998, NEUROSCIENCE, V82, P397; Bidmon HJ, 2001, EXP NEUROL, V168, P1, DOI 10.1006/exnr.2000.7456; Brandt C, 2004, EPILEPSIA, V45, P1488, DOI 10.1111/j.0013-9580.2004.16904.x; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; Chung CK, 2005, EPILEPSIA, V46, P25, DOI 10.1111/j.0013-9580.2005.461008.x; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dube C, 2004, ANN NEUROL, V56, P709, DOI 10.1002/ana.20266; Ellerkmann RK, 2003, NEUROSCIENCE, V119, P323, DOI 10.1016/S0306-4522(03)00168-4; Elliott RC, 2003, J NEUROSCI, V23, P2218; Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x; Gadamski R, 2001, FOLIA NEUROPATHOL, V39, P155; GENNARELLI TA, 2000, TXB TRAUMATIC BRAIN, P27; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hendriksen H, 2001, EUR J NEUROSCI, V14, P1475, DOI 10.1046/j.0953-816x.2001.01778.x; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Jutila L, 2002, ADV TECH STAND NEUR, V27, P3; Karhunen H, 2005, NEUROCHEM RES, V30, P1529, DOI 10.1007/s11064-005-8831-y; Kharatishvili I, 2003, EPILEPSIA, V44, P36; Kluska MM, 2005, NEUROSCIENCE, V135, P723, DOI 10.1016/j.neuroscience.2005.06.082; Koistinaho J, 1997, NEUROREPORT, V8, pR1; LEITE JP, 1995, EPILEPSY RES, V20, P93, DOI 10.1016/0920-1211(94)00070-D; Lin DD, 2006, MODELS OF SEIZURES AND EPILEPSY, P315, DOI 10.1016/B978-012088554-1/50026-8; Lossius MI, 2005, EPILEPSIA, V46, P1246, DOI 10.1111/j.1528-1167.2005.57904.x; Luhmann HJ, 2006, MODELS OF SEIZURES AND EPILEPSY, P295, DOI 10.1016/B978-012088554-1/50024-4; Lukasiuk K, 2004, NEUROCHEM RES, V29, P1169, DOI 10.1023/B:NERE.0000023604.91584.6c; Lukasiuk K, 2003, EUR J NEUROSCI, V17, P271, DOI 10.1046/j.1460-9568.2003.02461.x; Lukasiuk K, 2006, PROG BRAIN RES, V158, P223, DOI 10.1016/S0079-6123(06)58011-2; Majak K, 2004, EPILEPSY BEHAV, V5, pS35, DOI 10.1016/j.yebeh.2003.11.012; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; Mazarati AM, 2006, MODELS OF SEIZURES AND EPILEPSY, P449, DOI 10.1016/B978-012088554-1/50038-4; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nairismagi J, 2004, EPILEPSIA, V45, P1024, DOI 10.1111/j.0013-9580.2004.08904.x; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rochefeuille S, 2002, MAT SCI ENG C-BIO S, V21, P43, DOI 10.1016/S0928-4931(02)00056-5; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Su H, 2002, J NEUROSCI, V22, P3645; THEODORE WH, 1994, NEUROLOGY, V44, P1403, DOI 10.1212/WNL.44.8.1403; Zagulska-Szymczak S, 2001, NEUROCHEM INT, V38, P485, DOI 10.1016/S0197-0186(00)00101-7	48	136	143	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2007	48			2			13	20		10.1111/j.1528-1167.2007.01063.x			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	160NG	WOS:000245949000003	17571349				2022-02-06	
J	Prins, ML; Fujima, LS; Hovda, DA				Prins, ML; Fujima, LS; Hovda, DA			Age-dependent reduction of cortical contusion volume by ketones after traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						brain injury; age; ketones; metabolism; ketogenic diet	FUNCTION IMPROVING AGENT; BETA-HYDROXYBUTYRATE; HEAD-INJURY; RAT-BRAIN; CEREBRAL-ISCHEMIA; FLUID PERCUSSION; KETOGENIC DIET; GLUCOSE-UTILIZATION; ENERGY-METABOLISM; ADULT RATS	Although the adult brain primarily metabolizes glucose, the evidence from the starvation literature has demonstrated that the adult brain retains some potential to revert to ketone metabolism. This attribute has been exploited recently to shift the adult brain toward ketone metabolism after traumatic brain injury (TBI), resulting in increased cerebral uptake and oxidation of exogenously administered ketones and improved cerebral energy. The ability to utilize ketones as an alternative substrate decreases with cerebral maturation, suggesting that the younger brain has a greater ability to metabolize this substrate and may be more receptive to this therapy. It was hypothesized that the administration of ketones after TBI in the developing brain will decrease lesion size in an age-dependent manner. Postnatal day (PND) 17, 35, 45, and 65 rats were placed on either a standard or ketogenic (KG) diet after controlled cortical impact (CCI) injury. PND35 and PND45 KG-fed animals showed a 58% and 39% reduction in cortical contusion volume, respectively, at 7 days post-injury. The KG diet had no effect on contusion volume in PND17 and PND65 injured rats. Both PND35 and PND45 KG-fed groups revealed fewer Fluoro-Jade-positive cells in the cortex and hippocampus at 6 hr and showed earlier decreases in plasma lactate compared to standard-fed animals. The age-dependent ketogenic neuroprotection is likely related to age-related differences in cerebral metabolism of ketones and suggests that alternative substrate therapy has potential applications for younger head-injured patients. (c) 2005 Wiley-Liss, Inc.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA		Prins, ML (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Room NPI 18-228,Box 957039, Los Angeles, CA 90095 USA.	lmprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, R01NS037363, R01NS052406] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS37363, NS052406] Funding Source: Medline		BARTNIK BL, 2005, IN PRESS J NEUROTRAU; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Biros MH, 1996, AM J EMERG MED, V14, P27, DOI 10.1016/S0735-6757(96)90008-X; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; GUELDRY S, 1990, STROKE, V21, P1458, DOI 10.1161/01.STR.21.10.1458; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; Hovda D.A., 1996, NEUROTRAUMA, P1459; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Izumi Y, 1998, J CLIN INVEST, V101, P1121, DOI 10.1172/JCI1009; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; KATAYAMA M, 1994, JPEN-PARENTER ENTER, V18, P442, DOI 10.1177/0148607194018005442; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Leino RL, 1999, DEV BRAIN RES, V113, P47, DOI 10.1016/S0165-3806(98)00188-6; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; MARIE C, 1990, METAB BRAIN DIS, V5, P65, DOI 10.1007/BF01001047; MARIE C, 1991, CEREBROVAS BRAIN MET, V3, P29; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; MOORE TJ, 1976, AM J PHYSIOL, V230, P619, DOI 10.1152/ajplegacy.1976.230.3.619; NEDERGAARD M, 1987, ACTA NEUROPATHOL, V73, P131, DOI 10.1007/BF00693778; NEHLIG A, 1991, NEUROSCIENCE, V40, P871, DOI 10.1016/0306-4522(91)90018-J; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Ritter AM, 1996, J NEUROTRAUM, V13, P473, DOI 10.1089/neu.1996.13.473; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Slator, 1969, ENERGY LEVEL METABOL, P329; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Suzuki M, 2002, JPN J PHARMACOL, V89, P36, DOI 10.1254/jjp.89.36; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; Veech RL, 2001, IUBMB LIFE, V51, P241; VOLL CL, 1991, J CEREBR BLOOD F MET, V11, P1006, DOI 10.1038/jcbfm.1991.168; YAGER JY, 1992, PEDIATR RES, V31, P138, DOI 10.1203/00006450-199202000-00009; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	50	136	137	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV 1	2005	82	3					413	420		10.1002/jnr.20633			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	983GC	WOS:000233218400012	16180224				2022-02-06	
J	Vaynman, S; Ying, Z; Gomez-Pinilla, F				Vaynman, S; Ying, Z; Gomez-Pinilla, F			Exercise induces BDNF and synapsin I to specific hippocampal subfields	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						exercise; hippocampus; circuitry; BDNF; synapsin I; immunohistochemistry	LONG-TERM POTENTIATION; MESSENGER-RNA EXPRESSION; TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; PHYSICAL-ACTIVITY; COGNITIVE FUNCTION; RAT; SLICES; LOCALIZATION; PERFORMANCE	To assess the relationship between brain-derived neurotrophic factor (BDNF) and synapsin I in the hippocampus during exercise, we employed a novel microsphere injection method to block the action of BDNF through its tyrosine kinase (Trk) receptor and subsequently measure the mRNA levels of synapsin I, using real-time TaqMan RT-PCR for RNA quantification. After establishing a causal link between BDNF and exercise-induced synapsin I mRNA levels, we studied the exercise-induced distribution of BDNF and synapsin I in the rodent hippocampus. Quantitative immunohistochemical analysis revealed increases of BDNF and synapsin I in CA3 stratum lucidum and dentate gyrus, and synapsin I alone in CA1 stratum radiatum and stratum laconosum moleculare. These results indicate that exercise induces plasticity of select hippocampal transsynaptic circuitry, possibly comprising a spatial restriction on synapsin I regulation by BDNF. (C) 2004 Wiley-Liss, Inc.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA USA		Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	Fgomezpi@ucla.edu	Vaynman, Semyon/B-7538-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038978, R01NS039522] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39522, NS 38978] Funding Source: Medline		Adams B, 1997, BRAIN RES, V775, P193, DOI 10.1016/S0006-8993(97)01061-5; Akagi S, 1996, HISTOCHEM CELL BIOL, V105, P365, DOI 10.1007/BF01463657; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Connor B, 1997, MOL BRAIN RES, V49, P71, DOI 10.1016/S0169-328X(97)00125-3; Ferreira A, 1998, MOL MED, V4, P22, DOI 10.1007/BF03401726; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; FORDYCE DE, 1991, BEHAV BRAIN RES, V46, P123, DOI 10.1016/S0166-4328(05)80105-6; GEDDES JW, 1986, BRAIN RES, V399, P156, DOI 10.1016/0006-8993(86)90611-6; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Haubensak W, 1998, J CELL SCI, V111, P1483; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kim YH, 2001, NEUROREPORT, V12, P3243, DOI 10.1097/00001756-200110290-00020; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lom B, 1999, J NEUROSCI, V19, P9928; Lu B, 1997, REV NEUROSCIENCE, V8, P1; Mattson MP, 2000, BRAIN RES, V886, P47, DOI 10.1016/S0006-8993(00)02790-6; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; Messaoudi E, 1998, J NEUROPHYSIOL, V79, P496, DOI 10.1152/jn.1998.79.1.496; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Morimoto K, 1998, BRAIN RES, V783, P57, DOI 10.1016/S0006-8993(97)01154-2; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Nguyen PV, 1996, J NEUROSCI, V16, P3189; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; QUATTROCHI JJ, 1989, SCIENCE, V245, P984, DOI 10.1126/science.2475910; Riddle DR, 1997, BIOTECHNIQUES, V23, P928, DOI 10.2144/97235rr02; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Rocamora N, 1996, J NEUROSCI, V16, P4411; SAMORAJSKI T, 1985, NEUROBIOL AGING, V6, P17, DOI 10.1016/0197-4580(85)90066-1; Sato K, 2000, BRAIN RES, V872, P219, DOI 10.1016/S0006-8993(00)02460-4; Scharfman HE, 1999, J NEUROSCI, V19, P5619; Scharfman HE, 1997, J NEUROPHYSIOL, V78, P1082, DOI 10.1152/jn.1997.78.2.1082; Suemaru S, 2000, NEUROREPORT, V11, P1319, DOI 10.1097/00001756-200004270-00034; SUOMINENTROYER S, 1986, PERCEPT MOTOR SKILL, V62, P71, DOI 10.2466/pms.1986.62.1.71; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Watanabe Y, 1998, DISABIL REHABIL, V20, P62, DOI 10.3109/09638289809166055; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Zurmohle U, 1996, EXP BRAIN RES, V108, P441	51	136	144	2	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2004	76	3					356	362		10.1002/jnr.20077			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817NB	WOS:000221183100009	15079864				2022-02-06	
J	Huisman, TAGM				Huisman, TAGM			Diffusion-weighted imaging: basic concepts and application in cerebral stroke and head trauma	EUROPEAN RADIOLOGY			English	Article						diffusion-weighted imaging; apparent diffusion coefficient; fractional anisotropy; cerebral ischemia; traumatic brain injury	MAGNETIC-RESONANCE; TIME-COURSE; ARTERY OCCLUSION; AXONAL INJURY; MR; BRAIN; PERFUSION; TISSUE; ISCHEMIA; ANISOTROPY	Diffusion-weighted imaging (DWI) of the brain represents a new imaging technique that extends imaging from depiction of neuroanatomy to the level of function and physiology. DWI measures a fundamentally different physiological parameter compared with conventional MRI. Image contrast is related to differences in the diffusion rate of water molecules rather than to changes in total tissue water. DWI can reveal pathology in cases where conventional MRI remains unremarkable. DWI has proven to be highly sensitive in the early detection of acute cerebral ischemia and seems promising in the evaluation of traumatic brain injury. DWI can differentiate between lesions with decreased and increased diffusion. In addition, full-tensor DWI can evaluate the microscopic architecture of the brain, in particular white matter tracts, by measuring the degree and spatial distribution of anisotropic diffusion within the brain. This article reviews the basic concepts of DWI and its application in cerebral ischemia and traumatic brain injury.	Univ Zurich, Childrens Hosp, Dept Radiol, CH-8032 Zurich, Switzerland; Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Sect, Boston, MA 02129 USA; Massachusetts Gen Hosp, MGH NMR Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA		Huisman, TAGM (corresponding author), Univ Zurich, Childrens Hosp, Dept Radiol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	thierry.huisman@kispi.unizh.ch					ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Chu K, 2001, ARCH NEUROL-CHICAGO, V58, P1569, DOI 10.1001/archneur.58.10.1569; Copen WA, 2001, RADIOLOGY, V221, P27, DOI 10.1148/radiol.2211001397; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HEISS WD, 1994, J CEREBR BLOOD F MET, V14, P892, DOI 10.1038/jcbfm.1994.120; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; HUISMAN TAG, 2002, 40 ANN M S AM SOC NE, P57; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Keller E, 1999, STROKE, V30, P1144, DOI 10.1161/01.STR.30.5.1144; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lovblad KO, 2001, CEREBROVASC DIS, V11, P169, DOI 10.1159/000047634; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; Makris N, 1997, ANN NEUROL, V42, P951, DOI 10.1002/ana.410420617; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; Marks MP, 1996, RADIOLOGY, V199, P403, DOI 10.1148/radiology.199.2.8668785; MATSUMOTO K, 1995, AM J NEURORADIOL, V16, P1107; Melhem ER, 2000, AM J NEURORADIOL, V21, P1813; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Meyer JR, 2000, AM J NEURORADIOL, V21, P1821; MOHR JP, 1995, STROKE, V26, P807, DOI 10.1161/01.STR.26.5.807; NOMURA Y, 1994, AM J NEURORADIOL, V15, P231; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; QUAST MJ, 1993, MAGN RESON IMAGING, V11, P465, DOI 10.1016/0730-725X(93)90465-P; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rordorf G, 1998, STROKE, V29, P939, DOI 10.1161/01.STR.29.5.939; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SCHAEFER PW, 2002, 40 ANN M S AM SOC NE, P287; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; Schlaug G, 1999, NEUROLOGY, V53, P1528, DOI 10.1212/WNL.53.7.1528; Schwamm LH, 1998, STROKE, V29, P2268, DOI 10.1161/01.STR.29.11.2268; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; SORENSEN AG, 1996, MAGNETIC RESONANCE I, P1501; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Symon L, 1980, Acta Neurol Scand Suppl, V78, P175; Tuch DS, 2001, P NATL ACAD SCI USA, V98, P11697, DOI 10.1073/pnas.171473898; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; Wedeen VJ, 2000, P INT SOC MAGN RES M, V8, P82; WIMBERGER DM, 1995, J COMPUT ASSIST TOMO, V19, P28, DOI 10.1097/00004728-199501000-00005; Wu O, 2001, STROKE, V32, P933, DOI 10.1161/01.STR.32.4.933; WU O, 2000, P 8 SCI M INT SOC MA, P778; Yoshiura T, 2001, MAGNET RESON MED, V45, P734, DOI 10.1002/mrm.1100	55	136	144	0	9	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	OCT	2003	13	10					2283	2297		10.1007/s00330-003-1843-6			15	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	729TU	WOS:000185791000010	14534804	Green Submitted, Green Accepted			2022-02-06	
J	Hains, BC; Black, JA; Waxman, SG				Hains, BC; Black, JA; Waxman, SG			Primary cortical motor neurons undergo apoptosis after axotomizing spinal cord injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						cell death; motor cortex; locomotor; paralysis; neuronal survival; neurotrauma	RAT CORTICOSPINAL NEURONS; PROGRAMMED CELL-DEATH; PARTIAL FUNCTIONAL RECOVERY; NEURITE GROWTH-INHIBITORS; ADULT-RAT; RUBROSPINAL NEURONS; IN-VIVO; NERVOUS-SYSTEM; RED NUCLEUS; WALLERIAN DEGENERATION	Spinal cord injury (SCI) results in loss of voluntary motor control followed by incomplete recovery, which is partly mediated by the descending corticospinal tract (CST). This system is an important target for therapeutic repair strategies after SCI; however, the question of whether apoptotic cell death occurs in these axotomized neurons remains unanswered. In this study, adult (150-175 g) male Sprague-Dawley rats underwent T9 transection of the dorsal funiculus, which axotomizes the dorsal CST, and introduction of the retrograde tracer Fluoro-Gold into the lesion site. Primary motor cortex (M1) was then examined for evidence of apoptosis weekly for 4 weeks after injury. Axotomized pyramidal cells, identified by retrograde transport of Fluoro-Gold, were found in M1 (57.5 +/- 9.6/median section, 6,127 +/- 292 total), and a significant proportion were terminal deoxynucleotidyl transferase (TdT) -mediated deoxyuridine triphosphate (dUTP)rhodamine nick end labeling (TUNEL) -positive at 1 week after injury (39.3 +/- 5.6%), compared with animals undergoing sham surgery (1.2 +/- 1.4%). At 2-4 weeks, fewer cells were Fluoro-Gold-positive (24.6 +/- 65.06 to 25.3 +/- 6.4/median section, 2,338 +/- 233 to 2,393 +/- 124 total), of which very few were TUNEL-positive. In TUNEL-positive cells, Hoechst 33342 staining revealed nuclear morphology consistent with apoptosis, chromatin condensation, and formation of apoptotic bodies. Fluoro-Gold-positive cells showed increased caspase-3 and Bax immunoreactivity. Hematoxylin and eosin staining revealed similar nuclear changes and dystrophic cells. Internucleosomal DNA fragmentation was detected by gel electrophoresis at the 1-week time point. Lesioned animals not receiving Fluoro-Gold exhibited the same markers of apoptosis. These results document, for the first time, features of apoptotic cell death in a proportion of axotomized cortical motor neurons after SCI, suggesting that protection from apoptosis may be a prerequisite for regenerative approaches to SCL. (C) 2003 Wiley-Liss, Inc.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Paralyzed Vet Amer Eastern Paralyzed Vet Amer Neu, New Haven, CT 06510 USA; Vet Adm Connecticut Healthcare Syst, Rehabil Res Ctr, West Haven, CT 06516 USA		Waxman, SG (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06510 USA.		Waxman, Stephen/Z-2507-2019	Waxman, Stephen/0000-0001-5718-7177	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007224] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 T32 NS07224] Funding Source: Medline		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Abusaad I, 1999, J COMP NEUROL, V408, P560, DOI 10.1002/(SICI)1096-9861(19990614)408:4<560::AID-CNE9>3.0.CO;2-P; ARONIADOU VA, 1993, J NEUROPHYSIOL, V70, P1553, DOI 10.1152/jn.1993.70.4.1553; Baba N, 1999, BRAIN RES, V827, P122, DOI 10.1016/S0006-8993(99)01315-3; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; BARRON KD, 1988, J NEUROPATH EXP NEUR, V47, P62, DOI 10.1097/00005072-198801000-00008; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Blits P, 2000, EXP NEUROL, V164, P25, DOI 10.1006/exnr.2000.7413; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; Brosamle C, 1997, J COMP NEUROL, V386, P293, DOI 10.1002/(SICI)1096-9861(19970922)386:2<293::AID-CNE9>3.0.CO;2-X; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Cowley KC, 1997, J NEUROPHYSIOL, V77, P247, DOI 10.1152/jn.1997.77.1.247; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DAMATO CJ, 1980, EXP NEUROL, V70, P1, DOI 10.1016/0014-4886(80)90002-3; DeBilbao F, 1996, NEUROSCIENCE, V71, P1111, DOI 10.1016/0306-4522(95)00505-6; Dietz V, 1998, SPINAL CORD, V36, P380, DOI 10.1038/sj.sc.3100590; EIDELBERG E, 1981, EXP BRAIN RES, V43, P101; Elliott EJ, 1997, BRAIN RES, V755, P221, DOI 10.1016/S0006-8993(97)00100-5; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Ferguson IA, 2001, J NEUROSCI METH, V109, P81, DOI 10.1016/S0165-0270(01)00380-6; FERINGA ER, 1984, NEUROLOGY, V34, P1002, DOI 10.1212/WNL.34.8.1002; FERINGA ER, 1985, NEUROSCI LETT, V58, P283, DOI 10.1016/0304-3940(85)90067-9; Frost EE, 1999, CURR BIOL, V9, P1251, DOI 10.1016/S0960-9822(99)80506-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; GOSHGARIAN HG, 1983, J COMP NEUROL, V214, P251, DOI 10.1002/cne.902140303; Grill R, 1997, J NEUROSCI, V17, P5560; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Hadi B, 2000, J NEUROSURG, V93, P266, DOI 10.3171/spi.2000.93.2.0266; Hart AM, 2002, EXP BRAIN RES, V142, P308, DOI 10.1007/s00221-001-0929-0; HICKS SP, 1975, AM J ANAT, V143, P1, DOI 10.1002/aja.1001430102; Hill CE, 2001, EXP NEUROL, V171, P153, DOI 10.1006/exnr.2001.7734; HOLMES G, 1909, BRAIN, V33, P1; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Houweling DA, 1998, EXP NEUROL, V153, P49, DOI 10.1006/exnr.1998.6867; Isenmann S, 1999, CELL DEATH DIFFER, V6, P673, DOI 10.1038/sj.cdd.4400538; Kaneko T, 2000, J COMP NEUROL, V423, P52, DOI 10.1002/1096-9861(20000717)423:1<52::AID-CNE5>3.0.CO;2-F; Kanellopoulos GK, 1997, ANN THORAC SURG, V64, P1279, DOI 10.1016/S0003-4975(97)00903-X; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Katoh K, 1996, NEUROSCI LETT, V216, P9; Kermer P, 1999, FEBS LETT, V453, P361, DOI 10.1016/S0014-5793(99)00747-4; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; KRISHNAN RV, 1980, INT J NEUROSCI, V10, P89, DOI 10.3109/00207458009160486; KUANG RZ, 1990, J COMP NEUROL, V292, P585, DOI 10.1002/cne.902920408; Kwon BK, 2002, EXP NEUROL, V177, P332, DOI 10.1006/exnr.2002.7983; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; LANDRY P, 1984, EXP BRAIN RES, V57, P177; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; LIANG FY, 1993, SOMATOSENS MOT RES, V10, P51, DOI 10.3109/08990229309028823; Liu XZ, 1997, J NEUROSCI, V17, P5395; Liu Y, 1999, J NEUROSCI, V19, P4370; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Loy DN, 2002, J NEUROSCI, V22, P315, DOI 10.1523/JNEUROSCI.22-01-00315.2002; Lu P, 2001, J COMP NEUROL, V436, P456, DOI 10.1002/cne.1080; MCBRIDE RL, 1989, J NEUROPATH EXP NEUR, V48, P568, DOI 10.1097/00005072-198909000-00007; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MIGHELI A, 1995, J PATHOL, V176, P27, DOI 10.1002/path.1711760106; Mori F, 1997, EXP NEUROL, V143, P45, DOI 10.1006/exnr.1996.6318; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; PALLINI R, 1988, J NEUROSURG, V68, P163; Pasikova N V, 2001, Neurosci Behav Physiol, V31, P497, DOI 10.1023/A:1010470730416; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; PRENDERGAST J, 1976, J COMP NEUROL, V166, P163, DOI 10.1002/cne.901660204; Qiu JX, 2001, J NEUROTRAUM, V18, P1267, DOI 10.1089/089771501317095304; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SANNER CA, 1994, J NEUROSCI, V14, P6472; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SCHREYER DJ, 1988, DEV BRAIN RES, V38, P89; Schutte A, 2000, NEUROSCI LETT, V290, P185, DOI 10.1016/S0304-3940(00)01351-3; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; SMOLEN AJ, 1983, J NEUROCYTOL, V12, P739, DOI 10.1007/BF01258148; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; THERIAULT E, 1994, J COMP NEUROL, V342, P249, DOI 10.1002/cne.903420208; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSENG GF, 1993, J COMP NEUROL, V335, P92, DOI 10.1002/cne.903350107; Vanderluit JL, 2000, EUR J NEUROSCI, V12, P3469, DOI 10.1046/j.1460-9568.2000.00241.x; von Meyenburg J, 1998, EXP NEUROL, V154, P583, DOI 10.1006/exnr.1998.6912; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zurita M, 2002, J NEUROSURG, V96, P83, DOI 10.3171/spi.2002.96.1.0083; [No title captured]	93	136	157	0	7	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	JUL 28	2003	462	3					328	341		10.1002/cne.10733			14	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	692EA	WOS:000183646700005	12794736				2022-02-06	
J	Santhakumar, V; Bender, R; Frotscher, M; Ross, ST; Hollrigel, GS; Toth, Z; Soltesz, I				Santhakumar, V; Bender, R; Frotscher, M; Ross, ST; Hollrigel, GS; Toth, Z; Soltesz, I			Granule cell hyperexcitability in the early post-traumatic rat dentate gyrus: the 'irritable mossy cell' hypothesis	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							TEMPORAL-LOBE EPILEPSY; PATCH-CLAMP RECORDINGS; FASCIA-DENTATA; BRAIN INJURY; HIPPOCAMPAL-FORMATION; GABAERGIC INHIBITION; HILAR NEURONS; HEAD TRAUMA; INTERNEURONS; DENDRITES	1. Cytochemical and in vitro whole-cell patch clamp techniques were used to investigate granule cell hyperexcitability in the dentate gyrus 1 week after fluid percussion head trauma. 2. The percentage decrease in the number of hilar interneurones labelled with either GAD67 or parvalbumin mRNA probes following trauma was not different from the decrease in the total population of hilar cells, indicating no preferential survival of interneurones with respect to the non-GABAergic hilar cells, i.e. the mossy cells. 3. Dentate granule cells following trauma showed enhanced action potential discharges, and longer-lasting depolarizations, in response to perforant path stimulation, in the presence of the GABA, receptor antagonist bicuculline. 4. There was no post-traumatic alteration in the perforant path-evoked monosynaptic excitatory postsynaptic currents (EPSCs), or in the intrinsic properties of granule cells. However, after trauma, the monosynaptic EPSC was followed by late, polysynaptic EPSCs, which were not present in controls. 5. The late EPSCs in granule cells from fluid percussion-injured rats were not blocked by the NMDA receptor antagonist 2-amino-5-phosphonovaleric acid (APV), but were eliminated by both the non-NMDA glutamate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and the AMPA receptor antagonist GYKI 53655. 6. In addition, the late EPSCs were not present in low (0.5 mM) extracellular calcium, and they were also eliminated by the removal of the dentate hilus from the slice. 7. Mossy hilar cells in the traumatic dentate gyrus responded with significantly enhanced, prolonged trains of action potential discharges to perforant path stimulation. 8. These data indicate that surviving mossy cells play a crucial role in the hyperexcitable responses of the post-traumatic dentate gyrus.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92697 USA; Univ Freiburg, Inst Anat, Freiburg, Germany		Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	isoltesz@uci.edu	Santhakumar, Viji/K-4856-2019; Santhakumar, Vijayalakshmi/M-4192-2013	Santhakumar, Viji/0000-0001-6278-4187; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35916] Funding Source: Medline		AMARAL DG, 1978, J COMP NEUROL, V182, P851, DOI 10.1002/cne.901820508; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bernard C, 1998, EPILEPSY RES, V32, P93, DOI 10.1016/S0920-1211(98)00043-6; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bruton C., 1988, NEUROPATHOLOGY TEMPO; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; BUCKMASTER PS, 1993, J NEUROPHYSIOL, V70, P1281, DOI 10.1152/jn.1993.70.4.1281; Buckmaster PS, 1997, J NEUROPHYSIOL, V77, P2685, DOI 10.1152/jn.1997.77.5.2685; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; CAVAZOS JE, 1992, HIPPOCAMPUS, V2, P363, DOI 10.1002/hipo.450020404; CELIO MR, 1988, CELL CALCIUM, V9, P81, DOI 10.1016/0143-4160(88)90027-9; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; Deller T, 1996, J NEUROSCI, V16, P3322; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EPSTEIN P, 1986, J BIOL CHEM, V261, P5886; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; FROTSCHER M, 1991, J COMP NEUROL, V312, P145, DOI 10.1002/cne.903120111; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; GRADY MS, 1995, ANESTHETIC MANAGEMEN, P87; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412, DOI 10.1152/jn.1996.76.4.2412; Hollrigel GS, 1997, J NEUROSCI, V17, P5119; HOUSER CR, 1994, HIPPOCAMPUS, V4, P530, DOI 10.1002/hipo.450040503; HSU M, 1993, J NEUROSCI, V13, P3964; Jackson MB, 1996, J NEUROPHYSIOL, V76, P601, DOI 10.1152/jn.1996.76.1.601; Jefferys JGR, 1998, EPILEPSY RES, V32, P104, DOI 10.1016/S0920-1211(98)00044-8; JENG JM, 1998, SOC NEUR ABSTR; Jennet B, 1975, EPILEPSY NONMISSILE; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Leranth C, 1996, NEUROSCIENCE, V70, P631, DOI 10.1016/S0306-4522(96)83003-X; LEROUX PD, 1995, ANESTHETIC MANAGEMEN, P1; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lubke J, 1998, J NEUROPHYSIOL, V79, P1518, DOI 10.1152/jn.1998.79.3.1518; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Prince DA, 1998, EPILEPSY RES, V32, P83, DOI 10.1016/S0920-1211(98)00042-4; RempelClower NL, 1996, J NEUROSCI, V16, P5233; ROSS ST, 1999, SOC NEUR ABSTR; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179, DOI 10.1152/jn.1995.74.1.179; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; SCHARFMAN HE, 1992, EPILEPSY RES, P93; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763, DOI 10.1152/jn.1995.73.5.1763; SOLTESZ I, 1994, J NEUROSCI, V14, P2365; SOLTESZ I, 1993, NEUROSCIENCE, V57, P555, DOI 10.1016/0306-4522(93)90005-Z; SORIANO E, 1994, HIPPOCAMPUS, V4, P65, DOI 10.1002/hipo.450040108; Strowbridge BW, 1996, J PHYSIOL-LONDON, V494, P493, DOI 10.1113/jphysiol.1996.sp021508; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Toth Z, 1997, J NEUROSCI, V17, P8106; WILLMORE LJ, 1997, EPILEPSY COMPREHENSI, P1333	61	136	142	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	APR 1	2000	524	1					117	134		10.1111/j.1469-7793.2000.00117.x			18	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	305ZP	WOS:000086571900010	10747187	Bronze, Green Published, Green Submitted			2022-02-06	
J	Nonaka, M; Chen, XH; Pierce, JES; Leoni, MJ; McIntosh, TK; Wolf, JA; Smith, DH				Nonaka, M; Chen, XH; Pierce, JES; Leoni, MJ; McIntosh, TK; Wolf, JA; Smith, DH			Prolonged activation of NF-kappa B following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain atrophy; inflammation; NF-kappa B; p65; traumatic brain injury	NECROSIS-FACTOR-ALPHA; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE SYNTHASE; TRANSCRIPTION FACTOR; ALZHEIMERS-DISEASE; NEUTROPHIL ACCUMULATION; CEREBRAL-ISCHEMIA; ADHESION MOLECULE; SODIUM-SALICYLATE	Activation of transcription factor, nuclear factor kappa B (NF-kappa B), has been shown to play a key role in inflammatory response, neuronal survival and signaling. We investigated the regional and temporal distribution of activated NF-kappa B in rats at 1 h, 2 h, 24 h, 48 h, 1 week, 2 weeks, 1 month, 2 months, 6 months, and 1 year following brain injury in rats. Early after trauma (1-2 h), activated NF-kappa B was detected in axons, and subsequently found in the cytoplasm and nucleus of neurons by 24 h and lasting up to 1 week. In addition, by 24 h posttrauma, activated NF-kappa B was detected in microglia/macrophages and astrocytes in injured cortex. Surprisingly, this activation persisted for at least 1 year following injury in the cortex, primarily at the margins of progressively enlarging ventricle. Activated NF-kappa B was also detected in endothelial cells, as early as 1 h, and persisted for up to 1 year. These results suggest that a neuronal response to brain trauma includes the activation of NF-kappa B first in the axon with subsequent translocation to the nucleus. Furthermore, these results demonstrate;that remarkably prolonged activation of NF-kappa B in glia is found in the same regions undergoing persistent atrophy, suggesting NF-kappa B activation may play a role in long-term inflammatory processes following brain trauma.	Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Med Ctr, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.		Wolf, John A/A-1034-2007; smith, douglas/A-1321-2007	Wolf, John A/0000-0002-6950-2303; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS38104] Funding Source: Medline		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bethea JR, 1998, J NEUROSCI, V18, P3251; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; Gveric D, 1998, J NEUROPATH EXP NEUR, V57, P168, DOI 10.1097/00005072-199802000-00008; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povelones M, 1997, J NEUROSCI, V17, P4915; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Robertson R., 1994, J INT COMMUNICATION, V1, P33, DOI DOI 10.1080/13216597.1994.9751780; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; SCHEINMAN RI, 1995, SCIENCE, V270, P286; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Terai K, 1996, BRAIN RES, V735, P159; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Toulmond S, 1996, TRENDS NEUROSCI, V19, P409; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Whalen MJ, 1998, ACT NEUR S, V71, P212; XIE QW, 1994, J BIOL CHEM, V269, P4705; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	68	136	143	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1023	1034		10.1089/neu.1999.16.1023			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500001	10595819				2022-02-06	
J	Hanks, RA; Rapport, LJ; Millis, SR; Deshpande, SA				Hanks, RA; Rapport, LJ; Millis, SR; Deshpande, SA			Measures of executive functioning as predictors of functional ability and social integration in a rehabilitation sample	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; SEVERE HEAD TRAUMA; PREMORBID INTELLIGENCE; INDEPENDENCE MEASURE; PRACTICAL SCALE; STROKE PATIENTS; WORKING-MEMORY; READING TEST	Objective: To examine the utility of executive function tests in predicting rehabilitation outcome. Design: A prospective, descriptive study of the value of neuropsychologic and motor functioning measures in the prediction of functional outcome 6 months after acute rehabilitation. Setting: A Midwestern, urban, university-affiliate rehabilitation hospital. Patients: Ninety consecutive admissions to traumatic brain injury, orthopedic, and spinal cord injury units. Age of the participants ranged from 17 to 73. Main Outcome Measures: Community Integration Questionnaire (CIQ), Disability Rating Scale (DRS), SF-36 Health Survey. Results: Canonical correlation analyses indicated that measures of executive functioning and verbal memory were strongly related to measures of functional outcome 6 months after rehabilitation, as measured by the DRS and the CIQ. In contrast, perceived health status as measured by the SF-36 was highly related to estimated premorbid IQ and:modestly related to visuospatial impairment. Conclusions: Executive functioning, verbal memory,:and estimated premorbid intelligence predict functional dependence after discharge from rehabilitation beyond information regarding basic sensory and motor skills. Moreover, there is a dissociation between measures of functional outcome, such that objective and behaviorally oriented measures of disability (CIQ and DRS) are strongly related to each other; however, they are not related to perceptions of general health status (SF-36). (C) 1994 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA		Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, 261 Mack Ave,Suite 555, Detroit, MI 48201 USA.			Rapport, Lisa/0000-0001-8014-9523			Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; COPE DN, 1982, HEAD INJURY REHAB PR, V1; CREWE NM, 1987, REHABIL PSYCHOL, P3; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Felton J S, 1965, Arch Phys Med Rehabil, V46, P809; Fuster J., 1989, PREFRONTAL CORTEX AN; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GOLDMANRAKIC PS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P72; GRANT I, 1987, NEUROBEHAVIORAL RECO, P236; Hair JF, 1995, MULTIVARIATE DATA AN; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hamsher K., 1989, MULTILINGUAL APHASIA; Heaton R. K., 1982, MANUAL CARD SORTING; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Kosasih JB, 1998, ARCH PHYS MED REHAB, V79, P670, DOI 10.1016/S0003-9993(98)90042-9; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Lai SM, 1998, NEUROEPIDEMIOLOGY, V17, P21, DOI 10.1159/000026150; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LEVIN HS, 1990, J NERV MENT DIS, V178, P282; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; PECK EA, 1989, TXB HEAD INJURY, P378; Poduri KR, 1996, INT J REHABIL RES, V19, P111, DOI 10.1097/00004356-199606000-00002; PONSFORD J, 1995, J INT NEUROPSYCH SOC, V1, P198; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Shallice T, 1993, SUPERVISORY CONTROL, P171; Spilker B., 1996, QUALITY LIFE PHARMAC, P337; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; Stewart AL, 1992, MEASURING FUNCTIONIN; STEWART D, 1968, PSYCHOL BULL, V70, P160, DOI 10.1037/h0026143; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TEASDALE G, 1974, LANCET, V2, P81; Vangel SJ, 1997, REHABIL PSYCHOL, V42, P147; Wechsler D., 1997, MANUAL WECHSLER ADUL; Weschler D. A., 1987, WECHSLER MEMORY SCAL; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wolfson, 1993, HALSTEAD REITAN NEUR; [No title captured]	62	136	138	1	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1999	80	9					1030	1037		10.1016/S0003-9993(99)90056-4			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	234ZZ	WOS:000082515400009	10489004				2022-02-06	
J	Kelly, DF; Goodale, DB; Williams, J; Herr, DL; Chappell, ET; Rosner, MJ; Jacobson, J; Levy, ML; Croce, MA; Maniker, AH; Fulda, GJ; Lovett, JV; Mohan, O; Narayan, RK				Kelly, DF; Goodale, DB; Williams, J; Herr, DL; Chappell, ET; Rosner, MJ; Jacobson, J; Levy, ML; Croce, MA; Maniker, AH; Fulda, GJ; Lovett, JV; Mohan, O; Narayan, RK			Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial	JOURNAL OF NEUROSURGERY			English	Article						propofol; traumatic brain injury; intracranial hypertension; neuroprotection	CEREBRAL BLOOD-FLOW; ISCHEMIA-REPERFUSION INJURY; INTENSIVE-CARE UNIT; INTRACRANIAL-PRESSURE; HIPPOCAMPAL-NEURONS; PERFUSION-PRESSURE; ICU PATIENTS; SEDATION; ANESTHESIA; INFUSION	Object. Sedation regimens for head-injured patients are quite variable. The short-acting sedative-anesthetic agent propofol is being increasingly used in such patients, yet little is known regarding its safety and efficacy. In this multicenter double-blind trial, a titratable infusion of 2% propofol accompanied by low-dose morphine for analgesia was compared with a regimen of morphine sulfate in intubated head-injured patients. In both groups, other standard measures of controlling intracranial pressure (ICP) were also used. Methods. Forty-two patients from 11 centers were evaluated to assess both the safety and efficacy of propofol: 23 patients in the propofol group (mean time of propofol usage 95 +/- 87 hours) and 19 patients in the morphine group (mean time of morphine usage 70 +/- 54 hour;). There was a higher incidence of poor prognostic indicators in the propofol group than in the morphine group: patient age older than 55 years (30.4% compared with 10.5%. p < 0.05), initial Glasgow Coma Scale scores of 3 to 5 (39.1% compared with 15.8%, p < 0.05), compressed or absent cisterns on initial computerized tomography scanning (78.3% compared with 57.9% p < 0.05), early hypotension and/or hypoxia (26.1% compared with 10.5%, p = 0.07). During treatment there was a trend toward greater use of vasopressors in the propofol group. However, the mean daily ICP and cerebral perfusion pressure were generally similar between groups and, on therapy Day 3, ICP was lower in the propofol group compared with the morphine group (p < 0.05). Additionally, there was less use of neuromuscular blocking agents, benzodiazepines, pentobarbital, and cerebrospinal fluid drainage in the propofol group (p < 0.05). At 6 months postinjury, a favorable outcome (good recovery or moderate disability) was observed in 52.1% of patients receiving propofol and in 47.4% receiving morphine. the mortality rates were 17.4% and 21.1%, respectively. Patients who received the highest doses of propofol for the longest duration tended to have the best outcomes. There were no significant differences between groups in terms of adverse events. Conclusions. Despite a higher incidence of poor prognostic indicators in the propofol group, ICP therapy was less intensive, ICP was lower on therapy Day 3, and long-term outcome was similar to that of the morphine soup. These results suggest that a propofol-based sedation and an ICP control regimen is a safe, acceptable, and, possibly, desirable alternative to an opiate-based sedation regimen in intubated head-injured patients.	Univ Calif Los Angeles, Med Ctr, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif, Harbor Med Ctr, Torrance, CA USA; Washington Hosp Ctr, Washington, DC 20010 USA; Univ Calif Davis E Bay, Oakland, CA USA; Univ Alabama Hosp & Clin, Birmingham, AL USA; New Jersey Med Sch & Hosp, Newark, NJ USA; Univ Med Ctr, Las Vegas, NV USA; Univ So Calif, Los Angeles, CA USA; Med Ctr Delaware, Newark, DE USA; Univ Tennessee, Med Ctr, Memphis, TN USA; Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA		Kelly, DF (corresponding author), Univ Calif Los Angeles, Med Ctr, Div Neurosurg, Room 18-218A,NPI,Box 957039, Los Angeles, CA 90095 USA.	dfkelly@ucla.edu	Herr, Daniel/X-4215-2019	Herr, Daniel/0000-0001-8533-9000			AARTS L, 1995, FEBS LETT, V357, P83, DOI 10.1016/0014-5793(94)01337-Z; ALBANESE J, 1990, ANESTHESIOLOGY, V73, P214, DOI 10.1097/00000542-199008000-00004; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; AMORIM P, 1995, ANESTHESIOLOGY, V83, P1254, DOI 10.1097/00000542-199512000-00016; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAILIE GR, 1992, BRIT J ANAESTH, V68, P486, DOI 10.1093/bja/68.5.486; BARR J, 1995, INT ANESTHESIOL CLIN, V33, P131, DOI 10.1097/00004311-199500000-00008; Borgeat A, 1997, EUR J ANAESTH, V14, P17, DOI 10.1097/00003643-199705001-00004; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOYLE W A, 1990, Anesthesiology (Hagerstown), V73, pA245; Buckley PM, 1997, INTENS CARE MED, V23, P969, DOI 10.1007/s001340050440; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHESNUT RM, 1993, HEAD INJURY, P225; DAM M, 1990, ANESTHESIOLOGY, V73, P499, DOI 10.1097/00000542-199009000-00021; DERIU PL, 1992, BRIT J ANAESTH, V69, P177, DOI 10.1093/bja/69.2.177; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FARLING PA, 1989, ANAESTHESIA, V44, P222, DOI 10.1111/j.1365-2044.1989.tb11228.x; FELLOWS IW, 1983, BRIT MED J, V287, P1835, DOI 10.1136/bmj.287.6408.1835; FOSTER S J, 1989, Journal of Drug Development, V2, P73; FULTON B, 1995, DRUGS, V50, P636, DOI 10.2165/00003495-199550040-00006; Gelb A. W., 1993, Canadian Journal of Anaesthesia, V40, pA68; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GILMAN AG, 1980, GOODMAN GILMANS PHAR, P350; Hans P, 1997, J NEUROSURG ANESTH, V9, P234, DOI 10.1097/00008506-199707000-00006; Hans P, 1996, J NEUROSURG ANESTH, V8, P154, DOI 10.1097/00008506-199604000-00010; HANS P, 1994, J NEUROSURG ANESTH, V6, P249; HARA M, 1994, ANESTHESIOLOGY, V81, P988, DOI 10.1097/00000542-199410000-00026; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412, DOI 10.1152/jn.1996.76.4.2412; ILLIEVICH UM, 1993, ANESTH ANALG, V77, P155; JENNETT B, 1975, LANCET, V1, P480; Kahraman S, 1997, BRIT J ANAESTH, V78, P279, DOI 10.1093/bja/78.3.279; KOCHS E, 1992, ANESTHESIOLOGY, V76, P245, DOI 10.1097/00000542-199202000-00014; Lauer KK, 1997, CAN J ANAESTH, V44, P929, DOI 10.1007/BF03011963; LEVY ML, 1995, NEUROSURGERY, V37, P363, DOI 10.1227/00006123-199508000-00035; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; MERGAERT C, 1991, EUR J ANAESTH, V8, P324; MOORE RA, 1985, ANAESTHESIA, V40, P124; MOSS E, 1990, BRIT J ANAESTH, V65, P823, DOI 10.1093/bja/65.6.823; MURPHY PG, 1992, BRIT J ANAESTH, V68, P613, DOI 10.1093/bja/68.6.613; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; NOWACK WJ, 1994, CLIN ELECTROENCEPHAL, V25, P110, DOI 10.1177/155005949402500308; ORSER BA, 1995, BRIT J PHARMACOL, V116, P1761, DOI 10.1111/j.1476-5381.1995.tb16660.x; PAPAZIAN L, 1993, BRIT J ANAESTH, V71, P267, DOI 10.1093/bja/71.2.267; RAMANI R, 1992, J NEUROSURG ANESTH, V4, P110, DOI 10.1097/00008506-199204000-00006; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAVUSSIN P, 1991, J NEUROSURG ANESTH, V3, P85, DOI 10.1097/00008506-199106000-00002; RONAN KP, 1995, CRIT CARE MED, V23, P286, DOI 10.1097/00003246-199502000-00014; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; SHAFER SL, 1993, J CLIN ANESTH, V5, pS14; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; STEWART L, 1994, ACTA NEUROCHIR, P544; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; SUTHERLAND MJ, 1994, ANAESTH INTENS CARE, V22, P733, DOI 10.1177/0310057X9402200620; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Vandesteene A, 1988, Anaesthesia, V43 Suppl, P42, DOI 10.1111/j.1365-2044.1988.tb09067.x; VANHEMELRIJCK J, 1990, ANESTH ANALG, V71, P49; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WEINSTABL C, 1991, ANAESTHESIA, V46, P837, DOI 10.1111/j.1365-2044.1991.tb09596.x; Weir D L, 1989, J Neurosurg Anesthesiol, V1, P284, DOI 10.1097/00008506-198909000-00014; WOOD PR, 1988, LANCET, V1, P480; YOUNG W, 1996, NEUROTRAUMA, P1075; Young Y, 1997, EUR J ANAESTH, V14, P320, DOI 10.1046/j.1365-2346.1997.00130.x	72	136	139	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	1999	90	6					1042	1052		10.3171/jns.1999.90.6.1042			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	198PK	WOS:000080433000009	10350250				2022-02-06	
J	Kant, R; Duffy, JD; Pivovarnik, A				Kant, R; Duffy, JD; Pivovarnik, A			Prevalence of apathy following head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; RELIABILITY; VALIDITY; SCALE	Although several studies have examined the demographics of mood disorders and personality changes following closed head injury (CHI), there are no studies that address the prevalence of apathy after CHI. Utilizing standardized evaluation tools, this study examines the prevalence of apathy in 83 consecutive patients seen in a neuropsychiatric clinic. A total of 10.84% had apathy without depression while an equal number were depressed without apathy; another 60% of patients exhibited both apathy and depression. Younger patients were more likely to be apathetic than older patients who were more Likely to be depressed and apathetic. Patients with severe injury were more likely to exhibit apathy alone. Family members rated the patients higher on apathy scale. These findings suggest that apathy is a frequent symptom alter head injury and may occur either alone or in association with depression.	Head Injury Clin, Pittsburgh, PA 15224 USA; Univ Connecticut, Ctr Hlth, Dept Psychiat, Farmington, CT 06032 USA; Western Psychiat Inst & Clin, Dept Social Work, Pittsburgh, PA USA		Kant, R (corresponding author), Head Injury Clin, 4608 Penn Ave, Pittsburgh, PA 15224 USA.						BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; COLLINS JG, 1990, VITAL HLTH STAT S 10, V175; Epstein Richard S., 1994, P285; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; HILLBOM E, 1960, Acta Psychiatr Scand Suppl, V35, P1; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Silver Jonathan M., 1994, P313; Smeltzer Donald J., 1994, P251; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Stuss D., 1991, AWARENESS DEFICIT BR, P63; TEASDALE G, 1974, LANCET, V2, P81	16	136	140	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1998	12	1					87	92		10.1080/026990598122908			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	YT347	WOS:000071592500010	9483342				2022-02-06	
J	Corrigan, JD; SmithKnapp, K; Granger, CV				Corrigan, JD; SmithKnapp, K; Granger, CV			Validity of the functional independence measure for persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							ASSESSMENT SCALES; HEAD-INJURY	Objective: Replicate and extend studies of the construct validity of the Functional Independence Measure (FLM) for persons with traumatic brain injury (TBI). Design: A cross-sectional study of admissions to acute rehabilitation evaluated 6 months to 5 years after discharge. Setting: An inpatient brain injury rehabilitation unit in a large, academic medical center. Subjects: Ninety-five patients with primary diagnosis of TBI stratified by time postdischarge. Main Outcome Measures: Prediction of (1) average daily minutes of assistance and (2) supervision required in comparison to the Sickness Impact Profile (SIP) and SF-36. Results: The FIM was highly predictive of minutes of assistance (83% accuracy), supervision (82% accuracy), and the need for either type of assistance (78% accuracy). Prediction was only minimally improved by measures of neurobehavioral impairment. The accuracy of the FLM was superior to the SIP and SF-36. Conclusions: Results provided substantial support for the validity of the FLM as a measure of functional independence for persons with TBI. The importance of supervision as a type of assistance required after TBI was evident, with the FLM highly predictive of this need, as well. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	OHIO STATE UNIV,DEPT PHYS MED & REHABIL,COLUMBUS,OH 43210; MED COLL OHIO,DEPT PHYS MED & REHABIL,TOLEDO,OH 43699; SUNY BUFFALO,DEPT REHABIL MED,BUFFALO,NY 14260				Corrigan, John D./E-2921-2011				BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, NEUROREHABILITATION, V5, P205, DOI 10.3233/NRE-1995-5303; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HOSMER DW, 1988, APPL LOGISTIC REGRES; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JACOBS HE, 1990, J HEAD TRAUMA REHAB, V5, P1; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; *NO CAL NEUR GROUP, 1988, MAN NEUR COGN STAT E; PRIGATANO G, 1991, AWARENESS DENIAL BRA; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	20	136	137	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1997	78	8					828	834		10.1016/S0003-9993(97)90195-7			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	XQ791	WOS:A1997XQ79100008	9344301				2022-02-06	
J	DRAGUNOW, M; GOULDING, M; FAULL, RLM; RALPH, R; MEE, E; FRITH, R				DRAGUNOW, M; GOULDING, M; FAULL, RLM; RALPH, R; MEE, E; FRITH, R			INDUCTION OF C-FOS MESSENGER-RNA AND PROTEIN IN NEURONS AND GLIA AFTER TRAUMATIC BRAIN INJURY - PHARMACOLOGICAL CHARACTERIZATION	EXPERIMENTAL NEUROLOGY			English	Article									UNIV AUCKLAND,SCH MED,DEPT MOLEC & CELLULAR BIOL,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,SCH MED,DEPT NEUROSURG,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,SCH MED,DEPT NEUROPHYSIOL,AUCKLAND,NEW ZEALAND		DRAGUNOW, M (corresponding author), UNIV AUCKLAND,SCH MED,DEPT ANAT,AUCKLAND,NEW ZEALAND.			Faull, Richard/0000-0003-3385-9498			AMEMORI T, 1987, NEUROSCIENCE, V22, P29, DOI 10.1016/0306-4522(87)90195-3; ARENANDER AT, 1989, J NEUROSCI RES, V23, P247, DOI 10.1002/jnr.490230302; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BOLGER GT, 1985, N-S ARCH PHARMACOL, V328, P373, DOI 10.1007/BF00692903; CHANG SL, 1988, BIOCHEM BIOPH RES CO, V157, P698, DOI 10.1016/S0006-291X(88)80306-1; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; Davis LG., 1986, BASIC METHODS MOL BI; DOUGLAS RM, 1988, MOL BRAIN RES, V4, P259, DOI 10.1016/0169-328X(88)90033-2; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; DRAGUNOW M, 1989, BRAIN RES, V501, P382, DOI 10.1016/0006-8993(89)90655-0; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1988, BRAIN RES, V440, P252, DOI 10.1016/0006-8993(88)90993-6; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; DRAGUNOW M, 1990, IN PRESS NEUROSCI BI; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRANZA BR, 1987, ONCOGENE, V1, P213; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG DA, 1987, BRAIN RES, V404, P401, DOI 10.1016/0006-8993(87)91403-X; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KACZMAREK L, 1988, MOL BRAIN RES, V3, P183, DOI 10.1016/0169-328X(88)90064-2; Maniatis T, 1982, MOLECULAR; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; MOCCHETTI I, 1989, P NATL ACAD SCI USA, V86, P3891, DOI 10.1073/pnas.86.10.3891; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; QUIRION R, 1983, NEUROSCI LETT, V36, P267, DOI 10.1016/0304-3940(83)90011-3; ROBERTSON GS, 1989, EUR J PHARMACOL, V159, P99, DOI 10.1016/0014-2999(89)90049-6; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; RUPPERT C, 1987, MOL BRAIN RES, V2, P51, DOI 10.1016/0169-328X(87)90020-9; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SZEKELY AM, 1987, NEUROPHARMACOLOGY, V26, P1779, DOI 10.1016/0028-3908(87)90132-8; WHITE JD, 1987, MOL BRAIN RES, V3, P21, DOI 10.1016/0169-328X(87)90040-4; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	44	136	140	0	6	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	1990	107	3					236	248		10.1016/0014-4886(90)90141-E			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT480	WOS:A1990CT48000006	2106445				2022-02-06	
J	Thibaut, A; Bruno, MA; Ledoux, D; Demertzi, A; Laureys, S				Thibaut, Aurore; Bruno, Marie-Aurelie; Ledoux, Didier; Demertzi, Athena; Laureys, Steven			tDCS in patients with disorders of consciousness	NEUROLOGY			English	Article							DIRECT-CURRENT STIMULATION; PREFRONTAL CORTEX; NETWORKS; STATE; CONNECTIVITY; MODULATION; AWARENESS; CRITERIA; SYSTEM; INJURY	Objective:We assessed the effects of left dorsolateral prefrontal cortex transcranial direct current stimulation (DLPF-tDCS) on Coma Recovery Scale-Revised (CRS-R) scores in severely brain-damaged patients with disorders of consciousness.Methods:In a double-blind sham-controlled crossover design, anodal and sham tDCS were delivered in randomized order over the left DLPF cortex for 20 minutes in patients in a vegetative state/unresponsive wakefulness syndrome (VS/UWS) or in a minimally conscious state (MCS) assessed at least 1 week after acute traumatic or nontraumatic insult. Clinical assessments were performed using the CRS-R directly before and after anodal and sham tDCS stimulation. Follow-up outcome data were acquired 12 months after inclusion using the Glasgow Outcome Scale-Extended.Results:Patients in MCS (n = 30; interval 43 63 mo; 19 traumatic, 11 nontraumatic) showed a significant treatment effect (p = 0.003) as measured by CRS-R total scores. In patients with VS/UWS (n = 25; interval 24 48 mo; 6 traumatic, 19 nontraumatic), no treatment effect was observed (p = 0.952). Thirteen (43%) patients in MCS and 2 (8%) patients in VS/UWS further showed postanodal tDCS-related signs of consciousness, which were observed neither during the pre-tDCS evaluation nor during the pre- or post-sham evaluation (i.e., tDCS responders). Outcome did not differ between tDCS responders and nonresponders.Conclusion:tDCS over left DLPF cortex may transiently improve signs of consciousness in MCS following severe brain damage as measured by changes in CRS-R total scores.Classification of evidence:This study provides Class II evidence that short-duration tDCS of the left DLPF cortex transiently improves consciousness as measured by CRS-R assessment in patients with MCS.	[Thibaut, Aurore; Bruno, Marie-Aurelie; Ledoux, Didier; Demertzi, Athena; Laureys, Steven] Univ Hosp Liege, Coma Sci Grp, Liege, Belgium; [Thibaut, Aurore; Bruno, Marie-Aurelie; Demertzi, Athena; Laureys, Steven] Univ Hosp Liege, Cyclotron Res Ctr, Liege, Belgium; [Thibaut, Aurore; Bruno, Marie-Aurelie; Demertzi, Athena; Laureys, Steven] Univ Hosp Liege, Dept Neurol, Liege, Belgium; [Ledoux, Didier] Univ Hosp Liege, Dept Gen Intens Care, Liege, Belgium		Laureys, S (corresponding author), Univ Hosp Liege, Coma Sci Grp, Liege, Belgium.	steven.laureys@ulg.ac.be	Demertzi, Athena/I-1251-2019; Thibaut, Aurore/U-8101-2019; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Ledoux, Didier/ABA-8401-2021	Demertzi, Athena/0000-0001-8021-3759; Laureys, Steven/0000-0002-3096-3807; Ledoux, Didier/0000-0002-9314-6564	European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James S. McDonnell Foundation; Belgian National Fund for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Concerted Research Action; Public Utility Foundation "Universite Europeenne du Travail"; Fondazione Europea di Ricerca Biomedica	Supported by the European Commission, James S. McDonnell Foundation, Belgian National Fund for Scientific Research (FNRS), Concerted Research Action, and Public Utility Foundation "Universite Europeenne du Travail" and "Fondazione Europea di Ricerca Biomedica." The source of the funding of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. A. T., M.-A. B., D. L., A. D., and S. L. had full access to all the data in the study, and the corresponding author had final responsibility for the decision to submit for publication.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DEVINSKY O, 2004, NEUROLOGY COGNITIVE; Ferrucci R, 2008, NEUROLOGY, V71, P493, DOI 10.1212/01.wnl.0000317060.43722.a3; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2007, EXP NEUROL, V204, P462, DOI 10.1016/j.expneurol.2006.09.019; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Heekeren HR, 2006, P NATL ACAD SCI USA, V103, P10023, DOI 10.1073/pnas.0603949103; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kang EK, 2009, RESTOR NEUROL NEUROS, V27, P645, DOI 10.3233/RNN-2009-0514; Kang EK, 2012, J REHABIL MED, V44, P346, DOI 10.2340/16501977-0947; Keeser D, 2011, J NEUROSCI, V31, P15284, DOI 10.1523/JNEUROSCI.0542-11.2011; Kessler SK, 2012, BRAIN STIMUL, V5, P155, DOI 10.1016/j.brs.2011.02.007; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Monti MM, 2012, ANNU REV CLIN PSYCHO, V8, P431, DOI 10.1146/annurev-clinpsy-032511-143050; Nelson JT, 2014, NEUROIMAGE, V85, P909, DOI 10.1016/j.neuroimage.2012.11.061; Nitsche MA, 2006, EUR J NEUROSCI, V23, P1651, DOI 10.1111/j.1460-9568.2006.04676.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Priori A, 2009, BRAIN STIMUL, V2, P241, DOI 10.1016/j.brs.2009.02.004; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Sturm W, 2001, NEUROIMAGE, V14, pS76, DOI 10.1006/nimg.2001.0839; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021	40	135	152	1	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 1	2014	82	13					1112	1118		10.1212/WNL.0000000000000260			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AH2UN	WOS:000335977100006	24574549				2022-02-06	
J	Acosta, SA; Tajiri, N; Shinozuka, K; Ishikawa, H; Grimmig, B; Diamond, D; Sanberg, PR; Bickford, PC; Kaneko, Y; Borlongan, CV				Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Grimmig, Bethany; Diamond, David; Sanberg, Paul R.; Bickford, Paula C.; Kaneko, Yuji; Borlongan, Cesar V.			Long-Term Upregulation of Inflammation and Suppression of Cell Proliferation in the Brain of Adult Rats Exposed to Traumatic Brain Injury Using the Controlled Cortical Impact Model	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER; ALZHEIMERS-DISEASE; HEAD-INJURY; MICE; NEUROGENESIS; HIPPOCAMPUS; DEPRESSION; DEFICITS; ATROPHY	The long-term consequences of traumatic brain injury (TBI), specifically the detrimental effects of inflammation on the neurogenic niches, are not very well understood. In the present in vivo study, we examined the prolonged pathological outcomes of experimental TBI in different parts of the rat brain with special emphasis on inflammation and neurogenesis. Sixty days after moderate controlled cortical impact injury, adult Sprague-Dawley male rats were euthanized and brain tissues harvested. Antibodies against the activated microglial marker, OX6, the cell cycle-regulating protein marker, Ki67, and the immature neuronal marker, doublecortin, DCX, were used to estimate microglial activation, cell proliferation, and neuronal differentiation, respectively, in the subventricular zone (SVZ), subgranular zone (SGZ), striatum, thalamus, and cerebral peduncle. Stereology-based analyses revealed significant exacerbation of OX6-positive activated microglial cells in the striatum, thalamus, and cerebral peduncle. In parallel, significant decrements in Ki67-positive proliferating cells in SVZ and SGZ, but only trends of reduced DCX-positive immature neuronal cells in SVZ and SGZ were detected relative to sham control group. These results indicate a progressive deterioration of the TBI brain over time characterized by elevated inflammation and suppressed neurogenesis. Therapeutic intervention at the chronic stage of TBI may confer abrogation of these deleterious cell death processes.	[Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Grimmig, Bethany; Sanberg, Paul R.; Bickford, Paula C.; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA; [Grimmig, Bethany; Bickford, Paula C.] James A Haley Vet Affairs Hosp, Tampa, FL USA; [Diamond, David] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Sanberg, Paul R.] Univ S Florida, Off Res & Innovat, Tampa, FL USA		Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012; Kaneko, Yuji/J-6447-2012; Bickford, Paula C/J-5970-2012	Borlongan, Cesar/0000-0002-2966-9782; Bickford, Paula C/0000-0001-9657-7725; Shinozuka, Kazutaka/0000-0002-6435-4460; Ishikawa, Hiroto/0000-0003-0760-7203	Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; University of South Florida Signature Interdisciplinary Program in Neuroscience funds; University of South Florida and Veterans Administration Reintegration Funds; University of South Florida Neuroscience Collaborative Program; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS071956-01A1]; James and Esther King Biomedical Research Foundation [1KG01-33966]; SanBio Inc.; KMPHC; NeuralStem Inc.; National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01]; James and Esther King Foundation for Biomedical Research Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	Financial support for this study was through the Department of Defense W81XWH-11-1-0634, the University of South Florida Signature Interdisciplinary Program in Neuroscience funds, the University of South Florida and Veterans Administration Reintegration Funds, and the University of South Florida Neuroscience Collaborative Program. CVB is funded by the National Institutes of Health 1R01NS071956-01A1, James and Esther King Biomedical Research Foundation 1KG01-33966, SanBio Inc., KMPHC and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; CVB is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke 1R01NS071956-01, Department of Defense W81XWH-11-1-0634, James and Esther King Foundation for Biomedical Research Program, SanBio Inc., KMPHC and NeuralStem Inc. CVB is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bye N, 2010, INJURY S1, V41, pS42; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Faul M, 2010, TRAUMATIC BRAIN INJU; Filley CM, 1998, NEUROLOGY, V50, P1535, DOI 10.1212/WNL.50.6.1535; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Holschneider DP, 2011, J NEUROTRAUM, V28, P1909, DOI 10.1089/neu.2011.1978; Iijima T, 1998, J NEUROTRAUM, V15, P277, DOI 10.1089/neu.1998.15.277; Jia X, 2012, J TRAUMA ACUTE CARE; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Liu CY, 2008, NEUROSURGERY, V63, pN12, DOI 10.1227/01.NEU.0000339457.01711.3B; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Mannix RC, 2012, INT J ALZHEIMERS DIS, V2012; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; MAYHEW TM, 1991, EXP PHYSIOL, V76, P639, DOI 10.1113/expphysiol.1991.sp003533; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Pluchino S, 2008, BRAIN, V131, P2564, DOI 10.1093/brain/awn198; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Roher AE, 2002, BIOCHEMISTRY-US, V41, P11080, DOI 10.1021/bi026173d; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rovegno M, 2012, MED INTENSIVA, V36, P37, DOI 10.1016/j.medin.2011.06.008; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	51	135	136	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2013	8	1							e53376	10.1371/journal.pone.0053376			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	070BE	WOS:000313480000052	23301065	Green Submitted, Green Published, gold			2022-02-06	
J	Andelic, N; Bautz-Holter, E; Ronning, P; Olafsen, K; Sigurdardottir, S; Schanke, AK; Sveen, U; Tornas, S; Sandhaug, M; Roe, C				Andelic, Nada; Bautz-Holter, Erik; Ronning, Pal; Olafsen, Kjell; Sigurdardottir, Solrun; Schanke, Anne-Kristine; Sveen, Unni; Tornas, Sveinung; Sandhaug, Maria; Roe, Cecilie			Does an Early Onset and Continuous Chain of Rehabilitation Improve the Long-Term Functional Outcome of Patients with Severe Traumatic Brain Injury?	JOURNAL OF NEUROTRAUMA			English	Article						early rehabilitation; functional outcome; severe TBI	SEVERE HEAD-INJURY; PREDICTORS; RECOVERY; CARE; POPULATION; PROGRAM; ADULTS; SCALE; COMA	There are currently no international guidelines regarding treatment in the early rehabilitation phase for persons with severe traumatic brain injury (TBI), and only a few studies have investigated the effect of integrating rehabilitation into acute TBI care. The aim of the study was to evaluate whether a continuous chain of rehabilitation that begins with the acute phase could improve the functional outcome of severe TBI patients, compared to a broken chain of rehabilitation that starts in the sub-acute phase of TBI. A total of 61 surviving patients with severe TBI were included in a quasi-experimental study conducted at the Level I trauma center in Eastern Norway. In the study, 31 patients were in the early rehabilitation group (Group A) and 30 patients were in the delayed rehabilitation group (Group B). The functional outcomes were assessed 12 months post-injury with the Glasgow Outcome Scale Extended (GOSE) and the Disability Rating Scale (DRS). A favorable outcome (GOSE 68) occurred in 71% of the patients from Group A versus 37% in Group B (p = 0.007). The DRS score was significantly better in Group A (p = 0.03). The ordinal logistic regression analysis was used to quantify the relationship between the type of rehabilitation chain and the GOSE. A better GOSE outcome was found in patients from Group A (unadjusted OR 3.25 and adjusted OR 2.78, respectively). These results support the hypothesis that better functional outcome occurs in patients who receive early onset and a continuous chain of rehabilitation.	[Andelic, Nada; Bautz-Holter, Erik; Sveen, Unni; Roe, Cecilie] Univ Oslo, Ulleval Hosp, Dept Phys Med & Rehabil, N-0424 Oslo, Norway; [Ronning, Pal] Univ Oslo, Ulleval Hosp, Dept Neurosurg, N-0424 Oslo, Norway; [Olafsen, Kjell] Univ Oslo, Ulleval Hosp, Intens Care Unit, Dept Acute Med, N-0424 Oslo, Norway; [Bautz-Holter, Erik; Roe, Cecilie] Univ Oslo, Fac Med, N-0424 Oslo, Norway; [Schanke, Anne-Kristine] Univ Oslo, Dept Psychol, N-0424 Oslo, Norway; [Sigurdardottir, Solrun; Schanke, Anne-Kristine; Tornas, Sveinung] Sunnaas Rehabil Hosp, Nesoddtangen, Norway; [Sveen, Unni] Oslo Univ Coll, Oslo, Norway; [Sandhaug, Maria] Sorlandet Hosp, Rehabil Clin, Kristiansand, Norway; [Sandhaug, Maria] Agder Univ, Fac Hlth & Sport Sci, Kristiansand, Norway		Andelic, N (corresponding author), Univ Oslo, Ulleval Hosp, Dept Phys Med & Rehabil, N-0424 Oslo, Norway.	Nada.Andelic@oslo-universitetssykehus.no		Andelic, Nada/0000-0002-3719-4406	Norwegian Health South-East Authority	The authors thank all the patients for their participation. Special thanks are given to Tone Jerstad (neuroradiologist, Oslo University Hospital, Ulleval) for the CT assessments and Morten Hestnes (Trauma Register, Oslo University Hospital, Ulleval) for the extraction of trauma scores. This study was supported by grants from the Norwegian Health South-East Authority.	Affolter F, 1981, Int Rehabil Med, V3, P3; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blicher Jakob Udby, 2007, Ugeskr Laeger, V169, P228; BOBATH B, 1959, Physiotherapy, V45, P279; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; Choi JH, 2008, J TRAUMA, V65, P1028, DOI 10.1097/TA.0b013e31815eba9b; Coombes K., 2001, JUBILAUMSSCHRIFT 10; Elliott L, 2005, NEUROPSYCHOL REHABIL, V15, P480, DOI 10.1080/09602010443000506; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Greenwood RJ, 2004, BRIT J NEUROSURG, V18, P462, DOI 10.1080/02688690400012327; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gruner ML, 2000, BRAIN INJURY, V14, P585; Hanoa Rolf, 2008, Tidsskr Nor Laegeforen, V128, P66; Hoffmann B, 2002, ACTA NEUROCHIR SUPPL, V79, P25; Khan S, 2002, BRAIN INJURY, V16, P537, DOI 10.1080/02699050110119862; Kleffelgard I., 2008, BRAIN INJ S, V22, P193; Kompanje EJO, 2007, SCI ENG ETHICS, V13, P371, DOI 10.1007/s11948-007-9027-4; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Lippert-Gruener M, 2007, BRAIN INJURY, V21, P1001, DOI 10.1080/02699050701468933; Lippert-Gruner M, 2007, PHYSIOL RES, V56, P359, DOI 10.33549/physiolres.930971; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Mammi P, 2006, Eura Medicophys, V42, P17; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Oliff HS, 1998, MOL BRAIN RES, V61, P147, DOI 10.1016/S0169-328X(98)00222-8; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Sandhaug M, 2010, BRAIN INJURY, V24, P740, DOI 10.3109/02699051003652849; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skaga NO, 2006, J TRAUMA, V60, P538, DOI 10.1097/01.ta.0000205613.52586.d1; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; TEASDALE G, 1974, LANCET, V2, P81; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; von Wild KRH, 2006, ACTA NEUROCHIR SUPPL, V99, P3; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941; [No title captured]	40	135	140	0	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					66	74		10.1089/neu.2011.1811			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300007	21864138	Green Submitted			2022-02-06	
J	Beckwith, JG; Greenwald, RM; Chu, JJ				Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.			Measuring Head Kinematics in Football: Correlation Between the Head Impact Telemetry System and Hybrid III Headform	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Head impact; Concussion; Biomechanics; Football	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; ACCELERATION; ASSOCIATION; LOCATION; PLAYERS; RISK	Over the last decade, advances in technology have enabled researchers to evaluate concussion biomechanics through measurement of head impacts sustained during play using two primary methods: (1) laboratory reconstruction of open-field head contact, and (2) instrumented helmets. The purpose of this study was to correlate measures of head kinematics recorded by the Head Impact Telemetry (HIT) System (Simbex, NH) with those obtained from a Hybrid III (HIII) anthropometric headform under conditions that mimicked impacts occurring in the NFL. Linear regression analysis was performed to correlate peak linear acceleration, peak rotational acceleration, Gadd Severity Index (GSI), and Head Injury Criterion (HIC15) obtained from the instrumented helmet and HIII. The average absolute location error between instrumented helmet impact location and the direction of HIII head linear acceleration were also calculated. The HIT System overestimated Hybrid III peak linear acceleration by 0.9% and underestimated peak rotational acceleration by 6.1% for impact sites and velocities previously identified by the NFL as occurring during play. Acceleration measures for all impacts were correlated; however, linear was higher (r(2) = 0.903) than rotational (r(2) = 0.528) primarily due to lower HIT System rotational acceleration estimates at the frontal facemask test site. Severity measures GSI and HIC were also found to be correlated, albeit less than peak linear acceleration, with the overall difference between the two systems being less than 6.1% for either measure. Mean absolute impact location difference between systems was 31.2 +/- 46.3 degrees (approximately 0.038 +/- 0.050 m), which was less than the diameter of the impactor surface in the test. In instances of severe helmet deflection (2.54-7.62 cm off the head), the instrumented helmet accurately measured impact location but overpredicted all severity metrics recorded by the HIII. Results from this study indicate that measurements from the two methods of study are correlated and provide a link that can be used to better interpret findings from future study using either technology.	[Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.] Simbex, Lebanon, NH 03766 USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA		Beckwith, JG (corresponding author), Simbex, 10 Water St,Suite 410, Lebanon, NH 03766 USA.	jbeckwith@simbex.com	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, R44HD40743]; Riddell, Inc. (Chicago, IL); National Football League's Committee on Mild Traumatic Brain Injury; HIT System technology; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The authors gratefully acknowledge the funding for this study provided by the National Institutes of Health (R01HD048638). HIT System technology described in this study was developed with support from the National Institutes of Health (R44HD40743 and R01HD048638) and from Riddell, Inc. (Chicago, IL). Helmets and associated hardware were also provided by Riddell, Inc. The study protocol was developed in conjunction with the National Football League's Committee on Mild Traumatic Brain Injury, which provided funding to Biokinetics to operate the linear impactor. Following data collection at the said facility, data from both systems were mutually exchanged. Additional Contributions: David Viano, as co-chairman of the NFL's mTBI Committee at the time of this data collection, approved the initial protocol and funding to Biokinetics, but he did not participate in data collection, analysis, or interpretation of the data. At his request, following primary data collection and analysis by Simbex and Biokinetics, impact sites A ' and A '' were added to the test protocol. These data were collected 7 months after the initial testing. The interpretation of the material presented within this communication is solely that of the authors and not necessarily reflective of the sponsor's views. The authors would like to thank Mr. Chris Withnall and Mr. Michael Wonnacott from Biokinetics and Associates, Ltd who provided technical expertise when needed and assisted with data collection. In addition, the authors would like to thank Joseph Crisco from Brown University for assisting with data interpretation.; Jonathan Beckwith, Jeffrey Chu and Richard Greenwald, as employees or as beneficial owner of Simbex, have a financial interest in the HIT System technology used in this study.	Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beusenberg M., 2001, HEAD NECK BODY COUPL; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Craig M. J., 2007, THESIS WAYNE STATE U; Crisco J. J., 2011, J BIOMECH; Crisco J. J., 2011, J APPL BIOM IN PRESS; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick R, 2007, J ATHL TRAINING, V42, P221; DiMasi F. P., 1982, HS808282 NAT HIGHW T; Duma S., 2004, MEASURING REAL TIME; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; Greenwald R.M., 2009, SEVERITY HEAD IMPACT; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moon D W, 1971, Med Sci Sports, V3, P44; National Research Council, 2006, 08104M04 NAT COMM ST, P1; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Rowson S., 2011, ANN BIOMED IN PRESS; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]	45	135	135	1	32	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		237	248		10.1007/s10439-011-0422-2			12	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700021	21994068	Green Accepted			2022-02-06	
J	Goldfine, AM; Victor, JD; Conte, MM; Bardin, JC; Schiff, ND				Goldfine, Andrew M.; Victor, Jonathan D.; Conte, Mary M.; Bardin, Jonathan C.; Schiff, Nicholas D.			Determination of awareness in patients with severe brain injury using EEG power spectral analysis	CLINICAL NEUROPHYSIOLOGY			English	Article						Consciousness; EEG spectral analysis; Motor imagery; Traumatic brain injury; Locked-in-state; Minimally conscious state	MINIMALLY CONSCIOUS STATE; INDEPENDENT COMPONENT ANALYSIS; FALSE DISCOVERY RATE; LOCKED-IN SYNDROME; SINGLE-TRIAL EEG; VEGETATIVE STATE; MISMATCH NEGATIVITY; OWN NAME; DISORDERS; RECOVERY	Objective: To determine whether EEG spectral analysis could be used to demonstrate awareness in patients with severe brain injury. Methods: We recorded EEG from healthy controls and three patients with severe brain injury, ranging from minimally conscious state (MCS) to locked-in-state (LIS), while they were asked to imagine motor and spatial navigation tasks. We assessed EEG spectral differences from 4 to 24 Hz with univariate comparisons (individual frequencies) and multivariate comparisons (patterns across the frequency range). Results: In controls, EEG spectral power differed at multiple frequency bands and channels during performance of both tasks compared to a resting baseline. As patterns of signal change were inconsistent between controls, we defined a positive response in patient subjects as consistent spectral changes across task performances. One patient in MCS and one in LIS showed evidence of motor imagery task performance, though with patterns of spectral change different from the controls. Conclusions: EEG power spectral analysis demonstrates evidence for performance of mental imagery tasks in healthy controls and patients with severe brain injury. Significance: EEG power spectral analysis can be used as a flexible bedside tool to demonstrate awareness in brain-injured patients who are otherwise unable to communicate. (C) 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Goldfine, Andrew M.] Cornell Univ, Coll Med, Burke Med Res Inst, White Plains, NY 10605 USA; [Goldfine, Andrew M.; Victor, Jonathan D.; Conte, Mary M.; Bardin, Jonathan C.; Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA		Goldfine, AM (corresponding author), Cornell Univ, Coll Med, Burke Med Res Inst, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	andygoldfine@gmail.com		Goldfine, Andrew/0000-0003-1962-5564	NIH-NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [51912]; James S McDonnell Foundation; Weill-Cornell CTSC [UL 1RR02499]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051912] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR002499, UL1RR024996] Funding Source: NIH RePORTER	We thank Hemant Bokil for assistance with the use of the Chronux toolbox and for many helpful conversations on digital signal processing. We thank Jennifer Hersh for assistance with the data collection. This work was supported by NIH-NICHD 51912, the James S McDonnell Foundation, and Weill-Cornell CTSC UL 1RR02499. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Bai O, 2008, J NEURAL ENG, V5, P24, DOI 10.1088/1741-2560/5/1/003; Bai O, 2007, CLIN NEUROPHYSIOL, V118, P2637, DOI 10.1016/j.clinph.2007.08.025; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bokil H, 2007, J NEUROSCI METH, V159, P337, DOI 10.1016/j.jneumeth.2006.07.011; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fins JJ, 2010, HASTINGS CENT REP, V40, P21, DOI 10.1353/hcr.0.0257; Fisher RA, 1936, ANN EUGENIC, V7, P179, DOI 10.1111/j.1469-1809.1936.tb02137.x; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hart T, 2006, ARCH PHYS MED REHAB, V87, P647, DOI 10.1016/j.apmr.2006.01.016; HJORTH B, 1975, ELECTROEN CLIN NEURO, V39, P526, DOI 10.1016/0013-4694(75)90056-5; Hjorth B., 1980, AM J EEG TECHNOL, V20, P121, DOI DOI 10.1080/00029238.1980.11080015; Hung CI, 2005, ANN BIOMED ENG, V33, P1053, DOI 10.1007/s10439-005-5772-1; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Li Y, 2009, NEUROSCI RES, V65, P44, DOI 10.1016/j.neures.2009.05.004; McMenamin BW, 2010, NEUROIMAGE, V49, P2416, DOI 10.1016/j.neuroimage.2009.10.010; Menzer DL, 2010, J NEUROSCI METH, V186, P250, DOI 10.1016/j.jneumeth.2009.11.012; Mitra P, 2007, OBSERVED BRAIN DYNAM; Mitra PP, 1999, BIOPHYS J, V76, P691, DOI 10.1016/S0006-3495(99)77236-X; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Owen AM, 2007, SCIENCE, V315, DOI 10.1126/science.1135583; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Percival D.B., 1993, SPECTRAL ANAL PHYS A; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Qin PM, 2008, NEUROSCI LETT, V448, P24, DOI 10.1016/j.neulet.2008.10.029; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Schwartzman DJ, 2011, INT J PSYCHOPHYSIOL, V79, P73, DOI 10.1016/j.ijpsycho.2010.10.006; Shackman AJ, 2010, NEUROIMAGE, V51, P1319, DOI 10.1016/j.neuroimage.2010.03.037; Smart CM, 2008, NAT CLIN PRACT NEURO, V4, P448, DOI 10.1038/ncpneuro0823; THICKBROOM GW, 1984, ELECTROEN CLIN NEURO, V59, P279, DOI 10.1016/0168-5597(84)90045-5; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; Yuan H, 2010, NEUROIMAGE, V49, P2596, DOI 10.1016/j.neuroimage.2009.10.028	44	135	135	1	31	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	NOV	2011	122	11					2157	2168		10.1016/j.clinph.2011.03.022			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	827VE	WOS:000295456200007	21514214	Green Accepted			2022-02-06	
J	Luethcke, CA; Bryan, CJ; Morrow, CE; Isler, WC				Luethcke, Cynthia A.; Bryan, Craig J.; Morrow, Chad E.; Isler, William C.			Comparison of Concussive Symptoms, Cognitive Performance, and Psychological Symptoms Between Acute Blast-Versus Nonblast-Induced Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Blast injuries; Brain concussion; Brain injuries/psychology; Cognition disorder; Neuropsychological tests; Military personnel	NEUROPSYCHOLOGICAL ASSESSMENT METRICS; US SOLDIERS; IRAQ; AFGHANISTAN; MECHANISMS; TBI	Blast-related head injuries are one of the most prevalent injuries among military personnel deployed in service of Operation Iraqi Freedom. Although several studies have evaluated symptoms after blast injury in military personnel, few studies compared them to nonblast injuries or measured symptoms within the acute stage after traumatic brain injury (TB!). Knowledge of acute symptoms will help deployed clinicians make important decisions regarding recommendations for treatment and return to duty. Furthermore, differences more apparent during the acute stage might suggest important predictors of the long-term trajectory of recovery. This study evaluated concussive, psychological, and cognitive symptoms in military personnel and civilian contractors (N = 82) diagnosed with mild TBI (mTBI) at a combat support hospital in Iraq. Participants completed a clinical interview, the Automated Neuropsychological Assessment Metric (ANAM), PTSD Checklist-Military Version (PCL-M), Behavioral Health Measure (BHM), and Insomnia Severity Index (ISI) within 72 hr of injury. Results suggest that there are few differences in concussive symptoms, psychological symptoms, and neurocognitive performance between blast and nonblast mTBIs, although clinically significant impairment in cognitive reaction time for both blast and nonblast groups is observed. Reductions in ANAM accuracy were related to duration of loss of consciousness, not injury mechanism. (JINS, 2011, 17, 36-45)	[Luethcke, Cynthia A.; Bryan, Craig J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Morrow, Chad E.] Maxwell AFB, MDOS SGOMH 42, Montgomery, AL USA; [Isler, William C.] USAF, Med Operat Agcy, San Antonio, TX USA		Bryan, CJ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7550 W IH-10,Suite 1325, San Antonio, TX 78229 USA.	bryanc3@uthscsa.edu		Bryan, Craig/0000-0002-9714-0733			[Anonymous], 2007, AUT NEUR ASS METR VE; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Defense and Veterans Brain Injury Center [DVBIC], 2009, TBI FACTS; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; DVBIC, 2007, MIL AC CONC EV; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Johnson DR, 2008, ARCH CLIN NEUROPSYCH, V23, P73, DOI 10.1016/j.acn.2007.10.001; Kopta SM, 2002, PSYCHOTHER RES, V12, P413, DOI 10.1093/ptr/12.4.413; Leland A., 2009, AM WAR MILITARY OPER; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Pennardt A., 2009, BLAST INJURIES; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Traumatic Brain Injury Task Force, 2008, REP SURG GEN TRAUM B; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WEATHERS FW, 1993, M INT SOC TRAUM STRE; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	28	135	135	0	25	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2011	17	1					36	45		10.1017/S1355617710001207			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	702KX	WOS:000285894700005	21083963				2022-02-06	
J	Iverson, GL; Lange, RT; Brooks, BL; Rennison, VLA				Iverson, Grant L.; Lange, Rael T.; Brooks, Brian L.; Rennison, V. Lynn Ashton			"Good Old Days" Bias Following Mild Traumatic Brain Injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Post-concussion syndrome; Response bias; Symptom validity testing	POST-CONCUSSION SYMPTOMS; EMOTIONAL RISK-FACTORS; COMPLAINT BASE RATES; HEAD-INJURY; POSTCONCUSSION-SYNDROME; COGNITIVE PERFORMANCE; MISERABLE MINORITY; DIAGNOSIS THREAT; RESPONSE BIAS; CHRONIC PAIN	A small percentage of people with a mild traumatic brain injury (MTBI) report persistent symptoms and problems many months or even years following injury. Preliminary research suggests that people who sustain an injury often underestimate past problems (i.e., ogood old dayso bias), which can impact their perceived level of current problems and recovery. The purpose of this study was to examine the influence of the good old bays bias on symptom reporting following MTBI. The MTBI sample consisted of 90 referrals to a concussion clinic (mean time from injury to evaluation = 2.1 months, SD = 1.5, range = 0.8-8.1). All were considered temporarily fully disabled from an MTBI and they were receiving financial compensation through the Worker's Compensation system. Patients provided post-injury and pre-injury retrospective ratings on the 16-item British Columbia Post-concussion Symptom Inventory (BC-PSI). Ratings were compared to 177 healthy controls recruited from the community and a local university. Consistent with the good old bays bias, MTBI patients retrospectively endorsed the presence of fewer pre-injury symptoms compared to the control group. Individuals who failed effort testing tended to retrospectively report fewer symptoms pre-injury compared to those patients who passed effort testing. Many MTBI patients report their pre-injury functioning as better than the average person. This can negatively impact their perception of current problems, recovery from injury, and return to work.	[Iverson, Grant L.; Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.; Lange, Rael T.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada; [Brooks, Brian L.] Univ Calgary, Calgary, AB, Canada; [Rennison, V. Lynn Ashton] Fraser Hlth Author Concuss Clin, Vancouver, BC, Canada; [Rennison, V. Lynn Ashton] Royal Columbian Hosp, Vancouver, BC, Canada		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1990, PEDIATRICS, V86, P337; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 2013, STAT POWER ANAL BEHA; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Epley N, 2000, J PERS SOC PSYCHOL, V79, P861, DOI 10.1037//0022-3514.79.6.861; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Furnham A, 2004, BRIT J PSYCHOL, V95, P149, DOI 10.1348/000712604773952395; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2002, PSYCHOL ASSESSMENT, V14, P202, DOI 10.1037//1040-3590.14.2.202; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Heilbronner RL, 1993, TRIAL DIPLOMACY J, V16, P161; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hill S. K., 2003, J FORENSIC NEUROPSYC, P1, DOI [10.1300/J151v03n03_01, DOI 10.1300/J151V03N03_01]; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Horner MD, 2006, INT J NEUROSCI, V116, P1181, DOI 10.1080/00207450500514029; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; Kinard EM, 2001, CHILD ABUSE NEGLECT, V25, P33; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Larrabee, 1997, Semin Clin Neuropsychiatry, V2, P196; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LeesHaley PR, 1996, PSYCHOL REP, V79, P811, DOI 10.2466/pr0.1996.79.3.811; LeesHaley PR, 1997, BRAIN INJURY, V11, P791; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; O'Bryant SE, 2008, APPL NEUROPSYCHOL, V15, P113, DOI 10.1080/09084280802083921; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stone CA, 2002, J LEARN DISABIL-US, V35, P370, DOI 10.1177/00222194020350040801; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	100	135	135	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	1					17	37	PII 915817610	10.1080/13854040903190797			21	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535MK	WOS:000272972300002	19830628				2022-02-06	
J	Yu, TS; Zhang, G; Liebl, DJ; Kernie, SG				Yu, Tzong-Shiue; Zhang, Gui; Liebl, Daniel J.; Kernie, Steven G.			Traumatic Brain Injury-Induced Hippocampal Neurogenesis Requires Activation of Early Nestin-Expressing Progenitors	JOURNAL OF NEUROSCIENCE			English	Article						traumatic brain injury; hippocampus; dentate gyrus; neurogenesis; neuroprotection; neuronal progenitor cell	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; ADULT TRANSGENIC MICE; DENTATE GYRUS; REACTIVE ASTROCYTES; PROLIFERATING CELLS; COGNITIVE FUNCTION; WORKING-MEMORY; POSITIVE CELLS; ABLATION	It is becoming increasingly clear that brain injuries from a variety of causes stimulate neurogenesis within the hippocampus. It remains unclear, however, how robust this response may be and what primary cell types are involved. Here, using a controlled cortical impact model of traumatic brain injury on a previously characterized transgenic mouse line that expresses enhanced green fluorescent protein (eGFP) under the control of the nestin promoter, we demonstrate that it is the earliest type-1 quiescent progenitor cells that are induced to proliferate and migrate outside the subgranular layer of the dentate gyrus. This type-1 cell activation occurs at the same time that we observe adjacent but more differentiated doublecortin-expressing progenitors (type-2 cells) being eliminated. Also, although type-2 cells remain intact in the contralateral (uninjured) dentate gyrus, the type-1 cells there are also activated and result in increased numbers of the doublecortin-expressing type-2 cells. In addition, we have generated a novel mouse transgenic that expresses a modified version of the herpes simplex virus thymidine kinase along with eGFP that allows for the visualization and inducible ablation of early dividing progenitors by exposing them to ganciclovir. Using this transgenic in the context of traumatic brain injury, we demonstrate that these early progenitors are required for injury-induced remodeling to occur. This work suggests that injury-induced hippocampal remodeling following brain injury likely requires sustained activation of quiescent early progenitors.	[Yu, Tzong-Shiue; Zhang, Gui; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA; [Yu, Tzong-Shiue; Zhang, Gui; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Liebl, Daniel J.] Miami Project Cure Paralysis, Miami, FL 33136 USA; [Liebl, Daniel J.] Univ Miami, Sch Med, Miami, FL 33136 USA		Kernie, SG (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.Kernie@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020	Kernie, Steven/0000-0003-1371-0549; Yu, Tzong-Shiue/0000-0003-4277-6213	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS048192, R01NS049545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049545, R01NS048192] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants R01 NS048192 ( S. G. K.) and R01NS049545 ( D. J. L., S. G. K.). We thank Ben Orr for his technical assistance and Josh Koch for help with statistical analysis. This article is freely available online through the J Neurosci Open Choice option.	Aguirre A, 2004, J NEUROSCI, V24, P10530, DOI 10.1523/JNEUROSCI.3572-04.2004; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cohen JL, 1998, TRANSGENIC RES, V7, P321, DOI 10.1023/A:1008893206208; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Fukuda S, 2003, J NEUROSCI, V23, P9357; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Godinho L, 2007, NEURON, V56, P597, DOI 10.1016/j.neuron.2007.09.036; Gourevitch R, 2004, BEHAV PHARMACOL, V15, P287, DOI 10.1097/01.fbp.0000135703.48799.71; Guillery RW, 2002, J COMP NEUROL, V447, P1, DOI 10.1002/cne.10221; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Mandyam CD, 2004, J NEUROSCI RES, V76, P783, DOI 10.1002/jnr.20090; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Miles DK, 2008, HIPPOCAMPUS, V18, P793, DOI 10.1002/hipo.20439; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mori T, 2005, CURR TOP DEV BIOL, V69, P67, DOI 10.1016/S0070-2153(05)69004-7; Morshead CM, 2003, EUR J NEUROSCI, V18, P76, DOI 10.1046/j.1460-9568.2003.02727.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 2006, ANN NEUROL, V59, P81, DOI 10.1002/ana.20699; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; SALOMON B, 1995, MOL CELL BIOL, V15, P5322; Saxe MD, 2007, P NATL ACAD SCI USA, V104, P4642, DOI 10.1073/pnas.0611718104; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P844, DOI 10.1128/AAC.31.6.844; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Wojtowicz JM, 2006, HIPPOCAMPUS, V16, P261, DOI 10.1002/hipo.20158; Yamaguchi M, 2000, NEUROREPORT, V11, P1991, DOI 10.1097/00001756-200006260-00037; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; Yu TS, 2005, GENESIS, V41, P147, DOI 10.1002/gene.20110; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	53	135	145	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 26	2008	28	48					12901	12912		10.1523/JNEUROSCI.4629-08.2008			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	376OA	WOS:000261191700032	19036984	Bronze, Green Accepted, Green Published			2022-02-06	
J	Wang, JY; Bakhadirov, K; Devous, MD; Abdi, H; McColl, R; Moore, C; de la Plata, CDM; Ding, K; Whittemore, A; Babcock, E; Rickbeil, T; Dobervich, J; Kroll, D; Dao, B; Mohindra, N; Madden, CJ; Diaz-Arrastia, R				Wang, Jun Yi; Bakhadirov, Khamid; Devous, Michael D., Sr.; Abdi, Herve; McColl, Roddy; Moore, Carol; de la Plata, Carlos D. Marquez; Ding, Kan; Whittemore, Anthony; Babcock, Evelyn; Rickbeil, Tiffany; Dobervich, Julia; Kroll, David; Dao, Bao; Mohindra, Nisha; Madden, Christopher J.; Diaz-Arrastia, Ramon			Diffusion tensor tractography of traumatic diffuse axonal injury	ARCHIVES OF NEUROLOGY			English	Article							GLASGOW OUTCOME SCALE; BRAIN-INJURY; WHITE-MATTER; CORPUS-CALLOSUM; FIBER TRACKING; CHILDREN; MODERATE; LESIONS	Background: Diffuse axonal injury is a common consequence of traumatic brain injury that frequently involves the parasagittal white matter, corpus callosum, and brainstem. Objective: To examine the potential of diffusion tensor tractography in detecting diffuse axonal injury at the acute stage of injury and predicting long-term functional outcome. Design: Tract-derived fiber variables were analyzed to distinguish patients from control subjects and to determine their relationship to outcome. Setting: Inpatient traumatic brain injury unit. Patients: From 2005 to 2006, magnetic resonance images were acquired in 12 patients approximately 7 days after injury and in 12 age- and sex-matched controls. Main Outcome Measures: Six fiber variables of the corpus callosum, fornix, and peduncular projections were obtained. Glasgow Outcome Scale - Extended scores were assessed approximately 9 months after injury in 11 of the 12 patients. Results: At least 1 fiber variable of each region showed diffuse axonal injury - associated alterations. At least 1 fiber variable of the anterior body and splenium of the corpus callosum correlated significantly with the Glasgow Outcome Scale - Extended scores. The predicted outcome scores correlated significantly with actual scores in a mixed-effects model. Conclusion: Diffusion tensor tractography - based quantitative analysis at the acute stage of injury has the potential to serve as a valuable biomarker of diffuse axonal injury and predict long-term outcome.	[Wang, Jun Yi; Bakhadirov, Khamid; Abdi, Herve; Moore, Carol; de la Plata, Carlos D. Marquez; Ding, Kan; Rickbeil, Tiffany; Dobervich, Julia; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Wang, Jun Yi; Bakhadirov, Khamid; Abdi, Herve] Univ Texas Dallas, Dept Cognit & Neuro Sci, Richardson, TX 75083 USA; [Devous, Michael D., Sr.; McColl, Roddy; Whittemore, Anthony; Babcock, Evelyn; Kroll, David; Dao, Bao; Mohindra, Nisha] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA		Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ramon.diaz-arrastia@utsouthwestern.edu	Abdi, Herve/G-6620-2011	Abdi, Herve/0000-0002-9522-1978; Diaz-Arrastia, Ramon/0000-0001-6051-3594; , Kan/0000-0003-3485-8200; McColl, Roderick/0000-0001-7022-100X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD42652, R01 HD48179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER		ABDI H, 2007, STATIS; Abdi H., 2007, PARTIAL LEAST SQUARE; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Concha L, 2005, AM J NEURORADIOL, V26, P2267; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Huang H, 2005, NEUROIMAGE, V26, P195, DOI 10.1016/j.neuroimage.2005.01.019; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	33	135	137	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	MAY	2008	65	5					619	626		10.1001/archneur.65.5.619			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	299WJ	WOS:000255785600009	18474737	Bronze			2022-02-06	
J	Nguyen, HX; O'Barr, TJ; Anderson, AJ				Nguyen, Hal X.; O'Barr, Thaddeus J.; Anderson, Aileen J.			Polymorphonuclear leukocytes promote neurotoxicity through release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha	JOURNAL OF NEUROCHEMISTRY			English	Article						neurotoxicity; neutrophils; spinal cord injury; matrix metalloproteinase; reactive oxygen species; tumor necrosis factor-alpha	SPINAL-CORD-INJURY; TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; DORSAL-ROOT GANGLIA; NF-KAPPA-B; NITRIC-OXIDE; IN-VITRO; INFLAMMATORY RESPONSE; OXIDATIVE STRESS	As the first immune cells to infiltrate the nervous system after traumatic PNS and CNS injury, neutrophils (polymorphonuclear leukocytes, PMNs) may promote injury by releasing toxic soluble factors that may affect neuronal survival. Direct neurotoxicity of matrix metalloproteinases (MMPs), reactive oxygen species (ROS), and cytokines released by PMNs was investigated by culturing dorsal root ganglion (DRG) cells with PMN-conditioned media containing MMP inhibitor (GM6001), ROS scavengers, or tumor necrosis factor alpha R (TNF-alpha R) neutralizing antibody. Although DRGs exposed to PMN-conditioned media had 53% fewer surviving neurons than controls, neuronal cell loss was prevented by GM6001 (20 mu mol/L), catalase (1000 U/mL), or TNF-alpha R neutralizing antibody (1.5 mu g/mL), elevating survival to 77%, 94%, and 95%, respectively. In accordance with protection by GM6001, conditioned media collected from MMP-9 null PMNs was less neurotoxic than that collected from wild-type PMNs. Additionally, MMP inhibition reduced PMN-derived ROS; removal of ROS reduced PMN-derived MMP-9 activity; and TNF-alpha inhibition reduced both PMN-derived MMP-9 activity and ROS in PMN cultures. Our data provide the first direct evidence that PMN-driven neurotoxicity is dependent on MMPs, ROS, and TNF-alpha, and that these factors may regulate PMN release of these soluble factors or interact with one another to mediate PMN-driven neurotoxicity.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA USA; Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA USA; Univ Calif Irvine, Dept Phys Med & Rehabil, Irvine, CA USA		Anderson, AJ (corresponding author), Phys Med & Rehabil, Gillespie Neurosci Res Facil 1105, Irvine, CA 92697 USA.	aja@uci.edu	Anderson, Aileen J/H-5926-2012		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS43428-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043428] Funding Source: NIH RePORTER		Aoshiba K, 2001, AM J PHYSIOL-LUNG C, V281, pL556; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; de Castro R, 2000, NEUROREPORT, V11, P3551, DOI 10.1097/00001756-200011090-00029; Degn J, 1999, J COMP NEUROL, V412, P186, DOI 10.1002/(SICI)1096-9861(19990913)412:1<186::AID-CNE14>3.0.CO;2-H; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; EGGERT HR, 1985, NEUROSURGERY, V16, P443, DOI 10.1227/00006123-198504000-00001; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; Kato N, 2003, NEUROSCI RES, V45, P297, DOI 10.1016/S0168-0102(02)00234-1; Kato N, 2002, J NEUROL SCI, V202, P69, DOI 10.1016/S0022-510X(02)00209-5; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leonoudakis D, 2004, NEURON GLIA BIOL, V1, P263, DOI 10.1017/S1740925X05000608; Li XJ, 1999, SEED SCI RES, V9, P247, DOI 10.1017/S0960258599000252; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; Miller BA, 2005, NEUROCHEM RES, V30, P867, DOI 10.1007/s11064-005-6880-x; Moro MA, 2004, CELL CALCIUM, V36, P265, DOI 10.1016/j.ceca.2004.02.011; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203, DOI 10.1152/ajpregu.1998.274.5.R1203; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Nagaoka I, 2000, INFLAMM RES, V49, P55, DOI 10.1007/s000110050559; Nguyen HX, 2005, J PHYSIOL-LONDON, V565, P403, DOI 10.1113/jphysiol.2005.085506; Nguyen HX, 2003, J PHYSIOL-LONDON, V547, P125, DOI 10.1113/jphysiol.2002.031450; Niwa Y, 1996, CLIN IMMUNOL IMMUNOP, V79, P303, DOI 10.1006/clin.1996.0083; Noble LJ, 2002, J NEUROSCI, V22, P7526; Pannu R, 2005, J BIOL CHEM, V280, P13742, DOI 10.1074/jbc.M411959200; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Penkowa M, 1999, GLIA, V25, P343; Pfeifer K, 2004, EUR J NEUROSCI, V20, P1695, DOI 10.1111/j.1460-9568.2004.03657.x; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; REDFORD EJ, 1995, BRAIN, V118, P869, DOI 10.1093/brain/118.4.869; Rinecker M, 2003, ACTA NEUROCHIR, V145, P977, DOI 10.1007/s00701-003-0131-1; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SELMAJ KW, 1990, J IMMUNOL, V144, P129; TALPAIN E, 1995, BRIT J PHARMACOL, V114, P1459, DOI 10.1111/j.1476-5381.1995.tb13370.x; TCHELINGERIAN JL, 1995, J NEUROCHEM, V65, P2377; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang SW, 1999, ANN CLIN LAB SCI, V29, P192; Yagisawa M, 1996, BIOCHEM BIOPH RES CO, V228, P510, DOI 10.1006/bbrc.1996.1691; Yang JJ, 1996, AM J PATHOL, V149, P1617; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; Zhu Y, 2005, J IMMUNOL, V175, P1118, DOI 10.4049/jimmunol.175.2.1118; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	66	135	140	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2007	102	3					900	912		10.1111/j.1471-4159.2007.04643.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	196TD	WOS:000248504200031	17561941				2022-02-06	
J	McLeod, TCV; Schwartz, C; Bay, RC				McLeod, Tamara C. Valovich; Schwartz, Christian; Bay, R. Curtis			Sport-related concussion misunderstandings among youth coaches	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head injury; symptoms; pediatrics; mild traumatic brain injury	SCHOOL FOOTBALL PLAYERS; MANAGEMENT	Objective: To determine the understanding of sport-related concussion among youth sports coaches. Design: Cross-sectional survey. Setting: The survey was administered at coaches' meetings, following practices, and via mail. Participants: 156 active youth sports coaches, with 5.88 +/- 3.16 years (range 1-22) of coaching experience. Interventions: An original survey instrument developed to assess concussion knowledge. Internal validity of the instrument was established prior to the study (Cronbach's alpha = 0.83). Main Outcome Measurements: Scores on the survey instrument reflecting symptom recognition and management knowledge. Results: For the 16 items comprising the symptom recognition survey, the mean number of correct responses was 9.78 +/- 2.07. Previous coaching education was predictive of better symptom recognition. On the true/false portion, between 49.4% and 61.5% of coaches correctly answered the 4 statements. Conclusion: This investigation revealed that, among youth sports coaches, coaching education was predictive of the ability to recognize signs and symptoms of sport-related concussion. However, several misconceptions about concussion still exist, highlighting that education regarding concussion is necessary. The presence of qualified health care personnel, such as an athletic trainer, at the youth organization level may enhance early recognition, treatment, and referral of concussions.					Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Bay, Ralph/0000-0003-3525-9269			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P934; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; KIMIECIK JC, 1988, PHYSICIAN SPORTSMED, P124; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Ransone J, 1999, J ATHL TRAINING, V34, P267; Sefton J. M., 2004, J ATHL TRAINING, V39, pS52	10	135	135	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2007	17	2					140	142		10.1097/JSM.0b013e31803212ae			3	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	147GU	WOS:000244992200009	17414483				2022-02-06	
J	Thornton, E; Vink, R; Blumbergs, PC; Van den Heuvel, C				Thornton, Emma; Vink, Robert; Blumbergs, Peter C.; Van den Heuvel, Corinna			Soluble amyloid precursor protein a reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats	BRAIN RESEARCH			English	Article						axonal injury; caspase-3; immunohistochemistry; rat; soluble amyloid precursor protein alpha; traumatic brain injury	CEREBRAL CORTICAL-NEURONS; LONG-TERM ACCUMULATION; INDUCED AXONAL INJURY; ALZHEIMERS-DISEASE; SECRETED FORMS; CYCLOSPORINE-A; BETA-SECRETASE; GROWTH-FACTOR; HIPPOCAMPAL-NEURONS; UP-REGULATION	Amyloid precursor protein (APP) has previously been shown to increase following traumatic brain injury (TBI). Whereas a number of investigators assume that increased APP may lead to the production of neurotoxic A beta and be deleterious to outcome, the soluble alpha form of APP (sAPP alpha) is a product of the non-amyloidogenic cleavage of amyloid precursor protein that has previously been shown in vitro to have many neuroprotective and neurotrophic functions. However, no study to date has addressed whether sAPP alpha may be neuroprotective in vivo. The present study examined the effects of in vivo, posttraumatic sAPP alpha. administration on functional motor outcome, cellular apoptosis, and axonal injury following severe impact-acceleration TBI in rats. Intracerebroventricular administration of sAPP alpha at 30 min posttrauma significantly improved motor outcome compared to vehicle-treated controls as assessed using the rotarod task. Immunohistochemical analysis using antibodies directed toward caspase-3 showed that posttraumatic treatment with sAPP alpha. significantly reduced the number of apoptotic neuronal perikarya. within the hippocampal CA3 region and within the cortex 3 days after injury compared to vehicle-treated animals. Similarly, sAPP alpha-treated animals demonstrated a reduction in axonal injury within the corpus callosum at all time points, with the reduction being significant at both 3 and 7 days postinjury. Our results demonstrate that in vivo administration of sAPP alpha improves functional outcome and reduces neuronal cell loss and axonal injury following severe diffuse TBI in rats. Promotion of APP processing toward sAPP alpha. may thus be a novel therapeutic strategy in the treatment of TBI. (c) 2006 Elsevier B.V. All rights reserved.	Univ Adelaide, Dept Pathol, Med Sch N, Adelaide, SA 5005, Australia; Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia		Van den Heuvel, C (corresponding author), Univ Adelaide, Dept Pathol, Med Sch N, Level 3, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; , Corinna/0000-0003-0664-8935			ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Arbel M, 2005, P NATL ACAD SCI USA, V102, P7718, DOI 10.1073/pnas.0502427102; Auer RN, 2004, FORENSIC SCI INT, V146, P105, DOI 10.1016/j.forsciint.2004.08.001; Barger SW, 1996, MOL BRAIN RES, V40, P116; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; BUSH AI, 1990, J BIOL CHEM, V265, P15977; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cheng GJ, 2002, EXP NEUROL, V175, P407, DOI 10.1006/exnr.2002.7920; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Csordas A, 2003, ACTA NEUROPATHOL, V106, P37, DOI 10.1007/s00401-003-0694-1; Dewachter I, 2002, LANCET NEUROL, V1, P409, DOI 10.1016/S1474-4422(02)00188-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Gora-Kupilas K, 2005, FOLIA NEUROPATHOL, V43, P31; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Henry A, 1998, BRIT J HAEMATOL, V103, P402, DOI 10.1046/j.1365-2141.1998.01005.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; JIN LW, 1994, J NEUROSCI, V14, P5461; Kraus JF, 1993, HEAD INJURY, P1; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; Masliah E, 1997, NEUROSCIENCE, V78, P135, DOI 10.1016/S0306-4522(96)00553-2; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pierce JES, 1996, J NEUROSCI, V16, P1083; RINK A, 1995, AM J PATHOL, V147, P1575; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van den Heuvel C, 2004, J NEUROTRAUM, V21, P1562, DOI 10.1089/0897715042441783; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAMOTO K, 1994, J NEUROBIOL, V25, P585, DOI 10.1002/neu.480250510; [No title captured]	58	135	140	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 13	2006	1094						38	46		10.1016/j.brainres.2006.03.107			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	064DC	WOS:000239068400004	16697978				2022-02-06	
J	Gosselin, N; Theriault, M; Leclerc, S; Montplaisir, J; Lassonde, M				Gosselin, Nadia; Theriault, Martin; Leclerc, Suzanne; Montplaisir, Jacques; Lassonde, Maryse			Neurophysiological anomalies in symptomatic and asymptomatic concussed athletes	NEUROSURGERY			English	Article						athletic injury; concussion; event-related potentials; neuropsychology	TRAUMATIC BRAIN-INJURY; EVENT-RELATED POTENTIALS; MILD HEAD-INJURY; P300 LATENCY; SPORTS; PERFORMANCE; ATTENTION; TASK; RECOVERY; DEFICITS	OBJECTIVE: Concussion in sports is a problem of such magnitude that improvements in diagnosis and management are desirable. The aim of the present study was to investigate the effect of concussion on event-related potentials, in symptomatic as well as in asymptomatic athletes. METHODS: Twenty symptomatic and asymptomatic athletes who sustained a concussion were compared with 10 control athletes in a modified auditory Oddball task. The task included a sequence of tones containing standard and deviant stimuli. Participants were asked to respond to the target tone presented in the left ear and to ignore tones presented in the right ear. The electroencephalogram was recorded from 28 electrodes during the task. RESULTS: The results showed a reduction in the amplitude of N1, P2, and P3 components in symptomatic and asymptomatic athletes in comparison with control athletes. No between-group differences were observed in reaction times or in latency of the event-related potentials components, except for P3 latency, in which the controls showed shorter latency than the concussed groups. CONCLUSION: Concussions seem to produce deficits in the early and late stages of auditory information processing, which possibly reflect impaired brain functioning in symptomatic and asymptomatic concussed athletes. The fact that asymptomatic athletes have an electrophysiological profile similar to that of symptomatic athletes challenges the validity of return-to-play guidelines for which the absence of symptoms is a major issue.	Univ Montreal, Res Ctr Neuropsychol & Cognit, Dept Psychol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; Hop Sacre Coeur, Sleep Res Ctr, Montreal, PQ H4J 1C5, Canada		Lassonde, M (corresponding author), Univ Montreal, Res Ctr Neuropsychol & Cognit, Dept Psychol, CP 628,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	maryse.lassonde@umontreal.ca					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; [Anonymous], 1991, J CLIN NEUROPHYSIOL, V8, P200, DOI 10.1097/00004691-199104000-00007; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barry RJ, 2003, CLIN NEUROPHYSIOL, V114, P184, DOI 10.1016/S1388-2457(02)00363-2; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; INGEBRIGSTEN T, 2001, J NEUROL, V245, P609; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAMER AF, 1988, BIOL PSYCHOL, V26, P231, DOI 10.1016/0301-0511(88)90022-1; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POLICH J, 1994, INT J PSYCHOPHYSIOL, V17, P25, DOI 10.1016/0167-8760(94)90052-3; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V254, P538; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207	48	135	136	1	24	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2006	58	6					1151	1160		10.1227/01.NEU.0000215953.44097.FA			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	046BH	WOS:000237785900037	16723894				2022-02-06	
J	Jaeger, M; Schuhmann, MU; Soehle, M; Meixensberger, A				Jaeger, Matthias; Schuhmann, Martin U.; Soehle, Martin; Meixensberger, Argen			Continuous assessment of cerebrovascular autoregulation after traumatic brain injury using brain tissue oxygen pressure reactivity	CRITICAL CARE MEDICINE			English	Article						autoregulation; brain injury; brain tissue oxygen reactivity; cerebrovascular pressure reactivity; cerebral perfusion pressure; oxygenation	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; VASOMOTOR REACTIVITY; PERFUSION-PRESSURE; TENSION	Objective: To evaluate whether two newly developed indexes of brain tissue oxygen pressure reactivity (ORx and b(ptiO2)) provide information on the status of cerebrovascular autoregulation after traumatic brain injury. This was accomplished by analyzing the relationship between these indexes and an index of cerebrovascular pressure reactivity (PRx). PRx is an established parameter for estimation of cerebrovascular autoregulation. Design: Retrospective analysis of prospectively collected data. Setting: Neurosurgical intensive care unit of a university hospital. Patients: Twenty-seven patients suffering from severe traumatic brain injury. Interventions: Continuous monitoring of mean arterial blood pressure, intracranial pressure, cerebral perfusion pressure, and partial pressure of brain tissue oxygen (p(tiO2)) was performed for an average of 6.5 days. ORx was calculated as a moving correlation coefficient between values of cerebral perfusion pressure and P-tiO2. The b(ptiO2) was calculated as a moving value of the slope of the linear regression function between cerebral perfusion pres- sure and P-tiO2. PRx was calculated as a moving correlation coefficient between values for intracranial pressure and mean arterial blood pressure. Outcome was assessed at 6 months after traumatic brain injury (Glasgow Outcome Scale). Measurements and Main Results: Both ORx and b(PtiO2) correlated significantly with PRx (r =.55 for ORx, r =, 52 for b PV02' p < .01). PRx and ORx showed a significantly negative correlation to the monitored P-tiO2 values (r = -.42 for PRx, r = -.41 for ORx, p < .05) and outcome (r = -.52 for PRx, r = -.62 for ORx, p < .01), whereas b(ptiO2) did not. Conclusions: ORx and, to a lesser extent, b(ptiO2) correlated with the autoregulatory marker PRx and provide additional information about the status of cerebrovascular autoregulation after traumatic brain injury. The data also suggested that patients with impaired autoregulation are at increased risk for secondary cerebral hypoxia.	Univ Leipzig, Dept Neurosurg, D-04103 Leipzig, Germany; Univ Bonn, Dept Anaesthesiol & Intens Care Med, D-5300 Bonn, Germany		Jaeger, M (corresponding author), Univ Leipzig, Dept Neurosurg, Liebigstr 20, D-04103 Leipzig, Germany.	jaem@medizin.uni-leipzig.de					AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JENNETT B, 1975, LANCET, V1, P480; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 2002, J NEUROTRAUM, V19, P1127, DOI 10.1089/08977150260337949; TEASDALE G, 1974, LANCET, V2, P81; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	27	135	141	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2006	34	6					1783	1788		10.1097/01.CCM.0000218413.51546.9E			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	047MV	WOS:000237884300029	16625135				2022-02-06	
J	Wade, SL; Carey, J; Wolfe, CR				Wade, Shari L.; Carey, JoAnne; Wolfe, Christopher R.			An online family intervention to reduce parental distress following pediatric brain injury	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article; Proceedings Paper	66th Annual Assembly of the American-Academy-for-Physical-Medicine-and-Rehabilitation	OCT 27-30, 2005	Philadelphia, PA	Amer Acad Phys Med & Rehabil		brain injury; tele-health; problem solving; pediatric; family	NEWLY-DIAGNOSED CANCER; INITIAL YEAR; CHILDREN; ADOLESCENTS; PREDICTORS; RELIABILITY; ADAPTATION; CAREGIVER; EFFICACY; MOTHERS	This study examined whether an online problem-solving intervention could improve parental adjustment following pediatric traumatic brain injury ITBI). Families of children with moderate-to-severe TBI were recruited from the trauma registry of a large children's hospital and randomly assigned to receive online family problem solving therapy (FPS n = 20) or Internet resources (IRC n = 20) in addition to usual care. The FPS group reported significantly less global distress, depressive symptoms, and anxiety at follow-up than did the IRC group after controlling for baseline symptoms. The FPS group also reported significant improvements in problem-solving skills, although the groups did not differ significantly at follow-up. Finding, suggest that an online, skill-building approach can be effective in facilitating parental adaptation after TBI.	Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA		Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Cohen J., 2013, STAT POWER ANAL BEHA; D'Zurilla T.J., 1999, PROBLEM SOLVING THER, V2nd edn; D'Zurilla T.J., 1990, PSYCHOL ASSESSMENT, V2, P156, DOI DOI 10.1037/1040-3590.2.2.156; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Greene RW, 2004, J CONSULT CLIN PSYCH, V72, P1157, DOI 10.1037/0022-006X.72.6.1157; Greist JH, 1998, PSYCHIAT SERV, V49, P887, DOI 10.1176/ps.49.7.887; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Marks I, 1998, CLIN PSYCHOL-SCI PR, V5, P151, DOI 10.1111/j.1468-2850.1998.tb00141.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MEZU AM, 1998, HELPING CANC PATIENT; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOBER D, 2001, JAMA-J AM MED ASSOC, V285, P1987; Nezu AM, 2003, J CONSULT CLIN PSYCH, V71, P1036, DOI 10.1037/0022-006X.71.6.1036; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Robin AL, 1989, NEGOTIATING PARENT A; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Sahler OJZ, 2005, J CONSULT CLIN PSYCH, V73, P272, DOI 10.1037/0022-006X.73.2.272; Sahler OJZ, 2002, J DEV BEHAV PEDIATR, V23, P77, DOI 10.1097/00004703-200204000-00003; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Speilberger CD., 1983, STATE TRAIT ANXIETY; Sturges JW, 1998, PROF PSYCHOL-RES PR, V29, P183, DOI 10.1037/0735-7028.29.2.183; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WADE SL, IN PRESS REHABILITAT; WADE SL, IN PRESS J PEDIAT PS; Ylvisaker M., 1998, COLLABORATIVE BRAIN	41	135	135	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X	1939-2117		J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	JUN	2006	74	3					445	454		10.1037/0022-006X.74.3.445			10	Psychology, Clinical	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology	060FB	WOS:000238786700005	16822102				2022-02-06	
J	Emery, CA; Meeuwisse, WH; McAllister, JR				Emery, CA; Meeuwisse, WH; McAllister, JR			Survey of sport participation and sport injury in calgary and area high schools	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article; Proceedings Paper	Conference of the Canadian-Academy-of-Sport-Medicine	MAR, 2005	Ottawa, CANADA	Canadian Acad Sport Med		adolescent; athletic injury; sport participation; injury prevention	AGED CHILDREN; RECREATION INJURIES; YOUTH; RISK; EPIDEMIOLOGY; ADOLESCENTS; PATTERNS; SOCCER; BEHAVIOR	Objective: To examine (1) sport participation and (2) sport injury in adolescents. Design, Setting, and Participants: This was a retrospective survey design. In total, 2873 adolescents were recruited from a random sample of classes from 24 Calgary and area high schools. Each subject completed an in-class questionnaire in March 2004. Main Outcome Measurements: Overall and sport-specific participation rates (number of sport participants/number of students completing survey). Overall and sport-specific injury rates (number of injuries/number of participants). Results: In the previous 1 year, 94% of students participated in sport. The top 5 sports by participation for males were basketball, hockey, football, snowboarding, and soccer, and for females, basketball, dance, volleyball, snowboarding, and soccer, The injury rate including only injuries requiring medical attention was 40,2 injuries/ 100 adolescents/y (95% Cl, 38.4-42.1), presenting to a hospital emergency department was 8.1 injuries/100 adolescents/y (95% Cl, 7.1-9.2). resulting in time loss from sport was 49.9 injuries/100 adolescents/y (95% CI, 48-51.8), and resulting in loss of consciousness was 9.3 injuries/100 adolescents/y (95% Cl, 8.3-10.5). The greatest proportion of injuries occurred in basketball, hockey, soccer, and snowboarding. The top 5 body parts injured were the ankle, knee, head, back, and wrist. The top 5 injury types were sprain, contusion, concussion, fracture, and muscle strain. A previous injury was associated with 49% of the injuries and direct contact with 45% of injuries. Conclusions: Rates of participation in sport and sport injury are high in adolescents. Future research should focus on prevention strategies in sports with high participation and injury rates to maximize population health impact.	Univ Calgary, Fac Kinesiol, Roger Jackson Ctr Hlth & Wellness Res, Sport Med Ctr, Calgary, AB T2N 4E4, Canada		Emery, CA (corresponding author), Univ Calgary, Fac Kinesiol, Roger Jackson Ctr Hlth & Wellness Res, Sport Med Ctr, 2500 Univ Dr NW, Calgary, AB T2N 4E4, Canada.	caemery@ucalgary.ca	Emery, Carolyn/AAI-2761-2020				BACKOUS DD, 1988, AM J DIS CHILD, V142, P839, DOI 10.1001/archpedi.1988.02150080045019; BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; BACKX FJG, 1989, AM J SPORT MED, V17, P234, DOI 10.1177/036354658901700214; BENKIBLER W, 1993, MED SCI SPORT EXER, V25, P1330; Bienefeld M, 1996, Chronic Dis Can, V17, P21; BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; DANIEL DM, 1994, AM J SPORT MED, V22, P632, DOI 10.1177/036354659402200511; DELOES M, 1995, INT J SPORTS MED, V16, P134, DOI 10.1055/s-2007-972980; Drawer S, 2001, BRIT J SPORT MED, V35, P402, DOI 10.1136/bjsm.35.6.402; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; GARRICK JG, 1978, PEDIATRICS, V61, P465, DOI 10.1542/peds.61.3.465; Gillquist J, 1999, SPORTS MED, V27, P143, DOI 10.2165/00007256-199927030-00001; GOLDBERG B, 1988, PEDIATRICS, V81, P255; Grimmer KA, 2000, J ADOLESCENT HEALTH, V27, P266, DOI 10.1016/S1054-139X(00)00120-8; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; King MA, 1998, CAN J PUBLIC HEALTH, V89, P397, DOI 10.1007/BF03404082; LENAWAY DD, 1992, AM J PREV MED, V8, P193, DOI 10.1016/S0749-3797(18)30831-6; LYSENS R, 1984, SPORTS MED, V1, P6, DOI 10.2165/00007256-198401010-00002; MAFFULLI N, 1994, BRIT J SPORT MED, V28, P123, DOI 10.1136/bjsm.28.2.123; Mummery WK, 1998, CAN J PUBLIC HEALTH, V89, P53, DOI 10.1007/BF03405796; NILLSON S, 1978, AM J SPORTS MED, V6, P358; *NO SYDN AR HLTH S, 1997, NEW S WAL YOUTH SPOR; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; Pickett W, 2002, ARCH PEDIAT ADOL MED, V156, P786, DOI 10.1001/archpedi.156.8.786; Pickett W, 2002, SOC SCI MED, V55, P1055, DOI 10.1016/S0277-9536(01)00224-6; POWELL JW, 2002, AM J SPORTS MED, V28, P385; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; SCHMIDTOLSEN S, 1985, BRIT J SPORT MED, V19, P151; SCHOOTMAN M, 1994, SPORTS MED, V18, P22, DOI 10.2165/00007256-199418010-00004; STANITSKI CL, 1994, PEDIAT ADOLESCENT SP, V3; *STAT CAN CULT TOU, 1997, CAN CULT HER ID STAT; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; ZARICZNYJ B, 1980, AM J SPORT MED, V8, P318, DOI 10.1177/036354658000800504	36	135	136	4	48	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2006	16	1					20	26		10.1097/01.jsm.0000184638.72075.b7			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Orthopedics; Physiology; Sport Sciences	004HW	WOS:000234743600005	16377971				2022-02-06	
J	Henry, JD; Phillips, LH; Crawford, JR; Ietswaart, M; Summers, F				Henry, Julie D.; Phillips, Louise H.; Crawford, John R.; Ietswaart, Magdalena; Summers, Fiona			Theory of mind following traumatic brain injury: The role of emotion recognition and executive dysfunction	NEUROPSYCHOLOGIA			English	Article						head injury; social cognition; executive functioning	VERBAL FLUENCY PERFORMANCE; SOCIAL COGNITION; FRONTAL-LOBE; HEAD-INJURY; BEHAVIOR; IMPAIRMENTS; DEFICITS; ABILITY; ADULTS	A number of studies have now documented that traumatic brain injury (TBI) is associated with deficits in the recognition of basic emotions, the capacity to infer mental states of others (theory of mind), as well as executive functioning. However, no study to date has investigated the relationship between these three constructs in the context of TBI. In the current study TBI participants (N = 16) were compared with demographically matched healthy controls (N = 17). It was found that TBI participants' recognition of basic emotions, as well as their capacity for mental state attribution, was significantly reduced relative to controls. Performance on both of these measures was strongly correlated in the healthy control, but not in the TBI sample. In contrast, in the TBI (but not the control) sample, theory of mind was substantially correlated with performance on phonemic fluency, a measure of executive functioning considered to impose particular demands upon cognitive flexibility and self-regulation. These results are consistent with other evidence indicating that deficits in some aspects of executive functioning may at least partially underlie deficits in social cognition following TBI, and thus help explain the prevalence of social dysfunction in TBI. (c) 2006 Elsevier Ltd. All rights reserved.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Aberdeen, Sch Psychol, Aberdeen AB9 1FX, Scotland; Univ Durham, Sch Psychol, Durham DH1 3HP, England; Univ Aberdeen, Dept Neurosurg, Aberdeen AB9 1FX, Scotland		Henry, JD (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	julie.henry@unsw.edu.au	Phillips, Louise H/A-7952-2008; Crawford, John R/A-4165-2008	Phillips, Louise H/0000-0003-1005-8567; Crawford, John R/0000-0003-3403-3428; Ietswaart, Magdalena/0000-0003-4576-9393; Phillips, Louise/0000-0002-0988-3028; Henry, Julie/0000-0002-2081-3717			Adolphs R, 2002, J COGNITIVE NEUROSCI, V14, P1264, DOI 10.1162/089892902760807258; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bora E, 2005, ACTA PSYCHIAT SCAND, V112, P110, DOI 10.1111/j.1600-0447.2005.00570.x; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Brune M, 2005, PSYCHIAT RES, V133, P135, DOI 10.1016/j.psychres.2004.10.007; Buitelaar JK, 1999, J CHILD PSYCHOL PSYC, V40, P869, DOI 10.1017/S0021963099004321; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Cohen J, 1977, STAT POWER ANAL BEHA; Crawford J.R, 2005, EFFECTIVENESS REHABI, P233, DOI DOI 10.1093/ACPROF:OSO/9780198526544.003.0019; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Ekman P., 1976, PICTURES FACIAL AFFE; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Frith U, 2001, CURR DIR PSYCHOL SCI, V10, P151, DOI 10.1111/1467-8721.00137; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; HUGHES C, 1993, DEV PSYCHOL, V29, P498, DOI 10.1037/0012-1649.29.3.498; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; Lee KH, 2004, PSYCHOL MED, V34, P391, DOI 10.1017/S0033291703001284; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lough S, 2002, J PSYCHOSOM RES, V53, P639, DOI 10.1016/S0022-3999(02)00433-6; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Ochsner KN, 2001, AM PSYCHOL, V56, P717, DOI 10.1037//0003-066X.56.9.717; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Powell J., 2000, COGNITIVE NEUROPSYCH, V5, P175, DOI [DOI 10.1080/13546800050083520, 10.1080/13546800050083520]; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; Snowden JS, 2003, NEUROPSYCHOLOGIA, V41, P688, DOI 10.1016/S0028-3932(02)00221-X; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Varley R, 2001, NEUROCASE, V7, P489, DOI 10.1093/neucas/7.6.489; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	40	135	135	1	71	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	10					1623	1628		10.1016/j.neuropsychologia.2006.03.020			6	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	068VS	WOS:000239403200001	16643969				2022-02-06	
J	Chen, Q; Long, Y; Yuan, XQ; Zou, LL; Sun, J; Chen, SD; Perez-Polo, JR; Yang, KY				Chen, Q; Long, Y; Yuan, XQ; Zou, LL; Sun, J; Chen, SD; Perez-Polo, JR; Yang, KY			Protective effects of bone marrow stromal cell transplantation in injured rodent brain: Synthesis of neurotrophic factors	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						marrow stromal cells; traumatic brain injury; nerve growth factor; transplantation; neurotrophic factor	NERVE GROWTH-FACTOR; ADULT RATS; INTRACEREBRAL TRANSPLANTATION; FUNCTIONAL RECOVERY; PURKINJE NEURONS; UP-REGULATION; STEM-CELLS; IN-VIVO; EXPRESSION; MICE	Several groups have suggested that transplantation of marrow stromal cells (MSCs) promotes functional recovery in animal models of brain trauma. Recent studies indicate that tissue replacement by this method may not be the main source of therapeutic benefit, as transplanted MSCs have only limited ability to replace injured central nervous system (CNS) tissue. To gain insight into the mechanisms responsible for such effects, we systematically investigated the therapeutic potential of MSCs for treatment of brain injury. Using in vitro studies, we detected the synthesis of various growth factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and neurotrophin-3 (NT-3). Enzyme-linked immunosorbent assay (ELISA) demonstrated that MSCs cultured in Dulbecco's modified Eagle medium (DMEM) produced substantial amounts of NGF for at least 7 weeks, whereas the levels of BDNF, GDNF and NT-3 remained unchanged. In studies in mice, after intraventricular injection of MSCs, NGF levels were increased significantly in cerebrospinal fluid by ELISA, confirming our cell culture results. Further studies showed that treatment of traumatic brain injury with MSCs could attenuate the loss of cholinergic neuronal immunostaining in the medial septum of mice. These studies demonstrate for the first time that by increasing the brain concentration of NGF, intraventricularly transplanted MSCs might play an important role in the treatment of traumatic brain injury. (c) 2005 Wiley-Liss, Inc.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; VA Med Ctr, PADRECC, Houston, TX USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Shanghai Med Univ 2, Ruijin Hosp, Dept Neurol, Shanghai, Peoples R China		Chen, Q (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza, Houston, TX 77030 USA.	qchen1@bcm.tmc.edu	Perez-Polo, Jose R./B-6250-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035502] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS35502-05] Funding Source: Medline		Ader M, 2001, EUR J NEUROSCI, V14, P561, DOI 10.1046/j.0953-816x.2001.01673.x; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FLEMING JO, 1983, J NEUROIMMUNOL, V4, P129, DOI 10.1016/0165-5728(83)90017-6; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; HAGG T, 1993, EXP NEUROL, V119, P37, DOI 10.1006/exnr.1993.1005; Hermann DM, 2001, NEUROBIOL DIS, V8, P964, DOI 10.1006/nbdi.2001.0448; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Laurenzi MA, 1998, J LEUKOCYTE BIOL, V64, P228, DOI 10.1002/jlb.64.2.228; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tirassa P, 2003, J NEUROSCI RES, V72, P557, DOI 10.1002/jnr.10614; Vallieres L, 2003, J NEUROSCI, V23, P5197; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Zou LL, 1999, GENE THER, V6, P994, DOI 10.1038/sj.gt.3300936	45	135	157	0	5	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUN 1	2005	80	5					611	619		10.1002/jnr.20494			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	931KS	WOS:000229484800003	15880454				2022-02-06	
J	Ylvisaker, M; Adelson, PD; Braga, LW; Burnett, SM; Glang, A; Feeney, T; Moore, W; Rumney, P; Todis, B				Ylvisaker, M; Adelson, PD; Braga, LW; Burnett, SM; Glang, A; Feeney, T; Moore, W; Rumney, P; Todis, B			Rehabilitation and ongoing support after pediatric TBI - Twenty years of progress	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; education; family; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; HETEROTOPIC OSSIFICATION; HYPERBARIC-OXYGEN; CEREBRAL-PALSY; CHILDREN; ADOLESCENTS; OUTCOMES; TRIAL; POPULATION	This article summarizes major developments of the past 20 years in both acute and chronic management of children with traumatic brain injury. The article begins with brief summaries of developments in acute and rehabilitative medical management and physical rehabilitation. Because long-term cognitive, behavioral, academic, and family issues tend to be dominant after pediatric TBI, more attention is given to these topics. The article ends with a list of general themes that have been identified as critical in providing effective long-term services and supports to children with TBI and their families.	Coll St Rose, Sch Educ, Albany, NY USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA USA; SARAH Network Rehabil Hosp, Neuropsychol Dept, Brasilia, DF, Brazil; Teaching Res, Eugene, OR USA; Sch & Community Support Serv, Schenectady, NY USA; SW Brain Injury Rehabil Serv, Albury, NSW, Australia; Bloorview MacMillan Childrens Ctr, Neurorehabil Program, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada		Ylvisaker, M (corresponding author), 1171 Van Antwerp Rd, Schenectady, NY 12309 USA.	ylvisakm@mail.strose.edu	Braga, Lucia/AAQ-1030-2020; Adelson, David/W-2083-2019				Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 2003, J NEUROTRAUM, V20, P1116; ARMSTRONG K, 2003, PEDIAT REHABIL, V5, P149; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Boyd RN, 2000, DEV MED CHILD NEUROL, V42, P32, DOI 10.1017/S0012162200000074; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COOLEY E, 1991, J HEAD TRAUMA REHAB, V6, P47; COSTEFF H, 1985, SCAND J REHABIL MED, P10; Curtis, 1988, ALTERNATIVE ED DELIV, P391; Damasio A., 1994, DESCARTES ERROR EMOT; Detterman DL, 1993, TRANSFER TRIAL INTEL; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Feeney TJ, 2001, J HEAD TRAUMA REHAB, V16, P61, DOI 10.1097/00001199-200102000-00008; Glang A, 2004, NEUROREHABILITATION, V19, P219; Hadders-Algra M, 2000, DEV MED CHILD NEUROL, V42, P566, DOI 10.1017/S0012162200001067; HURVITZ EA, 1992, ARCH PHYS MED REHAB, V73, P459; Jaffe J., 1998, CURRENT CONCEPTS PED, P1; JANUS PL, 1994, ED DIMENSIONS ACQUIR, P475; KAVALE K, 1983, J LEARN DISABIL, V16, P165, DOI 10.1177/002221948301600307; Kluger G, 2000, J CHILD NEUROL, V15, P406, DOI 10.1177/088307380001500610; Koman LA, 1996, J CHILD NEUROL, V11, pS23, DOI 10.1177/0883073896011001S04; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Mann L, 1979, TRAIL PROCESS HIST P; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; McDonagh M, 2004, ARCH PHYS MED REHAB, V85, P1198, DOI 10.1016/j.apmr.2003.12.026; MCLEAN DE, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510000-00003; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Mitler MM, 1998, ANN NEUROL, V43, P88; Page S, 2003, BRAIN INJURY, V17, P675, DOI 10.1080/0269905031000107160; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PRESSLEY M, 1995, STRATEGY INSTRUCTION; RADECKI RT, 1994, ARCH PHYS MED REHAB, V75, P248, DOI 10.1016/0003-9993(94)90023-X; Resnick LB., 1987, ED LEARNING THINK; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; Schlund MW, 2002, BRAIN INJURY, V16, P527, DOI 10.1080/02699050110113679; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SILVER J, 1987, AM PSYCHIAT PRESS TX, P173; SILVERMAN SL, 1994, ARCH PHYS MED REHAB, V75, P118; SPARKS GM, 1983, EDUC LEADERSHIP, V41, P65; Sweet AP, 2002, IMPROVING COMPREHENS, P17; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; *US DEP ED OFF SPE, 2002, IMPL IND DIS ED ACT; Walker NW, 1999, CHILD NEUROPSYCHOL, V5, P137, DOI 10.1076/chin.5.2.137.3168; Wehmeyer ML, 2000, EXCEPT CHILDREN, V66, P439, DOI 10.1177/001440290006600401; Whyte J, 2004, ARCH PHYS MED REHAB, V85, P1732, DOI 10.1016/j.apmr.2004.07.349; WILLIAMS DT, 1982, J AM ACAD CHILD PSY, V21, P129, DOI 10.1016/S0002-7138(09)60911-0; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2007, INT CLASS FUNCT DIS; YIVISAKER M, 2003, BRAIN IMPAIRMENT, V4, P1; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker M., 1985, HEAD INJURY REHABILI; Ylvisaker M., 2000, BRAIN IMPAIR, V1, P12, DOI [DOI 10.1375/BRIM.1.1.12, 10.1375/brim.1.1.12]; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	64	135	137	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2005	20	1					95	109		10.1097/00001199-200501000-00009			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	894AT	WOS:000226762900008	15668573				2022-02-06	
J	Nortje, J; Menon, DK				Nortje, J; Menon, DK			Traumatic brain injury: physiology, mechanisms, and outcome	CURRENT OPINION IN NEUROLOGY			English	Article						traumatic brain injury; neuroprotection; outcomes; ischaemia	CLOSED-HEAD INJURY; CEREBRAL PERFUSION-PRESSURE; CENTRAL-NERVOUS-SYSTEM; GLASGOW COMA SCALE; PROMISING TREATMENT MODALITY; THERAPEUTIC HYPOTHERMIA; INTRACRANIAL HYPERTENSION; COMPUTED-TOMOGRAPHY; SUBVENTRICULAR ZONE; MILD HYPOTHERMIA	Purpose of review This review on traumatic brain injury consolidates the substantial current literature available on the pathophysiology, mechanisms, developments, and their subsequent effects on outcome. In particular, it tries to conceptualize why our greatly improved understanding of pathophysiology and neurobiology in traumatic brain injury has not translated into clear outcome improvements. Recent findings Early cerebral ischaemia has been characterized further, with ischaemic brain volume correlating with 6-month outcome. The Brain Trauma Foundation has revised perfusion pressure targets, and there are additional data on the outcome impact of brain tissue oxygen response and asymmetric patterns of cerebral autoregulation. Mechanistic studies have highlighted the role of inflammation and introduced concepts such as therapeutic vaccination and immune modulation. Experimental neurogenesis and repair strategies show promise. Despite continuing gains in knowledge, the experimental successes have not yet translated to the clinic. Indeed, several major articles have attempted to understand the clinical failure of highly promising strategies such as hypothermia, and set out the framework for further studies (e.g. addressing decompressive craniectomy). High-dose mannitol has shown promise in poor grade patients, while hypertonic saline has shown better intracranial pressure control. Negative results may be the consequence of ineffective therapies. However, there is a gathering body of work that highlights the outcome impact of subtle neurocognitive changes, which may not be quantified adequately by outcome measures used in previous trials. Such knowledge has also informed improved definition of mild traumatic brain injury, and allowed validation of management guidelines. Summary The evidence base for current therapies in this heterogeneous patient group is being refined, with greater emphasis on long-term functional outcomes. Improved monitoring techniques emphasize the need for individualization of therapeutic interventions.	Univ Cambridge, Addenbrookes Hosp, Dept Anesthesia, Cambridge CB2 2QQ, England		Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Anesthesia, Box 93, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk					af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Armstrong BD, 2003, J NEUROSCI RES, V74, P240, DOI 10.1002/jnr.10750; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chieregato A, 2003, J NEUROL NEUROSUR PS, V74, P784, DOI 10.1136/jnnp.74.6.784; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; DATSUR DK, 1963, HUMAN AGING BIOL BEH, P59; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Falimirski ME, 2003, J TRAUMA, V55, P1, DOI 10.1097/01.TA.0000071295.67263.A2; Ford J, 2004, J NEUROTRAUM, V21, P187, DOI 10.1089/089771504322778640; Gibbs EL, 1942, J BIOL CHEM, V144, P325; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hattori N, 2003, J NUCL MED, V44, P1709; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kabon Barbara, 2003, Best Pract Res Clin Anaesthesiol, V17, P551, DOI 10.1016/S1521-6896(03)00050-8; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kipnis J, 2003, J NEUROTRAUM, V20, P559, DOI 10.1089/089771503767168483; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lee A, 2003, INJURY, V34, P815, DOI 10.1016/S0020-1383(02)00395-9; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Marion DW, 2004, CRIT CARE MED, V32, pS43, DOI 10.1097/01.CCM.0000110731.69637.16; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Nourhaghighi N, 2003, LAB INVEST, V83, P1211, DOI 10.1097/01.LAB.0000082383.40635.FE; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; Shaked I, 2004, J NEUROIMMUNOL, V146, P84, DOI 10.1016/j.jneuroim.2003.10.049; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Toschlog EA, 2003, AM SURGEON, V69, P491; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844; Zygun DA, 2003, CAN J NEUROL SCI, V30, P307, DOI 10.1017/S0317167100003000	91	135	137	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2004	17	6					711	718		10.1097/00019052-200412000-00011			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	878XY	WOS:000225682000010	15542980				2022-02-06	
J	Krassioukov, AV; Furlan, JC; Fehlings, MG				Krassioukov, AV; Furlan, JC; Fehlings, MG			Autonomic dysreflexia in acute spinal cord injury: An under-recognized clinical entity	JOURNAL OF NEUROTRAUMA			English	Article						autonomic dysreflexia; autonomic dysfunction; cardiovascular control; neurotrauma; spinal cord injury	SYMPATHETIC PREGANGLIONIC NEURONS; CORONARY-HEART-DISEASE; RISK-FACTORS; SHOCK; SECONDARY; EMPHASIS	While autonomic dysreflexia (AD) is well recognized in the chronic stage of spinal cord injury (SCI) this potentially life-threatening complication has been only rarely documented in the acute phase (1 month) after SCI. Based on our clinical experience we hypothesized that AD is under-recognized in the acute phase of SCI. This study was undertaken to determine the incidence and clinical associations of early AD in our center. We reviewed the charts of patients with acute traumatic SCI admitted to the Toronto Western Hospital Spinal Program between 1998 and 2000. Among 58 patients with acute traumatic SCI (15F, 43M; ages 17-89 years, mean of 55.4), all three individuals who developed evidence of early AD had complete cervical tetraplegia (IF, 2M; ages 31-42 years, mean of 38.3). The incidence of early AD was 5.2% (3 of 58), whereas the adjusted incidence for the population at risk (SCI at T6 or above) was 5.7% (3 of 53). A significant number of patients in this series (87.9%, or 51 of 58) had a cervical SCI. While the mean resting systolic arterial blood pressure among these three individuals was 105.7 +/- 3 mm Hg, the mean systolic blood pressure at the time of early AD was 173.3 +/- 14.8 mm Hg (increase in systolic blood pressure over baseline ranged from 35.5% to 95%). The earliest episode of AD occurred on the 4(th) post-injury day. The trigger mechanisms for AD were somatic pain, fecal impaction, and abdominal distention. Although numerous reports emphasize AD as a potential complication of chronic SCI, our study demonstrates that AD occurs in 5.7% of patients with acute SCI above T6. Patients with severe cervical SCI are particularly susceptible to the early onset of AD. Clinicians need to be aware and highly vigilant of the potential development of AD in the acute phase of SCI.	Univ Toronto, Div Neurosurg, Dept Surg, Toronto, ON, Canada; Univ Toronto, Spinal Program, Krembil Neurosci Ctr, Toronto Western Hosp,Hlth Network, Toronto, ON, Canada; Univ Toronto, Toronto Western Res Inst, Hlth Network, Toronto Western Hosp, Toronto, ON, Canada; Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada		Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Dept Surg, Div Neurosurg, 399 Bathurst St,McLaughlin Pavil,Room 12-407, Toronto, ON M5T 2S8, Canada.		Krassioukov, Andrei V/K-3131-2017; Furlan, Julio/Q-8290-2018	Fehlings, Michael/0000-0002-5722-6364; Furlan, Julio/0000-0002-2038-0018			[Anonymous], 2002, NEUROSURGERY, V50, pS58; Atkinson PP, 1996, MAYO CLIN PROC, V71, P384, DOI 10.4065/71.4.384; Ball PA, 2001, SPINE, V26, pS27, DOI 10.1097/00007632-200112151-00006; CALARESU FR, 1988, ANNU REV PHYSIOL, V50, P511, DOI 10.1146/annurev.ph.50.030188.002455; Consumer Product Testing Co, 1997, CLIN PRACT GUID, P1; Curt A, 1997, J NEUROL NEUROSUR PS, V62, P473, DOI 10.1136/jnnp.62.5.473; Demirel S, 2001, SPINAL CORD, V39, P134, DOI 10.1038/sj.sc.3101135; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; ELTORAI I, 1992, PARAPLEGIA, V30, P355, DOI 10.1038/sc.1992.82; GUTTMANN L, 1947, BRAIN, V70, P361, DOI 10.1093/brain/70.4.361; GUTTMANN L, 1976, SPINAL CORD INJURIES, P1; Head H, 1917, BRAIN, V40, P188, DOI 10.1093/brain/40.2-3.188; Hiersemenzel LP, 2000, NEUROLOGY, V54, P1574, DOI 10.1212/WNL.54.8.1574; HILTON J, 1860, LANCET          1027, P401; Janssen TWJ, 1997, ARCH PHYS MED REHAB, V78, P697, DOI 10.1016/S0003-9993(97)90076-9; Karlsson AK, 1999, SPINAL CORD, V37, P383, DOI 10.1038/sj.sc.3100867; KEWALRAMANI LS, 1980, AM J PHYS MED REHAB, V59, P1; Ko HY, 1999, SPINAL CORD, V37, P402, DOI 10.1038/sj.sc.3100840; Krassioukov AV, 2002, J NEUROTRAUM, V19, P1521, DOI 10.1089/089771502762300193; Krassioukov AV, 1999, NEUROSCIENCE, V88, P959, DOI 10.1016/S0306-4522(98)00267-X; Krassioukov AV, 1999, SPINAL CORD, V37, P6, DOI 10.1038/sj.sc.3100718; Krassioukov AV, 1996, NEUROSCIENCE, V70, P211, DOI 10.1016/0306-4522(95)00294-S; Krenz NR, 1999, J NEUROSCI, V19, P7405, DOI 10.1523/JNEUROSCI.19-17-07405.1999; KRUM H, 1992, PARAPLEGIA, V30, P381, DOI 10.1038/sc.1992.87; Lee B, 1994, J SPINAL CORD MED, V18, P75; LEHMANN KG, 1987, J AM COLL CARDIOL, V10, P46, DOI 10.1016/S0735-1097(87)80158-4; LINDAN R, 1980, PARAPLEGIA, V18, P285, DOI 10.1038/sc.1980.51; Mathias CF, 1992, AUTONOMIC FAILURE TX, P839; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1402, DOI 10.1016/S0003-9993(99)90251-4; Nacimiento W, 1999, ARCH NEUROL-CHICAGO, V56, P1033, DOI 10.1001/archneur.56.8.1033; Noreau L, 2000, AM J PHYS MED REHAB, V79, P526, DOI 10.1097/00002060-200011000-00009; PINE ZM, 1991, AM J PHYS MED REHAB, V70, P271, DOI 10.1097/00002060-199110000-00008; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; SHEA JD, 1973, SOUTHERN MED J, V66, P869, DOI 10.1097/00007611-197308000-00006; Silver J R, 1971, Paraplegia, V8, P231; Silver JR, 2000, SPINAL CORD, V38, P229, DOI 10.1038/sj.sc.3100996; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; YARKONY GM, 1986, ARCH PHYS MED REHAB, V67, P834; 2002, NEUROSURGERY, V50, pS51	42	135	147	1	11	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					707	716		10.1089/089771503767869944			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000002	12965050				2022-02-06	
J	Cuevas, P; Carceller, F; Dujovny, M; Garcia-Gomez, I; Cuevas, B; Gonzalez-Corrochano, R; Diaz-Gonzalez, D; Reimers, D				Cuevas, P; Carceller, F; Dujovny, M; Garcia-Gomez, I; Cuevas, B; Gonzalez-Corrochano, R; Diaz-Gonzalez, D; Reimers, D			Peripheral nerve regeneration by bone marrow stromal cells	NEUROLOGICAL RESEARCH			English	Article						sciatic nerve transection; bone marrow stromal cells; implantation; regeneration	TRAUMATIC BRAIN INJURY; TRANSPLANTATION; RATS; RECOVERY; STROKE	Adult bone marrow contains stem cells that have attracted interest through their possible use for cell therapy in neurological diseases. Bone marrow stromal cells (MSCs) were harvested from donor adult rats, cultured and pre-labeled with bromodeoxyuridine (BrdU) previously to be injected in the distal stump of transected sciatic nerve of the rats. Distal nerve stump of control rats received culture medium solution. MSCs-treated rats exhibit significant improvement on walking track test at days 18 and 33 compared to controls. Dual immunofluorescence labeling shows that BrdU reactive cells survive in the injected area of transected sciatic nerve at least 33 days after implantation, and almost 5% of BrdU cells express Schwann cell-like phenotype (S 100 immunoreactivity). Because MSCs injected in a lesioned peripheral nerve can survive, migrate, differentiate in Schwann cells, and promote functional recovery, they may be an important source for cellular therapy in several neurological diseases.	Univ Alcala de Henares, Serv Histol, Dept Invest, Hosp Ramon y Cajal, E-28034 Madrid, Spain; Wayne State Univ, Dept Neurosurg, Detroit, MI USA		Cuevas, P (corresponding author), Univ Alcala de Henares, Serv Histol, Dept Invest, Hosp Ramon y Cajal, E-28034 Madrid, Spain.	pedro.cuevas@hrc.es	Reimers, Diana/K-6584-2017	Reimers, Diana/0000-0002-2837-099X			Ansselin AD, 1997, NEUROPATH APPL NEURO, V23, P387, DOI 10.1111/j.1365-2990.1997.tb01313.x; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Brehm M, 2002, EUR J CLIN INVESTIG, V32, P77; BREHM M, 2002, EUR J CLIN INVEST, V32, P76; BRUNELLI GA, 1994, MICROSURG, V15, P176, DOI 10.1002/micr.1920150307; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dijkstra JR, 2000, J NEUROSCI METH, V96, P89, DOI 10.1016/S0165-0270(99)00174-0; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; MADISON RD, 1992, WOUND HEALING BIOCH, P450; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MILLESI H, 1972, J BONE JOINT SURG AM, VA 54, P727, DOI 10.2106/00004623-197254040-00004; MILLESI H, 1990, WORLD J SURG, V14, P733, DOI 10.1007/BF01670520; Mosahebi A, 2002, EXP NEUROL, V173, P213, DOI 10.1006/exnr.2001.7846; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Strauer BE, 2001, DEUT MED WOCHENSCHR, V126, P932, DOI 10.1055/s-2001-16579-1; Vanderhooft E, 2000, HAND CLIN, V16, P93; Varejao ASP, 2001, J NEUROSCI METH, V108, P1, DOI 10.1016/S0165-0270(01)00378-8; WALL PD, 1979, PAIN, V7, P103, DOI 10.1016/0304-3959(79)90002-2	25	135	163	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	OCT	2002	24	7					634	638		10.1179/016164102101200564			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	604AE	WOS:000178592800001	12392196				2022-02-06	
J	Yatsiv, I; Morganti-Kossmann, MC; Perez, D; Dinarello, CA; Novick, D; Rubinstein, M; Otto, VI; Rancan, M; Kossmann, T; Redaelli, CA; Trentz, O; Shohami, E; Stahel, PF				Yatsiv, I; Morganti-Kossmann, MC; Perez, D; Dinarello, CA; Novick, D; Rubinstein, M; Otto, VI; Rancan, M; Kossmann, T; Redaelli, CA; Trentz, O; Shohami, E; Stahel, PF			Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						inflammatory response; traumatic brain injury; CSF	INTERLEUKIN-18 BINDING-PROTEIN; RAT-BRAIN; PROINFLAMMATORY CYTOKINE; IFN-GAMMA; TNF-ALPHA; EXPRESSION; RESPONSES; CLONING; INFECTION; INDUCTION	Proinflammatory cytokines are important mediators of neuroinflammation after traumatic brain injury. The role of interleukin (IL)-18. a new member of the IL-1 family, in brain trauma has not been reported to date. The authors investigated the posttraumatic release of IL-18 in murine brains following experimental closed head injury (CHI) and in CSF of CHI patients. In the mouse model, intracerebral IL-18 was induced within 24 hours by ether anesthesia and sham operation. Significantly elevated levels of IL-18 were detected at 7 days after CHI and in human CSF up to 10 days after trauma. Published data imply that IL-18 may play a pathophysiological role in inflammatory CNS diseases; therefore its inhibition may ameliorate outcome after CHI. To evaluate the functional aspects of IL-18 in the injured brain, mice were injected systemically with IL-18-binding protein (IL-18BP), a specific inhibitor of IL-18, I hour after trauma, IL-18BP-treated mice showed a significantly improved neurological recovery by 7 clays, accompanied by attenuated intracerebral IL-18 levels. This demonstrates that inhibition of IL-18 is associated with improved recovery. However, brain edema at 24 hours was not influenced by IL-18BP, suggesting that inflammatory mediators other than IL-18 induce the early detrimental effects of intracerebral inflammation.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, Hadassah Med Ctr, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Pediat Intens Care Unit, IL-91120 Jerusalem, Israel; Free Univ Berlin, Univ Hosp Bejamin Franklin, Dept Trauma & Reconstruct Surg, D-1000 Berlin, Germany; Univ Bern, Inselspital, Sch Med, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO USA; Monash Univ, Alfred Hosp, Dept Trauma Surg, Prahran, Vic, Australia; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Div Res, CH-8091 Zurich, Switzerland		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, Hadassah Med Ctr, IL-91120 Jerusalem, Israel.		Dinarello, Charles/C-8524-2013	Morganti-Kossmann, Cristina/0000-0002-0807-2063; Perez, Daniel/0000-0002-3154-7311	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI015614, R37AI015614] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI-15614] Funding Source: Medline		Aizawa Y, 1999, FEBS LETT, V445, P338, DOI 10.1016/S0014-5793(99)00148-9; Akira S, 2000, CURR OPIN IMMUNOL, V12, P59, DOI 10.1016/S0952-7915(99)00051-5; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conti B, 1999, MOL BRAIN RES, V67, P46, DOI 10.1016/S0169-328X(99)00034-0; Culhane AC, 1998, MOL PSYCHIATR, V3, P362, DOI 10.1038/sj.mp.4000389; Dinarello CA, 2000, ANN RHEUM DIS, V59, P17; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Fassbender K, 1999, NEUROLOGY, V53, P1104, DOI 10.1212/WNL.53.5.1104; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hodges JL, 2001, VIRAL IMMUNOL, V14, P181, DOI 10.1089/088282401750234556; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jander S, 1998, J NEUROIMMUNOL, V91, P93, DOI 10.1016/S0165-5728(98)00162-3; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; JENNETT B, 1975, LANCET, V1, P480; Kampfer H, 2000, EUR CYTOKINE NETW, V11, P626; Kim SH, 2000, P NATL ACAD SCI USA, V97, P1190, DOI 10.1073/pnas.97.3.1190; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Losy J, 2001, ACTA NEUROL SCAND, V104, P171, DOI 10.1034/j.1600-0404.2001.00356.x; McInnes IB, 2000, IMMUNOL TODAY, V21, P312, DOI 10.1016/S0167-5699(00)01648-0; Menge T, 2001, J NEUROSCI RES, V65, P332, DOI 10.1002/jnr.1158; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Novick D, 2001, CYTOKINE, V14, P334, DOI 10.1006/cyto.2001.0914; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471-4159.1999.0722215.x; Reznikov LL, 2000, P NATL ACAD SCI USA, V97, P2174, DOI 10.1073/pnas.040582597; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; TEASDALE G, 1974, LANCET, V2, P81; Wei XQ, 1999, J IMMUNOL, V163, P2821; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wheeler RD, 2000, MOL BRAIN RES, V77, P290, DOI 10.1016/S0169-328X(00)00069-3	39	135	138	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2002	22	8					971	978		10.1097/00004647-200208000-00008			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	579PL	WOS:000177187000008	12172382	Bronze			2022-02-06	
J	McCrory, P				McCrory, P			Does second impact syndrome exist?	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; cerebral edema; second impact syndrome	MINOR HEAD-INJURY; DELAYED DETERIORATION; BRAIN INJURY; 2ND IMPACT; CONCUSSION; TALK; SPORTS; FOOTBALLERS; MANAGEMENT; CHILDREN	Second impact syndrome (SIS) is a widely feared complication of traumatic brain injury. Although postulated to occur after repeated concussion, the evidence for such a premise is nor compelling. This paper reviews the published evidence for and against the existence of this controversial entity. Rather than SIS being a complication nf recurrent concussion it is far more likely that the clinical condition represents "diffuse cerebral swelling," a well-recognized complication of traumatic brain injury. This condition is more common in children and adolescents. which reflects the known demographics of so-called "second impact syndrome." We propose that clinicians abandon the misleading term second impact syndrome and refer to the syndrome as diffuse cerebral swelling.	Univ Melbourne, Ctr Sports Med Res & Educ, Melbourne, Vic, Australia; Univ Melbourne, Brain Res Inst, Melbourne, Vic, Australia		McCrory, P (corresponding author), 31 Grosvenor Parade, Balwyn, Vic 3101, Australia.		McCrory, Paul/Q-8688-2019				Barth JT, 1989, MILD HEAD INJURY, P257; BOLLINGER O, 1891, INT BEITRAGE WEISSEN, P457; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CANTU R, 1995, BOXING MED; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; *CO MED SOC, 1991, REP SPORTS MED COMM; CORALES RL, 1980, INTRACRANIAL PRESSUR, V4, P280; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hugenholtz H, 1983, Phys Sportsmed, V11, P71, DOI 10.1080/00913847.1983.11708560; JOKL E, 1941, MED ASPECTS BOXING; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; JORDAN BD, 1991, HOSP MED, V27, P93; JORDAN BD, 1993, MED ASPECTS BOXING; Joseph R, 1998, CHILD PSYCHIAT HUM D, V29, P169, DOI 10.1023/A:1025092117657; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KOBRINE AI, 1977, J NEUROSURG, V46, P256, DOI 10.3171/jns.1977.46.2.0256; KULUND D, 1982, INJURED ATHLETE, P225; Levin H.S., 1989, MILD HEAD INJURY; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS25; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MELLION BT, 1992, COMPLICATIONS SEQUEL, P51; Mueller F., 1996, CATASTROPHIC INJURIE; NEE PA, 1993, BRIT MED J, V306, P1665, DOI 10.1136/bmj.306.6893.1665; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; REILLY PL, 1975, LANCET, V2, P375; RICE SG, 1995, SPORTS MED PRIM CARE, V1, P9; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SACKETT D, 1991, CLIN EPIDEMIOLOGY BA, P126; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider RC., 1973, HEAD NECK INJURIES F; SCHNITKER MT, 1949, J PEDIATR-US, V35, P557, DOI 10.1016/S0022-3476(49)80138-7; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TORG JF, 1991, ATHLETIC INJURIES HE, P54; Wako N, 1989, INTRACRANIAL PRESSUR, P593; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011	59	135	136	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2001	11	3					144	149		10.1097/00042752-200107000-00004			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	454YG	WOS:000169998900003	11495318				2022-02-06	
J	Hall, KM; Bushnik, T; Lakisic-Kazazic, B; Wright, J; Cantagallo, A				Hall, KM; Bushnik, T; Lakisic-Kazazic, B; Wright, J; Cantagallo, A			Assessing traumatic brain injury outcome measures for long-term follow-up of community-based individuals	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; follow-up studies; treatment outcome; rehabilitation	DISABILITY RATING-SCALE; FUNCTIONAL INDEPENDENCE MEASURE; SEVERE HEAD-INJURY; INTEGRATION QUESTIONNAIRE; REHABILITATION OUTCOMES; RELIABILITY; AWARENESS; RELATIVES; VALIDITY; RECOVERY	Objectives: To determine which outcome measures are best and least suited for assessing long-term functional outcome of individuals with traumatic brain injury (TBI) in the community. Design: Survey of participants in the community an average of 5 years after TBI. A battery of outcome measures was given. Setting: Community in northern California after inpatient rehabilitation. Participants: Forty-eight adult individuals with prior moderate to severe TBI. All subjects had received inpatient rehabilitation 2 to 9 years previously and could be reached for telephone interview. Main Outcome Measures: The Community Integration Questionnaire, Neurobehavioral Functioning Inventory (NFI), Patient Competency Rating Scale (PCRS), Level of Cognitive Functioning Scale (LCFS), FLM(TM) instrument, Functional Assessment Measure (FIM+FAM), Supervision Rating Scale (SRS), Disability Rating Scale (DRS), Revised Craig Handicap Assessment and Reporting Technique (R-CHART), and Glasgow Outcome Scale (GOS). The number of maximal scores on each of the surveys was studied to determine which instruments continued to reveal deficits years after TBI. Results: Most individuals obtained maximum scores, ie, functional independence, on these scales: LCFS, FIM motor subscale and total score, R-CHART physical independence subscale, FIM+FAM, GOS, and the SRS. Measures with the fewest maximum scores (<36%, measuring deficits still extant in the group) were the R-CHART cognition subscale and the NFI memory/attention and communication subscales, and employment subscales. Items, subscales, and total scores that showed good variability and correlated most highly and frequently with other scales also demonstrating good variability were the PCRS, the DRS and FIM+FAM employment items, the R-CHART cognition subscale, and the NFI motor, memory/attention, communication, and depression subscales (the R-CHART cognition subscale and NFI memory/attention subscale were highly correlated with the PCRS;.84,.83). Conclusions: Measures that appeared to contribute little to assessing functional status of a TBI sample years postinjury were the FIM, FIM+FAM, SRS, GOS, and LCFS. Measures that showed a range of deficits across participants were DRS employability, the NFI, PCRS, and the R-CHART cognition subscale.	Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Hosp Ferrara, Unita Operat Med Riabilitat, Ferrara, Italy		Bushnik, T (corresponding author), 950 S Bascom Ave,Suite 2011, San Jose, CA 95128 USA.			Bushnik, Tamara/0000-0003-3328-257X			Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bowers D., 1989, ARCH PHYS MED REHAB, V70, pA58; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; COHEN TD, 1995, ARCH PHYS MED REHAB, V76, P797; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; EMHOFF TA, 1991, J TRAUMA, V9, P1227; FISHER WP, 1995, ARCH PHYS MED REHAB, V76, P113, DOI 10.1016/S0003-9993(95)80020-4; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOKA RS, 1994, BRAIN INJ REHABIL, V26, P420; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hagan C., 1982, COGNITIVE REHABILITA, P131; HAGAN C, 1994, NEUROREHABILITATION, V4, P58; Hall K M, 1994, NeuroRehabilitation, V4, P76, DOI 10.3233/NRE-1994-4204; Hall K.M., 1998, J REHABIL OUTCOMES M, V2, P39; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann Allen W, 1994, Top Stroke Rehabil, V1, P1; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KILGORE KM, 1995, ARCH PHYS MED REHAB, V76, pSC21; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LONG WB, 1994, ARCH PHYS MED REHAB, V75, P144; MALKMUS D, 1979, REHABILITATION HEAD; McPherson KM, 1997, INT J REHABIL RES, V20, P1, DOI 10.1097/00004356-199703000-00001; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENGREN L, 1993, TUNN UNDERGR SP TECH, V8, P75, DOI 10.1016/0886-7798(93)90140-Q; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCRANTON J, 1970, Archives of Physical Medicine and Rehabilitation, V51, P1; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; *STAT U NEW YORK B, 1993, GUID UN DAT SYST MED; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; World Health Organization, 1997, ICIDH 2 INT CLASS IM	54	135	137	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2001	82	3					367	374		10.1053/apmr.2001.21525			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	407RG	WOS:000167284100013	11245760				2022-02-06	
J	Harvey, AG; Bryant, RA				Harvey, AG; Bryant, RA			Two-year prospective evaluation of the relationship between acute stress disorder and posttraumatic stress disorder following mild traumatic brain injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							INTERVIEW	Objective: To assess the ability of acute stress disorder to predict posttraumatic stress disorder (PTSD), the relationship between acute stress disorder and PTSD over the 2 years following mild traumatic brain injury was determined. Method: Survivors of motor vehicle accidents who sustained mild traumatic brain injuries were assessed for acute stress disorder within 1 month of the trauma (N=79) and for PTSD at 6 months (N=63) and 2 years (N=50) posttrauma, Results: Acute stress disorder was diagnosed in 14% of the patients. Among the patients who participated in all three assessments, 80% of the subjects who met the criteria for acute stress disorder were diagnosed with PTSD at 2 years. Of the total initial group, 73% of those diagnosed with acute stress disorder had PTSD at 2 years. Conclusions: This study provides further support for the utility of the acute stress disorder diagnosis as a predictor of PTSD but indicates that the predictive power of the diagnostic criteria can be increased by placing greater emphasis on reexperiencing, avoidance, and arousal symptoms.	Univ New S Wales, Sch Psychol, Sydney, NSW, Australia		Harvey, AG (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, IN PRESS J ABNORM PS; Fleiss J.L., 1981, STAT METHODS RATES P; Foa Edna B., 1996, P207; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hyman IE, 1998, CLIN PSYCHOL REV, V18, P933, DOI 10.1016/S0272-7358(98)00041-5; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; RATTOCK J, 1993, J CLIN EXPT NEUROPSY, V6, P243; ROBINS E, 1970, AM J PSYCHIAT, V126, P983, DOI 10.1176/ajp.126.7.983; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553	19	135	144	1	6	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	APR	2000	157	4					626	628		10.1176/appi.ajp.157.4.626			3	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	300BE	WOS:000086232300021	10739425				2022-02-06	
J	Wang, CX; Olschowka, JA; Wrathall, JR				Wang, CX; Olschowka, JA; Wrathall, JR			Increase of interleukin-1 beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat	BRAIN RESEARCH			English	Article						cytokine; CNS; spinal cord injury; contusion; mRNA; ELISA	TUMOR-NECROSIS-FACTOR; FACTOR MESSENGER-RNA; FACTOR-ALPHA; BRAIN INJURY; EXPRESSION; CYTOKINES; INDUCTION; CONTUSION; ISCHEMIA; IL-6	Interleukin-1 beta (IL-1 beta) is a major mediator of inflammation and a growth promoter for many cell types that could play an important role in the consequences of traumatic spinal cord injury (SCI). In the present study, the expression of IL-1 beta and its mRNA was determined in the rat spinal cord following a standardized contusion injury. IL-1 beta mRNA, measured with quantitative RT-PCR, was significantly increased in the lesion site by 1 h after SCI (35.2 +/- 5.9 vs. 9.1 +/- 2.1 pg/mg RNA, n = 3, P < 0.05) and remained significantly higher than in the normal spinal cord for at least 72 h post-injury (p.i.). IL-1 beta mRNA levels in tissue immediately caudal to the lesion site did not change after the injury. IL-1 beta protein levels, measured by an ELISA, were determined at the lesion site and in cerebrospinal fluid (CSF) and serum samples. IL-1 beta levels in the CSF and serum were much lower than in the spinal cord. At the lesion site, IL-1 beta was increased significantly by 1 h p.i., peaked at 8 h (32.3 +/- 0.1 vs. 7.6 +/- 1.9, ng/g tissue, n = 5, P < 0.05) and remained significantly higher than normal through at least 7 days p.i. These results suggest that the increased IL-1 beta mRNA and protein levels are an early and local response at the lesion site that could trigger other, later, responses to traumatic SCI.	GEORGETOWN UNIV, DEPT CELL BIOL, WASHINGTON, DC 20007 USA; UNIV ROCHESTER, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS032671] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS32671] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01-28130] Funding Source: Medline		AGGARWAL BB, 1992, TUMOR NECROSIS FACTO, P61; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BAKHIT C, 1991, BRAIN RES, V554, P264, DOI 10.1016/0006-8993(91)90199-6; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; BENVENISTE EN, 1990, AM J PHYSIOL, V269, pC1; BEULTER B, 1988, ANNU REV BIOCHEM, V57, P505; BRENNEMAN DE, 1992, J NEUROCHEM, V58, P454, DOI 10.1111/j.1471-4159.1992.tb09743.x; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; ENG LF, 1992, PROG BRAIN RES, V94, P353; FAN L, 1995, MOL BRAIN RES, V30, P125; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; FORSTER E, 1994, BIOTECHNIQUES, V16, P18; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1988, J NEUROSCI, V8, P2485; HIGGINS GA, 1991, MOL BRAIN RES, V9, P143, DOI 10.1016/0169-328X(91)90139-O; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; KLIR JJ, 1993, AM J PHYSIOL, V265, pR512, DOI 10.1152/ajpregu.1993.265.3.R512; LE JM, 1987, LAB INVEST, V56, P234; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; MEHTA VK, 1994, EUR J ENDOCRINOL, V130, P208, DOI 10.1530/eje.0.1300208; MILLER LG, 1991, MOL PHARMACOL, V39, P105; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; MOKATA T, 1991, J CBFM, V11, P966; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1994, NEUROBIOLOGY CENTRAL, P99; NUTTIN B, 1994, ACTA NEUROL BELG, V94, P64; PANJABI MM, 1988, SPINE, V13, P1365, DOI 10.1097/00007632-198812000-00007; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; RAINES A, 1988, Journal of Neurotrauma, V5, P151, DOI 10.1089/neu.1988.5.151; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; REYNOLDS ME, 1991, BRAIN RES, V559, P149, DOI 10.1016/0006-8993(91)90298-A; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; WANG J, 1994, J NEUROSURG, V80, P484, DOI 10.3171/jns.1994.80.3.0484; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; WRATHALL JR, 1994, NEUROBIOLOGY CENTRAL, P79; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; YOSHIDA K, 1992, J NEUROCHEM, V59, P919, DOI 10.1111/j.1471-4159.1992.tb08331.x	50	135	148	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 13	1997	759	2					190	196		10.1016/S0006-8993(97)00254-0			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XG545	WOS:A1997XG54500002	9221936				2022-02-06	
J	Posmantur, R; Kampfl, A; Siman, R; Liu, SJ; Zhao, X; Clifton, GL; Hayes, RL				Posmantur, R; Kampfl, A; Siman, R; Liu, SJ; Zhao, X; Clifton, GL; Hayes, RL			A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat	NEUROSCIENCE			English	Article						calpain inhibitor 2; TBI; neurofilament proteins; spectrin; axons; dendrites	MICROTUBULE-ASSOCIATED PROTEIN-2; MIDDLE CEREBRAL-ARTERY; EXCITATORY AMINO-ACIDS; CALCIUM-ACTIVATED PROTEOLYSIS; TRANSIENT FOREBRAIN ISCHEMIA; LONG-TERM POTENTIATION; FLUID-PERCUSSION MODEL; SPINAL-CORD INJURY; NEUROFILAMENT PROTEINS; HIPPOCAMPAL-NEURONS	The capacity of a calpain inhibitor to reduce losses of neurofilament 200-, neurofilament 68- and calpain 1-mediated spectrin breakdown products was examined following traumatic brain injury in the rat. Twenty-four hours after unilateral cortical impact injury, western blot analyses detected neurofilament 200 losses of 65% (ipsilateral) and 36% (contralateral) of levels observed in naive, uninjured rat cortices. Neurofilament 68 protein levels decreased only in the ipsilateral cortex by 35% relative to naive protein levels. Calpain inhibitor 2. administered 10 min after injury via continuous arterial infusion into the right external carotid artery for 24 h, significantly reduced neurofilament 200 losses to 17% and 3% relative to naive neurofilament 200 protein levels in the ipsilateral and contralateral cortices, respectively. Calpain inhibitor administration abolished neurofilament 68 loss in the ipsilateral cortex and was accompanied by a reduction of putative calpain-mediated neurofilament 68 breakdown products. Spectrin breakdown products mediated by calpain 1 activation were detectable in both hemispheres 23 h after traumatic brain injury and were substantially reduced in animals treated with calpain inhibitor 2 both ipsilaterally and contralaterally to the site of injury. Qualitative immunofluorescence studies of neurofilament 200 and neurofilament 68 confirmed western blot data, demonstrating morphological protection of neuronal structure throughout cortical regions of the traumatically injured brain. Morphological protection included preservation of dendritic structure and reduction of axonal retraction balls. In addition, histopathological studies employing hematoxylin and eosin staining indicated reduced extent of contusion al the injury site. These data indicate that calpain inhibitors could represent a viable strategy for preserving the cytoskeletal structure of injured neurons after experimental traumatic brain injury in vivo. (C) 1997 IBRO.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; CEPHALON INC,W CHESTER,PA 19380						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458, P01 NS31998] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER		BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DELCERRO S, 1990, BRAIN RES, V530, P91; DENNY JB, 1990, BRAIN RES, V534, P317, DOI 10.1016/0006-8993(90)90148-5; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GOTO K, 1994, MOL BRAIN RES, V23, P40, DOI 10.1016/0169-328X(94)90209-7; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; KAMPFL A, 1995, NEUROSCI LETT, V194, P149, DOI 10.1016/0304-3940(95)11745-I; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MORIOKA M, 1992, J NEUROCHEM, V58, P1798, DOI 10.1111/j.1471-4159.1992.tb10056.x; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NISHIDA A, 1994, STROKE, V25, P1247, DOI 10.1161/01.STR.25.6.1247; NIXON RA, 1990, J NEUROCHEM, V55, P1950, DOI 10.1111/j.1471-4159.1990.tb05781.x; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; North M, 1989, PROTEOLYTIC ENZYMES, P105; OGATA N, 1989, J NEUROSURG, V70, P103, DOI 10.3171/jns.1989.70.1.0103; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PERLMUTTER LS, 1988, SYNAPSE, V2, P79, DOI 10.1002/syn.890020111; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; SAATMAN KE, 1996, J NEUROPATH EXP NEUR, V55, P852; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SHAW G, 1986, BIOESSAYS, V4, P161, DOI 10.1002/bies.950040406; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WEILOCH T, 1991, J NEUROCHEM, V56, P1227; WHITSON JS, 1995, BRAIN RES, V694, P213, DOI 10.1016/0006-8993(95)00745-C; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523	77	135	139	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience	APR	1997	77	3					875	888		10.1016/S0306-4522(96)00483-6			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL304	WOS:A1997WL30400021	9070759				2022-02-06	
J	Kampfl, A; Posmantur, R; Nixon, R; Grynspan, F; Zhao, X; Liu, SJ; Newcomb, JK; Clifton, GL; Hayes, RL				Kampfl, A; Posmantur, R; Nixon, R; Grynspan, F; Zhao, X; Liu, SJ; Newcomb, JK; Clifton, GL; Hayes, RL			mu-Calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						mu-calpain; autolysis; cytoskeleton; alpha-spectrin; traumatic brain injury	MICROTUBULE-ASSOCIATED PROTEIN-2; EXCITATORY AMINO-ACIDS; TRANSIENT FOREBRAIN ISCHEMIA; MIDDLE CEREBRAL-ARTERY; NEUROFILAMENT PROTEINS; HIPPOCAMPAL-NEURONS; NEUTRAL PROTEASE; LEVELS DECREASE; RAT-BRAIN; CALCIUM	Increasing evidence suggests that excessive activation of the calcium-activated neutral protease mu-calpain could play a major role in calcium-mediated neuronal degeneration after acute brain injuries. To further investigate the changes of the in vivo activity of mu-calpain after unilateral cortical impact injury in vivo, the ratio of the 76-kDa activated isoform of mu-calpain to its 80-kDa precursor was measured by western blotting. This mu-calpain activation ratio increased to threefold in the pellet of cortical samples ipsilateral to the injury site at 15 min, 1 h, 3 h, and 6 h after injury and returned to control levels at 24-48 h after injury. We also investigated the effect of mu-calpain activation on proteolysis of the neuronal cytoskeletal protein alpha-spectrin. Immunoreactivity for alpha-spectrin breakdown products was detectable within 15 min after injury in cortical samples ipsilateral to the injury site. The levels of alpha-spectrin breakdown products increased in a biphasic manner, with a large increase between 15 min and 6 h after injury, followed by a smaller increase between 6 and 24 h after the insult. No further accumulation of alpha-spectrin breakdown products was observed between 24 and 48 h after injury. Histopathological examinations using hematoxylin and eosin staining demonstrated dark, shrunken neurons within 15 min after traumatic brain injury. No evidence of mu-calpain autolysis, calpain-mediated alpha-spectrin degradation, or hematoxylin and eosin neuronal pathology was detected in the contralateral cortex. Although mu-calpain autolysis and cytoskeletal proteolysis occurred concurrently with early morphological alterations, evidence of calpain-mediated proteolysis preceded the full expression of evolutionary histopathological changes. Our results indicate that rapid and persistent mu-calpain activation plays an important role in cortical neuronal degeneration after traumatic brain injury. Our data also suggest that specific inhibitors of calpain could be potential therapeutic agents for the treatment of traumatic brain injury in vivo.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; HARVARD UNIV,SCH MED,MCLEAN HOSP,LABS MOL NEUROSCI,BELMONT,MA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31998, R01 NS21458] Funding Source: Medline		BANIK NL, 1987, METAB BRAIN DIS, V2, P117, DOI 10.1007/BF00999722; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CONG JY, 1989, J BIOL CHEM, V264, P10096; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDMUNDS T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P197, DOI 10.1016/0167-4838(91)90059-9; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GEORGE EB, 1995, J NEUROSCI, V15, P6445; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; KAMPFL A, 1995, NEUROSCI LETT, V194, P149, DOI 10.1016/0304-3940(95)11745-I; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kleese W.C., 1990, INTRACELLULAR CALCIU, P3; KMAPFL A, 1996, EUR J NEUROSCI, V8, P344; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MORIOKA M, 1992, J NEUROCHEM, V58, P1798, DOI 10.1111/j.1471-4159.1992.tb10056.x; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; Neumar RW, 1996, J NEUROCHEM, V66, P421; NISHIDA A, 1994, STROKE, V25, P1247, DOI 10.1161/01.STR.25.6.1247; NIXON RA, 1990, J NEUROCHEM, V55, P1950, DOI 10.1111/j.1471-4159.1990.tb05781.x; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; OSTWALD K, 1994, J NEUROCHEM, V63, P1069; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POSMANTUR RM, 1995, J NEUROTRAUM, V12, P972; POSMANTUR RM, 1996, IN PRESS NEUROSCIENC; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman K. E., 1995, Journal of Neurotrauma, V12, P481; SAATMAN KE, 1995, J NEUROTRAUMA, V12, P138; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; YAMASAKI Y, 1992, NEUROSCIENCE, V49, P545, DOI 10.1016/0306-4522(92)90225-Q; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	67	135	139	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	1996	67	4					1575	1583					9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	VH578	WOS:A1996VH57800030	8858942				2022-02-06	
J	Young, B; Runge, JW; Waxman, KS; Harrington, T; Wilberger, J; Muizelaar, JP; Boddy, A; Kupiec, JW				Young, B; Runge, JW; Waxman, KS; Harrington, T; Wilberger, J; Muizelaar, JP; Boddy, A; Kupiec, JW			Effects of pegorgotein on neurologic outcome of patients with severe head injury - A multicenter, randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONJUGATED SUPEROXIDE-DISMUTASE; CEREBRAL ISCHEMIA-REPERFUSION; SCALE; COMA	Objective.-To evaluate outcome of patients with severe closed head injury treated with pegorgotein, a scavenger of oxygen-derived free radicals. Design.-Randomized, parallel, placebo-controlled, third-party-blind, multicenter trial, with a blinded, multicenter follow-up protocol. Setting.-Twenty-nine centers in the United States. Patients.-A total of 463 patients with severe closed head injury and a Glasgow Coma Scale score of 8 or less after resuscitation and stabilization. Interventions.-Patients received a single intravenous dose of placebo, 10 000 U/kg of pegorgotein, or 20 000 U/kg of pegorgotein within 8 hours after injury. Outcome Measures.-The primary endpoint was the Glasgow Outcome Scale (GOS) score at 3 months after brain injury with GOS data trichotomized into good, fair, or poor outcome. Secondary efficacy endpoints included the Disability Rating Scale (DRS) and mortality. A secondary analysis was performed using GOS scores dichotomized into favorable and unfavorable outcomes. In a follow-up protocol at 6 months, GOS and DRS scores were again determined. Results.-Of 463 patients randomized, 162 received placebo; 149, pegorgotein 10 000 U/kg; and 152, pegorgotein 20 000 U/kg. Treatment groups were comparable with respect to demographic characteristics, mechanism of injury, and time to treatment. Pegorgotein was well tolerated at both dose levels. At month 3, the trichotomized analysis found no significant statistical difference in neurologic outcome between the pegorgotein and the placebo groups. Although differences were not statistically significant, there were more favorable outcomes and no increase in the number of deaths or vegetative states among the patients given pegorgotein, more subjects had good or favorable outcomes with the 10 000-U/kg dose than with the 20 000-U/kg dose or placebo, and less disability was observed with the 10 000-U/kg dose than with either the 20 000-U/kg dose or placebo. No differences in mortality rate or cause of death were found between the 10 000-U/kg and placebo groups at either month 3 or month 6. The only statistically significant difference between the groups was a decreased incidence of adult respiratory distress syndrome in the 10 000-U/kg group as compared with the placebo group (P<.015). Conclusions-in this clinical trial of 463 patients with severe head injury, no statistically significant difference in neurologic outcome or mortality was observed between patients treated with pegorgotein and those receiving placebo.	CAROLINAS MED CTR, DEPT EMERGENCY MED, CHARLOTTE, NC 28203 USA; SANTA BARBARA COTTAGE HOSP, SANTA BARBARA, CA USA; BARROW NEUROL INST, DEPT NEUROSURG, PHOENIX, AZ 85013 USA; ALLEGHENY GEN HOSP, PITTSBURGH, PA 15212 USA; WAYNE STATE UNIV, DEPT NEUROSURG, DETROIT, MI USA; SANOFI WINTHROP INC, SANOFI RES DIV, MALVERN, PA USA		Young, B (corresponding author), UNIV KENTUCKY, ALBERT B CHANDLER MED CTR,DEPT SURG,COLL MED, DIV NEUROSURG, 800 ROSE ST, LEXINGTON, KY 40536 USA.						ABRAMSON NS, 1990, ANN EMERG MED, V19, P781, DOI 10.1016/S0196-0644(05)81703-2; BRIGHAM KL, 1991, KLIN WOCHENSCHR, V69, P1004, DOI 10.1007/BF01645147; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CROSS CE, 1990, ADV EXP MED BIOL, V264, P435; HALL ED, 1993, RES P ARNMD, V71, P81; HE YY, 1993, AM J PHYSIOL, V265, pH252, DOI 10.1152/ajpheart.1993.265.1.H252; JENNETT B, 1975, LANCET, V1, P480; LEFF JA, 1993, AM J PHYSIOL, V265, pL501, DOI 10.1152/ajplung.1993.265.5.L501; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE G, 1974, LANCET, V2, P81; VANASBECK BS, 1989, RESUSCITATION, V18, pS63, DOI 10.1016/0300-9572(89)90054-3	14	135	136	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					538	543		10.1001/jama.276.7.538			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	WOS:A1996VC10100029	8709402				2022-02-06	
J	Schwab, S; Aschoff, A; Spranger, M; Albert, F; Hacke, W				Schwab, S; Aschoff, A; Spranger, M; Albert, F; Hacke, W			The value of intracranial pressure monitoring in acute hemispheric stroke	NEUROLOGY			English	Article							SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; CEREBRAL INFARCTION; MASS LESIONS; INTENSIVE-CARE; BRAIN EDEMA; MANAGEMENT; THERAPY; DETERIORATION; COMPLICATIONS	Background and purpose: Persistently elevated intracranial pressure (ICP) has been associated with poor clinical outcome after severe brain injury, such as neurotrauma, intracerebral hemorrhage, and subarachnoidal hemorrhage. Although ICP monitoring is increasingly being used in intensive care treatment of patients with ischemic stroke, its value has not been established. Patients and methods: The clinical course of 48 patients with the clinical signs of increased ICP due to large hemispheric or middle cerebral artery territory infarction defined by CT and subjected to ICP monitoring was prospectively evaluated. Epidural ICP probes were inserted ipsilaterally to the site of primary brain injury in all and also contralaterally in seven patients. Initial clinical presentation was assessed by the Scandinavian Stroke Scale (SSS) and the Glasgow Coma Score (GCS). All patients were treated according to a standardized treatment protocol for elevated ICP. ICP values were correlated with the clinical presentation at the time point of deterioration, with outcome, and with CT findings. Different treatment strategies to lower ICP were analyzed as to their effectiveness. Results: Only nine of the 48 patients survived the infarct (19%). The cause of death was transtentorial herniation with subsequent brain death in all 39 patients. The patients' mean SSS on admission was 20.6 (survivors 21.5 +/- 5.6, nonsurvivors 19.8 +/- 6.5). In all patients clinical signs of herniation preceded the increase in ICP. Patients with ICP values > 35 mm Hg did not survive. CT changes did not always correspond with the measured ICP values. All medical strategies to lower ICP, including osmotherapy, hyperventilation, THAM-buffer, and barbiturates, were initially effective, but only in a minority of patients was ICP control sustained. Conclusions: TCP monitoring of large hemispheric infarction can predict clinical outcome. Pharmacologic intervention had no sustained effect. ICP monitoring was not helpful in guiding long-term treatment of increased ICP. It remains doubtful that ICP monitoring in acute ischemic stroke has a positive influence on clinical outcome.	UNIV HEIDELBERG, DEPT NEUROSURG, D-69120 HEIDELBERG, GERMANY		Schwab, S (corresponding author), UNIV HEIDELBERG, DEPT NEUROL, NEUENHEIMER FELD 400, D-69120 HEIDELBERG, GERMANY.		Hacke, Werner/ABE-8661-2020				ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASPLUND K, 1985, STROKE, V16, P885; BARNETT GH, 1988, J NEUROSURG, V68, P585, DOI 10.3171/jns.1988.68.4.0585; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOUNDS JV, 1981, STROKE, V12, P474, DOI 10.1161/01.STR.12.4.474; CLARK WC, 1989, NEUROSURGERY, V25, P20; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; GROTTA J, 1995, NEUROLOGY, V45, P640, DOI 10.1212/WNL.45.4.640; HACKE W, 1994, CEREBROVASC DIS, V4, P385, DOI 10.1159/000108517; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; KRIEGER D, 1995, CRIT CARE MED, V23, P1123, DOI 10.1097/00003246-199506000-00020; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; MAHONEY F I, 1965, Md State Med J, V14, P61; MARSHALL LF, 1978, CRIT CARE MED, V6, P1, DOI 10.1097/00003246-197801000-00001; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; RANKIN J, 1957, Scott Med J, V2, P200; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; ROPPER AH, 1992, ANN NEUROL, V32, P564, DOI 10.1002/ana.410320413; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P725, DOI 10.1001/archneur.1984.04050180047016; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SATO M, 1989, RESUSCITATION, V17, P233, DOI 10.1016/0300-9572(89)90039-7; SHAW CM, 1959, ARCH NEUROL-CHICAGO, V1, P161; TEASDALE G, 1975, LANCET, V1, P480; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; WOODCOCK J, 1982, STROKE, V13, P785, DOI 10.1161/01.STR.13.6.785	40	135	143	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG	1996	47	2					393	398		10.1212/WNL.47.2.393			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VC634	WOS:A1996VC63400013	8757010				2022-02-06	
J	Nichol, A; French, C; Little, L; Haddad, S; Presneill, J; Arabi, Y; Bailey, M; Cooper, DJ; Duranteau, J; Huet, O; Mak, A; McArthur, C; Pettila, V; Skrifvars, M; Vallance, S; Varma, D; Wills, J; Bellomo, R				Nichol, Alistair; French, Craig; Little, Lorraine; Haddad, Samir; Presneill, Jeffrey; Arabi, Yaseen; Bailey, Michael; Cooper, D. James; Duranteau, Jacques; Huet, Olivier; Mak, Anne; McArthur, Colin; Pettilae, Ville; Skrifvars, Markus; Vallance, Shirley; Varma, Dinesh; Wills, Judy; Bellomo, Rinaldo		EPO-TBI Investigators; ANZICS Clinical Trials Grp	Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial	LANCET			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; CRITICALLY-ILL PATIENTS; GLASGOW OUTCOME SCALE; EPOETIN-ALPHA; PROGESTERONE; RECOVERY; EFFICACY	Background Erythropoietin might have neurocytoprotective effects. In this trial, we studied its effect on neurological recovery, mortality, and venous thrombotic events in patients with traumatic brain injury. Methods Erythropoietin in Traumatic Brain Injury (IEPO-TBI) was a double-blind, placebo-controlled trial undertaken in 29 centres (all university-affiliated teaching hospitals) in seven countries (Australia, New Zealand, France, Germany, Finland, Ireland, and Saudi Arabia). Within 24 h of brain injury, 606 patients were randomly assigned by a concealed web-based computer-generated randomisation schedule to erythropoietin (40 000 units subcutaneously) or placebo (0.9% sodium chloride subcutaneously) once per week for a maximum of three doses. Randomisation was stratified by severity of traumatic brain injury (moderate vs severe) and participating site. With the exception of designated site pharmacists, the site dosing nurses at all sites, and the pharmacists at the central pharmacy in France, all study personnel, patients, and patients' relatives were masked to treatment assignment. The primary outcome, assessed at 6 months by modified intention-to-treat analysis, was improvement in the patients' neurological status, summarised as a reduction in the proportion of patients with an Extended Glasgow Outcome Scale (GOS-E) of 1-4 (death, vegetative state, and severe disability). Two equally spaced preplanned interim analyses were done (after 202 and 404 participants were enrolled). This study is registered with ClinicalTrials.gov, number NCT00987454. Findings Between May 3, 2010, and Nov 1, 2014, 606 patients were enrolled and randomly assigned to erythropoietin (n=308) or placebo (n=298). Ten of these patients (six in the erythropoietin group and four in the placebo group) were lost to follow up at 6 months; therefore, data for the primary outcome analysis was available for 596 patients (302 in the erythropoietin group and 294 in the placebo group). Compared with placebo, erythropoietin did not reduce the proportion of patients with a GOS-E level of 1-4 (134 [44%] of 302 patients in the erythropoietin group vs 132 [45%] of 294 in the placebo group; relative risk [RR] 0.99 [95% CI 0.83-1.18], p=0.90). In terms of safety, erythropoietin did not significantly affect 6-month mortality versus placebo (32 [11%] of 305 patients had died at 6 months in the erythropoietin group vs 46 [16%] of 297 [16%] in the placebo group; RR 0.68 [95% CI 0.44-1.03], p=0.07) or increase the occurrence of deep venous thrombosis of the lower limbs (48 [16%] of 305 vs 54 [18%] of 298; RR 0.87 [95% CI 0.61-1.24], p=0.44). Interpretation Following moderate or severe traumatic brain injury, erythropoietin did not reduce the number of patients with severe neurological dysfunction (IGOS-E level 1-4) or increase the incidence of deep venous thrombosis of the lower limbs. The effect of erythropoietin on mortality remains uncertain.	[Nichol, Alistair; Little, Lorraine; Presneill, Jeffrey; Arabi, Yaseen; Bailey, Michael; Cooper, D. James; Huet, Olivier; Mak, Anne; McArthur, Colin; Pettilae, Ville; Vallance, Shirley; Wills, Judy; Bellomo, Rinaldo] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [French, Craig] Univ Melbourne, Melbourne, Vic, Australia; [Nichol, Alistair; Cooper, D. James; Mak, Anne; Vallance, Shirley] The Alfred, Melbourne, Vic, Australia; [Nichol, Alistair] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland; [Nichol, Alistair] St Vincents Univ Hosp, Dublin 4, Ireland; [French, Craig] Western Hlth, Melbourne, Vic, Australia; [Haddad, Samir] King Abdul Aziz Med City, Natl Guard Hlth Aff airs, Riyadh, Saudi Arabia; [Presneill, Jeffrey] Univ Queensland, Brisbane, Qld, Australia; [Presneill, Jeffrey] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Arabi, Yaseen] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Duranteau, Jacques] Univ Paris 11, Hop Bicetre, Assistance Publ Hop Paris, Dept Anesthesie Reanimat, Paris, France; [Huet, Olivier] CHU La Cavale Blanche, Dept Anaesthesiol & Intens Care Med, Brest, France; [Pettilae, Ville; Skrifvars, Markus] Univ Helsinki, Helsinki, Finland; [Pettilae, Ville; Skrifvars, Markus] Helsinki Univ Hosp, Helsinki, Finland; [McArthur, Colin] Auckland City Hosp, Auckland, New Zealand; [Bellomo, Rinaldo] Austin Hosp, Melbourne, Vic 3084, Australia		French, C (corresponding author), Western Hlth, Dept Intens Care, Gordon St, Footscray, Vic 3011, Australia.	craig.french@wh.org.au	Arabi, Yaseen/ABF-3316-2020; Cooper, D. James/G-7961-2013; Bailey, Michael J/A-4499-2012; Presneill, Jeffrey J/B-4894-2012; French, Craig/ABF-5087-2020	Arabi, Yaseen/0000-0001-5735-6241; Cooper, D. James/0000-0002-5872-9051; Bailey, Michael J/0000-0002-5551-1401; Presneill, Jeffrey J/0000-0001-7177-7667; French, Craig/0000-0003-1363-9711; Nichol, Alistair Dualta/0000-0002-4771-5615; Whitehead, Christina/0000-0003-4561-7082; Richards, Brent/0000-0003-2613-0308; Harrois, Anatole/0000-0002-5098-4656; Huet, Olivier/0000-0001-7345-0334; Micallef, Sharon/0000-0002-8496-2324; Bellomo, Rinaldo/0000-0002-1650-8939; Nichol, Alistair/0000-0002-4689-1238	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Transport Accident Commission; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [545902]; Transport Accident Commission of Victoria [D162]	The National Health and Medical Research Council and the Transport Accident Commission.; EPO-TBI was supported by grants from the National Health and Medical Research Council of Australia (grant 545902) and the Transport Accident Commission of Victoria (grant D162). The members of the writing committee assume responsibility for the overall content and integrity of the article.	Abrishamkar S, 2012, J RES MED SCI, V17, P51; Aloizos S, 2015, TURK NEUROSURG, V25, P552, DOI 10.5137/1019-5149.JTN.9685-14.4; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Cook DJ, 2005, J CRIT CARE, V20, P364, DOI 10.1016/j.jcrc.2005.09.010; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2007, CAN MED ASSOC J, V177, P747, DOI 10.1503/cmaj.071150; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Corwin HL, 2014, J TRAUMA ACUTE CARE, V77, P774, DOI 10.1097/TA.0000000000000442; Hebert PC, 2007, CAN MED ASSOC J, V177, P697, DOI 10.1503/cmaj.071223; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lykissas MG, 2007, CLIN NEUROL NEUROSUR, V109, P639, DOI 10.1016/j.clineuro.2007.05.013; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nichol A, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0528-6; Nichol A, 2014, JAMA-J AM MED ASSOC, V312, P1928, DOI 10.1001/jama.2014.12738; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Presneill Jeffrey, 2014, Trials, V15, P501, DOI 10.1186/1745-6215-15-501; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; *US FDA, FDA STRENGTH SAF INF; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	30	134	140	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	2015	386	10012					2499	2506		10.1016/S0140-6736(15)00386-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ1LD	WOS:000366866400024	26452709				2022-02-06	
J	Rice, RA; Spangenberg, EE; Yamate-Morgan, H; Lee, RJ; Arora, RPS; Hernandez, MX; Tenner, AJ; West, BL; Green, KN				Rice, Rachel A.; Spangenberg, Elizabeth E.; Yamate-Morgan, Hana; Lee, Rafael J.; Arora, Rajan P. S.; Hernandez, Michael X.; Tenner, Andrea J.; West, Brian L.; Green, Kim N.			Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus	JOURNAL OF NEUROSCIENCE			English	Article						behavior; glia; inflammation; lesion; spines; synapse	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; TAU PATHOLOGY; IN-VIVO; CELLS; MICE; EXPRESSION; MONOCYTES; MODEL; MEMORY	With severe injury or disease, microglia become chronically activated and damage the local brain environment, likely contributing to cognitive decline. We previously discovered that microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for survival in the healthy adult brain, and we have exploited this dependence to determine whether such activated microglia contribute deleteriously to functional recovery following a neuronal lesion. Here, we induced a hippocampal lesion in mice for 25 d via neuronal expression of diphtheria toxin A-chain, producing both a neuroinflammatory reaction and behavioral alterations. Following the 25 d lesion, we administered PLX3397, a CSF1R inhibitor, for 30 d to eliminate microglia. This post-lesion treatment paradigm improved functional recovery on elevated plus maze and Morris water maze, concomitant with reductions in elevated proinflammatory molecules, as well as normalization of lesion-induced alterations in synaptophysin and PSD-95. Further exploration of the effects of microglia on synapses in a second cohort of mice revealed that dendritic spine densities are increased with long-term microglial elimination, providing evidence that microglia shape the synaptic landscape in the adult mouse brain. Furthermore, in these same animals, we determined that microglia play a protective role during lesioning, whereby neuronal loss was potentiated in the absence of these cells. Collectively, we demonstrate that microglia exert beneficial effects during a diphtheria toxin-induced neuronal lesion, but impede recovery following insult.	[Rice, Rachel A.; Spangenberg, Elizabeth E.; Yamate-Morgan, Hana; Lee, Rafael J.; Arora, Rajan P. S.; Hernandez, Michael X.; Tenner, Andrea J.; Green, Kim N.] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Dept Neurobiol & Behav, Irvine, CA 92697 USA; [West, Brian L.] Plexxikon Inc, Berkeley, CA 94710 USA		Green, KN (corresponding author), Univ Calif Irvine, 3208 Biol Sci 3, Irvine, CA 92697 USA.	kngreen@uci.edu		West, Brian/0000-0002-5320-3691	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS083801, P50 AG016573, F31NS086409, PPG AG 00538, T32 AG000096]; Whitehall Foundation; American Federation of Aging Research; Alzheimer's AssociationAlzheimer's Association; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS083801, F31NS086409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG016573, P01AG000538, T32AG000096] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health under awards 1R01NS083801 (NINDS) and P50 AG016573 (NIA) to K.N.G., F31NS086409 (NINDS) to R.A.R., PPG AG 00538 (NIA) to A.J.T., T32 AG000096 (NIA) to M.X.H., the Whitehall Foundation to K.N.G., American Federation of Aging Research to K.N.G., and the Alzheimer's Association to K.N.G. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Baglietto-Vargas D, 2013, BIOL PSYCHIAT, V74, P357, DOI 10.1016/j.biopsych.2012.12.003; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Butovsky O, 2012, J CLIN INVEST, V122, P3063, DOI 10.1172/JCI62636; Castello NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091453; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erblich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026317; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fiala M, 2002, EUR J CLIN INVEST, V32, P360, DOI 10.1046/j.1365-2362.2002.00994.x; Gao L, 2015, J EXP MED, V212, P469, DOI 10.1084/jem.20132423; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Ji K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056293; Kitazawa M, 2011, J IMMUNOL, V187, P6539, DOI 10.4049/jimmunol.1100620; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; Lee P, 1998, P NATL ACAD SCI USA, V95, P11371, DOI 10.1073/pnas.95.19.11371; Liu JSH, 1998, J IMMUNOL, V161, P1989; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Myczek K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106009; Neely KM, 2011, J NEUROSCI, V31, P2781, DOI 10.1523/JNEUROSCI.5156-10.2010; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Perry VH, 2010, ASN NEURO, V2, P281, DOI 10.1042/AN20100024; Pessac B, 2001, B ACAD NAT MED PARIS, V185, P337, DOI 10.1016/S0001-4079(19)34561-3; PETERS A, 1970, AM J ANAT, V127, P321, DOI 10.1002/aja.1001270402; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; RENNO T, 1995, J IMMUNOL, V154, P944; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schilling M, 2009, NEUROSCIENCE, V161, P806, DOI 10.1016/j.neuroscience.2009.04.025; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Valero J, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00083; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wirenfeldt M, 2005, J NEUROSCI RES, V82, P507, DOI 10.1002/jnr.20659; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Yamasaki TR, 2007, J NEUROSCI, V27, P11925, DOI 10.1523/JNEUROSCI.1627-07.2007; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zhan Y, 2014, NAT NEUROSCI, V17, P400, DOI 10.1038/nn.3641	39	134	138	1	22	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 8	2015	35	27					9977	9989		10.1523/JNEUROSCI.0336-15.2015			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CN2LT	WOS:000358253400018	26156998	Bronze, Green Published			2022-02-06	
J	Morgan, CD; Zuckerman, SL; Lee, YM; King, L; Beaird, S; Sills, AK; Solomon, GS				Morgan, Clinton D.; Zuckerman, Scott L.; Lee, Young M.; King, Lauren; Beaird, Susan; Sills, Allen K.; Solomon, Gary S.			Predictors of postconcussion syndrome after sports-related concussion in young athletes: a matched case-control study	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; sports; mild traumatic brain injury; ImPACT; postconcussion syndrome; trauma	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; EMERGENCY-DEPARTMENT; HIGH-SCHOOL; RECOVERY-TIME; POSTTRAUMATIC MIGRAINE; PERSISTENT SYMPTOMS; MISERABLE MINORITY; ETHNIC DISPARITIES	OBJECT Sport-related concussion (SRC) is a major public health problem. Approximately 90% of SRCs in high school athletes are transient; symptoms recover to baseline within 1 week. However, a small percentage, of patients remain symptomatic several months after injury, with a condition known as postconcussion syndrome (PCS). The authors aimed to identify risk factors for PCS development in a cohort of exclusively young athletes (9-18 years of age) who sustained SRCs while playing a sport. METHODS The authors conducted a retrospective case-control study by using the Vanderbilt Sports Concussion Clinic database. They identified 40 patients with PCS and matched them by age at injury and sex to SRC control patients (1 PCS to 2 control). PCS patients were those experiencing persistent symptoms at 3 months after an SRC. Control patients were those with documented resolution of symptoms within 3 weeks of an SRC. Data were collected in 4 categories: 1) demographic variables; 2) key medical, psychiatric, and family history; 3) acute-phase Postinjury symptoms (at 0-24 hours); and 4) subacute-phase postinjury features (at 0-3 weeks). The chi-square Fisher exact test was used to assess categorical variables, and the Mann-Whitney U-test was used to evaluate continuous variables. Forward step-wise regression models (P-in= 0.05, P-out=0.10) were used to identify variables associated with PCS. RESULTS PCS patients were more likely than control patients to have a concussion history (p = 0.010), premorbid mood disorders (p = 0.002), other psychiatric illness (p = 0.039), or significant life stressors (p = 0.036). Other factors that increased the likelihood of PCS development were a family history of mood disorders, other psychiatric illness, and migraine. Development of PCS was not predicted by race, insurance status, body mass index, sport, helmet use, medication use, and type of symptom endorsement. A final logistic regression analysis of candidate variables showed PCS to be predicted by a history of concussion (OR 1.8, 95% Cl 1.1-2.8, p = 0.016), preinjury mood disorders (OR 17.9, 95% CI 2.9-113.0, p = 0.002), family history of mood disorders (OR 3.1, 95% Cl 1.1-8.5, p = 0.026), and delayed symptom onset (OR 20.7, 95% Cl 3.2-132.0, p < 0.001). CONCLUSIONS In this age- and sex-matched case-control study of risk factors for PCS among youth with SRC, risk for development of PCS was higher in those with a personal and/or family history of mood disorders, other psychiatric illness, and migraine. These findings highlight the unique nature of SRC in youth. For this population, providers must recognize the value of establishing the baseline health and psychiatric status of children and their primary caregivers with regard to symptom reporting and recovery expectations. In addition, delayed symptom onset was an unexpected but strong risk factor for PCS in this cohort. Delayed symptoms could potentially result in late removal from play, rest, and care by qualified health care professionals. Taken together, these results may help practitioners identify young athletes with concussion who are at a greater danger for PCS and inform larger prospective studies for validation of risk factors from this cohort.	[Morgan, Clinton D.; Zuckerman, Scott L.; Lee, Young M.; Sills, Allen K.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37212 USA; [King, Lauren; Beaird, Susan] Vanderbilt Univ, Sch Med, Div Pediat Neurol, Nashville, TN 37212 USA		Zuckerman, SL (corresponding author), Vanderbilt Dept Neurol Surg, 1211 Med Ctr Dr,Med Ctr North T-4224, Nashville, TN 37212 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019	Morgan, Clinton/0000-0002-7511-0488	Rawlings	Support for this study came from an unrestricted educational grant from Rawlings. Dr. Solomon is a consultant for ImPACT, Nashville Predators, and Tennessee Titans.	Babcock L, 2013, PEDIATR EMERG CARE, V29, P458, DOI 10.1097/PEC.0b013e31828a202d; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Blume H, 2012, CURR OPIN PEDIATR, V24, P724, DOI 10.1097/MOP.0b013e328359e4cc; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Coker TR, 2009, ACAD PEDIATR, V9, P89, DOI 10.1016/j.acap.2008.11.007; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Flores G, 2008, PEDIATRICS, V121, pE286, DOI 10.1542/peds.2007-1243; Flores G, 2010, PEDIATRICS, V125, pE979, DOI 10.1542/peds.2010-0188; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Meehan WP, AM J SPORTS MED, V38, P2405; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Smyth K, 2014, DEV MED CHILD NEUROL, V56, P73, DOI 10.1111/dmcn.12263; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Upchurch C., 2014, CLIN J SPORT MED; Wojcik SM, 2014, BRAIN INJURY, V28, P422, DOI 10.3109/02699052.2014.884241; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	70	134	134	1	51	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2015	15	6					589	598		10.3171/2014.10.PEDS14356			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CI8OL	WOS:000355031500007	25745949	Bronze			2022-02-06	
J	Sady, MD; Vaughan, CG; Gioia, GA				Sady, Maegan D.; Vaughan, Christopher G.; Gioia, Gerard A.			School and the Concussed Youth: Recommendations for Concussion Education and Management	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Concussion; Mild traumatic brain injury; Student-athlete; Student; School; Accommodations; Management	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; NEUROCOGNITIVE PERFORMANCE; NCAA CONCUSSION; RECOVERY; SYMPTOMS; RETURN; METAANALYSIS; CHILDREN	School learning and performance is arguably the critical centerpiece of child and adolescent development, and there can be significant temporary upset in cognitive processing after a mild traumatic brain injury, also called a concussion. This injury results in a cascade of neurochemical abnormalities, and, in the wake of this dysfunction, both physical and cognitive activities become sources of additional neurometabolic demand on the brain and may cause symptoms to reemerge or worsen. This article provides a foundation for postinjury management of cognitive activity, particularly in the school setting, including design and implementation of schoolwide concussion education and management programs.	[Sady, Maegan D.; Vaughan, Christopher G.; Gioia, Gerard A.] Childrens Natl Med Ctr, Div Pediat Neuropsychol, Safe Concuss Outcome Recovery & Educ SCORE Progra, Rockville, MD 20850 USA; [Vaughan, Christopher G.; Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Psychiat & Behav Sci, Washington, DC 20037 USA; [Vaughan, Christopher G.; Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20037 USA		Sady, MD (corresponding author), Childrens Natl Med Ctr, Div Pediat Neuropsychol, Safe Concuss Outcome Recovery & Educ SCORE Progra, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	msady@childrensnational.org		Sady, Maegan/0000-0002-1438-4477	CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30/HDO40677-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER	This publication was made possible in part by CDC Award number U17/CCU323352 and grant M01RR020359 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Other grant support included NIH number P30/HDO40677-07.	Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; *CDC, 2010, HEADS SCH KNOW YOUR; Centers for Disease Control and Prevention (CDC), 2007, HEADS BRAIN INJ YOUR; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Lincoln AE, 2011, AM J SPORTS MED; LOGAN K, 2009, ATHLETIC TRAINING SP, V1, P251; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Mather FJ, 2003, BRAIN INJURY, V17, P1077, DOI 10.1080/0269905031000114045; McAvoy K., 2010, REAP BENEFITS GOOD C; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2004, LANCET NEUROL, V3, P435, DOI 10.1016/S1474-4422(04)00810-5; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; O'Brien LM, 2009, CHILD ADOL PSYCH CL, V18, P813, DOI 10.1016/j.chc.2009.04.008; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	46	134	135	0	30	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	NOV	2011	22	4					701	+		10.1016/j.pmr.2011.08.008			20	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	858SI	WOS:000297822600010	22050944	Green Accepted			2022-02-06	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			Long-Term Complications of Decompressive Craniectomy for Head Injury	JOURNAL OF NEUROTRAUMA			English	Article						complications; decompressive craniectomy; neurotrauma	TRAUMATIC BRAIN-INJURY; NEUROSURGICAL SITE INFECTIONS; SURGICAL DECOMPRESSION; SUBDURAL HYGROMA; RISK-FACTORS; CRANIOPLASTY; EDEMA; PATHOGENESIS; MULTICENTER; CRANIOTOMY	There is currently much interest in the use of decompressive craniectomy for intracranial hypertension. Though technically straightforward, the procedure is not without significant complications. A retrospective analysis was undertaken of 164 patients who had had a decompressive craniectomy for severe head injury in the years 2004 to 2009 at the two major hospitals in Western Australia. Eighty-six patients had a bifrontal decompression and seventy-eight had a unilateral decompression. Two patients died due to post-operative care issues. Complications attributable to the decompressive surgery were: herniation of the cortex through the bone defect (42 patients, 25.6%), subdural effusion (81 patients, 49.4%), seizures (36 patients, 22%), hydrocephalus (23 patients, 14%), and syndrome of the trephined (2 patients, 1.2%). Complications attributable to the subsequent cranioplasty included: sudden death due to massive cerebral swelling in 3 patients (2.2%), infection requiring removal of the bone flap in 16 patients (11.6%), and bone flap resorption requiring augmentation in 10 patients (7.2%). After excluding simple complications such as subdural effusion and brain herniation through the skull defect and some patients who died as a direct consequence of traumatic brain or extracranial injury, 81 patients (55.5%) had at least one complication after decompressive craniectomy. The occurrence of at least one complication after decompressive craniectomy was significantly associated with an increased risk of prolonged stay in the hospital or rehabilitation facility (odds ratio 2.54, 95%confidence interval 1.22,5.24, p = 0.013), after adjusting for predicted risk of unfavorable outcome.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6019, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Dept Intens Care Med, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6019, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BLOMSTEDT GC, 1985, ACTA NEUROCHIR, V78, P81, DOI 10.1007/BF01808684; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Csokay A, 2001, NEUROSURG REV, V24, P209, DOI 10.1007/s101430100158; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Groswasser Z, 1988, Brain Inj, V2, P267, DOI 10.3109/02699058809150897; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guyot LL, 2000, NEUROL RES, V22, P25; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; Licata C, 2001, J Neurosurg Sci, V45, P141; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Tokoro K, 1989, Neurol Med Chir (Tokyo), V29, P196, DOI 10.2176/nmc.29.196; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	38	134	139	0	19	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					929	935		10.1089/neu.2010.1612			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600007	21091342				2022-02-06	
J	Blyth, BJ; Farhavar, A; Gee, C; Hawthorn, B; He, H; Nayak, A; Stocklein, V; Bazarian, JJ				Blyth, Brian J.; Farhavar, Arash; Gee, Christopher; Hawthorn, Brendan; He, Hua; Nayak, Akshata; Stocklein, Veit; Bazarian, Jeffrey J.			Validation of Serum Markers for Blood-Brain Barrier Disruption in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; blood-brain barrier dysfunction; traumatic brain injury	CEREBROSPINAL-FLUID; S-100B PROTEIN; S100B LEVELS; NEUROLOGICAL DISORDERS; MULTIPLE-SCLEROSIS; CLINICAL-TRIALS; DRUG-DELIVERY; AXONAL INJURY; ELITE PLAYERS; IGG ANALYSES	The blood-brain barrier (BBB), which prevents the entry into the central nervous system (CNS) of most water-soluble molecules over 500 Da, is often disrupted after trauma. Post-traumatic BBB disruption may have important implications for prognosis and therapy. Assessment of BBB status is not routine in clinical practice because available techniques are invasive. The gold-standard measure, the cerebrospinal fluide (CSF)-serum albumin quotient (Q(A)), requires the measurement of albumin in CSF and serum collected contemporaneously. Accurate, less invasive techniques are necessary. The objective of this study was to evaluate the relationship between Q(A) and serum concentrations of monomeric transthyretin (TTR) or S100B. Nine subjects with severe traumatic brain injury (TBI; Glasgow Coma Scale [GCS] score <= 8) and 11 subjects with non-traumatic headache who had CSF collected by ventriculostomy or lumbar puncture (LP) were enrolled. Serum and CSF were collected at the time of LP for headache subjects and at 12, 24, and 48 h after ventriculostomy for TBI subjects. The Q(A) was calculated for all time points at which paired CSF and serum samples were available. Serum S100B and TTR levels were also measured. Pearson's correlation coefficient and area under the receiver operating characteristic (ROC) curve were used to determine the relationship between the serum proteins and Q(A). Seven TBI subjects had abnormal Q(A)'s indicating BBB dysfunction. The remaining TBI and control subjects had normal BBB function. No significant relationship between TTR and Q(A) was found. A statistically significant linear correlation between serum S100B and Q(A) was present (r = 0.432, p = 0.02). ROC analysis demonstrated a significant relationship between Q(A) and serum S100B concentrations at 12 h after TBI (AUC = 0.800; SE 0.147, 95% CI 0.511-1.089). Using an S100B concentration cutoff of 0.027 ng/ml, specificity for abnormal Q(A) was 90% or higher at each time point. We conclude that serum S100B concentrations accurately indicate BBB dysfunction at 12 h after TBI.	[Blyth, Brian J.; Gee, Christopher; Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Dept Emergency Med, Med Ctr, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Dept Neurol, Med Ctr, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Dept Neurosurg, Med Ctr, Rochester, NY 14642 USA; [Blyth, Brian J.; Bazarian, Jeffrey J.] Univ Rochester, Ctr Neural Dev & Dis, Med Ctr, Rochester, NY 14642 USA; [Hawthorn, Brendan] Case Western Reserve Univ, Metrohlth Med Ctr, Dept Emergency Med, Cleveland, OH 44106 USA; [He, Hua] Univ Rochester, Dept Biostat & Computat Biol, Med Ctr, Rochester, NY 14642 USA; [Stocklein, Veit] Univ Munich, Sch Med, Munich, Germany		Bazarian, JJ (corresponding author), Univ Rochester, Dept Emergency Med, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.	Jeff_Bazarian@urmc.rochester.edu	Stoecklein, Veit/D-3262-2012		American Geriatrics Society; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01HD051865-02]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051865] Funding Source: NIH RePORTER	This work was supported by the following: American Geriatrics Society Jahnigen Career Development Scholars Award (to B. J. B.) and the National Institutes of Health (grant 5R01HD051865-02 to J. J. B., B. J. B., and A. N.).	Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; ANDERSSON M, 1994, J NEUROL NEUROSUR PS, V57, P897, DOI 10.1136/jnnp.57.8.897; Bertsch T, 2001, CLIN CHEM LAB MED, V39, P319, DOI 10.1515/CCLM.2001.050; Bickel U, 2001, ADV DRUG DELIVER REV, V46, P247, DOI 10.1016/S0169-409X(00)00139-3; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Foerch C, 2007, STROKE, V38, P2491, DOI 10.1161/STROKEAHA.106.480111; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; Hamilton JA, 2001, CELL MOL LIFE SCI, V58, P1491, DOI 10.1007/PL00000791; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Hofmeijer J, 2004, BRAIN RES, V1013, P74, DOI 10.1016/j.brainres.2004.03.057; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jaranyi Z, 2003, CLIN CHEM LAB MED, V41, P1320, DOI 10.1515/CCLM.2003.201; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Langham J, 2003, COCHRANE DB SYST REV; Larsson A, 2005, ANESTH ANALG, V101, P1465, DOI 10.1213/01.ANE.0000180193.29655.6A; LINK H, 1977, SCAND J CLIN LAB INV, V37, P391, DOI 10.3109/00365517709091497; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2003, J NEUROSCI, V23, P1949; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Obuchowski NA, 1997, BIOMETRICS, V53, P567, DOI 10.2307/2533958; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; PAPA L, 2008, ACAD EMERG MED, V15, pS73; Pardridge WM, 1997, J CEREBR BLOOD F MET, V17, P713, DOI 10.1097/00004647-199707000-00001; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Reiber H, 2001, J NEUROL SCI, V184, P101, DOI 10.1016/S0022-510X(00)00501-3; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Stieg PE, 1998, NEUROL CLIN, V16, P373, DOI 10.1016/S0733-8619(05)70069-4; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; TOURTELLOTTE WW, 1980, NEUROLOGY, V30, P240, DOI 10.1212/WNL.30.3.240; Watson P, 2005, AM J PHYSIOL-REG I, V288, pR1689, DOI 10.1152/ajpregu.00676.2004; Watson P, 2006, MED SCI SPORT EXER, V38, P2118, DOI 10.1249/01.mss.0000235356.31932.0a; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; Wunderlich MT, 2004, J NEUROL SCI, V227, P49, DOI 10.1016/j.jns.2004.08.005	59	134	140	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1497	1507		10.1089/neu.2008.0738			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200007	19257803	Green Published			2022-02-06	
J	Fazio, VC; Lovell, MR; Pardini, JE; Collins, MW				Fazio, Vanessa C.; Lovell, Mark R.; Pardini, Jamie E.; Collins, Michael W.			The relation between post concussion symptoms and neurocognitive performance in concussed athletes	NEUROREHABILITATION			English	Article						concussion; mTBI; symptoms	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; RECOVERY; SPORT; INJURIES	The objective of this study was to examine differences in neurocognitive performance between symptomatic concussed athletes, a group of concussed athletes with no subjective symptoms, and a non-concussed control group of athletes. All concussed athletes were evaluated within one week of injury using the ImPACT computerized test battery. Results indicate that concussed athletes who denied subjective symptoms demonstrated poorer performance than control subjects on all four composite scores of the ImPACT test batters (Verbal Memory, Visual Memory, Reaction Time and Processing Speed However, the concussed but asymptomatic group demonstrated significantly better performance than did the concussed and symptomatic group. Thus, concussed athletes who did not report subjective symptoms were not fully recovered based on neurocognitive testing. This study underscores the importance of neurocognitive testing in the assessment of concussion sequelae and recovery.	Univ Pittsburgh, Med Ctr, Dept Orthopaed, Sports Med Concuss Program, Pittsburgh, PA 15203 USA		Lovell, MR (corresponding author), Univ Pittsburgh, Med Ctr, Dept Orthopaed, Sports Med Concuss Program, 3200 S Water St, Pittsburgh, PA 15203 USA.	lovellmr@upmc.edu					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; BAILES JE, 1999, SPORTS RELATED CONCU; Barth JT, 1989, MILD HEAD INJURY, P257; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; COLLINS MW, 1999, JAMA            0908, P964; Echemendia RJ, 2003, NEURO S B C, P351; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; IVERSON G, 2004, J INT NEUROPSYCH SOC, V10, P1; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; IVERSON GL, IN PRESS J CLIN EXPT; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell M, 2000, IMPACT IMMEDIATE POS; LOVELL M, IN PRESS APPL NEUROP; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; PELLMAN EJ, IN PRESS MTBI PROFES; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Podell K, 2004, STUD NEUROPSYCHOL DE, P375; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; VANKAMPEN DA, IN PRESS AM J SPORTS	44	134	135	0	22	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					207	216					10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800007	17917171				2022-02-06	
J	Gujar, SK; Maheshwari, S; Bjorkman-Burtscher, I; Sundgren, PC				Gujar, SK; Maheshwari, S; Bjorkman-Burtscher, I; Sundgren, PC			Magnetic resonance spectroscopy	JOURNAL OF NEURO-OPHTHALMOLOGY			English	Article							PROTON MR SPECTROSCOPY; INTRACRANIAL MASS LESIONS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TRAUMATIC BRAIN-INJURY; IN-VIVO; LOCALIZED PROTON; MULTIPLE-SCLEROSIS; CANAVANS DISEASE; NEURONAL DAMAGE; POSTERIOR-FOSSA	Magnetic resonance spectroscopy (MRS) complements magnetic resonance imaging (MRI) as a non-invasive means for the characterization of tissue. While MRI uses the signal from hydrogen protons to form anatomic images, proton MRS uses this information to determine the concentration of brain metabolites such as N-acetyl aspartate (NAA), choline (Cho), creatine (Cr) and lactate in the tissue examined. The most widely used clinical application of MRS has been in the evaluation of central nervous system disorders. MRS has its limitations and is not always specific but, with good technique and in combination with clinical information and conventional MRI, can be very helpful in diagnosing certain entities. For example, a specific pattern of metabolites can be seen in disorders such as Canavan's disease, creatine deficiency, and untreated bacterial brain abscess. MRS may also be helpful in the differentiation of high grade from low grade brain tumors, and perhaps in separating recurrent brain neoplasm from radiation injury.	Univ Michigan, Hlth Syst, Dept Radiol, Ann Arbor, MI 48109 USA; Jaslok Hosp & Med Res Ctr, Dept Imaging, Bombay 400026, Maharashtra, India; Lund Univ, Dept Diagnost Radiol, Ctr Med Imaging & Physiol IB B, S-22185 Lund, Sweden		Sundgren, PC (corresponding author), Univ Michigan, Hlth Syst, Dept Radiol, UH-B2-A209D,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sundgren@umich.edu	Bjorkman-Burtscher, Isabella/AAC-8480-2020	Sundgren, Pia/0000-0001-9237-1236; Bjorkman-Burtscher, Isabella/0000-0002-9023-3363			AlaKorpela M, 1995, MAGN RESON MATER PHY, V3, P129, DOI 10.1007/BF01771697; AUSTIN SJ, 1991, MAGNET RESON MED, V19, P439, DOI 10.1002/mrm.1910190235; Axford JS, 2001, ANN RHEUM DIS, V60, P106, DOI 10.1136/ard.60.2.106; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; BARKER PB, 2005, CLIN MR NEUROIMAGING, P1; BARKOVICH AJ, 1993, AM J NEURORADIOL, V14, P1119; Battistini S, 1991, Funct Neurol, V6, P177; Bizzi A, 2001, AM J NEURORADIOL, V22, P1125; BJORKMANBURTSCH.IM, ISMRM 2004 P, P394; Brockmann K, 2003, J NEUROL, V250, P300, DOI 10.1007/s00415-003-0995-2; Brooks WM, 1997, J RHEUMATOL, V24, P2323; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; BRUHN H, 1989, RADIOLOGY, V172, P541, DOI 10.1148/radiology.172.2.2748837; Burtscher IM, 1999, AM J NEURORADIOL, V20, P1049; Burtscher IM, 2001, J MAGN RESON IMAGING, V13, P560, DOI 10.1002/jmri.1079; Burtscher IM, 2000, AM J NEURORADIOL, V21, P84; Burtscher IM, 2001, NEURORADIOLOGY, V43, P345, DOI 10.1007/s002340000427; Cappellini Maria, 2002, Radiol Med, V104, P332; CASTILLO M, 1995, AM J NEURORADIOL, V16, P233; Castillo M, 1996, AM J NEURORADIOL, V17, P1; Castillo M, 2001, AM J NEURORADIOL, V22, P152; Chang L, 1997, NEUROIMAG CLIN N AM, V7, P409; CHANG L, 1995, AM J NEURORADIOL, V16, P1653; CHINN RJS, 1995, RADIOLOGY, V197, P649, DOI 10.1148/radiology.197.3.7480733; CONNELLY A, 1994, NEUROLOGY, V44, P1411, DOI 10.1212/WNL.44.8.1411; CROSS JH, 1993, J INHERIT METAB DIS, V16, P800, DOI 10.1007/BF00711912; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; DANIELSEN ER, 1999, MAGNETIC RESONANCE S; Demaerel P, 1997, INT J NEURORADIOL, V3, P94; DENBURG SD, 1994, ARTHRITIS RHEUM, V37, P369, DOI 10.1002/art.1780370310; Dowling C, 2001, AM J NEURORADIOL, V22, P604; FELBER SR, 1993, ANN NEUROL, V33, P396, DOI 10.1002/ana.410330412; FRAHM J, 1989, MAGNET RESON MED, V11, P47, DOI 10.1002/mrm.1910110105; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Fu L, 1998, BRAIN, V121, P103, DOI 10.1093/brain/121.1.103; Galanaud D, 2001, MAGN RESON MATER PHY, V13, P127, DOI 10.1016/S1352-8661(01)00135-1; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Harada M, 2000, JMRI-J MAGN RESON IM, V11, P559, DOI 10.1002/(SICI)1522-2586(200005)11:5<559::AID-JMRI12>3.0.CO;2-C; Herminghaus S, 2003, J NEUROSURG, V98, P74, DOI 10.3171/jns.2003.98.1.0074; HETHERINGTON HP, 1994, MAGNET RESON MED, V32, P565, DOI 10.1002/mrm.1910320504; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Kawaguchi S, 1995, No To Shinkei, V47, P43; Kojic J, 2005, PEDIATR NEUROL, V32, P143, DOI 10.1016/j.pediatrneurol.2004.07.013; KOVACS JAJ, 1993, RHEUM DIS CLIN N AM, V19, P795; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; KRUSE B, 1994, ANN NEUROL, V36, P595, DOI 10.1002/ana.410360408; KRUSE B, 1993, J NEUROL, V241, P68, DOI 10.1007/BF00869766; Laubenberger J, 1996, RADIOLOGY, V199, P805, DOI 10.1148/radiology.199.3.8638009; LENKINSKI RE, 1991, MAGNETIC RESONANCE I, P1099; Liang MH, 1999, ARTHRITIS RHEUM-US, V42, P599; Lim MK, 2000, RADIOLOGY, V217, P43, DOI 10.1148/radiology.217.1.r00oc1543; Maheshwari SR, 2000, SEMIN ULTRASOUND CT, V21, P434, DOI 10.1016/S0887-2171(00)90036-2; Mainero C, 2001, NEUROLOGY, V56, P1331, DOI 10.1212/WNL.56.10.1331; MARKS HG, 1991, ANN NEUROL, V30, P106, DOI 10.1002/ana.410300120; MCCONNELL JR, 1994, AIDS RES HUM RETROV, V10, P977, DOI 10.1089/aid.1994.10.977; MENON DK, 1990, J COMPUT ASSIST TOMO, V14, P882, DOI 10.1097/00004728-199011000-00003; Meyerhoff DJ, 1999, NEUROLOGY, V52, P995, DOI 10.1212/WNL.52.5.995; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; Moller HE, 1999, J MAGN RESON IMAGING, V9, P10, DOI 10.1002/(SICI)1522-2586(199901)9:1<10::AID-JMRI2>3.0.CO;2-W; Moller-Hartmann W, 2002, NEURORADIOLOGY, V44, P371, DOI 10.1007/s00234-001-0760-0; Movsas B, 2001, RADIOLOGY, V221, P327, DOI 10.1148/radiol.2212001648; Naressi A, 2001, MAGN RESON MATER PHY, V12, P141, DOI 10.1007/BF02668096; Nelson SJ, 2002, NEUROIMAG CLIN N AM, V12, P599, DOI 10.1016/S1052-5149(02)00037-0; NOVOTNY EJ, 1995, PEDIATR RES, V37, P244, DOI 10.1203/00006450-199502000-00020; Novotny EJ, 2003, ANN NEUROL, V54, pS25, DOI 10.1002/ana.10697; Pietz J, 1996, RADIOLOGY, V201, P413, DOI 10.1148/radiology.201.2.8888233; Pomper M G, 2000, Magn Reson Imaging Clin N Am, V8, P691; Poptani H, 1995, MAGN RESON IMAGING, V13, P1019, DOI 10.1016/0730-725X(95)00045-I; POPTANI H, 1995, AM J NEURORADIOL, V16, P1593; Pouwels PJW, 1998, NEUROPEDIATRICS, V29, P254, DOI 10.1055/s-2007-973571; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Roelants-Van Rijn AM, 2001, PEDIATR RES, V49, P356, DOI 10.1203/00006450-200103000-00009; Rovaris M, 2003, BRIT MED BULL, V65, P133, DOI 10.1093/bmb/65.1.133; Sibbitt WL, 1997, AM J NEURORADIOL, V18, P1271; Smith JK, 2002, NEURORADIOLOGY, V44, P825, DOI 10.1007/s00234-002.0821-z; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; SUNDGREN PC, 2005, IN PRESS NEURORADIOL; TEDESCHI G, 1995, NEUROLOGY, V45, P1384, DOI 10.1212/WNL.45.7.1384; Valk J, 2002, MAGNETIC RESONANCE D; van Walderveen MAA, 1999, ANN NEUROL, V46, P79, DOI 10.1002/1531-8249(199907)46:1<79::AID-ANA12>3.0.CO;2-9; VANDERKNAAP MS, 1990, RADIOLOGY, V176, P509, DOI 10.1148/radiology.176.2.2164237; Vigneron DB, 2001, AM J NEURORADIOL, V22, P1424; Wang ZYJ, 1998, NEUROIMAG CLIN N AM, V8, P781; Weybright P, 2004, NEURORADIOLOGY, V46, P541, DOI 10.1007/s00234-004-1195-1; WEYBRIGHT P, 2005, IN PRESS AJR; Wolinsky JS, 2002, CURR OPIN NEUROL, V15, P247, DOI 10.1097/00019052-200206000-00004; Zarifi MK, 2001, J CHILD NEUROL, V16, P522, DOI 10.2310/7010.2001.17863; Zimmerman RA, 1997, AM J NEURORADIOL, V18, P1872; 2005, J NEURO-OPHTHALMOL, V25, P217	90	134	149	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1070-8022	1536-5166		J NEURO-OPHTHALMOL	J. Neuro-Ophthal.	SEP	2005	25	3					217	226		10.1097/01.wno.0000177307.21081.81			10	Clinical Neurology; Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Ophthalmology	964NR	WOS:000231888300015	16148633				2022-02-06	
J	Lammi, MH; Smith, VH; Tate, RL; Taylor, CM				Lammi, MH; Smith, VH; Tate, RL; Taylor, CM			The minimally conscious state and recovery potential: A follow-up study 2 to 5 years after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; minimally conscious state; rehabilitation	POSTTRAUMATIC AMNESIA; VEGETATIVE STATE; FAMILY; CONCORDANCE; ADJUSTMENT; MANAGEMENT; DISABILITY; SCALE	Objective: To document recovery in persons who were in the minimally conscious state (MCS) for at least 1 month after traumatic brain injury (TBI). Design: Patient series. Setting: Participants who had been discharged from an inpatient rehabilitation unit. Participants: Eighteen people with TBI and their relatives. Interventions: Not applicable. Main Outcome Measures: Western Neuro Sensory Stimulation Profile, Disability Rating Scale (DRS), FIM instrument, Dementia Rating Scale, and Sydney Psychosocial Reintegration Scale (SPRS). Results: Level of functioning at follow-up varied from extremely severe disability or greater on the DRS (n = 4) to mild disability (n = 1). These outcomes were corroborated by results of the FIM and the Dementia Rating Scale. All participants experienced some (44%) or major (56%) change in their level of psychosocial functioning on the SPRS compared with their preinjury level. There were no significant correlations between duration of time in the MCS and outcome on FIM, DRS, or SPRS. Conclusions: These results highlight the heterogeneity of outcome even after a prolonged duration of MCS after TBI. A large proportion of the patients was functionally independent in basic daily activities, although all experienced residual impairments and disabilities. The low correlation coefficients between duration of MCS and the outcome measures suggest that prognostic statements based on length of time a person is in the MCS cannot be made with confidence. (c) 2005 by American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	Royal Rehabil Ctr Sydney, Brain Injury Rehabil Unit, N Ryde, NSW 1680, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Tate, RL (corresponding author), Royal Rehabil Ctr Sydney, Rehabil Studies Unit, POB 6, N Ryde, NSW 1680, Australia.	rtate@mail.usyd.edu.au					Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, W NEURO SENSORY STIM; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GRANGER CV, 1986, GUIDE USE UNIFORM DA; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 1994, TOP STROKE REHABIL, V75, P1; JURICA PJ, 2001, DRS 2 DEMENTIAL RATI; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MALKAMUS D, 1980, REHABILITATION HEAD; MATTIS S, 1988, DRS DEMENTIA RATING; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Randolph C., 1998, REPEATABLE BATTERY A; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; Smith VH, 2001, BRAIN IMPAIR, V2, P29, DOI DOI 10.1375/BRIM.2.1.29; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Wilson BA, 2001, BRAIN INJURY, V15, P1083, DOI 10.1080/02699050110082197; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	37	134	141	1	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2005	86	4					746	754		10.1016/j.apmr.2004.11.004			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	914ON	WOS:000228237300020	15827927				2022-02-06	
J	Van Glabbeek, F; van Riet, RR; Baumfeld, JA; Neale, PG; O'Driscoll, SW; Morrey, BF; An, KN				Van Glabbeek, F; van Riet, RR; Baumfeld, JA; Neale, PG; O'Driscoll, SW; Morrey, BF; An, KN			Detrimental effects of overstuffing or understuffing with a radial head replacement in the medial collater-alligament deficient elbow	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							VALGUS STABILITY; CLOSED FRACTURE; EXCISION; JOINT; TRANSMISSION; ARTHROPLASTY; PROSTHESIS; RESECTION	Background: Comminuted radial head fractures associated with an injury of the medial collateral ligament can be treated with a radial head implant. We hypothesized that lengthening and shortening of the radial neck would alter the kinematics and the pressure through the radiocapitellar joint in the medial collateral ligament-deficient elbow. Methods: The effects of lengthening (2.5 and 5 mm) and shortening (2.5 and 5 mm) of the radial neck were assessed in six human cadaveric upper extremities in which the medial collateral ligament had been surgically released. The three-dimensional spatial orientation of the ulna was recorded during simulated active motion from extension to flexion. Total varus-valgus laxity and ulnar rotation were measured, Radiocapitellar joint pressure was assessed with use of pressure-sensitive film. Results: Radial neck lengthening or shortening of greater than or equal to2.5 mm significantly changed the kinematics in the medial collateral ligament-deficient elbow. Lengthening caused a significant decrease (p < 0.05) in varus-valgus laxity and ulnar rotation (p < 0.05), with the ulna tracking in varus and external rotation. Shortening caused a significant increase in varus-vaigus laxity (p < 0.05) and ulnar rotation (p < 0.05), with the ulna tracking in valgus and internal rotation. The pressure on the radiocapitellar joint was significantly increased after 2.5 mm of lengthening. Conclusions: This study suggests that accurate restoration of radial length is important and that axial understuffing or overstuffing of the radiolhurneral joint by greater than or equal to2.5 mm alters both elbow kinematics and radiocapitellar pressure. Clinical Relevance: This in vitro cadaver study indicates that a radial head replacement should be performed with the same level of concern for accuracy and reproducibility of component position and orientation as is appropriate with any other prosthesis.	Univ Antwerp Hosp, B-2650 Antwerp, Belgium; Mayo Clin, Rochester, MN 55905 USA		Van Glabbeek, F (corresponding author), Univ Antwerp Hosp, Wilrijkstr 10, B-2650 Antwerp, Belgium.	odriscoll.shawn@mayo.edu		O'Driscoll, Shawn/0000-0002-8225-3372			AMIS AA, 1979, J MED ENG TECHNOL, V3, P229, DOI 10.3109/03091907909160661; AMIS AA, 1980, J BIOMECH, V13, P765, DOI 10.1016/0021-9290(80)90238-9; AN KN, 1988, J BIOMECH, V21, P613, DOI 10.1016/0021-9290(88)90225-4; BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; GOLDBERG I, 1986, J BONE JOINT SURG AM, V68A, P675, DOI 10.2106/00004623-198668050-00006; Gupta GG, 1997, J SHOULDER ELB SURG, V6, P37, DOI 10.1016/S1058-2746(97)90069-0; HALLS AA, 1964, ANAT REC, V150, P243, DOI 10.1002/ar.1091500305; Harrington IJ, 2001, J TRAUMA, V50, P46, DOI 10.1097/00005373-200101000-00009; HARRINGTON IJ, 1981, INJURY, V12, P405, DOI 10.1016/0020-1383(81)90012-7; Ikeda M, 2000, ACTA ORTHOP SCAND, V71, P191, DOI 10.1080/000164700317413184; Janssen RPA, 1998, J BONE JOINT SURG BR, V80B, P231, DOI 10.1302/0301-620X.80B2.8255; Judet T, 1996, J BONE JOINT SURG BR, V78B, P244, DOI 10.1302/0301-620X.78B2.0780244; King GJW, 1999, CLIN ORTHOP RELAT R, P114; MASON ML, 1954, BRIT J SURG, V42, P123, DOI 10.1002/bjs.18004217203; MIKIC ZD, 1983, CLIN ORTHOP RELAT R, P220; Moro JK, 2001, J BONE JOINT SURG AM, V83A, P1201, DOI 10.2106/00004623-200108000-00010; MORREY BF, 1991, CLIN ORTHOP RELAT R, P187; MORREY BF, 1988, J BONE JOINT SURG AM, V70A, P250, DOI 10.2106/00004623-198870020-00014; MORREY BF, 1979, J BONE JOINT SURG AM, V61, P63, DOI 10.2106/00004623-197961010-00012; MORRISON MCT, 1995, ANN ROY COLL SURG, V77, P316; Pomianowski S, 2001, CLIN BIOMECH, V16, P401, DOI 10.1016/S0268-0033(01)00021-3; Pomianowski S, 2001, J BONE JOINT SURG AM, V83A, P1829, DOI 10.2106/00004623-200112000-00010; Smets S, 2000, Acta Orthop Belg, V66, P353; STEPHEN IBM, 1981, ACTA ORTHOP SCAND, V52, P409, DOI 10.3109/17453678109050121; Van Glabbeek F, 2001, Acta Orthop Belg, V67, P430	25	134	136	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	DEC	2004	86A	12					2629	2635		10.2106/00004623-200412000-00007			7	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	879LQ	WOS:000225719700007	15590846				2022-02-06	
J	Henry, JD; Crawford, JR				Henry, JD; Crawford, JR			A meta-analytic review of verbal fluency performance in patients with traumatic brain injury	NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE; MILD; MEMORY; SEQUELAE	A meta-analysis of 30 studies with 1,269 participants was conducted to investigate the sensitivity of tests of verbal fluency to the presence of traumatic brain injury (TBI). As has been found for patients with focal frontal lobe injuries (but not for patients with focal temporal lobe lesions), TBI patients were comparably impaired on tests of phonemic and semantic fluency. The phonemic fluency deficit could not be accounted for by patients' level of premorbid or current verbal IQ and was also substantially (although not significantly) in excess of the deficit on a measure of psychomotor speed. Phonemic fluency was also significantly more sensitive to the presence of TBI than was the Wisconsin Card Sorting Test (R. K. Heaton, 1981).	Univ Aberdeen, Kings Coll, Dept Psychol, Aberdeen AB24 3HN, Scotland		Henry, JD (corresponding author), Univ Aberdeen, Kings Coll, Dept Psychol, Aberdeen AB24 3HN, Scotland.	julie.henry@unsw.edu.au	Crawford, John R/A-4165-2008	Crawford, John R/0000-0003-3403-3428; Henry, Julie/0000-0002-2081-3717			Baddeley, 1990, HUMAN MEMORY THEORY; BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; Benson D.F., 1986, FRONTAL LOBES; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; Cohen J, 1977, STAT POWER ANAL BEHA; COOKE DL, 1995, J CLIN EXP NEUROPSYC, V17, P90, DOI 10.1080/13803399508406585; Crawford JR, 2000, AGING NEUROPSYCHOL C, V7, P9, DOI 10.1076/anec.7.1.9.806; DALLORA P, 1989, CORTEX, V25, P197, DOI 10.1016/S0010-9452(89)80037-1; Delis DC, 1987, CALIFORNIA VERBAL LE; Goldstein FC, 1996, NEUROPSYCHOLOGY, V10, P147; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Heaton R.K., 1981, WISCONSIN CARD SORTI; Hedges L. V., 1985, STAT METHODS META AN; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Lannoo E, 1998, INTENS CARE MED, V24, P236, DOI 10.1007/s001340050556; Laws K R, 1999, Cogn Neuropsychiatry, V4, P1, DOI 10.1080/135468099396025; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MILLER E, 1984, BRIT J CLIN PSYCHOL, V23, P53, DOI 10.1111/j.2044-8260.1984.tb00626.x; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; *NAT RES COUN, 1992, COMB INF STAT ISS OP; Nelson H.E., 1982, NATL ADULT READING T; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; REITAN W, 1990, HALSTEAD RIVER NEURO; Stanley TD, 2001, J ECON PERSPECT, V15, P131, DOI 10.1257/jep.15.3.131; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WERTZ RT, 1986, CLIN APHASIOLOGY, V16, P257; Wilkinson, 1984, WIDE RANGE ACHIEVEME	42	134	139	0	19	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2004	18	4					621	628		10.1037/0894-4105.18.4.621			8	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	862SC	WOS:000224510200003	15506829				2022-02-06	
J	Lifshitz, J; Sullivan, PG; Hovda, DA; Wieloch, T; McIntosh, TK				Lifshitz, J; Sullivan, PG; Hovda, DA; Wieloch, T; McIntosh, TK			Mitochondrial damage and dysfunction in traumatic brain injury	MITOCHONDRION			English	Article; Proceedings Paper	1st Mitochondrial Standards Workshop	2002	Dallas, TX	United Mitochondrial Dis Fdn, Mitochondrial Res Soc, Natl Inst Stand & Technol		brain injury; mitochondria; metabolism	FLUID-PERCUSSION INJURY; CYTOCHROME-C RELEASE; CEREBRAL GLUCOSE-METABOLISM; ENERGY-RELATED METABOLITES; CYCLOSPORINE-A; PERMEABILITY TRANSITION; GENE-EXPRESSION; MEMBRANE-PERMEABILITY; HIPPOCAMPAL-NEURONS; OXYGEN-CONSUMPTION	The enduring cognitive deficits and histopathology associated with traumatic brain injury (TBI) may arise from damage to mitochondrial populations, which initiates the metabolic dysfunction observed in clinical and experimental TBI. The anecdotal evidence for in vivo structural damage to mitochondria corroborates metabolic and physiologic dysfunction, which depletes substrates and promotes free radical generation. Excessive calcium pathology differentially disrupts the heterogeneous mitochondrial population, such that calcium sensitivity increases after TBI. The ongoing pathology may escalate to include protein and DNA oxidation that impacts mitochondrial function and promotes cell death. Thus, in vivo TBI damages, if not eliminates, mitochondrial populations depending on injury severity, with the remaining population left to provide metabolic support for survival or repair in the wake of cellular pathology. With a considerable understanding of post-injury mitochondrial populations, therapeutic interventions targeted to the mitochondria may delay or prevent secondary cascades that lead to long-term cell death and neurobehavioral disability. (C) 2004 Elsevier B.V. and Mitochondria Research Society. All rights reserved.	Univ Penn, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Dept Mol & Med Pharmacol,Daivd Geffen Sch Med, Los Angeles, CA 90095 USA; Lund Univ, Expt Brain Res Lab, Wallenberg Neurosci Ctr, SE-22184 Lund, Sweden		Lifshitz, J (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jlifshit@mail.med.upenn.edu		Wieloch, Tadeusz/0000-0002-7669-2520			Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bentzer P, 2000, J NEUROTRAUM, V17, P441, DOI 10.1089/neu.2000.17.441; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Buki A, 2000, J NEUROSCI, V20, P2825; CARBONELL WS, 1999, J NEUROTRAUM, V16, P1000; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Gsell W, 2000, J CHEM NEUROANAT, V20, P215, DOI 10.1016/S0891-0618(00)00095-8; HALESTRAP AP, 1986, BIOCHEM J, V236, P779, DOI 10.1042/bj2360779; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HILLERED L, 1983, FEBS LETT, V154, P247, DOI 10.1016/0014-5793(83)80158-6; HOVDA DA, 1990, ACT NEUR S, V51, P331; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McDonald RPA, 1999, NEUROREPORT, V10, P1875, DOI 10.1097/00001756-199906230-00014; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Mecocci P, 1997, MOL CHEM NEUROPATHOL, V31, P53, DOI 10.1007/BF02815160; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Peng TI, 1998, MOL PHARMACOL, V53, P974; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock J T, 1992, Hum Cell, V5, P345; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Roy M, 1999, TRENDS NEUROSCI, V22, P419, DOI 10.1016/S0166-2236(99)01435-6; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sakata JT, 2003, NEUROSCI LETT, V337, P159, DOI 10.1016/S0304-3940(02)01328-9; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Seo SY, 1999, J NEUROSCI, V19, P8849, DOI 10.1523/JNEUROSCI.19-20-08849.1999; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; SZABO I, 1992, J BIOL CHEM, V267, P2940; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Wagner OI, 2003, J NEUROSCI, V23, P9046; Wang GJ, 2002, J NEUROPHYSIOL, V87, P740, DOI 10.1152/jn.00345.2001; Wang XD, 2001, GENE DEV, V15, P2922; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	110	134	138	1	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1567-7249	1872-8278		MITOCHONDRION	Mitochondrion	SEP	2004	4	5-6					705	713		10.1016/j.mito.2004.07.021			9	Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Cell Biology; Genetics & Heredity	885QS	WOS:000226172600031	16120426				2022-02-06	
J	Goss, CW; Hoffman, SW; Stein, DG				Goss, CW; Hoffman, SW; Stein, DG			Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						progesterone; traumatic brain injury; dose-response; elevated plus maze; Morris water maze; forepaw neglect; GABA-A receptor; medial prefrontal cortex	MALE-RATS; GABA(A) RECEPTORS; MEDIODORSAL NUCLEUS; ANXIOLYTIC ACTIVITY; CORTICAL CONTUSION; PREFRONTAL CORTEX; CEREBRAL-ISCHEMIA; INCREASED ANXIETY; EYE FIELD; WITHDRAWAL	Evidence suggests that progesterone enhances functional recovery in rats after medial frontal cortical contusions; however, a high dose of progesterone exacerbates tissue loss in a stroke model when administered chronically (7-10 days) prior to injury [Stroke 31 (2000) 1173)]. This study attempts to determine progesterone's dose-response effects on behavioral performance and GABA-A receptor expression following a cortical contusion. Male rats received injections of 0, 8, 16, or 32 mg/kg progesterone in 22.5% 2-hydroxypropyl-beta-cyclodextrin following cortical impact. Lesion 8 mg/kg and lesion 16 mg/kg groups displayed less thigmotaxis in the Morris water maze (MWM) than 0 and 32 mg/kg groups and were not significantly impaired relative to shams on other water maze measures. Increased variability in the 32 mg/kg group during somatosensory neglect testing was the only evidence indicating that a high dose of progesterone was disruptive to a few animals. These results suggest that low and moderate doses of progesterone are optimal for facilitating recovery of select behaviors and that postinjury progesterone treatment permits a wider dose range than preinjury treatment. Progesterone did not affect lesion size, but a strong negative correlation was observed between thalamic GABA-A receptor density and water maze performance. Future studies could explore causes for this relationship. (C) 2003 Elsevier Inc. All rights reserved.	Emory Univ, Brain Res Lab, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Dept Psychol, 1648 Pierce Dr, Atlanta, GA 30322 USA.		Stein, Donald/AAJ-5139-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38664] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664] Funding Source: NIH RePORTER		Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; [Anonymous], 1998, REH PERS TRAUM BRAIN; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Autere AM, 1999, J NEUROPHYSIOL, V81, P811, DOI 10.1152/jn.1999.81.2.811; BITRAN D, 1995, J NEUROENDOCRINOL, V7, P171, DOI 10.1111/j.1365-2826.1995.tb00744.x; Cavalli R, 1999, INT J PHARM, V182, P59, DOI 10.1016/S0378-5173(99)00066-6; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Churchill L, 1996, NEUROSCIENCE, V70, P93, DOI 10.1016/0306-4522(95)00351-I; COSTA AMN, 1995, J NEUROPHYSIOL, V74, P464, DOI 10.1152/jn.1995.74.1.464; CROWNE DP, 1986, BEHAV BRAIN RES, V22, P227, DOI 10.1016/0166-4328(86)90067-7; CROWNE DP, 1982, BEHAV BRAIN RES, V6, P25, DOI 10.1016/0166-4328(82)90079-1; Devan BD, 1999, BEHAV BRAIN RES, V100, P5, DOI 10.1016/S0166-4328(98)00107-7; FILE SE, 1995, ADV BIOCHEM PSYCHOPH, V48, P93; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; GALLO MA, 1993, PHARMACOL BIOCHEM BE, V46, P897, DOI 10.1016/0091-3057(93)90219-J; Games P. A., 1976, J EDUC STAT, V1, P113, DOI DOI 10.2307/1164979; GAMES PA, 1981, PSYCHOL BULL, V90, P594, DOI 10.1037/0033-2909.90.3.594; Gomez C, 2002, PHARMACOL BIOCHEM BE, V72, P543, DOI 10.1016/S0091-3057(02)00722-0; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; GROSSMAN KJ, 2002, EFFECTS PROGESTERONE; Guandalini P, 1998, BRAIN RES BULL, V47, P377, DOI 10.1016/S0361-9230(98)00122-1; Gulinello M, 2001, BRAIN RES, V910, P55, DOI 10.1016/S0006-8993(01)02565-3; Gulinello M, 2002, NEUROPHARMACOLOGY, V43, P701, DOI 10.1016/S0028-3908(02)00171-5; HE J, 2000, ABSTR SOC NEUROSCI; Hoffman SW, 1997, RESTOR NEUROL NEUROS, V11, P1, DOI 10.3233/RNN-1997-111201; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kalivas PW, 1999, ANN NY ACAD SCI, V877, P64, DOI 10.1111/j.1749-6632.1999.tb09261.x; Kalivas PW, 2001, NEUROSCIENCE, V104, P129, DOI 10.1016/S0306-4522(01)00054-9; Kolb B., 1999, COGNITIVE NEUROREHAB, P9; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LEONARD CM, 1969, BRAIN RES, V12, P321, DOI 10.1016/0006-8993(69)90003-1; Lukasiuk K, 2000, J NEUROCHEM, V74, P2445, DOI 10.1046/j.1471-4159.2000.0742445.x; MCKIM WA, 1996, DRUGS BEHAV INTRO BE; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; PAULSON PE, 1994, BEHAV NEUROSCI, V108, P624, DOI 10.1037/0735-7044.108.3.624; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Povlishock John T., 1995, P504; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Smith SS, 1998, J NEUROSCI, V18, P5275, DOI 10.1523/JNEUROSCI.18-14-05275.1998; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; TREIT D, 1988, PHARMACOL BIOCHEM BE, V31, P959, DOI 10.1016/0091-3057(88)90413-3; vandenPol AN, 1996, J NEUROSCI, V16, P4283; WILCOX RR, 1987, ANNU REV PSYCHOL, V38, P29, DOI 10.1146/annurev.psych.38.1.29; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	49	134	140	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2003	76	2					231	242		10.1016/j.pbb.2003.07.003			12	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	743AL	WOS:000186550200003	14592674				2022-02-06	
J	Chen, JL; Chopp, M; Li, Y				Chen, JL; Chopp, M; Li, Y			Neuroprotective effects of progesterone after transient middle cerebral artery occlusion in rat	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						stroke; progesterone; rat; middle cerebral artery occlusion; free radical; GABA(A); sensorimotor function	TRAUMATIC BRAIN INJURY; ISCHEMIC CELL-DAMAGE; A RECEPTOR; GABA(A) RECEPTOR; METABOLITES; STEROIDS; RECOVERY; PROTEIN; EDEMA; MODULATION	Treatment of focal cerebral ischemia in the rat with intraperitoneal administration of progesterone dissolved in dimethyl sulfoxide (DMSO) has demonstrated therapeutic efficacy. In the present study we test whether iv administration of water soluble progesterone 2 h after the onset of middle cerebral artery occlusion provides therapeutic benefit for the treatment of stroke. In addition, we perform a battery of functional tests: rotarod, adhesive-backed somatosensory, and neurological score, as well as a dose-response study. The data indicate that iv administration of progesterone at a dose of 8 mg/kg significantly reduces the volume of cerebral infarction and significantly improves outcome on the array of functional measures employed. Treatment with 4 mg/kg or 32 mg/kg of progesterone failed to provide any therapeutic benefit. Progesterone, a non toxic, clinically employed, pluripotent therapeutic agent which targets both neuroprotective as well as neuroregenerative strategies, may have important therapeutic benefits for the treatment of stroke. (C) 1999 Published by Elsevier Science B.V. All rights reserved.	Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI 48202 USA; Oakland Univ, Dept Phys, Rochester, MI 48309 USA		Chopp, M (corresponding author), Henry Ford Hlth Sci Ctr, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu					BELELLI D, 1989, EUR J PHARMACOL, V166, P325, DOI 10.1016/0014-2999(89)90077-0; BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1989, STROKE, V20, P1253, DOI 10.1161/01.STR.20.9.1253; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bielefeldt K, 1996, AM J PHYSIOL-GASTR L, V271, pG370, DOI 10.1152/ajpgi.1996.271.2.G370; BITRAN D, 1991, BRAIN RES, V561, P157, DOI 10.1016/0006-8993(91)90761-J; BUREAU M, 1990, MOL PHARMACOL, V37, P497; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Gibbs RB, 1998, BRAIN RES, V787, P259, DOI 10.1016/S0006-8993(97)01511-4; GINSBERG MD, 1988, NEUROCHEM PATHOL, V9, P171; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HARRISON NL, 1987, J PHARMACOL EXP THER, V241, P346; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KARAVOLAS HJ, 1979, ENDOCRINOLOGY, V104, P1418, DOI 10.1210/endo-104-5-1418; KATAYAMA Y, 1994, ACTA NEUROCHIR, P242; KOKATE TG, 1994, J PHARMACOL EXP THER, V270, P1223; Kuang P, 1994, J Tradit Chin Med, V14, P45; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MIZOI K, 1986, Neurological Research, V8, P75; OLSON JJ, 1988, BRAIN RES, V439, P259, DOI 10.1016/0006-8993(88)91482-5; Peluso JJ, 1998, BIOL REPROD, V58, P1131, DOI 10.1095/biolreprod58.5.1131; PEPE GJ, 1973, ENDOCRINOLOGY, V93, P1200, DOI 10.1210/endo-93-5-1200; PETERS JA, 1988, BRIT J PHARMACOL, V94, P1257, DOI 10.1111/j.1476-5381.1988.tb11646.x; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; Qu M, 1998, NEUROSCIENCE, V85, P29, DOI 10.1016/S0306-4522(97)00656-8; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TWYMAN RE, 1992, J PHYSIOL-LONDON, V456, P215, DOI 10.1113/jphysiol.1992.sp019334; VIRGILI M, 1995, HIPPOCAMPUS, V5, P91, DOI 10.1002/hipo.450050111; WEILAND NG, 1995, MOL BRAIN RES, V32, P271, DOI 10.1016/0169-328X(95)00087-9; WU FS, 1991, MOL PHARMACOL, V40, P333; WU FS, 1990, MOL PHARMACOL, V37, P597; Zea Longa E. L., 1989, STROKE, V20, P84	46	134	135	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	DEC 1	1999	171	1					24	30		10.1016/S0022-510X(99)00247-6			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	269PX	WOS:000084487700006	10567046				2022-02-06	
J	Ingebrigtsen, T; Waterloo, K; Marup-Jensen, S; Attner, E; Romner, B				Ingebrigtsen, T; Waterloo, K; Marup-Jensen, S; Attner, E; Romner, B			Quantification of post-concussion symptoms 3 months after minor head injury in 100 consecutive patients	JOURNAL OF NEUROLOGY			English	Article						head injury; outcome; post-concussion symptoms; Rivermead Postconcussion Symptoms Questionnaire	TRAUMATIC BRAIN INJURY; FOLLOW-UP; NATURAL-HISTORY	Post-concussion symptoms (PCS) (such as headaches, irritability, anxiety, dizziness, fatigue and impaired concentration) are frequently experienced by patients who have sustained a minor head injury (MHI). The post-concussion syn drome has been defined as a clinical state where 3 or more symptoms persist for more than 3 months. This report focuses on the quantification of PCS according to the Rivermead Postconcussion Symptoms Questionnaire (RPQ). We studied 100 consecutive patients with MHI and normal computed tomography of the brain, At 3 months after injury, 62% reported the presence of one or more symptoms, and 40% fulfilled the diagnostic criteria for post-concussion syndrome, Patients with postconcussion syndrome had significantly (P < 0.001) higher RPQ scores (mean 19.1, SD 11.9) than those without (mean 1.2, SD 1.8). Patients on sick leave owing to the injury reported significantly (P = 0.05) higher RPQ scores (mean 10.3, SD 13.2) than those not on sick leave (mean 5.5, SD 8.6). We observed no association between age, gender, cause of injury, severity of injury, duration of amnesia and RPQ score. RPQ score provides useful information about the severity of PCS regardless of whether the diagnostic criteria for the post-concussion syndrome are met or not.	Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden; Univ Tromso Hosp, Dept Neurosurg, N-9038 Tromso, Norway; Univ Tromso Hosp, Dept Neurol, N-9038 Tromso, Norway; Univ Lund Hosp, Dept Neurol, S-22185 Lund, Sweden		Romner, B (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.			Ingebrigtsen, Tor/0000-0001-5966-9786			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bennett T L, 1997, Appl Neuropsychol, V4, P1, DOI 10.1207/s15324826an0401_1; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; Kibby M Y, 1997, Appl Neuropsychol, V4, P34, DOI 10.1207/s15324826an0401_4; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; World Health Organization, 1978, ICD 9 CLASS MENT BEH	20	134	135	0	11	DR DIETRICH STEINKOPFF VERLAG	DARMSTADT	PLATZ DER DEUTSCHEN EINHEIT 25, D-64293 DARMSTADT, GERMANY	0340-5354			J NEUROL	J. Neurol.	SEP	1998	245	9					609	612		10.1007/s004150050254			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	118WJ	WOS:000075863700008	9758300				2022-02-06	
J	Whyte, J; Hart, T; Schuster, K; Fleming, M; Polansky, M; Coslett, HB				Whyte, J; Hart, T; Schuster, K; Fleming, M; Polansky, M; Coslett, HB			Effects of methylphenidate on attentional function after traumatic brain injury - A randomized, placebo-controlled trial	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						brain injury; attention; reaction time; methylphenidate	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD-INJURY; AROUSAL	Attention deficits after traumatic brain injury (TBI) are common and disabling. Many pharmacologic agents have been used to ameliorate attention deficits, and considerable interest has focused on methylphenidate (MP) because of its documented efficacy in attention deficit disorder. However, clinical studies of MP in subjects with TBI have yielded mixed results. We examined the effects of MP on attentional function in individuals with TBI referred specifically for attentional assessment and treatment. Subjects were studied in a double-blind, placebo-controlled, repeated crossover design, using five different tasks designed to measure various facets of attentional function. MP produced a significant improvement in the speed of mental processing. Orienting to distractions, most aspects of sustained attention, and measures of motor speed were unaffected. These results suggest that MP may be a useful treatment in TBI but is primarily useful for symptoms that can be attributed to slowed mental processing.	Temple Univ, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Drucker Brain Injury Ctr, Philadelphia, PA 19141 USA; Temple Univ, Dept Phys Med & Rehabil, MossRehab, Philadelphia, PA 19141 USA; Temple Univ, Dept Neurol, Philadelphia, PA 19141 USA; Allegheny Univ Hlth Sci, Dept Clin & Hlth Psychol, Philadelphia, PA 19102 USA; Allegheny Univ Hlth Sci, Sch Publ Hlth, Philadelphia, PA 19102 USA		Whyte, J (corresponding author), Temple Univ, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS027715] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS27715] Funding Source: Medline		AKRITAS MG, 1994, J AM STAT ASSOC, V89, P336, DOI 10.2307/2291230; Cohen J., 2013, STAT POWER ANAL BEHA; DESONNEVILLE LMJ, 1994, J CLIN EXP NEUROPSYC, V16, P877, DOI 10.1080/01688639408402700; Evans R. W., 1987, J HEAD TRAUMA REHAB, V2, P29; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVANS RW, 1986, PSYCHOPHARMACOLOGY, V90, P211; GAULTIERI CT, 1988, BRAIN INJURY, V2, P101; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; MALONE MA, 1994, J CHILD NEUROL, V9, P181, DOI 10.1177/088307389400900216; MATTES JA, 1980, COMPR PSYCHIAT, V21, P358, DOI 10.1016/0010-440X(80)90017-6; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Parmelee D X, 1987, Brain Inj, V1, P41, DOI 10.3109/02699058709034443; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; POSNER MI, 1986, CHRONIMETRIC EXPLORA; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAPPORT MD, 1986, J CONSULT CLIN PSYCH, V54, P334; SHUE KL, 1992, BRAIN COGNITION, V20, P104, DOI 10.1016/0278-2626(92)90064-S; Siegel S., 1988, NONPARAMETRIC STAT B, P87; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; VONZOMEREN AH, 1981, REACTION TIME ATTENT; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 1993, REHABILITATION MED P, P825; WHYTE J, IN PRESS J INT NEURO; WHYTE J, 1996, J INT NEUROPSYCH SOC, V2, P271; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004	35	134	137	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	1997	76	6					440	450		10.1097/00002060-199711000-00002			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	YP029	WOS:000071234100002	9431261				2022-02-06	
J	SYMONDS, C				SYMONDS, C			CONCUSSION AND ITS SEQUELAE	LANCET			English	Article																	BECKER RF, 1945, FED PROC, V4, P6; BECKER RF, 1946, FED PROC, V5, P7; Cooper A, 1836, PRINCIPLES PRACTICE; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GROAT R, 1950, J NEUROPATH EXP NEUR, V9, P150, DOI 10.1097/00005072-195004000-00003; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; HILTON J, 1963, LECTURES REST PAIN; Holbourn AHS, 1943, LANCET, V2, P438; JAKOB A, CITED INDIRECTLY; Jefferson G, 1944, BRIT MED J, V1944, P1; MERRITT HH, 1959, TEXTBOOK NEUROLOGY L; MILNER B, 1959, 11 AM PSYCH ASS PSYC; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; ROSE FC, 1960, BRAIN, V83, P195, DOI 10.1093/brain/83.2.195; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS CP, 1940, INJURIES SKULL BRAIN; TROTTER W, 1932, SYSTEM SURGERY; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1944, T AM NEUROL ASSOC, P117; [No title captured]	21	134	134	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet		1962	1	7219					1	+					1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	7761B	WOS:A19627761B00059					2022-02-06	
J	Stocchetti, N; Carbonara, M; Citerio, G; Ercole, A; Skrifvars, MB; Smielewski, P; Zoerle, T; Menon, DK				Stocchetti, Nino; Carbonara, Marco; Citerio, Giuseppe; Ercole, Ari; Skrifvars, Markus B.; Smielewski, Peter; Zoerle, Tommaso; Menon, David K.			Severe traumatic brain injury: targeted management in the intensive care unit	LANCET NEUROLOGY			English	Article							CEREBRAL PERFUSION-PRESSURE; GLASGOW COMA SCALE; WAKE-UP TEST; INTRACRANIAL-PRESSURE; TISSUE OXYGEN; DECOMPRESSIVE CRANIECTOMY; METABOLIC CRISIS; OLDER-ADULTS; HEAD-INJURY; NEUROLOGICAL DETERIORATION	Severe traumatic brain injury (TBI) is currently managed in the intensive care unit with a combined medical-surgical approach. Treatment aims to prevent additional brain damage and to optimise conditions for brain recovery. TBI is typically considered and treated as one pathological entity, although in fact it is a syndrome comprising a range of lesions that can require different therapies and physiological goals. Owing to advances in monitoring and imaging, there is now the potential to identify specific mechanisms of brain damage and to better target treatment to individuals or subsets of patients. Targeted treatment is especially relevant for elderly people-who now represent an increasing proportion of patients with TBI-as preinjury comorbidities and their therapies demand tailored management strategies. Progress in monitoring and in understanding pathophysiological mechanisms of TBI could change current management in the intensive care unit, enabling targeted interventions that could ultimately improve outcomes.	[Stocchetti, Nino; Carbonara, Marco; Zoerle, Tommaso] Fdn IRCCS CaGranda, Osped Maggiore Policlin, Dept Anaesthesia & Crit Care, Neurosci Intens Care Unit, I-20133 Milan, Italy; [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, Milan, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] San Gerardo Hosp, Neurointens Care, ASST, Monza, Italy; [Ercole, Ari; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Skrifvars, Markus B.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Skrifvars, Markus B.] Univ Helsinki, Helsinki, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Div Intens Care, Dept Anaesthesiol Intens Care & Pain Med, Helsinki, Finland; [Smielewski, Peter] Univ Cambridge, Brain Phys Lab, Dept Clin Neurosci, Div Neurosurg, Cambridge, England		Stocchetti, N (corresponding author), Fdn IRCCS CaGranda, Osped Maggiore Policlin, Dept Anaesthesia & Crit Care, Neurosci Intens Care Unit, I-20133 Milan, Italy.	nino.stocchetti@policlinico.mi.it	Stocchetti, Nino/O-7444-2017; Citerio, Giuseppe/B-1839-2015; Carbonara, Marco/N-3793-2015; Ercole, Ari/B-6288-2009	Stocchetti, Nino/0000-0003-3250-6834; Citerio, Giuseppe/0000-0002-5374-3161; Carbonara, Marco/0000-0002-1431-8322; Ercole, Ari/0000-0001-8350-8093; Zoerle, Tommaso/0000-0001-8713-8085; Smielewski, Peter/0000-0001-5096-3938	Helsinki University, Finland; Finska Lakaresallskapet; Svenska Kulturfonden; Stiftelsen for Perklens Minne; European UnionEuropean Commission; National Institute for Healthcare Research, UK; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986] Funding Source: UKRI	MBS reports grants from Helsinki University, Finland, Finska Lakaresallskapet, Svenska Kulturfonden, and Stiftelsen for Perklens Minne during the preparation of this review. DKM reports grants from the European Union (FP7 grant for the CENTER-TBI study) and support from the National Institute for Healthcare Research, UK, during the preparation of this review.	Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Aries MJH, 2016, CRIT CARE MED, V44, pE996, DOI 10.1097/CCM.0000000000001816; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Bauer DF, 2011, NEUROSURGERY, V69, P255, DOI 10.1227/NEU.0b013e31821a45ba; Bragge P, 2016, J NEUROTRAUM, V33, P1461, DOI 10.1089/neu.2015.4233; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; Centers for Disease Control and Prevention, 2016, TBI DAT STAT; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Couret D, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1239-z; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; Depreitere B, 2012, Acta Neurochir Suppl, V114, P289, DOI 10.1007/978-3-7091-0956-4_56; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Flechet M, 2016, CURR OPIN CRIT CARE, V22, P87, DOI 10.1097/MCC.0000000000000287; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x; Gaist D, 2017, JAMA-J AM MED ASSOC, V317, P836, DOI 10.1001/jama.2017.0639; Gillespie LD, 2012, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD007146; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Helbok R, 2012, CRIT CARE, V16, DOI 10.1186/cc11880; Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226; Hollis S, 2006, J TRAUMA, V61, P1255, DOI 10.1097/01.ta.0000243889.07090.da; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Iaccarino C, 2014, J NEUROSURG, V120, P908, DOI 10.3171/2013.12.JNS131090; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kehoe A, 2016, EMERG MED J, V33, P381, DOI 10.1136/emermed-2015-205180; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kirkman MA, 2013, J NEUROTRAUM, V30, P1385, DOI 10.1089/neu.2013.2881; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Larson MD, 2015, ANESTH ANALG, V120, P1242, DOI 10.1213/ANE.0000000000000314; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Magnoni S, 2015, BRAIN, V138, P2263, DOI 10.1093/brain/awv152; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mathias JL, 2015, NEUROSCI BIOBEHAV R, V55, P573, DOI 10.1016/j.neubiorev.2015.06.001; McAllister Thomas W, 2015, Handb Clin Neurol, V128, P723, DOI 10.1016/B978-0-444-63521-1.00045-5; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Miley Jefferson T, 2008, J Vasc Interv Neurol, V1, P79; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Mrozek S, 2014, CRIT CARE, V18, DOI 10.1186/cc13841; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nangunoori R, 2012, NEUROCRIT CARE, V17, P131, DOI 10.1007/s12028-011-9621-9; National Institute of Neurological Disorders and Stroke (NINDS), 2017, COMM DAT EL TRAUM BA; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nordstrom CH, 2016, ACTA NEUROCHIR, V158, P1231, DOI 10.1007/s00701-016-2835-z; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; O'Leary R, 2016, NEW ENGL J MED, V374, P1383, DOI 10.1056/NEJMc1600339; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Peck KA, 2014, J TRAUMA ACUTE CARE, V76, P431, DOI 10.1097/TA.0000000000000107; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Prins ML, 2014, J LIPID RES, V55, P2450, DOI 10.1194/jlr.R046706; Quintard H, 2016, J NEUROTRAUM, V33, P681, DOI 10.1089/neu.2015.4057; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROPPER AH, 1991, ARCH NEUROL-CHICAGO, V48, P1166, DOI 10.1001/archneur.1991.00530230074025; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Sinclair HL, 2010, CRIT CARE, V14, DOI 10.1186/cc8220; Skoglund K, 2014, NEUROCRIT CARE, V20, P413, DOI 10.1007/s12028-013-9876-4; Skoglund K, 2012, CRIT CARE MED, V40, P216, DOI 10.1097/CCM.0b013e31822d7dbd; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; Stocchetti N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0887-8; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brand CL, 2017, J NEUROTRAUM, V34, P1, DOI 10.1089/neu.2015.4393; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Veenith TV, 2014, J CEREBR BLOOD F MET, V34, P1622, DOI 10.1038/jcbfm.2014.123; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2016, ANN NEUROL, V79, P579, DOI 10.1002/ana.24606; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wijayatilake DS, 2015, J NEUROSURG ANESTH, V27, P241, DOI 10.1097/ANA.0000000000000143; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; World Health Organization, GLOB HLT OBS DAT LIF; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	120	133	144	2	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2017	16	6					452	464		10.1016/S1474-4422(17)30118-7			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EU1WD	WOS:000400815800012	28504109	Green Published, Green Submitted			2022-02-06	
J	Elder, GA; Dorr, NP; De Gasperi, R; Sosa, MAG; Shaughness, MC; Maudlin-Jeronimo, E; Hall, AA; McCarron, RM; Ahlers, ST				Elder, Gregory A.; Dorr, Nathan P.; De Gasperi, Rita; Sosa, Miguel A. Gama; Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; McCarron, Richard M.; Ahlers, Stephen T.			Blast Exposure Induces Post-Traumatic Stress Disorder-Related Traits in a Rat Model of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast; PTSD; rat; stathmin 1; TBI	STARTLE RESPONSE; INTRACRANIAL-PRESSURE; BEHAVIORAL CRITERIA; VIETNAM VETERANS; SERUM BIOMARKER; WAR VETERANS; MOUSE MODEL; MICE; OVERPRESSURE; PATHOLOGY	Blast related traumatic brain injury (TBI) has been a major cause of injury in the wars in Iraq and Afghanistan. A striking feature of the mild TBI (mTBI) cases has been the prominent association with post-traumatic stress disorder (PTSD). However, because of the overlapping symptoms, distinction between the two disorders has been difficult. We studied a rat model of mTBI in which adult male rats were exposed to repetitive blast injury while under anesthesia. Blast exposure induced a variety of PTSD-related behavioral traits that were present many months after the blast exposure, including increased anxiety, enhanced contextual fear conditioning, and an altered response in a predator scent assay. We also found elevation in the amygdala of the protein stathmin 1, which is known to influence the generation of fear responses. Because the blast overpressure injuries occurred while animals were under general anesthesia, our results suggest that a blast-related mTBI exposure can, in the absence of any psychological stressor, induce PTSD-related traits that are chronic and persistent. These studies have implications for understanding the relationship of PTSD to mTBI in the population of veterans returning from the wars in Iraq and Afghanistan.	[Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA; [De Gasperi, Rita; Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA; [Elder, Gregory A.; Dorr, Nathan P.; De Gasperi, Rita; Sosa, Miguel A. Gama] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA; [Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; McCarron, Richard M.; Ahlers, Stephen T.] USN, Dept Neurotrauma, Operat & Undersea Med Directorate, Med Res Ctr, Silver Spring, MD USA; [Elder, Gregory A.; De Gasperi, Rita; Sosa, Miguel A. Gama] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY USA		Elder, GA (corresponding author), James J Peters VA Med Ctr, Neurol Serv 3E16, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.	gregory.elder@va.gov			Department of Veterans AffairsUS Department of Veterans Affairs [1I01RX000179-01]	This work was supported by grant 1I01RX000179-01 from the Department of Veterans Affairs.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Arun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033798; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Brocke B, 2010, AM J MED GENET B, V153B, P243, DOI 10.1002/ajmg.b.30989; BUTLER RW, 1990, AM J PSYCHIAT, V147, P1308; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Cohen H, 2004, NEUROPSYCHOPHARMACOL, V29, P1962, DOI 10.1038/sj.npp.1300523; Cohen H, 2004, ANN NY ACAD SCI, V1032, P167, DOI 10.1196/annals.1314.014; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; Ehlis AC, 2011, AM J MED GENET B, V156B, P291, DOI 10.1002/ajmg.b.31161; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Floresco SB, 1997, J NEUROSCI, V17, P1880; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Morgan CA, 1996, AM J PSYCHIAT, V153, P64; ORR SP, 1995, J ABNORM PSYCHOL, V104, P75, DOI 10.1037/0021-843X.104.1.75; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Paylor R, 1997, PSYCHOPHARMACOLOGY, V132, P169, DOI 10.1007/s002130050333; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038; Sosa MAG, 2010, AM J PATHOL, V176, P353, DOI 10.2353/ajpath.2010.090482; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Valiyaveettil M, 2012, NEUROSCI LETT, V506, P141, DOI 10.1016/j.neulet.2011.10.067; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vieweg WVR, 2006, AM J MED, V119, P383, DOI 10.1016/j.amjmed.2005.09.027; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990	54	133	133	0	27	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	16					2564	2575		10.1089/neu.2012.2510			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	035CS	WOS:000310920900005	22780833	Green Published			2022-02-06	
J	Anderson, V; Godfrey, C; Rosenfeld, JV; Catroppa, C				Anderson, Vicki; Godfrey, Celia; Rosenfeld, Jeffrey V.; Catroppa, Cathy			Predictors of Cognitive Function and Recovery 10 Years After Traumatic Brain Injury in Young Children	PEDIATRICS			English	Article						traumatic brain injury; young; children; recovery of function; intelligence	CHILDHOOD HEAD-INJURY; NEUROBEHAVIORAL RECOVERY; PSYCHOSOCIAL OUTCOMES; SHORT-TERM; AGE; ACHIEVEMENT; PLASTICITY; TBI	BACKGROUND AND OBJECTIVES: Childhood traumatic brain injury (TBI) has implications for functional outcomes, but few studies have documented long-term outcomes. The purpose of this study was to plot recovery of cognitive and functional skills after early childhood TBI to 10 years postinjury and to identify the contribution of injury, environment, preinjury characteristics, and acute functional recovery. METHODS: Subjects were recruited consecutively to this prospective, longitudinal study, which used a between-factor design, with injury severity as the independent variable. Forty children with TBI aged 2 and 7 years were recruited on admission to a tertiary pediatric hospital, divided according to injury severity, and compared with 16 healthy controls acutely and 12 and 30 months and 10 years postinjury. Cognition, adaptive ability, executive function, and social/behavioral skills were examined. RESULTS: Children with severe TBI had poorest outcomes, with deficits greatest for cognition. Recovery trajectories were similar across severity groups but with significant gains in verbal skills from 12 and 30 months to 12 months and 10 years. Predictors of outcome included preinjury ability (for adaptive function) and family function (social/behavioral skills). CONCLUSIONS: Results confirm a high risk of persisting deficits after severe TBI in early childhood. Children with less severe TBI appear to recover to function normally. Contrary to speculation about "growing into deficits," after protracted recovery to 30 months, young children make age-appropriate progress at least to 10 years postinsult. Environmental factors were found to contribute to adaptive and social/behavioral recovery. Pediatrics 2012;129:e254-e261	[Anderson, Vicki; Godfrey, Celia; Catroppa, Cathy] Murdoch Childrens Res Inst, Dept Child Neuropsychol, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Catroppa, Cathy/AAX-9458-2021; Rosenfeld, Jeffrey V/B-7249-2011	Catroppa, Cathy/0000-0002-9750-0436; 	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Victorian Government	This research was supported by a grant from the Australian National Health and Medical Research Council (Anderson, Catroppa & Rosenfeld) and by the Victorian Government Operational Infrastructure Support Program	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Bayley N., 1969, BAYLEY SCALES INFANT; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia GA IP, 2000, BEHAV RATING INVENTO; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kraus JF., 1995, TRAUMATIC HEAD INJUR, P117; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Noller P, 1988, FAMILY FUNCTIO UNPUB; Oakland T, 2008, PRACT RESOUR MENT, P1; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Walsh K., 1985, NEUROPSYCHOLOGY CLIN; Wechsler D, 1997, MANUAL WECHSLER ADUL; Wechsler D., 1989, MANUAL PRESCHOOL PRI; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; [No title captured]	37	133	134	3	32	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2012	129	2					E254	E261		10.1542/peds.2011-0311			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	893YZ	WOS:000300395100001	22271691				2022-02-06	
J	Gao, X; Deng, P; Xu, ZC; Chen, JH				Gao, Xiang; Deng, Ping; Xu, Zao C.; Chen, Jinhui			Moderate Traumatic Brain Injury Causes Acute Dendritic and Synaptic Degeneration in the Hippocampal Dentate Gyrus	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; INDUCED AXONAL INJURY; STEREOLOGICAL ESTIMATION; CHOLINERGIC INNERVATION; ALZHEIMERS-DISEASE; MEMORY DYSFUNCTION; PYRAMIDAL NEURONS; IMMATURE RAT; TIME-COURSE	Hippocampal injury-associated learning and memory deficits are frequent hallmarks of brain trauma and are the most enduring and devastating consequences following traumatic brain injury (TBI). Several reports, including our recent paper, showed that TBI brought on by a moderate level of controlled cortical impact (CCI) induces immature newborn neuron death in the hippocampal dentate gyrus. In contrast, the majority of mature neurons are spared. Less research has been focused on these spared neurons, which may also be injured or compromised by TBI. Here we examined the dendrite morphologies, dendritic spines, and synaptic structures using a genetic approach in combination with immunohistochemistry and Golgi staining. We found that although most of the mature granular neurons were spared following TBI at a moderate level of impact, they exhibited dramatic dendritic beading and fragmentation, decreased number of dendritic branches, and a lower density of dendritic spines, particularly the mushroom-shaped mature spines. Further studies showed that the density of synapses in the molecular layer of the hippocampal dentate gyrus was significantly reduced. The electrophysiological activity of neurons was impaired as well. These results indicate that TBI not only induces cell death in immature granular neurons, it also causes significant dendritic and synaptic degeneration in pathohistology. TBI also impairs the function of the spared mature granular neurons in the hippocampal dentate gyrus. These observations point to a potential anatomic substrate to explain, in part, the development of posttraumatic memory deficits. They also indicate that dendritic damage in the hippocampal dentate gyrus may serve as a therapeutic target following TBI.	[Gao, Xiang; Xu, Zao C.; Chen, Jinhui] Stark Neurosci Res Inst, Dept Neurosurg, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN USA; [Deng, Ping] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA		Gao, X (corresponding author), Stark Neurosci Res Inst, Dept Neurosurg, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN USA.	chen204@iupui.edu			Indiana Spinal Cord & Brain Injury Research Fund (SCBI) [200-12]; Ralph W. and Grace M. Showalter Research Award; Indiana University; Showalter award; biomedical research award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER	This work was supported by grants from the Indiana Spinal Cord & Brain Injury Research Fund (SCBI 200-12)(http://www.in.gov/isdh/23657.htm); the Ralph W. and Grace M. Showalter Research Award, and the Indiana University Biological Research Grant to J. Chen. Both the Showalter award and the biomedical research award are internal funding, and do not have grant numbers and specific websites. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Dunaevsky A, 1999, P NATL ACAD SCI USA, V96, P13438, DOI 10.1073/pnas.96.23.13438; Ehlers MD, 2005, J CELL BIOL, V170, P517, DOI 10.1083/jcb.200507096; EMERY DG, 1995, BRAIN RES, V692, P161, DOI 10.1016/0006-8993(95)00726-7; FELDMAN ML, 1979, J COMP NEUROL, V188, P527, DOI 10.1002/cne.901880403; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Gao X., 2009, J NEUROTRAUMA; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2007, J NEUROSCI, V27, P14317, DOI 10.1523/JNEUROSCI.3206-07.2007; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gao X, 2009, EXP NEUROL, V215, P178, DOI 10.1016/j.expneurol.2008.10.009; Geula C, 1998, NEUROLOGY, V51, pS18, DOI 10.1212/WNL.51.1_Suppl_1.S18; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Jan YN, 2001, GENE DEV, V15, P2627, DOI 10.1101/gad.916501; Kelly Kevin M, 2004, Epilepsy Curr, V4, P160, DOI 10.1111/j.1535-7597.2004.44015.x; Leuner B, 2010, ANNU REV PSYCHOL, V61, P111, DOI 10.1146/annurev.psych.093008.100359; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDROOS OFC, 1983, STAIN TECHNOL, V58, P240, DOI 10.3109/10520298309066795; Lister JP, 2009, ARCH NEUROL-CHICAGO, V66, P829, DOI 10.1001/archneurol.2009.125; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; NORRIS CM, 2009, J NEUROTRAUMA; Novak K, 2000, NAT MED, V6, P864, DOI 10.1038/78615; Petrak LJ, 2005, J COMP NEUROL, V484, P183, DOI 10.1002/cne.20468; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Portera-Cailliau C, 2003, J NEUROSCI, V23, P7129, DOI 10.1523/JNEUROSCI.23-18-07129.2003; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Pruss H, 2005, MOL BRAIN RES, V139, P63, DOI 10.1016/j.molbrainres.2005.05.006; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; REISINE TD, 1978, BRAIN RES, V159, P477, DOI 10.1016/0006-8993(78)90562-0; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Santhakumar V, 2005, J NEUROPHYSIOL, V93, P437, DOI 10.1152/jn.00777.2004; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Selkoe Dennis, 2002, Harv Health Lett, V27, P5; SERESS L, 1981, J ANAT, V133, P181; SHOLL D A, 1956, Prog Neurobiol, P324; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SOTREL A, 1993, NEUROLOGY, V43, P2088, DOI 10.1212/WNL.43.10.2088; Stewart TH, 2010, J NEUROPHYSIOL, V104, P3345, DOI 10.1152/jn.00398.2010; SUETSUGU M, 1980, ACTA NEUROPATHOL, V50, P207, DOI 10.1007/BF00688755; Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Travis K, 2005, DEV NEUROSCI-BASEL, V27, P277, DOI 10.1159/000086707; UYLINGS HBM, 1986, J NEUROSCI METH, V18, P127, DOI 10.1016/0165-0270(86)90116-0; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Young CC, 2009, J PHYSIOL-LONDON, V587, P4213, DOI 10.1113/jphysiol.2009.170746; Zeng LH, 2007, J NEUROSCI, V27, P11604, DOI 10.1523/JNEUROSCI.0983-07.2007	74	133	135	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2011	6	9							e24566	10.1371/journal.pone.0024566			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825ZV	WOS:000295321800033	21931758	Green Published, Green Submitted, gold			2022-02-06	
J	Brandt, C; Nozadze, M; Heuchert, N; Rattka, M; Loscher, W				Brandt, Claudia; Nozadze, Maia; Heuchert, Nina; Rattka, Marta; Loescher, Wolfgang			Disease-Modifying Effects of Phenobarbital and the NKCC1 Inhibitor Bumetanide in the Pilocarpine Model of Temporal Lobe Epilepsy	JOURNAL OF NEUROSCIENCE			English	Article							INDUCED-STATUS-EPILEPTICUS; TRAUMATIC BRAIN-INJURY; NEURONAL DAMAGE; ANTIEPILEPTIC DRUGS; P-GLYCOPROTEIN; BEHAVIORAL ALTERATIONS; SPONTANEOUS SEIZURES; RAT MODELS; PHARMACOKINETICS; EXPRESSION	Accumulating evidence suggests that changes in neuronal chloride homeostasis may be involved in the mechanisms by which brain insults induce the development of epilepsy. A variety of brain insults, including status epilepticus (SE), lead to changes in the expression of the cation-chloride cotransporters KCC2 and NKCC1, resulting in intracellular chloride accumulation and reappearance of immature, depolarizing synaptic responses to GABA(A) receptor activation, which may critically contribute to the neuronal hyperexcitability underlying epileptogenesis. In the present study, it was evaluated whether prolonged administration of the selective NKCC1 inhibitor, bumetanide, after a pilocarpine-induced SE modifies the development of epilepsy in adult female rats. The antiepileptic drug phenobarbital, either alone or in combination, was used for comparison. Based on pharmacokinetic studies with bumetanide, which showed extremely rapid elimination and low brain penetration of this drug in rats, bumetanide was administered systemically with different dosing protocols, including continuous intravenous infusion. As shown by immunohistochemistry, neuronal NKCC1 expression was markedly upregulated shortly after SE. Prophylactic treatment with phenobarbital after SE reduced the number of rats developing spontaneous seizures and decreased seizure frequency, indicating a disease-modifying effect. Bumetanide did not exert any significant effects on development of spontaneous seizures nor did it enhance the effects of phenobarbital. However, combined treatment with both drugs counteracted several of the behavioral consequences of SE, which was not observed with single drug treatment. These data do not indicate that bumetanide can prevent epilepsy after SE, but the disease-modifying effect of this drug warrants further studies with more lipophilic prodrugs of bumetanide.	[Brandt, Claudia; Nozadze, Maia; Heuchert, Nina; Rattka, Marta; Loescher, Wolfgang] Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; [Brandt, Claudia; Nozadze, Maia; Heuchert, Nina; Rattka, Marta; Loescher, Wolfgang] Univ Vet Med Hannover, Ctr Syst Neurosci, D-30559 Hannover, Germany		Loscher, W (corresponding author), Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [Lo 274/11-1]; German Academic Exchange ServiceDeutscher Akademischer Austausch Dienst (DAAD)	The study was supported by a grant (Lo 274/11-1) from the Deutsche Forschungsgemeinschaft. Maia Nozadze received a scholarship from the German Academic Exchange Service. We thank Prof. Hans-Hasso Frey and Dr. Peter W. Feit, who were responsible for the discovery and development of bumetanide at Leo Pharmaceutical Products, for extremely helpful discussions, Dr. Feit for advice during development of the HPLC analysis of bumetanide, and Prof. Kai Kaila for critical reading of the manuscript. We thank Martina Gramer, Maria Hausknecht, and Julia Forster for skilful technical assistance, Prof. Andrea Tipold for help with the electrolyte analysis, Dr. Johanna Kuhlmann-Gottke for help and advice in establishing the continuous intravenous infusion protocol, and Prof. Kietzmann for calculation of the bumetanide infusion rate by WinNonLin.	Armstrong C, 2009, EPILEPSIA, V50, P1657, DOI 10.1111/j.1528-1167.2009.02173.x; Bankstahl JP, 2008, NEUROPHARMACOLOGY, V54, P1006, DOI 10.1016/j.neuropharm.2008.02.008; Bankstahl JP, 2008, EPILEPSY RES, V82, P70, DOI 10.1016/j.eplepsyres.2008.07.007; Baulac M., 2002, ANTIEPILEPTIC DRUGS, P514; Ben-Ari Y, 2005, CURR OPIN NEUROL, V18, P141, DOI 10.1097/01.wco.0000162855.75391.6a; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; Bolanos AR, 1998, NEUROLOGY, V51, P41, DOI 10.1212/WNL.51.1.41; Bragin DE, 2009, EUR J NEUROSCI, V30, P611, DOI 10.1111/j.1460-9568.2009.06863.x; Brandt C, 2004, EPILEPSIA, V45, P1488, DOI 10.1111/j.0013-9580.2004.16904.x; Brandt C, 2004, EPILEPSY RES, V62, P135, DOI 10.1016/j.eplepsyres.2004.08.008; Brandt C, 2007, NEUROPHARMACOLOGY, V53, P207, DOI 10.1016/j.neuropharm.2007.05.001; Brandt C, 2006, NEUROPHARMACOLOGY, V51, P789, DOI 10.1016/j.neuropharm.2006.05.021; BUSCH U, 1979, ARZNEIMITTEL-FORSCH, V29-1, P315; Clayton GH, 1998, DEV BRAIN RES, V109, P281, DOI 10.1016/S0165-3806(98)00078-9; COHEN MR, 1976, J PHARMACOL EXP THER, V197, P697; Detour J, 2005, EPILEPSIA, V46, P499, DOI 10.1111/j.0013-9580.2005.38704.x; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; dos Santos JG, 2005, BRAIN RES, V1066, P37, DOI 10.1016/j.brainres.2005.09.037; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Dzhala VI, 2008, ANN NEUROL, V63, P222, DOI 10.1002/ana.21229; FEIT PW, 1990, BUMETANIDE, P1; FILE SE, 1993, BEHAV BRAIN RES, V58, P199, DOI 10.1016/0166-4328(93)90103-W; Freichel C, 2006, NEUROSCIENCE, V141, P2177, DOI 10.1016/j.neuroscience.2006.05.040; Galanopoulou AS, 2007, EPILEPSIA, V48, P14, DOI 10.1111/j.1528-1167.2007.01284.x; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; HALLADAY SC, 1977, DRUG METAB DISPOS, V6, P45; Hannaert P, 2002, N-S ARCH PHARMACOL, V365, P193, DOI 10.1007/s00210-001-0521-y; Jacobs MP, 2009, EPILEPSY BEHAV, V14, P438, DOI 10.1016/j.yebeh.2009.02.036; Kim EJ, 2001, BIOPHARM DRUG DISPOS, V22, P147, DOI 10.1002/bdd.267; Kohling R, 2002, SCIENCE, V298, P1350; Kuteykin-Teplyakov K, 2009, EPILEPSIA, V50, P887, DOI 10.1111/j.1528-1167.2008.01916.x; LEE SH, 1994, J PHARMACOKINET BIOP, V22, P1, DOI 10.1007/BF02353407; Li XB, 2008, BRAIN RES, V1221, P141, DOI 10.1016/j.brainres.2008.04.047; Loscher W, 2007, EPILEPSIA, V48, P1245, DOI 10.1111/j.1528-1167.2007.01093.x; LopezSamblas AM, 1997, BIOL NEONATE, V72, P265; LOSCHER W, 1995, EPILEPSIA, V36, P929, DOI 10.1111/j.1528-1157.1995.tb01637.x; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Marty S, 2002, EUR J NEUROSCI, V15, P233, DOI 10.1046/j.0953-816x.2001.01854.x; Mattes Henri, 2006, Recent Pat CNS Drug Discov, V1, P247, DOI 10.2174/157488906778773698; Mazarati A, 2009, EPILEPSIA, V50, P2117, DOI 10.1111/j.1528-1167.2009.02048.x; McCloskey DP, 2006, EUR J NEUROSCI, V24, P2203, DOI 10.1111/j.1460-9568.2006.05101.x; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; Olsen RW, 2002, ANTIEPILEPTIC DRUGS, P489; OSTERGAARD EH, 1972, ARZNEI-FORSCHUNG, V22, P66; Parsons CG, 2002, IONOTROPIC GLUTAMATE, P91; Pathak HR, 2007, J NEUROSCI, V27, P14012, DOI 10.1523/JNEUROSCI.4390-07.2007; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Potschka H, 2002, NEUROSCI LETT, V327, P173, DOI 10.1016/S0304-3940(02)00423-8; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rice AC, 1998, EPILEPSIA, V39, P1148, DOI 10.1111/j.1528-1157.1998.tb01305.x; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Yan YP, 2001, BRAIN RES, V911, P43, DOI 10.1016/S0006-8993(01)02649-X	59	133	133	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 23	2010	30	25					8602	8612		10.1523/JNEUROSCI.0633-10.2010			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	614RH	WOS:000279076900025	20573906	Bronze, Green Published			2022-02-06	
J	Orff, HJ; Ayalon, L; Drummond, SPA				Orff, Henry J.; Ayalon, Liat; Drummond, Sean P. A.			Traumatic Brain Injury and Sleep Disturbance: A Review of Current Research	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						delayed sleep phase; insomnia; sleep disturbance; traumatic brain injury	PHASE SYNDROME; WAKE SYNDROME; DISORDERS; INSOMNIA; PREVALENCE; COMPLAINTS; ADOLESCENTS; SYMPTOMS; FATIGUE; RHYTHM	Objective: To summarize the current literature regarding the significant prevalence and potential consequences of sleep disturbance following traumatic brain injury (TBI), particularly mild TBI. Design: PubMed and Ovid/MEDLINE databases were searched by using key words "sleep disturbance," "Insomnia," "TBI," "brain injury," and "circadian rhythms." Additional sources (eg, abstracts from the annual Associated Professional Sleep Societies meeting) were also reviewed. Results: Sequelae of TBI include both medical and psychiatric symptoms and frequent complaints of sleep disturbance. Sleep disturbance likely result from and contribute to multiple factors associated with the injury, all of which complicate recovery and resolution of symptoms. Interestingly, research now seems to indicate that mild TBI may be more correlated with increased likelihood of sleep disturbance than are severe forms of TBI. Conclusions: Sleep disturbance is a common consequence of TBI, but much more research is required to elucidate the nature and extent of this relation. Research needs to focus on (1) uncovering the specific types, causes, and severity of TBI that most often lead to sleep problems; (2) the specific consequences of sleep disturbance in this population (eg, impaired physical or cognitive recovery); and (3) the most effective strategies for the treatment of sleep-wake abnormalities in this population.	[Orff, Henry J.] Univ Calif San Diego, San Diego State Univ, Joint Doctoral Program Clin Psychol, San Diego, CA 92103 USA; [Ayalon, Liat; Drummond, Sean P. A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Ayalon, Liat] Univ Calif San Diego, VA San Diego Healthcare Syst, Res Serv, San Diego, CA 92103 USA; [Drummond, Sean P. A.] Univ Calif San Diego, VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92103 USA		Drummond, SPA (corresponding author), 9151B Univ Calif San Diego, VA San Diego Healthcare Syst, Dept Psychiat, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	drummond@ucsd.edu	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Drummond, Sean/0000-0002-9815-626X	National Sleep Foundation;  [F31 MH077411-01A1]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH077411] Funding Source: NIH RePORTER	This study was supported by F31 MH077411-01A1 (H.J.O.) and National Sleep Foundation Pickwick Fellowship (L.A).	*AM AC SLEEP MED, 2001, INT CLASS SLEEP DIS; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4; Aurora R, 2007, SLEEP, V30, pA299; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2006, SLEEP, V29, pA301; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Bradshaw DA, 2001, SLEEP, V24, pA374; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chaput G, 2007, SLEEP, V30, pA302; Chung SA, 2004, SLEEP, V27, P314; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; Gosselin N, 2007, SLEEP, V30, pA301; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; LAI J, 1999, SLEEP S, V22, P314; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley M, 2007, SLEEP, V30, pA305; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553; Nagtegaal JE, 1997, FUNCT NEUROL, V12, P345; *NAT I NEUR DIS ST, 2002, STROK NINDS TRAUM BR; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Shibui K, 1999, J BIOL RHYTHM, V14, P72, DOI 10.1177/074873099129000371; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Uchiyama M, 2000, NEUROSCI LETT, V294, P101, DOI 10.1016/S0304-3940(00)01551-2; Verma A, 2007, J CLIN SLEEP MED, V3, P357; WEITZMAN ED, 1981, ARCH GEN PSYCHIAT, V38, P737; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249	45	133	137	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					155	165		10.1097/HTR.0b013e3181a0b281			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800002	19461363				2022-02-06	
J	Fausti, SA; Wilmington, DJ; Gallun, FJ; Myers, PJ; Henry, JA				Fausti, Stephen A.; Wilmington, Debra J.; Gallun, Frederick J.; Myers, Paula J.; Henry, James A.			Auditory and vestibular dysfunction associated with blast-related traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						auditory dysfunction; blast; central auditory processing; hearing loss; polytrauma; prevention; rehabilitation; tinnitus; traumatic brain injury; vestibular	INDUCED HEARING-LOSS; CLINICAL MANAGEMENT; HEAD-INJURY; NOISE; BOMB; OTOTOXICITY; EXPOSURE; CONSEQUENCES; PREVENTION; EXPLOSION	The dramatic escalation of blast exposure in military deployments has created an unprecedented amount of traumatic brain injury (TBI) and associated auditory impairment. Auditory dysfunction has become the most prevalent individual service-connected disability, with compensation totaling more than 1 billion dollars annually. Impairment due to blast can include peripheral hearing loss, central auditory processing deficits, vestibular impairment, and tinnitus. These deficits are particularly challenging in the TBI population, as symptoms can be mistaken for posttraumatic stress disorder, mental-health issues, and cognitive deficits. In addition, comorbid factors such as attention, cognition, neuronal loss, noise toxicity, etc., can confound assessment, causing misdiagnosis. Furthermore, some auditory impairments, such as sensorineural hearing loss, will continue to progress with age, unlike many other injuries. In the TBI population, significant clinical challenges are the accurate differentiation of auditory and vestibular impairments from multiple, many times overlapping, symptoms and the development of multidisciplinary rehabilitation strategies to improve treatment outcomes and quality of life for these patients.	[Fausti, Stephen A.; Wilmington, Debra J.; Gallun, Frederick J.; Henry, James A.] Natl Ctr Rehabil Auditory Res, VA Rehabil Res & Dev Serv, Portland VA Med Ctr, Dept Vet Affairs, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA; [Myers, Paula J.] James A Haley Vet Hosp, Polytrauma Rehabil Ctr, Tampa, FL 33612 USA		Wilmington, DJ (corresponding author), Natl Ctr Rehabil Auditory Res, VA Rehabil Res & Dev Serv, Portland VA Med Ctr, Dept Vet Affairs, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	debra.wilmington@med.va.gov	Gallun, Frederick J./G-3792-2012	Gallun, Frederick J./0000-0002-4145-2199	VA Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [C4844C, B5067R, C4488R, C6770R, CDA2 C4963W]; National Center for Rehabilitative Auditory Research	This material was based on work supported by the VA Rehabilitation Research and Development Service (grants C4844C, B5067R, C4488R, C6770R, C4488R, CDA2 C4963W) and the National Center for Rehabilitative Auditory Research.	ALBERTI PW, 1992, BRIT MED J, V304, P522, DOI 10.1136/bmj.304.6826.522; *AM AC PED, 2006, AHRQ PUBL; *AM COLL EM PHYS, 2000, EM MED COMPR STUD GU, P1275; American Speech-Language-Hearing Association, 1994, GUID AUD MAN IND REC; [Anonymous], 1990, NIH CONSENSUS STATE, V8, P1; ARAN JM, 1995, HEARING RES, V82, P179, DOI 10.1016/0378-5955(94)00175-P; Arlinger S., 2003, INT J AUDIOL S2, V42; Axelsson A, 1992, NOISE INDUCED HEARIN, P269; BARBER H O, 1964, Laryngoscope, V74, P891; Basta D, 2005, HUM MOVEMENT SCI, V24, P268, DOI 10.1016/j.humov.2005.04.002; Basta D, 2008, GAIT POSTURE, V28, P397, DOI 10.1016/j.gaitpost.2008.01.006; Bergemalm PO, 2001, ACTA OTO-LARYNGOL, V121, P724, DOI 10.1080/00016480152583674; BERMAN JM, 1978, J OTOLARYNGOL, V7, P237; Bokemeyer C, 1998, BRIT J CANCER, V77, P1355, DOI 10.1038/bjc.1998.226; BROWN JJ, 1978, ACTA OTO-LARYNGOL, V86, P394, DOI 10.3109/00016487809107518; Campbell KCM, 2007, HEARING RES, V226, P92, DOI 10.1016/j.heares.2006.11.012; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CHANDLER D, 2006, ASHA LEADER, V11, P29; Chandler D, 2006, ASHA LEADER, V11, p[8, 29]; Chandler D W, 1997, J Am Acad Audiol, V8, P81; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; COLES RRA, 1984, J LARYNGOL OTOL S, V9, P195; CORNISPOP M, 2006, ASHA LEADER, V11, P6; CORNISPOP M, 2006, ASHA LEADER, V11, P28; Darwin CJ, 2008, PHILOS T R SOC B, V363, P1011, DOI 10.1098/rstb.2007.2156; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dobie R. A. J. B., 2004, TINNITUS THEORY MANA, p1 7; FAUSTI S, 1994, EAR HEARING, V15, P232, DOI 10.1097/00003446-199406000-00004; FAUSTI SA, 1981, J ACOUST SOC AM, V69, P1343, DOI 10.1121/1.385805; FAUSTI SA, 1993, ARCH OTOLARYNGOL, V119, P661; FAUSTI SA, 1992, J INFECT DIS, V165, P1026, DOI 10.1093/infdis/165.6.1026; Fechter LD, 2007, TOXICOL SCI, V98, P510, DOI 10.1093/toxsci/kfm101; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Helling ER, 2004, MIL MED, V169, P872, DOI 10.7205/MILMED.169.11.872; Henry JA, 2005, J REHABIL RES DEV, V42, P95, DOI 10.1682/JRRD.2005.01.0005; Henry James A, 2008, Trends Amplif, V12, P188, DOI 10.1177/1084713808321184; Henry James A, 2008, Trends Amplif, V12, P170, DOI 10.1177/1084713808319941; Herdman SJ, 2001, ARCH OTOLARYNGOL, V127, P1205, DOI 10.1001/archotol.127.10.1205; Herdman SJ, 1997, PHYS THER, V77, P602, DOI 10.1093/ptj/77.6.602; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Joris PX, 2004, PHYSIOL REV, V84, P541, DOI 10.1152/physrev.00029.2003; Kaas JH, 2000, P NATL ACAD SCI USA, V97, P11793, DOI 10.1073/pnas.97.22.11793; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; Kopke R, 2005, ACTA OTO-LARYNGOL, V125, P235, DOI 10.1080/00016480410023038; Kovack P, 2008, MED HYPOTHESES, V70, P914, DOI 10.1016/j.mehy.2007.06.045; KRONENBERG J, 1988, AM J OTOL, V9, P127; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; LUCIC M, 1995, ANN EMERG MED, V4, P168; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; MACDONALD MR, 1994, J OTOLARYNGOL, V23, P151; Meikle MB, 2007, PROG BRAIN RES, V166, P511, DOI 10.1016/S0079-6123(07)66049-X; Mickey BJ, 2003, J NEUROSCI, V23, P8649; Mrena R, 2004, ACTA OTO-LARYNGOL, V124, P946, DOI 10.1080/00016480310017045; Mrena R, 2002, AUDIOL NEURO-OTOL, V7, P122, DOI 10.1159/000057660; NEWMAN CW, 1990, EAR HEARING, V11, P430, DOI 10.1097/00003446-199012000-00004; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; Penner MJ, 1995, MECHANISMS TINNITUS, P219; Perez R, 2000, ARCH OTOLARYNGOL, V126, P1249, DOI 10.1001/archotol.126.10.1249; Persaud R, 2003, CLIN OTOLARYNGOL, V28, P203, DOI 10.1046/j.1365-2273.2003.00688.x; Petkov CI, 2004, NAT NEUROSCI, V7, P658, DOI 10.1038/nn1256; PROCTOR B, 1956, Laryngoscope, V66, P16; ROTH Y, 1989, Harefuah, V117, P297; SCHULZ TY, 2004, HEARING HLTH, V20, P18; Sheft S, 2007, J ACOUST SOC AM, V121, pEL84, DOI 10.1121/1.2430766; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Van Campen L E, 1999, J Am Acad Audiol, V10, P231; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Zajtchuk J T, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P5	75	133	138	0	22	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					797	809		10.1682/JRRD.2008.09.0118			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	531BQ	WOS:000272638100011	20104403	Bronze			2022-02-06	
J	Sigurdardottir, S; Andelic, N; Roe, C; Jerstad, T; Schanke, AK				Sigurdardottir, Solrun; Andelic, Nada; Roe, Cecilie; Jerstad, Tone; Schanke, Anne-Kristine			Post-concussion symptoms after traumatic brain injury at 3 and 12 months post-injury: A prospective study	BRAIN INJURY			English	Article						Post-concussion syndrome; mild TBI; predictors; cognitive; somatic; anxiety; MRI	MILD HEAD-INJURY; POSTCONCUSSION SYNDROME; DEPRESSION SCALE; HOSPITAL ANXIETY; PRACTICAL SCALE; MODERATE; RECOVERY; QUESTIONNAIRE; EPIDEMIOLOGY; POPULATION	Primary objectives: To examine self-reported post-concussion symptoms from 3-12 months post-injury in adults with traumatic brain injury (TBI) and to identify predictors of these symptoms. Methods and procedures: A 1-year prospective study in Eastern Norway including 115 persons (16-55 years), with mild, moderate and severe TBI. The Rivermead Post Concussion Symptoms Questionnaire (RPQ) and Hospital Anxiety and Depression Scale (HADS) were administered. Magnetic resonance imaging (MRI) was performed at 12 months. Results: In the whole sample of TBI, 27.8% of cases developed post-concussion syndrome (PCS) at 3 months and 23.6% at 12 months post-injury. The mild and moderate groups showed a decline of PCS symptoms over time, in contrast to the severe TBI group. Greater levels of somatic, cognitive and anxiety symptoms at 3 months, as well as shorter PTA duration, were found to be important predictors for the severity of PCS symptoms at 12 months. Intracranial pathology, Glasgow Coma Scale (GCS) and demographic variables were not related to the severity of PCS symptoms. Conclusions: PCS symptoms were reported to a greater degree in persons with mild TBI at 3 months post-injury. One year after injury, no differences were found between TBI groups on the presence of PCS.	[Sigurdardottir, Solrun; Schanke, Anne-Kristine] Univ Oslo, Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; [Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway; [Jerstad, Tone] Oslo Univ Hosp, Dept Neuroradiol, Ulleval, Norway		Sigurdardottir, S (corresponding author), Univ Oslo, Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@sunnaas.no		Andelic, Nada/0000-0002-3719-4406	South-Eastern Norway Regional Health Authority	The authors thank all persons for their participation. Special thanks to Ivar Reinvang, Professor, University of Oslo, for valuable comments, to Katrine Frey Froslie, The National University Hospital, for statistical assistance, and to Susan Schanche for the proof reading the English text. This study was supported by grants from the South-Eastern Norway Regional Health Authority.	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SIGURDARDOTTIR S, COGNITIVE RECO UNPUB; Silver JM, 1997, J NEUROPSYCH CLIN N, V9, P102; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; World Health Organization, 2004, ICD 10 INT STAT CLAS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	133	136	0	18	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	6					489	497	PII 911809542	10.1080/02699050902926309			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800002	19484622				2022-02-06	
J	Francony, G; Fauvage, B; Falcon, D; Canet, C; Dilou, H; Lavagne, P; Jacquot, C; Payen, JF				Francony, Gilles; Fauvage, Bertrand; Falcon, Dominique; Canet, Charles; Dilou, Henri; Lavagne, Pierre; Jacquot, Claude; Payen, Jean-Francois			Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure	CRITICAL CARE MEDICINE			English	Article						intracranial pressure; mannitol; hypertonic saline solution; brain injury; traumatic brain injury	HEAD-INJURED PATIENTS; CEREBRAL BLOOD-FLOW; 20-PERCENT MANNITOL; BRAIN-INJURY; HYPERTENSION; 7.2-PERCENT; ICP; TRIAL	Objective: To compare the effects of equimolar doses of 20% mannitol solution and of 7.45% hypertonic saline solution (HSS) in the treatment of patients with sustained elevated intracranial pressure (ICP). Design: Parallel, randomized, controlled trial. Setting. Two intensive care units in a university hospital. Patients. A total of 20 stable patients with a sustained ICP of > 20 mm Hg secondary to traumatic brain injury (n = 17) or stroke (n = 3). Interventions. A single equimolar infusion (255 mOsm dose) of either 231 mL of 20% mannitol (mannitol group; n = 10 patients) or 100 mL of 7.45% hypertonic saline (HSS group; n = 10 patients) during 20 mins of administration. Measurements: ICP, arterial blood pressure, cerebral perfusion pressure, blood flow velocities of middle cerebral artery using continuous transcranial Doppler, brain tissue oxygen tension, serum sodium and osmolality, and urine output during a study period of 120 mins. Main Results: The two treatments equally and durably reduced ICP during the experiment. At 60 mins after the start of the infusion, ICP was reduced by 45% +/- 19% of baseline values (mean +/- SD) in the mannitol group vs. 35%+/- 14% of baseline values in the HSS group. Cerebral perfusion pressure and diastolic and mean blood flow velocities were durably increased in the mannitol group, resulting in lower values of pulsatility index at the different times of the experiment (p <.01 vs. HSS). No major changes in brain tissue oxygen tension were found after each treatment. Mannitol caused a significantly greater increase in urine output (p <.05) than HSS, although there was no difference in the vascular filling requirement between the two treatments. HSS caused a significant elevation of serum sodium and chloride at 120 mins after the start of the infusion (p <.01). Conclusions: A single equimolar infusion of 20% mannitol is as effective as 7.45% HSS in decreasing ICP in patients with brain injury. Mannitol exerts additional effects on brain circulation through a possible improvement in blood rheology. Pretreatment factors, such as serum sodium, systemic hemodynamics, and brain hemodynamics, thus should be considered when choosing between mannitol and HSS for patients with increased ICP.	[Francony, Gilles; Fauvage, Bertrand; Falcon, Dominique; Canet, Charles; Dilou, Henri; Lavagne, Pierre; Jacquot, Claude; Payen, Jean-Francois] Albert Michallon Hosp, Dept Anesthesiol & Crit Care, Grenoble, France		Payen, JF (corresponding author), Albert Michallon Hosp, Dept Anesthesiol & Crit Care, Grenoble, France.	jfpayen@uif-grenoble.fr	Payen, Jean-Francois/L-6667-2014				Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Hartl R, 1997, ACT NEUR S, V70, P40; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Kirkpatrick PJ, 1996, NEUROSURGERY, V39, P714, DOI 10.1097/00006123-199610000-00013; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P521; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56	21	133	142	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2008	36	3					795	800		10.1097/CCM.0B013E3181643B41			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266QD	WOS:000253450500018	18209674				2022-02-06	
J	Ropper, AH; Gorson, KC				Ropper, Allan H.; Gorson, Kenneth C.			Concussion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILD HEAD-INJURY; TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; NEW-ORLEANS CRITERIA; NCAA CONCUSSION; MANAGEMENT; DIAGNOSIS; RECOVERY; GUIDELINES	A 64-year-old woman slipped on an icy walk, falling forward and striking her forehead. She had a brief convulsion immediately after the fall, was unresponsive for less than 1 minute, and awakened with a severe generalized headache and nausea but no vomiting. In addition to being perplexed about the circumstances of the fall, she could not recall the previous few hours. She was awake and oriented and had no abnormalities on neurologic examination. Tenderness and a scalp contusion were apparent at the site of the impact, and there were abrasions on her right cheek. What is the expected course, and how should her case be managed?	Caritas St Elizabeths Med Ctr, Dept Neurol, Boston, MA 02135 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA		Ropper, AH (corresponding author), Caritas St Elizabeths Med Ctr, Dept Neurol, 736 Cambridge St, Boston, MA 02135 USA.						Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; BURTON HL, 1931, P ROY SOC MED, V24, P1405; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Evans RW., 1992, PROGNOSIS NEUROLOGIC, P97; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Goadsby PJ, 2006, BMJ-BRIT MED J, V332, P25, DOI 10.1136/bmj.332.7532.25; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; JENNETT B, 1992, DIS NERVOUS SYSTEM C, P1229; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Kelly JP, 1997, NEUROLOGY, V48, P581; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Perron AD, 2001, ACAD EMERG MED, V8, P296, DOI 10.1111/j.1553-2712.2001.tb01312.x; POVLISHOCK JT, 1995, NEUROTRAUMA, P1325; QUIGLEY T B, 1959, Med Times, V87, P1241; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sakas DE, 1997, MED HYPOTHESES, V48, P431, DOI 10.1016/S0306-9877(97)90042-6; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001	45	133	138	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					166	172		10.1056/NEJMcp064645			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124NE	WOS:000243373700009	17215534				2022-02-06	
J	Jiang, JY; Xu, W; Li, WP; Gao, GY; Bao, YH; Liang, YM; Luo, QZ				Jiang, JY; Xu, W; Li, WP; Gao, GY; Bao, YH; Liang, YM; Luo, QZ			Effect of long-term mild hypothermia or short-term mild hypothermia on outcome of patients with severe traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						contusion; cooling; head injury; head trauma; intracranial hypertension; outcome	CONTROLLED CORTICAL IMPACT; HOSPITAL CARDIAC-ARREST; MODERATE HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; INTRACRANIAL HYPERTENSION; COMATOSE SURVIVORS; RAT; TEMPERATURE; FLUID; ISCHEMIA	To compare the effect of long-term mild hypothermia versus short-term mild hypothermia on the outcome of 215 severe traumatic brain injured patients with cerebral contusion and intracranial hypertension. At three medical centers, 215 patients aged 18 to 45 years old with an admission Glasgow Coma Scale <= 8 within 4 h after injury were randomly divided into two groups: long-term mild hypothermia group (n = 108) for 5 +/- 1.3 days mild hypothermia therapy and short-term mild hypothermia group ( n = 107) for 2 +/- 0.6 days mild hypothermia therapy. All patients had intracranial hypertension and frontotemporoparietal contusion with midline shift > 1cm confirmed on computed tomographic scan. Glasgow Outcome Scale at 6-month follow-up, 47 cases had favorable outcome (43.5%), and other 61 cases had unfavorable outcome (56.5%) in the long-term mild hypothermia group. However, only 31 cases had favorable outcome (29.0%), and other 76 cases had unfavorable outcome (71.0%) in the short-term mild hypothermia group (P < 0.05). The intracranial pressure significantly rebounded after rewarming in the short-term mild hypothermia group, but not in the long-term mild hypothermia ( P < 0.05). Furthermore, the incidence of stress ulcer, epilepsy, pulmonary infection, intracranial infection did not significantly differ between the two groups (P > 0.05). Compared with short-term mild hypothermia, long-term mild hypothermia significantly improves the outcome of severe traumatic brain injured patients with cerebral contusion and intracranial hypertension without significant complications. Our data suggest that 5 days of long-term cooling is more efficacious than 2 days of short-term cooling when mild hypothermia is used to control refractory intracranial hypertension in patients with severe traumatic brain injury.	Shanghai Med Univ 2, Renji Hosp, Dept Neurosurg, Shanghai 200001, Peoples R China; Kuming Med Coll, Teaching Hosp 2, Dept Neurosurg, Yuennan, Peoples R China; Shenzheng Second Peoples Hosp, Dept Neurosurg, Shenzheng, Guangdong, Peoples R China		Jiang, JY (corresponding author), Shanghai Med Univ 2, Renji Hosp, Dept Neurosurg, Shanghai 200001, Peoples R China.	Jiangjyb@online.sh.cn					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; GADKARY CS, 2003, THERAPEUTIC HYPOTHER; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; HAGERDAL M, 1979, ACTA ANAESTH SCAND, V23, P89; Hayashi N, 1997, NEUROCHEMISTRY, P97; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iida K, 2003, J NEUROSURG, V98, P793, DOI 10.3171/jns.2003.98.4.0793; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; Safar PJ, 2002, NEW ENGL J MED, V346, P612, DOI 10.1056/NEJM200202213460811; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; TEASDALE G, 1974, LANCET, V2, P81; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98	40	133	149	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2006	26	6					771	776		10.1038/sj.jcbfm.9600253			6	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	045OU	WOS:000237752200004	16306933	Bronze			2022-02-06	
J	Reden, J; Mueller, A; Mueller, C; Konstantinidis, I; Frasnelli, J; Landis, BN; Hummel, T				Reden, J; Mueller, A; Mueller, C; Konstantinidis, I; Frasnelli, J; Landis, BN; Hummel, T			Recovery of olfactory function following closed head injury or infections of the upper respiratory tract	ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY			English	Article							ODOR DISCRIMINATION; DYSFUNCTION; AGE; SMELL; IDENTIFICATION; DISORDERS; TASTE; DISTURBANCES; IMPAIRMENT; PREVALENCE	Objective: To investigate the outcome of olfactory function in patients with olfactory loss following infections of the upper respiratory tract (post-URTI) or head trauma. Design: Retrospective patient-based study. Setting: Smell and Taste Outpatient Clinic at a university hospital. Patients: A total of 361 patients ( 228 women, 133 men) were included. Main Outcome Measures: Olfactory function was assessed using the "Sniffin' Sticks" test battery, which result in a threshold, discrimination, and identification score. The mean interval between first and last visit was 14 months. Results: In comparing the overall threshold, discrimination, and identification scores between the last and first visit, olfactory function improved in 26% of the patients whereas it decreased in 6%. The cause of olfactory impairment had a significant effect on the recovery rate of olfactory function. Within the post-URTI group (n = 262), 32% of the patients improved, but in the posttraumatic group (n = 99) only 10% improved. In patients with post-URTI olfactory loss, a negative correlation was found between age and recovery of olfactory function. In general, the factor "sex" had no significant effect on recovery of smell function. Conclusions: To our knowledge, the series of patients presented herein is the largest in the literature to date in which standardized testing methods were used to assess the progression of impaired olfaction. It showed that the rate of improvement of olfactory function was significantly higher in patients with post-URTI dysosmia compared with patients with posttraumatic dysosmia. During an observation period of approximately 1 year, more than 30% of patients with post-URTI olfactory loss experienced improvement, whereas only 10% of patients with posttraumatic olfactory loss experienced improvement. Furthermore, age plays a significant role in the recovery of olfactory function.	Univ Dresden, Sch Med, Dept Otorhinolaryngol, Smell & Taste Clin, D-01307 Dresden, Germany; Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; Hop Univ Geneva, Unite Rhinol Olfactol, Serv Otorhinol Laryngol, Geneva, Switzerland		Hummel, T (corresponding author), Univ Dresden, Sch Med, Dept Otorhinolaryngol, Smell & Taste Clin, Fetscherstr 74, D-01307 Dresden, Germany.	thummel@rcs.urz.tu-dresden.de		Frasnelli, Johannes/0000-0002-8863-3982			Bednar M., 1930, MED KLIN, V48, P1787; Bramerson A, 2004, LARYNGOSCOPE, V114, P733; Conley DB, 2003, AM J RHINOL, V17, P169, DOI 10.1177/194589240301700311; Costanzo RM, 2005, CHEM SENSES, V30, pI133, DOI 10.1093/chemse/bjh150; Costanzo RM, 1986, CLIN MEASUREMENTS TA, P565; Damm M, 2004, HNO, V52, P112, DOI 10.1007/s00106-003-0877-z; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Delank KW, 1996, LARYNGO RHINO OTOL, V75, P154, DOI 10.1055/s-2007-997554; DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DUNCAN HJ, 1995, ARCH OTOLARYNGOL, V121, P1183; DUNCAN HJ, 1995, NEUROL DIS, V32, P345; Feron F, 1998, ARCH OTOLARYNGOL, V124, P861, DOI 10.1001/archotol.124.8.861; HENDRIKS A P J, 1988, Rhinology (Utrecht), V26, P229; Hummel T, 2005, ACTA OTO-LARYNGOL, V125, P116, DOI 10.1080/00016480410022787; Hummel T, 1998, EVOKED POTENTIAL, V108, P208, DOI 10.1016/S0168-5597(97)00074-9; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; Hummel T, 2002, LARYNGOSCOPE, V112, P2076, DOI 10.1097/00005537-200211000-00031; Jimenez D F, 1997, J Craniomaxillofac Trauma, V3, P8; KEM RC, 2004, LARYNGOSCOPE, V114, P279; Kobal G., 1996, Rhinology (Utrecht), V34, P222; Kobal G, 2000, EUR ARCH OTO-RHINO-L, V257, P205, DOI 10.1007/s004050050223; Landis BN, 2004, LARYNGOSCOPE, V114, P1764, DOI 10.1097/00005537-200410000-00017; Landis BN, 2003, CHEM SENSES, V28, P691, DOI 10.1093/chemse/bjg061; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; Mori J, 1998, ACTA OTO-LARYNGOL, P197; Murphy C, 2002, JAMA-J AM MED ASSOC, V288, P2307, DOI 10.1001/jama.288.18.2307; NAESSEN R, 1971, ACTA OTO-LARYNGOL, V71, P49, DOI 10.3109/00016487109125332; PAIK SI, 1992, ARCH OTOLARYNGOL, V118, P731; Rawson NE, 1998, ANN NY ACAD SCI, V855, P701, DOI 10.1111/j.1749-6632.1998.tb10648.x; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; Santos DV, 2004, ARCH OTOLARYNGOL, V130, P317, DOI 10.1001/archotol.130.3.317; Sugiura M, 1998, ACTA OTO-LARYNGOL, P191; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; Temmel AFP, 2002, ARCH OTOLARYNGOL, V128, P635, DOI 10.1001/archotol.128.6.635; VANDAMME PA, 1992, J CRANIO MAXILL SURG, V20, P248, DOI 10.1016/S1010-5182(05)80436-6; YEE KK, 1995, PHYSIOL BEHAV, V58, P959, DOI 10.1016/0031-9384(95)00159-G; ZASLER ND, 1990, ARCH PHYS MED REHAB, V71, P814	38	133	136	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0886-4470	1538-361X		ARCH OTOLARYNGOL	Arch. Otolaryngol. Head Neck Surg.	MAR	2006	132	3					265	269		10.1001/archotol.132.3.265			5	Otorhinolaryngology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology; Surgery	023IK	WOS:000236120100004	16549746	Bronze			2022-02-06	
J	Johnston, AJ; Steiner, LA; Coles, JP; Chatfield, DA; Fryer, TD; Smielewski, P; Hutchinson, PJ; O'Connell, MT; Al-Rawi, PG; Aigbirihio, FI; Clark, JC; Pickard, JD; Gupta, AK; Menon, DK				Johnston, AJ; Steiner, LA; Coles, JP; Chatfield, DA; Fryer, TD; Smielewski, P; Hutchinson, PJ; O'Connell, MT; Al-Rawi, PG; Aigbirihio, FI; Clark, JC; Pickard, JD; Gupta, AK; Menon, DK			Effect of cerebral perfusion pressure augmentation on regional oxygenation and metabolism after head injury	CRITICAL CARE MEDICINE			English	Article						head injury; ischemia; oxygenation; cerebral perfusion pressure; brain tissue oxygen	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; TISSUE OXYGEN; BLOOD-FLOW; SUBSTRATE DELIVERY; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; NEUROSURGICAL PATIENTS; INTRACRANIAL-PRESSURE; ARTERIAL HYPEROXIA	Objective: In this study we have used O-15 positron emission tomography, brain tissue oxygen monitoring, and cerebral micro-dialysis to assess the effects of cerebral perfusion pressure augmentation on regional physiology and metabolism in the setting of traumatic brain injury. Design. Prospective interventional study. Setting. Neurosciences critical care unit of a university hospital. Patients., Eleven acutely head-injured patients requiring norepinephrine to maintain cerebral perfusion pressure. Interventions., Using positron emission tomography, we have quantified the response to an increase in cerebral perfusion pressure in a region of interest around a brain tissue oxygen sensor (Neurotrend) and microdialysis catheter. Oxygen extraction fraction and cerebral blood flow were measured with positron emission tomography at a cerebral perfusion pressure of similar to70 mm Hg and similar to90 mm Hg using norepinephrine to control cerebral perfusion pressure. All other aspects of physiology were kept stable. Measurements and Main Results. Cerebral perfusion pressure augmentation resulted in a significant increase in brain tissue oxygen (17 +/- 8 vs. 22 +/- 8 mm Hg; 2.2 +/- 1.0 vs. 2.9 +/- 1.0 kPa, p <.001) and cerebral blood flow (27.5 +/- 5.1 vs. 29.7 +/- 6.0 ml/100 mL/min, p <.05) and a significant, decrease in oxygen extraction fraction (33.4 +/- 5.9 vs. 30.3 +/- 4.6 %, p <.05). There were no significant changes in any of the microdialysis variables (glucose, lactate, pyruvate, lactate/pyruvate ratio, glycerol). There was a significant linear relationship between brain tissue oxygen and oxygen extraction fraction (r(2) =.21, p <.05); the brain tissue oxygen value associated with an oxygen extraction fraction of 40% (the mean value for oxygen extraction fraction in normal controls) was 14 mm Hg (1.8 kPa). The cerebral perfusion pressure intervention resulted in a greater percentage increase in brain tissue oxygen than the percentage decrease in oxygen extraction fraction; this suggests that the oxygen gradients between the vascular and tissue compartments were reduced by the cerebral perfusion pressure intervention. Conclusions. Cerebral perfusion pressure augmentation significantly increased levels of brain tissue oxygen and significantly reduced regional oxygen extraction fraction. However, these changes did not translate into predictable changes in regional chemistry. Our results suggest that the ischemic level of brain tissue oxygen may lie at a level below 14 mm Hg (1.8 kPa); however, the data do not allow us to be more specific.	Addenbrookes Hosp, Dept Anaesthet, Cambridge CB2 2QB, England; Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QB, England		Johnston, AJ (corresponding author), Addenbrookes Hosp, Dept Anaesthet, Hills Rd, Cambridge CB2 2QB, England.		Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011	Smielewski, Peter/0000-0001-5096-3938; Coles, Jonathan/0000-0003-4013-679X; O'Connell, Mark/0000-0001-6272-8767	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline		*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P507; *AM ASS NEUR SURG, 2003, GUID MAN SEV TRAUM; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bardt TF, 1998, ACT NEUR S, V71, P153; Bruzzone P, 1998, ACT NEUR S, V71, P111; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; COLES JP, 2001, J NEUROTRAUM, V18, pL11; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Doppenberg EMR, 1997, J NEUROSURG, V87, P809, DOI 10.3171/jns.1997.87.6.0809; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; JOHNSTON AJ, 2002, J NEUROTRAUM, V19, pP212; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Smielewski Peter, 1800, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Stocchetti N, 1998, ACT NEUR S, V71, P162; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; YONAS H, 1994, CEREBROVAS BRAIN MET, V6, P325; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	52	133	137	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2005	33	1					189	195		10.1097/01.CCM.0000149837.09225.BD			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887WN	WOS:000226336300027	15644668				2022-02-06	
J	Zhang, J; Li, Y; Chen, JL; Yang, MZ; Katakowski, M; Lu, M; Chopp, M				Zhang, J; Li, Y; Chen, JL; Yang, MZ; Katakowski, M; Lu, M; Chopp, M			Expression of insulin-like growth factor 1 and receptor in ischemic rats treated with human marrow stromal cells	BRAIN RESEARCH			English	Article						insulin-like growth factor 1; insulin-like growth factor 1 receptor; human marrow stromal cells; stroke; rat	GROWTH-FACTOR-I; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; MESENCHYMAL STEM-CELLS; SUBVENTRICULAR ZONE; STROKE; NEUROGENESIS; PROLIFERATION; APOPTOSIS; DIFFERENTIATION	Human bone marrow stromal cells (hMSCs) enhance neurological recovery after stroke in rodents, possibly via induction of growth factors. We therefore elected to test the effects of hMSC treatment on insulin-like growth factor 1 (IGF-1) which plays an important role in growth, development, neuroprotection and repair in the adult. Rats (n=57) were subjected to permanent middle cerebral artery occlusion (MCAo) and injected intravenously with 3 X 10(6) hMSCs or phosphate-buffered saline (PBS) at 1 day after MCAo. Functional outcome was measured after MCAo using a modified Neurological Severity Score (mNSS). Gene expression of IGF-1 and IGF-1 receptor (IGF-1R) in the ischemic brain tissue were measured at 2 and 7 days after MCAo using reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemistry was performed to measure the expression of bromodeoxyuridine (BrdU), doublecortin (DCX), IGF-1 and IGF-1R at 7, 14 and 30 days after MCAo. Treatment of MCAo with hMSCs significantly improved functional recovery from 14 to 30 days. MAB1281-labeled hMSCs entered the ischemic brain and increased time-dependently. hMSC treatment significantly increased IGF-1 mRNA and BrdU(+), DCX+, IGF-1(+) and IGF-1R(+) cells compared to PBS-treated rats (p<0.05). The percentage of BrdU(+) or DCX+ cells colocalized with IGF-1 increased in the hMSC-treated rats compared to the PBS-treated rats (p<0.05). IGF-1 and IGF-1R may contribute to improved functional recovery and increased neurogenesis after treatment of stroke with hMSCs. (C) 2004 Elsevier B.V. All rights reserved.	Henry Ford Hosp, Ctr Hlth Sci, Dept Neurol, Detroit, MI 48202 USA; Henry Ford Hosp, Ctr Hlth Sci, Ctr Bone & Joint, Detroit, MI 48202 USA; Oakland Univ, Dept Phys, Rochester, MI 48309 USA		Chopp, M (corresponding author), Henry Ford Hosp, Ctr Hlth Sci, Dept Neurol, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS045041] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS45041, P01 NS42345] Funding Source: Medline		Abe K, 2000, J CEREBR BLOOD F MET, V20, P1393, DOI 10.1097/00004647-200010000-00001; Anlar B, 1999, HORM METAB RES, V31, P120, DOI 10.1055/s-2007-978708; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Carro E, 2003, MOL NEUROBIOL, V27, P153, DOI 10.1385/MN:27:2:153; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; de Rouvroit CL, 2001, MECH DEVELOP, V105, P47, DOI 10.1016/S0925-4773(01)00396-3; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Dempsey RJ, 2003, J NEUROCHEM, V87, P586, DOI 10.1046/j.1471-4159.2003.02022.x; Doetsch F, 1997, J NEUROSCI, V17, P5046; Fukudome Y, 2003, EUR J NEUROSCI, V17, P2006, DOI 10.1046/j.1460-9568.2003.02640.x; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galli R, 2003, CIRC RES, V92, P598, DOI 10.1161/01.RES.0000065580.02404.F4; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jorgensen C, 2003, GENE THER, V10, P928, DOI 10.1038/sj.gt.3302019; Kveiborg M, 2001, EUR J ENDOCRINOL, V144, P549, DOI 10.1530/eje.0.1440549; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Reiner O, 1999, MOL NEUROBIOL, V20, P143, DOI 10.1007/BF02742439; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Sambrook J., 1989, MOL CLONING LAB MANU; Schabitz WR, 2001, STROKE, V32, P1226, DOI 10.1161/01.STR.32.5.1226; Scotto-Lomassese S, 2003, J NEUROSCI, V23, P9289; Tagami M, 1997, LAB INVEST, V76, P613; Tagami M, 1997, LAB INVEST, V76, P603; Thalmeier K, 2001, ACTA HAEMATOL-BASEL, V105, P159, DOI 10.1159/000046559; Thomas T, 1999, ENDOCRINOLOGY, V140, P5036, DOI 10.1210/en.140.11.5036; Trejo JL, 2004, GROWTH HORM IGF RES, V14, pS39, DOI 10.1016/j.ghir.2004.03.010; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang X, 2002, BIOCHEM BIOPH RES CO, V290, P526, DOI 10.1006/bbrc.2001.6217	50	133	157	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 24	2004	1030	1					19	27		10.1016/j.brainres.2004.09.061			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	880WL	WOS:000225820600003	15567334				2022-02-06	
J	Blasko, I; Beer, R; Bigl, M; Apelt, J; Franz, G; Rudzki, D; Ransmayr, G; Kampfl, A; Schliebs, R				Blasko, I; Beer, R; Bigl, M; Apelt, J; Franz, G; Rudzki, D; Ransmayr, G; Kampfl, A; Schliebs, R			Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1)	JOURNAL OF NEURAL TRANSMISSION			English	Article						brain trauma; Alzheimer's disease; BACE-1; BACE-1 activity; A beta PP	AMYLOID PRECURSOR PROTEIN; A-BETA; PLAQUE PATHOLOGY; AXONAL INJURY; MOUSE-BRAIN; HEAD TRAUMA; CLEAVAGE; PEPTIDE; MICE; DEPOSITION	Traumatic brain injury (TBI) is a risk factor for the development of Alzheimer's disease (AD). After a traumatic brain injury depositions of amyloid beta (Abeta) in the brain parenchyma were found. In this study we investigated the expression pattern of beta-secretase (BACE-1) in ipsi- or contralateral hippocampus and cortex following controlled cortical TBI in rats. BACE-1 mRNA levels, estimated by real time RT-PCR, were elevated 24 h post injury, and persisting up to 72 h, in the ipsi- and contralateral hippocampus and cerebral cortex as compared to the sham-treated animals (p<0.01). The TBI-induced changes in BACE-1 mRNA are due to enhanced hippocampal and cortical expression of BACE-1 mRNA in neurons and reactive astrocytes as revealed by in situ hybridization. The alterations in hippocampal BACE-1 mRNA levels are accompanied by corresponding increases in BACE-1 protein levels in ipsi- and contralateral hippocampus and ipsilateral cortex as demonstrated by Western blot analysis. In contrast, in the contralateral cortex only a weak increase of traumatically induced BACE-1 protein production was found. The activity of BACE-1 as measured by the formation of the cleavage product of amyloid beta precursor protein, transiently increased up to 48 h after injury, but returned to basal level 7 days post injury. This study demonstrates that the beta-secretase is stimulated following TBI and may suggest a mechanism for the temporal increase of Abeta levels observed in patients with brain trauma.	Univ Innsbruck Hosp, Dept Psychiat, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Univ Leipzig, Paul Flechsig Inst Brain Res, Leipzig, Germany; Univ Leipzig, Fac Med, Inst Biochem, Leipzig, Germany		Blasko, I (corresponding author), Univ Innsbruck Hosp, Dept Psychiat, Anichstr 35, A-6020 Innsbruck, Austria.	imrich.blasko@uibk.ac.at					Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bigl M, 2000, NEUROSCI LETT, V292, P107, DOI 10.1016/S0304-3940(00)01452-X; Blasko I, 2000, NEUROBIOL DIS, V7, P682, DOI 10.1006/nbdi.2000.0321; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fan L, 1999, J NEUROTRAUM, V16, P357, DOI 10.1089/neu.1999.16.357; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; HAASS C, 1991, J NEUROSCI, V11, P3783; HOWLAND DS, 1995, NEUROBIOL AGING, V16, P685, DOI 10.1016/0197-4580(95)00078-S; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Lange-Dohna C, 2003, J NEUROSCI RES, V73, P73, DOI 10.1002/jnr.10639; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; NISHIMURA A, 1990, NUCLEIC ACIDS RES, V18, P6169, DOI 10.1093/nar/18.20.6169; Pierce JES, 1996, J NEUROSCI, V16, P1083; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rossner S, 2001, J NEUROSCI RES, V64, P437; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walton M, 1999, BRAIN RES REV, V29, P137, DOI 10.1016/S0165-0173(98)00053-8; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	33	133	135	0	9	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0300-9564			J NEURAL TRANSM	J. Neural Transm.	APR	2004	111	4					523	536		10.1007/s00702-003-0095-6			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	808HS	WOS:000220560800008	15057522				2022-02-06	
J	Sahin, V; Karakas, ES; Aksu, S; Atlihan, D; Turk, CY; Halici, M				Sahin, V; Karakas, ES; Aksu, S; Atlihan, D; Turk, CY; Halici, M			Traumatic dislocation and fracture-dislocation of the hip: A long-term follow-up study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						hip dislocation; hip fractures; prognosis; multiple injuries; femoral head necrosis; osteoarthritis	POSTERIOR DISLOCATION	Objective: Traumatic dislocation and fracture-dislocation of the hip is an absolute orthopedic emergency that is steadily increasing in incidence. Early recognition and prompt, stable reduction is the essence of successful management. A delay in recognition and reduction leads to preventable complications and morbidity. The purpose of this retrospective study is to identify prognostic factors that predict long-term outcome after hip dislocation. Methods: Between 1980 and 1994, 107 patients with traumatic dislocation of the hips were treated, and 62 are reviewed in this study. There were 57 posterior fracture-dislocations and 5 anterior-obturator dislocations. All of the patients' charts were reviewed. The physical examinations and radiologic controls of the patients who were called for last follow-up examination were performed by the first two authors (V.S. and E.K.). Anterior and posterior fracture-dislocations were classified according to the classification system developed by Steward and Milford and femoral head fractures were classified according to the Pipkin classification. All of the hips were classified as very good, good, medium, fair, and poor according to the functional evaluation system described by Merle d'Aubigne. Statistical analysis of the results was performed. Results: There were 47 male patients and 15 female patients, with ages ranging from 14 to 72 years (mean, 34.5 years). Traffic accidents constituted the leading cause of traumatic dislocation in this series (52 cases [83.9%]). Associated injuries were found in 44 cases (71%). Fifty patients were treated with closed reduction, and 12 patients were treated with open reduction. Thirty-five hips (56.5%) were reduced within 12 hours. Full weight-bearing was resumed between 2 and 10 weeks (average, 8 weeks) after injury. In follow-up periods ranging from 3.6 years to 18.4 years (mean, 9.6 years), 44 patients (71%) had very good or good to medium results. Ten patients (16.1%) developed late posttraumatic osteoarthritis of the hip, and 5 patients (9.6%) developed osteonecrosis of the femoral head. In this study, it is found that the time between injury and reduction and the associated injuries are the most important factors in long-term prognosis. Conclusion: We believe that good results were obtained in patients with early, stable, and accurate reductions by either closed or open methods. Concentric reduction absolutely should be confirmed by radiographs of the pelvis and, if necessary, by computed tomographic scan. The routine use of seat belts could have prevented many of these injuries.	Ankara Educ & Training Hosp, Orthopaed Clin 2, Ankara, Turkey; Taksim Educ & Training Hosp, Dept Orthopaed Surg & Traumatol, Taksim, Turkey; Istanbul Directory Hlth, Dept Orthopaed Surg, Istanbul, Turkey; Erciyes Univ, Sch Med, Dept Orthopaed Surg & Traumatol, Erciyes, Turkey		Sahin, V (corresponding author), Halaskargazi Caddesi Pinar, Apt 306-312,Kat 5,Daire 5, Istanbul, Turkey.						AMIHOOD S, 1975, INJURY, V7, P107, DOI 10.1016/0020-1383(75)90007-8; BRAV EA, 1962, J BONE JOINT SURG AM, V44, P1115, DOI 10.2106/00004623-196244060-00007; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623-197355080-00006; DAUBIGNE RM, 1954, J BONE JOINT SURG AM, V36-A, P451, DOI 10.2106/00004623-195436030-00001; DREINHOFER KE, 1994, J BONE JOINT SURG BR, V76B, P6, DOI 10.1302/0301-620X.76B1.8300683; DUNCAN CP, 1977, SURG GYNECOL OBSTET, V144, P185; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1974, J BONE JOINT SURG AM, VA 56, P1103, DOI 10.2106/00004623-197456060-00001; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, P9; FICAT RP, 1980, ISCHEMIA NECROSES BO, P43; GHORMLEY RK, 1953, AM J SURG, V85, P298, DOI 10.1016/0002-9610(53)90613-8; GLASS A, 1961, J BONE JOINT SURG BR, V43, P29; HOUGAARD K, 1986, ARCH ORTHOP TRAUM SU, V106, P32, DOI 10.1007/BF00435649; HOUGAARD K, 1987, J BONE JOINT SURG AM, V69A, P679, DOI 10.2106/00004623-198769050-00007; HUNTER G A, 1969, Journal of Bone and Joint Surgery British Volume, V51, P38; JACOB JR, 1987, CLIN ORTHOP RELAT R, P249; JASKULKA RA, 1991, J BONE JOINT SURG BR, V73, P465, DOI 10.1302/0301-620X.73B3.1670451; ORDWAY CB, 1984, J TRAUMA, V24, P76; Pennsylvania Orthopedic Society, 1968, J BONE JOINT SURG AM, V50A, P79; PIETRAFESA CA, 1983, JAMA-J AM MED ASSOC, V249, P3342; PIPKIN G, 1957, J BONE JOINT SURG AM, V39, P1027, DOI 10.2106/00004623-195739050-00004; REIGSTAD A, 1980, J TRAUMA, V20, P603, DOI 10.1097/00005373-198007000-00010; ROEDER LF, 1980, CLIN ORTHOP RELAT R, P121; ROSENTHAL RE, 1979, J TRAUMA, V19, P572, DOI 10.1097/00005373-197908000-00005; ROWE CR, 1961, J BONE JOINT SURG AM, V43, P30, DOI 10.2106/00004623-196143010-00002; SCHLICKEWEI W, 1993, INJURY, V24, P27, DOI 10.1016/0020-1383(93)90078-K; SMITH GR, 1976, RADIOLOGY, V119, P569, DOI 10.1148/119.3.569; STEWART MJ, 1954, J BONE JOINT SURG AM, V36-A, P315, DOI 10.2106/00004623-195436020-00010; STEWART MJ, 1975, ACTA ORTHOP SCAND, V46, P507; SURACI AJ, 1986, J TRAUMA, V26, P458, DOI 10.1097/00005373-198605000-00008; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; UPADHYAY SS, 1983, J BONE JOINT SURG BR, V65, P150, DOI 10.1302/0301-620X.65B2.6826619; UPADHYAY SS, 1981, J BONE JOINT SURG BR, V63, P548, DOI 10.1302/0301-620X.63B4.7298682; WHITEHOUSE GH, 1978, CLIN RADIOL, V29, P431, DOI 10.1016/S0009-9260(78)80106-8; YANG RS, 1991, CLIN ORTHOP RELAT R, P218	35	133	146	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2003	54	3					520	529		10.1097/01.TA.0000020394.32496.52			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	660EA	WOS:000181819800015	12634533				2022-02-06	
J	Rapoport, MJ; McCullagh, S; Streiner, D; Feinstein, A				Rapoport, MJ; McCullagh, S; Streiner, D; Feinstein, A			The clinical significance of major depression following mild traumatic brain injury	PSYCHOSOMATICS			English	Article; Proceedings Paper	13th Annual Meeting of the American-Neuropsychiatric-Association	MAR 10-12, 2002	La Jolla, CA	Amer Neuropsychiat Assoc			HEAD-INJURY; GENERAL HEALTH; RATING-SCALE; VALIDITY; QUESTIONNAIRE; DISORDER; SENSITIVITY; DISABILITY; RECOVERY; SYMPTOMS	Objective: The authors assessed the association of major depression with behavioral outcome following mild traumatic brain injury. Method: Consecutive patients with mild traumatic brain injury (N= 170) were assessed for major depression. Those with major depression were compared with those without on self-report measures of psychosocial dysfunction, psychological distress, and postconcussive symptoms in addition to examiner-rated neurobehavioral disturbance. Results: Major depression was seen in 15.3% (N=26) of the subjects after traumatic brain injury, and these individuals showed subjective and objective evidence of poorer outcome. Conclusions: Major depression is associated with poor outcome across multiple domains. This study highlights the need for the early diagnosis and prompt treatment of major depression following mild traumatic brain injury.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Traumat Brain Injury Clin, Toronto, ON M4N 3M5, Canada; Univ Toronto, Kunin Lunenfeld Appl Res Ctr, Baycrest Ctr Geriatr Care, Toronto, ON, Canada		Rapoport, MJ (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Psychiat, 2075 Bayview Ave,FG37, Toronto, ON M4N 3M5, Canada.		Streiner, David/E-6563-2011; Rapoport, Mark/AAD-8581-2020	Streiner, David/0000-0003-0610-6271; 			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Christensen B, 1994, ADV MED PSYCHOTHERAP, V7, P23; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DEPAULO JR, 1980, PSYCHOL MED, V10, P125, DOI 10.1017/S0033291700039659; DEPAULO JR, 1978, ANN NEUROL, V4, P225, DOI 10.1002/ana.410040306; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; JENNETT B, 1975, LANCET, V1, P480; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Martin J, 2001, J TURBUL, V2, P1; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Newburn G, 1999, BRAIN INJURY, V13, P637; Putnam S. H., 1994, ADV MED PSYCHOTHERAP, V7, P1; RABINS PV, 1981, PSYCHOL MED, V11, P425, DOI 10.1017/S0033291700052259; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X	39	133	137	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0033-3182	1545-7206		PSYCHOSOMATICS	Psychosomatics	JAN-FEB	2003	44	1					31	37		10.1176/appi.psy.44.1.31			7	Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychiatry; Psychology	631MG	WOS:000180171100004	12515835				2022-02-06	
J	Rohling, ML; Green, P; Allen, LM; Iverson, GL				Rohling, ML; Green, P; Allen, LM; Iverson, GL			Depressive symptoms and neurocognitive test scores in patients passing symptom validity tests	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						effortful; depression; malingering; assessment; neurocognition; forensics	TRAUMATIC BRAIN INJURY; HEAD-INJURY; WORD MEMORY; EFFORTFUL; IMPAIRMENT; RECOVERY; SEVERITY; MANIA	This study examined the effect of depression on neurocognitive performance in patients who passed symptom validity testing. The Beck Depression Inventory (BDI) was used to assess depression in 420 patients with heterogeneous referral diagnoses (more than half of these cases were head injury or neurological disease). All patients had demonstrated satisfactory effort by passing two symptom validity tests. No differences were found on objective cognitive and psychomotor measures in groups sorted based on their self-reported depression. In contrast, on the self-report measures [i.e., Minnesota Multiphasic Personality Inventory-2 (MMPI-2), Symptom Checklist-90-Revised (SCL-90-R), and Memory Complaints Inventory (MCI)], differences were found indicating that patients with depression report more emotional, somatic, and cognitive problems. Contrary to expectation, these data suggest that depression has no impact on objective neurocognitive functioning. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; Neurobehav Associates, Edmonton, AB, Canada; CogniSyst Inc, Durham, NC USA; Univ British Columbia, Vancouver, BC, Canada; Riverview Hosp, Vancouver, BC, Canada		Rohling, ML (corresponding author), Univ S Alabama, Dept Psychol, 381 Life Sci Bldg, Mobile, AL 36688 USA.			Iverson, Grant/0000-0001-7348-9570			Allen L. M., 1997, COMPUTERIZED ASSESSM; ALLEN LM, 1998, ANN M NAT AC NEUR NO; ALLEN LM, 1999, SUPPLEMENT CARB WMT; Beck, 1978, BECK DEPRESSION INVE; Beck A. T., 1993, BECK DEPRESSION INVE; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Cassens G, 1990, J Neuropsychiatry Clin Neurosci, V2, P202; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Crews WD, 1999, ARCH CLIN NEUROPSYCH, V14, P517, DOI 10.1016/S0887-6177(98)00050-X; DALGLEISH T, 1990, CLIN PSYCHOL REV, V10, P589, DOI 10.1016/0272-7358(90)90098-U; DAVIS RK, 1980, PERCEPT MOTOR SKILL, V51, P699; DELIS D, 1987, CALIFORNIA VERBAL LE; DEROGATIS LR, 1983, SYMPTOM CHECKLIST 90; DERRY PA, 1981, J ABNORM PSYCHOL, V90, P286, DOI 10.1037/0021-843X.90.4.286; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; GREEN P, 1996, COGNISYSTS STORY REC; Green P., 1996, WORD MEMORY TEST USE; GROSSMAN I, 1994, PSYCHIAT RES, V51, P231, DOI 10.1016/0165-1781(94)90011-6; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HARTLAGE S, 1993, PSYCHOL BULL, V113, P247, DOI 10.1037/0033-2909.113.2.247; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Hathaway S.R., 1989, MINNESOTA MULTIPHASI; HEATON RK, 1993, WISCONSIN SORTING TE; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Jackson, 1984, MULTIDIMENSIONAL APT; JOHNSON MH, 1987, PSYCHOL BULL, V101, P28, DOI 10.1037/0033-2909.101.1.28; JORM AF, 1986, PSYCHOL MED, V16, P77, DOI 10.1017/S0033291700002567; KAHN RL, 1975, ARCH GEN PSYCHIAT, V32, P1560; KAUFMAN AS, 1994, J PSYCHOEDUC ASSESS, V12, P112, DOI 10.1177/073428299401200201; KILOH LG, 1961, ACTA PSYCHIAT SCAND, V37, P336, DOI 10.1111/j.1600-0447.1961.tb07367.x; *LAF INSTR, INSTR 32025 FORM 420; LEESHALEY PR, 1989, PSYCHOL REP, V65, P623, DOI 10.2466/pr0.1989.65.2.623; MARSELLA AJ, 1974, J CLIN PSYCHOL, V36, P428; MEYERS J, 1995, MEYERS SCORING SYSTE; MILLER LS, 1991, PSYCHIAT RES, V37, P219, DOI 10.1016/0165-1781(91)90058-W; MILLER WR, 1975, PSYCHOL BULL, V82, P238, DOI 10.1037/h0076367; NIEDEREHE G, 1986, HDB CLIN MEMORY ASSE; PARRINGTON JE, 1949, PSYCHOL SERVICE CTR, V1, P9; PENDLETON MG, 1982, J CLIN NEUROPSYCHOL, V4, P307, DOI 10.1080/01688638208401139; POPKIN SJ, 1982, EXP AGING RES, V8, P141, DOI 10.1080/03610738208260271; POSNER MI, 1975, INFORMATION PROCESSI; Reitan R, 1969, MANUAL ADM NEUROPSYC; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; ROHLING ML, 1991, J GERONTOL PSYCHOL S, V46, P137; ROHLING ML, 1993, J GERONTOL B-PSYCHOL, V48, P122; ROYBYRNE PP, 1986, ARCH GEN PSYCHIAT, V43, P265; RUFF R, 1988, RUFF FIGURE FLUENCY; RUSSELL EW, 1987, J CONSULT CLIN PSYCH, V55, P898, DOI 10.1037/0022-006X.55.6.898; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SCHEINDER W, 1977, PSYCHOL REV, V84, P127; SCOGIN F, 1989, J AGING HEALTH, V1, P507; THOMPSON L, 1986, HDB CLIN MEMORY ASSE; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler, 1997, WECHSLER ADULT INTEL; WEINGARTNER H, 1986, CLIN MEMORY ASSESSME; WETZLER S, 1993, J PERS ASSESS, V60, P1, DOI 10.1207/s15327752jpa6001_1	59	133	133	1	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	APR	2002	17	3					205	222	PII S0887-6177(01)00109-3	10.1016/S0887-6177(01)00109-3			18	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	536ZN	WOS:000174731900001	14589724				2022-02-06	
J	Woiciechowsky, C; Schoning, B; Cobanov, J; Lanksch, WR; Volk, HD; Docke, WD				Woiciechowsky, C; Schoning, B; Cobanov, J; Lanksch, WR; Volk, HD; Docke, WD			Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						brain injury; interleukin-6; interleukin-10; interleukin-1 receptor antagonist; cytokines; cortisol; adrenocorticotropic hormone; tumor necrosis factor-alpha; procalcitonin; inflammation; critical illness	SEVERE HEAD-INJURY; INTERLEUKIN-1 RECEPTOR ANTAGONIST; INTENSIVE-CARE UNIT; NEUROSURGICAL PROCEDURES; CYTOKINE CONCENTRATIONS; OUTCOME PREDICTION; SERUM; PROFILES; RELEASE; EXTENT	Background: Brain injury as well as early inflammatory and endocrine responses were found to be indicators for infectious complications in patients with multiple injuries. In this context, brain-derived inflammatory response as well as centrally triggered neuroendocrine activation and systemic immunodepression seem to be of major importance. Therefore, we hypothesize that a circulating index of inflammatory or endocrine function measured soon after brain injury (in patients with admission Glasgow Coma Scale [GCS] score of 4-7) would discriminate severe from moderate injury as indexed by GCS status on postinjury day 7. Methods: In a retrospective study, 25 patients with either acute traumatic brain injury or cerebral hemorrhage and an initial GCS score of 4 to 7 were examined. Blood samples were obtained at different time points, and different immune variables and neuroendocrine hormones were determined. According to the GCS score on day 7, patients were divided into two groups (GCS score greater than or equal to 8, moderate brain injury; and GCS score < 8, severe brain injury or patients who died within the first week) for comparison of variables. Concluding from the results of this retrospective analysis, in a prospective study patients (n = 26) were divided into two groups according to their interleukin (IL)-6 plasma concentrations on day 1 (IL-6 &GE; 100 pg/mL and IL 6 < 100 pg/mL). After 7 days, the GCS score, the infection rate, and the mortality were compared between these two groups. Results: In the retrospective study, we could show that severe brain injury (as assessed by GCS score and mortality on day 7) was associated with high plasma levels of pro- and anti-inflammatory cytokines, acute phase proteins, and neuroendocrine hormones within 2 to 6 hours after the acute event. Among the investigated variables, elevated IL-6 plasma concentrations were stable up to 1 day after the acute event with a high predictive value with regard to the short-term prognosis and incidence of infectious complications within the first week. Because of this stability during the first 24 hours, we selected IL-6 for further studies. In the prospective study with a calculated cut-off IL-6 plasma concentration of 100 pg/mL on day 1, the predictive value of this parameter regarding the severity of the brain injury was fully confirmed (positive predictive value, 0.94; this value represents the observed pretest probability of 0.62). All patients who died (n = 5) or developed infectious complications within the first week (n = 8) showed plasma IL-6 levels greater than or equal to 100 pg/mL on day 1. Conclusion: The IL-6 plasma level 1 day after the acute event with a cut-off of 100 pg/mL (Immulite) seems to be a predictor for short-term prognosis and infectious complications in brain-injured patients.	Humboldt Univ, Dept Neurosurg, D-13353 Berlin, Germany; Humboldt Univ, Inst Med Immunol, D-13353 Berlin, Germany		Woiciechowsky, C (corresponding author), Humboldt Univ, Dept Neurosurg, Charite Campus Virchow Klinikum,Augustenburger Pl, D-13353 Berlin, Germany.		volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668			ASADULLAH K, 1995, CRIT CARE MED, V23, P1976, DOI 10.1097/00003246-199512000-00006; ASADULLAH K, 1996, EUR J EMERG MED, V2, P184; BEAMER NB, 1995, ANN NEUROL, V37, P800, DOI 10.1002/ana.410370614; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; FASSBENDER K, 1994, J NEUROL SCI, V122, P135, DOI 10.1016/0022-510X(94)90289-5; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Heesen M, 1996, ACTA NEUROCHIR, V138, P77, DOI 10.1007/BF01411728; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; IKEDA K, 1994, J TRAUMA, V36, P624; JAREK MJ, 1993, CRIT CARE MED, V21, P543, DOI 10.1097/00003246-199304000-00015; JENNETT B, 1976, LANCET, V1, P1031; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kuster H, 1998, LANCET, V352, P1271, DOI 10.1016/S0140-6736(98)08148-3; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; LOTZ M, 1993, CANCER INVEST, V11, P732, DOI 10.3109/07357909309046948; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; Matuschak GM, 1996, CRIT CARE MED, V24, P1769, DOI 10.1097/00003246-199611000-00001; McKeating EG, 1998, ACT NEUR S, V71, P200; McKeating EG, 1998, ACT NEUR S, V71, P117; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; Osuka K, 1996, ACTA NEUROCHIR, V138, P970, DOI 10.1007/BF01411287; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Woiciechowsky C, 1999, BRAIN RES, V816, P563, DOI 10.1016/S0006-8993(98)01238-4; Woiciechowsky C, 1997, ACTA NEUROCHIR, V139, P619, DOI 10.1007/BF01411996; YAMAUCHITAKIHARA K, 1995, CIRCULATION, V91, P1520, DOI 10.1161/01.CIR.91.5.1520; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	36	133	139	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2002	52	2					339	345		10.1097/00005373-200202000-00021			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	522XQ	WOS:000173922600029	11834998				2022-02-06	
J	Lannoo, E; Van Rietvelde, F; Colardyn, F; Lemmerling, M; Vandekerckhove, T; Jannes, C; De Soete, G				Lannoo, E; Van Rietvelde, F; Colardyn, F; Lemmerling, M; Vandekerckhove, T; Jannes, C; De Soete, G			Early predictors of mortality and morbidity after severe closed head injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; mortality; neuropsychology; outcome; prediction; quality of life; regression analysis	SICKNESS IMPACT PROFILE; TRAUMATIC BRAIN INJURY; HEALTH-STATUS MEASURE; OUTCOME PREDICTION; EXPERIENCE; ADMISSION; PRESSURE; 1-YEAR	Mortality and morbidity of 158 patients with severe head injury were studied in relation to age, and early (24-h) clinical and computed tomography data. For comparison of outcome data in survivors, a group of 32 patients with traumatic injuries to parts of the body other than the head was used as controls. Within the head-injured group, the mortality rate was 51%. Logistic regression analyses combined 13 out of 16 predictors into a model with an accuracy of 93%, a sensitivity of 90%, and a specificity of 95%. These include age, Glasgow Coma Scale (GCS) score, pupillary reactivity, blood pressure, intracranial pressure, blood glucose, platelet count, body temperature, cerebral lactate, and subdural, intracranial, subarachnoid, and ventricular hemorrhage. At 6 months postinjury, head-injury survivors and trauma controls were evaluated with the Glasgow Outcome Scale (GOS), a neuropsychological test battery and the Sickness Impact Profile (SIP). Head-injury survivors had a higher proportion of disabilities and neuropsychological dysfunctions than trauma controls. They also report more quality of life-related functional limitations on the SIP scales for mobility, intellectual behavior, communication, home management, eating, and work. Linear regression analysis resulted in age being the only important predictor of outcome on the GOS, the GCS score being the best predictor of neuropsychological functioning, and pupillary reactivity being the most predictive for self-reported quality of life as measured by SIP. Those factors important for predicting mortality (clinical variables such as ICP or blood glucose level, and CT observations) failed to show any significant relationship with morbidity.	State Univ Ghent Hosp, Rehabil Ctr K7, Dept Neuropsychol & Rehabil, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Radiol, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Intens Care Med, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Neurosurg, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Psychiat, B-9000 Ghent, Belgium; State Univ Ghent, Dept Data Anal, Ghent, Belgium		Lannoo, E (corresponding author), State Univ Ghent Hosp, Rehabil Ctr K7, Dept Neuropsychol & Rehabil, Pintelaan 185, B-9000 Ghent, Belgium.						BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; BRAAKMAN R, 1992, ACTA NEUROCHIR, V116, P161, DOI 10.1007/BF01540870; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; CARTER WB, 1976, HEALTH SERV RES, V11, P516; Chesnut R M, 1995, New Horiz, V3, P366; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; DEDEYNE C, 1998, EUR J ANAESTHESI S17, V15, P102; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; *FEPSY, 1995, NORM DAT, V2; GILSON BS, 1975, AM J PUBLIC HEALTH, V65, P1304, DOI 10.2105/AJPH.65.12.1304; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jacobs H M, 1990, Ned Tijdschr Geneeskd, V134, P1950; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lannoo E, 1997, PSYCHOL BELG, V37, P141; Lannoo E, 1998, INTENS CARE MED, V24, P236, DOI 10.1007/s001340050556; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MARMAROU A, 1991, J NEUROSURG S, V75, P59; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PFENNINGER EG, 1991, ACTA ANAESTH SCAND, V35, P148, DOI 10.1111/j.1399-6576.1991.tb03263.x; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Spreen O, 1991, COMPENDIUM NEUROPSYC; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089	42	133	139	0	11	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2000	17	5					403	414		10.1089/neu.2000.17.403			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	316BB	WOS:000087146500003	10833059				2022-02-06	
J	Hindman, BJ; Todd, MM; Gelb, AW; Loftus, CM; Craen, RA; Schubert, A; Mahla, ME; Torner, JC				Hindman, BJ; Todd, MM; Gelb, AW; Loftus, CM; Craen, RA; Schubert, A; Mahla, ME; Torner, JC			Mild hypothermia as a protective therapy during intracranial aneurysm surgery: A randomized prospective pilot trial	NEUROSURGERY			English	Article						aneurysm; cerebral; hypothermia; subarachnoid hemorrhage	TRAUMATIC BRAIN INJURY; SOMATOSENSORY EVOKED-POTENTIALS; TISSUE-PLASMINOGEN-ACTIVATOR; TEMPORARY ARTERIAL-OCCLUSION; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; MODERATE HYPOTHERMIA; INTRAOPERATIVE HYPOTHERMIA; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA	OBJECTIVE: To conduct a pilot trial of mild intraoperative hypothermia during cerebral aneurysm surgery. METHODS: One hundred fourteen patients undergoing cerebral aneurysm clipping with (n = 52) (World Federation of Neurological Surgeons score less than or equal to III) and without (n = 62) acute aneurysmal subarachnoid hemorrhage (SAH) were randomized to normothermic (target esophageal temperature at clip application of 36.5 degrees C) and hypothermic (target temperature of 33.5 degrees C) groups. Neurological status was prospectively evaluated before surgery, 24 and 72 hours postoperatively (National Institutes of Health Stroke Scale), and 3 to 6 months after surgery (Glasgow Outcome Scale). Secondary outcomes included postoperative critical care requirements, respiratory and cardiovascular complications, duration of hospitalization, and discharge disposition. RESULTS: Seven hypothermic patients (12%) could not be cooled to within 1 degrees C of target temperature; three of the seven were obese. Patients randomized to the hypothermic group more frequently required intubation and rewarming for the first 2 hours after surgery. Although not achieving statistical significance, patients with SAH randomized to the hypothermic group, when compared with patients in the normothermic group, had the following: 1) a lower frequency of neurological deterioration at 24 and 72 hours after surgery (21 versus 37-41 %), 2) a greater frequency of discharge to home (75 versus 57%), and 3) a greater incidence of good long-term outcomes (71 versus 57%). For patients without acute SAH, there were no outcome differences between the temperature groups, There was no suggestion that hypothermia was associated with excess morbidity or mortality. CONCLUSION: Mild hypothermia during cerebral aneurysm surgery is feasible in nonobese patients and is well tolerated. Our results indicate that a multicenter trial enrolling 300 to 900 patients with acute aneurysmal SAH will be required to demonstrate a statistically significant benefit with mild intraoperative hypothermia.	Univ Iowa, Dept Anesthesia, Iowa City, IA 52242 USA; Univ Iowa, Dept Surg Neurosurg, Iowa City, IA 52242 USA; Univ Iowa, Dept Prevent Med, Iowa City, IA 52242 USA; Univ Western Ontario, Dept Anaesthesia, London, ON, Canada; Cleveland Clin, Dept Gen Anesthesiol, Cleveland, OH 44106 USA; Univ Florida, Dept Anesthesiol, Gainesville, FL 32611 USA		Todd, MM (corresponding author), Univ Iowa, Dept Anesthesia, Iowa City, IA 52242 USA.		Schubert, Armin/D-3589-2011	Hindman, Bradley/0000-0003-2242-7980			ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052; BAKER KZ, 1994, ANESTHESIOLOGY, V81, P361, DOI 10.1097/00000542-199408000-00014; BOTTERELL EH, 1958, J NEUROSURG, V15, P4, DOI 10.3171/jns.1958.15.1.0004; BOTTERELL EH, 1956, J NEUROSURG, V13, P1, DOI 10.3171/jns.1956.13.1.0001; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; BROUWERS PJAM, 1989, STROKE, V20, P1162, DOI 10.1161/01.STR.20.9.1162; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLESHAW SRK, 1983, J APPL PHYSIOL, V55, P27, DOI 10.1152/jappl.1983.55.1.27; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DRAKE CG, 1988, J NEUROSURG, V68, P985; DRAKE CG, 1964, J NEUROSURG, V21, P575, DOI 10.3171/jns.1964.21.7.0575; EDNER G, 1992, BRIT J NEUROSURG, V6, P409, DOI 10.3109/02688699208995029; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; FRANK SM, 1993, ANESTHESIOLOGY, V78, P468, DOI 10.1097/00000542-199303000-00010; FRIEDMAN WA, 1991, NEUROSURGERY, V29, P83, DOI 10.1227/00006123-199107000-00014; GILSBACH JM, 1989, ACTA NEUROCHIR, V96, P1, DOI 10.1007/BF01403488; GOTO Y, 1993, NEUROSURGERY, V32, P980, DOI 10.1227/00006123-199306000-00017; HALEY EC, 1992, STROKE, V23, P205, DOI 10.1161/01.STR.23.2.205; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; HAMBY WB, 1963, J NEUROSURG, V20, P41, DOI 10.3171/jns.1963.20.1.0041; HERNESNIEMI J, 1993, ACTA NEUROCHIR, V122, P1, DOI 10.1007/BF01446980; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNETT B, 1975, LANCET, V1, P480; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KATO H, 1990, ACTA NEUROPATHOL, V79, P494, DOI 10.1007/BF00296108; Khanna RK, 1996, J NEUROSURG, V84, P49, DOI 10.3171/jns.1996.84.1.0049; KURZ A, 1995, ANESTH ANALG, V80, P562, DOI 10.1097/00000539-199503000-00023; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; KURZ A, 1995, ANESTHESIOLOGY, V82, P870, DOI 10.1097/00000542-199504000-00008; Lenhardt R, 1997, ANESTHESIOLOGY, V87, P1318, DOI 10.1097/00000542-199712000-00009; LeRoux PD, 1996, NEUROSURGERY, V38, P887, DOI 10.1097/00006123-199605000-00006; LOUGHEED WM, 1955, J NEUROSURG, V12, P240, DOI 10.3171/jns.1955.12.3.0240; LYDEN P, 1994, STROKE, V25, P220; MANNINEN PH, 1995, J NEUROSURG ANESTH, V7, P12, DOI 10.1097/00008506-199501000-00003; MANNINEN PH, 1990, J NEUROSURG ANESTH, V2, P97, DOI 10.1097/00008506-199006000-00007; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MICHENFELDER JD, 1964, ANN SURG, V159, P125, DOI 10.1097/00000658-196401000-00022; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; Ogilvy CS, 1996, J NEUROSURG, V84, P785, DOI 10.3171/jns.1996.84.5.0785; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PROUST F, 1995, STROKE, V26, P1553, DOI 10.1161/01.STR.26.9.1553; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; SAMSON D, 1994, NEUROSURGERY, V34, P22; SANO T, 1992, ANESTHESIOLOGY, V76, P221, DOI 10.1097/00000542-199202000-00011; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Sessler DI, 1997, NEW ENGL J MED, V336, P1730, DOI 10.1056/NEJM199706123362407; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; UIHLEIN A, 1966, J AMER MED ASSOC, V195, P639, DOI 10.1001/jama.195.8.639; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Yundt KD, 1997, NEUROSURGERY, V40, P442, DOI 10.1097/00006123-199703000-00003	59	133	137	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	1999	44	1					23	32		10.1097/00006123-199901000-00009			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	152AD	WOS:000077752300009	9894960				2022-02-06	
J	O'Neill, J; Hibbard, MR; Brown, M; Jaffe, M; Sliwinski, M; Vandergoot, D; Weiss, MJ				O'Neill, J; Hibbard, MR; Brown, M; Jaffe, M; Sliwinski, M; Vandergoot, D; Weiss, MJ			The effect of employment on quality of life and community integration after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; WORK STATUS; PREDICTORS; IMPAIRMENTS; INDICATORS; HANDICAP; OUTCOMES; RETURN; MODEL	Objectives: To investigate the effect of employment on perceived quality of life (QOL), social integration, and home and leisure activities for individuals with traumatic brain injuries (TBIs). Design: A number of demographic and injury-related variables (age at injury, time since injury, severity of injury, education, gender, preinjury household income, and marital status) were analyzed for their association first with employment and then with the QOL, social integration, and home and leisure activities. Any of these variables showing significant associations were then included along with level of employment in three final multivariate analyses of variance (MANOVAs), again predicting QOL, social integration, and home and leisure activities. Setting: Urban, suburban, and rural New York state. Participants: 337 adults with TBI who resided in New York state and were between the ages of 18 and 65 years. Main Outcome Measures: The Craig Handicap Assessment Capacity Technique, the Bigelow Quality of Life Questionnaire, the Flanagan Scale of Needs (adapted), and a global QOL measure. Results: Employment showed a strong and consistent relationship with perceived QOL, social integration within the community, and home and leisure activities. Part-time employment may have been superior to full-time employment for individuals with TBI: part-time workers had fewer unmet needs, were more socially integrated, and were more engaged in home activities than full-time workers. Loss of consciousness, as a measure of severity, was unexpectedly predictive of diminished sense of QOL for individuals with less severe injuries. Conclusions: Being employed contributes to one's sense of well-being, social integration, and pursuit of leisure and home activities. Select advantages of working part-time for individuals with TDI were identified.	CUNY Hunter Coll, Dept Educ Fdn & Counseling Programs, New York, NY 10021 USA; Mt Sinai Med Ctr, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA		O'Neill, J (corresponding author), CUNY Hunter Coll, Dept Educ Fdn & Counseling Programs, 695 Pk Ave, New York, NY 10021 USA.						Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Andrews F. M., 1976, SOCIAL INDICATORS WE; BIGELOW D, 1992, PSYCHOL REHABIL J, V14, P94; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FRASER RT, 1994, TOP LANG DISORD, V15, P55, DOI 10.1097/00011363-199411000-00006; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; KRIEL RL, 1988, PEDIATR NEUROL, V7, P101; MANN WC, 1994, AM J OCCUP THER, V48, P446, DOI 10.5014/ajot.48.5.446; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; PRESTON B, 1992, REHABIL COUNS BULL, V35, P230; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; *SPSS INC, 1996, SPSS WIND 95 VERS 7; STAMBROOK M, 1990, CAN J SURG, V33, P115; Stevens JP., 1996, APPL MULTIVARIATE ST; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P113; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519	28	133	134	0	18	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1998	13	4					68	79		10.1097/00001199-199808000-00007			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DZ	WOS:000075366000007	9651241				2022-02-06	
J	Marsh, NV; Kersel, DA; Havill, JH; Sleigh, JW				Marsh, NV; Kersel, DA; Havill, JH; Sleigh, JW			Caregiver burden at 6 months following severe traumatic brain injury	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; SOCIAL ADJUSTMENT; RELATIVES VIEW; SELF-REPORT; FAMILY	Sixty-nine primary caregivers of people with a severe traumatic brain injury (TBI) were assessed at 6 months post injury. Caregivers completed questionnaires on the physical, cognitive, emotional, behavioural, and social functioning of the person with the TBI. Caregiver psychosocial functioning and levels of subjective and objective burden were also assessed. Clinically significant levels of anxiety, depression, and impairment in social adjustment were evident in over a third of the caregivers. The frequency with which various changes in the person with the TBI and types of objective burden were reported had little relationship to the degree of distress caused by these changes. The person with TBI's social isolation and negative emotional behaviours caused the greatest degree of stress for caregivers. Caregivers were also most distressed by the impact that caregiving had on their personal health and free time. The results from a multiple regression analysis suggest that it is the presence of behavioural problems in the person with the TBI that has the most severe and pervasive impact on all aspects of caregiver functioning. It is suggested that these findings be taken into account when providing rehabilitation services to people with TBI and their families.	Univ Waikato, Dept Psychol, Hamilton, New Zealand; Waikato Hosp, Intens Care Unit, Hamilton, New Zealand		Marsh, NV (corresponding author), Univ Waikato, Dept Psychol, Private Bag 3105, Hamilton, New Zealand.		Marsh, Nigel/ABA-3609-2021; Marsh, Nigel V./F-5433-2019	Marsh, Nigel/0000-0002-4060-6432; Marsh, Nigel V./0000-0002-4060-6432			BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; GRAD J, 1963, LANCET, V1, P544; JENNETT B, 1975, LANCET, V1, P480; KNIGHT RG, 1984, J CLIN PSYCHOL, V40, P751, DOI 10.1002/1097-4679(198405)40:3<751::AID-JCLP2270400320>3.0.CO;2-Y; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1990, NEUROPSYCHOLOGY, V4, P13, DOI 10.1037/0894-4105.4.1.13; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A, 1972, REHABILITATION, V38, P33; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Smith LM, 1995, FAMILY SUPPORT PROGR; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Walker A E, 1972, Scand J Rehabil Med, V4, P5; WEISSMAN MM, 1978, J NERV MENT DIS, V166, P317, DOI 10.1097/00005053-197805000-00002; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; [No title captured], DOI DOI 10.1097/00001199-198812000-00004	30	133	134	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	1998	12	3					225	238		10.1080/026990598122700			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZA456	WOS:000072365100006	9547953				2022-02-06	
J	McIntosh, TK; Faden, AI; Yamakami, I; Vink, R				McIntosh, Tracy K.; Faden, Alan I.; Yamakami, Iwao; Vink, Robert			Magnesium Deficiency Exacerbates and Pretreatment Improves Outcome Following Traumatic Brain Injury in Rats: P-31 Magnetic Resonance Spectroscopy and Behavioral Studies	JOURNAL OF NEUROTRAUMA			English	Article							ENDOGENOUS OPIOIDS; METABOLISM; GLUTAMATE; SPECTRA; DAMAGE; MG-2+; DIFFERENCE; RESPONSES; PROTECT; PH	The biochemical mechanisms mediating delayed or secondary tissue injury after central nervous system trauma remain speculative. We have demonstrated previously that traumatic brain injury in rats causes a rapid decline in tissue intracellular free magnesium [Mg](f) and total magnesium [Mg](t) concentrations, which were significantly correlated with injury severity. In order to examine the relationship between magnesium and traumatic brain injury, we assessed whether (1) magnesium deficiency exacerbates or (2) magnesium treatment improves posttraumatic outcome following fluid-percussion brain injury (2.0-2.4 atm) in rats. Animals placed on magnesium-deficient diet for 14 days showed a 15% decrease in brain [Mg](f) as measured by phosphorus (P-31) magnetic resonance spectroscopy (MRS). Magnesium deficiency significantly exacerbated neurologic dysfunction and increased mortality following injury when compared to normally fed saline-treated controls. Conversely, pretreatment with magnesium sulfate (0.1 mEq) 15 min before brain injury prevented the fall in [Mg](f) observed by P-31 MRS in saline-treated animals and significantly improved both cellular bioenergetic state and chronic posttraumatic neurologic outcome. These combined observations suggest that alterations in brain [Mg](f) after trauma may play a role in the pathophysiology of traumatic brain injury.	[McIntosh, Tracy K.] Univ Connecticut, Ctr Hlth, Dept Surg, Surg Res Ctr, Farmington, CT 06032 USA; [Faden, Alan I.; Yamakami, Iwao] Univ Calif San Francisco, Dept Neurol, Ctr Neural Injury, San Francisco, CA USA; [Faden, Alan I.; Yamakami, Iwao] Vet Adm Med Ctr, San Francisco, CA 94121 USA; [Vink, Robert] James Cook Univ, Dept Chem & Biochem, Townsville, Qld 4811, Australia		McIntosh, TK (corresponding author), Univ Connecticut, Ctr Hlth, Dept Surg, Surg Res Ctr, Farmington, CT 06032 USA.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; Veterans AdministrationUS Department of Veterans Affairs [74R]; Queen Elizabeth II Fellowship	This work was supported, in part, by a CDC grant to A. I. F. and T. K. M. and Veterans Administration Merit Review 74R to T. K. M. R. V. is a recipient of a Queen Elizabeth II Fellowship. We gratefully acknowledge Jane Vink and Carmen Warri for preparation of the manuscript. In these studies, we carefully adhered to the animal welfare guidelines set forth in Guide for the Care and Use of Laboratory Animals, U. S. Dept of Health and Human Services Pub. No. 85-23, 1985.	Ackerman J.H., 1984, J MAGN RESON, V56, P318; Aikawa J.W., 1981, MAGNESIUM ITS BIOL S, P21; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; CHOI DW, 1987, J NEUROSCI, V7, P369; CLARK AF, 1980, J BIOL CHEM, V255, P6556; COHN M, 1962, J BIOL CHEM, V237, P176; Cooper P.R., 1985, CENTRAL NERVOUS SYST; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; Faden A.I., 1988, ANN NEUROL IN PRESS; FAGG GE, 1985, TRENDS NEUROSCI, V8, P207, DOI 10.1016/0166-2236(85)90080-3; GARFINKEL L, 1985, Magnesium, V4, P60; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes R.L., 1987, SOC NEUR ABST, V2, P1254; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McIntosh T.K., 1988, RECENT ADV EXCITATOR; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1987, J CEREB BLOOD FLOW M, V7, pS620; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; Nigam R., 1986, PROSTAGLANDINS LEUKO, V23, P1; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SEELIG JM, 1983, AM J PHYSIOL, V245, pH22, DOI 10.1152/ajpheart.1983.245.1.H22; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Yamakami I., 1988, J CEREB BLO IN PRESS; Young W, 1987, Cent Nerv Syst Trauma, V4, P27	50	133	135	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	1					17	31		10.1089/neu.1988.5.17			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V22HC	WOS:000208265300002	3193462				2022-02-06	
J	Jha, MK; Lee, WH; Suk, K				Jha, Mithilesh Kumar; Lee, Won-Ha; Suk, Kyoungho			Functional polarization of neuroglia: Implications in neuroinflammation and neurological disorders	BIOCHEMICAL PHARMACOLOGY			English	Article						Central nervous system; Neuroglia; Functional polarization; Neuroinflammation; Neurological disorders	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SATELLITE GLIAL-CELLS; DORSAL-ROOT GANGLIA; RHO-KINASE INHIBITOR; FACTOR-KAPPA-B; CHONDROITIN SULFATE PROTEOGLYCANS; CRITICAL TRANSCRIPTION FACTOR; PERIPHERAL-NERVE INJURY; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE	Recent neuroscience research has established the adult brain as a dynamic organ having a unique ability to undergo changes with time. Neuroglia, especially microglia and astrocytes, provide dynamicity to the brain. Activation of these glial cells is a major component of the neuroinflammatory responses underlying brain injury and neurodegeneration. Glial cells execute functional reaction programs in response to diverse microenvironmental signals manifested by neuropathological conditions. Activated microglia exist along a continuum of two functional states of polarization namely M1-type (classical/proinflammatory activation) and M2-type (alternative/anti-inflammatory activation) as in macrophages. The balance between classically and alternatively activated microglial phenotypes influences disease progression in the CNS. The classically activated state of microglia drives the neuroinflammatory response and mediates the detrimental effects on neurons, whereas in their alternative activation state, which is apparently a beneficial activation state, the microglia play a crucial role in tissue maintenance and repair. Likewise, in response to immune or inflammatory microenvironments astrocytes also adopt neurotoxic or neuroprotective phenotypes. Reactive astrocytes exhibit two distinctive functional phenotypes defined by pro- or anti-inflammatory gene expression profile. In this review, we have thoroughly covered recent advances in the understanding of the functional polarization of brain and peripheral glia and its implications in neuroinflammation and neurological disorders. The identifiable phenotypes adopted by neuroglia in response to specific insult or injury can be exploited as promising diagnostic markers of neuroinflammatory diseases. Furthermore, harnessing the beneficial effects of the polarized glia could undoubtedly pave the way for the formulation of novel glia-based therapeutic strategies for diverse neurological disorders. (C) 2015 Elsevier Inc. All rights reserved.	[Jha, Mithilesh Kumar; Suk, Kyoungho] Kyungpook Natl Univ, Brain Sci & Engn Inst, Dept Pharmacol, Plus KNU Biomed Convergence Program BK21, Daegu, South Korea; [Lee, Won-Ha] Kyungpook Natl Univ, Plus KNU Creat BioRes Grp BK21, Sch Life Sci, Daegu, South Korea		Suk, K (corresponding author), Kyungpook Natl Univ, Dept Pharmacol, Sch Med, 680 Gukchaebosang St, Daegu 700422, South Korea.	ksuk@knu.ac.kr		Jha, Mithilesh Kumar/0000-0002-9526-0053; Suk, Kyoungho/0000-0002-9555-4203	Korea Healthcare Technology RAMP;D Project, Ministry of Health AMP; Welfare, Republic of Korea [A111345, HI140331]; Basic Science Research Program through the National Research Foundation (NRF) - Korean Ministry of Education, Science, and Technology (MEST) [2008-0062282]	We apologize to those authors whose works are not cited owing to space constraints. This work was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345, HI140331). This work was also supported by the Basic Science Research Program through the National Research Foundation (NRF) funded by the Korean Ministry of Education, Science, and Technology (MEST) (2008-0062282).	Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Ambrosini E, 2003, GLIA, V41, P290, DOI 10.1002/glia.10193; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Armati PJ, 2014, J PERIPHER NERV SYST, V19, P14, DOI 10.1111/jns5.12057; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Austin PJ, 2012, PAIN, V153, P1916, DOI 10.1016/j.pain.2012.06.005; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001; Barakat R., 2015, MED PRINC P IN PRESS; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Blumenthal NR, 2014, P NATL ACAD SCI USA, V111, P16124, DOI 10.1073/pnas.1412740111; Bohacek I, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-191; Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006; Boumezbeur F, 2010, J CEREBR BLOOD F MET, V30, P211, DOI 10.1038/jcbfm.2009.197; Brambilla R, 2009, J IMMUNOL, V182, P2628, DOI 10.4049/jimmunol.0802954; Bramow S, 2010, BRAIN, V133, P2983, DOI 10.1093/brain/awq250; Bremer M, 2011, GLIA, V59, P1022, DOI 10.1002/glia.21173; Brifault C, 2015, STROKE, V46, P520, DOI 10.1161/STROKEAHA.114.006864; Burda J. E., 2015, EXP NEUROL IN PRESS; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Campuzano O, 2009, J NEUROSCI RES, V87, P2484, DOI 10.1002/jnr.22074; Cantarella G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.286; Carpentier PA, 2008, BRAIN BEHAV IMMUN, V22, P140, DOI 10.1016/j.bbi.2007.08.011; Chen C, 2014, ACTA PHARMACOL SIN, V35, P1428, DOI 10.1038/aps.2014.68; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Cohan CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124918; Criste G, 2014, HAND CLINIC, V122, P101, DOI 10.1016/B978-0-444-52001-2.00005-4; Cuevas CD, 2014, J VIROL, V88, P7703, DOI 10.1128/JVI.00050-14; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Delgado M, 2001, J BIOL CHEM, V276, P369, DOI 10.1074/jbc.M006923200; Dienel GA, 2001, J NEUROSCI RES, V66, P824, DOI 10.1002/jnr.10079; Dilger RN, 2008, J LEUKOCYTE BIOL, V84, P932, DOI 10.1189/jlb.0208108; Donega V, 2014, EXP NEUROL, V261, P53, DOI 10.1016/j.expneurol.2014.06.009; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Doring Axinia, 2011, Front Biosci (Schol Ed), V3, P846; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Dubovy P, 2013, INT REV NEUROBIOL, V108, P173, DOI 10.1016/B978-0-12-410499-0.00007-1; Ellert-Miklaszewska A, 2013, GLIA, V61, P1178, DOI 10.1002/glia.22510; Emmrich JV, 2013, FEBS J, V280, P5030, DOI 10.1111/febs.12401; Endo F, 2015, CELL REP, V11, P592, DOI 10.1016/j.celrep.2015.03.053; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fledrich R, 2014, NAT MED, V20, P1055, DOI 10.1038/nm.3664; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Fraussen J, 2014, AUTOIMMUN REV, V13, P1126, DOI 10.1016/j.autrev.2014.07.002; Fruhbeis C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00182; Fruhbeis C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00119; Gabrielli M, 2015, EMBO REP, V16, P213, DOI 10.15252/embr.201439668; Gaire BP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120203; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Galvan-Pena S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420; Gao C, 2013, NEUROIMMUNOMODULAT, V20, P334, DOI 10.1159/000353568; Garidou L, 2004, J IMMUNOL, V173, P2435, DOI 10.4049/jimmunol.173.4.2435; Gibbons HM, 2011, NEUROBIOL DIS, V41, P96, DOI 10.1016/j.nbd.2010.08.024; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Goldmann T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/208093; Goncalves NP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0177-8; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graff JW, 2012, J BIOL CHEM, V287, P21816, DOI 10.1074/jbc.M111.327031; Gregori N, 2002, J NEUROSCI, V22, P248, DOI 10.1523/JNEUROSCI.22-01-00248.2002; Groh J, 2015, GLIA, V63, P977, DOI 10.1002/glia.22796; Gu WL, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-128; Gundersen GA, 2014, BRAIN STRUCT FUNCT, V219, P2181, DOI 10.1007/s00429-013-0629-0; Han MS, 2013, SCIENCE, V339, P218, DOI 10.1126/science.1227568; Hanani M, 2005, BRAIN RES REV, V48, P457, DOI 10.1016/j.brainresrev.2004.09.001; Hanani M, 2002, NEUROSCIENCE, V114, P279, DOI 10.1016/S0306-4522(02)00279-8; Hanani M, 2014, J CELL MOL MED, V18, P2367, DOI 10.1111/jcmm.12406; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harish G, 2015, J NEUROCHEM, V134, P156, DOI 10.1111/jnc.13082; Hashioka S, 2015, CNS NEUROL DISORD-DR, V14, P251, DOI 10.2174/1871527314666150217122305; Hayakawa K, 2014, J NEUROSCI RES, V92, P1647, DOI 10.1002/jnr.23448; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Herrera AJ, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3382/fncel.2015.00312, 10.3389/fncel.2015.00312]; Herrera J, 2001, EXP NEUROL, V171, P11, DOI 10.1006/exnr.2001.7729; Horiuchi M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-227; Horner PJ, 2000, J NEUROSCI, V20, P2218; Hosokawa Y, 2013, CELL IMMUNOL, V283, P8, DOI 10.1016/j.cellimm.2013.05.005; Hsiao HY, 2013, HUM MOL GENET, V22, P1826, DOI 10.1093/hmg/ddt036; Hu F, 2015, NEURO-ONCOLOGY, V17, P200, DOI 10.1093/neuonc/nou324; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2014, PROG NEUROBIOL, V119, P60, DOI 10.1016/j.pneurobio.2014.06.002; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Hua LWL, 2002, J NEUROCHEM, V83, P1120, DOI 10.1046/j.1471-4159.2002.01226.x; Jack C, 2005, J NEUROSCI RES, V81, P363, DOI 10.1002/jnr.20482; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Jang E, 2013, FASEB J, V27, P1176, DOI 10.1096/fj.12-222257; Janssens K, 2015, GLIA, V63, P1729, DOI 10.1002/glia.22840; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Jha MK, 2015, J NEUROSCI, V35, P14353, DOI 10.1523/JNEUROSCI.1910-15.2015; Jha MK, 2015, NEUROSCI BIOBEHAV R, V49, P135, DOI 10.1016/j.neubiorev.2014.12.006; Jiang TY, 2013, AGING CELL, V12, P1021, DOI 10.1111/acel.12127; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Joshi P, 2015, INT J MOL SCI, V16, P4800, DOI 10.3390/ijms16034800; Jukkola P, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-70; Kang SS, 2012, J NEUROSCI, V32, P9277, DOI 10.1523/JNEUROSCI.1746-12.2012; Karve I. P., 2015, BR J PHARM IN PRESS; Kawabori M, 2015, J NEUROSCI, V35, P3384, DOI 10.1523/JNEUROSCI.2620-14.2015; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kimelberg HK, 2010, NEUROTHERAPEUTICS, V7, P338, DOI 10.1016/j.nurt.2010.07.006; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klein D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0267-y; Klein D, 2014, GLIA, V62, P736, DOI 10.1002/glia.22638; Kobayashi M, 2015, GLIA, V63, P1073, DOI 10.1002/glia.22802; Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005; Kopatz J, 2013, GLIA, V61, P1122, DOI 10.1002/glia.22501; Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990; Lampron A, 2013, NEURON, V78, P214, DOI 10.1016/j.neuron.2013.04.005; Lanier LL, 2009, IMMUNOL REV, V227, P150, DOI 10.1111/j.1600-065X.2008.00720.x; LeComte MD, 2015, P NATL ACAD SCI USA, V112, P8726, DOI 10.1073/pnas.1501029112; Lees JG, 2015, CYTOKINE, V71, P207, DOI 10.1016/j.cyto.2014.10.028; Li R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094320; Li WC, 2013, INT J NEUROSCI, V123, P240, DOI 10.3109/00207454.2012.755181; Li YH, 2014, IMMUNOLOGY, V143, P219, DOI 10.1111/imm.12303; Lindner M, 2015, BRAIN, V138, P1875, DOI 10.1093/brain/awv102; Lisi L, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-125; Lisi L, 2014, ASN NEURO, V6, DOI 10.1042/AN20130045; Liston A, 2009, J IMMUNOL, V182, P3121, DOI 10.4049/jimmunol.0713169; Liu SM, 2015, PURINERG SIGNAL, V11, P161, DOI 10.1007/s11302-014-9439-y; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Lunde LK, 2015, BRAIN STRUCT FUNCT, V220, P2087, DOI 10.1007/s00429-014-0775-z; Ma ZF, 2014, INT J NEUROSCI, V124, P824, DOI 10.3109/00207454.2014.884088; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Magistretti PJ, 2011, EXP PHYSIOL, V96, P407, DOI 10.1113/expphysiol.2010.053157; Mallard C, 2015, STROKE, V46, P3006, DOI 10.1161/STROKEAHA.115.007776; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martini R, 2016, GLIA, V64, P475, DOI 10.1002/glia.22899; Martini R, 2013, AM J PATHOL, V183, P655, DOI 10.1016/j.ajpath.2013.06.002; Masuda T, 2012, CELL REP, V1, P334, DOI 10.1016/j.celrep.2012.02.014; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Mayo L, 2014, NAT MED, V20, P1147, DOI 10.1038/nm.3681; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Meares GP, 2012, GLIA, V60, P771, DOI 10.1002/glia.22307; Mehan S, 2011, J MOL NEUROSCI, V43, P376, DOI 10.1007/s12031-010-9454-6; Mensah-Brown EP, 2011, J NEUROIMMUNOL, V232, P68, DOI 10.1016/j.jneuroim.2010.10.010; Mesci P, 2015, BRAIN, V138, P53, DOI 10.1093/brain/awu312; Mietto BS, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/251204; Millward JM, 2007, J IMMUNOL, V178, P8175, DOI 10.4049/jimmunol.178.12.8175; Min H, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0116-z; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Neher JJ, 2013, P NATL ACAD SCI USA, V110, pE4098, DOI 10.1073/pnas.1308679110; Ni JS, 2015, BRAIN BEHAV IMMUN, V49, P75, DOI 10.1016/j.bbi.2015.04.014; Nijaguna MB, 2015, J BIOL CHEM, V290, P23401, DOI 10.1074/jbc.M115.664037; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Ohara PT, 2009, NEUROSCIENTIST, V15, P450, DOI 10.1177/1073858409336094; Ohtori S, 2004, SPINE, V29, P1082, DOI 10.1097/00007632-200405150-00006; Orihuela R, 2015, BR J PHARM, DOI 10.1111/bph.13139; Pan LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099526; Parmar J, 2015, INT J DEV NEUROSCI, V43, P35, DOI 10.1016/j.ijdevneu.2015.03.010; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Patel JR, 2010, P NATL ACAD SCI USA, V107, P11062, DOI 10.1073/pnas.1006301107; Peferoen L, 2014, IMMUNOLOGY, V141, P302, DOI 10.1111/imm.12163; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perera CJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0253-4; Politis M, 2012, NEUROLOGY, V79, P523, DOI 10.1212/WNL.0b013e3182635645; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Popiolek-Barczyk K, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/676473; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Porrini V, 2015, NEUROSCIENCE, V302, P112, DOI 10.1016/j.neuroscience.2014.10.029; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Przanowski P, 2014, J MOL MED, V92, P239, DOI 10.1007/s00109-013-1090-5; Qian L, 2012, J NEUROL, V259, P2111, DOI 10.1007/s00415-012-6465-y; Quattromani MJ, 2014, NEUROBIOL DIS, V66, P66, DOI 10.1016/j.nbd.2014.02.010; Rajendran L, 2014, J NEUROSCI, V34, P15482, DOI 10.1523/JNEUROSCI.3258-14.2014; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Rodriguez JJ, 2011, MOL NEUROBIOL, V43, P87, DOI 10.1007/s12035-010-8157-x; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Rusnakova V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069734; Salem M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-181; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920; Schlegelmilch T, 2011, CURR OPIN NEUROBIOL, V21, P5, DOI 10.1016/j.conb.2010.08.004; Seifert HA, 2014, TRANSL STROKE RES, V5, P543, DOI 10.1007/s12975-014-0349-7; Shin JY, 2005, J CELL BIOL, V171, P1001, DOI 10.1083/jcb.200508072; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Singh S, 2013, ACTA NEUROPATHOL, V125, P595, DOI 10.1007/s00401-013-1082-0; Smith AM, 2014, TRENDS NEUROSCI, V37, P125, DOI 10.1016/j.tins.2013.12.001; Smith AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080463; Smith AM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-85; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song DD, 2014, AM J PHYSIOL-GASTR L, V306, pG788, DOI 10.1152/ajpgi.00318.2013; Stevens SL, 2011, J NEUROSCI, V31, P8456, DOI 10.1523/JNEUROSCI.0821-11.2011; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0142-6; Streit WJ, 2014, CURR OPIN IMMUNOL, V29, P93, DOI 10.1016/j.coi.2014.05.005; Streit WJ, 2013, CNS NEUROL DISORD-DR, V12, P763, DOI 10.2174/18715273113126660176; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Suenaga J, 2015, EXP NEUROL, V272, P109, DOI 10.1016/j.expneurol.2015.03.021; Suh HS, 2009, CURR TOP MICROBIOL, V336, P63, DOI 10.1007/978-3-642-00549-7_4; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644; Takeda M, 2009, NEUROSCI BIOBEHAV R, V33, P784, DOI 10.1016/j.neubiorev.2008.12.005; Tanaka T, 2015, GLIA, V63, P595, DOI 10.1002/glia.22770; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Tannahill GM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00106; Tarassishin L, 2011, GLIA, V59, P1911, DOI 10.1002/glia.21233; Theodosis DT, 2008, PHYSIOL REV, V88, P983, DOI 10.1152/physrev.00036.2007; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Trebst C, 2008, MULT SCLER, V14, P728, DOI 10.1177/1352458508089359; Turola E, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00149; Umschweif G, 2013, J CEREBR BLOOD F MET, V33, P524, DOI 10.1038/jcbfm.2012.193; van der Valk P, 2009, CURR OPIN NEUROL, V22, P207, DOI 10.1097/WCO.0b013e32832b4c76; Varin A, 2009, IMMUNOBIOLOGY, V214, P630, DOI 10.1016/j.imbio.2008.11.009; VESIN MF, 1995, J NEUROSCI, V15, P470; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JM, 2013, J CEREBR BLOOD F MET, V33, P1574, DOI 10.1038/jcbfm.2013.111; Wang X, 2012, TOXICOL SCI, V127, P412, DOI 10.1093/toxsci/kfs106; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Warwick RA, 2013, EUR J PAIN, V17, P571, DOI 10.1002/j.1532-2149.2012.00219.x; Weinstein JR, 2010, FUTUR NEUROL, V5, P227, DOI 10.2217/FNL.10.1; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Xanthos DN, 2014, NAT REV NEUROSCI, V15, P43, DOI 10.1038/nrn3617; Xiao BG, 1998, J NEUROL SCI, V157, P1, DOI 10.1016/S0022-510X(98)00049-5; Xu HX, 2012, NAT IMMUNOL, V13, P642, DOI 10.1038/ni.2304; Yang QW, 2011, J CEREBR BLOOD F MET, V31, P593, DOI 10.1038/jcbfm.2010.129; Ydens E, 2013, NEUROBIOL DIS, V55, P95, DOI 10.1016/j.nbd.2013.03.005; Yin F, 2013, BIOCHEM SOC T, V41, P101, DOI 10.1042/BST20120260; Yong V Wee, 2010, Rinsho Shinkeigaku, V50, P869; Yu ZW, 2015, J NEUROSCI, V35, P6350, DOI 10.1523/JNEUROSCI.2468-14.2015; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zeiner PS, 2015, BRAIN PATHOL, V25, P491, DOI 10.1111/bpa.12194; Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143; Zhang Q., 2014, MOL NEUROBIOL; Zhao XR, 2015, J NEUROSCI, V35, P11281, DOI 10.1523/JNEUROSCI.1685-15.2015; Zhao YF, 2015, J MOL NEUROSCI, V55, P725, DOI 10.1007/s12031-014-0411-7; Zhong L, 2015, J BIOL CHEM, V290, P15866, DOI 10.1074/jbc.M115.645986; Zong H, 2012, EXPERT REV MOL DIAGN, V12, P383, DOI [10.1586/ERM.12.30, 10.1586/erm.12.30]	242	132	139	12	94	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	MAR 1	2016	103						1	16		10.1016/j.bcp.2015.11.003			16	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	DH5UW	WOS:000372858600001	26556658		Y	N	2022-02-06	
J	Rawji, KS; Mishra, MK; Michaels, NJ; Rivest, S; Stys, PK; Yong, VW				Rawji, Khalil S.; Mishra, Manoj K.; Michaels, Nathan J.; Rivest, Serge; Stys, Peter K.; Yong, V. Wee			Immunosenescence of microglia and macrophages: impact on the ageing central nervous system	BRAIN			English	Article						microglia; macrophage; white matter injury; ageing; rejuvenation	COLONY-STIMULATING FACTOR; MONOPHOSPHORYL-LIPID-A; AMYLOID-BETA; SPINAL-CORD; INFLAMMATORY RESPONSES; ALZHEIMERS-DISEASE; ANALYSIS REVEALS; IMMUNE CELLS; AGED MICE; BRAIN	The nervous system's capacity to repair itself declines with age. Rawji et al. discuss the effects of ageing on neurological diseases and propose that some of these effects may reflect differential senescence of macrophages and microglia. Therapeutic strategies to reverse macrophage/microglia senescence may promote regeneration in the ageing nervous system.The nervous system's capacity to repair itself declines with age. Rawji et al. discuss the effects of ageing on neurological diseases and propose that some of these effects may reflect differential senescence of macrophages and microglia. Therapeutic strategies to reverse macrophage/microglia senescence may promote regeneration in the ageing nervous system.Ageing of the central nervous system results in a loss of both grey and white matter, leading to cognitive decline. Additional injury to both the grey and white matter is documented in many neurological disorders with ageing, including Alzheimer's disease, traumatic brain and spinal cord injury, stroke, and multiple sclerosis. Accompanying neuronal and glial damage is an inflammatory response consisting of activated macrophages and microglia, innate immune cells demonstrated to be both beneficial and detrimental in neurological repair. This article will propose the following: (i) infiltrating macrophages age differently from central nervous system-intrinsic microglia; (ii) several mechanisms underlie the differential ageing process of these two distinct cell types; and (iii) therapeutic strategies that selectively target these diverse mechanisms may rejuvenate macrophages and microglia for repair in the ageing central nervous system. Most responses of macrophages are diminished with senescence, but activated microglia increase their expression of pro-inflammatory cytokines while diminishing chemotactic and phagocytic activities. The senescence of macrophages and microglia has a negative impact on several neurological diseases, and the mechanisms underlying their age-dependent phenotypic changes vary from extrinsic microenvironmental changes to intrinsic changes in genomic integrity. We discuss the negative effects of age on neurological diseases, examine the response of senescent macrophages and microglia in these conditions, and propose a theoretical framework of therapeutic strategies that target the different mechanisms contributing to the ageing phenotype in these two distinct cell types. Rejuvenation of ageing macrophage/microglia may preserve neurological integrity and promote regeneration in the ageing central nervous system.	[Rawji, Khalil S.; Mishra, Manoj K.; Michaels, Nathan J.; Stys, Peter K.; Yong, V. Wee] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; [Rawji, Khalil S.; Mishra, Manoj K.; Michaels, Nathan J.; Stys, Peter K.; Yong, V. Wee] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada; [Rivest, Serge] Univ Laval, Fac Med, Dept Mol Med, CHU Quebec,Res Ctr,Neurosci Lab, Quebec City, PQ G1V 4G2, Canada		Yong, VW (corresponding author), Univ Calgary, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canada.	vyong@ucalgary.ca	Mishra, Manoj/A-7105-2018	Mishra, Manoj/0000-0001-9636-4930; Rawji, Khalil Sherali/0000-0002-9687-8330; Yong, V. Wee/0000-0002-2600-3563	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Multiple Sclerosis Scientific Research Foundation; Multiple Sclerosis Society of Canada; Alberta Innovates - Health Solutions CRIO Team; Vanier Canada Graduate Scholarship; Alberta Innovates Health Solutions; Multiple Sclerosis Society of Canada Studentship; Eyes High Doctoral Scholarship from the University of Calgary; Canada Research Chair programCanada Research Chairs; Alberta Innovates [201300669] Funding Source: researchfish	We thank the Canadian Institutes of Health Research, the Multiple Sclerosis Scientific Research Foundation, the Multiple Sclerosis Society of Canada and Alberta Innovates - Health Solutions CRIO Team program for support of operating funds. K.S.R. is supported by a Vanier Canada Graduate Scholarship and a studentship from the University of Calgary Faculty of Medicine. M.K.M. was supported by a fellowship from Alberta Innovates Health Solutions. N.J.M. is supported by a Multiple Sclerosis Society of Canada Studentship and the Eyes High Doctoral Scholarship from the University of Calgary. V.W.Y., P.K.S. and S.R. acknowledge salary support from the Canada Research Chair program.	Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Baruch K, 2013, BRAIN BEHAV IMMUN, V34, P11, DOI 10.1016/j.bbi.2013.04.002; Baruch K, 2013, P NATL ACAD SCI USA, V110, P2264, DOI 10.1073/pnas.1211270110; Beerman I, 2013, CELL STEM CELL, V12, P413, DOI 10.1016/j.stem.2013.01.017; Blasko I, 2004, AGING CELL, V3, P169, DOI 10.1111/j.1474-9728.2004.00101.x; Boehmer ED, 2004, J LEUKOCYTE BIOL, V75, P342, DOI 10.1189/jlb.0803389; Boehmer ED, 2005, MECH AGEING DEV, V126, P1305, DOI 10.1016/j.mad.2005.07.009; Boissonneault V, 2009, BRAIN, V132, P1078, DOI 10.1093/brain/awn331; Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chambers SM, 2007, PLOS BIOL, V5, P1750, DOI 10.1371/journal.pbio.0050201; Chang AS, 2012, ANN NEUROL, V72, P918, DOI 10.1002/ana.23693; Chelvarajan RL, 2005, J LEUKOCYTE BIOL, V77, P503, DOI 10.1189/jlb.0804449; Chen C, 2009, SCI SIGNAL, V2, pra75; Cohen M, 2014, EMBO J, V33, P2906, DOI 10.15252/embj.201489293; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conde JR, 2006, J NEUROPATH EXP NEUR, V65, P199, DOI 10.1097/01.jnen.0000202887.22082.63; Dai LY, 2001, INJURY, V32, P195, DOI 10.1016/S0020-1383(00)00176-5; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Doring A, 2015, J NEUROSCI, V35, P1136, DOI [10.1523/JNEUROSCI.1797-14.2015, 10.1523/JNEUROSCI.1797-14]; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; Ergen AV, 2012, BLOOD, V119, P2500, DOI 10.1182/blood-2011-11-391730; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Flanary BE, 2007, REJUV RES, V10, P61, DOI 10.1089/rej.2006.9096; Floden AM, 2011, J ALZHEIMERS DIS, V25, P279, DOI 10.3233/JAD-2011-101014; Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007; Frenkel D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3030; Geiger H, 2013, NAT REV IMMUNOL, V13, P376, DOI 10.1038/nri3433; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Goldschmidt T, 2009, NEUROLOGY, V72, P1914, DOI 10.1212/WNL.0b013e3181a8260a; Gon Y, 1996, CLIN EXP IMMUNOL, V106, P120; Gosselin D, 2014, CELL, V159, P1327, DOI 10.1016/j.cell.2014.11.023; Greenhalgh AD, 2014, J NEUROSCI, V34, P6316, DOI 10.1523/JNEUROSCI.4912-13.2014; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kotter MR, 2006, J NEUROSCI, V26, P328, DOI 10.1523/JNEUROSCI.2615-05.2006; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lampron A, 2013, J COMP NEUROL, V521, P3863, DOI 10.1002/cne.23363; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; Mayack SR, 2010, NATURE, V463, P495, DOI 10.1038/nature08749; Michaud JP, 2013, P NATL ACAD SCI USA, V110, P1941, DOI 10.1073/pnas.1215165110; Michell-Robinson MA, 2015, BRAIN, V138, P1138, DOI 10.1093/brain/awv066; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mishra MK, 2014, ANN CLIN TRANSL NEUR, V1, P409, DOI 10.1002/acn3.67; Natrajan MS, 2015, BRAIN, V138, P3581, DOI 10.1093/brain/awv289; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008; Oh J, 2014, NAT MED, V20, P870, DOI 10.1038/nm.3651; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Rawji KS, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/948976; Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019; Rube CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017487; Sacco RL, 1997, NEUROLOGY, V49, pS39, DOI 10.1212/WNL.49.5_Suppl_4.S39; Samanani S, 2013, CNS NEUROL DISORD-DR, V12, P741, DOI 10.2174/18715273113126660177; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sarkar S, 2014, NAT NEUROSCI, V17, P46, DOI 10.1038/nn.3597; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; Schwartz M, 2013, J NEUROSCI, V33, P17587, DOI 10.1523/JNEUROSCI.3241-13.2013; Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shemer A, 2015, TRENDS IMMUNOL, V36, P614, DOI 10.1016/j.it.2015.08.003; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Tremblay ME, 2012, GLIA, V60, P541, DOI 10.1002/glia.22287; van Duin D, 2007, J IMMUNOL, V178, P970, DOI 10.4049/jimmunol.178.2.970; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; WHITELAW DM, 1972, CELL TISSUE KINET, V5, P311, DOI 10.1111/j.1365-2184.1972.tb00369.x; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Yamanaka M, 2012, J NEUROSCI, V32, P17321, DOI 10.1523/JNEUROSCI.1569-12.2012; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Zhao C, 2006, NEUROBIOL AGING, V27, P1298, DOI 10.1016/j.neurobiolaging.2005.06.008	86	132	134	3	27	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR 1	2016	139		3				653	661		10.1093/brain/awv395			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DF9PX	WOS:000371694600012	26912633	Green Published, Bronze			2022-02-06	
J	Collins, CL; Fletcher, EN; Fields, SK; Kluchurosky, L; Rohrkemper, MK; Comstock, RD; Cantu, RC				Collins, Christy L.; Fletcher, Erica N.; Fields, Sarah K.; Kluchurosky, Lisa; Rohrkemper, Mary Kay; Comstock, R. Dawn; Cantu, Robert C.			Neck Strength: A Protective Factor Reducing Risk for Concussion in High School Sports	JOURNAL OF PRIMARY PREVENTION			English	Article						Head injury; Prevention; Athlete; Soccer; Basketball; Lacrosse	SEGMENT DYNAMIC STABILIZATION; SEX-DIFFERENCES; UNITED-STATES; HEAD ACCELERATION; INJURIES; MANAGEMENT; RECOVERY; FOOTBALL; DISEASE; HEALTH	As the number of high school students participating in athletics continues to increase, so will the number of sports-related concussions unless effective concussion prevention programs are developed. We sought to develop and validate a cost-effective tool to measure neck strength in a high school setting, conduct a feasibility study to determine if the developed tool could be reliably applied by certified athletic trainers (ATs) in a high school setting, and conduct a pilot study to determine if anthropometric measurements captured by ATs can predict concussion risk. In the study's first phase, 16 adult subjects underwent repeated neck strength testing by a group of five ATs to validate the developed hand-held tension scale, a cost effective alternative to a hand-held dynamometer. In the second phase, during the 2010 and 2011 academic years, ATs from 51 high schools in 25 states captured pre-season anthropometric measurements for 6,704 high school athletes in boys' and girls' soccer, basketball, and lacrosse, as well as reported concussion incidence and athletic exposure data. We found high correlations between neck strength measurements taken with the developed tool and a hand-held dynamometer and the measurements taken by five ATs. Smaller mean neck circumference, smaller mean neck to head circumference ratio, and weaker mean overall neck strength were significantly associated with concussion. Overall neck strength (p < 0.001), gender (p < 0.001), and sport (p = 0.007) were significant predictors of concussions in unadjusted models. After adjusting for gender and sport, overall neck strength remained a significant predictor of concussion (p = 0.004). For every one pound increase in neck strength, odds of concussion decreased by 5 % (OR = 0.95, 95 % CI 0.92-0.98). We conclude that identifying differences in overall neck strength may be useful in developing a screening tool to determine which high school athletes are at higher risk of concussion. Once identified, these athletes could be targeted for concussion prevention programs.	[Collins, Christy L.; Fletcher, Erica N.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH USA; [Fields, Sarah K.] Univ Colorado, Dept Commun, Denver, CO 80202 USA; [Kluchurosky, Lisa] Nationwide Childrens Hosp, Columbus, OH USA; [Rohrkemper, Mary Kay] Cent Ohio Primary Care, Columbus, OH USA; [Comstock, R. Dawn] Colorado Sch Publ Hlth, Dept Epidemiol, Pediat Injury Prevent Educ & Res PIPER Program, Aurora, CO 80045 USA; [Comstock, R. Dawn] Univ Colorado, Sch Med, Aurora, CO USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurol, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Cantu, Robert C.] Sports Legacy Inst, Waltham, MA USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Surg, Concord, MA USA; [Cantu, Robert C.] Brigham & Womens Hosp, Dept Neurosurg, Neurol Sports Injury Ctr, Boston, MA 02115 USA		Comstock, RD (corresponding author), Colorado Sch Publ Hlth, Dept Epidemiol, Pediat Injury Prevent Educ & Res PIPER Program, Aurora, CO 80045 USA.	dawn.comstock@ucdenver.edu					Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Conley MS, 1997, J APPL PHYSIOL, V83, P2105, DOI 10.1152/jappl.1997.83.6.2105; Cross KM, 2003, CLIN SPORT MED, V22, P639, DOI 10.1016/S0278-5919(02)00099-6; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dietz WH, 1998, PEDIATRICS, V101, P518; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Mansell J, 2005, J ATHL TRAINING, V40, P310; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; National Federation of State High School Associations, 2012, 2011 2012 HIGH SCH A; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Patel Dilip R, 2002, Adolesc Med, V13, P569; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Prasad D S, 2009, Indian J Med Sci, V63, P33; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Salmon DM, 2011, AVIAT SPACE ENVIR MD, V82, P978, DOI 10.3357/ASEM.2841.2011; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0	27	132	131	4	79	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0278-095X	1573-6547		J PRIM PREV	J. Prim. Prev.	OCT	2014	35	5					309	319		10.1007/s10935-014-0355-2			11	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	AO8UX	WOS:000341631600002	24930131		Y	N	2022-02-06	
J	de Riva, N; Budohoski, KP; Smielewski, P; Kasprowicz, M; Zweifel, C; Steiner, LA; Reinhard, M; Fabregas, N; Pickard, JD; Czosnyka, M				de Riva, Nicolas; Budohoski, Karol P.; Smielewski, Peter; Kasprowicz, Magdalena; Zweifel, Christian; Steiner, Luzius A.; Reinhard, Matthias; Fabregas, Neus; Pickard, John D.; Czosnyka, Marek			Transcranial Doppler Pulsatility Index: What it is and What it Isn't	NEUROCRITICAL CARE			English	Article						Cerebral hemodynamics; Plateau waves; Transcranial doppler; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; INTRACRANIAL-PRESSURE; CEREBROVASCULAR RESISTANCE; PLATEAU WAVES; VELOCITY	Transcranial Doppler (TCD) pulsatility index (PI) has traditionally been interpreted as a descriptor of distal cerebrovascular resistance (CVR). We sought to evaluate the relationship between PI and CVR in situations, where CVR increases (mild hypocapnia) and decreases (plateau waves of intracranial pressure-ICP). Recordings from patients with head-injury undergoing monitoring of arterial blood pressure (ABP), ICP, cerebral perfusion pressure (CPP), and TCD assessed cerebral blood flow velocities (FV) were analyzed. The Gosling pulsatility index (PI) was compared between baseline and ICP plateau waves (n = 20 patients) or short term (30-60 min) hypocapnia (n = 31). In addition, a modeling study was conducted with the "spectral" PI (calculated using fundamental harmonic of FV) resulting in a theoretical formula expressing the dependence of PI on balance of cerebrovascular impedances. PI increased significantly (p < 0.001) while CVR decreased (p < 0.001) during plateau waves. During hypocapnia PI and CVR increased (p < 0.001). The modeling formula explained more than 65% of the variability of Gosling PI and 90% of the variability of the "spectral" PI (R = 0.81 and R = 0.95, respectively). TCD pulsatility index can be easily and quickly assessed but is usually misinterpreted as a descriptor of CVR. The mathematical model presents a complex relationship between PI and multiple haemodynamic variables.	[de Riva, Nicolas; Budohoski, Karol P.; Smielewski, Peter; Kasprowicz, Magdalena; Zweifel, Christian; Steiner, Luzius A.; Reinhard, Matthias; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [de Riva, Nicolas; Fabregas, Neus] Univ Barcelona, Dept Anesthesiol, Hosp Clin, Barcelona, Spain; [Kasprowicz, Magdalena] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, PL-50370 Wroclaw, Poland; [Zweifel, Christian] Univ Basel Hosp, Dept Neurosurg, CH-4031 Basel, Switzerland; [Steiner, Luzius A.] Univ Lausanne Hosp, Dept Anaesthesia, Lausanne, Switzerland; [Reinhard, Matthias] Univ Freiburg, Dept Neurol, Freiburg, Germany; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland		Czosnyka, M (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Hills Rd,Box 167, Cambridge CB2 0QQ, England.	mc141@medschl.cam.ac.uk	de Riva, Nicolas/AAN-3347-2020; Steiner, Luzius/J-1987-2019	de Riva, Nicolas/0000-0003-2691-5770; Kasprowicz, Magdalena/0000-0002-2271-7737; Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; NIHRNational Institute for Health Research (NIHR); Hospital Clinic, Barcelona, Spain; Swiss National Science Foundation, Bern, SwitzerlandSwiss National Science Foundation (SNSF) [PBBSP3-125550]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This study was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), the Medical Research Council (Grants G0600986 and G9439390), and NIHR Senior Investigator Awards (JDP); the Hospital Clinic Grant, Barcelona, Spain (NR) and also by the Swiss National Science Foundation (PBBSP3-125550 to CZ), Bern, Switzerland.	Alperin N, 2005, J NEUROSURG, V103, P46, DOI 10.3171/jns.2005.103.1.0046; Baledent O, 2006, J MAGN RESON IMAGING, V24, P995, DOI 10.1002/jmri.20722; Behrens A, 2010, NEUROSURGERY, V66, P1050, DOI 10.1227/01.NEU.0000369519.35932.F2; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Carrera E, 2011, J NEUROTRAUM, V28, P889, DOI 10.1089/neu.2010.1377; Czosnyka M, 1996, J NEUROSURG, V84, P79, DOI 10.3171/jns.1996.84.1.0079; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 2012, NEUROL RES, V34, P17, DOI 10.1179/1743132811Y.0000000040; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; GILLER CA, 1990, J NEUROSURG, V72, P901, DOI 10.3171/jns.1990.72.6.0901; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hsu HY, 2004, ULTRASOUND MED BIOL, V30, P1329, DOI 10.1016/j.ultrasmedbio.2004.08.006; Kim DJ, 2009, PHYSIOL MEAS, V30, P647, DOI 10.1088/0967-3334/30/7/009; KONTOS HA, 1989, STROKE, V20, P1; Lim MH, 2009, STROKE, V40, P3216, DOI 10.1161/STROKEAHA.109.558403; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Michel E, 1998, ULTRASOUND MED BIOL, V24, P597, DOI 10.1016/S0301-5629(98)00024-6; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Soehle M, 2007, ACTA NEUROCHIR, V149, P575, DOI 10.1007/s00701-007-1149-6; Steiner LA, 2004, INTENS CARE MED, V30, P2180, DOI 10.1007/s00134-004-2463-6; The Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons. 2007; Joint Section on Neurotrauma and Critical Care; AANS/CNS, 2007, J NEUROTRAUMA S1, V24, pS87; Melo JRT, 2011, CHILD NERV SYST, V27, P979, DOI 10.1007/s00381-010-1367-8	25	132	132	1	24	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	AUG	2012	17	1					58	66		10.1007/s12028-012-9672-6			9	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	976NG	WOS:000306591000008	22311229				2022-02-06	
J	Morandi, A; Rogers, BP; Gunther, ML; Merkle, K; Pandharipande, P; Girard, TD; Jackson, JC; Thompson, J; Shintani, AK; Geevarghese, S; Miller, RR; Canonico, A; Cannistraci, CJ; Gore, JC; Ely, EW; Hopkins, RO				Morandi, Alessandro; Rogers, Baxter P.; Gunther, Max L.; Merkle, Kristen; Pandharipande, Pratik; Girard, Timothy D.; Jackson, James C.; Thompson, Jennifer; Shintani, Ayumi K.; Geevarghese, Sunil; Miller, Russell R., III; Canonico, Angelo; Cannistraci, Christopher J.; Gore, John C.; Ely, E. Wesley; Hopkins, Ramona O.		VISIONS Invest VISualizing Icu	The relationship between delirium duration, white matter integrity, and cognitive impairment in intensive care unit survivors as determined by diffusion tensor imaging: The VISIONS prospective cohort magnetic resonance imaging study	CRITICAL CARE MEDICINE			English	Article						critical care; delirium; diffusion tensor imaging; geriatrics; magnetic resonance imaging; neuroimaging; white matter integrity	TRAUMATIC BRAIN-INJURY; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; AGITATION-SEDATION SCALE; CRITICAL ILLNESS; AXONAL INJURY; SERIAL CHANGES; VALIDITY; RELIABILITY; LESIONS	Objective: Evidence is emerging that delirium duration is a predictor of long-term cognitive impairment in intensive care unit survivors. Relationships between 1) delirium duration and brain white matter integrity, and 2) white matter integrity and long-term cognitive impairment are poorly understood and could be explored using magnetic resonance imaging. Design, Setting, Patients: A two-center, prospective cohort study incorporating delirium monitoring, neuroimaging, and cognitive testing in intensive care unit survivors. Measurements: Delirium was evaluated with the Confusion Assessment Method for the Intensive Care Unit and cognitive outcomes were tested at 3 and 12-month follow-up. Following the intensive care unit stay, fractional anisotropy, a measure of white matter integrity, was calculated quantitatively using diffusion tensor imaging with a 3-T magnetic resonance imaging scanner at hospital discharge and 3-month follow-up. We examined associations between 1) delirium duration and fractional anisotropy and 2) fractional anisotropy and cognitive outcomes using linear regression adjusted for age and sepsis. Results: A total of 47 patients with a median age of 50 yrs completed the diffusion tensor imaging-magnetic resonance imaging protocol. Greater duration of delirium (3 vs. 0 days) was associated with lower fractional anisotropy (i.e., reduced fractional anisotropy = white matter disruption) in the genu (-0.02; p =. 04) and splenium (-0.01; p = .02) of the corpus callosum and anterior limb of the internal capsule (-0.02; p = .01) at hospital discharge. These associations persisted at 3 months for the genu (-0.02; p = .02) and splenium (-0.01; p =.004). Lower fractional anisotropy in the anterior limb of internal capsule at discharge and in genu of corpus callosum at three months was associated with worse cognitive scores at 3 and 12 months. Conclusions: In this pilot investigation, delirium duration in the intensive care unit was associated with white matter disruption at both discharge and 3 months. Similarly, white matter disruption was associated with worse cognitive scores up to 12 months later. This hypothesis-generating investigation may help design future studies to explore these complex relationships in greater depth. (Crit Care Med 2012;40:2182-2189)	[Morandi, Alessandro; Girard, Timothy D.; Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Ctr Qual Aging, Nashville, TN 37232 USA; [Morandi, Alessandro; Girard, Timothy D.; Jackson, James C.; Ely, E. Wesley] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Dept Med, Nashville, TN 37232 USA; [Morandi, Alessandro; Girard, Timothy D.; Ely, E. Wesley] Vanderbilt Univ, Sch Med, Div Allergy, Nashville, TN 37232 USA; [Rogers, Baxter P.; Gunther, Max L.; Jackson, James C.; Gore, John C.] Vanderbilt Univ, Med Ctr, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA; [Rogers, Baxter P.; Gunther, Max L.; Merkle, Kristen; Cannistraci, Christopher J.; Gore, John C.] Vanderbilt Univ, Inst Imaging Sci, Nashville, TN 37232 USA; [Rogers, Baxter P.; Gore, John C.] Vanderbilt Univ, Med Ctr, Dept Biomed Engn, Nashville, TN 37232 USA; [Gunther, Max L.; Jackson, James C.] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN 37232 USA; [Pandharipande, Pratik] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, Anesthesia Serv, Nashville, TN USA; [Pandharipande, Pratik] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Div Crit Care, Nashville, TN 37232 USA; [Girard, Timothy D.; Jackson, James C.; Ely, E. Wesley] Tennessee Valley Healthcare Syst, Educ & Clin Ctr Serv, Dept Vet Affairs Med Ctr, Nashville, TN USA; [Thompson, Jennifer; Shintani, Ayumi K.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Geevarghese, Sunil] Vanderbilt Univ, Sch Med, Div Hepatobiliary Surg & Liver Transplantat, Nashville, TN 37232 USA; [Miller, Russell R., III; Hopkins, Ramona O.] Intermt Med Ctr, Pulm & Crit Care Div, Dept Med, Murray, UT USA; [Canonico, Angelo] St Thomas Hosp, Dept Med, Nashville, TN USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA		Morandi, A (corresponding author), Vanderbilt Univ, Med Ctr E 6109, 221 Kirkland Hall, Nashville, TN 37232 USA.	morandi.alessandro@gmail.com	Girard, Timothy/I-3008-2019; Ely, E. Wesley/Z-2018-2019	Girard, Timothy/0000-0002-9833-4871; Ely, E. Wesley/0000-0003-3957-2172; Pandharipande, Pratik/0000-0002-1389-8580; Rogers, Baxter/0000-0002-5666-2797	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG027472, AG034257, RR024975, EB001628]; Saint Thomas Foundation (Nashville, TN); Veterans Affairs Tennessee Valley Geriatric Research, Education, and Clinical Center; Eli LillyEli Lilly; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024977, UL1RR024975, TL1RR024978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB001628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG031322, K23AG034257, R01AG027472] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health (AG027472, AG034257, RR024975, EB001628), Saint Thomas Foundation (Nashville, TN) and Veterans Affairs Tennessee Valley Geriatric Research, Education, and Clinical Center.; Drs. Girard and Pandiharipande received honoraria from Hospira, Inc. Dr. Geevarghese consulted for Onyx-Bayer and received honararia from Bayer Healthcare/Onyx Pharmaceuticals. Dr. Ely consulted for Cumberland, Masimo, received honoraria from Hospira, and received grant support from Eli Lilly. The remaining authors have not disclosed any potential conflicts of interest.	Andrew Melissa K, 2005, BMC Geriatr, V5, P5, DOI 10.1186/1471-2318-5-5; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; Bigler ED, 2003, NEUROPSYCHOLOGY, V17, P339, DOI 10.1037/0894-4105.17.3.339; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ehlenbach WJ, 2010, JAMA-J AM MED ASSOC, V303, P763, DOI 10.1001/jama.2010.167; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fong TG, 2006, J GERONTOL A-BIOL, V61, P1294, DOI 10.1093/gerona/61.12.1294; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GIRARD TD, 2006, P AM THORAC SOC, V3, pA501; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Gunther ML, 2008, CRIT CARE CLIN, V24, P45, DOI 10.1016/j.ccc.2007.10.002; Gunther ML, 2007, CRIT CARE CLIN, V23, P491, DOI 10.1016/j.ccc.2007.07.001; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI 10.2307/1390807; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Jackson JC, 2010, AM J RESP CRIT CARE, V182, P183, DOI 10.1164/rccm.200903-0442OC; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jones C, 2006, INTENS CARE MED, V32, P923, DOI 10.1007/s00134-006-0112-y; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; Little DM, 2010, NEUROREHABILITATION, V26, P15, DOI 10.3233/NRE-2010-0532; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; MacLullich AMJ, 2008, J PSYCHOSOM RES, V65, P229, DOI 10.1016/j.jpsychores.2008.05.019; Maldonado JR, 2008, CRIT CARE CLIN, V24, P789, DOI 10.1016/j.ccc.2008.06.004; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; McAvay GJ, 2007, J AM GERIATR SOC, V55, P684, DOI 10.1111/j.1532-5415.2007.01150.x; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Morandi Alessandro, 2010, Psychiatry (Edgmont), V7, P28; Mori S, 2005, MRI ATLAS HUMAN WHIT; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Salam A, 2004, INTENS CARE MED, V30, P1334, DOI 10.1007/s00134-004-2231-7; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y; Shehabi Y, 2010, CRIT CARE MED, V38, P2311, DOI 10.1097/CCM.0b013e3181f85759; Shioiri A, 2010, AM J GERIAT PSYCHIAT, V18, P743, DOI 10.1097/JGP.0b013e3181d145c5; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Suchyta MR, 2010, BRAIN IMAGING BEHAV, V4, P22, DOI 10.1007/s11682-009-9082-3; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Suskauer SJ, 2009, J PEDIATR REHAB MED, V2, P249, DOI 10.3233/PRM-2009-0099; TRZEPACZ PT, 1994, PSYCHOSOMATICS, V35, P374, DOI 10.1016/S0033-3182(94)71759-X; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yokota H, 2003, PSYCHIAT CLIN NEUROS, V57, P337, DOI 10.1046/j.1440-1819.2003.01126.x	67	132	138	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2012	40	7					2182	2189		10.1097/CCM.0b013e318250acdc			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	965KX	WOS:000305767800023	22584766	Green Accepted			2022-02-06	
J	Grishchuk, Y; Ginet, V; Truttmann, AC; Clarke, PGH; Puyal, J				Grishchuk, Yulia; Ginet, Vanessa; Truttmann, Anita C.; Clarke, Peter G. H.; Puyal, Julien			Beclin 1-independent autophagy contributes to apoptosis in cortical neurons	AUTOPHAGY			English	Article						autophagy; apoptosis; neurons; cell death; lysosomes; caspases	CELL-DEATH; UP-REGULATION; CEREBRAL-ISCHEMIA; INHIBITION; MECHANISM; TARGET; GROWTH; MACROAUTOPHAGY; STAUROSPORINE; ENDOCYTOSIS	Neuronal autophagy is enhanced in many neurological conditions, such as cerebral ischemia and traumatic brain injury, but its role in associated neuronal death is controversial, especially under conditions of apoptosis. We therefore investigated the role of autophagy in the apoptosis of primary cortical neurons treated with the widely used and potent pro-apoptotic agent, staurosporine (STS). Even before apoptosis, STS enhanced autophagic flux, as shown by increases in autophagosomal (LC3-II level, LC3 punctate labeling) and lysosomal (cathepsin D, LAMP1, acid phosphatase, beta-hexasominidase) markers. Inhibition of autophagy by 3-methyladenine, or by lentivirally-delivered shRNAs against Atg5 and Atg7, strongly reduced the STS-induced activation of caspase-3 and nuclear translocation of AIF, and gave partial protection against neuronal death. Pan-caspase inhibition with Q-VD-OPH likewise protected partially against neuronal death, but failed to affect autophagy. Combined inhibition of both autophagy and caspases gave strong synergistic neuroprotection. The autophagy contributing to apoptosis was Beclin 1-independent, as shown by the fact that Beclin 1 knockdown failed to reduce it but efficiently reduced rapamycin-induced autophagy. Moreover the Beclin 1 knockdown sensitized neurons to STS-induced apoptosis, indicating a cytoprotective role of Beclin 1 in cortical neurons. Caspase-3 activation and pyknosis induced by two other pro-apoptotic stimuli, MK801 and etoposide, were likewise found to be associated with Beclin 1-independent autophagy and reduced by the knockdown of Atg7 but not Beclin 1. In conclusion, Beclin 1-independent autophagy is an important contributor to both the caspase-dependent and -independent components of neuronal apoptosis and may be considered as an important therapeutic target in neural conditions involving apoptosis.	[Grishchuk, Yulia; Ginet, Vanessa; Clarke, Peter G. H.; Puyal, Julien] Univ Lausanne, Dept Biol Cellulaire & Morphol, Lausanne, Switzerland; [Ginet, Vanessa; Truttmann, Anita C.] Ctr Hosp Univ Vaudois Lausanne, Div Neonatol, Dept Med Chirurg Pediat, Lausanne, Switzerland		Puyal, J (corresponding author), Univ Lausanne, Dept Biol Cellulaire & Morphol, Lausanne, Switzerland.	JulienPierre.Puyal@unil.ch	Puyal, Julien P/G-4210-2018	Puyal, Julien P/0000-0002-8140-7026	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [3100A0-113925, 310030-130769]; Fondation Motrice; Societe Academique Vaudoise; Fondation Marie-Therese et Rene Planiol; Fondation Emma Muschamp	We thank Coralie Rummel, Florine Fonknechten and Vincent Mottier for technical assistance and Jean-Yves Chatton and Yannick Krempp of the Cellular Imaging Facility (University of Lausanne) for experimental support. This research was supported by grants from the Swiss National Science Foundation (3100A0-113925 and 310030-130769), from the Fondation Motrice, from the Societe Academique Vaudoise, from the Fondation Marie-Therese et Rene Planiol and from the Fondation Emma Muschamp.	Adamec E, 2000, NEUROSCIENCE, V100, P663, DOI 10.1016/S0306-4522(00)00281-5; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Beart PM, 2007, J NEUROCHEM, V103, P2408, DOI 10.1111/j.1471-4159.2007.04937.x; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250; Bialik S, 2008, ADV EXP MED BIOL, V615, P177, DOI 10.1007/978-1-4020-6554-5_9; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Chu CT, 2007, AUTOPHAGY, V3, P663, DOI 10.4161/auto.4625; Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Deglon N, 2000, HUM GENE THER, V11, P179, DOI 10.1089/10430340050016256; Denton D, 2009, CURR BIOL, V19, P1741, DOI 10.1016/j.cub.2009.08.042; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Espert L, 2008, AUTOPHAGY, V4, P273, DOI 10.4161/auto.5211; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Finan PM, 2004, BIOCHEM SOC T, V32, P378, DOI 10.1042/BST0320378; Ginet V, 2009, AM J PATHOL, V175, P1962, DOI 10.2353/ajpath.2009.090463; Guillon-Munos A, 2005, APOPTOSIS, V10, P1031, DOI 10.1007/s10495-005-0741-6; Hwang JY, 1999, EXP NEUROL, V159, P124, DOI 10.1006/exnr.1999.7126; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; Jantas D, 2009, APOPTOSIS, V14, P900, DOI 10.1007/s10495-009-0370-6; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Maycotte P, 2010, J NEUROSCI RES, V88, P73, DOI 10.1002/jnr.22168; McCoy F, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.86; NAKAJIMA M, 1994, BRAIN RES, V641, P350, DOI 10.1016/0006-8993(94)90165-1; Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014; Perrin V, 2007, MOL THER, V15, P903, DOI 10.1038/mt.sj.6300141; PUYAL J, 2011, NEUROSCIENTIST; Puyal J, 2009, AUTOPHAGY, V5, P1060, DOI 10.4161/auto.5.7.9728; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; Scarlatti F, 2008, AUTOPHAGY, V4, P1083, DOI 10.4161/auto.7068; Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053; Seo G, 2011, FREE RADICAL RES, V45, P389, DOI 10.3109/10715762.2010.535530; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Takacs-Vellai K, 2005, CURR BIOL, V15, P1513, DOI 10.1016/j.cub.2005.07.035; Takadera T, 1999, J NEUROCHEM, V73, P548, DOI 10.1046/j.1471-4159.1999.0730548.x; Takahashi Y, 2009, CELL DEATH DIFFER, V16, P947, DOI 10.1038/cdd.2009.19; Tian SH, 2010, AUTOPHAGY, V6, P1032, DOI 10.4161/auto.6.8.13336; Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233; Valentim L, 2006, J MOL CELL CARDIOL, V40, P846, DOI 10.1016/j.yjmcc.2006.03.428; Vaslin A, 2007, J NEUROCHEM, V102, P789, DOI 10.1111/j.1471-4159.2007.04564.x; Vaslin A, 2009, ANN NEUROL, V65, P337, DOI 10.1002/ana.21584; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Wilson CA, 2004, J CELL BIOL, V165, P335, DOI 10.1083/jcb.200403061; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937; Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524; Zucker B, 2005, HUM MOL GENET, V14, P179, DOI 10.1093/hmg/ddi014	66	132	137	0	18	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1554-8627	1554-8635		AUTOPHAGY	Autophagy	OCT	2011	7	10					1115	1131		10.4161/auto.7.10.16608			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	827CZ	WOS:000295405700004	21646862	Bronze, Green Submitted			2022-02-06	
J	Monif, M; Burnstock, G; Williams, DA				Monif, Mastura; Burnstock, Geoffrey; Williams, David A.			Microglia: Proliferation and activation driven by the P2X7 receptor	INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY			English	Article						Microglia; P2X7 receptor; Activation; Proliferation; Neuroinflammation	PURINERGIC P2X(7) RECEPTOR; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; SPINAL MICROGLIA; BRAIN MICROGLIA; UP-REGULATION; NERVE INJURY; CELLS; ATP; MACROPHAGES	microglial activation is associated with the pathogenesis and progression of conditions such as Alzheimer's disease (AD), Parkinsons' disease, prion disease, multiple sclerosis, and ischemic and traumatic brain injury. The molecular mechanism of microglial activation is largely unknown. The expression of the purinergic, P2X7 receptor (P2X7R), is known to be enhanced in many brain pathologies where presence of activated microglia is a concurrent feature. This review focuses on the links between P2X7R expression and microglial activation and proliferation. The P2X7R is identified as a key player in the process of microgliosis, where by driving microglial activation, it can potentially lead to a deleterious cycle of neuroinflammation and neurodegeneration. (C) 2010 Elsevier Ltd. All rights reserved.	[Monif, Mastura; Williams, David A.] Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia; [Burnstock, Geoffrey] Royal Free & Univ Coll Med Sch, Sch Med, Auton Neurosci Ctr, London, England		Williams, DA (corresponding author), Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia.	davidaw@unimelb.edu.au	Monif, Mastura/L-4124-2019	Monif, Mastura/0000-0001-6404-9768			Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; Bianco F, 2006, J NEUROCHEM, V99, P745, DOI 10.1111/j.1471-4159.2006.04101.x; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Bringmann A, 2001, INVEST OPHTH VIS SCI, V42, P860; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Choi HB, 2007, J NEUROSCI, V27, P4957, DOI 10.1523/JNEUROSCI.5417-06.2007; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Di Virgilio F, 1998, BIOFACTORS, V8, P301; Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275; DOWDING AJ, 1991, GLIA, V4, P345, DOI 10.1002/glia.440040403; Elkabes S, 1996, J NEUROSCI, V16, P2508; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; HICKMAN SE, 1994, BLOOD, V84, P2452; Kaur C, 2001, MICROSC RES TECHNIQ, V54, P2, DOI 10.1002/jemt.1114; Kim YS, 2006, EXP MOL MED, V38, P333, DOI 10.1038/emm.2006.40; Kohl A, 2003, EXP NEUROL, V181, P1, DOI 10.1016/S0014-4886(02)00049-3; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Le Stunff H, 2007, CELL SIGNAL, V19, P1909, DOI 10.1016/j.cellsig.2007.04.015; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; McLarnon JG, 2006, J NEUROPATH EXP NEUR, V65, P1090, DOI 10.1097/01.jnen.0000240470.97295.d3; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; SHIMOJO M, 1991, NEUROSCI LETT, V123, P229, DOI 10.1016/0304-3940(91)90937-O; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Tan J, 1999, J NEUROIMMUNOL, V97, P77, DOI 10.1016/S0165-5728(99)00053-3; THEELE DP, 1993, GLIA, V7, P5, DOI 10.1002/glia.440070104; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Vianna EPM, 2002, EPILEPSIA, V43, P227, DOI 10.1046/j.1528-1157.43.s.5.26.x; WILLIAMS JRK, 1993, J NEUROSCI RES, V36, P382; Xiang ZH, 2006, J NEUROSCI RES, V83, P91, DOI 10.1002/jnr.20709; Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12	39	132	137	1	25	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1357-2725	1878-5875		INT J BIOCHEM CELL B	Int. J. Biochem. Cell Biol.	NOV	2010	42	11					1753	1756		10.1016/j.biocel.2010.06.021			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	673YA	WOS:000283698900001	20599520				2022-02-06	
J	Zhou, C; Eucker, SA; Durduran, T; Yu, GQ; Ralston, J; Friess, SH; Ichord, RN; Margulies, SS; Yodh, AG				Zhou, Chao; Eucker, Stephanie A.; Durduran, Turgut; Yu, Guoqiang; Ralston, Jill; Friess, Stuart H.; Ichord, Rebecca N.; Margulies, Susan S.; Yodh, Arjun G.			Diffuse optical monitoring of hemodynamic changes in piglet brain with closed head injury	JOURNAL OF BIOMEDICAL OPTICS			English	Article						diffuse correlation spectroscopy (DCS); diffuse reflectance spectroscopy (DRS); cerebral hemodynamics; cerebral blood flow; traumatic brain injury; near-infrared spectroscopy (NIRS)	CEREBRAL-BLOOD-FLOW; NEAR-INFRARED SPECTROSCOPY; WAVE SPECTROSCOPY; FREQUENCY-DOMAIN; NEWBORN-INFANTS; NEONATAL PIG; OXYGEN; TISSUE; RAT; CIRCULATION	We used a nonimpact inertial rotational model of a closed head injury in neonatal piglets to simulate the conditions following traumatic brain injury in infants. Diffuse optical techniques, including diffuse reflectance spectroscopy and diffuse correlation spectroscopy (DCS), were used to measure cerebral blood oxygenation and blood flow continuously and noninvasively before injury and up to 6 h after the injury. The DCS measurements of relative cerebral blood flow were validated against the fluorescent microsphere method. A strong linear correlation was observed between the two techniques (R=0.89, p<0.00001). Injury-induced cerebral hemodynamic changes were quantified, and significant changes were found in oxy- and deoxy-hemoglobin concentrations, total hemoglobin concentration, blood oxygen saturation, and cerebral blood flow after the injury. The diffuse optical measurements were robust and also correlated well with recordings of vital physiological parameters over the 6-h monitoring period, such as mean arterial blood pressure, arterial oxygen saturation, and heart rate. Finally, the diffuse optical techniques demonstrated sensitivity to dynamic physiological events, such as apnea, cardiac arrest, and hypertonic saline infusion. In total, the investigation corraborates potential of the optical methods for bedside monitoring of pediatric and adult human patients in the neurointensive care unit. (C) 2009 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3146814]	[Zhou, Chao; Durduran, Turgut; Yu, Guoqiang; Yodh, Arjun G.] Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; [Eucker, Stephanie A.; Ralston, Jill; Friess, Stuart H.; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Durduran, Turgut] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Durduran, Turgut] ICFO Inst Ciencies Foton, Barcelona 08860, Spain; [Yu, Guoqiang] Univ Kentucky, Ctr Biomed Engn, Wenner Gren Res Lab, Lexington, KY 40506 USA; [Ichord, Rebecca N.] Univ Penn, Sch Med, Div Neurol, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA		Yodh, AG (corresponding author), Univ Penn, Dept Phys & Astron, 209 S 33rd St, Philadelphia, PA 19104 USA.	yodh@physics.upenn.edu	Eucker, Stephanie/AAL-1828-2021; Durduran, Turgut/N-7768-2015; Zhou, Chao/A-1327-2007	Eucker, Stephanie/0000-0001-9986-5773; Durduran, Turgut/0000-0001-5838-1027; Zhou, Chao/0000-0002-8679-3413	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1-HL-077699, RO1-NS-39679, ED-26979]; Thrasher research Fund New Researcher Awar [NR-0016]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL077699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB002109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060653, R01NS039679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [Z01NR000016] Funding Source: NIH RePORTER	This work was supported by the NIH grants No. RO1-HL-077699 (A. G. Y.), No. RO1-NS-39679 (S. S. M.), and No. ED-26979 (T. D.) and Thrasher research Fund New Researcher Award NR-0016 (T. D.). The authors thank Regine Choe, Erin Buckley, and Janos Luckl for their assistance in this study, and Joel H. Greenberg for useful discussions.	ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BOAS DA, 1995, PHYS REV LETT, V75, P1855, DOI 10.1103/PhysRevLett.75.1855; Boas DA, 1997, J OPT SOC AM A, V14, P192, DOI 10.1364/JOSAA.14.000192; BONNER R, 1981, APPL OPTICS, V20, P2097, DOI 10.1364/AO.20.002097; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brown DW, 2003, PEDIATR RES, V54, P861, DOI 10.1203/01.PDR.0000090928.93045.BE; Cheung C, 2001, PHYS MED BIOL, V46, P2053, DOI 10.1088/0031-9155/46/8/302; COPE M, 1988, MED BIOL ENG COMPUT, V26, P289, DOI 10.1007/BF02447083; Culver JP, 2003, J CEREBR BLOOD F MET, V23, P911, DOI 10.1097/01.WCB.0000076703.71231.BB; De Visscher G, 2003, J NEUROSCI METH, V122, P149, DOI 10.1016/S0165-0270(02)00316-3; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Dietsche G, 2007, APPL OPTICS, V46, P8506, DOI 10.1364/AO.46.008506; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Durduran T, 2005, OPT LETT, V30, P2915, DOI 10.1364/OL.30.002915; Durduran T, 2004, OPT LETT, V29, P1766, DOI 10.1364/OL.29.001766; DURDURAN T, 2007, INT STROKE C P, V37; Durduran T., 2004, THESIS U PENNSYLVANI; DURDURAN T, 2008, ANN M AM NEUR ASS; Durduran T, 2009, OPT EXPRESS, V17, P3884, DOI 10.1364/OE.17.003884; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; EDWARDS AD, 1988, LANCET, V2, P770; Fantini S, 1999, PHYS MED BIOL, V44, P1543, DOI 10.1088/0031-9155/44/6/308; Fisher M D, 1997, Crit Care Nurs Q, V20, P36; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Gibson AP, 2005, PHYS MED BIOL, V50, pR1, DOI 10.1088/0031-9155/50/4/R01; Hoge RD, 1999, MAGNET RESON MED, V42, P849, DOI 10.1002/(SICI)1522-2594(199911)42:5<849::AID-MRM4>3.0.CO;2-Z; Hueber DM, 2001, PHYS MED BIOL, V46, P41, DOI 10.1088/0031-9155/46/1/304; Hyder F, 1998, J APPL PHYSIOL, V85, P554, DOI 10.1152/jappl.1998.85.2.554; Ijichi S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1899184; Isobe K, 2000, J BIOMED OPT, V5, P283, DOI 10.1117/1.429997; Jaillon F, 2007, OPT EXPRESS, V15, P6643, DOI 10.1364/OE.15.006643; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Kernick DP, 1999, PFLUG ARCH EUR J PHY, V437, P624, DOI 10.1007/s004240050826; Li J, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2007987; Mandeville JB, 1999, MAGN RESON MED, V42, P944, DOI 10.1002/(SICI)1522-2594(199911)42:5<944::AID-MRM15>3.0.CO;2-W; MARET G, 1987, Z PHYS B CON MAT, V65, P409, DOI 10.1007/BF01303762; Nomura F, 1996, PEDIATR RES, V40, P790, DOI 10.1203/00006450-199612000-00003; NUNN JF, 1993, APPL RESP PHYSL; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PINE DJ, 1988, PHYS REV LETT, V60, P1134, DOI 10.1103/PhysRevLett.60.1134; Polito Angelo, 2006, Cardiovasc Ultrasound, V4, P47, DOI 10.1186/1476-7120-4-47; Powers KM, 1999, J NEUROSCI METH, V87, P159, DOI 10.1016/S0165-0270(98)00180-0; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; Villringer A, 1997, TRENDS NEUROSCI, V20, P435, DOI 10.1016/S0166-2236(97)01132-6; Yu GQ, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1884603; Yu GQ, 2005, CLIN CANCER RES, V11, P3543, DOI 10.1158/1078-0432.CCR-04-2582; Yu GQ, 2007, OPT EXPRESS, V15, P1064, DOI 10.1364/OE.15.001064; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zhang G, 2000, PHYS MED BIOL, V45, P3143, DOI 10.1088/0031-9155/45/11/303; Zhou C, 2006, OPT EXPRESS, V14, P1125, DOI 10.1364/OE.14.001125; Zhou C, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2798595	53	132	132	1	20	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668	1560-2281		J BIOMED OPT	J. Biomed. Opt.	MAY-JUN	2009	14	3							034015	10.1117/1.3146814			11	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	477RN	WOS:000268536300024	19566308	Green Accepted, Green Published			2022-02-06	
J	Ichai, C; Armando, G; Orban, JC; Berthier, F; Rami, L; Samat-Long, C; Grimaud, D; Leverve, X				Ichai, Carole; Armando, Guy; Orban, Jean-Christophe; Berthier, Frederic; Rami, Laurent; Samat-Long, Corine; Grimaud, Dominique; Leverve, Xavier			Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients	INTENSIVE CARE MEDICINE			English	Article						TBI; Osmotherapy; Cerebral edema; Plasma ions; Neurological outcome; Disability	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; HYPERTONIC SALINE; CONTROLLED-TRIAL; 20-PERCENT MANNITOL; COGNITIVE DEFICITS; ENERGY SUBSTRATE; PRESSURE; MANAGEMENT; GLUCOSE	Traumatic brain injury (TBI) is still a major cause of mortality and morbidity. Recent trials have failed to demonstrate a beneficial outcome from therapeutic treatments such as corticosteroids, hypothermia and hypertonic saline. We investigated the effect of a new hyperosmolar solution based on sodium lactate in controlling raised intracranial pressure (ICP). Prospective open randomized study in an adult ICU. Thirty-four patients with isolated severe TBI (Glasgow Coma Scale a parts per thousand currency sign 8) and intracranial hypertension were allocated to receive equally hyperosmolar and isovolumic therapy, consisting of either mannitol or sodium lactate. Rescue therapy by crossover to the alternative treatment was indicated when ICP could not be controlled. The primary endpoint was efficacy in lowering ICP after 4 h, with a secondary endpoint of the percentage of successfully treated episodes of intracranial hypertension. The analysis was performed with both intention-to-treat and actual treatments provided. Compared to mannitol, the effect of the lactate solution on ICP was significantly more pronounced (7 vs. 4 mmHg, P = 0.016), more prolonged (fourth-hour-ICP decrease: -5.9 +/- A 1 vs. -3.2 +/- A 0.9 mmHg, P = 0.009) and more frequently successful (90.4 vs. 70.4%, P = 0.053). Acute infusion of a sodium lactate-based hyperosmolar solution is effective in treating intracranial hypertension following traumatic brain injury. This effect is significantly more pronounced than that of an equivalent osmotic load of mannitol. Additionally, in this specific group of patients, long-term outcome was better in terms of GOS in those receiving as compared to mannitol. Larger trials are warranted to confirm our findings.	[Ichai, Carole; Armando, Guy; Orban, Jean-Christophe; Rami, Laurent; Samat-Long, Corine; Grimaud, Dominique] St Roch Hosp, Fac Med, Serv Reanimat, F-06006 Nice 1, France; [Ichai, Carole; Armando, Guy; Orban, Jean-Christophe; Rami, Laurent; Samat-Long, Corine; Grimaud, Dominique] St Roch Hosp, CHU Nice, F-06006 Nice 1, France; [Berthier, Frederic] Hop Cimiez, CHU Nice, Dept Med Informat, F-06000 Nice, France; [Leverve, Xavier] INSERM, U884, F-38041 Grenoble, France; [Leverve, Xavier] Univ Grenoble 1, F-38041 Grenoble, France		Ichai, C (corresponding author), St Roch Hosp, Fac Med, Serv Reanimat, 5 Rue Pierre Devoluy, F-06006 Nice 1, France.	ichai@unice.fr					Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERGER S, 1994, ACTA NEUROCHIR, P494; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chiolero R, 1999, ANN SURG, V229, P505, DOI 10.1097/00000658-199904000-00009; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; King P, 1998, CLIN SCI, V94, P157, DOI 10.1042/cs0940157; MARAN A, 1994, LANCET, V343, P16, DOI 10.1016/S0140-6736(94)90876-1; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Mustafa I, 2003, INTENS CARE MED, V29, P1279, DOI 10.1007/s00134-003-1860-6; Mustafa I, 2002, SHOCK, V18, P306, DOI 10.1097/00024382-200210000-00003; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Pellerin L, 2005, J NEUROSCI RES, V79, P55, DOI 10.1002/jnr.20307; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; SCHIERHOUT G, 2000, COCHRANE DB SYST REV; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; Schurr A, 2002, INT J MOL MED, V10, P131, DOI 10.3892/ijmm.10.2.131; Schurr A, 2001, J NEUROSCI RES, V66, P782, DOI 10.1002/jnr.10065; Schurr A, 1997, J NEUROCHEM, V69, P423; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; Sorani MD, 2008, J NEUROSURG, V108, P80, DOI 10.3171/JNS/2008/108/01/0080; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC	44	132	136	1	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2009	35	3					471	479		10.1007/s00134-008-1283-5			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	408FR	WOS:000263421400011	18807008				2022-02-06	
J	Sandhir, R; Onyszchuk, G; Berman, NEJ				Sandhir, Rajat; Onyszchuk, Gregory; Berman, Nancy E. J.			Exacerbated glial response in the aged mouse hippocampus following controlled cortical impact injury	EXPERIMENTAL NEUROLOGY			English	Article						aging; astrocyte; CD11b; GFAP; Iba1; hippocampus; inflammation; microglia; traumatic brain injury; S100B	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; GENE-EXPRESSION; MICROGLIAL ACTIVATION; MESSENGER-RNA; AGING BRAIN; INFLAMMATION; ASTROCYTES; YOUNG; MICE	Old age is associated with enhanced Susceptibility to and poor recovery from brain injury. An exacerbated microglial and astrocyte response to brain injury might be involved in poor outcomes observed in the elderly. The present study was therefore designed to quantitate the expression of markers of microglia and astrocyte activation using real-time RT-PCR, immunoblot and immunohistochemical analysis in aging brain in response to brain injury. We examined the hippocampus, a region that undergoes secondary neuron death, in aged (21-24 months) and adult (5-6 months) mice following controlled cortical impact (CCI) injury to the sensorimotor cortex. Basal mRNA expression of CD11b and Iba1, markers of activated microglia, was higher in aged hippocampus as compared to the adult. The mRNA expression of microglial markers increased and reached maximum 3 days post-injury in both adult and aged mice. but was higher in the aged mice at all time points studied, and in the aged mice the return to baseline levels was delayed. Basal mRNA expression of GFAP and S100B. markers of activated astrocytes, was higher in aged mice. Both markers increased and reached maximum 7 days post-injury. The mRNA expression of astrocyte markers returned to near basal levels rapidly after injury in the adult mice, whereas again in the aged mice return to baseline was delayed. Immunochemical analysis using Iba1 and GFAP antibodies indicated accentuated glial responses in the aged hippocampus after injury. The pronounced and prolonged activation of microglia and astrocytes in hippocampus may contribute to worse cognitive outcomes in the elderly following TBI. (c) 2008 Elsevier Inc. All rights reserved.	[Sandhir, Rajat; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Sandhir, Rajat; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66160 USA		Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	nberman@kumc.edu			National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG026482, P30 NICHD HD 02528]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026482] Funding Source: NIH RePORTER	The authors acknowledge the assistance of Eugene Gregory in carrying out the work and Eileen Roach with processing of the images. Special thanks to Dr. Y.Y. He for his help with controlled cortical impact injury. The study was supported in part by the Steve Palermo Endowment and grant from the National Institute of Aging (AG026482 and P30 NICHD HD 02528).	Ashcroft GS, 2002, BIOGERONTOLOGY, V3, P337, DOI 10.1023/A:1021399228395; Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Chung JH, 2008, AGEING RES REV, V7, P126, DOI 10.1016/j.arr.2008.01.001; Conde JR, 2006, J NEUROPATH EXP NEUR, V65, P199, DOI 10.1097/01.jnen.0000202887.22082.63; Conde JR, 2006, NEUROBIOL AGING, V27, P1451, DOI 10.1016/j.neurobiolaging.2005.07.012; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Deng XH, 2006, NEUROSCIENCE, V141, P645, DOI 10.1016/j.neuroscience.2006.04.016; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Felzien LK, 2001, BRAIN RES, V890, P137, DOI 10.1016/S0006-8993(00)03090-0; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; FRANEK KJ, 1998, CURR TREND IMMUNOL, V1, P29; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; GOSS JR, 1991, NEUROBIOL AGING, V12, P165, DOI 10.1016/0197-4580(91)90056-P; Hauwel M, 2005, BRAIN RES REV, V48, P220, DOI 10.1016/j.brainresrev.2004.12.012; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Kim KY, 2004, NEUROBIOL AGING, V25, P491, DOI 10.1016/j.neurobiolaging.2003.07.005; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; LETARTE P, 2006, TRAUMA, P397; Liu B, 2003, ENVIRON HEALTH PERSP, V111, P1065, DOI 10.1289/ehp.6361; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Mahesh VB, 2006, MOL CELL ENDOCRINOL, V246, P1, DOI 10.1016/j.mce.2005.11.017; Major DE, 1997, NEUROBIOL AGING, V18, P523, DOI 10.1016/S0197-4580(97)00102-4; Marchetti B, 2005, TRENDS PHARMACOL SCI, V26, P517, DOI 10.1016/j.tips.2005.08.007; MOHINDRA S, SURG NEUROL IN PRESS; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Ohsawa K, 2000, J CELL SCI, V113, P3073; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pertusa M, 2007, J NEUROCHEM, V101, P794, DOI 10.1111/j.1471-4159.2006.04369.x; PETCU EB, 2007, GERONTOLOGY; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Popa-Wagner A, 2007, CURR NEUROVASC RES, V4, P216; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; RINK A, 1995, AM J PATHOL, V147, P1575; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sawada M, 2008, NEURODEGENER DIS, V5, P254, DOI 10.1159/000113717; Schmidt O.I., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; SCHOLZ J, 2008, PAIN; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; Sheffield LG, 1998, NEUROBIOL AGING, V19, P47, DOI 10.1016/S0197-4580(97)00168-1; Stolzing A, 2005, REDOX REP, V10, P207, DOI 10.1179/135100005X70198; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Sugama S, 2003, BRAIN RES, V964, P288, DOI 10.1016/S0006-8993(02)04085-4; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wu DY, 2007, J IMMUNOL, V179, P4829, DOI 10.4049/jimmunol.179.7.4829; Yoshida T, 1996, NEUROSCI LETT, V215, P107, DOI 10.1016/0304-3940(96)12966-9; Zhu W, 2003, J GERONTOL A-BIOL, V58, P117	62	132	136	2	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2008	213	2					372	380		10.1016/j.expneurol.2008.06.013			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	351ZG	WOS:000259464200014	18692046	Green Accepted			2022-02-06	
J	Brady, KM; Lee, JK; Kibler, KK; Easley, RB; Koehler, RC; Shaffner, DH				Brady, Ken M.; Lee, Jennifer K.; Kibler, Kathleen K.; Easley, R. Blaine; Koehler, Raymond C.; Shaffner, Donald H.			Continuous measurement of autoregulation by spontaneous fluctuations in cerebral perfusion pressure - Comparison of 3 methods	STROKE			English	Article						autoregulation; cerebral blood flow; hypotension; neonates; oxygenation; piglets	TRAUMATIC BRAIN-INJURY; CEREBROVASCULAR AUTOREGULATION; HEAD-INJURY; REACTIVITY	Background and Purpose-Clinical application of continuous autoregulation monitoring would benefit from a comparison of curves generated by online monitoring with standard autoregulation curves in animal models. We characterized the accuracy of 3 continuous monitors of autoregulation in a piglet model of hypotension. Methods-Piglets 5 to 10 days old with intracranial pressure (ICP) at naive or elevated (20 mm Hg) levels had gradual arterial hypotension induced by a balloon catheter in the inferior vena cava. Elevated ICP was maintained by a continuous infusion of artificial cerebrospinal fluid. Three indices of autoregulation were simultaneously and continuously calculated. A moving, linear Pearson's coefficient between spontaneous slow waves of cerebral perfusion pressure and slow waves of laser-Doppler flux or cortical oxygenation rendered the laser-Doppler index and cerebral-oximetry index, respectively. Similar correlation between slow waves of arterial blood pressure and ICP rendered the pressure-reactivity index. The lower limit of autoregulation was determined directly for each animal by plotting laser-Doppler cortical red blood cell flux as a function of cerebral perfusion pressure. Receiver-operator characteristics were determined for the 3 indices. Results-The areas under the receiver-operator characteristics curves for discriminating the individual lower limit of autoregulation at low and high ICP were 0.89 and 0.85 for the laser-Doppler index, 0.89 and 0.84 for the cerebral-oximetry index, and 0.79 and 0.79 for the pressure-reactivity index. The pressure-reactivity index performed equally well at low and high ICPs. Conclusions-Continuous monitoring of autoregulation by spontaneous slow waves of cerebral perfusion pressure can accurately detect loss of autoregulation due to hypotension in piglets by all 3 modalities.	[Brady, Ken M.; Lee, Jennifer K.; Kibler, Kathleen K.; Easley, R. Blaine; Koehler, Raymond C.; Shaffner, Donald H.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA		Brady, KM (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Anesthesiol & Crit Care Med, Dept Anesthesiol, 600 N Wolfe St,Blalock 904, Baltimore, MD 21287 USA.	kbrady5@jhmi.edu		SHAFFNER, DONALD/0000-0001-5530-0746	Hartwell Foundation; Foundation for Anesthesia Education and Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS020020] Funding Source: NIH RePORTER	This work was supported by grants from the Hartwell Foundation and the Foundation for Anesthesia Education and Research.	Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brain Trauma Foundation: American association of Neurological surgeons, 2007, J NEUROTRAUMA S1, V24, pS59; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1997, NEUROSURGERY, V41, P17; Guendling K, 2006, ACTA NEUROCHIR SUPPL, V96, P108; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lemaire JJ, 2002, ACTA NEUROCHIR, V144, P243, DOI 10.1007/s007010200032; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002	16	132	132	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	SEP	2008	39	9					2531	2537		10.1161/STROKEAHA.108.514877			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	341PP	WOS:000258727000021	18669896	Green Submitted, Green Accepted, Bronze			2022-02-06	
J	Lloyd, E; Somera-Molina, K; Van Eldik, LJ; Watterson, DM; Wainwright, MS				Lloyd, Eric; Somera-Molina, Kathleen; Van Eldik, Linda J.; Watterson, D. Martin; Wainwright, Mark S.			Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article							CLOSED-HEAD INJURY; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; ATTENUATES SYNAPTIC DYSFUNCTION; CENTRAL-NERVOUS-SYSTEM; FACTOR-ALPHA; BEHAVIORAL DEFICITS; NEUROPROTECTIVE AGENTS	Background: Traumatic brain injury (TBI) with its associated morbidity is a major area of unmet medical need that lacks effective therapies. TBI initiates a neuroinflammatory cascade characterized by activation of astrocytes and microglia, and increased production of immune mediators including proinflammatory cytokines and chemokines. This inflammatory response contributes both to the acute pathologic processes following TBI including cerebral edema, in addition to longer-term neuronal damage and cognitive impairment. However, activated glia also play a neuroprotective and reparative role in recovery from injury. Thus, potential therapeutic strategies targeting the neuroinflammatory cascade must use careful dosing considerations, such as amount of drug and timing of administration post injury, in order not to interfere with the reparative contribution of activated glia. Methods: We tested the hypothesis that attenuation of the acute increase in proinflammatory cytokines and chemokines following TBI would decrease neurologic injury and improve functional neurologic outcome. We used the small molecule experimental therapeutic, Minozac (Mzc), to suppress TBI-induced up-regulation of glial activation and proinflammatory cytokines back towards basal levels. Mzc was administered in a clinically relevant time window post-injury in a murine closed-skull, cortical impact model of TBI. Mzc effects on the acute increase in brain cytokine and chemokine levels were measured as well as the effect on neuronal injury and neurobehavioral function. Results: Administration of Mzc (5 mg/kg) at 3 h and 9 h post-TBI attenuates the acute increase in proinflammatory cytokine and chemokine levels, reduces astrocyte activation, and the longer term neurologic injury, and neurobehavioral deficits measured by Y maze performance over a 28-day recovery period. Mzc-treated animals also have no significant increase in brain water content (edema), a major cause of the neurologic morbidity associated with TBI. Conclusion: These results support the hypothesis that proinflammatory cytokines contribute to a glial activation cycle that produces neuronal dysfunction or injury following TBI. The improvement in long-term functional neurologic outcome following suppression of cytokine upregulation in a clinically relevant therapeutic window indicates that selective targeting of neuroinflammation may lead to novel therapies for the major neurologic morbidities resulting from head injury, and indicates the potential of Mzc as a future therapeutic for TBI.	[Somera-Molina, Kathleen; Wainwright, Mark S.] Childrens Mem Hosp, Dept Pediat, Div Neurol, Chicago, IL 60614 USA; [Lloyd, Eric] Childrens Mem Hosp, Div Crit Care, Dept Pediat, Chicago, IL 60614 USA; [Somera-Molina, Kathleen; Van Eldik, Linda J.; Watterson, D. Martin; Wainwright, Mark S.] Northwestern Univ, Ctr Drug Discovery & Chem Biol, Chicago, IL 60611 USA; [Wainwright, Mark S.] Childrens Mem Hosp, Ctr Interdisciplinary Res Pediat Crit Illness & I, Chicago, IL 60614 USA		Wainwright, MS (corresponding author), Childrens Mem Hosp, Dept Pediat, Div Neurol, 2300 Childrens Plaza, Chicago, IL 60614 USA.	Eal1@neoucom.edu; kathleensomeramolina2008@u.northwestern.edu; vaneldik@northwestern.edu; m-watterson@northwestern.edu; m-wainwright@northwestern.edu	Lloyd, Eric/E-3530-2011	Watterson, Daniel/0000-0001-7605-5866	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG013939, R37 AG013939, R01 AG031311, T32 AG000260, AG013939] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS044998, R01 NS056051, KO8 NS044998, NS056051] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS044998, R01NS056051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG013939, T32AG000260, R37AG013939, R01AG031311] Funding Source: NIH RePORTER		Berman JW, 1996, J IMMUNOL, V156, P3017; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; *CDC, FACT TRAUM BRAIN INJ; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Craft JM, 2004, J MOL NEUROSCI, V24, P115, DOI 10.1385/JMN:24:1:115; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Guo X, 2007, NEUROSCI RES, V59, P457, DOI 10.1016/j.neures.2007.08.014; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; LASKOWITZ D, J NEUROTRAUMA, V24, P1093; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Maas Andrew I.R., 2000, Curr Opin Crit Care, V6, P281, DOI 10.1097/00075198-200008000-00008; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Mirzoeva S, 2002, J MED CHEM, V45, P563, DOI 10.1021/jm015573g; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; *NAT CTR INJ PREV, 1999, EP TRAUM BRAIN INJ U; National Institute of Neurological Disorders and Stroke Traumatic Brain Injury: Hope through research National Institutes of Health, 2002, NIH PUBL; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Pineda JA, 2001, J NEUROTRAUM, V18, P625, DOI 10.1089/089771501750291864; Ranaivo HR, 2006, J NEUROSCI, V26, P662, DOI 10.1523/JNEUROSCI.4652-05.2006; Ransohoff RM, 2002, ANN NY ACAD SCI, V961, P346, DOI 10.1111/j.1749-6632.2002.tb03120.x; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rossi JL, 2007, AM J PHYSIOL-LUNG C, V292, pL1327, DOI 10.1152/ajplung.00380.2006; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Van Eldik LJ, 2007, INT REV NEUROBIOL, V82, P277, DOI 10.1016/S0074-7742(07)82015-0; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Weiss C, 1998, NEUROSCI RES COMMUN, V23, P77, DOI 10.1002/(SICI)1520-6769(199809/10)23:2<77::AID-NRC2>3.0.CO;2-Y; Wosik K, 2007, J NEUROSCI, V27, P9032, DOI 10.1523/JNEUROSCI.2088-07.2007	66	132	133	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 30	2008	5								28	10.1186/1742-2094-5-28			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	337AA	WOS:000258406700001	18590543	Green Published, gold			2022-02-06	
J	Papadia, S; Hardingham, GE				Papadia, Sofia; Hardingham, Giles E.			The dichotomy of NMDA receptor signaling	NEUROSCIENTIST			English	Article						apoptosis; necrosis; neuroprotection; stroke; NMDA receptor; extrasynaptic; synaptic activity; CREB; Akt; calcium	ELEMENT-BINDING PROTEIN; ACTIVITY-DEPENDENT NEUROPROTECTION; SENSITIVE COINCIDENCE DETECTOR; FAMILY TRANSCRIPTION FACTOR; RAT HIPPOCAMPAL-NEURONS; D-ASPARTATE ANTAGONISTS; TRAUMATIC BRAIN-INJURY; CORTICAL CELL-CULTURE; ACUTE ISCHEMIC-STROKE; GENOME-WIDE ANALYSIS	The N-methyl-D-aspartate (NMDA) subtype of ionotropic glutamate receptors plays a Jekyll and Hyde role in the mammalian central nervous system. In pathological scenarios such as ischemia, Ca2+ influx through the NMDA receptor is a key mediator of cell death. However, physiological levels of NMDA-receptor activity can promote neuronal survival and resistance to trauma and play important roles in synaptic plasticity and transmission. This dichotomy may explain the poor tolerance and efficacy of NMDA-receptor antagonists in clinical trials for excitotoxic trauma. There is a growing understanding of the signaling events that mediate the opposing effects of NMDA-receptor activity and the factors that determine whether an episode of NMDA-receptor activity will promote survival or death. This knowledge may lead to therapeutic strategies that enable the selective blockade of prodeath signaling cassettes while sparing physiological signaling to survival and plasticity.	Univ Edinburgh, Neurosci Res Ctr, Edinburgh EH8 9XD, Midlothian, Scotland		Papadia, S (corresponding author), Univ Edinburgh, Neurosci Res Ctr, Hugh Robson Bldg, Edinburgh EH8 9XD, Midlothian, Scotland.			Hardingham, Giles/0000-0002-7629-5314	Wellcome TrustWellcome TrustEuropean Commission [078178] Funding Source: Medline		Aamodt S M, 1999, Adv Neurol, V79, P133; Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Adams SM, 2004, J NEUROSCI, V24, P9441, DOI 10.1523/JNEUROSCI.3290-04.2004; Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Collins MO, 2006, J NEUROCHEM, V97, P16, DOI 10.1111/j.1471-4159.2005.03507.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dyker AG, 1999, STROKE, V30, P2038, DOI 10.1161/01.STR.30.10.2038; Frizelle PA, 2006, MOL PHARMACOL, V70, P1022, DOI 10.1124/mol.106.024042; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; GOULD E, 1994, J COMP NEUROL, V340, P551, DOI 10.1002/cne.903400408; Grabb MC, 1999, J NEUROSCI, V19, P1657; Hansen HH, 2004, NEUROBIOL DIS, V16, P440, DOI 10.1016/j.nbd.2004.03.013; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/S0092-8674(04)01159-6; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Jaworski J, 2003, J NEUROSCI, V23, P4519; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kohr G, 2006, CELL TISSUE RES, V326, P439, DOI 10.1007/s00441-006-0273-6; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; Lafon-Cazal M, 2002, EUR J NEUROSCI, V16, P575, DOI 10.1046/j.1460-9568.2002.02124.x; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Limback-Stokin K, 2004, J NEUROSCI, V24, P10858, DOI 10.1523/JNEUROSCI.1022-04.2004; Lipton SA, 1999, NAT MED, V5, P270, DOI 10.1038/6481; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Monti B, 2000, EUR J NEUROSCI, V12, P3117, DOI 10.1046/j.1460-9568.2000.00189.x; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Neyton J, 2006, J NEUROSCI, V26, P1331, DOI 10.1523/JNEUROSCI.5242-05.2006; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Pottorf WJ, 2006, J NEUROCHEM, V98, P1646, DOI 10.1111/j.1471-4159.2006.04063.x; Rameau GA, 2007, J NEUROSCI, V27, P3445, DOI 10.1523/JNEUROSCI.4799-06.2007; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Semenova MM, 2007, NAT NEUROSCI, V10, P436, DOI 10.1038/nn1869; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Szczesniak AM, 2005, BONE, V37, P63, DOI 10.1016/j.bone.2003.10.016; Tanaka K, 1999, BRAIN RES, V818, P520, DOI 10.1016/S0006-8993(98)01263-3; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; Tompa P, 1996, J BIOL CHEM, V271, P33161, DOI 10.1074/jbc.271.52.33161; Tuneva EO, 2003, B EXP BIOL MED+, V136, P159, DOI 10.1023/A:1026366907084; Walton M, 1999, J NEUROCHEM, V73, P1836; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	93	132	136	1	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	DEC	2007	13	6					572	579		10.1177/1073858407305833			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	233BR	WOS:000251065900009	18000068	Green Submitted, Green Accepted			2022-02-06	
J	Kelley, BJ; Lifshitz, J; Povlishock, JT				Kelley, Brian Joseph; Lifshitz, Jonathan; Povlishock, John Theodore			Neuroinflammatory responses after experimental diffuse traumatic brain injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						fluid percussion; macrophage; microglia; rat; traumatic axonal injury	AXONAL INJURY; INFLAMMATORY RESPONSE; MICROGLIAL ACTIVATION; NERVOUS-SYSTEM; CELL-DYNAMICS; BARRIER; NUCLEUS; AXOTOMY; MODEL; SITES	Little is known about microglial activation and macrophage localization after diffuse brain injury (DBI). DBI-mediated perisomatic traumatic axonal injury (TAI) was recently identified within the neocortex, hippocampus, and thalamus, providing an opportunity to characterize immune cell responses within diffusely injured brain loci uncomplicated by contusion. By using moderate midline/central fluid percussion injury, microglial/macrophage responses were examined with antibodies targeting immune cell phenotypes and amyloid precursor protein, a marker of TAI. Parallel assessments of blood-brain barrier alterations were also performed. Within 6 to 48 hours postinjury, microglial activation within injured loci was observed, whereas microglia within non-TAI-containing regions maintained a resting phenotype. Microglial activation shared a spatiotemporal relationship with TAI though no clear interactions were observed. By 7 to 28 days postinjury, activated microglia contained myelin debris, yet revealed limited aggregation. Immunophenotypic macrophages were also localized to injured loci. Select macrophages approximated somatic membranes of perisomatically axotomized neurons with evidence of bouton disruption. No causality was established between blood-brain barrier alterations and these inflammatory responses. These findings indicate rapid, yet initially nonspecific, and persistent microglial/macrophage responses to DBI. DBI-mediated inflammatory responses suggest further expansion of traumatic brain injury histopathologic evaluations to identify neuroinflammation indicative of diffuse pathology.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Sch Med, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Sch Med, 1101 E Marshall St,Sanger Hall Room 12-050,POB 98, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD055813, F32 HD049343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045824, 5P30-NS047463, T32NS007288] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS045824, T32NS007288] Funding Source: NIH RePORTER		Adams A, 2001, BCS CONF SERIES, P49; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Babcock AA, 2003, J NEUROSCI, V23, P7922; Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Carbonell WS, 2005, J NEUROSCI, V25, P7040, DOI 10.1523/JNEUROSCI.5171-04.2005; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cho BP, 2006, GLIA, V53, P92, DOI 10.1002/glia.20265; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Dailey ME, 1999, METHODS, V18, P222, DOI 10.1006/meth.1999.0775; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; Grossmann R, 2002, GLIA, V37, P229, DOI 10.1002/glia.10031; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Hartl R, 1997, ACT NEUR S, V70, P240; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hermann DM, 2000, ACTA NEUROPATHOL, V99, P147, DOI 10.1007/PL00007418; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kreutzberg Georg W., 1995, P355; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; MATHEW P, 1994, ACTA NEUROCHIR, P428; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; OEHMICHEN M, 2006, FORENSIC NEUROPATHOL, P15; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raivich G, 1998, J NEUROSCI, V18, P5804; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHOLAMI E, 1999, CYTOKINE GROWTH F R, V10, P119; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Soares HD, 1995, J NEUROSCI, V15, P8223; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111	59	132	136	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	2007	66	11					989	1001		10.1097/NEN.0b013e3181588245			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	229HE	WOS:000250793100003	17984681	Bronze			2022-02-06	
J	Agel, J; Dompier, TP; Dick, R; Marshall, SW				Agel, Julie; Dompier, Thomas P.; Dick, Randall; Marshall, Stephen W.			Descriptive epidemiology of collegiate men's ice hockey injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; knee injuries; pelvis injuries; hip injuries	CONCUSSIONS; PLAYERS; LEAGUE; HEAD; MULTIVARIATE; RATES; TIME	Objective: To review 16 years of National Collegiate Athletic Association (NCAA) injury surveillance data for men's ice hockey and to identify potential areas for injury prevention initiatives. Background. The NCAA began injury surveillance of men's ice hockey during the 1988-1989 academic year. These data represent all 3 NCAA divsions; the last Division II championship, however, was held during the 1998-1999 academic year. Main Results: The rate of injury was more than 8 times higher in games than in practices (16.27 versus 1.96 injuries per 1000 athlete-exposures [A-Es], rate ratio = 8.3, 95% confidence interval [CI] = 7.9, 8.8). A significant average annual increase of 1.3% in game injury rates occurred over the sample period (P =.05), but practice rates stayed static (P =.77). Preseason practice injury rates were more than twice as high as regular-season practice rates (5.05 versus 1.94 injuries per 1000 A-Es, rate ratio = 2.6, 95% CI = 2.4, 2.9, P <.01). The majority of game and practice injuries occurred to the lower extremity. Knee internal derangement (13.5%) was the most common lower extremity injury reported for games, whereas pelvis and hip muscle strains (13.1%) were the most common injury reported during practices. Player-to-player contact was the most frequent game mechanism of injury (50.0%). The majority of injuries occurred between the blue line and face-off circles (28.0%), in the corner (23.5%), and in the neutral zone (21.4%). Recommendations: Preventive efforts should focus on strategies that limit player-to-player contact in the neutral zone and at the top of the offensive and defensive zones. In addition, clinicians and researchers should identify risk factors and interventions for muscle strains at the pelvis and hip region.	Univ No Iowa, Cedar Falls, IA 50614 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Natl Coll Athlet Assoc, Indianapolis, IN USA; Univ N Carolina, Chapel Hill, NC 27515 USA		Dompier, TP (corresponding author), Univ No Iowa, 203 Wellness & Recreat Ctr, Cedar Falls, IA 50614 USA.	thomas.dompier@uni.edu		Marshall, Stephen/0000-0002-2664-9233			Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Dick R, 2007, J ATHL TRAINING, V42, P173; Emery CA, 1999, CLIN J SPORT MED, V9, P151, DOI 10.1097/00042752-199907000-00006; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Hawn KL, 2002, J ATHL TRAINING, V37, P204; Hayes Don, 1975, Phys Sportsmed, V3, P61, DOI 10.1080/00913847.1975.11948128; Hostetler SG, 2004, PEDIATRICS, V114, pE661, DOI 10.1542/peds.2004-1565; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Molsa J, 2000, AM J SPORT MED, V28, P322; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Powell JW, 2004, J ATHL TRAINING, V39, P56; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Wennberg R, 2005, CLIN J SPORT MED, V15, P67, DOI 10.1097/01.jsm.0000152712.27968.fe; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596	18	132	133	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					241	248					8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	180RC	WOS:000247382300010	17710172				2022-02-06	
J	Van Beek, JGM; Mushkudiani, NA; Steyerberg, EW; Butcher, I; McHugh, GS; Lu, J; Marmarou, A; Murray, GD; Maas, AIR				Van Beek, Jackelien G. M.; Mushkudiani, Nino A.; Steyerberg, Ewout W.; Butcher, Isabella; McHugh, Gillian S.; Lu, Juan; Marmarou, Anthony; Murray, Gordon D.; Maas, Andrew I. R.			Prognostic value of admission laboratory parameters in traumatic brain injury: Results from the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						glucose; hemoglobin; laboratory parameters; outcome; prognosis; sodium; traumatic brain injury	SEVERE HEAD-INJURY; BLOOD-GLUCOSE; INTRAVASCULAR COAGULATION; PROGRESSIVE HEMORRHAGE; MYOCARDIAL-INFARCTION; STRESS HYPERGLYCEMIA; COAGULOPATHY; MORTALITY; CHILDREN; RISK	Abnormalities in laboratory parameters are frequent following traumatic brain injury (TBI), but few studies have investigated their predictive value. We aimed to describe and quantify the relation between laboratory parameters that are routinely determined on admission and final outcome following TBI. Individual patient data were available in the IMPACT database from six Phase III randomized controlled trials and one observational study in TBI. We studied glucose (N = 4834), sodium (N = 5270), pH (N = 3398), hemoglobin (Hb, N = 3875), platelet count (N = 1629), and prothrombin time (PT; N = 840) for their associations with outcome at 6 months (Glasgow Outcome Scale [GOS]). We used logistic regression models with linear, quadratic, and restricted cubic spline functions. The strength of the associations was expressed as an unadjusted odds ratio, calculated over the shift in outcome between the 25th and 75th percentiles. Proportional odds methodology was further applied to quantify the strength of the associations across the full range of the GOS. All parameters were consistently associated with outcome in a continuous relationship: glucose and prothrombin time showed a positive linear relation to outcome (i.e., increasing values associated with poorer outcome) and Hb, platelets, and pH an inverse linear relation (i.e., low values associated with poorer outcome). Sodium demonstrated a U-shaped relation to outcome, with low levels being more strongly related to poorer outcome. Effects were strongest for increasing levels of glucose (odds ratio 1.7; 95% CI 1.54-1.83) and decreasing levels of Hb (odds ratio 0.7; CI 0.60-0.78). Higher glucose values were associated with increasing age, but on adjusted analysis, the strength of the association with outcome remained. Whether treatment of abnormal values may improve outcome needs further rigorous study.	Erasmus MC, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Ctr Clin Decis Making, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA		Maas, AIR (corresponding author), Erasmus MC, Dept Neurosurg, POB 2040, NL-3000 CA Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734; Lu, Juan/0000-0002-5389-7603	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Alessandri B, 1998, ACT NEUR S, V71, P237; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Cely CM, 2004, CHEST, V126, P879, DOI 10.1378/chest.126.3.879; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Deloof T, 1979, Acta Neurochir Suppl (Wien), V28, P113; Deshpande AA, 1997, ARCH PHYS MED REHAB, V78, P350, DOI 10.1016/S0003-9993(97)90224-0; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; du Cheyron D, 2005, INTENS CARE MED, V31, P1529, DOI 10.1007/s00134-005-2739-5; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; FLORES EA, 1990, METABOLISM, V39, P738, DOI 10.1016/0026-0495(90)90110-X; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Goodnough LT, 2001, NEW ENGL J MED, V345, P1272, DOI 10.1056/NEJM200110253451711; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; HILL M, 1991, J CLIN INVEST, V88, P811, DOI 10.1172/JCI115381; Hoots WK, 1997, SEMIN THROMB HEMOST, V23, P3; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Khani S, 2001, CLIN SCI, V101, P739, DOI [10.1042/CS20010180, 10.1042/cs1010739]; Kushi H, 1999, ACT NEUR S, V75, P67; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Li W, 2001, Chin J Traumatol, V4, P20; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARGULIES DR, 1994, AM SURGEON, V60, P387; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Norhammar AM, 1999, DIABETES CARE, V22, P1827, DOI 10.2337/diacare.22.11.1827; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Paret G, 1999, J ACCID EMERG MED, V16, P186; PENTELENYI T, 1977, INJURY, V8, P264, DOI 10.1016/0020-1383(77)90099-7; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Sakurai Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE864, DOI 10.1152/ajpendo.1996.270.5.E864; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Watt MJ, 2001, J PHYSIOL-LONDON, V534, P269, DOI 10.1111/j.1469-7793.2001.t01-1-00269.x; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zou MH, 2002, DIABETES, V51, P198, DOI 10.2337/diabetes.51.1.198; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	67	132	136	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					315	328		10.1089/neu.2006.0034			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900011	17375996				2022-02-06	
J	Saatman, KE; Feeko, KJ; Pape, RL; Raghupathi, R				Saatman, Kathryn E.; Feeko, Kristofer J.; Pape, Rebecca L.; Raghupathi, Ramesh			Differential behavioral and histopathological responses to graded cortical impact lnjur in mice	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; cognition; contusion; MAP-2; motor function; reactive astrocytes; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; COGNITIVE DEFICITS; TRANSGENIC MICE; RATS; MODEL; CONTUSION; APOPTOSIS; MODERATE; BCL-2	Controlled cortical impact (CCI) injury, a model of contusive brain injury in humans, is being used with increasing frequency in mice to investigate post-traumatic cell damage and death and to evaluate treatment strategies. Because cellular injury mechanisms and therapeutic approaches may depend on the severity of the initial insult, it is important to utilize a model in which outcomes are sensitive to injury severity. Adult male C57B1/6 mice were anesthetized and subjected to sham injury (n = 23) or CCI injury at either 0.5 mm (n = 22) or 1.0 nun (n = 22) depth of impact at a velocity of 5 m/sec. At 2 days, brain-injured mice exhibited significant memory (P < 0.05) and motor function (p < 0.001) deficits compared to sham-injured mice; furthermore, mice subjected to an impact of 1.0 mm were significantly more impaired in both outcome measures than those injured at 0.5 rum (p < 0.05). The cortical lesion increased in size between 24 h and 7 days in both injury groups, but was significantly larger in the 1.0 mm group. Hippocampal cell loss was observed in the hilar and CA3 regions in both groups, and in the CA1 and dentate granule cell layers in the 1.0 mm group. Regional patterns of IgG extravasation and reactive astrocytosis were similar in the two injured groups, but changes were more persistent in the 1.0 mm group. Both levels of injury resulted in acute loss of neuronal MAP-2 immunoreactivity in the cortex and sub-region specific changes in the hippocampus. Thus, increasing the depth of impact led to similar structural alterations in neurons, astrocytes and the vasculature, but resulted in greater behavioral deficits and cortical and hippocampal cell death.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA		Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B367,BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	k.saatman@uky.edu	Raghupathi, Ramesh/AAX-5538-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS041561, R01NS045131] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS45131, P50-NS08803, R01-NS41561] Funding Source: Medline		ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GRUBBS FE, 1972, TECHNOMETRICS, V14, P847, DOI 10.2307/1267134; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Huh JW, 2003, J NEUROTRAUM, V20, P975, DOI 10.1089/089771503770195821; JENKINS A, 1986, LANCET, V2, P445; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	35	132	133	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2006	23	8					1241	1253		10.1089/neu.2006.23.1241			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	075CF	WOS:000239859300006	16928182				2022-02-06	
J	Oertel, M; Boscardin, WJ; Obrist, WD; Glenn, TC; McArthur, DL; Gravori, T; Lee, JH; Martin, NA				Oertel, M; Boscardin, WJ; Obrist, WD; Glenn, TC; McArthur, DL; Gravori, T; Lee, JH; Martin, NA			Posttraumatic vasospasm: the epidemiology, severity, and time course of an underestimated phenomenon: a prospective study performed in 299 patients	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; head injury; transcranial Doppler ultrasonography; time course	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; TRANSCRANIAL DOPPLER ULTRASOUND; ARTERIAL SPASM; BRAIN INJURY; INTRACRANIAL HYPERTENSION; INTRAARTERIAL PAPAVERINE; CT SCAN; NIMODIPINE	Object. The purpose of this prospective study was to evaluate the cumulative incidence, duration, and time course of cerebral vasospasm after traumatic brain injury (TBI) in a cohort of 299 patients. Methods. Transcranial Doppler (TCD) ultrasonography studies of blood flow velocity in the middle cerebral and basilar arteries (V-MCA and V-BA, respectively) were performed at regular intervals during the first 2 weeks posttrauma in association with Xe-133 cerebral blood flow (CBF) measurements. According to cur-rent definitions of vasospasm, five different criteria were used to classify the patients: A (V-MCA > 120 cm/second); B (V-MCA > 120 cm/second and a Lindegaard ratio [LR] > 3); C (spasm index [SI] in the anterior circulation > 3.4); D (V-BA > 90 cm/second); and E (SI in the posterior circulation > 2.5). Criteria C and E were considered to represent hemodynamically significant vasospasm. Mixed-effects spline models were used to analyze the data of multiple measurements with an inconsistent sampling rate. Overall 45.2% of the patients demonstrated at least one criterion for vasospasm. The patients in whom vasospasin developed were significantly younger and had lower Glasgow Coma Scale scores on admission. The normalized cumulative incidences were 36.9 and 36.2% for patients with Criteria A and B, respectively. Hemodynamically significant vasospasm in the anterior circulation (Criterion Q was found in 44.6% of the patients, whereas vasospasm in the BA-Criterion D or E-was found in only 19 and 22.5% of the patients, respectively. The most common day of onset for Criteria A, B, D, and E was postinjury Day 2. The highest risk of developing hemodynamically significant vasospasm in the anterior circulation was found on Day 3. The daily prevalence of vasospasm in patients in the intensive care unit was 30% from postinjury Day 2 to Day 13. Vasospasm resolved after a duration of 5 days in 50% of the patients with Criterion A or B and after a period of 3.5 days in 50% of those patients with Criterion D or E. Hemodynamically significant vasospasm in the anterior circulation resolved after 2.5 days in 50% of the patients. The time course of that vasospasm was primarily determined by a decrease in CBF. Conclusions. The incidence of vasospasm after TBI is similar to that following aneurysmal subarachnoid hemorrhage. Because vasospasm is a significant event in a high proportion of patients after severe head injury, close TCD and CBF monitoring is recommended for the treatment of such patients.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; Univ Hosp Giessen, Dept Neurosurg, Giessen, Germany		Glenn, TC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Cerebral Blood Flow Lab, Box 957039,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	tglenn@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Glenn, Thomas/0000-0003-4273-3408	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 303008] Funding Source: Medline		AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ALEXANDER M, 1993, STROKE, V24, P520; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; AWAD IA, 1987, STROKE, V18, P365, DOI 10.1161/01.STR.18.2.365; Barker FG, 1996, J NEUROSURG, V84, P405, DOI 10.3171/jns.1996.84.3.0405; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHUI M, 1983, NEUROSURGERY, V12, P542, DOI 10.1227/00006123-198305000-00011; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; Devlin JW, 2000, NEUROSURGERY, V47, P1243, DOI 10.1097/00006123-200011000-00048; Dorsch N., 1993, Canadian Journal of Neurological Sciences, V20, pS28; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Firlik AD, 1997, J NEUROSURG, V86, P830, DOI 10.3171/jns.1997.86.5.0830; Firlik KS, 1999, SURG NEUROL, V51, P66, DOI 10.1016/S0090-3019(97)00370-4; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GABRIELSEN TO, 1970, ACTA RADIOL DIAGN, V10, P1; GELNN TC, 2003, J CEREB BLOOD FLO S1, V23, P394; GOSLING RG, 1971, ANGIOLOGY, V22, P52, DOI 10.1177/000331977102200109; Greene KA, 1997, J NEUROSURG, V87, P134; GROLIMUND P, 1988, LANCET, V1, P1173; GRUBB RL, 1977, J NEUROSURG, V46, P446, DOI 10.3171/jns.1977.46.4.0446; Hadani M, 1997, J NEUROTRAUM, V14, P629, DOI 10.1089/neu.1997.14.629; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; Horn P, 2001, CEREBROVASC DIS, V12, P197, DOI 10.1159/000047704; JAKOBSEN J, 1992, ACTA NEUROL SCAND, V86, P1, DOI 10.1111/j.1600-0404.1992.tb08044.x; JAKOBSEN M, 1990, ACTA NEUROL SCAND, V82, P174, DOI 10.1111/j.1600-0404.1990.tb04485.x; JAKOBSEN M, 1990, ACTA NEUROL SCAND, V82, P311; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAKARIEKA A, 1994, J NEURAL TRANSM-SUPP, P13; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001; KASSELL NF, 1992, J NEUROSURG, V77, P848, DOI 10.3171/jns.1992.77.6.0848; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; LAUMER R, 1993, NEUROSURGERY, V33, P1, DOI 10.1227/00006123-199307000-00001; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LEEDS NE, 1966, ACTA RADIOL DIAGN, V5, P320, DOI 10.1177/02841851660050P135; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; Martin NA, 1996, NEUROSURGERY, V39, P1059, DOI 10.1097/00006123-199611000-00040; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Mascia L, 2003, INTENS CARE MED, V29, P1088, DOI 10.1007/s00134-003-1780-5; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Morgan MK, 2000, J CLIN NEUROSCI, V7, P305, DOI 10.1054/jocn.1999.0224; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; NEWELL DW, 1989, J NEUROSURG, V71, P654, DOI 10.3171/jns.1989.71.5.0654; OBRIST WD, 1990, CEREBROVAS BRAIN MET, V2, P283; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1975, STROKE, V6, P245, DOI 10.1161/01.STR.6.3.245; OBRIST WD, 2001, J CEREB BLOOD FLO S1, V21, P105; Oskouian RJ, 2002, NEUROSURGERY, V51, P30, DOI 10.1097/00006123-200207000-00005; POTT W, 1991, NERVENARZT, V62, P493; Rabinstein AA, 2004, STROKE, V35, P1862, DOI 10.1161/01.STR.0000133132.76983.8e; Radhakrishnan D, 1997, ANAESTHESIA, V52, P489, DOI 10.1111/j.1365-2044.1997.112-az0105.x; Rice JA, 2001, BIOMETRICS, V57, P253, DOI 10.1111/j.0006-341X.2001.00253.x; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Soustiel JF, 1998, NEUROSURGERY, V43, P282, DOI 10.1097/00006123-199808000-00061; Suarez JI, 2002, CRIT CARE MED, V30, P1348, DOI 10.1097/00003246-200206000-00035; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1967, J NEUROL NEUROSUR PS, V30, P497, DOI 10.1136/jnnp.30.6.497; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; VOLDBY B, 1984, ACTA NEUROCHIR, V70, P243, DOI 10.1007/BF01406653; WADWORTH AN, 1992, DRUG AGING, V2, P262, DOI 10.2165/00002512-199202040-00002; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P33, DOI 10.1016/0022-510X(95)00172-9	78	132	145	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2005	103	5					812	824		10.3171/jns.2005.103.5.0812			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	979GN	WOS:000232930500010	16304984				2022-02-06	
J	Winter, CD; Pringle, AK; Clough, GF; Church, MK				Winter, CD; Pringle, AK; Clough, GF; Church, MK			Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury	BRAIN			English	Article						microdialysis; cytokine, neuroinflammation; traumatic brain injury (TBI); interleukin-6	NERVE GROWTH-FACTOR; ORGANOTYPIC HIPPOCAMPAL CULTURES; NMDA RECEPTOR ANTAGONISTS; CEREBROSPINAL-FLUID; HEAD-INJURY; INFLAMMATORY RESPONSE; NEURONAL DAMAGE; IN-VITRO; ISCHEMIA; PROTECTION	Previous studies have suggested that an increased production of the pro-inflammatory cytokines interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) can influence patient outcome following a severe head injury. However, these studies have relied upon measurements of cytokine levels in CSF or serum, rather than the brain parenchyma itself. Recently, a method of intracranial microdialysis has been developed which permits the efficient recovery of macromolecules from the parenchyma. We have used this technique to investigate whether there is a correlation between patient outcome and parenchymally derived cytokines. Fourteen patients who were admitted to the Wessex Neurological Centre with severe head injury were selected for the study. This group of patients consisted of seven males and seven females with an age range of 21-77 years. Patients were treated according to standard protocols including emergency craniotomy where necessary. Microdialysis probes were implanted into the frontal region contralateral to the site of the primary injury. Approximately 200 mul of dialysate was recovered every 8-12 h, and the concentrations of IL-6, IL-1beta and nerve growth factor (NGF) were determined by commercial enzyme-linked immunosorbent assays. Patients were assessed initially using the Glasgow coma score, and survivors were assessed after 6 months using the Glasgow outcome scale. Significantly (P = 0.04) higher levels of IL-6 were found in patients who survived compared with those who died. Also, there was a significant correlation between peak IL-6 levels and Glasgow outcome scores (r(2) = 0.34, P = 0.03, n = 14). The levels of IL-1beta and NGF were similar in both groups of patients. From these data, we suggest that IL-6 is an endogenous neuroprotective cytokine produced in response to severe head trauma.	Univ Southampton, Sch Med, Dept Clin Neurosci, Southampton SO16 7PX, Hants, England; Univ Hosp NHS Trust, Wessex Neurol Ctr, Dept Neurosurg, Southampton, Hants, England; Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Southampton SO16 7PX, Hants, England		Pringle, AK (corresponding author), Univ Southampton, Sch Med, Dept Clin Neurosci, Biomed Sci Bldg,Bassett Crescent E, Southampton SO16 7PX, Hants, England.	akp1@soton.ac.uk		WINTER, Craig/0000-0003-4626-7280; Pringle, Ashley/0000-0003-2421-4380			Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; ARVIN B, 1995, ANN NY ACAD SCI, V765, P63; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Clough GF, 2002, J PHARMACOL EXP THER, V302, P681, DOI 10.1124/jpet.102.035634; Fisher J, 2001, J NEUROIMMUNOL, V119, P1, DOI 10.1016/S0165-5728(01)00342-3; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Muller M, 2001, Eur J Ultrasound, V12, P203, DOI 10.1016/S0929-8266(00)00118-X; NEWELL DW, 1995, BRAIN RES, V675, P38, DOI 10.1016/0006-8993(95)00039-S; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 1999, GLIA, V25, P343; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; PRINGLE AK, 2002, FENS ABSTR, V1; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; STRASSER U, 1995, BRAIN RES, V687, P167, DOI 10.1016/0006-8993(95)00519-V; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VORNOV JJ, 1994, STROKE, V25, P457, DOI 10.1161/01.STR.25.2.457; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; Westerink BHC, 2001, J NEUROSCI METH, V109, P53, DOI 10.1016/S0165-0270(01)00401-0; Wilde GJC, 2000, EUR J NEUROSCI, V12, P3863, DOI 10.1046/j.1460-9568.2000.00273.x; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X	37	132	142	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2004	127		2				315	320		10.1093/brain/awh039			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	766RT	WOS:000188389900008	14645145	Bronze			2022-02-06	
J	Doonan, F; Donovan, M; Cotter, TG				Doonan, F; Donovan, M; Cotter, TG			Caspase-independent photoreceptor apoptosis in mouse models of retinal degeneration	JOURNAL OF NEUROSCIENCE			English	Article						photoreceptor; apoptosis; caspase; independent; cytochrome c; rd; MNU	METHYL-N-NITROSOUREA; DOMINANT RETINITIS-PIGMENTOSA; ETOPOSIDE-INDUCED APOPTOSIS; TRAUMATIC BRAIN INJURY; CYTOCHROME-C RELEASE; SPRAGUE-DAWLEY RATS; ACTIVATING FACTOR-I; CELL-DEATH; DIFFERENTIAL EXPRESSION; DNA FRAGMENTATION	Apoptosis is the mode of cell death in retinitis pigmentosa, a group of retinal degenerative disorders primarily affecting rod photoreceptors. Although caspases have been demonstrated to play a central role in many incidences of apoptosis, accumulating evidence suggests that they may not be required for all forms of apoptotic cell death. The present study examined the mechanism of cell death in two in vivo models of photoreceptor apoptosis: the retinal degeneration (rd) mouse, a naturally occurring mutant model, and N-methyl-N-nitrosourea-induced retinal degeneration. Specifically, we examined the activation status of caspase-9, -8, -7, -3, and -2 and determined the caspase requirements for cytochrome c release, DNA fragmentation, and apoptosis-associated proteolysis of specific caspase substrates. We show that apoptosis in both in vivo models is independent of caspase-9, -8, -7, -3, and -2 activation. DNA fragmentation occurs in the absence of caspase-mediated ICAD (inhibitor of caspase-activated DNase) proteolysis, suggesting that an alternative endonuclease is responsible for DNA cleavage in these models. Importantly, we show that apoptosome activation is prevented because of an absence of mitochondrial cytochrome c release. Experiments performed using a cell-free system indicate that cytochrome c-dependent proteolysis and activation of caspase-9 can be restored in a neonatal cell-free system. However, we found that cytochrome c-dependent proteolysis and activation of caspase-9 could not be restored in an adult cell-free system because of an age-related decrease in the expression of Apaf-1 in the normal developing mouse retina. In the rd mouse, however, this age-related downregulation of apoptotic proteins was not observed, highlighting a critical feature of this model and the prevention of cytochrome c release as an apical event in caspase-independent apoptosis in this system.	Natl Univ Ireland Univ Coll Cork, Dept Biochem, Tumour Biol Lab, Cork, Ireland		Cotter, TG (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Tumour Biol Lab, Cork, Ireland.			Cotter, Thomas/0000-0003-4626-5613			AZARIAN SM, 1995, CURR EYE RES, V14, P731, DOI 10.3109/02713689508998502; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Boulares AH, 2002, J BIOL CHEM, V277, P372, DOI 10.1074/jbc.M107738200; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Caffe AR, 2001, INVEST OPHTH VIS SCI, V42, P275; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Bilbao F, 1999, J COMP NEUROL, V409, P339, DOI 10.1002/(SICI)1096-9861(19990705)409:3<339::AID-CNE1>3.0.CO;2-Q; Donovan M, 2002, CELL DEATH DIFFER, V9, P1220, DOI 10.1038/sj.cdd.4401105; FARRAR GJ, 1990, GENOMICS, V8, P35; FARRAR GJ, 1992, GENOMICS, V14, P805; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Jomary C, 2001, MOL CELL NEUROSCI, V18, P335, DOI 10.1006/mcne.2001.1036; Katai N, 1999, INVEST OPHTH VIS SCI, V40, P1802; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Liu CD, 1999, J NEUROSCI, V19, P4778; LOLLEY RN, 1994, INVEST OPHTH VIS SCI, V35, P358; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Mooney SM, 2000, DEV BRAIN RES, V123, P103, DOI 10.1016/S0165-3806(00)00081-X; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; Nakajima M, 1996, PATHOL INT, V46, P874, DOI 10.1111/j.1440-1827.1996.tb03561.x; Nambu H, 1997, PATHOL INT, V47, P377, DOI 10.1111/j.1440-1827.1997.tb04511.x; Nicotera P, 2002, TOXICOL LETT, V127, P189, DOI 10.1016/S0378-4274(01)00500-8; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; OGINO H, 1993, TOXICOL PATHOL, V21, P21, DOI 10.1177/019262339302100103; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Read DS, 2002, EXP EYE RES, V75, P415, DOI 10.1006/exer.2002.2034; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakamoto Y, 2000, CURR EYE RES, V21, P571, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT571; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamada Y, 2002, COMP BIOCHEM PHYS B, V131, P221, DOI 10.1016/S1096-4959(01)00489-4; Taomoto M, 1998, GRAEF ARCH CLIN EXP, V236, P688, DOI 10.1007/s004170050142; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; Ueyama H, 1998, J NEUROL SCI, V155, P163, DOI 10.1016/S0022-510X(97)00309-2; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yoshizawa K, 1999, LAB INVEST, V79, P1359; Yoshizawa K, 2002, GRAEF ARCH CLIN EXP, V240, P214, DOI 10.1007/s00417-002-0427-5; Yoshizawa K, 2000, EXP EYE RES, V71, P629, DOI 10.1006/exer.2000.0921; Yuge K, 1996, IN VIVO, V10, P483; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	58	132	134	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 2	2003	23	13					5723	5731					9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	697CF	WOS:000183924100039	12843276				2022-02-06	
J	Sherer, M; Sander, AM; Nick, TG; High, WM; Malec, JF; Rosenthal, M				Sherer, M; Sander, AM; Nick, TG; High, WM; Malec, JF; Rosenthal, M			Early cognitive status and productivity outcome after traumatic brain injury: Findings from the TBI model systems	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; cognition disorders; employment; neuropsychological tests; rehabilitation; treatment outcome	CLOSED-HEAD-INJURY; COMA-DATA-BANK; COMMUNITY INTEGRATION; POSTTRAUMATIC AMNESIA; REGRESSION-MODELS; FOLLOW-UP; REHABILITATION; PREDICTORS; WORK; INDICATORS	Objective: To evaluate the contribution of early cognitive assessment to the prediction of productivity outcome after traumatic brain injury (TBI) adjusted for severity of Injury, demographic factors, and preinjury employment status. Design: Inception cohort. Setting: Six inpatient brain injury rehabilitation programs. Participants: A total of 388 adults with TBI whose post-traumatic amnesia (PTA) resolved before discharge from inpatient rehabilitation. Interventions: Administered neuropsychologic tests during inpatient stay on emergence from PTA. Follow-up interview and evaluation. Predictor measures also determined. Main Outcome Measure: Productivity status at follow-up 12 months postinjury. Results: Multiple logistic regression analysis revealed that preinjury productivity status, duration of PTA, education level, and early cognitive status each made significant, independent contributions to the prediction of productivity status at follow-up. When adjusted for all other predictors, persons scoring at the 75th percentile on early cognitive status (less impaired) had 1.61 times greater odds (95% confidence interval [CI], 1.07-2.41) of being productive follow-up than those scoring at the 25th percentile (more impaired). Without adjustment, persons scoring at the 75th percentile had 2.46 times greater odds (95% CI, 1.77-3.43) of being productive at follow-up. Conclusions: Findings support the utility of early cognitive assessment by using neuropsychologic tests. In addition to other benefits, early cognitive assessment makes an independent contribution to prediction of late outcome. Findings support the clinical practice of performing initial neuropsychologic evaluations after resolution of PTA.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Hlth Sci, Jackson, MS 39216 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Mayo Med Ctr, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA		Sherer, M (corresponding author), Methodist Rehabil Ctr, Jackson, MS 39216 USA.	marks@mmrcrehab.org					*AM AC NEUR, 1996, ASS NEUR TEST AD CON, V47, P592; [Anonymous], 1944, ARMY INDIVIDUAL TEST; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Be lin T. R., 2000, HLTH SERV OUTCOMES R, V1, P7; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Hamsher K., 1989, MULTILINGUAL APHASIA; Hanlon RE, 1999, BRAIN INJURY, V13, P873; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HORN LJ, 1999, KLPHYSICAL MED REHAB, V6, P1281; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KlOve H, 1963, MED CLIN N AM; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1994, ARCH NEUROL-CHICAGO, V51, P854, DOI 10.1001/archneur.1994.00540210024009; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1993, HEAD INJURY, P525; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Matthews CG., 1964, INSTRUCTION MANUAL A; MELAMED S, 1985, SCAND J REHABIL MED, P21; Najenson T, 1980, Int Rehabil Med, V2, P17; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Rey A, 1958, LEXAMEN CLINIQUE PSY; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUSK H A, 1969, Medical Clinics of North America, V53, P677; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sbordone R. J., 1998, ECOLOGICAL VALIDITY, P15; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; SHORDONE RJ, 1998, ECOLOGICAL VALIDITY; Smith A., 1982, SYMBOL DIGIT MODALIT; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.3.CO;2-S; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Taylor E. M., 1959, APPRAISAL CHILDREN C; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1981, WAIS R MANUAL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	62	132	133	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2002	83	2					183	192		10.1053/apmr.2002.28802			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	519DP	WOS:000173709900008	11833021				2022-02-06	
J	Schwartz, M; Kipnis, J				Schwartz, M; Kipnis, J			Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries	TRENDS IN MOLECULAR MEDICINE			English	Article							MYELIN BASIC-PROTEIN; POTENTIAL NEUROPROTECTIVE THERAPY; FACIAL-NERVE TRANSECTION; RETINAL GANGLION-CELLS; T-CELLS; DEMYELINATING DISEASE; NEUROTROPHIC FACTOR; MULTIPLE-SCLEROSIS; MOTONEURON LOSS; OPTIC-NERVE	Neuronal degeneration after traumatic injury to the central nervous system (CNS) can be reduced by active immunization or passive transfer of T cells against CNS-associated myelin antigens, We propose that a protective autoimmunity is evoked by CNS insult when non-immunological local protective mechanisms cannot adequately buffer the injury-induced toxicity. The ability of a particular strain to develop a protective autoimmune response appears to be inversely related to its susceptibility to autoimmune disease. We also propose that vaccination with specific CNS-derived 'safe' (non-pathogenic) peptides after traumatic CNS insult, and possibly at any stage of chronic neurodegenerative disease, can be used to boost the protective autoimmunity acid thereby to reduce further injury-induced damage. Such therapeutic vaccination ensures that the augmented beneficial autoimmunity will be free of accompanying disease.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel		Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	michal.schwartz@weizmann.ac.il					Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Bernard C C, 1991, Acta Neurol (Napoli), V13, P171; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Butovsky Oleg, 2001, FASEB Journal, V15, P1065; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; Diaz-Villoslada P, 1999, J NEUROIMMUNOL, V99, P36, DOI 10.1016/S0165-5728(99)00099-5; Drescher KM, 2000, INT IMMUNOL, V12, P271, DOI 10.1093/intimm/12.3.271; DUONG TT, 1994, J NEUROIMMUNOL, V53, P101, DOI 10.1016/0165-5728(94)90069-8; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Gaur A, 1997, J NEUROIMMUNOL, V74, P149, DOI 10.1016/S0165-5728(96)00220-2; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Heath VL, 1998, J AUTOIMMUN, V11, P309, DOI 10.1006/jaut.1998.0210; Hohlfeld R, 2000, J NEUROIMMUNOL, V107, P161, DOI 10.1016/S0165-5728(00)00233-2; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; KIPNIS J, IN PRESS J NEUROSCI; Klocker N, 1998, J NEUROSCI, V18, P1038; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Nicholson SM, 1999, J NEUROIMMUNOL, V98, P136, DOI 10.1016/S0165-5728(99)00090-9; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Pribyl TM, 1996, J NEUROSCI RES, V45, P812; Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498; Schwartz M, 2000, Curr Opin Ophthalmol, V11, P107, DOI 10.1097/00055735-200004000-00007; Schwartz M, 2000, INVEST OPHTH VIS SCI, V41, P349; Seddon B, 2000, IMMUNOL TODAY, V21, P95, DOI 10.1016/S0167-5699(99)01559-5; Seddon B, 1999, J EXP MED, V189, P279, DOI 10.1084/jem.189.2.279; Seddon Benedict, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P339; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.3.CO;2-3; Serpe CJ, 1999, J NEUROSCI, V19; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Spinnewyn B, 1999, J CEREBR BLOOD F MET, V19, P139, DOI 10.1097/00004647-199902000-00004; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Vergelli M, 1996, EUR J IMMUNOL, V26, P2624, DOI 10.1002/eji.1830261113; Walport M., 1999, IMMUNOBIOLOGY IMMUNE; Yoles E, 1998, SURV OPHTHALMOL, V42, P367, DOI 10.1016/S0039-6257(97)00123-9; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; YOLES E, 2001, IN PRESS J NEUROSCI	50	132	133	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4914	1471-499X		TRENDS MOL MED	Trends Mol. Med	JUN	2001	7	6					252	258		10.1016/S1471-4914(01)01993-1			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454MG	WOS:000169975900006	11378514				2022-02-06	
J	Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J				Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J			Recovery of intellectual ability following traumatic brain injury in childhood: Impact of injury severity and age at injury	PEDIATRIC NEUROSURGERY			English	Article						recovery; traumatic brain injury	CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS; SEQUELAE; SKILLS; COHORT	Traumatic brain injury (TBI) may have a profound impact on a child's ongoing development. Various risk factors have been found to predict outcome, but considerable variability remains unexplained. This study used a prospective, longitudinal design to examine the relationship between recovery, injury severity, age at injury and pre-injury ability. 124 children were divided according to (1) age at injury:'young' (3-7 years) 'old' (8-12) and (2) injury severity (mild, moderate, severe). Children were evaluated acutely (T1) and at 12 months post-injury (T2), using standardized intellectual measures (IQ). Results showed a relationship between greater injury severity and poorer IQ. Age at injury was not predictive of outcome for children with mild/moderate TBI, For severe TBI, younger age at injury led to minimal recovery in IQ, while recovery from later injury was similar to that for adults. Findings suggest that children sustaining severe TBI in early childhood may be particularly at risk for residual problems post-injury. Copyright (C) 2000 S. Karger AG. Basel.	Univ Melbourne, Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Dept Neurosurg, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Dept Speech Pathol, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Anderson, V (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia.	v.anderson@psych.unimelb.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, IN PRESS PEDIAT NEUR; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BOND M, 1975, OUTCOME SEVERE DAMAG; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COUSENS P, 1991, J PEDIATR PSYCHOL, V16, P475, DOI 10.1093/jpepsy/16.4.475; Daniel A., 1983, POWER PRIVILEGE PRES; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1127, DOI 10.1136/jnnp.38.11.1127; PONSFORD J, 1997, J INT NEUROPSYCH SOC, V3, P225; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Wechsler D., 1987, MANUAL PRESCHOOL PRI; [No title captured]	37	132	132	0	20	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	JUN	2000	32	6					282	290		10.1159/000028956			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics; Surgery	354RQ	WOS:000089343800002	10971189				2022-02-06	
J	Mittenberg, W; Strauman, S				Mittenberg, W; Strauman, S			Diagnosis of mild head injury and the postconcussion syndrome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; head trauma; mild head injury; postconcussive syndrome; postconcussional symptoms; traumatic brain injury	POST-CONCUSSION SYNDROME; BRAIN INJURY; SYMPTOMS; MODERATE; TRAUMA; IDENTIFICATION; MMPI-2	Mild head injuries can cause acute transient cognitive inefficiency that typically resolves within 3 months. Postconcussion syndrome may initially be related to acute cerebral dysfunction but can also arise as a psychological consequence of head trauma. The syndrome persists beyond 3 months in a significant number of patients with mild head trauma as a psychological disorder. International Classification of Diseases diagnostic criteria for postconcussion syndrome are currently recommended for clinical purposes. These criteria are contrasted with research diagnostic criteria used in the Diagnostic and Statistical Manual of Mental Disorders. The differential diagnosis of persistent cognitive and postconcussive symptoms in forensic practice is reviewed.	Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA		Mittenberg, W (corresponding author), Nova SE Univ, Ctr Psychol Studies, 3301 Coll Ave, Ft Lauderdale, FL 33314 USA.						American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Eisenberg H.M., 1989, MILD HEAD INJURY, P133; FERGUSON RJ, IN PRESS NEUROPSYCHO; FERGUSON RJ, 1995, SOURCEBOOK PSYCHOL T; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Gronwall D, 1989, MILD HEAD INJURY, P153; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Larrabee, 1997, Semin Clin Neuropsychiatry, V2, P196; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LARRABEE GJ, IN PRESS DIFFERENTIA; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; MITTENBERG W, 1993, PSYCHOTHER PRIV PRAC, V12, P615; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Ruff R. M., 1989, MILD HEAD INJURY, P176; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Sosin DM, 1996, BRAIN INJURY, V10, P47; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; World Health Organization, 2004, ICD 10 INT STAT CLAS; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; [No title captured]	43	132	135	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2000	15	2					783	791		10.1097/00001199-200004000-00003			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	305FY	WOS:000086529800003	10739967				2022-02-06	
J	Coelho, CA; McHugh, RE; Boyle, M				Coelho, CA; McHugh, RE; Boyle, M			Semantic feature analysis as a treatment for aphasic dysnomia: A replication	APHASIOLOGY			English	Article								Semantic Feature analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The purpose of this study was to replicate the Boyle and Coelho (1995) study in which SFA was applied with a mild non-fluent aphasic individual resulting in improved confrontation naming of trained and untrained items but no generalization to connected speech. The present study investigated whether a comparable treatment effect could be demonstrated, and to what extent severity and type aphasia might impact overall outcome. SFA was applied to an individual with a moderate fluent aphasia secondary to a closed head injury. Gains in confrontation naming of both trained and untrained stimulus pictures were noted as well as measures of connected speech. Potential explanations for these findings are discussed.	Univ Connecticut, Dept Commun Sci, Storrs, CT 06269 USA; Brooklyn Hosp, New York, NY USA; Cornell Univ, Coll Med, Burke Rehabil Ctr, White Plains, NY 10605 USA		Coelho, CA (corresponding author), Univ Connecticut, Dept Commun Sci, U-85,850 Bolton Rd, Storrs, CT 06269 USA.	coelho@uconnvm.uconn.edu					BENSON DF, 1996, APHATIA CLIN PERSPEC; Boyle M., 1995, AM J SPEECH-LANG PAT, V4, P135, DOI DOI 10.1044/1058-0360.0404.94; COLLINS AM, 1975, PSYCHOL REV, V82, P407, DOI 10.1037/0033-295X.82.6.407; Duffy J., 1994, LANGUAGE INTERVENTIO, P146; FREED DB, 1995, J SPEECH HEAR RES, V38, P1081, DOI 10.1044/jshr.3805.1081; German D. J., 1990, TEST ADOLESCENT ADUL; Holland, 1995, AM J SPEECH-LANG PAT, V4, P109, DOI [https://doi.org/10.1044/1058-0360.0404.109, DOI 10.1044/1058-0360.0404.109]; Kaplan E, 1983, BOSTON NAMING TEST; KERTESZ A, 1982, W APHASTIA BATTERY; LI EC, 1987, J COMMUN DISORD, V20, P469, DOI 10.1016/0021-9924(87)90034-7; LIEBAUGH CW, 1977, P CLIN APH C MINN, P248; MASSARO M, 1994, CLIN APHASIOL, V22, P245; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; PEASE DM, 1978, CORTEX, V14, P179, DOI 10.1016/S0010-9452(78)80043-4; ROSENBECK JC, 1989, APHATIA CLIN APPROAC; SCHNEIDER SL, 1997, CLIN APH C WHIT MT J; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; STOKES TF, 1977, J APPL BEHAV ANAL, V10, P349, DOI 10.1901/jaba.1977.10-349; Thompson C. K., 1989, GEN STRATEGIES TREAT, P82; THOMPSON CK, 1981, P CLIN APH C MINN, P35; YLVISAKER M, 1985, ANN C ILL SPEECH LAN	21	132	135	0	30	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	FEB	2000	14	2					133	142		10.1080/026870300401513			10	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	289DB	WOS:000085604300002					2022-02-06	
J	Raabe, A; Grolms, C; Keller, M; Dohnert, J; Sorge, O; Seifert, V				Raabe, A; Grolms, C; Keller, M; Dohnert, J; Sorge, O; Seifert, V			Correlation of computed tomography findings and serum brain damage markers following severe head injury	ACTA NEUROCHIRURGICA			English	Article						computed tomography; neuron specific enolase; S-100B protein; head injury	NEURON-SPECIFIC ENOLASE; S-100 PROTEIN; PROGNOSTIC VALUE; CARDIAC-SURGERY; BLOOD; INFARCTION; MELANOMA; STROKE	The objective of our study was to investigate the association between the initial levels of serum S-100B protein and neuron specific enolase and the severitiy of radiologically visible brain damage and outcome after severe head injury. Admission computed tomography (CT) scans of forty-four patients with severe head injury were analysed. Initial levels of S-100B protein and neuron specific enolase were compared between the different outcome groups at 6 month, the different categories of the Marshall classification, the presence of traumatic subarachnoid haemorrhage, the type of haematoma and the volume of contusion. Serum S-100B was significantly higher in patients with unfavourable outcome (1.1 mu g/l versus 0.3 mu g/l, p < 0.005, Mann-Whitney U test). In diffuse injury, unfavourable outcome significantly increased with higher Marshall grades (p < 0.05). There was a significant correlation between the four grades of diffuse injury and initial serum S-100B protein (r = 0.48, p < 0.001). Patients with focal mass lesions and a favourable outcome after 6 month had significantly lower S-100B values than those who had an unfavourable outcome (0.51 mu g/l versus 1.3 mu g/l, p < 0.05). A significant correlation was demonstrated between the volume of contusion visible on CT scans and serum S-100B (r = 0.58, p < 0.001). In our study, initial serum S-100B protein was a powerful predictor of outcome even within the same category of radiologically visible brain damage. Serum S-100B protein may provide independent information about the severity of primary brain damage after head injury.	Univ Leipzig, Dept Neurosurg, D-04103 Leipzig, Germany; Klinikum Chemnitz, Dept Neurosurg, Chemnitz, Germany		Raabe, A (corresponding author), Univ Leipzig, Dept Neurosurg, Johannisallee 34, D-04103 Leipzig, Germany.						Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Clatterbuck RE, 1997, NEUROSURGERY, V40, P339, DOI 10.1097/00006123-199702000-00019; FAGNART OC, 1988, CLIN CHEM, V34, P1387; GRILL M, 1998, PHARMACOPSYCHIATRY, V31; GUO HB, 1995, EUR J CANCER, V31A, P1898, DOI 10.1016/0959-8049(95)00087-Y; HANS P, 1993, J NEUROSURG ANESTH, V5, P111; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; KIM JS, 1996, STROKE, V27, P1533; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miliotes G, 1996, ANN SURG ONCOL, V3, P558, DOI 10.1007/BF02306089; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; RAABE A, 1998, IN PRESS J NEUROL NE; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Taggart DP, 1997, ANN THORAC SURG, V63, P492; USUI A, 1989, CLIN CHEM, V35, P1942; VOLLMER DG, 1993, HEAD INJURY, P553; vonSchoultz E, 1996, MELANOMA RES, V6, P133, DOI 10.1097/00008390-199604000-00008; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	28	132	136	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1998	140	8					787	792		10.1007/s007010050180			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	123UY	WOS:000076144700016	9810445				2022-02-06	
J	Sinson, G; Perri, BR; Trojanowski, JQ; Flamm, ES; McIntosh, TK				Sinson, G; Perri, BR; Trojanowski, JQ; Flamm, ES; McIntosh, TK			Improvement of cognitive deficits and decreased cholinergic neuronal cell loss and apoptotic cell death following neurotrophin infusion after experimental traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						apoptosis; fluid-percussion injury; nerve growth factor; cognitive dysfunction; traumatic brain injury; rat	NERVE GROWTH-FACTOR; NUCLEAR-DNA FRAGMENTATION; FLUID-PERCUSSION INJURY; DIFFUSE AXONAL INJURY; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; MEMORY IMPAIRMENT; RAT HIPPOCAMPAL; NGF; ISCHEMIA	This study explores the effects of infusion of nerve growth factor (NGF) on behavioral outcome and cell death in the septal region using the clinically relevant model of fluid-percussion brain injury in the rat. Animals were subjected to fluid-percussion brain injury and 24 hours later a miniosmotic pump was implanted to infuse NGF (12 animals) or vehicle (12 animals) directly into the region of maximum injury for 2 weeks. Four weeks postinjury the animals were tested for cognitive function using a Morris Water Maze paradigm. Neurological motor function was evaluated over a 4-week postinjury period. The rats receiving NGF infusions had significantly higher memory scores than vehicle-treated animals. Examination of the cholinergic neurons in the medial septal region using choline acetyltransferase immunohistochemistry demonstrated significant cell loss after injury. infusion of NGF significantly attenuated loss of these cholinergic neurons. A second group of animals was subjected to fluid-percussion brain injury alone (23 rats) or injury followed by NGF infusion(18 rats). These animals were killed between 24 hours and 2 weeks postinjury and the septal region was examined for the presence of apoptotic cells using the terminal deoxynucleotidyl transferase-mediated biotinylated-deoxyuridinetriphosphate nick-end labeling technique. Apoptotic cells were identified as early as 24 hours postinjury; their numbers peaked at 4 and 7 days, and then declined by 14 days. The NGF-treated animals had some apoptotic cells; however, even at 7 days there were significantly fewer of these cells. No significant motor differences were observed between the NCF- and vehicle treated groups. These data indicate that NGF administration beginning 24 hours after fluid-percussion brain injury has a beneficial effect on cognition and results in sparing of cholinergic septal neurons. These improvements persist after cessation of NGF administration. The beneficial effects of NGF may be related to its ability to attenuate traumatically induced apoptotic cell death.	UNIV PENN, SCH MED, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19104 USA						NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS PO1-08803, NS RO1-26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DACEY RG, 1993, HEAD INJURY, P159; DAVIES P, 1976, LANCET, V2, P1403; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DEKKER AJ, 1994, BRAIN RES, V639, P149, DOI 10.1016/0006-8993(94)91775-2; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; EHNI G, 1987, SURG 3 VENTRICLE, P326; FERRER I, 1994, BRAIN PATHOL, V4, P115, DOI 10.1111/j.1750-3639.1994.tb00821.x; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FRANCIS PT, 1985, NEW ENGL J MED, V313, P7, DOI 10.1056/NEJM198507043130102; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; GAGE FH, 1990, PROG BRAIN RES, V83, P357; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HAGG T, 1990, J NEUROSCI, V10, P3087; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, P86; HEFTI F, 1993, PROG BRAIN RES, V98, P257; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HILLBOM E, 1969, LATE EFFECTS HEAD IN, P98; JACOBSON M, 1991, DEV NEUROBIOL, P5; KAUFMANN Y, 1995, NEW ENGL J MED, V332, P507, DOI 10.1056/NEJM199502233320805; Kerr JFR, 1991, APOPTOSIS MOL BASIS, P5; KORSCHING S, 1993, J NEUROSCI, V13, P2739; Kraus JF, 1993, HEAD INJURY, P1; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P63; LOCKSHIN RA, 1992, ANN NY ACAD SCI, V663, P234, DOI 10.1111/j.1749-6632.1992.tb38667.x; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLSON L, 1993, EXP NEUROL, V124, P5, DOI 10.1006/exnr.1993.1167; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SEIGER A, 1993, BEHAV BRAIN RES, V57, P255, DOI 10.1016/0166-4328(93)90141-C; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOFRONIEW MV, 1993, J NEUROSCI, V13, P5263, DOI 10.1523/JNEUROSCI.13-12-05263.1993; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1976, GREENFIELDS NEUROPAT, P327; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YUNSHAO H, 1992, Brain Research, V586, P27; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	69	132	141	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1997	86	3					511	518		10.3171/jns.1997.86.3.0511			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	WJ267	WOS:A1997WJ26700012	9046309				2022-02-06	
J	Prins, ML; Lee, SM; Cheng, CLY; Becker, DP; Hovda, DA				Prins, ML; Lee, SM; Cheng, CLY; Becker, DP; Hovda, DA			Fluid percussion brain injury in the developing and adult rat: A comparative study of mortality, morphology: Intracranial pressure and mean arterial blood pressure	DEVELOPMENTAL BRAIN RESEARCH			English	Article						brain injury; fluid percussion; concussion; development; intracranial pressure; mean arterial blood pressure	CEREBRAL GLUCOSE-UTILIZATION; POSITRON EMISSION TOMOGRAPHY; PEDIATRIC HEAD-INJURY; FREELY MOVING RATS; CORTICAL-LESIONS; FETAL KITTENS; MATURATION; CHILDREN; MODEL; EDEMA	Changes in intracranial pressure (ICP) and mean arterial blood pressure (MABP) were measured for 30 min following an experimental fluid percussion traumatic brain injury in postnatal day 17 (P17), P28 and adult rats. Under enflurane anesthesia the left femoral artery was cannulated for MABP measurements and a 20 gauge needle was stereotaxically positioned into the right lateral ventricle for ICP measurements. Three different injury severities (mild: 1.35-1.45 atm, moderate: 2.65-2.75 atm, severe: 3.65-3.75 atm) were delivered over the left parietal cortex to each of the age groups. The biomechanical/physiological results indicated that fluid percussion generated reproducible traumatic brain injuries in the developing mt. Furthermore, with increasing injury severity the physiological responses (in terms of ICP and MABP) became more pronounced, resulting in a corresponding increase in mortality (mild, moderate, severe, respectively, P17: 27%, 36%, 100%; P28: 33%, 30%, 75%; adult: 0%. 20%, 55%). Compared to adult animals, developing rats exhibited pronounced hypotension in response to closed head injury, which most likely explains the greater percent mortality among the younger animals. The utilization of this model will allow for future studies addressing the consequences of traumatic brain injury when it is sustained early in development.			Prins, ML (corresponding author), UNIV CALIF LOS ANGELES, SCH MED,DIV NEUROSURG,BRAIN RES INST,ROOM 18-228, BOX 957039, LOS ANGELES, CA 90025 USA.		Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308] Funding Source: Medline		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BAER M J, 1954, Hum Biol, V26, P80; BAIMBRIDGE KG, 1982, BRAIN RES, V239, P519, DOI 10.1016/0006-8993(82)90526-1; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BOOCK RJ, 1993, ANN BIOMED ENG, V21, P645, DOI 10.1007/BF02368644; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; CHUGANI HT, 1991, J CEREBR BLOOD F MET, V11, P35, DOI 10.1038/jcbfm.1991.4; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Finger S., 1988, BRAIN INJURY RECOVER, P117; Ford D H, 1973, Prog Brain Res, V40, P1; GINSBERG MD, 1989, STROKE, V20, P1627, DOI 10.1161/01.STR.20.12.1627; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HATASHITA S, 1988, STROKE, V19, P91, DOI 10.1161/01.STR.19.1.91; HAYS WL, 1973, STAT SOCIAL SCI, P169; Hornig G W, 1987, Z Kinderchir, V42 Suppl 1, P23; HOVDA DA, 1992, J CEREBR BLOOD F MET, V12, P1039, DOI 10.1038/jcbfm.1992.141; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; KOLB B, 1987, BEHAV BRAIN RES, V26, P119, DOI 10.1016/0166-4328(87)90161-6; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANDRY CF, 1990, J NEUROSCI RES, V25, P194, DOI 10.1002/jnr.490250207; LE HM, 1994, J NEUROTRAUM, V12, P128; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P49; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOSS ML, 1972, ACTA ANAT, V81, P161; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NEHLIG A, 1988, J NEUROSCI, V8, P2321; OTSUBO H, 1991, PEDIATR NEUROSURG, V16, P208, DOI 10.1159/000120609; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; PICCOLI F, 1971, J NEUROCHEM, V18, P1135, DOI 10.1111/j.1471-4159.1971.tb12042.x; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RODBARD S, 1955, CIRCULATION, V12, P883, DOI 10.1161/01.CIR.12.5.883; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SMITH ML, 1995, J CEREB BLOOD FLOW M, V15, pS723; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; VANDENBRINK WA, 1990, ACT NEUR S, V51, P261; VILLABLANCA JR, 1993, BEHAV BRAIN RES, V57, P63, DOI 10.1016/0166-4328(93)90062-U; VILLABLANCA JR, 1993, BEHAV BRAIN RES, V57, P79, DOI 10.1016/0166-4328(93)90063-V; WILLIAMSON DH, 1993, DEV NEUROSCI-BASEL, V15, P156, DOI 10.1159/000111331; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	65	132	133	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-3806			DEV BRAIN RES	Dev. Brain Res.	SEP 2	1996	95	2					272	282		10.1016/S0165-3806(96)00098-3			11	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	VE640	WOS:A1996VE64000015	8874903				2022-02-06	
J	SCHRODER, ML; MUIZELAAR, JP; BULLOCK, MR; SALVANT, JB; POVLISHOCK, JT				SCHRODER, ML; MUIZELAAR, JP; BULLOCK, MR; SALVANT, JB; POVLISHOCK, JT			FOCAL ISCHEMIA DUE TO TRAUMATIC CONTUSIONS DOCUMENTED BY STABLE XENON-CT AND ULTRASTRUCTURAL STUDIES	JOURNAL OF NEUROSURGERY			English	Article						CEREBRAL CONTUSION; CEREBRAL BLOOD FLOW; CEREBRAL BLOOD VOLUME; CEREBRAL EDEMA; ULTRASTRUCTURE; MICROVASCULATURE	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; INTRACEREBRAL HEMATOMA; SUPEROXIDE-DISMUTASE; ACUTE PHASE; ADHESION; SYSTEM; REPERFUSION; DAMAGE; COMA	A traumatic cerebral contusion causes a zone of perifocal neuronal necrosis, the cause of which is not known; the surgical management of these lesions remains controversial. To determine the pathophysiological mechanisms responsible for brain damage after contusions, the authors performed cerebral blood now (CBF) mapping studies and related these to change in local cerebral blood volume (CBV) and ultrastructure. In 11 severely head injured patients with contusion, CBF and CBV were measured in pericontusional areas using stable xenon-computerized tomography (CT). These studies demonstrated a profound reduction in perilesional CBF (mean 17.5 +/- 4 ml/100 g/min), which was always accompanied by a zone of edema defined by CT density measurements. Mean CBV in these regions was 2.3 +/- 0.4 ml/100 g, a reduction to approximately one-half the value of 4.8 ml/100 g found in the nonedematous regions, and to approximately 35% of the value of 6.0 ml/100 g found in normal volunteers. Ultrastructural analysis of the pericontusional tissue, taken at surgery in four patients with high intracranial pressure showed glial swelling with narrowing of the microvascular lumina due to massive podocytic process swelling. Additionally, some suggestion of vascular occlusion due to erythrocyte and leukocyte stasis was seen. These data support the conclusion that microvascular compromise by compression and/or occlusion is a major event associated with profound perilesional hypoperfusion, which is a uniform finding within edematous pericontusional tissue.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029412] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19469, 5RO1NS29412-03] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Adams JH, 1990, HDB CLIN NEUROLOGY, P43; Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; AMES A, 1968, AM J PATHOL, V52, P437; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BELL BA, 1985, J NEUROSURG, V62, P31, DOI 10.3171/jns.1985.62.1.0031; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; BONVENTO G, 1991, BRAIN RES REV, V16, P257, DOI 10.1016/0165-0173(91)90009-W; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; Bullock R, 1984, Neurol Res, V6, P184; BULLOCK R, 1990, ACT NEUR S, V51, P286; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BULLOCK R, 1985, J NEUROSURG, V63, P64, DOI 10.3171/jns.1985.63.1.0064; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; BULLOCK R, 1990, HDB CLIN NEUROLOGY, V57, P249; CHESLER M, 1993, J NEUROTRAUMA, V11, P104; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; DOREDUFFY P, 1994, MOL CHEM NEUROPATHOL, V22, P161, DOI 10.1007/BF03160103; EIDE PK, 1992, ACTA NEUROL SCAND, V86, P194, DOI 10.1111/j.1600-0404.1992.tb05065.x; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FATOUROS PP, 1987, INVEST RADIOL, V22, P705, DOI 10.1097/00004424-198709000-00003; FATOUROS PP, 1995, IN PRESS QUANTITATIV; FEUERSTEIN G, 1990, STROKE, V21, P90; FRANKE CL, 1988, NEURORADIOLOGY, V30, P73, DOI 10.1007/BF00341948; FREEMAN BA, 1982, LAB INVEST, V47, P412; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; KIRSCH JR, 1992, J NEUROTRAUM, V9, pS157; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; LINDENBERG R, 1957, ARCH PATHOL, V63, P23; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MAXWELL WL, 1994, ACTA NEUROCHIR, P465; Mendelow A D, 1984, Neurol Res, V6, P189; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; MYSEROS JS, 1994, J NEUROTRAUMA, V11, P120; OLNEY JW, 1988, EXCITATORY AMINO ACI, P337; PALMBLAD J, 1994, J IMMUNOL, V152, P262; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SCHRODER ML, 1995, IN PRESS QUANTITATIV; SCHRODER ML, 1994, THESIS FREE U AMSTER, P81; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STALHAMMER DH, 1990, HDB CLIN NEUROLOGY, P17; STEWART L, 1994, J NEUROTRAUMA S, V10, P104; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TEASDALE G, 1974, LANCET, V2, P81; TODD NV, 1990, ACT NEUR S, V51, P296; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	59	132	133	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	1995	82	6					966	971		10.3171/jns.1995.82.6.0966			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	QZ904	WOS:A1995QZ90400008	7760199				2022-02-06	
J	LYNCH, DR; DAWSON, TM				LYNCH, DR; DAWSON, TM			SECONDARY MECHANISMS IN NEURONAL TRAUMA	CURRENT OPINION IN NEUROLOGY			English	Article							EXCITATORY AMINO-ACIDS; RECEPTOR CHANNEL COMPLEX; CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN MEMBRANES; SPINAL-CORD INJURY; NITRIC-OXIDE; NMDA-RECEPTORS; SUPEROXIDE PRODUCTION; IMPACT INJURY; ANTAGONISTS	Secondary damage in central nervous system trauma results from toxic effects of a variety of modulators that magnify the initial traumatic damage. These modulators include the excitatory transmitter glutamate, the intracellular messenger calcium, and the intercellular messenger nitric oxide. Glutamate-induced toxicity, called excitotoxicity, occurs from excess glutamate release following trauma. Passage of calcium into the cell through a specific postsynaptic glutamate receptor ion channel, the N-methyl-D-aspartate (NMDA) receptor, is crucial in activating cellular pathways leading to excitotoxic damage. The NMDA receptor requires both glutamate and glycine for activation and is blocked by many drugs that act at either of these sites. It is also blocked by agents that selectively block the ion channel of this receptor. Blocking NMDA receptors at any of these sites decreases the cellular damage mediated by glutamate in neuronal trauma and improves physiological measures associated with traumatic damage. Other strategies to limit secondary damage include blockade of other calcium channels, of calcium-activated enzymes, and of processes that mediate the effects of calcium. Calcium-activated enzymes include nitric oxide synthase and phospholipases, which cause production of free radicals. In combination with NMDA receptor blockade, these sites represent promising areas for therapeutic intervention in secondary traumatic damage.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL & NEUROSCI, BALTIMORE, MD 21287 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NSO1578] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001578] Funding Source: NIH RePORTER		BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BENEVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131; CARREAU A, 1994, EUR J PHARMACOL, V256, P241, DOI 10.1016/0014-2999(94)90549-5; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHOI D, 1988, TRENDS NEUROSCI, V7, P357; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1994, IN PRESS NEUROSCIENT; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAGE D, 1993, NEUROSCI LETT, V149, P173, DOI 10.1016/0304-3940(93)90764-C; FAGG GE, 1987, NEUROSCI LETT, V76, P221, DOI 10.1016/0304-3940(87)90719-1; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; ISHII T, 1993, J BIOL CHEM, V268, P2836; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LNCH DR, 1994, MOL PHARMACOL, V45, P540; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4845; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1107; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; ROCK DM, 1992, MOL PHARMACOL, V41, P83; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; WILLIAMS K, 1994, IN PRESS MOL PHARM; WONG EHF, 1988, J NEUROCHEM, V50, P274, DOI 10.1111/j.1471-4159.1988.tb13260.x; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	50	132	138	0	1	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	1994	7	6					510	516		10.1097/00019052-199412000-00007			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV143	WOS:A1994PV14300007	7866582				2022-02-06	
J	DIETRICH, WD				DIETRICH, WD			THE IMPORTANCE OF BRAIN TEMPERATURE IN CEREBRAL INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	9TH ANNUAL MEETING OF THE NEUROTRAUMA SOC	NOV 09-10, 1991	NEW ORLEANS, LA	NEUROTRAUMA SOC			ISCHEMIC NEURONAL INJURY; FOREBRAIN ISCHEMIA; MILD HYPOTHERMIA; INTRACEREBRAL MICRODIALYSIS; GLOBAL-ISCHEMIA; BLOOD-FLOW; RAT-BRAIN; RELEASE; DAMAGE; HYPERTHERMIA	The recent finding that small variations in brain temperature can critically determine the extent of histopathological injury in animal models of brain injury has generated renewed interest in hypothermic brain protection. Whereas mild hypothermia protects the brain from ischemic and traumatic brain injury, mild hyperthermia worsens ischemic outcome. Selective brain cooling has many advantages over whole body cooling, including the elimination of harmful side effects, such as cardiac arrhythmias. In addition to the clinical issue of brain protection, manipulating brain temperature has become a powerful tool with which to investigate the pathophysiology of ischemic and traumatic brain injury. The purpose of this article is to review and discuss recent findings demonstrating the importance of brain temperature in ischemic and traumatic brain injury. Potential mechanisms by which mild hypothermia may attenuate and mild hyperthermia accentuate the detrimental consequences of brain injury are reviewed.	UNIV MIAMI,SCH MED,CEREBRAL VASC DIS RES CTR,DEPT CELL BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,CEREBRAL VASC DIS RES CTR,DEPT ANAT,MIAMI,FL 33101		DIETRICH, WD (corresponding author), UNIV MIAMI,SCH MED,CEREBRAL VASC DIS RES CTR,DEPT NEUROL D4-5,POB 016960,MIAMI,FL 33101, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27127, NS05820] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS005820, R01NS027127, P50NS005820] Funding Source: NIH RePORTER		ARAKI N, 1991, J CEREB BLOOD FLO S2, V11, pS843; BAKER AJ, 1992, ROLE NEUROTRANSMITTE; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHOPP M, 1988, STROKE, V19, P1521, DOI 10.1161/01.STR.19.12.1521; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; Dietrich W, 1991, J CEREB BLOOD FLO S2, V11, pS846; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P405, DOI 10.1038/jcbfm.1986.73; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DIETRICH WD, 1984, J NEUROPATH EXP NEUR, V43, P72, DOI 10.1097/00005072-198401000-00006; DRAKE CG, 1962, CAN MED ASSOC J, V87, P887; DRAKE CG, 1964, J NEUROSURG, V21, P575, DOI 10.3171/jns.1964.21.7.0575; GARCIA JH, 1971, ACTA NEUROPATHOL, V18, P273, DOI 10.1007/BF00688441; GINSBERG MD, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P499; GINSBERG MD, 1989, J CEREB BLOOD FLO S1, V9, P380; GINSBERG MD, 1980, CEREBRAL VASCULAR DI, V3, P195; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GLOBUS MYT, 1991, J CEREB BLOOD FLO S2, V11, pS10; HAGERDAL M, 1979, ACTA ANAESTH SCAND, V23, P89; HAGERDAL M, 1978, ANESTHESIOLOGY, V49, P165, DOI 10.1097/00000542-197809000-00003; HOSSMANN KA, 1971, ACTA NEUROPATHOL, V18, P103, DOI 10.1007/BF00687598; HOSSMANN KA, 1987, J NEUROL SCI, V77, P305, DOI 10.1016/0022-510X(87)90130-4; IKONOMIDOU C, 1989, BRAIN RES, V487, P184, DOI 10.1016/0006-8993(89)90956-6; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JIANG JY, 1992, ROLE NEUROTRANSMITTE; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; KRANTIS A, 1983, ACTA NEUROPATHOL, V60, P61, DOI 10.1007/BF00685348; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; KUROIWA T, 1990, J CEREBR BLOOD F MET, V10, P550, DOI 10.1038/jcbfm.1990.97; LEONOV T, 1990, J CEREB BLOOD FLOW M, V10, P57; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; MCDONALD JW, 1991, NEUROSCI LETT, V126, P83, DOI 10.1016/0304-3940(91)90377-6; MELLERGARD P, 1990, British Journal of Neurosurgery, V4, P31, DOI 10.3109/02688699009000679; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; MICHENFELDER JD, 1977, STROKE, V8, P87, DOI 10.1161/01.STR.8.1.87; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758; MORIKAWA E, 1991, STROKE, V22, P130; MORIKAWA E, 1991, J CEREB BLOOD FLO S2, V11, pS116; MULLAN S, 1961, ARCH NEUROL-CHICAGO, V5, P545, DOI 10.1001/archneur.1961.00450170083010; NATALE JE, 1989, STROKE, V20, P770, DOI 10.1161/01.STR.20.6.770; ONESTI ST, 1991, NEUROSURGERY, V29, P369, DOI 10.1227/00006123-199109000-00005; PETITO CK, 1979, J NEUROPATH EXP NEUR, V38, P222, DOI 10.1097/00005072-197905000-00003; PULSINELLI WA, 1982, ANN NEUROL, V11, P499, DOI 10.1002/ana.410110510; QUOCK RM, 1987, LIFE SCI, V41, P683; ROSOMOFF HL, 1957, ARCH NEURO PSYCHIATR, V78, P454, DOI 10.1001/archneurpsyc.1957.02330410018002; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; SAITO N, 1992, ROLE NEUROTRANSMITTE; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; STERNAU L, 1991, J CEREB BLOOD FLO S2, V11, pS123; STERNAU LL, 1991, NEUR ABSTR, V17, P1081; UEKI M, 1988, J CEREBR BLOOD F MET, V8, P486, DOI 10.1038/jcbfm.1988.89; UIHLEIN A, 1966, JAMA-J AM MED ASSOC, V195, P127; VANDIJK F, 1991, SOC NEUR ABSTR, V17, P1080; VIBULSRESTH S, 1987, STROKE, V18, P210, DOI 10.1161/01.STR.18.1.210; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98	71	132	132	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S475	S485					11	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900005	1613807				2022-02-06	
J	POVLISHOCK, JT; ERB, DE; ASTRUC, J				POVLISHOCK, JT; ERB, DE; ASTRUC, J			AXONAL RESPONSE TO TRAUMATIC BRAIN INJURY - REACTIVE AXONAL CHANGE, DEAFFERENTATION, AND NEUROPLASTICITY	JOURNAL OF NEUROTRAUMA			English	Article							MINOR HEAD-INJURY; CEREBRAL BLOOD-FLOW; SPINAL-CORD TRAUMA; HORSERADISH-PEROXIDASE; CELL NEURONS; NERVE; NEUROFILAMENTS; DAMAGE; RAT; DEGENERATION	Axonal injury appears to be a feature common to all traumatic brain injuries, and has been linked to much of the morbidity seen in head-injured patients. We consider how such axonal injury contributes to morbidity and also sets the stage for CNS reorganization postinjury. Efforts should continue to determine the correlates of such reorganization and to rind therapeutic strategies to expedite it.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROL,RICHMOND,VA 23298		POVLISHOCK, JT (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BALENTINE JD, 1978, LAB INVEST, V39, P254; BALENTINE JD, 1977, ANN NEUROL, V2, P520, DOI 10.1002/ana.410020612; BALENTINE JD, 1980, J NEUROPATH EXP NEUR, V39, P339, DOI 10.1097/00005072-198005000-00015; BALENTINE JD, 1985, CENTRAL NERVOUS SYST, P455; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ERB DE, 1991, EXP BRAIN RES, V83, P253; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KRISTENSSON K, 1978, ANNU REV PHARMACOL, V18, P97, DOI 10.1146/annurev.pa.18.040178.000525; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MALMGREN LT, 1979, NEUROSCI LETT, V13, P13, DOI 10.1016/0304-3940(79)90067-3; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; MAXWELL WL, 1990, J NEUROCYTOL, V19, P235, DOI 10.1007/BF01217301; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NIXON RA, 1987, J NEUROSCI, V7, P1145; OLSSON TP, 1978, J NEUROCYTOL, V7, P323, DOI 10.1007/BF01176997; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; POVLISHOCK JT, 1990, ADV NEUROTRAUMA RES, V2, P1; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SCHLAEPFER WW, 1978, J CELL BIOL, V78, P369, DOI 10.1083/jcb.78.2.369; SCHLAEPFER WW, 1974, BRAIN RES, V69, P203, DOI 10.1016/0006-8993(74)90002-X; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	49	132	135	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S189	S200					12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600018	1588608				2022-02-06	
J	Schinke, RJ; Stambulova, NB; Si, GY; Moore, Z				Schinke, Robert J.; Stambulova, Natalia B.; Si, Gangyan; Moore, Zella			International society of sport psychology position stand: Athletes' mental health, performance, and development	INTERNATIONAL JOURNAL OF SPORT AND EXERCISE PSYCHOLOGY			English	Article						mental health; elite athletes; career stressors; holistic development	BRUNEL MOOD SCALE; ELITE; MINDFULNESS; PREVALENCE; TRANSITIONS; CONCUSSION; DEPRESSION; SYMPTOMS; CAREERS; INJURY	Mental health is a major resource for athletes in relation to their performance and development. Concurrently, athletes experience additional mental health risk factors compared to non-athletic population, such as high training loads, tough competitions, and a stressful lifestyle. Contemporary statistics demonstrate a substantial growth in athletes' mental health-related problems, such as concussion, overtraining, and identity crisis. Therefore, the International Society of Sport Psychology through this Position Stand provides support to sport psychology researchers, practitioners, sport participants, and stakeholders in understanding: (a) mental health phenomenon based on continuum-type models outlining mental illness (prevalence vs. absence) and mental health in association with peak performance, (b) major findings of research dealing with athletes' performance, career and personal (e.g. identity) development in relation to mental health issues, and (c) interventions aimed at monitoring and maintaining athletes' mental health as well as preventing various forms of mental ill-being. Five major sections reflect the logic outlined above (i.e. from definitions and theories to research and practice), complemented by 10 postulates summarising the International Society of Sport Psychology message intended to spur further discussions on how to make athletes healthier and, thus, more resourceful for (and through) sport.	[Schinke, Robert J.] Laurentian Univ, Sch Human Kinet, Sudbury, ON, Canada; [Stambulova, Natalia B.] Halmstad Univ, Sch Hlth & Welf, Halmstad, Sweden; [Si, Gangyan] Hong Kong Inst Educ, Dept Hlth & Phys Educ, Hong Kong, Peoples R China; [Moore, Zella] Manhattan Coll, Dept Psychol, Bronx, NY 10471 USA		Schinke, RJ (corresponding author), Laurentian Univ, Sch Human Kinet, Sudbury, ON, Canada.	rschinke@laurentian.ca	Schinke, Robert/AAS-2966-2020	Schinke, Robert J./0000-0002-4432-0730; Stambulova, Natalia/0000-0001-6198-0784			American Sports Data Inc, 2006, COMPR STUD SPORTS IN; [Anonymous], 2007, NEUR DIS PUBL HLTH C; Appaneal R. N, 2013, PSYCHOL SPORT INJURY, P117; Australian Institute of Health and Welfare , 2014, INJURY RES STAT SERI, V92; Bapat S, 2009, AUSTRALAS PSYCHIATRY, V17, P475, DOI 10.1080/10398560902964586; Battochio RC, 2013, INT J SPORT EXERC PS, V11, P101, DOI 10.1080/1612197X.2013.748996; Blodgett AT, 2015, PSYCHOL SPORT EXERC, V21, P115, DOI 10.1016/j.psychsport.2015.03.001; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Boffano P, 2011, J CRANIOFAC SURG, V22, P2053, DOI 10.1097/SCS.0b013e318231988d; Brannon L., 2014, HLTH PSYCHOL INTRO B; BUDGETT R, 1994, BRIT MED J, V309, P465, DOI 10.1136/bmj.309.6952.465; Budgett R, 1998, BRIT J SPORT MED, V32, P107, DOI 10.1136/bjsm.32.2.107; Campbell E.E, 2009, ATHLETIC INSIGHT, V11, pXXX; Castonguay L. G., 2013, PSYCHOPATHOLOGY SCI; Creswell JD, 2014, CURR DIR PSYCHOL SCI, V23, P401, DOI 10.1177/0963721414547415; Davydov DM, 2010, CLIN PSYCHOL REV, V30, P479, DOI 10.1016/j.cpr.2010.03.003; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Dworkin SL, 1998, SOCIOL SPORT J, V15, P1, DOI 10.1123/ssj.15.1.1; Brandao MRF, 2013, INT PER KEY ISS SPO, P43; Foot J., 2012, WHAT MAKES US HLTH A; Franck A, 2018, INT J SPORT EXERC PS, V16, P398, DOI [10.1080/1612197x.2016.1256339, 10.1080/1612197X.2016.1256339]; Gardner F, 2007, PSYCHOL ENHANCING HU; Gardner F, 2001, ANN C ASS ADV APPL S; Gardner F., 2006, CLIN SPORT PSYCHOL; Gardner FL, 2004, BEHAV THER, V35, P707, DOI 10.1016/S0005-7894(04)80016-9; Gardner FL, 2012, CAN PSYCHOL, V53, P309, DOI 10.1037/a0030220; Gastin PB, 2013, J STRENGTH COND RES, V27, P2518, DOI 10.1519/JSC.0b013e31827fd600; Gill D., 2010, CULTURAL TURN SPORT, P53; Gordon S, 1986, SPORT SCI PERIODICAL, P1; Gouttebarge V, 2015, OCCUP MED-OXFORD, V65, P190, DOI 10.1093/occmed/kqu202; Gouttebarge V, 2017, J SPORT SCI, V35, P2148, DOI 10.1080/02640414.2016.1258485; Gouttebarge V, 2016, KNEE SURG SPORT TR A, V24, P3934, DOI 10.1007/s00167-015-3729-y; Gouttebarge V, 2016, EUR J SPORT SCI, V16, P595, DOI 10.1080/17461391.2015.1086819; Gross M., 2016, INT J SPORT EXERCISE; Guignon C., 2015, INT S NAT OL COMM NA; Gulliver A, 2015, J SCI MED SPORT, V18, P255, DOI 10.1016/j.jsams.2014.04.006; Gulliver A, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-157; Gulliver Amelia, 2012, J Med Internet Res, V14, pe69, DOI 10.2196/jmir.1864; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Gustafsson H, 2015, J CLIN SPORT PSYCHOL, V9, P263, DOI 10.1123/jcsp.2014-0051; Hammond T, 2013, CLIN J SPORT MED, V23, P273, DOI 10.1097/JSM.0b013e318287b870; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hendry LB., 2002, LIFESPAN DEV RESOURC; Henriksen K, 2010, PSYCHOL SPORT EXERC, V11, P212, DOI 10.1016/j.psychsport.2009.10.005; Hughes L, 2012, BRIT J PSYCHIAT, V200, P95, DOI 10.1192/bjp.bp.111.095976; Ivarsson A, 2018, INT J SPORT EXERC PS, V16, P365, DOI 10.1080/1612197X.2016.1242149; Ivarsson A, 2013, J SPORT REHABIL, V22, P19, DOI 10.1123/jsr.22.1.19; Ivarsson A, 2010, J SPORT SCI MED, V9, P347; Kbler-Ross E., 1969, DEATH DYING; Kentta G, 1998, SPORTS MED, V26, P1; Keyes CLM, 2002, J HEALTH SOC BEHAV, V43, P207, DOI 10.2307/3090197; Kontos A. P., 2016, ROUTLEDGE INT HDB SP, P204; Kontos A. P., 2009, CULTURAL SPORT PSYCH, P103, DOI DOI 10.5040/9781492595366.CH-009; Koutedakis Y, 1990, Br J Sports Med, V24, P248; KRANE V, 2000, OLYMPICS MILLENNIUM, P147; Krane V, 2015, INT PER KEY ISS SPO, P48; Lan MF, 2012, J SPORT SCI MED, V11, P131; Lardon MT, 2013, CLINICAL SPORTS PSYCHIATRY: AN INTERNATIONAL PERSPECTIVE, P132; Lavallee D, 2005, SPORT PSYCHOL, V19, P193, DOI 10.1123/tsp.19.2.193; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Main L, 2009, EUR J SPORT SCI, V9, P195, DOI 10.1080/17461390902818260; Markser VZ, 2011, EUR ARCH PSY CLIN N, V261, P182, DOI 10.1007/s00406-011-0239-x; Matos NF, 2011, MED SCI SPORT EXER, V43, P1287, DOI 10.1249/MSS.0b013e318207f87b; Meeusen R, 2006, EUR J SPORT SCI, V6, P1, DOI 10.1080/17461390600617717; Moore Z. E., 2011, NEW SPORT EXERCISE P, P381; Moore Z. E., 2012, OXFORD HDB SPORT PER; Moore Z.E., 2016, ROUTLEDGE COMPANION, P51; Murphy S., 2012, OXFORD HDB SPORT PER; NCAA (Author), 2014, NCAA STUD ATHL SUBST; NCAA Sport Science Institute, 2016, MENT HLTH LANDSC SPO; Pedersen P, 1986, ATHLETIC TRAINING, V21, P1; Peluso Marco Aurélio Monteiro, 2005, Clinics, V60, P61, DOI 10.1590/S1807-59322005000100012; Poczwardowski A, 2014, J APPL SPORT PSYCHOL, V26, P33, DOI 10.1080/10413200.2013.773950; Podlog L., 2016, ROUTLEDGE INT HDB SP, P167; Raglin JS, 2001, SPORTS MED, V31, P875, DOI 10.2165/00007256-200131120-00004; Raglin JS., 2000, EMOTIONS SPORT, P191; Reints Anke., 2011, THESIS; Rice SM, 2016, SPORTS MED, V46, P1333, DOI 10.1007/s40279-016-0492-2; ROSE J, 1993, SPORT PSYCHOL, V7, P309, DOI 10.1123/tsp.7.3.309; Ryba TV, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00427; Ryba TV, 2013, INT J SPORT EXERC PS, V11, P123, DOI 10.1080/1612197X.2013.779812; Ryba TV, 2005, QUEST, V57, P192, DOI 10.1080/00336297.2005.10491853; Samuel RD, 2015, J SPORT PSYCHOL ACTI, V6, P99, DOI 10.1080/21520704.2015.1012249; Samuel RD, 2013, SPORT PSYCHOL, V27, P78, DOI 10.1123/tsp.27.1.78; Samuel RD, 2011, SPORT PSYCHOL, V25, P233, DOI 10.1123/tsp.25.2.233; Schaal K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019007; Schinke RJ, 2006, SPORT PSYCHOL, V20, P435, DOI 10.1123/tsp.20.4.435; Schinke RJ, 2016, PSYCHOL SPORT EXERC, V25, P36, DOI 10.1016/j.psychsport.2016.04.001; Schinke RJ, 2015, INT J SPORT EXERC PS, V13, P74, DOI 10.1080/1612197X.2014.959982; Schinke RJ, 2015, PSYCHOL SPORT EXERC, V17, P45, DOI 10.1016/j.psychsport.2014.10.010; Schinke RJ, 2014, INT J SPORT EXERC PS, V12, P64, DOI 10.1080/1612197X.2013.785093; Schwenk TL, 2000, BRIT J SPORT MED, V34, P4, DOI 10.1136/bjsm.34.1.4; Si GY, 2008, INT J SPORT EXERC PS, V6, P319, DOI 10.1080/1612197X.2008.9671876; Stambulova N., 2009, PSYCHOL SPORT EXCELL, P63; Stambulova N., 2016, ROUTLEDGE INT HDB SP, P519; Stambulova N, 2009, INT J SPORT EXERC PS, V7, P395, DOI 10.1080/1612197X.2009.9671916; Stambulova Natalia., 2003, SIPF YB 2003, P97; Stambulova Natalia., 2014, ROUTLEDGE COMPANION, P603; Stambulova NB, 2014, INT REV SPORT EXER P, V7, P1, DOI 10.1080/1750984X.2013.851727; Stambulova NB, 2000, INT J SPORT PSYCHOL, V31, P584; Taylor K., 2012, J AUST STRENGTH COND, V20, P12, DOI DOI 10.1017/CB09781107415324.004; Tenenbaum G., 2010, CULTURAL TURN SPORT, P153; Terry PC, 2003, PSYCHOL SPORT EXERC, V4, P125, DOI 10.1016/S1469-0292(01)00035-8; Uphill M, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00935; US Department of Health and Human Services, 1999, MENT HLTH REP SURG G; Watson JC, 2005, J COLL STUDENT DEV, V46, P442, DOI 10.1353/csd.2005.0044; Wiese-Bjornstal D. M., 1995, ATHLETIC TRAINING, V1, P17; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wolanin A, 2015, CURR SPORT MED REP, V14, P56, DOI 10.1249/JSR.0000000000000123; Wylleman P., 2013, MANAGING HIGH PERFOR, P159; Wylleman P., 2015, HIGH PERF TEAM TEAM; Wylleman P., 2014, ENCY SPORT EXERCISE, P105; Wylleman P, 2015, ROUTL RES SPORT CULT, V38, P99; Wylleman P, 2012, PSYCHOL SPORT EXERC, V13, P687, DOI 10.1016/j.psychsport.2012.04.005; Zhang CQ, 2014, J SPORT SCI, V32, P1465, DOI 10.1080/02640414.2014.898184	116	131	136	26	85	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1612-197X	1557-251X		INT J SPORT EXERC PS	Int. J. Sport Exerc. Psychol.		2018	16	6					622	639		10.1080/1612197X.2017.1295557			18	Hospitality, Leisure, Sport & Tourism; Psychology, Applied	Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Psychology	IA9LI	WOS:000469878300004			Y	N	2022-02-06	
J	Kerr, ZY; Register-Mihalik, JK; Kroshus, E; Baugh, CM; Marshall, SW				Kerr, Zachary Y.; Register-Mihalik, Johna K.; Kroshus, Emily; Baugh, Christine M.; Marshall, Stephen W.			Motivations Associated With Nondisclosure of Self-Reported Concussions in Former Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; sport; reporting; traumatic brain injury	PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; NCAA CONCUSSION; HOCKEY PLAYERS; ICE HOCKEY; KNOWLEDGE; SYMPTOMS; SPORTS; RISK; DEPRESSION	Background: Previous studies examining nondisclosure among athletes in various settings have found substantial proportions of athletes with undisclosed concussions. Substantial gaps exist in our understanding of the factors influencing athletes' disclosure of sports-related concussions. Purpose: To examine the prevalence of, and factors associated with, nondisclosure of recalled concussions in former collegiate athletes. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Former collegiate athletes (N = 797) completed an online questionnaire. Respondents recalled self-identified sports-related concussions (SISRCs) that they sustained while playing sports in high school, college, or professionally, and whether they disclosed these SISRCs to others. Respondents also recalled motivations for nondisclosure. The prevalence of nondisclosure was calculated among those who recalled SISRCs. Multivariate binomial regression estimated adjusted prevalence ratios (PRs) with 95% CIs, controlling for sex, level of contact in sports, and year the athletes began playing collegiate sports. Results: A total of 214 respondents (26.9%) reported sustaining at least 1 SISRC. Of these, 71 (33.2%) reported not disclosing at least 1 SISRC. Former football athletes were most likely to report nondisclosure (68.3% of those recalling SISRCs); female athletes who participated in low/noncontact sports were the least likely to report nondisclosure (11.1% of those recalling SISRC). The prevalence of nondisclosure was higher among men than women in the univariate analysis (PR, 2.88; 95% CI, 1.62-5.14), multivariate analysis (PR, 2.11; 95% CI, 1.13-3.96), and multivariate analysis excluding former football athletes (PR, 2.11; 95% CI, 1.12-3.94). The most commonly reported motivations were as follows: did not want to leave the game/practice (78.9%), did not want to let the team down (71.8%), did not know it was a concussion (70.4%), and did not think it was serious enough (70.4%). Conclusion: Consistent with previous studies, a substantial proportion of former athletes recalled SISRCs that were not disclosed. Male athletes were less likely to disclose all of their SISRCs than female athletes.	[Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN 46202 USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.; Marshall, Stephen W.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.; Marshall, Stephen W.] Univ N Carolina, Ctr Study Retired Athletes, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.; Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Kerr, Zachary Y.; Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Kroshus, Emily] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Baugh, Christine M.] Harvard Univ, Harvard Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.; Kroshus, Emily; Baugh, Christine M.; Marshall, Stephen W.] Univ N Carolina, Chapel Hill, NC USA		Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Kerr, Zachary/0000-0003-1423-1259	ALLCDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [5R49CE002479-02] Funding Source: Federal RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE002479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019733, T32MH019733] Funding Source: Medline; ACL HHS [R49CE002479] Funding Source: Medline; NCIPC CDC HHS [R49-CE002479] Funding Source: Medline		[Anonymous], CONC GUID; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Casa DJ, 2012, J ATHL TRAINING, V47, P96; Covassin T, 2003, J ATHL TRAINING, V38, P238; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Fraas MR, 2014, PHYS THER SPORT, V15, P136, DOI 10.1016/j.ptsp.2013.08.002; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Mueller FO, 2012, FATAL CATASTROPHIC I; National Collegiate Athletic Association, SSI TASK FORC EXPL I; Patel AV, 2007, J ATHL TRAINING, V42, P66; Piland SG, 2003, J ATHL TRAINING, V38, P104; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	32	131	132	1	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN	2016	44	1					220	225		10.1177/0363546515612082			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	DA2GU	WOS:000367614100034	26582799	Green Submitted, Green Accepted			2022-02-06	
J	Yuh, EL; Cooper, SR; Mukherjee, P; Yue, JK; Lingsma, HF; Gordon, WA; Valadka, AB; Okonkwo, DO; Schnyer, DM; Vassar, MJ; Maas, AIR; Manley, GT; Casey, SS; Cheong, M; Dams-O'Connor, K; Hricik, AJ; Inoue, T; Menon, DK; Morabito, DJ; Pacheco, JL; Puccio, AM; Sinha, TK				Yuh, Esther L.; Cooper, Shelly R.; Mukherjee, Pratik; Yue, John K.; Lingsma, Hester F.; Gordon, Wayne A.; Valadka, Alex B.; Okonkwo, David O.; Schnyer, David M.; Vassar, Mary J.; Maas, Andrew I. R.; Manley, Geoffrey T.; Casey, Scott S.; Cheong, Maxwell; Dams-O'Connor, Kristen; Hricik, Allison J.; Inoue, Tomoo; Menon, David K.; Morabito, Diane J.; Pacheco, Jennifer L.; Puccio, Ava M.; Sinha, Tuhin K.		TRACK-TBI INVESTIGATORS	Diffusion Tensor Imaging for Outcome Prediction in Mild Traumatic Brain Injury: A TRACK-TBI Study	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; computed tomography; diffusion tensor imaging; magnetic resonance imaging; traumatic brain injury	POST-CONCUSSION SYMPTOMS; COMMON DATA ELEMENTS; WHITE-MATTER; HEAD-INJURY; AXONAL INJURY; QUESTIONNAIRE; MEMORY; CLASSIFICATION; RELIABILITY; DISABILITY	We evaluated 3T diffusion tensor imaging (DTI) for white matter injury in 76 adult mild traumatic brain injury (mTBI) patients at the semiacute stage (11.2 +/- 3.3 days), employing both whole-brain voxel-wise and region-of-interest (ROI) approaches. The subgroup of 32 patients with any traumatic intracranial lesion on either day-of-injury computed tomography (CT) or semiacute magnetic resonance imaging (MRI) demonstrated reduced fractional anisotropy (FA) in numerous white matter tracts, compared to 50 control subjects. In contrast, 44 CT/MRI-negative mTBI patients demonstrated no significant difference in any DTI parameter, compared to controls. To determine the clinical relevance of DTI, we evaluated correlations between 3- and 6-month outcome and imaging, demographic/socioeconomic, and clinical predictors. Statistically significant univariable predictors of 3-month Glasgow Outcome Scale-Extended (GOS-E) included MRI evidence for contusion (odds ratio [OR] 4.9 per unit decrease in GOS-E; p=0.01), >= 1 ROI with severely reduced FA (OR, 3.9; p=0.005), neuropsychiatric history (OR, 3.3; p=0.02), age (OR, 1.07/year; p=0.002), and years of education (OR, 0.79/year; p=0.01). Significant predictors of 6-month GOS-E included >= 1 ROI with severely reduced FA (OR, 2.7; p=0.048), neuropsychiatric history (OR, 3.7; p=0.01), and years of education (OR, 0.82/year; p=0.03). For the subset of 37 patients lacking neuropsychiatric and substance abuse history, MRI surpassed all other predictors for both 3- and 6-month outcome prediction. This is the first study to compare DTI in individual mTBI patients to conventional imaging, clinical, and demographic/socioeconomic characteristics for outcome prediction. DTI demonstrated utility in an inclusive group of patients with heterogeneous backgrounds, as well as in a subset of patients without neuropsychiatric or substance abuse history.	[Yuh, Esther L.; Cooper, Shelly R.; Mukherjee, Pratik; Yue, John K.; Vassar, Mary J.; Manley, Geoffrey T.; Casey, Scott S.; Inoue, Tomoo; Morabito, Diane J.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Yuh, Esther L.; Mukherjee, Pratik; Cheong, Maxwell; Sinha, Tuhin K.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94110 USA; [Cooper, Shelly R.; Yue, John K.; Vassar, Mary J.; Manley, Geoffrey T.; Casey, Scott S.; Inoue, Tomoo; Morabito, Diane J.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94110 USA; [Lingsma, Hester F.] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Gordon, Wayne A.; Dams-O'Connor, Kristen] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Okonkwo, David O.; Hricik, Allison J.; Puccio, Ava M.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Okonkwo, David O.; Hricik, Allison J.; Puccio, Ava M.] Univ Pittsburgh, Med Ctr, Neurotrauma Clin Trials Ctr, Pittsburgh, PA USA; [Schnyer, David M.; Pacheco, Jennifer L.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge CB2 2QQ, England		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Pacheco, Jenni/AAX-5423-2021; Schnyer, David/ABD-6372-2021; Yue, John K/P-1348-2015	Schnyer, David/0000-0002-7472-2853; Yue, John K/0000-0001-9694-7722; Mukherjee, Pratik/0000-0001-7473-7409; Cooper, Shelly/0000-0003-0026-6688	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS069409, NS069409-02S1, NS60776]; Department of Defense United States Army Medical Research Acquisition ActivityUnited States Department of Defense [W81XWH-13-1-0441]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health (NIH) grants NS069409 and NS069409-02S1 (principal investigator [PI]: G. T. M.) and NS60776 (PI: P. M.) and Department of Defense United States Army Medical Research Acquisition Activity W81XWH-13-1-0441 (PI: G. T. M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIH.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Delis D.C., 2000, CALIFORNIA VERBAL LE; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M, 2010, TRAUMATIC BRAIN INJU; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hessen E, 2009, BRAIN INJURY, V23, P234, DOI 10.1080/02699050902748349; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy JE, 2003, CLIN NEUROPSYCHOL, V17, P303, DOI 10.1076/clin.17.3.303.18091; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Lichtenberger ElizabethO., 2013, ESSENTIALS WAIS 4 AS, V2nd ed.; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; Sveen U, 2010, SCAND J OCCUP THER, V17, P225, DOI 10.3109/11038120903171295; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wortzel HS, 2011, J AM ACAD PSYCHIATRY, V39, P511; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	60	131	135	1	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2014	31	17					1457	1477		10.1089/neu.2013.3171			21	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AO7GO	WOS:000341520700001	24742275	Green Published, Green Submitted			2022-02-06	
J	Ponsford, JL; Ziino, C; Parcell, DL; Shekleton, JA; Roper, M; Redman, JR; Phipps-Nelson, J; Rajaratnam, SMW				Ponsford, Jennie L.; Ziino, Carlo; Parcell, Diane L.; Shekleton, Julia A.; Roper, Monique; Redman, Jennifer R.; Phipps-Nelson, Jo; Rajaratnam, Shantha M. W.			Fatigue and Sleep Disturbance Following Traumatic Brain Injury-Their Nature, Causes, and Potential Treatments	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						attention; circadian rhythm; depression; fatigue; sleep disturbance; melatonin; polysomnography; treatments	EXCESSIVE DAYTIME SLEEPINESS; CLOSED-HEAD INJURY; OBJECTIVE MEASURES; MELATONIN; DISORDERS; INSOMNIA; SCALE; DEPRESSION; QUALITY; LIGHT	Background: Although fatigue and sleep disturbance are commonly reported following traumatic brain injury (TBI), understanding of their nature and treatment remains limited. Objectives: This article reviews a series of investigations of the nature and causes of fatigue and sleep disturbance following TBI. Methods: A large cohort of community-based patients with TBI, recruited from a TBI rehabilitation program, completed measures of subjective fatigue and sleep disturbances, as well as attentional measures. A subgroup of participants completed polysomnography and assessment of dim light melatonin onset. Results: Fatigue and sleep disturbance are common. Both are associated with anxiety, depression, and pain. However, fatigue is also associated with slowed information processing and the need for increased effort in performing tasks. Sleep disturbances contribute to fatigue. Objective sleep studies show reduced sleep efficiency, increased sleep onset latency, and increased time awake after sleep onset. Depression and pain exacerbate but cannot entirely account for these problems. There is increased slow-wave sleep. Individuals with TBI show lower levels of evening melatonin production, associated with less rapid-eye movement sleep. Conclusions: These findings suggest potential treatments including cognitive behavior therapy supporting lifestyle modifications, pharmacologic treatments with modafinil and melatonin, and light therapy to enhance alertness, vigilance, and mood. Controlled trials of these interventions are needed.	[Ponsford, Jennie L.; Ziino, Carlo; Parcell, Diane L.; Shekleton, Julia A.; Roper, Monique; Redman, Jennifer R.; Phipps-Nelson, Jo; Rajaratnam, Shantha M. W.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Ponsford, Jennie L.; Roper, Monique] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Rajaratnam, Shantha/D-8144-2012	Rajaratnam, Shantha/0000-0001-7527-8558	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [334002]; Monash UniversityMonash University	The projects described in the article received funding from the National Health and Medical Research Council (Project ID 334002) and Monash University.	Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cajochen C, 2005, J CLIN ENDOCR METAB, V90, P1311, DOI 10.1210/jc.2004-0957; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; Glickman G, 2006, BIOL PSYCHIAT, V59, P502, DOI 10.1016/j.biopsych.2005.07.006; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Grunstein Ron, 2002, Aust Fam Physician, V31, P995; Guler AD, 2008, NATURE, V453, P102, DOI 10.1038/nature06829; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leavitt VM, 2010, PM&R, V2, P332, DOI 10.1016/j.pmrj.2010.03.027; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; Lockley SW, 2006, SLEEP, V29, P161; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Nelson H.E., 1982, NATL ADULT READING T; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rajaratnam SMW, 2009, SLEEP MED CLIN, V4, P179, DOI 10.1016/j.jsmc.2009.02.007; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snaith R., 1994, HOSP ANXIETY DEPRESS; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Tobe EH, 1999, J NEUROPSYCH CLIN N, V11, P504, DOI 10.1176/jnp.11.4.504; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Zhdanova IV, 2001, J CLIN ENDOCR METAB, V86, P4727, DOI 10.1210/jc.86.10.4727; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	62	131	131	0	74	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					224	233		10.1097/HTR.0b013e31824ee1a8			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500012	22573041				2022-02-06	
J	Brophy, GM; Mondello, S; Papa, L; Robicsek, SA; Gabrielli, A; Tepas, J; Buki, A; Robertson, C; Tortella, FC; Hayes, RL; Wang, KKW				Brophy, Gretchen M.; Mondello, Stefania; Papa, Linda; Robicsek, Steven A.; Gabrielli, Andrea; Tepas, Joseph, III; Buki, Andras; Robertson, Claudia; Tortella, Frank C.; Hayes, Ronald L.; Wang, Kevin K. W.			Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in Severe Traumatic Brain Injury Patient Biofluids	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; clinical trial; neural injury; outcome measures; traumatic brain injury	NEURON-SPECIFIC ENOLASE; BIOMARKER; PROGESTERONE; RATS	Ubiquitin C-terminal hydrolase-L1 (UCH-L1) is a neuron-specific enzyme that has been identified as a potential biomarker of traumatic brain injury (TBI). The study objectives were to determine UCH-L1 exposure and kinetic metrics, determine correlations between biofluids, and assess outcome correlations in severe TBI patients. Data were analyzed from a prospective, multicenter study of severe TBI (Glasgow Coma Scale [GCS] score <= 8). Cerebrospinal fluid (CSF) and serum data from samples taken every 6 h after injury were analyzed by enzyme-linked immunosorbent assay (ELISA). UCH-L1 CSF and serum data from 59 patients were used to determine biofluid correlations. Serum samples from 86 patients and CSF from 59 patients were used to determine outcome correlations. Exposure and kinetic metrics were evaluated acutely and up to 7 days post-injury and compared to mortality at 3 months. There were significant correlations between UCH-L1 CSF and serum median concentrations (r(s) = 0.59, p < 0.001), AUC (r(s) = 0.3, p = 0.027), Tmax (r(s) = 0.68, p < 0.001), and MRT (r(s) = 0.65, p < 0.001). Outcome analysis showed significant increases in median serum AUC (2016 versus 265 ng/mL(star)min, p = 0.006), and Cmax (2 versus 0.4 ng/mL, p = 0.003), and a shorter Tmax (8 versus 19 h, p = 0.04) in those who died versus those who survived, respectively. In the first 24 h after injury, there was a statistically significant acute increase in CSF and serum median Cmax((0-24h)) in those who died. This study shows a significant correlation between UCH-L1 CSF and serum median concentrations and biokinetics in severe TBI patients, and relationships with clinical outcome were detected.	[Brophy, Gretchen M.] Virginia Commonwealth Univ, Richmond, VA 23298 USA; [Hayes, Ronald L.] Univ Florida, Dept Clin Programs, Banyan Biomarkers Inc, Gainesville, FL USA; [Mondello, Stefania] Univ Florida, Ctr Innovat Res, Gainesville, FL USA; [Mondello, Stefania; Robicsek, Steven A.; Gabrielli, Andrea; Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Orlando, FL USA; [Tepas, Joseph, III] Univ Florida, Dept Surg & Pediat, Jacksonville, FL USA; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Robertson, Claudia] Baylor Coll Med, Dept Crit Care, Houston, TX 77030 USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Silver Spring, MD USA; [Wang, Kevin K. W.] Univ Florida, Ctr Innovat Res, Banyan Biomarkers Inc, Gainesville, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA		Brophy, GM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia Campus,410 N 12th St,POB 980533, Richmond, VA 23298 USA.	gbrophy@vcu.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473; Brophy, Gretchen/0000-0002-4749-2693	Department of DefenseUnited States Department of Defense [DoD W81XWH-06-1-0517]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052831]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676, R01NS052831] Funding Source: NIH RePORTER	This study was supported in part by Department of Defense Award number DoD W81XWH-06-1-0517, and National Institutes of Health Award number R01 NS052831.	Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BRUNS J, 2009, EPILIPSIA, V44, P2; Gibaldi M., 1982, PHARMACOKINETICS; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; KRUSE A, 1991, ACTA NEUROCHIR, V110, P106, DOI 10.1007/BF01400675; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; PAPA L, 2008, EXPERT OPIN MED DIAG, V28, P1; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	16	131	137	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					861	870		10.1089/neu.2010.1564			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600002	21309726	Green Published			2022-02-06	
J	Spiotta, AM; Stiefel, MF; Gracias, VH; Garuffe, AM; Kofke, WA; Maloney-Wilensky, E; Troxel, AB; Levine, JM; Le Roux, PD				Spiotta, Alejandro M.; Stiefel, Michael F.; Gracias, Vicente H.; Garuffe, Alicia M.; Kofke, W. Andrew; Maloney-Wilensky, Eileen; Troxel, Andrea B.; Levine, Joshua M.; Le Roux, Peter D.			Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain oxygen; intracranial pressure; outcome; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; CONTROLLED-TRIAL; THERAPY; EXPERIENCE; CARE; MECHANISMS; INFARCTION; INCREASES; ISCHEMIA	Object. The object of this study was to determine whether brain tissue oxygen (PbtO(2)) based therapy or intracranial pressure (ICP)/cerebral perfusion pressure (CPP)-based therapy is associated with improved patient outcome after severe traumatic brain injury (TBI). Methods. Seventy patients with severe TBI (postresuscitation GCS score <= 8), admitted to a neurosurgical intensive care unit at a university-based Level I trauma center and tertiary care hospital and managed with an ICP and PbtO(2) monitor (mean age 40 +/- 19 years [SD]) were compared with 53 historical controls who received only an ICP monitor (mean age 43 +/- 18 years). Therapy for both patient groups was aimed to maintain ICP < 20 mm Hg and CPP > 60 mm Hg. Patients with PbtO(2) monitors also had therapy to maintain PbtO(2)> 20 mm Hg. Results. Data were obtained from 12,148 hours of continuous ICP monitoring and 6,816 hours of continuous PbtO(2) monitoring. The mean daily ICP and CPP and the frequency of elevated ICP (> 20 mm Hg) or suboptimal CPP (< 60 mm Hg) episodes were similar in each group. The mortality rate was significantly lower in patients who received PbtO(2)-directed care (25.7%) than in those who received conventional ICP and CPP based therapy (45.3%, p < 0.05). Overall, 40% of patients receiving ICP/CPP-guided Management and 64.3% of those receiving PbtO(2)-guided management had a favorable short-term outcome (p = 0.01). Among patients who received PbtO(2)-directed therapy, mortality was associated with lower mean daily PbtO(2) (p < 0.05), longer durations of compromised brain oxygen (PbtO(2) < 20 mm Hg, p = 0.013) and brain hypoxia (PbtO(2) < 15 mm Hg, p = 0.001), more episodes and a longer cumulative duration of compromised PbtO(2) (p < 0.001), and less successful treatment of compromised PbtO(2) (p = 0.03). Conclusions. These results suggest that PbtO(2)-based therapy, particularly when compromised PbtO(2) can be corrected, may be associated with reduced patient mortality and improved patient outcome after severe TBI. (DOI: 10.3171/2010.1.JNS09506)	[Spiotta, Alejandro M.; Stiefel, Michael F.; Kofke, W. Andrew; Maloney-Wilensky, Eileen; Levine, Joshua M.; Le Roux, Peter D.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA; [Levine, Joshua M.] Univ Penn, Dept Neurol, Philadelphia, PA 19107 USA; [Kofke, W. Andrew; Levine, Joshua M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19107 USA; [Troxel, Andrea B.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19107 USA; [Gracias, Vicente H.; Garuffe, Alicia M.] Univ Penn, Div Trauma Surg & Surg Crit Care, Philadelphia, PA 19107 USA		Le Roux, PD (corresponding author), Univ Penn, Dept Neurosurg, 330 S 9th St, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu		Troxel, Andrea/0000-0002-1393-3075			ALVES WM, 2006, HDB NEUROEMERGENCY C, P205; *AM ASS NEUR SURG, 2007, J NEUROTRAUMA S, V24; American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP C; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; Bardt TF, 1998, ACT NEUR S, V71, P153; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Birmingham K, 2002, NAT MED, V8, P5, DOI 10.1038/nm0102-5a; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brain Trauma Foundation, 2000, GUID MAN PROGN SEV T; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Edwards P, 2005, LANCET, V365, P1957; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mazzeo AT, 2007, J NEUROL SCI, V261, P1, DOI 10.1016/j.jns.2007.04.026; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nordstrom CH, 2005, NEUROCRIT CARE, V2, P83, DOI 10.1385/NCC:2:1:083; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278	60	131	136	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					571	580		10.3171/2010.1.JNS09506			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100021	20415526				2022-02-06	
J	Chu, Z; Wilde, EA; Hunter, JV; McCauley, SR; Bigler, ED; Troyanskaya, M; Yallampalli, R; Chia, JM; Levin, HS				Chu, Z.; Wilde, E. A.; Hunter, J. V.; McCauley, S. R.; Bigler, E. D.; Troyanskaya, M.; Yallampalli, R.; Chia, J. M.; Levin, H. S.			Voxel-Based Analysis of Diffusion Tensor Imaging in Mild Traumatic Brain Injury in Adolescents	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							AXONAL INJURY; CONCUSSION; ABNORMALITIES; DEFORMATION; SEVERITY; SYMPTOMS; DETECTS; STRAIN; IMAGES; NERVE	BACKGROUND AND PURPOSE: DTI of normal-appearing WM as evaluated by conventional MR imaging in mTBI has the potential to identify important regional abnormalities that relate to PCS. VBA was used to examine WM changes in acute mTBI. MATERIALS AND METHODS: WM was assessed between 1 and 6 days postinjury with voxel-based DTI analyses in 10 adolescent patients with mTBI and 10 age-matched control participants. In addition to the voxel-based group, analysis used to identify brain pathology across all patients with mTBI, 2 voxel-based linear regressions were performed. These analyses investigated the relation between 1) the ADC and PCS severity scores, and 2) ADC and scores on the BSI of emotional symptoms associated with mTBI. We hypothesized that frontotemporal WM changes would relate to symptoms associated with PCS and endorsed on the BSI. RESULTS: Patients with mTBI demonstrated significant reductions in ADC in several WM regions and in the left thalamus. As expected, no increases in ADC were found in any region of interest. All injury-affected regions showed decreased radial diffusivity, unchanged AD, and increased FA, which is consistent with axonal cytotoxic edema, reflective of acute injury. CONCLUSIONS: Whole-brain WM DTI measures can detect abnormalities in acute mTBI associated with PCS symptoms in adolescents.	[Chu, Z.; Wilde, E. A.; Hunter, J. V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Chu, Z.; Wilde, E. A.; Hunter, J. V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, E. A.; McCauley, S. R.; Troyanskaya, M.; Yallampalli, R.; Levin, H. S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; Univ Texas Houston, Sch Med, Houston, TX USA; [Bigler, E. D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, E. D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, E. D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, E. D.] Univ Utah, Inst Brain, Salt Lake City, UT USA; [Chia, J. M.] Philips Med Syst, Cleveland, OH USA		Chu, Z (corresponding author), Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, 6621 Fannin St,MC 2-2521, Houston, TX 77030 USA.	zxchu@texaschildrens.org			National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS056202]; National Institutes of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 NS21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202, R01NS021889] Funding Source: NIH RePORTER	This work was supported by grant P01 NS056202 from the National Institutes of Neurological Disorders and Stroke and grant R01 NS21889 from the National Institutes of Child Health and Human Development.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bayly PV, 2004, J BIOMECH ENG-T ASME, V126, P523, DOI 10.1115/1.1785811; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mami Ahmed G, 2008, Adv Pediatr, V55, P385, DOI 10.1016/j.yapd.2008.07.011; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Poline J.B., 2002, P 8 INT C FUNCT MAPP; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Takhounts EG, 2008, STAPP CAR C, V52, P1; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	39	131	143	0	14	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2010	31	2					340	346		10.3174/ajnr.A1806			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	563NX	WOS:000275140500027	19959772	hybrid, Green Published			2022-02-06	
J	Wilk, JE; Thomas, JL; McGurk, DM; Riviere, LA; Castro, CA; Hoge, CW				Wilk, Joshua E.; Thomas, Jefftey L.; McGurk, Dennis M.; Riviere, Lyndon A.; Castro, Carl A.; Hoge, Charles W.			Mild Traumatic Brain Injury (Concussion) During Combat: Lack of Association of Blast Mechanism With Persistent Postconcussive Symptoms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast injuries; concussion; mild; military personnel; postconcussive symptoms	MENTAL-HEALTH PROBLEMS; IRAQ; AFGHANISTAN; CARE	Objective: To determine whether screening for a blast mechanism of concussion identifies individuals at higher risk of persistent postconcussive symptoms (PCS). Setting: United States Army post. Participants: 3952 US Army infantry soldiers were administered anonymous surveys 3 to 6 months after returning from a yearlong deployment to Iraq. Main Outcome Measures: Self-reported concussion (defined as an injury that resulted in being "dazed, confused, or 'seeing stars'"; "not remembering the injury"; or "losing consciousness [knocked out]): Patient Health Questionnaire 15-item scale for physical symptoms and PCS; Posttraumatic Stress Disorder Checklist; and Patient Health Questionnaire depression module. Results: Of the 587 soldiers (14.9% of the total sample) who met criteria for concussion, 201 (34.2%) reported loss of consciousness, and 373 (63.5%) reported only an alteration of consciousness without loss of consciousness; 424 (72.2%) reported a blast mechanism, and 150 (25.6%) reported a nonblast mechanism. Among soldiers who lost consciousness, blast mechanism was significantly associated with headaches and tinnitus 3 to 6 months postdeployment compared with a nonblast mechanism. However, among the larger group of soldiers reporting concussions without loss of consciousness, blast was not associated with adverse health outcomes. Conclusions: Blast mechanism of concussion was inconsistently associated with PCS, depending on the definition of concussion utilized. A self-reported history of blast mechanism was not associated with persistent PCS for the majority of US soldiers with concussions.	[Wilk, Joshua E.] USA, Med Res & Mat Command, Div Psychiat & Neurosci, Walter Reed Army Inst Res,Dept Mil Psychiat, Silver Spring, MD 20910 USA; [McGurk, Dennis M.] US Army Med Res & Mat Command, Walter Reed Army Inst Res, US Army Med Res Unit Europe, Heidelberg, Germany; [Castro, Carl A.] USA, Med Res & Mat Command, Mil Operat Med Res Program, Ft Detrick, MD USA		Wilk, JE (corresponding author), USA, Med Res & Mat Command, Div Psychiat & Neurosci, Walter Reed Army Inst Res,Dept Mil Psychiat, 503 Robert Giant Ave, Silver Spring, MD 20910 USA.	joshua.wilk@amedd.army.mil					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; [Anonymous], 2007, LANCET, V370, P1879; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; BLIESE PD, 2005, 2005003 USA MED RES; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; Department of Defense Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; *GAO, GAO08276; *GOV ACC OFF, GAO08615; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Institute of Medicine, 2008, GULF WAR HLTH, V7; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1993, ANN CONV INT SOC TRA; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	26	131	131	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					9	14		10.1097/HTR.0b013e3181bd090f			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800002	20051900				2022-02-06	
J	Oron, A; Oron, U; Streeter, J; De Taboada, L; Alexandrovich, A; Trembovler, V; Shohami, E				Oron, Amir; Oron, Uri; Streeter, Jackson; De Taboada, Luis; Alexandrovich, Alexander; Trembovler, Victoria; Shohami, Esther			Low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits	JOURNAL OF NEUROTRAUMA			English	Article						histopathology; low-level laser therapy; mice; motor function; traumatic brain injury	CLOSED-HEAD INJURY; MYOCARDIAL-INFARCTION; IRRADIATION; RATS; MECHANISMS; PROTEIN; STROKE	Low-level laser therapy (LLLT) has been evaluated in this study as a potential therapy for traumatic brain injury (TBI). LLLT has been found to modulate various biological processes. Following TBI in mice, we assessed the hypothesis that LLLT might have a beneficial effect on their neurobehavioral and histological outcome. TBI was induced by a weight-drop device, and motor function was assessed 1 h post-trauma using a neurological severity score (NSS). Mice were then divided into three groups of eight mice each: one control group that received a sham LLLT procedure and was not irradiated; and two groups that received LLLT at two different doses (10 and 20 mW/cm(2)) transcranially. An 808-nm Ga-As diode laser was employed transcranially 4 h post-trauma to illuminate the entire cortex of the brain. Motor function was assessed up to 4 weeks, and lesion volume was measured. There were no significant changes in NSS at 24 and 48 h between the laser-treated and non-treated mice. Yet, from 5 days and up to 28 days, the NSS of the laser-treated mice were significantly lower (p < 0.05) than the traumatized control mice that were not treated with the laser. The lesion volume of the laser treated mice was significantly lower (1.4%) than the non-treated group (12.1%). Our data suggest that a non-invasive transcranial application of LLLT given 4 h following TBI provides a significant long-term functional neurological benefit. Further confirmatory trials are warranted.	Assaf Harofeh Med Ctr, Dept Orthoped A, IL-70300 Zerifin, Israel; Photothera Inc, Carlsbad, CA USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		Oron, A (corresponding author), Assaf Harofeh Med Ctr, Dept Orthoped A, IL-70300 Zerifin, Israel.	amiroronmd@gmail.com		De Taboada, Luis/0000-0002-0153-6419			Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Avni D, 2005, PHOTOMED LASER SURG, V23, P273, DOI 10.1089/pho.2005.23.273; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; LANGLOIS JA, 2004, TRAMATIC BRAIN INJUR; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Mirsky N, 2002, ANTIOXID REDOX SIGN, V4, P785, DOI 10.1089/152308602760598936; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Oron U, 2001, CIRCULATION, V103, P296; Oron U, 2006, PHOTOMED LASER SURG, V24, P111, DOI 10.1089/pho.2006.24.111; Shefer G, 2002, J CELL SCI, V115, P1461; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Yaakobi T, 2001, J APPL PHYSIOL, V90, P2411, DOI 10.1152/jappl.2001.90.6.2411; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	21	131	132	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					651	656		10.1089/neu.2006.0198			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000007	17439348				2022-02-06	
J	Rola, R; Mizumatsu, S; Otsuka, S; Morhardt, DR; Noble-Haeusslein, LJ; Fishman, K; Potts, MB; Fike, JR				Rola, Radoslaw; Mizumatsu, Shinichiro; Otsuka, Shinji; Morhardt, Duncan R.; Noble-Haeusslein, Linda J.; Fishman, Kelly; Potts, Matthew B.; Fike, John R.			Alterations in hippocampal neurogenesis following traumatic brain injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						cortical impactor; precursor cells; neurogenesis; subgranular zone; mice	CORTICAL IMPACT INJURY; CLOSED HEAD-INJURY; DENTATE GYRUS; ADULT-RAT; ENHANCED NEUROGENESIS; AXONAL PROJECTIONS; MEMORY DEFICITS; SOCIAL RECOVERY; SPINAL-CORD; NEURONS	Clinical and experimental data show that traumatic brain injury (TBI)-induced cognitive changes are often manifest as deficits in hippocampal-dependent functions of spatial information processing. The underlying mechanisms for these effects have remained elusive, although recent studies have suggested that the changes in neuronal precursor cells in the dentate subgranular zone (SGZ) of the hippocampus might be involved. Here, we assessed the effects of unilateral controlled cortical impact on neurogenic cell populations in the SGZ in 2-month-old male C57BL6 mice by quantifying numbers of dying cells (TUNEL), proliferating cells (Ki-67) and immature neurons (Doublecortin, Dex) up to 14 days after TBI. Dying cells were seen 6 h after injury, peaked at 24 h and returned to control levels at 14 days. Proliferating cells were decreased on the ipsilateral and contralateral sides at all the time points studied except 48 h after injury when a transient increase was seen. Simultaneously, immature neurons were reduced up to 84% relative to controls on the ipsilateral side. In the first week post-TBI, reduced numbers of Dcx-positive cells were also seen in the contralateral side; a return to control levels occurred at 14 days. To determine if these changes translated into longer-term effects, BrdU was administered 1 week post-injury and 3 weeks later the phenotypes of the newly born cells were assessed. TBI induced decreases in the numbers of BrdU-positive cells and new neurons (BrdU/NeuN) on the ipsilateral side without apparent changes on the contralateral side, whereas astrocytes (BrdU/GFAP) were increased on the ipsilateral side and activated microglia (BrdU/CD68) were increased on both ipsi- and contralateral sides. No differences were noted in oligodendrocytes (BrdU/NG2). Taken together, these data demonstrate that TBI alters both neurogenesis and gliogenesis. Such alterations may play a contributory role in TBI-induced cognitive impainnent. (c) 2006 Elsevier Inc. All rights reserved.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Med Univ Lublin, Dept Neurol Surg, Lublin, Poland; Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA		Fike, JR (corresponding author), Univ Calif San Francisco, Brain & Spinal Cord Injury Ctr, Box 0899, San Francisco, CA 94110 USA.	John.Fike@ucsf.edu	Rola, Radoslaw/AAQ-5587-2021; Rola, Radoslaw/V-6749-2018	Rola, Radoslaw/0000-0003-0613-6593; Rola, Radoslaw/0000-0003-0613-6593	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159] Funding Source: Medline		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fisher BJ, 2002, INT J RADIAT ONCOL, V52, P996, DOI 10.1016/S0360-3016(01)02720-1; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Herrera DG, 2003, P NATL ACAD SCI USA, V100, P7919, DOI 10.1073/pnas.1230907100; Huh JW, 2003, J NEUROTRAUM, V20, P975, DOI 10.1089/089771503770195821; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Jessberger S, 2003, EUR J NEUROSCI, V18, P2707, DOI 10.1111/j.1460-9568.2003.02986.x; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Markakis EA, 1999, J COMP NEUROL, V406, P449; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mizuguchi M, 1999, AM J PATHOL, V155, P1713, DOI 10.1016/S0002-9440(10)65486-7; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 1999, J NEUROSCI, V19, P4508; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Seki Tatsunori, 2003, Anatomical Science International, V78, P69, DOI 10.1046/j.0022-7722.2003.00043.x; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; Shinohara C, 1997, CANCER RES, V57, P2694; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Slotnick B.M., 1975, STEREOTAXIC ATLAS AL; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; STANFIELD BB, 1988, EXP BRAIN RES, V72, P399; Tada E, 1999, EXP NEUROL, V160, P66, DOI 10.1006/exnr.1999.7172; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	72	131	134	0	18	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2006	202	1					189	199		10.1016/j.expneurol.2006.05.034			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	104XE	WOS:000241993100020	16876159				2022-02-06	
J	Coronado, VG; Thomas, KE; Sattin, RW; Johnson, RL				Coronado, VG; Thomas, KE; Sattin, RW; Johnson, RL			The CDC traumatic brain injury surveillance system - Characteristics of persons aged 65 years and older hospitalized with a TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						elderly; epidemiology; falls; motor vehicle incidents; prevention; traffic incidents; traumatic brain injury	PREVENTING FALLS; HEAD-INJURIES; RISK-FACTORS; POPULATION; MORTALITY; SURVIVAL; BALANCE; WOMEN; EPIDEMIOLOGY; DISABILITY	Objective: To examine the epidemiologic and clinical characteristics of older persons (ie, those aged 65-74, 75-84, and >= 85 years) hospitalized with traumatic brain injury (TBI). Methods: Data from the 1999 CDC 15-state TBI surveillance system were analyzed. Results: In 1999, there were 17,657 persons 65 years and older hospitalized with TBI in the 15 states for an age-adjusted rate of 155.9 per 100,000 population. Rates among persons aged 65 years or older increased with age and were higher for males. Most TBIs resulted from fall- or motor vehicle (MV)-traffic-related incidents. Most older persons with TBI had an initial TBI severity of mild (73.4%); however, the proportions of both moderate and severe disability for those discharged alive and of in-hospital mortality were relatively high (23.5%, 9.7%, and 12%, respectively). Persons who fell were also more likely to have had 3 or more comorbid conditions than were those who sustained a TBI from an MV-traffic incident. Conclusions: TBI is a substantial public health problem among older persons. As the population of older persons continues to increase in the United States, the need to design and implement proven and cost-effective prevention measures that focus on the leading causes of TBI (unintentional falls and MV-traffic incidents) becomes more urgent.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA		Coronado, VG (corresponding author), 4770 Buford Highway,MS F-41, Atlanta, GA 30341 USA.	VGC1@cdc.gov					Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; AIZENBERG R, 2004, TRANSP RES BOARD C P, V27, P302; American Geriatrics Society British Geriatrics Society and American Academy of Orthopaedic Surgeons Panel on Falls Prevention., 2001, J AM GERIATR SOC, V49, P64; Anderson R N, 1998, Natl Vital Stat Rep, V47, P1; BINDER S, 2002, INJ PREV S4, V8, P2; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; BUTLER JA, 2001, CENTRAL NERVOUS SYST; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; *CDCP, 2004, REC FRAM EC GROUP PR; *CDCP, 1997, BEHAV RISK FACT SURV; *CDCP, 1997, TOOL KIT PREV SEN FA; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Connell BR, 1996, CLIN GERIATR MED, V12, P859; Cumming RG, 1998, DRUG AGING, V12, P43, DOI 10.2165/00002512-199812010-00005; Dellinger AM, 2002, AM J EPIDEMIOL, V155, P234, DOI 10.1093/aje/155.3.234; Dolinis J, 1997, AUST NZ J PUBL HEAL, V21, P462, DOI 10.1111/j.1467-842X.1997.tb01736.x; DUNN JE, 1992, AM J PUBLIC HEALTH, V82, P395, DOI 10.2105/AJPH.82.3.395; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Ellis AA, 2001, J GERONTOL A-BIOL, V56, pM686, DOI 10.1093/gerona/56.11.M686; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Gill TM, 1999, AM J PUBLIC HEALTH, V89, P553, DOI 10.2105/AJPH.89.4.553; GILLESPIE LD, 2004, COCHRANE LIB; Grabowski DC, 2004, JAMA-J AM MED ASSOC, V291, P2840, DOI 10.1001/jama.291.23.2840; HANNAN EL, 1995, J TRAUMA, V38, P697, DOI 10.1097/00005373-199505000-00004; HARRIS PB, 1989, MED CARE, V27, P737, DOI 10.1097/00005650-198907000-00007; HUNGERFORD DW, 2002, ALCOHOL PROBLEMS EME; Ingram Deborah D, 2003, Vital Health Stat 2, P1; Institute of Medicine, 1990, BROAD BAS TREATM ALC; Insurance Institute for Highway Safety, 2001, INSUR I HIGHW SAF ST, V36, P1; Ivers RQ, 1998, J AM GERIATR SOC, V46, P58; Janke M. K, 1994, RSS94156 CAL DEP MOT; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JUDGE JO, 1993, PHYS THER, V73, P254, DOI 10.1093/ptj/73.4.254; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LORD SR, 1993, ARCH PHYS MED REHAB, V74, P837, DOI 10.1016/0003-9993(93)90010-8; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; National Highway Traffic Safety Administration, 2001, TRAFF SAF FACTS 2001; National Highway Traffic Safety Administration, 1999, TRAFF SAF FACTS 1999; National Highway Traffic Safety Administration, 2004, TRAFF SAF FACTS 2002; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NORTHRIDGE ME, 1995, AM J PUBLIC HEALTH, V85, P509, DOI 10.2105/AJPH.85.4.509; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; RAKIER A, 1995, BRAIN INJURY, V9, P187, DOI 10.3109/02699059509008191; RAY WA, 1990, TOP GERIATR REHABIL, V5, P12; Ritchie MA, 2000, ONLINE J KNOWL SYN N, V7; Rivara FP, 1997, NEW ENGL J MED, V337, P543, DOI 10.1056/NEJM199708213370807; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; Sahyoun N R, 2001, Aging Trends, P1; SAS, 1999, SAS STAT US GUID VER, V10th; Sasser H C, 2001, N C Med J, V62, P364; SATTIN RW, 1992, ANNU REV PUBL HEALTH, V13, P489, DOI 10.1146/annurev.pu.13.050192.002421; SCALEA TM, 1990, J TRAUMA, V30, P129, DOI 10.1097/00005373-199002000-00001; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; Tromp AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895-4356(01)00349-3; *US CENS BUR, 1996, PROJ POP US AG SEX; US Census Bureau, 2000, CENS 2000 SUMM FIL 1; Wilkins K, 1998, Health Rep, V10, P47; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wu G, 2002, J AM GERIATR SOC, V50, P746, DOI 10.1046/j.1532-5415.2002.50173.x; [No title captured]	74	131	134	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					215	228		10.1097/00001199-200505000-00005			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500005	15908822				2022-02-06	
J	Kaut, KP; DePompei, R; Kerr, J; Congeni, J				Kaut, KP; DePompei, R; Kerr, J; Congeni, J			Reports of head injury and symptom knowledge among college athletes: Implications for assessment and educational intervention	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						athlete knowledge; concussion; education; symptoms	TRAUMATIC BRAIN-INJURY; STANDARDIZED ASSESSMENT; CONCUSSION; MANAGEMENT	Objective: To identify the prevalence of head injuries and related symptoms among college athletes and examine knowledge of head injury consequences and behavioral tendencies of athletes in the presence of symptoms. Design: Retrospective survey. Participants: A total of 461 male and female athletes beginning competitive play at the University of Akron (Akron, OH) during the years 1995 to 2001. Main Outcome Measures: Responses to survey questions were analyzed to determine the frequency of concussions and injury-related symptoms (eg, dizziness, headache, nausea or vomiting) in addition to behavioral responses in the presence of certain symptoms (eg, playing with headache, failure to report symptoms while playing). Written responses to queries regarding symptom knowledge were analyzed for thematic content and were used to identify deficiencies in signs and symptoms of concussion. Results: Nearly 32% of all athletes had experienced a blow to the head causing dizziness, with over 1/4 confirming various somatic symptoms following a blow to the head (eg, seeing stars, nausea or vomiting, head pain). Continuing to play despite symptom presence was noted (eg, dizziness, 28.2%, headache, 30.4%), with 19.5% reporting a concussion diagnosis. Knowledge of head injury consequences was found to be deficient, with 56% indicating no knowledge of the possible consequences following a head injury. Of those providing responses, the majority reflected awareness of cognitive (eg, memory problems) and physical (eg, brain damage) consequences. Conclusions: A sizable number of athletes may enter collegiate play with a previous concussion diagnosis, and many more are likely to have experienced symptoms suggestive of a mild head injury. Of considerable concern is the tendency to play while symptomatic (eg, headache, dizziness) and the failure to report symptoms while playing-especially among football players (25.2%). The apparent deficiency in athlete knowledge of head injury consequences raises concern regarding athlete recognition of potentially problematic symptoms and represents an important area for educational intervention.	Univ Akron, Dept Psychol, Akron, OH 44325 USA; Univ Akron, Dept Speech Pathol & Audiol, Akron, OH 44325 USA; Childrens Hosp, Sports Med Ctr Akron, Akron, OH 44308 USA		Kaut, KP (corresponding author), Univ Akron, Dept Psychol, Arts & Sci Bldg,Room 363, Akron, OH 44325 USA.	kpk@uakron.edu					BARTH J, 1990, REHABILITATION ADULT, P471; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; GILLES RJ, 1996, TRAUMATIC BRAIN INJU, P73; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 2000, SEMIN NEUROL, V20, P165, DOI 10.1055/s-2000-9835; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mandera M, 2000, CHILD NERV SYST, V16, P156, DOI 10.1007/s003810050484; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Nagurney J T, 1998, J Emerg Med, V16, P709, DOI 10.1016/S0736-4679(98)00083-3; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; SLOAT B, 2001, CLEVELAND PLAIN 1130, pA16; SLOAT B, 2001, CLEVELAND PLAIN 1130, pA1; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	23	131	134	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2003	13	4					213	221		10.1097/00042752-200307000-00004			9	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	705AQ	WOS:000184374400004	12855923				2022-02-06	
J	Warden, DL; Bleiberg, J; Cameron, KL; Ecklund, J; Walter, J; Sparling, MB; Reeves, D; Reynolds, KY; Arciero, R				Warden, DL; Bleiberg, J; Cameron, KL; Ecklund, J; Walter, J; Sparling, MB; Reeves, D; Reynolds, KY; Arciero, R			Persistent prolongation of simple reaction time in sports concussion	NEUROLOGY			English	Article							BRAIN INJURY; HEAD-INJURY; RECOVERY; LONG	A baseline computerized cognitive assessment was completed by 483 military cadets before their initial school year. Fourteen cadets concussed during physical education boxing were retested <1 hour after injury and again on return to full activity 4 days later. Compared with baseline testing, postinjury performance on simple reaction time and continuous performance tests was significantly slowed, even after cadets experienced resolution of physical symptoms and were cleared to resume full activity. These findings may be relevant to current concussion management guidelines.	Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Natl Rehabil Hosp, Washington, DC USA; US Mil Acad, Dept Phys Educ, W Point, NY 10996 USA; US Mil Acad, Dept Orthoped, W Point, NY 10996 USA; USN Hosp, Camp Pendleton, CA USA		Warden, DL (corresponding author), Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA.			Cameron, Kenneth/0000-0002-6276-4482			Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Cameron KL, 1999, J ATHL TRAINING, V34, P34; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kelly JP, 1997, NEUROLOGY, V48, P581; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452	10	131	132	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	AUG 14	2001	57	3					524	526		10.1212/WNL.57.3.524			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	462FR	WOS:000170410500032	11502926				2022-02-06	
J	Swartz, KR; Liu, F; Sewell, D; Schochet, T; Campbell, I; Sandor, M; Fabry, Z				Swartz, KR; Liu, F; Sewell, D; Schochet, T; Campbell, I; Sandor, M; Fabry, Z			Interleukin-6 promotes post-traumatic healing in the central nervous system	BRAIN RESEARCH			English	Article						interleukin-6 (IL-6); central nervous system (CNS); injury; healing; vascularization	ENDOTHELIAL GROWTH-FACTOR; RAT-BRAIN; TRANSGENIC MICE; CEREBRAL OVEREXPRESSION; FACTOR VEGF; EXPRESSION; INJURY; CELLS; CYTOKINES; ANGIOGENESIS	The central nervous system (CNS) is an immune-privileged site where the role of immune cells and mediators in traumatic brain injury is poorly understood. Previously we have demonstrated that interleukin (IL)-6, a cytokine that acts on a wide range of tissues: influencing cell growth and differentiation, is an agonist for vascular endothelial growth factor (VEGF), in in vitro vascularization assays for brain microvessel endothelial cells. In this present work we focus on the role of IL-6 in promoting tissue repair in the CNS in vivo. An aseptic cerebral injury (ACI) was created in the right parietal cortex, using both wild type (C57B1/6J) and IL-6-deficient (C57B1/6J-IL-6-/-) mice to study the consequences of the absence of IL-6 on the pathology of brain injuries. We monitored the immediate, early, and late responses to this traumatic injury by characterizing several histologic features in the CNS at days 1, 4, 7 and 14 following injury. Acellular necrosis, cellular infiltration, and re-vascularization were characterized in the injured tissues, and each of these histologic features was individually graded and totaled to assign a healing index. IL-B-deficient mice were found to have a comparatively slower rate of recovery and healing. Furthermore, fluorescein isothiocyanate (FITC)-dextran intravenous injection demonstrated leaky vessels in IL-6-deficient but not in wild type animals following ACI. Additionally, chronic expression of IL-6 in the CNS using transgenic GFAP-IL-6 mice resulted in more rapid healing following ACI. The accelerated tissue repair in GFAP-IL-6 transgenic animals is primarily due to extensive re-vascularization as detected by endothelial cell markers. Combined, this data suggests an important role of IL-6 in tissue repair processes following traumatic injury in the CNS. (C) 2001 Published by Elsevier Science B.V.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA		Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH050426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570, R56NS037570] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 50426] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 37570-01A2] Funding Source: Medline		AKANEYA Y, 1995, EXP NEUROL, V136, P44, DOI 10.1006/exnr.1995.1082; Arai Y, 1998, PEDIATR NEUROL, V19, P45, DOI 10.1016/S0887-8994(98)00018-6; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; Campbell IL, 1998, ANN NY ACAD SCI, V840, P83, DOI 10.1111/j.1749-6632.1998.tb09552.x; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cancilla P A, 1980, Adv Exp Med Biol, V131, P257; CANCILLA PA, 1979, LAB INVEST, V40, P74; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Cook JL, 1998, MOL BRAIN RES, V55, P9, DOI 10.1016/S0169-328X(97)00350-1; Couraud PO, 1998, PATHOL BIOL, V46, P176; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO;2-5; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Lemke R, 1999, GLIA, V27, P75, DOI 10.1002/(SICI)1098-1136(199907)27:1<75::AID-GLIA8>3.0.CO;2-J; Lemke R, 1998, J NEUROSCI RES, V51, P223, DOI 10.1002/(SICI)1097-4547(19980115)51:2<223::AID-JNR11>3.3.CO;2-Z; LeVine SM, 1997, J NEUROIMMUNOL, V73, P47, DOI 10.1016/S0165-5728(96)00166-X; McCourt M, 1999, ARCH SURG-CHICAGO, V134, P1325, DOI 10.1001/archsurg.134.12.1325; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; Pedchenko TV, 1999, EXP NEUROL, V158, P459, DOI 10.1006/exnr.1999.7125; Penkowa M, 1999, GLIA, V25, P343; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Reyes TM, 1999, BRAIN RES, V851, P215, DOI 10.1016/S0006-8993(99)02189-7; Risau W., 1994, Arzneimittel-Forschung, V44, P416; SAHAGUN G, 1989, AM J PATHOL, V134, P1227; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; Sterneck E, 1996, J NEUROCHEM, V67, P1365; Sun D, 1997, AM J PHYSIOL-CELL PH, V272, pC1829, DOI 10.1152/ajpcell.1997.272.6.C1829; Suzuki S, 1999, J CEREBR BLOOD F MET, V19, P1256, DOI 10.1097/00004647-199911000-00010; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Tsao MN, 1999, J NEUROPATH EXP NEUR, V58, P1051, DOI 10.1097/00005072-199910000-00003; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zhang ZG, 1999, J CEREBR BLOOD F MET, V19, P68, DOI 10.1097/00004647-199901000-00008	47	131	137	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 30	2001	896	1-2					86	95		10.1016/S0006-8993(01)02013-3			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	419KL	WOS:000167947900011	11277977				2022-02-06	
J	Wilson, JTL; Pettigrew, LEL; Teasdale, GM				Wilson, JTL; Pettigrew, LEL; Teasdale, GM			Emotional and cognitive consequences of head injury in relation to the Glasgow outcome scale	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; outcome; Glasgow outcome scale	TRAUMATIC BRAIN INJURY; DISABILITY RATING-SCALE; RELIABILITY; COMA	Objective-There is current debate over the issue of the best way of assessing outcome after head injury. One criticism of scales of disability and handicap such as the Glasgow outcome scale (GOS) is that they fail to capture the subjective perspective of the person with head injury. The aims of the study were to investigate aspects of the validity of structured interviews for the GOS, and address the issue of the relation between the GOS and subjective reports of health outcome. Methods-A total of 135 patients with head injury were assessed using the GOS and an extended GOS (GOSE) and other measures of outcome and clinical status at 6 months after injury. Results-There were robust correlations between the GOS and measures of initial injury severity (particularly posttraumatic amnesia) and outcome assessed by disability scales (particularly the disbility rating scale (DRS)); however, associations with cognitive tests were generally modest. There were also strong correlations with self report measures of health outcome: both the GOS and GOSE were related to depression measured by the Beck depression inventory, mental wellbeing assessed by the general health questionnaire, and to all subscales of the short form-36. The GOS scales were also strongly associated with frequency of reported symptoms and problems on the neurobehavioural functioning inventory. Conclusions-The GOS and GOSE show consistent relations with other outcome measures including subjective reports of health outcome; they thus remain useful overall summary assessments of outcome of head injury.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; Univ Glasgow, So Gen Hosp, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland		Wilson, JTL (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.	j.t.l.wilson@stir.ac.uk	Wilson, Lindsay/O-8883-2019; Wilson, Lindsay/A-3659-2009	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328			Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Beck AT, 1987, BECK DEPRESSION INVE; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Collin C, 1988, Int Disabil Stud, V10, P61; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Goldberg D., 1988, USERS GUIDE GEN HLTH; GOUVIER WD, 1986, INT J CLIN NEUROPSYC, V8, P1; GRANT I, 1987, NEUROBEHAVIORAL RECO, P57; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JENKINSON C, 1996, UK SF 36 ANAL INTERP; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wechsler D, 1987, MEMORY SCALE REVISED; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	131	134	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2000	69	2					204	209		10.1136/jnnp.69.2.204			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	338XM	WOS:000088448600013	10896694	Green Published, Bronze			2022-02-06	
J	Aibiki, M; Maekawa, S; Ogura, S; Kinoshita, Y; Kawai, N; Yokono, S				Aibiki, M; Maekawa, S; Ogura, S; Kinoshita, Y; Kawai, N; Yokono, S			Effect of moderate hypothermia on systemic and internal jugular plasma IL-6 levels after traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; humans IL-6; moderate hypothermia; traumatic brain injury	TUMOR-NECROSIS-FACTOR; SERUM INTERLEUKIN-6; HEAD-INJURY; RAT-BRAIN; CYTOKINES; EXPRESSION; ASTROCYTES; PROTEINS; ISCHEMIA; BIOLOGY	Moderate hypothermia may reduce subsequent neuronal damage after traumatic brain injury. Interleukin (IL)-6 may have a role in the pathogenesis of traumatic neuronal damage or repair. Using the enzyme-linked immunological sorbent assay (ELISA), we serially measured IL-6 levels in plasma obtained from the radial artery (systemic) and internal jugular vein (regional) in 13 cerebral trauma patients who underwent hypothermia of 32-33 degrees C ranged from 4-9 days postinjury and 10 head-injured patients who were maintained at normothermic levels (36-37 degrees C). In both patient populations, surface cooling was used since even in the normothermic group, cooling was needed to maintain patient temperature in the normothermic range. All patients were mechanically ventilated after injection of midazolam and vecuronium. The administration of these agents were continued until the end of the study. Hypothermia was typically maintained for four days, however, in some cases based upon CT findings and/or intra-cranial pressure change, the duration was prolonged. No significant differences were found between the two groups in age, gender and Glasgow Coma Scale upon admission. Further, no differences were found in terms of the classification of computed tomography findings or the occurrence of pupillary abnormalities on admission. The patients in this study had not sustained either abdominal or thoracic trauma. Before inducing hypothermia, IL-6 levels in the arterial and internal jugular venous blood exceeded the normal range. Specifically, the internal jugular plasma levels were significantly higher than those in the arterial plasma. While IL-6 levels in the normothermic group did not decrease even at 4 days postinjury, the plasma cytokine levels fell at both sites sharply after moderate hypothermia. The cytokine suppression found in the hypothermic group continued even after rewarming in these patients showing an improved clinical course, but not in those whose condition worsened. In addition to these changes in cytokine levels, the Glasgow Outcome Scale at 6 months postinjury was significantly higher in the hypothermic group than in the normothermia group. Based on the above, this clinical study with its small patient sample size suggests the need for further prospective randomized studies to examine the role of cytokine suppression in the beneficial effects of moderate hypothermia in patients with traumatic brain injury.	Kagawa Med Univ, Dept Neurosurg, Intens Care Unit, Kagawa, Japan; Kagawa Med Univ, Dept Emergency Med, Kagawa, Japan; Ehime Univ, Sch Med, Dept Emergency Med, Matsuyama, Ehime 790, Japan		Aibiki, M (corresponding author), Kagawa Med Univ Hosp, Intens Care Unit, 1750-1 Ikenobe, Miki, Kagawa 76107, Japan.	aibiki@kms.ac.jp		Ogura, Shinji/0000-0001-7686-6001			AIBIKI M, 1997, PERSPECTIVES BRAIN R, P85; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ASAGA T, 1997, JPN J INTENSIVE CARE, V21, P967; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BAUER J, 1988, BLOOD, V72, P1134; BIGGAR WD, 1986, J APPL PHYSIOL, V60, P1186, DOI 10.1152/jappl.1986.60.4.1186; BROM J, 1992, IMMUNOLOGY, V75, P281; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; JANNET B, 1981, PSYCHIATRY, V44, P285; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MUKAIDA N, 1991, J IMMUNOL, V146, P1212; NISHIMOTO N, 1989, CLIN IMMUNOL IMMUNOP, V50, P399, DOI 10.1016/0090-1229(89)90147-5; Okimura Y, 1996, J NEUROTRAUM, V13, P385, DOI 10.1089/neu.1996.13.385; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Young B, 1991, Neurosurg Clin N Am, V2, P301	31	131	139	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1999	16	3					225	232		10.1089/neu.1999.16.225			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	178QQ	WOS:000079277800004	10195470				2022-02-06	
J	Marti, HH; Gassmann, M; Wenger, RH; Kvietikova, I; MorgantiKossmann, MC; Kossmann, T; Trentz, O; Bauer, C				Marti, HH; Gassmann, M; Wenger, RH; Kvietikova, I; MorgantiKossmann, MC; Kossmann, T; Trentz, O; Bauer, C			Detection of erythropoietin in human liquor: Intrinsic erythropoietin production in the brain	KIDNEY INTERNATIONAL			English	Article; Proceedings Paper	Meeting on Forefronts in Nephrology: Oxygen Sensing on the Cellular and Molecular Levels	JUN 23-26, 1996	REGENSBURG, GERMANY	Int Soc Nephrol, Deut Forschungsgemeinsch, Vielberth Foundat, Regensburg, Boehringer Mannheim Co, Byk-Gulden Co, Cilag Co			INSITU HYBRIDIZATION; MESSENGER-RNA; CELLS; LOCALIZATION; ERYTHROCYTOSIS; EXPRESSION; LIVER; TUMOR	Detection of erythropoietin in human liquor: Intrinsic erythropoietin production in the brain. Until now, erythropoietin (EPO) was thought to be produced exclusively in fetal liver and adult kidney and to regulate mammalian erythropoiesis. However, we recently showed that steady slate levels of EPO mRNA could be induced up to 100-fold in primary mouse astrocytes cultured under hypoxic conditions, and also reported the presence of mRNA for EPO and its receptor in the brain of mouse, monkey and human. In extending these studies on humans we now show that immunoreactive EPO is present in ventricular cerebrospinal fluid (CSF) of 5 patients with traumatic brain injuries: EPO was found in 15 out of lj CSF samples. There was no correlation between the serum EPO concentration and the concentration in the CSF. However, EPO concentrations in CSF correlated with the degree of blood-brain-barrier dysfunction. This suggests that EPO does not cross the intact blood-brain-barrier, implying that EPO is produced in the brain itself most probably by astrocytes in an oxygen-dependent manner. In view that neuronal cells carry the EPO receptor, we propose that EPO acts in a paracrine fashion in the central nervous system and might function as a protective factor against hypoxia-induced damage of neurons.	UNIV ZURICH IRCHEL,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,DEPT SURG,DIV RES,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,DIV TRAUMA SURG,CH-8091 ZURICH,SWITZERLAND				Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Morganti-Kossmann, Cristina/0000-0002-0807-2063			BRUNEVAL P, 1993, BLOOD, V81, P1593; Conrad KP, 1996, FASEB J, V10, P760, DOI 10.1096/fasebj.10.7.8635693; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; ECKARDT KU, 1988, KLIN WOCHENSCHR, V66, P241, DOI 10.1007/BF01748163; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; GASSMANN M, 1995, TOXICOL IN VITRO, V9, P429, DOI 10.1016/0887-2333(95)00036-8; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY ST, 1988, BLOOD, V71, P524; KOURY ST, 1991, BLOOD, V77, P2497; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MAXWELL PH, 1994, BLOOD, V84, P1823; TAN CC, 1992, AM J PHYSIOL, V263, pF474, DOI 10.1152/ajprenal.1992.263.3.F474; TRIMBLE M, 1991, BLOOD, V78, P599	18	131	138	0	2	BLACKWELL SCIENCE INC	MALDEN	350 MAIN ST, MALDEN, MA 02148	0085-2538			KIDNEY INT	Kidney Int.	FEB	1997	51	2					416	418		10.1038/ki.1997.55			3	Urology & Nephrology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Urology & Nephrology	WF307	WOS:A1997WF30700008	9027715	Bronze			2022-02-06	
J	McMillan, TM; Jongen, ELMM; Greenwood, RJ				McMillan, TM; Jongen, ELMM; Greenwood, RJ			Assessment of post-traumatic amnesia after severe closed head injury: Retrospective or prospective?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						post-traumatic amnesia; retrospective assessment; prospective assessment	SCALE	Background-Post-traumatic amnesia is considered to be the best single indicator of the severity of closed head injury. Usually, it has been estimated retrospectively. For practical reasons this also tends to be the most common clinical method. It has been argued that prospective assessment is more accurate and reliable, but this has never been evaluated empirically in severe head injury. Methods-Post-traumatic amnesia was initially assessed prospectively and later retrospectively by a separate observer in the same patients. Results-The correlation between the two methods was high. In addition, both measures significantly correlated with other measures of severity of brain injury and with measures of outcome. Conclusion-Retrospective measurement of post-traumatic amnesia is a valid method.	ST BARTHOLOMEWS HOSP,DEPT NEUROL SCI,LONDON,ENGLAND		McMillan, TM (corresponding author), ATKINSON MORLEYS HOSP,ST GEORGES HLTHCARE TRUST,WOLFSON REHABIL CTR,DEPT CLIN NEUROPSYCHOL,LONDON,ENGLAND.						ANASTASI A, 1982, PSYCHOL TESTING, P123; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BISIHARA SN, 1992, BRAIN INJURY, V6, P373; Brooks D. N, 1990, REHABILITATION ADULT, P163; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Jennett B, 1981, MANAGEMENT HEAD INJU; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1955, NEUROPSYCHOLOGICAL A; MCMILLAN T, 1993, NEUROLOGICAL REHABIL, P437; NORUSIS MJ, 1993, SPSS WINDOWS BASE SY, P303; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WADE DT, 1993, MEASUREMENT NEUROLOG; Wechsler, 1984, WECHSLER MEMORY SCAL; Wilson BA., 1992, NEUROPSYCHOL REHABIL, V2, P231, DOI [DOI 10.1080/09602019208401410, 10.1080/09602019208401410]; WILSON JTL, 1993, J NEUROL NEUROSUR PS, V56, P198; 1961, LANCET, V2, P1445	23	131	134	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	1996	60	4					422	427		10.1136/jnnp.60.4.422			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	UD872	WOS:A1996UD87200014	8774408	Bronze, Green Published			2022-02-06	
J	GOSS, JR; STYREN, SD; MILLER, PD; KOCHANEK, PM; PALMER, AM; MARION, DW; DEKOSKY, ST				GOSS, JR; STYREN, SD; MILLER, PD; KOCHANEK, PM; PALMER, AM; MARION, DW; DEKOSKY, ST			HYPOTHERMIA ATTENUATES THE NORMAL INCREASE IN INTERLEUKIN-1-BETA RNA AND NERVE GROWTH-FACTOR FOLLOWING TRAUMATIC BRAIN INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article						HYPOTHERMIA; INTERLEUKIN 1 (IL-1); NERVE GROWTH FACTOR (NGF); TRAUMATIC BRAIN INJURY	COLONY-STIMULATING FACTORS; TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURIES; MODERATE HYPOTHERMIA; NEUROTROPHIC FACTOR; MESSENGER-RNA; DIFFERENTIAL REGULATION; ASTROCYTE CULTURES; MILD HYPOTHERMIA; ASTROGLIAL CELLS	Significant morbidity and mortality associated with traumatic brain injury(TBI) are allied with secondary posttrauma inflammatory complications, Hypothermia has been suggested as a possible treatment to lessen or suppress these inflammatory reactions, We report here that interleukin 1 beta, a cytokine responsible for initiating inflammatory cascades, is elevated in rat cortex within 6 h of TBI in the rat, Nerve growth factor (NGF) RNA and protein also increased subsequently, and NGF protein remained elevated for up to 7 days, Four hours of whole body hypothermia (32 degrees C), applied immediately after the TBI, attenuated the posttrauma increase in IL-1 beta RNA and eliminated the increase in NGF RNA and protein observed in cerebral cortex following TBI, Thus, hypothermia may be an effective therapy to diminish the posttrauma inflammatory cascade in the brain (as suggested by the decrease in IL-1 beta), However, the same treatment may hinder the brain's intrinsic repair mechanisms, Optimal treatment may, therefore, require supplemental administration of neurotrophic factors or other agents along with hypothermia.	UNIV PITTSBURGH, WESTERN PSYCHIAT INST & CLIN, DEPT PSYCHIAT, PITTSBURGH, PA 15213 USA; WESTERN PSYCHIAT INST & CLIN, DEPT NEUROL SURG, PITTSBURGH, PA USA; WESTERN PSYCHIAT INST & CLIN, DEPT ANESTHESIOL, PITTSBURGH, PA USA; WESTERN PSYCHIAT INST & CLIN, DEPT PHARMACOL, PITTSBURGH, PA USA; WESTERN PSYCHIAT INST & CLIN, DEPT NEUROL, PITTSBURGH, PA USA; WESTERN PSYCHIAT INST & CLIN, DEPT NEUROBIOL, PITTSBURGH, PA USA		GOSS, JR (corresponding author), UNIV PITTSBURGH, SCH MED, MED CTR, 3811 OHARA ST, PITTSBURGH, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015; Palmer, Alan/AAP-8650-2020; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758			ALOISI F, 1992, J IMMUNOL, V149, P2358; ASHMAN RB, 1984, IMMUNOL TODAY, V5, P268, DOI 10.1016/0167-5699(84)90138-5; BAKHIT C, 1991, BRAIN RES, V560, P76, DOI 10.1016/0006-8993(91)91217-O; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; EBMEYER U, 1993, SOC CRIT CARE MED, V21, pS236; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAN L, 1993, SOC NEUR ABST, V19; FONTANA A, 1984, SPRINGER SEMIN IMMUN, V7, P375; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HOFMAN FM, 1989, NEUROIMMUNE NETWORKS, P65; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LINDSAY RM, 1982, BRAIN RES, V243, P329, DOI 10.1016/0006-8993(82)90257-8; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; MANTOVANI A, 1987, BIOCHEM PHARMACOL, V36, P301, DOI 10.1016/0006-2952(87)90285-1; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PETTY BG, 1994, ANN NEUROL, V36, P244, DOI 10.1002/ana.410360221; POBER JS, 1986, J IMMUNOL, V137, P1893; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; SEIGER A, 1993, BEHAV BRAIN RES, V57, P255, DOI 10.1016/0166-4328(93)90141-C; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; SUNDAR SK, 1989, P NATL ACAD SCI USA, V86, P6398, DOI 10.1073/pnas.86.16.6398; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	63	131	136	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1995	12	2					159	167		10.1089/neu.1995.12.159			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	QZ508	WOS:A1995QZ50800002	7629862				2022-02-06	
J	SMITH, DH; OKIYAMA, K; THOMAS, MJ; MCINTOSH, TK				SMITH, DH; OKIYAMA, K; THOMAS, MJ; MCINTOSH, TK			EFFECTS OF THE EXCITATORY AMINO-ACID RECEPTOR ANTAGONISTS KYNURENATE AND INDOLE-2-CARBOXYLIC ACID ON BEHAVIORAL AND NEUROCHEMICAL OUTCOME FOLLOWING EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROSCIENCE			English	Article						BRAIN INJURY; GLYCINE ANTAGONISTS; MEMORY DYSFUNCTION; NEUROLOGIC DYSFUNCTION; CEREBRAL EDEMA; CATION HOMEOSTASIS	D-ASPARTATE RECEPTOR; LONG-TERM POTENTIATION; FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; NMDA-RECEPTOR; RAT-BRAIN; GLUTAMATE NEUROTOXICITY; ENHANCES PERFORMANCE; NEURONAL DAMAGE; GLYCINE BINDING	The overactivation of the NMDA receptor is thought to be a major contributor to the pathophysiologic sequelae of traumatic brain injury (TBI), which commonly includes memory dysfunction. Uniquely, potentiation of the NMDA receptor is dependent on the binding of glycine to a distinct site on the receptor. Despite the potential role of the NMDA receptor in the development of post-TBI cognitive deficits, no studies to date have evaluated the efficacy of NMDA receptor antagonists on memory dysfunction after brain injury. Moreover, glycine site antagonists have not been employed as potential therapeutic agents in models of TBI. In the present study, we evaluated the effects of two glycine site antagonists, kynurenate (KYNA) and indole-2-carboxylic acid (12CA), on memory and motor dysfunction, cerebral edema formation, and changes in regional total tissue brain [Na], [K], [Ca], [Mg], and [Zn], following lateral fluid-percussion brain injury in the rat. We found that both KYNA (300 mg/kg) and 12CA (50 mg/kg and 20 mg/kg) administered 15 min postinjury dramatically attenuated trauma-induced cognitive dysfunction (p < 0.01). In addition, both compounds improved neurologic motor deficits measured at 2 weeks following injury (p < 0.05). KYNA (300 mg/kg) reduced edema in the cortex, hippocampus, and thalamus, while 12CA (20 mg/kg) reduced edema formation only in the thalamus. Differential effects of KYNA and I2CA on cation concentrations were also noted. KYNA attenuated the postinjury increase in regional tissue [Ca]; however, it had little effect on other cation concentrations. 12CA reversed the postinjury regional increases in [Na] and decreases in [K], [Mg], and [Zn], but had little effect on [Ca] changes. These results indicate that KYNA and 12CA may have differential, but beneficial effects on both behavioral and neurochemical sequelae of TBI.	UNIV CONNECTICUT, SCH MED, CTR HLTH, FARMINGTON, CT 06050 USA		SMITH, DH (corresponding author), UNIV PENN, DIV NEUROSURG, 105 HAYDEN HALL, 240 S 33RD ST, PHILADELPHIA, PA 19104 USA.		smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818] Funding Source: Medline		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BUCHAN A, 1990, J NEUROSCI, V10, P311; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P357; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HANDELMANN GE, 1989, PHARMACOL BIOCHEM BE, V34, P823, DOI 10.1016/0091-3057(89)90281-5; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERBERG LJ, 1990, PHARMACOL BIOCHEM BE, V36, P735, DOI 10.1016/0091-3057(90)90069-T; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUETTNER JE, 1989, SCIENCE, V243, P1611, DOI 10.1126/science.2467381; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KESSLER M, 1989, BRAIN RES, V489, P377, DOI 10.1016/0006-8993(89)90875-5; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MCDONALD JW, 1990, NEUROSCIENCE, V35, P653, DOI 10.1016/0306-4522(90)90336-3; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYZAKI S, 1989, INTRACRANIAL PRESSUR, V7, P651; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MONAHAN JB, 1989, PHARMACOL BIOCHEM BE, V34, P649, DOI 10.1016/0091-3057(89)90571-6; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PARKIN AJ, 1984, CORTEX, V20, P479, DOI 10.1016/S0010-9452(84)80053-2; PRIESTLEY T, 1990, BRAIN RES, V531, P183, DOI 10.1016/0006-8993(90)90772-4; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; REYNOLDS IJ, 1988, MOL PHARMACOL, V33, P581; REYNOLDS IJ, 1987, P NATL ACAD SCI USA, V84, P7744, DOI 10.1073/pnas.84.21.7744; REYNOLDS M, 1989, Society for Neuroscience Abstracts, V15, P130; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHALABY I, 1989, EUR J PHARMACOL, V160, P309, DOI 10.1016/0014-2999(89)90506-2; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; Smith D. H., 1992, Society for Neuroscience Abstracts, V18, P170; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOMJEN GG, 1985, J NEUROPHYSIOL, V53, P1098, DOI 10.1152/jn.1985.53.4.1098; THOMAS M J, 1990, Society for Neuroscience Abstracts, V16, P777; VINK R, 1988, J BIOL CHEM, V263, P757; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YEH GC, 1990, MOL PHARMACOL, V38, P14; Young W, 1986, Cent Nerv Syst Trauma, V3, P215; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; [No title captured]	72	131	132	0	0	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC	1993	13	12					5383	5392		10.1523/JNEUROSCI.13-12-05383.1993			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MN040	WOS:A1993MN04000031	8254381	Green Published, Bronze			2022-02-06	
J	Kumar, A; Stoica, BA; Loane, DJ; Yang, M; Abulwerdi, G; Khan, N; Kumar, A; Thom, SR; Faden, AI				Kumar, Alok; Stoica, Bogdan A.; Loane, David J.; Yang, Ming; Abulwerdi, Gelareh; Khan, Niaz; Kumar, Asit; Thom, Stephen R.; Faden, Alan I.			Microglial-derived microparticles mediate neuroinflammation after traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Microparticles; Microglia; Neuroinflammation; Traumatic brain injury; Interleukin-1 beta; miR-155	NANOPARTICLE TRACKING ANALYSIS; INDUCED NEUTROPHIL ACTIVATION; IMPROVES FUNCTIONAL RECOVERY; IN-VIVO; EXTRACELLULAR VESICLES; VASCULAR INJURY; PLATELET MICROPARTICLES; INFLAMMATORY RESPONSE; ALZHEIMERS-DISEASE; OXIDATIVE STRESS	Background: Local and systemic inflammatory responses are initiated early after traumatic brain injury (TBI), and may play a key role in the secondary injury processes resulting in neuronal loss and neurological deficits. However, the mechanisms responsible for the rapid expansion of neuroinflammation and its long-term progression have yet to be elucidated. Here, we investigate the role of microparticles (MP), a member of the extracellular vesicle family, in the exchange of pro-inflammatory molecules between brain immune cells, as well as their transfer to the systemic circulation, as key pathways of inflammation propagation following brain trauma. Methods: Adult male C57BL/6 mice were subjected to controlled cortical impact TBI for 24 h, and enriched MP were isolated in the blood, while neuroinflammation was assessed in the TBI cortex. MP were characterized by flow cytometry, and MP content was assayed using gene and protein markers for pro-inflammatory mediators. Enriched MP co-cultured with BV2 or primary microglial cells were used for immune propagation assays. Enriched MP from BV2 microglia or CD11b-positive microglia from the TBI brain were stereotactically injected into the cortex of uninjured mice to evaluate MP-related seeding of neuroinflammation in vivo. Results: As the neuroinflammatory response is developing in the brain after TBI, microglial-derived MP are released into the circulation. Circulating enriched MP from the TBI animals can activate microglia in vitro. Lipopolysaccharide stimulation increases MP release from microglia in vitro and enhances their content of pro-inflammatory mediators, interleukin-1 beta and microRNA-155. Enriched MP from activated microglia in vitro or CD11b-isolated microglia/macrophage from the TBI brain ex vivo are sufficient to initiate neuroinflammation following their injection into the cortex of naive (uninjured) animals. Conclusions: These data provide further insights into the mechanisms underlying the development and dissemination of neuroinflammation after TBI. MP loaded with pro-inflammatory molecules initially released by microglia following trauma can activate additional microglia that may contribute to progressive neuroinflammatory response in the injured brain, as well as stimulate systemic immune responses. Due to their ability to independently initiate inflammatory responses, MP derived from activated microglia may provide a potential target for other neurological disorders in which neuroinflammation may be a contributing factor.	[Kumar, Alok; Stoica, Bogdan A.; Loane, David J.; Abulwerdi, Gelareh; Khan, Niaz; Kumar, Asit; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Kumar, Alok; Stoica, Bogdan A.; Loane, David J.; Abulwerdi, Gelareh; Khan, Niaz; Kumar, Asit; Faden, Alan I.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Hlth Sci Facil 2, S247 20 Penn St, Baltimore, MD 21201 USA; [Yang, Ming; Thom, Stephen R.] Univ Maryland, Sch Med, Dept Emergency Med, Baltimore, MD 21201 USA		Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.; Faden, AI (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Hlth Sci Facil 2, S247 20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013; Kumar, Asit/AAG-3916-2021	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434; Kumar, Asit/0000-0003-1735-7033; Faden, Alan I./0000-0003-0128-2348; Vinueza, Gelareh/0000-0002-1036-6378	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037313, R01 NS082308, R01 NS052568] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568, R01NS082308, R01NS037313] Funding Source: NIH RePORTER		An K, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-47; Andrews AM, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00043; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Basso M, 2013, J BIOL CHEM, V288, P15699, DOI 10.1074/jbc.M112.425066; Bhullar J, 2016, FREE RADICAL BIO MED, V101, P154, DOI 10.1016/j.freeradbiomed.2016.10.010; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Bohman LE, 2016, J NEUROTRAUM, V33, P168, DOI 10.1089/neu.2015.3885; Burnier L, 2009, THROMB HAEMOSTASIS, V101, P439, DOI 10.1160/TH08-08-0521; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Pena-Philippides JC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0753-x; Castro-Seoane R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002538; Chan HC, 2013, BLOOD, V122, P3632, DOI 10.1182/blood-2013-05-504639; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davizon P, 2010, SEMIN THROMB HEMOST, V36, P857, DOI 10.1055/s-0030-1267039; Dinkins MB, 2014, NEUROBIOL AGING, V35, P1792, DOI 10.1016/j.neurobiolaging.2014.02.012; Dragovic RA, 2011, NANOMED-NANOTECHNOL, V7, P780, DOI 10.1016/j.nano.2011.04.003; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; French SL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165565; Gachet C, 2012, PURINERG SIGNAL, V8, P609, DOI 10.1007/s11302-012-9303-x; Grad LI, 2015, NEUROBIOL DIS, V77, P257, DOI 10.1016/j.nbd.2015.02.009; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Klohn PC, 2013, J INFECTION, V67, P359, DOI 10.1016/j.jinf.2013.07.024; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lawrie AS, 2009, VOX SANG, V96, P206, DOI 10.1111/j.1423-0410.2008.01151.x; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mause SF, 2010, CIRCULATION, V122, P495, DOI 10.1161/CIRCULATIONAHA.109.909473; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Nie DM, 2016, AM J PHYSIOL-CELL PH, V310, pC821, DOI 10.1152/ajpcell.00372.2015; Oosthuyzen W, 2013, J PHYSIOL-LONDON, V591, P5833, DOI 10.1113/jphysiol.2013.264069; Perez-Pujol S, 2007, CYTOM PART A, V71A, P38, DOI 10.1002/cyto.a.20354; Porro C, 2013, J CYST FIBROS, V12, P721, DOI 10.1016/j.jcf.2013.03.002; Qu Y, 2009, J IMMUNOL, V182, P5052, DOI 10.4049/jimmunol.0802968; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Rozmyslowicz T, 2003, AIDS, V17, P33, DOI 10.1097/00002030-200301030-00006; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; Su W, 2016, BRAIN BEHAV IMMUN, V52, P1, DOI 10.1016/j.bbi.2015.07.003; Takeshita J, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000507; Thom SR, 2014, J BIOL CHEM, V289, P18831, DOI 10.1074/jbc.M113.543702; Thom SR, 2013, J APPL PHYSIOL, V114, P550, DOI 10.1152/japplphysiol.01386.2012; Thom SR, 2011, J APPL PHYSIOL, V110, P340, DOI 10.1152/japplphysiol.00811.2010; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Verderio C, 2012, ANN NEUROL, V72, P610, DOI 10.1002/ana.23627; Xu JJ, 2013, TOXICOL APPL PHARM, V273, P410, DOI 10.1016/j.taap.2013.09.019; Yang M, 2015, J APPL PHYSIOL, V119, P219, DOI 10.1152/japplphysiol.00384.2015; Yang M, 2015, J APPL PHYSIOL, V119, P77, DOI 10.1152/japplphysiol.00183.2015; Yang M, 2013, J APPL PHYSIOL, V115, P1481, DOI 10.1152/japplphysiol.00745.2013; Yuyama K, 2014, J BIOL CHEM, V289, P24488, DOI 10.1074/jbc.M114.577213; Zappulli V, 2016, J CLIN INVEST, V126, P1198, DOI 10.1172/JCI81134; Zhang YQ, 2016, J MOL CELL BIOL, V8, P505, DOI 10.1093/jmcb/mjw040	64	130	132	5	26	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 15	2017	14								47	10.1186/s12974-017-0819-4			17	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	EP1NK	WOS:000397151400001	28292310	gold, Green Published			2022-02-06	
J	Houlden, A; Goldrick, M; Brough, D; Vizi, ES; Lenart, N; Martinecz, B; Roberts, IS; Denes, A				Houlden, A.; Goldrick, M.; Brough, D.; Vizi, E. S.; Lenart, N.; Martinecz, B.; Roberts, I. S.; Denes, A.			Brain injury induces specific changes in the caecal microbiota of mice via altered autonomic activity and mucoprotein production	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Stroke; Microbiota; Cerebral ischemia; Inflammation; Noradrenaline; Gut; Mucoprotein	EXPERIMENTAL STROKE; NERVOUS-SYSTEM; GUT MICROBIOTA; ACTIVATION; CATECHOLAMINES; ENDOCRINOLOGY; CONSTIPATION; DISORDERS; PATTERNS; BACTERIA	Intestinal microbiota are critical for health with changes associated with diverse human diseases. Research suggests that altered intestinal microbiota can profoundly affect brain function. However, whether altering brain function directly affects the microbiota is unknown. Since it is currently unclear how brain injury induces clinical complications such as infections or paralytic ileus, key contributors to prolonged hospitalization and death post-stroke, we tested in mice the hypothesis that brain damage induced changes in the intestinal microbiota. Experimental stroke altered the composition of caeca( microbiota, with specific changes in Peptococcaceae and Prevotellaceae correlating with the extent of injury. These effects are mediated by noradrenaline release from the autonomic nervous system with altered caecal mucoprotein production and goblet cell numbers. Traumatic brain injury also caused changes in the gut microbiota, confirming brain injury effects gut microbiota. Changes in intestinal microbiota after brain injury may affect recovery and treatment of patients should appreciate such changes. (C) 2016 The Authors. Published by Elsevier Inc.	[Houlden, A.; Goldrick, M.; Brough, D.; Roberts, I. S.; Denes, A.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Lenart, N.; Martinecz, B.; Denes, A.] Inst Expt Med, Lab Neuroimmunol, Budapest, Hungary; [Vizi, E. S.] Hungarian Acad Sci, Inst Expt Med, Lab Drug Res, POB 67, H-1450 Budapest, Hungary; [Vizi, E. S.] Semmelweis Univ, Dept Pharmacol & Pharmacotherapy, Budapest, Hungary		Roberts, IS (corresponding author), Univ Manchester, Fac Life Sci, Manchester, Lancs, England.; Denes, A (corresponding author), Inst Expt Med, Lab Neuroimmunol, Budapest, Hungary.	i.s.roberts@manchester.ac.uk; denesa@koki.hu		Brough, David/0000-0002-2250-2381	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1100076]; OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K109743]; Hungarian Brain Research Program [KTIA_13_NAP-A-I/2]; Bolyai Janos Research Scholarship from the Hungarian Academy of Sciences; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1100076] Funding Source: UKRI	We are grateful to Thomas Curl-Roper and Erica Roche who performed experiments on this project as part of their degree programmes at the University of Manchester. We thank Maria Bako for her help and advice in histology. We thank Ping Wang for assistance in denoising sequencing data. We thank Prof. Ulrich Dirnagl and Prof. Andreas Meisel for the critical discussions of the work. We are also grateful to Prof. Mark Lyte (Texas Tech University Health Sciences Center) for useful discussions. This work was in part funded through Medical Research Council grant G1100076 to ISR. Funding for AD was provided by OTKA K109743 and the Hungarian Brain Research Program KTIA_13_NAP-A-I/2. AD is supported by the Bolyai Janos Research Scholarship from the Hungarian Academy of Sciences.	Abt MC, 2012, IMMUNITY, V37, P158, DOI 10.1016/j.immuni.2012.04.011; Asano Y, 2012, AM J PHYSIOL-GASTR L, V303, pG1288, DOI 10.1152/ajpgi.00341.2012; Ayres JS, 2012, NAT MED, V18, P799, DOI 10.1038/nm.2729; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bracci F, 2007, WORLD J GASTROENTERO, V13, P3967, DOI 10.3748/wjg.v13.i29.3967; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caso JR, 2008, STROKE, V39, P1314, DOI 10.1161/STROKEAHA.107.498212; CECHETTO DF, 1989, BRAIN RES, V502, P296, DOI 10.1016/0006-8993(89)90625-2; de Jonge Wouter J, 2013, ISRN Gastroenterol, V2013, P630159, DOI 10.1155/2013/630159; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Denes A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-164; Denes A, 2011, J CEREBR BLOOD F MET, V31, P1036, DOI 10.1038/jcbfm.2010.198; Denes A, 2010, J NEUROSCI, V30, P10086, DOI 10.1523/JNEUROSCI.1227-10.2010; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; DuPont AW, 2011, NAT REV GASTRO HEPAT, V8, P523, DOI 10.1038/nrgastro.2011.133; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Mejia-Leon ME, 2014, SCI REP-UK, V4, DOI 10.1038/srep03814; Flint HJ, 2012, NAT REV GASTRO HEPAT, V9, P577, DOI 10.1038/nrgastro.2012.156; Ganal SC, 2012, IMMUNITY, V37, P171, DOI 10.1016/j.immuni.2012.05.020; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; Goslee SC, 2007, J STAT SOFTW, V22, P1, DOI 10.18637/jss.v022.i07; Gu SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074957; Reyes-Garcia MG, 2009, J NEUROIMMUNOL, V216, P20, DOI 10.1016/j.jneuroim.2009.06.024; Hetze S, 2013, J CEREBR BLOOD F MET, V33, P846, DOI 10.1038/jcbfm.2013.6; Hilz MJ, 2011, STROKE, V42, P1528, DOI 10.1161/STROKEAHA.110.607721; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Jentsch HFR, 2013, ANAEROBE, V24, P49, DOI 10.1016/j.anaerobe.2013.09.001; Kang DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068322; Karavolos MH, 2013, MOL MICROBIOL, V87, P455, DOI 10.1111/mmi.12110; Kim Young S, 2010, Curr Gastroenterol Rep, V12, P319, DOI 10.1007/s11894-010-0131-2; Korpelainen JT, 1999, CLIN AUTON RES, V9, P325, DOI 10.1007/BF02318379; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Luczynski P, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw020; Lyte M, 2004, TRENDS MICROBIOL, V12, P14, DOI 10.1016/j.tim.2003.11.004; Lyte M, 1997, J SURG RES, V70, P195, DOI 10.1006/jsre.1997.5130; Lyte M, 2014, GUT MICROBES, V5, P381, DOI 10.4161/gmic.28682; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695, DOI 10.1128/AEM.59.3.695-700.1993; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; O'Mahony SM, 2009, BIOL PSYCHIAT, V65, P263, DOI 10.1016/j.biopsych.2008.06.026; Oksanen J, 2012, VEGAN COMMUNITY ECOL; Polz MF, 1998, APPL ENVIRON MICROB, V64, P3724; Prindiville T, 2004, INFLAMM BOWEL DIS, V10, P824, DOI 10.1097/00054725-200411000-00017; Pullinger GD, 2010, VET RES, V41, DOI 10.1051/vetres/2010040; Quince C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-38; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Spor A, 2011, NAT REV MICROBIOL, V9, P279, DOI 10.1038/nrmicro2540; Su YJ, 2009, STROKE, V40, P1304, DOI 10.1161/STROKEAHA.108.534776; Thompson JR, 2002, NUCLEIC ACIDS RES, V30, P2083, DOI 10.1093/nar/30.9.2083; Umschweif G., 2014, J CEREB BLOOD FLOW M, V34, P1; VIZI ES, 1985, NEUROSCIENCE, V16, P907, DOI 10.1016/0306-4522(85)90105-8; VIZI ES, 1995, NEUROSCIENCE, V68, P1263, DOI 10.1016/0306-4522(95)00215-5; WILLIAMS JM, 1981, BRAIN RES BULL, V6, P83, DOI 10.1016/S0361-9230(81)80072-X; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899; Wright DP, 2000, FEMS MICROBIOL LETT, V190, P73, DOI 10.1111/j.1574-6968.2000.tb09265.x; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347	59	130	143	4	31	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	OCT	2016	57						10	20		10.1016/j.bbi.2016.04.003			11	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	DW0BP	WOS:000383306200003	27060191	Green Published, hybrid, Green Accepted			2022-02-06	
J	Sierink, JC; Treskes, K; Edwards, MJR; Beuker, JA; den Hartog, D; Hohmann, J; Dijkgraaf, MGW; Luitse, JSK; Beenen, LFM; Hollmann, MW; Goslings, JC				Sierink, Joanne C.; Treskes, Kaij; Edwards, Michael J. R.; Beuker, J. A.; den Hartog, Dennis; Hohmann, Joachim; Dijkgraaf, Marcel G. W.; Luitse, Jan S. K.; Beenen, Ludo F. M.; Hollmann, Markus W.; Goslings, J. Carel		REACT-2 Study Grp	Immediate total-body CT scanning versus conventional imaging and selective CT scanning in patients with severe trauma (REACT-2): a randomised controlled trial	LANCET			English	Article							MULTISLICE COMPUTED-TOMOGRAPHY; EMERGENCY-ROOM MANAGEMENT; SEVERE BLUNT TRAUMA; MAJOR TRAUMA; INCIDENTAL FINDINGS; INJURED PATIENTS; MULTIPLE TRAUMA; METAANALYSIS; MORTALITY; SURVIVAL	Background Published work suggests a survival benefit for patients with trauma who undergo total-body CT scanning during the initial trauma assessment; however, level 1 evidence is absent. We aimed to assess the effect of total-body CT scanning compared with the standard work-up on in-hospital mortality in patients with trauma. Methods We undertook an international, multicentre, randomised controlled trial at four hospitals in the Netherlands and one in Switzerland. Patients aged 18 years or older with trauma with compromised vital parameters, clinical suspicion of life-threatening injuries, or severe injury were randomly assigned (1:1) by ALEA randomisation to immediate total-body CT scanning or to a standard work-up with conventional imaging supplemented with selective CT scanning. Neither doctors nor patients were masked to treatment allocation. The primary endpoint was in-hospital mortality, analysed in the intention-to-treat population and in subgroups of patients with polytrauma and those with traumatic brain injury. The. chi(2) test was used to assess differences in mortality. This trial is registered with ClinicalTrials.gov, number NCT01523626. Findings Between April 22, 2011, and Jan 1, 2014, 5475 patients were assessed for eligibility, 1403 of whom were randomly assigned:702 to immediate total-body CT scanning and 701 to the standard work-up. 541 patients in the immediate total-body CT scanning group and 542 in the standard work-up group were included in the primary analysis. In-hospital mortality did not differ between groups (total-body CT 86 [16%] of 541 vs standard work-up 85 [16%] of 542; p=0.92). In-hospital mortality also did not differ between groups in subgroup analyses in patients with polytrauma (total-body CT 81 [22%] of 362 vs standard work-up 82 [25%] of 331; p=0.46) and traumatic brain injury (68 [38%] of 178 vs 66 [44%] of 151; p=0.31). Three serious adverse events were reported in patients in the total-body CT group (1%), one in the standard work-up group (<1%), and one in a patient who was excluded after random allocation. All five patients died. Interpretation Diagnosing patients with an immediate total-body CT scan does not reduce in-hospital mortality compared with the standard radiological work-up. Because of the increased radiation dose, future research should focus on the selection of patients who will benefit from immediate total-body CT.	[Sierink, Joanne C.; Treskes, Kaij; Luitse, Jan S. K.; Goslings, J. Carel] Acad Med Ctr, Dept Surg, Trauma Unit, NL-1105 AZ Amsterdam, Netherlands; [Dijkgraaf, Marcel G. W.] Acad Med Ctr, Clin Res Unit, Amsterdam, Netherlands; [Beenen, Ludo F. M.] Acad Med Ctr, Dept Radiol, Amsterdam, Netherlands; [Hollmann, Markus W.] Acad Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands; [Edwards, Michael J. R.] Radboud Univ Nijmegen, Med Ctr, Dept Surg, Trauma Unit, Nijmegen, Netherlands; [Beuker, J. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Trauma Unit, Groningen, Netherlands; [den Hartog, Dennis] Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg, Trauma Res Unit, Rotterdam, Netherlands; [Hohmann, Joachim] Univ Basel Hosp, Dept Radiol & Nucl Med, Basel, Switzerland		Goslings, JC (corresponding author), Acad Med Ctr, Dept Surg, Trauma Unit, NL-1105 AZ Amsterdam, Netherlands.	j.c.goslings@amc.nl	Edwards, M.J.R./H-8026-2014; Beenen, Ludo F/AAA-3114-2021; Treskes, Kaij/AAI-4686-2021; Tromp, Tjarda N/A-6583-2016; Brink, Monique/P-6085-2015; Hohmann, Joachim/B-4483-2014	Beenen, Ludo F/0000-0001-9204-1026; Treskes, Kaij/0000-0002-9462-5372; Brink, Monique/0000-0002-4146-1052; Klimek, Markus/0000-0002-0122-9929; Tromp, Tjarda/0000-0003-2037-8388	ZonMw, the Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development	ZonMw, the Netherlands Organisation for Health Research and Development.	American College of Surgeons Committee on Trauma, 2012, STUDENT COURSE MANUA; [Anonymous], 1996, GUIDELINE GOOD CLIN; Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Barrett TW, 2009, AM J EMERG MED, V27, P428, DOI 10.1016/j.ajem.2008.03.025; Beenen LFM, 2015, ACTA RADIOL, V56, P873, DOI 10.1177/0284185114539319; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/radiol.2323031095; Bruns B, 2008, J TRAUMA, V65, P1217, DOI 10.1097/TA.0b013e318184ee63; Caputo ND, 2014, J TRAUMA ACUTE CARE, V77, P534, DOI 10.1097/TA.0000000000000414; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Healy DA, 2014, EMERG MED J, V31, P101, DOI 10.1136/emermed-2012-201892; Hilbert P, 2007, INJURY, V38, P552, DOI 10.1016/j.injury.2006.12.023; Hoffstetter P, 2008, ROFO-FORTSCHR RONTG, V180, P120, DOI 10.1055/s-2007-963594; Huber-Wagner S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068880; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Hutter M, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-73; Jiang LB, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0054-2; Kanz Karl-Georg, 2010, J Trauma Manag Outcomes, V4, P4, DOI 10.1186/1752-2897-4-4; Kimura A, 2013, J TRAUMA ACUTE CARE, V75, P202, DOI 10.1097/TA.0b013e3182905ef7; Mettler FA, 2008, RADIOLOGY, V248, P254, DOI 10.1148/radiol.2481071451; Salim A, 2006, ARCH SURG-CHICAGO, V141, P468, DOI 10.1001/archsurg.141.5.468; Sedlic A, 2013, EMERG RADIOL, V20, P401, DOI 10.1007/s10140-013-1139-3; Sierink JC, 2014, INJURY, V45, P840, DOI 10.1016/j.injury.2013.10.009; Sierink JC, 2013, EMERG RADIOL, V20, P507, DOI 10.1007/s10140-013-1147-3; Sierink JC, 2012, BRIT J SURG, V99, P52, DOI 10.1002/bjs.7760; Sierink JC, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-4; Statline, CONS PRIC PRIC IND 2; Surendran A, 2014, J TRAUMA ACUTE CARE, V76, P1122, DOI 10.1097/TA.0000000000000178; van Vugt R, 2012, J TRAUMA ACUTE CARE, V72, P553, DOI 10.1097/TA.0b013e31822dd93b; Venugopal K, 2012, EUR J EMERG MED, V19, P193, DOI 10.1097/MEJ.0b013e32834ada14; Wada D, 2013, CRIT CARE, V17, DOI 10.1186/cc12861; Weninger P, 2007, J TRAUMA, V62, P584, DOI 10.1097/01.ta.0000221797.46249.ee; Wurmb TE, 2011, EMERG MED J, V28, P300, DOI 10.1136/emj.2009.082164; Wurmb TE, 2009, J TRAUMA, V66, P658, DOI 10.1097/TA.0b013e31817de3f4; Yeguiayan JM, 2012, CRIT CARE, V16, DOI 10.1186/cc11375	36	130	133	1	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2016	388	10045					673	683		10.1016/S0140-6736(16)30932-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT1UX	WOS:000381268700027	27371185				2022-02-06	
J	Jiang, T; Yu, JT; Tian, Y; Tan, L				Jiang, Teng; Yu, Jin-Tai; Tian, Yan; Tan, Lan			Epidemiology and Etiology of Alzheimer's disease: From Genetic to Non-Genetic Factors	CURRENT ALZHEIMER RESEARCH			English	Article						Alzheimer's disease; epidemiology; etiology; risk factor; genetic; environmental	MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; TRAUMATIC BRAIN-INJURY; BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; LIFE ASSOCIATED REGULATION; FREQUENCY MAGNETIC-FIELDS; APOLIPOPROTEIN-E GENOTYPE; TOTAL CHOLESTEROL LEVEL; OCCUPATIONAL-EXPOSURE	At present, the etiology of Alzheimer's disease (AD) is still unclear, but both genetic and non-genetic factors are thought to take part in the etiopathogenesis of AD. Epidemiologic researches revealed that genetic factors played a decisive role in the development of both early-onset AD (EOAD) and late-onset AD (LOAD). The mutations in APP, PSEN1 and PSEN2 are inherited in a Mendelian fashion and directly lead to the EOAD, while recent genome-wide association studies have identified numbers of risky genes, which influences the susceptibility to LOAD. Although genetic factors are inherited and fixed, non-genetic factors, such as occupational exposures (exposure to pesticides, electromagnetic fields, organic solvents and volatile anesthetics), pre-existing medical conditions (cerebrovascular disease, hypertension, diabetes, dyslipidemia, traumatic brain injury, depression and cancer) and lifestyle factors (smoking, consumptions of alcohol and coffee, body mass index, physical activity and cognitive activity), are partly environmentally-determined. Timely interventions targeted at these non-genetic risk factors may offer opportunities for prevention and treatment of AD. In the future, more high-quality and large-sample epidemiologic studies are needed to identify risk factors for AD, and the interaction models between genetic and non-genetic risk factors required further investigation. In addition, public health campaigns targeted at modification of non-genetic risk factors should be developed among population at high risk of AD.	[Jiang, Teng; Yu, Jin-Tai; Tan, Lan] Nanjing Med Univ, Qingdao Municipal Hosp, Dept Neurol, Nanjing, Peoples R China; [Yu, Jin-Tai; Tian, Yan; Tan, Lan] Qingdao Univ, Sch Med, Qingdao Municipal Hosp, Dept Neurol, Qingdao 266071, Shandong, Peoples R China; [Yu, Jin-Tai; Tan, Lan] Ocean Univ China, Coll Med & Pharmaceut, Qingdao, Peoples R China		Yu, JT (corresponding author), Qingdao Univ, Sch Med, Qingdao Municipal Hosp, Dept Neurol, 5 Donghai Middle Rd, Qingdao 266071, Shandong, Peoples R China.	yu-jintai@163.com; dr.tanlan@163.com		Yu, Jin-Tai/0000-0002-7686-0547	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81000544, 81171209]; Shandong Provincial Natural Science Foundation, ChinaNatural Science Foundation of Shandong Province [ZR2010HQ004, ZR2011HZ001]; Shandong Provincial Outstanding Medical Academic Professional Program	This work was supported by grants from the National Natural Science Foundation of China (81000544, 81171209), the Shandong Provincial Natural Science Foundation, China (ZR2010HQ004, ZR2011HZ001) and the Shandong Provincial Outstanding Medical Academic Professional Program.	Abraham R, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-44; Akbaraly TN, 2009, NEUROLOGY, V73, P854, DOI 10.1212/WNL.0b013e3181b7849b; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Alim I, 2010, BRAIN RES, V1330, P72, DOI 10.1016/j.brainres.2010.02.076; Allan LM, 2007, J NEUROL NEUROSUR PS, V78, P671, DOI 10.1136/jnnp.2006.102343; Alzheimers Assoc, 2012, ALZHEIMERS DEMENT, V8, P131, DOI 10.1016/j.jalz.2012.02.001; Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Anstey KJ, 2008, AM J GERIAT PSYCHIAT, V16, P343, DOI 10.1097/JGP.0b013e31816b72d4; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Anttila T, 2004, BMJ-BRIT MED J, V329, P539, DOI 10.1136/bmj.38181.418958.BE; Arendash GW, 2006, NEUROSCIENCE, V142, P941, DOI 10.1016/j.neuroscience.2006.07.021; Arvanitakis Z, 2011, STROKE, V42, P722, DOI 10.1161/STROKEAHA.110.595082; Ashford JW, 2002, J ALZHEIMERS DIS, V4, P169, DOI 10.3233/JAD-2002-4307; Avidan MS, 2011, J ALZHEIMERS DIS, V24, P201, DOI 10.3233/JAD-2011-101680; BAKER EL, 1994, J OCCUP ENVIRON MED, V36, P1079, DOI 10.1097/00043764-199410000-00010; Baldi I, 2003, AM J EPIDEMIOL, V157, P409, DOI 10.1093/aje/kwf216; Barnes DE, 2012, ARCH GEN PSYCHIAT, V69, P493, DOI 10.1001/archgenpsychiatry.2011.1481; Beecham GW, 2009, AM J HUM GENET, V84, P35, DOI 10.1016/j.ajhg.2008.12.008; Behrens MI, 2009, CURR ALZHEIMER RES, V6, P196, DOI 10.2174/156720509788486608; Belleville J, 2002, NUTRITION, V18, P173, DOI 10.1016/S0899-9007(01)00721-3; Bennett DA, 2012, CURR ALZHEIMER RES, V9, P628; Bertram L, 2008, AM J HUM GENET, V83, P623, DOI 10.1016/j.ajhg.2008.10.008; Bilotta F, 2010, J ALZHEIMERS DIS, V22, pS81, DOI 10.3233/JAD-2010-100825; BLAIN PG, 1990, ADVERSE DRUG REACT T, V9, P37; Blum S, 2012, NEUROLOGY, V78, P38, DOI 10.1212/WNL.0b013e31823ed0cc; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Brown BM, 2013, MOL PSYCHIATR, V18, P875, DOI 10.1038/mp.2012.107; Buchman AS, 2012, NEUROLOGY, V78, P1323, DOI 10.1212/WNL.0b013e3182535d35; Cai H, 2012, CURR ALZHEIMER RES, V9, P5, DOI 10.2174/156720512799015064; Cao CH, 2012, J ALZHEIMERS DIS, V30, P559, DOI 10.3233/JAD-2012-111781; Cao CH, 2011, J ALZHEIMERS DIS, V25, P323, DOI 10.3233/JAD-2011-110110; Cao CH, 2009, J ALZHEIMERS DIS, V17, P681, DOI 10.3233/JAD-2009-1071; Caraci F, 2010, EUR J PHARMACOL, V626, P64, DOI 10.1016/j.ejphar.2009.10.022; Carrasquillo MM, 2009, NAT GENET, V41, P192, DOI 10.1038/ng.305; Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925; Cataldo JK, 2010, J ALZHEIMERS DIS, V19, P465, DOI 10.3233/JAD-2010-1240; Chang-Quan H, 2011, INT J CLIN PRACT, V65, P1295, DOI 10.1111/j.1742-1241.2011.02810.x; Chen XS, 2010, J ALZHEIMERS DIS, V20, pS127, DOI 10.3233/JAD-2010-1376; Chua LW, 2009, J ALZHEIMERS DIS, V17, P223, DOI 10.3233/JAD-2009-1043; Coon KD, 2007, J CLIN PSYCHIAT, V68, P613, DOI 10.4088/JCP.v68n0419; Corasaniti M T, 1991, Funct Neurol, V6, P385; Cordonnier C, 2011, BRAIN, V134, P335, DOI 10.1093/brain/awq321; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233; Davanipour Z, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-13; Davies NM, 2011, J ALZHEIMERS DIS, V26, P699, DOI 10.3233/JAD-2011-110347; Doruk H, 2010, J NUTR HEALTH AGING, V14, P834, DOI 10.1007/s12603-010-0113-y; Dotson VM, 2010, NEUROLOGY, V75, P27, DOI 10.1212/WNL.0b013e3181e62124; Dridi S, 2009, J NUTR BIOCHEM, V20, P831, DOI 10.1016/j.jnutbio.2009.06.003; Driver JA, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1442; Duron E, 2009, AM J HYPERTENS, V22, P1020, DOI 10.1038/ajh.2009.119; Elias PK, 2004, HYPERTENSION, V44, P631, DOI 10.1161/01.HYP.0000145858.07252.99; Eskelinen MH, 2010, J ALZHEIMERS DIS, V20, pS167, DOI 10.3233/JAD-2010-1404; Eskelinen MH, 2009, J ALZHEIMERS DIS, V16, P85, DOI 10.3233/JAD-2009-0920; Feldman HH, 2010, NEUROLOGY, V74, P956, DOI 10.1212/WNL.0b013e3181d6476a; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Finder VH, 2010, J ALZHEIMERS DIS, V22, pS5, DOI 10.3233/JAD-2010-100975; Fitzpatrick AL, 2009, ARCH NEUROL-CHICAGO, V66, P336, DOI 10.1001/archneurol.2008.582; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; Garcia AM, 2008, INT J EPIDEMIOL, V37, P329, DOI 10.1093/ije/dym295; Garcia AM, 2010, J ALZHEIMERS DIS, V20, P577, DOI 10.3233/JAD-2010-1399; Garcia-Alloza M, 2011, BRAIN, V134, P3694, DOI 10.1093/brain/awr300; Garcia-Mesa Y, 2011, J ALZHEIMERS DIS, V24, P421, DOI 10.3233/JAD-2011-101635; Gasparini M, 2002, NEUROL SCI, V23, P11, DOI 10.1007/s100720200017; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Gatz M, 1997, J GERONTOL A-BIOL, V52, pM117, DOI 10.1093/gerona/52A.2.M117; Gauthier E, 2001, ENVIRON RES, V86, P37, DOI 10.1006/enrs.2001.4254; Gelber RP, 2011, J ALZHEIMERS DIS, V23, P607, DOI 10.3233/JAD-2010-101428; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; Grupe A, 2007, HUM MOL GENET, V16, P865, DOI 10.1093/hmg/ddm031; Gun RT, 1997, ALZ DIS ASSOC DIS, V11, P21, DOI 10.1097/00002093-199703000-00005; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Haag MDM, 2009, NEUROLOGY, V72, P1727, DOI 10.1212/01.wnl.0000345062.86148.3f; Haag MDM, 2009, J NEUROL NEUROSUR PS, V80, P13, DOI 10.1136/jnnp.2008.150433; Hamer M, 2009, PSYCHOL MED, V39, P3, DOI 10.1017/S0033291708003681; Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440; Harwood DG, 2010, INT J GERIATR PSYCH, V25, P511, DOI 10.1002/gps.2372; Hayden KM, 2010, NEUROLOGY, V74, P1524, DOI 10.1212/WNL.0b013e3181dd4423; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hebert LE, 2001, ALZ DIS ASSOC DIS, V15, P169, DOI 10.1097/00002093-200110000-00002; Ho AJ, 2010, NEUROBIOL AGING, V31, P1326, DOI 10.1016/j.neurobiolaging.2010.04.006; Hoffman LB, 2009, NEUROLOGY, V72, P1720, DOI 10.1212/01.wnl.0000345881.82856.d5; Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803; Honig LS, 2003, ARCH NEUROL-CHICAGO, V60, P1707, DOI 10.1001/archneur.60.12.1707; Huang WY, 2002, J CLIN EPIDEMIOL, V55, P959, DOI 10.1016/S0895-4356(02)00462-6; Hughes TF, 2009, NEUROLOGY, V72, P1741, DOI 10.1212/WNL.0b013e3181a60a58; Hulse GK, 2005, INT PSYCHOGERIATR, V17, pS109, DOI 10.1017/S1041610205001985; Inaba M, 2011, J AM GERIATR SOC, V59, P1484, DOI 10.1111/j.1532-5415.2011.03490.x; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Jequier E, 2002, ANN NY ACAD SCI, V967, P379, DOI 10.1111/j.1749-6632.2002.tb04293.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kamel F, 2004, ENVIRON HEALTH PERSP, V112, P950, DOI 10.1289/ehp.7135; Kennelly SP, 2009, AGEING RES REV, V8, P61, DOI 10.1016/j.arr.2008.11.001; KIMBROUGH RD, 1971, ARCH ENVIRON HEALTH, V22, P460, DOI 10.1080/00039896.1971.10665879; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Kivipelto M, 2002, ANN INTERN MED, V137, P149, DOI 10.7326/0003-4819-137-3-200208060-00006; Kroner Z, 2009, ALTERN MED REV, V14, P373; KUKULL WA, 1995, AM J EPIDEMIOL, V141, P1059, DOI 10.1093/oxfordjournals.aje.a117370; Lahiri DK, 2009, MOL PSYCHIATR, V14, P992, DOI 10.1038/mp.2009.82; Lahiri DK, 2007, CURR ALZHEIMER RES, V4, P219, DOI 10.2174/156720507780362164; Lahiri DK, 2010, EXP GERONTOL, V45, P291, DOI 10.1016/j.exger.2010.01.001; Laitala VS, 2009, AM J CLIN NUTR, V90, P640, DOI 10.3945/ajcn.2009.27660; Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439; Landau SM, 2012, ARCH NEUROL-CHICAGO, V69, P623, DOI 10.1001/archneurol.2011.2748; Larrieu S, 2004, J Nutr Health Aging, V8, P150; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Launer LJ, 2011, ANN NEUROL, V70, P774, DOI 10.1002/ana.22520; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; Lee JH, 2011, ARCH NEUROL-CHICAGO, V68, P320, DOI 10.1001/archneurol.2010.292; LEE PN, 1994, NEUROEPIDEMIOLOGY, V13, P131, DOI 10.1159/000110372; Li CY, 2002, J OCCUP ENVIRON MED, V44, P66, DOI 10.1097/00043764-200201000-00011; Li H, 2008, ARCH NEUROL-CHICAGO, V65, P45, DOI 10.1001/archneurol.2007.3; Li J, 2011, LIFE SCI, V89, P86, DOI 10.1016/j.lfs.2011.04.024; Lieb W, 2009, JAMA-J AM MED ASSOC, V302, P2565, DOI 10.1001/jama.2009.1836; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; LINDSTROM K, 1984, SCAND J WORK ENV HEA, V10, P321, DOI 10.5271/sjweh.2322; Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002; Maes A, 2012, J APPL TOXICOL, V32, P81, DOI 10.1002/jat.1724; Maloney B, 2012, CURR ALZHEIMER RES, V9, P589, DOI 10.2174/156720512800617955; Maruszak A, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-115; Matsuzaki T, 2010, NEUROLOGY, V75, P764, DOI 10.1212/WNL.0b013e3181eee25f; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mielke MM, 2005, NEUROLOGY, V64, P1689, DOI 10.1212/01.WNL.0000161870.78572.A5; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Naj AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001130; Ninomiya T, 2011, HYPERTENSION, V58, P22, DOI 10.1161/HYPERTENSIONAHA.110.163055; Nomura S, 2009, J ATHEROSCLER THROMB, V16, P878; Noonan CW, 2002, SCAND J WORK ENV HEA, V28, P42, DOI 10.5271/sjweh.645; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Olsson T, 1998, BIOL PSYCHIAT, V44, P374; Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Paul CA, 2008, ARCH NEUROL-CHICAGO, V65, P1363, DOI 10.1001/archneur.65.10.1363; Pedersen NL, 2004, ANN NEUROL, V55, P180, DOI 10.1002/ana.10999; Peila R, 2006, STROKE, V37, P1165, DOI 10.1161/01.STR.0000217653.01615.93; Peila R, 2002, DIABETES, V51, P1256, DOI 10.2337/diabetes.51.4.1256; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Perucho J, 2010, J ALZHEIMERS DIS, V19, P1245, DOI 10.3233/JAD-2010-1318; Peters R, 2008, AGE AGEING, V37, P505, DOI 10.1093/ageing/afn095; Pietropaolo S, 2008, BEHAV BRAIN RES, V192, P42, DOI 10.1016/j.bbr.2008.03.014; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Poduslo SE, 2009, AM J MED GENET B, V150B, P50, DOI 10.1002/ajmg.b.30767; Potkin SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006501; Power DA, 2001, DEMENT GERIATR COGN, V12, P167, DOI 10.1159/000051252; Power MC, 2011, EPIDEMIOLOGY, V22, P646, DOI 10.1097/EDE.0b013e31822708b5; Prasad K, 2011, DEMENT GERIATR COGN, V31, P431, DOI 10.1159/000330019; Prasanthi JRP, 2010, FREE RADICAL BIO MED, V49, P1212, DOI 10.1016/j.freeradbiomed.2010.07.007; Presecki P, 2011, COLLEGIUM ANTROPOL, V35, P115; Profenno LA, 2010, BIOL PSYCHIAT, V67, P505, DOI 10.1016/j.biopsych.2009.02.013; Purandare N, 2012, AM J PSYCHIAT, V169, P300, DOI 10.1176/appi.ajp.2011.11010009; Qiu CX, 2004, EPIDEMIOLOGY, V15, P687, DOI 10.1097/01.ede.0000142147.49297.9d; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Raiha I, 1996, LANCET, V347, P573, DOI 10.1016/S0140-6736(96)91272-6; Reiman EM, 2007, NEURON, V54, P713, DOI 10.1016/j.neuron.2007.05.022; Reitz C, 2008, STROKE, V39, P36, DOI 10.1161/STROKEAHA.107.490334; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI [10.1038/nrneurol.2011.2, 10.1101/cshperspect.a006239]; Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523; Roberts RO, 2008, ARCH NEUROL-CHICAGO, V65, P1066, DOI 10.1001/archneur.65.8.1066; Ronnemaa E, 2008, NEUROLOGY, V71, P1065, DOI 10.1212/01.wnl.0000310646.32212.3a; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Ruitenberg A, 2005, ANN NEUROL, V57, P789, DOI 10.1002/ana.20493; Run XQ, 2010, J ALZHEIMERS DIS, V22, pS49, DOI 10.3233/JAD-2010-100813; Rusanen M, 2010, DEMENT GERIATR COGN, V30, P277, DOI 10.1159/000320484; Rusanen M, 2011, ARCH INTERN MED, V171, P333, DOI 10.1001/archinternmed.2010.393; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saczynski JS, 2010, NEUROLOGY, V75, P35, DOI 10.1212/WNL.0b013e3181e62138; Sano M, 2011, NEUROLOGY, V77, P556, DOI 10.1212/WNL.0b013e318228bf11; Santos C, 2010, J ALZHEIMERS DIS, V20, pS175, DOI 10.3233/JAD-2010-091303; Santos C, 2010, J ALZHEIMERS DIS, V20, pS187, DOI 10.3233/JAD-2010-091387; Sato T, 2011, NEUROBIOL AGING, V32, P1626, DOI 10.1016/j.neurobiolaging.2009.10.009; Sattler C, 2012, PSYCHIAT RES, V196, P90, DOI 10.1016/j.psychres.2011.11.012; Scarmeas N, 2011, AM J GERIAT PSYCHIAT, V19, P471, DOI 10.1097/JGP.0b013e3181eb00a9; Schellenberg GD, 2012, ACTA NEUROPATHOL, V124, P305, DOI 10.1007/s00401-012-0996-2; Schneider JA, 2010, STROKE, V41, pS144, DOI 10.1161/STROKEAHA.110.598326; Seidler A, 2007, OCCUP ENVIRON MED, V64, P108, DOI 10.1136/oem.2005.024190; Seitz DP, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-83; Serrano-Pozo A, 2010, ALZ DIS ASSOC DIS, V24, P220, DOI 10.1097/WAD.0b013e3181d61fea; Seshadri S, 2010, JAMA-J AM MED ASSOC, V303, P1832, DOI 10.1001/jama.2010.574; Sherva R, 2011, J ALZHEIMERS DIS, V23, P349, DOI 10.3233/JAD-2010-100714; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Smargiassi A, 1998, NEUROTOXICOLOGY, V19, P709; Sobel E, 1996, NEUROLOGY, V47, P1594, DOI 10.1212/WNL.47.6.1594; Sparks DL, 2010, NEURODEGENER DIS, V7, P183, DOI 10.1159/000295660; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Stern C, 2010, INT J EVID-BASED HEA, V8, P2, DOI 10.1111/j.1744-1609.2010.00150.x; Stranahan AM, 2012, CURR ALZHEIMER RES, V9, P86; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Theodoropoulou A, 2012, J NUTR HEALTH AGING, V16, P472, DOI 10.1007/s12603-012-0058-4; Thinnes FP, 2012, MOL GENET METAB, V107, P630, DOI 10.1016/j.ymgme.2012.06.016; TIRUMALASETTI F, 1991, J AM GERIATR SOC, V39, P840, DOI 10.1111/j.1532-5415.1991.tb02713.x; Tyas SL, 1996, ADDICT BIOL, V1, P237, DOI 10.1080/1355621961000124856; Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590; Une K, 2011, EUR J NEUROL, V18, P1006, DOI 10.1111/j.1468-1331.2010.03194.x; van Heemst D, 2005, EXP GERONTOL, V40, P11, DOI 10.1016/j.exger.2004.10.001; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vanderweyde T, 2010, J ALZHEIMERS DIS, V22, pS91, DOI 10.3233/JAD-2010-100843; Verghese J, 2003, NEUROLOGY, V61, P1667, DOI 10.1212/01.WNL.0000098934.18300.BE; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Vidoni ED, 2011, NEUROLOGY, V77, P1913, DOI 10.1212/WNL.0b013e318238eec1; Vilalta-Franch J, 2013, INT J GERIATR PSYCH, V28, P341, DOI 10.1002/gps.3826; Vingtdeux V, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S6; Warren MW, 2012, J ALZHEIMERS DIS, V29, P151, DOI 10.3233/JAD-2012-111385; Watson GS, 2005, AM J GERIAT PSYCHIAT, V13, P950, DOI 10.1176/appi.ajgp.13.11.950; Whitmer RA, 2005, NEUROLOGY, V64, P277, DOI 10.1212/01.WNL.0000149519.47454.F2; Whitmer RA, 2005, BMJ-BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0; Wijsman EM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001308; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Wilson RS, 2007, NEUROLOGY, V69, P1911, DOI 10.1212/01.wnl.0000271087.67782.cb; Wilson RS, 2008, ARCH GEN PSYCHIAT, V65, P439, DOI 10.1001/archpsyc.65.4.439; Wysocki M, 2012, AM J GERIAT PSYCHIAT, V20, P179, DOI 10.1097/JGP.0b013e31820ee833; Xu WL, 2011, NEUROLOGY, V76, P1568, DOI 10.1212/WNL.0b013e3182190d09; Xu WL, 2009, DIABETOLOGIA, V52, P1031, DOI 10.1007/s00125-009-1323-x; Xu WL, 2009, DIABETES, V58, P71, DOI 10.2337/db08-0586; Zhang YY, 2012, ANN NEUROL, V71, P687, DOI 10.1002/ana.23536; Zuo CS, 2010, DEMENT GERIATR COGN, V29, P233, DOI 10.1159/000295114	222	130	132	5	93	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	OCT	2013	10	8					852	867					16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	224EF	WOS:000324864400008	23919770				2022-02-06	
J	Jacobs, B; Beems, T; Stulemeijer, M; van Vugt, AB; van der Vliet, TM; Borm, GF; Vos, PE				Jacobs, Bram; Beems, Tjemme; Stulemeijer, Maja; van Vugt, Arie B.; van der Vliet, Ton M.; Borm, George F.; Vos, Pieter E.			Outcome Prediction in Mild Traumatic Brain Injury: Age and Clinical Variables Are Stronger Predictors than CT Abnormalities	JOURNAL OF NEUROTRAUMA			English	Article						CT-scan; head injury; mild traumatic brain injury; outcome; prediction	MODERATE HEAD-INJURY; CRANIAL COMPUTED-TOMOGRAPHY; NEW-ORLEANS CRITERIA; ALCOHOL-INTOXICATION; INTRACRANIAL INJURY; HIGH-RISK; CLASSIFICATION; RELIABILITY; GUIDELINES; SCORE	Mild traumatic brain injury (mTBI) is a common heterogeneous neurological disorder with a wide range of possible clinical outcomes. Accurate prediction of outcome is desirable for optimal treatment. This study aimed both to identify the demographic, clinical, and computed tomographic (CT) characteristics associated with unfavorable outcome at 6 months after mTBI, and to design a prediction model for application in daily practice. All consecutive mTBI patients (Glasgow Coma Scale [GCS] score: 13-15) admitted to our hospital who were age 16 or older were included during an 8-year period as part of the prospective Radboud University Brain Injury Cohort Study (RUBICS). Outcome was assessed at 6 months post-trauma using the Glasgow Outcome Scale-Extended (GOSE), dichotomized into unfavorable (GOSE score 1-6) and favorable (GOSE score 7-8) outcome groups. The predictive value of several variables was determined using multivariate binary logistic regression analysis. We included 2784 mTBI patients and found CT abnormalities in 20.7% of the 1999 patients that underwent a head CT. Age, extracranial injuries, and day-of-injury alcohol intoxication proved to be the strongest outcome predictors. The presence of facial fractures and the number of hemorrhagic contusions emerged as CT predictors. Furthermore, we showed that the predictive value of a scheme based on a modified Injury Severity Score (ISS), alcohol intoxication, and age equalled the value of one that also included CT characteristics. In fact, it exceeded one that was based on CT characteristics alone. We conclude that, although valuable for the identification of the individual mTBI patient at risk for deterioration and eventual neurosurgical intervention, CT characteristics are imperfect predictors of outcome after mTBI.	[Jacobs, Bram; Stulemeijer, Maja; Vos, Pieter E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Beems, Tjemme] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands; [van Vugt, Arie B.] Radboud Univ Nijmegen, Med Ctr, Dept Emergency Med, NL-6500 HB Nijmegen, Netherlands; [van der Vliet, Ton M.] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6500 HB Nijmegen, Netherlands; [Borm, George F.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6500 HB Nijmegen, Netherlands		Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol 935, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012				af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; *AM COLL SURG COMM, 2004, ADV TRAUM LIF SUPP D, P69; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bisson JI, 1997, J TRAUMA, V43, P496, DOI 10.1097/00005373-199709000-00018; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Bordignon KC, 2002, ARQ NEURO-PSIQUIAT, V60, P204, DOI 10.1590/S0004-282X2002000200004; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Andrade AF, 2006, SURG NEUROL, V65, pS10, DOI 10.1016/j.surneu.2005.11.034; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson GL, 2000, BRAIN INJURY, V14, P1057; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; Lange RT, 2008, ARCH CLIN NEUROPSYCH, V23, P809, DOI 10.1016/j.acn.2008.07.004; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin RCG, 2002, AM SURGEON, V68, P477; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MORAN SG, 1994, AM SURGEON, V60, P533; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; *NAT I CLIN EXC, 2003, HEAD INJ INF CHILDR; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2007, J NEUROL NEUROSUR PS, V78, P1359, DOI 10.1136/jnnp.2007.117143; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tate PS, 1999, BRAIN INJURY, V13, P767; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Viola L, 2000, ACTA NEUROCHIR, V142, P1281, DOI 10.1007/s007010070026; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	74	130	132	2	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2010	27	4					655	668		10.1089/neu.2009.1059			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	584CG	WOS:000276727000001	20035619	Green Submitted			2022-02-06	
J	Mayes, SD; Calhoun, SL				Mayes, Susan Dickerson; Calhoun, Susan L.			Variables related to sleep problems in children with autism	RESEARCH IN AUTISM SPECTRUM DISORDERS			English	Article						Autism; Sleep; Child characteristics; Medication	TRAUMATIC BRAIN-INJURY; GORDON DIAGNOSTIC SYSTEM; WISC-III PROFILES; SPECTRUM DISORDERS; PSYCHIATRIC-DISORDERS; NORMAL INTELLIGENCE; ASPERGERS-DISORDER; MENTAL-RETARDATION; AGE-CHILDREN; ADHD	Our study of 477 children with autism (1-15 years, IQs 9-146) showed that parent reported sleep problems are found in most children with aUtiSM and are not significantly related to age, IQ gender, race, parent occupation, neuropsychological functioning, and learning ability. However, sleep problems increased with severity of autistic symptoms and with severity of parent reported symptoms known to be associated with autism (i.e., oppositional behavior, aggression, explosiveness, attention deficit, impulsivity, hyperactivity, anxiety, depression. and mood variability). This suggests that sleep disturbance is part of the autism symptom complex and increases with increasing autism severity. The strongest predictors of sleep disturbance were parent ratings of autism severity, hyperactivity, mood variability, and aggression. The most frequent sleep problems were difficulty failing asleep and restlessness during sleep. Daytime sleepiness was not significantly correlated with sleeping less than normal, but was associated with sleeping more than normal. Children who were sleepier during the day were also sleepier at night. Medical practitioners and clinicians should be aware of the risk of sleep disturbance in children with autism and should routinely screen for this. Empirically proven interventions (e.g., behavior therapy and melatonin) are available to improve sleep in children with autism. (C) 2009 Elsevier Ltd. All rights reserved.	[Mayes, Susan Dickerson; Calhoun, Susan L.] Penn State Coll Med, Dept Psychiat, Hershey, PA USA		Mayes, SD (corresponding author), Milton S Hershey Med Ctr, Dept Psychiat H073, 500 Univ Dr, Hershey, PA 17033 USA.	smayes@psu.edu					Allik H, 2006, J AUTISM DEV DISORD, V36, P585, DOI 10.1007/s10803-006-0099-9; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; CALHOUN SL, J CLIN SLEE IN PRESS; Chervin RD, 2000, SLEEP MED, V1, P21, DOI 10.1016/S1389-9457(99)00009-X; Couturier JL, 2005, J AM ACAD CHILD PSY, V44, P815, DOI 10.1097/01.chi.0000166377.22651.87; Crowell E., 1998, J ATTEN DISORD, V2, P217, DOI [10.1177/108705479800200402, DOI 10.1177/108705479800200402]; DeVincent CJ, 2007, J CHILD NEUROL, V22, P161, DOI 10.1177/0883073807300310; Diomedi M, 1999, BRAIN DEV-JPN, V21, P548, DOI 10.1016/S0387-7604(99)00077-7; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; Elia M, 2000, BRAIN DEV-JPN, V22, P88, DOI 10.1016/S0387-7604(99)00119-9; Garstang J, 2006, CHILD CARE HLTH DEV, V32, P585, DOI 10.1111/j.1365-2214.2006.00616.x; Gordon M, 1983, GORDON DIAGNOSTIC SY; Gupta M, 2005, J CHILD NEUROL, V20, P112, DOI 10.1177/08830738050200020501; Hering E, 1999, J AUTISM DEV DISORD, V29, P143, DOI 10.1023/A:1023092627223; Honomichl RD, 2002, J AUTISM DEV DISORD, V32, P553, DOI 10.1023/A:1021254914276; Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899; Johnson CR, 1996, CHILD ADOL PSYCH CL, V5, P673, DOI 10.1016/S1056-4993(18)30355-9; Krakowiak P, 2008, J SLEEP RES, V17, P197, DOI 10.1111/j.1365-2869.2008.00650.x; LeBourgeois MK, 2004, SLEEP, V27, P520; Lecendreux M, 2000, J CHILD PSYCHOL PSYC, V41, P803, DOI 10.1017/S0021963099005971; Liu XC, 2006, CHILD PSYCHIAT HUM D, V37, P179, DOI 10.1007/s10578-006-0028-3; Malow BA, 2006, SLEEP, V29, P1563, DOI 10.1093/sleep/29.12.1563; MANJIVIONA J, 1995, J AUTISM DEV DISORD, V25, P23, DOI 10.1007/BF02178165; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Mayes SD, 1998, PSYCHOL SCHOOLS, V35, P309; Mayes SD, 2004, CLIN NEUROPSYCHOL, V18, P559, DOI 10.1080/13854040490888530; Mayes SD, 2004, J DEV PHYS DISABIL, V16, P257, DOI 10.1023/B:JODD.0000032301.07550.0e; Mayes SD, 2003, AUTISM, V7, P65, DOI 10.1177/1362361303007001006; Mayes SD, 2002, PSYCHOL REP, V91, P575, DOI 10.2466/PR0.91.6.575-587; Mayes SD, 2001, CHILD NEUROPSYCHOL, V7, P32, DOI 10.1076/chin.7.1.32.3151; Mayes SD, 2001, AUTISM, V5, P81, DOI 10.1177/1362361301005001008; Mayes SD, 2001, J ABNORM CHILD PSYCH, V29, P263, DOI 10.1023/A:1010337916636; Mayes SD, 2000, J LEARN DISABIL-US, V33, P417, DOI 10.1177/002221940003300502; Mayes SD, 1999, INFANT YOUNG CHILD, V12, P90, DOI 10.1097/00001163-199910000-00011; Mayes SD, 2003, J AUTISM DEV DISORD, V33, P329, DOI 10.1023/A:1024462719081; Mayes SD, 2008, J DEV BEHAV PEDIATR, V29, P206, DOI 10.1097/DBP.0b013e31816d924f; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; Mayes SD, 2006, LEARN INDIVID DIFFER, V16, P145, DOI 10.1016/j.lindif.2005.07.004; Mayes SD, 2009, SLEEP MED CLIN, V4, P19, DOI 10.1016/j.jsmc.2008.12.004; Mayes SD, 2009, J PEDIATR PSYCHOL, V34, P328, DOI 10.1093/jpepsy/jsn083; Miller JN, 1997, J CHILD PSYCHOL PSYC, V38, P247; Nichols S, 2000, J PEDIATR PSYCHOL, V25, P545, DOI 10.1093/jpepsy/25.8.545; *NIH, 2005, NAT HEART LUNG BLOOD; Patzold LM, 1998, J PAEDIATR CHILD H, V34, P528, DOI 10.1046/j.1440-1754.1998.00291.x; Polimeni MA, 2005, J INTELL DISABIL RES, V49, P260, DOI 10.1111/j.1365-2788.2005.00642.x; Prinz R., 1987, ADV BEHAV ASSESSMENT, P57; RICHDALE AL, 1995, EUR CHILD ADOLES PSY, V4, P175, DOI 10.1007/BF01980456; Schreck KA, 2000, J AUTISM DEV DISORD, V30, P127, DOI 10.1023/A:1005407622050; Schreck KA, 2004, RES DEV DISABIL, V25, P57, DOI 10.1016/j.ridd.2003.04.007; SZATMARI P, 1995, J AM ACAD CHILD PSY, V34, P1662, DOI 10.1097/00004583-199512000-00017; Thirumalai SS, 2002, J CHILD NEUROL, V17, P173, DOI 10.1177/088307380201700304; TRYON P. A., 2006, FOCUS AUTISM OTHER D, V21, P2, DOI DOI 10.1177/10883576060210010101; Van Der Heijden KB, 2007, J AM ACAD CHILD PSY, V46, P233, DOI 10.1097/01.chi.0000246055.76167.0d; Weiskop S, 2005, DEV MED CHILD NEUROL, V47, P94, DOI 10.1017/S0012162205000186; Weiss MD, 2006, J AM ACAD CHILD PSY, V45, P512, DOI [10.1097/01.chi.0000205706.78818.ef, 10.1097/01 chi.0000205706.78818.ef]; Wiggs L, 2004, DEV MED CHILD NEUROL, V46, P372; Williams PG, 2004, J SLEEP RES, V13, P265; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501; [No title captured]	61	130	132	0	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-9467	1878-0237		RES AUTISM SPECT DIS	Res. Autism Spectr. Disord.	OCT-DEC	2009	3	4					931	941		10.1016/j.rasd.2009.04.002			11	Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Psychology; Psychiatry; Rehabilitation	496RL	WOS:000269993400010					2022-02-06	
J	Tam, J; Trembovler, V; Di Marzo, V; Petrosino, S; Leo, G; Alexandrovich, A; Regev, E; Casap, N; Shteyer, A; Ledent, C; Karsak, M; Zimmer, A; Mechoulam, R; Yirmiya, R; Shohami, E; Bab, I				Tam, Joseph; Trembovler, Victoria; Di Marzo, Vincenzo; Petrosino, Stefania; Leo, Gabriella; Alexandrovich, Alex; Regev, Eran; Casap, Nardy; Shteyer, Arie; Ledent, Catherine; Karsak, Meliha; Zimmer, Andreas; Mechoulam, Raphael; Yirmiya, Raz; Shohami, Esther; Bab, Itai			The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling	FASEB JOURNAL			English	Article						2-arachidonoylglycerol; norepinephrine; sympathetic nervous system; traumatic brain injury	SYMPATHETIC-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; NORADRENALINE RELEASE; MEDIATED INHIBITION; VAS-DEFERENS; ANANDAMIDE; MICE; PATHOGENESIS; PROTEIN	We have recently reported that in bone the cannabinoid CB1 receptor is present in sympathetic terminals. Here we show that traumatic brain injury (TBI), which in humans enhances peripheral osteogenesis and fracture healing, acutely stimulates bone formation in a distant skeletal site. At this site we demonstrate i) a high level of the main endocannabinoid, 2-arachidonoylglycerol (2-AG), and expression of diacylglycerol lipases, enzymes essential for 2-AG synthesis; ii) that the TBI-induced increase in bone formation is preceded by elevation of the 2-AG and a decrease in norepinephrine (NE) levels. The TBI stimulation of bone formation was absent in CB1-null mice. In wild-type animals it could be mimicked, including the suppression of NE levels, by 2-AG administration. The TBI- and 2-AG-induced stimulation of osteogenesis was restrained by the beta-adrenergic receptor agonist isoproterenol. NE from sympathetic terminals is known to tonically inhibit bone formation by activating osteoblastic beta 2- adrenergic receptors. The present findings further demonstrate that the sympathetic control of bone formation is regulated through 2-AG activation of prejunctional CB1. Elevation of bone 2-AG apparently suppresses NE release from bone sympathetic terminals, thus alleviating the inhibition of bone formation. The involvement of osteoblastic CB2 signaling in this process is minimal, if any.	[Tam, Joseph; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel; [Trembovler, Victoria; Alexandrovich, Alex] Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Regev, Eran; Casap, Nardy; Shteyer, Arie] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral & Maxillofacial Surg, IL-91120 Jerusalem, Israel; [Mechoulam, Raphael] Hebrew Univ Jerusalem, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; [Yirmiya, Raz] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Di Marzo, Vincenzo; Petrosino, Stefania; Leo, Gabriella] Inst Biomol Chem, Consiglio Nazl Ric, Endocannabinoid Res Grp, Pozzilli, Italy; [Petrosino, Stefania] Univ Salerno, Dipartimento Sci Farmaceut, Fisciano, Italy; [Ledent, Catherine] Univ Libre Bruxelles, Inst Rech Interdisciplinaire & Biol Humaine & Mol, Brussels, Belgium; [Karsak, Meliha; Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany		Bab, I (corresponding author), Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel.	babi@cc.huji.ac.il	Di Marzo, Vincenzo/AAD-7742-2019; Yirmiya, Raz/D-1090-2014; Zimmer, Andreas/B-8357-2009	Di Marzo, Vincenzo/0000-0002-1490-3070; Yirmiya, Raz/0000-0002-4009-7316; Tam, Joseph/0000-0002-0948-0093			Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Contractor A, 2003, J NEUROSCI, V23, P422, DOI 10.1523/JNEUROSCI.23-02-00422.2003; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; FRIED A, 1993, J CELL PHYSIOL, V155, P472, DOI 10.1002/jcp.1041550306; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Malinowska B, 1997, N-S ARCH PHARMACOL, V356, P197, DOI 10.1007/PL00005041; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Monteleone P, 2005, NEUROPSYCHOPHARMACOL, V30, P1216, DOI 10.1038/sj.npp.1300695; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Niederhoffer N, 2003, N-S ARCH PHARMACOL, V367, P434, DOI 10.1007/s00210-003-0755-y; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PERTWEE RG, 1992, BRIT J PHARMACOL, V105, P980, DOI 10.1111/j.1476-5381.1992.tb09088.x; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Rhee MH, 1997, J MED CHEM, V40, P3228, DOI 10.1021/jm970126f; Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012; Rouzer CA, 2002, CHEM PHYS LIPIDS, V119, P69, DOI 10.1016/S0009-3084(02)00068-3; Schlicker E, 2003, BRIT J PHARMACOL, V140, P323, DOI 10.1038/sj.bjp.0705449; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Szabo B, 2005, HANDB EXP PHARMACOL, V168, P327; Szabo B, 2001, J PHARMACOL EXP THER, V297, P819; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435; Vizi ES, 2001, EUR J PHARMACOL, V431, P237, DOI 10.1016/S0014-2999(01)01413-3; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Yao M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P319; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	57	130	138	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2008	22	1					285	294		10.1096/fj.06-7957com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	250OM	WOS:000252309900030	17704191				2022-02-06	
J	Docherty, CL; McLeod, TCV; Shultz, SJ				Docherty, Carrie L.; McLeod, Tamara C. Valovich; Shultz, Sandra J.			Postural control deficits in participants with functional ankle instability as measured by the balance error scoring system	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						postural sway; balance; proprioception	STABILITY; SPRAIN; JOINT; INVERSION; INJURY; SWAY; STABILOMETRY; CONCUSSION; STRENGTH	Objective: To determine if postural control deficits are present in participants with functional ankle instability (FAI) as measured by the Balance Error Scoring System (BESS). Design and Setting: We used a between-groups design to assess postural control. All testing was conducted in a university athletic training facility. Participants: Sixty collegiate Division I athletes were included in this study. Thirty participants had functional ankle instability and thirty participants had no history of ankle injuries. Main Outcome Measurements: Postural control was measured using the BESS. The BESS test battery requires participants to stand unsupported on two different surfaces (firm and foam) in three different stances (double, single, and in tandem). Each condition lasted 20 seconds. The number of errors were calculated for each individual condition and then summed to produce a total BESS score. Results: We found a significant group by condition interaction (F-5,F-290 = 5.12, P < 0.001) and significant main effects for group (F-1,F-58 = 16.01, P < 0.001) and condition (F-5,F-290 = 228.88, P < 0.001). Post hoc analyses revealed that subjects with functional ankle instability scored more errors (poorer balance) on the single stancefirm condition (2.9 +/- 2.1 versus 1.6 +/- 1.3 errors), tandem stancefoam condition (4.3 +/- 2.4 versus 2.7 +/- 1.6 errors), single stancefoam condition (7.0 +/- 1.6 versus 5.6 +/- 1.8 errors), and total BESS score (15.7 +/- 6.0 versus 10.7 +/- 3.2). Conclusions: Postural control deficits were identified in participants with functional ankle instability using the BESS. These deficits could be a contributing factor to the repeated episodes of instability and giving way that often occurs following an inversion ankle sprain. These results suggest the BESS, traditionally used for monitoring recovery from mild head injury, may also be useful in screening athletes for postural deficits following lower extremity injury.	Univ N Carolina, Dept Exercise & Sport Sci, Greensboro, NC 27412 USA; AT Still Univ, Arizona Sch Heath Sci, Dept Interdisciplinary Hlth Sci, Sports Hlth Care Program, Mesa, AZ USA; Indiana Univ, Dept Kinesiol, Bloomington, IN 47405 USA		Docherty, CL (corresponding author), Ralph L Smith Res Ctr, 2805 E 10th St, Bloomington, IN 47408 USA.	cdochert@indiana.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722			Allum JHJ, 2002, GAIT POSTURE, V16, P264, DOI 10.1016/S0966-6362(02)00011-5; Bernier JN, 1997, J ATHL TRAINING, V32, P226; CORNWALL MW, 1991, J AM PODIAT MED ASSN, V81, P243, DOI 10.7547/87507315-81-5-243; Forkin DM, 1996, J ORTHOP SPORT PHYS, V23, P245, DOI 10.2519/jospt.1996.23.4.245; Freeman M A, 1965, J Bone Joint Surg Br, V47, P678; Freeman M A, 1965, J Bone Joint Surg Br, V47, P669; FRIDEN T, 1989, AM J SPORT MED, V17, P118, DOI 10.1177/036354658901700120; GARN SN, 1988, PHYS THER, V68, P1667, DOI 10.1093/ptj/68.11.1667; GAUFFIN H, 1988, INT J SPORTS MED, V9, P141, DOI 10.1055/s-2007-1024996; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hertel J, 2001, J ATHL TRAINING, V36, P363; Hertel J, 1999, MED SCI SPORT EXER, V31, P1501, DOI 10.1097/00005768-199911000-00002; Hertel J, 2000, SPORTS MED, V29, P361, DOI 10.2165/00007256-200029050-00005; Holder-Powell HM, 2000, ARCH PHYS MED REHAB, V81, P265, DOI 10.1053/apmr.2000.0810265; Isakov E, 1997, BRIT J SPORT MED, V31, P65, DOI 10.1136/bjsm.31.1.65; JANSEN EC, 1982, ACTA NEUROL SCAND, V66, P93; Kaminski TW, 2002, J ATHL TRAINING, V37, P394; KONRADSEN L, 1991, INT J SPORTS MED, V12, P290, DOI 10.1055/s-2007-1024683; LENTELL G L, 1990, Journal of Orthopaedic and Sports Physical Therapy, V11, P605; McGuine TA, 2000, CLIN J SPORT MED, V10, P239, DOI 10.1097/00042752-200010000-00003; Olmsted LC, 2002, J ATHL TRAINING, V37, P501; Riemann BL, 2002, J ATHL TRAINING, V37, P386; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ross SE, 2004, CLIN J SPORT MED, V14, P332, DOI 10.1097/00042752-200411000-00002; STAPLES OS, 1975, J BONE JOINT SURG AM, VA 57, P101, DOI 10.2106/00004623-197557010-00018; TROPP H, 1984, MED SCI SPORT EXER, V16, P64; TROPP H, 1986, INT J SPORTS MED, V7, P291, DOI 10.1055/s-2008-1025777; TROPP H, 1985, INT J SPORTS MED, V6, P180, DOI 10.1055/s-2008-1025836; Valovich TC, 2003, J ATHL TRAINING, V38, P51; VERHAGEN RAW, 1995, ARCH ORTHOP TRAUM SU, V114, P92, DOI 10.1007/BF00422833; Wikstrom EA, 2005, MED SCI SPORT EXER, V37, P169, DOI 10.1249/01.MSS.0000149887.84238.6C; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	33	130	131	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2006	16	3					203	208		10.1097/00042752-200605000-00003			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	051BY	WOS:000238136600003	16778539	Green Submitted			2022-02-06	
J	Nylen, K; Ost, M; Csajbok, LZ; Nilsson, I; Blennow, K; Nellgard, B; Rosengren, L				Nylen, K; Ost, M; Csajbok, LZ; Nilsson, I; Blennow, K; Nellgard, B; Rosengren, L			Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						glial fibrillary acidic protein (GFAP); serum; traumatic brain injury; outcome; GOS; biochemical brain markers	FIBRILLARY ACIDIC PROTEIN; SEVERE HEAD-INJURY; SCALE; GUIDELINES; THERAPY; CSF	Objectives: Several studies have established the relevance of S-100 in blood as a marker of brain damage after traumatic brain injury. However, a more specific marker is required and glial fibrillary acidic protein (GFAP) is considered to be a good candidate. Methods: In order to assess the increase of GFAP in serum (s-GFAP) after a severe traumatic brain injury (TBI) we collected daily serum samples from 59 patients with severe TBI starting oil the day of the trauma. S-GFAP was measured using a sandwich ELISA. The Glasgow outcome scale (GOS) assessed Outcome after 1 year. Results: All but one patient had maximal s-GFAP values above the laboratory reference value (median increased 10-fold). The highest detected levels were seen during the first days after TBI and then decreased gradually. Patients with unfavourable outcome had significantly (p < 0.001) higher maximal s-GFAP values in the acute phase compared with patients with favourable outcome. All patients (n=5) with s-GFAP > 15.04 mu g/L died (reference level < 0. 15 mu g/L). We found no significant difference in the maximal s-GFAP levels of patients with isolated brain injury in comparison with patients with multiple traumas. Conclusion: Serum-GFAP is increased during the first days after a severe traumatic brain injury and related to clinical outcome. (c) 2005 Elsevier B.V. All rights reserved.	Gothenburg Univ, Sahlgrens Hosp, Inst Clin Neurosci, Dept Neurol, S-41345 Gothenburg, Sweden; Gothenburg Univ, Sahlgrens Hosp, Dept Anaesthesia, Neurointens Care Unit, S-41345 Gothenburg, Sweden; Gothenburg Univ, Sahlgrens Hosp, Dept Neuroradiol, S-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Neurosci, Unit Expt Neurosci, Molndal, Sweden		Nylen, K (corresponding author), Gothenburg Univ, Sahlgrens Hosp, Inst Clin Neurosci, Dept Neurol, S-41345 Gothenburg, Sweden.	karin.nylen@neuro.gu.se	Ost, Martin/AAY-5827-2020	Rosengren, Lars/0000-0003-0505-8896			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; GRANDE PO, 1997, J TRAUMA, V42, P23; MATSHALL LF, 1991, J NEUROSURG, V75, P14; Missler U, 1999, CLIN CHEM, V45, P138; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Tullberg M, 1998, NEUROLOGY, V50, P1122, DOI 10.1212/WNL.50.4.1122; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	17	130	136	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JAN 15	2006	240	1-2					85	91		10.1016/j.jns.2005.09.007			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	003OU	WOS:000234692300014	16266720				2022-02-06	
J	Gozes, I; Morimoto, BH; Tiong, J; Fox, A; Sutherland, K; Dangoor, D; Holser-Cochav, M; Vered, K; Newton, P; Aisen, PS; Matsuoka, Y; van Dyck, CH; Thal, L				Gozes, Illana; Morimoto, Bruce H.; Tiong, Jacqueline; Fox, Anthony; Sutherland, Karole; Dangoor, David; Holser-Cochav, Miriam; Vered, Karin; Newton, Paul; Aisen, Paul S.; Matsuoka, Yasuji; van Dyck, Christopher H.; Thal, Leon			NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)	CNS DRUG REVIEWS			English	Article						ADNP; Alzheimer's disease; animal models; glial cells; head injury; NAP; neuropeptides; neuroprotection; stroke	VASOACTIVE-INTESTINAL-PEPTIDE; FEMTOMOLAR-ACTING PEPTIDES; NEUROTROPHIC FACTOR ADNF; CLOSED-HEAD INJURY; MICROTUBULE-BINDING; ALZHEIMERS-DISEASE; FATTY NEUROPEPTIDE; CORTICAL CULTURES; NEURONAL CULTURES; AMYLOID PEPTIDE	Activity-dependent neuroprotective protein (ADNP) is essential for brain formation. Peptide activity scanning identified NAP (NAPVSIPQ) as a small active fragment of ADNP that provides neuroprotection at very low concentrations. In cell culture, NAP has demonstrated protection against toxicity associated with the beta-amyloid peptide, N-methyl-D-aspartate, electrical blockade, the envelope protein of the AIDS virus, dopamine, H2O2, nutrient starvation and zinc overload. NAP has also provided neuroprotection in animal models of apolipoprotein E deficiency, cholinergic toxicity, closed head injury, stroke, middle aged anxiety and cognitive dysfunction. NAP binds to tubulin and facilitates microtubule assembly leading to enhanced cellular survival that is associated with fundamental cytoskeletal elements. A liquid-chromatography, mass spectrometry assay demonstrated that NAP reaches the brain after either intravenous or intranasal administration. In a battery of toxicological tests including repeated dose toxicity in rats and dogs, cardiopulmonary tests in dogs, and functional behavioral assays in rats, no adverse side effects were observed with NAP concentrations that were similar to 500-fold higher than the biologically active dose. A Phase la clinical trial in the US assessed the tolerability and pharmacokinetics of intranasal administration of NAP in sequential ascending doses. The results supported the safety and tolerability of a single dose of NAP administered at up to 15 mg intranasally. Furthermore, dosing was recently completed for a second Phase I clinical trial in healthy adults and elderly volunteers with an intravenous formulation of NAP. NAP is poised for further clinical development targeting several indications, including Alzheimer's disease.	Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel; Allon Therapeut Inc, Vancouver, BC, Canada; Univ Calif San Diego, Skaggs SPPS, San Diego, CA USA; MPI Res, Mattawan, MI USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA		Gozes, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [N01AG092117] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [N01-AG-9-2117] Funding Source: Medline		Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; Ashur-Fabian O, 1997, J MOL NEUROSCI, V9, P211, DOI 10.1007/BF02800503; Ashur-Fabian O, 2003, PEPTIDES, V24, P1413, DOI 10.1016/j.peptides.2003.08.005; Ashur-Fabian O, 2001, NEUROSCI LETT, V307, P167, DOI 10.1016/S0304-3940(01)01954-1; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Blondel O, 2000, J NEUROSCI, V20, P8012; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Brenneman DE, 1998, J PHARMACOL EXP THER, V285, P619; Bruno MA, 2004, J NEUROSCI, V24, P8009, DOI 10.1523/JNEUROSCI.1508-04.2004; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; BUSCIGLIO J, 2005, IN PRESS CURR PHARM; Divinski I, 2004, J BIOL CHEM, V279, P28531, DOI 10.1074/jbc.M403197200; FISHER A, 1989, NEUROSCI LETT, V102, P325, DOI 10.1016/0304-3940(89)90100-6; Frey WH, 2002, DRUG DELIV TECH, V2, P46; Furman S, 2005, NEUROSCI LETT, V373, P73, DOI 10.1016/j.neulet.2004.09.077; Furman S, 2004, NEURON GLIA BIOL, V1, P193, DOI 10.1017/S1740925X05000013; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; Gozes I, 1999, CURR MED CHEM, V6, P1019; Gozes I, 1999, P NATL ACAD SCI USA, V96, P4143, DOI 10.1073/pnas.96.7.4143; Gozes I, 1997, J NEUROBIOL, V33, P329, DOI 10.1002/(SICI)1097-4695(199709)33:3<329::AID-NEU10>3.0.CO;2-A; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; Gozes I, 2004, J ALZHEIMERS DIS, V6, pS37; Gozes I, 1997, DEV BRAIN RES, V99, P167, DOI 10.1016/S0165-3806(96)00215-5; Gozes I, 2004, J MOL NEUROSCI, V24, P67, DOI 10.1385/JMN:24:1:067; Gozes I, 1996, P NATL ACAD SCI USA, V93, P427, DOI 10.1073/pnas.93.1.427; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; Gozes I, 2003, CURR PHARM DESIGN, V9, P483, DOI 10.2174/1381612033391667; Gozes I, 2002, J MOL NEUROSCI, V19, P167, DOI 10.1007/s12031-002-0028-0; Gozes I, 1996, J MOL NEUROSCI, V7, P235, DOI 10.1007/BF02737061; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; Gozes I, 2000, J MOL NEUROSCI, V14, P61, DOI 10.1385/JMN:14:1-2:061; GOZES I, 2003, TREATMENT EXPT ENCEP; GOZES I, 2005, NEUROPROTECTIVE DRUG; Gozes Illana, 2005, Current Alzheimer Research, V2, P149, DOI 10.2174/1567205053585873; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; Hashimoto Y, 2004, J NEUROCHEM, V90, P549, DOI 10.1111/j.1471-4159.2004.02513.x; Lagreze WA, 2005, INVEST OPHTH VIS SCI, V46, P933, DOI 10.1167/iovs.04-0766; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Massa SM, 2003, J MOL NEUROSCI, V20, P323, DOI 10.1385/JMN:20:3:323; Michaelis ML, 2002, J MOL NEUROSCI, V19, P101, DOI 10.1007/s12031-002-0018-2; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Pelsman A, 1998, J NEUROCHEM, V71, pS54; Perras B, 2004, J CLIN ENDOCR METAB, V89, P4642, DOI 10.1210/jc.2004-0089; Pinhasov A, 2003, DEV BRAIN RES, V144, P83, DOI 10.1016/S0165-3806(03)00162-7; REGER MA, 2004, EFFECTS INTRANSAL IN; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Smith-Swintosky VL, 2005, J MOL NEUROSCI, V25, P225, DOI 10.1385/JMN:25:3:225; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; Steingart RA, 2000, J MOL NEUROSCI, V15, P137, DOI 10.1385/JMN:15:3:137; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005; Wilkemeyer MF, 2003, P NATL ACAD SCI USA, V100, P8543, DOI 10.1073/pnas.1331636100; Wilkemeyer MF, 2002, J PHARMACOL EXP THER, V303, P110, DOI 10.1124/jpet.102.036277; Zaltzman R, 2005, PEPTIDES, V26, P1520, DOI 10.1016/j.peptides.2005.03.014; Zaltzman R, 2004, J MOL NEUROSCI, V24, P181, DOI 10.1385/JMN:24:2:181; Zaltzman R, 2003, NEUROREPORT, V14, P481, DOI 10.1097/01.wnr.0000058036.29600.ff; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1; Zhang B, 2005, P NATL ACAD SCI USA, V102, P227, DOI 10.1073/pnas.0406361102; Zusev M, 2004, REGUL PEPTIDES, V123, P33, DOI 10.1016/j.regpep.2004.05.021	65	130	134	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1080-563X			CNS DRUG REV	CNS Drug Rev.	WIN	2005	11	4					353	368					16	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	042TN	WOS:000237552500002	16614735				2022-02-06	
J	Polderman, KH; Rijnsburger, ER; Peerdeman, SM; Girbes, ARJ				Polderman, KH; Rijnsburger, ER; Peerdeman, SM; Girbes, ARJ			Induction of hypothermia in patients with various types of neurologic injury with use of large volumes of ice-cold intravenous fluid	CRITICAL CARE MEDICINE			English	Article						therapeutic hypothermia; neurologic injury; myocardial injury; cardiac arrest; cardiopulmonary resuscitation; traumatic brain injury; refrigerated fluids; intracranial pressure; side effects	PROMISING TREATMENT MODALITY; HOSPITAL CARDIAC-ARREST; THERAPEUTIC HYPOTHERMIA; MYOCARDIAL TEMPERATURE; MILD HYPOTHERMIA; BODY-TEMPERATURE; INFARCT SIZE; THERMOREGULATORY THRESHOLDS; COMATOSE SURVIVORS; NECROSIS	Objective: Mounting evidence suggests that mild to moderate hypothermia can mitigate neurologic and myocardial injury. The speed of induction appears to be a key factor in determining its efficacy. However, even when the fastest currently available cooling techniques are used, reaching target temperatures takes at least 2 hrs and usually longer. We hypothesized that infusion of refrigerated fluids could be a safe accessory method to increase cooling speed. Design: Prospective intervention study. Setting: University teaching hospital. Patients: One hundred thirty-four patients with various types of neurologic injury (postanoxic encephalopathy, subarachnoid hemorrhage, or traumatic brain injury). Measurements and Main Results: Hypothermia was induced in 134 patients with various types of neurologic injury, by means ice-water cooling blankets and infusion of refrigerated (4 degrees C) saline (110 patients) or saline and colloids (24 patients). An average volume of 2340 +/- 890 mL of refrigerated fluids was infused in 50 mins. Core temperatures decreased from 36.9 +/- 1.9 degrees C to 34.6 +/- 1.5 degrees C at t = 30 mins and to 32.9 +/- 0.9 degrees C at t = 60 mins (target temperature: 32 degrees C-33 degrees C). Monitoring of blood pressure, heart rhythm, central venous pressure, blood gasses, electrolyte and glucose levels, and platelet and white blood cell count revealed no additional adverse effects. Mean arterial pressure increased by 15 mm Hg, with larger increases in blood pressure occurring in hemodynamically unstable patients. No patient developed pulmonary edema. Conclusions. Induction of hypothermia by means of cold-fluid infusion combined with ice-water cooling blankets is safe, efficacious, and quick. Because the speed of cooling is important to increase its protective effects, we recommend that cold-fluid infusion be used in all patients treated with induced hypothermia. This should be combined with another method to safely and accurately maintain hypothermia once target temperatures have been reached.	Vrije Univ Amsterdam, Med Ctr, Dept Intens Care, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands		Polderman, KH (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Intens Care, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.		Polderman, Kees H/K-3623-2012				Baumgardner JE, 1999, ANESTH ANALG, V89, P163, DOI 10.1097/00000539-199907000-00029; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Dae MW, 2002, AM J PHYSIOL-HEART C, V282, pH1584, DOI 10.1152/ajpheart.00980.2001; DELAUNAY L, 1993, ANESTHESIOLOGY, V79, P470, DOI 10.1097/00000542-199309000-00009; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; DIXON SR, 2005, HEART S3, V91, P2; Fritz HG, 2002, ANESTH ANALG, V94, P626, DOI 10.1097/00000539-200203000-00027; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hale SL, 1998, CARDIOVASC RES, V40, P502, DOI 10.1016/S0008-6363(98)00191-6; Hale SL, 2003, J AM COLL CARDIOL, V41, p381A; Hale SL, 2003, CARDIOVASC RES, V59, P715, DOI 10.1016/S0008-6363(03)00456-5; Hale SL, 1997, AM J PHYSIOL-HEART C, V273, pH220, DOI 10.1152/ajpheart.1997.273.1.H220; Hale SL, 2002, CORONARY ARTERY DIS, V13, P177, DOI 10.1097/00019501-200205000-00007; Hale SL, 1997, BASIC RES CARDIOL, V92, P351, DOI 10.1007/s003950050044; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2002, NEW ENGL J MED, V346, P549; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; Lefrant JY, 2003, INTENS CARE MED, V29, P414, DOI 10.1007/s00134-002-1619-5; Markarian GZ, 1996, NEUROSURGERY, V38, P542; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Miki T, 1998, BASIC RES CARDIOL, V93, P372, DOI 10.1007/s003950050105; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, CRIT CARE MED, V32, P2558, DOI 10.1097/01.CCM.0000148087.41418.0A; Polderman KH, 2003, CIRCULATION, V108, P581; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Rajek A, 2000, ANESTHESIOLOGY, V93, P629, DOI 10.1097/00000542-200009000-00010; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Sen J, 2003, LANCET NEUROL, V2, P614, DOI 10.1016/S1474-4422(03)00531-3; Takata K, 2005, CRIT CARE MED, V33, P1340, DOI 10.1097/01.CCM.0000166351.19369.D3; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; van Zanten ARH, 2005, CRIT CARE MED, V33, P1449, DOI 10.1097/01.CCM.0000166710.64724.34; Virkkunen I, 2004, RESUSCITATION, V62, P299, DOI 10.1016/j.resuscitation.2004.04.003; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404	41	130	138	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2005	33	12					2744	2751		10.1097/01.CCM.0000190427.88735.19			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	999XE	WOS:000234423700004	16352954				2022-02-06	
J	Shear, DA; Tate, MC; Archer, DR; Hoffman, SW; Hulce, VD; LaPlaca, MC; Stein, DG				Shear, DA; Tate, MC; Archer, DR; Hoffman, SW; Hulce, VD; LaPlaca, MC; Stein, DG			Neural progenitor cell transplants promote long-term functional recovery after traumatic brain injury	BRAIN RESEARCH			English	Article						traumatic brain injury; rotorod; spatial learning; Morris water maze; neural stem cell; NG2; oligodendrocyte progenitor cell; neurosphere	CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; NEUROTROPHIC FACTORS; SPINAL-CORD; RESTRICTED PRECURSORS; CLINICAL-APPLICATION; ADULT BRAIN; RAT MODEL; DIFFERENTIATE; LESIONS	Studies demonstrating the versatility of neural progenitor cells (NPCs) have recently rekindled interest in neurotransplantation methods aimed at treating traumatic brain injury (TBI). However, few studies have evaluated the safety and functional efficacy of transplanted NPCs beyond a few months. The purpose of this study was to assess the long-term survival, migration, differentiation and functional significance of NPCs transplanted into a mouse model of TBI out to 1 year post-transplant. NPCs were derived from E14.5 mouse brains containing a transgene-expressing green fluorescent protein (GFP) and cultured as neurospheres in FGF2-containing medium. Neurospheres were injected into the ipsilateral striatum of adult C57BL/6 mice I week following unilateral cortical impact injury. Behavioral testing revealed significant improvements in motor abilities in NPC-treated mice as early as I week, and the recovery was sustained out to I year post-transplant. In addition, mice receiving NPC transplants showed significant improvement in spatial learning abilities at 3 months and 1 year, whereas an intermediate treatment effect on this behavioral parameter was detected at 1 month. At 14 months post-transplant, GFP(+) NPCs were observed throughout the injured hippocampus and adjacent cortical regions of transplanted brains. Immumohistochemical analysis revealed that the majority of transplanted cells co-labeled for NG2, an oligodendrocyte progenitor cell marker, but not for neuronal, astrocytic or microglial markers. In conclusion, transplanted NPCs survive in the host brain up to 14 months, migrate to the site of injury, enhance motor and cognitive recovery, and may play a role in trophic support following TBI. (C) 2004 Elsevier B.V. All rights reserved.	Emory Univ, Brain Res Lab, Dept Psychol, Atlanta, GA 30322 USA; Field Neurosci Inst, Saginaw, MI USA; Emory Univ, Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Dept Psychol, Evans Bldg,Room 261B,1648 Pierce Dr, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020; Shear, Deborah/B-3607-2011				Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; AEBISCHER P, 1994, EXP NEUROL, V126, P151, DOI 10.1006/exnr.1994.1053; Benninger Y, 2000, BRAIN PATHOL, V10, P330; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; BORLONGAN CV, 2004, IN PRESS STROKE; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; CHEN LS, 1991, J CELL BIOCHEM, V45, P252, DOI 10.1002/jcb.240450305; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gray JA, 1999, PHILOS T R SOC B, V354, P1407, DOI 10.1098/rstb.1999.0488; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; Levison SW, 1997, J NEUROSCI RES, V48, P83, DOI 10.1002/(SICI)1097-4547(19970415)48:2<83::AID-JNR1>3.0.CO;2-8; Lindvall Olle, 1994, Current Opinion in Neurobiology, V4, P752, DOI 10.1016/0959-4388(94)90019-1; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Milward EA, 1997, J NEUROSCI RES, V50, P862, DOI 10.1002/(SICI)1097-4547(19971201)50:5<862::AID-JNR22>3.3.CO;2-O; NIETOSAMPEDRO M, 1987, ANN NY ACAD SCI, V495, P108, DOI 10.1111/j.1749-6632.1987.tb23670.x; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nishiyama A, 1997, J NEUROSCI RES, V48, P299, DOI 10.1002/(SICI)1097-4547(19970515)48:4<299::AID-JNR2>3.0.CO;2-6; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Rakic S, 2003, GLIA, V41, P117, DOI 10.1002/glia.10140; Rao MS, 1999, ANAT RECORD, V257, P137; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; STEIN DG, 1988, BRAIN INJURY RECOVER, P249; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Watanabe M, 2002, J NEUROSCI RES, V69, P826, DOI 10.1002/jnr.10338; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397	43	130	138	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 5	2004	1026	1					11	22		10.1016/j.brainres.2004.07.087			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865OU	WOS:000224713200002	15476693				2022-02-06	
J	Fastenau, PS; Shen, JZ; Dunn, DW; Perkins, SM; Hermann, BP; Austin, JK				Fastenau, PS; Shen, JZ; Dunn, DW; Perkins, SM; Hermann, BP; Austin, JK			Neuropsychological predictors of academic underachievement in pediatric epilepsy: Moderating roles of demographic, seizure, and psychosocial variables	EPILEPSIA			English	Article						epilepsy; children; family; cognition; academic achievement	EPILEPTIFORM EEG DISCHARGES; TRAUMATIC BRAIN INJURY; INDIVIDUAL-DIFFERENCES; IDIOPATHIC EPILEPSY; WORKING-MEMORY; LEARNED HELPLESSNESS; ATTRIBUTIONAL STYLE; CHILDHOOD EPILEPSY; SCHOOL-ACHIEVEMENT; TREATMENT PROGRAM	Purpose: Academic underachievement is common in pediatric epilepsy. Attempts to identify seizure and psychosocial risk factors for underachievement have yielded inconsistent findings, raising the possibility that seizure and psychosocial variables play a complex role in combination with other variables such as neuropsychological functioning. This study cross-validated a neuropsychological measurement model for childhood epilepsy, examined the relation between neuropsychological functioning and academic achievement, and tested the degree to which demographic, seizure, and psychosocial variables moderate that relation. Methods: Children with chronic epilepsy (N = 173; ages 8 to 15 years; 49% girls; 91% white/non-Hispanic; 79% one seizure type; 79% taking one medication; 69% with active seizures) completed a comprehensive neuropsychological battery. Children diagnosed with mental retardation were excluded. Results: Structural equation modeling identified a three-factor measurement model of neuropsychological function: Verbal/Memory/Executive (VME), Rapid Naming/Working Memory (RN/WM), and Psychomotor (PM). VME and RN/WM were strongly related to reading, math, and writing; PM predicted writing only. Family environment moderated the impact of neuropsychological deficits on writing (p less than or equal to 0.01) and possibly for reading (p = 0.05); neuropsychological deficits had a smaller impact on achievement for children in supportive/organized homes compared with children in unsupportive/disorganized homes. Conclusions: These findings lend partial support for our theoretical model showing direct effects of neuropsychological function oil achievement and the moderating role of family factors. This study suggests that a subgroup of children with epilepsy (those who have not only neuropsychological deficits but also disorganized/Unsupportive home environments) are particularly at risk for adverse academic outcomes. Implications for intervention are discussed.	IUPUI, Indiana Univ, Sch Med, Dept Psychol,Purdue Sch Sci, Indianapolis, IN 46202 USA; IUPUI, Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; IUPUI, Indiana Univ, Sch Med, Div Biostat,Dept Med, Indianapolis, IN 46202 USA; IUPUI, Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; Univ Wisconsin, Sch Med, Dept Neurol, Madison, WI USA; IUPUI, Sch Nursing, Indiana Univ, Dept Environm Hlth, Indianapolis, IN 46204 USA		Fastenau, PS (corresponding author), IUPUI, Indiana Univ, Sch Med, Dept Psychol,Purdue Sch Sci, LD 124,402 N Blackford ST, Indianapolis, IN 46202 USA.	pfastena@iupui.edu			NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01 NR004536, R01 NR004536-03, R01 NR04536, R01 NR004536-05, R01 NR004536-04] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004536] Funding Source: NIH RePORTER		Adams W., 1990, WIDE RANGE ASSESSMEN; Aicardi J, 1996, EPILEPSY CHILDREN; AUSTIN JK, 1993, J PEDIATR PSYCHOL, V18, P467, DOI 10.1093/jpepsy/18.4.467; Austin JK, 1998, DEV MED CHILD NEUROL, V40, P248, DOI 10.1111/j.1469-8749.1998.tb15457.x; AUSTIN JK, 1994, EPILEPSIA, V35, P608, DOI 10.1111/j.1528-1157.1994.tb02481.x; Baddeley A, 1998, PSYCHOL REV, V105, P158, DOI 10.1037/0033-295X.105.1.158; Bailet LL, 2000, EPILEPSIA, V41, P426, DOI 10.1111/j.1528-1157.2000.tb00184.x; BERNINGER VW, 1994, READ WRIT, V6, P161, DOI 10.1007/BF01026911; BOLL T, 1993, CHILDRENS CATEGORY T; Bulteau C, 2000, DEV MED CHILD NEUROL, V42, P319, DOI 10.1017/S0012162200000566; CAMFIELD C, 1993, J PEDIATR-US, V122, P869, DOI 10.1016/S0022-3476(09)90009-9; Christenson S.L., 1999, HDB SCH PSYCHOL, P709; Cockerell OC, 1997, EPILEPSIA, V38, P31, DOI 10.1111/j.1528-1157.1997.tb01075.x; Conners CK., 1995, CONNERS CONTINUOUS P; DAHL J, 1992, EPILEPSIA, V33, P98, DOI 10.1111/j.1528-1157.1992.tb02289.x; DAHL J, 1985, EPILEPSIA, V26, P303, DOI 10.1111/j.1528-1157.1985.tb05654.x; DISIMONI F, 1978, TOKEN TEST CHILDREN; DODRILL CB, 1978, EPILEPSIA, V19, P453, DOI 10.1111/j.1528-1157.1978.tb05172.x; DODRILL CB, 1984, J CONSULT CLIN PSYCH, V52, P520, DOI 10.1037/0022-006X.52.4.520; Dunn DW, 1999, J AM ACAD CHILD PSY, V38, P1132, DOI 10.1097/00004583-199909000-00017; FARWELL JR, 1985, EPILEPSIA, V26, P395, DOI 10.1111/j.1528-1157.1985.tb05670.x; FASTENAU PS, 2003, PRINCIPLES PRACTICE, P965; Ferrell M., 1998, PSYCHIAT COMORBIDITY, P363; FISH MC, 1995, BEST PRACTICES SCH P, V3, P1061; FOWLER MG, 1985, J PEDIATR-US, V106, P683, DOI 10.1016/S0022-3476(85)80103-7; Frost R, 1998, PSYCHOL BULL, V123, P71, DOI 10.1037/0033-2909.123.1.71; Golden CJ, 1978, STROOP COLOR WORD TE; Hecht SA, 2001, J EXP CHILD PSYCHOL, V79, P192, DOI 10.1006/jecp.2000.2586; Heimlich TE, 2000, J PEDIATR PSYCHOL, V25, P339, DOI 10.1093/jpepsy/25.5.339; Herman ST, 2002, SLEEP AND EPILEPSY: THE CLINICAL SPECTRUM, P165; Hermann BP, 1996, EPILEPSIA, V37, P680, DOI 10.1111/j.1528-1157.1996.tb00633.x; HITCH GJ, 1991, BRIT J PSYCHOL, V82, P375, DOI 10.1111/j.2044-8295.1991.tb02406.x; HOWE GW, 1993, J CHILD PSYCHOL PSYC, V34, P1153, DOI 10.1111/j.1469-7610.1993.tb01780.x; Johnson M.B., 1989, WOODCOCK JOHNSON PSY; Joreskog K, 1996, LISREL 8 USERS REFER; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; KASTELEIJNNOLSTTRENITE DGA, 1988, EPILEPSY RES, V2, P111, DOI 10.1016/0920-1211(88)90027-7; KAUFMAN AS, 1983, K BIT KAUFMAN BRIEF; KNIGHTS RM, 1968, PERCEPT MOTOR SKILL, V26, P643, DOI 10.2466/pms.1968.26.2.643; KOOP JI, 2000, J INT NEUROPSYCH SOC, V6, P227; KUTTNER MJ, 1990, J PEDIATR PSYCHOL, V15, P581, DOI 10.1093/jpepsy/15.5.581; Maki HS, 2001, READ WRIT, V14, P643, DOI 10.1023/A:1012071514719; Mandelbaum DE, 1997, DEV MED CHILD NEUROL, V39, P731; McCubbin H. I., 1996, FAMILY ASSESSMENT RE; MITCHELL WG, 1991, J CHILD NEUROL, V6, P65, DOI 10.1177/088307389100600114; OLEARY DS, 1981, EPILEPSIA, V22, P197, DOI 10.1111/j.1528-1157.1981.tb04102.x; Peterson C., 1993, LEARNED HELPLESSNESS; Piers E.V., 1984, PIERS HARRIS CHILDRE; Sammaritano MR, 2002, SLEEP AND EPILEPSY: THE CLINICAL SPECTRUM, P157; *SAS I, 2001, SAS PROPR SOFTW VERS; Schoenfeld J, 1999, DEV MED CHILD NEUROL, V41, P724, DOI 10.1017/S0012162299001486; SEIDENBERG M, 1986, EPILEPSIA, V27, P753, DOI 10.1111/j.1528-1157.1986.tb03606.x; Seidenberg M, 1987, J EPILEPSY, V1, P23; SELIGMAN MEP, 1984, J ABNORM PSYCHOL, V93, P235, DOI 10.1037/0021-843X.93.2.235; SIEBELINK BM, 1988, EPILEPSY RES, V2, P117, DOI 10.1016/0920-1211(88)90028-9; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; STURNIOLO MG, 1994, ARCH DIS CHILD, V70, P424, DOI 10.1136/adc.70.5.424; Swanson HL, 1996, J EXP CHILD PSYCHOL, V63, P358, DOI 10.1006/jecp.1996.0054; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TIZARD J, 1982, BRIT J EDUC PSYCHOL, V52, P1, DOI 10.1111/j.2044-8279.1982.tb02498.x; TOWNES BD, 1980, J CONSULT CLIN PSYCH, V48, P675, DOI 10.1037/0022-006X.48.6.675; WAGNER RK, 1987, PSYCHOL BULL, V101, P192, DOI 10.1037/0033-2909.101.2.192; Weber AM, 1988, NEUROPSYCHOLOGY, V2, P59, DOI 10.1037//0894-4105.2.2.59; WESTBROOK LE, 1991, J EPILEPSY, V4, P87, DOI 10.1016/S0896-6974(05)80066-0; WILKUS RJ, 1976, EPILEPSIA, V17, P89, DOI 10.1111/j.1528-1157.1976.tb03387.x; Williamson KS, 2002, MOL ECOL NOTES, V2, P17, DOI 10.1046/j.1471-8286.2002.00129.x; Wirrell EC, 1997, ARCH PEDIAT ADOL MED, V151, P152, DOI 10.1001/archpedi.1997.02170390042008; Wolfson, 1993, HALSTEAD REITAN NEUR; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	69	130	131	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	OCT	2004	45	10					1261	1272		10.1111/j.0013-9580.2004.15204.x			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	861MH	WOS:000224420300012	15461681	Green Accepted, Bronze			2022-02-06	
J	Ashman, TA; Spielman, LA; Hibbard, MR; Silver, JM; Chandna, T; Gordon, WA				Ashman, TA; Spielman, LA; Hibbard, MR; Silver, JM; Chandna, T; Gordon, WA			Psychiatric challenges in the first 6 years after traumatic brain injury: Cross-sequential analyses of axis I disorders	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	brain injuries; psychiatry; rehabilitation; research design	POSTTRAUMATIC-STRESS-DISORDER; STRUCTURED CLINICAL INTERVIEW; DSM-III; DEPRESSION; PREVALENCE; SYMPTOMS; EXTENT; 2-YEAR; RISK	Objective: To examine the preinjury rates of Axis I disorders and the prospective rates within the first 6 years after traumatic brain injury (TBI). Design: Cross-sectional, longitudinal, and cross-sequential. Setting: Community-based research and training center. Participants: Persons (N = 188) who had sustained TBI within 4 years of enrollment into the project were interviewed at either 2 and 3 assessments. Each assessment was approximately I year apart. Several Axis I diagnoses were analyzed to detect cross-sectional differences (by age and time postinjury) and average individual changes over the multiple measurement time points. Interventions: Not applicable. Main Outcome Measure: Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders. Results: The odds ratios changed longitudinally within each subject, indicating a decreased probability of having an Axis I diagnosis over time. There were few cross-sectional differences in age; therefore, age at the time of injury had little impact on Axis I diagnoses. Cross-sectional time since injury was not associated with more psychiatric disorders, whereas cross-sectional preinjury history of psychiatric disorders was predictive of postinjury psychiatric disorders. After controlling for cross-sectional effects, the frequencies of Axis I disorders increased in depression, anxiety, and posttraumatic stress disorders in the first assessment postinjury and declined in subsequent assessments. Conclusions: Cross-sequential analyses that control for cross-sectional and longitudinal differences produced a more complete description of psychiatric disorders after TBI.	Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Lenox Hill Hosp, Dept Psychiat, New York, NY USA		Ashman, TA (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave Levy Pl Box 1240, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013	Ashman, Teresa/0000-0003-2401-7192			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; FALLON BA, 1991, J CLIN PSYCHIAT, V52, P272; FANN JR, 1995, AM J PSYCHIAT, V152, P493; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; Gibbon M., 1997, USERS GUIDE STRUCTUR; GLENN MB, 2001, BRIAN INJ, V15, P81118; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Grieco E. M., 2001, CENSUS 2000 BRIEF OV; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus Jess F., 1994, P3; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KURTZKE JF, 1984, ANN NEUROL, V16, P265, DOI 10.1002/ana.410160302; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RISKIND JH, 1987, ARCH GEN PSYCHIAT, V44, P817; ROBINS LN, 1991, PSYCHIAT DISORDERS A; SPITZER R L, 1988, Journal of Psychiatric Research, V22, P55, DOI 10.1016/0022-3956(88)90069-6; STEINBERG M, 1990, AM J PSYCHIAT, V147, P76; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Wallace CA, 2000, BRAIN INJURY, V14, P549; Weitzenkamp DA, 2001, SPINAL CORD, V39, P301, DOI 10.1038/sj.sc.3101146; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	39	130	130	2	11	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S36	S42		10.1016/j.apmr.2003.08.117			7	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	812FL	WOS:000220825300005	15083420				2022-02-06	
J	Diaz-Arrastia, R; Gong, YH; Fair, S; Scott, KD; Garcia, MC; Carlile, MC; Agostini, MA; Van Ness, PC				Diaz-Arrastia, R; Gong, YH; Fair, S; Scott, KD; Garcia, MC; Carlile, MC; Agostini, MA; Van Ness, PC			Increased risk of late posttraumatic seizures associated with inheritance of APOE epsilon 4 allele	ARCHIVES OF NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; APOLIPOPROTEIN-E EPSILON-4; TEMPORAL-LOBE EPILEPSY; E-DEFICIENT MICE; ALZHEIMERS-DISEASE; CEREBROVASCULAR-DISEASE; HEAD-INJURY; E GENOTYPE; ONSET; REHABILITATION	Background: Late posttraumatic seizures are a common complication of moderate and severe traumatic brain injury. Inheritance of the apolipoprotein E (APOE) E4 allele is associated with increased risk of Alzheimer disease, progression to disability in multiple sclerosis, and poor outcome after traumatic brain injury. Objective: To determine whether inheritance of APOE E4 is associated with increased risk of developing late posttraumatic seizures. Design: Prospective study Setting: Neurosurgical service at an urban level I trauma center. Patients: Patients admitted-with a diagnosis of moderate and severe traumatic brain injury were enrolled. Methods: Six months after injury, patients were contacted to determine functional outcome (according to the Glasgow Outcome Scale-Expanded [GOS-E]) and the presence of late posttraumatic seizures. Genotype at the APOE locus was determined by restriction fragment length polymorphism analysis. Results: DNA and outcome information was obtained from 106 subjects. Six months after injury, 31 (29%) had a poor outcome (GOS-E score, 1-4), 47 (44%) had an intermediate outcome (GOS-E score, 5-6), and 28 (26%) had a favorable outcome (GOS-E score, 7-8). Twenty-one patients (20%) had at least I late posttraumatic seizure. The relative risk of late posttraumatic seizures for patients with the E4 allele was 2.41 (95% confidence interval, 1.15-5.07; P = .03). In this cohort, inheritance of APOE E4 was not associated with aft unfavorable GOS-E score 6 (P = .47). Conclusions: Inheritance of the APOE E4 allele is associated with increased risk of late posttraumatic seizures. In this cohort, this risk appears to be independent of an effect Of E4 on functional outcome. A better understanding of the molecular role of APOE in neurodegenerative diseases may be helpful in developing antiepileptogenic therapies.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Baylor Inst Rehabil, Dept Phys Med & Rehabil, Dallas, TX USA		Diaz-Arrastia, R (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG1786R03] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R24 MH59656, MH64889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH064889, R24MH059656] Funding Source: NIH RePORTER		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF., 1996, TREATMENT EPILEPSY P, P165; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bazan N G, 1999, Adv Neurol, V79, P659; Blumcke I, 1997, NEUROREPORT, V8, P1235; Briellmann RS, 2000, NEUROLOGY, V55, P435, DOI 10.1212/WNL.55.3.435; Buttini M, 1999, J NEUROSCI, V19, P4867; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Christensen B, 1999, AM J MED GENET, V84, P151, DOI 10.1002/(SICI)1096-8628(19990521)84:2<151::AID-AJMG12>3.3.CO;2-K; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gouras GK, 1997, ANN NEUROL, V41, P402, DOI 10.1002/ana.410410317; Graff-Radford NR, 2002, ARCH NEUROL-CHICAGO, V59, P594, DOI 10.1001/archneur.59.4.594; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Krzywkowski P, 1999, NEUROSCIENCE, V92, P1273, DOI 10.1016/S0306-4522(99)00061-5; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Overmyer M, 1999, DEMENT GERIATR COGN, V10, P252, DOI 10.1159/000017128; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Prince D A, 1999, Adv Neurol, V79, P665; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Tamaoka A, 2000, NEUROLOGY, V54, P2319, DOI 10.1212/WNL.54.12.2319; Tang MX, 1996, AM J HUM GENET, V58, P574; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; THOMSON DM, 1992, CLIN CHIM ACTA, V207, P169, DOI 10.1016/0009-8981(92)90116-8; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	43	130	135	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JUN	2003	60	6					818	822		10.1001/archneur.60.6.818			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	688AK	WOS:000183409800005	12810485				2022-02-06	
J	Pittet, JF; Lee, H; Morabito, D; Howard, MB; Welch, WJ; Mackersie, RC				Pittet, JF; Lee, H; Morabito, D; Howard, MB; Welch, WJ; Mackersie, RC			Serum levels of Hsp 72 measured early after trauma correlate with survival	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						heat shock protein; multiple injuries; head injury; mortality	HEAT-SHOCK PROTEINS; HEAT-SHOCK-PROTEIN-70 HSP70; NORMAL INDIVIDUALS; CELLS; STRESS; IDENTIFICATION; FIBROBLASTS; EXPRESSION; ANTIBODIES; INDUCTION	Background. Experimental studies have shown that hemorrhagic shock is associated with the expression of inducible heat proteins, especially heat shock protein (Hsp) 72, in liver, brain, heart, and kidney. Moreover, induction of Hsp 72 by various stressors before the onset of shock has been associated with the attenuation of organ injury caused by hemorrhage. However, it is not known whether Hsp 72 is expressed after severe trauma in humans. The purpose of this study was therefore to determine whether Hsp 72 could be detected in the serum of patients early after severe trauma and whether serum levels of Hsp 72 might correlate with survival of trauma patients or the severity of the postinjury inflammatory response. Methods. Clinical data were collected prospectively over a 3-year period for trauma patients mechanically ventilated for more than 2 days who met the following inclusion criteria: Injury Severity Score greater than or equal to 16, and age > 18 years. Physiologic data for quantitative assessment of organ dysfunction were collected for each patient. Hsp 72 and nitrate and nitrite levels were measured in the serum of trauma patients collected at or 12 to 48 hours after the admission to the emergency department. Results. Sixty-seven patients with severe trauma were enrolled in the study. Hsp 72 was detected in the serum of all trauma patients. All patients with high initial serum levels of Hsp 72 (serum levels > 15 ng/mL) survived, whereas 29% of the patients with low Hsp 72 serum levels died from their traumatic injuries (p = 0.01). The overall mortality was 21%, occurring within 5 to 7 days. Patients who died were older (mean age, 54 +/- 15 years) than those who survived (mean age, 36 +/- 15 years) (p < 0.0.05). The cause of death was attributable to head injury in 79%, although the severity of head injury (Abbreviated Injury Scale score) was not statistically different between survivors with high serum values of Hsp 72 and patients who died. There was no correlation between the initial serum Hsp 72 values and the severity of organ dysfunction or clinical indicators of the inflammatory response. Conclusion. Hsp 72 can be detected in the serum of severely traumatized patients within 30 minutes after injury. Elevated initial serum levels of Hsp 72 (serum levels > 15 ng/mL) are associated with survival after severe trauma, but are not related to the incidence or severity of the postinjury inflammatory response or organ dysfunction.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Surg, San Francisco, CA 94110 USA		Pittet, JF (corresponding author), San Francisco Gen Hosp, Dept Anesthesia 3C 38, 1001 Potrero Ave, San Francisco, CA 94110 USA.		Xia, Xianfeng/F-9169-2011	Lee, Hyon/0000-0002-0273-8960	ODCDC CDC HHS [R49-CCR903697-07] Funding Source: Medline		Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Callahan TE, 1999, J SURG RES, V85, P317, DOI 10.1006/jsre.1999.5651; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4; FINCATO G, 1991, BLOOD, V77, P579; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOYT DB, 1993, J TRAUMA, V35, P524, DOI 10.1097/00005373-199310000-00005; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; LIU AYC, 1989, J BIOL CHEM, V264, P12037; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; Moseley P, 2000, IMMUNOPHARMACOLOGY, V48, P299, DOI 10.1016/S0162-3109(00)00227-7; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Pockley AG, 1999, CELL STRESS CHAPERON, V4, P29, DOI 10.1379/1466-1268(1999)004<0029:IOHHSP>2.3.CO;2; Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710; Rea IM, 2001, EXP GERONTOL, V36, P341, DOI 10.1016/S0531-5565(00)00215-1; van Eden W, 1998, IMMUNOL TODAY, V19, P303, DOI 10.1016/S0167-5699(98)01283-3; WELCH WJ, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0593-56; Xu QB, 2000, CIRCULATION, V102, P14, DOI 10.1161/01.CIR.102.1.14; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3; Zhu S, 2001, AM J RESP CRIT CARE, V163, P166, DOI 10.1164/ajrccm.163.1.2005068	26	130	142	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2002	52	4					611	617		10.1097/00005373-200204000-00001			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	540ZP	WOS:000174961000001	11956372				2022-02-06	
J	Newman, TA; Woolley, ST; Hughes, PM; Sibson, NR; Anthony, DC; Perry, VH				Newman, TA; Woolley, ST; Hughes, PM; Sibson, NR; Anthony, DC; Perry, VH			T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases	BRAIN			English	Article						axon damage; APP; DTH; MMP; multiple sclerosis	AMYLOID PRECURSOR PROTEIN; DELAYED-TYPE HYPERSENSITIVITY; BACILLUS-CALMETTE-GUERIN; MAGNETIC-RESONANCE SPECTROSCOPY; MULTIPLE-SCLEROSIS LESIONS; TRAUMATIC BRAIN INJURY; APPEARING WHITE-MATTER; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE; MATRIX METALLOPROTEINASES	Recent evidence has highlighted the fact that axon injury is an important component of multiple sclerosis pathology. The issue of whether a CNS antigen-specific immune response is required to produce axon injury remains unresolved. We investigated the extent and time course of axon injury in a rodent model of a delayed-type hypersensitivity (DTH) reaction directed against the mycobacterium bacille Calmette-Guerin (BCG). Using MRI, we determined whether the ongoing axon injury is restricted to the period during which the blood-brain barrier is compromised. DTH lesions were initiated in adult rats by intracerebral injection of heat-killed BCG followed by a peripheral challenge with BCG. Our findings demonstrate that a DTH reaction to a non-CNS antigen within a CNS white matter tract leads to axon injury. Ongoing axon injury persisted throughout the 3-month period studied and was not restricted to the period of blood-brain barrier breakdown, as detected by MRI enhancing lesions. We have previously demonstrated that matrix metalloproteinases (MMPs) are upregulated in multiple sclerosis plaques and DTH lesions. In this study we demonstrated that microinjection of activated MMPs into the cortical white matter results in axon injury. Our results show that axon injury, possibly mediated by MMPs, is immunologically non-specific and may continue behind an intact blood-brain barrier.	Univ Southampton, Sch Biol Sci, CNS Inflammat Grp, Southampton SO16 7PX, Hants, England; Univ Oxford, Dept Biochem, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX1 2JD, England		Newman, TA (corresponding author), Univ Southampton, Sch Biol Sci, CNS Inflammat Grp, Biomed Sci Bldg, Southampton SO16 7PX, Hants, England.		Anthony, Daniel C/F-7765-2010; Perry, V. Hugh/Y-2935-2019; Newman, Tracey A/I-8884-2012	Anthony, Daniel C/0000-0003-1380-6655; Newman, Tracey A/0000-0002-3727-9258			Ahlgren S, 1996, ACTA NEUROPATHOL, V92, P49, DOI 10.1007/s004010050488; Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Anthony DC, 1998, J NEUROIMMUNOL, V87, P62, DOI 10.1016/S0165-5728(98)00046-0; Bhakoo KK, 2000, J NEUROCHEM, V74, P254, DOI 10.1046/j.1471-4159.2000.0740254.x; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Blamire AM, 2000, J NEUROSCI, V20, P8153; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; De Stefano N, 1999, BRAIN, V122, P1933, DOI 10.1093/brain/122.10.1933; Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.0.CO;2-J; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Fu L, 1998, BRAIN, V121, P103, DOI 10.1093/brain/121.1.103; Ganter P, 1999, NEUROPATH APPL NEURO, V25, P459; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GOBAN Y, 1986, J NEUROL SCI, V74, P97, DOI 10.1016/0022-510X(86)90194-2; Ishizuya-Oka A, 2000, J CELL BIOL, V150, P1177, DOI 10.1083/jcb.150.5.1177; Kappos L, 1999, LANCET, V353, P964, DOI 10.1016/S0140-6736(98)03053-0; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kornek B, 1999, BRAIN PATHOL, V9, P651; LaFleur M, 1996, J EXP MED, V184, P2311; Lassmann H, 1999, PHILOS T ROY SOC B, V354, P1635, DOI 10.1098/rstb.1999.0508; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Matyszak MK, 1998, J NEUROIMMUNOL, V82, P73, DOI 10.1016/S0165-5728(97)00190-2; MATYSZAK MK, 1995, NEUROSCIENCE, V64, P967, DOI 10.1016/0306-4522(94)00448-E; Matyszak MK, 1996, J NEUROIMMUNOL, V69, P141; Matyszak MK, 1996, NEUROPATH APPL NEURO, V22, P44, DOI 10.1111/j.1365-2990.1996.tb00845.x; Matyszak MK, 1997, NEUROSCIENCE, V78, P549, DOI 10.1016/S0306-4522(96)00578-7; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Mun-Bryce S, 1998, AM J PHYSIOL, V274, P1203; Murray PD, 1998, J NEUROSCI, V18, P7306; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; Powell H C, 1987, J Neurol Sci, V78, P357, DOI 10.1016/0022-510X(87)90049-9; RAINE CS, 1989, LAB INVEST, V60, P714; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; STYS PK, 1992, J NEUROSCI, V12, P430; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; WISNIEWSKI HM, 1975, J EXP MED, V141, P346, DOI 10.1084/jem.141.2.346	42	130	138	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	NOV	2001	124		11				2203	2214		10.1093/brain/124.11.2203			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	494QC	WOS:000172295500008	11673322				2022-02-06	
J	Cernak, I; Wang, ZG; Jiang, JX; Bian, XW; Savic, J				Cernak, I; Wang, ZG; Jiang, JX; Bian, XW; Savic, J			Cognitive deficits following blast injury-induced neurotrauma: possible involvement of nitric oxide	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; MORRIS WATER MAZE; MISSILE EXTREMITY IMPACT; PRESSURE WAVE INJURIES; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; SYNTHASE EXPRESSION; SELECTIVE VULNERABILITY; HIPPOCAMPAL-NEURONS; RETICULAR-FORMATION	Blast injuries, that is injuries caused by the complex pressure wave generated by some explosions, show increasing frequency throughout the world. However, whether blast injury is capable of inducing memory dysfunction has not been previously investigated. The present study examines the effects of blast injury-induced neurotrauma on memory deficit in rats. Furthermore, it is hypothesized that blast injury, stimulating nitric oxide production in the medial mesodiencephalic reticular formation and the dorsal hippocampus, both structures being involved in memory processing, may induce memory deficits. Prior to blast injury, Wistar rats were trained for an active avoidance task for 6 days. On day 6, rats that had acquired the avoidance response were subjected to whole-body blast injury, using a BT-I shock tube. Neurotrauma was confirmed by electron microscopical examination. At the completion of cognitive testing, rats were sacrificed at 3,24 hours and 5 days after injury. The nitric oxide production in the brain structures was determined by the total nitrite/nitrate concentration, and by the expression of inducible nitric oxide synthase mRNA. The rats with blast injury revealed significant deficits in performance of the active avoidance task that persisted up to 5 days post-injury. Electron microscopical findings in both brain structures showed swellings of neurons, glial reaction, myelin debris, and increased pinocytotic activity on the fifth day following trauma. In blast injured rats, there was a significant elevation in total nitrite/nitrate levels 3 and 24 hours following injury which was comparable with the changes in the expression of inducible nitric oxide synthase mRNA. The results indicate that blast injury-induced neurotrauma is able to cause cognitive deficits.	Mil Med Acad, Inst Med Res, YU-11002 Belgrade, Serbia Monteneg; 3rd Mil Med Univ, Inst Surg Res, Chongqing, Peoples R China		Cernak, I (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.	Ibolja.Cernak@jcu.edu.au	Bian, Xiuwu/F-1569-2011; Bian, Xiu-Wu/D-4736-2017; Cernak, Ibolja/A-6399-2008	Bian, Xiu-Wu/0000-0003-4383-0197; Ibolja, Cernak/0000-0003-3214-698X			ARUSHANYAN EB, 1975, FARMAKOL TOKSIKOL, V38, P389; Baratti CM, 1996, NEUROBIOL LEARN MEM, V65, P197, DOI 10.1006/nlme.1996.0023; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BERLIN R, 1979, J TRAUMA, V19, P170, DOI 10.1097/00005373-197903000-00007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak Ibolja, 1995, Magnesium Research, V8, P249; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336, DOI 10.1152/physrev.1956.36.3.336; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Coupland RM, 1999, BRIT MED J, V319, P410, DOI 10.1136/bmj.319.7207.410; Coupland RM, 1999, BRIT MED J, V319, P407, DOI 10.1136/bmj.319.7207.407; DAVIS HP, 1987, PHYSIOL BEHAV, V39, P783, DOI 10.1016/0031-9384(87)90267-8; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Furchgott R F, 1998, An R Acad Nac Med (Madr), V115, P317; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; Golier J, 1998, DEV PSYCHOPATHOL, V10, P857, DOI 10.1017/S0954579498001904; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; Hawkins RD, 1998, PROG BRAIN RES, V118, P155; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Ishikawa Y, 1999, BRAIN RES, V824, P71, DOI 10.1016/S0006-8993(99)01108-7; KAASIK AE, 1994, ZH VOPROSY NEIROKHIR, V1, P26; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; KLINGBERG F, 1989, ACTA PHYSIOL HUNG, V74, P121; Kopelman MD, 1999, NEUROPSYCHOLOGIA, V37, P939, DOI 10.1016/S0028-3932(98)00143-2; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Krug EG, 1999, BMJ-BRIT MED J, V319, P450, DOI 10.1136/bmj.319.7207.450; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAATSCH JL, 1959, J COMP PHYSIOL PSYCH, V52, P408, DOI 10.1037/h0048310; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MONCADA S, 1988, HYPERTENSION, V12, P365, DOI 10.1161/01.HYP.12.4.365; Mori T, 1998, ACT NEUR S, V71, P120; Onaya M, 1991, No To Shinkei, V43, P283; PAIVA T, 1976, ELECTROEN CLIN NEURO, V40, P470, DOI 10.1016/0013-4694(76)90077-8; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; PHILLIPS YY, 1986, ANN EMERG MED, V15, P1446, DOI 10.1016/S0196-0644(86)80940-4; Popovic M, 1996, INT J NEUROSCI, V86, P281, DOI 10.3109/00207459608986719; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRADELLES P, 1989, ANAL CHEM, V61, P447, DOI 10.1021/ac00180a014; Qiang M, 1997, BEHAV PHARMACOL, V8, P183; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ross ME, 1996, METHOD ENZYMOL, V269, P408; Salter M, 1996, J NEUROCHEM, V66, P1683; Sayama T, 1999, NEUROL RES, V21, P293, DOI 10.1080/01616412.1999.11740934; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOUTHAM E, 1993, NEUROPHARMACOLOGY, V32, P1267, DOI 10.1016/0028-3908(93)90021-T; SPARROW JR, 1994, J MOL NEUROSCI, V5, P219, DOI 10.1007/BF02736723; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Squire LR, 1998, CR ACAD SCI III-VIE, V321, P153, DOI 10.1016/S0764-4469(97)89814-9; Strijbos PJLM, 1998, CRIT REV NEUROBIOL, V12, P223, DOI 10.1615/CritRevNeurobiol.v12.i3.40; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; SUNESON A, 1990, J TRAUMA, V30, P281, DOI 10.1097/00005373-199003000-00006; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/0361-9230(96)00159-1; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Telegdy G, 1997, NEUROPHARMACOLOGY, V36, P1583, DOI 10.1016/S0028-3908(97)00154-8; THOMPSON R, 1978, BEHAV ATLAS RAT BRAI; TOMINAGA T, 1993, BRAIN RES, V614, P342, DOI 10.1016/0006-8993(93)91053-U; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Turnbull AV, 1998, ANN NY ACAD SCI, V840, P434, DOI 10.1111/j.1749-6632.1998.tb09582.x; VERTES RP, 1986, NEUROSCIENCE, V19, P873, DOI 10.1016/0306-4522(86)90305-2; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang ZG, 1998, CHINESE MED J-PEKING, V111, P109; WILCOCK J, 1973, J COMP PHYSIOL PSYCH, V82, P247, DOI 10.1037/h0033914; Yamada K, 1999, NEUROSCIENCE, V88, P281, DOI 10.1016/S0306-4522(98)00237-1; Yamaki T, 1998, BRAIN RES PROTOC, V3, P100, DOI 10.1016/S1385-299X(98)00030-0; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3	95	130	134	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2001	15	7					593	612		10.1080/02699050010009559			20	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	444PD	WOS:000169407900005	11429089				2022-02-06	
J	Grindel, SH; Lovell, MR; Collins, MW				Grindel, SH; Lovell, MR; Collins, MW			The assessment of sport-related concussion: The evidence behind neuropsychological testing and management	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						neuropsychological tests; brain concussion; brain injury, chronic; postconcussion syndrome; second impact syndrome; pediatric athletic injuries	MILD HEAD-INJURY; AUSTRALIAN RULES FOOTBALL; VERBAL-LEARNING TEST; CEREBRAL CONCUSSION; STANDARDIZED ASSESSMENT; UNITED-STATES; MENTAL STATUS; BRAIN INJURY; PLAYERS; PERFORMANCE	Because of the lack of valid evidence to support the current recommendations for the management of mild traumatic brain injury (concussion), many physicians, athletic trainers, coaches, and athletes have called into question the way concussions are treated in athletics. This review article discusses the current evidence for the management of concussion in high school, college, and professional sports. A complete review of the epidemiologic and neuropsychological studies to date is presented and critically reviewed, as are other assessment and management tools in concussion. The appropriate use of neuropsychological testing, grading scales, and return-to-play recommendations are discussed in depth based on the current evidence. Additionally, areas requiring further research are identified and future trends are briefly discussed.	St Vincent Sports Med Fellowship, Erie, PA 16502 USA; Univ Pittsburgh, Pittsburgh, PA USA		Grindel, SH (corresponding author), St Vincent Sports Med Fellowship, 2314 Sassafras St,Suite 300, Erie, PA 16502 USA.						Baddeley A., 1992, SPEED CAPACITY LANGU; BAILES JE, 1999, SPORTS RELATED CONCU; BAILES JE, 1998, SPORTS NEUROLOGY, P215; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Barth JT, 1989, MILD HEAD INJURY, P257; Bashford G, 1993, Aust Fam Physician, V22, P2067; BAYRE ADH, 1999, J CLIN EXP NEUROPSYC, V21, P70; BAYRE ADH, 1997, J CLIN EXP NEUROPSYC, V19, P275; Benedict RH, 1997, BRIEF VISUOSPATIAL T; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; BROOKS DN, 1989, RECOVERY BRAIN INJUR, P67; Cantu RC, 2000, NEUROSURGERY, V47, P669; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; CUMMINGS JL, 1996, NEUROLOGY, V47, P592; Dicker G, 1986, Aust Fam Physician, V15, P455; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1998, RECOVERY, V9, P10; Elwood RW, 1995, NEUROPSYCHOL REV, V5, P173, DOI 10.1007/BF02214761; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Goldstein G., 1984, HDB PSYCHOL ASSESSME; Graham FK, 1960, PERCEPT MOTOR SKILL, V11, P147, DOI DOI 10.2466/PMS.11.6.147-188; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1977, PERP MOTOR SKILLS, V4, P343; Heck J F, 1996, J Athl Train, V31, P31; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; KlOve H, 1963, MED CLIN N AM; LARRABEE GJ, 1998, RECOVERY, V9, P12; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Luteyn, 1966, DUTCH J PSYCHOL, V2, P675; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 1998, SPORTS NEUROLOGY, P441; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; MCINTOSH AS, 2000, MED J AUSTRALIA, V172, P217; Posner MI., 1978, MODES PERCEIVING PRO, P137; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; PRIGATANO GP, 1993, NEUROL CLIN, V11, P219, DOI 10.1016/S0733-8619(18)30179-8; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; RUFF RM, 1989, J CLIN EXP NEUROPSYC, V11, P539, DOI 10.1080/01688638908400912; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith A., 1982, SYMBOL DIGIT MODALIT; Sosin DM, 1996, BRAIN INJURY, V10, P47; SWENSON EJ, 1996, ANN M AM MED SOC SPO, P141; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Young CC, 1997, CLIN J SPORT MED, V7, P196, DOI 10.1097/00042752-199707000-00008; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	74	130	132	2	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2001	11	3					134	143		10.1097/00042752-200107000-00003			10	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	454YG	WOS:000169998900002	11495317				2022-02-06	
S	Youdim, MBH; Wadia, A; Tatton, W; Weinstock, M		Slikker, W; Trembly, B		Youdim, MBH; Wadia, A; Tatton, W; Weinstock, M			The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	5th International Conference on Neuroprotective Agents	SEP 17-21, 2000	LAKE TAHOE, NV	Natl Ctr Toxicol Res /FDA, Cent Arkansas Chapter Sigma Xi		propargylamine; monoamine oxidase inhibitor; Bcl-2; closed head injury; neuroprotection; cholinesterase inhibitors	NERVE GROWTH-FACTOR; CLOSED-HEAD INJURY; MONOAMINE; APOPTOSIS; WITHDRAWAL; AGN-1135; SERUM	The antiapoptotic and neuroprotective activity of irreversible monoamine oxidase (MAO) B inhibitor, rasagiline [R(+)-N-propargyl-1-aminioindan], its S-isomer (TVP1022) and TV 3219, a novel anti-Alzheimer cholinesterase-MAO inhibitor drug derived from rasagiline were examined in PC12 cells cultures and in vivo. We found that these drugs have potent antiapoptotic and neuroprotective activities in response to serum and NGF withdrawal in partially neuronally differentiated PC12 cells and prevent the fall in mitochondrial membrane potential, the first step in cell death. Closed head injury studies in mice have shown that both rasagiline and TVP1022 are neuroprotective. All these compounds possess a propargyl moiety, which normally is responsible for irreversible inactivation of MAO, as is seen with rasagiline. However, neither TVP1022 nor TV3219 are MAO inhibitors, both share the antiapoptotic and neuroprotective actions of rasagiline, indicating that MAO inhibition is not a prerequisite for neuroprotection and that the propargyl moiety exhibits intrinsic neuroprotective pharmacological activity that requires identification.	Technion Israel Inst Technol, Fac Med, Natl Parkinson Fdn Ctr, Haifa, Israel; Mt Sinai Sch Med, New York, NY USA; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel		Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Eve Topf Ctr, Efron St, Haifa, Israel.	youdim@tx.technion.ac.il					Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; Carlile GW, 2000, MOL PHARMACOL, V57, P2; Carrillo MC, 2000, LIFE SCI, V67, P577, DOI 10.1016/S0024-3205(00)00643-3; DRIGUES N, 2000, NEUROSCI LETT S, V55, pS15; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Finberg J P, 1999, Adv Neurol, V80, P495; Finberg JPM, 1996, J NEURAL TRANSM-SUPP, P95; FINBERG JPM, 1985, BRIT J PHARMACOL, V85, P541, DOI 10.1111/j.1476-5381.1985.tb08891.x; Finberg JPM, 1998, J NEURAL TRANSM-SUPP, P279; FINBERG JPM, 1981, BRIT J PHARMACOL, V73, P65, DOI 10.1111/j.1476-5381.1981.tb16772.x; HEIKKILA RE, 1985, EUR J PHARMACOL, V116, P313, DOI 10.1016/0014-2999(85)90168-2; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; KALIR A, 1981, BRIT J PHARMACOL, V73, P55, DOI 10.1111/j.1476-5381.1981.tb16771.x; Koutsilieri E, 2001, EUR J PHARMACOL, V411, pR1, DOI 10.1016/S0014-2999(00)00874-8; Maruyama W, 1999, MECH AGEING DEV, V111, P189, DOI 10.1016/S0047-6374(99)00066-4; Maruyama W, 2000, MECH AGEING DEV, V116, P181, DOI 10.1016/S0047-6374(00)00144-5; Naoi M, 2000, J NEURAL TRANSM-SUPP, P111; *PARK STUD GROUP, 2000, CONTR CLIN TRIAL RAS; SAGI Y, 2001, 14 INT C PARK DIS HE; Speiser Z, 1998, J NEURAL TRANSM-SUPP, P287; Speiser Z, 1998, PHARMACOL BIOCHEM BE, V60, P387, DOI 10.1016/S0091-3057(97)00603-5; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; TATTON WG, 1994, J NEUROCHEM, V63, P1572; Wadia JS, 1998, J NEUROSCI, V18, P932; WEINSTOCK M, 2000, DRUG DEVELOP RES, P216; WEINSTOCK M, 2000, TV3326 NOVEL NEUROPR, P139; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; YOUDIM MBH, 2001, IN PRESS NEUROSCI S, V55; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45	29	130	131	0	6	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-353-X; 1-57331-352-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2001	939						450	458					9	Multidisciplinary Sciences; Clinical Neurology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology	BT12V	WOS:000172028600052	11462801				2022-02-06	
J	Haggard, P; Cockburn, J; Cock, J; Fordham, C; Wade, D				Haggard, P; Cockburn, J; Cock, J; Fordham, C; Wade, D			Interference between gait and cognitive tasks in a rehabilitating neurological population	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						motor control; dual task interference; neurological rehabilitation	CLOSED-HEAD INJURY; TRAUMATIC BRAIN INJURY; ATTENTIONAL DEFICITS; DUAL-TASK; PERFORMANCE; STROKE	Objectives-To quantify the extent of interference between gait and cognitive tasks after brain injury; to investigate whether such interference is common to various cognitive tasks, or confined to specific cognitive modules; to investigate whether such interference declines during recovery from brain injury. Method-Fifty participants were recruited from a neurological rehabilitation unit (33 people, 75% of sample); the stroke rehabilitation ward of an acute hospital (11 people, 20%); and a young disabled unit (six people, 5%). Measures of stride duration were taken in single task conditions, and in conjunction with each of four cognitive tasks. Outcome measures were dual task decrements in gait and in cognitive task performance. Results-Overall, a 7% decrement in stride duration was recorded under dual task conditions compared with single task, with stride duration being significantly longer during simultaneous performance of each cognitive task. There was a 4% decrement on average in cognitive task performance under dual task conditions, with significant decrements being recorded for word generation while walking and paired associate monitoring while walking. A significant correlation (r=0.45) was found between dual task decrements and scores on a standard measure of disability-the Barthel activities of daily living scale-but the correlation with 10 m walking time was not significant (r=0.18). Conclusion-Interference between cognitive tasks and motor control activities such as gait is a problem in neurological rehabilitation settings, interference between cognition and locomotor tasks may be important in assessing neurological patients' ability to function independently, and in designing therapies for both cognitive and motor rehabilitation.	UCL, Inst Cognit Neurosci, London, England; UCL, Dept Psychol, London, England; Univ Reading, Dept Psychol, Reading RG6 2AH, Berks, England; Univ Oxford, Dept Clin Neurol, Oxford, England; Rivermead Rehabil Ctr, Oxford OX1 4XD, England		Haggard, P (corresponding author), UCL, Inst Cognit Neurosci, London, England.	p.haggard@ucl.ac.uk	Haggard, Patrick/A-5081-2010	Haggard, Patrick/0000-0001-7798-793X; Wade, Derick/0000-0002-1188-8442			ADA L, 1994, ADV PSYCHOL, V105, P239, DOI DOI 10.1016/S0166-4115(08)61281-9; Broadbent D.E., 1958, PERCEPTION COMMUNICA, DOI [10.1037/10037-000, DOI 10.1037/10037-000]; BROADBENT DE, 1982, ACTA PSYCHOL, V50, P253, DOI 10.1016/0001-6918(82)90043-9; Camicioli R, 1997, NEUROLOGY, V48, P955, DOI 10.1212/WNL.48.4.955; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Collin C, 1988, Int Disabil Stud, V10, P61; CRAWFORD JR, 1992, BRIT J CLIN PSYCHOL, V31, P327, DOI 10.1111/j.2044-8260.1992.tb00999.x; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Haggard P, 1998, NEUROPSYCHOL REHABIL, V8, P155; Hockey GRJ, 1997, BIOL PSYCHOL, V45, P73; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P60; LINDENBERGER U, IN PRESS PSYCHOL AGI; Marshall SC, 1997, ARCH PHYS MED REHAB, V78, P7, DOI 10.1016/S0003-9993(97)90002-2; MAYLOR EA, 1996, J GERONTOL B-PSYCHOL, V51, P143; Mulder T, 1996, AMBULANTE TEILSTATIO, P52; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHALLICE TE, 1985, Q J EXP PSYCHOL-A, V41, P235; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Wade D.T., 1992, MEASUREMENT NEUROLOG, P78; WADE DT, 1988, J NEUROL NEUROSUR PS, V51, P10, DOI 10.1136/jnnp.51.1.10; [No title captured]	23	130	141	0	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2000	69	4					479	486		10.1136/jnnp.69.4.479			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	358LH	WOS:000089559200011	10990508	Green Published, Green Submitted, Bronze			2022-02-06	
J	Schmitz, MA; Finnegan, M; Natarajan, R; Champine, J				Schmitz, MA; Finnegan, M; Natarajan, R; Champine, J			Effect of smoking on tibial shaft fracture healing	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							MIDDLE-AGED WOMEN; OSTEOBLAST-LIKE CELLS; BONE-MINERAL CONTENT; CIGARETTE-SMOKING; TOBACCO SMOKING; SLENDER SMOKER; HEAD-INJURY; BLOOD-FLOW; IN-VITRO; NICOTINE	Of 146 consecutive closed and Grade I open tibia shaft fractures treated with cast immobilization, external fixation, or intramedullary rod fixation during a 4-year period, 44 of 76 (58%) tibias of patients who smoked and 59 of 70 (84%) tibias of patients who did not smoke had followup to union or followup beyond 1 year. The demographics, fracture patterns, and treatments of the two groups were similar. Two of the 44 patients who smoked had nonunions at the 1-year followup, whereas none of the patients who did not smoke had nonunions, Of the 103 tibias with complete followup to union, the median time to clinical healing for patients who smelted (269 days) was significantly greater than that of patients who did not smoke (136 days). Likewise, there was a 69% delay in radiographic union in the group that smoked as interpreted by a radiologist blinded to the two groups. Statistical differences in clinical and radiographic healing rates between those who smoked and those who did not smoke were observed for patients receiving intramedullary fixation or external fixation, Statistical differences were not seen in the clinical and radiographic healing of tibias treated with cast immobilization, although tibias of patients who smoked took 62% longer to heal, The current data suggest that tibias of patients who smoke who require treatment with intramedullary nailing or external fixation require more time to heal than do those of patients who do not smoke.	Lake Orthopaed Clin, Lakewood, CO 80215 USA; Univ Texas, Parkland Mem Hosp, Dept Orthopaed Surg, Dallas, TX USA; Univ Texas, Parkland Mem Hosp, Dept Radiol, Dallas, TX USA; Univ Rochester, Dept Biostat, Rochester, NY USA		Schmitz, MA (corresponding author), Lake Orthopaed Clin, 1805 Kipling St, Lakewood, CO 80215 USA.						ASHCROFT GP, 1992, J BONE JOINT SURG BR, V74, P673, DOI 10.1302/0301-620X.74B5.1527111; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; BLUMENTHAL SL, 1988, SPINE, V13, P566, DOI 10.1097/00007632-198805000-00023; BRIGHTON CT, 1972, J BONE JOINT SURG AM, VA 54, P323, DOI 10.2106/00004623-197254020-00010; BROWN CW, 1986, SPINE, V11, P942, DOI 10.1097/00007632-198611000-00015; BRUMBACK RJ, 1994, J BONE JOINT SURG AM, V76A, P1162, DOI 10.2106/00004623-199408000-00006; CAMPEAU RJ, 1987, CLIN NUCL MED, V12, P510, DOI 10.1097/00003072-198707000-00004; COBB TK, 1994, FOOT ANKLE, V15, P64, DOI 10.1177/107110079401500202; CRUESS RL, 1972, CLIN ORTHOP RELAT R, P253, DOI 10.1097/00003086-197207000-00038; DAFTARI TK, 1994, SPINE, V19, P904, DOI 10.1097/00007632-199404150-00007; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DEVERNEJOUL MC, 1983, CLIN ORTHOP RELAT R, P107; DINTENFASS L, 1975, MED J AUSTRALIA, V1, P617, DOI 10.5694/j.1326-5377.1975.tb111612.x; EINHORN TA, 1990, ORTHOP CLIN N AM, V21, P43; FANG MA, 1991, BONE, V12, P283, DOI 10.1016/8756-3282(91)90077-V; GOLDHABER P, 1958, ARCH PATHOL, V66, P635; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HEPPENSTALL RB, 1975, CLIN ORTHOP RELAT R, P357; HEPPENSTALL RB, 1976, J BONE JOINT SURG AM, V58, P1153, DOI 10.2106/00004623-197658080-00022; HERBSMAN H, 1966, J TRAUM, V6, P75, DOI 10.1097/00005373-196601000-00009; HERBSMAN H, 1968, J SURG RES, V8, P424, DOI 10.1016/0022-4804(68)90058-9; HOEKMAN P, 1991, J BONE JOINT SURG AM, V73A, P675, DOI 10.2106/00004623-199173050-00005; HOOPER GJ, 1991, J BONE JOINT SURG BR, V73, P83, DOI 10.1302/0301-620X.73B1.1991783; HOPPER JL, 1994, NEW ENGL J MED, V330, P387, DOI 10.1056/NEJM199402103300603; Hunt T K, 1972, Surg Forum, V23, P47; Jenkins Lee Thomas, 1994, Contemporary Orthopaedics, V29, P173; JENSEN GF, 1986, EUR J CLIN INVEST, V16, P239, DOI 10.1111/j.1365-2362.1986.tb01335.x; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; JENSEN JA, 1991, ARCH SURG-CHICAGO, V126, P1131; JOHNELL O, 1984, CALCIFIED TISSUE INT, V36, P354, DOI 10.1007/BF02405345; JONES JK, 1992, J ORAL MAXIL SURG, V50, P237, DOI 10.1016/0278-2391(92)90318-T; KONNO S, 1991, BIOCHEM INT, V25, P7; KRALL EA, 1991, J BONE MINER RES, V6, P331; KYRO A, 1993, ANN CHIR GYNAECOL FE, V82, P254; LAU KHW, 1995, J CLIN ENDOCR METAB, V80, P2347, DOI 10.1210/jc.80.8.2347; LAWRENCE WT, 1984, BRIT J PLAST SURG, V37, P216; LEHMANN HW, 1992, EUR J PEDIATR SURG, V2, P281, DOI 10.1055/s-2008-1063459; LIND J, 1991, CLIN ORTHOP RELAT R, P211; LINDQUIST O, 1981, SCAND J CLIN LAB INV, V41, P215, DOI 10.3109/00365518109092037; MACEY LR, 1989, J BONE JOINT SURG AM, V71A, P722, DOI 10.2106/00004623-198971050-00014; *MATHSOFT INC, 1996, SPLUS VERS 3 4; MCNAIR P, 1980, MINER ELECTROL METAB, V3, P94; MELLSTROM D, 1982, AGE AGEING, V11, P45, DOI 10.1093/ageing/11.1.45; MOSELY LH, 1978, PLAST RECONSTR SURG, V61, P570, DOI 10.1097/00006534-197804000-00013; MULLER ME, 1990, MANUAL INTERNAL FIXA, P144; NOLAN J, 1985, PLAST RECONSTR SURG, V75, P544, DOI 10.1097/00006534-198504000-00018; NORDENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1556, DOI 10.1001/jama.264.12.1556; PAI MP, 1972, SURG GYNECOL OBSTETR, V135, P756; PAPPAS AM, 1968, SURG GYNECOL OBSTETR, V126, P1287; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; RAMP WK, 1991, P SOC EXP BIOL MED, V197, P36; RICO H, 1991, MINER ELECTROL METAB, V17, P321; RIEFKOHL R, 1986, PLAST RECONSTR SURG, V77, P592, DOI 10.1097/00006534-198604000-00013; ROKKANEN P, 1964, ACTA ORTHOP SCAND, V35, P21; ROUX C, 1994, BONE, V15, P41, DOI 10.1016/8756-3282(94)90890-7; RUNDGREN A, 1984, MECH AGEING DEV, V28, P273, DOI 10.1016/0047-6374(84)90027-7; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211; SARIN CL, 1974, JAMA-J AM MED ASSOC, V229, P1327, DOI 10.1001/jama.229.10.1327; *SAS I INC, 1997, SAS STAT AN SYST VER; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SELZNICK HS, 1993, EFFECT CIGARETTE SMO; SILCOX DH, 1995, ORTHOP T, V19, P39; Simmons D J, 1967, Clin Orthop Relat Res, V55, P201; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SOWERS MF, 1985, PREV MED, V14, P585, DOI 10.1016/0091-7435(85)90079-9; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; STINCHFIELD FE, 1956, J BONE JOINT SURG AM, V38, P270, DOI 10.2106/00004623-195638020-00003; UENG W, 1992, 59 ANN AM AC ORTH SU; VANADRICHEM LNA, 1992, BRIT J PLAST SURG, V45, P9, DOI 10.1016/0007-1226(92)90106-8; VANHEMERT AM, 1990, AM J EPIDEMIOL, V132, P123, DOI 10.1093/oxfordjournals.aje.a115624; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WRAY JB, 1967, CLIN ORTHOP RELAT R, V50, P324; YABLON IG, 1968, J TRAUM, V8, P186, DOI 10.1097/00005373-196803000-00007; ZIMMERMANN B, 1994, EUR J CELL BIOL, V63, P114	75	130	138	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	1999		365					184	200		10.1097/00003086-199908000-00024			17	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	225PR	WOS:000081970400024	10627703				2022-02-06	
J	Yeates, KO; Luria, J; Bartkowski, H; Rusin, J; Martin, L; Bigler, ED				Yeates, KO; Luria, J; Bartkowski, H; Rusin, J; Martin, L; Bigler, ED			Postconcussive symptoms in children with mild closed head injuries	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	26th Annual Meeting of the International-Neuropsychological-Society	FEB 04-05, 1998	HONOLULU, HI	Int Neuropsychol Soc		mild head injury; postconcussive symptoms	TRAUMATIC BRAIN INJURY; ADOLESCENTS; SCALE	Objective: To examine the incidence and neuropsychological, behavioral, and neuroimaging correlates of postconcussive symptoms (PCS) in children with mild closed head injuries (CHI). Design: 26 Children with mild CHI and 8 of their uninjured siblings, from 8 to 15 years old, were recruited prospectively and assessed at baseline (ie, within 7 days of injury) and at 3 months postinjury. Parents rated PCS, motivation and affective lability, and behavioral adjustment. Baseline ratings assessed premorbid functioning retrospectively, and follow-up ratings assessed postinjury status. On both occasions, children completed neuropsychological testing, and those with mild CHI also underwent magnetic resonance imaging (MRI). Results: Children with mild CHI did not differ from siblings in baseline ratings of premorbid PCS but displayed higher ratings on several PCS at 3 months postinjury. Thirty-five percent of children with mild CHI showed increases in PCS, compared with baseline premorbid ratings, but none of the siblings did so. Children with mild CHI whose PCS increased from premorbid levels showed poorer neuropsychological functioning at baseline than did children whose PCS did not increase, although the differences had partially resolved by 3 months. They also displayed decreased motivation over time. Their behavioral adjustment was poorer and they had smaller white matter volumes on MRI, but the latter differences were present at baseline and did not change over time, suggesting that they existed prior to the injury. Conclusion: Postinjury increases in PCS occur in a sizable minority of children with mild CHI and more often than among uninjured siblings. Increases in PCS following mild CHI are associated with premorbid neurological and psychosocial vulnerability, but also with postinjury decrements in neuropsychological and neurobehavioral functioning.	Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; Childrens Hosp, Dept Neurosurg, Columbus, OH 43205 USA; Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA		Yeates, KO (corresponding author), Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.		Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892			Achenbach T., 1991, INTEGRATIVE GUIDE 19; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM MED ASS, 1994, DIAGN STAT MAN MENT; *AM MED ASS, 1997, INT CLASS DIS; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 2013, STAT POWER ANAL BEHA; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gerring JP, 1996, PSYCHIAT RES, V63, P205, DOI 10.1016/0165-1781(96)02841-7; Gerson AC, 1996, PSYCHIAT RES, V65, P189, DOI 10.1016/S0165-1781(96)02851-X; Giedd JN, 1996, CEREB CORTEX, V6, P551, DOI 10.1093/cercor/6.4.551; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KRAUS JF, 1995, TRAUMATIC HEAD INJUR; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; TAYLOR HG, 1995, TRAUMATIC HEAD INJUR; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; YEATES KO, PEDIAT NEUROPSYCHOLO	31	130	130	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1999	14	4					337	350		10.1097/00001199-199908000-00003			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Rehabilitation	224LW	WOS:000081901400004	10407207				2022-02-06	
J	Turski, L; Huth, A; Sheardown, M; McDonald, F; Neuhaus, R; Schneider, HH; Dirnagl, U; Wiegand, F; Jacobsen, P; Ottow, E				Turski, L; Huth, A; Sheardown, M; McDonald, F; Neuhaus, R; Schneider, HH; Dirnagl, U; Wiegand, F; Jacobsen, P; Ottow, E			ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						glutamate antagonists; ischemic brain damage; traumatic brain injury; therapeutic time window	METHYL-D-ASPARTATE; RAT CORTICAL MEMBRANES; ACUTE ISCHEMIC STROKE; QUISQUALATE RECEPTORS; CEREBRAL-ISCHEMIA; AMINO-ACIDS; GLUTAMATE; BINDING; PHENCYCLIDINE; AFFINITY	Stroke and head trauma are worldwide public health problems and leading causes of death and disability in humans, yet, no adequate neuroprotective treatment is available for therapy. Glutamate antagonists are considered major drug candidates for neuroprotection in stroke and trauma. However, N-methyl-D-aspartate antagonists failed clinical trials because of unacceptable side effects and short therapeutic time window. alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) antagonists derived from the quinoxalinedione scaffold cannot be used in humans because of their insolubility and resulting renal toxicity. Therefore, achieving water solubility of quinoxalinediones without loss of selectivity and potency profiles becomes a major challenge for medicinal chemistry. One of the major tenets in the chemistry of glutamate antagonists is that the incorporation of phosphonate into the glutamate framework results in preferential N-methyl-D-aspartate antagonism. Therefore, synthesis of phosphonate derivatives of quinoxalinediones was not pursued because of a predicted loss of their selectivity toward AMPA. Here, we report that introduction of a methylphosphonate group into the quinoxalinedione skeleton leaves potency as AMPA antagonists and selectivity for the AMPA receptor unchanged and dramatically improves solubility. One such novel phosphonate quinoxalinedione derivative and competitive AMPA antagonist ZK200775 exhibited a surprisingly long therapeutic time window of >4 h after permanent occlusion of the middle cerebral artery in rats and was devoid of renal toxicity. Furthermore, delayed treatment with ZK200775 commencing 2 h after onset of reperfusion in transient middle cerebral artery occlusion resulted in a dramatic reduction of the infarct size. ZK200775 alleviated also both cortical and hippocampal damage induced by head trauma in the rat. These observations suggest that phosphonate quinoxalinedione-based AMPA antagonists may offer new prospects for treatment of stroke and trauma in humans.	Schering AG, Res Labs, D-13342 Berlin, Germany; Novo Nordisk AS, DK-2760 Malov, Denmark; Humboldt Univ, Dept Neurol, D-10098 Berlin, Germany		Turski, L (corresponding author), UCL, Eisai London Res Labs, Bernard Katz Bldg,Gower St, London WC1E 6BT, England.	lturski@elrl.co.uk		Dirnagl, Ulrich/0000-0003-0755-6119			Barinaga M, 1996, SCIENCE, V272, P664; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BUCHAN AM, 1990, CEREBROVAS BRAIN MET, V2, P1; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; CANTON T, 1992, J PHARM PHARMACOL, V44, P812, DOI 10.1111/j.2042-7158.1992.tb03211.x; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Deutsch SI, 1997, CLIN NEUROPHARMACOL, V20, P375, DOI 10.1097/00002826-199710000-00001; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARING R, 1991, J NEUROCHEM, V57, P323, DOI 10.1111/j.1471-4159.1991.tb02131.x; HARRISON NL, 1985, BRIT J PHARMACOL, V84, P381, DOI 10.1111/j.1476-5381.1985.tb12922.x; Herrling P, 1997, EXCITATORY AMINO ACI; HONORE T, 1989, BIOCHEM PHARMACOL, V38, P3207, DOI 10.1016/0006-2952(89)90615-1; HONORE T, 1988, J NEUROCHEM, V51, P457, DOI 10.1111/j.1471-4159.1988.tb01060.x; HONORE T, 1989, NEUROSCI LETT, V65, P47; IKONOMIDOU C, 1997, ANN NY ACAD SCI, V827, P394; LIPPERT K, 1994, EUR J PHARMACOL, V253, P207, DOI 10.1016/0014-2999(94)90193-7; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; OLVERMAN HJ, 1986, EUR J PHARMACOL, V131, P161, DOI 10.1016/0014-2999(86)90533-9; Pinna G, 1997, P NATL ACAD SCI USA, V94, P2719, DOI 10.1073/pnas.94.6.2719; PULSINELLI W, 1992, LANCET, V339, P533, DOI 10.1016/0140-6736(92)90347-6; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SHEARDOWN MJ, 1993, BRAIN RES, V607, P189, DOI 10.1016/0006-8993(93)91506-N; ShimizuSasamata M, 1996, J PHARMACOL EXP THER, V276, P84; STEPHENS DN, 1985, PSYCHOPHARMACOLOGY, V85, P143, DOI 10.1007/BF00428403; STEPPUHN KG, 1993, P NATL ACAD SCI USA, V90, P6889, DOI 10.1073/pnas.90.14.6889; STIRLING JM, 1989, NEUROPHARMACOLOGY, V28, P1, DOI 10.1016/0028-3908(89)90059-2; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; TURSKI L, 1980, PSYCHOPHARMACOLOGY, V71, P35, DOI 10.1007/BF00433249; Turski L., 1996, Society for Neuroscience Abstracts, V22, P1529; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; XUE D, 1994, J CEREBR BLOOD F MET, V14, P251, DOI 10.1038/jcbfm.1994.32	33	130	130	0	4	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	SEP 1	1998	95	18					10960	10965		10.1073/pnas.95.18.10960			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116NB	WOS:000075730500110	9724812	Green Published			2022-02-06	
J	Kitazaki, S; Griffin, MJ				Kitazaki, S; Griffin, MJ			Resonance behaviour of the seated human body and effects of posture	JOURNAL OF BIOMECHANICS			English	Article						whole-body vibration; resonances; experimental modal analysis; posture	VIBRATION	Understanding of the resonance behaviour of the human body is important in the identification of vibration frequencies and body postures associated with back problems. In this study, experimental modal analysis was applied to whole-body vibration. Eight subjects were exposed to vertical random vibration while adopting three different postures on a rigid seat without a backrest. Motions of the spine, pelvis and viscera in the mid-sagittal plane were derived from skin-mounted accelerometers; head responses were measured using a bite-bar. Eight modes of vibration response were extracted below 10 Hz. A principal resonance of the human body at about 5 Hz consisted of an entire body mode, in which the skeleton moved vertically due to axial and shear deformations of buttocks tissue, in phase with a vertical visceral mode, and a bending mode of the upper thoracic and cervical spine. A bending mode of the lumbar and lower thoracic spine was found with a pitching mode of the head in the next higher mode located close to the principal mode. The second principal resonance at about 8 Hz corresponded to pitching modes of the pelvis and a second visceral mode. When subjects changed posture from erect to slouched, the natural frequency of the entire body mode decreased, resulting in a decrease in the principal resonance frequency. Shear deformation of buttocks tissue increased in the entire body mode due to the same change of posture. The complex body motions suggest that any forces causing injury from whole-body vibration will not be well-predicted by biodynamic models incapable of representing the appropriate body motions and the effects of body posture. It seems likely that the greatest risk of back problems will arise from the bending deformations of the spine. (C) 1998 Elsevier Science Ltd. All rights reserved.	Univ Southampton, Inst Sound & Vibrat Res, Human Factors Res Unit, Southampton SO17 1BJ, Hants, England		Griffin, MJ (corresponding author), Univ Southampton, Inst Sound & Vibrat Res, Human Factors Res Unit, Southampton SO17 1BJ, Hants, England.			Griffin, Michael/0000-0003-0743-9502			BOVENZI M, 1997, P INT C WHOL BOD VIB, P1; COERMANN RR, 1962, HUM FACTORS, V4, P227, DOI 10.1177/001872086200400502; DOBSON BJ, 1987, MECH SYST SIGNAL PR, V1, P29, DOI 10.1016/0888-3270(87)90081-1; FAIRLEY TE, 1989, J BIOMECH, V22, P81, DOI 10.1016/0021-9290(89)90031-6; Griffin M., 1990, HDB HUMAN VIBRATION; HARRIS J, 1987, J VEHICLE DESIGN, V8, P553; HINZ B, 1988, CLIN BIOMECH, V3, P241, DOI 10.1016/0268-0033(88)90044-7; HULSHOF C, 1987, INT ARCH OCC ENV HEA, V59, P205, DOI 10.1007/BF00377733; KITAZAKI S, 1995, J BIOMECH, V28, P885, DOI 10.1016/0021-9290(95)95279-E; KJELLBERG A, 1994, ARBETE HALSA VETENSK, V41; MAGNUSSON M, 1993, CLIN BIOMECH, V8, P5, DOI 10.1016/S0268-0033(05)80003-8; Paddan GS, 1993, 218 ISVR U SOUTH; PANJABI MM, 1986, J BONE JOINT SURG AM, V68A, P695, DOI 10.2106/00004623-198668050-00009; PAYNE PR, 1971, AMRLTR7035; SANDOVER J, 1978, AVIAT SPACE ENVIR MD, V49, P335; SANDOVER J, 1987, ERGONOMICS, V30, P675; WHITE GH, 1962, HUM FACTORS, V4, P275, DOI 10.1177/001872086200400504; [No title captured]	18	130	132	3	24	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	FEB	1998	31	2					143	149					7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	ZR430	WOS:000073974800005	9593207				2022-02-06	
J	Wade, CE; Grady, JJ; Kramer, GC; Younes, RN; Gehlsen, K; Holcroft, JW				Wade, CE; Grady, JJ; Kramer, GC; Younes, RN; Gehlsen, K; Holcroft, JW			Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	14th Bodensee Symposium on Microcirculation: Small Volume Resuscitation in Head Injury	JUN 14-16, 1996	BODENSEE, GERMANY				7.5-PERCENT SODIUM-CHLORIDE; MULTICENTER TRIAL; RESUSCITATION; DEXTRAN; SHOCK	Background: Resuscitation with hypertonic saline/dextran (HSD) has been suggested to be efficacious in patients who have traumatic brain injury and are hypotensive. We undertook a cohort analysis of individual patient data from previous prospective randomized double-blinded trials to evaluate improvements in survival at 24 hours and discharge after initial treatment with HSD in patients who had traumatic brain injury (head region Abbreviated Injury Score greater than or equal to 4) and hypotension (systolic blood pressure less than or equal to 90 mm Hg). Methods: All variables and end points were defined before initiation of data handling. Investigators were blind as to the treatment. Case report forms were received from six studies. Of these, 223 patients met the inclusion for traumatic brain injury. Comparisons between HSD and standard of care were made using stratified analysis and logistic regression to assess efficacy, confounding, and interaction. Potential confounding variables of pre-fluid treatment, Glasgow Coma Scale score (3-8 vs. 9-15), injury type, and systolic blood pressure can be considered a priori factors that were known before randomization. Effects of the various trials was also considered. Results: Treatment with HSD resulted in a survival until discharge of 37.9% (39 of 103) compared with 26.9% (32 of 119) with standard of care (p = 0.080). Using logistic regression, adjusting for trial and potential confounding variables, the treatment effect can be summarized by the odds ratio of 2.12 (p = 0.048) for survival until discharge. Conclusion: Patients who have traumatic brain injuries in the presence of hypotension and receive HSD are about twice as likely to survive as those who receive standard of care.	MEDISAN PHARMACEUT INC,UPPSALA,SWEDEN; UNIV TEXAS,MED BRANCH,DEPT BIOSTAT,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT ANESTHESIOL,GALVESTON,TX 77550; UNIV SAO PAULO,SCH MED,TRAUMA SERV,SAO PAULO,BRAZIL; UNIV SAO PAULO,SCH MED,DEPT SURG,SAO PAULO,BRAZIL; SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA; UNIV CALIF DAVIS,MED CTR,SCH MED,DEPT SURG,SACRAMENTO,CA 95817								Agresti A., 1990, CATEGORICAL DATA ANA; *AM ASS NEUR SURG, 1995, GUID MAN SEV HEAD IN; American Association for Automotive Medicine, 1990, ABBR INJ SCAL; American College of Surgeons, 1993, ADV TRAUM LIF SUPP P; BULLOCK R, 1995, CRIT CARE MED, V3, P448; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; FELDMAN J A, 1991, Journal of Emergency Medicine, V9, P465, DOI 10.1016/0736-4679(91)90219-6; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; Hosmer DW, 1989, APPLIED LOGISTIC REG; JENNETT B, 1975, LANCET, V1, P480; MANINGAS PA, 1989, AM J SURG, V157, P528, DOI 10.1016/0002-9610(89)90654-5; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; *SAS I INC, 1992, SAS STAT US GUID, V2; *SAS I INC, 1992, SAS STAT US GUID, V1; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; YOUNES RN, 1994, SHOCK S, V1, P2; YOUNES RN, 1992, SURGERY, V111, P70; ZORNOW MH, 1995, CRIT CARE MED, V3, P488	23	130	142	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1997	42	5		S			S61	S65		10.1097/00005373-199705001-00011			5	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	XE879	WOS:A1997XE87900012	9191698				2022-02-06	
J	ROTHWELL, NJ; STRIJBOS, PJLM				ROTHWELL, NJ; STRIJBOS, PJLM			CYTOKINES IN NEURODEGENERATION AND REPAIR	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						CYTOKINES; NEURODEGENERATION; INTERLEUKINS; NEUROPROTECTION	RAT-BRAIN; GROWTH-FACTOR; NEURONAL DIFFERENTIATION; INTERLEUKIN-1; CULTURES; INVOLVEMENT; SURVIVAL; INJURY; CELLS; IL-1	Cytokines have diverse actions in the brain, some of which may facilitate either neurodegeneration or neuroprotection. The expression of cytokines, particularly interleukins-1 and -6 (IL-1, IL-6) and tumor necrosis factor alpha, is rapidly and markedly induced in response to experimentally induced or clinical neurodegeneration. We have demonstrated that central administration of the IL-1 receptor antagonist (IL-1ra) markedly inhibits neurodegeneration induced by focal cerebral ischaemia, local infusion of glutamate receptor agonists or traumatic brain injury in the rat. In contrast, IL-1ra offers no I protection against degeneration of primary cortical neurones in culture caused by exposure to agonists of ionotrophic or metabotrophic receptors. In vivo, administration of IL-1 beta exacerbates ischaemic brain damage, whereas in cell culture, exogenous IL-1 is neuroprotective at concentrations in the nM range, an effect which appears to be mediated by release of endogenous nerve growth factor. Higher concentrations of IL-1 (mu M range) are neurotoxic to neurones in culture and may mimic the involvement of IL-1 in neurodegeneration in vivo. Thus, excessive production of cytokines such as IL-1 appears to mediate experimentally induced neurodegeneration in vivo, while neuroprotective effects of low concentrations of the cytokine suggest a dual role for IL-1 in neuronal survival.	WELLCOME RES LABS, NEUROSCI RES GRP BLDG 120, DEPT MOLEC PHARMACOL, BECKENHAM BR3 3BS, KENT, ENGLAND		ROTHWELL, NJ (corresponding author), UNIV MANCHESTER, SCH BIOL SCI, 1124 STOPFORD BLDG, MANCHESTER M13 9PT, LANCS, ENGLAND.						ARAUJO DM, 1993, BRAIN RES, V600, P49, DOI 10.1016/0006-8993(93)90400-H; ARAUJO DM, 1992, ADV BEHAV BIOL, V40, P113; BANKS WA, 1989, BRAIN RES BULL, V23, P433, DOI 10.1016/0361-9230(89)90185-8; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; BRENNEMAN DE, 1992, J NEUROCHEM, V58, P454, DOI 10.1111/j.1471-4159.1992.tb09743.x; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CARMANKRAZAN M, 1991, J NEUROCHEM, V56, P663; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; FAGAN AM, 1990, EXP NEUROL, V110, P105, DOI 10.1016/0014-4886(90)90055-W; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HAUGEN PK, 1990, J NEUROSCI RES, V25, P443, DOI 10.1002/jnr.490250402; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; HILLHOUSE EW, 1993, BRIT J PHARMACOL, V109, P289, DOI 10.1111/j.1476-5381.1993.tb13567.x; KAMEGAI M, 1990, NEURON, V4, P429, DOI 10.1016/0896-6273(90)90055-K; LAWRENCE CB, 1994, IN PRESS BR J PHARM; LECHAN RM, 1990, BRAIN RES, V514, P134; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LODDICK S, 1995, SOC NEUR ABST, V20; LUI T, 1993, STROKE, V24, P1746; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P27; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MINAMI M, 1992, SOC NEUR ABSTR, V18; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; PLATASALAMAN CR, 1994, EUR J PHARM-MOLEC PH, V266, P1, DOI 10.1016/0922-4106(94)90202-X; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; RELTON JK, 1993, SOC NEUR ABSTR, V19; Rothwell N J, 1994, Adv Pharmacol, V25, P1, DOI 10.1016/S1054-3589(08)60428-7; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; ROTHWELL NJ, 1992, PERG S NEUR, V5, P115; SARDER M, 1993, BRAIN RES, V625, P347, DOI 10.1016/0006-8993(93)91080-C; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SHIMOHAMA S, 1993, BRAIN RES, V632, P296, DOI 10.1016/0006-8993(93)91164-N; SIMS JE, 1994, CLIN IMMUNOL IMMUNOP, V72, P9, DOI 10.1006/clin.1994.1100; STRIJBOS P, 1993, SOC NEUR ABSTR, V19; STRIJBOS PLJ, 1995, IN PRESS J NEUROSCI; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOULMOND S, 1995, IN PRESS BRAIN RES; UNSICKER K, 1992, DEV BRAIN RES, V65, P285, DOI 10.1016/0165-3806(92)90191-X; VANDAM AM, 1992, BRAIN RES, V588, P2391; WALUCKE P, 1988, DEV BRAIN RES, V40, P71; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F; YOSHIDA K, 1992, J NEUROCHEM, V59, P919, DOI 10.1111/j.1471-4159.1992.tb08331.x; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	52	130	130	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748			INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	JUN-JUL	1995	13	3-4					179	185		10.1016/0736-5748(95)00018-C			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	RG088	WOS:A1995RG08800006	7572274				2022-02-06	
J	JORGE, RE; ROBINSON, RG; STARKSTEIN, SE; ARNDT, SV; FORRESTER, AW; GEISLER, FH				JORGE, RE; ROBINSON, RG; STARKSTEIN, SE; ARNDT, SV; FORRESTER, AW; GEISLER, FH			SECONDARY MANIA FOLLOWING TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							SEIZURES; PATIENT; MONKEY	Objective: In this study patients were examined during the first year after traumatic brain injury to determine the presence of secondary mania. Method: A consecutive series of 66 patients with closed-bead injury were evaluated in the hospital and at 3-, 6-, and 12-month follow-ups. The patients were examined with a semistructured psychiatric interview and scales for measurement of impairment in activities of daily living, intellectual function, and social functioning. Patients fulfilling the DSM-III-R criteria for mania were compared to patients with major depression and to patients without affective disturbances in regard to their back-ground characteristics, impairment variables, and lesion locations. Results: Six patients (9%) met the criteria for mania at some point during follow-up. The presence of temporal basal polar lesions was significantly associated with secondary mania even when the effect of other lesion locations was taken into account. Secondary mania was not found to be associated with the severity of brain injury, degree of physical or cognitive impairment, level of social functioning, or previous family or personal history of psychiatric disorder. The duration of mania, however, appeared to be brief, lasting approximately 2 months. Conclusions: The 9% frequency of secondary mania in these patients with traumatic brain injury is significantly greater than that seen in other brain-injured populations (e.g., patients with stroke). The major correlate was the presence of a temporal basal polar lesion.	UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,MENT HLTH CLIN RES CTR,BIOSTAT CORE UNIT,IOWA CITY,IA 52242; RAUL CARREA INST NEUROL INVEST,BUENOS AIRES,ARGENTINA; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; UNIV MARYLAND,SCH MED,MARYLAND INST EMERGENCY MED SERV SYST,CTR SHOCK TRAUMA,DEPT SURG,BALTIMORE,MD 21201				Robinson, Robert/AAF-6191-2021; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-40355, MH-00163, MH-43271] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355, P50MH043271, P30MH043271] Funding Source: NIH RePORTER		ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; ADAMEC RE, 1983, BIOL PSYCHIAT, V18, P269; BAMRAH JS, 1991, B J PSYCHIATRY, V258, P117; BLACKWELL MJ, 1991, BRIT J PSYCHIAT, V159, P279, DOI 10.1192/bjp.159.2.279; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; CORN TH, 1983, BRIT J PSYCHIAT, V143, P74, DOI 10.1192/bjp.143.1.74; CSERNANSKY JG, 1988, BIOL PSYCHIAT, V23, P285, DOI 10.1016/0006-3223(88)90039-X; CUMMINGS JL, 1984, AM J PSYCHIAT, V141, P1084; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FAWCETT RG, 1991, J CLIN PSYCHIAT, V52, P352; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOGGANS FC, 1984, AM J PSYCHIAT, V141, P300; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; ISLES LJ, 1991, BRIT J PSYCHIAT, V159, P280, DOI 10.1192/bjp.159.2.280; JAMIESON RC, 1979, J CLIN PSYCHIAT, V40, P280; JORGE R, IN PRESS J AFFECTIVE; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; KHANNA R, 1991, J CLIN PSYCHIAT, V52, P280; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MARKOWITSCH HD, 1985, J COMP NEUROL, V242, P424; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MORAN MA, 1987, J COMP NEUROL, V256, P88, DOI 10.1002/cne.902560108; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; RUSSCHEN FT, 1987, J COMP NEUROL, V256, P175, DOI 10.1002/cne.902560202; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; STEVENS JR, 1990, PSYCHOL MED, V20, P529, DOI 10.1017/S0033291700017049; STOUDEMIRE A, 1984, AM J PSYCHIAT, V141, P1251; TENNENT T, 1937, P ROY SOC MED, V30, P1092; THIENHAUS OJ, 1984, AM J PSYCHIAT, V141, P1459, DOI 10.1176/ajp.141.11.1459; THOMAS CS, 1991, BRIT J PSYCHIAT, V158, P119, DOI 10.1192/bjp.158.1.119; Wing J. K., 1974, MEASUREMENT CLASSIFI; ZOLESE G, 1987, BRIT MED J, V295, P1026, DOI 10.1136/bmj.295.6605.1026	38	130	132	1	7	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	JUN	1993	150	6					916	921					6	Psychiatry	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychiatry	LD843	WOS:A1993LD84300012	8494069				2022-02-06	
J	SKOGSEID, IM; NORDBY, HK; URDAL, P; PAUS, E; LILLEAAS, F				SKOGSEID, IM; NORDBY, HK; URDAL, P; PAUS, E; LILLEAAS, F			INCREASED SERUM CREATINE-KINASE BB AND NEURON SPECIFIC ENOLASE FOLLOWING HEAD-INJURY INDICATES BRAIN-DAMAGE	ACTA NEUROCHIRURGICA			English	Article						CREATINE KINASE BB; NEURON SPECIFIC ENOLASE; COMPUTED TOMOGRAPHY; TRAUMATIC DAMAGE	CEREBROSPINAL-FLUID; COMPUTERIZED-TOMOGRAPHY; RADIOIMMUNOASSAY; ISOENZYMES; CSF; TRAUMA; INDEX; MILD	The aim of this study was to examine whether an increase in the serum concentrations of the two brain enzymes creatine kinase BB (CK-BB) and neuron specific enolase (NSE) can be demonstrated in patients with acute head injury and whether such an increase reflects release from damaged brain tissue. In 60 patients who had suffered minor to sever head injury, serial blood samples were drawn during the first hours after impact, and CK-BB and NSE were measured by radio-immuno-assay. Computed tomography (CT) was also performed shortly after admission to hospital, and was repeated 1-3 days later in selected patients. Increased serum concentrations of both CK-BB and NSE were found in 88% of the patients with moderate to severe head injury (group 1, n = 18) and in 23% of the patients with minor head injury (group 2, n = 42), whereas CT showed contusion in only 41% and 2% of the group 1 and 2 patients, respectively. The following findings suggest that the enzymes had been released from brain tissue: 1) The maximum concentrations of CK-BB and NSE correlated with the severity of injury as assessed clinically and with the volume of contusion as estimated from CT(r = 0.79 with CK-BB, r = 0.72 with NSE). 2) The maximum concentrations of CK-BB and NSE were closely correlated (r = 0.87). 3) The ratio between CK-BB and NSE was approximately the same in a subgroup of 10 patients with multiple trauma as in the group as a whole (median 2.2 versus 2.0). Measurements of the serum concentrations of CK-BB and NSE in patients with acute head trauma, therefore, appears to provide information about the presence and, to some degree, extent or the resulting brain injury. Further studies are required to reveal the value of such measurements in the management of patients with acute head trauma.	ULLEVAL HOSP,DEPT CLIN CHEM,N-0407 OSLO 4,NORWAY; ULLEVAL HOSP,DEPT NEURORADIOL,OSLO 1,NORWAY; NORWEGIAN RADIUM HOSP,CENT RES LAB,OSLO 3,NORWAY				Paus, Elisabeth/F-9678-2014				BAKAY RAE, 1986, NEUROSURGERY, V18, P376, DOI 10.1227/00006123-198603000-00026; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; CHANDLER WL, 1988, STROKE, V19, P251, DOI 10.1161/01.STR.19.2.251; COOPER PR, 1983, NEUROSURGERY, V12, P536, DOI 10.1227/00006123-198305000-00010; HANS P, 1983, J NEUROSURG, V58, P689, DOI 10.3171/jns.1983.58.5.0689; HANS P, 1989, J NEUROSURG, V71, P54, DOI 10.3171/jns.1989.71.1.0054; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; JENKINS A, 1986, LANCET, V2, P445; KASTE M, 1981, J NEUROSURG, V55, P511, DOI 10.3171/jns.1981.55.4.0511; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; NIEDEGGEN A, 1986, ACTA NEUROCHIR WIEN, V101, P117; NORDBY HK, 1985, ACTA NEUROCHIR, V76, P131, DOI 10.1007/BF01418475; NORDBY HK, 1982, ACTA NEUROCHIR, V65, P93, DOI 10.1007/BF01405445; PAUS E, 1989, CLIN CHEM, V35, P2034; PHILLIPS JP, 1980, BRIT MED J, V281, P777, DOI 10.1136/bmj.281.6243.777; RABOW L, 1985, ACTA NEUROCHIR, V76, P137, DOI 10.1007/BF01418476; RABOW L, 1989, ACTA NEUROCHIR, V100, P155, DOI 10.1007/BF01403604; SCHWARTZ JG, CLIN CHEM, V35, P651; TEASDALE G, 1974, LANCET, V2, P81; URDAL P, 1983, CLIN CHEM, V29, P310; URDAL P, 1981, CLIN CHEM, V27, P83	22	130	136	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1992	115	3-4					106	111		10.1007/BF01406367			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HR487	WOS:A1992HR48700007	1605077				2022-02-06	
J	LEWIN, W				LEWIN, W			CEREBROSPINAL FLUID RHINORRHOEA IN CLOSED HEAD INJURIES	BRITISH JOURNAL OF SURGERY			English	Article																	ADSON AW, 1949, ARCH SURG-CHICAGO, V58, P623, DOI 10.1001/archsurg.1949.01240030633006; [Anonymous], 1942, Proc R Soc Med, V35, P805; Cairns H., 1937, J LARYNG, V52, P589, DOI 10.1017/S0022215100043991; Cushing H, 1927, SURG GYNECOL OBSTET, V44, P721; Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001; Dandy WE, 1944, ARCH SURG-CHICAGO, V49, P75, DOI 10.1001/archsurg.1944.01230020080001; ECKER A, 1947, J NEUROSURG, V4, P177, DOI 10.3171/jns.1947.4.2.0177; Eden K, 1942, BRIT J SURG, V29, P299, DOI 10.1002/bjs.18002911505; FRIBOURGBLANC O, 1934, REV NEUROL, V2, P51; German WJ, 1944, J NEUROSURG, V1, P60, DOI 10.3171/jns.1944.1.1.0060; GRAHAM TO, 1937, J LARYNGOL OTOL, V52, P344; JOHNSON RT, 1947, BRIT J SURG        S, V1, P141; LAWSON A, 1934, T OPHTHAL SOC UK, V54, P307; Leigh AD, 1943, LANCET, V1, P38; LEWIN W, 1951, BRIT MED J, V1, P1, DOI 10.1136/bmj.1.4696.1; PEET M. M., 1928, NEW YORK STATE J MED, V28, P555; Plum FA, 1931, ARCHIV OTOLARYNGOL, V13, P84; SCHEPPEGRELL, 1898, J AM MED ASS, V30, P480; SMALL J M, 1947, Br J Surg, V55, P62; TAYLOR J, 1934, T OPHTHAL SOC UK, V54, P312; Teachenor FR, 1927, J AMER MED ASSOC, V88, P0987, DOI 10.1001/jama.1927.02680390015005	21	130	133	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0007-1323			BRIT J SURG	Br. J. Surg.		1954	42	171					1	18		10.1002/bjs.18004217102			18	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	UZ987	WOS:A1954UZ98700001	13190185				2022-02-06	
J	Barnes, DE; Byers, AL; Gardner, RC; Seal, KH; Boscardin, WJ; Yaffe, K				Barnes, Deborah E.; Byers, Amy L.; Gardner, Raquel C.; Seal, Karen H.; Boscardin, W. John; Yaffe, Kristine			Association of Mild Traumatic Brain Injury With and Without Loss of Consciousness With Dementia in US Military Veterans	JAMA NEUROLOGY			English	Article							FOOTBALL-LEAGUE PLAYER; HEAD-INJURY; ALZHEIMERS-DISEASE; INCREASED RISK; ENCEPHALOPATHY; CONCUSSION; HISTORY; ONSET; AGE	IMPORTANCE Traumatic brain injury (TBI) is common in both veteran and civilian populations. Prior studies have linked moderate and severe TBI with increased dementia risk, but the association between dementia and mild TBI, particularly mild TBI without loss of consciousness (LOC), remains unclear. OBJECTIVE To examine the association between TBI severity, LOC, and dementia diagnosis in veterans. DESIGN, SETTING, AND PARTICIPANTS This cohort study of all patients diagnosed with a TBI in the Veterans Health Administration health care system from October 1, 2001, to September 30, 2014, and a propensity-matched comparison group. Patients with dementia at baseline were excluded. Researchers identified TBIs through the Comprehensive TBI Evaluation database, which is restricted to Iraq and Afghanistan veterans, and the National Patient Care Database, which includes veterans of all eras. The severity of each TBI was based on the most severe injury recorded and classified as mild without LOC, mild with LOC, mild with LOC status unknown, or moderate or severe using Department of Defense or Defense and Veterans Brain Injury Center criteria. International Classification of Diseases, Ninth Revision codes were used to identify dementia diagnoses during follow-up and medical and psychiatric comorbidities in the 2 years prior to the index date. MAIN OUTCOMES AND MEASURES Dementia diagnosis in veterans who had experienced TBI with or without LOC and control participants without TBI exposure. RESULTS The study included 178 779 patients diagnosed with a TBI in the Veterans Health Administration health care system and 178 779 patients in a propensity-matched comparison group. Veterans had a mean (SD) age of nearly 49.5 (18.2) years at baseline; 33 250 (9.3%) were women, and 259 136 (72.5%) were non-Hispanic white individuals. Differences between veterans with and without TBI were small. A total of 4698 veterans (2.6%) without TBI developed dementia compared with 10 835 (6.1%) of those with TBI. After adjustment for demographics and medical and psychiatric comobidities, adjusted hazard ratios for dementia were 2.36 (95% Cl, 2.10-2.66) for mild TBI without LOC, 2.51 (95% Cl, 2.29-2.76) for mild TBI with LOC, 3.19 ( 95% Cl, 3.05-3.33) for mild TBI with LOC status unknown, and 3.77 ( 95% Cl, 3.63-3.91) for moderate to severe TBI. CONCLUSIONS AND RELEVANCE In this cohort study of more than 350 000 veterans, even mild TBI without LOC was associated with more than a 2-fold increase in the risk of dementia diagnosis. Studies of strategies to determine mechanisms, prevention, and treatment of TBI-related dementia in veterans are urgently needed.	[Barnes, Deborah E.; Byers, Amy L.; Gardner, Raquel C.; Seal, Karen H.; Boscardin, W. John; Yaffe, Kristine] San Francisco Vet Affairs Hlth Care Syst, 4150 Clement St,151R, San Francisco, CA 94121 USA; [Barnes, Deborah E.; Byers, Amy L.; Seal, Karen H.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Barnes, Deborah E.; Byers, Amy L.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Seal, Karen H.; Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA		Barnes, DE (corresponding author), San Francisco Vet Affairs Hlth Care Syst, 4150 Clement St,151R, San Francisco, CA 94121 USA.	deborah.barnes@ucsf.edu			US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); US Department of Veterans AffairsUS Department of Veterans Affairs; Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095, 1I01CX001246]	This work is supported by the US Army Medical Research and Material Command, the US Department of Veterans Affairs, and the Chronic Effects of Neurotrauma Consortium (grants W81XWH-13-2-0095 and 1I01CX001246).	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; [Anonymous], 2016, SURV CAS DEF; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chu SF, 2016, ASIA-PAC J PUBLIC HE, V28, P519, DOI 10.1177/1010539516662956; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, 2010, DEF CTR EXC PSYCH HL; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; Institute of Medicine, 2008, LONG TERM CONS TRAUM, V7; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; LoBue C, 2017, CLIN NEUROPSYCHOL, V31, P85, DOI 10.1080/13854046.2016.1257069; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2016, NEUROSURG CLIN N AM, V27, P529, DOI 10.1016/j.nec.2016.05.009; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Weiner MW, 2017, NEUROLOGY, V89, P1923, DOI 10.1212/WNL.0000000000004608; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604	46	129	129	2	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	SEP	2018	75	9					1055	1061		10.1001/jamaneurol.2018.0815			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GT1EJ	WOS:000444201900005	29801145	Green Submitted, Green Published, Bronze	Y	N	2022-02-06	
J	van der Naalt, J; Timmerman, ME; de Koning, ME; van der Horn, HJ; Scheenen, ME; Jacobs, B; Hageman, G; Yilmaz, T; Roks, G; Spikman, JM				van der Naalt, Joukje; Timmerman, Marieke E.; de Koning, Myrthe E.; van der Horn, Harm J.; Scheenen, Myrthe E.; Jacobs, Bram; Hageman, Gerard; Yilmaz, Tansel; Roks, Gerwin; Spikman, Jacoba M.			Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study	LANCET NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION SYNDROME; SYMPTOMS; DEPRESSION; COMPLAINTS; HEALTH; IMPACT; SCALE; AGE	Background Mild traumatic brain injury (mTBI) accounts for most cases of TBI, and many patients show incomplete long-term functional recovery. We aimed to create a prognostic model for functional outcome by combining demographics, injury severity, and psychological factors to identify patients at risk for incomplete recovery at 6 months. In particular, we investigated additional indicators of emotional distress and coping style at 2 weeks above early predictors measured at the emergency department. Methods The UPFRONT study was an observational cohort study done at the emergency departments of three level-1 trauma centres in the Netherlands, which included patients with mTBI, defined by a Glasgow Coma Scale score of 13-15 and either post-traumatic amnesia lasting less than 24 h or loss of consciousness for less than 30 min. Emergency department predictors were measured either on admission with mTBI-comprising injury severity (GCS score, post-traumatic amnesia, and CT abnormalities), demographics (age, gender, educational level, pre-injury mental health, and previous brain injury), and physical conditions (alcohol use on the day of injury, neck pain, headache, nausea, dizziness)-or at 2 weeks, when we obtained data on mood (Hospital Anxiety and Depression Scale), emotional distress (Impact of Event Scale), coping (Utrecht Coping List), and post-traumatic complaints. The functional outcome was recovery, assessed at 6 months after injury with the Glasgow Outcome Scale Extended (GOSE). We dichotomised recovery into complete (GOSE=8) and incomplete (GOSE <= 7) recovery. We used logistic regression analyses to assess the predictive value of patient information collected at the time of admission to an emergency department (eg, demographics, injury severity) alone, and combined with predictors of outcome collected at 2 weeks after injury (eg, emotional distress and coping). Findings Between Jan 25, 2013, and Jan 6, 2015, data from 910 patients with mTBI were collected 2 weeks after injury; the final date for 6-month follow-up was July 6, 2015. Of these patients, 764 (84%) had post-traumatic complaints and 414 (45%) showed emotional distress. At 6 months after injury, outcome data were available for 671 patients; complete recovery (GOSE=8) was observed in 373 (56%) patients and incomplete recovery (GOSE <= 7) in 298 (44%) patients. Logistic regression analyses identified several predictors for 6-month outcome, including education and age, with a clear surplus value of indicators of emotional distress and coping obtained at 2 weeks (area under the curve [AUC] = 0.79, optimism 0.02; Nagelkerke R-2 = 0.32, optimism 0.05) than only emergency department predictors at the time of admission (AUC= 0.72, optimism 0.03; Nagelkerke R-2 = 0.19, optimism 0.05). Interpretation Psychological factors (ie, emotional distress and maladaptive coping experienced early after injury) in combination with pre-injury mental health problems, education, and age are important predictors for recovery at 6 months following mTBI. These findings provide targets for early interventions to improve outcome in a subgroup of patients at risk of incomplete recovery from mTBI, and warrant validation.	[van der Naalt, Joukje; de Koning, Myrthe E.; van der Horn, Harm J.; Jacobs, Bram; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 GZ Groningen, Netherlands; [Timmerman, Marieke E.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychometr & Stat, Groningen, Netherlands; [Scheenen, Myrthe E.; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Neuropsychol, Groningen, Netherlands; [Hageman, Gerard] Hosp Med Spectrum Twente Enschede, Dept Neurol, Enschede, Netherlands; [Yilmaz, Tansel; Roks, Gerwin] Elisabeth Hosp Tilburg, Dept Neurol, Tilburg, Netherlands		van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 GZ Groningen, Netherlands.	j.van.der.naalt@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763; van der Naalt, Joukje/0000-0001-9873-2418	Dutch Brain Foundation	Dutch Brain Foundation.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; de Koning ME, 2016, INJURY, V47, P2041, DOI 10.1016/j.injury.2016.04.036; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Gregorio GW, 2016, J NEUROTRAUM, V33, P696, DOI 10.1089/neu.2015.3900; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Maestas KL, 2014, J HEAD TRAUMA REHAB, V29, P407, DOI 10.1097/HTR.0b013e31828654b4; McIntyre A, 2013, NEUROREHABILITATION, V32, P409, DOI 10.3233/NRE-130862; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; SCHREURS PJG, 1984, GEDRAG GEZOND, V12, P101; Shin SS, 2017, BRAIN IMAGING BEHAV, V11, P591, DOI 10.1007/s11682-017-9684-0; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696	36	129	129	3	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2017	16	7					532	540		10.1016/S1474-4422(17)30117-5			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	EX4MH	WOS:000403208400016	28653646				2022-02-06	
J	Simon, MJ; Iliff, JJ				Simon, Matthew J.; Iliff, Jeffrey J.			Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						CSF; Glymphatic; Alzheimer's disease; Multiple sclerosis; Cerebral ischemia; Diurnal variation	TRAUMATIC BRAIN-INJURY; CEREBRAL AMYLOID ANGIOPATHY; CENTRAL-NERVOUS-SYSTEM; CHOROID-PLEXUS; INTERSTITIAL FLUID; ALZHEIMERS-DISEASE; BULK FLOW; AQUAPORIN 4; SUBARACHNOID HEMORRHAGE; NEUROMYELITIS-OPTICA	Cerebrospinal fluid (CSF) circulation and turnover provides a sink for the elimination of solutes from the brain interstitium, serving an important homeostatic role for the function of the central nervous system. Disruption of normal CSF circulation and turnover is believed to contribute to the development of many diseases, including neurodegenerative conditions such as Alzheimer's disease, ischemic and traumatic brain injury, and neuroinflammatory conditions such as multiple sclerosis. Recent insights into CSF biology suggesting that CSF and interstitial fluid exchange along a brain-wide network of perivascular spaces termed the 'glymphatic' system suggest that CSF circulation may interact intimately with glial and vascular function to regulate basic aspects of brain function. Dysfunction within this glial vascular network, which is a feature of the aging and injured brain, is a potentially critical link between brain injury, neuroinflammation and the development of chronic neurodegeneration. Ongoing research within this field may provide a powerful new framework for understanding the common links between neurodegenerative, neurovascular and neuroinflammatory disease, in addition to providing potentially novel therapeutic targets for these conditions. This article is part of a Special Issue entitled: Neuro Inflammation edited by Helga E. de Vries and Markus Schwaninger. (C) 2015 Elsevier B.V. All rights reserved.	[Simon, Matthew J.; Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd,Mail Code HRC5N, Portland, OR 97239 USA; [Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA; [Simon, Matthew J.; Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Grad Program Neurosci, Portland, OR 97239 USA		Iliff, JJ (corresponding author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd,Mail Code HRC5N, Portland, OR 97239 USA.	iliffj@ohsu.edu		Simon, Matthew/0000-0002-0065-6486	American Heart AssociationAmerican Heart Association [12SDG11820014]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS089709]; Paul G. Allen Family Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089709] Funding Source: NIH RePORTER	Work in the authors' lab is supported by grants from the American Heart Association (12SDG11820014), the National Institutes of Health (NS089709) and the Paul G. Allen Family Foundation. The authors thank Douglas Zeppenfeld for helpful discussion of this review article.	Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Akanuma S, 2015, FLUIDS BARRIERS CNS, V12, DOI 10.1186/s12987-015-0006-x; Albeck MJ, 1998, J NEUROSURG, V89, P275, DOI 10.3171/jns.1998.89.2.0275; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Attems J, 2011, NEUROPATH APPL NEURO, V37, P75, DOI 10.1111/j.1365-2990.2010.01137.x; Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BLACK PM, 1985, NEUROSURGERY, V17, P57, DOI 10.1227/00006123-198507000-00009; BLASBERG R, 1981, NEUROSURGERY, V9, P686, DOI 10.1227/00006123-198112000-00012; BRINKER T, 1991, J NEUROSURG, V74, P789, DOI 10.3171/jns.1991.74.5.0789; Brinker T, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-10; Camassa LM., 2015, GLIA; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Crane JM, 2010, NEUROSCIENCE, V168, P892, DOI 10.1016/j.neuroscience.2009.08.034; Cserr H F, 1988, Ann N Y Acad Sci, V529, P9, DOI 10.1111/j.1749-6632.1988.tb51415.x; CSERR HF, 1981, AM J PHYSIOL, V240, pF319, DOI 10.1152/ajprenal.1981.240.4.F319; CSERR HF, 1971, PHYSIOL REV, V51, P273, DOI 10.1152/physrev.1971.51.2.273; Damkier HH, 2013, PHYSIOL REV, V93, P1847, DOI 10.1152/physrev.00004.2013; Dandy WE, 1918, ANN SURG, V68, P569, DOI 10.1097/00000658-191812000-00001; DAVSON H, 1967, PHYSL CEREBROSPINAL; Davson H., 1996, PHYSL CSF BLOOD BRAI; de ROUGEMONT, 1960, J Neurophysiol, V23, P485; Deane R, 2009, CNS NEUROL DISORD-DR, V8, P16, DOI 10.2174/187152709787601867; Dreha-Kulaczewski S, 2015, J NEUROSCI, V35, P2485, DOI 10.1523/JNEUROSCI.3246-14.2015; Eid T, 2005, P NATL ACAD SCI USA, V102, P1193, DOI 10.1073/pnas.0409308102; Engelhardt B, 2012, TRENDS IMMUNOL, V33, P579, DOI 10.1016/j.it.2012.07.004; FEINBERG DA, 1987, RADIOLOGY, V163, P793, DOI 10.1148/radiology.163.3.3575734; Fenton RA, 2010, CELL MOL LIFE SCI, V67, P829, DOI 10.1007/s00018-009-0218-9; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Furman CS, 2003, P NATL ACAD SCI USA, V100, P13609, DOI 10.1073/pnas.2235843100; Gaberel T, 2014, STROKE, V45, P3092, DOI 10.1161/STROKEAHA.114.006617; Groothuis DR, 2007, J CEREBR BLOOD F MET, V27, P43, DOI 10.1038/sj.jcbfm.9600315; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Haglund M, 2006, INT J GERIATR PSYCH, V21, P681, DOI 10.1002/gps.1550; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Hawkes CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041636; Hawkes CA, 2011, ACTA NEUROPATHOL, V121, P431, DOI 10.1007/s00401-011-0801-7; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Hladky SB, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-26; Holmes BB, 2014, J BIOL CHEM, V289, P19855, DOI 10.1074/jbc.R114.549295; ICHIMURA T, 1991, BRAIN RES, V545, P103, DOI 10.1016/0006-8993(91)91275-6; Iliff JJ, 2015, LANCET NEUROL, V14, P977, DOI 10.1016/S1474-4422(15)00221-5; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, STROKE, V44, pS93, DOI 10.1161/STROKEAHA.112.678698; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Johanson C, 2011, TOXICOL PATHOL, V39, P186, DOI 10.1177/0192623310394214; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962; Kao LY, 2011, J BIOL CHEM, V286, P32563, DOI 10.1074/jbc.M111.249961; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Kervezee L, 2014, AAPS J, V16, P1029, DOI 10.1208/s12248-014-9625-4; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Lee HD, 2015, J NEUROSCI, V35, P11034, DOI 10.1523/JNEUROSCI.1625-15.2015; Lehtinen MK, 2011, NEURON, V69, P893, DOI 10.1016/j.neuron.2011.01.023; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Lochhead JJ, 2015, J CEREBR BLOOD F MET, V35, P371, DOI 10.1038/jcbfm.2014.215; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lu DC, 2011, J NEUROTRAUM; Lucchinetti CF, 2011, NEW ENGL J MED, V365, P2188, DOI 10.1056/NEJMoa1100648; MacAulay N, 2010, NEUROSCIENCE, V168, P941, DOI 10.1016/j.neuroscience.2009.09.016; Masseguin C, 2005, NEUROBIOL AGING, V26, P917, DOI 10.1016/j.neurobiolaging.2004.07.013; Matsumae M, 2014, J NEUROSURG, V120, P218, DOI 10.3171/2013.7.JNS121859; McCandless EE, 2008, AM J PATHOL, V172, P799, DOI 10.2353/ajpath.2008.070918; McCandless EE, 2006, J IMMUNOL, V177, P8053, DOI 10.4049/jimmunol.177.11.8053; Meyers SP, 2004, NEURORADIOLOGY, V46, P770, DOI 10.1007/s00234-004-1238-7; Millar ID, 2008, BIOCHEM BIOPH RES CO, V373, P550, DOI 10.1016/j.bbrc.2008.06.053; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Ohshiro K, 2001, ARCH HISTOL CYTOL, V64, P329, DOI 10.1679/aohc.64.329; Oi SZ, 2011, CHILD NERV SYST, V27, P1523, DOI 10.1007/s00381-011-1542-6; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Pascale Crissey L, 2011, Fluids Barriers CNS, V8, P21, DOI 10.1186/2045-8118-8-21; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; POLLAY M, 1967, AM J PHYSIOL, V213, P1031, DOI 10.1152/ajplegacy.1967.213.4.1031; PULLEN RGL, 1987, AM J PHYSIOL, V253, pF538, DOI 10.1152/ajprenal.1987.253.3.F538; Ramanathan A, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00136; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Rennels M L, 1990, Adv Neurol, V52, P431; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Roemer SF, 2007, BRAIN, V130, P1194, DOI 10.1093/brain/awl371; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; ROSENBERG GA, 1980, AM J PHYSIOL, V238, pF42, DOI 10.1152/ajprenal.1980.238.1.F42; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P426; Sheldon CA, 2015, PEDIATR RES, V77, P282, DOI 10.1038/pr.2014.188; Silberstein C, 2004, AM J PHYSIOL-RENAL, V287, pF501, DOI 10.1152/ajprenal.00439.2003; Siler DA, 2014, TRANSL STROKE RES, V5, P227, DOI 10.1007/s12975-014-0329-y; Silverberg GD, 2001, NEUROLOGY, V57, P1763, DOI 10.1212/WNL.57.10.1763; Smith AJ, 2015, TRENDS NEUROSCI, V38, P331, DOI 10.1016/j.tins.2015.04.006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SPECTOR R, 1989, J NEUROCHEM, V53, P1667, DOI 10.1111/j.1471-4159.1989.tb09229.x; Spector R, 2006, PHARM RES-DORDR, V23, P2515, DOI 10.1007/s11095-006-9091-5; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; SZENTISTVANYI I, 1984, AM J PHYSIOL, V246, pF835, DOI 10.1152/ajprenal.1984.246.6.F835; Thrane AS, 2015, TRENDS NEUROSCI, V38, P333, DOI 10.1016/j.tins.2015.04.009; Thrane AS, 2014, TRENDS NEUROSCI, V37, P620, DOI 10.1016/j.tins.2014.08.010; Thrane VR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02582; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Vinters HV, 2000, J NEUROPATH EXP NEUR, V59, P931, DOI 10.1093/jnen/59.11.931; Wang MH, 2012, J NEUROSCI, V32, P17948, DOI 10.1523/JNEUROSCI.1860-12.2012; Weller RO, 2008, BRAIN PATHOL, V18, P253, DOI 10.1111/j.1750-3639.2008.00133.x; Weller RO, 2009, ACTA NEUROPATHOL, V117, P1, DOI 10.1007/s00401-008-0457-0; Wolburg H, 2001, NEUROSCI LETT, V307, P77, DOI 10.1016/S0304-3940(01)01927-9; Wolburg H, 2010, ACTA NEUROPATHOL, V119, P75, DOI 10.1007/s00401-009-0627-8; Wolburg-Buchholz K, 2009, ACTA NEUROPATHOL, V118, P219, DOI 10.1007/s00401-009-0558-4; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yamada K, 2014, J EXP MED, V211, P387, DOI 10.1084/jem.20131685; Yamada S, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-36; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yang J, 2011, J ALZHEIMERS DIS, V27, P711, DOI 10.3233/JAD-2011-110725; Yang LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-107; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG ET, 1990, J ANAT, V170, P111; Zhao RB, 2009, J BIOL CHEM, V284, P4267, DOI 10.1074/jbc.M807665200	129	129	134	1	45	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	1879-260X		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	MAR	2016	1862	3			SI		442	451		10.1016/j.bbadis.2015.10.014			10	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Cell Biology	DF9BD	WOS:000371654400014	26499397	Green Accepted, Bronze			2022-02-06	
J	Nakka, VP; Prakash-babu, P; Vemuganti, R				Nakka, Venkata Prasuja; Prakash-babu, Phanithi; Vemuganti, Raghu			Crosstalk Between Endoplasmic Reticulum Stress, Oxidative Stress, and Autophagy: Potential Therapeutic Targets for Acute CNS Injuries	MOLECULAR NEUROBIOLOGY			English	Article						ER stress; Oxidative stress; Autophagy; Crosstalk; Acute CNS injury	UNFOLDED PROTEIN RESPONSE; TRANSIENT CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; INITIATION-FACTOR 2-ALPHA; CYTOCHROME-C BINDS; N-TERMINAL KINASE; ER STRESS; RAT MODEL; NADPH OXIDASE	Endoplasmic reticulum (ER) stress induces a variety of neuronal cell death pathways that play a critical role in the pathophysiology of stroke. ER stress occurs when unfolded/misfolded proteins accumulate and the folding capacity of ER chaperones exceeds the capacity of ER lumen to facilitate their disposal. As a consequence, a complex set of signaling pathways will be induced that transmit from ER to cytosol and nucleus to compensate damage and to restore the normal cellular homeostasis, collectively known as unfolded protein response (UPR). However, failure of UPR due to severe or prolonged stress leads to cell death. Following acute CNS injuries, chronic disturbances in protein folding and oxidative stress prolong ER stress leading to sustained ER dysfunction and neuronal cell death. While ER stress responses have been well studied after stroke, there is an emerging need to study the association of ER stress with other cell pathways that exacerbate neuronal death after an injury. In this review, we summarize the current understanding of the role for ER stress in acute brain injuries, highlighting the diverse molecular mechanisms associated with ER stress and its relation to oxidative stress and autophagy. We also discussed the existing and developing therapeutic options aimed to reduce ER stress to protect the CNS after acute injuries.	[Nakka, Venkata Prasuja; Vemuganti, Raghu] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA; [Nakka, Venkata Prasuja; Prakash-babu, Phanithi] Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Hyderabad 500134, Andhra Pradesh, India		Vemuganti, R (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA.	vemuganti@neurosurgery.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS082957, R03NS083007] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS082957, R03 NS083007] Funding Source: Medline		Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Aoyama K, 2005, J CEREBR BLOOD F MET, V25, P358, DOI 10.1038/sj.jcbfm.9600043; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Beresewicz M, 2006, NEUROCHEM INT, V48, P568, DOI 10.1016/j.neuint.2005.11.020; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bhandary B, 2013, INT J MOL SCI, V14, P434, DOI 10.3390/ijms14010434; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boland Barry, 2006, Molecular Aspects of Medicine, V27, P503, DOI 10.1016/j.mam.2006.08.009; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Cooper LL, 2013, J PHYSIOL-LONDON, V591, P5895, DOI 10.1113/jphysiol.2013.260521; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; DeGracia DJ, 2002, J CEREBR BLOOD F MET, V22, P127, DOI 10.1097/00004647-200202000-00001; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188; Egawa N, 2011, J BIOL CHEM, V286, P7947, DOI 10.1074/jbc.M110.156430; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujita E, 2007, HUM MOL GENET, V16, P618, DOI 10.1093/hmg/ddm002; Gao B, 2013, ACTA PHARMACOL SIN, V34, P657, DOI 10.1038/aps.2013.34; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Gogvadze V, 2006, BBA-BIOENERGETICS, V1757, P639, DOI 10.1016/j.bbabio.2006.03.016; Gorman AM, 2012, PHARMACOL THERAPEUT, V134, P306, DOI 10.1016/j.pharmthera.2012.02.003; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gotoh T, 2006, ARTERIOSCL THROM VAS, V26, P1439, DOI 10.1161/01.ATV.0000223900.67024.15; Gupta S., 2010, INT J CELL BIOL, V2010, DOI DOI 10.1155/2010/17021520169117; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harraz MM, 2008, STROKE, V39, P286, DOI 10.1161/STROKEAHA.107.511857; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; He ZH, 2012, EXP NEUROL, V238, P218, DOI 10.1016/j.expneurol.2012.08.025; Hetz C, 2014, NAT REV NEUROSCI, V15, P233, DOI 10.1038/nrn3689; Hetz C, 2009, GENE DEV, V23, P2294, DOI 10.1101/gad.1830709; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; Iadecola C, 1997, J NEUROSCI, V17, P9157; Itoh T, 2009, NEUROTOX RES, V16, P378, DOI 10.1007/s12640-009-9081-6; Jacobson J, 2002, J CELL SCI, V115, P1175; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Kahles T, 2012, CELL MOL LIFE SCI, V69, P2345, DOI 10.1007/s00018-012-1011-8; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Klee M, 2009, EMBO J, V28, P1757, DOI 10.1038/emboj.2009.90; Kohno K, 1997, NEUROSCI LETT, V224, P17, DOI 10.1016/S0304-3940(97)13459-0; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Kolattukudy PE, 2012, CIRC RES, V110, P174, DOI 10.1161/CIRCRESAHA.111.243212; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006; Kudo T, 2008, CELL DEATH DIFFER, V15, P364, DOI 10.1038/sj.cdd.4402276; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Lange PS, 2008, J EXP MED, V205, P1227, DOI 10.1084/jem.20071460; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee HY, 2013, SCI REP-UK, V3, DOI 10.1038/srep03398; Lehotsky J, 2009, CELL MOL NEUROBIOL, V29, P917, DOI 10.1007/s10571-009-9376-4; Lerner AG, 2012, CELL METAB, V16, P250, DOI 10.1016/j.cmet.2012.07.007; Li G, 2010, J CELL BIOL, V191, P1113, DOI 10.1083/jcb.201006121; Li G, 2009, J CELL BIOL, V186, P783, DOI 10.1083/jcb.200904060; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Martinez JA, 2006, J PHYSIOL BIOCHEM, V62, P303, DOI 10.1007/BF03165759; Matsuyama D, 2014, SPINAL CORD, V52, P9, DOI 10.1038/sc.2013.118; Mengesdorf T, 2002, EXP NEUROL, V177, P538, DOI 10.1006/exnr.2002.8002; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Moro MA, 2005, FREE RADICAL BIO MED, V39, P1291, DOI 10.1016/j.freeradbiomed.2005.07.010; Mouw G, 2003, NEUROREPORT, V14, P183, DOI 10.1097/00001756-200302100-00004; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakka VP, 2014, J NEUROTRAUM, V31, pA107; Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Ness JM, 2006, BRAIN RES, V1099, P150, DOI 10.1016/j.brainres.2006.04.132; Niizuma K, 2009, STROKE, V40, P618, DOI 10.1161/STROKEAHA.108.524447; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ohri SS, 2011, GLIA, V59, P1489, DOI 10.1002/glia.21191; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Owen CR, 2005, J NEUROCHEM, V94, P1235, DOI 10.1111/j.1471-4159.2005.03276.x; Paschen W, 1998, MOL BRAIN RES, V60, P115, DOI 10.1016/S0169-328X(98)00180-6; Paschen W, 2003, J CEREBR BLOOD F MET, V23, P449, DOI 10.1097/01.WCB.0000054216.21675.AC; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Penas C, 2007, J NEUROCHEM, V102, P1242, DOI 10.1111/j.1471-4159.2007.04671.x; Perez-Pinzon MA, 1999, J CEREBR BLOOD F MET, V19, P39, DOI 10.1097/00004647-199901000-00004; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; Qi X, 2004, J PHARMACOL EXP THER, V311, P388, DOI 10.1124/jpet.104.069088; Rami A, 2008, AUTOPHAGY, V4, P422, DOI 10.4161/auto.5778; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roussel BD, 2013, LANCET NEUROL, V12, P105, DOI 10.1016/S1474-4422(12)70238-7; Ruiz A, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.31; Ruiz A, 2009, CELL CALCIUM, V46, P273, DOI 10.1016/j.ceca.2009.08.005; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Santos CXC, 2009, ANTIOXID REDOX SIGN, V11, P2409, DOI 10.1089/ARS.2009.2625; Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Sekiguchi F, 2004, NEUROSCI LETT, V365, P111, DOI 10.1016/j.neulet.2004.04.069; Semenza GL, 2008, AUTOPHAGY, V4, P534, DOI 10.4161/auto.5956; Sheng R, 2010, AUTOPHAGY, V6, P482, DOI 10.4161/auto.6.4.11737; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shoichet Molly S., 2008, P221; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Srinivasan K, 2011, BEHAV BRAIN RES, V225, P110, DOI 10.1016/j.bbr.2011.07.004; Sugawara T, 1999, J NEUROSCI, V19, part. no.; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Terpolilli NA, 2012, J CEREBR BLOOD F MET, V32, P1332, DOI 10.1038/jcbfm.2012.12; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; UCHIKAWA O, 2008, Patent No. 2008016131; Upton JP, 2012, SCIENCE, V338, P818, DOI 10.1126/science.1226191; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vidal RL, 2012, HUM MOL GENET, V21, P2245, DOI 10.1093/hmg/dds040; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Vosler PS, 2009, STROKE, V40, P3149, DOI 10.1161/STROKEAHA.108.543769; Wei H, 2008, HUM MOL GENET, V17, P469, DOI 10.1093/hmg/ddm324; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Xilouri M, 2010, CNS NEUROL DISORD-DR, V9, P701, DOI 10.2174/187152710793237421; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yan F, 2014, NEUROSCI LETT, V563, P160, DOI 10.1016/j.neulet.2014.01.058; Yao CY, 2014, MOL MED REP, V9, P69, DOI 10.3892/mmr.2013.1778; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhang HY, 2014, MOL NEUROBIOL; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	161	129	138	1	65	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JAN	2016	53	1					532	544		10.1007/s12035-014-9029-6			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DB0CN	WOS:000368176300046	25482050	Green Accepted			2022-02-06	
J	Corwin, DJ; Zonfrillo, MR; Master, CL; Arbogast, KB; Grady, MF; Robinson, RL; Goodman, AM; Wiebe, DJ				Corwin, Daniel J.; Zonfrillo, Mark R.; Master, Christina L.; Arbogast, Kristy B.; Grady, Matthew F.; Robinson, Roni L.; Goodman, Arlene M.; Wiebe, Douglas J.			Characteristics of Prolonged Concussion Recovery in a Pediatric Subspecialty Referral Population	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; 3RD INTERNATIONAL-CONFERENCE; HIGH-SCHOOL; CONSENSUS STATEMENT; SPORTS CONCUSSION; POSTTRAUMATIC MIGRAINE; SYMPTOMS; ZURICH; CONVERGENCE; PREDICTORS	Objective To identify pre-existing characteristics associated with prolonged recovery from concussion in a sample of patients referred to a pediatric sports medicine clinic. Study design This was a retrospective, exploratory cohort study of 247 patients age 5-18 years with concussion referred to a tertiary pediatric hospital-affiliated sports medicine clinic from July 1, 2010, through December 31, 2011. A random sample of all eligible patient visits (3740) was chosen for further review and abstraction. Statistical comparisons between subsets of patients were conducted using exact x(2) tests, logistic regression, quantile regression, and Kaplan-Meier survival curves. Results The median time until returning to school part-time was 12 days (IQR 6-21); until returning to school full-time without accommodations was 35 days (IQR 11-105); until becoming symptom-free was 64 days (IQR 18-119); and until being fully cleared to return to sports was 75 days (IQR 30-153). Furthermore, 73% of all patients were symptomatic for >4 weeks, 73% were prescribed some form of school accommodation, and 61% reported a decline in grades. Characteristics associated with a prolonged recovery included a history of depression or anxiety; an initial complaint of dizziness; abnormal convergence or symptom provocation following oculomotor examination on physical examination; and history of prior concussion. Conclusions Pediatric and adolescent patients with concussion may experience cognitive and emotional morbidity that can last for several months following injury. Clinicians should consider specific pre-existing characteristics and presenting symptoms that may be associated with a more complicated recovery for concussion patients.	[Corwin, Daniel J.; Zonfrillo, Mark R.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Wiebe, Douglas J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Master, Christina L.; Arbogast, Kristy B.; Grady, Matthew F.; Wiebe, Douglas J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.; Robinson, Roni L.; Goodman, Arlene M.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA		Corwin, DJ (corresponding author), Childrens Hosp Philadelphia, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	corwind@email.chop.edu	Meijer, Anna/K-5118-2016; Wiebe, Douglas J/Q-1168-2017; Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Arbogast, Kristy/0000-0002-1694-4562; Master, Christina/0000-0002-6717-4270	Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003]; Children's Hospital of Philadelphia Clinical Translational Sciences Award; Comparative Effectiveness Program; Eunice Kennedy Shriver National Institute of Child HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Human Development [K08HD073241]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003] Funding Source: NIH RePORTER	Supported by The Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative, the National Institutes of Health, National Center for Advancing Translational Sciences (UL1TR000003 for the University of Pennsylvania Health System), the Children's Hospital of Philadelphia Clinical Translational Sciences Award and Research Institute funding for the Comparative Effectiveness Program), and the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (K08HD073241 [to M.Z.]). The authors declare no conflicts of interest.	Atabaki SM, 2013, PEDIATR CLIN N AM, V60, P1107, DOI 10.1016/j.pcl.2013.06.001; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bade A, 2013, OPTOMETRY VISION SCI, V90, P988, DOI 10.1097/OPX.0000000000000012; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chamberlain, 1994, ADV ECONOMETRICS, V1, P171, DOI DOI 10.1017/CCOL0521444594.005; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lavrich JB, 2010, CURR OPIN OPHTHALMOL, V21, P356, DOI 10.1097/ICU.0b013e32833cf03a; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2014, ANN INTERN MED, V160, DOI 10.7326/0003-4819-160-3-201402040-01002; Master CL, 2012, PEDIATR ANN, V41, pE174, DOI 10.3928/00904481-20120827-08; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Piland SG, 2003, J ATHL TRAINING, V38, P104; Preece MHW, 2007, BRAIN INJURY, V21, P951, DOI 10.1080/02699050701481647; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P123; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Scheiman M, 2011, OPTOMETRY VISION SCI, V88, P1343, DOI 10.1097/OPX.0b013e31822f4d7c; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thiagarajan P, 2013, OPTOMETRY VISION SCI, V90, P57, DOI 10.1097/OPX.0b013e31827a233e	50	129	129	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	DEC	2014	165	6					1207	1215		10.1016/j.jpeds.2014.08.034			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AU3PS	WOS:000345526500028	25262302	Green Accepted			2022-02-06	
J	Petrie, EC; Cross, DJ; Yarnykh, VL; Richards, T; Martin, NM; Pagulayan, K; Hoff, D; Hart, K; Mayer, C; Tarabochia, M; Raskind, MA; Minoshima, S; Peskind, ER				Petrie, Eric C.; Cross, Donna J.; Yarnykh, Vasily L.; Richards, Todd; Martin, Nathalie M.; Pagulayan, Kathleen; Hoff, David; Hart, Kim; Mayer, Cynthia; Tarabochia, Matthew; Raskind, Murray A.; Minoshima, Satoshi; Peskind, Elaine R.			Neuroimaging, Behavioral, and Psychological Sequelae of Repetitive Combined Blast/Impact Mild Traumatic Brain Injury in Iraq and Afghanistan War Veterans	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; macromolecular proton fraction; mild traumatic brain injury; positron emission tomography; veterans	POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER; AXONAL INJURY; MULTIPLE-SCLEROSIS; STEADY-STATE; FDG-PET; MODERATE; DIFFUSE; DISEASE; DAMAGE	Whether persisting cognitive complaints and postconcussive symptoms (PCS) reported by Iraq and Afghanistan war veterans with blast- and/or combined blast/impact-related mild traumatic brain injuries (mTBIs) are associated with enduring structural and/or functional brain abnormalities versus comorbid depression or posttraumatic stress disorder (PTSD) remains unclear. We sought to characterize relationships among these variables in a convenience sample of Iraq and Afghanistan-deployed veterans with (n=34) and without (n=18) a history of one or more combined blast/impact-related mTBIs. Participants underwent magnetic resonance imaging of fractional anisotropy (FA) and macromolecular proton fraction (MPF) to assess brain white matter (WM) integrity; [F-18]-fluorodeoxyglucose positron emission tomography imaging of cerebral glucose metabolism (CMRglu); structured clinical assessments of blast exposure, psychiatric diagnoses, and PTSD symptoms; neurologic evaluations; and self-report scales of PCS, combat exposure, depression, sleep quality, and alcohol use. Veterans with versus without blast/impact-mTBIs exhibited reduced FA in the corpus callosum; reduced MPF values in subgyral, longitudinal, and cortical/subcortical WM tracts and gray matter (GM)/WM border regions (with a possible threshold effect beginning at 20 blast-mTBIs); reduced CMRglu in parietal, somatosensory, and visual cortices; and higher scores on measures of PCS, PTSD, combat exposure, depression, sleep disturbance, and alcohol use. Neuroimaging metrics did not differ between participants with versus without PTSD. Iraq and Afghanistan veterans with one or more blast-related mTBIs exhibit abnormalities of brain WM structural integrity and macromolecular organization and CMRglu that are not related to comorbid PTSD. These findings are congruent with recent neuropathological evidence of chronic brain injury in this cohort of veterans.	[Petrie, Eric C.; Pagulayan, Kathleen; Hoff, David; Hart, Kim; Mayer, Cynthia; Tarabochia, Matthew; Raskind, Murray A.; Peskind, Elaine R.] VA Puget Sound, MIRECC, Vet Affairs VA Northwest Network VISN 20, Seattle, WA 98108 USA; [Petrie, Eric C.; Pagulayan, Kathleen; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Petrie, Eric C.; Cross, Donna J.; Yarnykh, Vasily L.; Richards, Todd; Martin, Nathalie M.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA		Petrie, EC (corresponding author), VA Puget Sound, MIRECC, 1660 S Columbian Way,Mail Code S-116, Seattle, WA 98108 USA.	epetrie@uw.edu	Pagulayan, Kati/AAR-9225-2020; Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasily/ABF-7873-2021; Yarnykh, Vasiliy L./N-7635-2014	Yarnykh, Vasily/0000-0002-1583-8979; Cross, Donna/0000-0003-1918-2214; Minoshima, Satoshi/0000-0002-0043-3047; Petrie, Eric/0000-0003-1188-6321	Department of Veterans Affairs Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B77421]; VA Clinical Science Research and Development CAREER development award [TK2 CX000516]; VA Northwest Network MIRECC; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG05136, 5K08AG23670, R21EB009908]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD083091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136, K08AG023670] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001612, I01RX000521] Funding Source: NIH RePORTER	This material is based on work supported, in part, by the Department of Veterans Affairs Rehabilitation Research and Development Service (B77421), VA Clinical Science Research and Development CAREER development award TK2 CX000516, and VA Northwest Network MIRECC; National Institute of Health grants AG05136, 5K08AG23670, and R21EB009908; and an anonymous foundation.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ayling E, 2012, CURR PSYCHIAT REP, V14, P197, DOI 10.1007/s11920-012-0273-z; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; BOOKSTEIN FL, 1989, IEEE T PATTERN ANAL, V11, P567, DOI 10.1109/34.24792; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Edden RA, 2011, J NEUROSCI METH, V201, P213, DOI 10.1016/j.jneumeth.2011.07.025; Eibner C, 2009, NEW ENGL J MED, V361, P537; First M. B., 2002, STRUCTURED CLINICAL; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hosaka K, 2005, EUR J NUCL MED MOL I, V32, P92, DOI 10.1007/s00259-004-1576-z; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kang XJ, 2012, MAGN RESON IMAGING, V30, P1111, DOI 10.1016/j.mri.2012.04.004; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEGROS C, 1936, J ANAT, V71, P7; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu XD, 2009, INT GEOSCI REMOTE SE, P885, DOI 10.1109/IGARSS.2009.5418166; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; MARTINEZMARTIN P, 1994, MOVEMENT DISORD, V9, P76, DOI 10.1002/mds.870090112; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1992, J NUCL MED, V33, P1579; MINOSHIMA S, 1993, J NUCL MED, V34, P322; MINOSHIMA S, 1994, J NUCL MED, V35, P949; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Minoshima S, 2002, J GERIATR PSYCH NEUR, V15, P200, DOI 10.1177/089198870201500405; Minoshima S., 2009, PRINCIPLES AND PRACT, P500; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Oishi K., 2011, MRI ATLAS OF HUMAN W; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Rausch M, 2009, MULT SCLER, V15, P16, DOI 10.1177/1352458508096006; Samsonov A, 2012, NEUROIMAGE, V62, P1390, DOI 10.1016/j.neuroimage.2012.05.077; Schmierer K, 2007, J MAGN RESON IMAGING, V26, P41, DOI 10.1002/jmri.20984; Sigford B, 2009, NEW ENGL J MED, V361, P536, DOI 10.1056/NEJMc096180; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Skinner TE, 1997, MAGN RESON MED, V37, P628, DOI 10.1002/mrm.1910370426; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Talairach J., 1988, COPLANAR STEREOTAXIC; Tustison N. J., 2012, HUM BRAIN MAPP, DOI [10.1002/hbm.22211, DOI 10.1002/HBM.22211.EPUB]; Underhil HR, 2009, NEUROIMAGE, V47, P1568, DOI 10.1016/j.neuroimage.2009.05.075; Underhill HR, 2011, NEUROIMAGE, V54, P2052, DOI 10.1016/j.neuroimage.2010.10.065; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Yarnykh VL, 2007, MAGN RESON MED, V57, P192, DOI 10.1002/mrm.21120; Yarnykh VL, 2012, MAGN RESON MED, V68, P166, DOI 10.1002/mrm.23224; Yarnykh VL, 2010, MAGN RESON MED, V63, P1610, DOI 10.1002/mrm.22394; Yarnykh VL, 2004, NEUROIMAGE, V23, P409, DOI 10.1016/j.neuroimage.2004.04.029; Yarnykh VL, 2002, MAGNET RESON MED, V47, P929, DOI 10.1002/mrm.10120	71	129	130	1	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					425	436		10.1089/NEU.2013.2952			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600241	24102309	Green Published			2022-02-06	
J	Kaindl, AM; Degos, V; Peineau, S; Gouadon, E; Chhor, V; Loron, G; Le Charpentier, T; Josserand, J; Ali, C; Vivien, D; Collingridge, GL; Lombet, A; Issa, L; Rene, F; Loeffler, JP; Kavelaars, A; Verney, C; Mantz, J; Gressens, P				Kaindl, Angela M.; Degos, Vincent; Peineau, Stephane; Gouadon, Elodie; Chhor, Vibol; Loron, Gauthier; Le Charpentier, Tifenn; Josserand, Julien; Ali, Carine; Vivien, Denis; Collingridge, Graham L.; Lombet, Alain; Issa, Lina; Rene, Frederique; Loeffler, Jean-Philippe; Kavelaars, Annemieke; Verney, Catherine; Mantz, Jean; Gressens, Pierre			Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain	ANNALS OF NEUROLOGY			English	Article							PERIVENTRICULAR WHITE-MATTER; DATA-ACQUISITION PROGRAM; MEDIATED NEUROTOXICITY; EXCITOTOXIC LESIONS; GLUTAMATE UPTAKE; NMDA; EXPRESSION; CYTOKINES; INTERLEUKIN-1-BETA; NEUROPROTECTION	Objective: Activated microglia play a central role in the inflammatory and excitotoxic component of various acute and chronic neurological disorders. However, the mechanisms leading to their activation in the latter context are poorly understood, particularly the involvement of N-methyl-D-aspartate receptors (NMDARs), which are critical for excitotoxicity in neurons. We hypothesized that microglia express functional NMDARs and that their activation would trigger neuronal cell death in the brain by modulating inflammation. Methods and Results: We demonstrate that microglia express NMDARs in the murine and human central nervous system and that these receptors are functional in vitro. We show that NMDAR stimulation triggers microglia activation in vitro and secretion of factors that induce cell death of cortical neurons. These damaged neurons are further shown to activate microglial NMDARs and trigger a release of neurotoxic factors from microglia in vitro, indicating that microglia can signal back to neurons and possibly induce, aggravate, and/or maintain neurologic disease. Neuronal cell death was significantly reduced through pharmacological inhibition or genetically induced loss of function of the microglial NMDARs. We generated Nr1 LoxP(+/+) LysM Cre(+/-) mice lacking the NMDAR subunit NR1 in cells of the myeloid lineage. In this model, we further demonstrate that a loss of function of the essential NMDAR subunit NR1 protects from excitotoxic neuronal cell death in vivo and from traumatic brain injury. Interpretation: Our findings link inflammation and excitotoxicity in a potential vicious circle and indicate that an activation of the microglial NMDARs plays a pivotal role in neuronal cell death in the perinatal and adult brain. ANN NEUROL 2012;72:536549	[Kaindl, Angela M.; Degos, Vincent; Peineau, Stephane; Chhor, Vibol; Loron, Gauthier; Le Charpentier, Tifenn; Josserand, Julien; Verney, Catherine; Mantz, Jean; Gressens, Pierre] Hop Robert Debre, French Inst Hlth & Med Res, U676, F-75019 Paris, France; [Kaindl, Angela M.; Degos, Vincent; Peineau, Stephane; Chhor, Vibol; Loron, Gauthier; Le Charpentier, Tifenn; Josserand, Julien; Verney, Catherine; Mantz, Jean; Gressens, Pierre] Univ Paris 07, Denis Diderot Fac Med, Paris, France; [Kaindl, Angela M.; Degos, Vincent; Peineau, Stephane; Chhor, Vibol; Loron, Gauthier; Le Charpentier, Tifenn; Verney, Catherine; Mantz, Jean; Gressens, Pierre] PremUP, Paris, France; [Kaindl, Angela M.; Issa, Lina] Charite, Dept Pediat Neurol, D-13353 Berlin, Germany; [Kaindl, Angela M.; Lombet, Alain; Issa, Lina] Charite, Inst Neurobiol & Cell Biol, D-13353 Berlin, Germany; [Peineau, Stephane; Collingridge, Graham L.; Lombet, Alain] MRC, Ctr Synapt Plast, Dept Anat, Sch Med Sci, Bristol, Avon, England; [Gouadon, Elodie; Lombet, Alain] Natl Ctr Sci Res, UMR 8162, Le Plessis Robinson, France; [Gouadon, Elodie] Marie Lannelongue Hosp, Le Plessis Robinson, France; [Gouadon, Elodie] Univ Paris S, Le Plessis Robinson, France; [Ali, Carine; Vivien, Denis] French Inst Hlth & Med Res, U919, Caen, France; [Ali, Carine; Vivien, Denis] Natl Ctr Sci Res, Mixed Unit Res 6232, Caen, France; [Collingridge, Graham L.] Seoul Natl Univ, Dept Brain & Cognit Sci, Seoul, South Korea; [Rene, Frederique; Loeffler, Jean-Philippe] French Inst Hlth & Med Res, U692, Strasbourg, France; [Kavelaars, Annemieke] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Mantz, Jean] Publ Assistance Hosp Paris, Anesthesiol & Intens Care Serv, Paris, France; [Gressens, Pierre] Univ London Imperial Coll Sci Technol & Med, Ctr Developing Brain Inst Reprod & Dev Biol, London, England		Kaindl, AM (corresponding author), Charite, Inst Cell Biol & Neurobiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	angela.kaindl@charite.de; pierre.gressens@inserm.fr	collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015; gressens, pierre/M-7557-2017; LOEFFLER, Jean-Philippe/AAS-4401-2020	Collingridge, Graham L/0000-0002-9572-5359; gressens, pierre/0000-0002-0909-4221; LORON, Gauthier/0000-0001-9536-9510; VIVIEN, DENIS/0000-0002-7636-2185; Ali, Carine/0000-0001-8007-7910; Peineau, Stephane/0000-0002-4721-6795; Kaindl, Angela/0000-0001-9454-206X	InsermInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; Universite Paris 7; Leducq FoundationLeducq Foundation; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [LSHM-CT-2006-036534/neobrain]; PremUP; Institut pour la Recherche sur la Moelle epiniere et l'Encephale; Fondation des Gueules Cassees; Fondation Motrice; ELA Foundation; Fondation Grace de Monaco; Sonnenfeld Stiftung; German Research FoundationGerman Research Foundation (DFG) [SFB665]; Berliner Krebsgesellschaft e.V.; Societe Francaise d'Anesthesie Reanimation, MRC (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); APHP (Contrat d'Interface); EUEuropean Commission; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601841B, G0601813] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601813] Funding Source: UKRI	This work was supported by Inserm, Universite Paris 7, Leducq Foundation, Sixth Framework Program of the European Commission (contract No. LSHM-CT-2006-036534/neobrain), PremUP, Institut pour la Recherche sur la Moelle epiniere et l'Encephale, Fondation des Gueules Cassees, Fondation Motrice, ELA Foundation, Fondation Grace de Monaco, Sonnenfeld Stiftung, German Research Foundation (SFB665), Berliner Krebsgesellschaft e.V., Societe Francaise d'Anesthesie Reanimation, MRC (UK), and APHP (Contrat d'Interface to P.G.).; A.K.: employment, University Medical Center Utrecht; grants/grants pending, EU, NIH.	AGNATI LF, 1995, NEUROSCIENCE, V69, P711, DOI 10.1016/0306-4522(95)00308-6; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Anderson WW, 2007, J NEUROSCI METH, V162, P346, DOI 10.1016/j.jneumeth.2006.12.018; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Aronica E, 2005, J NEUROIMMUNOL, V160, P188, DOI 10.1016/j.jneuroim.2004.11.015; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boucsein C, 2003, EUR J NEUROSCI, V17, P2267, DOI 10.1046/j.1460-9568.2003.02663.x; Cacci E, 2005, J NEUROSCI RES, V80, P789, DOI 10.1002/jnr.20531; Cheret C, 2008, J NEUROSCI, V28, P12039, DOI 10.1523/JNEUROSCI.3568-08.2008; Chung S, 1998, NEUROSCI LETT, V249, P139, DOI 10.1016/S0304-3940(98)00409-1; Chung S, 1998, NEUROSCI LETT, V242, P73, DOI 10.1016/S0304-3940(98)00029-9; Dazy AC, 2003, TOXICOL IN VITRO, V17, P575, DOI 10.1016/S0887-2333(03)00092-4; Degos V, 2010, J NEURAL TRANSM, V117, P1009, DOI 10.1007/s00702-010-0411-x; Dommergues MA, 2000, ANN NEUROL, V47, P54, DOI 10.1002/1531-8249(200001)47:1<54::AID-ANA10>3.0.CO;2-Y; Eriksson C, 2000, MOL BRAIN RES, V85, P103, DOI 10.1016/S0169-328X(00)00251-5; Farber K, 2005, BRAIN RES REV, V48, P133, DOI 10.1016/j.brainresrev.2004.12.003; Fontaine RH, 2008, CELL DEATH DIFFER, V15, P1542, DOI 10.1038/cdd.2008.79; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; GASPAR P, 1989, J COMP NEUROL, V279, P249, DOI 10.1002/cne.902790208; GEHRMANN J, 1992, J CEREBR BLOOD F MET, V12, P257, DOI 10.1038/jcbfm.1992.36; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gottlieb M, 1997, J CEREBR BLOOD F MET, V17, P290, DOI 10.1097/00004647-199703000-00006; Gressens P, 1997, J CLIN INVEST, V100, P390, DOI 10.1172/JCI119545; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hansen HS, 1997, J NEUROCHEM, V69, P753; Husson I, 2002, ANN NEUROL, V51, P82, DOI 10.1002/ana.10072; Kaindl AM, 2007, PROTEOM CLIN APPL, V1, P640, DOI 10.1002/prca.200600696; Kalia LV, 2006, EMBO J, V25, P4971, DOI 10.1038/sj.emboj.7601342; Kaur C, 2005, J PINEAL RES, V39, P294, DOI 10.1111/j.1600-079X.2005.00245.x; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Liang JF, 2010, BRAIN RES, V1322, P8, DOI 10.1016/j.brainres.2010.01.083; Liao SL, 2001, NEUROSCI LETT, V299, P113, DOI 10.1016/S0304-3940(01)01499-9; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; MARRET S, 1995, J NEUROPATH EXP NEUR, V54, P358, DOI 10.1097/00005072-199505000-00009; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112; Moller T, 2000, BRAIN RES, V853, P49, DOI 10.1016/S0006-8993(99)02244-1; Monier A, 2007, J NEUROPATH EXP NEUR, V66, P372, DOI 10.1097/nen.0b013e3180517b46; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; Murugan M, 2011, GLIA, V59, P521, DOI 10.1002/glia.21121; Nair A, 2006, J NEUROIMMUNOL, V171, P72, DOI 10.1016/j.jneuroim.2005.09.012; Newcombe J, 2008, BRAIN PATHOL, V18, P52, DOI 10.1111/j.1750-3639.2007.00101.x; Newell EW, 2005, J PHYSIOL-LONDON, V567, P869, DOI 10.1113/jphysiol.2005.092056; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1989, J NEUROSCI, V9, P1701; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Salinska E, 2005, FOLIA NEUROPATHOL, V43, P322; Sharp FR, 2000, J CEREBR BLOOD F MET, V20, P1011, DOI 10.1097/00004647-200007000-00001; Tahraoui SL, 2001, BRAIN PATHOL, V11, P56; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Tilleux S, 2007, J NEUROSCI RES, V85, P2059, DOI 10.1002/jnr.21325; Titomanlio L, 2011, STEM CELLS DEV, V20, P865, DOI 10.1089/scd.2010.0302; Tribouillard-Tanvier D, 2009, J VIROL, V83, P11244, DOI 10.1128/JVI.01413-09; Verney C, 2010, J ANAT, V217, P436, DOI 10.1111/j.1469-7580.2010.01245.x	60	129	133	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2012	72	4					536	549		10.1002/ana.23626			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	030CG	WOS:000310544900011	23109148				2022-02-06	
J	Lin, DW; Zuo, ZY				Lin, Daowei; Zuo, Zhiyi			Isoflurane induces hippocampal cell injury and cognitive impairments in adult rats	NEUROPHARMACOLOGY			English	Article						Cell injury; Cognitive functions; Cytokines; Isoflurane; Rats	NITROUS OXIDE ANESTHESIA; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEUROCOGNITIVE FUNCTION; AGED RATS; DYSFUNCTION; BETA; ACQUISITION; ACTIVATION; APOPTOSIS	Post-operative cognitive dysfunction (POCD) is a clinical phenomenon characterized with cognitive decline in patients after anesthesia and surgery. It has been shown that interleukin-1 beta (IL-1 beta) contributes to the cognitive impairment of mice after surgery and isoflurane anesthesia. This study is designed to determine whether isoflurane alone increases inflammatory cytokines and causes cell injury and cognitive impairment. Four-month-old male Fisher 344 rats were exposed to or were not exposed to 1.2% isoflurane for 2 h. Two weeks later, rats were subjected to Barnes maze and fear conditioning tests. Although animals exposed to or non-exposed to isoflurane developed spatial learning, animals exposed to isoflurane had significant impairments in long-term spatial memory assessed by Barnes maze. They also had impaired hippocampus-dependent learning and memory in fear conditioning test. IL-1 beta in the hippocampus was increased at 6 h after isoflurane exposure. Isoflurane also increased activated caspase 3 in the hippocampus and decreased the neuronal density in the CA1 region. However, isoflurane did not change the amount of beta-amyloid peptide in the cerebral cortex at 29 days after isoflurane exposure when cognitive impairment was present. These results suggest that isoflurane increases inflammatory cytokine expression and causes cell injury in the hippocampus, which may contribute to isoflurane-induced cognitive impairment in rats. (C) 2011 Elsevier Ltd. All rights reserved.	[Lin, Daowei; Zuo, Zhiyi] Univ Virginia, Dept Anesthesiol, Charlottesville, VA 22908 USA; [Lin, Daowei; Zuo, Zhiyi] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Anesthesiol, Guangzhou 510120, Guangdong, Peoples R China		Zuo, ZY (corresponding author), Univ Virginia, Dept Anesthesiol, 1 Hosp Dr,POB 800710, Charlottesville, VA 22908 USA.	zz3c@virginia.edu	Zuo, Zhiyi/F-3950-2010	Zuo, Zhiyi/0000-0002-3542-5047	National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 GM065211]; International Anesthesia Research Society, Cleveland, Ohio; American Heart Association Mid-Atlantic Affiliate, Baltimore, MarylandAmerican Heart Association [10GRNT3900019]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM065211] Funding Source: NIH RePORTER	This study was supported by a grant (R01 GM065211 to Z Zuo) from the National Institutes of Health, Bethesda, Maryland, by a grant from the International Anesthesia Research Society (2007 Frontiers in Anesthesia Research Award to Z Zuo), Cleveland, Ohio, by a Grant-in-Aid from the American Heart Association Mid-Atlantic Affiliate (10GRNT3900019 to Z Zuo), Baltimore, Maryland	Baranov D, 2009, ANESTH ANALG, V108, P1627, DOI 10.1213/ane.0b013e318199dc72; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Cibelli M, 2010, ANN NEUROL, V68, P360, DOI 10.1002/ana.22082; Clergue F, 1999, ANESTHESIOLOGY, V91, P1509, DOI 10.1097/00000542-199911000-00045; Culley DJ, 2004, ANESTH ANALG, V99, P1393, DOI 10.1213/01.ANE.0000135408.14319.CC; Culley DJ, 2004, ANESTHESIOLOGY, V100, P309, DOI 10.1097/00000542-200402000-00020; Culley DJ, 2003, ANESTH ANALG, V96, P1004, DOI 10.1213/01.ANE.0000052712.67573.12; Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KOMATSU H, 1993, ANESTH ANALG, V76, P609; Lee JJ, 2008, ANESTHESIOLOGY, V108, P1055, DOI 10.1097/ALN.0b013e3181730257; Li L, 2009, NEUROSCIENCE, V164, P497, DOI 10.1016/j.neuroscience.2009.08.011; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martin DSD, 2002, J BIOL CHEM, V277, P34239, DOI 10.1074/jbc.M205289200; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Rammes G, 2009, NEUROPHARMACOLOGY, V56, P626, DOI 10.1016/j.neuropharm.2008.11.002; Sanderson DJ, 2009, BEHAV BRAIN RES, V201, P103, DOI 10.1016/j.bbr.2009.01.038; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Stratmann G, 2009, ANESTHESIOLOGY, V110, P834, DOI 10.1097/ALN.0b013e31819c463d; Valentim AM, 2010, ANESTHESIOLOGY, V113, P1099, DOI 10.1097/ALN.0b013e3181f79c7c; Xie ZC, 2007, J NEUROSCI, V27, P1247, DOI 10.1523/JNEUROSCI.5320-06.2007; Xie ZC, 2008, ANN NEUROL, V64, P618, DOI 10.1002/ana.21548; Zarifkar A, 2010, EUR J PHARMACOL, V634, P84, DOI 10.1016/j.ejphar.2010.02.029; Zhao P, 2004, ANESTHESIOLOGY, V101, P695, DOI 10.1097/00000542-200409000-00018	31	129	149	1	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908			NEUROPHARMACOLOGY	Neuropharmacology	DEC	2011	61	8					1354	1359		10.1016/j.neuropharm.2011.08.011			6	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	848VB	WOS:000297082100021	21864548	Green Accepted			2022-02-06	
J	Naeser, MA; Saltmarche, A; Krengel, MH; Hamblin, MR; Knight, JA				Naeser, Margaret A.; Saltmarche, Anita; Krengel, Maxine H.; Hamblin, Michael R.; Knight, Jeffrey A.			Improved Cognitive Function After Transcranial, Light-Emitting Diode Treatments in Chronic, Traumatic Brain Injury: Two Case Reports	PHOTOMEDICINE AND LASER SURGERY			English	Article							LEVEL LASER THERAPY; TERM NEUROLOGICAL DEFICITS; ANTERIOR CINGULATE CORTEX; NEAR-INFRARED LIGHT; SUSTAINED ATTENTION; ISCHEMIC-STROKE; WORKING-MEMORY; UNITED-STATES; RAT-BRAIN; IRRADIATION	Objective: Two chronic, traumatic brain injury (TBI) cases, where cognition improved following treatment with red and near-infrared light-emitting diodes (LEDs), applied transcranially to forehead and scalp areas, are presented. Background: Significant benefits have been reported following application of transcranial, low-level laser therapy (LLLT) to humans with acute stroke and mice with acute TBI. These are the first case reports documenting improved cognitive function in chronic, TBI patients treated with transcranial LED. Methods: Treatments were applied bilaterally and to midline sagittal areas using LED cluster heads [2.1 '' diameter, 61 diodes (9 x 633 nm, 52 x 870 nm); 12-15 mW per diode; total power: 500 mW; 22.2 mW/cm(2); 13.3 J/cm(2) at scalp (estimated 0.4 J/cm(2) to cortex)]. Results: Seven years after closed-head TBI from a motor vehicle accident, Patient 1 began transcranial LED treatments. Pre-LED, her ability for sustained attention (computer work) lasted 20 min. After eight weekly LED treatments, her sustained attention time increased to 3 h. The patient performs nightly home treatments (5 years); if she stops treating for more than 2 weeks, she regresses. Patient 2 had a history of closed-head trauma (sports/military, and recent fall), and magnetic resonance imaging showed frontoparietal atrophy. Pre-LED, she was on medical disability for 5 months. After 4 months of nightly LED treatments at home, medical disability discontinued; she returned to working full-time as an executive consultant with an international technology consulting firm. Neuropsychological testing after 9 months of transcranial LED indicated significant improvement (+1, +2SD) in executive function (inhibition, inhibition accuracy) and memory, as well as reduction in post-traumatic stress disorder. If she stops treating for more than 1 week, she regresses. At the time of this report, both patients are continuing treatment. Conclusions: Transcranial LED may improve cognition, reduce costs in TBI treatment, and be applied at home. Controlled studies are warranted.	[Naeser, Margaret A.; Knight, Jeffrey A.] VA Boston Healthcare Syst, Natl Ctr, PTSD Behav Sci Div, Boston, MA 02130 USA; [Naeser, Margaret A.; Krengel, Maxine H.; Knight, Jeffrey A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Saltmarche, Anita] MedX Hlth Inc, Mississauga, ON, Canada; [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA		Naeser, MA (corresponding author), VA Boston Healthcare Syst, Natl Ctr, PTSD Behav Sci Div, 12-A,150 So Huntington Ave, Boston, MA 02130 USA.	mnaeser@bu.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605; Krengel, Maxine/0000-0001-7632-590X	Department of Veterans AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1AI050875]; US Air ForceUnited States Department of Defense [FA9550-04-1-0079]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-09-1-0514]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA083882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	The authors thank Charles Foltz for the graphics art in Figure 5; Carole Palumbo, Ph.D. for assistance with MRI analysis; Paula Martin, Anna Kharaz, Michael Ho, Ph.D., and Ethan Treglia, M. S., for manuscript assistance; and Michael and Winter Robinson for photography. M. Naeser was supported by Merit Review Funding, Department of Veterans Affairs. M. Hamblin was supported by the NIH (grant RO1AI050875), US Air Force MFEL program (contract FA9550-04-1-0079), Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), and Congressionally Directed Medical Research Program (W81XWH-09-1-0514).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Avni D, 2005, PHOTOMED LASER SURG, V23, P273, DOI 10.1089/pho.2005.23.273; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chen A C-H, 2010, PHOTOMED LASER SURG; CHEN ACH, 2009, SPIE, V7165; CHEN GS, 1977, COMP MED EAST WEST, V5, P147, DOI 10.1142/S0147291777000210; De Scheerder IK, 2001, LASER SURG MED, V28, P212, DOI 10.1002/lsm.1040; DEADMAN P, 1998, MANUAL ACUPUNCTURE H, P256; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Delis DC., 2001, DELIS KAPLAN EXECUTI; Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; FROST E A M, 1976, American Journal of Acupuncture, V4, P45; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Karu T, 2000, PROC SPIE, V4159, P1, DOI 10.1117/12.405918; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; KNIGHT JA, 2004, ASSESSING PSYCHOL TR, P344; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Leung MCP, 2002, LASER SURG MED, V31, P283, DOI 10.1002/lsm.10096; Lewin JS, 1996, J COMPUT ASSIST TOMO, V20, P695, DOI 10.1097/00004728-199609000-00002; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mi XQ, 2004, PHOTOMED LASER SURG, V22, P477, DOI 10.1089/pho.2004.22.477; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; NAESER MA, 2010, P SPIE, V7552; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2007, PHOTOMED LASER SURG, V25, P180, DOI 10.1089/pho.2007.2064; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Petrides M, 1995, ANN NY ACAD SCI, V769, P85, DOI 10.1111/j.1749-6632.1995.tb38133.x; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Shin L., 2005, STRUCTURAL FUNCTIONA; Siedentopf CM, 2002, NEUROSCI LETT, V327, P53, DOI 10.1016/S0304-3940(02)00383-X; Sompol P, 2006, J MOL NEUROSCI, V29, P279, DOI 10.1385/JMN:29:3:279; Sosin DM, 1996, BRAIN INJURY, V10, P47; Storz P, 2007, TRENDS CELL BIOL, V17, P13, DOI 10.1016/j.tcb.2006.11.003; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Swick D, 2002, NEUROPSYCHOLOGIA, V40, P1240, DOI 10.1016/S0028-3932(01)00226-3; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tuby H, 2006, LASER SURG MED, V38, P682, DOI 10.1002/lsm.20377; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; Wechsler D, 1987, MEMORY SCALE REVISED; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x; ZHANG YH, 1994, INFECT IMMUN, V62, P4140, DOI 10.1128/IAI.62.10.4140-4144.1994; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	56	129	133	0	19	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1549-5418			PHOTOMED LASER SURG	Photomed. Laser Surg.	MAY	2011	29	5					351	358		10.1089/pho.2010.2814			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	762JC	WOS:000290471400009	21182447	Green Published			2022-02-06	
J	Bryant, RA				Bryant, Richard A.			Acute Stress Disorder as a Predictor of Posttraumatic Stress Disorder: A Systematic Review	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; 2-YEAR PROSPECTIVE EVALUATION; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; MOTOR-VEHICLE ACCIDENTS; PERITRAUMATIC DISSOCIATION; HEART-RATE; PERSISTENT DISSOCIATION; DIAGNOSTIC-TESTS; RAPE VICTIMS	Objective: The utility of the acute stress disorder diagnosis to describe acute stress reactions and predict subsequent posttraumatic stress disorder (PTSD) was evaluated. Data Sources: A systematic search was conducted in the PsycINFO, MEDLINE, and PubMed databases for English-language articles published between 1994 and 2009 using keywords that combined acute stress disorder and posttraumatic stress disorder. Study Selection: Studies were selected that assessed for acute stress disorder within 1 month of trauma exposure and assessed at a later time for PTSD, using established measures of acute stress disorder and PTSD. Data Extraction: For each study, capacity of the acute stress disorder diagnosis to predict PTSD was calculated in terms of sensitivity, specificity, and positive and negative predictive power. For studies that reported subsyndromal acute stress disorder, the same analyses were calculated for cases that initially satisfied subsyndromal acute stress disorder criteria. Data Synthesis: Twenty-two studies were identified as suitable for analysis (19 with adults and 3 with children). Diagnosis of acute stress disorder resulted in half the rate of distressed people in the acute phase being identified relative to including cases with subsyndromal acute stress disorder. In terms of prediction, the acute stress disorder diagnosis had reasonable positive predictive power (proportion of people with acute stress disorder who later developed PTSD). In contrast, the sensitivity (proportion of people who developed PTSD who initially met criteria for acute stress disorder) was poor. Conclusions: The acute stress disorder diagnosis does not adequately identify the majority of people who will eventually develop PTSD. There is a need to formally describe acute stress reactions, but this goal may be achieved more usefully by describing the broad range of initial reactions rather than by attempting to predict subsequent PTSD. J Clin Psychiatry 2011;72(2):233-239 (C) Copyright 2010 Physicians Postgraduate Press, Inc.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [300403]	This research was supported by a National Health and Medical Research Council Program Grant (300403).	American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Balluffi Andrew, 2004, Pediatr Crit Care Med, V5, P547, DOI 10.1097/01.PCC.0000137354.19807.44; Bisson JI, 2004, BRIT J PSYCHIAT, V184, P63, DOI 10.1192/bjp.184.1.63; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Breh Doris C, 2007, J Trauma Dissociation, V8, P53, DOI 10.1300/J229v08n01_04; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Briere J, 2005, AM J PSYCHIAT, V162, P2295, DOI 10.1176/appi.ajp.162.12.2295; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 2004, PSYCHOSOM MED, V66, P760, DOI 10.1097/01.psy.0000138121.13198.84; Bryant RA, 2001, BEHAV RES THER, V39, P961, DOI 10.1016/S0005-7967(00)00086-3; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2008, J CLIN PSYCHIAT, V69, P923, DOI 10.4088/JCP.v69n0606; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Bryant RA, 2007, J TRAUMA STRESS, V20, P1075, DOI 10.1002/jts.20282; Bryant RA, 2007, BEHAV RES THER, V45, P2502, DOI 10.1016/j.brat.2007.04.009; Bryant RA, 2007, J ANXIETY DISORD, V21, P183, DOI 10.1016/j.janxdis.2006.09.012; Bryant Richard A, 2002, CNS Spectr, V7, P650; Bryant RA, 2008, J CLIN PSYCHIAT, V69, P1694, DOI 10.4088/JCP.v69n1104; Dalgleish T, 2008, BRIT J PSYCHIAT, V192, P392, DOI 10.1192/bjp.bp.107.040451; Dunmore E, 2001, BEHAV RES THER, V39, P1063, DOI 10.1016/S0005-7967(00)00088-7; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Elklit A, 2004, J INTERPERS VIOLENCE, V19, P709, DOI 10.1177/0886260504263872; Elklit A, 2010, J INTERPERS VIOLENCE, V25, P1470, DOI 10.1177/0886260509354587; Fikretoglu D, 2006, J NERV MENT DIS, V194, P853, DOI 10.1097/01.nmd.0000244563.22864.f1; Fikretoglu D, 2007, BEHAV RES THER, V45, P39, DOI 10.1016/j.brat.2006.01.008; Friedman MJ, 2000, J CLIN PSYCHIAT, V61, P44; Fuglsang AK, 2004, NORD J PSYCHIAT, V58, P223, DOI 10.1080/08039480410006278; Fullerton CS, 2004, AM J PSYCHIAT, V161, P1370, DOI 10.1176/appi.ajp.161.8.1370; Galea S, 2007, CAN MED ASSOC J, V176, P1293, DOI 10.1503/cmaj.070368; GERARDI R, 1989, J CLIN PSYCHOL, V45, P691, DOI 10.1002/1097-4679(198909)45:5<691::AID-JCLP2270450503>3.0.CO;2-C; Ginzburg K, 2006, J NERV MENT DIS, V194, P945, DOI 10.1097/01.nmd.0000249061.65454.54; HARNANAKA S, 2006, GEN HOSP PSYCHIAT, V28, P234; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; Holeva V, 2001, BEHAV THER, V32, P65, DOI 10.1016/S0005-7894(01)80044-7; JANET P, 2007, MAJOR SYMPTOMS HYSTE; Kangas M, 2005, J CONSULT CLIN PSYCH, V73, P360, DOI 10.1037/0022-006X.73.2.360; Kassam-Adams N, 2004, J AM ACAD CHILD PSY, V43, P403, DOI 10.1097/00004583-200404000-00006; Kassam-Adarns N, 2009, J TRAUMA STRESS, V22, P294, DOI 10.1002/jts.20424; Keane T., 2001, DISSOCIATIVE STATES, P21; Kessler RC, 2008, MOL PSYCHIATR, V13, P374, DOI 10.1038/sj.mp.4002119; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; KRYSTAL JH, 1991, COMPR PSYCHIAT, V32, P474, DOI 10.1016/0010-440X(91)90026-9; Kuhn M, 2006, EUR ARCH PSY CLIN N, V256, P497, DOI 10.1007/s00406-006-0670-6; Marshall RD, 1999, AM J PSYCHIAT, V156, P1677; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; Nixon RDV, 2006, BEHAV COGN PSYCHOTH, V34, P343, DOI 10.1017/S1352465806002931; NOYES R, 1977, COMPR PSYCHIAT, V18, P375, DOI 10.1016/0010-440X(77)90010-4; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Panasetis P, 2003, J TRAUMA STRESS, V16, P563, DOI 10.1023/B:JOTS.0000004079.74606.ba; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; RIGGS DS, 1995, J INTERPERS VIOLENCE, V10, P201, DOI 10.1177/0886260595010002005; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; Salmon K, 2002, CLIN PSYCHOL REV, V22, P163, DOI 10.1016/S0272-7358(01)00086-1; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1997, BRIT J PSYCHIAT, V170, P558, DOI 10.1192/bjp.170.6.558; SOLOMON S, 1996, TRAUMATIC STRESS EFF, P102; SOUTHWICK SM, 1993, ARCH GEN PSYCHIAT, V50, P266; SPIEGEL D, 1991, J ABNORM PSYCHOL, V100, P366, DOI 10.1037/0021-843X.100.3.366; SPIEGEL D, 1994, INT J CLIN EXP HYP, V42, P474; Spiegel David, 1996, P367; Staab JP, 1996, ANXIETY, V2, P219, DOI 10.1002/(SICI)1522-7154(1996)2:5<219::AID-ANXI3>3.0.CO;2-H; Vaiva G, 2004, BIOL PSYCHIAT, V55, P250, DOI 10.1016/j.biopsych.2003.08.009; van der Velden PG, 2008, CLIN PSYCHOL REV, V28, P1009, DOI 10.1016/j.cpr.2008.02.006; VANDERKOLK BA, 1989, AM J PSYCHIAT, V146, P1530; WHO, 1992, ICD 10 INT STAT CLAS; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	79	129	134	7	51	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689			J CLIN PSYCHIAT	J. Clin. Psychiatry	FEB	2011	72	2					233	239		10.4088/JCP.09r05072blu			7	Psychology, Clinical; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	729WR	WOS:000287985400013	21208593				2022-02-06	
J	Grujicic, M; Bell, WC; Pandurangan, B; He, T				Grujicic, M.; Bell, W. C.; Pandurangan, B.; He, T.			Blast-wave impact-mitigation capability of polyurea when used as helmet suspension-pad material	MATERIALS & DESIGN			English	Article						Traumatic brain injury; Helmet design; Polyurea; Computational analysis	TRAUMATIC BRAIN-INJURY; PRESSURE	Traumatic brain injury (TBI) is generally considered as a signature injury of the current military conflicts, with costly and life-altering long-term effects. Hence, there is an urgent need to combat this problem by both gaining a better understanding of the mechanisms responsible for the blast-induced TBI and by designing/developing more effective head protection systems. In the present work, the blast-wave impact-mitigation ability of polyurea when used as a helmet suspension-pad material is investigated computationally. Towards that end, a combined Eulerian/Lagrangian fluid/solid transient non-linear dynamics computational analysis is carried out at two levels of blast peak overpressure: (a) one level corresponding to the unprotected-lung- injury-threshold; and (b) the other level associated with the corresponding 50% lethal dose (LD50), i.e. with a 50% probability for lung-injury induced death. To assess the blast-wave impact-mitigation ability of polyurea, the temporal evolution of the axial stress and the particle (axial) velocity at different locations within the intra-cranial cavity are analyzed. The results are compared with their counterparts obtained in the case of a conventional foam suspension-pad material. This comparison showed that, the use of polyurea suspension pads is associated with a substantially greater reduction in the peak loading experienced by the brain relative to that observed in the case of the conventional foam. The observed differences in the blast-wave mitigation capability of the conventional foam and polyurea are next rationalized in terms of the differences in their microstructure and in their mechanical response when subjected to blast loading. (C) 2010 Elsevier Ltd. All rights reserved.	[Grujicic, M.; Bell, W. C.; Pandurangan, B.; He, T.] Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA		Grujicic, M (corresponding author), Clemson Univ, Dept Mech Engn, 241 Engn Innovat Bldg, Clemson, SC 29634 USA.	mica.grujicic@ces.clemson.edu			Office of Naval Research (ONR) through the Pennsylvania State UniversityOffice of Naval Research [4036-CU-ONR-1125]	The material presented in this paper is based on work supported by the Office of Naval Research (ONR) research contract entitled "Elastomeric Polymer-By-Design to Protect the Warfighter Against Traumatic Brain Injury by Diverting the Blast Induced Shock Waves from the Head", Contract Number 4036-CU-ONR-1125 as funded through the Pennsylvania State University. The authors are indebted to Dr. Roshdy Barsoum of ONR for continuing support and interest in the present work and to professors J. Runt, J. Tarter, G. Settles, G. Dillon and M. Hargether for stimulating discussions and friendship.	Amini MR, 2010, INT J IMPACT ENG, V37, P90, DOI 10.1016/j.ijimpeng.2009.04.005; Amirkhizi AV, 2006, PHILOS MAG, V86, P5847, DOI 10.1080/14786430600833198; *ANSYS INC, 2007, ANSYS AUT 2D 3D VERS; Bahei-El-Din YA, 2006, INT J SOLIDS STRUCT, V43, P7644, DOI 10.1016/j.ijsolstr.2006.03.021; Bake W.E., 1973, EXPLOSIONS AIR; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bogoslovov RB, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2745212; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CHEUNG JT, 2006, 19 ABAQUS US C BOST, P145; Cooper PW., 1996, EXPLOSIVES ENG; Cuitino A., 1992, ENG COMPUT-GERMANY, V9, P437, DOI DOI 10.1108/EB023876>; *DASS SYST, 2008, ABAQUS VERS 6 8 1 US; DAVID FM, 2009, NEUROIMAGE      0224; Davison L, 2008, FUNDAMENTALS SHOCKWA; Grujicic M., 2009, J AUTOMOBILE ENG, V223, P903; GRUJICIC M, MAT STRUCTU IN PRESS; Moore DF, 2008, ANN NEUROL, V64, pS30; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Roland CM, 2007, POLYMER, V48, P5747, DOI 10.1016/j.polymer.2007.07.017; STUHMILLER JH, 2008, QUANTITATIVE PHYSL P; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tham CY, 2008, INT J IMPACT ENG, V35, P304, DOI 10.1016/j.ijimpeng.2007.03.008; *USA CORPS ENG, CONWEP BLAST SIM SOF; Wallsten S. J., 2005, 0519 SOC SCI RES NET; Walsh S. M., 2005, ARLTR3700; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	26	129	133	2	54	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-1275	1873-4197		MATER DESIGN	Mater. Des.	OCT	2010	31	9					4050	4065		10.1016/j.matdes.2010.05.002			16	Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Materials Science	620SD	WOS:000279518900002					2022-02-06	
J	Mondello, S; Robicsek, SA; Gabrielli, A; Brophy, GM; Papa, L; Tepas, J; Robertson, C; Buki, A; Scharf, D; Mo, JX; Akinyi, L; Muller, U; Wang, KKW; Hayes, RL				Mondello, Stefania; Robicsek, Steven A.; Gabrielli, Andrea; Brophy, Gretchen M.; Papa, Linda; Tepas, Joseph, III; Robertson, Claudia; Buki, Andras; Scharf, Dancia; Mo Jixiang; Akinyi, Linnet; Muller, Uwe; Wang, Kevin K. W.; Hayes, Ronald L.			alpha II-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; brain injury; diagnostic; outcome; neuronal death; spectrin breakdown products	SEVERE HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; NEURON-SPECIFIC ENOLASE; SERUM S-100B PROTEIN; GLASGOW COMA SCALE; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; AXONAL INJURY; CEREBROSPINAL-FLUID; CALPAIN ACTIVATION	In this study we assessed the clinical utility of quantitative assessments of alpha II-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score <= 8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (> 6 ng/mL) and SBDP120 levels (> 17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.	[Hayes, Ronald L.] Banyan Biomarkers Inc, Dept Clin Programs, Gainesville, FL USA; [Mondello, Stefania; Robicsek, Steven A.; Gabrielli, Andrea; Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Mondello, Stefania] Univ Florida, Dept Clin Programs, Gainesville, FL USA; [Mondello, Stefania] Univ Florida, Ctr Innovat Res, Gainesville, FL USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Richmond, VA USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Tepas, Joseph, III] Univ Florida, Dept Surg & Pediat, Jacksonville, FL USA; [Robertson, Claudia] Baylor Coll Med, Dept Crit Care, Houston, TX 77030 USA; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Scharf, Dancia; Mo Jixiang; Akinyi, Linnet; Muller, Uwe; Hayes, Ronald L.] Banyan Biomarkers Inc, Dept Res & Dev, Alachua, FL 32615 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Gainesville, FL USA		Hayes, RL (corresponding author), Banyan Biomarkers Inc, Dept Res & Dev, 12085 Res Dr, Alachua, FL 32615 USA.	rhayes@banyanbio.com	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Brophy, Gretchen/0000-0002-4749-2693; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-031-0066]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01, P01-NS38660]; University of FloridaUniversity of Florida [N00014-06-1-1029]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660, R01NS052831, R01NS051431, R01NS049175] Funding Source: NIH RePORTER	This study was supported in part by Department of Defense Award numbers DAMD17-03-1-0772 and DAMD17-031-0066; National Institutes of Health Award numbers R01 NS049175-01, R01-NS052831-01, and R01 NS051431-01; Navy grant number N00014-06-1-1029 (University of Florida); and National Institutes of Health grant #P01-NS38660 (Baylor College of Medicine).	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Blennow M, 1996, ACTA PAEDIATR, V85, P485, DOI 10.1111/j.1651-2227.1996.tb14068.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; BRUNS J, 2009, EPILIPSIA, V44, P2; BULLARD T, 2007, ACAD EMERG MED S1, V14, P5; Cardali S, 2006, J Neurosurg Sci, V50, P25; CHOI SC, 1996, NEUROTRAUMA, P779; COLE TB, 2004, JAMA-J AM MED ASSOC, V291, P531; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; ENG LF, 1980, PROTEINS NERVOUS SYS, P85; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herrmann M, 2001, NEUROSURGERY, V49, P1272, DOI 10.1097/00006123-200111000-00058; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jennett B, 1975, J R Coll Physicians Lond, V9, P231; JENNETT B, 1977, LANCET, V1, P878; JOHNSON AM, 1999, TIETZ TXB CLIN CHEM, P516; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kmietowicz Z, 2007, BRIT MED J, V335, P1182, DOI 10.1136/bmj.39415.528623.AD; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Lewis SB, 2007, J NEUROSURG, V107, P792, DOI 10.3171/JNS-07/10/0792; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARION DW, 1996, NEUROTRAUMA, P767; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McKeating EG, 1998, ACT NEUR S, V71, P117; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; PALFREYMAN JW, 1978, CLIN CHIM ACTA, V82, P259, DOI 10.1016/0009-8981(78)90008-6; PAPA L, 2008, EXPERT OPIN MED DIAG, V28, P1; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; POVLISHOCK JT, 1995, NEUROTRAUMA, V124, P555; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Robertson RL, 2003, PEDIATR RADIOL, V33, P442, DOI 10.1007/s00247-003-0933-6; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothoerl RD, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00054; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stein S. C., 1996, NEUROTRAUMA, P31; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; THOMAS DW, 1978, PHYSIOL BEHAV, V21, P113, DOI 10.1016/0031-9384(78)90284-6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Xiong H, 2000, Sheng Li Ke Xue Jin Zhan, V31, P217	84	129	132	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1203	1213		10.1089/neu.2010.1278			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100005	20408766	Green Published			2022-02-06	
J	Thau-Zuchman, O; Shohami, E; Alexandrovich, AG; Leker, RR				Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.; Leker, Ronen R.			Vascular endothelial growth factor increases neurogenesis after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						angiogenesis; neurogenesis; neuroprotection; traumatic brain injury; vascular endothelial growth factor	CLOSED-HEAD-INJURY; FOCAL CEREBRAL-ISCHEMIA; INDUCED NEUROPROTECTION; BARRIER PERMEABILITY; CELL-PROLIFERATION; STEM-CELLS; IN-VITRO; VEGF; ANGIOGENESIS; HIPPOCAMPUS	Activation of endogenous stem cells has been proposed as a novel form of therapy in a variety of neurologic disorders including traumatic brain injury (TBI). Vascular endothelial growth factor (VEGF) is expressed in the brain after TBI and serves as a potent activator of angiogenesis and neurogenesis. In this study, we infused exogenous VEGF into the lateral ventricles of mice for 7 days after TBI using mini-osmotic pumps to evaluate the effects on recovery and functional outcome. The results of our study show that VEGF significantly increases the number of proliferating cells in the subventricular zone and in the perilesion cortex. Fate analysis showed that most newborn cells differentiated into astrocytes and oligodendroglia and only a few cells differentiated into neurons. Functional outcome was significantly better in mice treated with VEGF compared with vehicle-treated animals after TBI. Injury size was significantly smaller at 90 days after TBI in VEGF-treated animals, suggesting additional neuroprotective effects of VEGF. In conclusion, VEGF significantly augments neurogenesis and angiogenesis and reduces lesion volumes after TBI. These changes are associated with significant improvement in recovery rates and functional outcome. Journal of Cerebral Blood Flow & Metabolism ( 2010) 30, 1008-1016; doi: 10.1038/jcbfm.2009.271; published online 13 January 2010	[Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ Med Ctr, Dept Neurol, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Jerusalem, Israel; [Shohami, Esther; Alexandrovich, Alexander G.] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		Leker, RR (corresponding author), Hadassah Univ Hosp, Dept Neurol, POB 12000, IL-91120 Jerusalem, Israel.	leker@cc.huji.ac.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334; Thau-Zuchman, Orli/0000-0003-0403-7962	Sol Irwin Juni Trust Fund; Peritz and Chantal Scheinberg Cerebrovascular Research Fund	This study was supported by the Sol Irwin Juni Trust Fund and by the Peritz and Chantal Scheinberg Cerebrovascular Research Fund.	Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Ben-Hur T, 2008, J NEUROL SCI, V265, P102, DOI 10.1016/j.jns.2007.05.007; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cirulli V, 2007, NAT REV MOL CELL BIO, V8, P296, DOI 10.1038/nrm2142; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Forsberg-Nilsson K, 1998, J NEUROSCI RES, V53, P521, DOI 10.1002/(SICI)1097-4547(19980901)53:5<521::AID-JNR2>3.0.CO;2-B; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gotts JE, 2005, EXP NEUROL, V194, P139, DOI 10.1016/j.expneurol.2005.02.001; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; Horner PJ, 2003, TRENDS NEUROSCI, V26, P597, DOI 10.1016/j.tins.2003.09.010; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wang WY, 2005, NEUROSCIENCE, V134, P1167, DOI 10.1016/j.neuroscience.2005.04.064; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Zhao XH, 2007, MOL CELL NEUROSCI, V36, P260, DOI 10.1016/j.mcn.2007.07.008	40	129	133	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2010	30	5					1008	1016		10.1038/jcbfm.2009.271			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	590TM	WOS:000277250900013	20068579	Green Published, Bronze			2022-02-06	
J	Chafi, MS; Karami, G; Ziejewski, M				Chafi, M. S.; Karami, G.; Ziejewski, M.			Biomechanical Assessment of Brain Dynamic Responses Due to Blast Pressure Waves	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Blast-head interactions; Blast simulation and validation; Arbitrary Lagrangian-Eulerian (ALE) formulation; Intracranial pressure (ICP); Shear stress; Principal strain and traumatic brain injury (TBI)	HEAD; INJURY; IMPACT	A mechanized and integrated computational scheme is introduced to determine the human brain responses in an environment where the human head is exposed to explosions from trinitrotoluene (TNT), or other high-yield explosives, in military applications. The procedure is based on a three-dimensional (3-D) non-linear finite element method (FEM) that implements a simultaneous conduction of explosive detonation, shock wave propagation, blast-head interactions, and the confronting human head. The processes of blast propagation in the air and blast interaction with the head are modeled by an Arbitrary Lagrangian-Eulerian (ALE) multi-material FEM formulation, together with a penalty-based fluid/structure interaction (FSI) algorithm. Such a model has already been successfully validated against experimental data regarding air-free blast and plate-blast interactions. The human head model is a 3-D geometrically realistic configuration that has been previously validated against the brain intracranial pressure (ICP), as well as shear and principal strains under different impact loadings of cadaveric experimental tests of Hardy et al. [Hardy W. N., C. Foster, M. Mason, S. Chirag, J. Bishop, M. Bey, W. Anderst, and S. Tashman. A study of the response of the human cadaver head to impact. Proc. 51 (st) Stapp. Car Crash J. 17-80, 2007]. Different scenarios have been assumed to capture an appropriate picture of the brain response at a constant stand-off distance of nearly 80 cm from the core of the explosion, but exposed to different amounts of a highly explosive (HE) material such as TNT. The overpressures at the vicinity of the head are in the range of about 2.4-8.7 atmosphere (atm), considering the reflected pressure from the head. The methodology provides brain ICP, maximum shear stresses and maximum principal strain within the milli-scale time frame of this highly dynamic phenomenon. While focusing on the two mechanical parameters of pressure, and also on the maximum shear stress and maximum principal strain to predict the brain injury, the research provides an assessment of the brain responses to different amounts of overpressure. The research also demonstrates the ability to predict the ICP, as well as the stress and strain within the brain, due to such an event. The research cannot identify, however, the specific levels of ICP, stress and strain that necessarily lead to traumatic brain injury (TBI) because there is no access to experimental data regarding head-blast interactions.	[Chafi, M. S.; Karami, G.; Ziejewski, M.] N Dakota State Univ, Dept Mech Engn & Appl Mech, Fargo, ND 58105 USA		Chafi, MS (corresponding author), N Dakota State Univ, Dept Mech Engn & Appl Mech, Fargo, ND 58105 USA.	m.sotudehchafi@ndsu.edu			Air Force Office of Scientific Research (AFOSR)United States Department of DefenseAir Force Office of Scientific Research (AFOSR)	The authors would like to acknowledge the Air Force Office of Scientific Research (AFOSR) for the financial support of this work.	Alia A, 2006, APPL THERM ENG, V26, P1032, DOI 10.1016/j.applthermaleng.2005.10.018; Anderson RWG, 1999, P INT IRCOBI C BIOM, P107; BAIN BC, 2000, J BIOMECH ENG, V16, P615; Benson DJ, 1997, COMPUT METHOD APPL M, V140, P59, DOI 10.1016/S0045-7825(96)01050-X; BRADSHAW DRS, 2001, P 17  INT TECHN C EN; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Chafi MS, 2009, INT J IMPACT ENG, V36, P1269, DOI 10.1016/j.ijimpeng.2009.03.007; CHAFI MS, 2009, COMPUT MATH IN PRESS; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Dobratz B M, 1981, UCRL52997; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; GURDJIAN ES, 1978, SURG GYNECOL OBSTET, V146, P805; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Kang HS, 1997, P 41 STAPP CAR CRASH; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; MILLER RT, 1998, P 42 STAPP CAR CRASH, P155; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Nahum AM, 1977, P 21 STAPP CAR CRASH, P337; O'Donoghue D., 1998, IRISH J MED SCI, V167, P263; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; Shreiber D.I., 1997, STAPP CAR CRASH J, V41, P277; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; *SOFTW TECHN CORP, 2006, LS DYN KEYW US MAN V; Souli M, 2000, COMPUT METHOD APPL M, V190, P659, DOI 10.1016/S0045-7825(99)00432-6; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Ward C, 1980, P 24 STAPP CAR CRASH; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Willinger R., 1995, P IRCOBI C BRUNN SWI, P245; Zhou C, 1995, P STAPP CAR CRASH J, V39, P121, DOI DOI 10.4271/952714	42	129	133	1	42	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	FEB	2010	38	2					490	504		10.1007/s10439-009-9813-z			15	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	551US	WOS:000274237000021	19806456				2022-02-06	
J	Bogner, J; Corrigan, JD				Bogner, Jennifer; Corrigan, John D.			Reliability and Predictive Validity of the Ohio State University TBI Identification Method With Prisoners	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						screening; substance use disorders; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CALIFORNIA PSYCHOLOGICAL INVENTORY; NEUROPSYCHIATRIC INTERVIEW MINI; ADDICTION SEVERITY INDEX; SICKNESS IMPACT PROFILE; SUBSTANCE-ABUSE; AGGRESSION QUESTIONNAIRE; SOCIALIZATION SCALE; PSYCHOMETRIC PROPERTIES; SCREENING TOOL	Objectives: Evaluate the psychometric properties of indices of lifetime exposure to traumatic brain injury (TBI) among prisoners. Participants: Convenience samples recruited from male (N = 105) and female (N = 105) state prison facilities. Design: Assess test/retest reliability and criterion-related validity. Primary Measures: Summary indices of the number, severity, timing, and effects of lifetime exposure to TBI calculated from data elicited via a structured interview. Results: Test/retest reliability ranged from acceptable to high. Factor analysis showed that indices of lifetime exposure could be characterized by (1) age of onset (especially childhood onset), (2) combinations of number and likely severity of injuries, and (3) number of symptoms and functional effects. Age at injury, number of TBIs with loss of consciousness, and symptoms persisting contributed independently to the prediction of common cognitive and behavioral consequences of TBI. Conclusion: These results provide further support for the reliability and validity of summary indices of lifetime exposure to TBI when elicited via a structured interview.	[Bogner, Jennifer; Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Bogner, J (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.	bogner.1@osu.edu	Corrigan, John D./E-2921-2011		National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention [U491CE000359-01]	Preparation of this manuscript was supported by a grant from the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention grant U491CE000359-01.	Adami H, 2002, PSYCHIAT RES, V113, P295, DOI 10.1016/S0165-1781(02)00265-2; Barnfield TV, 1998, BRAIN INJURY, V12, P951, DOI 10.1080/026990598122007; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Beck AT, 1987, BECK DEPRESSION INVE; BECKER JV, 1991, CHILD ABUSE NEGLECT, V15, P531, DOI 10.1016/0145-2134(91)90037-E; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Black DW, 2004, J AM ACAD PSYCHIATRY, V32, P158; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Center for Disease Control and Prevention, 2004, MMWR, V53; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; DAVIS GL, 1991, J OFFENDER REHABIL, V17, P77; DEFRANCESCO JJ, 1993, J PSYCHOPATHOL BEHAV, V15, P53, DOI 10.1007/BF00964323; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Donnellan MB, 2002, PERS INDIV DIFFER, V33, P727; Fox S, 2003, PERS INDIV DIFFER, V34, P1467, DOI 10.1016/S0191-8869(02)00128-9; Ge XJ, 2003, J AM ACAD PSYCHIATRY, V31, P68; GORDON W, 2002, AM C REH MED OCT 4 P; Gough H. G., 1957, MANUAL CALIFORNIA PS; GOUGH HG, 1992, J CLIN PSYCHOL, V48, P298, DOI 10.1002/1097-4679(199205)48:3<298::AID-JCLP2270480306>3.0.CO;2-X; GOUGH HG, 1994, PSYCHOL REP, V75, P651, DOI 10.2466/pr0.1994.75.1.651; Gough HG, 1987, MANUAL CALIFORNIA PS; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Harris JA, 1997, BEHAV RES THER, V35, P1047, DOI 10.1016/S0005-7967(97)00064-8; Heinemann AW, 2004, REHABIL PSYCHOL, V49, P156, DOI 10.1037/0090-5550.49.2.156; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Kadden RM, 1996, PSYCHOL ADDICT BEHAV, V10, P131, DOI 10.1037/0893-164X.10.3.131; Kenny DT, 2007, CONT ISSUES CRIME JU, V107, P1; Kolakowsky-Hayner SA, 2001, BRAIN INJURY, V15, P53, DOI 10.1080/02699050150209138; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lejuez C, 2003, J ADOLESCENCE, V26, P475, DOI 10.1016/S0140-1971(03)00036-8; LEZAK M, 1999, NEUROPSYCHOLOGICAL A; MALLOY P, 1990, ADDICT BEHAV, V15, P431, DOI 10.1016/0306-4603(90)90029-W; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Megargee EI, 1972, CALIFORNIA PSYCHOL I; Morrell R.F., 1998, J OFFENDER REHABIL, V27, P1, DOI [DOI 10.1300/J076V27N03_01, https://doi.org/10.1300/J076v27n03_01]; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; *PSYCH CORP INC, 1997, WAIS 3 WMS 3 TECHN M; Sandoval AMR, 2000, J PERS ASSESS, V74, P262, DOI 10.1207/S15327752JPA7402_7; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Spitzer R. L., 1990, STRUCTURED CLIN INTE; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Thurman DJ., 1995, GUIDELINES SURVEILLA; *TRAUM BRAIN INJ N, 2003, TRAUM BRAIN INJ MOD; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Wang EW, 1999, BEHAV SCI LAW, V17, P377, DOI 10.1002/(SICI)1099-0798(199907/09)17:3<377::AID-BSL351>3.3.CO;2-D; Warner M, 2005, INJURY PREV, V11, P282, DOI 10.1136/ip.2004.006965; WARNER M, 2000, VITAL HLTH STAT, V10, P202; Whiteneck G, 2001, COLORADO TRAUMATIC B; Williams TY, 1996, PSYCHOL ASSESSMENT, V8, P398, DOI 10.1037/1040-3590.8.4.398; [No title captured]	65	129	129	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					279	291		10.1097/HTR.0b013e3181a66356			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000007	19625867				2022-02-06	
J	Pervin, F; Chen, WW				Pervin, Farhana; Chen, Weinong W.			Dynamic mechanical response of bovine gray matter and white matter brain tissues under compression	JOURNAL OF BIOMECHANICS			English	Article						Brain tissues; Mechanical behavior; Strain-rate effects; SHPB	HOPKINSON PRESSURE BAR	Dynamic responses of brain tissues are needed for predicting traumatic brain injury (TBI). We modified a dynamic experimental technique for characterizing high strain-rate mechanical behavior of brain tissues. Using the setup, the gray and white matters from bovine brains were characterized under compression to large strains at five different strain rates ranging from 0.01 to 3000/s. The white matter was examined both along and perpendicular to the coronal section for anisotropy characterization. The results show that both brain tissue matters are highly strain-rate sensitive. Differences between the white matter and gray matter in their mechanical responses are recorded. The white matter shows insignificant anisotropy over all strain rates. These results will lead to rate-dependent material modeling for dynamic event simulations. (C) 2009 Elsevier Ltd. All rights reserved.	[Chen, Weinong W.] Purdue Univ, Sch Aeronaut Astronaut, W Lafayette, IN 47907 USA; Purdue Univ, Sch Mat Engn, W Lafayette, IN 47907 USA		Chen, WW (corresponding author), Purdue Univ, Sch Aeronaut Astronaut, W Lafayette, IN 47907 USA.	wchen@purdue.edu			US Army Research Office (ARO); Joint Improvised Explosive Device Defeat Organization (JIEDDO)	This research was financially supported by US Army Research Office (ARO) and Joint Improvised Explosive Device Defeat Organization (JIEDDO) through Massachusetts Institute of Technology (MIT).	Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Bilston LE, 2001, BIORHEOLOGY, V38, P335; BRANDS D, 2000, ASME WAM C CRASHW OC, P175; Casem D, 2005, EXP MECH, V45, P368, DOI 10.1177/0014485105056090; Chen W, 1999, EXP MECH, V39, P81, DOI 10.1007/BF02331109; Chen W, 2000, EXP MECH, V40, P1, DOI 10.1007/BF02327540; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; DUFFY J, 1971, ASME J APPL MECH, V37, P83; ESTES MS, 1970, 70BHF13 AM SOC MECH, P1; Frew DJ, 2001, EXP MECH, V41, P40, DOI 10.1007/BF02323102; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kohandel M, 2005, PHYS MED BIOL, V50, P2799, DOI 10.1088/0031-9155/50/12/005; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Song B, 2007, J BIOMECH, V40, P2999, DOI 10.1016/j.jbiomech.2007.02.001; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Zhang L, 2001, Stapp Car Crash J, V45, P369	23	129	131	7	38	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	APR 16	2009	42	6					731	735		10.1016/j.jbiomech.2009.01.023			5	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	436WS	WOS:000265447400009	19269640				2022-02-06	
J	Bell, RS; Vo, AH; Neal, CJ; Tigno, J; Roberts, R; Mossop, C; Dunne, JR; Armonda, RA				Bell, Randy S.; Vo, Alexander H.; Neal, Christopher J.; Tigno, June; Roberts, Ryan; Mossop, Corey; Dunne, James R.; Armonda, Rocco A.			Military Traumatic Brain and Spinal Column Injury: A 5-Year Study of the Impact Blast and Other Military Grade Weaponry on the Central Nervous System	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Military; Spinal column injury	PENETRATING CRANIOCEREBRAL INJURIES; SEVERE HEAD-INJURY; GUNSHOT WOUNDS; PULMONARY-EMBOLISM; ANEURYSMS; MORTALITY; SECONDARY; INVOLVEMENT; PREDICTORS; MANAGEMENT	Background: During the past 5 years of Operation Iraqi Freedom (OIF), a significant majority of the severe closed and penetrating head trauma has presented for definitive care at the National Naval Medical Center (NNMC) in Bethesda, MD, and at the Walter Reed Army Medical Center (WRAMC) in Washington, DC. The purpose of this article is to review our experience with this population of patients. Materials: A retrospective review of all inpatient admissions from OIF was performed during a 5-year period (April 2003 to April 2008). Criteria for inclusion in this study included either a closed or penetrating head trauma suffered during combat operations in Iraq who subsequently received a neurosurgical evaluation at NNMC or WRAMC. Exclusion criteria included all patients for whom primary demographic data could not be verified. Primary outcome data included the type and mechanism of injury, Glasgow coma scale (GCS) and injury severity score at admission, and Glasgow outcome scale (GOS) at discharge, 6 months, and 1 to 2 years. Results: Five hundred thirteen consultations were performed by the neurosurgery service on the aforementioned population. Four hundred eight patients met the inclusion criteria for this study (401:7, male: female; 228 penetrating brain injury, 139 closed head injury, 41 not specified). Explosive blast injury (229 patients; 56%) constituted the predominant mechanism of injury. The rates of pulmonary embolism (7%), cerebrospinal fluid leak (8.6%), meningitis (9.1%), spinal cord or column injury (9.8%), and cerebrovascular injury (27%) were characterized. Cerebrospinal fluid leak, vasospasm, penetrating head injury, and lower presenting GCS were statistically associated with longer intensive care unit stays and higher presenting injury severity scores (p < 0.05). While presenting GCS 3-5 correlated with worsened short-term and long-term GOS scores (p < 0.001), almost half of these patients achieved GOS >= 3 at 1- to 2-year follow-up. Total mortality after reaching NNMC/WRAMC was 4.4%. Conclusions. OIF has resulted in the highest concentration of severe closed and penetrating head trauma to return to NNMC and WRAMC since the Vietnam Conflict. Management scenarios were complex, incorporating principles designed to maximize outcomes in all body systems. Meaningful survival can potentially be achieved in a subset of patients with presenting GCS <= 5.	[Bell, Randy S.; Neal, Christopher J.; Armonda, Rocco A.] Natl Naval Med Ctr, Dept Neurosurg, Bethesda, MD 20889 USA; [Dunne, James R.; Armonda, Rocco A.] Natl Naval Med Ctr, Dept Trauma Crit Care, Bethesda, MD 20889 USA; [Vo, Alexander H.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA; [Bell, Randy S.; Neal, Christopher J.; Tigno, June; Roberts, Ryan; Mossop, Corey; Armonda, Rocco A.] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA		Bell, RS (corresponding author), Natl Naval Med Ctr, Dept Neurosurg, Bethesda, MD 20889 USA.	randy.bell@med.navy.mil					Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bakir A, 2005, NEUROL MED-CHIR, V45, P281, DOI 10.2176/nmc.45.281; BELLAMY RF, 1984, MIL MED, V149, P55; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cushing H, 1918, BRIT J SURG, V5, P558; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HALBACH VV, 1993, J NEUROSURG, V79, P183, DOI 10.3171/jns.1993.79.2.0183; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Horowitz MB, 1999, SURG NEUROL, V51, P31, DOI 10.1016/S0090-3019(98)00029-9; KENNEDY FR, 1994, SOUTHERN MED J, V87, P621, DOI 10.1097/00007611-199406000-00008; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; Lu J, 2005, ACT NEUR S, V95, P281; Marcikic M, 1998, INJURY, V29, P613, DOI 10.1016/S0020-1383(98)00146-6; MATSON D, 1958, MANAGEMENT ACUTE CRA; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Page RB, 2004, NEUROSURGERY, V54, P143, DOI 10.1227/01.NEU.0000097514.60813.1B; Piatt JH, 2006, J NEUROSURG-SPINE, V5, P210, DOI 10.3171/spi.2006.5.3.210; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Reister FA, 1975, MED STAT WORLD WAR 2; Reister FA, 1973, BATTLE CASUALTIES ME; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Stawicki SP, 2005, AM SURGEON, V71, P387; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Whelan T J Jr, 1968, Adv Surg, V3, P227	35	129	133	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2009	66	4		S			S104	S111		10.1097/TA.0b013e31819d88c8			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	431OW	WOS:000265073100017	19359953				2022-02-06	
J	Sim, A; Terryberry-Spohr, L; Wilson, KR				Sim, Anita; Terryberry-Spohr, Low; Wilson, Kathryn R.			Prolonged recovery of memory functioning after mild traumatic brain injury in adolescent athletes	JOURNAL OF NEUROSURGERY			English	Article						brain injury; mild traumatic brain injury; neurocognitive deficit; recovery; sports-related concussion	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; PERFORMANCE; CONSISTENCY; TIME	Object. The current body of sports-related concussion literature is hampered by a lack of research conducted in high school athletes. Accordingly, the authors sought to examine the neuropsychological deficits and recovery patterns after concussive injuries in this population. Methods. Participants included 419 male and female athletes with a mean age of 15.69 years who underwent baseline testing of their neuropsychological functioning prior to their sports season. Fourteen participants sustained an in-season concussion and were serially reassessed at similar to 2.5, 6, and 10 days postinjury. Fourteen uninjured matched control participants were also reassessed at the end of the school year. Results. Individuals who sustained in-season concussions demonstrated impairments in reaction time, processing speed, and had delayed memory functioning. Although reaction time and processing speed deficits returned to baseline levels by similar to 6 days postinjury, participants continued to show memory impairments up to 7 days postinjury. Memory impairments were found to resolve by Day 10, however. Conclusions. The results of the present study suggest that high school athletes demonstrate prolonged memory dysfunction compared with college athletes, and should therefore be treated more conservatively.	[Sim, Anita] Univ Virginia Hlth Syst, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22908 USA; [Sim, Anita; Terryberry-Spohr, Low; Wilson, Kathryn R.] Madonna Rehabil Hosp, Lincoln, NE USA; [Sim, Anita; Terryberry-Spohr, Low; Wilson, Kathryn R.] Univ Nebraska, Lincoln, NE 68583 USA		Sim, A (corresponding author), Univ Virginia Hlth Syst, Dept Psychiat & Neurobehav Sci, POB 800203, Charlottesville, VA 22908 USA.	anitasim1@gmail.com					Barth JT, 1989, MILD HEAD INJURY, P257; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Bleiberg J., 2006, SPORTS NEUROPSYCHOLO, P263; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; COOK AW, 1996, CLIN NEUROSURG, V12, P386; Cummings J., 2003, NEUROPSYCHIATRY BEHA; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Hatfield R, 2004, STUD NEUROPSYCHOL DE, P129; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Metzl JD, 2006, PEDIATRICS, V117, P1813, DOI 10.1542/peds.2006-0480; *NAT CTR INJ PREV, 2003, STEPS PREV SER PUBL; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Powell JW, 2001, J ATHL TRAINING, V36, P307; POWELL JW, 2001, JAMA-J AM MED ASSOC, V22, P958; REEVES D, 1989, 891 UTCPAB; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Warden DL, 2004, NEUROLOGY, V62, P1462, DOI 10.1212/WNL.62.9.1462; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	29	129	130	0	25	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2008	108	3					511	516		10.3171/JNS/2008/108/3/0511			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	270PM	WOS:000253732700013	18312098				2022-02-06	
J	Byrnes, KR; Stoica, BA; Fricke, S; Di Giovanni, S; Faden, AI				Byrnes, Kimberly R.; Stoica, Bogdan A.; Fricke, Stanley; Di Giovanni, Simone; Faden, Alan I.			Cell cycle activation contributes to post-mitotic cell death and secondary damage after spinal cord injury	BRAIN			English	Article						apoptosis; astrocyte; inflammation; microglia; neuron	DEPENDENT KINASE INHIBITOR; TRAUMATIC BRAIN-INJURY; NEURONAL DEATH; SCAR FORMATION; EXPRESSION; APOPTOSIS; RATS; FLAVOPIRIDOL; MICROGLIA; REGENERATION	Spinal cord injury (SCI) causes delayed secondary biochemical alterations that lead to tissue loss and associated neurological dysfunction. Up-regulation of cell cycle proteins occurs in both neurons and glia after SCI and may contribute to these changes. The present study examined the role of cell cycle activation on secondary injury after severe SCI in rat. SCI caused cell cycle protein up-regulation associated with neuronal and oligodendroglial apoptosis, glial scar formation and microglial activation. Treatment with the cell cycle inhibitor flavopiridol reduced cell cycle protein induction and significantly improved functional recovery versus vehicle-treated controls at 21 and 28 days post-injury. Treatment also significantly reduced lesion volume, as measured by MRI and histology, decreased astrocytic reactivity, attenuated neuronal and oligodendroglial apoptosis and reduced the production of factors associated with microglial activation. Thus, flavopiridol treatment improves outcome after SCI by inhibiting cell cycle pathways, resulting in beneficial multifactorial actions on neurons and glia.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany		Byrnes, KR (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bldg,Room EP16A 3970 Reservoir Rd,NW, Washington, DC 20057 USA.	krb27@georgetown.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-1-2339, 5T32NS041218-04] Funding Source: Medline		Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Becker EBE, 2004, PROG NEUROBIOL, V72, P1, DOI 10.1016/j.pneurobio.2003.12.005; Benton RL, 2003, NEUROCHEM RES, V28, P1693, DOI 10.1023/A:1026013106016; Boonstra J, 2003, J CELL BIOCHEM, V90, P244, DOI 10.1002/jcb.10617; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; De Biase A, 2005, PHYSIOL GENOMICS, V22, P368, DOI 10.1152/physiolgenomics.00081.2005; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; FADEN AI, 1992, J PHARMACOL EXP THER, V261, P1064; Fehlings MG, 2001, SPINE, V26, pS56, DOI 10.1097/00007632-200112151-00012; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HOKE A, 1994, PERSPECT DEV NEUROBI, V2, P269; HUREBERT RJ, 2006, SPINE, V31, pS16; HUREBERT RJ, 2006, SPINE, V31, pS36; Iannotti C, 2004, EXP NEUROL, V189, P317, DOI 10.1016/j.expneurol.2004.05.033; Jorda EG, 2003, NEUROPHARMACOLOGY, V45, P672, DOI 10.1016/S0028-3908(03)00204-1; Kato H, 2003, BRAIN RES BULL, V60, P215, DOI 10.1016/S0361-9230(03)00036-4; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knoblach SM, 2005, J NEUROSCI RES, V80, P369, DOI 10.1002/jnr.20465; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; McBride CB, 2003, MOL CELL NEUROSCI, V23, P383, DOI 10.1016/S1044-7431(03)00063-0; Miller DH, 1998, BRAIN, V121, P3, DOI 10.1093/brain/121.1.3; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Newcomb EW, 2004, CELL CYCLE, V3, P230; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Pirko Istvan, 2005, NeuroRx, V2, P250, DOI 10.1602/neurorx.2.2.250; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; POPOVICH PG, 2001, INFLAMMATORY EVENTS, P276; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Sayer Faisal T, 2006, Spine J, V6, P335, DOI 10.1016/j.spinee.2005.11.001; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Senderowicz AM, 2005, PROG DRUG RES, V63, P183; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; 't Hart BA, 1998, AM J PATHOL, V153, P649, DOI 10.1016/S0002-9440(10)65606-4; Tator C H, 1996, J Spinal Cord Med, V19, P206; TATOR CH, 2002, INJ PREV S4, V8, P6; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Verdaguer E, 2004, J PHARMACOL EXP THER, V308, P609, DOI 10.1124/jpet.103.057497; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200	64	129	137	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2007	130		11				2977	2992		10.1093/brain/awm179			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	227RJ	WOS:000250675200024	17690131	Bronze			2022-02-06	
J	Lew, HL; Poole, JH; Vanderploeg, RD; Goodrich, GL; Dekelboum, S; Guillory, SB; Sigford, B; Cifu, DX				Lew, Henry L.; Poole, John H.; Vanderploeg, Rodney D.; Goodrich, Gregory L.; Dekelboum, Sharon; Guillory, Sylvia B.; Sigford, Barbara; Cifu, David X.			Program development and defining characteristics of returning military in a VA Polytrauma Network Site	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain concussion; brain injuries; hearing disorders; needs assessment; neuropsychology; pain; physical medicine; posttraumatic; rehabilitation; stress disorders; vision disorders	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SYMPTOMS	The conflicts in Iraq and Afghanistan have resulted in a new generation of combat survivors with complex physical injuries and emotional trauma. This article reports the initial implementation of the Polytrauma Network Site (PNS) clinic, which is a key component of the Department of Veterans Affairs (VA) Polytrauma System of Care and serves military personnel returning from combat. The PNS clinic in Palo Alto, California, is described to demonstrate the VA healthcare system's evolving effort to meet the clinical needs of this population. We summarize the following features of this interdisciplinary program: (1) sequential assessment, from initial traumatic brain injury screening throughout our catchment area to evaluation by the PNS clinic team, and (2) clinical evaluation results for the first 62 clinic patients. In summary, this population shows a high prevalence of postconcussion symptoms, posttraumatic stress, poor cognitive performance, head and back pain, auditory and visual symptoms, and problems with dizziness or balance. An anonymous patient feedback survey, which we used to fine-tune the clinic process, reflected high satisfaction with this new program. We hope that the lessons learned at one site will enhance the identification and treatment of veterans with polytrauma across the country.	[Lew, Henry L.; Poole, John H.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; [Lew, Henry L.; Poole, John H.] DVBIC, Palo Alto, CA USA; [Lew, Henry L.; Poole, John H.] Stanford Univ, Sch Med, Div Phys Med & Rehabil, Stanford, CA 94305 USA; [Vanderploeg, Rodney D.] DVBIC, Tampa, FL USA; [Vanderploeg, Rodney D.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Tampa, FL USA; [Sigford, Barbara] DVBIC, Minneapolis, MN USA; [Sigford, Barbara] Minneapolis VA Med Ctr, Minneapolis, MN USA; [Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA; [Cifu, David X.] Virginia Commonwealth Univ, Richmond, VA USA		Lew, HL (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave,B117, Palo Alto, CA 94304 USA.	henrylew@stanford.edu	Goodrich, Gregory L./AAF-7184-2019	Cifu, David/0000-0003-1600-9387			Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2004, AM J PHYS MED REHAB, V83, P210, DOI 10.1097/01.PHM.0000113402.85460.59; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	14	129	129	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					1027	1034		10.1682/JRRD.2007.05.0073			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	253NL	WOS:000252524800015	18075959	Bronze			2022-02-06	
J	Kobeissy, FH; Ottens, AK; Zhang, ZQ; Liu, MC; Denslow, ND; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW				Kobeissy, Firas H.; Ottens, Andrew K.; Zhang, Zhiqun; Liu, Ming Cheng; Denslow, Nancy D.; Dave, Jitendra R.; Tortella, Frank C.; Hayes, Ronald L.; Wang, Kevin K. W.			Novel differential neuroproteomics analysis of traumatic brain injury in rats	MOLECULAR & CELLULAR PROTEOMICS			English	Article							SPECTRIN BREAKDOWN PRODUCTS; TANDEM MASS-SPECTROMETRY; STROKE-PRONE RATS; BIOMARKER DISCOVERY; PROTEOMIC IDENTIFICATION; CEREBROSPINAL-FLUID; SHOTGUN PROTEOMICS; HEAD-INJURY; CELL-DEATH; PROTEINS	Approximately two million traumatic brain injury (TBI) incidents occur annually in the United States, yet there are no specific therapeutic treatments. The absence of brain injury diagnostic endpoints was identified as a significant roadblock to TBI therapeutic development. To this end, our laboratory has studied mechanisms of cellular injury for biomarker discovery and possible therapeutic strategies. In this study, pooled naive and injured cortical samples (48 h postinjury; rat controlled cortical impact model) were processed and analyzed using a differential neuroproteomics platform. Protein separation was performed using combined cation/anion exchange chromatography-PAGE. Differential proteins were then trypsinized and analyzed with reversed-phase LC-MSMS for protein identification and quantitative confirmation. The results included 59 differential protein components of which 21 decreased and 38 increased in abundance after TBI. Proteins with decreased abundance included collapsin response mediator protein 2 (CRMP-2), glyceraldehyde-3-phosphate dehydrogenase, microtubule-associated proteins MAP2A/2B, and hexokinase. Conversely C-reactive protein, transferrin, and breakdown products of CRMP-2, synaptotagmin, and alpha II-spectrin were found to be elevated after TBI. Differential changes in the above mentioned proteins were confirmed by quantitative immunoblotting. Results from this work provide insight into mechanisms of traumatic brain injury and yield putative biochemical markers to potentially facilitate patient management by monitoring the severity, progression, and treatment of injury.	Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Physiol Sci, Gainesville, FL 32611 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32611 USA; Walter Reed Army Inst Res, Dept Neuropharmacol & Mol Biol, Div Neurosci, Silver Spring, MD 20910 USA		Kobeissy, FH (corresponding author), Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, POB 100256, Gainesville, FL 32610 USA.	firasko@ufl.edu; aottens@mbi.ufl.edu; kwang@psychiatry.ufl.edu	Dave, Jitendra R/A-8940-2011; Ottens, Andrew/K-3352-2012; Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473; Ottens, Andrew/0000-0002-2118-3796	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40182, R01 NS39091, R01 NS049175] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091, R01NS049175] Funding Source: NIH RePORTER		Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Bodovitz S, 2004, TRENDS BIOTECHNOL, V22, P4, DOI 10.1016/j.tibtech.2003.10.013; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Celis JE, 2004, MOL CELL PROTEOMICS, V3, P327, DOI 10.1074/mcp.M400009-MCP200; Czech T, 2004, NEUROCHEM RES, V29, P2189, DOI 10.1007/s11064-004-7025-3; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Davidsson P, 2005, DIS MARKERS, V21, P81, DOI 10.1155/2005/848676; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Di Napoli M, 2001, STROKE, V32, P917, DOI 10.1161/01.STR.32.4.917; Dunckley T, 2005, DRUG DISCOV TODAY, V10, P326, DOI 10.1016/S1359-6446(04)03353-7; Fan L, 2001, J NEUROCHEM, V76, P1275, DOI 10.1046/j.1471-4159.2001.00176.x; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Gao J, 2005, METHODS, V35, P291, DOI 10.1016/j.ymeth.2004.08.020; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kosinska K, 1992, Ann Acad Med Stetin, V38, P67; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Lubec G, 2003, PROG NEUROBIOL, V69, P193, DOI 10.1016/S0301-0082(03)00036-4; McDonald WH, 2002, DIS MARKERS, V18, P99, DOI 10.1155/2002/505397; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; *NINDS, 2006, NIH PUBL, V2; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Ottens AK, 2005, ANAL CHEM, V77, P4836, DOI 10.1021/ac050478r; Pelsers MMAL, 2005, CLIN CHIM ACTA, V352, P15, DOI 10.1016/j.cccn.2004.09.001; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Shin BK, 2002, J MAMMARY GLAND BIOL, V7, P407, DOI 10.1023/A:1024038132381; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Sironi L, 2004, J NEUROSCI RES, V78, P115, DOI 10.1002/jnr.20219; Sironi L, 2001, STROKE, V32, P753, DOI 10.1161/01.STR.32.3.753; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Van den Bergh G, 2004, CURR OPIN BIOTECH, V15, P38, DOI 10.1016/j.copbio.2003.12.001; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y	45	129	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	1535-9476	1535-9484		MOL CELL PROTEOMICS	Mol. Cell. Proteomics	OCT	2006	5	10					1887	1898		10.1074/mcp.M600157-MCP200			12	Biochemical Research Methods	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	098KL	WOS:000241519300016	16801361	hybrid			2022-02-06	
J	McIntyre, LA; Fergusson, DA; Hutchison, JS; Pagliarello, G; Marshall, JC; Yetisir, E; Hare, GMT; Hebert, PC				McIntyre, Lauralyn A.; Fergusson, Dean A.; Hutchison, James S.; Pagliarello, Giuseppe; Marshall, John C.; Yetisir, Elizabeth; Hare, Gregory M. T.; Hebert, Paul C.		Canadian Critical Care Trials Grp	Effect of a liberal versus restrictive transfusion strategy on mortality in patients with moderate to severe head injury	NEUROCRITICAL CARE			English	Article						critical care; brain injuries; wounds and injuries; erythrocyte transfusion; randomized controlled trial	TRAUMATIC BRAIN-INJURY; BLOOD-TRANSFUSION; SECONDARY INSULTS; HYPOTENSION; HYPOXIA; MANAGEMENT; SCORE; SAFE	Objective: To compare a restrictive versus a liberal transfusion strategy in patients with moderate to severe closed head injury following multiple trauma in 13 Canadian intensive care units (ICUs). Methods: This is a subgroup analysis of a multicenter randomized controlled clinical trial involving sixty-seven critically ill patients from the Transfusion Requirements in the Critical Care trial who sustained a closed head injury. Patients had a hemoglobin concentration less than 9.0 g/dL within 72 hours of admission to the ICU. Patients were randomized to a restrictive allogeneic red blood cell transfusion strategy (hemoglobin 7.0 g/dL and maintained between 7.0 and 9.0 g/dL) or a liberal strategy (hemoglobin 10.0 g/dL and maintained between 10.0 and 12.0 g/dL). Results: Baseline characteristics in the restrictive (n = 29) and the liberal (n = 38) transfusion groups were comparable. Average hemoglobin concentrations and red blood cell units transfused per patient were significantly lower in the restrictive compared to the liberal group. The 30-day all-cause mortality rates in the restrictive group were 17% as compared to 13% in the liberal group (risk difference 4.1 with 95% confidence interval [CI], 13.4 to 21.5, p = 0.64). Presence of multiple organ dysfunction (12.1 +/- 6.4 versus 10.6 +/- 6.3, p = 0.35) and changes in multiple organ dysfunction from baseline scores adjusted for death (4.5 +/- 6.2 versus 3.4 +/- 6.2, p = 0.49) were similar between the restrictive and liberal transfusion groups, respectively. Median length of stay in ICU (10 days, interquartile range 5 to 21 days versus 8 days, interquartile range 5 to 11 days, p = 0.26) and hospital (27 days, interquartile range 14 to 39 days versus 30.5 days, interquartile range 17 to 47 days, p = 0.72) were similar between the restrictive and liberal transfusion groups. Conclusions: We were unable to detect significant improvements in mortality with a liberal as compared to restrictive transfusion strategy in critically ill trauma victims with moderate to severe head injury.	Ottawa Hlth Res Inst, Ctr Transfus Res, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ctr Transfus & Crit Care Res, Clin Epidemiol Unit, Crit Care Program, Ottawa, ON K1N 6N5, Canada; Univ Toronto, Hosp Sick Children, Dept Crit Care, Toronto, ON, Canada; Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Ottawa Hosp, Crit Care Program, Ottawa, ON, Canada; Univ Toronto, Dept Surg, Crit Care Program, Toronto, ON, Canada; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Univ Toronto, St Michaels Hosp, Dept Anesthesia & Physiol, Toronto, ON, Canada		McIntyre, LA (corresponding author), Ottawa Hlth Res Inst, Ctr Transfus Res, Gen Campus,501 Smyth Rd,Box 201, Ottawa, ON K1H 8L6, Canada.	lmcintyre@ottawahospital.on.ca	Hare, Greg/AAM-5599-2021; McIntyre, Lauralyn/AAR-7710-2021	McIntyre, Lauralyn/0000-0001-7421-1407; Fergusson, Dean/0000-0002-3389-2485			American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP D; AUDET AM, 1992, ANN INTERN MED, V116, P403, DOI 10.7326/0003-4819-116-5-403; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blajchman MA, 1999, TRANSFUSION, V39, P665, DOI 10.1046/j.1537-2995.1999.39070665.x; Carson JL, 2002, TRANSFUS MED REV, V16, P187, DOI 10.1053/tmrv.2002.33461; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FORTUNE JB, 1987, J TRAUMA, V27, P243, DOI 10.1097/00005373-198703000-00003; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Hare GMT, 2003, J NEUROTRAUM, V20, P1134; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McIntyre L, 2004, J TRAUMA, V57, P563, DOI 10.1097/01.TA.0000136158.93864.54; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Tinmouth A, 2001, TRANSFUS MED REV, V15, P91, DOI 10.1053/tmrv.2001.22613; TOPLEY E, 1956, BR J CLIN PRACT, V1, P770; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615	36	129	134	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2006	5	1					4	9		10.1385/NCC:5:1:4			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	073UB	WOS:000239767000002	16960287				2022-02-06	
J	Butler, RW; Mulhern, RK				Butler, RW; Mulhern, RK			Neurocognitive interventions for children and adolescents surviving cancer	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article; Proceedings Paper	Pediatric Psycho-Oncology Research Summit	OCT, 2001	San Antonio, TX	Childhood Canc Grp, NCI		pediatric brain injury; rehabilitation; childhood cancer	DEFICIT HYPERACTIVITY DISORDER; ACUTE LYMPHOBLASTIC-LEUKEMIA; SYSTEM PROPHYLACTIC TREATMENT; CRANIAL RADIATION-THERAPY; TRAUMATIC BRAIN-INJURY; CHILDHOOD-CANCER; DEVELOPMENTAL MODEL; PEER RELATIONSHIPS; WORKING-MEMORY; TUMOR PATIENTS	Background It is well recognized that many cures for childhood leukemia and brain tumors entail some relatively permanent neurocognitive and psychological costs to the patient and family. As cure rates have improved over the past three decades, increasing efforts have been directed toward reducing treatment-related late effects. Objective The particular focus of this review will be on interventions for the neuropsychological late effects associated with the treatment of acute lymphoblastic leukemia (ALL) and malignant brain tumors. Summary We will first briefly review current approaches to the medical treatment of ALL and brain tumors to provide an appreciation of potential sources of brain injury. We will then summarize the existing literature on types of neuropsychological deficits found among survivors, with special attention to variables that place some children at greater risk. Then, there will be a discussion of approaches to intervention for these deficits-specifically, cognitive remediation, pharmacology, and ecological alterations in the classroom. Finally, we will present directions for future research in the field.	Oregon Hlth & Sci Univ, Div Pediat Hematol Oncol, Portland, OR 97239 USA; St Jude Childrens Res Hosp, Memphis, TN USA		Butler, RW (corresponding author), Oregon Hlth & Sci Univ, Div Pediat Hematol Oncol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	butlerr@ohsu.edu			NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA083936] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA83936-01] Funding Source: Medline		Andrews K, 2001, J PEDIATR PSYCHOL, V26, P1, DOI 10.1093/jpepsy/26.1.1; Armstrong FD, 1999, SCHOOL PSYCHOL REV, V28, P194; BARKLEY RA, 1990, PEDIATRICS, V86, P184; BARON IS, 1993, NEUROPSYCHOL REHABIL, V3, P389, DOI 10.1080/09602019308401448; Brett A W, 1998, Pediatr Rehabil, V2, P27; BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; BROUWERS P, 1985, J PEDIATR-US, V106, P723, DOI 10.1016/S0022-3476(85)80343-7; Brown RT, 1998, J PEDIATR PSYCHOL, V23, P333, DOI 10.1093/jpepsy/23.5.333; BROWN RT, 1997, HDB CLIN CHILD NEURO, P539; BROWN RT, 1998, MED SCH AGE CHILDREN, P29; BUTLER R, 1999, J INT NEUROPSYCH SOC, V5, P108; Butler RW, 1998, MED PEDIATR ONCOL, P75; Butler RW, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P97; BUTLER RW, 1994, J CLIN ONCOL, V12, P2621, DOI 10.1200/JCO.1994.12.12.2621; BUTLER RW, 1993, J PEDIATR PSYCHOL, V18, P319, DOI 10.1093/jpepsy/18.3.319; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Butler RW, 1999, CHILD HEALTH CARE, V28, P311, DOI 10.1207/s15326888chc2804_3; BUTLER RW, 1988, J NEUROLOGICAL REHAB, V2, P97; CAMPBELL T, 1990, COGNITIVE REMEDIATIO; CHRISTENSEN AL, 2000, INT HDB NEUROPSYCHOL; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Copeland DR, 1996, J CLIN ONCOL, V14, P2826, DOI 10.1200/JCO.1996.14.10.2826; CROWLEY JA, 1991, J PEDIATR PSYCHOL, V16, P611, DOI 10.1093/jpepsy/16.5.611; DEATON AV, 1987, J LEARN DISABIL, V20, P581, DOI 10.1177/002221948702001003; DELONG R, 1992, J CHILD NEUROL, V7, P462, DOI 10.1177/088307389200700425; Efron D, 1997, PEDIATRICS, V100, P662, DOI 10.1542/peds.100.4.662; FLETCHER JM, 1988, J CLIN EXP NEUROPSYC, V10, P495, DOI 10.1080/01688638808408255; HANDEN BL, 1990, PEDIATRICS, V86, P922; HARRINGTON JA, 1958, J MENT SCI, V104, P1205, DOI 10.1192/bjp.104.437.1205; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; Kerns K A, 1998, Pediatr Rehabil, V2, P77; LAURIA AR, 1963, RESTORATION FUNCTION; LEICHTMAN M, 1992, B MENNINGER CLIN, V56, P321; Leigh L.D., 2002, PRINCIPLES PRACTICE, P1463; Leung W, 2000, LEUKEMIA, V14, P1185, DOI 10.1038/sj.leu.2401818; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Lockwood KA, 1999, J PEDIATR PSYCHOL, V24, P55, DOI 10.1093/jpepsy/24.1.55; MARGOLIN JF, 2002, PRINCIPLES PRACTICE, P489; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Meichenbaum, 1977, COGNITIVE BEHAV MODI; Meyers CA, 1998, J CLIN ONCOL, V16, P2522, DOI 10.1200/JCO.1998.16.7.2522; Moleski M, 2000, ARCH CLIN NEUROPSYCH, V15, P603, DOI 10.1016/S0887-6177(99)00050-5; MOORE IM, 2000, SEMINARS ONCOLOGY NU, V16, P276; Mulhern RK, 2001, J CLIN ONCOL, V19, P472, DOI 10.1200/JCO.2001.19.2.472; *NIH, 1998, REH PERS TRAUM BRA I; NOLL RB, 1991, J PEDIATR PSYCHOL, V16, P307, DOI 10.1093/jpepsy/16.3.307; NOLL RB, 1993, J PEDIATR PSYCHOL, V18, P351, DOI 10.1093/jpepsy/18.3.351; Palmer SL, 2001, J CLIN ONCOL, V19, P2302, DOI 10.1200/JCO.2001.19.8.2302; PELHAM WE, 1989, J AM ACAD CHILD PSY, V28, P773, DOI 10.1097/00004583-198909000-00021; Posner MI., 1994, IMAGES MIND; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; RAPPORT MD, 1994, J AM ACAD CHILD PSY, V33, P882, DOI 10.1097/00004583-199407000-00015; RAPPORT MD, 1986, J CONSULT CLIN PSYCH, V54, P334; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; Reddick WE, 2003, CANCER-AM CANCER SOC, V97, P2512, DOI 10.1002/cncr.11355; Ris MD, 2001, J CLIN ONCOL, V19, P3470, DOI 10.1200/JCO.2001.19.15.3470; RIS MD, 1994, J CLIN EXP NEUROPSYC, V16, P21, DOI 10.1080/01688639408402615; Rodgers J, 1999, ARCH DIS CHILD, V80, P318, DOI 10.1136/adc.80.4.318; Schatz J, 2000, NEUROPSYCHOLOGY, V14, P189, DOI 10.1037//0894-4105.14.2.189; SILVER BV, 1994, ARCH PHYS MED REHAB, V75, P742; Slifer KJ, 1997, BRAIN INJURY, V11, P877; Sohlberg M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 1996, ATTENTION PROCESS TR, V2; STUSS DT, 1999, COGNITIVE NEUROREHAB; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; TANNOCK R, 1995, J AM ACAD CHILD PSY, V34, P886, DOI 10.1097/00004583-199507000-00012; TANNOCK R, 1989, PEDIATRICS, V84, P648; Teichner G, 1999, Rehabil Nurs, V24, P207; Thompson SJ, 2001, J CLIN ONCOL, V19, P1802, DOI 10.1200/JCO.2001.19.6.1802; Torres CF, 1996, ANN NEUROL, V40, P174; Vannatta K, 1998, J PEDIATR PSYCHOL, V23, P279, DOI 10.1093/jpepsy/23.5.279; Waber DP, 2000, J PEDIAT HEMATOL ONC, V22, P206, DOI 10.1097/00043426-200005000-00004; Warschausky S, 1999, J HEAD TRAUMA REHAB, V14, P373, DOI 10.1097/00001199-199908000-00006; Weber P, 2002, PEDIATR NEUROL, V26, P261, DOI 10.1016/S0887-8994(01)00408-8; WHALEN CK, 1991, J LEARN DISABIL, V24, P231, DOI 10.1177/002221949102400407; Williams DJ., 1989, PROCESS SPECIFIC TRA; Worthington J, 1989, Rehabil Nurs, V14, P118; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; [No title captured]	80	129	130	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JAN-FEB	2005	30	1					65	78		10.1093/jpepsy/jsi017			14	Psychology, Developmental	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology	884OL	WOS:000226094800008	15610986	Bronze			2022-02-06	
J	Griesbach, GS; Gomez-Pinilla, F; Hovda, DA				Griesbach, GS; Gomez-Pinilla, F; Hovda, DA			The upregulation of plasticity-related proteins following TBI is disrupted with acute voluntary exercise	BRAIN RESEARCH			English	Article						exercise; traumatic brain injury; neuroplasticity; CREB; synapsin I; MAPK; CAMKII	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; NEUROTROPHIC FACTOR; SYNAPSIN-I; NEUROTRANSMITTER RELEASE; SYNAPTIC-PLASTICITY; RAT HIPPOCAMPUS; KINASE-II; FLUID PERCUSSION; MESSENGER-RNA	Following traumatic brain injury (TBI), the brain undergoes a period of metabolic and neurochemical alterations that may compromise the reactivity of neuroplasticity-related molecular systems to physiological stimulation. In order to address the molecular mechanisms underlying plasticity following TBI and the effects of physical stimulation in the acute phase of TBI, levels of intracellular signaling molecules were assessed following voluntary exercise. Lateral fluid percussion injury (FPI) and sham-operated (Sham) rats were housed with or without access to a running wheel (RW) from postsurgery day 0 to 6. Parietal and occipital cortical tissues were analyzed for brain-derived neurotrophic factor (BDNF) using an enzyme-linked immunoabsorbant assay (ELISA). In addition, synapsin I, phospho-synapsin I, cyclic-AMP response-element-binding protein (CR-EB), phospho-CREB, calcium-calmodulin-dependent protein kinase II (CAMKII), mitogen-activated protein (MAP) kinase I and II (MAPKI and MAPKII), and protein kinase C (PKC) were analyzed by western blot. Results from this study indicated that FPI alone lead to significant increases in synapsin 1, CAMKII, and phosphorylated (P) MAPKI (p44) and MAPKII (p42). Exercise in the sham operates led to significant cortical increases of CREB and synapsin I. However, in the FPI rats, the response to exercise was opposite to that seen in the shams in that exercise resulted in significant decreases of CREB, synapsin I, PKC, CAMKII, MAPKI, and MAPKII. Indeed, all the observed proteins in the acutely exercised FPI rats tended to be lower compared to the FPI sedentary (Sed) rats. These results indicate that intracellular signaling proteins are increased during the first week following FPI and that premature voluntary exercise may compromise plasticity. (C) 2004 Elsevier B.V. All rights reserved.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA		Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, RM 18-228, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38978, NS27544, NS30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038978, P50NS030308, R01NS027544] Funding Source: NIH RePORTER		Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; Bareyre FM, 2001, J NEUROCHEM, V77, P173, DOI 10.1046/j.1471-4159.2001.t01-1-00215.x; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; BRONSTEIN JM, 1993, BRAIN RES REV, V18, P135, DOI 10.1016/0165-0173(93)90011-N; Cammarota M, 2000, MOL BRAIN RES, V76, P36, DOI 10.1016/S0169-328X(99)00329-0; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Finkbeiner S, 2000, CELL MOL LIFE SCI, V57, P394, DOI 10.1007/PL00000701; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; Gomez-Pinilla F, 1998, NEUROSCIENCE, V85, P53, DOI 10.1016/S0306-4522(97)00576-9; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Gottschalk WA, 1999, LEARN MEMORY, V6, P243; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Harada K, 2002, J NEUROSCI RES, V67, P664, DOI 10.1002/jnr.10159; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kesslak JP, 2003, NEUROSCI LETT, V353, P95, DOI 10.1016/j.neulet.2003.08.078; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; Platenik J, 2000, LIFE SCI, V67, P335, DOI 10.1016/S0024-3205(00)00632-9; SAMORAJSKI T, 1985, NEUROBIOL AGING, V6, P17, DOI 10.1016/0197-4580(85)90066-1; Shen H, 2001, NEUROSCIENCE, V107, P219, DOI 10.1016/S0306-4522(01)00315-3; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; Soderling TR, 1996, NEUROCHEM INT, V28, P359, DOI 10.1016/0197-0186(95)00098-4; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Tyler WJ, 2002, LEARN MEMORY, V9, P224, DOI 10.1101/lm.51202; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; [No title captured]	41	129	140	1	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 6	2004	1016	2					154	162		10.1016/j.brainres.2004.04.079			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	841IH	WOS:000222923000003	15246851				2022-02-06	
J	Wilkins, JC; McLeod, TCV; Perrin, DH; Gansneder, BM				Wilkins, JC; McLeod, TCV; Perrin, DH; Gansneder, BM			Performance on the balance error scoring system decreases after fatigue	JOURNAL OF ATHLETIC TRAINING			English	Article						balance; exertion; concussion; injury assessment	MILD HEAD-INJURY; UNILATERAL POSTURAL CONTROL; PERCEIVED EXERTION; MUSCULAR FATIGUE; STABILITY; CONCUSSION; EXERCISE	Objective: To determine the immediate effects of a whole-body fatigue protocol on performance of the Balance Error Scoring System (BESS), a postural-stability test commonly used as part of a concussion-assessment battery. Design and Setting: Subjects were assigned to a fatigue or control group and were assessed before and immediately after a 20-minute fatigue protocol or rest period. Subjects: Fourteen fatigue subjects and 13 control subjects participated in this study. All subjects were male and free of vestibular disorders, and none had suffered a mild head injury or lower extremity injury in the preceding 6 months, as described through self-report. Measurements: We measured performance on the BESS for 9 stance-surface conditions and summed each condition to obtain a total score. Using the Borg scale, we also measured ratings of perceived exertion before, during, and after the fatigue protocol or rest period. Results: We found a significant increase in total errors from pretest to posttest in the fatigue group (14.36 +/- 4.73 versus 16.93 +/- 4.32), a significant decrease in errors in the control group (13.32 +/- 3.77 versus 11.08 +/- 3.88), and a significant difference between groups on the posttest. The rating of perceived exertion scores were significantly different between the fatigue and control groups at the middle (13.29 +/- 1.59 versus 6.23 +/- 0.83) and end (15.86 +/- 2.38 versus 6.15 +/- 0.55) of the fatigue or rest period. Conclusions: The BESS error scores increased immediately after the fatigue protocol, demonstrating that balance ability diminished. Clinicians who use the BESS as part of their sideline assessment for concussion should not administer the test immediately after a concussion due to the effects of fatigue.	Arizona Sch Hlth Sci, Dept Sports Hlth Care, Mesa, AZ 85205 USA; Lakewood High Sch, Hebron, OH USA; Univ N Carolina, Greensboro, NC 27412 USA; Univ Virginia, Charlottesville, VA 22903 USA		McLeod, TCV (corresponding author), Arizona Sch Hlth Sci, Dept Sports Hlth Care, 5850 E Still Circle, Mesa, AZ 85205 USA.	tvalovich@ashs.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722			Alderton A.-K., 1996, Scandinavian Journal of Medicine and Science in Sports, V6, P211; Arnold BL, 1998, J ATHL TRAINING, V33, P323; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BROOKS GA, 1996, EXERCISE PHYSL; Crowell DH, 2001, J ATHL TRAINING, V36, pS; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; Guskiewicz KM, 2002, ORTHOP PHYS THER CLI, V11, P143; Hoffman M, 1998, J ATHL TRAINING, V33, P319; Johnston RB, 1998, MED SCI SPORT EXER, V30, P1703, DOI 10.1097/00005768-199812000-00008; Lee C T, 1998, SPUMS J, V28, P125; Lepers R, 1997, EUR J APPL PHYSIOL, V76, P55, DOI 10.1007/s004210050212; LUNDIN TM, 1993, J APPL BIOMECH, V9, P191, DOI 10.1123/jab.9.3.191; Mahon AD, 1997, MED SCI SPORT EXER, V29, P1332, DOI 10.1097/00005768-199710000-00009; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; McComas AJ, 1996, SKELETAL MUSCLE FORM, P230; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; Nardone A, 1998, ARCH PHYS MED REHAB, V79, P920, DOI 10.1016/S0003-9993(98)90088-0; Ochsendorf DT, 2000, J ATHL TRAINING, V35, P26; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Robertson RJ, 2000, MED SCI SPORT EXER, V32, P2120, DOI 10.1097/00005768-200012000-00024; Rozzi S, 2000, PROPRIOCEPTION AND NEUROMUSCULAR CONTROL IN JOINT STABILITY, P375; SELIGA R, 1991, AM IND HYG ASSOC J, V52, P417, DOI 10.1202/0002-8894(1991)052<0417:EOWLAR>2.0.CO;2; SKINNER HB, 1986, J ORTHOP RES, V4, P112, DOI 10.1002/jor.1100040115; Sparto PJ, 1997, J ORTHOP SPORT PHYS, V25, P3, DOI 10.2519/jospt.1997.25.1.3; THOMAS JR, 1975, MED SCI SPORT EXER, V7, P203; Valovich TC, 2003, J ATHL TRAINING, V38, P51; VALOVICH TC, 2002, USE STANDARDIZED ASS; Vuillerme N, 2001, NEUROSCI LETT, V308, P103, DOI 10.1016/S0304-3940(01)01987-5; Westcott Sarah L., 1994, Physical and Occupational Therapy in Pediatrics, V14, P1, DOI 10.1300/J006v14n01_01; Yaggie J. A., 1999, Medicine and Science in Sports and Exercise, V31, pS284, DOI 10.1097/00005768-199905001-01399	38	129	132	1	13	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2004	39	2					156	161					6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	825EQ	WOS:000221739200006	15173867				2022-02-06	
J	Tehranian, R; Andell-Jonsson, S; Beni, SM; Yatsiv, I; Shohami, E; Bartfai, T; Lundkvist, J; Iverfeldt, K				Tehranian, R; Andell-Jonsson, S; Beni, SM; Yatsiv, I; Shohami, E; Bartfai, T; Lundkvist, J; Iverfeldt, K			Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist	JOURNAL OF NEUROTRAUMA			English	Article						closed head injury; cytokines; IL-1 receptor antagonist; transgenic mice; traumatic brain injury	TUMOR-NECROSIS-FACTOR; ISCHEMIC BRAIN-INJURY; IL-1 RECEPTOR; MESSENGER-RNA; FACTOR-ALPHA; MOUSE-BRAIN; RAT-BRAIN; NEURONAL DAMAGE; TNF-ALPHA; EXPRESSION	The acute inflammatory response following traumatic brain injury (TBI) has been shown to play an important role in the development of secondary tissue damage. The proinflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNFalpha), are induced early after brain injury and have been implicated in the delayed damage. The IL-1 receptor antagonist (IL-1ra) has been shown to modulate the proinflammatory cytokine cascade by blocking the binding of IL-1 to its signaling receptor. In this study, we investigated the effect of transgenic overexpression of IL-1ra on the cytokine expression and neurological damage in a closed head injury (CHI) model of TBI. The neurological recovery, as analyzed by neurological severity score (NSS), was significantly higher in transgenic mice overexpressing the human secreted form of IL-1ra in astrocytes, directed by the murine glial fibrillary acidic protein promoter, as compared to wild-type mice. Analysis of tissue levels of cytokines by ELISA showed increased levels of TNFa in the cerebral cortex from the wild type mice 1 h after injury. After 4 h significant increases in the levels of IL-1beta and IL-6 were observed in the wild type mice. In the transgenic mice, on the other hand, no effect on TNFa levels was observed and no significant increases in IL-1beta and IL-6 levels could be detected until 6 h after injury. Thus, it can be concluded that blockage of IL-1 signaling by elevated levels of IL-1ra has a neuroprotective effect, in agreement with previous reports, and that central overexpression of IL-1ra results in delayed proinflammatory cytokine induction and improved neurological recovery after traumatic brain injury.	Stockholm Univ, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden; Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Jerusalem, Israel; Hebrew Univ Jerusalem, Pediat Intens Care Unit, Hadassah Med Ctr, Jerusalem, Israel; Scripps Res Inst, La Jolla, CA USA		Iverfeldt, K (corresponding author), Stockholm Univ, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden.	kerstin@neurochem.su.se					BALASINGAM V, 1994, J NEUROSCI, V14, P846; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BEAMER NB, 1995, ANN NEUROL, V37, P800, DOI 10.1002/ana.410370614; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; DANIS VA, 1995, CLIN EXP IMMUNOL, V99, P303; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DINARELLO CA, 1991, BLOOD, V77, P1627; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Eriksson C, 1998, MOL BRAIN RES, V58, P195, DOI 10.1016/S0169-328X(98)00125-9; Eriksson C, 2000, J NEUROSCI RES, V60, P266, DOI 10.1002/(SICI)1097-4547(20000415)60:2<266::AID-JNR16>3.0.CO;2-P; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gabellec MM, 1999, NEUROSCI RES, V33, P251, DOI 10.1016/S0168-0102(99)00014-0; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GOSHEN I, 2000, NEUROSCI LETT, V55, pS22; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hirsch E, 1996, P NATL ACAD SCI USA, V93, P11008, DOI 10.1073/pnas.93.20.11008; Hurme M, 1998, EUR J IMMUNOL, V28, P2598, DOI 10.1002/(SICI)1521-4141(199808)28:08<2598::AID-IMMU2598>3.3.CO;2-B; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Lieb K, 1996, J NEUROCHEM, V66, P1496; LIU LX, 1993, INFECT MED, V10, P24; Loddick SA, 1997, BIOCHEM BIOPH RES CO, V234, P211, DOI 10.1006/bbrc.1997.6436; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Lundkvist J, 1999, AM J PHYSIOL-REG I, V276, pR644, DOI 10.1152/ajpregu.1999.276.3.R644; MATYAK M, 1998, J IMMUNOL, V161, P1997; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MUZIO M, 1995, J EXP MED, V182, P623, DOI 10.1084/jem.182.2.623; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STAHEL PF, 2000, RESTOR NEUROL NEUROS, V16, P214; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tountas NA, 1999, GASTROENTEROLOGY, V117, P806, DOI 10.1016/S0016-5085(99)70338-0; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; YABUUCHI K, 1994, MOL BRAIN RES, V26, P135, DOI 10.1016/0169-328X(94)90084-1; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2	68	129	135	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2002	19	8					939	951		10.1089/089771502320317096			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	585JC	WOS:000177520800004	12225654				2022-02-06	
J	Labella, CR; Smith, BW; Sigurdsson, A				Labella, CR; Smith, BW; Sigurdsson, A			Effect of mouthguards on dental injuries and concussions in college basketball	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						oral injuries; mouth protectors; epidemiology; sports injuries; intercollegiate athletes	MOUTH PROTECTORS; OROFACIAL INJURIES; FOOTBALL; SPORTS; TRAUMA	Purpose: Dental injuries can be permanent and disfiguring. They are also universally expensive to treat. Many dentists, sports, physicians, and athletic trainers recommend mouthguards for athletes participating in certain competitive sports, including men's college basketball, because of a common perception that mouthguards afford protection from dental injuries, and even some concussions. However, there are few reliable reports of the incidence of dental injuries and concussions in men's college basketball, and good evidence that mouthguards reduce the risk of these injuries in this population of athletes is notably lacking. This study prospectively recorded dental injuries and concussions among 50 men's Division I college basketball teams during one competitive season, then compared injury rates between mouthguard users and nonusers. Methods: During the 1999 to 2000 basketball season, athletic trainers from 50 men's Division I college basketball programs used an Internet Web site it) submit weekly reports of the number of athlete exposures, mouthguard users, concussions, oral soft tissue injuries, dental injuries, and dentist referrals, Results: Response rate was 86%. There were 70,936 athlete exposures. Athletes using custom-fitted mouthguards accounted for 8663 exposures. Injury rates were expressed as number of injuries per 1000 athlete exposures. There were no significant differences between mouthguard users and nonusers in rates of concussions (0.35 vs 0.55) or oral soft tissue injuries (0,69 vs 1.06). Mouthguard users had significantly lower rates of dental injuries (0, 12 vs 0,67; P < 0.05) and dentist referrals (0.00 vs 0.72 P < 0.05) than nonusers. Conclusion: Custom-fitted mouthguards do not significantly affect rates of concussions or oral soft tissue injuries, but can significantly reduce (he morbidity and expense resulting from dental injuries in men's Division I college basketball.	Univ N Carolina, Div Sports Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Endodont, Chapel Hill, NC 27599 USA		Smith, BW (corresponding author), Univ N Carolina, Div Sports Med, CB 7470,Student Hlth Serv Bldg, Chapel Hill, NC 27599 USA.	smithbw@email.unc.edu	Sigurdsson, Asgeir/ABA-8829-2021				[Anonymous], 2000, Natl Toxicol Program Tech Rep Ser, P1; Berg R, 1998, J AM DENT ASSOC, V129, P1425, DOI 10.14219/jada.archive.1998.0077; *BUR DENT HLTH ED, 1963, J AM DENT ASSOC, V66, P539; de Wet F A, 1981, J Dent Assoc S Afr, V36, P249; FLANDERS RA, 1995, J AM DENT ASSOC, V126, P491, DOI 10.14219/jada.archive.1995.0213; GARON MW, 1986, J AM DENT ASSOC, V112, P663, DOI 10.14219/jada.archive.1986.0063; HEINTZ WD, 1968, J AM DENT ASSOC, V77, P632; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Kvittem B, 1998, J PUBLIC HEALTH DENT, V58, P288, DOI 10.1111/j.1752-7325.1998.tb03011.x; Lee-Knight C T, 1992, J Can Dent Assoc, V58, P810; MAESTRELLODEMOYA MG, 1989, J DENT CHILD, V56, P36; MCNUTT T, 1989, Pediatric Dentistry, V11, P209; MOON DG, 1961, J AM DENT ASSOC, V62, P568, DOI 10.14219/jada.archive.1961.0104; MORROW R M, 1989, Athletic Training, V24, P236; MORROW RM, 1991, ATHLETIC TRAINING, V26, P344; MORROW RM, 1991, ATHLETIC TRAINING JN, V26, P339; SANE J, 1988, AM J SPORT MED, V16, P647, DOI 10.1177/036354658801600616; SIGURDSSON A, IN PRESS DENT TRAUMA; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; 1972, J AM DENT ASS, V84, P531	20	129	134	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JAN	2002	34	1					41	44		10.1097/00005768-200201000-00007			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	510FA	WOS:000173197000007	11782645				2022-02-06	
J	Naunheim, RS; Standeven, J; Richter, C; Lewis, LM				Naunheim, RS; Standeven, J; Richter, C; Lewis, LM			Comparison of impact data in hockey, football, and soccer	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							HEAD-INJURIES; CONCUSSION; BRAIN; MILD	Purpose: To compare accelerational forces to the head in high school-level football, hockey, and soccer athletes. Methods: Acceleration of impact was measured within the helmet of high school hockey and football players during actual game play, A triaxial accelerometer was placed at the vertex of the helmet immediately adjacent to the players head. Peak acceleration tin g's) was measured and the Gadd Severity Index and Head Injury Criterion score calculated during actual play periods in several games over four seasons. We also recorded acceleration of head impacts in high school-level soccer players who headed a soccer hall while equipped with a football helmet instrumented identically to the helmet used to record during football games. Results: Peak accelerations inside the helmet for football averaged 29.2 g compared with 35 g for hockey (p =.004). There were no incidents of concussion or other traumatic brain injury during the recorded periods. In contrast, the peak accelerations associated with heading a soccer ball was 54.7 g (p = 2 x 10(-5) vs, hockey). Conclusion: Peak accelerations as measured at the surface of the head were 160 to 180% greater from heading a soccer ball than from routine (noninjurious) impacts during hockey or football, respectively. The effect of cumulative impacts at this level may lead to neurologic sequelae.	Washington Univ, Sch Med, Div Emergency Med, Injury Prevent Ctr, St Louis, MO 63110 USA		Naunheim, RS (corresponding author), Washington Univ, Sch Med, Div Emergency Med, Injury Prevent Ctr, 660 S Euclid Ave,Campus Box 8072, St Louis, MO 63110 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Gadd C. W., 1966, P 10 STAPP CAR CRASH; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GOLDSMITH W, 1970, BIOMECHANICS ITS FDN, P585; GRONWALL D, 1975, LANCET, V2, P995; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KIKUCHI A, 1993, BIOMECHANICS IMPACT, P361; LEWIS LM, 1993, ANN EMERG MED, V22, P900; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thibault L.E.O.A., 1993, BIOMECHANICS IMPACT, P411; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; UNTERHARNSCHEID.F, 1993, BIOMECHANICS IMPACT, P407; Versace, 1971, P 15 STAPP CAR CRASH, DOI DOI 10.4271/710881; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	17	129	130	0	40	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2000	48	5					938	941		10.1097/00005373-200005000-00020			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	314WH	WOS:000087080200034	10823540				2022-02-06	
J	Subach, BR; McLaughlin, MR; Albright, AL; Pollack, LF				Subach, BR; McLaughlin, MR; Albright, AL; Pollack, LF			Current management of pediatric atlantoaxial rotatory subluxation	SPINE			English	Article						atlantoaxial; cervical spine; Grisel's syndrome; rotatory subluxation	AXIAL JOINT; FIXATION; DIAGNOSIS	Study Design. A retrospective clinical review of 20 children seen during a 7-year period who had atlantoaxial rotatory subluxation. Objective. To define the effectiveness of imaging and treatment measures and to identify risk factors for reoccurrence, the series was reviewed to analyze cause, management, and outcome. Summary of Background Data. Rotatory subluxation of the atlantoaxial complex remains a poorly understood entity. Despite many reports in the literature, there is no consensus about which imaging studies should be used for diagnosis and which patients benefit from collar immobilization, traction, or surgical fusion, Methods. Between August 1990 and April 1997, 20 children with atlantoaxial rotatory subluxation were treated. Fourteen patients (70%) were girls and six (30%)were boys(mean age, 6.4 years). All patients had torticollis and neck pain with decreased cervical motion for a mean of 11.2 days before diagnosis. Seven patients (35%) had a history of pharyngitis or otitis media, four (20%) had recently undergone head or neck surgery, and four (20%) had sustained a traumatic injury; in five patients (25%), no clear cause was determined. All patients were neurologically intact and underwent plain cervical radiographs and dynamic cervical computed tomography document atlantoaxial rotatory subluxation. Patients were then treated with a rigid cervical collar and and anti- inflammatory agents (n = 5) or with cervical traction followed by immobilization (n = 15). Results. In four of the five patients in collars, reduction occurred spontaneously, whereas the fifth required cervical traction and eventual fusion for recurrence. In the 16 patients treated with traction (median, 1.8 kg), the normal atlantoaxial alignment was restored in 15 patients (94%) within a mean of 4 days. Of the 20 patients treated overall, conservative management failed in 6 (30%), and they required posterior fusion because of recurrence of atlantoaxial rotatory subluxation or unsuccessful reduction. The major factor predicting the failure of conservative management was the duration of subluxation before initial reduction. Patients with long standing subluxation were more likely to experience recurrence and require surgery. There were no complications noted. At follow-up, all patients who were treated conservatively remained neurologically intact with a normal atlantoaxial relation. All patients who underwent surgery remained neurologically intact and had radiographic documentation of fusion. Conclusion. Optimal management of atlantoaxial rotatory subluxation entails early diagnosis with plain cervical radiographs and dynamic computed tomography. Closed reduction with cervical traction followed by rigid immobilization accomplished reduction in 15 or 16 patients (94%) and was curative in 10 of 16 patients (63%). Although reduction was achieved more rapidly and effectively with traction than with a collar, there may be a role for simple immobilization without reduction in patients with a short duration of symptoms. There does not appear to be a correlation between cause of atlantoaxial rotatory subluxation, age, or sex and the likelihood of recurrence.	Childrens Hosp Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA		Albright, AL (corresponding author), Childrens Hosp Pittsburgh, Dept Neurol Surg, 3705 5th Ave, Pittsburgh, PA 15213 USA.						Bell C., 1830, CASE, V143, P403; BROOKS AL, 1978, J BONE JOINT SURG AM, V60, P279, DOI 10.2106/00004623-197860030-00001; Corner EM, 1907, ANN SURG, V45, P9, DOI 10.1097/00000658-190701000-00002; DVORAK J, 1987, SPINE, V12, P197, DOI 10.1097/00007632-198704000-00001; EADIE PA, 1989, BRIT J PLAST SURG, V42, P722, DOI 10.1016/0007-1226(89)90089-1; ELKHOURY GY, 1984, J BONE JOINT SURG AM, V66A, P774, DOI 10.2106/00004623-198466050-00019; FESMIRE F M, 1989, Journal of Emergency Medicine, V7, P133, DOI 10.1016/0736-4679(89)90258-8; FIELDING JW, 1977, J BONE JOINT SURG AM, V59, P37, DOI 10.2106/00004623-197759010-00005; FIELDING JW, 1978, ORTHOP CLIN N AM, V9, P955; Gallie WE, 1939, AM J SURG, V46, P495, DOI DOI 10.1016/S0002-9610(39)90309-0; Grisel P., 1930, PRESSE MED, V38, P50; JOHNSON DP, 1986, J BONE JOINT SURG BR, V68, P698, DOI 10.1302/0301-620X.68B5.3782225; KAWABE N, 1989, J PEDIATR ORTHOPED, V9, P569, DOI 10.1097/01241398-198909010-00012; KLEIN DM, 1985, NEUROSURGERY, V5, P26; KOWALSKI HM, 1987, AM J ROENTGENOL, V149, P595, DOI 10.2214/ajr.149.3.595; Li Veetai, 1995, P531; MCRAE DL, 1953, ACTA RADIOL, V40, P335, DOI 10.3109/00016925309176595; ONO K, 1985, SPINE, V10, P602, DOI 10.1097/00007632-198509000-00002; PARKE WW, 1984, J BONE JOINT SURG AM, V66A, P568, DOI 10.2106/00004623-198466040-00012; PHILLIPS WA, 1989, J BONE JOINT SURG AM, V71A, P664, DOI 10.2106/00004623-198971050-00004; RINALDI I, 1979, J NEUROSURG, V50, P115, DOI 10.3171/jns.1979.50.1.0115; SHERK HH, 1969, J BONE JOINT SURG AM, VA 51, P957, DOI 10.2106/00004623-196951050-00012; SUDECK P, 1923, DTSCH Z CHIR, V183, P289; SULLIVAN CR, 1958, AM J SURG, V95, P636, DOI 10.1016/0002-9610(58)90445-8; SULLIVAN WA, 1949, J PEDIAT S LOUIS, V35, P451; VANHOLSBEECK EMA, 1989, J BONE JOINT SURG BR, V71, P90, DOI 10.1302/0301-620X.71B1.2915014; WHITE AA, 1978, ORTHOP CLIN N AM, V9, P867; WILSON BC, 1987, ANN OTO RHINOL LARYN, V96, P705, DOI 10.1177/000348948709600620	28	129	135	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0362-2436			SPINE	SPINE	OCT 15	1998	23	20					2174	2179		10.1097/00007632-199810150-00006			6	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	130LT	WOS:000076522100005	9802157				2022-02-06	
J	Arbogast, KB; Margulies, SS				Arbogast, KB; Margulies, SS			Material characterization of the brainstem from oscillatory shear tests	JOURNAL OF BIOMECHANICS			English	Article						constitutive properties; material properties; biomechanics; viscoelastic	INJURY	Traumatic damage to the brainstem occurs frequently when the brain-skull complex experiences injurious loading especially during those traumatic situations that produce diffuse axonal injury (DAI). DAI has been shown to be dependent on load direction and correlated with regional tissue deformation in response to rotational inertial loads. Possible mechanisms for the selective vulnerability of the brainstem are (1) the geometry of the central nervous system is responsible for producing high tissue strains in these regions, (2) regional differences in overall material stiffness result in larger deformations at these sites, and (3) the anisotropic mechanical properties of these regions lead to a sensitivity to the rotational load direction and magnitude. This paper investigates the latter two hypotheses by performing oscillatory shear tests on adult porcine brainstem in three mutually perpendicular directions. The complex shear moduli were calculated over a range of frequencies (20-200 Hz), for three levels of peak engineering strain (2.5%, 5.0%, and 7.5%). The directional data demonstrated that the brainstem exhibits significant transversely isotropic behavior. Both components of the complex modulus in which the axonal fibers are oriented parallel to the plane of shear but transverse to the shear direction were significantly higher than those of the other two, mutually indistinguishable test cases across the range of strains tested. By comparison with similar tests on cerebral tissue, these data demonstrated that the brainstem displays a stiffer biomechanical response. These differences were present for both components of the complex shear modulus and were greater as the magnitude of the applied strain increased. The regional stiffness and anisotropic response of the brainstem coupled with its location as a narrow bridge between CNS regions interact to result in the selective vulnerability of this region in rotational loading. (C) 1998 Elsevier Science Ltd. All rights reserved.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 240 S 33rd St, Philadelphia, PA 19104 USA.			Arbogast, Kristy/0000-0002-1694-4562	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 312712, R49/CCR 304684] Funding Source: Medline		ARBOGAST K, 1994, P ASME WINT ANN M CH; Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; ARBOGAST KB, 1997, THESIS U PENNSYLVANI; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gennarelli TA, 1987, 31 STAPP CAR CRASH C; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; Jellinger KA, 1983, ADV NEUROTRAUMATOLOG, P58; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McElhaney JH, 1976, HDB HUMAN TOLERANCE; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SHUCK L, 1972, J BASIC ENG, P905; THIBAULT K, 1997, THESIS U PENNSYLVANI; Zhou C., 1995, 39 STAPP CAR CRASH C	16	129	133	1	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	SEP	1998	31	9					801	807		10.1016/S0021-9290(98)00068-2			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	129EJ	WOS:000076450300005	9802780				2022-02-06	
J	Bratton, SL; Davis, RL				Bratton, SL; Davis, RL			Acute lung injury in isolated traumatic brain injury	NEUROSURGERY			English	Article						acute lung injury; acute respiratory distress syndrome; neurogenic pulmonary edema; traumatic brain injury	NEUROGENIC PULMONARY-EDEMA; HEAD-INJURY; INSUFFICIENCY; HYPERTENSION; NEURONS; RABBIT	OBJECTIVE: To determine the incidence of acute lung injury (ALI) in comatose patients after isolated traumatic brain injury, to determine whether specific brain lesions diagnosed by cranial computed tomographic scans are associated with ALI, and to determine the outcome of patients with head injuries who developed ALI. METHODS: Descriptive epidemiology and a case-control study using the Traumatic Coma Data Bank was performed to evaluate clinical features and brain lesions associated with ALI in patients with isolated head trauma. Patients with ALI were defined as those who demonstrated a ratio of partial pressure of arterial oxygen to fractional expired oxygen of 300 or less. RESULTS: Twenty of 100 comatose patients developed ALI. Patients with ALI were almost three times more likely to die or survive in a vegetative state (odds ratio, 2.8; 95% confidence in terval, 1.6-4.9). Specific anatomic brain lesions diagnosed by cranial computed tomographic scans were not associated with ALI. However, patients with more severe injuries, i.e., large nonevacuated mass lesions, and those with midline shift demonstrated a 10- and 5-fold increased risk of ALI (odds ratio, 9.9; 95% confidence interval, 1.2-217.1; and odds ratio, 5.5; 95% confidence interval, 1.5-20.0). CONCLUSIONS: ALI was common in comatose victims with an isolated traumatic brain injury and was associated with an increased risk of death or a severe neurological morbidity. ALI was associated with the global severity of head injury but not with specific anatomic lesions diagnosed by cranial computed tomographic scans.	UNIV WASHINGTON,SCH MED,SCH PUBL HLTH & COMMUNITY MED,DEPT ANESTHESIOL & PEDIAT CRIT CARE,SEATTLE,WA; UNIV WASHINGTON,SCH MED,SCH PUBL HLTH & COMMUNITY MED,DEPT PEDIAT,SEATTLE,WA				Bratton, Susan L./O-2353-2013	Bratton, Susan L./0000-0002-4605-8078			BAIGELMAN W, 1981, NEUROSURGERY, V9, P729, DOI 10.1227/00006123-198112000-00021; BERKEMEYER WB, 1989, SO MED J, V82, P380; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BLESSING WW, 1981, CIRC RES, V49, P949, DOI 10.1161/01.RES.49.4.949; BLESSING WW, 1982, SCIENCE, V217, P661, DOI 10.1126/science.6124043; CARLSON RW, 1909, CHEST, V75, P731; COLICE GL, 1984, AM REV RESPIR DIS, V130, P941; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; FEIN IA, 1982, CHEST, V81, P318, DOI 10.1378/chest.81.3.318; FOULKES MA, 1991, J NEUROSURG, V75, pS1, DOI 10.3171/sup.1991.75.1s.00s1; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; GAMBLE JE, 1953, AM J PHYSIOL, V172, P623, DOI 10.1152/ajplegacy.1953.172.3.623; GAMBLE JE, 1951, SCIENCE, V113, P626, DOI 10.1126/science.113.2944.626; GRAF C J, 1975, Surgical Neurology, V4, P319; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KATSURADA K, 1973, SURGERY, V73, P191; LOEWY AD, 1980, FED PROC, V39, P2495; MACKERSIE RC, 1983, J TRAUMA, V23, P968, DOI 10.1097/00005373-198311000-00002; MAIRE FW, 1956, AM J PHYSIOL, V184, P351, DOI 10.1152/ajplegacy.1956.184.2.351; MAIRE FW, 1956, AM J PHYSIOL, V184, P345, DOI 10.1152/ajplegacy.1956.184.2.345; MARON MB, 1989, AM J PHYSIOL, V76, P305; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MASRSHALL LF, 1991, J NEUROSURG, V75, pS14; MULROY JJ, 1985, NEUROLOGY, V35, P403, DOI 10.1212/WNL.35.3.403; SARNOFF SJ, 1952, DIS CHEST, V22, P685, DOI 10.1378/chest.22.6.685; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; THEODORE J, 1976, AM REV RESPIR DIS, V113, P405; WAUCHOB TD, 1984, ANAESTHESIA, V39, P529, DOI 10.1111/j.1365-2044.1984.tb07355.x; Weisman SJ, 1939, SURGERY, V6, P722	30	129	131	1	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	APR	1997	40	4					707	712		10.1097/00006123-199704000-00009			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	WQ299	WOS:A1997WQ29900026	9092843				2022-02-06	
J	CAPRUSO, DX; LEVIN, HS				CAPRUSO, DX; LEVIN, HS			COGNITIVE IMPAIRMENT FOLLOWING CLOSED HEAD-INJURY	NEUROLOGIC CLINICS			English	Article							PRACTICAL SCALE; AMNESIA TEST; MEMORY; RECOVERY; CHILDREN; ORIENTATION; ADOLESCENTS; CONCUSSION; LANGUAGE; SEVERITY		UNIV TEXAS,MED BRANCH,DEPT NEUROSURG,GALVESTON,TX 77550		CAPRUSO, DX (corresponding author), UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550, USA.						ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; BENSON DF, 1967, J NEUROL NEUROSUR PS, V30, P457; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1987, NEUROBEHAVIORAL RECO; Heaton R.K., 1981, WISCONSIN CARD SORTI; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; LEIN HS, 1977, CORTEX, V13, P119; LENNENBERG E, 1967, BIOL F LANGUAGE; Levin H. S., 1983, PEDIATRIC HEAD TRAUM, P223; Levin H. S., 1991, ACQUIRED APHASIA, P455; Levin H. S., 1984, NEURAL TRAUMA TREATM, P89; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; LEVIN HS, 1983, ARCH NEUROL-CHICAGO, V40, P601, DOI 10.1001/archneur.1983.04050090037004; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS, 1984, NEUROPSYCHOLOGY MEMO, P247; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; Lezak, 1989, ASSESSMENT BEHAV CON, V7, P113; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MATARAZZO JD, 1972, MEASUREMENT APPRAISA; MENDELSOHN D, IN PRESS CHILDS NERV; Miller E, 1970, Cortex, V6, P121; MILNER B, 1974, NEUROSCIENCES 3RD ST; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ribot T., 1882, DISEASES MEMORY ESSA; RISSER AH, 1990, 18TH ANN M INT NEUR; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1946, BRAIN, V69, P183; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; TEASDALE G, 1974, LANCET, V2, P81; TEUBER HL, 1978, PERCEPTION; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; UZZELL BP, 1979, CORTEX, V15, P391, DOI 10.1016/S0010-9452(79)80066-0; VONZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452; Wechsler, 1997, WECHSLER ADULT INTEL; WILSON PJE, 1970, BRAIN, V93, P147, DOI 10.1093/brain/93.1.147	68	129	134	0	14	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0733-8619			NEUROL CLIN	Neurol. Clin.	NOV	1992	10	4					879	893		10.1016/S0733-8619(18)30185-3			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	JW158	WOS:A1992JW15800005	1435662				2022-02-06	
J	TAFT, WC; YANG, K; DIXON, CE; HAYES, RL				TAFT, WC; YANG, K; DIXON, CE; HAYES, RL			MICROTUBULE-ASSOCIATED PROTEIN 2 LEVELS DECREASE IN HIPPOCAMPUS FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							LONG-TERM POTENTIATION; EXCITATORY AMINO-ACIDS; SPINAL-CORD INJURY; CYTOSKELETAL PROTEINS; NEURONAL DAMAGE; NMDA RECEPTORS; RAT-BRAIN; CALPAIN-I; PROTEOLYSIS; DEGRADATION	We examined microtubule-associated protein 2 (MAP2) levels in hippocampal and cortical tissue 3 h following moderate traumatic brain injury (TBI) in the rat. MAP2 levels were assayed by quantitative immunoreactivity in tissue fractions obtained from naive, sham-injured, or fluid percussion-injured animals. Tissues were homogenized in the presence of protease inhibitors (0.3 mM phenylmethylsulfonyl flouride, PMSF), specific calpain inhibitors (0.1 mM leupeptin), and chelators (2 mM ethylene glycol-bis-tetraacetic acid, EGTA; 1 mM ethylenedinitrilo-tetraacetic acid, EDTA) to eliminate in vitro MAP2 proteolysis during tissue processing. Compared to naive rats, sham injury had no effect on soluble MAP2 levels in either cortex (105.0 +/- 4.4 % of naive value) or hippocampus (106.6 +/- 5.2 % of naive value). However, TBI caused a significant (p < 0.005) decrease in hippocampal MAP2 levels (55.7 +/- 5.9% of sham-injured controls). The effect appeared to be regionally selective, since the MAP2 decrease did not occur in cortex (89.1 +/- 1.4%). The degree of MAP2 decrease in hippocampus was similar in both membrane (57.8 %) and cytosolic (55.7 %) fractions, ruling out the possibility of partitioning artifacts. The data suggest that sublethal alterations of neuronal structure and function caused by MAP2 degradation may play an important role in the development of TBI-induced functional deficits. Since MAP2 is exclusively associated with the cytoskeleton in somal and dendritic compartments of neurons, the pathophysiology of sublethal magnitudes of TBI may also involve dendritic and somal dysfunction.			TAFT, WC (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,6431 FANNIN,SUITE 7154,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER		BANIK NL, 1985, J NEUROCHEM, V45, P581, DOI 10.1111/j.1471-4159.1985.tb04026.x; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRAY D, 1978, P NATIONAL ACADEMY S, V81, P5626; CACERES A, 1988, MOL BRAIN RES, V3, P233, DOI 10.1016/0169-328X(88)90046-0; DELCERRO S, 1990, BRAIN RES, V530, P91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; FLAMENT S, 1990, BRAIN RES, V516, P15, DOI 10.1016/0006-8993(90)90891-E; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARA H, 1990, J PHARMACOL EXP THER, V255, P906; HARA H, 1990, J CEREBR BLOOD F MET, V10, P646, DOI 10.1038/jcbfm.1990.117; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEIMANN R, 1985, J BIOL CHEM, V260, P2160; INZUKA T, 1990, BRAIN RES, V21, P9147; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KUWAKI T, 1989, STROKE, V20, P78, DOI 10.1161/01.STR.20.1.78; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARECK A, 1980, NATURE, V284, P353, DOI 10.1038/284353a0; Mayer R J, 1989, Prog Clin Biol Res, V317, P809; MIYAZAKI I, 1992, IN PRESS BRAIN RES; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; NEWLON PG, 1991, BRAIN RES, V544, P320, DOI 10.1016/0006-8993(91)90072-4; OLIVER MW, 1989, BRAIN RES, V505, P233, DOI 10.1016/0006-8993(89)91448-0; PETERSON C, 1991, NEUROSCI LETT, V121, P239, DOI 10.1016/0304-3940(91)90694-O; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SMITH DH, 1992, J NEUROTRAUM, V8, P259; STAUBLI U, 1988, BRAIN RES, V444, P153, DOI 10.1016/0006-8993(88)90922-5; TAFT W C, 1991, Society for Neuroscience Abstracts, V17, P164; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; ZHANG H, 1989, P NATL ACAD SCI USA, V86, P8045, DOI 10.1073/pnas.86.20.8045; ZIMMERMAN UJP, 1982, BIOCHEMISTRY-US, V21, P3977, DOI 10.1021/bi00260a012	51	129	131	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FAL	1992	9	3					281	290		10.1089/neu.1992.9.281			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	JW451	WOS:A1992JW45100008	1474611				2022-02-06	
J	ROCKSWOLD, GL; FORD, SE; ANDERSON, DC; BERGMAN, TA; SHERMAN, RE				ROCKSWOLD, GL; FORD, SE; ANDERSON, DC; BERGMAN, TA; SHERMAN, RE			RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL FOR TREATMENT OF SEVERELY BRAIN-INJURED PATIENTS WITH HYPERBARIC-OXYGEN	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; HYPERBARIC OXYGEN; INTRACRANIAL PRESSURE; CLINICAL TRIAL	HEAD-INJURY; VITAMIN-E; UNITED-STATES; RAT-BRAIN; REGIONS; TRAUMA; EDEMA; SCALE; MICE	The authors enrolled 168 patients with closed-head trauma into a prospective trial to evaluate the effect of hyperbaric oxygen in the treatment of brain injury. Patients were included if they had a total Glasgow Coma Scale (GCS) score of 9 or less for at least 6 hours. After the GCS score was established and consent obtained, the patient was randomly assigned, stratified by GCS score and age, to either a treatment or a control group. Hyperbaric oxygen was administered to the treatment group in a monoplace chamber every 8 hours for 1 hour at 1.5 atm absolute; this treatment course continued for 2 weeks or until the patient was either brain dead or awake. An average of 21 treatments per patient was given. Outcome was assessed by blinded independent examiners. The entire group of 168 patients was followed for 12 months, with two patients lost to follow-up study. The mortality rate was 17% for the 84 hyperbaric oxygen-treated patients and 32% for the 82 control patients (chi-squared test, 1 df, p = 0.037). Among the 80 patients with an initial GCS score of 4, 5, or 6, the mortality rate was 17% for the hyperbaric oxygen-treated group and 42% for the controls (chi-squared test, 1 df, p = 0.04). Analysis of the 87 patients with peak intracranial pressures (ICP) greater than 20 mm Hg revealed a 2 1 % mortality rate for the hyperbaric oxygen-treated patients, as opposed to 48% for the control group (chi-squared test, 1 df, p = 0.02). Myringotomy to reduce pain during hyperbaric oxygen treatment helped to reduce ICP. Analysis of the outcome of survivors reveals that hyperbaric oxygen treatment did not increase the number of patients in the favorable outcome categories (good recovery and moderate disability). The possibility that a different hyperbaric oxygen treatment paradigm or the addition of other agents, such as a 21-aminosteroid, may improve quality of survival is being explored.	HENNEPIN CTY MED CTR,DEPT NEUROL,MINNEAPOLIS,MN 55415; UNIV MINNESOTA,DEPT NEUROSURG,MINNEAPOLIS,MN 55455; HENEPIN CTY ADM,DEPT PLANNING & DEV,MINNEAPOLIS,MN		ROCKSWOLD, GL (corresponding author), HENNEPIN CTY MED CTR,DIV NEUROSURG,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.			Anderson, David/0000-0001-9874-5649			ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; ANDERSON DW, 1983, PUBLIC HEALTH REP, V98, P475; BERGMAN TA, 1987, MINN MED, V70, P397; CLARK JM, 1977, HYPERBARIC OXYGEN TH, P61; CONTRERAS FL, 1988, J NEUROSURG, V68, P137, DOI 10.3171/jns.1988.68.1.0137; GAMACHE FW, 1984, INFECT SURG, V3, P485; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HARPER AM, 1965, J NEUROL NEUROSUR PS, V28, P449, DOI 10.1136/jnnp.28.5.449; HAYAKAWA T, 1971, J NEUROL NEUROSUR PS, V34, P580, DOI 10.1136/jnnp.34.5.580; HOLBACH KH, 1974, ACTA NEUROCHIR, V30, P247, DOI 10.1007/BF01405583; HOLBACH KH, 1977, J NEUROL, V217, P17, DOI 10.1007/BF00316313; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JACOBSON I, 1963, LANCET, V2, P549; JACOBSON I, 1964, SURG GYNECOL OBSTET, V119, P737; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KANAI N, 1973, NEUROLOGY, V23, P159, DOI 10.1212/WNL.23.2.159; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471, DOI 10.1152/jappl.1953.5.9.471; MILLER JD, 1971, ARCH NEUROL-CHICAGO, V24, P210, DOI 10.1001/archneur.1971.00480330038003; MILLER JD, 1970, J NEUROSURG, V33, P287, DOI 10.3171/jns.1970.33.3.0287; MILLER JD, 1973, EUR NEUROL, V10, P11; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; Nagao S, 1975, Resuscitation, V4, P51, DOI 10.1016/0300-9572(75)90065-9; REIVICH M, 1961, NEW ENGL J MED, V265, P878, DOI 10.1056/NEJM196111022651804; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROCKSWOLD G L, 1985, HYPERBARIC OXYGEN RE, V6, P161; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SUKOFF MH, 1982, NEUROSURGERY, V10, P29, DOI 10.1227/00006123-198201000-00006; TEASDALE G, 1974, LANCET, V2, P81; VATASSERY GT, 1984, J NEUROCHEM, V42, P554, DOI 10.1111/j.1471-4159.1984.tb02713.x; VATASSERY GT, 1984, BIOCHIM BIOPHYS ACTA, V792, P118, DOI 10.1016/0005-2760(84)90211-X; VATASSERY GT, 1988, J NEUROCHEM, V51, P621, DOI 10.1111/j.1471-4159.1988.tb01083.x; 1984, NIH842478 NAT I NEUR	34	129	146	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUN	1992	76	6					929	934		10.3171/jns.1992.76.6.0929			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HV485	WOS:A1992HV48500006	1588426				2022-02-06	
J	EWINGCOBBS, L; MINER, ME; FLETCHER, JM; LEVIN, HS				EWINGCOBBS, L; MINER, ME; FLETCHER, JM; LEVIN, HS			INTELLECTUAL, MOTOR, AND LANGUAGE SEQUELAE FOLLOWING CLOSED HEAD-INJURY IN INFANTS AND PRESCHOOLERS	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article									UNIV HOUSTON,HOUSTON,TX 77004; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550		EWINGCOBBS, L (corresponding author), UNIV TEXAS,SCH MED,DEPT PEDIAT,SUITE 7142,BOX 20708,HOUSTON,TX 77225, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ALOJAUANINE T, 1965, BRAIN, V88, P653; ANNEGERS JF, 1963, PEDIATRIC HEAD TRAUM, P1; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Bayley N., 1969, MANUAL BAYLEY SCALES; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DENNIS M, 1985, J CLIN EXP NEUROPSYC, V7, P526, DOI 10.1080/01688638508401283; Dunn LM., 1981, PEABODY PICTURE VOCA; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, CLOSED HEAD INJURY R, P71; FLETCHER JM, 1981, HDB PEDIATRIC PSYCHO, P258; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; GOLDBERGER ME, 1974, PLASTICITY RECOVERY, P149; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; HEDRICK DL, 1974, SEQUENCED INVENTORY; Hendrick E B, 1964, Clin Neurosurg, V11, P46; Hollingshead AB, 1958, SOCIAL CLASS MENTAL; JENNETT B, 1972, DEV MED CHILD NEUROL, V14, P137; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; McCarthy, 1972, MCCARTHY SCALES CHIL; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; SATZ P, 1981, ACQUIRED APHASIA, P399; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; STRICH SJ, 1961, LANCET, V2, P443; TEASDALE G, 1974, LANCET, V2, P81; Terman L. M., 1972, STANFORD BINET INTEL	36	129	129	1	7	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	DEC	1989	14	4					531	547		10.1093/jpepsy/14.4.531			17	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	CG010	WOS:A1989CG01000004	2607392				2022-02-06	
J	Jilka, SR; Scott, G; Ham, T; Pickering, A; Bonnelle, V; Braga, RM; Leech, R; Sharp, DJ				Jilka, Sagar R.; Scott, Gregory; Ham, Timothy; Pickering, Alan; Bonnelle, Valerie; Braga, Rodrigo M.; Leech, Robert; Sharp, David J.			Damage to the Salience Network and Interactions with the Default Mode Network	JOURNAL OF NEUROSCIENCE			English	Article						Default Mode Network; functional connectivity; psychophysiological interactions; salience network; traumatic brain injury	POSTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; CONNECTIVITY; ROBUST; IMPLEMENTATION; INHIBITION; ANATOMY; SYSTEM	Interactions between the Salience Network (SN) and the Default Mode Network (DMN) are thought to be important for cognitive control. However, evidence for a causal relationship between the networks is limited. Previously, we have reported that traumatic damage to white matter tracts within the SN predicts abnormal DMN function. Here we investigate the effect of this damage on network interactions that accompany changing motor control. We initially used fMRI of the Stop Signal Task to study response inhibition in humans. In healthy subjects, functional connectivity (FC) between the right anterior insula (rAI), a key node of the SN, and the DMN transiently increased during stopping. This change in FC was not seen in a group of traumatic brain injury (TBI) patients with impaired cognitive control. Furthermore, the amount of SN tract damage negatively correlated with FC between the networks. We confirmed these findings in a second group of TBI patients. Here, switching rather than inhibiting a motor response: (1) was accompanied by a similar increase in network FC in healthy controls; (2) was not seen in TBI patients; and (3) tract damage after TBI again correlated with FC breakdown. This shows that coupling between the rAI and DMN increases with cognitive control and that damage within the SN impairs this dynamic network interaction. This work provides compelling evidence for a model of cognitive control where the SN is involved in the attentional capture of salient external stimuli and signals the DMN to reduce its activity when attention is externally focused.	[Jilka, Sagar R.; Scott, Gregory; Braga, Rodrigo M.; Leech, Robert; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Ctr Neurosci, Computat Cognit & Clin Neuroimaging Lab, London W12 0NN, England; [Jilka, Sagar R.; Pickering, Alan] Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; [Braga, Rodrigo M.] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Fac Med, London W12 0NN, England; [Ham, Timothy] Univ Cambridge, Neurol Unit, Cambridge CB2 0SZ, England; [Bonnelle, Valerie] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England		Sharp, DJ (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013; Leech, Robert/AAE-8254-2019	Leech, Robert/0000-0002-5801-6318; Pickering, Alan/0000-0002-7301-5321; Scott, Gregory/0000-0001-8063-5871	Medical Research Council (United Kingdom)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute of Health Research Professorship [RP-011-048]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701951] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0701951] Funding Source: UKRI	This work was supported by the Medical Research Council (United Kingdom) and the National Institute of Health Research Professorship (RP-011-048).	Alderson RM, 2008, J ABNORM CHILD PSYCH, V36, P989, DOI 10.1007/s10802-008-9230-z; Allman JM, 2010, BRAIN STRUCT FUNCT, V214, P495, DOI 10.1007/s00429-010-0254-0; Baddeley AD, 2003, HDB MEMORY DISORDERS; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chen AC, 2013, P NATL ACAD SCI USA, V110, P19944, DOI 10.1073/pnas.1311772110; Chiong W, 2013, BRAIN, V136, P1929, DOI 10.1093/brain/awt066; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kim C, 2011, J NEUROSCI, V31, P4771, DOI 10.1523/JNEUROSCI.5923-10.2011; Koskinas GN., 1925, CYTOARCHITECTONIK HI; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012; Leech R, 2011, J NEUROSCI, V31, P3217, DOI 10.1523/JNEUROSCI.5626-10.2011; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; O'Reilly JX, 2012, SOC COGN AFFECT NEUR, V7, P604, DOI 10.1093/scan/nss055; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reitan RM, 2004, ARCH CLIN NEUROPSYCH, V19, P281, DOI 10.1016/S0887-6177(03)00042-8; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Singh AK, 2011, NEUROIMAGE, V58, P148, DOI 10.1016/j.neuroimage.2011.05.082; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; SUDEVAN P, 1987, J EXP PSYCHOL HUMAN, V13, P89, DOI 10.1037/0096-1523.13.1.89; Wechsler D., 2011, WECHSLER ABBREVIATED; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080	49	128	132	1	31	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	AUG 13	2014	34	33					10798	10807		10.1523/JNEUROSCI.0518-14.2014			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO0RJ	WOS:000341018900003	25122883	Green Published, hybrid, Green Accepted			2022-02-06	
J	Yurgil, KA; Barkauskas, DA; Vasterling, JJ; Nievergelt, CM; Larson, GE; Schork, NJ; Litz, BT; Nash, WP; Baker, DG				Yurgil, Kate A.; Barkauskas, Donald A.; Vasterling, Jennifer J.; Nievergelt, Caroline M.; Larson, Gerald E.; Schork, Nicholas J.; Litz, Brett T.; Nash, William P.; Baker, Dewleen G.		Marine Resiliency Study Team	Association Between Traumatic Brain Injury and Risk of Posttraumatic Stress Disorder in Active-Duty Marines	JAMA PSYCHIATRY			English	Article							ADMINISTERED PTSD SCALE; OPERATION IRAQI FREEDOM; MILITARY PERSONNEL; MENTAL-HEALTH; PSYCHOLOGICAL SYMPTOMS; PSYCHIATRIC DIAGNOSES; SUICIDE RISK; MILD; COMBAT; DEPLOYMENT	IMPORTANCE Whether traumatic brain injury (TBI) is a risk factor for posttraumatic stress disorder (PTSD) has been difficult to determine because of the prevalence of comorbid conditions, overlapping symptoms, and cross-sectional samples. OBJECTIVE To examine the extent to which self-reported predeployment and deployment-related TBI confers increased risk of PTSD when accounting for combat intensity and predeployment mental health symptoms. DESIGN, SETTING, AND PARTICIPANTS As part of the prospective, longitudinal Marine Resiliency Study (June 2008 to May 2012), structured clinical interviews and self-report assessments were administered approximately 1 month before a 7-month deployment to Iraq or Afghanistan and again 3 to 6 months after deployment. The study was conducted at training areas on a Marine Corps base in southern California or at Veterans Affairs San Diego Medical Center. Participants for the final analytic sample were 1648 active-duty Marine and Navy servicemen who completed predeployment and postdeployment assessments. Reasons for exclusions were nondeployment (n = 34), missing data (n = 181), and rank of noncommissioned and commissioned officers (n = 66). MAIN OUTCOMES AND MEASURES The primary outcome was the total score on the Clinician-Administered PTSD Scale (CAPS) 3 months after deployment. RESULTS At the predeployment assessment, 56.8% of the participants reported prior TBI; at postdeployment assessment, 19.8% reported sustaining TBI between predeployment and postdeployment assessments (ie, deployment-related TBI). Approximately 87.2% of deployment-related TBIs were mild; 250 of 287 participants (87.1%) who reported posttraumatic amnesia reported less than 24 hours of posttraumatic amnesia (37 reported >= 24 hours), and 111 of 117 of those who lost consciousness (94.9%) reported less than 30 minutes of unconsciousness. Predeployment CAPS score and combat intensity score raised predicted 3-month postdeployment CAPS scores by factors of 1.02 (P < .001; 95% CI, 1.02-1.02) and 1.02 (P < .001; 95% CI, 1.01-1.02) per unit increase, respectively. Deployment-related mild TBI raised predicted CAPS scores by a factor of 1.23 (P < .001; 95% CI, 1.11-1.36), and moderate/severe TBI raised predicted scores by a factor of 1.71 (P < .001; 95% CI, 1.37-2.12). Probability of PTSD was highest for participants with severe predeployment symptoms, high combat intensity, and deployment-related TBI. Traumatic brain injury doubled or nearly doubled the PTSD rates for participants with less severe predeployment PTSD symptoms. CONCLUSIONS AND RELEVANCE Even when accounting for predeployment symptoms, prior TBI, and combat intensity, TBI during the most recent deployment is the strongest predictor of postdeployment PTSD symptoms.	[Yurgil, Kate A.; Nievergelt, Caroline M.; Baker, Dewleen G.] Vet Affairs San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA; [Yurgil, Kate A.; Nievergelt, Caroline M.; Baker, Dewleen G.] Vet Affairs Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Barkauskas, Donald A.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Vasterling, Jennifer J.; Litz, Brett T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Vasterling, Jennifer J.; Litz, Brett T.] Vet Affairs Natl Ctr Posttraumat Stress Syndrome, Div Behav Sci, Boston, MA USA; [Vasterling, Jennifer J.; Litz, Brett T.] Vet Affairs Boston Healthcare Syst, Dept Psychol, Boston, MA USA; [Nievergelt, Caroline M.; Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, Sch Med, San Diego, CA 92103 USA; [Larson, Gerald E.] Naval Hlth Res Ctr, Dept Behav Sci & Epidemiol, San Diego, CA USA; [Schork, Nicholas J.] Scripps Translat Res Inst, Dept Mol & Expt Med, San Diego, CA USA; [Litz, Brett T.] Boston Univ, Dept Psychol, Sch Med, Boston, MA 02215 USA; [Nash, William P.] Boston Vet Affairs Res Inst, Boston, MA USA		Baker, DG (corresponding author), VA San Diego Healthcare Syst, Vet Affairs Ctr Excellence Stress & Mental Hlth 1, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	dgbaker@ucsd.edu	Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838; Schork, Nicholas/0000-0003-0920-5013; Litz, Brett/0000-0002-0479-8887; Nievergelt, Caroline/0000-0001-5766-8923	Veterans Affairs Health Service Research and Development project [SDR 09-0128]; Marine Corps; Navy Bureau of Medicine and Surgery; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH093500] Funding Source: NIH RePORTER	This work was supported by Veterans Affairs Health Service Research and Development project SDR 09-0128, the Marine Corps, and the Navy Bureau of Medicine and Surgery.	[Anonymous], 2007, LANCET, V370, P1879; [Anonymous], 2006, CLINICAL PRACTICE GU; [Anonymous], 2012, PRESENTED AT THE ANN; Atkins DC, 2007, J FAM PSYCHOL, V21, P726, DOI 10.1037/0893-3200.21.4.726; Baker DG, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110134; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Breslau N, 2004, PSYCHOL MED, V34, P889, DOI 10.1017/S0033291703001612; Brown VM, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00449; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Eulion JF, 1942, NEW ENGL J MED, V226, P1; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein EA, 2006, INCIDENCE AND ECONOM; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galea S, 2008, EPIDEMIOLOGY, V19, P47, DOI 10.1097/EDE.0b013e31815c1dbf; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Highfill-McRoy RM, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-88; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; Larson GE, 2011, PSYCHIAT SERV, V62, P15, DOI 10.1176/ps.62.1.pss6201_0015; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Marques L, 2011, EXPERT REV NEUROTHER, V11, P313, DOI [10.1586/ern.10.122, 10.1586/ERN.10.122]; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; MOREY RA, HUM BRAIN MAPP; Myers CS, 1915, LANCET, V1, P316; National Center for Injury Prevention and Control, 2003, REPORT TO CONGRESS O; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; R Development Core Team, 2008, R LANG ENV STAT COMP; Rauch SL, 1997, ANN NY ACAD SCI, V821, P83, DOI 10.1111/j.1749-6632.1997.tb48271.x; Roberts AL, 2011, PSYCHOL MED, V41, P71, DOI 10.1017/S0033291710000401; Rona RJ, 2009, J TRAUMA STRESS, V22, P11, DOI 10.1002/jts.20383; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tanielian T, 2008, INVISIBLE WOUNDS OFW; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; US Department of Defense, 1984, TEST MANUAL FOR THE; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; VUONG QH, 1989, ECONOMETRICA, V57, P307, DOI 10.2307/1912557; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003	71	128	129	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	FEB	2014	71	2					149	157		10.1001/jamapsychiatry.2013.3080			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AA8UN	WOS:000331370600006	24337530	Bronze, Green Published			2022-02-06	
J	Skandsen, T; Kvistad, KA; Solheim, O; Strand, IH; Folvik, M; Vik, A				Skandsen, Toril; Kvistad, Kjell Arne; Solheim, Ole; Strand, Ingrid Haavde; Folvik, Mari; Vik, Anne			Prevalence and impact of diffuse axonal injury in patients with moderate and severe head injury: a cohort study of early magnetic resonance imaging findings and 1-year outcome	JOURNAL OF NEUROSURGERY			English	Article						craniocerebral trauma; diffuse axonal injury; magnetic resonance imaging; Glasgow Outcome Scale; treatment outcome; cohort study	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; STEM; CLASSIFICATION; LESION; MRI; PROGNOSIS; CHILDREN; RECOVERY; DAMAGE	Object. In this prospective cohort study the authors examined patients with moderate to severe head injuries using MR imaging in the early phase. The objective was to explore the occurrence of diffuse axonal injury (DAI) and determine whether DAI was related to level of consciousness and patient outcome. Methods. One hundred and fifty-nine patients (age range 5-65 years) with traumatic brain injury, who survived the acute phase, and who had a Glasgow Coma Scale (GCS) score of 3-13 were admitted between October 2004 and August 2008. Of these 159 patients, 106 were examined using MR imaging within 4 weeks postinjury. Patients were classified into 1 of 3 stages of DAI: Stage 1, in which lesions were confined to the lobar white matter; Stage 2, in which there were callosal lesions; and Stage 3, in which lesions occurred in the dorsolateral brainstem. The outcome measure used 12 months postinjury was the Glasgow Outcome Scale Extended (GOSE). Results. Diffuse axonal injury was detected in 72% of the patients and a combination of DAI and contusions or hematomas was found in 50%. The GCS score was significantly lower in patients with "pure DAI" (median GCS Score 9) than in patients without DAI (median GCS Score 12; p < 0.001). The GCS score was related to outcome only in those patients with DAI (r = 0.47; p = 0.001). Patients with DAI had a median GOSE score of 7, and patients without DAI had a median GOSE score of 8 (p = 0.10). Outcome was better in patients with DAI Stage I (median GOSE Score 8) and DAI Stage 2 (median GOSE Score 7.5) than in patients with DAI Stage 3 (median GOSE Score 4; p < 0.001). Thus, in patients without any brainstem injury, there was no difference in good recovery between patients with DAI (67%) and patients without DAI (66%). Conclusions. Diffuse axonal injury was found in almost three-quarters of the patients with moderate and severe head injury who survived the acute phase. Diffuse axonal injury influenced the level of consciousness, and only in patients with DAI was GCS score related to outcome. Finally, DAI was a negative prognostic sign only when located in the brainstem. (DOI: 10.3171/2009.9.JNS09626)	[Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway; [Kvistad, Kjell Arne; Strand, Ingrid Haavde; Folvik, Mari] Univ Trondheim Hosp, St Olavs Hosp, Dept Diagnost Imaging, N-7006 Trondheim, Norway; [Skandsen, Toril; Solheim, Ole; Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, N-7006 Trondheim, Norway; [Skandsen, Toril; Solheim, Ole; Vik, Anne] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, Trondheim, Norway; [Kvistad, Kjell Arne] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Imaging, Trondheim, Norway		Skandsen, T (corresponding author), Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway.	toril.skandsen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Solheim, Ole/0000-0002-5954-4817			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Altman D.G., 1990, PRACTICAL STAT MED R; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; LeGrand SA, 2007, J NEUROTRAUM, V24, P1437, DOI 10.1089/neu.2007.0293; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LD, 1991, J NEUROSURG, V75, P514; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	35	128	132	1	15	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					556	563		10.3171/2009.9.JNS09626			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100019	19852541				2022-02-06	
J	Slobounov, SM; Zhang, K; Pennell, D; Ray, W; Johnson, B; Sebastianelli, W				Slobounov, Semyon M.; Zhang, K.; Pennell, D.; Ray, W.; Johnson, B.; Sebastianelli, W.			Functional abnormalities in normally appearing athletes following mild traumatic brain injury: a functional MRI study	EXPERIMENTAL BRAIN RESEARCH			English	Article						Concussion; fMRI; Virtual reality; Spatial memory; Spatial navigation	WORKING-MEMORY PERFORMANCE; MULTIPLE-SCLEROSIS; HUMAN HIPPOCAMPUS; EPISODIC MEMORY; SPATIAL MEMORY; COGNITIVE MAPS; FMRI; CONCUSSION; ACTIVATION; REORGANIZATION	Memory problems are one of the most common symptoms of sport-related mild traumatic brain injury (MTBI), known as concussion. Surprisingly, little research has examined spatial memory in concussed athletes given its importance in athletic environments. Here, we combine functional magnetic resonance imaging (fMRI) with a virtual reality (VR) paradigm designed to investigate the possibility of residual functional deficits in recently concussed but asymptomatic individuals. Specifically, we report performance of spatial memory navigation tasks in a VR environment and fMRI data in 15 athletes suffering from MTBI and 15 neurologically normal, athletically active age matched controls. No differences in performance were observed between these two groups of subjects in terms of success rate (94 and 92%) and time to complete the spatial memory navigation tasks (mean = 19.5 and 19.7 s). Whole brain analysis revealed that similar brain activation patterns were observed during both encoding and retrieval among the groups. However, concussed athletes showed larger cortical networks with additional increases in activity outside of the shared region of interest (ROI) during encoding. Quantitative analysis of blood oxygen level dependent (BOLD) signal revealed that concussed individuals had a significantly larger cluster size during encoding at parietal cortex, right dorsolateral prefrontal cortex, and right hippocampus. In addition, there was a significantly larger BOLD signal percent change at the right hippocampus. Neither cluster size nor BOLD signal percent change at shared ROIs was different between groups during retrieval. These major findings are discussed with respect to current hypotheses regarding the neural mechanism responsible for alteration of brain functions in a clinical setting.	[Slobounov, Semyon M.; Zhang, K.; Johnson, B.] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Ray, W.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Pennell, D.] Penn State Univ, Chandlee Lab, Social Life & Engn Sci Imaging Ctr, University Pk, PA 16802 USA; [Slobounov, Semyon M.; Sebastianelli, W.] Penn State Univ, Ctr Sport Med, University Pk, PA 16802 USA; [Slobounov, Semyon M.; Sebastianelli, W.] Penn State Univ, Hershey Med Sch, University Pk, PA 16802 USA		Slobounov, SM (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	This study was supported by NIH Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury" awarded to Dr. Slobounov, PI. We would like to thank Elena Slobounov for VR programming and Dr. Susan Lemieux for fMRI design development. All human studies have been approved by the The Pennsylvania State University IRB and all subjects gave their informed consent prior to their inclusion in the study.	Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Bluml S, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P197, DOI 10.1007/0-387-32565-4_9; Brett M., 2002, 8 INT C FUNCT MAPP H, V16; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; CAO C, 2009, IEEE IN PRESS; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chiaravalloti ND, 2005, J CLIN EXP NEUROPSYC, V27, P33, DOI 10.1080/138033990513609; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Daselaar SM, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.013.2009; DENNIS N, 2007, HDB AGING COGNITION; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Guskiewicz KM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P65, DOI 10.1007/0-387-32565-4_4; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Hartley T, 2003, NEURON, V37, P877, DOI 10.1016/S0896-6273(03)00095-3; Hayes SM, 2004, BEHAV NEUROSCI, V118, P885, DOI 10.1037/0735-7044.118.5.885; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P965, DOI 10.1076/jcen.25.7.965.16490; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Iaria G, 2007, EUR J NEUROSCI, V25, P890, DOI 10.1111/j.1460-9568.2007.05371.x; Jancke L, 2009, FRONT NEUROSCI-SWITZ, V3, P52, DOI 10.3389/neuro.01.006.2009; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Janzen G, 2007, BRAIN RES, V1165, P116, DOI 10.1016/j.brainres.2007.05.074; Kessels RPC, 2001, BRAIN RES REV, V35, P295, DOI 10.1016/S0165-0173(01)00058-3; Kessels RPC, 2000, NEUROPSYCHOL REV, V10, P101, DOI 10.1023/A:1009016820717; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P., 2009, BRIT J SPORT MED, V43, pi76; McNamara TP, 2003, TRENDS COGN SCI, V7, P333, DOI 10.1016/S1364-6613(03)00167-0; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pantano P, 2006, J NEUROIMAGING, V16, P104, DOI 10.1111/j.1552-6569.2006.00029.x; Parslow DM, 2004, NEUROPSYCHOLOGY, V18, P450, DOI 10.1037/0894-4105.18.3.450; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; ROSENBAUM R, 2008, NEUROBIOL AGING, V10, P724; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; SCHRADER H, 2009, BMC MED IMAG, V9; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Voermans NC, 2004, NEURON, V43, P427, DOI 10.1016/j.neuron.2004.07.009; Ward NS, 2005, INT J PSYCHOPHYSIOL, V58, P158, DOI 10.1016/j.ijpsycho.2005.02.009; Wirth W, 2007, MEDIA PSYCHOL, V9, P493, DOI 10.1080/15213260701283079; Witmer BG, 1998, PRESENCE-TELEOP VIRT, V7, P225, DOI 10.1162/105474698565686; Zhou YX, 2008, ALZHEIMERS DEMENT, V4, P265, DOI 10.1016/j.jalz.2008.04.006	59	128	130	0	40	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	APR	2010	202	2					341	354		10.1007/s00221-009-2141-6			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	577JW	WOS:000276220300008	20039023	Green Accepted			2022-02-06	
J	Hauser, WA; Beghi, E				Hauser, W. Allen; Beghi, Ettore			First seizure definitions and worldwide incidence and mortality	EPILEPSIA			English	Article						first seizure; definition; incidence; mortality	SHORT-TERM MORTALITY; UNPROVOKED SEIZURES; EPILEPTIC SEIZURES; RISK; RECURRENCE; ROCHESTER; PREVALENCE; DISORDERS; MINNESOTA; EPISODE	While all patients with epilepsy experience seizures, not all individuals with seizures have epilepsy. Seizures may be acute symptomatic or unprovoked. Acute symptomatic seizures are seizures occurring at the time of a systemic insult or in close temporal association with a documented brain insult. Unprovoked seizures are seizures occurring in the absence of precipitating factors and may be caused by a static injury (remote symptomatic seizures) or a progressing injury (progressive symptomatic seizures). Unprovoked seizures may be single or recurrent (epilepsy). The incidence of acute symptomatic seizures is 29-39 per 100,000 per year. These predominate in men, in the youngest age class, and in the elderly. Traumatic brain injury, cerebrovascular disease, drug withdrawal, infarction, and metabolic insults are the commonest causes. The incidence of single unprovoked seizures is 23-61 per 100,000 person-years. As with epilepsy, single unprovoked seizures predominate in men and in patients less than 12 months and older than 65 years. Studies on the mortality of acute symptomatic seizures are lacking. A standardized mortality ratio (SMR) of 2.3 has been reported in patients experiencing a single unprovoked seizure. The SMR in patients with a newly diagnosed unprovoked seizure ranges from 2.5 to 4.1 according to the study population and design. The SMR is highest in the youngest patients and in those with symptomatic seizures.	[Beghi, Ettore] Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, I-20157 Milan, Italy; [Hauser, W. Allen] Columbia Univ, Sergievsky Ctr, New York, NY USA; [Beghi, Ettore] Univ Milano Bicocca, Epilepsy Ctr, Monza, Italy		Beghi, E (corresponding author), Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, Via Eritrea 62, I-20157 Milan, Italy.	beghi@marionegri.it	Hauser, W Allen/AAB-5277-2020; Beghi, Ettore/AAA-7426-2020	Beghi, Ettore/0000-0003-2542-0469			ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1993, EPILEPSIA, V34, P592; Beghi E, 2005, EPILEPSIA, V46, P40, DOI 10.1111/j.1528-1167.2005.00407.x; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; Hauser WA, 1996, MAYO CLIN PROC, V71, P576, DOI 10.4065/71.6.576; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; Hesdorffer DC, 2005, EPILEPSIA, V46, P43, DOI 10.1111/j.1528-1167.2005.00408.x; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Jallon P, 1997, EPILEPSIA, V38, P547, DOI 10.1111/j.1528-1157.1997.tb01139.x; Lindsten H, 2000, EPILEPSIA, V41, P1469, DOI 10.1111/j.1528-1157.2000.tb00124.x; Logroscino G, 2002, NEUROLOGY, V58, P537, DOI 10.1212/WNL.58.4.537; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; LOISEAU J, 1990, EPILEPSIA, V31, P391, DOI 10.1111/j.1528-1157.1990.tb05493.x; Loiseau J, 1999, EPILEPSIA, V40, P1388, DOI 10.1111/j.1528-1157.1999.tb02010.x; LUHDORF K, 1986, EPILEPSIA, V27, P135, DOI 10.1111/j.1528-1157.1986.tb03516.x; MacDonald BK, 2000, BRAIN, V123, P665, DOI 10.1093/brain/123.4.665; Olafsson E, 2005, LANCET NEUROL, V4, P627, DOI 10.1016/S1474-4422(05)70172-1; Olafsson E, 1998, EPILEPSIA, V39, P89, DOI 10.1111/j.1528-1157.1998.tb01279.x; Pal DK, 2000, J NEUROL NEUROSUR PS, V68, P137, DOI 10.1136/jnnp.68.2.137; PLACENCIA M, 1992, BRAIN, V115, P771, DOI 10.1093/brain/115.3.771; SIDENVALL R, 1993, ACTA PAEDIATR, V82, P60, DOI 10.1111/j.1651-2227.1993.tb12518.x	26	128	139	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2008	49			1			8	12		10.1111/j.1528-1167.2008.01443.x			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	248FA	WOS:000252136200003	18184148	Bronze			2022-02-06	
J	Parsons, TD; Bowerly, T; Buckwalter, JG; Rizzo, AA				Parsons, Thomas D.; Bowerly, Todd; Buckwalter, J. Galen; Rizzo, Albert A.			A controlled clinical comparison of attention performance in children with ADHD in a virtual reality classroom compared to standard neuropsychological methods	CHILD NEUROPSYCHOLOGY			English	Article						virtual reality; attention deficit hyperactivity disorder; neurocognitive	DEFICIT-HYPERACTIVITY DISORDER; ALLOCENTRIC SPATIAL MEMORY; TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE FUNCTIONS; DEFICIT/HYPERACTIVITY DISORDER; ECOLOGICAL VALIDITY; DSM-IV; INHIBITION DEFICIT; REHABILITATION; CHILDHOOD	In this initial pilot study, a controlled clinical comparison was made of attention perforance in children with attention deficit-hyperactivity disorder (ADHD) in a virtual reality (VR) classroom. Ten boys diagnosed with ADHD and ten normal control boys participated in the study. Groups did not significantly differ in mean age, grade level, ethnicity, or handedness. No participants reported simulator sickness following VR exposure. Children with ADHD exhibited more omission errors, commission errors, and overall body movement than normal control children in the VR classroom. Children with ADHD were more impacted by distraction in the VR classroom. VR classroom measures were correlated with traditional ADHD assessment tools and the flatscreen CPT. Of note, the small sample size incorporated in each group and higher WISC-III scores of normal controls might have some beating on the overall interpretation of results. These data suggested that the Virtual Classroom had good potential for controlled performance assessment within an ecologically valid environment and appeared to parse out significant effects due to the presence of distraction stimuli	Univ So Calif, Inst Creat Technol, Marina Del Rey, CA 90292 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; So Calif Kaiser Permanente Med Grp, Pasadena, CA USA		Parsons, TD (corresponding author), Univ So Calif, Inst Creat Technol, 13274 Fiji Way,Off 301, Marina Del Rey, CA 90292 USA.	tparsons@ict.usc.edu		Parsons, Thomas/0000-0003-0331-5019			ABIKOFF H, 1993, J ABNORM CHILD PSYCH, V21, P519, DOI 10.1007/BF00916317; BARKLEY RA, 1991, J ABNORM CHILD PSYCH, V19, P149, DOI 10.1007/BF00909976; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Barkley RA, 2000, J AM ACAD CHILD PSY, V39, P1064, DOI 10.1097/00004583-200008000-00025; Barkley RA, 2004, PSYCHIAT CLIN N AM, V27, P233, DOI 10.1016/S0193-953X(03)00091-1; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; Barkley RA, 1997, J DEV BEHAV PEDIATR, V18, P271; Baumgartner T, 2006, CYBERPSYCHOL BEHAV, V9, P30, DOI 10.1089/cpb.2006.9.30; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Biederman J, 2005, BIOL PSYCHIAT, V57, P1215, DOI 10.1016/j.biopsych.2004.10.020; Bleckley MK, 2003, PSYCHON B REV, V10, P884, DOI 10.3758/BF03196548; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Brooks BM, 2003, NEUROREHABILITATION, V18, P147; Buckwalter J G, 1997, Stud Health Technol Inform, V39, P17; Burgess N, 2006, REV NEUROSCIENCE, V17, P239; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Cho BH, 2004, CYBERPSYCHOL BEHAV, V7, P519, DOI 10.1089/cpb.2004.7.519; Cho BH, 2002, ST HEAL T, V85, P89; Cho BH, 2002, CYBERPSYCHOL BEHAV, V5, P129, DOI 10.1089/109493102753770516; Clancy TA, 2006, J CLIN CHILD ADOLESC, V35, P203, DOI 10.1207/s15374424jccp3502_4; Conners C. K., 2000, CONNERS CPT 2 WINDOW; CORKUM PV, 1993, J CHILD PSYCHOL PSYC, V34, P1217, DOI 10.1111/j.1469-7610.1993.tb01784.x; ELIASON MJ, 1987, J LEARN DISABIL, V20, P614, DOI 10.1177/002221948702001007; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Farias ST, 2003, ARCH CLIN NEUROPSYCH, V18, P655, DOI 10.1016/S0887-6177(02)00159-2; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; GOLDEN C, 1978, STROOP COLOR WORLD T; Grodzinsky GM, 1999, CLIN NEUROPSYCHOL, V13, P12, DOI 10.1076/clin.13.1.12.1983; GRODZINSKY GM, 1992, DEV NEUROPSYCHOL, V8, P427, DOI 10.1080/87565649209540536; Kaplan E, 1983, BOSTON NAMING TEST; KENNEDY RS, 1992, AVIAT SPACE ENVIR MD, V63, P588; Korkman M, 1997, NEPSY; Lahey BB, 2006, J CHILD PSYCHOL PSYC, V47, P472, DOI 10.1111/j.1469-7610.2005.01590.x; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Losier BJ, 1996, J CHILD PSYCHOL PSYC, V37, P971, DOI 10.1111/j.1469-7610.1996.tb01494.x; McClusky DA, 2005, AM SURGEON, V71, P13; Morganti F, 2004, ST HEAL T, V99, P55; Nichols SL, 2004, CHILD PSYCHIAT HUM D, V34, P297; Nigg JT, 1999, J ABNORM CHILD PSYCH, V27, P393, DOI 10.1023/A:1021980002473; Odhuba RA, 2005, BRIT J CLIN PSYCHOL, V44, P269, DOI 10.1348/014466505X29431; Pani JR, 2005, COGNITIVE PSYCHOL, V51, P285, DOI 10.1016/j.cogpsych.2005.06.002; Parslow DM, 2005, ACTA PSYCHOL, V118, P123, DOI 10.1016/j.actpsy.2004.10.006; Parsons TD, 2004, NEUROPSYCHOLOGIA, V42, P555, DOI 10.1016/j.neuropsychologia.2003.08.014; Phelps A, 2004, ST HEAL T, V98, P298; Pineda D, 1998, INT J NEUROSCI, V96, P177, DOI 10.3109/00207459808986466; Plehn K, 2004, CLIN NEUROPSYCHOL, V18, P101, DOI 10.1080/13854040490507190; Rapport LJ, 2001, CLIN NEUROPSYCHOL, V15, P479, DOI 10.1076/clin.15.4.479.1878; Rapport MD, 2000, J CLIN CHILD PSYCHOL, V29, P555, DOI 10.1207/S15374424JCCP2904_8; Ready RE, 2001, CLIN NEUROPSYCHOL, V15, P314, DOI 10.1076/clin.15.3.314.10269; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Reitan RM, 2004, ARCH CLIN NEUROPSYCH, V19, P281, DOI 10.1016/S0887-6177(03)00042-8; Reitan RM, 1992, TRAIL MAKING TEST MA; Rizzo A A, 1997, Stud Health Technol Inform, V39, P22; Rizzo AA, 2006, CNS SPECTRUMS, V11, P35, DOI 10.1017/S1092852900024196; Rizzo AA, 2004, COMPUTER, V37, P87, DOI 10.1109/MC.2004.23; Rizzo AA, 2003, CLIN NEUROPSYCHOL, V17, P100; Rizzo AA, 1997, ST HEAL T, V44, P123; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Sayal K, 2005, ACTA PSYCHIAT SCAND, V111, P460, DOI 10.1111/j.1600-0447.2004.00487.x; Schachar R, 2000, J ABNORM CHILD PSYCH, V28, P227, DOI 10.1023/A:1005140103162; Scheres A, 2004, ARCH CLIN NEUROPSYCH, V19, P569, DOI 10.1016/j.acn.2003.08.005; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P378, DOI 10.1097/00001199-200210000-00002; Scotti JR, 1996, J CONSULT CLIN PSYCH, V64, P1177, DOI 10.1037/0022-006X.64.6.1177; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Swanson J, 2005, CATEGORICAL DIMENSIO; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wolbers T, 2004, COGNITIVE BRAIN RES, V21, P401, DOI 10.1016/j.cogbrainres.2004.06.013	68	128	132	3	41	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	JUL	2007	13	4					363	381		10.1080/13825580600943473			19	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	207ZU	WOS:000249290400005	17564852				2022-02-06	
J	Perianez, JA; Rios-Lago, M; Rodriguez-Sanchez, JM; Adrover-Roig, D; Sanchez-Cubillo, I; Crespo-Facorro, B; Quemada, JI; Barcelo, F				Perianez, J. A.; Rios-Lago, M.; Rodriguez-Sanchez, J. M.; Adrover-Roig, D.; Sanchez-Cubillo, I.; Crespo-Facorro, B.; Quemada, J. I.; Barcelo, F.			Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing: Sample comparisons and normative data	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						attentional control; brain damage; clinical norms; executive function; neuropsychological assessment; schizophrenia	EXECUTIVE SYSTEM IMPAIRMENT; PREFRONTAL CORTEX; CULTURAL NEUROPSYCHOLOGY; DYSEXECUTIVE SYNDROME; PRACTICAL SCALE; TEST INDEXES; STROOP TEST; MAKING TEST; PART-B; AGE	The Trail Making Test (TMT) has been a useful assessment tool to investigate executive function. Several studies have recently improved the existing TMT norms by mean of large samples of healthy individuals stratified by a number of demographic variables from different populations. In contrast, criticisms have been raised about the utility of norms from healthy samples to detect changes across time in clinical samples where TMT performance used to be altered. In addition, few studies have compared groups of patients with deficits in TMT performance, making it difficult to decide whether a single set of norms is sufficient to assess different clinical populations. We provide normative data from three large samples of patients with traumatic brain injury (TBI) (n = 90), schizophrenia spectrum disorders (n = 127), and healthy Spanish speakers (it = 223). Differences between healthy participants and patients in all TMT direct (TMT-A, TMT-B) and derived (B-A, B:A, B-A/A) scores were found. TMT performance was poorer in TBI patients than in schizophrenia patients except for the B:A and B-A/A scores, suggesting a similar underlying executive deficit. Normal ageing impaired both direct and derived TMT indices, as revealed by lower scores in the healthy elderly group (55-80 years old) as compared with young (16-24) and middle-aged (25-54) healthy participants. Three different sets of norms stratified by age, education, or both are presented for clinical use. Recommendations on TMT scores are made for future research. (c) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Balearic Isl, Dept Psychol, Palma de Mallorca 07122, Spain; IUNICS, Baleares, Spain; Hosp Beata Maria Ana, Brain Damage Unit, Madrid, Spain; Univ Nacl Educ Distancia, Dept Basic Psychol 2, Madrid, Spain; Hosp Univ Marques Valdecilla, Santander, Spain; Hosp Aita Menni, Brain Damage Unit, Bilbao, Spain; Univ Cantabria, Sch Med, Dept Psychiat, E-39005 Santander, Spain		Perianez, JA (corresponding author), Univ Balearic Isl, Dept Psychol, Ctra Valldemossa Km 7-5,Edif Beatriu Pinos Desp 2, Palma de Mallorca 07122, Spain.	ja.perianez@uib.es	Rios-Lago, Marcos/C-9568-2012; Rios-Lago, Marcos/P-6930-2019; Adrover-Roig, Daniel/B-9645-2009; Crespo-Facorro, BENEDICTO/AAY-2238-2021; Perianez, Jose Antonio/AAI-3988-2021; Barcelo, Francisco/B-3629-2011	Rios-Lago, Marcos/0000-0003-0187-5047; Rios-Lago, Marcos/0000-0003-0187-5047; Adrover-Roig, Daniel/0000-0002-4337-1325; Crespo-Facorro, BENEDICTO/0000-0003-0033-7132; Perianez, Jose Antonio/0000-0003-4310-4021; Barcelo, Francisco/0000-0001-6012-7116			Albert MS, 2001, J INT NEUROPSYCH SOC, V7, P631, DOI 10.1017/S1355617701755105; Amodio P, 2002, AGING CLIN EXP RES, V14, P117, DOI 10.1007/BF03324425; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; ARDILA A, 1995, J CLIN EXP NEUROPSYC, V17, P143, DOI 10.1080/13803399508406589; Ardila A, 2005, NEUROPSYCHOL REV, V15, P185, DOI 10.1007/s11065-005-9180-y; Army Individual Test Battery, 1944, MAN DIR SCOR; Bilder RM, 2000, AM J PSYCHIAT, V157, P549, DOI 10.1176/appi.ajp.157.4.549; Brazo P, 2005, PSYCHIAT RES, V133, P45, DOI 10.1016/j.psychres.2004.10.001; Chao LL, 1997, CEREB CORTEX, V7, P63, DOI 10.1093/cercor/7.1.63; Ciaramelli E, 2006, BRAIN COGNITION, V60, P198; Crespo-Facorro B, 2000, BIOL PSYCHIAT, V48, P110, DOI 10.1016/S0006-2332(00)00238-9; Crespo-Facorro B, 2006, J CLIN PSYCHIAT, V67, P1511, DOI 10.4088/JCP.v67n1004; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.3.CO;2-M; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Drane DL, 2002, NEUROPSY NEUROPSY BE, V15, P39; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAUDINO EA, 1995, J CLIN EXP NEUROPSYC, V17, P529, DOI 10.1080/01688639508405143; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; Hashimoto R, 2006, PSYCHIAT CLIN NEUROS, V60, P422, DOI 10.1111/j.1440-1819.2006.01526.x; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Hester RL, 2005, CLIN NEUROPSYCHOL, V19, P45, DOI 10.1080/13854040490524137; Kennepohl S, 1999, BRAIN COGNITION, V41, P365, DOI 10.1006/brcg.1999.1138; Kizilbash A, 2000, Pediatr Rehabil, V4, P71; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; Krabbendam L, 1999, CLIN NEUROPSYCHOL, V13, P370, DOI 10.1076/clin.13.3.370.1739; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D, 1995, NEUROPSYCHOLOGICAL A, V3rd, P650; Lu Lei, 2002, Appl Neuropsychol, V9, P219, DOI 10.1207/S15324826AN0904_4; Manoach DS, 2003, SCHIZOPHR RES, V60, P285, DOI 10.1016/S0920-9964(02)00294-3; Miner T, 1998, BRAIN COGNITION, V38, P246, DOI 10.1006/brcg.1998.1034; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; Mitrushina MN, 1999, HDB NORMATIVE DATA N; Perianez JA, 2001, REV NEUROLOGIA, V33, P611, DOI 10.33588/rn.3307.2001045; Raz N, 2004, NEUROBIOL AGING, V25, P377, DOI 10.1016/S0197-4580(03)00118-0; Reitan R, 1985, HALSTEAD REITAN NEUR; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM, 1992, TRAIL MAKING TEST MA; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Rios M., 2004, ATENCION CONTROL EJE; Rodriguez-Sanchez JM, 2005, SCHIZOPHR RES, V77, P279, DOI 10.1016/j.schres.2005.04.023; Rose, 1982, CLIN GERONTOLOGIST, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; Salat DH, 1999, ARCH NEUROL-CHICAGO, V56, P338, DOI 10.1001/archneur.56.3.338; SALTHOUSE TA, 1995, NEUROPSYCHOLOGY, V9, P518, DOI 10.1037/0894-4105.9.4.518; Salthouse TA, 2000, NEUROPSYCHOLOGY, V14, P102, DOI 10.1037/0894-4105.14.1.102; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seo EH, 2006, INT J GERIATR PSYCH, V21, P844, DOI 10.1002/gps.1570; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Soukup V M, 1998, Appl Neuropsychol, V5, P65, DOI 10.1207/s15324826an0502_2; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Szoke A, 2005, PSYCHOL MED, V35, P771, DOI 10.1017/S0033291704003460; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Turner-Stokes L., 2005, COCHRANE DATABASE SY, V3; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P83, DOI 10.1016/j.acn.2005.07.008; [No title captured]	69	128	131	0	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2007	22	4					433	447		10.1016/j.acn.2007.01.022			15	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	182OP	WOS:000247514200002	17336493	Bronze			2022-02-06	
J	Vaquero, J; Zurita, M; Oya, S; Santos, M				Vaquero, J; Zurita, M; Oya, S; Santos, M			Cell therapy using bone marrow stromal cells in chronic paraplegic rats: Systemic or local administration?	NEUROSCIENCE LETTERS			English	Article						bone marrow stromal cells; stem cells; spinal cord injury; paraplegia	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; FUNCTIONAL RECOVERY; INTRACEREBRAL TRANSPLANTATION; ADULT RATS; TISSUE	Recent studies showed the therapeutic effect of bone marrow stromal cells (BMSC) after spinal cord injury (SCI). In the present study, we compared the effect of systemic and local administration of BMSC in adult Wistar rats suffering chronic paraplegia as consequence of severe SCI. Adult Wistar rats were subjected to a weight-drop impact causing complete paraplegia, and 3 months later, all the animals remained without signs of functional recovery. At this moment, 3 x 106 BMSC were injected intravenously (n: 20) or into traumatic spinal cord cavity (n: 20). Outcome was evaluated until sacrifice of the animals, 6 months later, using the Basso-Beattie-Bresnehan (BBB) score, the cold spray test, and measuring the thigh perimeter. After sacrifice, samples of spinal cord tissue were studied histologically. The results showed that intravenous administration of BMSC achieves some degree of functional recovery when compared to controls. Nevertheless, administration of BMSC into postraumatic spinal cord cavity promotes a clear and progressive functional recovery, significantly superior to the recovery obtained by means of the intravenous administration. This effect is associated to long-term presence of BMSC in the injured spinal cord tissue, with images suggesting neuronal differentiation and spinal cord reconstruction. (C) 2005 Elsevier Ireland Ltd. All rights reserved.	Autonomous Univ Madrid, Puerta Hierro Hosp, Neurosurg & Expt Surg Serv, Mapfre Med Fdn,Neurosci Res Unit, Madrid 28035, Spain		Vaquero, J (corresponding author), Autonomous Univ Madrid, Puerta Hierro Hosp, Neurosurg & Expt Surg Serv, Mapfre Med Fdn,Neurosci Res Unit, San Martin Porres 4, Madrid 28035, Spain.	jvaqueroc@telefonica.net	Santos, Martin/AAM-7198-2021	Santos, Martin/0000-0002-5928-6010			Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; BARONVANEVERCOOREN A, 1991, NEUROSCI LETT, V131, P241, DOI 10.1016/0304-3940(91)90623-2; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; de Haro J, 2005, NEUROSCI LETT, V377, P7, DOI 10.1016/j.neulet.2004.11.060; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; WEI Y, 1998, PAIN, V74, P115; Zurita M, 2000, SURG NEUROL, V54, P117, DOI 10.1016/S0090-3019(00)00287-1; Zurita M, 2001, SURG NEUROL, V55, P249, DOI 10.1016/S0090-3019(01)00442-6; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004; ZURITA M, 1994, POLYTRAUMATIZED, P343	18	128	152	1	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAY 1	2006	398	1-2					129	134		10.1016/j.neulet.2005.12.072			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	034FN	WOS:000236914500026	16423458				2022-02-06	
J	Bazarian, JJ; Veazie, P; Mookerjee, S; Lerner, EB				Bazarian, JJ; Veazie, P; Mookerjee, S; Lerner, EB			Accuracy of mild traumatic brain injury case ascertainment using ICD-9 codes	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	National Injury Prevention and Control Conference	MAY 09-09, 2005	Denver, CO			brain injuries; emergency service; hospital; International Classification of Diseases; population surveillance; sensitivity; specificity	MINOR HEAD-INJURY; MISSED INJURIES	Objectives: To determine the accuracy of mild traumatic brain injury (TBI) case ascertainment using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes proposed by the Centers for Disease Control and Prevention (CDC) in a 2003 Report to Congress. Methods: This was a prospective cohort study of all patients presenting to an urban academic emergency department (ED) over six months in 2003. A real-time clinical assessment of mild TBI was compared with the ICD-9 codes assigned after ED or hospital discharge for a determination of sensitivity and specificity. Results: Of the 35,096 patients presenting to the ED, 516 had clinically defined mild TBI and 1,000 were assigned one or more of the mild TBI ICD-9 codes proposed by the CDC. The sensitivity of these codes was 45.9% (95% confidence interval [95%, CI] = 41.3%, to 50.2%) with a specificity of 97.8% (95% CI = 97.6% to 97.9%). Conclusions: The identification of mild TBI patients using retrospectively assigned ICD-9 codes appears to be inaccurate. These codes are associated with a significant number of raise-positive and false-negative code assignments. Mild TBI incidence and prevalence estimates using these codes should be interpreted with caution. ICD-9 codes should not replace a clinical assessment for mild TBI when accurate case ascertainment is required.	Univ Rochester, Med Ctr, Sch Med, Dept Emergency Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Community & Prevent Med, Rochester, NY 14642 USA		Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Sch Med, Dept Emergency Med, 601 Elmwood Ave,Box 655, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS41952-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER		Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Beattie T F, 1995, Health Bull (Edinb), V53, P395; Berger Rachel, 2003, Pediatr Crit Care Med, V4, P391, DOI 10.1097/01.PCC.0000075324.45784.8A; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Buchbinder R, 1996, AM J IND MED, V29, P171, DOI 10.1002/(SICI)1097-0274(199602)29:2<171::AID-AJIM7>3.0.CO;2-V; Buduhan G, 2000, J TRAUMA, V49, P600, DOI 10.1097/00005373-200010000-00005; *CDCP, BRAIN INJ MASS TRAUM; Centers for Disease Control and Prevention, 2003, MILD TRAUM BRAIN INJ; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Cobaugh DJ, 1997, ACAD EMERG MED, V4, P231, DOI 10.1111/j.1553-2712.1997.tb03748.x; Cohen J., 1983, APPL MULTIPLE REGRES; Curtis Kate, 2002, Aust Health Rev, V25, P73; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Espino JU, 2001, J AM MED INFORM ASSN, P164; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Houshian S, 2002, J TRAUMA, V52, P715, DOI 10.1097/00005373-200204000-00018; Hunt JP, 2000, J TRAUMA, V49, P679, DOI 10.1097/00005373-200010000-00016; Janjua KJ, 1998, J TRAUMA, V44, P1000, DOI 10.1097/00005373-199806000-00012; Jay G W, 1996, J Insur Med, V27, P262; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING G, 2001, POLITICAL ANAL, V0009; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MacIntyre CR, 1997, AUST NZ J PUBL HEAL, V21, P779; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIZOLI SB, 1994, ACCIDENT ANAL PREV, V26, P681, DOI 10.1016/0001-4575(94)90030-2; *US DEP HHS, 2003, GEN ICD9CM HOSP VERS, V1, P4; Wynn A, 2001, J TRAUMA, V51, P464, DOI 10.1097/00005373-200109000-00007	31	128	128	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JAN	2006	13	1					31	38		10.1197/j.aem.2005.07.038			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	000PO	WOS:000234474500006	16365331	Bronze			2022-02-06	
J	Starling, SP; Patel, S; Burke, BL; Sirotnak, AP; Stronks, S; Rosquist, P				Starling, SP; Patel, S; Burke, BL; Sirotnak, AP; Stronks, S; Rosquist, P			Analysis of perpetrator admissions to inflicted traumatic brain injury in children	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article; Proceedings Paper	29th National Neurology Seminar	2003	Candanchu, SPAIN				NONACCIDENTAL HEAD-INJURY; SHAKEN IMPACT SYNDROME; RETINAL HEMORRHAGES; YOUNG-CHILDREN; BABY SYNDROME; INFANTS; CHILDHOOD; SHAKING; ABUSE	Background: Scientific and courtroom debate exists regarding the timing of onset of symptoms and the mechanism of injury in infants and children with inflicted traumatic brain injury (ITBI). Objectives: To determine the time interval between ITBI and the onset of symptoms and to explore the mechanism of ITBI. Design, Setting, and Patients: Retrospective review of all cases of pediatric ITBI admitted between January 1, 1981, and July 31, 2001, to a large academic medical center and cases admitted to 2 additional academic institutions between January 1, 1996, and August 31, 2000, and January 1, 200 1, and July 31, 2001, comparing 81 cases of ITBI in which perpetrators admitted to abuse with 90 cases in which no abuse admission was made. The patients with perpetrator admissions to ITBI consisted of 53 boys (65%) and 28 girls (35%). Their ages ranged from 2 weeks to 52 months. Main Outcome Measures: Characteristics associated with perpetrator admissions to ITBI in children. Results: Shaking was the most common mechanism of injury among all cases with perpetrator admissions: 55 (68%) of the 81 perpetrators admitted to shaking the children. Impact was not described in 44 (54%) of the 81 cases. In cases in which only impact was described, 60% (12/20) of the children showed skull or scalp injury, compared wit-h 12% (4/32) with skull or scalp injury in the shake only group. In 52 (91%) of 57 cases in which the time to the onset of symptoms was described, symptoms appeared immediately after the abuse. In 5 cases (9%), the timing of symptoms was less clear, but they occurred within 24 hours. None of the children were described as behaving normally after the event. Conclusions: The symptoms of inflicted head injury in children are immediate. Most perpetrators admitted to shaking without impact. These data, combined with the relative lack of skull and scalp injury, suggest that shaking alone can produce the symptoms seen in children with ITBI.	Childrens Hosp Kings Daughter, Child Abuse Program, Norfolk, VA 23507 USA; Eastern Virginia Med Sch, Dept Pediat, Norfolk, VA 23501 USA; Univ Colorado, Sch Med, Childrens Hosp, Dept Pediat, Denver, CO 80202 USA		Starling, SP (corresponding author), Childrens Hosp Kings Daughter, Child Abuse Program, 935 Redgate Ave, Norfolk, VA 23507 USA.	StarliSP@chkd.com					ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; BRUCE DA, 1989, PEDIATR ANN, V18, P486; BRUCE DA, 1989, PEDIATR ANN, V18, P492; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; ELDER JE, 1991, J PAEDIATR CHILD H, V27, P286, DOI 10.1111/j.1440-1754.1991.tb02539.x; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; Gilliland MGF, 1998, J FORENSIC SCI, V43, P723; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; Luerssen T G, 1991, Neurosurg Clin N Am, V2, P399; Rao P, 1999, CLIN RADIOL, V54, P495, DOI 10.1016/S0009-9260(99)90845-0; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Starling S P, 2000, Child Maltreat, V5, P58, DOI 10.1177/1077559500005001007; STARLING SP, 1995, PEDIATRICS, V95, P259; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9; Winston, 1998, CHILD MALTREATMENT, V3, P116, DOI [DOI 10.1177/1077559598003002006, 10.1177/1077559598003002006]	27	128	132	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAY	2004	158	5					454	458		10.1001/archpedi.158.5.454			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pediatrics	818VI	WOS:000221272200013	15123478	Bronze			2022-02-06	
J	Lifshitz, J; Friberg, T; Neumar, RW; Raghupathi, R; Welsh, FA; Janmey, P; Saatman, KE; Wieloch, T; Grady, MS; McIntosh, TK				Lifshitz, J; Friberg, T; Neumar, RW; Raghupathi, R; Welsh, FA; Janmey, P; Saatman, KE; Wieloch, T; Grady, MS; McIntosh, TK			Structural and functional damage sustained by mitochondria after traumatic brain injury in the rat: Evidence for differentially sensitive populations in the cortex and hippocampus	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						head injury; mitochondrial permeability transition; mitochondrial; swelling; photon correlation spectroscopy; cell death; dynamic light scatter	PERMEABILITY TRANSITION PORE; LATERAL FLUID-PERCUSSION; CYTOCHROME-C RELEASE; CYCLOSPORINE-A; CELL-DEATH; MEMBRANE-PERMEABILITY; CNS MITOCHONDRIA; OXIDATIVE STRESS; AXONAL INJURY; AMINO-ACIDS	The cellular and molecular pathways initiated by traumatic brain injury (TBI) may compromise the function and structural integrity of mitochondria, thereby contributing to cerebral metabolic dysfunction and cell death. The extent to which TBI affects regional mitochondrial populations with respect to structure, function, and swelling was assessed 3 hours and 24 hours after lateral fluid-percussion brain injury in the rat. Significantly less mitochondrial protein was isolated from the injured compared with uninjured parietotemporal cortex, whereas comparable yields were obtained from the hippocampus. After injury, cortical and hippocampal tissue ATP concentrations declined significantly to 60% and 40% of control, respectively, in the absence of respiratory deficits in isolated mitochondria. Mitochondria with ultrastructural morphologic damage comprised a significantly greater percent of the population isolated from injured than uninjured brain. As determined by photon correlation spectroscopy, the mean mitochondrial radius decreased significantly in injured cortical populations (361 +/- 40 nm at 24 hours) and increased significantly in injured hippocampal populations (442 +/- 36 at 3 hours) compared with uninjured populations (Ctx: 418 +/- 44; Hipp: 393 +/- 24). Calcium-induced deenergized swelling rates of isolated mitochondrial populations were significantly slower in injured compared with uninjured samples, suggesting that injury alters the kinetics of mitochondrial permeability transition (MPT) pore activation. Cyclosporin A (CsA)-insensitive swelling was reduced in the cortex, and CsA-sensitive and CsA-insensitive swelling both were reduced in the hippocampus, demonstrating that regulated MPT pores remain in mitochondria isolated from injured brain. A proposed mitochondrial population model synthesizes these data and suggests that cortical mitochondria may be depleted after TBI, with a physically smaller, MPT-regulated population remaining. Hippocampal mitochondria may sustain damage associated with ballooned membranes and reduced MPT pore calcium sensitivity. The heterogeneous mitochondrial response to TBI may underlie posttraumatic metabolic dysfunction and contribute to the pathophysiology of TBI.	Univ Pittsburgh, Dept Neurosurg, Head Injury Ctr, Philadelphia, PA 19104 USA; Univ Lund Hosp, Wallenberg Neurosci Ctr, Lab Expt Brain Res, S-22185 Lund, Sweden; Univ Penn, Expt Brain Res Lab, Philadelphia, PA 19104 USA; Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; VA Med Ctr, Philadelphia, PA USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA		Lifshitz, J (corresponding author), Univ Pittsburgh, Dept Neurosurg, Head Injury Ctr, 3320 Smith Walk,105C, Philadelphia, PA 19104 USA.		Raghupathi, Ramesh/AAX-5538-2021	Wieloch, Tadeusz/0000-0002-7669-2520	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG-00255] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690, 5-T32-GM07517] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS40978] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-41561] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690, T32GM007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000255] Funding Source: NIH RePORTER		Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; BROWN AW, 1972, J NEUROL SCI, V16, P59, DOI 10.1016/0022-510X(72)90102-5; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buki A, 2000, J NEUROSCI, V20, P2825; Cahill A, 1997, BIOCHEM BIOPH RES CO, V235, P286, DOI 10.1006/bbrc.1997.6774; Clark RSB, 1997, J NEUROSCI, V17, P9172; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GLATTER O, 1991, PART PART SYST CHAR, V8, P274, DOI 10.1002/ppsc.19910080150; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HYLTON CM, 1995, J CEREBR BLOOD F MET, V15, P1137, DOI 10.1038/jcbfm.1995.141; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kristal BS, 2000, DEV NEUROSCI-BASEL, V22, P376, DOI 10.1159/000017463; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAI JCK, 1989, CARBOHYDRATES ENERGY, P43; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LIPPOLD HJ, 1982, HISTOCHEMISTRY, V76, P381, DOI 10.1007/BF00543959; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Novgorodov SA, 1996, J BIOENERG BIOMEMBR, V28, P139, DOI 10.1007/BF02110644; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHWEIGER H, 1988, BIOCHEM MED METAB B, V40, P162, DOI 10.1016/0885-4505(88)90117-X; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; WUTHIER RE, 1985, CALCIFIED TISSUE INT, V37, P401, DOI 10.1007/BF02553710; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	79	128	131	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2003	23	2					219	231		10.1097/01.WCB.0000040581.43808.03			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	643ZQ	WOS:000180893800009	12571453				2022-02-06	
J	Rabadi, MH; Jordan, BD				Rabadi, MH; Jordan, BD			The cumulative effect of repetitive concussion in sports	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						chronic traumatic brain injury; concussion; boxing; football; soccer; ice hockey; martial arts	TRAUMATIC BRAIN-INJURY; AMATEUR BOXING LEAD; SOCCER INJURIES; DEMENTIA-PUGILISTICA; COMPUTED-TOMOGRAPHY; FOOTBALL PLAYERS; NECK INJURIES; DAMAGE; BOXERS; PERFORMANCE	The increased popularity of contact sports worldwide exposes a large number of participants to both acute and chronic traumatic brain injury. Chronic traumatic brain injury (CTBI) represents the cumulative, long-term neurological consequences of repetitive concussive and subconcussive blows to the brain. Although this condition has been described primarily in boxing, it may be anticipated in other contact sports such as soccer, football, ice hockey, and the martial arts. Since treatment options in CTBI are relatively limited, the prevention of CTBI is of paramount importance. Minimizing the frequency and severity of acute brain injury in sport a ill Is instrumental in accomplishing this peal. The prevention of CTBI will need to be sport specific and a ill undoubtedly rely on limiting the exposure of high-risk athletes, utilizing of protective equipment. enforcing strict rule adherence, training and supervising athletes, and increasing medical surveillance.	Burke Rehabil Hosp, Brain Injury Program, White Plains, NY 10605 USA; Cornell Univ, Weill Med Coll, Dept Neurol, New York, NY USA		Jordan, BD (corresponding author), Burke Rehabil Hosp, Brain Injury Program, 785 Mamaroneck Ave, White Plains, NY 10605 USA.		Rabadi, Meheroz/W-9953-2019; Esquivel, Darci M.S./G-1581-2012; Wajnberg, Eliane/G-7446-2014; Leal, Inara R./E-8362-2010	Leal, Inara R./0000-0002-8125-2191			[Anonymous], 1992, J NEUROIMAGING; Aotsuka A, 1990, Rinsho Shinkeigaku, V30, P1243; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; CLARKE KS, 1998, SPORTS NEUROLOGY, P3; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1978, SENILE DEMENTIA RELA, P125; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; DAVIE CA, 1995, J NEUROL NEUROSUR PS, V58, P688, DOI 10.1136/jnnp.58.6.688; Drachman DA, 1999, NEW ENGL J MED, V340, P1269, DOI 10.1056/NEJM199904223401609; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jordan B. D., 1998, SPORTS NEUROLOGY, P351; jordan B. D., 1999, J NEUROIMAGING, V9, P59; Jordan BD, 2000, NEUROLOGY, V54, pA410; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.02.928; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; JORDAN BD, 1993, MED ASPECTS BOXING, P147; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Sironi V A, 1982, J Neurosurg Sci, V26, P165; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Tsuang D, 1996, J AM GERIATR SOC, V44, P704, DOI 10.1111/j.1532-5415.1996.tb01836.x; Tucker AM, 1997, SPORTS MED, V23, P21, DOI 10.2165/00007256-199723010-00003; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; UHL GR, 1982, ANN NEUROL, V12, P99	59	128	128	0	49	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2001	11	3					194	198		10.1097/00042752-200107000-00011			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	454YG	WOS:000169998900010	11495325				2022-02-06	
J	Tretter, YP; Hertel, M; Munz, B; ten Bruggencate, G; Werner, S; Alzheimer, C				Tretter, YP; Hertel, M; Munz, B; ten Bruggencate, G; Werner, S; Alzheimer, C			Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo	NATURE MEDICINE			English	Article							MIDBRAIN DOPAMINERGIC-NEURONS; TRANSGENIC MICE REVEALS; BRAIN INJURY; EXPRESSION; RAT; FOLLISTATIN; BINDING; PROTECTS; LESION; REPAIR	Exogenous application of neurotrophic growth factors has emerged as a new and particularly promising approach not only to promote functional recovery after acute brain injury but also to protect neurons against the immediate effect of the injury. Among the various growth factors and cytokines studied so far, the neuroprotective and neurotrophic profile of basic fibroblast growth factor (bFGF) Is the best documented(1-5). Using an animal model of acute excitotoxic brain injury(6), we report here that the neuroprotective action of bFGF, which is now being tested in stroke patients, depends on the induction of activin A, a member of the transforming growth factor-beta superfamily. Our evidence for this previously unknown mechanism of action of bFGF is that bFGF strongly enhanced lesion-associated induction of activin A; in the presence of the activin-neutralizing protein follistatin, bFGF was no longer capable of rescuing neurons from excitotoxic death; and recombinant activin A exerted a neuroprotective effect by itself. Our data indicate that the development of substances influencing activin expression or receptor binding should offer new ways to fight neuronal loss in ischemic and traumatic brain injury.	Univ Munich, Dept Physiol, D-80336 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Swiss Fed Inst Technol, Dept Cell Biol, CH-8093 Zurich, Switzerland		Alzheimer, C (corresponding author), Univ Munich, Dept Physiol, Pettenkoferstr 12, D-80336 Munich, Germany.			Werner, Sabine/0000-0001-7397-8710			ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; Ay H, 1999, CEREBROVASC DIS, V9, P131, DOI 10.1159/000015941; Bethel A, 1997, STROKE, V28, P609, DOI 10.1161/01.STR.28.3.609; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; Hughes PE, 1999, NEUROSCIENCE, V92, P197, DOI 10.1016/S0306-4522(98)00724-6; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; Krieglstein K, 1998, EUR J NEUROSCI, V10, P2746, DOI 10.1046/j.1460-9568.1998.t01-1-00324.x; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Lai M, 1997, NEUROREPORT, V8, P2691, DOI 10.1097/00001756-199708180-00011; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Munz B, 1999, J ENDOCRINOL, V161, P187, DOI 10.1677/joe.0.1610187; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Peterson DA, 1996, J NEUROSCI, V16, P886; RIVA MA, 1994, NEUROSCIENCE, V59, P55, DOI 10.1016/0306-4522(94)90098-1; Sugino Hiromu, 1997, Journal of Medical Investigation, V44, P1; Tretter YP, 1996, NEUROREPORT, V7, P1819, DOI 10.1097/00001756-199607290-00026; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; Wu DD, 1999, BRAIN RES, V835, P369, DOI 10.1016/S0006-8993(99)01638-8; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727	25	128	133	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					812	+		10.1038/77548			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	WOS:000088040100040	10888932				2022-02-06	
J	Whalen, MJ; Clark, RSB; Dixon, CE; Robichaud, P; Marion, DW; Vagni, V; Graham, SH; Virag, L; Hasko, G; Stachlewitz, R; Szabo, C; Kochanek, PM				Whalen, MJ; Clark, RSB; Dixon, CE; Robichaud, P; Marion, DW; Vagni, V; Graham, SH; Virag, L; Hasko, G; Stachlewitz, R; Szabo, C; Kochanek, PM			Reduction of cognitive and motor deficits after traumatic brain injury in mice deficient in poly(ADP-ribose) polymerase	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article; Proceedings Paper	11th International Symposium on Brain Oedema and Mechanisms of Cellular Injury	JUN   06, 1999	NEWCASTLE, ENGLAND			brain injury; poly(ADP-ribose) polymerase; controlled cortical impact; mice	CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE; HYDROGEN-PEROXIDE; CEREBRAL-ISCHEMIA; ADP-RIBOSYLATION; SYNTHETASE ACTIVATION; GRANULE CELLS; DNA-DAMAGE; RATS; INHIBITORS	Poly(ADP-ribose) polymerase (PARP), or poly (ADP-ribose) synthetase, is a nuclear enzyme that consumes NAD when activated by DNA damage. The role of PARP in the pathogenesis of traumatic brain injury (TBI) is unknown. Using a controlled cortical impact (CCI) model of TBI and mice deficient in PARP, the authors studied the effect of PARP on functional and histologic outcome after CCI using two protocols. In protocol 1, naive mice (n = 7 +/+, n = 6 -/-) were evaluated for motor and memory acquisition before CCI. Mice were then subjected to severe CCI and killed at 24 hours for immunohistochemical detection of nitrated tyrosine, an indicator of peroxynitrite formation. Motor and memory performance did not differ between naive PARP +/+ and -/- mice. Both groups showed nitrotyrosine staining in the contusion, suggesting that peroxynitrite is produced in contused brain. In protocol 2, mice (PARP +/+, n = 8; PARP -/-, n = 10) subjected to CCI were tested for motor and memory function, and contusion volume was determined by image analysis. PARP -/- mice demonstrated improved motor and memory function after CCI versus PARP +/+ mice (P < 0.05). However, contusion volume was not different between groups. The results suggest a detrimental effect of PARP on functional outcome after TBI.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Debrecen Univ Med, Dept Pathophysiol, Debrecen, Hungary; Inotek Corp, Beverly, MA USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Szabo, Csaba/ABG-2644-2021; Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015; Szabo, Csaba/D-1882-2013	Kochanek, Patrick M/0000-0002-2627-913X; Virag, Laszlo/0000-0002-7099-6718	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318, R43 NS37985] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, R43NS037985, P50NS030318] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; BELL M, 1996, CRIT CARE MED S, V24, pA136; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Cookson MR, 1998, J NEUROCHEM, V70, P501; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1997, ANN NY ACAD SCI, V825, P366, DOI 10.1111/j.1749-6632.1997.tb48447.x; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Hivert B, 1998, NEUROREPORT, V9, P1835, DOI 10.1097/00001756-199806010-00031; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; LAPLACA MC, 1998, J NEUROTRAUM, V15, P878; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Nishio S, 1997, ACT NEUR S, V70, P84; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; RINK A, 1995, AM J PATHOL, V147, P1575; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 1998, FASEB J, V12, pA753; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SINZ EH, 1997, J NEUROTRAUM, V14, P769; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1997, BIOCHEM SOC T, V25, P919, DOI 10.1042/bst0250919; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WALLIS RA, 1993, NEUROREPORT, V5, P245; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whalen M, 1999, CRIT CARE MED, V27, pA103, DOI 10.1097/00003246-199901001-00262; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; WHALEN MJ, 1998, 16 ANN NAT NEUR SOC; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	62	128	130	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	1999	19	8					835	842		10.1097/00004647-199908000-00002			8	Endocrinology & Metabolism; Hematology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	277TD	WOS:000084948900002	10458590	Bronze			2022-02-06	
J	Barbarotto, R; Laiacona, M; Frosio, R; Vecchio, M; Farinato, A; Capitani, E				Barbarotto, R; Laiacona, M; Frosio, R; Vecchio, M; Farinato, A; Capitani, E			A normative study on visual reaction times and two Stroop colour-word tests	ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article						reaction times; stroop test; normative data; demographic correction	CLOSED-HEAD-INJURY; SELECTIVE ATTENTION; PARKINSONS-DISEASE; DEFICITS; PERFORMANCE; TASKS	Two-hundred and nine normal subjects underwent a study aimed at providing norms for some attention tests currently used in neuropsychological examination. Norms were calculated taking into account the demographic variables. Our battery included single visuo-manual and go/no-go reaction times, and two versions of the Stroop Colour-Word Test. For the latter test, we employed a traditional version based on card presentation and a new version based on computer-assisted presentation. We evaluated the intercorrelation of the different tests, and studied the statistical regression models in order to adjust the original scores according to age, education and gender. Normative values were calculated following the Equivalent Scores method. The pattern of intercorrelation of our battery and the regression models of the scores are discussed with reference to the literature. The newly developed computer-assisted presentation of the Stroop test offers some advantages over the traditional version, especially with patients affected by spatial disorders.	Univ Milan, San Paolo Hosp, Neurol Clin, I-20142 Milano, Italy; Fdn S Maugeri, IRCCS, Div Neurol, Veruno, NO, Italy; Fdn S Maugeri, IRCCR, Div Funct Recovery & Reeduc, Veruno, NO, Italy; Inst Rehabil Mentally Diabled, Cernusco Sul Naviglio, MI, Italy		Capitani, E (corresponding author), Univ Milan, San Paolo Hosp, Neurol Clin, Via di Rudini 8, I-20142 Milano, Italy.						ACKERMANN H, 1985, MEHRDIMENSIONALE NIC; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; Capitani E, 1997, J CLIN EXP NEUROPSYC, V19, P795, DOI 10.1080/01688639708403761; CAPITANI E, 1988, DEV NEUROPSYCHOL, V4, P325, DOI 10.1080/87565648809540416; Cattell J.M., 1886, MIND, V11, P63, DOI DOI 10.1093/MIND/OS-XI.41.63; CORNELL DG, 1984, J ABNORM PSYCHOL, V93, P150; DALRYMPLEALFORD EC, 1966, PERCEPT MOTOR SKILL, V23, P1211, DOI 10.2466/pms.1966.23.3f.1211; FERRIS S, 1976, J AM GERIATR SOC, V24, P529, DOI 10.1111/j.1532-5415.1976.tb03277.x; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; GRAF P, 1995, J CLIN EXP NEUROPSYC, V17, P390, DOI 10.1080/01688639508405132; HEEP HH, 1996, SCHIZOPHR RES, V22, P187; HORN JL, 1967, ACTA PSYCHOL, V26, P107, DOI 10.1016/0001-6918(67)90011-X; Jaensch Erich Rudolf, 1929, GRUNDFORMEN MENSCHLI; Jaquet I, 1997, ENCEPHALE, V23, P34; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; NAKASHIMA K, 1993, ACTA NEUROL SCAND, V87, P178; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Posner, 1978, CHRONOMETRIC EXPLORA; RABBITT P, 1993, Q J EXP PSYCHOL-A, V46, P385, DOI 10.1080/14640749308401055; Rousseaux M, 1996, REV NEUROL-FRANCE, V152, P678; SHRIFFIN RM, 1977, PSYCHOL REV, V84, P127; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; SPINNLER H, 1987, ITA J NEUROL SCI S8, V6; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tachibana H, 1997, J NEUROL SCI, V149, P47, DOI 10.1016/S0022-510X(97)05372-0; Taylor SF, 1996, J PSYCHIAT RES, V30, P251, DOI 10.1016/0022-3956(95)00046-1; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VENTURINI R, 1983, IL COLOUR WORD TEST; Welford A.T., 1980, REACTION TIMES; Wilks SS, 1941, ANN MATH STAT, V12, P91, DOI 10.1214/aoms/1177731788	32	128	129	0	17	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0392-0461			ITAL J NEUROL SCI	Ital. J. Neurol. Sci.	JUN	1998	19	3					161	170		10.1007/BF00831566			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	114AN	WOS:000075587100004	10933471				2022-02-06	
J	Blatter, DD; Bigler, ED; Gale, SD; Johnson, SC; Anderson, CV; Burnett, BM; Ryser, D; Macnamara, SE; Bailey, BJ				Blatter, DD; Bigler, ED; Gale, SD; Johnson, SC; Anderson, CV; Burnett, BM; Ryser, D; Macnamara, SE; Bailey, BJ			MR-based brain and cerebrospinal fluid measurement after traumatic brain injury: Correlation with neuropsychological outcome	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article						brain, injuries; brain, measurements; brain, magnetic resonance	MAGNETIC-RESONANCE IMAGES; DIFFUSE AXONAL INJURY; CLOSED HEAD-INJURY; SEGMENTATION; TOMOGRAPHY; LESIONS; ATROPHY; HUMANS; MATTER; MILD	PURPOSE: To determine the magnitude and time course of changes in the Volume of brain and intracranial cerebrospinal fluid (CSF) spaces in patients who have sustained traumatic brain injury and to assess the relationship between these findings and long-term cognitive outcome. METHODS: Axial intermediate and T2-weighted MR images of 123 patients with traumatic brain injury were quantified using a multispectral segmentation algorithm. Measurements were corrected for differences in age, sex, and head size using a previously reported normative database. Brain morphology was compared across groups formed on the basis of chronicity of injury. Cognitive functioning and severity of injury were statistically correlated with brain measurements. RESULTS: Time-dependent expansion of CSF spaces and decreases in brain volume were observed. Increases in Ventricular CSF volume, particularly in the temporal horns and third ventricle, preceded subsequent changes in total brain and subarachnoid CSF. High and moderate correlation was observed between Volume measures and cognitive outcome and injury severity. Particularly strong was the relation between the volume of the left temporal horn and Verbal IQ scores. CONCLUSION: Predictable time-dependent atrophic changes occurring after traumatic brain injury can be quantified using MR volumetric studies. Our results suggest significant contributions by both diffuse and focal mechanisms of injury. In the postacute period (more than 70 days after injury), MR volumetric studies may be predictive of eventual cognitive outcome.	LATTER DAY ST HOSP, DEPT REHABIL, SALT LAKE CITY, UT 84143 USA; BRIGHAM YOUNG UNIV, DEPT PSYCHOL, PROVO, UT 84602 USA		Blatter, DD (corresponding author), LATTER DAY ST HOSP, DEPT RADIOL, 8TH AVE & C ST, SALT LAKE CITY, UT 84143 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; BANDAK FA, 1996, TRAUMATIC BRAIN INJU; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; CLARKE LP, 1993, MAGN RESON IMAGING, V11, P95, DOI 10.1016/0730-725X(93)90417-C; CLINE HE, 1990, J COMPUT ASSIST TOMO, V14, P1037, DOI 10.1097/00004728-199011000-00041; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; CULLUM CM, 1990, TRAUMATIC BRAIN INJU, P129; Duda R.O., 1973, PATTERN CLASSIFICATI; Evans RW., 1992, PROGNOSIS NEUROLOGIC, P97; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; Holbourn AHS, 1943, LANCET, V2, P438; JENKINS A, 1986, LANCET, V2, P445; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LINDENBERG R, 1955, AM J PATHOL, V31, P297; PETERSON B, 1993, NEUROLOGY, V43, P941, DOI 10.1212/WNL.43.5.941; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REISS AL, 1993, ANN NEUROL, V34, P227, DOI 10.1002/ana.410340220; ROBB RA, 1990, NATO ADV SCI I F-COM, V60, P333; RUSINEK H, 1991, RADIOLOGY, V178, P109, DOI 10.1148/radiology.178.1.1984287; SALERNO JA, 1992, HYPERTENSION, V20, P340, DOI 10.1161/01.HYP.20.3.340; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; VANNIER MW, 1985, RADIOLOGY, V154, P221, DOI 10.1148/radiology.154.1.3964938; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1987, WECHSLER ADULT INTEL; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	39	128	129	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	1997	18	1					1	10					10	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	WC668	WOS:A1997WC66800001	9010514				2022-02-06	
J	POVLISHOCK, JT; JENKINS, LW				POVLISHOCK, JT; JENKINS, LW			ARE THE PATHOBIOLOGICAL CHANGES EVOKED BY TRAUMATIC BRAIN INJURY IMMEDIATE AND IRREVERSIBLE	BRAIN PATHOLOGY			English	Article							DIFFUSE AXONAL INJURY; ENERGY PHOSPHATE-METABOLISM; NONMISSILE HEAD-INJURY; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; RAT HIPPOCAMPUS; OPTIC-NERVE; CALCIUM; VULNERABILITY; PROTECTION	Traumatic brain injury has long been thought to evoke immediate and irreversible damage to the brain parenchyma and its intrinsic vasculature. In this review, we call into question the correctness of this assumption by citing two traumatically related brain parenchymal abnormalities that are the result of a progressive, traumatically induced perturbation. In this context, we first consider the pathogenesis of traumatically induced axonal damage to show that it is not the immediate consequence of traumatic tissue tearing. Rather, we illustrate that it is a delayed consequence of complex axolemmal and/or cytoskeletal changes evoked by the traumatic episode which then lead to cytoskeletal collapse and impairment of axoplasmic transport, ultimately progressing to axonal swelling and disconnection. Second, we consider the traumatized brain's increased neuronal sensitivity to secondary ischemic insult by showing that even after mild traumatic brain injury, CA1 neuronal cell loss can be precipitated by the induction of sublethal ischemic insult within 24 hrs of injury. In demonstrating this increased sensitivity to secondary insult, evidence is provided that it is triggered by the neurotransmitter storm evoked by traumatic brain injury, allowing for sublethal neuroexcitation. In relation to this phenomenon, the protective effect of receptor antagonists are discussed, as well as the concept that this relatively prolonged posttraumatic brain hypersensitivity offers a potential window for therapeutic intervention. Collectively, it is felt that both examples of the brain parenchyma's response to traumatic brain injury show that the resulting pathobiology is much more complex and progressive than previously envisioned, and as such, rejects many of the previous beliefs regarding the pathobiology of traumatic brain injury.	UNIV TEXAS, MED BRANCH, DEPT ANESTHESIOL, GALVESTON, TX 77555 USA		POVLISHOCK, JT (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT ANAT, POB 980709, RICHMOND, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193, R01-NS19550] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019550, R01NS020193] Funding Source: NIH RePORTER		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BADALAMENTE MA, 1986, J HAND SURG-BRIT EUR, V11B, P337, DOI 10.1016/0266-7681(86)90153-1; BALENTINE JD, 1985, CENTRAL NERVOUS SYST, P455; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; CHOI DW, 1987, J NEUROSCI, V7, P369; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EAGLES PAM, 1981, BIOCHEM J, V199, P101, DOI 10.1042/bj1990101; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GALLANT PE, 1992, J NEUROPATH EXP NEUR, V51, P220, DOI 10.1097/00005072-199203000-00011; Gennarelli T.A., 1986, MECHANISMS SECONDARY, P15; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATHOL EXP NE, V31, P299; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; Hammerschlag Richard, 1994, P545; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JENKINS LW, 1989, CONT ISSUES NEUROLOG, V1, P47; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KATO H, 1990, BRAIN RES, V516, P175, DOI 10.1016/0006-8993(90)90916-Y; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; Maxwell W. L., 1995, Journal of Neurotrauma, V12, P363; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MAXWELL WL, 1995, IN PRESS J NEUROCYTO, V34; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MITCHELL DE, 1973, LANCET, V2, P215; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PETTUS EH, 1995, 25TH ANN M SAN DIEG; PETTUS EH, 1995, IN PRESS BRAIN RES; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1995, IN PRESS ACTA NEUROC; POVLISHOCK JT, 1995, IN PRESS TRAUMATICAL; SCHLAEPFER WW, 1979, BRAIN RES, V168, P299, DOI 10.1016/0006-8993(79)90171-9; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SIEJO BK, 1985, CEREBROVASC DIS, P187; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; WAXMAN SG, 1993, BRAIN RES, V614, P137, DOI 10.1016/0006-8993(93)91027-P; ZIMMERMAN UJP, 1984, PROG NEUROBIOL, V23, P63, DOI 10.1016/0301-0082(84)90012-1	68	128	131	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	OCT	1995	5	4					415	426		10.1111/j.1750-3639.1995.tb00620.x			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	TK374	WOS:A1995TK37400008	8974624				2022-02-06	
J	BRAMLETT, HM; GREEN, EJ; DIETRICH, WD; BUSTO, R; GLOBUS, MYT; GINSBERG, MD				BRAMLETT, HM; GREEN, EJ; DIETRICH, WD; BUSTO, R; GLOBUS, MYT; GINSBERG, MD			POSTTRAUMATIC BRAIN HYPOTHERMIA PROVIDES PROTECTION FROM SENSORIMOTOR AND COGNITIVE-BEHAVIORAL DEFICITS	JOURNAL OF NEUROTRAUMA			English	Article						FLUID-PERCUSSION; FORELIMB PLACING; BEAM-WALKING; HYPOTHERMIA; CONCUSSION; CONTUSION; TRAUMATIC BRAIN INJURY	FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; MILD HEAD-INJURY; MODERATE HYPOTHERMIA; SPATIAL LOCALIZATION; AMINO-ACIDS; RAT; DISRUPTION; ISCHEMIA; BARRIER	The purpose of this study was to determine the degree of sensorimotor and cognitive protection conferred by posttraumatic brain hypothermia. Baseline measurements were taken on sensorimotor tasks involving forelimb placing and beam-walking, as well as on a spatial navigational task utilizing the water maze. Twenty-four hours after the last baseline measurements, normothermic (37 degrees C) animals were subjected to a fluid percussion pulse (1.9-2.4 atm) over the right parietal sensorimotor cortex. Following trauma, brain temperature was maintained for 3 h at either normothermic (37 degrees C, group TBI-N, n = 12) or hypothermic levels (30 degrees C, group TBI-H, n = 11). Shams (n = 10) underwent all surgical procedures including posttraumatic brain injury (TBI) temperature manipulation, but were not subjected to the fluid percussive pulse. Beam-walking and forelimb placing measures were begun 24 h post-TBI and continued for 2 weeks. Animals were tested on the water maze task for 2 days beginning 24 h post-TBI. TBI produced substantial deficits in contralateral limb placing, which recovered over approximately one week. Hypothermia provided partial protection from these deficits, with TBI-H animals exhibiting intermediate scores that differed from both sham and TBI-N animals (p < 0.03). In the water maze, there was a distinction between groups in the ability to navigate 48 h after TBI. TBI-N animals performed significantly worse than sham and TBI-H animals (both p < 0.01), whereas there was no significant difference between the scores of sham and TBI-H animals. The present data demonstrate that moderate postinjury brain hypothermia can provide protection from sensorimotor and cognitive behavioral deficits as well as neuropathology in a model of traumatic brain injury associated with early neuronal and microvascular injury.	UNIV MIAMI,DEPT PSYCHOL,CORAL GABLES,FL 33124; UNIV MIAMI,SCH MED,DEPT NEUROL,MIAMI,FL						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30291] Funding Source: Medline		BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DERYCK M, 1992, BRAIN RES, V573, P44; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Dietrich W, 1991, J CEREB BLOOD FLO S2, V11, pS846; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIETRICH WD, 1994, J CEREB BLOOD FLOW M, V13, P541; DIETRICH WD, 1995, IN PRESS NEUROTRAUMA; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAKE CG, 1962, CAN MED ASSOC J, V87, P887; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; FAY T, 1945, RES PUBL ASS NERV ME, V24, P611; FEENEY DM, 1982, SCIENCE, V217, P53; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GLOLUS MYT, 1995, J NEUROTRAUM, V12, P119; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P318; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOLBOURN AHS, 1956, BR MED B, V3, P147; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1985, BRAIN EDEMA, P88; MCDONALD JW, 1991, NEUROSCI LETT, V126, P83, DOI 10.1016/0304-3940(91)90377-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P265; POVLISHOCK JT, 1990, ADV NEUROTRAUMA RES, V2, P1; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SHUCK LZ, 1972, J BASIC ENG, V12, P905; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZILLES L, 1985, CORTEX RAT STEREOTAX	68	128	134	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1995	12	3					289	298		10.1089/neu.1995.12.289			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	RM331	WOS:A1995RM33100006	7473803				2022-02-06	
J	RIVARA, JB; JAFFE, KM; POLISSAR, NL; FAY, GC; MARTIN, KM; SHURTLEFF, HA; LIAO, SQ				RIVARA, JB; JAFFE, KM; POLISSAR, NL; FAY, GC; MARTIN, KM; SHURTLEFF, HA; LIAO, SQ			FAMILY FUNCTIONING AND CHILDRENS ACADEMIC-PERFORMANCE AND BEHAVIOR PROBLEMS IN THE YEAR FOLLOWING TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY		CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,SEATTLE,WA; CHILDRENS HOSP & MED CTR,DEPT NEUROL,SEATTLE,WA; UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,CTR QUANTIAT SCI,SEATTLE,WA 98195					Shurtleff, Hillary/0000-0003-0959-2842	ODCDC CDC HHS [R49/CC002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ASARNOW RF, 1991, J PED PSYCHOL, V16, P545; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Edelbrock C., 1986, MANUAL TEACHERS REPO; EWINGCOBBS L, 1986, J HEAD TRAUMA REHABI, V4, P57; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FOWLER MG, 1985, J PEDIATR-US, V106, P683, DOI 10.1016/S0022-3476(85)80103-7; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JOHNSON SB, 1988, J CHILD PSYCHOL PSYC, V29, P729; KAY T, 1988, HEAD INJURY FAMILY I; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; MACLEAN WE, 1992, J PEDIATR PSYCHOL, V17, P159, DOI 10.1093/jpepsy/17.2.159; McCubbin HI, 1980, FAMILY ASSESSMENT RE; Miller R. G., 1981, SIMULTANEOUS STAT IN; Moos RH, 1974, SOCIAL CLIMATE SCALE; MRAZEK D, 1985, 32ND P ANN M AM AC C; MURCH RL, 1989, J PEDIATR PSYCHOL, V14, P193, DOI 10.1093/jpepsy/14.2.193; NIHIRA K, 1981, AM J MENT DEF, V86, P8; OBRIEN PC, 1984, BIOMETRICS, V40, P653; PERRIN ED, 1991, J PED PSYCHOL, V4, P411; PLESS IB, 1972, INT J EPIDEMIOL, V1, P271, DOI 10.1093/ije/1.3.271; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RJ, 1990, J PEDIATR PSYCHOL, V1, P3; Wechsler D., 1974, WECHSLER INTELLIGENC; Wilkinson, 1984, WIDE RANGE ACHIEVEME; Winer BJ., 1971, STAT PRINCIPLES EXPT	33	128	128	0	15	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1994	75	4					369	379		10.1016/0003-9993(94)90157-0			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	NH535	WOS:A1994NH53500001	8172493				2022-02-06	
J	ROSS, SA; HALLIDAY, MI; CAMPBELL, GC; BYRNES, DP; ROWLANDS, BJ				ROSS, SA; HALLIDAY, MI; CAMPBELL, GC; BYRNES, DP; ROWLANDS, BJ			THE PRESENCE OF TUMOR-NECROSIS-FACTOR IN CSF AND PLASMA AFTER SEVERE HEAD-INJURY	BRITISH JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; TUMOR NECROSIS FACTOR; METABOLISM; BRAIN METABOLISM	BRAIN INJURY; METABOLISM; INVIVO; CELLS	In a cohort of victims of traumatic brain injury, 18 out of 50 patients had a plasma tumour necrosis factor (TNF) concentration above 2 pg/ml within 24 h ofinjury (mean 12.19, SD 45.96 pg/ml). Twenty-six had CSF samples available of which 17 demonstrated TNF concentrations above 1 pg/ml (mean 3.98, SD 3.61 pg/ml). We conclude that traumatized brain parenchyma is a significant source of TNF activity and implicate the cytokine in cellular metabolic derangements following head injury.	QUEENS UNIV BELFAST, INST CLIN SCI, DEPT SURG, BELFAST, NORTH IRELAND								BEUTLER BA, 1985, J IMMUNOL, V135, P3972; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; DEGROOTE MA, 1989, JAMA-J AM MED ASSOC, V262, P249, DOI 10.1001/jama.262.2.249; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ENGELBERTS I, 1991, LYMPHOKINE CYTOK RES, V10, P69; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRANGER DL, 1986, ADV CELL BIOL SERIES, P164; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HOLMAN RG, 1990, AM REV RESPIR DIS, V141, P134, DOI 10.1164/ajrccm/141.1.134; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; MCCLAIN CJ, 1987, J LAB CLIN MED, V18, P155; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; Oettgen H F, 1987, Important Adv Oncol, P105; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; PLATASALAMAN CR, 1988, BRAIN RES, V448, P106, DOI 10.1016/0006-8993(88)91106-7; POMPOSELLI JJ, 1988, JPEN-PARENTER ENTER, V12, P212, DOI 10.1177/0148607188012002212; REMICK DG, 1987, LAB INVEST, V56, P583; SCUDERI P, 1986, LANCET, V2, P1364; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1990, J CLIN INVEST, V86, P2014, DOI 10.1172/JCI114937; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695	25	128	130	1	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		1994	8	4					419	425		10.3109/02688699408995109			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	PG479	WOS:A1994PG47900004	7811406				2022-02-06	
J	JORGE, RE; ROBINSON, RG; STARKSTEIN, SE; ARNDT, SV				JORGE, RE; ROBINSON, RG; STARKSTEIN, SE; ARNDT, SV			DEPRESSION AND ANXIETY FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							COMPUTERIZED-TOMOGRAPHY; CEREBRAL INFARCTION; LESIONS; STROKE	The frequency, course, and clinical correlates Of generalized anxiety disorder (GAD) and its relationship to major depression were examined in 66 patients with traumatic brain injury (TBI). Of 66 TBI patients, 7 (11%) had both GAD and major depression; 10 (15%) had major depression without GAD. Median duration was 1.5 months for nonanxious depressions, 7.5 months for anxious depressions, and 1.5 months for concurrent GAD. Anxious depressions were also associated with right hemisphere lesions, whereas major depressions alone were associated with left anterior lesions. These findings suggest that anxious major depression and major depression following TBI may be two different disorders with different underlying etiological mechanisms and perhaps differential response to treatment.	INST NEUROL RES RAUL CARREA,BUENOS AIRES,ARGENTINA; UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,MENTAL HLTH CLIN RES CTR,BIOSTAT CORE UNIT,IOWA CITY,IA 52242				Robinson, Robert/AAF-6191-2021; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH00163, MH40355] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS151178] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER		CASTILLO CS, 1993, J NERV MENT DIS, V181, P100, DOI 10.1097/00005053-199302000-00005; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FEDOROFF JP, 1991, J AFFECT DISORDERS, V22, P83, DOI 10.1016/0165-0327(91)90088-A; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1989, BRIT J PSYCHIAT, V154, P201, DOI 10.1192/bjp.154.2.201; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MAYBERG HS, 1988, AM J PSYCHIAT, V143, P527; PAUL SM, 1988, J CLIN PSYCHIAT, V49, P13; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROBINSON RG, 1979, SCIENCE, V205, P707, DOI 10.1126/science.462179; ROSS ED, 1981, ARCH NEUROL-CHICAGO, V38, P561, DOI 10.1001/archneur.1981.00510090055006; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; STARKSTEIN SE, 1990, ARCH GEN PSYCHIAT, V47, P246, DOI 10.1001/archpsyc.1990.01810150046008; STARKSTEIN SE, 1988, BRAIN RES, V473, P74, DOI 10.1016/0006-8993(88)90317-4; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STRAVRAKAKI C, 1986, BRIT J PSYCHIAT, V149, P7; TEASDALE G, 1974, LANCET, V2, P81; Wing J. K., 1974, MEASUREMENT CLASSIFI; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; [No title captured]	33	128	129	0	8	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	1993	5	4					369	374					6	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	MD593	WOS:A1993MD59300002	8286933				2022-02-06	
J	CHAPMAN, SB; CULHANE, KA; LEVIN, HS; HARWARD, H; MENDELSOHN, D; EWINGCOBBS, L; FLETCHER, JM; BRUCE, D				CHAPMAN, SB; CULHANE, KA; LEVIN, HS; HARWARD, H; MENDELSOHN, D; EWINGCOBBS, L; FLETCHER, JM; BRUCE, D			NARRATIVE DISCOURSE AFTER CLOSED HEAD-INJURY IN CHILDREN AND ADOLESCENTS	BRAIN AND LANGUAGE			English	Article							HEMIDECORTICATE ADOLESCENTS; FRONTAL LOBES; LANGUAGE; COMPREHENSION; ADULTS		UNIV TEXAS,MED BRANCH,DEPT NEUROSURG,GALVESTON,TX 77550; GREENERY REHABIL CTR,DALLAS,TX; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT RADIOL,DALLAS,TX 75235; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77025; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT NEUROSURG,DALLAS,TX 75235		CHAPMAN, SB (corresponding author), UNIV TEXAS,CALLIER CTR COMMUN DISORDERS,DALLAS,TX 75235, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889-07] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Bartlett RC., 1932, REMEMBERING; BOTVIN GJ, 1977, DEV PSYCHOL, V13, P377, DOI 10.1037/0012-1649.13.4.377; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CANNITO M P, 1988, Seminars in Speech and Language, V9, P117, DOI 10.1055/s-0028-1082459; CAPLAN D, 1990, BRAIN LANG, V39, P206, DOI 10.1016/0093-934X(90)90012-6; Chafe Wallace, 1980, PEAR STORIES; DELIS D, 1987, CALIFORNIA VERBAL LE; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1990, DISCOURSE ABILITY BR; DENNIS M, 1980, LANGUAGE DEV APHASIA; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, CLOSED HEAD INJURY R; Frederiksen C. H., 1990, DISCOURSE ABILITY BR; Halliday M. K., 1976, COHESION ENGLISH; Hunt K. W., 1965, 3 NAT COUNC TEACH EN; JORDAN FM, 1988, BRAIN INJURY, V2, P175; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Labov W., 1972, LANGUAGE INNER CITY; LEVELT WJM, 1989, SPEAKING INTENTION A; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1990, J CLIN EXPT NEUROPSY, V12, P541; LOVETT MW, 1986, BRAIN LANG, V29, P224, DOI 10.1016/0093-934X(86)90046-5; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; NEWCOMBE F, 1991, LATE CONSEQUENCES FO; NEWMAN JE, 1986, TOP LANG DISORD, V7, P31, DOI 10.1097/00011363-198612000-00006; ROTH FP, 1986, J SPEECH HEAR DISORD, V51, P8, DOI 10.1044/jshd.5101.08; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; STUSS DT, 1978, NEUROLOGY, V28, P1166, DOI 10.1212/WNL.28.11.1166; SZEKERES S, 1985, HEAD INJURY REHABILI; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; THOMSEN IV, 1976, FOLIA PHONIATR, V28, P362, DOI 10.1159/000264060; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; ULATOWSKA HK, 1991, DEMENTIA COMMUNICATI; ULATOWSKA HK, 1990, DISCOURSE ABILITY BR; VANDIJK TA, 1985, HDB DISCOURSE ANAL; Wechsler D., 1974, WECHSLER INTELLIGENC; WYCKOFF LH, 1984, NARRATIVE PROCEDURAL; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48	45	128	129	1	4	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0093-934X			BRAIN LANG	Brain Lang.	JUL	1992	43	1					42	65		10.1016/0093-934X(92)90020-F			24	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	JB320	WOS:A1992JB32000003	1643511				2022-02-06	
J	BOHNEN, N; JOLLES, J; TWIJNSTRA, A				BOHNEN, N; JOLLES, J; TWIJNSTRA, A			NEUROPSYCHOLOGICAL DEFICITS IN PATIENTS WITH PERSISTENT SYMPTOMS 6 MONTHS AFTER MILD HEAD-INJURY	NEUROSURGERY			English	Article						ATTENTION; MILD HEAD INJURY; POSTCONCUSSIVE SYMPTOMS	COGNITIVE SEQUELAE; CONCUSSION	There is much debate on the nature and duration of cognitive deficits and postconcussive symptoms (PCS) after mild head injury. Most studies performed so far have compared head-injured patients with subjects who had not suffered a concussion, instead of directly comparing patients with and without persistent PCS. The present study examined whether patients with PCS (n = 9) about 6 months after an uncomplicated mild head injury performed less well on selected neuropsychological tests than patients with mild head injuries who did not have PCS (n = 9) and healthy controls (n = 9). Patients with PCS were individually matched with controls for the time elapsed after the injury, age, sex, and education. We found that patients with PCS performed less well on tests of divided and selective attention than both patients without PCS and healthy controls. It is concluded that cognitive deficits may be present up to 6 months after mild head injury when symptoms persist. The findings indicate that patients with mild head injury and subjective symptoms may manifest demonstrable cognitive deficits.	UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS				Bohnen, Nicolaas/A-1312-2007				Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Ponsford J L, 1990, Brain Inj, V4, P111, DOI 10.3109/02699059009026156; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; TEASDALE G, 1974, LANCET, V2, P81; Verhage R, 1964, THESIS ASSEN; Weingartner H, 1982, Psychopharmacol Bull, V18, P27; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 1985, SAS USERS GUIDE STAT; 1983, JAMA-J AM MED ASSOC, V249, P254	33	128	130	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1992	30	5					692	696		10.1097/00006123-199205000-00007			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	HP340	WOS:A1992HP34000007	1584379	Green Submitted			2022-02-06	
J	Babl, FE; Borland, ML; Phillips, N; Kochar, A; Dalton, S; McCaskill, M; Cheek, JA; Gilhotra, Y; Furyk, J; Neutze, J; Lyttle, MD; Bressan, S; Donath, S; Molesworth, C; Jachno, K; Ward, B; Williams, A; Baylis, A; Crowe, L; Oakley, E; Dalziel, SR				Babl, Franz E.; Borland, Meredith L.; Phillips, Natalie; Kochar, Amit; Dalton, Sarah; McCaskill, Mary; Cheek, John A.; Gilhotra, Yuri; Furyk, Jeremy; Neutze, Jocelyn; Lyttle, Mark D.; Bressan, Silvia; Donath, Susan; Molesworth, Charlotte; Jachno, Kim; Ward, Brenton; Williams, Amanda; Baylis, Amy; Crowe, Louise; Oakley, Ed; Dalziel, Stuart R.		Paediat Res Emergency Dept Int	Accuracy of PECARN, CATCH, and CHALICE head injury decision rules in children: a prospective cohort study	LANCET			English	Article							CRANIAL COMPUTED-TOMOGRAPHY; EMERGENCY-DEPARTMENT; RADIATION-EXPOSURE; CT SCANS; TRAUMA; PREDICTION; METHODOLOGY; DERIVATION; SEDATION; RISK	Background Clinical decision rules can help to determine the need for CT imaging in children with head injuries. We aimed to validate three clinical decision rules (PECARN, CATCH, and CHALICE) in a large sample of children. Methods In this prospective observational study, we included children and adolescents (aged <18 years) with head injuries of any severity who presented to the emergency departments of ten Australian and New Zealand hospitals. We assessed the diagnostic accuracy of PECARN (stratified into children aged <2 years and >= 2 years), CATCH, and CHALICE in predicting each rule-specific outcome measure (clinically important traumatic brain injury [TBI], need for neurological intervention, and clinically significant intracranial injury, respectively). For each calculation we used rule-specific predictor variables in populations that satisfied inclusion and exclusion criteria for each rule (validation cohort). In a secondary analysis, we compiled a comparison cohort of patients with mild head injuries (Glasgow Coma Scale score 13-15) and calculated accuracy using rule-specific predictor variables for the standardised outcome of clinically important TBI. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12614000463673. Findings Between April 11, 2011, and Nov 30, 2014, we analysed 20 137 children and adolescents attending with head injuries. CTs were obtained for 2106 (10%) patients, 4544 (23%) were admitted, 83 (<1%) underwent neurosurgery, and 15 (<1%) died. PECARN was applicable for 4011 (75%) of 5374 patients younger than 2 years and 11 152 (76%) of 14 763 patients aged 2 years and older. CATCH was applicable for 4957 (25%) patients and CHALICE for 20 029 (99%). The highest point validation sensitivities were shown for PECARN in children younger than 2 years (100.0%, 95% CI 90.7-100.0; 38 patients identified of 38 with outcome [38/38]) and PECARN in children 2 years and older (99.0%, 94.4-100.0; 97/98), followed by CATCH (high-risk predictors only; 95.2%; 76.2-99.9; 20/21; medium-risk and high-risk predictors 88.7%; 82.2-93.4; 125/141) and CHALICE (92.3%, 89.2-94.7; 370/401). In the comparison cohort of 18 913 patients with mild injuries, sensitivities for clinically important TBI were similar. Negative predictive values in both analyses were higher than 99% for all rules. Interpretation The sensitivities of three clinical decision rules for head injuries in children were high when used as designed. The findings are an important starting point for clinicians considering the introduction of one of the rules. Funding National Health and Medical Research Council, Emergency Medicine Foundation, Perpetual Philanthropic Services, WA Health Targeted Research Funds, Townsville Hospital Private Practice Fund, Auckland Medical Research Foundation, A + Trust.	[Babl, Franz E.; Cheek, John A.; Baylis, Amy; Oakley, Ed] Royal Childrens Hosp, Melbourne, Vic, Australia; [Babl, Franz E.; Cheek, John A.; Lyttle, Mark D.; Bressan, Silvia; Donath, Susan; Molesworth, Charlotte; Jachno, Kim; Williams, Amanda; Crowe, Louise; Oakley, Ed] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Babl, Franz E.; Donath, Susan; Oakley, Ed] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Paediat, Melbourne, Vic, Australia; [Borland, Meredith L.] Princess Margaret Hosp Children, Perth, WA, Australia; [Borland, Meredith L.] Univ Western Australia, Sch Paediat & Child Hlth, Crawley, WA, Australia; [Borland, Meredith L.] Univ Western Australia, Sch Primary Aboriginal & Rural Healthcare, Crawley, WA, Australia; [Phillips, Natalie; Gilhotra, Yuri] Lady Cilento Childrens Hosp, Brisbane, Qld, Australia; [Phillips, Natalie; Gilhotra, Yuri] Univ Queensland, Sch Med, Child Hlth Res Ctr, Brisbane, Qld, Australia; [Kochar, Amit] Womens & Childrens Hosp, Adelaide, SA, Australia; [Dalton, Sarah; McCaskill, Mary] Childrens Hosp Westmead, Sydney, NSW, Australia; [Cheek, John A.] Monash Med Ctr, Melbourne, Vic, Australia; [Furyk, Jeremy] Townsville Hosp, Townsville, Qld, Australia; [Neutze, Jocelyn] Kidzfirst Middlemore Hosp, Auckland, New Zealand; [Lyttle, Mark D.] Bristol Royal Hosp Children, Bristol, Avon, England; [Lyttle, Mark D.] Univ West England, Acad Dept Emergency Care, Bristol, Avon, England; [Bressan, Silvia] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy; [Dalziel, Stuart R.] Starship Childrens Hlth, Auckland, New Zealand; [Dalziel, Stuart R.] Univ Auckland, Liggins Inst, Auckland, New Zealand		Babl, FE (corresponding author), Murdoch Childrens Res Inst, Emergency Res, Melbourne, Vic 3052, Australia.	franz.babl@rch.org.au		Jachno, Kim/0000-0003-2550-9674; Lyttle, Mark/0000-0002-8634-7210; Donath, Susan/0000-0003-2489-3977; Crowe, Louise/0000-0003-4619-9708	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Emergency Medicine Foundation; Perpetual Philanthropic Services; WA Health Targeted Research Funds; Townsville Hospital Private Practice Fund; Auckland Medical Research Foundation; A + Trust; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [GNT1046727, GNT1058560]; Murdoch Childrens Research Institute; Emergency Medicine Foundation [EMPJ-11162]; Perpetual Philanthropic Services Australia [2012/1140]; Auckland Medical Research Foundation [3112011]; A + Trust (Auckland District Health Board); Townsville Hospital and Health Service Private Practice Research and Education Trust Fund; Victorian Government's Infrastructure Support Program; Royal Children's Hospital Foundation, Melbourne, Australia; Health Research Council of New ZealandHealth Research Council of New Zealand [HRC13/556]	National Health and Medical Research Council, Emergency Medicine Foundation, Perpetual Philanthropic Services, WA Health Targeted Research Funds, Townsville Hospital Private Practice Fund, Auckland Medical Research Foundation, A + Trust.; The study was funded by grants from the National Health and Medical Research Council (project grant GNT1046727, Centre of Research Excellence for Paediatric Emergency Medicine GNT1058560); the Murdoch Childrens Research Institute; the Emergency Medicine Foundation (EMPJ-11162); Perpetual Philanthropic Services (2012/1140) Australia; Auckland Medical Research Foundation (number 3112011); the A + Trust (Auckland District Health Board); WA Health Targeted Research Funds 2013; the Townsville Hospital and Health Service Private Practice Research and Education Trust Fund; and supported by the Victorian Government's Infrastructure Support Program. FEB's time was part funded by a grant from the Royal Children's Hospital Foundation, Melbourne, Australia. SRD's time was part funded by the Health Research Council of New Zealand (HRC13/556). We thank the participating families and emergency department staff at participating sites. We thank research staff from the following sites: Kaya Gardiner, Nicola Williams, Elle Goss, Triona Stephens, Marta Arpone, and Joseph Mabuti (The Royal Children's Hospital, Melbourne, VIC, Australia); Sharon O'Brien, Timothy Loy, Jeremy Rogers, Samantha Oosterhof, and Verity Watt (Princess Margaret Hospital, Perth, WA, Australia); Susan Montgomery (The Townsville Hospital, Townsville, QLD, Australia); Rebecca Saul, Meegan Price, Petrina Hetherington, Emily Casey, Mary Lang, Jane O'Shea, Anne Cook, Kerrie-Ann Abel, and Bronwyn Griffin (The Royal Children's Hospital, Brisbane, QLD, Australia); Tamara Brunton (Monash Medical Centre, Melbourne, VIC, Australia); Shirley Lawrence (Kidzfirst Children's Hospital, Middlemore, Auckland, New Zealand); Megan Bonisch (Starship Children's Hospital, Auckland, New Zealand); Carey Alymer and Simone Green (Women's and Children's Hospital Adelaide, SA, Australia); Laura Phillips and Elizabeth Moss (Children's Hospital Westmead, Sydney, NSW, Australia); and Meg Jepperson (Mater Children's Hospital, Brisbane, QLD, Australia).	American Academy of Pediatrics, 2013, COMP TOM CT SCANS AR; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Babl Franz, 2006, Emerg Med Australas, V18, P143, DOI 10.1111/j.1742-6723.2006.00823.x; Babl FE, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-148; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Farrell CA, 2013, MANAGEMENT PAEDIATRI; Goldwasser T, 2015, EUR J EMERG MED, V22, P413, DOI 10.1097/MEJ.0000000000000201; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hoyle JD, 2014, PEDIATR EMERG CARE, V30, P1, DOI 10.1097/PEC.0000000000000059; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lockie FD, 2013, EMERG MED AUSTRALAS, V25, P75, DOI 10.1111/1742-6723.12019; Lyttle MD, 2013, EMERG MED J, V30, P790, DOI 10.1136/emermed-2012-201887; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; National Institute for Health and Care Excellence, 2014, HEAD INJ ASS EARL MA; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Stanley RM, 2014, J PEDIATR-US, V165, P1201, DOI 10.1016/j.jpeds.2014.08.008; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Thiam DW, 2015, ANN ACAD MED SINGAP, V44, P335	29	127	129	3	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 17	2017	389	10087					2393	2402		10.1016/S0140-6736(17)30555-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX6ED	WOS:000403334400025	28410792	Green Submitted	Y	N	2022-02-06	
J	Vaccari, JPD; Brand, F; Adamczak, S; Lee, SW; Perez-Barcena, J; Wang, MY; Bullock, MR; Dietrich, WD; Keane, RW				Vaccari, Juan Pablo de Rivero; Brand, Frank, III; Adamczak, Stephanie; Lee, Stephanie W.; Perez-Barcena, Jon; Wang, Michael Y.; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.			Exosome-mediated inflammasome signaling after central nervous system injury	JOURNAL OF NEUROCHEMISTRY			English	Article						brain injury; caspase 1; exosomes; inflammasome; spinal cord injury	BRAIN-INJURY; CEREBROSPINAL-FLUID; BARRIER PERMEABILITY; CELL-DEATH; BIOMARKERS; ASSOCIATION; IL-1-BETA; SECRETION; RELEASE; MARKERS	Neuroinflammation is a response against harmful effects of diverse stimuli and participates in the pathogenesis of brain and spinal cord injury (SCI). The innate immune response plays a role in neuroinflammation following CNS injury via activation of multiprotein complexes termed inflammasomes that regulate the activation of caspase 1 and the processing of the pro-inflammatory cytokines IL-1 and IL-18. We report here that the expression of components of the nucleotide-binding and oligomerization domain (NOD)-like receptor protein-1 (NLRP-1) inflammasome, apoptosis speck-like protein containing a caspase recruitment domain (ASC), and caspase 1 are significantly elevated in spinal cord motor neurons and cortical neurons after CNS trauma. Moreover, NLRP1 inflammasome proteins are present in exosomes derived from CSF of SCI and traumatic brain-injured patients following trauma. To investigate whether exosomes could be used to therapeutically block inflammasome activation in the CNS, exosomes were isolated from embryonic cortical neuronal cultures and loaded with short-interfering RNA (siRNA) against ASC and administered to spinal cord-injured animals. Neuronal-derived exosomes crossed the injured blood-spinal cord barrier, and delivered their cargo in vivo, resulting in knockdown of ASC protein levels by approximately 76% when compared to SCI rats treated with scrambled siRNA. Surprisingly, siRNA silencing of ASC also led to a significant decrease in caspase 1 activation and processing of IL-1 after SCI. These findings indicate that exosome-mediated siRNA delivery may be a strong candidate to block inflammasome activation following CNS injury.	[Vaccari, Juan Pablo de Rivero; Adamczak, Stephanie; Lee, Stephanie W.; Perez-Barcena, Jon; Wang, Michael Y.; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.] Univ Miami, Miller Sch Med, Neurol Surg & Miami Project Cure Paralysis, Miami, FL 33136 USA; [Brand, Frank, III; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol, Miami, FL 33136 USA; [Brand, Frank, III; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Biophys, Miami, FL 33136 USA		Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.	rkeane@med.miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; Zhang, Xiaolei/E-2761-2012; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	Zhang, Xiaolei/0000-0003-0117-7599; de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS 1RO1NS59836]; Craig Neilsen Foundation [221346]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS059836] Funding Source: NIH RePORTER	This work was supported by grants to RWK (NIH Grant NINDS 1RO1NS59836 and Craig Neilsen Foundation grant 221346) and The Miami Project to Cure Paralysis. We thank Dr Michael D. Norenberg and Dr Alex Marcillo for their expertise with the Human Spinal Cord sections, Dr Marine Dididze for obtaining the CSF samples from SCI patients, and the SCI core facility at the Miami Project to Cure Paralysis.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chivet M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00145; Clayton A, 2012, ONCOIMMUNOLOGY, V1, P78, DOI 10.4161/onci.1.1.17826; DeFazio MV, 2014, WORLD NEUROSURG, V81, P151, DOI 10.1016/j.wneu.2013.01.015; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Figley SA, 2014, J NEUROTRAUM, V31, P541, DOI 10.1089/neu.2013.3034; Filipazzi P, 2012, SEMIN CANCER BIOL, V22, P342, DOI 10.1016/j.semcancer.2012.02.005; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Gomes C, 2007, NEUROSCI LETT, V428, P43, DOI 10.1016/j.neulet.2007.09.024; Haneklaus M, 2013, CURR OPIN IMMUNOL, V25, P40, DOI 10.1016/j.coi.2012.12.004; Harrington MG, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-10; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Pant S, 2012, BIOCHEM PHARMACOL, V83, P1484, DOI 10.1016/j.bcp.2011.12.037; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128; Viaud S, 2010, CANCER RES, V70, P1281, DOI 10.1158/0008-5472.CAN-09-3276; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012	41	127	128	3	44	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2016	136			1	SI		39	48		10.1111/jnc.13036			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	DB8SH	WOS:000368786400005	25628216	Green Accepted, Bronze			2022-02-06	
J	Fenn, AM; Hall, JCE; Gensel, JC; Popovich, PG; Godbout, JP				Fenn, Ashley M.; Hall, Jodie C. E.; Gensel, John C.; Popovich, Phillip G.; Godbout, Jonathan P.			IL-4 Signaling Drives a Unique Arginase (+)/IL-1 beta(+) Microglia Phenotype and Recruits Macrophages to the Inflammatory CNS: Consequences of Age-Related Deficits in IL-4R alpha after Traumatic Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article						advanced age; IL-4; inflammation; M2a; microglia; spinal cord injury	ALTERNATIVE ACTIVATION; GERIATRIC-PATIENTS; MICE EXHIBIT; BRAIN-INJURY; T-CELLS; RECOVERY; PROMOTES; EXPRESSION; INTERLEUKIN-4; NEUROINFLAMMATION	Alternative activation of microglia/ macrophages (M2a) by interleukin (IL)-4 is purported to support intrinsic growth and repair processes after CNS injury. Nonetheless, alternative activation of microglia is poorly understood in vivo, particularly in the context of inflammation, injury, and aging. Here, we show that aged mice (18 -19 months) had reduced functional recovery after spinal cord injury (SCI) associated with impaired induction of IL-4 receptor alpha (IL-4R alpha) on microglia. The failure to successfully promote an IL-4/ IL-4R alpha response in aged mice resulted in attenuated arginase (M2a associated), IL-1, and chemokine ligand 2 (CCL2) expression, and diminished recruitment of IL-4R macrophages to the injured spinal cord. Furthermore, the link between reduced IL-4R beta expression and reduced arginase, IL-1, and CCL2 expression was confirmed using adult IL-4R beta knock-out (IL-4R alpha(KO)) mice. To better understand IL-4R -mediated regulation of active microglia, a series of studies was completed in mice that were peripherally injected with lipopolysaccharide and later provided IL-4 by intracerebroventricular infusion. These immune-based studies demonstrate that inflammatoryinduced IL-4R alpha upregulation on microglia was required for the induction of arginase by IL-4. In addition, IL-4-mediated reprogramming of active microglia enhanced neurite growth ex vivo and increased inflammatory gene expression (i. e., IL-1 beta and CCL2) and the corresponding recruitment of CCR2 alpha / IL-4R -/ arginase myeloid cells in vivo. IL-4 reprogrammed active microglia to a unique and previously unreported phenotype (arginase alpha/IL-1 beta+) that augmented neurite growth and enhanced recruitment of peripheral IL-4R alpha+ myeloid cells to the CNS. Moreover, this key signaling cascade was impaired with age corresponding with reduced functional recovery after SCI.	[Fenn, Ashley M.; Hall, Jodie C. E.; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Gensel, John C.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, Columbus, OH 43210 USA		Godbout, JP (corresponding author), Ohio State Univ, 259 IBMR Bldg,460 Med Ctr Dr, Columbus, OH 43210 USA.	jonathan.godbout@osumc.edu	Zhang, Xiaolei/E-2761-2012	Zhang, Xiaolei/0000-0003-0117-7599; , John/0000-0001-8980-108X; Hall, Jodie/0000-0002-4820-6070	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG-033028]; Howard Hughes Medical InstituteHoward Hughes Medical Institute; Ohio State Presidential Fellowship; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033028] Funding Source: NIH RePORTER	This research was supported by National Institute on Aging Grant R01-AG-033028 to J. P. G. A. M. F. was supported by a Med into Grad Fellowship from the Howard Hughes Medical Institute and is currently supported by an Ohio State Presidential Fellowship. We thank Zhen Guan (Ohio State University, OSU), Yan Huang (OSU), and Dr. Nicole Powell (OSU) for their technical assistance.	Barrette B, 2010, BRAIN BEHAV IMMUN, V24, P1254, DOI 10.1016/j.bbi.2010.07.249; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butti E, 2008, GENE THER, V15, P504, DOI 10.1038/gt.2008.10; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; Chen HY, 1997, NEUROEPIDEMIOLOGY, V16, P241, DOI 10.1159/000109693; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Fassett DR, 2007, J NEUROSURG-SPINE, V7, P277, DOI 10.3171/SPI-07/09/277; Fenn A.M., 2013, BIOL PSYCHIAT; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Gensel JC, 2009, J NEUROSCI, V29, P3956, DOI 10.1523/JNEUROSCI.3992-08.2009; Gwak YS, 2004, NEUROSCI LETT, V362, P232, DOI 10.1016/j.neulet.2004.03.019; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Huang Y, 2008, NEUROBIOL AGING, V29, P1744, DOI 10.1016/j.neurobiolaging.2007.04.012; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kitamura Y, 2000, J NEUROIMMUNOL, V106, P95, DOI 10.1016/S0165-5728(00)00239-3; Kohanbash G, 2013, CANCER RES, V73, P6413, DOI 10.1158/0008-5472.CAN-12-4124; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kwon MJ, 2013, J NEUROSCI, V33, P15095, DOI 10.1523/JNEUROSCI.0278-13.2013; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Lee SI, 2010, J NEUROSCI RES, V88, P2409, DOI 10.1002/jnr.22411; Lyons A, 2007, J NEUROCHEM, V101, P771, DOI 10.1111/j.1471-4159.2006.04370.x; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; National SCI Statistical Center, 2013, FACTS FIG GLANC; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000371; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Puntambekar SS, 2011, BRAIN BEHAV IMMUN, V25, P629, DOI 10.1016/j.bbi.2010.12.016; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; Saiwai H, 2013, J NEUROCHEM, V125, P74, DOI 10.1111/jnc.12135; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Slegenthaler MM, 2008, EXP NEUROL, V210, P207, DOI 10.1016/j.expneurol.2007.10.019; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Stirling DP, 2014, BRAIN, V137, P707, DOI 10.1093/brain/awt341; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Wohleb ES, 2011, J NEUROSCI, V31, P6277, DOI 10.1523/JNEUROSCI.0450-11.2011; Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x; Zhao WH, 2006, J NEUROCHEM, V99, P1176, DOI 10.1111/j.1471-4159.2006.04172.x	48	127	131	0	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 25	2014	34	26					8904	8917		10.1523/JNEUROSCI.1146-14.2014			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK9HI	WOS:000338737800024	24966389	Green Published, Bronze			2022-02-06	
J	Rashid, B; Destrade, M; Gilchrist, MD				Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.			Mechanical characterization of brain tissue in tension at dynamic strain rates	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Traumatic brain injury; TBI; Impact; Dynamic; Ogden; Axonal	IN-VIVO; MODEL; BEHAVIOR; INJURY; SHEAR; DEFORMATION; STRETCH; DEVICE; COMPRESSION; ELASTICITY	Mechanical characterization of brain tissue at high loading velocities is crucial for modeling Traumatic Brain Injury (TBI). During severe impact conditions, brain tissue experiences compression, tension and shear. Limited experimental data is available for brain tissue in extension at dynamic strain rates. In this research, a High Rate Tension Device (HRTD) was developed to obtain dynamic properties of brain tissue in extension at strain rates of <= 90/s. In vitro tensile tests were performed to obtain properties of brain tissue at strain rates of 30, 60 and 90/s up to 30% strain. The brain tissue showed a stiffer response with increasing strain rates, showing that hyperelastic models are not adequate. Specifically, the tensile engineering stress at 30% strain was 3.1+/-0.49 kPa, 4.3+/-0.86 kPa, 6.5+/-0.76 kPa (mean+/-SD) at strain rates of 30, 60 and 90/s, respectively.. Force relaxation tests in tension were also conducted at different strain magnitudes (10-60% strain) with the average rise time of 24 ms, which were used to derive time dependent parameters. One-term Ogden, Fung and Gent models were used to obtain material parameters from the experimental data. Numerical simulations were performed using a one-term Ogden model to analyze hyperelastic behavior of brain tissue up to 30% strain. The material parameters obtained in this study will help to develop biofidelic human brain finite element models, which can subsequently be used to predict brain injuries under impact conditions and as a reconstruction and simulation tool for forensic investigations. (C) 2012 Elsevier Ltd. All rights reserved.	[Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland; [Destrade, Michel] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland		Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland.	Badar.Rashid@ucdconnect.ie; michel.destrade@nuigalway.ie; michael.gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017; Destrade, Michel/O-5825-2019	Gilchrist, Michael D/0000-0003-1765-429X; Destrade, Michel/0000-0002-6266-1221	Irish Research Council for Science, Engineering and Technology (IRCSET), IrelandIrish Research Council for Science, Engineering and Technology	The authors thank John Gahan, Tony Dennis and Pat McNally of University College Dublin for their assistance in machining components and developing electronic circuits for the experimental setup. This work was supported for the first author by a Postgraduate Research Scholarship awarded by the Irish Research Council for Science, Engineering and Technology (IRCSET), Ireland.	Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; ESTES MS, 1970, 70BHF13 ASME; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Fung Y. C., 1993, BIOMECHANICS MECH PR; FUNG YC, 1979, AM J PHYSIOL, V237, pH620, DOI 10.1152/ajpheart.1979.237.5.H620; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532, DOI 10.1152/ajplegacy.1967.213.6.1532; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gent AN, 1996, RUBBER CHEM TECHNOL, V69, P59, DOI 10.5254/1.3538357; Gilchrist MD, 2004, STRAIN, V40, P180, DOI 10.1111/j.1475-1305.2004.00168.x; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Meaney D. F., 1990, INT C BIOM IMP IRCOB; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Ogden R.W., 1997, NONLINEAR ELASTIC DE; Ogden RW, 2004, COMPUT MECH, V34, P484, DOI 10.1007/s00466-004-0593-y; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Pervin F, 2011, NEUROIMAGE, V54, pS98, DOI 10.1016/j.neuroimage.2010.03.077; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rashid B, 2012, J MECH BEHAV BIOMED, V14, P113, DOI 10.1016/j.jmbbm.2012.04.005; Rashid B, 2012, P I MECH ENG P-J SPO, V226, P170, DOI 10.1177/1754337112436900; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tamura A, 2008, J BIOMECH SCI ENG, V3, P263, DOI DOI 10.1299/JBSE.3.263; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Zhang JY, 2011, J BIOMECH, V44, P391, DOI 10.1016/j.jbiomech.2010.10.024; Zhang L, 2001, Stapp Car Crash J, V45, P369	59	127	128	4	48	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	MAY	2014	33				SI		43	54		10.1016/j.jmbbm.2012.07.015			12	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	AG1VW	WOS:000335205300005	23127641	Green Submitted			2022-02-06	
J	Nordstrom, P; Michaelsson, K; Gustafson, Y; Nordstrom, A				Nordstrom, Peter; Michaelsson, Karl; Gustafson, Yngve; Nordstrom, Anna			Traumatic brain injury and young onset dementia: A nationwide cohort study	ANNALS OF NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; LATE-LIFE; COGNITIVE FUNCTION; MILD; MEN; IMPACT	Objective To investigate the association between traumatic brain injuries (TBIs) and the risk of young onset dementia (YOD), that is, dementia before 65 years of age. Methods The study cohort comprised 811,622 Swedish men (mean age = 18 years) conscripted for military service between 1969 and 1986. TBIs, dementia, and covariates were extracted from national registers. Time-dependent exposures using Cox proportional hazard regression models were evaluated. Results During a median follow-up period of 33 years, there were 45,249 men with at least 1 TBI in the cohort. After adjustment for covariates, 1 mild TBI (hazard ratio [HR] = 1.0, 95% confidence interval [CI] = 0.5-2.0), at least 2 mild TBIs (HR = 2.5, 95% CI = 0.8-8.1), or 1 severe TBI (HR = 0.7, 95% CI = 0.1-5.2) were not associated with Alzheimer dementia (AD). Other types of dementia were strongly associated with the risk of 1 mild TBI (HR = 3.8, 95% CI = 2.8-5.2), at least 2 mild TBIs (HR = 10.4, 95% CI = 6.3-17.2), and 1 severe TBI (HR = 11.4, 95% CI = 7.4-17.5) in age-adjusted analysis. However, these associations were largely attenuated after adjustment for covariates (1 mild TBI: HR = 1.7; at least 2 mild TBIs: HR = 1.7; 1 severe TBI: HR = 2.6; p < 0.05 for all). Interpretation In the present study, we found strong associations between YOD of non-AD forms and TBIs of different severity. These associations were, however, markedly attenuated after multivariate adjustment. Ann Neurol 2014;75:374-381	[Nordstrom, Peter; Gustafson, Yngve] Umea Univ, Dept Community Med & Rehabil, S-90187 Umea, Sweden; [Michaelsson, Karl] Uppsala Univ, Dept Surg Sci, Sect Orthoped, Uppsala, Sweden; [Nordstrom, Anna] Umea Univ, Dept Surg & Perioperat Sci, S-90187 Umea, Sweden		Nordstrom, P (corresponding author), Umea Univ, Dept Community Med & Rehabil, S-90187 Umea, Sweden.	peter.nordstrom@germed.umu.se	Michaelsson, Karl/AAM-9094-2021; Nordstrom, Anna/F-2238-2010; Nordstrom, Anna/O-2504-2018	Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Anna/0000-0003-3534-456X; Gustafson, Yngve/0000-0002-0999-377X; Michaelsson, Karl/0000-0003-2815-1217; Nordstrom, Peter/0000-0003-2924-508X	Swedish research councilSwedish Research CouncilEuropean Commission; Swedish Dementia Foundation; Swedish Alzheimer Foundation	The study was supported by grants from the Swedish research council, Swedish Dementia Foundation, and Swedish Alzheimer Foundation. The funding bodies did not have any active role in any part of the research performed within the present study.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; Ashman TA, 2006, MT SINAI J MED, V73, P999; Atkins ER, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001764; CARLSTEDT B, 1993, SCAND J PSYCHOL, V34, P353, DOI 10.1111/j.1467-9450.1993.tb01131.x; Carlstedt B, 2005, SCAND J PSYCHOL, V46, P31, DOI 10.1111/j.1467-9450.2005.00432.x; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107; Lee YR, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0056284, 10.1371/journal.pone.0063255]; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murray C. J., 1996, GLOBAL HLTH STAT COM; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Nordstrom A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001151; Nordstrom P, 2013, JAMA INTERN MED, V173, P1612, DOI 10.1001/jamainternmed.2013.9079; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rossor MN, 2010, LANCET NEUROL, V9, P793, DOI 10.1016/S1474-4422(10)70159-9; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Svanberg E, 2011, INT PSYCHOGERIATR, V23, P356, DOI 10.1017/S1041610210001353; Whalley LJ, 2001, BRIT MED J, V322, P819, DOI 10.1136/bmj.322.7290.819; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	33	127	129	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAR	2014	75	3					374	381		10.1002/ana.24101			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AD8WS	WOS:000333547000008	24812697				2022-02-06	
J	Meehan, WP; Mannix, RC; O'Brien, MJ; Collins, MW				Meehan, William P., III; Mannix, Rebekah C.; O'Brien, Michael J.; Collins, Michael W.			The Prevalence of Undiagnosed Concussions in Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mild traumatic brain injury; loss of consciousness; sports injury	FOOTBALL PLAYERS; RECURRENT CONCUSSION; HEAD-INJURY	Objective: Previous studies suggest athletes underreport concussions. We sought to determine whether athletes in our clinics have sustained previous concussions that went undiagnosed. Design: Multicentered cross sectional study. Setting: Two sport concussion clinics. Patients: Patients diagnosed with sport-related concussions or concussions with injury mechanisms and forces similar to those observed in sports were included. Main Outcome Measures: The proportion of patients who answered "yes" to the following question were defined as having a previously undiagnosed concussion: "Have you ever sustained a blow to the head which was NOT diagnosed as a concussion but was followed by one or more of the signs and symptoms listed in the Post Concussion Symptom Scale?" Results: Of the 486 patients included in the final analysis, 148 (30.5%) patients reported a previously undiagnosed concussion. Athletes reporting previously undiagnosed concussions had a higher mean Post Concussion Symptom Scale (PCSS) score (33 vs 25; P < 0.004) and were more likely to have lost consciousness (31% vs 22%; P = 0.038) with their current injury than athletes without previously undiagnosed concussions. Conclusions: Nearly one-third of athletes have sustained previously undiagnosed concussions, defined as a blow to the head followed by the signs and symptoms included in the PCSS. Furthermore, these previously undiagnosed concussions are associated with higher PCSS scores and higher loss of consciousness rates when future concussions occur.	[Meehan, William P., III; O'Brien, Michael J.] Boston Childrens Hosp, Sports Concuss Clin, Div Sports Med, Dept Orthopaed, Boston, MA 02115 USA; [Meehan, William P., III; O'Brien, Michael J.] Micheli Ctr Sports Injury Prevent, Boston, MA USA; [Meehan, William P., III; Mannix, Rebekah C.] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA; [Meehan, William P., III; Mannix, Rebekah C.] Boston Childrens Hosp, Dept Med, Div Emergency Med, Boston, MA 02115 USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed, Sports Med Concuss Program, Pittsburgh, PA USA		Meehan, WP (corresponding author), Boston Childrens Hosp, Sports Concuss Clin, Div Sports Med, 319 Longwood Ave,Floor 6, Boston, MA 02115 USA.	concussion.sportsmed@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD052896]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655, K12HD052896, T32HD040128] Funding Source: NIH RePORTER	Supported by National Institutes of Health Grants T32 HD040128 to 06A1 (to W.P. Meehan) and National Institute of Child Health and Human Development Grants K12 HD052896 to 01A1 (to R.C. Mannix).	CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; MacMullan J., BOSTON; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	14	127	127	2	57	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2013	23	5					339	342		10.1097/JSM.0b013e318291d3b3			4	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	212YD	WOS:000324017900003	23727697	Green Accepted			2022-02-06	
J	Lee, YK; Hou, SW; Lee, CC; Hsu, CY; Huang, YS; Su, YC				Lee, Yi-Kung; Hou, Sheng-Wen; Lee, Ching-Chih; Hsu, Chen-Yang; Huang, Yung-Sung; Su, Yung-Cheng			Increased Risk of Dementia in Patients with Mild Traumatic Brain Injury: A Nationwide Cohort Study	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PREVALENCE; ACCURACY	Background: It is known that the risk of dementia in patients with moderate to severe traumatic brain injury (TBI) is higher. However, the relationship between mild traumatic brain injury (mTBI) and dementia has never been established. Objectives: We investigated the incidences of dementia among patients with mTBI in Taiwan to evaluate if there is higher risk compared with general population. Methods: We utilized a sampled National Health Insurance (NHI) claims data containing one million beneficiaries. We followed all adult beneficiaries from January 1, 2005 till December 31, 2009 to see if they had been diagnosed with dementia. We further identify patients with mTBI and compared their risk of dementia with the general population. Results: We identified 28551 patients with mTBI and 692382 without. After controlled for age, gender, urbanization level, socioeconomic status, diabetes, hypertension, coronary artery disease, hyperlipidemia, history of alcohol intoxication, history of ischemic stroke, history of intracranial hemorrhage and Charlson Comorbidity Index Score, the adjusted hazard ratio is 3.26 (95% Confidence interval, 2.69-3.94). Conclusions: TBI is an independent significant risk factor of developing dementia even in the mild type.	[Lee, Yi-Kung; Su, Yung-Cheng] Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, Chiayi, Taiwan; [Lee, Yi-Kung; Lee, Ching-Chih; Su, Yung-Cheng] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Hou, Sheng-Wen] Shin Kong Wu Ho Mem Hosp, Emergency Dept, Taipei, Taiwan; [Lee, Ching-Chih] Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan; [Lee, Ching-Chih] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; [Lee, Ching-Chih] Buddhist Dalin Tzu Chi Gen Hosp, Dept Otolaryngol, Chiayi, Taiwan; [Lee, Ching-Chih] Buddhist Dalin Tzu Chi Gen Hosp, Ctr Canc, Chiayi, Taiwan; [Hsu, Chen-Yang] Natl Taiwan Univ, Dept Publ Hlth, Taipei 10764, Taiwan; [Huang, Yung-Sung] Buddhist Dalin Tzu Chi Gen Hosp, Dept Internal Med, Div Neurol, Chiayi, Taiwan		Su, YC (corresponding author), Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, Chiayi, Taiwan.	drsu119@gmail.com					American Psychiatric Association, 1994, AM PSYCHIAT ASS DIAG; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Corrada MM, 2008, NEUROLOGY, V71, P337, DOI 10.1212/01.wnl.0000310773.65918.cd; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Fuh J.L., 2008, TAIWAN GERIATR GERON, V3, P169, DOI [10.29461/TGG.200808.0002, DOI 10.29461/TGG.200808.0002]; Hebert LE, 2004, NEUROLOGY, V62, P2021, DOI 10.1212/01.WNL.0000129258.93137.4B; Howards PP, 2012, AM J EPIDEMIOL, V176, P506, DOI 10.1093/aje/kws127; Jawaid A, 2009, NEURODEGENER DIS, V6, P219, DOI 10.1159/000258704; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kovacic JC, 2012, MT SINAI J MED, V79, P664, DOI 10.1002/msj.21347; Lee CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035923; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pouryamout L, 2012, DRUGS, V72, P789, DOI 10.2165/11631830-000000000-00000; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Sattler C, 2012, PSYCHIAT RES, V196, P90, DOI 10.1016/j.psychres.2011.11.012; Schmidt R, 2008, NEUROPSYCHIATRIE, V22, P1; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Shively S, 2012, ARCH NEUROL-CHICAGO, P1; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Tan ZS, 2003, ARCH INTERN MED, V163, P1053, DOI 10.1001/archinte.163.9.1053; Tang BL, 2009, CELL ADHES MIGR, V3, P118, DOI 10.4161/cam.3.1.7254; Xu WL, 2004, NEUROLOGY, V63, P1181, DOI 10.1212/01.WNL.0000140291.86406.D1	25	127	128	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2013	8	5							e62422	10.1371/journal.pone.0062422			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147KY	WOS:000319167000044	23658727	Green Published, gold, Green Submitted			2022-02-06	
J	Molina, DK; DiMaio, VJM				Molina, D. Kimberley; DiMaio, Vincent J. M.			Normal Organ Weights in Men Part II-The Brain, Lungs, Liver, Spleen, and Kidneys	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						autopsy; forensic pathology; normal organ weights; liver; kidney; spleen; lung; brain	HEART	Organomegaly can be a sign of disease and pathologic abnormality, although standard tables defining organomegaly have yet to be established and universally accepted. This study was designed to address the issue and to determine a normal weight for the major organs in adult human males. A prospective study of healthy men aged 18 to 35 years who died of sudden, traumatic deaths was undertaken. Cases were excluded if there was a history of medical illness including illicit drug use, if prolonged medical treatment was performed, if there was a prolonged period between the time of injury and death, if body length and weight could not be accurately assessed, or if any illness or intoxication was identified after gross and microscopic analysis including evidence of systemic disease. Individual organs were excluded if there was significant injury to the organ, which could have affected the weight. A total of 232 cases met criteria for inclusion in the study during the approximately 6-year period of data collection from 2005 to 2011. The decedents had a mean age of 23.9 years and ranged in length from 146 to 193 cm, with a mean length of 173 cm. The weight ranged from 48.5 to 153 kg, with a mean weight of 76.4 kg. Most decedents (87%) died of either ballistic or blunt force (including craniocerebral) injuries. The mean weight of the brain was 1407 g (range, 1070-1767 g), that of the liver was 1561 g (range, 838-2584 g), that of the spleen was 139 g (range, 43-344 g), that of the right lung was 445 g (range, 185-967 g), that of the left lung was 395 g (range, 186-885 g), that of the right kidney was 129 g (range, 79-223 g), and that of the left kidney was 137 g (range, 74-235 g). Regression analysis was performed and showed that there were insufficient associations between organ weight and body length, body weight, and body mass index to allow for predictability. The authors, therefore, propose establishing a reference range for organ weights in men, much like those in use for other laboratory tests including hemoglobin, hematocrit, or glucose. The following reference ranges (95% inclusion) are proposed: brain, 1179-1621 g; liver, 968-1860 g; spleen, 28-226 g; right lung, 155-720 g; left lung, 112-675 g; right kidney, 81-160 g; and left kidney, 83-176 g.	[Molina, D. Kimberley; DiMaio, Vincent J. M.] Bexar Cty Med Examiners Off, San Antonio, TX 78229 USA		Molina, DK (corresponding author), Bexar Cty Med Examiners Off, 7337 Louis Pasteur, San Antonio, TX 78229 USA.	kmolina@bexar.org					[Anonymous], 1997, 11622AIE A D CO LTD; Boyd E, 1933, ARCH PATHOL, V16, P350; CLSI, 2008, C28A3 CLSI; de la Grandmaison GL, 2001, FORENSIC SCI INT, V119, P149, DOI 10.1016/S0379-0738(00)00401-1; DELAND FH, 1968, RADIOLOGY, V91, P1195, DOI 10.1148/91.6.1195; DELAND FH, 1970, RADIOLOGY, V97, P589, DOI 10.1148/97.3.589; GARBY L, 1993, AM J HUM BIOL, V5, P291, DOI 10.1002/ajhb.1310050307; KASISKE BL, 1986, ARCH PATHOL LAB MED, V110, P55; Lindboe CF, 2003, CLIN NEUROPATHOL, V22, P263; MOAR JJ, 1988, AM J PHYS ANTHROPOL, V76, P105, DOI 10.1002/ajpa.1330760109; MYERS J, 1974, ARCH PATHOL, V98, P33; Sanchez R, 1997, Invest Clin, V38, P83; Smith HL, 1928, AM HEART J, V4, P79, DOI 10.1016/S0002-8703(29)90099-5; SprogoeJakobsen S, 1997, FORENSIC SCI INT, V88, P215, DOI 10.1016/S0379-0738(97)00103-5; WHIMSTER WF, 1971, AM REV RESPIR DIS, V103, P85; WHIMSTER WF, 1974, AM REV RESPIR DIS, V110, P478	16	127	128	4	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2012	33	4					368	372		10.1097/PAF.0b013e31823d29ad			5	Medicine, Legal; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine; Pathology	041TK	WOS:000311423900024	22182984				2022-02-06	
J	Farahvar, A; Gerber, LM; Chiu, YL; Carney, N; Hartl, R; Ghajar, J				Farahvar, Arash; Gerber, Linda M.; Chiu, Ya-Lin; Carney, Nancy; Haertl, Roger; Ghajar, Jamshid			Increased mortality in patients with severe traumatic brain injury treated without intracranial pressure monitoring Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; mortality rate; traumatic brain injury; evidence-based guidelines	SEVERE HEAD-INJURY; INTENSIVE-CARE; OUTCOMES; GUIDELINES; AGE	Object. Evidence-based guidelines recommend intracranial pressure (ICP) monitoring for patients with severe traumatic brain injury (TBI), but there is limited evidence that monitoring and treating intracranial hypertension reduces mortality. This study uses a large, prospectively collected database to examine the effect on 2-week mortality of ICP reduction therapies administered to patients with severe TBI treated either with or without an ICP monitor. Methods. From a population of 2134 patients with severe TBI (Glasgow Coma Scale [GCS] Score < 9), 1446 patients were treated with ICP-lowering therapies. Of those, 1202 had an ICP monitor inserted and 244 were treated without monitoring. Patients were admitted to one of 20 Level I and two Level II trauma centers, part of a New York State quality improvement program administered by the Brain Trauma Foundation between 2000 and 2009. This database also contains information on known independent early prognostic indicators of mortality, including age, admission GCS score, pupillary status, CT scanning findings, and hypotension. Results. Age, initial GCS score, hypotension, and CT scan findings were associated with 2-week mortality. In addition, patients of all ages treated with an ICP monitor in place had lower mortality at 2 weeks (p = 0.02) than those treated without an ICP monitor, after adjusting for parameters that independently affect mortality. Conclusions. In patients with severe TBI treated for intracranial hypertension, the use of an ICP monitor is associated with significantly lower mortality when compared with patients treated without an ICP monitor. Based on these findings, the authors conclude that ICP-directed therapy in patients with severe TBI should be guided by ICP monitoring. (http://thejns.org/doi/abs/10.3171/2012.7.JNS111816)	[Ghajar, Jamshid] Brain Trauma Fdn, World Trade Ctr 7, New York, NY 10007 USA; [Farahvar, Arash] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Gerber, Linda M.; Chiu, Ya-Lin] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Haertl, Roger; Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Carney, Nancy] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA		Ghajar, J (corresponding author), Brain Trauma Fdn, World Trade Ctr 7, 34th Floor,250 Greenwich St, New York, NY 10007 USA.	ghajar@braintrauma.org			New York State Department of Health; New York Presbyterian Hospital TBI fund	The authors thank the New York State Department of Health and the New York Presbyterian Hospital TBI fund for their financial support. Dr. Hard is a consultant for Brainlab, Synthes, and Spine-Wave. Dr. Ghajar is president of the Brain Trauma Foundation. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Akopian G, 2007, AM SURGEON, V73, P447; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bhullar IS, 2010, AM SURGEON, V76, P966; BORN JD, 1984, NEUROCHIRURGIE, V30, P329; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; BULLOCK R, 2000, MANAGEMENT PROGNOSIS; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Edwards WH, 2005, CLIN PERINATOL, V32, P97, DOI 10.1016/j.clp.2004.11.009; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; FALCAO ALE, 1995, ARQ NEURO-PSIQUIAT, V53, P390, DOI 10.1590/S0004-282X1995000300004; Falk AC, 2010, DEV NEUROREHABIL, V13, P315, DOI 10.3109/17518423.2010.496766; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Roberts Susan R, 2004, Crit Care Nurs Clin North Am, V16, P537, DOI 10.1016/S0899-5885(04)00068-1; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stover JF, 2006, CRIT CARE MED, V34, P1582, DOI 10.1097/01.CCM.0000216697.37348.FC; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003	30	127	138	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2012	117	4					729	734		10.3171/2012.7.JNS111816			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	015YZ	WOS:000309485600022	22900846	Bronze			2022-02-06	
J	Vasterling, JJ; Brailey, K; Proctor, SP; Kane, R; Heeren, T; Franz, M				Vasterling, Jennifer J.; Brailey, Kevin; Proctor, Susan P.; Kane, Robert; Heeren, Timothy; Franz, Molly			Neuropsychological outcomes of mild traumatic brain injury, post-traumatic stress disorder and depression in Iraq-deployed US Army soldiers	BRITISH JOURNAL OF PSYCHIATRY			English	Article							UK MILITARY PERSONNEL; PERSIAN-GULF-WAR; SYMPTOMS; VETERANS; HEALTH; COHORT; AFGHANISTAN; SEQUELAE; TBI; INFORMATION	Background Traumatic brain injury (TBI) is a concern of contemporary military deployments. Whether milder TBI leads to enduring impairment remains controversial. Aims To determine the influence of deployment TBI, and post-traumatic stress disorder (PTSD) and depression symptoms on neuropsychological and functional outcomes. Method A sample of 760 US Army soldiers were assessed pre- and post-deployment. Outcomes included neuropsychological performances and subjective functional impairment. Results In total, 9% of the participants reported (predominantly mild) TBI with loss of consciousness between pre- and post-deployment. At post-deployment, 17.6% of individuals with TBI screened positive for PTSD and 31.3% screened positive for depression. Before and after adjustment for psychiatric symptoms, TBI was significantly associated only with functional impairment. Both PTSD and depression symptoms adjusted for TBI were significantly associated with several neuropsychological performance deficits and functional impairment. Conclusions Milder TBI reported by deployed service members typically has limited lasting neuropsychological consequences; PTSD and depression are associated with more enduring cognitive compromise.	[Vasterling, Jennifer J.; Proctor, Susan P.] USA, VA Boston Healthcare Syst, Environm Med Res Inst, Mil Performance Div,Res Serv, Boston, MA 02130 USA; [Vasterling, Jennifer J.; Brailey, Kevin] Boston Univ, Sch Med, Boston, MA 02118 USA; [Proctor, Susan P.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Kane, Robert] Def & Vet Brain Injury Ctr, Washington, DC USA; [Heeren, Timothy] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA		Vasterling, JJ (corresponding author), USA, VA Boston Healthcare Syst, Environm Med Res Inst, Mil Performance Div,Res Serv, 150 S Huntington Ave, Boston, MA 02130 USA.	jennifer.vasterling@va.gov		Heeren, Timothy/0000-0001-5643-3559	US Department of Defense CDMRPUnited States Department of Defense [W81XWH-08-2-0035]; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD 17-03-0020]; US Veterans Affairs Clinical Sciences Research and Development	Funding was provided by the US Department of Defense CDMRP (W81XWH-08-2-0035), US Army Medical Research and Materiel Command (DAMD 17-03-0020); and US Veterans Affairs Clinical Sciences Research and Development. The primary funding organisation had no role in the scientific aspects of the study or the preparation of the manuscript. The manuscript underwent scientific and administrative review within the US Army Research Institute for Environmental Medicine and US Army Medical Research and Materiel Command. The content of this article does not necessarily reflect the position or policy of the US government, and no official endorsement should be inferred.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Committee on Gulf War and Health, 2009, GULF WAR HLTH, V7; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; David AS, 2002, PSYCHOL MED, V32, P1357, DOI 10.1017/S0033291702006359; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Douglas KM, 2009, AUST NZ J PSYCHIAT, V43, P1105, DOI 10.3109/00048670903279887; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Santor DA, 1997, PSYCHOL ASSESSMENT, V9, P233, DOI 10.1037/1040-3590.9.3.233; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Selim A, 2009, QUAL LIFE RES, V18, P43, DOI 10.1007/s11136-008-9418-2; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Southwick SM, 2005, NEUROPSYCHOLOGY PTSD, P27; Stewart AL, 1992, MEASURING FUNCTIONIN; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2006, MIL MED, V171, P253, DOI 10.7205/MILMED.171.3.253; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314	36	127	127	0	27	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0007-1250	1472-1465		BRIT J PSYCHIAT	Br. J. Psychiatry	SEP	2012	201	3					186	192		10.1192/bjp.bp.111.096461			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	007OR	WOS:000308898500006	22743844				2022-02-06	
J	Stevens, MC; Lovejoy, D; Kim, J; Oakes, H; Kureshi, I; Witt, ST				Stevens, Michael C.; Lovejoy, David; Kim, Jinsuh; Oakes, Howard; Kureshi, Inam; Witt, Suzanne T.			Multiple resting state network functional connectivity abnormalities in mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						TBI; Functional connectivity; DTI; Resting state; Postconcussive	WHITE-MATTER INJURY; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; DEFAULT-MODE; WORKING-MEMORY; STRUCTURAL CONNECTIVITY; REACTION-TIME; FMRI; CT; CORTEX	Several reports show that traumatic brain injury (TBI) results in abnormalities in the coordinated activation among brain regions. Because most previous studies examined moderate/severe TBI, the extensiveness of functional connectivity abnormalities and their relationship to postconcussive complaints or white matter microstructural damage are unclear in mild TBI. This study characterized widespread injury effects on multiple integrated neural networks typically observed during a task-unconstrained "resting state" in mild TBI patients. Whole brain functional connectivity for twelve separate networks was identified using independent component analysis (ICA) of fMRI data collected from thirty mild TBI patients mostly free of macroscopic intracerebral injury and thirty demographically-matched healthy control participants. Voxelwise group comparisons found abnormal mild TBI functional connectivity in every brain network identified by ICA, including visual processing, motor, limbic, and numerous circuits believed to underlie executive cognition. Abnormalities not only included functional connectivity deficits, but also enhancements possibly reflecting compensatory neural processes. Postconcussive symptom severity was linked to abnormal regional connectivity within nearly every brain network identified, particularly anterior cingulate. A recently developed multivariate technique that identifies links between whole brain profiles of functional and anatomical connectivity identified several novel mild TBI abnormalities, and represents a potentially important new tool in the study of the complex neurobiological sequelae of TBI.	[Stevens, Michael C.] Olin Neuropsychiat Res Ctr, Inst Living, Hartford, CT 06106 USA; [Stevens, Michael C.; Witt, Suzanne T.] Hartford Hosp, Olin Neuropsychiat Res Ctr, Inst Living, Hartford, CT 06115 USA; [Stevens, Michael C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Lovejoy, David; Oakes, Howard; Kureshi, Inam] Hartford Hosp, Dept Neurosurg, Hartford, CT 06115 USA; [Lovejoy, David; Oakes, Howard] Univ Connecticut, Dept Emergency Med & Traumatol, Sch Med, Farmington, CT USA; [Kim, Jinsuh] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; [Kureshi, Inam] Univ Connecticut, Sch Med, Dept Surg, Farmington, CT USA		Stevens, MC (corresponding author), Olin Neuropsychiat Res Ctr, Inst Living, 200 Retreat Ave,Whitehall Bldg, Hartford, CT 06106 USA.	msteven@harthosp.org	Witt, Suzanne/AAW-1413-2021; Stevens, Michael/M-7678-2017	Witt, Suzanne/0000-0002-5530-0807; Stevens, Michael/0000-0002-3799-5465	Hartford Hospital	This study was funded by a Hartford Hospital Open Competition Grant.	Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf M, 2010, NEUROIMAGE, V53, P247, DOI 10.1016/j.neuroimage.2010.05.067; Atlas S., 2001, IMAGING BRAIN SPINE; Babiloni C, 2004, BEHAV NEUROSCI, V118, P687, DOI 10.1037/0735-7044.118.4.687; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P227, DOI 10.1016/S0887-6177(00)00081-0; Bigler ED, 2005, TXB TRAUMATIC BRAIN; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, ACTA NEUROL BELG, V93, P23; Botvinick MM, 2007, COGN AFFECT BEHAV NE, V7, P356, DOI 10.3758/CABN.7.4.356; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Cauda F, 2010, J NEUROL NEUROSUR PS, V81, P806, DOI 10.1136/jnnp.2009.188631; Cohen J., 2013, STAT POWER ANAL BEHA; Cordes D, 2000, AM J NEURORADIOL, V21, P1636; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deco G, 2011, NEUROSCIENTIST, V17, P107, DOI 10.1177/1073858409354384; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dosenbach NUF, 2008, TRENDS COGN SCI, V12, P99, DOI 10.1016/j.tics.2008.01.001; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Eickhoff SB, 2011, CLIN EEG NEUROSCI, V42, P107, DOI 10.1177/155005941104200211; Eisenberg H. M., 1989, MILD HEAD INJURY; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; Etkin A, 2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Freire L, 2002, IEEE T MED IMAGING, V21, P470, DOI 10.1109/TMI.2002.1009383; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Friston KJ, 2002, PROG NEUROBIOL, V68, P113, DOI 10.1016/S0301-0082(02)00076-X; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Gazzaley Adam, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P580, DOI 10.3758/CABN.4.4.580; Gean A. D., 1984, IMAGING HEAD TRAUMA; Gentilini M., 1989, MILD HEAD INJURY; Glahn DC, 2010, P NATL ACAD SCI USA, V107, P1223, DOI 10.1073/pnas.0909969107; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Griffin SL, 2002, ARCH CLIN NEUROPSYCH, V17, P497, DOI 10.1016/S0887-6177(01)00136-6; GRONWALL D, 1989, MILD HEAD INJURY; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENKINS A, 1986, LANCET, V2, P445; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Laird AR, 2009, J NEUROSCI, V29, P14496, DOI 10.1523/JNEUROSCI.4004-09.2009; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Li YO, 2007, HUM BRAIN MAPP, V28, P1251, DOI 10.1002/hbm.20359; Linden DEJ, 2007, NEUROSCIENTIST, V13, P257, DOI 10.1177/1073858406298480; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Orrison WW., 2000, NEUROIMAGING; Ploner M, 2011, CEREB CORTEX, V21, P719, DOI 10.1093/cercor/bhq146; Posner MI, 2007, COGN AFFECT BEHAV NE, V7, P391, DOI 10.3758/CABN.7.4.391; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roth JK, 2007, NEUROIMAGE, V38, P617, DOI 10.1016/j.neuroimage.2007.06.037; Rudebeck PH, 2008, COGN AFFECT BEHAV NE, V8, P485, DOI 10.3758/CABN.8.4.485; Ruff R. M., 1989, MILD HEAD INJURY; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schmahmann J.D., 2006, FIBER PATHWAYS BRAIN; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seminowicz DA, 2007, J NEUROPHYSIOL, V97, P3651, DOI 10.1152/jn.01210.2006; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Sui J, 2011, NEUROIMAGE, V57, P839, DOI 10.1016/j.neuroimage.2011.05.055; Teipel SJ, 2010, NEUROIMAGE, V49, P2021, DOI 10.1016/j.neuroimage.2009.10.067; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Upadhyay J, 2010, BRAIN, V133, P2098, DOI 10.1093/brain/awq138; van de Ven VG, 2004, HUM BRAIN MAPP, V22, P165, DOI 10.1002/hbm.20022; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Woodward TS, 2006, NEUROSCIENCE, V139, P317, DOI 10.1016/j.neuroscience.2005.05.043; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Zaki J, 2007, SOC NEUROSCI-UK, V2, P276, DOI 10.1080/17470910701401973	134	127	127	0	28	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		293	318		10.1007/s11682-012-9157-4			26	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900010	22555821				2022-02-06	
J	Ling, JM; Pena, A; Yeo, RA; Merideth, FL; Klimaj, S; Gasparovic, C; Mayer, AR				Ling, Josef M.; Pena, Amanda; Yeo, Ronald A.; Merideth, Flannery L.; Klimaj, Stefan; Gasparovic, Charles; Mayer, Andrew R.			Biomarkers of increased diffusion anisotropy in semi-acute mild traumatic brain injury: a longitudinal perspective	BRAIN			English	Article						mild traumatic brain injury; DTI; longitudinal	AXONAL INJURY; CORPUS-CALLOSUM; WATER DIFFUSION; MOUSE MODEL; TENSOR; CONCUSSION; RECOVERY; DAMAGE; RAT; MRI	Mild traumatic brain injury is the most prevalent neurological insult and frequently results in neurobehavioural sequelae. However, little is known about the pathophysiology underlying the injury and how these injuries change as a function of time. Although diffusion tensor imaging holds promise for in vivo characterization of white matter pathology, both the direction and magnitude of anisotropic water diffusion abnormalities in axonal tracts are actively debated. The current study therefore represents both an independent replication effort (n = 28) of our previous findings (n = 22) of increased fractional anisotropy during semi-acute injury, as well as a prospective study (n = 26) on the putative recovery of diffusion abnormalities. Moreover, new analytical strategies were applied to capture spatially heterogeneous white matter injuries, which minimize implicit assumptions of uniform injury across diverse clinical presentations. Results indicate that whereas a general pattern of high anisotropic diffusion/low radial diffusivity was present in various white matter tracts in both the replication and original cohorts, this pattern was only consistently observed in the genu of the corpus callosum across both samples. Evidence for a greater number of localized clusters with increased anisotropic diffusion was identified across both cohorts at trend levels, confirming heterogeneity in white matter injury. Pooled analyses (50 patients; 50 controls) suggested that measures of diffusion within the genu were predictive of patient classification, albeit at very modest levels (71% accuracy). Finally, we observed evidence of recovery in lesion load in returning patients across a 4-month interval, which was correlated with a reduction in self-reported post-concussive symptomatology. In summary, the corpus callosum may serve as a common point of injury in mild traumatic brain injury secondary to anatomical (high frequency of long unmyelinated fibres) and biomechanics factors. A spatially heterogeneous pattern of increased anisotropic diffusion exists in various other white matter tracts, and these white matter anomalies appear to diminish with recovery. This macroscopic pattern of diffusion abnormalities may be associated with cytotoxic oedema following mechanical forces, resulting in changes in ionic homeostasis, and alterations in the ratio of intracellular and extracellular water. Animal models more specific to the types of mild traumatic brain injury typically incurred by humans are needed to confirm the histological correlates of these macroscopic markers of white matter pathology.	[Ling, Josef M.; Pena, Amanda; Yeo, Ronald A.; Merideth, Flannery L.; Klimaj, Stefan; Gasparovic, Charles; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87106 USA; [Yeo, Ronald A.; Gasparovic, Charles; Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21-NS064464-01A1, 3 R21 NS064464-01S1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	National Institutes of Health (R24-HD050836, R21-NS064464-01A1 and 3 R21 NS064464-01S1 to A.M.).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Faul M, 2010, TRAUMATIC BRAIN INJU; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Gons RAR, 2011, BRAIN, V134, P2116, DOI 10.1093/brain/awr145; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Koehnle TJ, 1999, J CELL BIOL, V144, P447, DOI 10.1083/jcb.144.3.447; Korgaonkar MS, 2011, HUM BRAIN MAPP, V32, P2161, DOI 10.1002/hbm.21178; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Miller KE, 2008, EXP CELL RES, V314, P1981, DOI 10.1016/j.yexcr.2008.03.004; Moraschi M, 2010, J MAGN RESON IMAGING, V31, P690, DOI 10.1002/jmri.22040; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Storey P, 2007, MAGN RESON MED, V57, P614, DOI 10.1002/mrm.21132; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van de Looij Y, 2012, NMR BIOMED, V25, P93, DOI 10.1002/nbm.1721; Van Hecke W, 2009, NEUROIMAGE, V46, P692, DOI 10.1016/j.neuroimage.2009.02.032; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	77	127	129	1	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2012	135		4				1281	1292		10.1093/brain/aws073			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	927ZH	WOS:000302948700030	22505633	Bronze, Green Published			2022-02-06	
J	Rubovitch, V; Ten-Bosch, M; Zohar, O; Harrison, CR; Tempel-Brami, C; Stein, E; Hoffer, BJ; Balaban, CD; Schreiber, S; Chiu, WT; Pick, CG				Rubovitch, Vardit; Ten-Bosch, Meital; Zohar, Ofer; Harrison, Catherine R.; Tempel-Brami, Catherine; Stein, Elliot; Hoffer, Barry J.; Balaban, Carey D.; Schreiber, Shaul; Chiu, Wen-Ta; Pick, Chaim G.			A mouse model of blast-induced mild traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Low level blast-induced brain injury; Behavior; MRI	MANGANESE-SUPEROXIDE-DISMUTASE; POSTTRAUMATIC-STRESS-DISORDER; MINOR HEAD-INJURY; DIFFUSION; MEMORY; EXPOSURE; PRESSURE; BARRIER; NEURONS; GANGLIOSIDES	Improvised explosive devices (IEDs) are one of the main causes for casualties among civilians and military personnel in the present war against terror. Mild traumatic brain injury from IEDs induces various degrees of cognitive, emotional and behavioral disturbances but knowledge of the exact brain pathophysiology following exposure to blast is poorly understood. The study was aimed at establishing a murine model for a mild BI-TBI that isolates low-level blast pressure effects to the brain without systemic injuries. An open-field explosives detonation was used to replicate, as closely as possible, low-level blast trauma in the battlefield or at a terror-attack site. No alterations in basic neurological assessment or brain gross pathology were found acutely in the blast-exposed mice. At 7 days post blast, cognitive and behavioral tests revealed significantly decreased performance at both 4 and 7 m distance from the blast (5.5 and 2.5 PSI, respectively). At 30 days post-blast, clear differences were found in animals at both distances in the object recognition test. and in the 7 m group in the Y maze test. Using MRI, T1 weighted images showed an increased BBB permeability I month post-blast. DTI analysis showed an increase in fractional anisotropy (FA) and a decrease in radial diffusivity. These changes correlated with sites of up-regulation of manganese superoxide dismutase 2 in neurons and CXC-motif chemokine receptor 3 around blood vessels in fiber tracts. These results may represent brain axonal and myelin abnormalities. Cellular and biochemical studies are underway in order to further correlate the blast-induced cognitive and behavioral changes and to identify possible underlying mechanisms that may help develop treatment- and neuroprotective modalities. Published by Elsevier Inc.	[Stein, Elliot; Hoffer, Barry J.] NIDA, Intramural Res Program, NIH, IRP, Baltimore, MD 21224 USA; [Rubovitch, Vardit; Ten-Bosch, Meital; Pick, Chaim G.] Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Zohar, Ofer] Johns Hopkins Univ Montgomery Cty Campus, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; [Harrison, Catherine R.] USAF, Res Lab, Wright Patterson AFB, OH 45433 USA; [Tempel-Brami, Catherine] Tel Aviv Univ, Alfredo Federico Strauss Ctr Computat Neuroimagin, IL-69978 Tel Aviv, Israel; [Balaban, Carey D.] Eye & Ear Inst 107, Dept Otolaryngol, Pittsburgh, PA 15213 USA; [Schreiber, Shaul] Tel Aviv Univ, Dept Psychiat, Tel Aviv Souraslry Med Ctr, IL-64239 Tel Aviv, Israel; [Schreiber, Shaul] Tel Aviv Univ, Sackler Fac Med, IL-64239 Tel Aviv, Israel; [Chiu, Wen-Ta] Taipei Med Univ, Dept Neurosurg, Taipei, Taiwan; [Balaban, Carey D.] 107 Eye & Ear Inst, Dept Neurobiol Commun Sci & Disorders, Pittsburgh, PA 15213 USA; [Balaban, Carey D.] 107 Eye & Ear Inst, Dept Bioengn, Pittsburgh, PA 15213 USA		Hoffer, BJ (corresponding author), NIDA, Intramural Res Program, NIH, IRP, 251 Bayview Blvd, Baltimore, MD 21224 USA.	barry.hoffer@nih.gov	Schreiber, Shaul/E-5821-2010; Balaban, Carey/I-3467-2017; Balaban, Carey/O-6586-2019	Schreiber, Shaul/0000-0002-2189-0693; Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	NIH (National Institute on Drug Abuse)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); Taiwan NSCMinistry of Science and Technology, Taiwan [NSC98-2321-B-038-003-MY3, NSC98-2314-B-038-012-MY3]; DOD-EOARD [FA8655-08-1-3010]	We thank Dr. Letizia Schreiber, Dr. Galia Tsarfati and Dr. Ronit Satchi-Fainaro for their help. In addition, we would like to express thanks to Mr. Boaz Hayun, Mr. Avi Icar, Mr. Lippe Sadwin, Ms. Gloria Limetti and Ms. Cynthia Stone for their expert technical assistance and support. This study was partially supported by the Intramural Research Programs at the NIH (National Institute on Drug Abuse), by Taiwan NSC grants NSC98-2321-B-038-003-MY3 and NSC98-2314-B-038-012-MY3, and by DOD-EOARD grant FA8655-08-1-3010.	Aggleton JP, 1997, BRAIN RES BULL, V43, P279, DOI 10.1016/S0361-9230(97)00007-5; [Anonymous], 2004, AM J PSYCHIAT, V161, P1321; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Barkai G., 2007, WORLD J BIOL PSYCHIA, P1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bidmon HJ, 1998, STROKE, V29, P203, DOI 10.1161/01.STR.29.1.203; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Crabtree J, 2006, J BURN CARE RES, V27, P576, DOI 10.1097/01.BCR.0000235459.60000.A5; DeKosky S.T., 2010, NEW ENGL J MED, V363, P14; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; DeVries HE, 1997, PHARMACOL REV, V49, P143; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Jiang Q, 2006, NEUROIMAGE, V32, P1080, DOI 10.1016/j.neuroimage.2006.05.025; Jiang Y, 2010, NEUROIMAGE, V50, P465, DOI 10.1016/j.neuroimage.2009.12.057; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Knake S, 2010, MOVEMENT DISORD, V25, P1232, DOI 10.1002/mds.23054; Lacotte S, 2009, ANN NY ACAD SCI, V1173, P310, DOI 10.1111/j.1749-6632.2009.04813.x; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIU XH, 1993, BRAIN RES, V625, P29, DOI 10.1016/0006-8993(93)90134-9; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; McTighe SM, 2010, SCIENCE, V330, P1408, DOI 10.1126/science.1194780; Mekel Michal, 2009, Am J Disaster Med, V4, P233; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Mintz Y, 2002, ISRAEL MED ASSOC J, V4, P554; Mori Susumu, 2006, Methods Mol Med, V124, P129; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Omari KM, 2005, BRAIN, V128, P1003, DOI 10.1093/brain/awh479; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ratiu P, 2004, J NEUROTRAUM, V21, P637, DOI 10.1089/089771504774129964; Rotondi M, 2007, ENDOCR REV, V28, P492, DOI 10.1210/er.2006-0044; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saha RN, 2007, FREE RADICAL BIO MED, V42, P1866, DOI 10.1016/j.freeradbiomed.2007.03.022; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schnaar RL, 2010, FEBS LETT, V584, P1741, DOI 10.1016/j.febslet.2009.10.011; Schreiber Shaul, 2007, Am J Disaster Med, V2, P307; SIMIAND J, 1984, PSYCHOPHARMACOLOGY, V84, P48, DOI 10.1007/BF00432023; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thompson JM, 2008, CAN FAM PHYSICIAN, V54, P1549; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	69	127	128	4	29	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2011	232	2					280	289		10.1016/j.expneurol.2011.09.018			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	852UX	WOS:000297384100023	21946269	Green Accepted			2022-02-06	
J	Elbin, RJ; Schatz, P; Covassin, T				Elbin, R. J.; Schatz, Philip; Covassin, Tracey			One-Year Test-Retest Reliability of the Online Version of ImPACT in High School Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; neurocognitive testing; reliability; ImPACT	SPORT-RELATED CONCUSSION; AGREEMENT STATEMENT; TEST-SCORES; MANAGEMENT; RECOVERY; BATTERY	Background: The ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) neurocognitive testing battery is a popular assessment tool used for concussion management. The stability of the baseline neurocognitive assessment is important for accurate comparisons between postconcussion and baseline neurocognitive performance. Psychometric properties of the recently released online version of ImPACT have yet to be established; therefore, research evaluating the reliability of this measure is warranted. Purpose: The authors investigated the 1-year test-retest reliability of the ImPACT online version in a sample of high school athletes. Study Design: Case series; Level of evidence, 4 Methods: A total of 369 varsity high school athletes completed 2 mandatory preseason baseline cognitive assessments approximately 1 year apart as required by their respective athletics program. No diagnosed concussion occurred between assessments. Results: Intraclass correlation coefficients (ICCs) for ImPACT online indicated that motor processing speed (.85) was the most stable composite score, followed by reaction time (.76), visual memory (.70), and verbal memory (.62). Unbiased estimates of reliability were consistent with ICCs: motor processing speed (.85), reaction time (.76), visual memory (.71), and verbal memory (.62). Conclusion: The online ImPACT baseline is a stable measure of neurocognitive performance across a 1-year time period for high school athletes. These reliability data for online ImPACT are higher than the 2-year ICCs previously reported from the desktop version. Clinical Relevance: It is recommended that the ImPACT baseline assessment (both desktop and online) continue to be updated every 2 years. The online version of ImPACT appears to be a stable measure of neurocognitive performance over a 1-year period, and systematic evaluation of its stability over a 2-year period is warranted.	[Elbin, R. J.; Schatz, Philip; Covassin, Tracey] St Josephs Univ, Philadelphia, PA 19131 USA		Elbin, RJ (corresponding author), E Tennessee State Univ, Dept Kinesiol Leisure & Sport Sci, Box 70654, Johnson City, TN 37614 USA.	elbinr@etsu.edu		Schatz, Philip/0000-0002-6222-6545			ALVES WM, 1987, CLIN SPORT MED, V6, P211; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BARR WB, 2002, CNS SPECTRUMS, V7, P304; Barr William B, 2002, CNS Spectr, V7, P300; Barth JT, 1989, MILD HEAD INJURY, P257; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Crawford JR, 2006, NEUROPSYCHOLOGY, V20, P259, DOI 10.1037/0894-4105.20.3.259; FLEISHMAN J, 1987, EDUC PSYCHOL MEAS, V47, P925, DOI 10.1177/0013164487474008; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, LUPUS, V10, P266, DOI 10.1191/096120301680416959; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; LOVELL MR, IMPACT ONLINE VERSIO; Maruff P, 2004, BRIT J SPORT MED, V38, P654; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; RODGERS JL, 1988, AM STAT, V42, P59, DOI 10.2307/2685263; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; SCHATZ P, J ATHL TRAI IN PRESS; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wilk CM, 2002, AM J PSYCHIAT, V159, P838, DOI 10.1176/appi.ajp.159.5.838	35	127	127	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2011	39	11					2319	2324		10.1177/0363546511417173			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	838KG	WOS:000296287900005	21841066				2022-02-06	
J	Babbage, DR; Yim, J; Zupan, B; Neumann, D; Tomita, MR; Willer, B				Babbage, Duncan R.; Yim, Jackki; Zupan, Barbra; Neumann, Dawn; Tomita, Machiko R.; Willer, Barry			Meta-Analysis of Facial Affect Recognition Difficulties After Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						affect recognition; emotion perception; traumatic brain injury; meta-analysis	CLOSED-HEAD INJURY; EMOTION RECOGNITION; SOCIAL-BEHAVIOR; PERCEPTION DEFICITS; COMMUNICATION; EXPRESSION; INDIVIDUALS; ADULTS; MIND; EPIDEMIOLOGY	Difficulties in communication and social relationships present a formidable challenge for many people after traumatic brain injury (TBI). These difficulties are likely to be partially attributable to problems with emotion perception. Mounting evidence shows facial affect recognition to be particularly difficult after TBI. However, no attempt has been made to systematically estimate the magnitude of this problem or the frequency with which it occurs. Method: A meta-analysis is presented examining the magnitude of facial affect recognition difficulties after TBI. From this, the frequency of these impairments in the TBI population is estimated. Effect sizes were calculated from 13 studies that compared adults with moderate to severe TBI to matched healthy controls on static measures of facial affect recognition. Results: The studies collectively presented data from 296 adults with TBI and 296 matched controls. The overall weighted mean effect size for the 13 studies was -1.11, indicating people with TBI on average perform about 1.1 SD below healthy peers on measures of facial affect recognition. Based on estimation of the TBI population standard deviation and modeling of likely distribution shape, it is estimated that between 13% and 39% of people with moderate to severe TBI may have significant difficulties with facial affect recognition, depending on the cut-off criterion used. Conclusion: This is clearly an area that warrants attention, particularly examining techniques for the rehabilitation of these deficits.	[Babbage, Duncan R.; Yim, Jackki] Massey Univ, Sch Psychol, Wellington 6140, New Zealand; [Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada; [Neumann, Dawn] Indiana Univ, Sch Med, Dept Phys Med & Rehabil, Bloomington, IN 47405 USA; [Tomita, Machiko R.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Rehabil Sci, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Sch Med & Biomed Sci, Dept Psychiat & Rehabil Med, Buffalo, NY 14260 USA		Babbage, DR (corresponding author), Massey Univ, Sch Psychol, POB 756, Wellington 6140, New Zealand.	D.R.Babbage@massey.ac.nz		Barbra, Zupan/0000-0002-4603-333X; Babbage, Duncan/0000-0002-9259-9246			Addington J, 2008, BRIT J PSYCHIAT, V192, P67, DOI 10.1192/bjp.bp.107.039784; Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Borgaro SR, 2004, BRAIN INJURY, V18, P33, DOI 10.1080/0269905031000110562; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ekman P., 2004, JAPANESE CAUCASIAN F; Ekman P, 1978, MANUAL FACIAL ACTION; Ekman P., 1976, PICTURES FACIAL AFFE; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Guercio JM, 2004, BRAIN INJURY, V18, P593, DOI 10.1080/02699050310001646116; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hedges LV., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.2307/1164588]; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; KUBU CS, 1993, J CLIN EXP NEUROPSYC, V15, P59; Kubu CS, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P451; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lipsey M.W., 2001, PRACTICAL META ANAL; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S., 2005, BRAIN IMPAIR, V6, P58, DOI [DOI 10.1375/BRIM.6.1.56.65481, 10.1375/brim.6.1.56.65481]; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Orwin R.G., 1983, J EDUC STAT, V8, P157, DOI [10.2307/1164923, DOI 10.2307/1164923]; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/PMS.73.8.1139-1150; Prigatano G. P., 1995, BNI Q, V9, P2; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; SPENCE SH, 1980, SOCIAL SKILLS TRAINI; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wood RLL, 2009, BRAIN INJURY, V23, P649, DOI 10.1080/02699050902970786; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Zupan B, 2009, J COMMUN DISORD, V42, P1, DOI 10.1016/j.jcomdis.2008.06.001	53	127	128	0	23	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	MAY	2011	25	3					277	285		10.1037/a0021908			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	765ZO	WOS:000290748100001	21463043				2022-02-06	
J	Hartings, JA; Watanabe, T; Bullock, MR; Okonkwo, DO; Fabricius, M; Woitzik, J; Dreier, JP; Puccio, A; Shutter, LA; Pahl, C; Strong, AJ				Hartings, Jed A.; Watanabe, Tomas; Bullock, M. Ross; Okonkwo, David O.; Fabricius, Martin; Woitzik, Johannes; Dreier, Jens P.; Puccio, Ava; Shutter, Lori A.; Pahl, Clemens; Strong, Anthony J.		Co-Operative Study Brain Injury De	Spreading depolarizations have prolonged direct current shifts and are associated with poor outcome in brain trauma	BRAIN			English	Article						cortical spreading depression; electroencephalography; craniotomy; signal processing; acute brain injury	FOCAL CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; SUBARACHNOID HEMORRHAGE; RAT-BRAIN; CORTICAL DEPOLARIZATIONS; NEUROLOGICAL DEFICITS; TISSUE OXYGENATION; ARTERY OCCLUSION; BLOOD-FLOW; DEPRESSION	Cortical spreading depolarizations occur spontaneously after ischaemic, haemorrhagic and traumatic brain injury. Their effects vary spatially and temporally as graded phenomena, from infarction to complete recovery, and are reflected in the duration of depolarization measured by the negative direct current shift of electrocorticographic recordings. In the focal ischaemic penumbra, peri-infarct depolarizations have prolonged direct current shifts and cause progressive recruitment of the penumbra into the core infarct. In traumatic brain injury, the effects of spreading depolarizations are unknown, although prolonged events have not been observed in animal models. To determine whether detrimental penumbral-type depolarizations occur in human brain trauma, we analysed electrocorticographic recordings obtained by subdural electrode-strip monitoring during intensive care. Of 53 patients studied, 10 exhibited spreading depolarizations in an electrophysiologic penumbra (i.e. isoelectric cortex with no spontaneous activity). All 10 patients (100%) with isoelectric spreading depolarizations had poor outcomes, defined as death, vegetative state, or severe disability at 6 months. In contrast, poor outcomes were observed in 60% of patients (12/20) who had spreading depolarizations with depression of spontaneous activity and only 26% of patients (6/23) who had no depolarizations (chi(2), P < 0.001). Spontaneous electrocorticographic activity and direct current shifts of depolarizations were further examined in nine patients. Direct current shift durations (n = 295) were distributed with a significant positive skew (range 0:51-16:19 min:s), evidencing a normally distributed group of short events and a sub-group of prolonged events. Prolonged direct current shifts were more commonly associated with isoelectric depolarizations (median 2 min 36 s), whereas shorter depolarizations occurred with depression of spontaneous activity (median 2 min 10 s; P < 0.001). In the latter group, direct current shift durations correlated with electrocorticographic depression periods, and were longer when preceded by periodic epileptiform discharges than by continuous delta (0.5-4.0 Hz) or higher frequency activity. Prolonged direct current shifts (> 3 min) also occurred mainly within temporal clusters of events. Our results show for the first time that spreading depolarizations are associated with worse clinical outcome after traumatic brain injury. Furthermore, based on animal models of brain injury, the prolonged durations of depolarizations raise the possibility that these events may contribute to maturation of cortical lesions. Prolonged depolarizations, measured by negative direct current shifts, were associated with (i) isoelectricity or periodic epileptiform discharges; (ii) prolonged depression of spontaneous activity and (iii) occurrence in temporal clusters. Depolarizations with these characteristics are likely to reflect a worse prognosis.	[Hartings, Jed A.; Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH 45219 USA; [Watanabe, Tomas] Naval Med Res Ctr, Undersea Med Dept, Silver Spring, MD 20910 USA; [Bullock, M. Ross] Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA 23298 USA; [Okonkwo, David O.; Puccio, Ava] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Fabricius, Martin] Glostrup Cty Hosp, Dept Clin Neurophysiol, DK-2600 Glostrup, Denmark; [Woitzik, Johannes; Dreier, Jens P.] Charite, Ctr Stroke Res, D-10117 Berlin, Germany; [Woitzik, Johannes] Univ Med Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; [Pahl, Clemens; Strong, Anthony J.] Kings Coll London, Dept Clin Neurosci, London SE5 8AF, England		Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, 260 Stetson St,Suite 2200, Cincinnati, OH 45219 USA.	jed.hartings@uc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628; Woitzik, Johannes/0000-0002-1865-4606; Dreier, Jens/0000-0001-7459-2828; Hartings, Jed/0000-0001-8583-3471	U.S. Army CDMRP Psychological Health/Traumatic Brain Injury Research Program [W81XWH-08-2-0016]; Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [DR 323/3-1, 323/5-1]; Bundesministerium fur Bildung und ForschungFederal Ministry of Education & Research (BMBF) [CSB 01 EO 0801, BCCN 01GQ1001C B2]	This work was funded in part by the U.S. Army CDMRP Psychological Health/Traumatic Brain Injury Research Program, Contract No. W81XWH-08-2-0016. J.P.D. was supported by grants of the Deutsche Forschungsgemeinschaft (DFG DR 323/3-1, 323/5-1) and Bundesministerium fur Bildung und Forschung (CSB 01 EO 0801, BCCN 01GQ1001C B2).	ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978, DOI 10.1097/00004647-199809000-00007; Dreier JP, 2001, J PHYSIOL-LONDON, V531, P515, DOI 10.1111/j.1469-7793.2001.0515i.x; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154, DOI 10.1152/jn.1956.19.2.154; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2008, NEUROL RES, V30, P876, DOI 10.1179/174313208X309739; Hartings JA, 2006, J CEREBR BLOOD F MET, V26, P696, DOI 10.1038/sj.jcbfm.9600223; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hartings JA, 2009, J NEUROPHYSIOL, V102, P2563, DOI 10.1152/jn.00345.2009; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; HERRERAS O, 1993, BRAIN RES, V610, P283, DOI 10.1016/0006-8993(93)91412-L; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Koroleva VI, 1996, P NATL ACAD SCI USA, V93, P3710, DOI 10.1073/pnas.93.8.3710; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; Mies G, 1997, NEUROSCI LETT, V221, P165, DOI 10.1016/S0304-3940(96)13317-6; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Nallet H, 1999, BRAIN RES, V842, P148, DOI 10.1016/S0006-8993(99)01859-4; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; Ohta K, 2001, STROKE, V32, P535, DOI 10.1161/01.STR.32.2.535; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; RICHTER F, 1993, NEUROSCI LETT, V152, P65, DOI 10.1016/0304-3940(93)90484-3; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; SHINOHARA M, 1979, SCIENCE, V203, P188, DOI 10.1126/science.758688; Strong AJ, 2005, ADV TECH STAND NEUR, V30, P3, DOI 10.1007/3-211-27208-9_1; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; Sukhotinsky I, 2010, J CEREBR BLOOD F MET, V30, P1168, DOI 10.1038/jcbfm.2009.285; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Turner DA, 2007, TRENDS NEUROSCI, V30, P390, DOI 10.1016/j.tins.2007.06.001; VANHARREVELD A, 1951, ELECTROEN CLIN NEURO, V3, P323, DOI 10.1016/0013-4694(51)90080-6; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313	55	127	127	1	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	MAY	2011	134		5				1529	1540		10.1093/brain/awr048			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	766WZ	WOS:000290818600030	21478187	Bronze			2022-02-06	
J	Kempf, J; Werth, E; Kaiser, PR; Bassetti, CL; Baumann, CR				Kempf, Julia; Werth, Esther; Kaiser, Philippe R.; Bassetti, Claudio L.; Baumann, Christian R.			Sleep-wake disturbances 3 years after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SCALE; NARCOLEPSY; VALIDATION; FATIGUE	Background 6 months after traumatic brain injury (TBI), almost three out of four patients suffer from sleep-wake disturbances (SWD) such as post-traumatic hypersomnia (increased sleep need of >= 2 h compared with before injury), excessive daytime sleepiness (EDS), fatigue and insomnia. The long-term course of post-traumatic SWD, however, is unknown. Objectives To assess the prevalence and characteristics of post-traumatic SWD 3 years after trauma. Design Prospective longitudinal clinical study in 51 consecutive TBI patients (43 males, eight females, mean age 40 +/- 16 years). Main outcome measures EDS (as assessed by the Epworth sleepiness scale), fatigue (fatigue severity scale), post-traumatic hypersomnia (sleep length per 24 h), insomnia, depression and anxiety. Results Post-traumatic SWD were found in 34 patients (67%): post-traumatic hypersomnia in 14 (27%), EDS in six (12%), fatigue in 18 patients (35%) and insomnia in five patients (10%). SWD were not associated with severity or localisation of, or time interval since, TBI. Insomnia was linked to depressive symptoms. Conclusions This prospective study shows that 3 years after TBI, two out of three patients suffer from residual SWD, particularly fatigue and post-traumatic hypersomnia. In 45% of TBI patients, SWD appear directly related to the trauma itself.	[Kempf, Julia; Werth, Esther; Kaiser, Philippe R.; Bassetti, Claudio L.; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Bassetti, Claudio L.] Osped Civ, Dept Neurol, Lugano, Switzerland		Baumann, CR (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	christian.baumann@usz.ch	Sanguansri, Luz/B-6630-2011; Werth, E/AAN-7955-2021	Sanguansri, Luz/0000-0003-1908-7604; Baumann, Christian/0000-0003-3417-1978; Werth, Esther/0000-0002-5099-3122	Schweizerischer Versicherungsverband SVV, Zurich, Switzerland	This study has been supported by the Schweizerischer Versicherungsverband SVV, Zurich, Switzerland.	AASM, 2005, INT CLASS SLEEP DIS; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bloch KE, 1999, RESPIRATION, V66, P440, DOI 10.1159/000029408; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P25, DOI 10.1097/01.HTR.0000308718.88214.bb; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; HUBLIN C, 1994, J SLEEP RES, V3, P52, DOI 10.1111/j.1365-2869.1994.tb00104.x; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Olsson I, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-46; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Sturzenegger C, 2004, J SLEEP RES, V13, P395, DOI 10.1111/j.1365-2869.2004.00422.x; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601	15	127	131	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2010	81	12					1402	1405		10.1136/jnnp.2009.201913			4	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	681KM	WOS:000284312200026	20884672	Green Accepted			2022-02-06	
J	von Steinbuchel, N; Wilson, L; Gibbons, H; Hawthorne, G; Hofer, S; Schmidt, S; Bullinger, M; Maas, A; Neugebauer, E; Powell, J; von Wild, K; Zitnay, G; Bakx, W; Christensen, AL; Koskinen, S; Formisano, R; Sarajuuri, J; Sasse, N; Truelle, JL				von Steinbuechel, Nicole; Wilson, Lindsay; Gibbons, Henning; Hawthorne, Graeme; Hoefer, Stefan; Schmidt, Silke; Bullinger, Monika; Maas, Andrew; Neugebauer, Edmund; Powell, Jane; von Wild, Klaus; Zitnay, George; Bakx, Wilbert; Christensen, Anne-Lise; Koskinen, Sanna; Formisano, Rita; Sarajuuri, Jaana; Sasse, Nadine; Truelle, Jean-Luc		QOLIBRI Task Force	Quality of Life after Brain Injury (QOLIBRI): Scale Validity and Correlates of Quality of Life	JOURNAL OF NEUROTRAUMA			English	Article						health-related quality of life; multi-national study; outcome instrument; traumatic brain injury	HEAD-INJURY; CLINICAL-TRIALS; SELF-AWARENESS; HEALTH; SATISFACTION; DEPRESSION; DISABILITY; MODERATE; TBI	The QOLIBRI (Quality of Life after Brain Injury) is a novel health-related quality-of-life (HRQoL) instrument specifically developed for traumatic brain injury (TBI). It provides a profile of HRQoL in six domains together with an overall score. Scale validity and factors associated with HRQoL were investigated in a multi-center international study. A total of 795 adults with brain injury were studied from 3 months to 15 years post-injury. The majority of participants (58%) had severe injuries as assessed by 24-h worst Glasgow Coma Scale (GCS) score. Systematic relationships were observed between the QOLIBRI and the Glasgow Outcome Scale-Extended (GOSE), Hospital Anxiety and Depression Scale (HADS), and SF-36. Within each scale patients with disability reported having low HRQoL in two to three times as many areas as those who had made a good recovery. The main correlates of the total QOLIBRI score were emotional state (HADS depression and anxiety), functional status (amount of help needed and outcome on the GOSE), and comorbid health conditions. Together these five variables accounted for 58% of the variance in total QOLIBRI scores. The QOLIBRI is the first tool developed to assess disease-specific HRQoL in brain injury, and it contains novel information not given by other currently available assessments.	[von Steinbuechel, Nicole; Gibbons, Henning; Sasse, Nadine] Univ Gottingen, Dept Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [Hawthorne, Graeme] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Psychiat, Melbourne, Vic, Australia; [Hoefer, Stefan] Med Univ Innsbruck, Dept Med Psychol, Innsbruck, Austria; [Schmidt, Silke] Ernst Moritz Arndt Univ Greifswald, Inst Psychol, Dept Hlth & Prevent, Greifswald, Germany; [Bullinger, Monika] Univ Hosp Eppendorf, Dept Med Psychol, Hamburg, Germany; [Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Neugebauer, Edmund] Private Univ Witten Herdecke, IFOM, Cologne, Germany; [Powell, Jane] Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; [von Wild, Klaus] Univ Munster, Clemens Hosp, Dept Neurosurg & Early Neurotraumatol Rehabil, Munster, Germany; [Zitnay, George] Assoc Martha Jefferson Hosp, Charlottesville, VA USA; [Bakx, Wilbert] Maastricht Univ, Maastricht, Netherlands; [Bakx, Wilbert] Hoensbroeck Rehabil Ctr, Hoensbroeck, Netherlands; [Christensen, Anne-Lise] Univ Kopenhagen, Ctr Cognit & Memory, Copenhagen, Denmark; [Christensen, Anne-Lise] Univ Kopenhagen, Ctr Rehabil Brain Injury, Copenhagen, Denmark; [Koskinen, Sanna; Sarajuuri, Jaana] Kapyla Rehabil Ctr, Helsinki, Finland; [Formisano, Rita] Rehabil Hosp, Santa Lucia Fdn, IRCCS, Rome, Italy; [Truelle, Jean-Luc] CHU Raymond Poincare, Serv Med Phys & Readapt, Garches, France		von Steinbuchel, N (corresponding author), Univ Gottingen, Dept Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany.	nvsteinbuechel@med.uni-goettingen.de	Hofer, Stefan/B-8393-2008; Wilson, Lindsay/O-8883-2019; Maas, Andrew IR/C-5584-2013; Hofer, Stefan/N-8253-2019; Wilson, Lindsay/A-3659-2009	Hofer, Stefan/0000-0002-6128-3687; Wilson, Lindsay/0000-0003-4113-2328; Maas, Andrew IR/0000-0003-1612-1264; Hofer, Stefan/0000-0002-6128-3687; Wilson, Lindsay/0000-0003-4113-2328; Koskinen, Sanna/0000-0002-3453-5084			Bampoe J, 2002, NEUROSURG QUART, V12, P132, DOI 10.1097/00013414-200206000-00006; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Bock W, 2006, SCHADEL HIRN VERLETZ; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P429, DOI 10.1348/014466501163904; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50241; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gladis MM, 1999, J CONSULT CLIN PSYCH, V67, P320, DOI 10.1037/0022-006X.67.3.320; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hofer S, 2005, PSYCHOSOMATICS, V46, P212, DOI 10.1176/appi.psy.46.3.212; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; King MT, 2008, LANCET, V371, P709, DOI 10.1016/S0140-6736(08)60324-4; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Patricia GF, 2007, ECON CHIL, V10, P137; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Power M, 2005, QUAL LIFE RES, V14, P2197, DOI 10.1007/s11136-005-7380-9; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; von Steinbuchel N, 2010, J NEUROTRAUMA, V27; von Steinbuchel Nicole, 2006, Eur J Ageing, V3, P116, DOI 10.1007/s10433-006-0024-2; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599	51	127	129	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1157	1165		10.1089/neu.2009.1077			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100001	20210602				2022-02-06	
J	Zweifel, C; Lavinio, A; Steiner, LA; Radolovich, D; Smielewski, P; Timofeev, I; Hiler, M; Balestreri, M; Kirkpatrick, PJ; Pickard, JD; Hutchinson, P; Czosnyka, M				Zweifel, Christian; Lavinio, Andrea; Steiner, Luzius A.; Radolovich, Danila; Smielewski, Peter; Timofeev, Ivan; Hiler, Magdalena; Balestreri, Marcella; Kirkpatrick, Peter J.; Pickard, John D.; Hutchinson, Peter; Czosnyka, Marek			Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury	NEUROSURGICAL FOCUS			English	Article						cerebral perfusion pressure; cerebrovascular pressure reactivity; head injury; intracranial pressure monitoring; static rate of autoregulation	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; BLOOD-FLOW; DECOMPRESSIVE CRANIECTOMY; AUTO-REGULATION; PREDICTIVE-VALUE; AUTOREGULATION; METABOLISM; MANAGEMENT	Object. Cerebrovascular pressure reactivity is the ability of cerebral vessels to respond to changes in transmural pressure. A cerebrovascular pressure reactivity index (PRx) can be determined as the moving correlation coefficient between mean intracranial pressure (ICP) and mean arterial blood pressure. Methods. The authors analyzed a database consisting of 398 patients with head injuries who underwent continuous monitoring of cerebrovascular pressure reactivity. In 298 patients, the PRx was compared with a transcranial Doppler ultrasonography assessment of cerebrovascular autoregulation (the mean index [Mx]), in 17 patients with the PET-assessed static rate of autoregulation, and in 22 patients with the cerebral metabolic rate for O-2. Patient outcome was assessed 6 months after injury. Results. There was a positive and significant association between the PRx and Mx (R-2 = 0.36, p < 0.001) and with the static rate of autoregulation (R-2 = 0.31, p = 0.02). A PRx > 0.35 was associated with a high mortality rate (> 50%). The PRx showed significant deterioration in refractory intracranial hypertension, was correlated with outcome, and was able to differentiate patients with good outcome, moderate disability, severe disability, and death. The graph of PRx compared with cerebral perfusion pressure (CPP) indicated a U-shaped curve, suggesting that too low and too high CPP was associated with a disturbance in pressure reactivity. Such an optimal CPP was confirmed in individual cases and a greater difference between current and optimal CPP was associated with worse outcome (for patients who, on average, were treated below optimal CPP [R-2 = 0.53, p < 0.001] and for patients whose mean CPP was above optimal CPP [R-2 = -0.40, p < 0.05]). Following decompressive craniectomy, pressure reactivity initially worsened (median -0.03 [interquartile range -0.13 to 0.06] to 0.14 [interquartile range 0.12-0.22]; p < 0.01) and improved in the later postoperative course. After therapeutic hypothermia, in 17 (70.8%) of 24 patients in whom rewarming exceeded the brain temperature threshold of 37 degrees C, ICP remained stable, but the average PRx increased to 0.32 (p < 0.0001), indicating significant derangement in cerebrovascular reactivity. Conclusions. The PRx is a secondary index derived from changes in ICP and arterial blood pressure and can be used as a surrogate marker of cerebrovascular impairment. In view of an autoregulation-guided CPP therapy, a continuous determination of a PRx is feasible, but its value has to be evaluated in a prospective controlled trial.	[Zweifel, Christian; Lavinio, Andrea; Radolovich, Danila; Smielewski, Peter; Timofeev, Ivan; Hiler, Magdalena; Balestreri, Marcella; Kirkpatrick, Peter J.; Pickard, John D.; Hutchinson, Peter; Czosnyka, Marek] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Steiner, Luzius A.] Univ Basel Hosp, Dept Anaesthesia, CH-4031 Basel, Switzerland		Czosnyka, M (corresponding author), Addenbrookes Hosp, Box 167, Cambridge CB2 2QQ, England.	MC141@medschl.cam.ac.uk	Steiner, Luzius/C-9836-2011; Timofeev, Ivan/AAE-7019-2019; Steiner, Luzius/J-1987-2019; Lavinio, Andrea/M-1778-2016	Smielewski, Peter/0000-0001-5096-3938; Timofeev, Ivan/0000-0002-1168-0393	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G0601025, G9439390, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [ID 65883, G0600986, G0601025, G9439390, G0001237] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Balestreri M, 2005, ACT NEUR S, V95, P25; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Lang E W, 1995, New Horiz, V3, P400; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Menon DK, 2004, ANAESTHESIA, V59, P785, DOI 10.1111/j.1365-2044.2004.03800.x; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	37	127	132	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E2	10.3171/FOC.2008.25.10.E2			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100002	18828700	Bronze			2022-02-06	
J	Leal-Noval, SR; Munoz-Gomez, M; Arellano-Orden, V; Marin-Caballos, A; Amaya-Villar, R; Marin, A; Puppo-Moreno, A; Ferrandiz-Millon, C; Flores-Cordero, JM; Murillo-Cabezas, F				Ramon Leal-Noval, Santiago; Munoz-Gomez, Manuel; Arellano-Orden, Victoria; Marin-Caballos, Antonio; Amaya-Villar, Rosario; Marin, Ana; Puppo-Moreno, Antonio; Ferrandiz-Millon, Carmen; Flores-Cordero, Juan Manuel; Murillo-Cabezas, Francisco			Impact of age of transfused blood on cerebral oxygenation in male patients with severe traumatic brain injuyy	CRITICAL CARE MEDICINE			English	Article						brain hypoxia; cerebral oxygenation; erythrocytes; neurotrauma; brain tissue oxygen pressure; red blood cells; severe brain injury; transfusion	TISSUE OXYGENATION; CRITICALLY-ILL; STORAGE TIME; RED-CELLS; CARDIAC-SURGERY; ERYTHROCYTE; MICROCIRCULATION; MORBIDITY; VISCOSITY; PERFUSION	Objective: Prolonged erythrocyte storage time might reduce the efficacy of transfusion. In this study, the effects of transfusion of erythrocytes with four different storage periods (<10 days, In = 18; 10-14 days, n = 15; 15-19 days, n = 17; and >19 days, n = 16 patients) on brain tissue oxygen tension (Ptio(2)) in stable male patients with severe traumatic brain injury were investigated during a 24-hr follow-up period. Design: Prospective, observational study. Setting. Neurotrauma critical care unit of a university hospital. Patients: Sixty-six male, nonbleeding, hemodynamically stable anemic patients (hemoglobin <95 g/L) with Glasgow Coma Scale score <9. Interventions: None: Measurements and Main Results. Ptio(2), cerebral perfusion pressure, mean arterial pressure, intracranial pressure, peripheral oxygen saturation, CO2 pressure at the end of expiration, and intracerebral temperature were recorded in all patients at baseline, immediately after the completion of transfusion, and 1, 2, 3, 4, 5, 6,12, and 24 hrs posttransfusion. All four groups were homogeneous with respect to multiple baseline variables, except for storage time of transfused erythrocytes (p <.0001). There was a significant short-lasting (3-4 hrs) increase in Ptio(2) values after transfusion of erythrocytes stored for <10 days, 10-14 days, or 15-19 days, compared with those at baseline. In contrast, no significant changes in Ptio(2) were observed after transfusion of erythrocytes stored >19 days. Conclusions. Transfusion of erythrocytes increased cerebral oxygenation in patients with severe traumatic brain injury, except in those transfused with erythrocytes stored > 19 days.	[Ramon Leal-Noval, Santiago; Arellano-Orden, Victoria; Marin-Caballos, Antonio; Amaya-Villar, Rosario; Marin, Ana; Puppo-Moreno, Antonio; Ferrandiz-Millon, Carmen; Flores-Cordero, Juan Manuel; Murillo-Cabezas, Francisco] Hosp Univ Virgen del Rocio, Serv Cuidados Crit & Urgenc, Seville 41013, Spain; [Munoz-Gomez, Manuel] Univ Malaga, Sch Med, E-29071 Malaga, Spain		Leal-Noval, SR (corresponding author), Hosp Univ Virgen del Rocio, Serv Cuidados Crit & Urgenc, Avda Manuel Siurot S-N, Seville 41013, Spain.		Murillo-Cabezas, Francisco/AAO-3348-2021; IBIS, NEUROCRITICOS/C-1805-2016; Noval, Santiago/K-4515-2019				Basran S, 2006, ANESTH ANALG, V103, P15, DOI 10.1213/01.ane.0000221167.58135.3d; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Ellsworth ML, 1995, AM J PHYSIOL-HEART C, V269, pH2155, DOI 10.1152/ajpheart.1995.269.6.H2155; Gonzalez AM, 2007, SURGERY, V141, P630, DOI 10.1016/j.surg.2006.09.015; Hebert PC, 2005, ANESTH ANALG, V100, P1433, DOI 10.1213/01.ANE.0000148690.48803.27; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Ho J, 2003, CRIT CARE MED, V31, pS687, DOI 10.1097/01.CCM.0000099349.17094.A3; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Leal-Noval SR, 2000, CRIT CARE MED, V28, P935, DOI 10.1097/00003246-200004000-00004; Leal-Noval SR, 2003, ANESTHESIOLOGY, V98, P815, DOI 10.1097/00000542-200304000-00005; LEALNOVAL SR, 2004, BLOOD TRANSFUS, V2, P15; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Martini J, 2006, CLIN HEMORHEOL MICRO, V35, P51; Martini J, 2006, J INTERN MED, V259, P364, DOI 10.1111/j.1365-2796.2006.01622.x; MORIYAMA R, 1993, J BIOL CHEM, V268, P10990; Munoz Gomez Manuel, 1999, Sangre (Saragossa), V44, P443; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; Piagnerelli M, 2003, INTENS CARE MED, V29, P1052, DOI 10.1007/s00134-003-1783-2; Raat NJH, 2007, VOX SANG, V93, P12, DOI 10.1111/j.1423-0410.2007.00909.x; Raat NJ, 2005, CRIT CARE MED, V33, P39, DOI 10.1097/01.CCM.0000150655.75519.02; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; SIMCHON S, 1987, AM J PHYSIOL, V253, pH898, DOI 10.1152/ajpheart.1987.253.4.H898; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; Tsai AG, 2004, TRANSFUSION, V44, P1626, DOI 10.1111/j.0041-1132.2004.04128.x; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0; WOLFE LC, 1985, TRANSFUSION, V25, P185, DOI 10.1046/j.1537-2995.1985.25385219897.x; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	28	127	129	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2008	36	4					1290	1296		10.1097/CCM.0b013e3181692dfc			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284BJ	WOS:000254679900034	18379257				2022-02-06	
J	Cotton, BA; Snodgrass, KB; Fleming, SB; Carpenter, RO; Kemp, CD; Arbogast, PG; Morris, JA				Cotton, Bryan A.; Snodgrass, Kimberly B.; Fleming, Sloan B.; Carpenter, Robert O.; Kemp, Clinton D.; Arbogast, Patrick G.; Morris, John A., Jr.			Beta-blocker exposure is associated with improved survival after severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		beta-blocker; trauma; brain injury	SEVERE HEAD-INJURY; WALL-MOTION ABNORMALITIES; SUBARACHNOID HEMORRHAGE; MYOCARDIAL-ISCHEMIA; NONCARDIAC SURGERY; PROPENSITY SCORE; PROPRANOLOL; MORTALITY; DEATH; CATECHOLAMINES	Background: Beta-blocker use in elective noncardiac surgery has been associated with a reduction in mortality and cardiovascular complications. Traumatic brain injury (TBI) is often associated with a hyperadrenergic state. We hypothesized that adrenergic blockade would confer improved survival among TBI patients. Methods: Retrospective review of the Trauma Registry of the American College of Surgeons database at a Level I trauma center was conducted. All trauma patients admitted from January 2004 to March 2005 with head Abbreviated Injury Scale score of 3 or greater were evaluated. Patients with length of stay < 4 or > 30 days were excluded. Beta-blocker exposure was defined as receiving beta-blockers for 2 or more consecutive days. Results: In all, 420 patients met inclusion criteria: 174 patients exposed to beta-blockers [BB(+)] and 246 not exposed [BB(-)]. Mean age in BB(+) group was 50 years and 36 years in BB(-) group (p < 0.001). Mean Injury Severity Score was 33.6 for BB(+) group and 30.8 for BB(-) group (p = 0.01). Predicted survival (by Trauma and Injury Severity Score) for BB(+) group was 59.1% compared with 70.3% for BB(-) group (p < 0.001). Observed mortality for BB(+) group was 5.1%, 10.8% for BB(-) group (p = 0.036). Adjusted incidence rate ratio of mortality among those exposed to beta-blockers compared with those not exposed was 0.29 (95% confidence interval). Conclusions: Beta-blocker exposure was associated with a significant reduction in mortality in patients with severe TBI. This reduction in mortality is even more impressive, considering that the BB(+) group was older, more severely injured, and had lower predicted survival.	Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37212 USA		Cotton, BA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 1211 21st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	bryan.cotton@vanderbilt.edu	Cotton, Bryan/A-7107-2009				Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Deng JP, 2004, AM J PHYSIOL-CELL PH, V287, pC730, DOI 10.1152/ajpcell.00562.2003; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FEIBEL JH, 1981, ANN NEUROL, V9, P340, DOI 10.1002/ana.410090405; Fonseca RB, 2005, J TRAUMA, V59, P884, DOI 10.1097/01.ta.0000187653.64300.f5; GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; HADFIELD JM, 1992, INJURY, V23, P177, DOI 10.1016/S0020-1383(05)80040-3; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hart DW, 2002, ANN SURG, V236, P450, DOI 10.1097/00000658-200210000-00007; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; KRAUS J, 1985, J NEUROSURG, V63, P537, DOI 10.3171/jns.1985.63.4.0537; Lindenauer PK, 2005, NEW ENGL J MED, V353, P349, DOI 10.1056/NEJMoa041895; MALING HM, 1958, AM J PHYSIOL, V194, P590, DOI 10.1152/ajplegacy.1958.194.3.590; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MCLEOD AA, 1982, BRIT HEART J, V47, P221; MOREL DR, 1984, INTENS CARE MED, V10, P133, DOI 10.1007/BF00265802; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Neil-Dwyer G, 1990, Acta Neurochir Suppl (Wien), V47, P102; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; NEILDWYER G, 1986, SURG NEUROL, V25, P163, DOI 10.1016/0090-3019(86)90287-9; Newgard CD, 2004, ACAD EMERG MED, V11, P953, DOI 10.1197/j.aem.2004.02.530; OPPENHEIMER SM, 1990, ARCH NEUROL-CHICAGO, V47, P513, DOI 10.1001/archneur.1990.00530050029008; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Poulat P, 1998, EUR J PHARMACOL, V344, P251, DOI 10.1016/S0014-2999(97)01569-0; Randell T, 1999, J NEUROSURG ANESTH, V11, P163, DOI 10.1097/00008506-199907000-00001; Roe SY, 1997, J NEUROTRAUM, V14, P399, DOI 10.1089/neu.1997.14.399; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; SPARKS HV, 1970, CARDIOVASC RES, V4, P363, DOI 10.1093/cvr/4.3.363; STONE JG, 1988, ANESTHESIOLOGY, V68, P495, DOI 10.1097/00000542-198804000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Urban MK, 2000, ANESTH ANALG, V90, P1257, DOI 10.1097/00000539-200006000-00001; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	57	127	130	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2007	62	1					26	33		10.1097/TA.0b013e31802d02d0			8	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	126CP	WOS:000243490100004	17215730				2022-02-06	
J	Richardson, RM; Sun, D; Bullock, MR				Richardson, R. Mark; Sun, Dong; Bullock, M. Ross			Neurogenesis after traumatic brain injury	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article							NEURAL STEM-CELLS; MICROTUBULE-ASSOCIATED PROTEIN; NEURONAL PROGENITOR CELLS; HUMAN HEAD-INJURY; ADULT HUMAN BRAIN; DENTATE GYRUS; INTRACRANIAL-PRESSURE; HIPPOCAMPAL NEUROGENESIS; NERVOUS-SYSTEM; ISCHEMIC BRAIN	With the hope of replacing neurons lost in traumatic brain injury (TBI), experimental models are being used to investigate TBI-induced neurogenesis. Although selectively vulnerable to TBI, the neurogenic hippocampus may have the unique ability to replace damaged neurons locally. Injury may also activate signaling pathways that induce neuroblasts from the subventricular zone to migrate to areas of focal cortical damage. Additionally, there is some evidence for local activation of latent neural progenitor cells in the injured neocortex itself. Each of these themes is discussed, with emphasis on the possibility of future therapeutic intervention.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol Surg, Richmond, VA 23298 USA		Richardson, RM (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Room M779, San Francisco, CA 94143 USA.	richardsonma@neurosurg.ucsf.edu	Richardson, R Mark/C-6819-2016; Richardson, Robert/AAY-4969-2021	Richardson, R Mark/0000-0003-2620-7387; 			Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bolognani F, 2004, NEUROSCI LETT, V371, P152, DOI 10.1016/j.neulet.2004.08.074; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Driscoll I, 2006, NEUROSCIENCE, V139, P1173, DOI 10.1016/j.neuroscience.2006.01.040; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leary SP, 2006, NEUROSURGERY, V58, P805, DOI 10.1227/01.NEU.0000216793.45952.ED; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Markakis EA, 1999, J COMP NEUROL, V406, P449; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rasmussen M, 2005, ACTA ANAESTH SCAND, V49, P341, DOI 10.1111/j.1399-6576.2005.00647.x; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2006, ACTA NEUROCHIR, V148, P773, DOI 10.1007/s00701-006-0778-5; Richardson RM, 2005, MOL CELL NEUROSCI, V28, P674, DOI 10.1016/j.mcn.2004.11.013; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Stilley CS, 2004, NEUROLOGY, V63, P1320, DOI 10.1212/01.WNL.0000140700.44904.53; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhang RL, 2005, NEUROSCIENTIST, V11, P408, DOI 10.1177/1073858405278865; Zhu J, 2005, CURR DRUG TARGETS, V6, P97, DOI 10.2174/1389450053345055	73	127	140	1	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680			NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	JAN	2007	18	1					169	+		10.1016/j.nec.2006.10.007			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	137SN	WOS:000244312600015	17244562				2022-02-06	
J	Walker, WC; Pickett, TC				Walker, William C.; Pickett, Treven C.			Motor impairment after severe traumatic brain injury: A longitudinal multicenter study	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						ataxia; brain injury; closed head injury; dyskinesias; measurement; neurological examination; outcomes; paresis; postural balance; rehabilitation	HEAD-INJURY; GOOD RECOVERY; BALANCE; REHABILITATION; DEFICITS; SWAY; INDIVIDUALS; PERFORMANCE; OUTCOMES; CHILDREN	Neuromotor impairment is a common sequela of severe traumatic brain injury (TBI) but has been understudied relative to neurocognitive outcomes. This multicenter cohort study describes the longitudinal course of neurological examination-based motor abnormalities after severe TBI. Subjects were enrolled from the four lead Department of Veterans Affairs and Defense and Veterans Brain Injury Center sites. The study cohort consisted of 102 consecutive patients (active duty, veteran, or military dependent) with severe TBI who consented during acute rehabilitation for data collection and completed all follow-up evaluations. Paresis, ataxia, and postural instability measures showed a pattern of improvement over time, with the greatest improvement occurring between the inpatient (baseline) and 6-month follow-up assessments. Involuntary movement disorders were rare at all time points. Two years following acute rehabilitation, more than one-third of subjects continued to display a neuromotor abnormality on basic neurological examination. Persistence of tandem gait abnormality was particularly common.	[Walker, William C.; Pickett, Treven C.] Vet Affairs Med Ctr, Hunter Holmes McGuire Dept, Richmond, VA USA; [Walker, William C.; Pickett, Treven C.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Walker, William C.; Pickett, Treven C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA		Walker, WC (corresponding author), MCV Campus,POB 980661, Richmond, VA 23298 USA.	wcwalker@mail2.vcu.edu	Walker, William C/N-3162-2014				Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Bode RK, 2002, ARCH PHYS MED REHAB, V83, P100, DOI 10.1053/apmr.2002.26073; Brown KE, 2006, ARCH PHYS MED REHAB, V87, P76, DOI 10.1016/j.apmr.2005.08.003; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; *COMM ACCR REH FAC, 2002, STAND MAN INT GUID M; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; Di Russo F, 2005, J NEUROTRAUM, V22, P297; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; GUERTS ACH, 1996, ARCH PHYSICAL MED RE, V77, P639; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hillier SL, 1997, BRAIN INJURY, V11, P661; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Juneja G, 1998, AM J PHYS MED REHAB, V77, P388, DOI 10.1097/00002060-199809000-00005; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RADFARBAUBLITZ LS, 2006, AM J PHYS MED REHABI, V85, P256; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SALAZAR AM, 1999, BRAIN INJ SOURCE, V3, P8; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	35	127	129	1	31	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					975	982		10.1682/JRRD.2006.12.0158			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	253NL	WOS:000252524800010	18075954	Bronze			2022-02-06	
J	Parry-Jones, BL; Vaughan, FL; Cox, WM				Parry-Jones, Beth L.; Vaughan, Frances L.; Cox, W. Miles			Traumatic brain injury and substance misuse: A systematic review of prevalence and outcomes research (1994-2004)	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							BLOOD-ALCOHOL LEVEL; HEAD-INJURY; COGNITIVE STATUS; ABUSE; PSYCHOPATHOLOGY; ADOLESCENTS; POPULATION; DISABILITY	A systematic review of the evidence on substance misuse prevalence in patients with traumatic brain injury (TBI) and outcomes associated with this population is presented. Building upon an earlier review of the area by Corigan (1995), this review is limited to research published between 1994 and 2004. Psycinfo and Medline abstract databases were searched for English-language publications citing research from Western countries on the epidemiology and outcomes of adult TBI patients (aged 15 years or older). The majority of reviewed studies were undertaken in the USA and the investigation foci and methods used were multifarious, constraining the generalisation of the review findings. Prevalence for alcohol intoxication at time of injury in the review was found to be almost identical to that in Corrigan's review: 37-51% and 36-51%, respectively. Pre-TBI history of alcohol misuse was found to be less prevalent in the present as opposed to Corrigan's review: 37-51% and 55-66%, respectively. Outcome findings were mixed (also found by Corrigan), but mainly in the expected direction of poorer outcomes (neurological, medical, neuropsychological, and functional) in patients with pre-TBI substance misuse. Further research and implications for services are outlined.	Univ Wales, Bangor, Gwynedd, Wales		Parry-Jones, BL (corresponding author), Univ Wales, Bangor, Gwynedd, Wales.	beth.parry-jones@nww-tr.wales.nhs.uk					Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; Christensen M A, 2001, J Neurosci Nurs, V33, P184; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jong CN, 1999, BRAIN INJURY, V13, P1017; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miller NS, 1995, ALCOHOLISM TREATMENT, V13, P15, DOI 10.1300/J020v13n03_02; Mulrow C. D., 1995, SYSTEMATIC REV, P1; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Roberts RE, 1998, AM J PSYCHIAT, V155, P715; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Schmidt M., 1996, REY AUDITORY VERBAL; Schmidt MF, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P211; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; *STAT U NEW YORK B, 1990, GUID US UN DAT SET M; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; *WAR DEV, 1944, ARM IND TEST BATT MA; Wechsler D, 1987, MANUAL WECHSLER MEMO; Wechsler D, 1981, WECHSLER ADULT INTEL	49	127	128	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT	2006	16	5					537	560		10.1080/09602010500231875			24	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	096FI	WOS:000241362600002	16952892				2022-02-06	
J	Gale, SD; Baxter, L; Roundy, N; Johnson, SC				Gale, SD; Baxter, L; Roundy, N; Johnson, SC			Traumatic brain injury and grey matter concentration: a preliminary voxel based morphometry study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD-INJURY; ATROPHY; GRAY; ATTENTION; DISEASE; CONSCIOUSNESS; COMPLAINTS; FORNIX; MEMORY	Background: Magnetic resonance imaging (MRI) studies have shown diffuse cerebral atrophy following traumatic brain injury. In the past, quantitative volumetric analysis of these changes was carried out by manually tracing specific regions of interest. In contrast, voxel based morphometry (VBM) is a fully automated technique that allows examination of the whole brain on a voxel by voxel basis. Objective: To use VBM to evaluate changes in grey matter concentration following traumatic brain injury. Methods: Nine patients with a history of traumatic brain injury (ranging from mild to severe) about one year previously were compared with nine age and sex matched healthy volunteers. T1 weighted three dimensional MRI images were acquired and then analysed with statistical parametric mapping software (SPM2). The patients with traumatic brain injury also completed cognitive testing to determine whether regional grey matter concentration correlated with a measure of attention and initial injury severity. Results: Compared with controls, the brain injured patients had decreased grey matter concentration in multiple brain regions including frontal and temporal cortices, cingulate gyrus, subcortical grey matter, and the cerebellum. Decreased grey matter concentration correlated with lower scores on tests of attention and lower Glasgow coma scale scores. Conclusions: Using VBM, regions of decreased grey matter concentration were observed in subjects with traumatic brain injury compared with well matched controls. In the brain injured patients, there was a relation between grey matter concentration and attentional ability.	Barrow Neurol Inst, Dept Clin Neuropsychol, Phoenix, AZ 85013 USA; Univ Wisconsin, Sch Med, Madison, WI USA		Gale, SD (corresponding author), Barrow Neurol Inst, Dept Clin Neuropsychol, 222 W Thomas Rd,Suite 315, Phoenix, AZ 85013 USA.	s2gale@chw.edu	; Gale, Shawn/M-3144-2013	Baxter, Leslie/0000-0002-3971-863X; Gale, Shawn/0000-0002-8989-0964	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH65723] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER		ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Baron JC, 2001, NEUROIMAGE, V14, P298, DOI 10.1006/nimg.2001.0848; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Boxer AL, 2003, ARCH NEUROL-CHICAGO, V60, P949, DOI 10.1001/archneur.60.7.949; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; Conners C. K., 2000, CONNERS CONTINUOUS P; Cossa FM, 1999, ITAL J NEUROL SCI, V20, P145, DOI 10.1007/s100720050024; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; JOHNSON SC, 1994, BRAIN RES BULL, V35, P373, DOI 10.1016/0361-9230(94)90116-3; Karas GB, 2003, NEUROIMAGE, V18, P895, DOI 10.1016/S1053-8119(03)00041-7; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mesulam M.-M., 2000, PRINC BEHAV COGN NEU, V2, P1, DOI [DOI 10.1017/9781108164320.002, 10.1017/9781108164320.002]; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1989, TXB HEAD INJURY, P451; Prat R, 1998, ACTA NEUROCHIR, V140, P1257, DOI 10.1007/s007010050247; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Rosen HJ, 2002, NEUROLOGY, V58, P198, DOI 10.1212/WNL.58.2.198; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; Salgado-Pineda P, 2003, NEUROIMAGE, V19, P365, DOI 10.1016/S1053-8119(03)00094-6; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wilke M, 2001, NEUROIMAGE, V13, P814, DOI 10.1006/nimg.2001.0751; Wright IC, 1995, NEUROIMAGE, V2, P244, DOI 10.1006/nimg.1995.1032	39	127	130	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2005	76	7					984	988		10.1136/jnnp.2004.036210			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	940IL	WOS:000230137200017	15965207	Green Published, Bronze			2022-02-06	
J	Youdim, MBH; Bar Am, O; Yogev-Falach, M; Weinreb, O; Maruyama, W; Naoi, M; Amit, T				Youdim, MBH; Bar Am, O; Yogev-Falach, M; Weinreb, O; Maruyama, W; Naoi, M; Amit, T			Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article; Proceedings Paper	6th International Meeting for Brain Energy Metabolism	MAY, 2004	Crete, GREECE			rasagiline; propargyl moiety; Bcl-2 family members; protein kinase C; caspase-3; SHSY5Y neuroblastoma cells	PROTEIN-KINASE-C; AMYLOID PRECURSOR PROTEIN; ANTI-PARKINSON DRUG; MAO-B INHIBITOR; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; CHOLINESTERASE INHIBITOR; DOPAMINERGIC-NEURONS; BCL-2 FAMILY; CELL-DEATH	Mitochondria are involved directly in cell survival and death. The assumption has been made that drugs that protect mitochondrial viability and prevent apoptotic cascade-induced mitochondrial permeability transition pore (MPTp) opening will be cytoprotective. Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor anti-Parkinson drug. Unlike selegiline, it is not derived from amphetamine, and is not metabolized to neurotoxic L-methamphetamine derivative. In addition, it does not have sympathomimetic activity. Rasagiline is effective as monotherapy or adjunct to levodopa for patients with early and late Parkinson's disease (PD) and adverse events do not occur with greater frequency in subjects receiving rasagiline than in those on placebo. Phase III controlled studies indicate that it might have a disease-modifying effect in PD that may be related to its neuroprotective activity. Its S isomer, TVP1022, is more than 1,000 times less potent as an MAO inhibitor. Both drugs, however, have neuroprotective activity in neuronal cell cultures in response to various neurotoxins, and in vivo in response to global ischemia, neurotrauma, head injury, anoxia, etc., indicating that MAO inhibition is not a prerequisite for neuro protection. Their neuroprotective effect has been demonstrated to be associated directly with the propargylamine moiety, which protects mitochondrial viability and MTPp by activating Bcl-2 and protein kinase C (PKC) and by downregulating the proapoptotic FAS and Bax protein families. Rasagiline and its derivatives also process amyloid precursor protein (APP) to the neuroprotective, neurotrophic, soluble APP a (sAPPalpha) by PKC- and MAP kinase-dependent activation of a-secretase. The identification of the propargylamine moiety as the neuroprotective component of rasagiline has led us to development of novel bifunctional anti-Alzheimer drugs (ladostigil) possessing cholinesterase and brain-selective MAO inhibitory activity and a similar neuroprotective mechanism of action. (C) 2004 Wiley-Liss, Inc.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf & USA Natl Paarkinson Fdn Ctr Excellence, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Res Inst, IL-31096 Haifa, Israel; Gifu Int Inst Biotechnol, Dept Neurosci, Gifu, Japan		Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akao Y, 2002, NEUROSCI LETT, V326, P105, DOI 10.1016/S0304-3940(02)00332-4; Bar Am O, 2004, NEUROSCI LETT, V355, P169, DOI 10.1016/j.neulet.2003.10.067; Bar-Am O, 2004, J NEUROCHEM, V89, P1119, DOI 10.1111/j.1471-4159.2004.02425.x; Belzacq AS, 2003, CURR DRUG TARGETS, V4, P517, DOI 10.2174/1389450033490867; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Blandini F, 2004, EXP NEUROL, V187, P455, DOI 10.1016/j.expneurol.2004.03.005; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Caputi A, 1997, J NEUROCHEM, V68, P2523; Carrillo MC, 2000, LIFE SCI, V67, P577, DOI 10.1016/S0024-3205(00)00643-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Durkin JP, 1997, J NEUROCHEM, V68, P1400; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Finberg JPM, 1998, NEUROREPORT, V9, P703; Finberg JPM, 2002, NEUROPHARMACOLOGY, V43, P1110, DOI 10.1016/S0028-3908(02)00216-2; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; Hsieh YC, 2003, SHOCK, V19, P582, DOI 10.1097/01.shk.0000065705.84144.ed; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Katsura K, 2003, NEUROL RES, V25, P522, DOI 10.1179/016164103101201760; KRIBBEN A, 1993, AM J PHYSIOL, V265, pC939, DOI 10.1152/ajpcell.1993.265.4.C939; Lin L, 1999, P NATL ACAD SCI USA, V96, P12108, DOI 10.1073/pnas.96.21.12108; LIN LW, 1995, DRUG AGING, V6, P136, DOI 10.2165/00002512-199506020-00006; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Maruyama W, 2004, NEUROCHEM INT, V44, P393, DOI 10.1016/j.neuint.2003.08.005; Maruyama W, 2003, NEUROSCI LETT, V341, P233, DOI 10.1016/S0304-3940(03)00211-8; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; Maruyama W, 2001, J NEURAL TRANSM, V108, P11, DOI 10.1007/s007020170093; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MASLIAH E, 1991, J NEUROSCI, V11, P2759; Matsushima H, 1996, J NEUROCHEM, V67, P317; Middleton G, 2001, DEVELOPMENT, V128, P447; Montz H P, 1985, Brain Res, V355, P150; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Naoi M, 2001, PARKINSONISM RELAT D, V8, P139, DOI 10.1016/S1353-8020(01)00028-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parain K, 1999, NEUROREPORT, V10, P557, DOI 10.1097/00001756-199902250-00021; Rossner S, 1997, EUR J NEUROSCI, V9, P2125, DOI 10.1111/j.1460-9568.1997.tb01379.x; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sagi Y, 2003, J NEUROCHEM, V86, P290, DOI 10.1046/j.1471-4159.2003.01801.x; SAGI Y, 2001, NEURAL PLAST, V8, P197; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Selvatici R, 2003, J NEUROSCI RES, V71, P64, DOI 10.1002/jnr.10464; SHIMOHAMA S, 1993, NEUROLOGY, V43, P1407, DOI 10.1212/WNL.43.7.1407; Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937; Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561; SLACK BE, 1993, J BIOL CHEM, V268, P21097; Speiser Z, 1999, J NEURAL TRANSM, V106, P593, DOI 10.1007/s007020050182; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tremblay R, 1999, J NEUROCHEM, V72, P102, DOI 10.1046/j.1471-4159.1999.0720102.x; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vianna MRM, 2000, PSYCHOPHARMACOLOGY, V150, P77, DOI 10.1007/s002130000396; Waibel S, 2004, J NEUROL, V251, P1080, DOI 10.1007/s00415-004-0481-5; WANG HY, 1994, NEUROBIOL AGING, V15, P293, DOI 10.1016/0197-4580(94)90023-X; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Weinstock M, 2003, PROG NEURO-PSYCHOPH, V27, P555, DOI 10.1016/S0278-5846(03)00053-8; Weinstock M, 2002, PSYCHOPHARMACOLOGY, V160, P318, DOI 10.1007/s00213-001-0978-x; Weinstock M, 2001, ANN NY ACAD SCI, V939, P148; Weinstock M, 2000, ADV RES NEURODEGENER, V8, P157; Yogev-Falach M, 2003, FASEB J, V17, P2325, DOI 10.1096/fj.03-0078fje; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim MBH, 2003, BIOCHEM PHARMACOL, V66, P1635, DOI 10.1016/S0006-2952(03)00535-5; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; Youdim Moussa Bh, 2003, Expert Rev Neurother, V3, P737, DOI 10.1586/14737175.3.6.737; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	77	127	132	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN 1	2005	79	1-2					172	179		10.1002/jnr.20350			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	888RB	WOS:000226390800023	15573406				2022-02-06	
J	Fischer, C; Luaute, J; Adeleine, P; Morlet, D				Fischer, C; Luaute, J; Adeleine, P; Morlet, D			Predictive value of sensory and cognitive evoked potentials for awakening from coma	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY; OUTCOME PREDICTION; PROGNOSTIC VALUE; MEDICAL ASPECTS; VARIABLES; RECOVERY	Objectives: To determine the prognostic role of late auditory (N100) and cognitive evoked potentials (MMN) for awakening in a cohort of comatose patients categorized by etiology. Methods: The authors prospectively studied a series of 346 comatose patients. Coma was caused by stroke (n=125), trauma (n=96), anoxia (n=64), complications of neurosurgery (n=54), and encephalitis (n=7). Patients were followed for 12 months and classified as awake or unawake. Univariate and multivariate analyses were performed using regression logistic and Cox models. Results: Pupillary light reflex, N100, middle-latency auditory evoked potentials, age, and etiology were the most discriminating factors for awakening. Statistical analysis showed that pupillary reflex was the strongest prognostic variable for awakening ( estimated probability 79.7%). The estimated probability of awakening rose to 87% when N100 was present and to 89.9% when middle-latency evoked potentials (MLAEPs) were present. It was 13.7% when pupillary reflex was absent in anoxic patients. When MMN was present, 88.6% of patients awakened. No patient in whom MMN was present became permanently vegetative. Conclusion: Pupillary reflex is the strongest prognostic variable, followed by N100 and MLAEPs allowing a reliable model for awakening. The presence of MMN is a predictor of awakening and precludes comatose patients from moving to a permanent vegetative state. Evaluation of primary sensory cortex and higher-order processes by middle-latency-, late, and cognitive evoked potentials should be performed in the prognosis for awakening in comatose patients.	Hospices Civils Lyon, Dept Clin Neurophysiol, Lyon, France; Hospices Civils Lyon, Dept Neurol Rehabil, Lyon, France; Hospices Civils Lyon, Dept Biostat, Lyon, France; Univ Lyon 1, EA1880, F-69365 Lyon, France; INSERM, U280, F-69008 Lyon, France		Fischer, C (corresponding author), Hop Neurol, 59 Blvd Pinel, F-69677 Bron, France.	catherine.fischer@chu-lyon.fr	Luaute, jacques/H-4618-2017	Luaute, jacques/0000-0002-6387-9572			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; Fischer C, 2000, AUDIOL NEURO-OTOL, V5, P192, DOI 10.1159/000013880; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; JENNETT B, 1975, LANCET, V1, P480; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; Kane NM, 2000, AUDIOL NEURO-OTOL, V5, P186, DOI 10.1159/000013879; Kass GV., 1980, J R STAT SOC C-APPL, V29, P119, DOI DOI 10.2307/2986296; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; Litscher G, 1995, INT J NEUROSCI, V83, P253, DOI 10.3109/00207459508986342; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; Naatanen R, 1995, Int J Neurosci, V80, P317, DOI 10.3109/00207459508986107; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	21	127	134	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	AUG 24	2004	63	4					669	673		10.1212/01.WNL.0000134670.10384.E2			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	848UP	WOS:000223493800014	15326240				2022-02-06	
J	Cherian, L; Hlatky, R; Robertson, CS				Cherian, L; Hlatky, R; Robertson, CS			Nitric oxide in traumatic brain injury	BRAIN PATHOLOGY			English	Article							CORTICAL IMPACT INJURY; CEREBRAL BLOOD-FLOW; L-ARGININE; HEAD-INJURY; SYNTHASE EXPRESSION; INTRACRANIAL HYPERTENSION; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; NERVOUS-SYSTEM; BINDING-SITES	Nitric oxide (NO) is a gaseous chemical messenger which has functions in the brain in a variety of broad physiological processes, including control of cerebral blood flow, interneuronal communications, synaptic plasticity, memory formation, receptor functions, intracellular signal transmission, and release of neurotransmitters. As might be expected from the numerous and complex roles that NO normally has, it can have both beneficial and detrimental effects in disease states, including traumatic brain injury. There are two periods of time after injury when NO accumulates in the brain, immediately after injury and then again several hours-days later. The initial immediate peak in NO after injury is probably due to the activity of endothelial NOS and neuronal NOS. Pre-injury treatment with 7-nitroindazole, which probably inhibits this immediate increase in NO by neuronal NOS, is effective in improving neurological outcome in some models of traumatic brain injury (TBI). After the initial peak in NO, there can be a period of relative deficiency in NO. This period of low NO levels is associated with a low cerebral blood flow (CBF). Administration of L-arginine at this early time improves CBF, and outcome in many models. The late peak in NO after traumatic injury is probably due primarily to the activity of inducible NOS. Inhibition of inducible NOS has neuroprotective effects in most models.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		BALCIOGLU A, 1993, J NEUROCHEM, V61, P2311, DOI 10.1111/j.1471-4159.1993.tb07475.x; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHERIAN L, 2004, IN PRESS J NEUROTRAU; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GOADSBY PJ, 1992, BRAIN RES, V595, P167, DOI 10.1016/0006-8993(92)91470-Y; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GROSS SS, 1992, J BIOL CHEM, V267, P25722; Henley CM, 1997, J NEUROCHEM, V69, P259; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HOVDA DA, 1990, ACT NEUR S, V51, P331; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; Huk I, 1997, CIRCULATION, V96, P667; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JIA YS, 1994, NEUROREPORT, V5, P793, DOI 10.1097/00001756-199403000-00014; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Koppenol WH, 1996, METHOD ENZYMOL, V268, P3; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LEE SM, 1997, J CEREB BLOOD FLOW S, V17, pS592; LEONE AM, 1991, J BIOL CHEM, V266, P23790; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Liu PK, 2001, TRENDS NEUROSCI, V24, P581, DOI 10.1016/S0166-2236(00)01918-4; Liu Q, 1996, METHOD ENZYMOL, V268, P311; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Ma JY, 1996, AM J PHYSIOL-HEART C, V270, pH1085, DOI 10.1152/ajpheart.1996.270.3.H1085; Ma JY, 1996, AM J PHYSIOL-HEART C, V271, pH1717, DOI 10.1152/ajpheart.1996.271.4.H1717; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARLETTA MA, 1994, J MED CHEM, V37, P1899, DOI 10.1021/jm00039a001; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P70, DOI 10.1038/jcbfm.1993.9; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Park CO, 2001, YONSEI MED J, V42, P518, DOI 10.3349/ymj.2001.42.5.518; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RENGASAMY A, 1991, J PHARMACOL EXP THER, V259, P310; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Salter M, 1996, J NEUROCHEM, V66, P1683; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sparapani M, 1997, EXP NEUROL, V148, P157, DOI 10.1006/exnr.1997.6627; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; TAHA Z, 1992, BIOCHEM BIOPH RES CO, V188, P734, DOI 10.1016/0006-291X(92)91117-9; UMANS JG, 1995, ANNU REV PHYSIOL, V57, P771, DOI 10.1146/annurev.ph.57.030195.004011; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WADA K, 1997, J NEUROTRAUM, V14, P760; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; Yamada K, 1997, J NEUROCHEM, V68, P1234; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141	92	127	140	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	APR	2004	14	2					195	201		10.1111/j.1750-3639.2004.tb00053.x			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	820SZ	WOS:000221410900010	15193032	Green Published			2022-02-06	
J	Fortin, S; Godbout, L; Braun, CMJ				Fortin, S; Godbout, L; Braun, CMJ			Cognitive structure of executive deficits in frontally lesioned head trauma patients performing activities of daily living	CORTEX			English	Article						closed head injury; activity of daily living; scripts; frontal lobe; executive function; memory	DUAL-TASK PERFORMANCE; PROSPECTIVE MEMORY; BRAIN-INJURY; WORKING-MEMORY; PRACTICAL SCALE; DAMAGE; LOBE; IMPAIRMENTS; REHABILITATION; ACQUISITION	Objective: Executive functions in activities of daily living (ADL) were investigated in 10 patients with frontal lobe lesions after a mild to severe closed head injury (CHI). Method: The CHI patients were compared to 12 normal controls with a neuropsychological test battery, a script recitation task and a realistic simulation of complex multitask ADL (planning and preparing a meal). Results: Though the CHI patients were significantly slow on one test and subject to interference on an attention test with parametric testing, the groups did not differ on any neuropsychological test with non parametric testing. However, the CHI patients manifested marked anomalies in the meal preparation task. While small sequences of actions were easily produced, large action sets could not be correctly executed. Conclusion: An outstanding deficit in strategic planning and prospective memory appears to be an important underpinning of the impairment of ADL observed in CHI patients with frontal lobe lesions.	Univ Quebec, Cognit Neurosci Lab, Dept Psychol, Ctr Neurosci Cognit, Montreal, PQ H3C 3P8, Canada; Univ Quebec Trois Rivieres, Dept Psychol, Lab Neuropsychol Expt & Comparee, Trois Rivieres, PQ, Canada		Braun, CMJ (corresponding author), Univ Quebec, Cognit Neurosci Lab, Dept Psychol, Ctr Neurosci Cognit, CP 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.	Braun.Claude@UQAM.CA					Acker MB, 1990, NEUROPSYCHOLOGY EVER, P19; ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; Arthur G, 1947, POINT SCALE PERFORMA; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; Baddeley A.D., 1986, WORKING MEMORY; BAILLARGEON J, 1994, UNPUB ADAPTATION FRA; Bisiacchi PS, 1996, PROSPECTIVE MEMORY T, P297; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; CHATELOIS J, 1993, UNPUB TEST STROOP RE; CLOUTIER P, 1997, THESIS U QUEBEC TROI; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Cooper R, 1997, PROCEEDINGS OF THE NINETEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P131; COOPER R, 1995, FR ART INT, V27, P27; Crepeau F, 1997, NEUROPSYCHOL REHABIL, V7, P147, DOI 10.1080/713755525; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; Crozier S, 1999, NEUROPSYCHOLOGIA, V37, P1469, DOI 10.1016/S0028-3932(99)00054-8; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duyckaerts C, 1998, REV NEUROL-FRANCE, V154, pS8; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; GABRIELI JDE, 1993, BEHAV NEUROSCI, V107, P899, DOI 10.1037/0735-7044.107.6.899; Godbout L, 2000, BRAIN COGNITION, V43, P220; Godbout L, 1995, NEUROPSYCHOLOGIA, V33, P1671, DOI 10.1016/0028-3932(95)00047-X; Godbout L, 1999, BRAIN COGNITION, V40, P136; GODBOUT L, 1994, THESIS U LAVAL ST FO; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Grafman J., 1989, INTEGRATING THEORY P, P93; GRENIER MC, 2000, THESIS U QUEBEC TROI; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; JENNETT B, 1975, LANCET, V1, P480; Katai S, 1999, Rinsho Shinkeigaku, V39, P913; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KOLB B, 1981, NEUROPSYCHOLOGIA, V19, P491, DOI 10.1016/0028-3932(81)90016-6; KOLB B, 1989, FONDAMENTALS HUMAN N; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MEACHAM JA, 1977, J PSYCHOL, V97, P191, DOI 10.1080/00223980.1977.9923962; MILLER MB, 1995, J ABNORM PSYCHOL, V104, P251, DOI 10.1037/0021-843X.104.2.251; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Partiot A, 1996, NEUROREPORT, V7, P761, DOI 10.1097/00001756-199602290-00020; Poldrack RA, 1999, NEUROPSYCHOLOGY, V13, P564, DOI 10.1037/0894-4105.13.4.564; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan R.M., 1993, HALSTEADREITAN NEURO; Rendell PG, 1999, J GERONTOL B-PSYCHOL, V54, pP256, DOI 10.1093/geronb/54B.4.P256; RUFF RM, 1996, RUFF 2 7 SELECTIVE A; Schwartz M. F., 1993, J HEAD TRAUMA REHAB, V8, P59, DOI [10.1097/00001199-199303000-00007, DOI 10.1097/00001199-199303000-00007]; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Sirigu A, 1996, CORTEX, V32, P297, DOI 10.1016/S0010-9452(96)80052-9; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81; Thurstone L. L, 1962, PRIMARY MENTAL ABILI; TRANEL D, 1994, HDB NEUROPSYCHOLOGY, P125; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1981, WAIS R MANUAL; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; Wise SP, 1996, SEMIN NEUROSCI, V8, P39, DOI 10.1006/smns.1996.0006; [No title captured]; [No title captured]	81	127	129	0	5	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	APR	2003	39	2					273	291		10.1016/S0010-9452(08)70109-6			19	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	677DR	WOS:000182792100007	12784889				2022-02-06	
J	Basu, A; Krady, JK; O'Malley, M; Styren, SD; DeKosky, ST; Levison, SW				Basu, A; Krady, JK; O'Malley, M; Styren, SD; DeKosky, ST; Levison, SW			The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury	JOURNAL OF NEUROSCIENCE			English	Article						cytokines; IL-1; IL-6; TNF-alpha; traumatic brain injury; prostaglandins; astrocytes; null mutant mice	NECROSIS-FACTOR-ALPHA; FACTOR MESSENGER-RNA; EXCITOTOXIC NEURONAL DAMAGE; NF-KAPPA-B; GROWTH-FACTOR; TRANSGENIC MICE; RAT-BRAIN; ALZHEIMERS-DISEASE; INFLAMMATORY RESPONSE; CONVERTING-ENZYME	Interleukin-1 (IL-1) is induced immediately after insults to the brain, and elevated levels of IL-1 have been strongly implicated in the neurodegeneration that accompanies stroke, Alzheimer's disease, and multiple sclerosis. In animal models, antagonizing IL-1 has been shown to reduce cell death; however, the basis for this protection has not been elucidated. Here we analyzed the response to penetrating brain injury in mice lacking the type 1 IL-1 receptor (IL-1R1) to determine which cellular and molecular mediators of tissue damage require IL-1 signaling. At the cellular level, fewer amoeboid microglia/macrophages appeared adjacent to the injured brain tissue in IL-1R1 null mice, and those microglia present at early postinjury intervals retained their resting morphology. Astrogliosis also was mildly abrogated. At the molecular level, cyclooxygenase-2 (Cox-2) and IL-6 expression were depressed and delayed. Interestingly, basal levels of Cox-2, IL-1, and IL-6 were significantly lower in the IL-1R1 null mice. In addition, stimulation of vascular cell adhesion molecule-1 mRNA was depressed in the IL-1R1 null mice, and correspondingly, there was reduced diapedesis of peripheral macrophages in the IL-1R1 null brain after injury. This observation correlated with a reduced number of Cox-2(+) amoeboid phagocytes adjacent to the injury. In contrast, several molecular aspects of the injury response were normal, including expression of tumor necrosis factor-alpha and the production of nerve growth factor. Because antagonizing IL-1 protects neural cells in experimental models of stroke and multiple sclerosis, our data suggest that cell preservation is achieved by abrogating microglial/macrophage activation and the subsequent self-propagating cycle of inflammation.	Penn State Univ, Dept Anat & Neurosci, Coll Med, Hershey, PA 17033 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA		Levison, SW (corresponding author), Penn State Univ, Dept Anat & Neurosci, Coll Med, H109,POB 850, Hershey, PA 17033 USA.		Levison, Steven W./Q-6903-2019; BASU, ANIRBAN/C-1166-2009	Levison, Steven W./0000-0002-1264-7309; Basu, Anirban/0000-0002-5200-2054; DeKosky, Steven/0000-0003-3743-2758			ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; ALOISI F, 1992, J IMMUNOL, V149, P2358; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; BASU A, 2002, IN PRESS GLIA; BASU A, 2001, J NEUROIMMUNOL, V118, P94; BOELENS JJ, 2000, INFECT IMMUN, V68, P6929; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CHUNG IY, 1990, J IMMUNOL, V144, P2999; DACUNHA A, 1992, J NEUROIMMUNOL, V36, P157; DECKERTSCHLUTER M, 1992, J NEUROL SCI, V113, P50, DOI 10.1016/0022-510X(92)90264-L; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedman WJ, 1996, J BIOL CHEM, V271, P31115, DOI 10.1074/jbc.271.49.31115; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Glaccum MB, 1997, J IMMUNOL, V159, P3364; Griffin WST, 2000, EXP GERONTOL, V35, P481, DOI 10.1016/S0531-5565(00)00110-8; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAHN M, 1994, GLIA, V10, P286, DOI 10.1002/glia.440100407; Hallenbeck JM, 1996, ACT NEUR S, V66, P27; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; HOFMAN FM, 1986, J IMMUNOL, V136, P3239; JACOBS CA, 1991, J IMMUNOL, V146, P2983; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; Levison SW, 1996, EXP NEUROL, V141, P256, DOI 10.1006/exnr.1996.0160; LING EA, 1980, J COMP NEUROL, V193, P631, DOI 10.1002/cne.901930304; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; McGuinness MC, 1997, J NEUROIMMUNOL, V75, P174, DOI 10.1016/S0165-5728(97)00020-9; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; Minghetti L, 1999, J NEUROPATH EXP NEUR, V58, P1184, DOI 10.1097/00005072-199911000-00008; NORRIS JG, 1994, J IMMUNOL, V152, P841; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Penkowa M, 1999, GLIA, V25, P343; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; Silverstein A.M., 1989, HIST IMMUNOLOGY; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; VIGE X, 1991, MOL PHARMACOL, V40, P186; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676	54	127	133	1	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 15	2002	22	14					6071	6082					12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	573PR	WOS:000176840500031	12122068				2022-02-06	
J	Burd, TA; Lowry, KJ; Anglen, JO				Burd, TA; Lowry, KJ; Anglen, JO			Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							TOTAL HIP-ARTHROPLASTY; FIXATION	Background: There is controversy surrounding the relative effectiveness of local irradiation and oral indomethacin for prophylaxis against heterotopic ossification following surgical treatment of acetabular fractures. The purpose of this study was to compare the efficacy of these two commonly used methods in a prospective, randomized trial. Methods: From July 1992 to June 1999, 166 patients in whom a fracture of the acetabulum was treated surgically through a posterior, extensile, or combination approach were randomized to receive either indomethacin or radiation therapy postoperatively. Seventy-eight patients received 800 cGy of local radiation therapy within seventy-two hours after surgery, and seventy-two patients received a six-week course of indomethacin (25 mg three times a day) beginning within twenty-four hours after surgery Sixteen additional patients were randomized but did not receive treatment with either prophylactic regimen. At an average of fourteen months, the extent of heterotopic ossification was assessed on plain radiographs with use of the classification of Brooker et al. The grade of ossification was correlated with hip motion. Results: There was no significant difference between treatment groups with regard to patient age, gender, Glasgow Coma Scale, operative time, estimated operative blood loss, duration of follow-up, or presence of closed head injury. The Injury Severity Score appeared to be the only covariate that was significantly different between the groups (p = 0.019). Grade-III or IV ossification developed in eight (11%) of the patients in the indomethacin group and three (4%) in the radiation therapy group. The difference was not significant (p = 0.22; 95% confidence interval, -1.1%, +15.7%). No complications related to the prophylaxis were noted in either group. Heterotopic ossification developed in all sixteen patients who did not receive prophylaxis, with six demonstrating grade-III or IV changes. The overall prevalence of grade-III or IV heterotopic ossification was 7% (eleven of 150) in the treated groups and 38% (six of sixteen) in the untreated group. We did not find any association between the prevalence of heterotopic ossification and fracture type (p = 0.296) or posterior hip dislocation (p = 0.306). Grade-I, II, and III heterotopic ossification did not decrease the range of motion of the hip except in flexion. Conclusions: Both local radiation therapy and indomethacin were found to provide effective prophylaxis against heterotopic ossification following surgical treatment of acetabular fractures through a posterior or extensile approach. We detected no significant difference in efficacy between the two prophylactic regimens.	Univ Missouri, Hosp & Clin, Dept Orthopaed Surg, Columbia, MO 65212 USA		Anglen, JO (corresponding author), Univ Missouri, Hosp & Clin, Dept Orthopaed Surg, MC213,1 Hosp Dr, Columbia, MO 65212 USA.	anglen@health.missouri.edu					AHRENGART L, 1988, CLIN ORTHOP RELAT R, V229, P265; ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131-199505000-00006; Anglen JO, 1996, J ORTHOP TRAUMA, V10, P258, DOI 10.1097/00005131-199605000-00006; AYERS DC, 1991, CLIN ORTHOP RELAT R, P87; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bhalla A K, 1984, Compr Ther, V10, P40; BOSSE A, 1994, CALCIFIED TISSUE INT, V54, P119, DOI 10.1007/BF00296062; BOSSE MJ, 1988, J BONE JOINT SURG AM, V70A, P1231, DOI 10.2106/00004623-198870080-00016; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623-197355080-00006; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36, DOI 10.1302/0301-620X.57B1.36; Daum W J, 1992, J Orthop Trauma, V6, P427, DOI 10.1097/00005131-199212000-00006; GHALAMBOR N, 1994, CLIN ORTHOP RELAT R, V305, P96; GREGORITCH SJ, 1994, INT J RADIAT ONCOL, V30, P55, DOI 10.1016/0360-3016(94)90519-3; Healy W L, 1990, J Arthroplasty, V5, P369, DOI 10.1016/S0883-5403(08)80097-6; Hofmann S, 1999, ORTHOPEDICS, V22, P207; JOHNSON EE, 1994, CLIN ORTHOP RELAT R, V305, P88; Kaempffe F A, 1991, J Orthop Trauma, V5, P439, DOI 10.1097/00005131-199112000-00009; Letournel E, 1993, FRACTURES ACETABULUM; Matta JM, 1997, J BONE JOINT SURG BR, V79B, P959, DOI 10.1302/0301-620X.79B6.6889; MAYO KA, 1994, CLIN ORTHOP RELAT R, V305, P31, DOI DOI 10.1097/00003086-199408000-00005; MCLAREN AC, 1990, J BONE JOINT SURG AM, V72A, P245, DOI 10.2106/00004623-199072020-00012; MOED BR, 1994, J BONE JOINT SURG BR, V76B, P895, DOI 10.1302/0301-620X.76B6.7983114; MOED BR, 1994, J ORTHOP TRAUMA, V8, P34, DOI 10.1097/00005131-199402000-00008; Moore KD, 1998, J BONE JOINT SURG BR, V80B, P259, DOI 10.1302/0301-620X.80B2.8157; MORREY BF, 1984, CLIN ORTHOP RELAT R, P160; NILSSON OS, 1986, CLIN ORTHOP RELAT R, P239; PANTAZOPOULOS T, 1989, CLIN ORTHOP RELAT R, V246, P57; Parkinson J R, 1982, Hip, P211; PELLEGRINI VD, 1992, J BONE JOINT SURG AM, V74A, P186, DOI 10.2106/00004623-199274020-00005; Pellegrini VD, 1996, J BONE JOINT SURG AM, V78A, P870, DOI 10.2106/00004623-199606000-00010; RITTER MA, 1977, J BONE JOINT SURG AM, V59, P345, DOI 10.2106/00004623-197759030-00009; ROUTT MLC, 1990, J BONE JOINT SURG AM, V72A, P897, DOI 10.2106/00004623-199072060-00016; RUBASH HE, 1985, ORTHOP T, V9, P27; SAWYER JR, 1991, CALCIFIED TISSUE INT, V49, P208, DOI 10.1007/BF02556120; STANNARD JP, 1998, CLIN ORTHOP RELAT R, V353, P74; Staszewska-Barczak J, 1975, Clin Exp Pharmacol Physiol, VSuppl 2, P71; STEINBERG GG, 1993, J ORTHOP TRAUMA, V7, P536, DOI 10.1097/00005131-199312000-00009; TEASDALE G, 1974, LANCET, V2, P81; Webb L X, 1990, J Orthop Trauma, V4, P376, DOI 10.1097/00005131-199012000-00002; WRIGHT R, 1994, J ORTHOP TRAUMA, V8, P397, DOI 10.1097/00005131-199410000-00005	40	127	143	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	DEC	2001	83A	12					1783	1788		10.2106/00004623-200112000-00003			6	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	502BT	WOS:000172724400003	11741055				2022-02-06	
J	Ke, CS; Poon, WS; Ng, HK; Pang, JCS; Chan, Y				Ke, CS; Poon, WS; Ng, HK; Pang, JCS; Chan, Y			Heterogeneous responses of aquaporin-4 in oedema formation in a replicated severe traumatic brain injury model in rats	NEUROSCIENCE LETTERS			English	Article						aquaporin-4; brain oedema; brain injuries; blood-brain barrier; rats	MEMBRANE DOMAINS; WATER TRANSPORT; EDEMA; EXPRESSION; CELLS	Aquaporin-4 (AQP4) is the most abundant water channel in the rat brain. In this study, the distribution pattern and mRNA expression levels of AQP4 were examined in a severe traumatic brain injury model by immunohistochemistry and reverse transcription-polymerase chain reaction. Oedema formation and blood-brain barrier (BBB) integrity were assessed by wet-dry weight measurements and immunostaining of endogenous IgG respectively. In the oedematous contusional cortex with impaired BBB integrity, negative immunostaining of AQP4 and down-regulation of its mRNA level were identified (P < 0.05) at 1 day post-injury, while in other oedamatous regions of the injured brain where BBB was intact, there was no significant change in the AQP4 expression level. This heterogeneous pattern of AQP4 responses can be interpreted as follows: focal brain injury (such as a contusion) with impaired BBB resulting in vasogenic oedema is associated with reduction of AQP4 expression, whereas, in cytotoxic oedema, associated with diffuse brain injury with intact BBB, changes in AQP4 expression are not significant. This study provides basic information for investigating new treatments for traumatic brain oedema. (C) 2001 Elsevier Science ireland Ltd. All rights reserved.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China		Poon, WS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin, Hong Kong, Peoples R China.		Ng, Ho Keung/I-3952-2015; Poon, Wai Sang/F-1558-2011				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DOCZI T, 1993, ACTA NEUROCHIR, V121, P1, DOI 10.1007/BF01405174; GEAN AD, 1994, IMAGING HEAD TRAUMA, P5; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Katayama Y, 1998, ACT NEUR S, V71, P289; KE C, 2000, IN PRESS ACTA NEUR S; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; NEWMAN EA, 1984, NATURE, V309, P155, DOI 10.1038/309155a0; Nielsen S, 1997, J NEUROSCI, V17, P171; Pardridge WM, 1999, J NEUROVIROL, V5, P556, DOI 10.3109/13550289909021285; RUDDY MK, 1998, AM J PHYSIOL, V274, pL1066; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093	21	127	155	0	6	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAR 23	2001	301	1					21	24		10.1016/S0304-3940(01)01589-0			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	411NB	WOS:000167505200006	11239707				2022-02-06	
J	Finfer, SR; Cohen, J				Finfer, SR; Cohen, J			Severe traumatic brain injury	RESUSCITATION			English	Article						young adults; injuries; traumatic brain injury	SEVERE HEAD-INJURY; TUMOR-NECROSIS-FACTOR; BLOOD-FLOW VELOCITY; INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; AGGRESSIVE TREATMENT; MANAGEMENT; GUIDELINES; VASOSPASM; PRESSURE	In western countries, injuries remain the leading cause of death in young adults (Jennett B. Epidemiology of head injury. J Neurol Neurosurg Psychiatry 1996; 60: 362-369). Worldwide, injuries are estimated to account for 15% of the burden of death and disability, and are projected to account for 20% in 2020 (Ad Hoc Committee on Health Research Relating to Future Intervention Options. Investing in Health Research and Development (Document TDR/Gen/96.1). Geneva: World Health Organisation, 1996). In developing countries road traffic injuries in particular are increasing in incidence and injuries are projected to be the third leading cause of death and disability worldwide by 2020 (Ad Hoc Committee on Health Research Relating to Future Intervention Options. Investing in Health Research and Development (Document TDR/Gen/96.1). Geneva: World Health Organisation, 1996). Head injury accounts for up to half of all deaths from trauma (Kraus J, Epidemiology of head injury. In: Cooper PR. Ed. Head Injury, 3rd ed. Baltimore, MD: William Wilkins. 1993), and in addition to causing death often causes severe and long-lasting functional impairment in survivors. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Royal N Shore Hosp, Intens Care Unit, Sydney, NSW 2065, Australia		Finfer, SR (corresponding author), Royal N Shore Hosp, Intens Care Unit, Sydney, NSW 2065, Australia.		Cohen, Jeremy/G-2086-2010	COHEN, Jeremy/0000-0002-1356-8506			American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP D; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bullock MR, 1996, J NEUROTRAUM, V13, P643; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; GALBRAITH S, 1976, BRIT J SURG, V63, P138; GERMAN TSA, 1996, J NEUROSURG, V85, P82; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HADDON W, 1961, J CHRON DIS, V14, P655, DOI 10.1016/0021-9681(61)90122-9; Heesen M, 1996, ACTA NEUROCHIR, V138, P77, DOI 10.1007/BF01411728; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1991, J NEUROSURG S, V75, P59; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; McKeating EG, 1998, BRIT J ANAESTH, V80, P77, DOI 10.1093/bja/80.1.77; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; MICHIE HR, 1988, SURGERY, V104, P280; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; Osuka K, 1996, ACTA NEUROCHIR, V138, P970, DOI 10.1007/BF01411287; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; *REC TRANSF PAT AC, 1996, NEUR SOC GREAT BRIT; ROCKOFF MA, 1979, ANN NEUROL, V6, P194, DOI 10.1002/ana.410060303; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SCHINDLER R, 1990, BLOOD, V75, P40; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X	67	127	132	0	7	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JAN	2001	48	1					77	90		10.1016/S0300-9572(00)00321-X			14	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	387UH	WOS:000166139900009	11162885				2022-02-06	
